TABLE OF CONTENTS
As filed with the Securities and Exchange Commission on May 23, 2025.
Registration No. 333-          ​
​
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
​
CARIS LIFE SCIENCES, INC.
(Exact name of registrant as specified in its charter)
​
Texas
​ ​
8071
​ ​
85-2077369
​
​
(State or other jurisdiction of
incorporation or organization)​
​ ​
(Primary Standard Industrial
Classification Code Number)​
​ ​
(I.R.S. Employer
Identification Number)
​
750 W. John Carpenter Freeway
Suite 800
Irving, TX 75039
Telephone: (866) 771-8946
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)​
​
David D. Halbert
Founder, Chairman, and Chief Executive Officer
Caris Life Sciences, Inc.
750 W. John Carpenter Freeway, Suite 800
Irving, TX 75039
Telephone: (866) 771-8946
(Name, address, including zip code, and telephone number, including area code, of agent for service)​
​
Copies to:
​
Nathan Ajiashvili
Alison Haggerty
Samer Zabaneh
Latham & Watkins LLP
1271 Avenue of the Americas
New York, NY 10020
Telephone: (212) 906-1200
​ ​
J. Russel Denton
Ginger Appleberry
Michael R. Sullivan
Caris Life Sciences, Inc.
750 W. John Carpenter Freeway, Suite 800
Irving, TX 75039
Telephone: (866) 771-8946
​ ​
Eric Blanchard
Divakar Gupta
Charles S. Kim
Cooley LLP
500 Boylston Street
Boston, MA 02116
Telephone: (617) 937-2300
​
​
Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.
​
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
​ Large accelerated filer ​ ​ ☐ ​ ​ Accelerated filer ​ ​
☐
​
​ Non-accelerated filer ​ ​ ☒ ​ ​ Smaller reporting company ​ ​
☐
​
​ ​ ​ ​ ​ ​ ​ Emerging growth company ​ ​
☒
​
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
​
The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.
​
​

TABLE OF CONTENTS
The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell, nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
Subject to Completion
Preliminary Prospectus dated            , 2025
P R O S P E C T U S
           Shares
[MISSING IMAGE: lg_carislifesciences-pn.jpg]
Caris Life Sciences, Inc.
Class A Common Stock
​
This is Caris Life Sciences, Inc.’s initial public offering. We are selling           shares of our Class A common stock.
We expect the public offering price to be between $      and $      per share. Currently, no public market exists for shares of our Class A common stock. After pricing of the offering, we expect that our Class A common stock will trade Nasdaq Global Select Market (“Nasdaq”) under the symbol “CAI.”
Upon the completion of this offering, we will have two classes of authorized common stock: Class A common stock and Class B common stock. The rights of the holders of Class A common stock and Class B common stock are identical, except with respect to voting, conversion, and transfer rights. Each share of Class A common stock is entitled to one vote. Each share of Class B common stock is entitled to 10 votes and is convertible at any time, at the option of the holder, and mandatorily upon the occurrence of certain events, into one share of Class A common stock. Immediately following the completion of this offering, the outstanding shares of our Class B common stock will collectively represent approximately     % of the voting power of our outstanding capital stock, with our executive officers, directors, and principal shareholders collectively holding approximately     % of the voting power of our outstanding capital stock, assuming no exercise by the underwriters of their option to purchase additional shares of Class A common stock. David D. Halbert, our Founder, Chairman, and Chief Executive Officer, will beneficially own shares of common stock representing approximately     % of our outstanding shares of capital stock and approximately     % of the voting power of our outstanding capital stock, assuming in each case, no exercise by the underwriters of their option to purchase additional shares of Class A common stock. As a result, Mr. Halbert will have the ability to exercise significant influence over the outcome of matters submitted to our shareholders for approval, including the election of our directors and the approval of any change of control transaction, and, following this offering, we may become a “controlled company” as defined under the corporate governance rules of Nasdaq. See “Principal Shareholders” and “Description of Capital Stock” for additional information.
At our request, the underwriters have reserved up to     % of the shares of Class A common stock offered by this prospectus, excluding the additional shares that the underwriters have a 30-day option to purchase, for sale, at the initial public offering price, to certain individuals identified by management, including certain of our directors, officers, employees, and certain other parties related to us. See “Underwriting—Reserved Share Program.”
We are an “emerging growth company” as defined under the federal securities laws and, as such, have elected to comply with certain reduced reporting requirements for this prospectus and may elect to do so in future filings. See “Prospectus Summary—​Implications of Being an Emerging Growth Company.”
Investing in our Class A common stock involves risks that are described in the “Risk Factors” section beginning on page 21 of this prospectus.
​
​ ​ ​
Per Share
​ ​
Total
​
Public offering price
​ ​ ​ $ ​ ​ ​ ​ ​ $ ​ ​ ​
Underwriting discount(1)
​ ​ ​ $ ​ ​ ​ ​ ​ $ ​ ​ ​
Proceeds, before expenses, to us
​ ​ ​ $ ​ ​ ​ ​ ​ $ ​ ​ ​
​
(1)
We refer you to “Underwriting” for additional information regarding underwriting compensation.
​
The underwriters may also exercise their option to purchase up to an additional           shares of Class A common stock from us, at the public offering price, less the underwriting discount, for 30 days after the date of this prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The shares will be ready for delivery on or about           , 2025.
​
BofA SecuritiesJ.P. Morgan Goldman Sachs & Co. LLC Citigroup
​
TD Cowen
​ ​
Evercore ISI
​ ​
Guggenheim Securities
​
​ BTIG ​ ​ ​ ​ ​
Wolfe | Nomura Alliance
​
​
The date of this prospectus is           , 2025.

TABLE OF CONTENTS
 Where Molecular Science Meets Artificial Intelligence Arizona blood lab; the entrance lobby of Caris’ Phoenix, Arizona tissue lab; tissue sample storage in Caris’ Phoenix, Arizona tissue lab; a Caris laboratory technician preparing a centrifuge for Caris Assure™ profiling of patient blood samples; a Caris laboratory technician preparing patient blood samples for Caris Assure™ profiling; a Caris laboratory technician microdissecting a patient tissue sample in preparation for MI Profile™ analysis; Caris laboratory technicians in our Phoenix, Arizona blood lab; sequencing machines in Caris’ Phoenix, Arizona blood lab.
[MISSING IMAGE: pg_carislifesciences-4c.jpg]

TABLE OF CONTENTS
  By the Numbers Profiling, Data & Technology Publications, Patents & People Data points are as of March 31, 2025.
[MISSING IMAGE: pg_bynumbers-4c.jpg]

TABLE OF CONTENTS
  Case Volume Growth (Thousands*) Clinical Cases Biopharma & External Research Cases 172.6 31% CAGR 136.9 2019-2024 103.4 162.9 77.5 30% Year-Over-Year Growth Rate 128.8 61.5 97.3 47.3 45.1 36.5 75.3 59.9 45.9 34.9 42.8 2019 2020 2021 2022 2023 2024 Q1 2024 Q1 2025 *Figures reflect case volume for the periods presented. Figures may not sum precisely due to rounding.
[MISSING IMAGE: pg_casevaluegrowth-4c.jpg]

TABLE OF CONTENTS
  Revenue Growth ($ Millions*) Molecular Profiling Services Pharma Research & Development Services 28% CAGR 2019-2024 $306.1 $258.5 $278.7 ($79.1) ($175.8) ($324.0) ($320.8) ($341.4) ($281.9) ($111.0) ($102.6) NET (LOSS) *Figures reflect revenue for the periods presented. Figures may not sum precisely due to rounding.
[MISSING IMAGE: pg_revenuegrowth-4c.jpg]

TABLE OF CONTENTS​
 
TABLE OF CONTENTS
​ ​ ​
PAGE
​
​ ​ ​ ​ iii ​ ​
​ ​ ​ ​ 1 ​ ​
​ ​ ​ ​ 21 ​ ​
​ ​ ​ ​ 100 ​ ​
​ ​ ​ ​ 102 ​ ​
​ ​ ​ ​ 103 ​ ​
​ ​ ​ ​ 104 ​ ​
​ ​ ​ ​ 105 ​ ​
​ ​ ​ ​ 108 ​ ​
​ ​ ​ ​ 111 ​ ​
​ ​ ​ ​ 138 ​ ​
​ ​ ​ ​ 213 ​ ​
​ ​ ​ ​ 223 ​ ​
​ ​ ​ ​ 233 ​ ​
​ ​ ​ ​ 237 ​ ​
​ ​ ​ ​ 241 ​ ​
​ ​ ​ ​ 252 ​ ​
​ ​ ​ ​ 257 ​ ​
​ ​ ​ ​ 261 ​ ​
​ ​ ​ ​ 272 ​ ​
​ ​ ​ ​ 272 ​ ​
​ ​ ​ ​ 273 ​ ​
​ ​ ​ ​ 274 ​ ​
​ ​ ​ ​ F-1 ​ ​
Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of Class A common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our Class A common stock. Our business, financial condition, results of operations, and prospects may have changed since that date.
For investors outside the United States: Neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus or any free writing prospectus we may provide to you in connection with this offering in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus and any such free writing prospectus outside of the United States.
 
i

TABLE OF CONTENTS
 
TRADEMARKS, TRADE NAMES AND SERVICE MARKS
This prospectus includes our trademarks and trade names, including, without limitation, Caris Life Sciences®, Caris®, Caris Discovery®, Caris Assure®, MI Profile®, Molecular Intelligence®, Caris Precision Oncology Alliance™, MI Tumor Seek®, MI Tumor Seek Hybrid™, ABCDai™, CODEai®, ESPai™, MI Cancer Seek®, GPSai™, FOLFIRSTai®, Caris ChromoSeq™, MGMTai™, and our logo, which are protected under applicable intellectual property laws and are our property. This prospectus also contains trademarks, trade names, and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names, and service marks referred to in this prospectus, including logos, artwork, and other visual displays, may appear without the ®, ™ or SM symbols, but such references are not intended to indicate in any way that we or the applicable owner will not assert, to the fullest extent under applicable law, our or its rights or the rights of the applicable licensor to these trademarks, trade names, and service marks. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other parties.
ROUNDING ADJUSTMENTS
Certain monetary amounts, percentages, and other figures included elsewhere in this prospectus have been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables or charts may not be the arithmetic aggregation of the figures that precede them, and figures expressed as percentages in the text may not total 100% or, as applicable, when aggregated may not be the arithmetic aggregation of the figures that precede them.
 
ii

TABLE OF CONTENTS​
 
LETTER FROM DAVID DEAN HALBERT, FOUNDER, CHAIRMAN, AND CEO
Hello, my name is David Dean Halbert, and I am the Founder, Chairman, and CEO of Caris Life Sciences. Caris is the first and only company that I’ve founded without a business model. Our only purpose is to help patients live longer and have a better quality of life by applying personalized medicine to disease. We believe that precise, data-driven, and personalized molecular information is crucial to eradicating chronic health conditions.
As a science-focused company, Caris has been at the forefront of precision medicine from the beginning and has driven the industry forward through our focus on science and investments into technology, instrumentation, facilities, and people. When I started Caris, next-generation sequencing, and other technologies needed to realize the benefits of personalized medicine, did not exist. However, we have benefited from tremendous advances in sequencing technology, cloud computing, and AI technologies to power our expertise and insights in molecular biology. We believe that these advances provide an unmatched resource to develop the next generation of precision medicine solutions.
Our platform is built on the premise that more data enables us to answer questions about biology that could not be answered until now due to limited or narrow information. In the course of completing over 6.5 million tests on over 849,000 cases, we have generated over 13 quadrillion molecular datapoints and measured over 38 billion molecular markers. We measure billions of data points per clinical case using Caris Assure, our universal blood-based whole exome/whole transcriptome sequencing solution, that we have created based on our vast experience in tissue sequencing. We are utilizing this tremendous amount of molecular information to pioneer the transition from intuitive medicine, where decisions for cancer patients are made based on prior experience or intuition, to empirical medicine, where decisions are based on the genetic make-up of each person’s disease.
Driven by over 17 years of innovation to help build a better world, we have gained vast expertise in sequencing and data interpretation. We believe we were the first to offer comprehensive molecular profiling as standard practice when we launched whole transcriptome sequencing in 2019, the first to offer whole exome sequencing as standard practice when we introduced our whole exome sequencing solution in 2020, and the first to offer whole exome and whole transcriptome sequencing in blood when we broadly launched Caris Assure in the first quarter of 2024.
We have utilized AI and machine learning algorithms across our dataset to identify approximately 915,000 unique pathogenic mutations, of which only approximately 17,000 were previously identified, with approximately 130 novel pathogenic mutations found on average in each person. We can now identify a person’s circulating pathogenic mutations and design a customized individualized therapy to that specific set of mutations. So, it becomes an individualized, customized immunotherapy. We believe this is going to create the opportunity for physicians to use our solutions to effectively prevent various chronic diseases before they ever get started at the earliest of stages.
It is a very exciting time because technology has finally advanced to the point where it enables this big idea. This is not something that could have been thought of in 2008 or even 2018 because the technologies were not available. Such as large sequencing capacity, AI, and the cloud, all of which have to be utilized to look at all of the different aberrations that are occurring at the molecular level with the outcomes. So over time, it’s just going to get better and better and better. We run the same assay in both blood and tissue on every eligible patient sample every day, so the only changes to the assay will be at the bioinformatic level utilizing specially-designed algorithms to provide new insights.
While we specialize in oncology today, we also believe that since we have designed the Caris Assure platform as a universal assay that runs on every coding gene in the blood, it can be utilized to identify alterations that drive other chronic disease states such as cardiovascular disease, neurological conditions, metabolic disorders, and many others.
We exist in a very exciting time of unprecedented technological disruption to benefit mankind and “go where no man has gone before”—something I have described as the molecular revolution—leading me to be bullish on humanity. Never before have we seen a convergence of molecular sequencing power, sophisticated AI technologies, and massive computer processing capabilities. We will continue to harness these and other advanced technologies, pushing the boundaries of what is possible and leading the precision medicine revolution in healthcare.
 
iii

TABLE OF CONTENTS
 
We feel honored to have served hundreds of thousands of patients in their battle against cancer. I would like to thank our Caris Life Sciences family for their tireless work to help our patients and to build a company that is actively changing the practice of medicine. We are excited about our future and welcome new shareholders that share our vision and passion to improve the human condition.
David Dean Halbert, D.Sc. (h.c.)
Founder, Chairman, and CEO
 
iv

TABLE OF CONTENTS​
 
PROSPECTUS SUMMARY
This summary highlights selected information contained elsewhere in this prospectus and is qualified in its entirety by the more detailed information and financial statements included elsewhere in this prospectus. It does not contain all of the information that may be important to you and your investment decision. You should carefully read this entire prospectus, including the sections titled “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Special Note Regarding Forward-Looking Statements” and our financial statements and related notes included elsewhere in this prospectus before making an investment decision. In this prospectus, unless context requires otherwise, references to “we,” “us,” “our,” “Caris,” or “the Company” refer to Caris Life Sciences, Inc. and its wholly owned subsidiaries.
Overview
We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.
We founded Caris in 2008 with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. We have spent the last 17 years developing and building our portfolio of comprehensive, proprietary molecular profiling solutions and generating what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology based on the more than 6.5 million tests we have run on over 849,000 cases, which have generated measurements of over 38 billion molecular markers. Our platform is purpose-built to leverage the convergence of next-generation sequencing (“NGS”), artificial intelligence (“AI”) and machine learning (“ML”) technologies, and high-performance computing. The power of our differentiated Caris platform has enabled us to develop the latest generation of advanced precision medicine diagnostic solutions designed to address the entire cancer care continuum, including early detection, minimal residual disease (“MRD”) tracking, therapy selection, and treatment monitoring, as well as to create molecular signatures and discover and develop novel precision medicine therapeutics. Our current commercial product portfolio is focused on oncology and consists of MI Profile, our tissue-based molecular profiling solution that has generated the majority of our revenue to date, and Caris Assure, our novel, universal blood-based molecular profiling solution that was broadly launched in the first quarter of 2024 for therapy selection.
Dysfunctionality at the molecular level underlies every chronic disease, and this dysfunction is now measurable using techniques such as NGS. Cells are embedded within highly complex biological networks that govern all aspects of life, including how these cells grow, divide, interact, and die. These biological networks and their inherent functions, as well as dysfunctions, are controlled and directed at the molecular level. The precise molecular origins or contributors to a given biological dysfunction, however, are often unknown, and a comprehensive molecular profile is necessary to determine these origins. The central dogma of molecular biology states that genetic information flows in one direction, from DNA, to RNA, to proteins. Our approach is designed to accurately capture the full breadth of the DNA and RNA coding information in cells as well as protein expression through immunohistochemical (“IHC”) tests, constructing a fulsome mosaic of disease, and ultimately unlocking the potential for precision medicine therapeutics to guide individualized patient diagnoses and treatment.
We believe we are well-positioned to realize the full potential of our vision and optimally leverage our vast datasets due to the recent convergence of several advancements in biology, medicine, and technology: (1) the medical community’s understanding and appreciation of the molecular nature of cancer has accelerated in recent years, resulting in a continued increase in molecular profiling of different cancer types and stages; (2) NGS costs have declined, making NGS more accessible to the healthcare ecosystem; (3) cloud-computing architecture has enabled massive scalability, distributed real-time collaboration, and greater cost efficiency for the analysis of previously unmanageable amounts of data; and (4) AI and ML computational capabilities have advanced to allow more effective interrogation of large biological datasets. We believe that our early foresight to generate comprehensive data at scale over the past many years and build a robust, foundational infrastructure have uniquely positioned Caris to leverage the benefits of these
 
1

TABLE OF CONTENTS
 
biological and technological advances to deliver transformative and advanced innovations in precision medicine and patient care into the future.
Our purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. We provide whole exome sequencing (“WES”) (all 23,000 encoding DNA genes) and whole transcriptome sequencing (“WTS”) (all 61,000 RNA transcripts that encode proteins) on every eligible patient sample (a sample provided by ordering physicians that contains sufficient genetic material for profiling). Since launching our WTS solution in 2019 and WES solution in 2020, we have performed over 400,000 WES and WTS cases, which we believe is more than any other company. We sequence at a sector-leading depth of coverage, which directly correlates with increased accuracy and detection of low frequency molecular markers of relevance. MI Cancer Seek, our U.S. Food and Drug Administration (‘‘FDA’’)-approved companion diagnostic assay to identify cancer patients who may benefit from treatment with targeted therapies (a component of MI Profile), consistently reaches 1,500 times depth of coverage for clinically relevant DNA genes, which is a higher sequencing depth than other assays available in the marketplace based on reported depths of coverage, and 300 times depth of coverage for the whole exome. Caris Assure features a raw average sequencing depth of 8,000 times for clinically relevant genes, similarly a higher sequencing depth than other assays available in the marketplace based on reported depths of coverage. We generate tens of billions of datapoints per clinical case to reveal an individualized molecular blueprint of the patient’s disease. We believe this approach best positions us to provide actionable treatment pathways from targeted therapies to drive superior clinical outcomes for patients while also generating a rich dataset to power insights and innovation. To our knowledge, we remain the only genomic profiling company to consistently utilize WES and WTS as standard practice on every eligible patient sample. We also evaluate protein molecular markers through an extensive menu of IHC tests performed in a tumor-type specific manner, which in combination with WES and WTS, provide a comprehensive view of a patient’s disease.
Our in-depth profiling of patient samples has led to the creation of what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology, including genomic data, clinical data, digitized slide images, and remnant tissue. As of March 31, 2025, we have run more than 6.5 million tests on over 849,000 cases, which have generated measurements of over 38 billion molecular markers. Leveraging high-powered computing and AI/ML algorithms, we, and our biopharma and research partners who use our data and bioinformatics services, analyze our datasets to determine the key molecular characteristics of a particular disease or dysfunction that drives disease, enabling signature identification and drug target discovery. As a leader in the transition to WES/WTS sequencing through our launch of a WTS solution in 2019 and a WES solution the following year, we believe we have more molecular data and information than any other company and are well-positioned to make precision medicine widely accessible.
Our molecular profiling solutions and the data generated by our multi-omic technology platform provide value to our more than 100 biopharma partners, such as Moderna, AbbVie, Xencor, and Merck KGaA, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines. In addition to biopharma, we leverage our datasets to partner with outside academic centers and researchers to further advance precision oncology research. The Caris Precision Oncology Alliance (“Caris POA”), which we established in 2015, is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. As of March 31, 2025, the Caris POA was comprised of 96 members, including 45 National Cancer Institute (“NCI”)-designated comprehensive cancer centers. This academic-industry collaborative network has been exceptionally productive with over 145 peer-reviewed manuscripts published since the beginning of 2022. Close connectivity with this vast network of key opinion leaders (“KOLs”) in oncology clinical care, research, and drug development has enabled us to remain at the forefront of precision oncology and closely attuned to the key needs of the most sophisticated researchers.
Our Caris platform is designed to create a virtuous cycle that can enable continued innovation and improved impact for patients and physicians. We believe our comprehensive approach to profiling will continue to drive demand for our genomic profiling capabilities, leading to further expansion of our clinico-genomic datasets, which provide additional valuable inputs to develop and enhance our solutions, with the
 
2

TABLE OF CONTENTS
 
ultimate goal of contributing to improved patient results. This continuous feedback loop enabled us to develop Caris Assure, which utilized genomic data generated by MI Profile to inform our blood-based bioinformatics algorithms, allowing us to detect previously unknown features and signals in the blood that provide advanced insights into disease development. We believe we will be able to further leverage this process to continue meaningful innovation in precision oncology as well as other chronic disease states, including cardiology, neurology, and metabolic conditions.
Our global annual clinical case volume has been growing rapidly, with year-over-year growth of 29% in 2022, 32% in 2023, 26% in 2024, and 31% in the first quarter of 2025, primarily driven by MI Profile. With our broad commercial launch of Caris Assure for therapy selection in the first quarter of 2024 and the FDA approval of MI Cancer Seek as a companion diagnostic in the fourth quarter of 2024 followed by the broad commercial launch of MI Cancer Seek in the first quarter of 2025 as the NGS component of MI Profile, we believe that increased profiling volumes will meaningfully contribute to our growth in 2025 and beyond. For the years ended December 31, 2024 and 2023, we generated total revenue of $412.3 million and $306.1 million, respectively. For the three months ended March 31, 2025 and 2024, we generated total revenue of $120.9 million and $80.7 million, respectively. We have incurred net losses and negative cash flows from operations since inception. For the years ended December 31, 2024 and 2023, we incurred net losses of $257.1 million and $341.4 million, respectively. For the three months ended March 31, 2025 and 2024, we incurred net losses of $102.6 million and $111.0 million, respectively. Our Adjusted EBITDA was $(189.6) million and $(255.3) million for the years ended December 31, 2024 and 2023, respectively. Our Adjusted EBITDA was $(36.2) million and $(70.1) million for the three months ended March 31, 2025 and 2024, respectively. For additional information regarding Adjusted EBITDA, a non-GAAP financial measure, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures.” We expect to incur additional net losses in the near future, and our expenses will increase as we continue to invest in developing new solutions, expand our organization, and increase our marketing efforts to continue to drive market adoption of our solutions. These investments, together with general and administrative expenses, have resulted in negative cash flows from operations of $245.2 million, $276.1 million, $31.3 million, and $73.9 million for the years ended December 31, 2024 and 2023 and the three months ended March 31, 2025 and 2024, respectively. Our free cash flow was $(253.6) million and $(298.4) million for the years ended December 31, 2024 and 2023, respectively, and, $(34.0 ) million and $(75.7) million for the three months ended March 31, 2025 and 2024, respectively. For additional information regarding free cash flow, a non-GAAP financial measure, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures.” Additionally, as of March 31, 2025, we had cash, cash equivalents, and short-term marketable securities of $33.4 million, and the aggregate principal amount of debt outstanding under our existing term loan was $400.0 million. For additional information regarding our liquidity and capital resources, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources.”
Industry Overview
Addressing the complexity of cancer remains a major challenge in healthcare and a critical area of unmet medical need, despite enormous investments in research and development (“R&D”), and the introduction of new oncology therapeutics and treatments. The molecular revolution is upending the traditional paradigm of complex workflows of diagnosis, treatment, and monitoring of diseases, which largely uses a symptomatic, reactive approach to medicine. Over the last several decades, significant advances in genomics, proteomics, molecular technology, and computing power have enabled a comprehensive, multi-omic approach to the molecular profiling of diseases, both efficiently and at scale. The information provided by comprehensive molecular profiling is driving a revolution in medicine, where molecular information is used to guide individualized patient diagnoses and treatment.
Comprehensive molecular profiling entails evaluating thousands of potential biomarkers, including DNA, RNA, proteins, and other molecular and clinical information for characteristics unique to a particular patient’s disease. Given the complexity of a cancer’s origin and drivers, comprehensive molecular information incorporating DNA, RNA, and protein profiles can help provide the most robust picture of a patient’s disease and potential treatment pathways. WES/WTS streamlines the patient experience and clinical decision-making and offers increased value to patients, physicians, and payers. We believe WES/WTS
 
3

TABLE OF CONTENTS
 
provides the most efficient and cost-effective way to obtain the maximum information on a patient’s cancer at the start of the patient journey. It enables accurate identification of a greater number of actionable genomic alterations that can be leveraged to match patients to the most effective treatments, yielding a higher probability of response and providing comprehensive predictive and prognostic information.
While the molecular revolution has already changed the way cancer is being diagnosed and treated, we believe that molecular testing faces several major challenges in its current form, which have hindered broader adoption of precision oncology. These challenges include: (1) targeted panels are subject to missing information and significant variability; (2) lack of consistent RNA profiling; (3) lack of clonal hematopoiesis (“CH”) derived variant subtraction technology in current blood assays, contributing to the inability to identify false positive mutations that are not tumor-derived; (4) disparate data sets collected across testing modalities; (5) logistical drawbacks and sensitivity limitations of current MRD assays; and (6) false positives and a lack of early-stage sensitivity with current multi-cancer early detection (“MCED”) assays.
As a result of these challenges, clinicians may make critical treatment decisions based on incomplete and/or inaccurate information and analytics, potentially resulting in suboptimal outcomes. We believe that our comprehensive molecular profiling solutions and the data generated by our multi-omic technology platform is well-suited to address the limitations and challenges of today’s molecular testing alternatives.
The Caris Platform
We are leading a molecular revolution and developing the latest generation of advanced precision medicine information solutions that we believe have applicability across the care continuum for a broad range of conditions. The fundamental differentiation of the Caris platform and our business model is the depth, breadth, and scale of data, including how that data is integrated vertically and horizontally across our business, as well as the resulting innovation which it fuels.
Our multi-omic technology platform is built on the following pillars: (1) Caris Assure; (2) MI Profile; (3) Caris Discovery; (4) Caris Strategic Data; and (5) Caris Infrastructure. These five pillars are designed to work together to create a virtuous cycle that can enable continued innovation and improved impact for patients and physicians. We believe our comprehensive approach to profiling will continue to drive demand for our genomic profiling capabilities, leading to further expansion of our clinico-genomic datasets, which provide additional valuable inputs to develop and enhance our solutions, with the ultimate goal of contributing to improved patient results. We believe this continuing cycle will deepen our competitive advantage and allow us to achieve meaningful innovation and business success in precision oncology, while illuminating a path to precision medicine for other chronic disease states, including cardiology, neurology, and metabolic conditions.
 
4

TABLE OF CONTENTS
 
[MISSING IMAGE: pc_platform-4c.jpg]
We believe our growth and competitive differentiation are driven by the five pillars of our platform, each of which are both a product of the upstream data and a foundation to further innovation and data generation across the platform:
•
Caris Assure.   Our universal blood-based WES/WTS profiling solution is designed to deploy a single assay across the entire continuum of cancer care, including early detection, MRD tracking, therapy selection, and treatment monitoring, and generates over 42 billion datapoints, spanning 168,000 molecular markers, per clinical case. We leveraged our experience and data from MI Profile to create Caris Assure, which enables us to understand how a patient’s disease started, what therapies the tumor may be sensitive to, how the tumor is transforming to resist therapies, and how best to control or cure the disease.
​
•
MI Profile.   Our tissue-based profiling solution for therapy selection includes MI Cancer Seek, our FDA-approved companion diagnostic WES/WTS profiling assay, and IHC protein expression testing. Our WES/WTS profiling solution generates over 28.8 billion datapoints, spanning 84,000 molecular markers, per clinical case.
​
•
Caris Discovery.   The combination of our data and our AI enables us to discover previously unknown drug targets for antibody-directed therapies (such as antibody drug conjugates, degrader-antibody conjugates, and T-cell engagers), small molecules, targeted protein degradation, synthetic lethal interactions, and cell therapy. In addition, we believe Caris Discovery is well-positioned for neoantigen discovery for personalized therapy development given our ability to detect variants, insertions, and deletions by WES and to assess gene expression and detect fusions by WTS on every patient’s tumor.
​
•
Caris Strategic Data.   As of March 31, 2025, we have run more than 6.5 million tests that have measured over 38 billion molecular markers from over 13 quadrillion datapoints. To assist us with analyzing the data we generate, we utilize over 220 AI and AI/ML tools across our
​
​
 
5

TABLE OF CONTENTS
 
clinical testing, R&D, and biopharma business. These tools include over 50 clinical sequencing automation and variant calling AIs, over 100 RNA expression AI signatures, approximately 20 multi-omic AI/ML therapy response predictors, two ADAPT target discovery AI/ML algorithms, 37 digital image AI/ML classifiers, and 12 AI/ML support tools. The breadth and depth of our data assets, along with our ability to create algorithms and discover signatures, represent a deep competitive moat for us.
•
Caris Infrastructure.   We have a well-developed laboratory, R&D, and sales infrastructure that we believe is foundational to our business. Our infrastructure includes substantial testing capacity and a dedicated workforce to support our R&D efforts, sales activity, and expansion.
​
Our Market Opportunity and Vision for Leveraging Molecular Information
We believe we are well-positioned to initially pursue a total addressable market in U.S. oncology of approximately $150 billion through the provision of precision medicine solutions across the entire cancer care continuum, as well as offerings to support biopharma drug discovery and development. While our tissue-based molecular profiling solution for cancer therapy has generated the majority of our revenue to date, we believe the launch of our blood-based profiling offering for therapy selection, our expansion of our blood-based profiling offering beyond therapy selection in particular, and further leveraging our platform to provide solutions to biopharma companies will enable us to benefit significantly from this large market opportunity. Our estimated total addressable U.S. oncology market, which is based on a market study by Nephron Research LLC that we commissioned, is comprised of opportunities in the following areas:
•
Early detection:   approximately $100 billion.
​
•
Therapy selection:   approximately $8 billion.
​
•
MRD tracking and treatment monitoring:   approximately $28 billion.
​
•
Core biopharma services:   approximately $4 billion.
​
•
Data services for biopharma:   approximately $10 billion.
​
We also believe there is a large market opportunity for our platform in other chronic disease states beyond oncology, including cardiology, neurology, and metabolic conditions, based on the fundamental premise that approaching blood-based disease detection with a comprehensive WES/WTS approach enables examination of biomarkers that go beyond oncology. For additional information, see “Business—Our Market Opportunity and Vision for Leveraging Molecular Information.”
The Caris Advantage
We believe our approach is differentiated and we have a competitive advantage because:
•
We purpose-built our Caris platform to put the patient first and make comprehensive precision medicine a reality.
​
•
We are a leading provider of tissue-based molecular profiling, including through our FDA-approved companion diagnostic tissue-based profiling solution, MI Cancer Seek.
​
•
Our novel, universal blood-based profiling solution, Caris Assure, is unique in the market and poised for rapid adoption.
​
•
We have built what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology.
​
•
Our first mover advantage, specialized commercial channel, robust infrastructure, and deep research collaborations enable our leadership and provide us with the ability to scale for future growth.
​
•
We are led by a founder with significant experience building and scaling businesses in the healthcare industry and a management team with scientific expertise.
​
​
 
6

TABLE OF CONTENTS
 
Our Strategies
To achieve our goal of leading a molecular revolution and developing the next generation of precision medicine information solutions for a broad range of conditions across the care continuum, we plan to:
•
Drive the continued adoption and use of our tissue-based profiling and expand blood-based profiling offering into early detection, MRD, and monitoring.
​
•
Utilize the data generated by our existing solutions to develop new solutions with additional revenue using our existing sales channel.
​
•
Leverage our platform to provide solutions to biopharma companies to drive advances in personalized medicine and accelerate the development of novel therapeutics.
​
•
Continue to expand and enrich our clinico-genomic datasets to drive breakthrough science and develop new solutions.
​
•
Maximize market reach through our regulatory approval and reimbursement strategy.
​
•
Capitalize on the ultimate potential of our novel, universal blood-based profiling solution, Caris Assure, and broader innovation platform in other chronic disease states beyond oncology, including in cardiology, neurology, and metabolic conditions.
​
Caris Assure—Our Universal Blood-Based Profiling Solution
Caris Assure is our novel, universal blood-based solution that is purpose-built to extend across the entire continuum of cancer treatment, including early detection, monitoring of MRD and recurrent cancers, and precision selection of molecularly targeted therapies. Caris Assure also has applications in therapeutic discovery and development. We believe Caris Assure represents the most comprehensive blood-based solution on the market, featuring over 23,000 gene coverage at a raw average sequencing depth of coverage of 8,000 times for clinically relevant genes, as compared to other blood-based offerings in the market that only assess 500 to 1,000 genes from DNA. Caris Assure performs WES and WTS for every eligible patient blood sample. We integrate WES and WTS with sophisticated AI and ML technologies to offer diagnostic, prognostic, and predictive utility in a single test.
For therapy selection, in addition to sequencing cell-free DNA and cell-free RNA isolated from the plasma to identify somatic tumor variants, Caris Assure also sequences genomic nucleic acid (gDNA and gRNA) isolated from the white blood cells, or buffy coat, from each sample. Sequencing the buffy coat in addition to the plasma allows Caris Assure to identify incidental germline mutations as well as CH mutations. CH mutations are age-related non-malignant mutations that occur in a substantial portion of the population, are not cancer-derived and are present in both the plasma and buffy coat and cannot be identified from sequencing plasma alone. Caris Assure “subtracts” CH mutations in the reporting of somatic tumor variants. This lessens the risk of incorrectly interpreting CH or germline mutations as tumor-derived and results in fewer false positive diagnoses and more accurate and effective treatment recommendations. We believe that CH subtraction is of critical importance to ensure optimal cancer care because of the prevalence of CH mutations. By identifying and distinguishing variants that are not from the tumor itself and, therefore not relevant to therapeutic decision-making, the CH subtraction feature of Caris Assure further separates our solution from other liquid biopsy tests currently on the market that do not sequence the white blood cells and therefore cannot definitively distinguish CH mutations from tumor-derived mutations. To our knowledge, Caris Assure is the only commercially available tissue-naive blood-based profiling assay that directly accounts for CH mutations instead of using algorithmic approximations, which we believe gives Caris Assure a differentiated ability to drive improved therapy selection.
Customers for Caris Assure include treating physicians as well as researchers and biopharma companies. The same benefits that blood-based WES, WTS, and CH subtraction bring to patients in the clinical setting also offer significant and previously unavailable advantages to biopharma companies.
We initiated a broad commercial launch of Caris Assure for therapy selection in the first quarter of 2024 and currently offer the solution as a laboratory developed test (“LDT”), which is an in vitro diagnostic (“IVD”) test intended for clinical use and designed, manufactured, and used within a single laboratory.
 
7

TABLE OF CONTENTS
 
The FDA has historically exercised enforcement discretion and not required marketing authorization for LDTs. Accordingly, we have not yet obtained FDA marketing authorization for Caris Assure. We anticipate seeking FDA marketing authorization for certain of our solutions in the future, including Caris Assure for therapy selection, in part as a result of the FDA’s planned phase out of its enforcement discretion policy with respect to LDTs. For additional information, see “Business—Government Regulation—U.S. Food and Drug Administration.” We have Medicare reimbursement and various levels of commercial payer adoption and/or reimbursement coverage for Caris Assure for therapy selection across the United States. The current pricing of Caris Assure for therapy selection under Medicare’s Molecular Diagnostic Services Program (“MolDX”) is $3,649.
Caris Assure for therapy selection is available in all U.S. states (other than New York, where we intend to apply in 2025 for approval from New York State’s Clinical Laboratory Evaluation Program (“NY CLEP”)) and in Puerto Rico. We also offer Caris Assure for therapy selection internationally through distributors and direct contracts with hospital systems, where permitted by applicable regulations.
Our Differentiated Approach to Address the Entire Cancer Care Continuum Through a Single Blood Test
Our universal approach to blood-based profiling is unique. Liquid biopsies can be used across the care continuum, including for: therapy selection in the advanced/metastatic setting; MRD and monitoring in the curative/adjuvant setting; and early detection in the diagnosis setting. Because many of our competitors’ liquid biopsy assays are designed to address only a single portion of this care continuum, in order to develop products for other portions of the care continuum, our competitors must invest in the development of new wet lab assays and generate disparate datasets across the patient journey for patients, oncologists, and researchers. In contrast, Caris Assure is designed as a single test applicable across the entire patient journey. To our knowledge, there is no other assay on the market that can be applied as broadly as Caris Assure. We believe that our approach will enable us to scale our R&D infrastructure to analyze increasingly larger testing volumes, process expanding datasets, and reach economies of scale in liquid biopsy across the entire cancer care continuum.
We believe that one of the most promising uses for Caris Assure is for detection of cancer at very early stages, such as stage 1 or stage 2. Our detection of cancer at very early stages would enable clinicians to treat disease sooner, which could significantly improve patient outcomes. We believe that Caris Assure for early detection of cancers will initially be available for early detection of certain types of cancers, such as breast cancer and colon cancer, and then we intend to expand Caris Assure for full MCED indications. In an internal validation study conducted by us, the performance of our Assure Blood-based Cancer Detection ai (“ABCDai”) for MCED (“ABCDai-MCED”) demonstrated a high level of sensitivity at a specificity that reduces the burden of false positives. For additional information on the validation study, see “Business—​Our Solutions—Caris Assure—Our Universal Blood-Based Profiling Solution—Caris Assure for Early Detection.”
For MRD, our detection methodology based on ABCDai takes a tumor naïve approach, and therefore does not require a bespoke panel to be created to track the recurrence of a patient’s tumor. This approach means that our MRD assay can be used without the need for a tissue sample and enables faster turn-around-time, enabling patients to be informed of additional therapy sooner to combat their disease.
MI Profile—Our Tissue-Based Profiling Solution
MI Profile is our tissue-based molecular profiling solution for cancer therapy selection, with over one million tests performed on approximately 146,500 clinical cases in 2024 and an additional approximately 40,000 clinical cases in the three months ended March 31, 2025. As of March 31, 2025, we have performed over 6.5 million tissue-based tests on over 790,000 clinical cases since inception. MI Profile includes MI Cancer Seek, our FDA-approved companion diagnostic WES/WTS NGS assay, and IHC protein expression testing.
Customers for MI Profile include treating physicians as well as researchers and biopharma companies. The information generated from profiling the patient’s tissue is used to create an interpretative report based on our bioinformatics pipeline and recommend individualized therapies for cancer patients. Our goal is to maximize the information generated and corresponding clinical utility for patients from the
 
8

TABLE OF CONTENTS
 
limited available tumor tissue. Molecular profiling also has broad applications for our biopharma partners, including prospective screening, retrospective testing and deep translational analyses, stratification of patients for existing or future trials, and treatment monitoring.
We have obtained Medicare and commercial reimbursement for MI Profile. We have also obtained a premarket approval (“PMA”) from the FDA for a companion diagnostic and tumor profiling designation for MI Cancer Seek, a WES/WTS NGS assay that uses the whole exome for tumor mutational burden (“TMB”) calling, and for which we have obtained a Proprietary Laboratory Analyses (“PLA”) code, Current Procedural Terminology (‘‘CPT’’) code 0211U, at a reimbursement rate of $8,455. In the first quarter of 2025, we began to market MI Cancer Seek as the WES/WTS NGS component of MI Profile. We have obtained Medicare coverage for MI Cancer Seek for CPT code 0211U under the NGS NCD. We currently offer MI Tumor Seek Hybrid, which is a WES/WTS NGS LDT assay, as an alternative assay if a specimen does not meet the eligibility requirements for MI Cancer Seek.
MI Profile, including our MI Cancer Seek assay and proprietary clinical molecular signatures GPSai and FOLFIRSTai, is available in all U.S. states and in Puerto Rico. We also offer MI Profile internationally in over 40 countries through distributors and direct contracts with hospital systems, where permitted by applicable regulations.
[MISSING IMAGE: fc_clinicalmole-4c.jpg]
Caris Discovery
Caris Discovery is our drug target and therapeutic discovery business. Caris Discovery leverages our profiling solutions, multi-modal clinico-genomic datasets, wet lab facilities, proprietary Adaptive Dynamic Artificial Polyligand Targeting (“ADAPT”) platform, and AI/ML-enabled in silico analyses to identify potential drug targets and develop therapeutics. We launched Caris Discovery in 2022 to partner with biopharma partners to address the lack of novel cancer-specific targets and the herding of biopharma pipelines around a discrete number of lower-risk targets. Caris Discovery is disease- and modality-agnostic
 
9

TABLE OF CONTENTS
 
and can be applied to any therapeutic modality, including antibody-directed therapies (such as antibody drug conjugates, degrader-antibody conjugates, and T-cell engagers), small molecules, targeted protein degradation, synthetic lethal interactions, and cell therapy. We have achieved external validation of our Caris Discovery approach through strategic partnerships with established biopharma companies, such as Merck KGaA and Xencor, to develop therapeutics against novel targets that emanate from our molecular insights and proprietary technology. In addition, we believe Caris Discovery is well-positioned for neoantigen discovery for personalized therapy development given our ability to detect variants, insertions, and deletions by WES and to assess gene expression and detect fusions by WTS on every patient’s tumor.
Our proprietary repositories of tissue and data, each of which we believe to be at an unmatched scale, are a resource that could not have been amassed without our underlying commercial profiling business, and as such are a significant differentiator and enabler of our discovery efforts.
Caris Strategic Data
Data and molecular information are at the core of every aspect of our business. Our team of more than 60 data scientists deploy our proprietary advanced AI/ML algorithms to decipher unique features from our resulting clinico-genomic datasets, helping us decode and further unravel the molecular complexity of disease. Our 17-year history of utilizing AI and ML algorithms, together with the breadth and depth of our clinico-genomic datasets, provide us a significant advantage in sophisticated analysis of cancer, and a foundation that we believe will have applications in additional disease states.
The tremendous amount of data generated through our profiling solutions, which we have deidentified for research use, provides us a differentiated capability to advance precision oncology research through many business models. For example, we launched our data licensing business in late 2022, through which we license deidentified data that we have generated from our clinical profiling business to biopharma companies with the aim of generating insights directly responsible for superior clinical outcomes for patients. We have a rich pipeline of data opportunities that we believe will deliver new partnerships, as we continue to introduce biopharma companies to this unique data offering. Additionally, through the Caris POA, which is a growing network of leading cancer centers and research consortia across the globe, we support research partner engagement, collaboration opportunities, and the advancement of precision oncology research. Since its establishment in 2015, the Caris POA has grown to comprise 96 members as of March 31, 2025, including 45 NCI-designated comprehensive cancer centers that work collaboratively toward a common goal: to advance tumor profiling and establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. We estimate that the members of the Caris POA have over 3,000 oncologists in over 650 locations that treat more than 650,000 new cancer patients annually.
Future Assays
Caris aims to develop the next generation of precision medicine tools that will allow us to transition from intuitive medicine to empirical medicine. As a leader in the transition to WES/WTS sequencing through our launch of a WTS solution in 2019 and a WES solution the following year, we believe we have more molecular data and information than any other company and are well-positioned to make precision medicine widely accessible. For example, we are developing Caris ChromoSeq, an assay to detect and analyze hematological (blood) cancers using whole genome sequencing (“WGS”) and WTS. We are internally validating this assay and developing it for commercial launch. We are also working to develop and validate the plasma portion of our Caris Assure assay for full germline testing. Additionally, we are using our molecular data to develop ESPai, an AI/ML algorithm to predict the risk of recurrence of early-stage breast cancer. We have obtained the samples and clinical data from the National Surgical Adjuvant Breast and Bowel Project and the ECOG-ACRIN Cancer Research Group. We are currently in the process of creating two AI/ML models for ESPai using these samples and are working to obtain additional samples for external validation studies. We are initially creating a model for late recurrence (five to 15 years following diagnosis), but we are also in the beginning stages of creating a model for early recurrence (zero to five years following diagnosis).
 
10

TABLE OF CONTENTS
 
Caris Infrastructure
We believe our well-developed laboratory, R&D, and sales infrastructure is foundational to our business. We have substantial testing capacity, including over 275,000 square feet of space across four precision medicine laboratories with throughput capabilities of over one trillion reads per day generated by 50 NovaSeq sequencing systems. We believe this capacity provides us with ample capability to manage our current operations and future growth. We also have a dedicated R&D infrastructure, including a specialized laboratory and over 200 employees dedicated to R&D efforts. In addition to our internal research, we regularly partner with outside academic centers and researchers, including through the Caris POA. Additionally, to support our sales activity and expansion, as of March 31, 2025, we have assembled a targeted sales organization in the United States of over 270 sales team members and nearly 50 highly trained Ph.D. or M.D. molecular science liaisons (“MSLs”) who focus on physician and provider education. We believe that our robust, foundational infrastructure, together with our expansive multi-modal clinico-genomic datasets, has uniquely positioned Caris to deliver transformative and advanced innovations in precision medicine and patient care into the future.
Summary Risk Factors
Participating in this offering involves substantial risk. Our ability to execute our strategy is also subject to certain risks. The risks described under the heading “Risk Factors” included elsewhere in this prospectus may cause us not to realize the full benefits of our strengths or may cause us to be unable to successfully execute all or part of our strategy. Some of the most significant challenges and risks we face include the following:
•
The precision medicine industry is highly competitive and subject to rapid change.
​
•
We have incurred significant losses since inception, expect to incur losses in the future, and may not be able to generate sufficient revenue to achieve and maintain profitability.
​
•
Our current or future solutions may not achieve or maintain sufficient commercial market acceptance.
​
•
Our solutions may not perform as expected, and the results of our validation studies or our clinical trials may not support the launch or use of our solutions and may not comply with the requirements, or be replicated in later trials required, for any necessary or desirable marketing authorizations. This could adversely affect our business, financial condition, results of operations, and growth prospects.
​
•
Our current revenue is primarily generated from the continued adoption and use of our tissue-based profiling solution.
​
•
Our future success and growth will depend in part on market acceptance and commercial success of our MI Cancer Seek and Caris Assure solutions. We may be unsuccessful in continuing the commercialization of MI Cancer Seek or Caris Assure, which would adversely affect our business, financial condition, results of operations, and growth prospects.
​
•
If we are unable to support demand for MI Profile, Caris Assure, and any other solutions we develop, including ensuring that we have adequate capacity to meet increased demand, or if we are unable to successfully manage our anticipated growth, our business could suffer.
​
•
Our results of operations may fluctuate significantly, which makes our future results of operations difficult to predict and could cause our results of operations to fall below expectations or any guidance we may provide.
​
•
If our solutions, or solutions we develop in the future, do not receive adequate coverage and reimbursement from third-party payers, including government and commercial payers, our ability to expand access to our solutions beyond our existing sales channels, and thus our overall commercial success, will be limited.
​
•
Our billing, collections, and claims processing activities are complex and time-consuming, and any delay in transmitting and collecting claims or failure to comply with applicable billing requirements could have an adverse effect on our future revenue.
​
​
 
11

TABLE OF CONTENTS
 
•
We rely on a limited number of third-party suppliers or, in many cases, sole suppliers, for some of our next-generation sequencers, lab materials, reagents, and supplies, and we may not be able to find replacements or immediately transition to alternative suppliers if necessary.
​
•
If we or our partners fail to comply with healthcare and other applicable laws and regulations, we could face substantial penalties and sanctions and our business, reputation, financial condition, and results of operations could be adversely affected.
​
•
If we are unable to obtain and maintain intellectual property protection for our technology, or if the scope of the intellectual property protection we obtain is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to our solutions, and our ability to successfully commercialize our solutions may be impaired.
​
•
We have incurred substantial indebtedness, and we may not generate sufficient cash flow from operations to meet our debt service requirements, continue our operations, and pursue our growth strategy, and we may be unable to raise capital when needed or on acceptable terms.
​
•
The dual class structure of our common stock will have the effect of concentrating voting control with our founder and the other shareholders who held our capital stock prior to the completion of this offering, including our executive officers, directors, principal shareholders, and their respective affiliates, which will limit the ability of our other shareholders to affect the outcome of key corporate decisions and transactions, including a change of control.
​
•
Following this offering, we may become a “controlled company” within the meaning of the rules of Nasdaq and, as a result, would qualify for, and could rely on, exemptions from certain corporate governance requirements. In such event, you would not have the same protections afforded to shareholders of companies that are subject to such requirements.
​
Before you invest in our Class A common stock, you should carefully consider all the information in this prospectus, including matters set forth in the section titled “Risk Factors.”
Corporate Information
We were founded in 2008 when we entered the field of precision oncology through our acquisition of Molecular Profiling Institute, a Delaware-incorporated molecular life sciences company. We were incorporated under the laws of the Cayman Islands in October 2011 as Caris Life Sciences, Ltd. and in July 2020, we changed our name to Caris Life Sciences, Inc. and re-domiciled to be incorporated in Texas.
Our principal executive offices are located at 750 West John Carpenter Freeway, Suite 800, Irving, Texas 75039, and our telephone number is (866) 771-8946. Our website address is www.carislifesciences.com. The information on, or that can be accessed through, our website is not incorporated into this prospectus. You should not consider information contained on our website to be part of this prospectus in deciding whether to purchase shares of our Class A common stock.
Implications of Being an Emerging Growth Company
We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”). We will remain an emerging growth company until the earliest to occur of: (i) the last day of the fiscal year in which we have at least $1.235 billion in total annual gross revenue; (ii) the last day of the fiscal year in which we are deemed to be a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which would occur if the market value of our Class A common stock held by non-affiliates exceeded $700 million as of the last business day of the second fiscal quarter of such year; (iii) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (iv) the last day of the fiscal year ending after the fifth anniversary of the date of the completion of this offering. An emerging growth company may take advantage of specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company:
 
12

TABLE OF CONTENTS
 
•
we will present in this prospectus only two years of audited financial statements, plus any required unaudited financial statements, and related management’s discussion and analysis of financial condition and results of operations;
​
•
we will avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (“SOX Section 404”);
​
•
we will provide less extensive disclosure about our executive compensation arrangements; and
​
•
we will not be required to hold shareholder non-binding advisory votes on executive compensation or golden parachute arrangements.
​
Accordingly, the information contained herein may be different than the information you receive from our competitors that are public companies or other public companies in which you hold stock.
In addition, the JOBS Act provides that an emerging growth company can delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period for complying with new or revised accounting standards and, as a result, our results of operations and financial statements may not be comparable to those of companies that have adopted the new or revised accounting standards.
 
13

TABLE OF CONTENTS
 
THE OFFERING
Class A common stock offered by us
           shares.
Option to purchase additional shares of Class A common stock
We have granted the underwriters an option for a period of 30 days to purchase up to             additional shares of our Class A common stock.
Class A common stock to be outstanding immediately after this offering
           shares (or             shares if the underwriters exercise their option to purchase additional shares of Class A common stock in full).
Class B common stock to be outstanding immediately after this offering
          shares.
Total common stock to be outstanding immediately after this offering
          shares (or        shares if the underwriters exercise their option to purchase additional shares of Class A common stock in full).
Reserved share program
At our request, the underwriters have reserved up to     % of the shares of Class A common stock offered by this prospectus, excluding the additional shares that the underwriters have a 30-day option to purchase, for sale, at the initial public offering price, to certain individuals identified by management, including certain of our directors, officers, employees and certain other parties related to us. If these persons purchase reserved shares it will reduce the number of shares of Class A common stock available for sale to the general public. Any reserved shares of Class A common stock that are not so purchased will be offered by the underwriters to the general public on the same terms as the other shares of Class A common stock offered by this prospectus. For more information, see “Underwriting —  Reserved Share Program.”
Use of proceeds
We estimate that the net proceeds from this offering will be approximately $      million (or $      million if the underwriters exercise their option to purchase additional shares of Class A common stock in full), based on an assumed initial public offering price of $      per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
We intend to use the net proceeds from this offering for general corporate purposes, including working capital, operating expenses, and capital expenditures. We also intend to use approximately $     million of the net proceeds, together with existing cash and cash equivalents, if necessary, to satisfy our anticipated tax withholding and remittance obligations related to the RSU Net Settlement (as defined below). We will have broad discretion in the way that we use the net proceeds from this offering. See the section titled “Use of Proceeds” for additional information.
Voting rights
Following the completion of this offering, we will have two classes of common stock: Class A common stock and Class B
 
14

TABLE OF CONTENTS
 
common stock. Our Class A common stock will be entitled to one vote per share, and shares of our Class B common stock will be entitled to 10 votes per share. Holders of our Class A common stock and Class B common stock will generally vote together as a single class, unless otherwise required by law or our amended and restated certificate of formation.
The holders of our outstanding Class B common stock will collectively hold approximately      % of the voting power of our outstanding capital stock immediately following the completion of this offering, with our executive officers, directors, principal shareholders, and their respective affiliates collectively holding approximately      % of the voting power of our outstanding capital stock. These shareholders will have the ability to exercise significant influence over the outcome of matters submitted to our shareholders for approval, including the election of our directors and the approval of any change of control transaction. See the sections titled “Principal Shareholders” and “Description of Capital Stock” for additional information.
Following the completion of this offering, each share of our Class B common stock will be convertible into one share of our Class A common stock at any time and will convert automatically upon certain transfers and upon certain other circumstances as described in our amended and restated certificate of formation. See the section titled “Description of Capital Stock — Common Stock — Conversion” for additional information.
Controlled company
David D. Halbert, our Founder, Chairman, and Chief Executive Officer, will beneficially own shares of common stock representing approximately     % of our outstanding shares of capital stock and approximately     % of the voting power of our outstanding capital stock, assuming in each case, no exercise by the underwriters of their option to purchase additional shares of Class A common stock. As a result, Mr. Halbert will have the ability to exercise significant influence over the outcome of matters submitted to our shareholders for approval, including the election of our directors and the approval of any change of control transaction, and, following this offering, we may become a “controlled company” as defined under the corporate governance rules of the Nasdaq.
Risk factors
See the section titled “Risk Factors” beginning on page 21 and the other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our Class A common stock.
Proposed Nasdaq trading symbol
“CAI”
The number of shares of our common stock to be outstanding after this offering is based on        shares of our Class A common stock and        shares of our Class B common stock outstanding as of March 31, 2025, after giving effect to (i) the Warrant Exercise, (ii) the Series E and F Issuance, (iii) the Preferred Stock Conversion, (iv) the issuance of the 2025 Convertible Notes and the related Notes Conversion, (v) the Common Stock Reclassification, and (vi) the RSU Net Settlement (each as defined below), and excludes:
 
15

TABLE OF CONTENTS
 
•
          shares of our Class A common stock issuable upon the exercise of options outstanding under our 2020 Incentive Plan, as amended and restated (the “2020 Plan”), as of March 31, 2025, at a weighted-average exercise price of $      per share;
​
•
          shares of our Class A common stock issuable upon the exercise of options granted under our 2020 Plan subsequent to March 31, 2025, at a weighted-average exercise price of $      per share;
​
•
       shares of our Class A common stock issuable upon the vesting and settlement of restricted stock units (‘‘RSUs”) granted under our 2020 Plan that are held by current executive officers, employees, directors, and consultants and are subject to vesting conditions that are not satisfied in connection with this offering;
​
•
       shares of our Class B common stock issuable upon the exercise of options held by David D. Halbert that were outstanding under our 2020 Plan as of March 31, 2025, at a weighted-average exercise price of $     per share;
​
•
       shares of our Class B common stock issuable upon the exercise of warrants issued in April 2025 at an exercise price of $0.01 per share (the “2025 Warrants”), based on an assumed initial public offering price of $     per share, which is the midpoint of the price range set forth on the cover page of this prospectus;
​
•
          shares of our Class A common stock reserved for future issuance under our 2025 Incentive Award Plan (the “2025 Plan”), which will become effective in connection with this offering, as well as shares of our Class A common stock that may be issued pursuant to provisions of our 2025 Plan that automatically increase the share reserve under our 2025 Plan; and
​
•
          shares of our Class A common stock reserved for future issuance under our 2025 Employee Stock Purchase Plan (the “ESPP”), which will become effective in connection with this offering, as well as shares of our Class A common stock that may be issued pursuant to provisions in our ESPP that automatically increase the share reserve under our ESPP.
​
Unless otherwise indicated, all information in this prospectus assumes:
•
a one-for-       reverse stock split of our common stock effected as of            , 2025;
​
•
the issuance of             shares of our Series C preferred stock upon the assumed exercise of warrants outstanding as of March 31, 2025, which warrants are exercisable to purchase, at the holder’s election, shares of either our common stock or our Series C preferred stock and will expire upon the completion of this offering unless earlier exercised (the “Warrant Exercise”);
​
•
the conversion of (i) all shares of our convertible preferred stock outstanding as of March 31, 2025 (including the            shares of Series C preferred stock issued upon the Warrant Exercise) and (ii) all shares of our Series E and Series F convertible preferred stock issued and sold in April 2025 (such issuance and sale, the “Series E and F Issuance”), into an aggregate of           shares of our common stock, which will occur immediately prior to and in connection with the completion of this offering (the “Preferred Stock Conversion”);
​
•
the issuance of            shares of our common stock upon the conversion of senior convertible notes issued by us in April 2025 (the “2025 Convertible Notes”), which conversion will occur immediately prior to and in connection with the completion of this offering (the “Notes Conversion”), based on an assumed initial public offering price of $      per share, which is the midpoint of the price range set forth on the cover page of this prospectus;
​
•
the effectiveness of our amended and restated certificate of formation, which, among other things, will reclassify all outstanding shares of our common stock (including shares issued pursuant to the Warrant Exercise, the Preferred Stock Conversion, and the Notes Conversion) into an equivalent number of shares of our Class B common stock (the “Common Stock Reclassification”) and which will occur immediately prior to the completion of this offering;
​
​
 
16

TABLE OF CONTENTS
 
•
the reclassification of all shares of common stock underlying equity awards outstanding under our 2020 Plan into                    shares of our Class A common stock and                    shares of our Class B common stock (in the case of equity awards held by David D. Halbert), which will occur immediately prior to the completion of this offering;
​
•
the net issuance of            shares of our Class A common stock underlying RSUs outstanding under our 2020 Plan that are held by current executive officers, employees, directors, and consultants and will vest in connection with this offering, after giving effect to the withholding of      shares of our Class A common stock to satisfy the estimated tax withholding and remittance obligations (based on an assumed initial offering price of $     per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and an assumed tax withholding rate of     %) (the “RSU Class A Net Settlement”);
​
•
the net issuance of            shares of our Class B common stock underlying RSUs outstanding under our 2020 Plan that are held by David D. Halbert and will vest in connection with this offering, after giving effect to the withholding of            shares of our Class B common stock to satisfy the estimated tax withholding and remittance obligations (based on an assumed initial offering price of $         per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and an assumed tax withholding rate of      %) (the “RSU Class B Net Settlement” and, together with the RSU Class A Net Settlement, the “RSU Net Settlement”);
​
•
the adoption of our amended and restated bylaws, which will occur immediately prior to the completion of this offering;
​
•
no exercise by the underwriters of their option to purchase additional shares of Class A common stock; and
​
•
no exercise of outstanding options or settlement of outstanding RSUs except as described above.
​
The assumed tax withholding rates applicable to the RSU Net Settlement used in this prospectus are estimates. The estimates in this prospectus relating to the RSU Net Settlement and related share withholding may differ from actual results due to, among other things, the actual initial public offering price and other terms of this offering determined at pricing, actual forfeitures through the date of this prospectus, and actual tax withholding rates.
 
17

TABLE OF CONTENTS
 
SUMMARY CONSOLIDATED FINANCIAL AND OTHER DATA
The following tables set forth a summary of our historical consolidated financial and other data as of, and for the periods ended on, the dates indicated. The summary consolidated statements of operations data for the years ended December 31, 2024 and 2023 and the summary consolidated balance sheet data as of December 31, 2024 are derived from our audited consolidated financial statements and related notes included elsewhere in this prospectus. The summary consolidated statements of operations data for the three months ended March 31, 2025 and 2024 and the summary consolidated balance sheet data as of March 31, 2025 are derived from our unaudited condensed consolidated financial statements and related notes included elsewhere in this prospectus. In our opinion, the unaudited interim financial statements have been prepared on a basis consistent with our audited financial statements and contain all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of such interim financial statements.
Our historical results are not necessarily indicative of results that may be expected in the future. You should read these data together with our financial statements and related notes appearing elsewhere in this prospectus and the information in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
​ ​ ​
Three Months Ended March 31,
​ ​
Years Ended December 31,
​
​ ​ ​
2025
​ ​
2024
​ ​
2024
​ ​
2023
​
​ ​ ​
(in thousands, except
per share data)
​
Consolidated Statements of Operations Data: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Molecular profiling services
​ ​ ​ $ 114,081 ​ ​ ​ ​ $ 73,233 ​ ​ ​ ​ $ 349,115 ​ ​ ​ ​ $ 278,748 ​ ​
Pharma research and development services
​ ​ ​ ​ 6,834 ​ ​ ​ ​ ​ 7,444 ​ ​ ​ ​ ​ 63,145 ​ ​ ​ ​ ​ 27,380 ​ ​
Total revenue
​ ​ ​
​
120,915
​ ​ ​ ​
​
80,677
​ ​ ​ ​
​
412,260
​ ​ ​ ​
​
306,128
​ ​
Costs and operating expenses: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Cost of services–Molecular profiling services
​ ​ ​ ​ 60,894 ​ ​ ​ ​ ​ 52,894 ​ ​ ​ ​ ​ 223,075 ​ ​ ​ ​ ​ 207,509 ​ ​
Cost of services–Pharma research and development services
​ ​ ​ ​ 2,958 ​ ​ ​ ​ ​ 1,669 ​ ​ ​ ​ ​ 10,403 ​ ​ ​ ​ ​ 9,309 ​ ​
Selling and marketing expense
​ ​ ​ ​ 39,829 ​ ​ ​ ​ ​ 39,609 ​ ​ ​ ​ ​ 152,602 ​ ​ ​ ​ ​ 142,925 ​ ​
General and administrative expense
​ ​ ​ ​ 52,119 ​ ​ ​ ​ ​ 44,354 ​ ​ ​ ​ ​ 169,386 ​ ​ ​ ​ ​ 149,053 ​ ​
Research and development expense
​ ​ ​ ​ 23,066 ​ ​ ​ ​ ​ 34,376 ​ ​ ​ ​ ​ 113,916 ​ ​ ​ ​ ​ 116,883 ​ ​
Total costs and operating expenses
​ ​ ​ ​ 178,867 ​ ​ ​ ​ ​ 172,902 ​ ​ ​ ​ ​ 669,382 ​ ​ ​ ​ ​ 625,679 ​ ​
Loss from operations
​ ​ ​
​
(57,952)
​ ​ ​ ​
​
(92,225)
​ ​ ​ ​
​
(257,122)
​ ​ ​ ​
​
(319,551)
​ ​
Other income (expense), net: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Interest income
​ ​ ​ ​ 503 ​ ​ ​ ​ ​ 1,768 ​ ​ ​ ​ ​ 7,122 ​ ​ ​ ​ ​ 11,258 ​ ​
Interest expense
​ ​ ​ ​ (12,782) ​ ​ ​ ​ ​ (9,290) ​ ​ ​ ​ ​ (50,025) ​ ​ ​ ​ ​ (31,610) ​ ​
Changes in fair value of financial instruments
​ ​ ​ ​ (32,333) ​ ​ ​ ​ ​ (11,064) ​ ​ ​ ​ ​ 18,484 ​ ​ ​ ​ ​ 11,094 ​ ​
Other expense, net
​ ​ ​ ​ (17) ​ ​ ​ ​ ​ (219) ​ ​ ​ ​ ​ (349) ​ ​ ​ ​ ​ (12,606) ​ ​
Total other expense, net
​ ​ ​
​
(44,629)
​ ​ ​ ​
​
(18,804)
​ ​ ​ ​
​
(24,768)
​ ​ ​ ​
​
(21,864)
​ ​
Loss before income taxes and provision for income taxes
​ ​ ​
​
(102,581)
​ ​ ​ ​
​
(111,028)
​ ​ ​ ​
​
(281,890)
​ ​ ​ ​
​
(341,415)
​ ​
Provision for income taxes
​ ​ ​
​
—
​ ​ ​ ​
​
—
​ ​ ​ ​
​
—
​ ​ ​ ​
​
—
​ ​
Net loss
​ ​ ​
$
(102,581)
​ ​ ​ ​
$
(111,028)
​ ​ ​ ​
$
(281,890)
​ ​ ​ ​
$
(341,415)
​ ​
Adjustments of redeemable convertible preferred stock to redemption value
​ ​ ​ ​ (24,262) ​ ​ ​ ​ ​ (23.113) ​ ​ ​ ​ ​ (96,367) ​ ​ ​ ​ ​ (121,112) ​ ​
Net loss attributable to common shareholders
​ ​ ​
$
(127,043)
​ ​ ​ ​
$
(134,141)
​ ​ ​ ​
$
(378,257)
​ ​ ​ ​
$
(462,527)
​ ​
Net loss per share attributable to common shareholders, basic and diluted(1)
​ ​ ​ $ (0.89) ​ ​ ​ ​ $ (0.95) ​ ​ ​ ​ $ (2.66) ​ ​ ​ ​ $ (3.31) ​ ​
 
18

TABLE OF CONTENTS
 
​ ​ ​
Three Months Ended March 31,
​ ​
Years Ended December 31,
​
​ ​ ​
2025
​ ​
2024
​ ​
2024
​ ​
2023
​
​ ​ ​
(in thousands, except
per share data)
​
Weighted-average shares used to compute net loss per share attributable to common shareholders, basic and diluted(1)
​ ​ ​ ​ 142,492 ​ ​ ​ ​ ​ 141,252 ​ ​ ​ ​ ​ 141,987 ​ ​ ​ ​ ​ 139,771 ​ ​
Pro forma net loss per share attributable to common shareholders, basic and diluted (unaudited)(1)(2)
​ ​ ​ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ ​ ​ ​ ​ ​ ​ ​ ​ ​
Weighted-average shares used to compute pro forma net loss per share attributable to common shareholders, basic and diluted (unaudited)(1)(2)
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
​
(1)
See Note 12 to our consolidated financial statements included elsewhere in this prospectus for an explanation of the method used to calculate our historical basic and diluted net loss per share attributable to common shareholders and the weighted-average number of shares of common stock used in the computation of these per share amounts.
​
(2)
Gives effect to (i) the Warrant Exercise, (ii) the Series E and F Issuance, (iii) the Preferred Stock Conversion, (iv) the issuance of the 2025 Convertible Notes and the related Notes Conversion, (v) the Common Stock Reclassification, and (vi) the RSU Net Settlement.
​
​ ​ ​
As of March 31, 2025
​
​ ​ ​
Actual
​ ​
Pro Forma(1)
​ ​
Pro Forma
As Adjusted(2)(3)
​
​ ​ ​
(in thousands)
​
Consolidated Balance Sheet Data: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Cash and cash equivalents
​ ​ ​ $ 31,201 ​ ​ ​ ​ $       ​ ​ ​ ​ $            ​ ​
Working capital(4)
​ ​ ​ ​ 8,679 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Total assets
​ ​ ​ ​ 291,583 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Total liabilities
​ ​ ​ ​ 645,335 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Total shareholders’ (deficit) equity
​ ​ ​ ​ (2,599,865) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
(1)
Gives effect to (i) the Warrant Exercise, (ii) the Series E and F Issuance, (iii) the Preferred Stock Conversion, (iv) the issuance of the 2025 Convertible Notes and the related Notes Conversion, (v) the Common Stock Reclassification, and (vi) the RSU Net Settlement.
​
(2)
Gives effect to (i) the pro forma adjustments described in footnote (1) above, (ii) the sale by us of                 shares of Class A common stock in this offering at an assumed initial public offering price of $      per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, and (iii) the use of approximately $     million of the net proceeds from this offering, together with existing cash and cash equivalents, if necessary, to satisfy our anticipated tax withholding and remittance obligations related to the RSU Net Settlement.
​
(3)
Each $1.00 increase (decrease) in the assumed initial public offering price of $      per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets, and total shareholders’ (deficit) equity by approximately $      million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1,000,000 in the number of shares of Class A common stock we are offering would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets, and total shareholders’ (deficit) equity by approximately $      million, assuming the assumed initial public offering price per share remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Pro forma adjustments in this footnote and the footnotes above, as
​
​
 
19

TABLE OF CONTENTS
 
well as the related information in the balance sheet data, are illustrative only and will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing.
(4)
We define working capital as current assets, less current liabilities. See our consolidated financial statements and related notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities.
​
Non-GAAP Financial Measures
​ ​ ​
Three Months Ended March 31,
​ ​
Years Ended December 31,
​
​ ​ ​
2025
​ ​
2024
​ ​
2024
​ ​
2023
​
​ ​ ​
(in thousands)
​ ​ ​
Adjusted EBITDA
​ ​ ​ $ (36,216) ​ ​ ​ ​ $ (70,062) ​ ​ ​ ​ $ (189,566) ​ ​ ​ ​ $ (255,309) ​ ​
Free cash flow
​ ​ ​ $ (34,027) ​ ​ ​ ​ $ (75,663) ​ ​ ​ ​ $ (253,643) ​ ​ ​ ​ $ (298,419) ​ ​
We use Adjusted EBITDA and free cash flow, financial measures not calculated in accordance with generally accepted accounting principles in the United States (“GAAP”) to supplement our consolidated financial statements, which are presented in accordance with GAAP. We believe the non-GAAP financial measures we use, Adjusted EBITDA and free cash flow, are useful in evaluating our performance and liquidity. Our non-GAAP financial measures have limitations as analytical tools, however, and you should not consider them in isolation or as substitutes for analysis of our results as reported under GAAP.
We define Adjusted EBITDA as net loss, adjusted to exclude interest income, interest expense, changes in fair value of financial instruments, other expense, net, the provision for (benefit from) income taxes, depreciation and amortization, and stock-based compensation expense. We use Adjusted EBITDA in conjunction with GAAP measures as part of our overall assessment of our performance, including the preparation of our annual operating budget and quarterly forecasts, to evaluate the effectiveness of our business strategies, and to communicate with our board of directors concerning our financial performance. We believe Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and board of directors. Adjusted EBITDA provides a useful measure for period-to-period comparisons of our business, as it removes the effect of certain non-cash expenses and certain variable charges. We define free cash flow as net cash used in operating activities less purchases of property and equipment. We believe free cash flow is a useful measure of liquidity that provides an additional basis for assessing our ability to generate cash. For additional information regarding Adjusted EBITDA and free cash flow, including a reconciliation of these measures to the most directly comparable financial measure calculated in accordance with GAAP, see the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures.”
 
20

TABLE OF CONTENTS​
 
RISK FACTORS
Investing in our Class A common stock involves risk. You should carefully consider the risks described below, as well as the other information in this prospectus, including our financial statements and the related notes and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this prospectus, before deciding whether to invest in our Class A common stock. This prospectus also contains forward-looking statements that involve risks and uncertainties. See the section titled “Special Note Regarding Forward-Looking Statements.” The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, and growth prospects. In such an event, the market price of our Class A common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.
Risks Related to Our Business and Industry
The precision medicine industry is highly competitive and subject to rapid change.
Our industry is highly competitive and characterized by rapid changes, including technological and scientific breakthroughs, frequent new product introductions and enhancements, and evolving industry standards. Our future success will depend on our ability to compete successfully and keep pace with the evolving needs of physicians, patients, and our biopharma partners on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of technological and scientific advances. In recent years, there have been numerous advances in technologies relating to the diagnosis and treatment of cancer and advances in methods used to analyze large amounts of genomic information. We must continuously enhance our proprietary profiling and signature offerings and develop new solutions in a cost-effective way to achieve meaningful innovation in precision oncology and other chronic disease states. If we do not update our suite of solutions to reflect new scientific knowledge or technological advancements, including as they relate to precision medicine, therapeutic developments, or relevant validation studies or clinical trials, adoption and use of our current solutions and any new solutions we may develop could decline, which would adversely affect our business, financial condition, and results of operations.
Moreover, as an AI TechBio company that has experienced significant recent growth in the rapidly evolving field of precision medicine, our current business, our future success, and the risks and challenges we may encounter can be difficult to evaluate or accurately predict. If we fail to address the risks and difficulties that we face, including those described elsewhere in this “Risk Factors” section, our business, financial condition, and results of operations could be adversely affected. We have encountered in the past, and expect to encounter in the future, risks and difficulties frequently experienced by companies operating in rapidly evolving fields. If our assumptions regarding these risks and difficulties, which we use to plan and operate our business, are incorrect or change, or if we do not address these risks and difficulties, our results of operations could differ materially from our or your expectations, and our business, financial condition, and results of operations could be adversely affected.
We have incurred significant losses since inception, expect to incur losses in the future, and may not be able to generate sufficient revenue to achieve and maintain profitability.
We have incurred significant losses since our inception. For the years ended December 31, 2024 and 2023, we incurred net losses of $281.9 million and $341.4 million, respectively. For the three months ended March 31, 2025 and 2024, we incurred net losses of $102.6 million and $111.0 million, respectively. As of March 31, 2025, we had an accumulated deficit of $2.6 billion. To date, we have financed our operations principally from the sale of convertible preferred stock, the incurrence of indebtedness, and revenue from molecular profiling and pharma R&D services. Over the last 17 years, we have devoted significant resources towards developing our current portfolio that consists of tissue- and blood-based profiling solutions, building our multi-modal clinico-genomic datasets, expanding our operational capacity, and strengthening our AI/ML-driven data analysis capabilities. We also devote significant resources to clinical and regulatory initiatives to obtain marketing authorization, sales and marketing activities, and R&D activities. We anticipate incurring significant costs to continue developing and commercializing our solutions.
 
21

TABLE OF CONTENTS
 
In addition, because of the various risks and uncertainties associated with developing and commercializing our solutions, we are unable to predict the extent of future costs that may impact our prospects for profitability. Our future expenses will depend, in part, on the level of our expenditures and our ability to generate revenue at scale. We expect to continue to incur significant expenses and operating losses for the foreseeable future if and as we, among other things:
•
attract, hire, and retain qualified personnel;
​
•
continue our R&D activities and scale our R&D infrastructure;
​
•
expand our laboratory capacity and operating capabilities, including completing the build-out of our laboratory facility in Irving, Texas;
​
•
further build our sales, marketing, and distribution infrastructure;
​
•
continue to invest in the expansion and enrichment of our clinico-genomic datasets and related analysis capabilities;
​
•
seek marketing authorization that may be necessary or desired for our solutions;
​
•
obtain, maintain, protect, and enforce our intellectual property portfolio, including intellectual property obtained through license agreements;
​
•
meet the requirements and demands of being a public company; and
​
•
defend against any claims or other lawsuits related to our solutions or otherwise.
​
Our expenses could increase beyond expectations if we are required by the FDA or other regulatory agencies to delay the launch of any new solutions, narrow or change our intended use or product claims, modify or expand our clinical trials or to perform additional clinical trials, either pre- or post-approval, in addition to those that we currently anticipate.
We will also need to generate significant additional revenue to achieve and then sustain profitability, and even if we achieve profitability, we cannot be sure that we will remain profitable for any substantial period of time. While we have commercially launched MI Cancer Seek, a new WES/WTS NGS assay, in the United States and seek to drive its increased adoption, and also plan to capitalize on the potential of Caris Assure applications for early detection, MRD tracking, and treatment monitoring and in chronic disease states beyond oncology, we cannot assure you that we will successfully be able to do so as planned, if at all, and our failure to do so may prevent us from generating increased revenue. Our failure to achieve or maintain profitability could negatively impact the value of our Class A common stock.
Our current or future solutions may not achieve or maintain sufficient commercial market acceptance.
The commercial success of any of our solutions, including MI Profile and Caris Assure, or solutions that are marketed in the future, will depend upon the degree of commercial market acceptance, including by government payers, insurance companies, integrated health systems, healthcare providers, patients, biopharma companies and other third-party payers. The degree of market acceptance of our solutions will depend on a number of factors, including:
•
the performance and clinical utility of such solutions as demonstrated in clinical trials and published in peer-reviewed journals;
​
•
the rate of adoption and/or endorsement of our solutions by clinicians, KOLs, advocacy groups, and biopharma companies;
​
•
the ability of our newer solutions, such as Caris Assure, and solutions that may be marketed in the future, to demonstrate the same performance in real-world intended use populations as in clinical trials or analytical or clinical validation studies;
​
•
the willingness of medical providers to utilize our solutions as they are commercially released;
​
•
the willingness of commercial third-party payers and government payers to cover and reimburse for our solutions;
​
 
22

TABLE OF CONTENTS
 
•
the development or introduction of competing products, including the expansion of the capabilities of existing products;
​
•
the market acceptance of existing competitive products, including tests that are currently reimbursed;
​
•
publicity concerning our solutions or competing products; and
​
•
the strength of our marketing and sales support.
​
We cannot assure you that we will be successful in addressing each of these factors or other factors that might affect the market acceptance of our solutions. Failure to achieve broad market acceptance of our solutions, would harm our business, financial condition, and results of operations. For additional information, see “—Our current revenue is primarily generated from the continued adoption and use of our tissue-based profiling solution, and we are highly dependent on it for our success” and “—Our future success and growth will depend in part on market acceptance and commercial success of our MI Cancer Seek and Caris Assure solutions. We may be unsuccessful in continuing the commercialization of MI Cancer Seek or Caris Assure, which would adversely affect our business, financial condition, results of operations, and growth prospects.”
Our solutions may not perform as expected, and the results of our validation studies or our clinical trials may not support the launch or use of our solutions and may not comply with the requirements, or be replicated in later trials required, for any necessary or desirable marketing authorizations. This could adversely affect our business, financial condition, results of operations, and growth prospects.
Our success depends on the market and the medical community’s confidence that we can provide reliable, high-quality solutions, as well as our ability to complete validation studies and clinical trials and comply with applicable regulatory requirements that would allow us to commercialize our solutions. Our solutions, including MI Cancer Seek, for which we have obtained PMA approval from the FDA, MI Tumor Seek Hybrid, and Caris Assure, may not perform as expected, and the results obtained from our ongoing or future studies and trials may be inconsistent with certain results obtained from our previous studies or trials. In addition, the application of Caris Assure in early detection, MRD tracking, and treatment monitoring, for which we are still collecting preliminary data to support, may not be as effective as we anticipate. If Caris Assure or our other solutions are ineffective or do not consistently perform as expected, either before or after launch, our business, financial condition, results of operations, and growth prospects would suffer.
Our solutions require a number of complex and sophisticated biochemical and bioinformatics processes, many of which are highly sensitive to external factors. An operational or technological failure in one of these complex processes or fluctuations in external variables may result in sensitivity and specificity rates that are lower than we anticipate or that vary between test runs or in a higher than anticipated number of tests that fail to produce consistent results. In addition, we regularly evaluate and refine our AI/ML algorithms and other processes under development. These refinements may inadvertently result in unanticipated issues that may reduce our sensitivity and specificity rates or otherwise adversely affect the performance of our solutions and their results, such that supplemental submissions to the FDA may be required.
We have obtained a PMA approval from the FDA for MI Cancer Seek and intend to seek FDA approval for Caris Assure and additional solutions, though the timing thereof is uncertain. The FDA and other regulators may request additional information or require that we generate additional clinical data to support such future approval applications, which could result in delays, increased costs, or other limitations on our ability to receive such approval. Additionally, the FDA included certain conditions of approval and limitations in the PMA approval letter for MI Cancer Seek, namely that we submit data evaluating the effects of interfering substances such as necrotic tissue, melanin, and fatty acids and also conduct a study and submit data regarding formalin-fixed paraffin-embedded block and slide stability duration claims. Our failure to comply with these limitations and conditions could result in the withdrawal of the PMA approval for MI Cancer Seek. Furthermore, in May 2024, the FDA finalized an amendment to its regulations via issuance of a final rule pursuant to which it plans to subject LDTs to medical device requirements through a phase-out of its historical policy of enforcement discretion over LDTs over a period of four years. On March 31,
 
23

TABLE OF CONTENTS
 
2025, the United States District Court for the Eastern District of Texas vacated the FDA's LDT final rule. The phase-in of medical device requirements to LDTs, including the potential requirement for FDA marketing authorization, will be costly and time-consuming, and if we fail to comply with such requirements, or if we cannot ultimately obtain marketing authorization for our LDTs where required, our business, financial condition, and results of operation could be adversely affected. For additional information, see “—Risks Related to Regulation and Legal Compliance—The marketing authorization processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and unpredictable. If we are ultimately unable to obtain any necessary or desirable marketing authorizations, or if such marketing authorizations are significantly delayed, our business will be substantially harmed” and “—We have current solutions marketed as LDTs and plan to launch future solutions as LDTs. The FDA recently finalized a rule, which has since been vacated by a federal court, pursuant to which it plans to subject LDTs to medical device requirements through a phase-out of its current policy of enforcement discretion over LDTs over a period of four years. The phase-in of medical device requirements to LDTs, including the potential requirement for FDA marketing authorization, will be costly and time-consuming, and if we fail to comply with such requirements, or if we cannot ultimately obtain marketing authorization for our LDTs where required, our business, financial condition, and results of operation could be adversely affected.” Further, we plan to enhance, iterate, and improve our solutions, scalability, and/or reduce our cost of goods. However, we may not be successful in transitioning our solutions to new or enhanced versions or iterations, or reducing our cost of goods. The improvement of our solutions involves a lengthy and complex process, may require regulatory approval, and we may be unable to commercialize, validate, or improve performance of any of our solutions on a timely basis, or at all. Our failure to successfully develop new and/or improved solutions (including new versions of existing solutions) on a timely basis could adversely affect our business, financial conditions, and results of operation.
Finally, generating the clinical data necessary to validate and support the launch of our solutions and new versions of solutions and subsequently obtain marketing authorization or third-party reimbursement, is time-consuming and carries with it the risk of not yielding the desired results. The performance achieved in our analytical validation studies, clinical trials, or published studies may not be replicated in later studies that may be required to obtain or maintain marketing authorization. For example, limited results from earlier-stage analytical validation studies, such as our analytical validation studies on the use of Caris Assure for early detection, MRD tracking, and treatment monitoring, may not predict results from studies in larger numbers of participants drawn from more diverse populations over a longer period of time. Unfavorable results from ongoing analytical validation studies or clinical trials, or delays in publication of such results, could lead to delays, modifications, or abandonment of ongoing or future studies and trials, or abandonment of a solution development program, or may delay, limit, or prevent marketing authorizations or commercialization of our solutions. In addition, results from such studies and trials may not be consistent with the results from real-world application of our solutions, if commercialized, for a particular care setting.
Our current revenue is primarily generated from the continued adoption and use of our tissue-based profiling solution.
Our ability to execute our growth strategy and become profitable is highly dependent on the continued adoption and use of MI Profile, our tissue-based profiling solution, which accounted for 78.2% and 91.0% of our revenue in the years ended December 31, 2024 and 2023, respectively, and 83.9% and 87.9% of our revenue for the three months ended March 31, 2025 and 2024, respectively. Continued adoption and use of MI Profile will depend on several factors, including the prices we charge for our solution, the scope of coverage and amount of reimbursement available from government and third-party payers for our solution, the availability of clinical data that supports the value of MI Profile and the inclusion of MI Profile solutions in industry treatment guidelines. The commercial success of our tissue-based profiling solution depends significantly on its broad adoption and use by oncologists and other physicians. Many physicians and biopharma companies have existing relationships with companies that develop molecular diagnostic tests, including our competitors, and may continue to use their tests instead of MI Profile. Despite our business development efforts, it could be difficult, expensive, and/or time-consuming for physicians and/or biopharma companies to switch diagnostic tests for their products, and MI Profile may not be widely accepted, if at all, which could in turn hinder the rate of adoption and continued use of our solutions. We cannot assure you that MI Profile will continue to maintain or gain market acceptance, and any failure to do so would harm our business, financial condition, and results of operations. Moreover, as we have leveraged the data we
 
24

TABLE OF CONTENTS
 
have generated to date with MI Profile to develop Caris Assure and other solutions, if the adoption and use of MI Profile wanes or if reliability or other issues with the data we generate with MI Profile are discovered, the further development and future success and growth of Caris Assure and other solutions would be adversely impacted.
Our future success and growth will depend in part on market acceptance and commercial success of our MI Cancer Seek and Caris Assure solutions. We may be unsuccessful in continuing the commercialization of MI Cancer Seek or Caris Assure, which would adversely affect our business, financial condition, results of operations, and growth prospects.
MI Cancer Seek, for which we obtained a PMA approval from the FDA in November 2024 and commercially launched in January 2025, is the new WES/WTS NGS assay component of MI Profile, our tissue-based molecular profiling solution for cancer therapy that has generated the majority of our revenue to date. Driving increased adoption among physicians of, and obtaining reimbursement for, MI Cancer Seek are key expected drivers of our growth, particular in the near and medium term. The success of MI Cancer Seek will depend upon, among other things, the extent to which our recent FDA approval drives increased adoption and use of the solution by physicians as a companion diagnostic tool.
Caris Assure, for which we initiated the broad commercial launch for therapy selection in the first quarter of 2024, ultimately aims to address the entire continuum of cancer treatment. Realizing the potential of Caris Assure across disease states is a key component of our long-term business strategy. The commercial success of Caris Assure for therapy selection and in other applications across the cancer treatment continuum will depend upon, among other things, additional analytical validation studies and clinical trials that demonstrate the effectiveness of Caris Assure, particularly for early detection, MRD tracking, and treatment monitoring, the continued adoption of Caris Assure by physicians, the medical community, patients, and third-party payers, and our ability to successfully run and market Caris Assure in substantial quantities or to manage and expand the required infrastructure to do so, including large-scale laboratory and information technology systems. Maintaining and expanding market acceptance of our solutions, marketing, and laboratory capabilities are expensive and time-consuming. If MI Cancer Seek or Caris Assure is not successfully commercialized, we will not be able to recover the significant investment we have made in developing these solutions, and our business, prospects, financial condition, and results of operations would be harmed.
If we are unable to support demand for MI Profile, Caris Assure, and any other solutions we develop, including ensuring that we have adequate capacity to meet increased demand, or if we are unable to successfully manage our anticipated growth, our business could suffer.
As and to the extent the volumes of our current and new solutions continue to grow, we will need to simultaneously increase our capacity for sample intake, storage, and processing enhance our customer service, improve our billing and general processes, expand our internal quality assurance programs, incorporate new equipment, implement new technology systems and processes, expand laboratory capacity, and otherwise extend our operational capabilities to support comprehensive genomic analyses at a larger scale while retaining expected turnaround times. We will also need additional equipment and certified and licensed laboratory personnel to process higher volumes of solutions. We may face difficulties increasing the scale of our operations, including implementing changes in infrastructure or programs or acquiring additional equipment or personnel. As we refine our solutions and develop additional solutions, we may need to bring new equipment on-line, implement new systems, technology, controls and procedures, and hire personnel with different qualifications, licenses, or certifications.
We are also in the process of constructing additional facilities in order to increase capacity, including our laboratory facility in Irving, Texas. We may not be able to complete construction of such facilities and obtain necessary certifications, permits, licenses, and accreditations in a timely or cost-effective manner, or at all. Therefore, we may be unable to support our development and commercial activities in a timely manner, if at all. There is no assurance that any of these increases in scale, expansion of personnel, equipment, software and computing capacities or process enhancements will be successfully implemented, or that we will have adequate resources and facilities to accommodate such required expansion.
 
25

TABLE OF CONTENTS
 
The value of MI Profile, Caris Assure, and related solutions will depend, in part, on our ability to perform tests and return test results to providers on a timely basis and at an appropriate quality standard, and on our reputation for such timeliness and quality. If our business grows too quickly, our ability to meet demand for our solutions in a timely and efficient manner could be challenged, and our quality standards or turnaround time may be compromised. Failure to implement necessary procedures, to transition to new equipment or processes, or to hire the appropriate, qualified personnel could result in higher costs of processing, longer turnaround times, declining product quality, deteriorating customer service, an inability to meet market demand, or slower responses to competitive challenges, all of which could make it difficult for us to meet market expectations for our solutions and could damage our reputation and the prospects for our business. There can be no assurance that we will be able to perform tests on a timely basis at a level consistent with demand, that we will be able to maintain the quality of our test results as we scale our commercial operations, or that we will be successful in responding to the growing complexity of our laboratory operations, including the related data analysis requirements.
We expect to add new associates in our Phoenix and Tempe, Arizona and Irving, Texas facilities. We will need additional laboratory scientists, technicians, and other scientific and technical personnel with different qualifications, licenses, or certifications. As our development plans and strategies develop, and as we transition into operating as a public company, we must add a significant number of additional managerial, operational, financial, and other personnel. Future growth will impose significant added responsibilities on members of management, including:
•
identifying, recruiting, integrating, retaining, and motivating employees;
​
•
managing our internal development and commercialization efforts effectively, including creating and maintaining compliant programs and processes, such as a laboratory and manufacturing quality system, and managing the regulatory requirements for our solutions, while adhering with our contractual obligations to contractors and other third parties;
​
•
expanding our operational, human resources, financial and management controls, reporting systems, and procedures; and
​
•
managing the increasing complexity associated with a larger organization and expanded operations.
​
Our growth may place a significant strain on our management, operating and financial systems, R&D, and our sales, marketing, and administrative resources. As a result of our growth, our operating costs may escalate even faster than planned, and some of our internal systems may need to be enhanced or replaced. If we cannot effectively manage our expanding operations and our costs, we may not be able to successfully commercialize future solutions and grow successfully, and our business could be adversely affected.
Our results of operations may fluctuate significantly, which makes our future results of operations difficult to predict and could cause our results of operations to fall below expectations or any guidance we may provide.
Our quarterly and annual results of operations may fluctuate significantly, which makes it difficult for us to predict our future results of operations. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:
•
the level of demand for our solutions, which may vary significantly;
​
•
the timing and cost of, and level of investment in, research, development, regulatory approval, or certification and commercialization activities relating to our solutions, which may change from time to time;
​
•
the volume and customer mix of our solutions;
​
•
the introduction of new solutions or solution enhancements by us or others in our industry;
​
•
coverage and reimbursement policies with respect to our solutions and products that compete with our solutions;
​
 
26

TABLE OF CONTENTS
 
•
expenditures that we may incur to acquire, develop, or commercialize additional solutions and technologies;
​
•
changes in governmental regulations or in the status of our regulatory approvals or certifications or applications;
​
•
future accounting pronouncements or changes in our accounting policies;
​
•
developments or disruptions in the business and operations of physicians and our biopharma partners;
​
•
the impact of natural disasters, political instability, including wars, terrorism, and political unrest, epidemics or pandemics, boycotts, and curtailment of trade and other business restrictions; and
​
•
the effects of high inflation or other general market and economic conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.
​
Additionally, due to the inherent variability and unpredictability of the reimbursement landscape, including related to the amount that payers reimburse us for any of our solutions, when we recognize revenue we estimate the transaction price based on our historical collection experience and on the historical selling price of similar transactions, where applicable, and subsequent changes to the estimate of the transaction price are generally recorded as adjustments to revenue in the period where such changes occur. Both the estimate and any subsequent revision are uncertain and require the use of management’s judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. Due to this variability and unpredictability, previously recorded revenue adjustments are not indicative of future revenue adjustments from actual cash collections, which may fluctuate significantly. Moreover, we receive a substantial portion of our revenue from a limited number of third-party commercial payers. If one or more of these payers were to significantly reduce or cease to pay the amount such payer reimburses us for our solutions, or if such payer does not reach or maintain favorable coverage and reimbursement decisions for our solutions, it could have an adverse effect on our business, financial condition, and results of operations. We have experienced situations where commercial payers proactively reduced the amounts they were willing to reimburse for our solutions, and in other situations, payers have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. For additional information regarding risks associated with the reimbursement landscape, see “—If our solutions, or solutions we develop in the future, do not receive adequate coverage and reimbursement from third-party payers, including government and commercial payers, our ability to expand access to our solutions beyond our existing sales channels, and thus our overall commercial success, will be limited.”
The cumulative effects of factors discussed above could result in large fluctuations and unpredictability in our quarterly and annual results of operations. As a result, comparing our results of operations on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.
This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our results of operations fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the price of our Class A common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide, and which could harm our business, financial condition, and results of operations.
If we do not have the support of KOLs or if clinical data using our solutions is not published in peer-reviewed journals or is otherwise not well received, it may be difficult to drive adoption and use of our solutions and establish them as a component of the standard of care for patients with cancer.
As of March 31, 2025, the Caris POA was comprised of 96 members, including 45 NCI-designated comprehensive cancer centers. If these KOLs or others within the broader precision oncology industry
 
27

TABLE OF CONTENTS
 
determine that our platform, our existing solutions, or other solutions that we develop are not clinically effective, that alternative technologies are more effective, or if they elect to use internally developed products or services, we may see lower demand for our solutions and face difficulty establishing our solutions as an integral component of the applicable standard of care, which would limit our revenue growth and our ability to achieve profitability.
The publication of clinical data using our solutions in peer-reviewed journals is also crucial to our success. We are unable to control when, if ever, results are published, which may delay or limit broad adoption and use of our solutions. Our ability to publish clinical data relating to our solutions in peer-reviewed publications may be limited by many factors, including increased difficulty in obtaining acceptance for publication from journals, conflicts of interest, lack of qualified experts willing to participate in the peer review process, delays in the completion of, poor design of, or lack of compelling data from, validation studies or clinical trials, as well as delays in the review, acceptance, and publication process. If our solutions do not receive sufficient favorable exposure in peer-reviewed publications or are not well received by clinicians, the rate of clinician adoption and use of our solutions and positive reimbursement coverage determinations for our solutions, even if approved with guideline inclusion, could be adversely affected.
If our solutions, or solutions we develop in the future, do not receive adequate coverage and reimbursement from third-party payers, including government and commercial payers, our ability to expand access to our solutions beyond our existing sales channels, and thus our overall commercial success, will be limited.
Our revenue and commercial success depend on achieving coverage and reimbursement for assays that comprise MI Profile, Caris Assure, and any solutions we may offer in the future, from third-party payers, including both government and commercial payers. Obtaining approvals from third-party payers to cover our solutions and establishing adequate coding recognition and reimbursement levels is an unpredictable, challenging, time-consuming, and costly process, and we may not always be successful. Coverage determinations from third-party payers may depend on a number of factors, including a payer’s determination that a solution is appropriate, medically necessary, and cost-effective. Each payer will make its own decision as to whether to establish a policy or enter into a contract to cover our solutions and the amount it will reimburse for such solutions. In addition, determinations by a payer whether to cover and the amount it will reimburse for our solutions are often made on an indication-by-indication basis. If we are unable to provide payers with sufficient evidence of the clinical utility and validity of our solutions, they may not provide coverage, may provide limited coverage, or may terminate coverage for our solutions, which will adversely affect our revenues and our financial condition. In addition, the fact that one of our solutions has been approved for reimbursement in the past does not guarantee that such solution will remain approved for reimbursement, that the approved reimbursement amount will not be reduced in the future, or that similar or additional solutions will be approved in the future. Moreover, there can be no assurance that any new solutions we launch will be reimbursed at rates that are comparable to the rates that we historically obtained for our existing portfolio or rates that other industry participants receive. Third-party payers may not cover or provide adequate payment for our current or future molecular and other solutions to enable us to maintain past levels of revenue or profitability with respect to such solutions. Further, third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in the development of our solutions.
Healthcare providers may not order our solutions unless third-party payers cover and provide reimbursement rates for a substantial portion of the price of our solutions. If we are unable to obtain adequate coverage and an acceptable level of reimbursement for our solutions from third-party payers, patients could incur a greater co-insurance, co-payment, and/or deductible obligation. Uninsured patients or patients whose insurance does not cover our solutions may also be forced to pay for our solutions out-of-pocket. Such scenarios could dissuade physicians from ordering our solutions or, if ordered, could result in delay in or decreased likelihood of our collection of payment. We thus believe our revenue and revenue growth will depend on our success in achieving broad coverage and adequate reimbursement for our solutions from third-party payers.
In addition, the coding process used by third-party payers to identify various medical procedures during the billing process is complex, may not adapt well to the types of solutions we offer, and may not enable coverage and adequate reimbursement rates. Current Procedural Terminology (“CPT”) coding plays
 
28

TABLE OF CONTENTS
 
a significant role in how our solutions are reimbursed both from commercial and governmental payers. The CPT code set is maintained by the American Medical Association (“AMA”) and includes the Proprietary Laboratory Analyses (“PLA”) codes that are used to describe many molecular diagnostic tests. In cases where there is not a specific CPT code to describe a test, or when required by a commercial payer, we bill under an unlisted molecular pathology procedure code or through the use of a combination of single gene CPT codes, depending on the payer. In addition, the Centers for Medicare and Medicaid Services (“CMS”) maintains the Healthcare Common Procedure Coding System (“HCPCS”) and may assign unique Level II HCPCS code to tests that are not already described by a unique CPT code. New CPT codes are issued annually and new HCPCS codes are issued as frequently as quarterly. In addition to CPT and HCPCS codes, Z-Code Identifiers are used by certain payers, including under MolDX, to supplement CPT codes for our solutions. Our MI Tumor Seek Hybrid solution is reported to Medicare and to some commercial payers using unlisted molecular pathology CPT code 81479 and unique test-specific identifier (“a DEX Z-Code”). Our MI Cancer Seek solution is reported to Medicare and to commercial payers using the 0211U CPT code and a unique DEX Z-Code identifier. Our Caris Assure solution is reported to Medicare and to non-contracted, commercial payers using the 0485U CPT code and a unique DEX Z-Code identifier. Commercial payers sometimes require other codes to be reported for our solutions, and we will bill in accordance with the respective contract terms. Changes to the codes used to report our solutions to payers may result in significant changes in reimbursement.
Third-party payers are increasingly attempting to contain healthcare costs by limiting both coverage of certain diagnostic tests and the amounts that they will pay for such tests. Payers may also create conditions for coverage or may contract with third-party vendors to manage laboratory benefits, in both cases creating administrative hurdles for ordering physicians and patients that may make our services more difficult to sell. U.S. and foreign governments continue to propose and pass legislation designed to reduce the cost of healthcare. In some foreign markets, the government controls the pricing of many healthcare products. In the United States, we expect that there will continue to be federal and state proposals to implement governmental controls or impose healthcare requirements, which may increase the pressure to reduce spending on genetic testing and comprehensive molecular profiling. In addition, the Medicare program and increasing emphasis on managed care in the United States will continue to put pressure on product pricing. Cost control initiatives could decrease the price that we would receive for any solutions in the future, which would limit our revenue and profitability.
Obtaining approvals from third-party payers to cover our existing and new solutions and establishing adequate coding recognition and reimbursement levels is an unpredictable, challenging, time-consuming, and costly process, and we may not always be successful. If third-party payers do not provide adequate coverage and reimbursement for our solutions, our ability to succeed commercially will be limited.
Medicare
Medicare is the single largest U.S. payer and a particularly important payer for many cancer-related laboratory services given the demographics of the Medicare population. Medicare coverage is limited to items and services that are within the scope of a Medicare benefit category that are reasonable and necessary for the diagnosis or treatment of an illness or injury. Medicare coverage criteria that define when items and services are reasonable and necessary are defined in National Coverage Determinations (“NCDs”) made by CMS through an evidence-based process, with opportunities for public participation, and Local Coverage Determinations (“LCDs”) made by Medicare Administrative Contractors (“MACs”) that apply within the specific jurisdictions. Medicare’s NCD for NGS (NCD 90.2), first established in 2018 and subsequently updated in 2020, provides national Medicare coverage for certain molecular diagnostic tests (1) performed in a laboratory certified by the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”), (2) ordered by a treating physician, (3) the patient meets certain clinical and treatment criteria, including having recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer, (4) the test is approved or cleared by the FDA as a companion IVD for an FDA-approved or -cleared therapeutic for use in that patient’s cancer, and (5) results are provided to the treating physician for management of the patient using a report template to specify treatment options. The NGS NCD also provides discretion to the MACs to provide local coverage of other NGS tests for cancer patients only when the test is performed by a CLIA-certified laboratory, ordered by a treating physician and the patient meets the same clinical and treatment criteria required of nationally covered NGS tests under the NGS NCD. Palmetto GBA is the MAC
 
29

TABLE OF CONTENTS
 
responsible for administering MolDX, which issues coverage determinations applicable to molecular diagnostic tests within the scope of the program, including for molecular assays that are LDTs. Our MAC for the Phoenix laboratory locations is Noridian, and Noridian relies on MolDX to make local coverage and pricing determinations relating to molecular testing. To achieve coverage under MolDX, laboratories must apply for and obtain a DEX Z-Code that is unique to the laboratory’s specific test and must also submit a technical assessment to demonstrate analytical and clinical validity, and clinical utility at a level that meets the Medicare reasonable and necessary requirement. Analytical validity relates to technical performance, such as that an assay accurately and reliably measures a specific feature. Clinical validity means whether a test can accurately identify, measure, or predict a clinical condition or characteristic in patients.
Molecular Diagnostic Tests: Tissue- and Blood-Based Solutions
We have received DEX Z-Codes and MolDX technical assessments for our MI Cancer Seek, Caris Assure, and MI Tumor Seek Hybrid solutions.
We received a PMA approval for MI Cancer Seek from the FDA in November 2024 and commercially launched the solution in January 2025. We have obtained Medicare coverage under the NGS NCD for MI Cancer Seek for CPT code 0211U at $8,455 under the CLFS.
Our MI Tumor Seek Hybrid solution is covered for solid tumor testing as allowable under the NGS NCD and related LCD and are reported to Medicare with unlisted molecular pathology CPT code 81479 and the unique DEX Z-Code identifier issued by MolDX. MI Tumor Seek Hybrid is covered by Medicare as of August 3, 2022, with current MolDX pricing of $3,500.
Our Caris Assure solution is currently reported to Medicare using a PLA code, CPT code 0485U, and a unique DEX Z-Code identifier issued by MolDX. Caris Assure is covered for therapy selection by Medicare as of December 8, 2023 for Comprehensive Genomic Profiling from ctDNA of patients with recurrent, relapsed, refractory, metastatic, or advanced solid tumors who are seeking treatment, and for whom tissue-based, comprehensive genomic profiling (“CGP”) is infeasible (for example, quantity not sufficient for tissue-based CGP or invasive biopsy is medically contraindicated), with current MolDX pricing of $3,649. In November 2024, CMS determined to price Caris Assure for therapy selection using the “Gapfill” method. There is no certainty regarding the pricing that we will obtain for Caris Assure during the Gapfill process. For additional information, see “Business—Government Regulation—Coverage and Reimbursement—Coverage and Reimbursement in the United States.”
Immunohistochemical Tests
As part of our MI Profile solution, we perform certain third-party IHC tests. Medicare coverage and payment for these tests is under the Molecular Pathology Procedures Billing and Coding Article, with payment amounts assigned to specific HCPCS and CPT codes.
Protecting Access to Medicare Act
Medicare payment for clinical diagnostic laboratory tests (“CDLTs”) is generally made under the CLFS based on payment rates that are assigned to specific HCPCS or CPT codes. Under the Protecting Access to Medicare Act of 2014 (“PAMA”), laboratories that meet certain requirements related to volume and type of Medicare revenues are required to report to CMS, beginning in 2017 and every three years thereafter (or annually for “advanced diagnostic laboratory tests” ​(“ADLTs”)), their private payer payment rates and volume for each test they perform that is reported with a specific HCPCS code (defined by PAMA to exclude miscellaneous or unlisted codes). ADLTs are subject to separate reporting and payment requirements under PAMA. New ADLTs are paid at a rate equal to their actual list charge during an initial period of three calendar quarters, after which CLFS payment is based on the weighted median of private payer rates, which must be reported annually for ADLTs. We are subject to these reporting requirements under PAMA for any solution we perform that is not reported with a miscellaneous HCPCS or CPT code, including the third-party IHC tests we perform, and for any profiling solutions that commercial payers currently require us to report using a HCPCS code that has been identified by CMS as subject to PAMA reporting requirements. In addition, MI Cancer Seek, which is reported with PLA code 0211U, Caris Assure, which is reported using PLA Code 0485U, and any other solution for which we obtain a specific HCPCS
 
30

TABLE OF CONTENTS
 
or CPT code, will be subject to these reporting requirements in future PAMA reporting cycles, and that the Medicare CLFS payment rates for such solutions will be calculated in the future based on our private payer rates. While we do not currently have ADLT status for any of our solutions, we may seek ADLT status for one or more of our solutions in the future. If we are successful in obtaining such ADLT status, any solution for which we obtain ADLT status will be subject to the PAMA reporting requirements and pricing methodology as an ADLT.
Congress passed legislation that delayed data reporting requirements for CDLTs that are not ADLTs and further delayed the phase-in of payment reductions under the CLFS from private payer rate implementation. Any reductions to reimbursement rates resulting from the new methodology are limited to 0% in 2025 and 15% per test per year in each of 2026 through 2028. The subsequent data reporting periods for CDLTs that are not ADLTs will occur in three-year cycles, with the next cycle beginning in 2026. CLFS rates for CDLTs will be updated every three years, and for ADLTs will be updated annually. For many tests and/or laboratories, the result of the PAMA pricing methodology has been lower pricing and reimbursement. As a result, our Medicare CLFS pricing for any solutions that may be subject to PAMA reporting requirements in the future could be negatively impacted by PAMA. In addition, private payer payment levels have more significance in setting Medicare reimbursement and, therefore, future Medicare payments may fluctuate more often and become subject to the willingness of private payers to recognize the value of diagnostic tests generally and any given test individually. Given the many uncertainties built into PAMA’s price-setting process, we cannot predict how payments we receive under the CLFS, and thus our revenue, may change from year to year.
In addition to the reporting requirements and pricing methodology described above, PAMA codified Medicare coverage rules for laboratory tests by requiring any local coverage determination to be made following the local coverage determination process. PAMA also authorizes CMS to consolidate coverage policies for clinical laboratory tests among one to four laboratory specific MACs. These same contractors may also be designated to process claims if CMS determines that such a model is appropriate. It is unclear whether CMS will proceed with contractor consolidation under this authorization.
Molecular Signature Tests, and Screening and Early Detection Intended Uses for Our Solutions
Our proprietary molecular signature tests, GPSai and FOLFIRSTai, as well as early detection indications for our blood and tissue-based profiling solutions, are not currently covered by Medicare. Obtaining Medicare coverage for these molecular signatures would require significant investments and may ultimately be unsuccessful or may take several years to achieve.
In addition, we are developing screening capabilities for Caris Assure for MRD tracking and treatment monitoring in colorectal cancer (“CRC”), breast cancer, lung cancer, and other indications. On January 19, 2021, CMS released an NCD that covers future tests for CRC screening if and when such screening tests have FDA approval and meet pre-specified CMS criteria. In addition, MolDX LCDs provide coverage for MRD for CRC, breast cancer, lung cancer, and other indications when applicable coverage criteria are satisfied. While this NCD and applicable LCDs may provide a pathway to coverage of Caris Assure in CRC and other indications under Medicare if applicable coverage criteria are satisfied, there is no assurance that we will be successful in completing the required studies, trials, or publications or obtaining FDA approval, or obtaining Medicare coverage even if we are successful in obtaining FDA approval, and if we are not successful, our business, financial condition, and results of operations would be harmed.
Commercial Payers and Other Payers
Our commercial success also depends on achieving acceptable coverage and reimbursement for our solutions from commercial payers. When we contract with a payer as a participating provider, reimbursements by the payer are generally made pursuant to a negotiated fee schedule and are limited to only covered indications, and in many cases require prior authorization. Becoming a participating provider can result in higher reimbursement amounts for covered uses of our solutions and, potentially, no reimbursement for non-covered uses identified under the payer’s medical policies or the contract. Although we are a participating provider with many commercial payers, certain payers may not cover based on existing medical policy and may treat our solutions or solutions that we develop in the future as experimental and investigational or
 
31

TABLE OF CONTENTS
 
import restrictive coverage criteria. If we are not successful in obtaining coverage from such payers, or if other payers issue non-coverage policies, our business, financial condition, and results of operations could be adversely affected.
Because current codes applicable to our solutions are not always test-specific, each insurance claim will have different submission criteria, including appending our DEX Z-Code, and typically must be examined to determine what test was provided, whether the test was appropriate and medically necessary, and whether payment should be rendered, which may require progress notes, medical records, or a letter of medical necessity from the ordering physician. This process can result in a delay in processing the claim, a lower reimbursement amount or denial of the claim. As a result, obtaining approvals from third-party payers to cover our solutions and establishing adequate reimbursement levels is an unpredictable, challenging, time-consuming, and costly process, and we may never be successful in obtaining such approvals.
Some payers have implemented, or are in the process of implementing, laboratory benefit management programs, often using third-party benefit managers to manage these programs. The stated goals of these programs are to help improve the quality of outpatient laboratory services, support evidence-based guidelines for patient care and lower costs. The impact on laboratories, such as ours, of active laboratory benefit management by third parties is unclear, and we expect that it would have a negative impact on our revenue in the short term. Payers may resist reimbursement for our solutions in favor of less expensive tests, require pre-authorization for our solutions, or impose additional pricing pressure on and substantial administrative burden for reimbursement for our solutions. We expect to continue to focus substantial resources on increasing adoption of, and coverage and reimbursement for, our current solutions and any future solutions we may develop. We believe it may take several years to achieve broad coverage and adequate contracted reimbursement with a majority of payers for our solutions. However, we cannot predict whether, under what circumstances, or at what price levels payers will cover and reimburse our solutions. If we fail to establish and maintain broad adoption of, and coverage and reimbursement for, our solutions, our ability to generate revenue could be harmed and our business, financial condition, and results of operations could be adversely affected.
Even if we establish relationships with commercial payers to provide our future solutions at negotiated rates, such agreements would not obligate any healthcare providers to order our solutions or guarantee that we would receive reimbursement for our solutions from these or any other payers at adequate levels. Thus, these payer relationships, or any similar relationships, may not result in acceptable levels of coverage and reimbursement for our solutions, or meaningful increases in the number of billable tests we perform. We believe it may take several years to achieve coverage and adequate reimbursement for our solutions with a majority of third-party payers, including with those payers offering negotiated rates. In addition, we cannot predict whether, under what circumstances, or at what payment levels payers will cover and reimburse for our solutions. In addition to the available Medicare coverage, we plan to market Caris Assure for early detection, MRD tracking, and treatment monitoring, as well as other solutions that we are developing or may develop in the future, to large self-insured employers, commercial insurance plans, certain physician directed channels, concierge medicine and executive health programs, and innovative health systems. Additionally, a third-party payer’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future. If we fail to establish and maintain broad-based coverage and reimbursement for certain solutions, our ability to expand access to our solutions, generate increased revenue, and grow our clinical case volume and customer base for such solutions will be limited and our overall commercial success may be limited.
Our billing, collections, and claims processing activities are complex and time-consuming, and any delay in transmitting and collecting claims or failure to comply with applicable billing requirements could have an adverse effect on our future revenue.
Depending on the billing arrangement and applicable law, we bill and expect to bill various payers, such as governmental payers, insurance companies, hospitals, and patients, which may each have different billing requirements. We may face increased risk in our collection efforts, including long collection cycles and the risk that we never collect at all, either of which could adversely affect our business, financial condition, and results of operations.
 
32

TABLE OF CONTENTS
 
Our failure to timely submit claims for our solutions to payers or failure to comply with applicable billing requirements could have an adverse effect on our revenue and our business, and could result in our inability to receive payment for our services or in attempts by private payers and state and federal healthcare programs, such as Medicare and Medicaid, to recover payments already made. Submission of claims in violation of billing requirements and applicable laws and regulations can result in recoupment of payments already received, substantial civil monetary penalties, and exclusion from state and federal health care programs, and can subject us to liability under the federal False Claims Act (the “FCA”) and similar laws. For example, in March 2025, we received a Civil Investigative Demand (“CID”) from the DOJ in connection with an investigation under the False Claims Act regarding our compliance with Medicare's date of service rule (also referred to as the 14-day rule). For additional information, see “ —We have been, are currently, and in the future may be the subject of government investigations, claims, audits, whistleblower and payer audits, overpayment and recoupment efforts and other litigation in the course of our business that could adversely affect our business and financial statements” and “Business—Legal Proceedings.” The failure to report and return an overpayment to the Medicare or Medicaid program within 60 days of identifying its existence can also give rise to liability under the FCA. Further, a government agency could attempt to hold us liable for causing the improper submission of claims by another entity for services that we performed if we were found to have knowingly participated in the arrangement at issue.
In addition, our claims for reimbursement may be denied and we may have to appeal such denials in order to get paid. Such appeals may not result in payment and can be time-consuming and costly. Moreover, payers often perform audits of historically paid claims and regularly attempt to recoup funds years after the funds were initially distributed if the payers believe the funds were paid in error or determine that our solutions were medically unnecessary. If a payer’s audit of our claims results in a negative finding, and we are unable to reverse the finding through appeal or subsequent litigation, any subsequent recoupment could have an adverse effect on our revenue. Additionally, in some cases commercial payers for whom we are not a participating provider may elect at any time to review claims previously paid and determine the amount they paid was excessive. In these situations, the payer typically notifies us of its decision and then offsets the amount it determines to be overpaid against amounts it owes us on current claims. We may not have a mechanism to dispute these retroactive adjustments, and we cannot predict when, or how often, a payer might engage in these reviews. We have been, are currently, and may in the future be, subject to overpayment demands, recoupment efforts, and related disputes from or with payers, managed care plans, and government healthcare programs relating to the billing and coding of our solutions.
Furthermore, we maintain financial assistance programs under which we assess patient financial need and offer to provide solutions at a discount, or at no cost, to certain eligible patients. These practices may result in scrutiny of our financial assistance programs by governmental and commercial payers and could result in recoupment actions or termination of coverage of our solutions, as well as scrutiny under health care fraud and abuse laws. For additional information, see “—We have been, are currently, and in the future may be the subject of government investigations, claims, audits, whistleblower and payer audits, overpayment and recoupment efforts and other litigation in the course of our business that could adversely affect our business and financial statements” and “Business—Legal Proceedings.”
We currently handle our own billing and coding for our solutions but have initiated the process of transitioning certain of our billing and coding software and other operations to a vendor for revenue cycle management services. Our business, financial condition, and results of operations may be affected by our ability to successfully transition these functions and the ability of our vendor to timely, accurately, and appropriately code and bill claims and collect payments in compliance with the stringent billing, coding and documentation requirements imposed by government healthcare programs and other payers. Terminating or transitioning arrangements with revenue cycle management vendors could result in additional costs and a risk of operational problems, delays in collections from payers, potential errors and possible control issues during the termination and transition processes, any of which could adversely affect our business, financial condition, and results of operations.
We rely on a limited number of third-party suppliers or, in many cases, sole suppliers, for some of our next-generation sequencers, lab materials, reagents, and supplies, and we may not be able to find replacements or immediately transition to alternative suppliers if necessary.
We rely on Illumina, Inc. (“Illumina”) as the sole supplier of NGS instruments and the associated sequencing reagent kits for our solutions. Illumina is also the sole provider of maintenance and repair
 
33

TABLE OF CONTENTS
 
services for these sequencing instruments. Without access to these sequencers, we may be unable to run our solutions and commercialize our solutions. Additionally, we rely on several sole suppliers, including, among others, Roche Diagnostics Corporation (“Roche”), Matsunami Glass USA (“Matsunami Glass”), and Agilent Technologies, Inc. (“Agilent”), for certain lab materials, reagents, and supplies. If we do not have timely access or access to sufficient quantities of these lab materials, reagents, and supplies, we may be unable to run our solutions and commercialize our solutions. We also rely on several sole suppliers, or manufacturers, for blood collection tubes, including the cfDNA PAXgene tubes for use with liquid biopsy profiling, for total nucleic acid extraction kits, and for the NGS panels and library preparation kits we use. Given the specialized function of certain instruments and reagents, suitable replacements may not be available if a product is discontinued or the product specification undergoes substantial changes due to their own external competition or otherwise. This may significantly delay our ability to continue to develop and commercialize any other future commercial products. All changes to instruments, associated software and reagents will undergo a risk evaluation to determine the level of validation required per the product regulatory status and may require supplementary submissions to, and approval of, regulatory agencies such as the FDA. Whether transitioning to a new supplier, instrument or reagent, the process is likely to be time-consuming, expensive and could affect test performance metrics.
We have obtained a PMA approval from the FDA for MI Cancer Seek and intend to seek FDA approval for Caris Assure and additional solutions. We do not manufacture the instruments or reagents used with our solutions, nor do we control such process, and we rely on external suppliers to maintain development and commercialization activities. The molecular testing performed by us is highly complex and requires specialized instruments and reagents, some of which are considered critical and could not be substituted without significant impact to our operations. Any failures or delays in negotiating appropriate agreements with our suppliers on reasonable terms, or their inability to obtain any required marketing authorizations, may increase our costs or delay or prevent us from obtaining or maintaining FDA marketing authorization of the related solutions.
Our current suppliers may also discontinue or substantially change the specification of products that we use or intend to use in our solutions. We believe there are few other manufacturers that are currently capable of supplying and servicing the equipment and materials necessary for our laboratory operations, including certain instruments, components, consumables, and reagents. Transitioning to a new supplier for this equipment or these materials would be time-consuming and expensive, could result in interruptions in or otherwise affect the performance specifications of our laboratory operations and sample processing or could require that we revalidate our solutions and could require a new submission to the FDA and other regulatory bodies to authorize such changes for any of our solutions that have received FDA approval. We also cannot guarantee that we will appropriately prioritize or select alternative suppliers, where necessary. In addition, we do not have written supply agreements with certain of our suppliers, including Agilent, Matsunami Glass, and PAXgene, and instead purchase certain products on a purchase order basis, which exposes us to potential price increases and termination of supply without notice or recourse. We cannot guarantee a consistent source of supply and cannot assure you that any efforts to enter into written agreements with our suppliers will be successful. The use of equipment or materials provided by a replacement supplier could require us to alter our laboratory operations and sample collection and processing and related procedures. Moreover, replacement instruments and associated reagents, tubes, and panels that meet our quality control and performance requirements may not be available at all, or may not be available on reasonable terms or in a timely manner. If we encounter delays or difficulties in securing, reconfiguring, or revalidating the equipment, reagents, and other materials that we require for our solutions, laboratory operations and same collection and processing, in particular for those products that are sole sourced, we would likely face significant disruptions or delays in commercializing our solutions and our business, financial condition, results of operations, and growth prospects would be adversely affected.
If we fail to obtain additional financing, we may be unable to execute on our business strategies and our growth prospects could be harmed.
Our operations have required substantial amounts of cash since our inception. The development of our solutions are expensive, and we expect to continue to spend substantial amounts as we continue to enhance our solutions, broaden the applications of our existing solutions, and develop new solutions. In
 
34

TABLE OF CONTENTS
 
addition, obtaining any necessary or desirable marketing authorizations for our solutions will require substantial additional funding.
We may consider raising additional capital in the future to expand our business, meet existing obligations, pursue acquisitions or strategic investments, take advantage of financing opportunities, or for other reasons, including to:
•
increase our sales and marketing efforts to drive market adoption of our current solutions and address competitive developments;
​
•
fund development and marketing efforts of new solutions or any other future solutions;
​
•
expand our technologies into other types of cancer management and detection solutions for other chronic disease states;
​
•
acquire, license, or invest in our existing and future technologies;
​
•
acquire or invest in complementary businesses or assets; and
​
•
finance capital expenditures and general and administrative expenses.
​
As of March 31, 2025, we had $31.2 million of cash and cash equivalents and $2.2 million of short-term marketable securities. We could use our available capital resources sooner than we expect, including due to changing circumstances or those beyond our control that may cause us to increase our spending significantly faster than we anticipate, requiring us to raise additional funds sooner than we anticipate.
We will require additional capital for the development and commercialization of MI Cancer Seek, Caris Assure, Caris ChromoSeq, and the development of additional solutions. Our future capital requirements depend on many additional factors, including:
•
the cost of development and commercialization activities, including marketing and sales, for our solutions;
​
•
our ability to achieve revenue growth;
​
•
the cost related to scaling operating capabilities to support demand for our solutions, including the cost of completing the build-out of our laboratory in Irving, Texas;
​
•
the timing of, and the costs involved in, obtaining any required or desired marketing authorizations for our solutions;
​
•
the timing, scope, progress, results and costs of developing additional solutions, and of conducting validation studies, clinical trials, and other studies that may be required in order to market our solutions;
​
•
the costs involved in obtaining, maintaining, protecting, and enforcing patent and other intellectual property rights and claims, including litigation costs and the outcome of such litigation;
​
•
the timing and amount of sales of our solutions, if any, and collection of related receivables;
​
•
the extent to which our solutions are eligible for coverage and reimbursement from third-party payers and government payers;
​
•
the emergence of new technologies, scientific breakthroughs, or any competing tests, products, or services, and other adverse market developments; and
​
•
other potential adverse developments.
​
Additional capital may not be available when we need it, on terms acceptable to us or at all. We have no committed source of additional capital, having borrowed the remaining principal amount of $200.0 million under the delayed draw loan of the 2023 Term Loan (as defined below) in March 2024. Furthermore, any additional capital raised through the sale of equity or equity-linked securities will dilute shareholders’ ownership interests in us, may require shareholder approval, may have an adverse effect on the
 
35

TABLE OF CONTENTS
 
price of our Class A common stock, and holders of these securities may have rights, preferences, or privileges senior to those of our then-existing shareholders. Debt financing, if available, may include restrictive covenants that could limit how we conduct our business. Our ability to incur additional indebtedness also is currently restricted by the terms of our 2023 Term Loan Agreement (as defined below). If adequate capital is not available to us on a timely basis, we may be required to significantly delay, scale back, or discontinue the commercialization of our solutions or R&D programs, or be unable to continue or expand our operations or otherwise capitalize on our business opportunities, as desired, which could adversely impact our business, financial condition, and results of operations and cause the price of our Class A common stock to decline.
If our facilities or those of our third-party collaborators are insufficient or become inoperable, our ability to provide our solutions will be significantly impaired and our business will be harmed.
We currently perform all R&D and commercial profiling in our multiple laboratories in Phoenix and Tempe, Arizona and are building out our newest facility in Irving, Texas. Any disruption to the operations of these facilities could compromise the integrity of our samples and impede our ability to accurately perform our profiling and ultimately adversely impact our reputation, business, financial condition, and results of operations. In addition, we may maintain samples for several years. It is possible that some, if not all, of these samples may degrade over time, which could negatively impact our ability to use such samples to validate future solutions and which could adversely impact our business, financial condition, and results of operations.
One or more of our facilities may be harmed, rendered inoperable by physical damage or otherwise become partially or completely unusable due to fire, floods, earthquakes, power loss, telecommunications failures, break-ins, accidents, water shortages, floods, tornadoes, hurricanes, fires, extreme weather conditions, health epidemics, pandemics, and similar events, which may render it difficult or impossible for us to provide our solutions for some period of time. Our laboratories and the equipment we use to perform our R&D or commercialization work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming, and expensive to rebuild one of our facilities, particularly in light of the licensure, permits, and accreditation requirements for clinical laboratories like ours. Although we carry insurance for damage to our properties and the disruption of our business, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all.
We have started the process of constructing a new laboratory facility in Irving, Texas to increase product development and operational capacity. Such construction requires significant resources, and we may encounter difficulties and delays in construction, procuring laboratory equipment, obtaining necessary validation, permits, licenses, and certifications (including CLIA certification and College of American Pathologists (“CAP”) accreditation, or completing the technology implementation) for this new facility. If we are unable to complete construction and go-live in a timely and satisfactory manner, obtain the necessary permits, licenses, certificates, and accreditations within our currently anticipated timelines, or meet demand for our solutions at our Arizona facilities, on a timely basis or at all, our reputation and commercial activities would be negatively impacted. We may be unable to regain customers or repair our reputation in the future, which would negatively impact our business, financial condition, and results of operations.
We also rely on our third-party collaborators, consultants, contractors, vendors, suppliers, and service providers. The facilities of these partners could be subject to fire, floods, earthquakes, power loss, telecommunications failures, break-ins, accidents, water shortages, floods, tornadoes, hurricanes, fires, extreme weather conditions, health epidemics, pandemics and other natural or man-made disasters or business interruptions. In addition, they may be affected by government shutdowns, changes to applicable laws, regulations, and policies, or withdrawn funding. The occurrence of any of these business disruptions could seriously harm their ability to complete their contracted services to us, which may adversely impact our business, financial condition, and results of operations.
If our solutions result in direct or indirect patient harm or injury, we could be subject to significant reputational and liability risks, and our business, financial condition, and results of operations could suffer.
Our success depends on the market’s confidence that our solutions, including MI Profile, MI Cancer Seek, Caris Assure, MI Tumor Seek Hybrid, and GPSai and other solutions that we may develop in the
 
36

TABLE OF CONTENTS
 
future, can provide reliable and high-quality results. We believe that patients, physicians, and regulators are likely to be particularly sensitive to errors in the use of our solutions or failure of our solutions to perform as described, and there can be no guarantee that our solutions will meet their expectations. Performance failures could establish a negative perception of our solutions among physicians, patients, and regulators, jeopardize our ability to successfully commercialize our solutions, impair our ability to obtain marketing authorizations or secure favorable coverage and reimbursement, or otherwise result in reputational harm. The costs incurred in correcting any defects or errors may be substantial and could adversely affect our operating margins. Identifying the root cause of quality issues, particularly those affecting reagents and third-party components, may be difficult, which increases the time needed to address quality issues as they arise, and increases the risk that similar problems could recur. In addition, we may be subject to legal claims arising from any errors in the use, manufacture, design, labeling or performance of our solutions, including any false-positive or false-negative results.
Our anticipated application of Caris Assure for early detection, MRD tracking, and treatment monitoring poses additional risks. Caris Assure is currently intended to be used to detect cancers in patients. A detection of cancer by Caris Assure would need to be followed up with a cancer diagnosis by a physician. Because Caris Assure is not currently able to detect all forms of cancer, a negative test would not rule out the presence of cancer. Additionally, an individual undergoing further diagnostic procedures on the basis of a false-positive result or an erroneous cancer lineage could expose us to significant liability and reputational risks, notwithstanding the emotional and mental health effects to which the patient may be exposed. Similarly, an individual who receives a cancer diagnosis shortly following an inaccurate result, such as a negative test or false negative result, may create adverse publicity about our solutions, which could damage our reputation and have a negative impact on our business, financial condition, and results of operations. Failure to accurately detect cancer and other performance failures could establish a negative perception of our solutions among physicians, patients, customers, and regulators, jeopardize our ability to successfully commercialize our solutions, impair our ability to obtain marketing authorizations or secure favorable coverage and reimbursement, or otherwise result in reputational harm or enforcement action or inquiry by a regulatory body. These risks may be more pronounced and could expose us to claims of injury or other adverse events under medical liability, product liability, or other liability laws if a provider uses our tests inaccurately or inappropriately for diagnosis purposes, as our solutions would be directly involved with the choice to use certain treatments. In addition, we may be subject to legal claims arising from any errors in the use, manufacture, design, labeling, marketing, or performance of our products, including from inaccurate results. If our solutions result in direct or indirect participant or patient harm or injury, we could be subject to significant reputational and liability risks, may be required to initiate corrective actions, recalls or suspend sales of our products, which may adversely impact our reputation, business, financial condition, and results of operations.
If we were to be sued for product liability or professional liability, we could face substantial liabilities that exceed our resources, including any insurance coverage.
The marketing, adoption, and use of our solutions could lead to the filing of product liability claims if someone alleges that our solutions identified inaccurate or incomplete information regarding the genomic alterations of the tumor or malignancy analyzed, reported inaccurate or incomplete information concerning the available therapies for a certain type of cancer, or otherwise failed to perform as designed. We may also be subject to professional liability for errors in, a misunderstanding of, or inappropriate reliance upon, the information we provide in the ordinary course of our business activities. A product liability or professional liability claim could result in substantial damages and be costly and time-consuming for us to defend.
We maintain product and professional liability insurance, but this insurance may not fully protect us from the financial impact of defending against product liability or professional liability claims. Any product liability or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability or professional liability lawsuit could damage our reputation or cause current clinical customers to terminate existing agreements with us and potential clinical customers to seek other partners, any of which could adversely impact our business, financial condition, and results of operations.
 
37

TABLE OF CONTENTS
 
Our business and results of operations will suffer if we fail to compete effectively.
The precision oncology industry, which is the focus of our current commercial portfolio, is intensely competitive. Our competitors include numerous companies offering or seeking to offer tissue-based molecular profiling, blood-based early detection, blood-based molecular profiling for therapy selection, MRD tracking, and/or treatment monitoring, core biopharma services, and genomic data and AI services to biopharma companies. For additional information, see “Business—Competition.” Our competitors have or may have substantially greater financial, technical, and other resources, such as larger R&D staff and more well-established marketing and sales forces. Our competitors may succeed in developing, acquiring, or licensing, on an exclusive basis or otherwise, tests or services that are more effective or less costly than our solutions. In addition, established medical technology, biotechnology, or biopharma companies, some of whom may be our customers, may invest heavily to accelerate discovery and development of tests that could make our solutions less competitive than we anticipate.
Our ability to compete successfully will depend largely on our ability to:
•
successfully commercialize and expand the features of our solutions and develop new solutions to achieve meaningful innovation in precision oncology and other chronic disease states;
​
•
demonstrate compelling advantages in the performance and convenience of our solutions, including on a cost competitive basis;
​
•
achieve market acceptance of our solutions by patients and healthcare providers;
​
•
the rate of adoption and/or endorsement of our solutions by clinicians, KOLs, advocacy groups, and biopharma companies;
​
•
achieve adequate coverage and reimbursement recognition from governmental payers, health insurance organizations, and other third-party payers for our solutions;
​
•
address any technological, scientific, and market developments to differentiate our solutions from products and services offered by current and potential competitors;
​
•
attract qualified scientific, data science, clinical development, solution development, and commercial personnel;
​
•
obtain, maintain, defend, and enforce patent and other proprietary protection as necessary for our solutions and platform;
​
•
obtain and maintain any necessary or desirable marketing authorizations from regulators in the United States and other jurisdictions for any versions of our current solutions and any future solutions that we may develop;
​
•
successfully collaborate with institutions in the discovery, development, and commercialization of our solutions;
​
•
establish and maintain supply and manufacturing relationships with third parties that can timely and consistently provide adequate, in both amount and quality, products and services to support clinical development and the market demand for our solutions; and
​
•
successfully expand our operations infrastructure and implement a successful sales and marketing strategy to support increased commercialization.
​
We may not be able to compete effectively or keep pace with the rapid rate of change in our industry if we are unable to accomplish one or more of these or similar objectives. This could render our solutions obsolete or less attractive, result in significant price reductions, or substantially limit the volume of products that we offer.
Failure of, or defects in, our AI/ML models and on-premise, co-located, and cloud-based computing infrastructure, including interruption of services through Amazon Web Services, or increased regulation in the AI/ML space, could impair our ability to process our data, develop solutions, or provide test results, and harm our business and results of operations.
The design, development, maintenance, and operation of our technology over time is expensive and complex, and may involve unforeseen difficulties including material performance problems, undetected
 
38

TABLE OF CONTENTS
 
defects, or errors. Overcoming technical obstacles and correcting defects or errors could prove to be impossible or impracticable, and the costs incurred may be substantial and adversely affect our business, financial condition, and results of operations. Additionally, regulation in the AI/ML space is constantly evolving. See “—Regulatory, social and ethical issues relating to our use of new and evolving technologies, such as AI and ML, may result in reputational harm and liability.” If our technology does not function reliably, fails to meet expectations in terms of performance, or cannot be fully utilized due to increasing regulation, including regulation by the FDA of AI or medical device software, we may be unable to provide, or our customers may stop using, our solutions.
We currently host our data on, and conduct certain data analysis through, Amazon Web Services (“AWS”) cloud-based hosting facilities as well as on our own co-located or on-premise computing infrastructure. Any technical problems or outages that may arise in connection with AWS’s or our data center hosting facilities could result in operational disruption, loss of our data or delayed or ineffective data processing. A variety of factors, including infrastructure changes, human or software errors, viruses, malware, security attacks, fraud, denial of service or technical support issues could cause interruptions in our service. Such service interruptions may reduce or inhibit our ability to provide our solutions, delay our clinical trials, and damage our relationships with our customers. We could also be exposed to potential lawsuits, customer reputational impact, liability claims or regulatory actions, for example, if AWS or we experienced a privacy or data security breach. If we were required to transfer our data to an alternative hosting provider, the transfer and acclimation to the new provider could result in significant business delays and subject us to technological risks and require additional resources.
Regulatory, social, and ethical issues relating to our use of new and evolving technologies, such as AI and ML, may result in reputational harm, additional costs, and liability.
We utilize AI/ML algorithms for data analysis of patient information and other data. As with many cutting-edge innovations, AI and ML present new risks and challenges, including social and ethical issues and a quickly evolving legal and regulatory environment, which may cause us to incur increased compliance or R&D costs, or to divert resources from other development efforts. Regulation of AI/ML usage continues to evolve, and limitations placed on the use of data, including personal information, health data, or genetic/genomic data in such systems may make it difficult or more costly for us to continue using our ML algorithms. Existing laws and regulations may be interpreted to apply to us in new ways due to our use of AI and ML, the nature and extent of which are difficult to predict. The risks and challenges presented by AI and ML could undermine public confidence in AI and ML, which could slow its adoption, impact patients’ and physicians’ confidence in our solutions, and otherwise affect our business. Failure to adequately address ethical and social issues related to our use of AI/ML could adversely affect the adoption of our solutions and subject us to reputational harm, regulatory action, or legal liability, which may harm our financial condition and results of operations.
Potential government regulation related to AI ethics or usage may also increase the burden and cost of R&D in this area. Certain U.S. states have passed or are considering the passage of laws intended to regulate and/or require disclosures in connection with the usage of AI, including in interactions with customers or other market participants. For example, Colorado passed the Colorado Artificial Intelligence Act, which will require disclosures and compliance efforts associated with different uses of AI, and Utah passed the Utah Artificial Intelligence Policy Act, which requires certain disclosures to customers and confirms companies’ responsibility for legal violations caused by their AI applications. It is possible that these or other states or the federal government could pass additional legislation or implement regulations impacting businesses’ use of AI/ML, which could impact our operations and impose additional costs or liability on us. Additionally, employees or customers who are dissatisfied with our public statements, policies, practices, or solutions related to the development and use of AI and ML may express opinions that could introduce reputational or business harm, or legal liability.
We use AI/ML to assist us in making certain diagnostic and benefit prediction decisions, which AI/ML is regulated by certain privacy laws. Due to inaccuracies or flaws in the training, development, inputs, outputs, and logic of an AI/ML model, the model could be biased. Any bias in a model could result in limits on the applicability or accuracy of the model across patient populations or could lead us to make decisions that could disadvantage certain individuals (or classes of individuals) and adversely impact their rights, employment, and ability to obtain certain pricing, products, services, or benefits.
 
39

TABLE OF CONTENTS
 
We are highly dependent on our key personnel, and if we lose key members of our senior management, scientific or technical teams or are not successful in attracting, motivating, and retaining highly qualified personnel, we may not be successful.
Our ability to compete in the competitive precision medicine industry depends upon our ability to attract, motivate, and retain highly qualified personnel. We are particularly dependent on key members of our senior management team, including David D. Halbert, our Founder, Chairman, and Chief Executive Officer. The loss or incapacity of existing members of our senior management team could adversely affect our operations if we experience difficulties in hiring qualified successors and could hamper or delay the development and commercialization of our solutions and harm our business, financial condition, and results of operations. We do not maintain “key person” insurance policies on the lives of these individuals or the lives of any of our other employees.
Our R&D programs and laboratory operations depend on our ability to attract and retain highly skilled scientists, technicians, and data scientists. We may not be able to attract or retain qualified scientists and technicians in the future due to the competition for qualified personnel among life science businesses. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. In addition, we may have difficulties locating, recruiting, or retaining qualified sales representatives and business development managers. Recruiting and retention difficulties can limit our ability to support our R&D and sales programs.
To induce valuable employees to remain at our company, in addition to salary and cash incentives, we provide stock option and RSU grants with vesting conditions. The value of these equity grants may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers made to our employees from other companies. Although we have employment agreements with certain key employees, consistent with all of our employment arrangements, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. If we are unable to attract and incentivize highly qualified personnel on acceptable terms, or at all, our business, financial condition, and results of operations may suffer.
If our information technology systems or those of third parties with whom we work, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions, litigation, fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits, and other adverse consequences.
In the ordinary course of our business, we and the third-parties with whom we work collect, store, receive, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, “Process”) personal information, including health-related information, individually identifiable health information and protected health information (“PHI”) as defined by the Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations (collectively, “HIPAA”), personally identifiable information, credit card and other financial information, and intellectual property and proprietary business information (collectively “Sensitive Information”).
As a result, we and the third parties with whom we work face numerous and evolving cybersecurity risks that threaten the confidentiality, integrity, and availability of our information technology and telecommunications systems and Sensitive Information. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including telecommunications or network failures, malicious human acts, and natural disasters.
We and the third parties with whom we work are subject to threats from various threat actors, such as state-sponsored organizations, criminal threat actors, organized crime outfits, opportunistic hackers and “hacktivists,” as well as a variety of evolving threats, such as social engineering/phishing (including through deep fakes, which may be increasingly more difficult to identify as fake), malware (including ransomware and as a result of advanced persistent threat intrusions), network reconnaissance and intellectual property theft, use of illegitimate virtual private networks or anonymization tools, malfeasance by insiders (such as personnel misconduct or error), human or technological error, malicious code (such as viruses and worms),
 
40

TABLE OF CONTENTS
 
denial-of-service attacks, database compromises, business email compromises, credential stuffing, credential harvesting, credential theft, software “bugs,” misconfigurations, or other vulnerabilities in software that is integrated into our (or the third parties with whom we work) IT systems, misuse of company resources and software, lack of adherence to company policy, products or services, adware, attacks enhanced or facilitated by AI, physical or electronic break-ins, earthquakes, fires, floods, and similar disruptive threats.
Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties with whom we work are vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our services.
Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities’ systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.
We depend on information technology and telecommunications systems, including those provided by third parties and their vendors (some of which are legacy systems developed internally and may carry additional information security vulnerabilities), for significant elements of our operations, such as our laboratory information management systems, including test validation, specimen tracking, and quality control; personal information collection, storage, maintenance, and transmission; our profiling report production systems; and our billing and reimbursement, R&D, scientific and medical data analysis, and general administrative activities that collect, store and transmit large amounts of Sensitive Information, including intellectual property, proprietary business information, PHI, and other personal information of our customers, patients, business partners, employees, and contractors on such systems. In turn, the third parties and vendors with whom we work depend upon technology and telecommunications systems provided by outside vendors.
Our ability to monitor these third parties’ information security practices is limited, and these third parties may not have adequate information security measures in place. If the third parties with whom we work experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if the third parties with whom we work fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties’ infrastructure in our supply chain or that of the third parties with whom we work have not been compromised.
Cyber-attacks, malicious internet-based activity, online and offline fraud, insider threats and other similar activities are increasing in their frequency, levels of persistence, sophistication, and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we and the third parties with whom we work may be unable to anticipate these techniques or implement adequate preventative measures. We and the third parties with whom we work may also experience security incidents that may remain undetected for an extended period. There can also be no assurance that our cybersecurity risk management program and processes, including our policies, controls, or procedures, will be fully implemented, complied with or effective in protecting our information technology and telecommunications systems and Sensitive Information.
In addition, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of Sensitive Information and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for
 
41

TABLE OF CONTENTS
 
example, applicable laws or regulations prohibiting such payments. Some of these attacks have also been coupled with attackers directly threatening executives with physical harm.
Applicable privacy and data security obligations may require us to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents, or to implement other requirements such as providing credit monitoring. Such disclosures and compliance with such requirements are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. For example, a growing number of legislative and regulatory bodies around the world have adopted breach notification and other requirements in the event that information subject to such laws is accessed by unauthorized persons and additional regulations regarding the use, access, accuracy, and security of such data are possible. In particular, we are a “Covered Entity” as defined under HIPAA, and, in the event of a breach as defined by HIPAA, we have specific reporting requirements under HIPAA regulations.
Under HIPAA, in the event of a significant breach, the reporting requirements could include notification to the general public, in addition to affected individuals and certain governmental agencies. In addition, in the United States, we are subject to state and other laws that require notification. Complying with such numerous and complex regulations in the event of unauthorized access would be expensive and difficult, and failure to comply with these regulations could subject us to regulatory scrutiny and additional liability, could harm our reputation and our ability to compete, and could adversely affect our business, financial condition, and results of operations.
We take steps designed to detect, mitigate, and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties with whom we work). We may not, however, detect or remediate all such vulnerabilities including on a timely basis. By way of example, in the spring of 2024, a security researcher informed us of a previously unknown vulnerability in one of our systems, which we have remediated. Further, we may experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident. If attackers are able to exploit vulnerabilities before patches are installed or mitigating measures are implemented, compromises could impact our information technology systems and Sensitive Information.
Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our Sensitive Information or our information technology systems, or those of the third parties with whom we work. A security incident or other interruption could disrupt our ability (and that of third parties with whom we work) to provide our services. If an attacker were to gain sufficient access to our systems, our data contained in those systems could be discovered by the attacker.
We, and the third parties with whom we work have been the target of cybersecurity attacks in the past and expect that such cybersecurity incidents will continue to occur in the future. For example, the February 2024 cybersecurity attack on Change Healthcare, who we used to process certain insurance claims, resulted in a delay in our ability to submit claims for payment and could require us to issue notifications to impacted individuals and various regulators if Change Healthcare determines that any PHI of our patients was impacted. While we may be entitled to damages as a result of this incident, any award may be insufficient to cover all such damages, or we may be unable to recover such award.
We may expend significant resources or modify our business activities to try to protect against security incidents. Additionally, certain privacy and data security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and Sensitive Information.
Despite the precautionary measures we and the third parties with whom we work have taken to detect and prevent or solve problems that could affect our information technology and telecommunications systems and Sensitive Information, there is a risk that our security measures will not be fully effective in the future. Failures or significant downtime of these systems or those used by the third parties with whom we work could prevent us from conducting tests, preparing and providing reports to future customers, billing payers, conducting R&D activities, maintaining our financial controls and other reporting functions, and
 
42

TABLE OF CONTENTS
 
managing the administrative aspects of our business. Any failure by us or the third parties with whom we work to prevent or mitigate security incidents, or other adverse impact to the availability, integrity, or confidentiality of our information technology systems or Sensitive Information, or improper access to, or use, acquisition, disclosure, alteration or destruction of, any such Sensitive Information, including loss of PHI or other data subject to privacy laws or proprietary business information, could result in operational or business delays, significant liability, regulatory action, a material loss of revenue resulting from the adverse impact on our reputation and brand, a diminished ability to retain or attract new customers, disruption to our business, and adversely affect our business, financial condition, and results of operations.
Our existing cyber liability insurance policies may not cover, or may cover only a portion of, any potential claims related to security breaches to which we are exposed or may not be adequate to indemnify us for all or any portion of liabilities that may be imposed. We also cannot be certain that our existing insurance coverage will continue to be available on acceptable terms or in amounts sufficient to cover the potentially significant losses that may result from a security incident or breach or that the insurer will not deny coverage of any future claim.
In addition to experiencing a security incident, third parties may gather, collect, or infer Sensitive Information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, Sensitive Information of the Company or our customers could be leaked, disclosed, or revealed as a result of or in connection with our employees’, personnel’s, or vendors’ use of AI/ML technologies.
We may not be successful in developing and commercializing new solutions or new applications for our current solutions.
We continue to expand our R&D efforts to use our solutions and our multi-modal clinico-genomic datasets to develop enhanced versions of our solutions and create new solutions. These initiatives include expanding the application of Caris Assure to early detection, MRD tracking, and treatment monitoring, developing Caris ChromoSeq for hematological (blood) cancers, developing additional AI signatures using NGS or image data, and additional solutions, including for chronic disease states beyond cancer. The commercialization of any new solutions or new applications for our current solutions will require the completion of certain clinical development activities, validation studies and/or clinical trials, having guidelines or recommendations for healthcare providers, administrators, payers, and patient communities relating to such solutions, and receiving favorable exposure in peer-reviewed publications and from KOLs. We cannot assure you that we can successfully complete the clinical development or applicable subsequent requirements of any such solutions in order to commercialize such solutions.
We may fail to build a sustainable data licensing business, and our data licensing efforts may result in reputational harm that has an adverse effect on our business, financial condition, and results of operations.
We and our biopharma and academic partners leverage high-powered computing and AI/ML algorithms to analyze our data to find the key molecular characteristics of a particular disease or dysfunction that drives disease. As part of these efforts, we license data to our partners, and certain of our partners license data to us. We are in the early stages of these data licensing efforts and may not be able to grow these efforts into a sustainable business.
The outbound licensing of data for research purposes is a novel business model without an established track record, which makes it difficult to evaluate our future prospects and the risks and challenges we may encounter in seeking to execute on this opportunity. Although we have negotiated data licensing agreements with several partners, these partners may have rights to terminate these agreements before the initial term has been completed, and these arrangements may not be renewed, or they may be renewed on less favorable terms. In addition, many of our data licensing agreements involve the use of third-party clinical data that is combined with our molecular data and then licensed to biopharma companies or other end users, and these third-party clinical data partners may not be willing to work with us in the future. We also depend on these third-party partners to provide access to data from their own data partners. We cannot guarantee that our third-party partners will enter into new data sharing arrangements with us, continue to provide their data, or that of their partners, to us, or include their data as part of combined data sets, and in
 
43

TABLE OF CONTENTS
 
the event that any of these arrangements terminate, we may not be able to find a replacement, or a replacement may not be available on reasonable terms or in a timely manner. Any of the foregoing could result in us losing access to real-world evidence, longitudinal patient data, and clinical outcomes that are key to maintaining, expanding, and enriching our datasets, which could have an adverse effect on our business, financial condition, and results of operations.
The commercial market for licensing this type of data may not develop or may be limited by regulation or other factors, which could diminish the value of licensing this data over time and make it challenging to secure arrangements with these partners on similar terms, or at all, with any additional licensees. While our data licensing arrangements include protections against abuse and misuse of patient data, we may be unable to adequately control how our partners, or the commercial customers that they license our data to as part of a combined data set, use the data, and any abuse or misuse could adversely impact our reputation, which could have an adverse effect on our business, financial condition, and results of operations.
If we cannot maintain our current relationships, or enter into new relationships, with biopharma companies, our development of solutions could be delayed or our business, financial condition, and results of operations could be adversely affected.
We deploy our proprietary profiling and signature offerings to analyze tissue and blood samples provided by biopharma partners.
Our success in the future depends in part on our ability to maintain and expand relationships with our biopharma partners. This can be difficult due to several factors, including internal and external constraints placed on these organizations that can limit the number and type of relationships with companies like us they can consider and consummate; that certain of our agreements governing our relationships are terminable at will by our biopharma partners; and that our biopharma partners may be dissatisfied with our services. Continued usage of our services by particular biopharma partners may also depend on whether the partner obtains positive data in its clinical trials, is able to successfully obtain regulatory approval and subsequently commercializes a therapy for which we have partnered with them to develop a companion diagnostic, or other administrative factors that are outside our control. Additionally, some of our biopharma partners have contracted with us to provide profiling for large numbers of samples, which could strain our testing capacity and restrict our ability to perform tests for other customers. If we fail to maintain these relationships or enter into new ones, our business could suffer.
From time to time, we expect to engage in discussions with biopharma companies regarding commercial opportunities. There is no assurance that any of these discussions will result in a commercial agreement, or if an agreement is reached, that the resulting engagement will be successful or that any clinical trials conducted as part of the engagement will produce successful outcomes. Speculation in the industry about our existing or potential engagements with biopharma companies can be a catalyst for adverse speculation about us, our services, and our technology, which can result in harm to our reputation and our business.
We rely on third-party services to collect, process, transport, and store our samples in a secure and cost-efficient manner. If these services were disrupted, our business would be harmed.
We rely on third-party providers to collect tissue and blood samples for our solutions. If third-party providers fail to adequately and properly obtain and collect viable blood and tissue samples from patients and to properly and timely package and ship the samples to us, our patients and their physicians may experience problems and delays in receiving test results, which could lead to dissatisfaction with our solutions, therefore harming our reputation and adversely affecting our business, financial condition, and results of operations. If our current third-party providers become unable to continue to collect samples for us or if our clients are unable to readily access a provider to collect a blood or tissue sample that we can analyze, we may be unable to compete effectively with other laboratories that have greater access to phlebotomy providers and our business, may be harmed.
In addition, we may maintain samples and extracted material for several years. It is possible that the long-term stability of these samples may not be maintained with the passage of time, which could
 
44

TABLE OF CONTENTS
 
negatively impact our ability to use such samples to validate our solutions. Further, interruptions in collection, processing, freezing, storing, or transportation of samples performed by third parties, whether due to labor disruptions, weather conditions, natural disaster, terrorist acts, threats, or for other reasons could adversely affect the samples and our ability to process the samples in a timely manner, which could negatively affect our ongoing research studies and harm our business.
The clinical trial process is lengthy and expensive with uncertain outcomes. We have encountered delays, and may encounter future substantial delays, in our clinical trials, and may therefore be unable to complete our clinical trials on the timelines we expect, if at all, which could adversely impact our ability to market our solutions or receive adequate reimbursement.
Clinical testing is expensive, time-consuming, and subject to uncertainty. Initiating and completing validation studies and clinical trials necessary to validate and market our solutions, and to support any submissions to CMS, MolDX, or other payers for reimbursement, or the FDA for marketing authorization for our solutions, will be time-consuming and expensive and the outcomes are inherently uncertain. Validation studies and clinical trials must be conducted in accordance with the laws and regulations of the FDA and other applicable regulatory authorities’ legal requirements and regulations, and are subject to oversight by these governmental agencies and institutional review boards (“IRBs”).
The results of preclinical studies and clinical trials of our solutions conducted to date and ongoing or future studies and trials of our current, planned, or future solutions may not be predictive of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Our interpretation of data and results from our validation studies and clinical trials do not ensure that we will achieve similar results in future validation studies or clinical trials. In addition, preclinical and clinical data are often susceptible to various interpretations and analyses, and many companies that have believed their products performed satisfactorily in validation studies, preclinical studies and earlier clinical trials have nonetheless failed to replicate results in later validation studies or clinical trials. Products in later stages of validation studies or clinical trials may fail to show the desired analytical validity and clinical validity despite having progressed through validation studies, nonclinical studies, and earlier clinical trials.
In addition, we cannot guarantee that any validation studies or clinical trials will be conducted as planned or completed on schedule, if at all. The timely completion of validation studies in accordance with their protocols depends, among other things, on our ability to locate and test a sufficient number of samples to demonstrate satisfaction of the validation study criteria. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of participants who remain in the trial until its conclusion. Many of our validation studies and clinical trials require enrolling a large number of participants without cancer who may not see value in enrollment. Additionally, we may encounter delays as a result of the administrative complexities in managing and recruiting for validation studies and trials of this scope and size. If we are unable to recruit and enroll sufficient participants for our validation studies or clinical trials, or maintain sufficient participation of enrolled participants, our product development, commercialization activities and our ability to seek marketing authorization for our solutions could be delayed, modified, or prevented.
The initiation and completion of validation studies and clinical trials may be prevented, delayed, or halted for numerous reasons, including related to the following:
•
the inability to generate sufficient in vitro or in vivo data to support the initiation or continuation of clinical trials;
​
•
the requirement to submit an IDE application to the FDA, which must become effective prior to commencing certain human clinical trials of significant risk medical devices, and which the FDA may disapprove;
​
•
delays caused by participants withdrawing from clinical trials or failing to return for follow-up or by institutions failing to timely submit data, including follow-up data, if at all;
​
•
delays or failure in reaching a consensus or agreement, if required, with regulatory agencies on trial design or feedback from regulatory agencies necessitating changes to ongoing or planned clinical trial design;
​
 
45

TABLE OF CONTENTS
 
•
delays or failure in reaching agreement on acceptable terms with prospective contract research organizations (“CROs”), service providers, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;
​
•
delays or failure in obtaining any required IRB approvals or ethics committee (“EC”) approvals for our clinical trial sites;
​
•
delays in amending, or the inability to amend, our IRB-approved protocols at clinical trial sites when necessary or desired;
​
•
difficulty or delays in collaborating with sites, institutions, and investigators;
​
•
failure by us, investigators, sites, or participants to comply with the applicable trial protocol or applicable regulatory requirements and standards for data collection, reporting, records maintenance, or data integrity;
​
•
failure by us, investigators, sites or any CROs or other third parties to adhere to clinical trial requirements, including the applicable protocol;
​
•
failure to perform in accordance with good clinical practice (“GCP”) and good laboratory practice requirements, and/or other applicable regulations and requirements of the FDA or other applicable governmental authorities;
​
•
failure to comply with applicable privacy and data security laws related to clinical trials;
​
•
failure of our solutions to achieve acceptable performance, and safety endpoints;
​
•
unacceptable safety findings, including findings related to the risk of the false positive tests (which could lead to unnecessary biopsy or anxiety) or false negative tests (which could lead to a delay in diagnosis or disease progression);
​
•
termination or suspension of a trial or site by us or the data safety monitoring board, suspension or termination of a trial or site by an IRB, EC, or institution, or clinical hold or termination of a trial or site by a regulatory authority, including the FDA;
​
•
disqualification, termination, or suspension of a clinical investigator;
​
•
adverse inspections of our clinical trial sites or results by any applicable regulatory authority, including the FDA;
​
•
changes in statutory or regulatory requirements or guidance, or clinical guidelines, that require amending existing or designing new clinical protocols, obtaining new IRB or EC approvals, modifying our clinical trials, modifying our consent process or obtaining additional consent from trial participants, or altering the pathway to marketing authorization of our solutions;
​
•
changes in the standard of care on which a clinical development plan was based, which may require new or additional clinical trials;
​
•
the cost of clinical trials of our solutions being greater than we anticipate;
​
•
destruction or compromise of, or other inability to access or receive, clinical trial samples processed, stored, or managed at a third-party site or otherwise in the control of a third party;
​
•
clinical trials of our solutions producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development programs; and
​
•
lack of adequate funding.
​
Any such delays could adversely affect the costs, timing, or successful completion of any future clinical trials. Moreover, we may depend on our collaborators and on medical institutions and CROs to conduct any future clinical trials in compliance with applicable GCP requirements, and while we may have agreements governing their committed activities, we may have limited influence over their actual performance. To the extent any future collaborators, the CROs, or clinical sites fail to enroll participants for our clinical
 
46

TABLE OF CONTENTS
 
trials, fail to conduct the trial to GCP requirements or are delayed for a significant time in the execution of trials, including achieving full enrollment, we may be affected by increased costs, program delays, and/or enforcement actions. In addition, any future clinical trials that are conducted in countries outside the United States may subject us to further delays and expenses.
Any inability to initiate or complete clinical trials successfully could result in additional costs to us, slow down or prevent our product development and receipt of positive reimbursement and coverage decisions, or impair our ability to generate revenue. Delays in initiating or completing our planned clinical trials could also allow our competitors to bring competing products to market before we do or sooner than expected, which could impair our ability to successfully commercialize our solutions, if launched, and may harm our business, financial condition, and results of operations. In addition, many of the factors that may cause, or lead to, a delay in initiation or completion of clinical trials may also ultimately lead to the delay or the narrowing or denial of any marketing authorization we may seek with respect to our solutions. Delays in the initiation or completion of any clinical trial of our solutions, such as Caris Assure for early detection, MRD tracking, or treatment monitoring, or seeking coverage and reimbursement, will increase our costs, slow down, or jeopardize our product development and marketing authorization process, and delay or potentially jeopardize broad adoption of our solutions and their ability to generate revenue.
Risks Related to Regulation and Legal Compliance
If we or our partners fail to comply with healthcare and other applicable laws and regulations, we could face substantial penalties and sanctions and our business, reputation, financial condition, and results of operations could be adversely affected.
Our operations in the United States are subject to various U.S. federal and state laws and regulations that govern, among other things, the manner in which we provide and bill for tests and collect reimbursement from governmental programs, third-party payers and patients, our relationships with referral sources, and our marketing and advertising activities. In addition, the commercialization of our solutions outside the United States would also subject us to foreign equivalents of the healthcare laws described below, among other foreign laws. The laws that may impact our operations include:
•
the federal Anti-Kickback Statute (the “AKS”), which prohibits, among other things, knowingly and willfully soliciting, receiving, offering, or paying any remuneration (including any kickback, bribe, rebate, a provision of free or discounted goods, services or items), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order, recommendation, or arrangement of any good, facility, item, or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation, and many courts have interpreted the AKS as being violated if merely one purpose of any arrangement is to induce referrals or purchases. The AKS includes statutory exceptions and regulatory safe harbors that protect certain arrangements. Failure to meet the requirements of an exception or safe harbor, however, does not render an arrangement illegal. Rather, the government may evaluate arrangements that do not fit into an exception or safe harbor on a case-by-case basis, taking into account all facts and circumstances, including the parties’ intent and the arrangement’s potential for abuse, and such arrangements may be subject to greater scrutiny by enforcement agencies;
​
•
the Eliminating Kickbacks in Recovery Act of 2018 (“EKRA”), which establishes an all-payer anti-kickback prohibition for, among other things, knowingly and willfully paying or offering any remuneration directly or indirectly to induce a referral of an individual to or in exchange for an individual using the services of a clinical laboratory. EKRA applies to all payers including commercial payers and government payers. EKRA adopted safe harbors that are not directly analogous to the safe harbors under the AKS, and certain conduct that is permissible under the AKS may violate EKRA;
​
•
the federal physician self-referral prohibition, commonly known as the Stark Law, which, in the absence of an applicable exception, prohibits a physician from making a referral for certain
​
 
47

TABLE OF CONTENTS
 
designated health services covered by the Medicare or Medicaid program if the physician or an immediate family member of the physician has a financial relationship (including an ownership interest or a compensation arrangement) with the entity providing the designated health services. The Stark Law also prohibits the entity furnishing the designated health services from billing, presenting, or causing to be presented a claim for the designated health services furnished pursuant to the prohibited referral. The term “designated health services” includes, among other things, clinical laboratory services. Unlike the AKS, the Stark Law is violated if the financial arrangement does not meet an applicable exception, regardless of any intent by the parties to induce or reward referrals or the reasons for the financial relationship and the referral;
•
the FCA, which imposes civil and criminal liability on individuals or entities that knowingly submit false or fraudulent claims for payment to the government or knowingly make, or cause to be made, a false statement in order to have a false claim paid. Actions under the FCA may be brought by the government or by a private person under a qui tam, or “whistleblower,” suit. There are many potential bases for liability under the FCA. For example, the government has used the FCA to prosecute Medicare and other government healthcare program fraud such as coding errors, coding and billing for tests not compliant with coverage and reimbursement requirements, including MolDX reimbursement and coverage standards and requirements, waiver of patient copayments and deductibles, and performing tests that are not medically necessary or that are substandard in quality. In addition, a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA, and courts have held that claims for services furnished pursuant to a referral prohibited by the Stark Law also are considered false for purposes of the FCA;
​
•
the criminal healthcare fraud provisions of HIPAA and related rules that prohibit knowingly and willfully executing a scheme or artifice to defraud any healthcare benefit program or falsifying, concealing, or covering up a material fact or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items, or services. These criminal healthcare fraud provisions are not limited to benefits, items, or services that may be paid for by federal or state healthcare programs, and similar to the AKS, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation;
​
•
the federal Civil Monetary Penalties Law, which provides civil penalties for a wide variety of conduct relating to federal and state healthcare programs, including, subject to certain exceptions, prohibiting, among other things, the offer or transfer of remuneration, including free services, discounts, or waivers of copayments and deductible amounts (or any part thereof), to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary’s selection of a particular provider, practitioner or supplier of services reimbursable by Medicare or a state healthcare program;
​
•
the federal Physician Payment Sunshine Act, created under the Affordable Care Act (the “ACA”), and its implementing regulations, which require manufacturers of drugs, devices, biologicals, and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program to report annually to the U.S. Department of Health and Human Services (“HHS”) under the Open Payments Program, information related to payments or other transfers of value made to physicians (as defined by statute), teaching hospitals and other healthcare practitioners such as physician assistants and nurse practitioners, as well as ownership and investment interests held by such physicians and their immediate family members and similar state laws with various reporting requirements;
​
•
state self-referral, kickback, false claim, fraud, and abuse laws, some of which may apply to items or services reimbursed by any payer, including patients and commercial insurers, and include “whistleblower” provisions;
​
•
federal and state “Anti-Markup” rules, which, among other things, typically prohibit a physician or supplier billing for clinical or diagnostic tests (with certain exceptions) from marking up the price of a purchased test performed by another physician or supplier that does not “share a practice” with the billing physician or supplier;
​
 
48

TABLE OF CONTENTS
 
•
federal and state laws applicable to test ordering, documentation of tests ordered, consent requirements, billing practices and claims payment and laws that prohibit other specified practices, such as providing tests at no or discounted cost to induce adoption, which may apply to laboratories; waiving co-insurance, deductibles or other amounts owed by patients; and billing a state healthcare program at a price that is higher than what is charged to other payers;
​
•
the “No Surprises Act,” which prohibits balance billing for certain non-emergency care, including for out-of-network clinical laboratory tests, and analogous state laws;
​
•
state corporate practice prohibitions and professional fee-splitting laws that prohibit employing, exercising control over, or splitting fees with licensed medical professionals;
​
•
federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and
​
•
analogous state and foreign laws and regulations, such as state and foreign anti-kickback, self-referral, false claims, consumer protection, and unfair competition laws that may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payer, including commercial insurers; state laws that require healthcare companies to comply with the medical device industry’s voluntary compliance guidelines, the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers, and other potential referral sources or state-specific standards on financial interactions with healthcare providers; state laws that require healthcare companies to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensation, and other remuneration and items of value provided to healthcare professionals and entities; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.
​
These laws and regulations, among other things, constrain our business and limit the types of financial arrangements we have with providers, customers, patients, vendors and third-party payers, and our billing, coding, and collection practices, including our patient financial assistance programs and our practices relating to collection of co-payments and deductibles. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available and lack of clear guidance, our business activities could be subject to challenge under one or more of such laws. To enforce compliance, the Office of the Inspector General (“OIG”) and the DOJ recently have increased their scrutiny of interactions between healthcare companies, on the one hand, and healthcare providers and patients on the other, which has led to a number of investigations, prosecutions, convictions, and settlements in the healthcare industry. These investigations often are focused on billing and coding practices as well as financial arrangements with referral sources and patients. We expect that the federal government will continue to devote substantial resources to investigating healthcare providers’ compliance with the FCA and other applicable fraud and abuse laws.
We also have been, are currently, and may be in the future, subject to actions or investigations relating to our arrangements and interactions with healthcare professionals and patients. For additional information, see “—We have been, are currently, and in the future may be the subject of government investigations, claims, audits, whistleblower and payer audits, overpayment and recoupment efforts and other litigation in the course of our business that could adversely affect our business and financial statements.”
Efforts to ensure that our business arrangements will comply with applicable laws, including healthcare laws and regulations, may involve substantial costs. In addition, the healthcare and other laws applicable to our business may change or be amended, and, it is possible that governmental and enforcement authorities will conclude that our business practices do not comply with current or then-existing statutes, regulations, or case law interpreting applicable fraud and abuse or other healthcare or applicable laws and regulations. We may not properly interpret certain requirements or fail to timely report activities, when required. If any such actions are instituted against us, and we are not successful in defending ourselves, those actions could have a material impact on our business, including the imposition of significant civil,
 
49

TABLE OF CONTENTS
 
criminal, and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, imposition of forward-looking compliance obligations, and curtailment of our operations, any of which could adversely affect our business, financial condition, and our results of operations.
We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign privacy and data security laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to privacy and data security. Our actual or perceived failure to comply with privacy and data security obligations (or such failure by the third parties with whom we work) could result in significant liability, administrative or governmental penalties, reputational harm and/or, other adverse business consequences.
In the ordinary course of business, we process Sensitive Information, including personal information, genetic information, and data about trial participants in connection with clinical trials. These data processing activities subject us to numerous federal, state, and foreign privacy and data security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations, including AI/ML usage, relating to privacy and data security.
In the United States, numerous state and federal laws and regulations govern the privacy and security of personal information, including health-related information, such as data breach notification laws, personal information privacy laws, consumer protection laws (for example, Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). HIPAA establishes a set of national privacy and security standards for the protection of individually identifiable health information, by health plans, healthcare clearinghouses and certain healthcare providers (“Covered Entities”), as well as for entities that perform certain services for or on behalf of such Covered Entities that involve creating, receiving, maintaining, or transmitting PHI (“Business Associates”), and their covered subcontractors. We are a Covered Entity when performing our healthcare services for customers, and also act as a Business Associate when performing certain services for or on behalf of Covered Entities.
When we act as a Covered Entity, for example, through services provided by Caris MPI, Inc., we are subject to certain obligations such as notice of privacy practices and secure handling of protected health information. In addition, when we act as a Business Associate of Covered Entities, for example, through services provided by our other entities, we are subject to certain provisions of HIPAA and the terms of any business associate agreements we enter into with such other Covered Entities. In addition, we may obtain health information from third parties that are subject to privacy and security requirements under HIPAA.
Under HIPAA, Covered Entities must report breaches of unsecured PHI to affected individuals without unreasonable delay, not to exceed 60 days following discovery of the breach by a Covered Entity or its agents. Notification also must be made to the HHS Office for Civil Rights and, in certain circumstances involving large breaches, to the media. Business associates must report breaches of unsecured PHI to Covered Entities during the timeframe outlined in the operative Business Associate Agreement, but in no even longer than 60 days of discovery of the breach by the Business Associate or its agents. A non-permitted use or disclosure of PHI is presumed to be a breach under HIPAA unless the Covered Entity or Business Associate establishes that there is a low probability the information has been compromised consistent with requirements enumerated in HIPAA.
Entities that are found to be in violation of HIPAA as the result of a breach of unsecured PHI, a complaint about privacy practices or an audit by HHS may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. HIPAA also authorizes state Attorneys General to file suit on behalf of their residents. Courts may award damages, costs and attorneys’ fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.
Certain states have also implemented genetic testing and privacy laws imposing specific patient consent requirements and protecting test results by strictly limiting the disclosure of those results. In
 
50

TABLE OF CONTENTS
 
addition, in the past few years, more than a dozen U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data; however, many of these laws have exceptions for entities subject to HIPAA or include exemptions for data subject to HIPAA, including clinical data protected under HIPAA and clinical trial data. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020 (“CPRA”) (collectively, “CCPA”), applies to personal information of consumers, business representatives, and employees who are California residents, and gives California residents expanded rights regarding their personal information, including the right to opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for fines of up to $7,500 per intentional violation, as well as a private right of action for certain data breaches. Although the CCPA exempts some data processed in the context of clinical trials and information subject to HIPAA, the CCPA increases compliance costs and potential liability with respect to other personal information we maintain about California residents.
We may also be subject to new laws governing the privacy of consumer health data, including genetic information. For example, Washington’s My Health My Data Act broadly defines consumer health data, imposes obligations and restrictions on processing consumer health data (including imposing stringent requirements for consents), provides consumers certain rights with respect to their health data, and creates a private right of action to allow individuals to sue for violations of the law. More than a dozen states have also adopted laws regarding the processing, privacy, and security of genetic information or expanded their comprehensive privacy laws to include additional restriction on companies with respect to processing of sensitive personal information, including genetic information; however, many of these laws have exceptions for entities subject to HIPAA or include exemptions for data subject to HIPAA, including clinical data protected under HIPAA and clinical trial data.
Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. While several of these laws exempt some data processed in the context of clinical trials or deidentified information under HIPAA, such laws could have potentially conflicting requirements and may increase our compliance costs and potential liability. We could be adversely affected if such laws and other state or federal legislation or regulations applicable to us require changes in our business practices (including our ability to license deidentified information to biopharma companies) or privacy policies, or if governing jurisdictions interpret or implement their legislation or regulations in ways that adversely affect our business, financial condition, and results of operations.
Furthermore, violation of consumers’ privacy rights or failure to take appropriate steps to keep consumers’ personal information secure may constitute unfair and/or deceptive acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act, including entities subject to HIPAA. The Federal Trade Commission (“FTC”) expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits particularly strong safeguards. We publish privacy policies, marketing materials, and other statements, such as compliance with certain certifications or self-regulatory principles, regarding privacy and data security. If these policies, materials, or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.
In addition, we seek to utilize biological samples and data from participants in our clinical trials and validation studies in accordance with applicable law, IRB requirements, and participant permissions (through consent forms and HIPAA authorizations). If we are unable or significantly restricted in using participant samples and data for secondary research purposes, our ability to develop additional solutions and/or improve or refine existing solutions will be limited, which may impact our business and prospects.
Moreover, we are subject to laws, regulations, and standards governing certain marketing, advertising, and other communications conducted by telephone, fax, or text. In particular, sending short message service text messages to participants and prospective participants in our clinical trials is governed by the Telephone Consumer Protection Act (“TCPA”) which imposes various consumer consent requirements
 
51

TABLE OF CONTENTS
 
and other restrictions on communications with consumers. Although we may be able to rely on certain exemptions for healthcare-related purposes, any actual or perceived violations of the TCPA can result in significant financial penalties, including penalties or criminal fines imposed by the Federal Communications Commission or fines of up to $1,500 per violation imposed through private litigation or by state authorities.
In addition, because we accept debit and credit cards payments, we are subject to the Payment Card Industry Security Standard (“PCI-DSS”), issued by the Payment Card Industry Security Standards Council; however, we rely on third-party payment processors to process such payments who are also separately subject to PCI-DSS. Noncompliance with PCI-DSS can result in penalties ranging from $5,000 to $100,000 per month by credit card companies, litigation, damage to our reputation, and revenue losses. If we or our third-party payment processors are unable to comply with the PCI-DSS, we may be subject to fines, restrictions, expulsion from card acceptance programs, or other consequences which could affect our business. Moreover, it is not guaranteed that PCI-DSS compliance will prevent illegal or improper use of our third-party payment processors’ payment systems or the theft, loss or misuse of payment card data or transaction information.
Our business also increasingly relies on AI to improve our services. However, the development and use of AI presents various privacy and data security risks that may impact our business and is subject to various laws. For example, several countries, states, and localities have proposed or enacted measures related to the use of AI in products and services, including the EU’s AI Act, which may limit our ability to utilize AI or make utilization of such technology more expensive. The effects of these regulations are difficult to predict, and we expect other jurisdictions will adopt similar laws. Additionally, certain privacy laws extend rights to consumers (such as the right to delete certain personal information) and regulate automated decision making, which may be incompatible with our use of artificial intelligence. These obligations may make it harder for us to conduct our business using artificial intelligence, lead to regulatory fines or penalties, require us to change our business practices, retrain our artificial intelligence, or prevent or limit our use of artificial intelligence. For example, the FTC has required other companies to turn over (or disgorge) valuable insights or trainings generated through the use of AI where they allege the company has violated privacy and consumer protection laws. If we cannot use AI or that use is restricted, our business may be less efficient, or we may be at a competitive disadvantage.
Outside the United States, an increasing number of laws, regulations, and industry standards may govern privacy and data security. For example, the European Union General Data Protection Regulation (the “EU GDPR”) and to the United Kingdom General Data Protection Regulation and Data Protection Act 2018 (collectively, the “UK GDPR”) (the EU GDPR and UK GDPR together referred to as the “GDPR”) impose strict requirements for processing personal data. The GDPR imposes stringent and comprehensive data protection requirements, and provides for greater penalties for noncompliance. The GDPR expands the rights that individuals have to request access, correction, and deletion of their personal data, although certain exceptions exist for scientific research, and makes notification of data breaches to supervisory authorities and data subjects mandatory in certain circumstances. In addition, the GDPR imposes additional compliance obligations and local law derogations in relation to the processing of special category or sensitive personal data under the GDPR (e.g., health data); we may be subject to diverging requirements under EU member state laws and the United Kingdom (“UK”) laws, such as whether consent can be used as a legal basis for processing. Where we rely on consent as a legal basis for processing, the validity of informed consent from patients may be challenged, which could force us to stop offering our services, which could hinder our business and operations. In addition, as laws develop, we may need to make operational changes to adapt to diverging rules, which could increase our costs and adversely affect our business. The GDPR also regulates cross-border transfers of personal data outside of the EEA (in the case of the EU GDPR) and UK (in the case of the UK GDPR) and recent case law and regulatory guidance have increased legal complexity and uncertainty regarding international personal data transfers, which we expect to continue. In particular, we expect international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. As the regulatory guidance and enforcement landscape in relation to data transfers continue to develop, we could suffer additional costs, complaints and/or regulatory investigations or fines; we may have to stop using certain tools and vendors and make other operational changes.
Penalties and fines for failure to comply with the GDPR include fines of up to 20 million euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual
 
52

TABLE OF CONTENTS
 
global revenue, whichever is greater, and since we are subject to the supervision of relevant data protection authorities under both the EU GDPR and UK GDPR, we could be fined under each of those regimes independently in respect of the same breach. In addition to fines, a breach of the EU GDPR and/or UK GDPR may result in regulatory investigations, reputational damage, orders to cease/ change our data processing activities, enforcement notices, assessment notices (for a compulsory audit) and/ or civil claims (including class actions).
In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, we expect the existing legal complexity and uncertainty regarding international data transfers from the European Economic Area (“EEA”) and the UK to continue. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA’s standard contractual clauses, the UK’s International Data Transfer Agreement/Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges. As the regulatory guidance and enforcement landscape in relation to data transfers continues to develop, there is no assurance that we can continue to satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR’s cross-border data transfer limitations.
We furnish to biopharma partners and academic researchers genomic information that has been de-identified in accordance with applicable laws, regulations, and the requirements governing the clinical trial. Any data transferred pursuant to international health information privacy regulations is transferred under relevant data protection agreements at the direction of the Data Controller. We may also furnish our biopharma partners and academic researchers with identifiable genomic information for research purposes, so long as such disclosure has been consented to by the patient and/or approved by an IRB or other ethical or privacy review board. The laws of certain states and countries may require specific consent from the individual either to retain or utilize certain genetic information for research or other purposes even if such information has been de-identified, or may require that we obtain a waiver of such consent from an ethical or privacy review board. Even where we furnish to biopharma partners and academic researchers genomic information that has been de-identified in accordance with applicable laws and regulations, biopharma partners or academic researchers may use technology or other methods to link that de-identified genomic information to the patient from whom it was obtained in contravention of one or more applicable laws and regulations. A finding that we have failed to comply with any such laws and any remedial activities required to ensure compliance with such laws could cause us to incur substantial costs, to be subject to unfavorable publicity or public opinion, to change our business practices, or to limit the retention or use of genetic information in a manner that, individually or collectively, could be adverse to our business.
Obligations related to privacy and data security (and consumers’ data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. For example, HHS issued a notice of proposed rulemaking on January 6, 2025, clarifying existing requirements and imposing new security requirements for entities subject to HIPAA. The agency received thousands of proposed comments, and may adjust or clarify the rule as part of the rule making process. Under President Trump’s Regulatory Freeze Pending Review executive order, HHS cannot issue a final rule until a President-appointed department
 
53

TABLE OF CONTENTS
 
head has reviewed and approved the rule. It is uncertain whether the proposed rule will move forward in its current state and what the timing of a final rule will be. If adopted in a form similar to the proposed rule, we anticipate our compliance costs could increase substantially. We would need to invest in additional cybersecurity technologies, hire specialized personnel, and potentially redesign certain aspects of our systems and processes. These investments were not contemplated in our current business plan and could impact our profitability. If we are unable to comply with new requirements by any prescribed deadlines, we could face penalties, enforcement actions, reputational damage, and potential loss of business from customers. While we have begun assessing our current security posture against the proposed requirements, the uncertainty regarding the final rule makes comprehensive preparation difficult.
Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. We also expect that there will continue to be new laws, regulations, and industry standards concerning privacy and data security proposed and enacted in various jurisdictions in which we do business. In addition to privacy and data security laws, we are also bound by other contractual obligations related to privacy and data security. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.
Compliance with privacy and data security obligations could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. We strive, and contractually obligate our vendors, to comply with applicable laws, regulations, policies, and other legal obligations relating to privacy and data security. However, the various regulatory frameworks for privacy and data protection are, and are likely to remain, uncertain, and it is possible that these or other actual or alleged obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other rules and subject our business practices to uncertainty. In addition, it is not guaranteed that regulators or consumers will agree with our interpretation of our obligations or our steps to comply with them. Any actual or perceived failure by us to comply with privacy and data security laws, rules, regulations, industry standards and other obligations could result in proceedings or actions against us by individuals, consumer rights groups, government agencies, or others, or orders to cease/ change our data processing activities. We could incur significant costs in investigating and defending such claims and, if found liable, pay significant damages or fines or be required to make changes to our business practices. Further, these proceedings and requires to any subsequent adverse outcomes may subject us to significant negative publicity and an erosion of trust. If any of these events were to occur, our business, financial condition, and results of operations could be adversely affected.
We have current solutions marketed as LDTs and plan to launch future solutions as LDTs. The FDA recently finalized a rule, which has since been vacated by a federal court, pursuant to which it plans to subject LDTs to medical device requirements through a phase-out of its historical policy of enforcement discretion over LDTs over a period of four years. The phase-in of medical device requirements to LDTs, including the potential requirement for FDA marketing authorization, will be costly and time-consuming, and if we fail to comply with such requirements, or if we cannot ultimately obtain marketing authorization for our LDTs where required, our business, financial condition, and results of operation could be adversely affected.
We have obtained a PMA approval from the FDA for MI Cancer Seek as a companion diagnostic device. We currently anticipate eventually seeking FDA approval for Caris Assure and additional solutions. Except for MI Cancer Seek, we currently offer our NGS solutions, MI Tumor Seek Hybrid and Caris Assure, and our AI solutions, such as GPSai and FOLFIRSTai, as LDTs. LDTs are IVD tests that are intended for clinical use and are designed, manufactured, and used within a single laboratory. Until recently, the FDA has historically exercised enforcement discretion and has not enforced certain otherwise potentially applicable FDA requirements, including premarket review, with respect to LDTs, with certain exceptions.
Even under that enforcement discretion policy, the FDA has issued warning letters to, and published Medical Device Safety Communications about, manufacturers for commercializing laboratory tests that were purported to be LDTs but the FDA alleged failed to meet the definition of an LDT or that otherwise were not subject to the FDA’s enforcement discretion policy. If our current solutions fail to meet the definition of an LDT, our business, financial condition, and results of operations could be adversely affected.
 
54

TABLE OF CONTENTS
 
The FDA has for a number of years stated its intention to modify its enforcement discretion policy with respect to LDTs and enforce applicable medical device requirements to LDTs more broadly. The FDA proposed an amendment to its regulations in October 2023 to clarify the FDA’s historical view that LDTs are medical devices subject to the requirements applicable to IVDs, and to phase out its enforcement discretion policy over a period of four years from issuance of the final rule, which would involve a phase-in of medical device requirements to these products over this time period. The FDA issued this final rule on May 6, 2024, which will subject our solutions currently marketed as LDTs and any solutions that we may market as LDTs in the future to the FDA’s regulatory requirements applicable to medical devices following this phase-in period, potentially including the requirement for an FDA premarket review and marketing authorization. On March 31, 2025, the United States District Court for the Eastern District of Texas vacated the FDA's LDT final rule.
In connection with the final rule, the FDA established certain new and targeted enforcement discretion policies, including, among others, for LDTs marketed as of the date of publication of the final rule on May 6, 2024, as well as for LDTs that have received approval from NY CLEP. Specifically, the FDA intends to exercise enforcement discretion and not enforce certain medical device requirements (including the requirements for marketing authorization and compliance with certain elements of the Quality System Regulation (“QSR”) with respect to LDTs that were marketed as of the date of the final rule’s publication, although such products must still comply with certain other FDA requirements, including registration and listing, portions of the QSR, medical device reporting, labeling, and corrections and removals reporting. However, where these tests are modified in certain ways from the version of the test marketed as of the final rule’s publication date, this enforcement discretion policy will no longer apply and the FDA intends to enforce all applicable FDA requirements (including premarket review and marketing authorization requirements) consistent with the phase-in policy. In addition, for LDTs that receive approval from NY CLEP, FDA intends to not enforce marketing authorization requirements when these requirements are phased in more generally at either three and a half or four years following the date of publication of the final rule. However, these tests will still be subject to the remaining medical device requirements, including registration and listing, medical device reporting, and quality system requirements, at the time that such requirements are phased in more generally.
Notwithstanding these new targeted enforcement discretion policies, depending on the kinds of future changes we make to our currently-marketed LDTs or any NY CLEP-approved LDT we offer, we may become subject to the application of the phase-in of all FDA medical device requirements, including the need to seek and obtain marketing authorization, at the time that those medical device requirements are phased in more generally. If we are unable to comply with the phase-in of medical device requirements applicable to LDTs over the phase-in period, we may be required to cease marketing any solutions that we market as LDTs. In addition, efforts by the FDA to actively regulate LDTs could create a negative public perception about the validity, safety, effectiveness, or performance of LDTs, including our solutions, which could adversely affect patient, provider, and customer perception about, and confidence in, our solutions.
Moreover, the FDA may assert that we are improperly marketing our LDTs and may take enforcement action against us and/or require premarket review and marketing authorization even before the deadline for phasing in medical device requirements for LDTs. If the FDA begins to phase out its policy of enforcement discretion for LDTs as recently described in its final rule affirmatively subjecting LDTs to medical device regulation, or if it asserts that our LDTs are not eligible for application of its new and targeted enforcement discretion policies, or we may be required to obtain marketing authorization for our LDT solutions from the FDA prior to initially launching our solutions or may be required to cease marketing any commercially marketed solutions that are marketed as LDTs until such marketing authorization is obtained or the applications are submitted. There can be no assurance that we will be able to obtain such marketing authorization or that any labeling claims will be consistent with the claims we have made or intend to make for such solutions when launched as LDTs, or that such claims will be adequate to support continued adoption of and reimbursement for our solutions. The FDA may request that we provide additional analyses and information beyond that which we intend to produce based on the designs of our current and planned validation studies or clinical trials, or that we modify or narrow our intended use or product claims. It is possible that the FDA, among other things, may disagree with our interpretation of data we have relied on to support our LDT launches for our intended uses. If we are required to provide additional analyses
 
55

TABLE OF CONTENTS
 
or additional data or perform additional clinical trials beyond those we currently contemplate to support the intended uses of our solutions, our planned commercial launches may be delayed and we may be required to cease commercialization of any solutions we currently market as LDTs. Even if our solutions are allowed to remain on the market prior to any required marketing authorization, demand or reimbursement for our solutions may decline if there is uncertainty about our solutions, if we are required by the FDA to label our solutions as investigational, or if the FDA limits the labeling claims we are permitted to make for our solutions. As a result, we could experience significantly increased development costs and a delay in generating additional revenue from our current or future solutions, which could reduce our revenues or increase our costs and adversely affect our business, financial condition, and results of operations. Additionally, an FDA enforcement action against us, a delay in the launch of our solutions, or significantly narrowing their intended uses, could negatively impact our business, financial condition, and results of operations.
In addition, Congress has, for over the past decade, considered a number of proposals, which if enacted, would subject LDTs to additional regulatory requirements. For example, in recent years Congress has worked on legislation to create a novel regulatory framework governing a new category of FDA-regulated products, referred to as in vitro clinical tests (“IVCTs”), which would govern LDTs and would be separate and distinct from the existing medical device regulatory framework. For example, in March 2023, the Verifying Accurate Leading-edge IVCT Development Act of 2023 (the “VALID Act”) was introduced. The bill would establish a risk-based approach to imposing requirements related to premarket review, quality systems, and labeling requirements on all IVCTs, including LDTs, but would grandfather certain LDTs marketed before the effective date of the bill and exempt them from certain requirements. It is unclear whether the VALID Act or any other legislative proposals (including any proposals to reduce FDA oversight of LDTs) will be passed by Congress or signed into law by the President and it is also unclear whether the FDA’s recent rulemaking around LDTs or related court decisions will impact Congress’s willingness to pass legislation relating to LDTs. Any such legislation could substantially alter our marketing of LDTs and negatively impact our business, financial condition, and results of operations.
Our early detection and MRD tracking assays are intended to introduce new approaches to cancer detection, which present a number of novel and complex issues for FDA review. Because the FDA has never provided marketing authorization for an early detection test and has only granted marketing authorization in limited instances for MRD tests, it is difficult to predict what information we will need to submit to obtain approval of a PMA from the FDA for a proposed intended use of early detection or MRD tracking, or if we will be able to obtain such approval on a timely basis or at all.
The FDA has never granted marketing authorization for a early detection test and has only granted marketing authorization in limited instances for MRD tests. Therefore, obtaining FDA approval for Caris Assure for early detection and/or MRD tracking presents a number of novel issues. For example, in November 2023, the Molecular and Clinical Genetics Panel (the “Panel”) of the FDA’s Medical Devices Advisory Committee held a public meeting in which the Panel discussed and made recommendations on the design of MCED IVD devices as well as potential study designs and study outcomes of interest that could inform the assessment of the probable benefits and risks of MCED screening tests. The FDA may continue to modify its thinking on how to evaluate the performance of these types of tests, as well as its views around MRD tests. As such, we believe the FDA requirements that will govern any early detection or MRD tracking test we develop, as well as the breadth and nature of data we must provide the FDA, to support the proposed intended use, will remain subject to change.
Given the novel nature and complexity of our early detection and MRD tracking assays, we cannot be certain whether we will receive FDA marketing authorization for our screening tests and whether the trials we eventually conduct will be sufficient to provide the data that the FDA requires to support a proposed intended use. The FDA may require us to perform new analyses of future clinical data or perform additional clinical trials beyond any trials that we may conduct in the future. We may be required to undertake significant efforts to address the FDA requests, which could delay or prevent approval, lead to a more limited intended use statement than the broader intended use statement we plan to pursue, and/or lead to significant post-approval limitations or restrictions, if approval is obtained at all.
Our business could be adversely affected by legal challenges to our business model or by actions restricting our ability to provide the full range of our solutions.
Many states prohibit, by statute, regulation, guidance from professional licensing boards or state attorneys general or under common law, the unlicensed practice of medicine. Corporate practice restrictions
 
56

TABLE OF CONTENTS
 
are generally designed to prohibit a non-professional entity, such as us, from practicing medicine, employing physicians, or controlling or unduly influencing the professional practice and clinical decision making of physicians. The laws relating to corporate practice vary from state to state and are subject to change and to evolving interpretations by courts, state licensing boards and state attorneys general, among others. Further, changes to the membership or staff of state agencies, licensing boards or attorney general offices could lead to increased enforcement of these laws and regulations. In addition, many states also have laws that prohibit a non-professional entity or individual from sharing in or splitting profits or professional fees for patient care, often referred to as “fee-splitting.” Some states also prohibit entities from engaging in certain financial arrangements, such as fee-splitting, with physicians. The laws relating to fee-splitting also vary from state to state and are not fully developed or uniformly enforced. Generally, these laws restrict business arrangements that involve a physician sharing professional fees with a non-professional source, but in some states, these laws have been interpreted to extend to other agreements between physicians and business entities under some circumstances.
Our test reports delivered to physicians provide information regarding solutions that oncologists and other physicians may use in making treatment decisions for their patients. We also employ pathologists and other medical professionals that interpret results of our solutions and sign our profiling results. These pathologists, physicians and other medical professionals are employed through our subsidiary non-profit corporation, Caris Molecular Pathology, which we believe complies with state corporate practice prohibitions and professional fee-splitting prohibitions. A governmental authority or other parties could allege that the business practices and services we provide constitute the practice of medicine or violate professional fee-splitting prohibitions and that our structure and arrangements are not compliant. A state may seek to have us discontinue the related services we provide, or subject us to fines, penalties, or other sanctions. Any determination that we are practicing medicine without a license may result in significant liability to us, and our business and reputation would be harmed.
Obtaining and maintaining regulatory authorization of our solutions in one jurisdiction does not mean that we will be successful in obtaining regulatory authorization of our solutions in other jurisdictions.
Obtaining and maintaining regulatory authorization of solutions in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory authorization in any other jurisdiction, but a failure or delay in obtaining regulatory authorization in one jurisdiction may have a negative effect on the regulatory authorization process in others. For example, even if the FDA or a comparable foreign regulatory authority grants marketing authorization for our solutions, comparable regulatory authorities in foreign jurisdictions may also need to authorize the solutions in those countries. Premarket authorization processes vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional clinical trials, because clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions or the data may not be considered applicable to the jurisdiction’s intended patient population. For example, while we have obtained a PMA approval from the FDA for MI Cancer Seek, we do not have any non-U.S. approvals for this solution, and there can be no assurance that we receive any such approvals in the future. In some cases, the price that we intend to charge for our solutions may also be subject to approval. In addition, NY CLEP approval is required in order to market LDTs in New York State. We have not received NY CLEP approval for Caris Assure.
Obtaining foreign regulatory authorization and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties, and costs for us and could delay or prevent the introduction of our solutions in certain countries. If we fail to comply with the regulatory requirements in other jurisdictions, or we fail to receive necessary or desirable marketing authorizations in other jurisdictions, our target market will be reduced and our ability to realize the full market potential of our solutions will be harmed.
Our employees, independent contractors, consultants, commercial partners, customers, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
We are exposed to the risk of fraud, misconduct, or other illegal activity by our employees, independent contractors, consultants, commercial partners, customers, and vendors. Misconduct by these
 
57

TABLE OF CONTENTS
 
parties could include intentional, reckless and negligent conduct that fails to: comply with the rules and regulations of the CMS, the FDA, and other comparable foreign regulatory authorities; provide true, complete and accurate information to such regulatory authorities; comply with manufacturing and clinical laboratory standards; comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. Since we began commercializing MI Profile, Caris Assure and our earlier solutions in the United States, our potential exposure under such laws has increased significantly, and our costs associated with compliance with such laws have, and will likely continue to, increase. In particular, research, sales, marketing, education, and other business arrangements in the healthcare industry are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing, and other abusive practices, as well as off-label product promotion. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs, and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of participant recruitment for clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a Corporate Compliance Program, but it is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. Even if it is later determined after an action is instituted against us that we were not in violation of these laws, we may be faced with negative publicity, incur significant expenses defending our actions, and have to divert significant management resources from other matters. We expect our exposure to and costs associated with compliance with healthcare fraud and abuse laws to increase significantly if we commercialize additional solutions in the future.
We use medical and hazardous materials that require considerable expertise and expense for handling, storage, or disposal and may result in claims against us.
We and our facilities are subject on an ongoing basis to federal, state, and local laws and regulations governing the use, storage, handling, and disposal of regulated medical waste, hazardous waste, and biohazardous waste, including chemicals, biological agents and compounds and blood and other tissue specimens. We cannot eliminate the risk of accidental contamination or injury to employees, consultants, or third parties from the use, storage, handling, or disposal of these materials. Typically, we use licensed or otherwise qualified outside vendors to dispose of this waste. However, many of these laws and regulations provide for strict liability, holding a party potentially liable without regard to fault or negligence. As a result, we could be held liable for damages and fines if our, or others’, business operations or other actions result in contamination of the environment or personal injury due to exposure to hazardous materials. Our costs for complying with these laws and regulations cannot be estimated or predicted with accuracy and depends on a number of factors, including the amount and nature of waste we produce, which depends in part on the number of tests we perform, and the terms we negotiate with our waste disposal vendors.
We have been, are currently, and in the future may be the subject of government investigations, claims, audits, whistleblower and payer audits, overpayment and recoupment efforts and other litigation in the course of our business that could adversely affect our business and financial statements.
Healthcare companies are subject to various criminal, civil, and administrative investigations and audits by governmental authorities. Both federal and state government agencies have heightened civil and criminal enforcement efforts in recent years and expanded collaborative program integrity initiatives. These efforts have led to a number of investigations, prosecutions, convictions, and settlements in the healthcare industry involving federal civil and criminal false claims laws, other healthcare fraud and abuse laws, and civil monetary penalties laws, including the FCA. Further, under the FCA, private parties may bring qui tam, or “whistleblower,” lawsuits on behalf of the government in connection with alleged false claims for payments submitted to the government or improper retention of overpayments, and these types of actions can be “under seal” for a long period of time while regulatory authorities investigate. The private parties who bring FCA lawsuits are entitled to share in any amounts recovered by the government. When an entity is
 
58

TABLE OF CONTENTS
 
determined to have violated the FCA and other criminal healthcare fraud laws, the government may impose substantial civil and criminal fines and penalties for each false claim, plus up to treble damages, and exclude the entity from participation in Medicare, Medicaid, and other federal healthcare programs. In addition, a number of states have adopted their own false claims and whistleblower provisions.
We have been, are currently, and may in the future be subject to lawsuits, qui tam actions, CIDs, subpoenas, investigations, audits, and other inquiries related to our operations. We have also been, are currently, and may be in the future, subject to subpoenas, CIDs, actions, or investigations relating to our arrangements and interactions with third parties such as healthcare professionals, healthcare institutions, market participants, or patients.
For example, in March 2025, we received a CID from the DOJ in connection with an investigation under the False Claims Act regarding our compliance with Medicare's date of service rule (also referred to as the 14-day rule), particularly focused on patients of certain health care providers, and our policies, procedures, and training related to compliance with the 14-day rule. The related investigation continues to evolve and is in too early a stage to assess potential outcomes. We are cooperating with the investigation. We have implemented compliance policies, procedures, and training designed to foster compliance with the 14-day rule, but there can be no certainties regarding the outcome of the CID. In June 2022, we entered into a settlement agreement with the United States in connection with a previous investigation into our compliance with the 14-day day rule. Pursuant to this settlement agreement, under which we admitted no fault or liability, we paid approximately $2.9 million in restitution and penalties and we obtained a nationwide release from all 14-day rule claims prior to January 1, 2018. For additional information see “Business—​Legal Proceedings.” These interactions could result in the government or other parties pursuing legal claims against us that may result in liabilities, including damages penalties, the potential for exclusion from participation in federal healthcare programs, or the imposition of additional compliance and reporting requirements as part of a corporate integrity agreement, any of which could have an adverse effect on our business, financial condition, reputation, and results of operations.
We are subject to audits and investigations of the ordering, billing, and coding of our solutions, including whether these services were properly ordered, billed, and coded or otherwise compliant with requirements for coverage and payment. In particular, as a result of our participation in the Medicare and Medicaid programs, we face and are currently subject to various governmental reviews, audits, and investigations to verify our compliance with these program requirements and applicable laws and regulations. Government agencies and their agents, such as the MACs and Recovery Audit Contractors (“RACs”), as well as the OIG, CMS, and state Medicaid programs, conduct audits of post-payment reviews to detect and correct improper payments in the Medicare program. Private third-party payers conduct similar reviews, audits and pre-payment and post-payment audits. Government agencies and their contractors and other third-party payers regularly conduct audits and request documentation to support claims submitted for payment of services rendered and compliance with claim submission requirements. We are routinely subject to audits under various government programs and third-party payers, and any delays timely providing requested records, negative audit findings or allegations of fraud or abuse may subject us to liability, such as overpayment liability, refunds or recoupments of previously paid claims, payment suspension or the revocation of billing or payment privileges in governmental healthcare programs or other third-party payer programs. Such actions, if imposed on us or our subsidiaries, could adversely impact our business, financial condition, and results of operations. In addition, we perform internal audits and monitoring. Depending on the nature of the conduct uncovered in such audits, and whether the underlying conduct could be considered systemic, the resolution of these audits could have an adverse effect on our business, financial condition, and results of operations.
Responding to government investigations, qui tam lawsuits, payer audits, subpoenas, CIDs, or other legal and administrative proceedings can be time- and resource-consuming and can divert management’s attention from the business. Even an unsuccessful challenge or investigation into our practices could cause unfavorable publicity and require us to incur significant costs, resulting in an adverse effect to our reputation and business. If our operations are found to be in violation of applicable laws or regulations, we may be subject to civil and criminal penalties, including significant fines or damages or other sanctions, including exclusion from government healthcare programs. Settlements of lawsuits involving Medicare and Medicaid issues routinely require both monetary payments and corporate integrity agreements that
 
59

TABLE OF CONTENTS
 
require the imposition of substantial compliance and reporting requirements, any of which could have an adverse effect on our business, financial condition, and results of operations.
Healthcare reform measures or changes in policy or government spending could cause significant harm to our business, financial condition, and results of operations.
Healthcare systems are subject to ongoing reform in the United States and abroad. Federal and state governments have made, and continue to make, significant modifications to the Medicare and Medicaid programs through statutory and regulatory changes, administrative rulings and other interpretations and determinations. For example, in the United States, the ACA made a number of substantial changes to the way healthcare is financed both by government and private insurers. The ACA, among other things, included provisions governing enrollment in federal and state healthcare programs, reimbursement matters, and fraud and abuse. We expect these and other provisions will influence our industry and our operations in ways that we cannot currently predict. Since its enactment, there have been judicial and congressional challenges to certain aspects of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the “IRA”) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that efforts to reform, modify, or repeal parts of the ACA may continue under the new presidential administration.
In recent years, legislative and regulatory changes have resulted in limitations and reductions in reimbursement levels and payments to healthcare providers for certain services under the Medicare program. For example, In April 2014, Congress passed PAMA, which included substantial changes to the way in which clinical laboratory services are paid under Medicare. In addition, Congress established automatic spending reductions under the Budget Control Act of 2011 (the “BCA”), resulting in a 2% reduction in Medicare payments that began in 2013, and due to subsequent legislative amendments, will remain in effect until 2032, unless additional Congressional action is taken. In addition, as a result of the American Rescue Plan Act of 2021 (“ARPA”), an additional Medicare payment reduction of up to 4% was required to take effect in January 2022; however, Congress has delayed implementation of this reduction until 2025. It is difficult to predict whether, when or what other deficit reduction initiatives may be proposed by Congress. We anticipate that the federal budget deficit will continue to place pressures on government healthcare programs and impose additional spending reductions.
In addition to changing federal policy and regulatory oversight, states and third-party payers may also introduce proposals and polices to reduce costs while expanding individual healthcare benefits. Certain of these proposals may limit the prices we will be able to charge for our solutions or limit coverage of or lower reimbursement for the procedures associated with the use of our solutions. Healthcare reform and pricing of prescription drugs and medical devices, including clinical laboratory tests, are and will remain a key bipartisan issue. Policies to be pursued in the future may be more aggressive, regardless of which party controls the White House or houses of Congress. Uncertainty surrounding future changes may adversely affect our operating environment and therefore our business, financial condition, results of operations, and growth prospects.
We cannot predict whether or when these or other recently enacted healthcare initiatives will be implemented at the federal or state level or in foreign jurisdictions, or the full impact of current or future healthcare reform measures on our business. For example, the payment reductions imposed by the ACA and the changes to the reimbursement amounts paid by Medicare for tests based on the procedures set forth in PAMA, could limit the prices we are able to charge or the amount, if any, of available reimbursement or coverage for our solutions, which would reduce our revenue. Additionally, these healthcare policy changes could be amended or additional healthcare initiatives could be implemented in the future.
Further, the impact on our business of the expansion of the federal and state governments’ role in the U.S. healthcare industry generally, including the social, governmental, and other pressures to reduce healthcare costs while expanding individual benefits is uncertain.
 
60

TABLE OF CONTENTS
 
Statutory, regulatory, and policy changes, or government budget and funding levels, may also impact the ability of the FDA, the Department of Health and Human Services (including CMS) and other regulatory authorities to perform their regulatory functions. Inadequate funding or staffing for such organizations and/or potentially shifting priorities, including under the new administration, could prevent or delay regulatory reviews and approval processes on which certain of our initiatives may rely, adversely affect agencies’ ability to hire and retain key personnel, or otherwise prevent those agencies from timely performing normal business functions on which the operation of our business may rely, any of which could negatively impact our business.
The current Trump administration is pursuing policies to reduce regulations and expenditures across government including at HHS, the FDA, CMS, and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. Further, in June 2024, the U.S. Supreme Court reversed its longstanding approach under the Chevron doctrine, which provided for judicial deference to regulatory agencies' interpretation of statutes that are silent or ambiguous, including the FDA and CMS. As a result of this decision, we cannot be sure whether there will be increased challenges to existing agency regulations or how lower courts will apply the decision in the context of other regulatory schemes without more specific guidance from the U.S. Supreme Court. For example, this decision may result in more companies bringing lawsuits against the regulatory agencies to challenge current regulations and longstanding decisions and policies of the FDA or CMS, which could lead to uncertainties in the industry. We cannot predict the full impact of this decision, future judicial challenges brought against the FDA, CMS, or other regulatory agencies, or the nature or extent of government regulation that may arise from future legislation or administrative action.
The marketing authorization processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and unpredictable. If we are ultimately unable to obtain any necessary or desirable marketing authorizations, or if such marketing authorizations are significantly delayed, our business will be substantially harmed.
Except for MI Cancer Seek, for which we have obtained a PMA approval from the FDA, we currently offer our NGS solutions, MI Tumor Seek Hybrid and Caris Assure, and our AI solutions, such as GPSai and FOLFIRSTai, as LDTs. See “—We have current solutions marketed as LDTs and plan to launch future solutions as LDTs. The FDA recently finalized a rule, which has since been vacated by a federal court, pursuant to which it plans to subject LDTs to medical device requirements through a phase-out of its historical policy of enforcement discretion over LDTs over a period of four years. The phase-in of medical device requirements to LDTs, including the potential requirement for FDA marketing authorization, will be costly and time-consuming, and if we fail to comply with such requirements, or if we cannot ultimately obtain marketing authorization for our LDTs where required, our business, financial condition, and results of operation could be adversely affected.” We currently anticipate eventually seeking FDA approval for Caris Assure and additional solutions. The time required and ability to obtain marketing authorization from the FDA and comparable foreign regulatory authorities is unpredictable and typically takes several years following the commencement of clinical trials, and depends upon numerous factors, including the type, complexity, and novelty of our solutions. In addition, policies, laws, regulations, or the type and amount of clinical data necessary to gain marketing authorization may change during the course of a test’s clinical development and may vary among jurisdictions, which may cause delays in the marketing authorization of, or the decision not to approve, an application. Regulatory authorities have substantial discretion in the premarket review process and may refuse to accept any application, decide that our data are insufficient for marketing authorization, require additional clinical or other data, or determine that our manufacturing and quality systems are insufficient or in violation of applicable requirements. Even if we believe our data are sufficient to support marketing authorization, regulatory authorities may disagree, or may require the generation and submission of additional data or analyses, which could significantly delay or preclude marketing authorization.
Before a new medical device can be marketed in the United States, a company must first submit a premarket notification to FDA and receive clearance by FDA under Section 510(k) of the FDCA, a PMA application and receive approval by FDA under Section 515 of the FDCA, or a de novo classification request and receive a grant of the request from the FDA under section 513(f)(2) of the FDCA, unless an exemption
 
61

TABLE OF CONTENTS
 
applies. In the 510(k) clearance process, before a device may be marketed, the FDA must determine that a proposed device is “substantially equivalent” to a legally-marketed “predicate” device, which includes a device that has been previously cleared through the 510(k) process, a device that was legally marketed prior to May 28, 1976 (pre-amendments device), a device that was originally on the U.S. market pursuant to an approved PMA and later down-classified, a device that was classified under the de novo classification pathway, or a 510(k)-exempt device. To be “substantially equivalent,” the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device and performance data show that the proposed device is as safe and effective as the predicate device. Clinical data are sometimes required to support substantial equivalence. In the process of obtaining PMA approval, the FDA must determine that a proposed device is safe and effective (which means analytically valid and clinically valid in the case of tests) for its intended use based, in part, on extensive data, including, but not limited to, technical, pre-clinical, clinical trial, manufacturing and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices. In the de novo classification process, a manufacturer whose novel device under the FDCA would otherwise be automatically classified as Class III and require the submission and approval of a PMA prior to marketing is able to request down-classification of the device to Class I or Class II on the basis that the device presents a low or moderate risk. If Class II, new special controls will be required to provide reasonable assurance of safety and effectiveness of the device. If the FDA grants the de novo classification request, the applicant will receive authorization to market the device. This device type may be used subsequently as a predicate device for future 510(k) submissions.
The PMA approval, 510(k) clearance and de novo classification processes can be expensive, lengthy, and uncertain. The FDA’s 510(k) clearance process usually takes from three to 12 months, but can take longer. The process of obtaining a PMA approval or de novo classification is much more costly and uncertain than the 510(k) clearance process and the FDA has 180 days from the day of filing under the FDC Act to complete its review of the PMA and FDA endeavors to review de novo classification requests within 150 days, although, in practice, the FDA’s review often takes significantly longer. In addition, a PMA generally requires the performance of one or more clinical trials. Despite the time, effort and cost, a device may not obtain marketing authorization by the FDA. Any delay or failure to obtain necessary marketing authorizations could harm our business. Furthermore, even if we are granted such marketing authorizations, they may include significant limitations on the indicated uses for the solution, which may limit the potential commercial market for the solution.
In the United States, any modification to a product for which we receive marketing authorization may require us to submit a new 510(k) notification and obtain clearance, to submit a supplemental PMA and obtain FDA approval, or to submit a de novo request prior to implementing the change. For example, any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design, or manufacture, generally requires a new 510(k) clearance or other marketing authorization. The FDA requires every manufacturer to make such determinations in the first instance, but the FDA may review any manufacturer’s decision. The FDA may not agree with a manufacturer’s decisions regarding whether new marketing authorizations is necessary. If we obtain market authorizations from the FDA, we may make modifications or add additional features in the future that we believe do not require a new 510(k) clearance, de novo request or approval of a PMA or supplement. If the FDA disagrees with our determination and requires us to seek new marketing authorizations for the modifications for which we have concluded that new marketing authorizations are unnecessary, we may be required to cease marketing and/or to recall the modified product until we obtain such marketing authorization, and we may be subject to significant regulatory fines or penalties. If the FDA requires us to go through a lengthier, more rigorous examination for future solutions or modifications to existing solutions than we had expected, solution introductions or modifications could be delayed or canceled, which could adversely affect our business.
The FDA or other regulators can delay, limit, or deny marketing authorization of a product for many reasons, including but not limited to the following:
•
the FDA or comparable foreign regulatory authorities may disagree with the design, implementation, or results of, or interpretation of the data from, our clinical trials;
​
 
62

TABLE OF CONTENTS
 
•
the FDA or comparable foreign regulatory authorities may determine that our solution has not been shown to be safe and effective or substantially equivalent to a predicate device, or has other characteristics that preclude us from obtaining marketing authorization or prevent or limit its commercial use (for example, a narrowed indication for use claim);
​
•
the population studied in the clinical program may not be sufficiently broad, generalizable, or representative of the intended target population of our solution to assure effectiveness and safety in the population for which we seek approval or clearance;
​
•
the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from clinical trials or may fail to accept data from clinical trials (or clinical sites), including if we fail to establish the integrity of our data;
​
•
the FDA or comparable foreign regulatory authorities may determine that our clinical trials otherwise fail to comply with applicable regulations;
​
•
serious or unexpected adverse effects or other performance issues are identified with our solutions;
​
•
the FDA or comparable foreign regulatory authorities may determine that our manufacturing or quality system fails to comply with applicable regulations or otherwise fails to meet the standards necessary to support approval; and
​
•
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.
​
There can be no assurance that our solutions for which we may seek marketing authorization will receive such marketing authorization from by the FDA or a comparable foreign regulatory authority on a timely basis, if at all, nor can there be assurance that labeling claims will be consistent with our anticipated claims or adequate to support continued adoption of, and reimbursement for, our solutions. If our solutions receive marketing authorization but there is uncertainty about such solutions among providers or payers, or if the approved or cleared indication or other labeling claims the FDA or a comparable foreign regulatory authority has authorized us to make are more limited than we expect, reimbursement may be adversely affected and we may not be able to sell our solutions. Compliance with FDA or comparable foreign regulatory authority regulations will require substantial costs, and subject us to heightened scrutiny by regulators and substantial penalties for failure to comply with such requirements or the inability to market our solutions, if authorized. The lengthy and unpredictable marketing authorization processes, as well as the unpredictability of the results of our clinical trials, may result in our failing to obtain marketing authorization to market our solutions, which would significantly harm our business, results of operations, reputation, and prospects.
Ethical, legal, and social concerns related to the use of genomic information could reduce demand for our solutions.
Genomic testing, like that conducted using our solutions, has raised ethical, legal, and social issues regarding privacy and the appropriate uses of the resulting information. Governmental authorities could, for social or other purposes, limit or regulate the use of genomic information or genomic testing or prohibit testing for genetic predisposition to certain conditions, particularly for those that have no known cure. Similarly, these concerns may lead patients to refuse to use genomic and somatic profiling tests even if permissible.
Ethical and social concerns may also influence U.S. and foreign patent offices and courts with regard to patent protection for technology relevant to our business. These and other ethical, legal, and social concerns may limit market acceptance of our solutions or reduce the potential markets for services enabled by our platform, either of which could have an adverse effect on our business, financial condition, and results of operations.
If the validity of an informed consent from patients regarding our solution was challenged and proven invalid, unlawful, or otherwise inadequate for our purposes, we could be forced to stop offering our solutions or using our resources, our business, financial condition, and results of operations will be adversely affected.
We offer our solutions to physicians and to biopharma companies in connection with clinical trials. We generally rely on treating physicians to obtain required informed consent under applicable state laws,
 
63

TABLE OF CONTENTS
 
but we have also recently implemented measures to ensure that data and biological samples that we receive have been collected from subjects who have provided appropriate informed consent. We also conduct validation studies, or act as a sponsor of clinical trials in connection with the development and validation of our solutions, which are frequently conducted in collaboration with different parties. We submit for projects that meet the definition of “human subjects research,” to the IRB, or other reviewing body for review and approval of processes for subject informed consent and authorization for use of personal information or waivers thereof. We and our biopharma partners could conduct clinical trials in a number of different countries. When we are acting as a vendor in connection with a clinical trial sponsored by our biopharma partners, we rely upon them to comply with the requirements to obtain the subject’s informed consent and to comply with applicable laws and regulations. The collection of data and samples in many different countries results in complex legal questions regarding the adequacy of informed consent and the status of genetic material under a large number of different legal systems. Those informed consents could be challenged and proven invalid, unlawful, or otherwise inadequate for our purposes. Any such findings against us, or our biopharma partners, could force us to stop accessing or using data and samples or servicing or conducting clinical trials, which would hinder our product offerings or development. We could also become involved in legal actions, which could consume our management and financial resources.
If we fail to comply with applicable data interoperability and information blocking rules, our business, financial condition, and results of operations could be adversely affected.
The 21st Century Cures Act (the “Cures Act”), which was passed and signed into law in December 2016, includes provisions related to data interoperability, information blocking and patient access. In March 2020, the HHS Office of the National Coordinator for Health Information Technology (“ONC”) finalized and issued complementary rules that are intended to clarify provisions of the Cures Act regarding interoperability and information blocking, and include, among other things, requirements surrounding information blocking and changes to ONC’s health IT certification program. The companion rules will transform the way in which healthcare providers, health IT developers, health information exchanges/​health information networks and health plans share patient information, and create significant new requirements for healthcare industry participants. For example, the ONC rule, which went into effect on April 5, 2021, prohibits healthcare providers from engaging in practices that are likely to interfere with, prevent, materially discourage, or otherwise inhibit the access, exchange, or use of electronic health information (“EHI”), also known as “information blocking.” To further support access and exchange of EHI, the ONC rule identifies eight “reasonable and necessary activities” as exceptions to information blocking activities, as long as specific conditions are met. On July 3, 2023, the HHS Office of the Inspector General (“HHS-OIG”) published its final rule implementing information blocking penalties for “actors,” which is supplemented by ONC’s January 9, 2024 final rule enhancing certain information blocking requirements, under which HHS-OIG may impose penalties for information blocking that has occurred after September 1, 2023. In addition, ONC and HHS proposed a rule on November 1, 2023, listing “appropriate disincentives” for noncompliance by healthcare providers. If we fail to comply with the requirements, it may negatively impact our business operations. The goals of increased use of electronic health data and interoperability are improved quality of care and lower healthcare costs generally. However, increased use of electronic health data and interoperability inherently magnifies the risk of security breaches involving that data and information systems used to share it. For additional information, see “—Risks Related to Our Business and Industry—If our information technology systems or those of third parties with whom we work, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.” Any failure to comply with these rules could adversely affect our business, financial condition, and results of operations.
If we or our partners fail to comply with federal, state, and foreign laboratory and other applicable licensing and registration requirements, we could be prevented from performing our solutions or experience disruptions to our business.
CLIA is a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention, or treatment of disease, or impairment of, or the assessment of the health of, human beings. CLIA regulations require,
 
64

TABLE OF CONTENTS
 
among other things, clinical laboratories to obtain a certificate and mandate specific standards in the areas of personnel qualifications, administration, participation in proficiency testing, test management, and quality assurance. CLIA certification is also required for us to be eligible to bill state and federal healthcare programs, if such reimbursement is otherwise available, as well as many private third-party payers, for our solutions. Certain product additions to our solution menu require notification to regulatory and accrediting bodies that regulate our laboratories. To renew these certifications, we are subject to routine surveys and inspections. Moreover, CLIA inspectors may make random or “for cause” inspections of our clinical laboratories.
We currently have two commercial clinical laboratory facilities in Phoenix, Arizona, and we are in the process of building out our newest clinical laboratory in Irving, Texas. Both of the Phoenix laboratory facilities hold independent CLIA Certificates of Accreditation. A CLIA Certificate of Accreditation is issued to a laboratory facility that performs moderate and/or high complexity testing after an accreditation organization conducts a survey and determines that the laboratory is in compliance with the CLIA regulations. Our laboratory facility in Irving, Texas will seek a CLIA Certificate of Registration from CMS, and upon required inspection, anticipate receiving a CLIA Certificate of Accreditation. The CLIA Certificate of Registration allows the laboratory facility to begin conducting moderate and/or high complexity testing, subject to a survey to determine compliance with the CLIA regulations. After a laboratory obtains a Certificate of Registration, CLIA begins scheduling regular, routine inspections. Once the inspection process for the laboratory facility is successfully completed, the facility qualifies for a CLIA Certificate of Accreditation and thereafter is inspected every two years.
Both of our Phoenix laboratories hold CAP accreditations upon which our CLIA Certificate of Accreditation are based. CAP typically conducts biannual surveys of each facility. Any failure to pass inspections, maintain our CAP accreditation, CLIA Certificate of Registration, CLIA Certificate of Accreditation, or state licenses, or add new validated solutions to our laboratory offerings could significantly harm our business, results of operations, and prospects.
In addition to obtaining federal certification for a laboratory under CLIA, we are also required to obtain and maintain state licenses to conduct profiling in our laboratories. Neither Arizona (where we currently operate two clinical laboratories) nor Texas (where we are completing the build-out of our newest clinical laboratory) requires us to obtain and maintain state licenses to conduct profiling in our laboratories. However, some states require out-of-state licensure if we test specimens originating from those states and return patient-specific results. Our tissue-based Arizona facility has obtained licenses from California, Rhode Island, Maryland, New York, and Pennsylvania, and our blood-based Arizona facility has obtained licenses from California, Maryland, Pennsylvania, and Rhode Island. If we have a blood-based profiling solution approved by New York state, we will also obtain a New York license for our blood-based facility.
For example, to be able to receive specimens originating from New York, we must obtain and maintain a New York State Department of Health clinical laboratory permit. We have a New York State Department of Health clinical laboratory permit for our tissue-based Arizona facility, and we intend to apply for such a permit for our other commercial facilities. Research testing (which we conduct at our R&D laboratory in Tempe, Arizona), however, does not require licensure if patient-specific results are not generated and/or returned for diagnostic purposes. As our blood-based Arizona facility does not currently operate in New York, we have not sought a New York laboratory permit. We cannot guarantee that the New York State Department of Health will issue a clinical laboratory permit for our Texas facility or our blood-based Arizona facility, and if we do not receive this permit, our business may be adversely impacted. In addition, New York laws and regulations establish rigorous standards for day-to-day operation of a clinical laboratory, including training and skill levels required of laboratory personnel, physical requirements of a facility, equipment, and validation and quality control, and we are required to abide by these laws and regulations as a permit holder. Failure to comply with these laws and regulations could result in various significant penalties, including loss of our New York permit, fines and other penalties, or limitations on our potential profiling population, which could adversely impact our business. New York also requires specific reporting for companies in the oncology space. Failure to comply with any established reporting requires could negatively impact our license.
The states that require us to hold an out-of-state license may change, and we are uncertain whether states will continue to grant or may require us to hold these licenses in the future. Any failure or inability on
 
65

TABLE OF CONTENTS
 
our part to obtain required state licensure may result in substantial penalties, including prohibition form billing certain payers and thus adversely affect our business.
In connection with CLIA certification and state laboratory licensing and permitting, we remain subject to a number of risks in the event of noncompliance. Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing licensure or permitting, or our failure to renew or maintain a CLIA certificate, a state license or permit, or accreditation (including CAP), could adversely affect our business and reputation. CMS also has the authority to impose a wide range of sanctions, including suspension, limitation, or revocation of the CLIA certification, termination of Medicare and Medicaid participation, civil money penalties, and a bar on the ownership or operation of a CLIA-certified laboratory by any owners or operators of the deficient laboratory. If we fail to obtain any required state licensure, or lose CLIA certification, CAP accreditation, or licensure once obtained, we would not be able to operate our clinical laboratories and offer our solutions in full or in particular states, which would adversely impact our business, financial condition, and results of operations. Even if we were able to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so.
In addition to state laboratory licensing laws, we may also be subject to foreign state registration and/or licensing requirements that apply to companies that manufacture medical devices. Certain states may require such registrations or licenses before the solutions are commercialized, including while manufacturers are evaluating the devices in clinical trials. Violations of these laws may result in a range of potential sanctions or penalties which could include the denial, suspension, limitation or revocation of the registration or license, as well as other fines and penalties, including imprisonment.
In addition, our pathologists are subject to individual medical licensure requirements and our pathologists, physicians, and geneticists could also be subject to in the future additional licensure requirements under state law. If the physicians and geneticists are not able to timely maintain, obtain or otherwise satisfy any new licensure requirements, this could have a negative impact on our operations.
Data from our clinical trials that we announce or publish from time to time before our trials are complete may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
From time to time, we may publicly disclose preliminary or topline data from our validation studies and clinical trials that we conduct ourselves or in partnership with other organizations, including on the application of Caris Assure in early detection, MRD tracking, and treatment monitoring, and Caris ChromoSeq, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular trial. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the topline or preliminary data we previously published. As a result, topline and preliminary data should be viewed with caution until the final data are available.
From time to time, we may also disclose interim data from our validation studies that we conduct or from our clinical trials. Interim data from these studies or trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as subject enrollment continues and more data become available. Adverse differences between interim data and top-line, preliminary, or final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our Class A common stock.
Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, and our ability to receive coverage, marketing authorization or commercialize a particular solution and our company in general. In addition, the information
 
66

TABLE OF CONTENTS
 
we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding our business. If the data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to commercialize or obtain marketing authorization for, our solutions may be harmed, which could harm our reputation, business, financial condition, results of operations, and prospects.
Any LDT solution we market during the phase-in period of the FDA’s LDT final rule (if it comes into effect) and any solution for which we obtain marketing authorization will become subject to extensive ongoing regulatory requirements, and we may be subject to penalties if we or our partners fail to comply with regulatory requirements or if we experience unanticipated problems with our solutions.
Any solution for which we obtain marketing authorization from the FDA or other regulators, along with the manufacturing processes, post-market surveillance, labeling, packaging, advertising, and promotion, distribution, storage, import, export, reporting, and recordkeeping for such solutions, will become subject to continued regulatory review, oversight, requirements, and periodic inspections by the FDA and comparable foreign regulatory authorities. These requirements, certain of which may also apply to solutions we market during the phase-in period of the FDA’s LDT final rule, include submissions of safety and other post-marketing information and reports; registration and listing requirements; requirements relating to quality control, quality assurance, cyber security, and corresponding maintenance of records and documents; requirements relating to recalls, removals, and corrections; and requirements relating to product labeling, advertising and promotion, and recordkeeping. Under the FDA’s LDT final rule issued on May 6, 2024, any LDT that receives marketing authorization would be subject to these medical device requirements, as applicable. On March 31, 2025, the United States District Court for the Eastern District of Texas vacated the FDA's LDT final rule. The regulations to which we are subject are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales. The FDA enforces these regulatory requirements through, among other means, periodic unannounced inspections. We do not know whether we will be found compliant in connection with any future regulatory inspections.
Marketing authorization of a test or device may be subject to limitations by the regulatory body as to the indicated uses for which the product may be marketed or to other conditions of marketing authorization. In addition, marketing authorization may contain requirements for costly post-marketing testing and surveillance to monitor the safety or effectiveness of the test or device. Discovery of problems with our solutions, suppliers, vendors, contract manufacturers, manufacturing processes (including software validation), and/or failure to comply with regulatory requirements, may result in actions such as:
•
restrictions on operations of our laboratories;
​
•
restrictions on manufacturing processes;
​
•
restrictions on marketing of a product;
​
•
Untitled or Warning letters;
​
•
withdrawal or recall of the product from the market or seizure of the product;
​
•
refusal to approve applications or supplements to approved applications that we may submit;
​
•
fines, restitution or disgorgement of profits or revenue;
​
•
suspension, limitation, or withdrawal of marketing authorization;
​
•
exclusion from participation in U.S. federal or state healthcare programs, such as Medicare and Medicaid;
​
•
safety communications;
​
•
refusal to permit the import or export of our solution;
​
 
67

TABLE OF CONTENTS
 
•
injunctions; or
​
•
imposition of civil or criminal penalties.
​
Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and adversely affect our reputation, business, financial condition, and results of operations.
In addition, the FDA may change its marketing authorization policies, adopt additional regulations or revise existing regulations, or take other actions. For example, in addition to the FDA’s LDT final rule, a few months earlier in February 2024, the FDA issued a final rule to amend and replace the Quality System Regulation (“QSR”), which sets forth the FDA’s current good manufacturing practice requirements for medical devices, to align more closely with the International Organization for Standardization standards. Specifically, this final rule, which the FDA expects to go into effect on February 2, 2026, establishes the Quality Management System Regulation (“QMSR”), which among other things, incorporates by reference the quality management system requirements of ISO 13485:2016. Although the FDA has stated that the standards contained in ISO 13485:2016 are substantially similar to those set forth in the QSR, it is unclear the extent to which this final rule, once effective, could impose additional or different regulatory requirements on us that could increase the costs of compliance or otherwise adversely affect our business. If we are unable to comply with the QMSR, once effective, or with any other changes in the laws or regulations enforced by the FDA or comparable regulatory authorities, we may be subject to enforcement action, which could have an adverse effect on our business, financial condition, and results of operations.
For any LDT solution we market during the phase-in period of the FDA’s LDT final rule (if it occurs) and any solution for which we obtain marketing authorization from the FDA we will become subject to regulatory requirements, which require us to report to the FDA certain information about adverse medical events or malfunctions for any of our solutions, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition, and results of operations. The discovery of serious safety issues with our solutions, or a recall of our solutions either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us.
Any LDT solution we market during the phase-in period of the FDA’s LDT final rule and any solution for which we obtain FDA marketing authorization, including MI Cancer Seek, or that are otherwise subject to affirmative FDA oversight, will become subject to the FDA’s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA when we receive or become aware of information that reasonably suggests that one or more of our solutions may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious injury. Under the FDA’s LDT final rule issued on May 6, 2024, and which was vacated by a federal court on March 31, 2025, any LDT that receives marketing authorization would be subject to these medical device reporting regulations, as applicable. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with our reporting obligations, the FDA could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device marketing authorization, withdrawal of our solutions from the market, seizure of our solutions, or delay in marketing authorization of future solutions.
The FDA and foreign regulatory bodies have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. The FDA’s authority to require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury or death. We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design deficiencies, packaging defects or other deficiencies, or failures to comply with applicable regulations. Product defects or other errors may occur in the future.
 
68

TABLE OF CONTENTS
 
Depending on the corrective action we take to redress a product’s deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new marketing authorizations for the device before we may market or distribute the corrected device. Seeking such marketing authorizations may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines.
Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals or corrections for our solutions in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, it could require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect the adoption and use of our solutions. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business and may harm our reputation and financial results.
To comply with the FDA’s LDT final rule and to obtain and maintain FDA marketing authorization, our solutions will need to be manufactured in accordance with federal and state regulations, and we could be forced to recall our devices or terminate production if we or our partners fail to comply with these regulations.
The methods used in, and the facilities used for, the manufacture of our solutions must comply with the FDA’s QSR requirements (applicability subject to the phase-in periods of the FDA’s LDT final rule, which rule was vacated by a federal court on March 31, 2025), which is a complex regulatory scheme that covers the procedures and documentation of the design, testing, production, process controls, quality assurance, labeling, packaging, handling, storage, distribution, installation, servicing, and shipping of medical devices. Furthermore, we are required to verify that our suppliers maintain facilities, procedures and operations that comply with our quality standards and applicable regulatory requirements. The FDA enforces the QSR requirements through periodic announced or unannounced inspections of medical device manufacturing facilities, which may include the facilities of subcontractors. Our solutions are also subject to similar state regulations and various laws and regulations of foreign countries governing manufacturing.
Our third-party manufacturers may not take the necessary steps to comply with applicable regulations, which could cause delays in the delivery of our solutions. In addition, in February 2024, the FDA issued a final rule to amend and replace the QSR, which sets forth the FDA’s current good manufacturing practice requirements for medical devices, to align more closely with the International Organization for Standardization standards. Specifically, this final rule, which the FDA expects to go into effect on February 2, 2026, establishes the QMSR, which among other things, incorporates by reference the quality management system requirements of ISO 13485:2016. Although the FDA has stated that the standards contained in ISO 13485:2106 are substantially similar to those set forth in the QSR, it is unclear the extent to which this final rule, once effective, could impose additional or different regulatory requirements on us that could increase the costs of compliance or otherwise negatively affect our business. Failure to comply with applicable FDA requirements or later discovery of previously unknown problems with our solutions or manufacturing processes could result in, among other things: warning letters or untitled letters; fines, injunctions or civil penalties; suspension or withdrawal of approvals; seizures or recalls of our solutions; total or partial suspension of production or distribution; administrative or judicially imposed sanctions; FDA’s refusal to grant pending or future marketing authorizations for our solutions; clinical holds; refusal to permit the import or export of our solutions; and criminal prosecution of us, our suppliers, or our employees.
Any of these actions could significantly and negatively affect supply of our solutions. If any of these events occurs, our reputation could be harmed, we could be exposed to product liability claims and we could lose customers, experience reduced sales, and increased costs.
The misuse or off-label use of our solutions may harm our reputation in the marketplace, lead to product liability suits or result in costly investigations, fines, or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business.
Any marketing authorization we may receive for our solutions will be limited to specified indications for use. We train our marketing personnel and direct sales force to not promote our solutions for uses
 
69

TABLE OF CONTENTS
 
outside of FDA cleared or approved indications for use, known as “off-label uses.” We cannot, however, prevent a physician from using our solutions off-label, when in the physician’s independent professional medical judgment, he or she deems it appropriate.
If the FDA or any foreign regulatory body determines that our promotional materials or training constitute promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance or imposition of an untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action under other regulatory authority, such as false claims laws, if they consider our business activities to constitute promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations.
In addition, physicians may misuse our solutions if they are not adequately trained, potentially leading to injury and an increased risk of product liability. If our solutions are misused, we may become subject to costly litigation by our customers or their patients. As described above, product liability claims could divert management’s attention from our core business, be expensive to defend and result in sizeable damage awards against us that may not be covered by insurance.
Misleading, untruthful, or unsubstantiated labeling, advertising, marketing, or promotional practices could adversely impact our business, financial condition, and results of operations. The FTC has instituted enforcement actions against certain healthcare testing companies for making false or misleading advertising claims and for failing to adequately substantiate claims made in advertising. These enforcement actions may result in warning letters, consent decrees, and the payment of civil penalties and/or restitution by the companies involved. Should the FTC determine that our claims are false or misleading or unsubstantiated, we could be subject to FTC enforcement action and may face significant penalties which may adversely impact our business, financial condition, and results of operations.
The labeling, advertising, marketing, and promotional practices related to our solutions is governed by numerous state and federal regulators, including the FDA and the FTC, as well as subject to third-party claims. Any statements related to our solutions that could be construed as misleading, untruthful, or unsubstantiated, could subject us to regulatory enforcement action, third-party lawsuits, or plaintiffs’ complaints. Any of these actions could significantly and negatively affect our reputation, expose us to liability claims, and we could lose customers and experience reduced sales and increased costs.
Our “research use only” and any potential “investigational use only” products could become subject to more onerous regulation by the FDA or other regulatory authorities in the future, which could increase our costs and delay our commercialization efforts, thereby materially and adversely affecting our business, financial condition, and results of operations.
In the United States, some of our products are currently available, or may become available, for research use only (“RUO”), or for investigational use only (“IUO”), depending on the proposed application. We make our RUO and IUO products available to a variety of parties, including pharmaceutical and biotechnology companies and research institutes. Because RUO and IUO products are not intended for use in clinical practice and cannot be advertised or promoted for clinical or diagnostic claims, they are exempt from many regulatory requirements otherwise applicable to medical devices. In particular, while the FDA regulations require that RUO products be labeled “For Research Use Only. Not for use in diagnostic procedures,” and IUO products be labeled “For Investigational Use Only. The performance characteristics of this product have not been established,” such products are not subject to the FDA’s pre- and post-market controls for medical devices.
A significant change in the laws governing RUO or IUO products or how they are enforced may require us to change our business model in order to maintain compliance. For instance, in November 2013, the FDA issued a guidance document entitled “Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only” ​(the “RUO/IUO Guidance”), which highlights the FDA’s interpretation that distribution of RUO or IUO products with any labeling, advertising or promotion that suggests that clinical laboratories can validate the test through their own procedures and subsequently
 
70

TABLE OF CONTENTS
 
offer it for clinical diagnostic use as an LDT is in conflict with the RUO or IUO status. The RUO/IUO Guidance further articulates the FDA’s position that any assistance offered in performing clinical validation or verification, or similar specialized technical support, to clinical laboratories, is in conflict with RUO or IUO status. If we engage in any activities that the FDA deems to be in conflict with the RUO or IUO status held by any of our products so labeled, we may be subject to immediate, severe, and broad FDA enforcement action that would adversely affect our ability to continue operations. Accordingly, if the FDA finds that we are distributing our RUO or IUO products in a manner that is inconsistent with its RUO/IUO Guidance, we may be forced to stop distribution of our RUO/IUO tests until we are in compliance, which would reduce our revenue, increase our costs, and adversely affect our business, financial condition, and results of operations.
Changes in funding or disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could adversely impact our business.
The ability of the FDA to review and provide marketing authorization new products or changes to existing products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA’s ability to hire and retain key personnel and accept the payment of user fees, federal government shutdowns, and other events that may otherwise affect the FDA’s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund R&D activities is subject to the political process, which is inherently fluid and unpredictable. Decreases in government funding of research and development, including any reductions in funding to the U.S. National Institutes of Health may impact our business, as could changes in government programs that provide funding to research institutions and companies, including changes in the amount of funds allocated to different areas of research or changes that have the effect of increasing the length of time of the funding process. Disruptions at the FDA and such other agencies may also slow the time necessary for new medical devices or modifications to FDA cleared or approved medical devices to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition, during the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has resumed standard inspection operations of domestic facilities where feasible, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates, and any resurgence of COVID-19 or emergence of new variants may lead to further inspectional delays. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could adversely affect our business.
The Federal Policy for the Protection of Human Subjects or related state regulations may be revised or altered in a way that negatively impacts our business.
The Federal Policy for the Protection of Human Subjects (typically referred to as the Common Rule) may be altered in a way that prevents or restricts us from using patient samples or clinical trial data to further develop or validate our solutions or future AI/ML algorithms which rely upon identifiable data. The revised Common Rule, effective as of July 19, 2018, allows the use of prospective consent to unspecified future research (i.e., “broad consent”) from a human subject for the storage, maintenance, and secondary use of identifiable private information and identifiable biospecimens in research activities. We obtain both identifiable and de-identified data which we use to develop our solutions through biospecimen repositories and from our biopharma partners. If regulations allowing broad consent or the regulatory definition of “research” changes in a way that excludes our research activities, our business may be negatively impacted. State laws governing clinical research may complicate our compliance efforts and add costs and delay to our R&D activities.
 
71

TABLE OF CONTENTS
 
Our business activities are subject to the FCPA and similar anti-bribery and anti-corruption laws, as well as export and import controls and economic sanctions laws and regulations of the United States and other jurisdictions.
Our business activities are subject to the Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”), and similar anti-bribery or anti-corruption laws, regulations, or rules of other countries, such as the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many countries, the healthcare providers who administer diagnostic tests are employed by their government, and the purchasers of diagnostics tests are government entities; therefore, our dealings with these providers and purchasers are subject to regulation under the FCPA. The Securities and Exchange Commission (“SEC”) and DOJ have increased their FCPA enforcement activities with respect to life sciences companies. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Filing of FCPA enforcement actions have been temporarily paused. Once enforcement resumes, companies may incur additional damage due to delayed prosecution.
Our business is also subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Control. Export controls and trade sanctions laws and regulations may restrict or prohibit altogether the provision, sale, or supply of our products to certain governments, persons, entities, countries, and territories, including those that are the target of comprehensive sanctions or an embargo. In particular, there is currently significant uncertainty about the future relationship between the United States and various other countries, including, without limitation, China, Mexico, and Canada, with respect to trade policies, treaties, tariffs, taxes, and other limitations on cross-border operations.
Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our solutions in one or more countries and could harm our reputation, brand, international expansion efforts, and ability to attract and retain employees, which could have an adverse effect on our business, financial condition, and results of operations.
Risks Related to Intellectual Property
If we are unable to obtain and maintain intellectual property protection for our technology, or if the scope of the intellectual property protection we obtain is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to our solutions, and our ability to successfully commercialize our solutions may be impaired.
Our success and ability to compete successfully will depend in part on our ability to obtain, maintain, and enforce issued patents, trademarks, and other intellectual property rights and proprietary technology protection for our solutions, preserve our trade secrets, and operate without infringing the intellectual property rights of third parties. Filing, prosecuting, enforcing, and defending patents on our solutions and other technologies in all countries throughout the world would be prohibitively expensive and time-consuming, and the laws of some foreign countries may not protect our rights to the same extent as the laws of the United States. We may not, and our exclusive licensors may not, be able to file, prosecute, maintain, enforce, or license all necessary or desirable patents or patent applications at a reasonable cost or in a timely manner, or in all jurisdictions, or at all, or may choose not to do any of the foregoing. Furthermore, in some cases, we have only filed provisional patent applications on certain aspects of our products and technologies and each of these provisional patent applications, or any future provisional patent application
 
72

TABLE OF CONTENTS
 
on certain aspects of our products and technologies, is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of the filing date of the applicable provisional patent application. In cases where we have not obtained, or decided not to obtain, patent protection for certain of our inventions, we may not be able to prevent third parties from practicing our inventions or from selling or importing tests made using our inventions in and into the United States or other jurisdictions.
The patent positions of companies, including our patent position, may involve complex legal and factual questions that have been the subject of much litigation in recent years, and, therefore, the scope of any patent claims that we have or may obtain cannot be predicted with certainty. Accordingly, we cannot provide any assurances about which of our patent applications will issue, the breadth of any resulting patent, whether any of the issued patents will be found to be infringed, that any of our issued patents have, or that any of our currently pending or future patent applications that mature into issued patents will include, claims with a scope sufficient to protect our solutions and services. Our pending and future patent applications may not result in the issuance of patents or, if issued, may not issue in a form that will be advantageous to us. The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. We cannot offer any assurances that the breadth of our granted patents will be sufficient to prevent a competitor from developing, manufacturing, and commercializing a solution or technologies in a non-infringing manner that would be competitive with one or more of our solutions or technologies, or otherwise provide us with any competitive advantage.
Moreover, although we have applied for patents covering aspects of our technology in the United States and several other countries, we cannot be certain that our owned and exclusively licensed patents will not be challenged, or that all patents for which we have applied, or that are covered by our exclusive in-licenses, will be issued on a timely basis or at all, or that such patents will protect our technology, in whole or in part, or be issued in a form that will provide us with meaningful protection, prevent competitors from competing with us, or otherwise provide us with any competitive advantage. As further described below, the enforceability of issued patents may be challenged on a number of fronts, including inventorship, scope, or validity, and certain of our owned or exclusively in-licensed patents have been, and others in the future may be, challenged in the courts or patent offices in the United States and abroad. As a result of such challenges, our issued patents may be held invalid or unenforceable and the scope of existing or future patents may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. For additional information, see “—Issued patents covering our solutions and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States and abroad.” We may fail to identify patentable technologies in a timely fashion, which could impair our ability to obtain patent protection on such technology at all. If we fail to timely file for patent protection in any jurisdiction, we may be precluded from doing so at a later date. Our competitors may be able to circumvent our owned or exclusively in-licensed patents by developing similar or alternative technologies or tests in a non-infringing manner. In addition, to the extent we have granted, or may grant in the future, licenses, or sublicenses of our intellectual property rights to third parties, we cannot be certain that such intellectual property rights will not be used by those third parties in a manner that could compete with our business or otherwise negatively impact any competitive advantage provided by such intellectual property rights.
Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are uncertain. Given the amount of time required for the development, testing, and regulatory review of biological tests, patents protecting or covering such tests might expire shortly after such solutions are commercialized. As a result, our owned or exclusively in-licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.
If a third party obtains an issued patent on a technology we use in our solutions, that party may be able to prevent us from using those inventions, and we may not be able to design around the third party’s
 
73

TABLE OF CONTENTS
 
patents or obtain a license on commercially reasonable terms, if at all. Third-party patents or other intellectual property may exist that our current technology, manufacturing methods, solutions, platform, or future methods or tests will be alleged to infringe, which could result in litigation, the imposition of injunctions preventing our use of the foregoing, or require us to obtain licenses or pay royalties and/or other forms of compensation to third parties, which could be significant and could harm our results of operations.
Some of our patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners’ interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products, services, and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us.
The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:
•
any of our patents, or any of our pending patent applications, if issued, will include claims having a scope sufficient to protect our solutions;
​
•
any of our pending patent applications will issue as patents;
​
•
we will be able to successfully manufacture and commercialize our solutions on a substantial scale, if approved, before relevant patents we may have expire;
​
•
we were the first to make the inventions covered by each of our patents and pending patent applications;
​
•
we were the first to file patent applications for these inventions;
​
•
others will not independently develop, manufacture and/or commercialize similar or alternative or duplicative solutions of any of our technologies or products that do not infringe our patents;
​
•
any of our challenged patents will be found to ultimately be valid and enforceable;
​
•
any patents issued to us will provide a basis for an exclusive market for our commercially viable solutions or technologies, and will provide us with any competitive advantages or will not be challenged by third parties;
​
•
we will develop additional proprietary technologies or solutions that are separately patentable;
​
•
our pending patent applications or those that we may own in the future will lead to issued patents;
​
•
our competitors will not conduct R&D activities in countries where we do not have patent rights and then use the information learned from such activities to develop, manufacture, and commercialize competitive products for sale in our major commercial markets;
​
•
the patents of others will not harm our business;
​
•
a third party does not subsequently file a patent covering trade secrets or know-how that we chose not to seek patent protection; or
​
•
our commercial activities or solutions will not infringe upon the patents of others.
​
Third parties may allege that we infringe, misappropriate, or violate their intellectual property rights, and if they prevail, could block sales of our solutions and force us to pay damages and/or royalties, which could adversely affect the success of our business.
Our commercial success in part depends upon our ability, and the ability of our relevant commercial partners, to market, sell, and distribute our solutions and use our proprietary technologies and platform without infringing, misappropriating, or otherwise violating the intellectual property rights of third parties. There is considerable intellectual property litigation in the medical technology, biotechnology, diagnostic, and pharmaceutical industries, and companies in these industries have used intellectual property litigation to
 
74

TABLE OF CONTENTS
 
gain a competitive advantage. In addition, there is ongoing intellectual property litigation involving the analysis of circulating nucleic acid, the outcome of which could also impact future litigation involving our intellectual property or our ability to commercialize our solutions. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights. Third parties may assert infringement claims against us based on existing patents or patents that issue in the future.
If we are found to infringe, misappropriate, or otherwise violate a third party’s intellectual property rights, we could be required to obtain a license from such third party to continue developing, marketing, selling, and distributing our solutions or platform, or to cease using the infringing technology. However, we may not be able to obtain any required license on commercially reasonable terms, if at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages if we are found to have willfully infringed a patent and attorneys’ fees if the court finds the case to be exceptional. A finding of infringement, misappropriation, or other violation could prevent us from commercializing our solutions or force us to cease some of our operations or develop alternate technologies, which could materially harm our business, financial condition, results of operations, and prospects. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our reputation and business.
Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can if they have greater financial resources and/or more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could adversely affect our ability to compete in the marketplace.
Issued patents covering our solutions and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States and abroad.
In addition to allegations of infringement of a third party’s intellectual property rights, a third party may also challenge the validity or enforceability of our owned or in-licensed patents in court or before administrative bodies in the United States or abroad. If we or one of our licensors were to initiate legal proceedings against a third party to enforce a patent covering a solution or a solution candidate, the defendant could counterclaim that the asserted patent is invalid and/or unenforceable. Though an issued patent is presumed valid and enforceable, defendant counterclaims alleging invalidity or unenforceability are commonplace in patent litigation in the United States. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements for patentability, including lack of novelty, obviousness, lack of subject matter eligibility, lack of written description, and non-enablement. Non-statutory grounds for unenforceability include inequitable conduct in obtaining the patent, such as an allegation that someone connected with prosecution of the patent withheld relevant information from the United States Patent and Trademark Office (the “USPTO”), or made a material misleading statement. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. In addition, the patent laws or interpretation thereof by the USPTO and courts could result in some of the claims of our patents to become invalidated. A court may decide that a patent or other intellectual property right of ours is invalid or unenforceable, in whole or in part, construe the patent’s claims or other intellectual property narrowly or refuse to stop a third party from using the technology at issue on the grounds that our patents or other intellectual property do not cover the technology in question and is therefore not infringed upon, violated, or misappropriated. For example, certain claims of five of our U.S. patents have previously been invalidated in inter partes review (“IPR”) proceedings, two of our European patents were challenged but ultimately upheld in their entirety in opposition proceedings, and one of our European patents was held unpatentable in an opposition that is currently under appeal. As a result of such challenges, our issued patents may be held invalid or unenforceable and the scope of existing or future patents may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.
 
75

TABLE OF CONTENTS
 
If a defendant were to prevail on its legal assertion of invalidity and/or unenforceability against our intellectual property related to a solution or a solution candidate, we could lose at least part, and perhaps all, of the patent protection on such solution or solution candidate. Such a loss of patent protection could adversely impact our business. Moreover, our competitors could counterclaim that we infringe their intellectual property, and some of our competitors have substantially greater intellectual property portfolios than we do. Even if our patents or other intellectual property rights are found to be valid and infringed, a court may refuse to grant injunctive relief against the infringer and instead grant us monetary damages and/or ongoing royalties. Such monetary compensation may be insufficient to adequately offset the damage to our business caused by the infringer’s competition in the market. An adverse result in any litigation or administrative proceeding could put one or more of our patents or other intellectual property rights at risk of being invalidated or interpreted narrowly, which could adversely affect our competitive business position, financial condition, and results of operations. Moreover, even if we are successful in any litigation, we may incur significant cost and expense in connection with such proceedings, and the amount of any monetary damages may be inadequate to compensate us for damage from the infringement and proceedings.
In addition to infringement claims against us, third parties have raised, and in the future may raise, claims challenging the validity or enforceability of our owned or in-licensed patents before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms before the USPTO include re-examination, post grant review, IPR, derivation proceedings, interference proceedings, and equivalent proceedings in foreign jurisdictions (such as opposition proceedings in Europe). Such administrative proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our technologies or solutions. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we may lose at least part, and perhaps all, of the patent protection on our solutions or technologies. Such a loss of patent protection could adversely impact our business, financial condition, and results of operations.
If we fail to comply with our obligations in the agreements under which we license or may license intellectual property rights from third parties or we otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.
We have entered into, and may further need to enter into, certain licenses or other collaboration agreements pertaining to the in-license of intellectual property rights from others to advance our research or allow commercialization of our solutions and technologies. Some of these licenses are for a limited term and may include the right for the licensor to terminate upon notice. If any such arrangement is terminated by the licensor, or if we need to enter into any additional licensing arrangements, then we may be unable to obtain such licenses at a reasonable cost or on reasonable terms, if at all, and as a result, we may be required to expend significant time and resources to redesign our technology or to develop or license replacement technology, any of which may not be feasible on a technical or commercial basis. If we are unable to obtain or maintain applicable licenses, we may be unable to commercialize certain solutions or continue to use certain technology, which could harm our business, financial condition, and results of operations.
Our intellectual property in-licenses may impose various reporting, development, diligence, milestone payment, royalty, insurance, commercialization, and other obligations on us, and we expect that our future license or development agreements will contain similar types of obligations. If we fail to comply with any of these obligations, our licensor or collaboration partners may have the right to terminate the relevant license or collaboration agreement, in which event we would not be able to develop or market the solutions or technologies covered by such licensed intellectual property, or to pursue other reasonable or alternative arrangements. Despite our efforts, our licensors or collaborators might conclude that we have materially breached our obligations under such license agreements. If our licensors or collaborators were to terminate the license agreements or otherwise modify our rights under those agreements, our ability to develop and commercialize solutions and technology covered by these license agreements could be limited if not halted. This could adversely affect our competitive position, business, financial condition, results of operations, and prospects.
Agreements under which we license or otherwise obtain rights to intellectual property or technology from third parties may be complex, and certain provisions in such agreements may be susceptible to multiple interpretations, which could lead to disputes between us and our licensor, including:
 
76

TABLE OF CONTENTS
 
•
the scope of rights granted under the license agreement;
​
•
the extent to which our solution and technology are alleged to infringe the licensor’s intellectual property that is not subject to the license agreement;
​
•
the right to sublicense patent and other rights under our collaborative development relationships;
​
•
our diligence and other obligations under the license agreement;
​
•
the priority of invention of patented technology; and
​
•
the inventorship and ownership of inventions and know-how resulting from the collaboration with a licensor or joint invention of intellectual property by us and our licensors and our partners.
​
The resolution of any contract disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could adversely affect our business, financial condition, results of operations, and prospects. If we were required to engage in litigation to enforce or defend our rights under our license or development agreements, even if we were successful, such litigation could require significant financial resources, divert the attention of management, and harm our business. Moreover, if disputes over intellectual property rights that we have licensed or otherwise obtained rights to prevent or impair our ability to maintain our current arrangements on commercially acceptable terms, or at all, we may be unable to successfully commercialize the affected solution or technology, which could adversely affect our business, financial condition, results of operations, and prospects.
In addition, we may have limited control over the maintenance and prosecution of in-licensed patents and patent applications, or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by any future licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. If any of our current or future licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property, or these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business and our competitors could market competing products using the intellectual property. In the event we breach any of our obligations related to such maintenance or prosecution, we may incur significant liability to our licensing partners, including loss of our right to the licensed patent applications or early termination of the license by our licensor. We also may have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that is licensed to us. It is possible that the licensor’s infringement proceeding or defense activities may be less vigorous than had we conducted such activities ourselves. Our ability to enforce in-licensed patents may be in question if our licensors refuse to join in such activities initiated by us.
Our technology licensed from third parties may be subject to retained rights.
Any license we may enter into could provide for the retention by the licensor of certain rights under their agreements with us, including for example, the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether any future licensors will limit their use of the technology to these uses, and we may incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.
In addition, the U.S. government retains certain rights in inventions produced with its financial assistance under the Patent and Trademark Law Amendments Act (the “Bayh-Dole Act”). The U.S. government retains a “nonexclusive, nontransferable, irrevocable, paid-up license” for its own benefit. The Bayh-Dole Act also provides federal agencies with “march-in rights.” March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a “nonexclusive, partially exclusive, or exclusive license” to a “responsible applicant or applicants.” If the patent owner refuses to do so, the government may grant the license itself. The Bayh-Dole Act also imposes
 
77

TABLE OF CONTENTS
 
other obligations, including the requirement that products covered by the government funded patents be manufactured in the United States. We sometimes collaborate with academic institutions to accelerate our R&D efforts. In the future, we may own or license technology which is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act. If the federal government exercises its rights under the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected.
We may become involved in lawsuits to protect or enforce or defend our patents or other intellectual property rights, which could be expensive, time-consuming, and unsuccessful.
Third parties, including our competitors, may currently, or in the future, infringe, misappropriate, or otherwise violate our issued patents or other intellectual property rights, and we may file lawsuits or initiate other proceedings to protect or enforce our patents or other intellectual property rights, which could be expensive, time-consuming, and unsuccessful. We monitor for unauthorized use of our intellectual property rights and, from time to time, analyze whether to seek enforce our rights against potential infringement, misappropriation, or violation of our intellectual property rights. However, the steps we have taken, and are taking, to protect our proprietary rights may not be adequate to enforce our rights as against such infringement, misappropriation, or violation of our intellectual property rights. In certain circumstances it may not be practicable or cost-effective for us to enforce our intellectual property rights fully, for example, in certain countries or where the initiation of a claim might harm our business relationships. We may also be hindered or prevented from enforcing our rights with respect to a government entity or instrumentality because of the doctrine of sovereign immunity. Our ability to enforce our patent or other intellectual property rights can depend on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products or technologies. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor’s or potential competitor’s product or technologies. Thus, we may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully enforce our intellectual property rights could harm our ability to compete and reduce demand for our solutions.
In addition, these lawsuits or other proceedings could be costly and could affect our operations and divert the attention of our managerial, legal, and scientific personnel. There is a risk that a court or administrative body would decide that our owned or in-licensed patents are invalid or not infringed by a third party’s activities, or that the scope of certain claims is more limited than we believe. An adverse outcome in a litigation or other proceeding involving our owned or in-licensed patents could limit our ability to enforce our patents against competitors, affect our ability to receive royalties or other licensing consideration, and may curtail or preclude our ability to exclude third parties from making, using, and selling similar or competitive products. We may become more susceptible to these types of lawsuits and proceedings given the proliferation of organizations pursuing intellectual property protections in the biomarker testing space, particularly as relates to cell free nucleic acids. Any of these occurrences could adversely affect our business, financial condition, results of operations, and prospects.
Intellectual property litigation may lead to public disclosures and unfavorable publicity that harms our reputation and causes the market price of our Class A common stock to decline.
Because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Further, during the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing solutions, programs or intellectual property could be diminished. Accordingly, the market price of shares of our Class A common stock may decline. Such announcements could also harm our reputation or the market for our future solutions, which could adversely affect our business.
Patent terms may be inadequate to protect our competitive position on our solutions for an adequate amount of time.
Patents have a limited lifespan in all jurisdictions around the world. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest
 
78

TABLE OF CONTENTS
 
U.S. non-provisional filing date. Various extensions may be available, but the protection offered by a patent remains time limited. Once a patent covering our solutions expires, we may be subject to additional competition. Given the amount of time required for the development, testing and regulatory review of new products, patents protecting such products might expire before or shortly after such products are commercialized or receive regulatory approval. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing solutions similar or identical to ours for a meaningful amount of time, or at all. Such an inability to exclude competitors from commercializing similar or identical products could have adversely impact our reputation, business, financial condition, results of operations, and prospects.
If we do not obtain patent term extension and data or regulatory exclusivity for any solutions we may develop, our business may be materially harmed.
Depending upon the timing, duration, and specifics of any FDA marketing approval of any therapeutic solutions we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984 (the “Hatch-Waxman Amendments”). The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable legal requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our solution will be shortened and our competitors may obtain approval of competing products following our patent expiration and may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch their product earlier than might otherwise be the case.
Additionally, depending upon the timing, duration, and specifics of any FDA approval of biological products we may develop as part of Caris Discovery or otherwise, such products may be eligible for a period of regulatory exclusivity under the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”), a subtitle of the Patient Protection and Affordable Care Act. The BPCIA created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a highly similar or “biosimilar” product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full biologics license application for the competing product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product.
Biological products we may develop, if any and if approved, could be considered reference products entitled to 12-year exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider a product candidate to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. The FDA only approved the first interchangeable biosimilar in July 2021, and the law is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. If competitors are able to obtain marketing approval for biosimilars
 
79

TABLE OF CONTENTS
 
referencing any biological products we may develop, our products may become subject to competition from such biosimilars, which could adversely impact our competitive position.
Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process to maintain patent applications and issued patents. In addition, periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications must be paid to the USPTO and similar patent agencies outside of the United States over the lifetime of our owned and in-licensed patents and applications. In some cases, we rely on our licensing partners to pay such fees and to take the necessary actions to comply with other requirements to maintain such in-licensed patents during their term. While an unintentional lapse of a patent or patent application can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, in some cases non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical tests or technology, which could adversely affect our competitive position.
Developments in patent law could have a negative impact on our business.
From time to time, the U.S. Supreme Court or other federal courts, the U.S. Congress, the USPTO, or similar governmental authorities in other jurisdictions may change the standards of patentability and any such changes could have a negative impact on our business.
Several decisions from the U.S. Supreme Court regarding patentable subject matter are of particular relevance in the medical diagnostics and computer-implemented applications space. The 2012 decision in Mayo Collaborative v. Prometheus Laboratories (“Mayo”) concerns patent claims directed to optimizing the amount of drug administered to a specific patient based on certain metabolite levels in blood. The Supreme Court held that the applicable patent’s claims were directed to a law of nature (i.e., a natural correlation between metabolite levels and efficacy or toxicity) and failed to incorporate a sufficiently inventive concept above and beyond routine and conventional method steps to allow the claimed methods of treatment to qualify as patent eligible. The 2014 decision in Alice Corporation Pty. Ltd. v. CLS Bank International (“Alice”) concerns a computer-implemented, electronic escrow service for facilitating financial transactions. The Supreme Court held that an abstract idea could not be patented just because it is implemented on a computer. It is generally believed that Mayo and Alice, and subsequent cases interpreting these decisions, have made it more difficult to patent medical diagnostic and computer-implemented inventions. Our efforts to seek patent protection for such technologies and solutions may be negatively impacted by this jurisprudence, or guidance or procedures issued by the USPTO or authorities in other jurisdictions.
We cannot predict the impact of the changing landscape of patent eligible subject matter on our ability, or that of our competitors, to obtain or enforce patents relating to products and services involving genomic or biomarker related discoveries, or computer-implemented technologies, such as molecular tests that implement ML. Indeed, many believe that the contours of whether claims are patent eligible, or recite laws of nature, natural phenomena, natural products, or abstract ideas remain unclear despite a decade of interpretation at the USPTO and in the courts. Third parties holding patents issued prior to Mayo, Myriad and Alice could allege that we infringe these patents, even if these patents are not likely enforceable under current U.S. laws. We could be forced to defend against claims of patent infringement or obtain license rights, if available on commercially reasonable terms or at all, under these patents. In jurisdictions other than the United States, gene- and computer-related patent claims may remain valid and may be enforceable against us.
The U.S. Congress has periodically sought to pass laws concerning subject matter eligibility for patent protection, aimed in large part at abrogating the holdings of Mayo and Alice. To date, these efforts
 
80

TABLE OF CONTENTS
 
have been unsuccessful, but are ongoing. We cannot fully predict the impact that such new laws may have on our ability to obtain patent protection on our solutions and technologies, and our ability to operate in view of the patents controlled by third parties.
We may not be able to enforce our intellectual property rights throughout the world.
The laws of foreign countries may not protect intellectual property rights to the same extent as the laws of the United States. In some cases, companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, some foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties.
On June 1, 2023, the European Union implemented a unitary patent system with the goal of providing a single pan-European Unitary Patent and a new European Unified Patent Court (“UPC”) for litigation involving European patents. As a result, all European patents, including those issued prior to ratification of the unitary patent system, now by default automatically fall under the jurisdiction of the UPC, although patent applicants and patent holders may elect to opt-out of the new system for a transitional period of at least seven years. It is uncertain how the UPC will impact European patents, including those in the biotechnology and pharmaceutical industries. If we do not opt-out, our European patents could be challenged in the UPC. Thus far, like many others, we have elected to opt-out of the UPC as it matures. We may continue to opt-out our future European patents, but doing so may preclude us from realizing its benefits. Moreover, if we do not meet all of the formalities and requirements for opt-out under the UPC, our future European patents could remain under the jurisdiction of the UPC. The UPC will provide our competitors with a new forum to centrally revoke our European patents, and allow for the possibility of a competitor to obtain a pan-European injunction. Such a loss of patent protection or injunction obtained by a competitor could adversely impact our business and our ability to commercialize our technology and solutions and, as a result, on our business, financial condition, prospects, and results of operations.
Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our solutions. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain and enforce adequate intellectual property protection for our solutions and technology.
If we are unable to protect the confidentiality of our trade secrets, our business and competitive position could be harmed.
In addition to seeking patents for certain of our solutions and other technologies, we rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, data, and other proprietary information and to maintain our competitive position. Trade secrets and know-how can be difficult to protect. Our trade secrets and know-how may over time become known to others through various means such as independent development, personnel movement, collaborative efforts or other intentional or unintentional disclosure.
We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with relevant parties, such as our employees, directors, corporate and scientific collaborators, contract research organizations, contract manufacturers, suppliers, service providers, consultants, advisors, and other third parties. We generally enter into confidentiality and invention assignment agreements with our employees and consultants upon their commencement of a relationship with us, and remind departing employees of their continuing confidentiality obligations. However, we may not be successful in entering into such agreements with all employees and consultants. Although we generally require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, processes, or technology to enter into confidentiality agreements, we cannot
 
81

TABLE OF CONTENTS
 
provide any assurances that we have entered into confidentiality agreements with each person or party that had or may have had access to our proprietary know-how, information, processes, or technology. In addition, monitoring unauthorized use and disclosure of our proprietary know-how, information, processes or technology by employees, consultants and other third parties who have access can be difficult, and we cannot be certain whether the steps we have taken to protect our proprietary know-how, information, processes, or technology will be adequate. Therefore, we may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by such employees, consultants, advisors or third parties, despite the existence of confidentiality restrictions. These agreements may also not provide meaningful protection against the unauthorized use or disclosure of our trade secrets, know-how or other proprietary information in the event the unwanted use is outside the scope of the provisions of the contracts or in the event of any unauthorized use, misappropriation, or disclosure of such trade secrets, know-how, or other proprietary information.
Despite our efforts, any of these persons or parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a person or party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts outside the United States may be less willing or unwilling to protect trade secrets. Further, agreement terms that address non-competition are difficult to enforce in many jurisdictions and might not be enforceable in certain cases. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. We may enter into collaboration, license, contract research and/or manufacturing relationships with contract organizations that operate in certain countries that are at heightened risk of theft of technology, data, and intellectual property through direct intrusion by private parties or foreign actors, including those affiliated with or controlled by state actors. If any of our trade secrets were to be misappropriated by, disclosed to, or independently developed by a competitor or other third party, our competitive position could be adversely harmed.
In addition to contractual measures, we try to protect the confidential nature of our proprietary information by maintaining physical security of our premises and electronic security of our information technology systems. Such security measures may not be adequate for all scenarios, for example, in the case of misappropriation of a trade secret by an employee, consultant, or other third party with authorized access. An employee, consultant or other third party who misappropriates our trade secrets may provide such information to a competitor, and any recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our solutions, platform, or services that we consider proprietary. Although we use commonly accepted security measures, trade secret violations are a matter of both federal and state law in the United States, and the criteria for protection of trade secrets can vary among different jurisdictions. If the steps we have taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our intellectual property rights or confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, it could adversely affect our competitive position, business, financial condition, results of operations, and prospects.
Accordingly, our efforts to protect and enforce our trade secrets, know-how and intellectual property rights around the world may be inadequate to obtain a significant commercial advantage, and we may be at heightened risk of losing our trade secrets, proprietary know-how and intellectual property rights around the world, to the extent such theft or intrusion destroys their secrecy or other proprietary nature.
We may be subject to claims by third parties asserting that we or our employees have infringed or misappropriated intellectual property rights, or to assertions by third parties or employees claiming ownership of what we regard as our own intellectual property.
Many of our former, current, and future employees, consultants and contractors have been previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors and strategic partners. Some of these employees, consultants and
 
82

TABLE OF CONTENTS
 
contractors may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment or engagement. We train our employees, consultants, and contractors not to bring, or use in their work proprietary information or technology from former employers. Although we intend for such training and other measures to ensure that our employees do not use the proprietary information or know-how of others in their work for us, to the extent that our employees, consultants or contractors use intellectual property rights or proprietary information owned by others in their work for us, we may be subject to claims that an employee has used or disclosed intellectual property, including trade secrets or other proprietary information, of such employee’s former employer. Litigation, which would be expensive, time-consuming, a distraction to management, and uncertain of outcome, may be necessary to defend against these claims.
In addition, we may be subject to claims from third parties challenging ownership interest in or inventorship of intellectual property rights we regard as our own, based on claims that our agreements with employees or consultants obligating them to assign their intellectual property rights to us are ineffective or in conflict with prior or competing contractual obligations to assign inventions and intellectual property rights to another employer, to a former employer, or to another person or entity. We are not aware of any threatened or pending claims related to these matters, but, in the future, litigation may be necessary to defend against such claims should they arise, and it may be necessary or we may desire to obtain a license to such third party’s intellectual property rights to settle any such claim. However, there can be no assurance that we would be able to obtain such license on commercially reasonable terms, if at all. If we fail in defending any such claims, in addition to paying monetary damages or a settlement payment, we may lose valuable intellectual property rights or personnel, or access to consultants and contractors. A court could prohibit us from using technologies, features or other intellectual property rights that are essential to our solutions or technologies, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of another person or entity, including another or former employers. An inability to incorporate technologies, features or other intellectual property rights that are important or essential to our solutions or technologies could adversely affect our business, financial condition, results of operations, and competitive position, and may prevent us from developing, manufacturing and/or commercializing our solutions or technologies. In addition, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and our employees. Any litigation or the threat of litigation may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to develop, manufacture and/or commercialize our solutions or services, which could adversely affect our business, financial condition, and results of operations.
In addition, we may be subject to claims that our former employees, contractors or collaborators, or other third parties have an ownership interest in our current or future patents, patent applications, or other intellectual property rights, including as an inventor or co-inventor. We may be subject to ownership or inventorship disputes in the future arising, for example, from conflicting obligations of employees, consultants or others who were or are involved in developing our solutions.
If we fail to prevail on any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, or be required to obtain a license, which may not be available to us on commercially reasonable terms or at all. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management, which could harm our business.
If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
We currently hold and/or have applied for a number of trademarks, covering Caris, MI Profile, MI Tumor Seek Hybrid, MI Cancer Seek, Caris Assure, and other solutions and services in certain jurisdictions. However, our pending or future trademark applications may not be approved or our registered or unregistered trademarks or trade names may be challenged, invalidated, infringed, or declared generic or determined to be infringing on other marks. If any of the foregoing occurs, we could be forced to re-brand our solutions or technologies, and we may not be able to protect our rights to these trademarks and trade
 
83

TABLE OF CONTENTS
 
names, which we view as valuable to building name recognition among partners and customers in our markets of interest. At times, competitors or other third parties have adopted or may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion and/or litigation. In addition, there have been and could be trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. There can be no assurance that competitors will not infringe our trademarks or that we will have adequate resources to enforce our trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, we may be unable to compete effectively and our business may be adversely affected. Our efforts to enforce, protect, or defend our trademarks may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our competitive position, business, financial condition, results of operations, and prospects.
Our use of open-source software could subject our proprietary technology to unwanted open-source license conditions that could negatively impact our business.
We use open-source software in some of our technologies and solutions, and we may incorporate open-source software into future technologies and solutions. From time to time, companies that use third-party open source software have faced claims challenging the use of such open source software and requesting compliance with the open source software license terms. Accordingly, we may be subject to suits by parties claiming ownership of what we believe to be open source software or claiming non-compliance with the applicable open source licensing terms. Some open source software licenses require end users, who use, distribute, or make available across a network software and services that include open source software, to make publicly available or to license all or part of such software (which in some circumstances could include valuable proprietary code, such as derivative works of the open source software) under the terms of the particular open source license. If a third party were to allege that we had not complied with the conditions of one or more of these licenses, we could be required to invest substantial time and resources to re-engineer some of our software or release certain portions of our proprietary source code, which could substantially help our competitors develop products that are similar to or improve upon ours and harm our business. We could also be required to incur significant legal expenses defending against such allegations. Further, the outcome of such litigation may be particularly uncertain because there are numerous open source software licenses which have not been tested in courts of law, and thus lack guidance regarding their proper legal interpretation. Any of the foregoing could disrupt and harm our business.
In addition, the use of third-party open source software typically exposes us to greater risks than the use of third-party commercial software because open source licensors generally do not provide warranties or controls on the functionality or origin of the software. Use of open source software may also present additional security risks because the public availability of such software may make it easier for hackers and other third parties to determine how to compromise platforms using such source code. Any of the foregoing could harm our business and could help our competitors develop products and services that are similar to or that improve upon ours.
The occurrence of any of these events could adversely affect our business, financial condition, results of operations, and prospects.
Risks Related to Our Indebtedness
We have incurred substantial indebtedness, and we may not generate sufficient cash flow from operations to meet our debt service requirements, continue our operations, and pursue our growth strategy, and we may be unable to raise capital when needed or on acceptable terms.
As of March 31, 2025, we and our subsidiaries had approximately $400.0 million aggregate principal amount of debt outstanding under the 2023 Term Loan. Subsequent to March 31, 2025, we issued $30.0 million aggregate principal amount of our 2025 Convertible Notes in April 2025, which will convert into shares of our common stock in connection with this offering, in accordance with their terms (and thereafter be reclassified into shares of our Class B common stock). Our substantial level of indebtedness increases the risk that we may be unable to generate cash sufficient to pay amounts due in respect of our
 
84

TABLE OF CONTENTS
 
indebtedness, pay dividends and to fund our general corporate and capital requirements. The substantial indebtedness of us and our subsidiaries could have important consequences to our shareholders, including:
•
a portion of our cash flow from operations must be dedicated to the payment of principal and interest on our debt, thereby reducing the funds available to us for other purposes;
​
•
our ability to satisfy our obligations under the 2023 Term Loan Agreement may be adversely affected;
​
•
our ability to make loans and investments or engage in acquisitions without issuing additional equity or obtaining additional debt financing may be impaired in the future;
​
•
our ability to obtain additional financing for working capital, capital expenditures, acquisitions, debt service requirements or general corporate purposes may be impaired in the future;
​
•
our ability to pay dividends or engage in share repurchases may continue to be restricted;
​
•
our flexibility may be limited in planning for, or reacting to, changes or challenges relating to the business we conduct;
​
•
we may be more vulnerable to general adverse economic and industry conditions;
​
•
we may be at a competitive disadvantage compared to our competitors who have less debt or comparable debt at more favorable interest rates or terms and who, as a result, may be better positioned to withstand economic downturns or to finance capital expenditures or acquisitions; our costs of borrowing may increase; and
​
•
we may be unable to refinance our debt on terms as favorable as our existing debt or at all.
​
The occurrence of any one of these events could have an adverse effect on our business, financial condition, results of operations, and ability to satisfy our obligations under the 2023 Term Loan Agreement. We may not be able to access capital on acceptable terms, raise additional capital in the future, or make effective capital allocation decisions, which could result in our inability to achieve operational objectives. Any disruption in access to capital could require us to take measures to conserve cash until alternative credit arrangements or other funding for business needs can be arranged. Such measures could include deferring capital expenditures, acquisitions or other discretionary uses of cash, or revising capital allocation decisions. Any of these risks could adversely affect our business, financial condition, and results of operations.
The agreements and instruments governing our debt contain restrictions and limitations that could significantly impact our management’s flexibility and our financial and operational flexibility to operate our business.
Restrictive covenants in the 2023 Term Loan Agreement place limits on our ability to conduct our business. Covenants in the 2023 Term Loan Agreement include those that, subject to certain exceptions, restrict our ability to:
•
materially alter the business we conduct;
​
•
incur certain additional indebtedness and guarantee indebtedness;
​
•
create or incur liens;
​
•
purchase, make, incur, assume, or permit to exist certain investments;
​
•
make any dividends, distributions, and certain other payments to our shareholders;
​
•
sell, transfer, or otherwise dispose of assets, including capital stock of our subsidiaries;
​
•
modify certain agreements that have an impact on our indebtedness;
​
•
engage in certain transactions with our affiliates;
​
•
enter into any restrictive agreements prohibiting (i) the creation of liens to secure our obligations under the 2023 Term Loan Agreement, (ii) our or our subsidiaries’ modification of the 2023 Term Loan Agreement, or (iii) our or our subsidiaries’ ability to pay dividends or make any other distributions on any capital securities;
​
 
85

TABLE OF CONTENTS
 
•
enter into sale and leaseback transactions;
​
•
make changes to name, location, executive office, executive management, or fiscal years without prior notice; and
​
•
incur any actual or potential liability on benefit plans or allow any employee benefit plans to cease to be tax qualified.
​
The 2023 Term Loan Agreement also imposes maintenance requirements on our liquidity and revenue base and restricts our ability to engage in certain mergers or consolidations. For additional information, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Indebtedness” and “—Risks Related to Our Business and Industry—Our business and results of operations will suffer if we fail to compete effectively.” These restrictions may prevent us from taking actions that we believe would be in the best interest of our business and may make it difficult for us to execute our business strategy successfully or compete effectively with companies that are not similarly restricted. We may also incur future debt obligations that might subject us to additional restrictive covenants that could affect our financial and operational flexibility. Our ability to comply with the covenants and restrictions contained in the 2023 Term Loan Agreement may be affected by economic, financial and industry conditions beyond our control. The breach of any of these covenants or restrictions could result in a default under the 2023 Term Loan Agreement that would permit the applicable lenders or noteholders, as the case may be, to declare all amounts outstanding thereunder to be due and payable, together with accrued and unpaid interest. In addition, such a default or acceleration may result in the acceleration of any other debt to which a cross-acceleration or cross-default provision applies. Our obligations under the 2023 Term Loan Agreement are secured by our intellectual property. If we are unable to repay debt, lenders having secured obligations under the 2023 Term Loan Agreement could proceed against the collateral securing the debt. This could have serious consequences to our business, financial condition, and results of operations and could cause us to become bankrupt or insolvent.
We rely on cash generated from our financing and operating activities as our primary source of liquidity. To support our operations, execute our growth strategy as planned and pay dividends, if declared, we will need to continue generating significant amounts of cash from operations, including funds required to pay our employees, related benefits and other operating expenses, finance future acquisitions, invest in the growth of our business and pay for the increased direct and indirect costs associated with operating as a public company. If our business does not generate sufficient cash flow from operations to fund these activities, we may need to seek additional capital, including by incurring additional debt or equity capital. Additional capital may not be available to us on acceptable terms or at all. In addition, incurring indebtedness requires that a portion of cash flow from operating activities be dedicated to interest and principal payments. Debt service requirements could reduce our ability to use our cash flow to fund operations and capital expenditures, to capitalize on future business opportunities, including additional acquisitions, or to pay dividends. Any of these risks could adversely affect our business, financial condition, and results of operations.
Our variable rate debt subjects us to interest rate risk, which could cause our debt service obligations to increase significantly and affect our operating results.
The indebtedness under the 2023 Term Loan is at variable rates of interest, which exposes us to interest rate risk. In addition, our 2023 Term Loan references the Secured Overnight Financing Rate (“SOFR”) as the primary benchmark rate for our variable rate indebtedness. If benchmark interest rates, including SOFR, were to increase, our debt service obligations on our variable rate indebtedness would increase even if the amount borrowed remains the same, and our net income and cash flows, including cash available for servicing our indebtedness, will correspondingly decrease. In addition, while our 2023 Term Loan will continue to be subject to SOFR, other factors may impact SOFR, including factors causing SOFR to cease to exist, new methods of calculating SOFR to be established, or the use of an alternative reference rate. Such circumstances are not entirely predictable, but could have an adverse impact on our financing costs and results of operations. As of March 31, 2025, we had $400.0 million outstanding principal amount of variable rate debt subject to interest rate exposure. While we currently hedge the interest rate risk on $200.0 million principal amount of this outstanding variable rate debt with a purchased interest rate cap derivative with a strike rate of 6.0% and a February 2026 maturity, the remainder of the outstanding amount is not similarly hedged. Accordingly, a 1% increase in interest rates would increase annual interest expense by $4 million.
 
86

TABLE OF CONTENTS
 
Despite our indebtedness level, we and our subsidiaries may incur substantially more debt, including secured debt. This could further exacerbate the risks associated with our substantial indebtedness.
We and our subsidiaries may incur substantial additional indebtedness in the future. Although the terms of the 2023 Term Loan Agreement contain restrictions on the incurrence of additional indebtedness, such restrictions are subject to a number of significant exceptions and qualifications and any additional indebtedness incurred in compliance with such restrictions could be substantial. These restrictions also will not prevent us from incurring obligations that do not constitute indebtedness. If we and our subsidiaries incur significant additional indebtedness or other obligations, the related risks that we face could increase, and we may not be able to meet all our debt obligations.
Risks Related to This Offering and Ownership of Our Class A Common Stock
An active, liquid, and orderly market for our Class A common stock may not develop or be sustained. As a result, it may be difficult to sell shares of our Class A common stock.
We currently expect our Class A common stock to be listed and traded on Nasdaq. Prior to listing on Nasdaq there has been no public trading market for our Class A common stock. If an active, liquid, and orderly trading market for our Class A common stock does not develop or is not sustained after this offering, it may be difficult to sell shares of our Class A common stock at an attractive price, if at all. We cannot predict the prices at which our Class A common stock will trade. It is possible that in one or more future periods our results of operations, regulatory approval process, and/or development of our platform and solutions may not meet the expectations of securities research analysts and investors. These and other factors could also significantly depress the market price of our Class A common stock.
The market price of our Class A common stock may be volatile, which could result in substantial losses for investors purchasing shares in this offering.
The initial public offering price for our Class A common stock will be determined by agreement among us and the representatives of the underwriters. This initial public offering price may differ from the market price of our Class A common stock after this offering. As a result, if you purchase shares of our Class A common stock in this offering, it may not be possible for you to sell those shares at or above the initial public offering price. Securities markets worldwide experience significant price and volume fluctuations. This market volatility, as well as general economic, market, or political conditions, could reduce the market price of our Class A common stock regardless of our operating performance. Some of the factors that may cause the market price of our Class A common stock to fluctuate include:
•
the timing or success of launch of our solutions, such as Caris Assure for early detection, MRD tracking, and treatment monitoring, as well as MI Cancer Seek or other solutions;
​
•
the degree to which the launch and commercialization of our solutions meet the expectations of securities analysts and investors;
​
•
changes in the structure of healthcare payment systems, including changes that would affect coverage and reimbursement by third-party or government payers;
​
•
the success of, or perception of success of, our research and development efforts and our ability to develop new solutions and enhance our existing solutions, as well as our solutions’ effectiveness or perceived effectiveness compared to those of our competitors;
​
•
the timing and results of validation studies and clinical trials for our solutions and solutions from our competitors;
​
•
commencement or termination of collaborations for our solution development and research programs;
​
•
failure or discontinuation of any of our solution development and research programs;
​
•
the success of existing or new competitive tests, services, or technologies;
​
•
results of validation studies, clinical trials, or regulatory approvals of diagnostic or other cancer-related screening tests of our competitors, or announcements about new research programs or diagnostic or other cancer-related tests of our competitors;
​
 
87

TABLE OF CONTENTS
 
•
regulatory or legal developments in the United States and other countries affecting our solutions or competing products;
​
•
developments or disputes concerning patent applications, issued patents, or other proprietary rights;
​
•
the impact of public health crises on our business and on global economic conditions;
​
•
the recruitment or departure of key personnel;
​
•
the level of expenses related to any of our research programs, clinical development programs or commercialization activities;
​
•
actual or anticipated changes in our estimates as to our financial results or development timelines;
​
•
whether our quarterly and annual financial results, forecasts, and development timelines meet the expectations of securities analysts or investors;
​
•
announcement or expectation of additional financing efforts;
​
•
sales of our Class A common stock by us, our insiders, or other shareholders;
​
•
expiration of lock-up agreements and market stand-off provisions;
​
•
variations in our quarterly and annual financial results or those of companies that are perceived to be similar to us;
​
•
changes in estimates or recommendations by securities analysts, if any, that cover our stock;
​
•
changes in accounting standards, policies, guidelines, interpretations, or principles;
​
•
market conditions in the healthcare sector;
​
•
general economic, industry, and market conditions; and
​
•
the other factors described in this “Risk Factors” section.
​
Stock markets in general, and the market for healthcare companies in particular (including companies in the precision oncology industry and broader precision medicine industry), experience significant price and volume fluctuations that are often unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may significantly affect the market price of our Class A common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company’s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management’s attention and resources from our business.
If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.
The trading market for our Class A common stock will rely in part on the research and reports that industry or securities analysts publish about us or our business. We do not currently have, and may never obtain, research coverage by industry or securities analysts. If no or few analysts commence coverage of us, the trading price of our Class A common stock could decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our Class A common stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our Class A common stock, which in turn could cause the price of our Class A common stock to decline.
Sales of a substantial number of shares of our Class A common stock following the completion of this offering could cause the price of our Class A common stock to decline.
Sales of a substantial number of shares of our Class A common stock in the public market following the completion of this offering, or the perception that these sales might occur, could depress the
 
88

TABLE OF CONTENTS
 
market price of our Class A common stock, and could impair our ability to raise capital through the sale of additional equity securities. Many of our existing equity holders have substantial unrecognized gains on the value of the equity they hold based upon the price of this offering, and therefore, may take steps to sell their shares or otherwise secure the unrecognized gains on those shares. We are unable to predict the timing of or the effect that such sales may have on the prevailing market price of our Class A common stock.
In connection with this offering, we, our directors and executive officers, and holders of substantially all of our common stock and securities exercisable for or convertible into our common stock, have entered or will enter into lock-up agreements with the underwriters that restrict our and their ability to sell or transfer shares of our common stock, and securities convertible into or exercisable or exchangeable for shares of our common stock, for a period of 180 days from the date of this prospectus, subject to certain customary exceptions and a potential earlier termination. See the sections titled “Shares Eligible for Future Sale” and “Underwriting” for a discussion of such exceptions that may allow for sales during the lock-up period. In addition, upon providing prior written notice to BofA Securities, Inc., J.P. Morgan Securities LLC, and Goldman Sachs & Co. LLC, BofA Securities, Inc. and either J.P. Morgan Securities LLC or Goldman Sachs & Co. LLC may, in their sole discretion, release certain shareholders from the lock-up agreements prior to the end of the lock-up period. Additionally, at our request, the underwriters have reserved up to        % of the shares of our Class A common stock offered by this prospectus, excluding the additional shares that the underwriters have a 30-day option to purchase, for sale, at the initial public offering price, to certain individuals identified by management under the reserved share program, including certain of our directors, officers, employees, and certain other parties related to us. Except for any shares acquired by our directors and officers, shares purchased pursuant to the reserved share program will not be subject to lock-up restrictions with the underwriters. If not earlier released, all of our shares of common stock, other than those sold in this offering, which are freely tradable, will become eligible for sale upon expiration of the lock-up period, except for any shares held by our affiliates as defined in Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”).
In addition, after this offering, up to                 shares of our Class B common stock (which is convertible into Class A common stock) may be issued upon exercise of outstanding stock options or vesting and settlement of outstanding RSUs, and up to           shares of our Class A common stock will be available for future issuance under our 2025 Plan and our ESPP, and will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, exercise limitations, the lock-up agreements, and Rule 144 and Rule 701 under the Securities Act. We intend to register all of the shares of common stock issuable upon exercise of outstanding options or other equity incentive awards we may grant in the future for public resale under the Securities Act. If any of these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our Class A common stock could decline.
Further, holders of approximately           shares as of March 31, 2025, or         approximately    % of our capital stock after the completion of this offering, will have rights, subject to some conditions and the lock-up agreements described above, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or other shareholders.
The dual class structure of our common stock will have the effect of concentrating voting control with our founder and the other shareholders who held our capital stock prior to the completion of this offering, including our executive officers, directors, principal shareholders, and their respective affiliates, which will limit the ability of our other shareholders to affect the outcome of key corporate decisions and transactions, including a change of control.
Following the completion of this offering, our Class B common stock will have 10 votes per share, and our Class A common stock, which is the stock we are offering in this offering, will have one vote per share. Upon the completion of this offering, all of our outstanding shares of Class B common stock will be held our existing shareholders. David D. Halbert, our Founder, Chairman, and Chief Executive Officer, will beneficially own shares of common stock representing approximately      % of our outstanding shares of capital stock and approximately      % of the voting power of our outstanding capital stock, assuming in each case, no exercise by the underwriters of their option to purchase additional shares of Class A
 
89

TABLE OF CONTENTS
 
common stock. As a result, Mr. Halbert will be able to significantly influence all matters submitted to our shareholders for approval, including the election of directors, amendments to our certificate of formation and bylaws, and the approval of significant corporate transactions, regardless of whether others believe that any such transaction is in our best interests. Additionally, immediately following the completion of this offering, our executive officers (including Mr. Halbert), directors, holders of more than 5% of our outstanding capital stock, and their respective affiliates will collectively beneficially own shares of Class B common stock representing approximately      % of our outstanding shares of capital stock and approximately      % of the voting power of our outstanding capital stock, assuming in each case, no exercise by the underwriters of their option to purchase additional shares of Class A common stock. If these shareholders act together, they will be able to influence our management and affairs and control all matters requiring shareholder approval, including the election of directors and approval of significant corporate transactions.
The holders of our Class B common stock collectively will continue to be able to control all matters submitted to our shareholders for approval even if their stock holdings represent less than 50% of the outstanding shares of our capital stock. Because of the 10-to-one voting ratio between our Class B common stock and Class A common stock, the holders of our Class B common stock collectively will continue to control a majority of the combined voting power of our common stock even when the shares of Class B common stock represent as little as      % of the outstanding shares of our Class A common stock and Class B common stock. This concentrated control will limit your ability to influence corporate matters for the foreseeable future. It could also have the effect of delaying, deferring, or preventing a change in control, impeding a merger, consolidation, takeover, or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other shareholders. Moreover, it could deprive shareholders of an opportunity to receive a premium for their common stock as part of a sale of our company and may adversely affect the trading price for our Class A common stock because some investors perceive disadvantages in owning shares in companies with concentrated control.
Future transfers by holders of shares of Class B common stock, subject to limited exceptions set forth in our amended and restated certificate of formation, such as transfers to immediate family members, certain trusts for estate planning purposes, and entities under common control with or controlled by such holder of our Class B common stock, and transfers that are approved in advance by our board of directors as permitted transfers, will generally result in those shares converting to shares of Class A common stock. The conversion of Class B common stock to Class A common stock will have the effect, over time, of increasing the relative voting power of those holders of Class B common stock who retain their shares in the long term. See the section titled “Description of Capital Stock” for additional information.
The dual class structure of our common stock may adversely affect the trading market for our Class A common stock.
We cannot predict whether our dual class structure will result in a lower or more volatile market price of our Class A common stock, adverse publicity, or other adverse consequences. Certain stock index providers exclude or limit the ability of companies with multi-class share structures from being added to certain of their indices. In addition, several shareholder advisory firms and large institutional investors oppose the use of multiple class structures. As a result, the dual class structure of our common stock may make us ineligible for inclusion in certain indices and may discourage other indices from selecting us for inclusion, notwithstanding our automatic termination provision. This dual class structure may also cause shareholder advisory firms to publish negative commentary about our corporate governance practices or otherwise seek to cause us to change our capital structure, and may result in large institutional investors not purchasing shares of our Class A common stock. Given the sustained flow of investment funds into passive strategies that seek to track certain indices, any exclusion from certain stock indices could result in less demand for our Class A common stock. Any actions or publications by shareholder advisory firms or institutional investors critical of our corporate governance practices or capital structure could also adversely affect the value of our Class A common stock.
Investors in our Class A common stock will incur immediate and substantial dilution as a result of this offering.
Our Class A common stock will incur immediate and substantial dilution of $      per share, representing the difference between the assumed initial public offering price of $      per share, which is
 
90

TABLE OF CONTENTS
 
the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, and our pro forma as adjusted net tangible book value per share after giving effect to this offering, the Preferred Stock Conversion, the Warrant Exercises, the Series E and F Issuance, the issuance of the 2025 Convertible Notes and the related Notes Conversion, the Common Stock Reclassification, and the RSU Net Settlement. As of March 31, 2025, there were           shares of common stock issuable upon exercise of outstanding stock options with a weighted-average exercise price of $      per share and           shares of common stock issuable upon the vesting and settlement of outstanding RSUs. To the extent that these outstanding options or RSUs, or any other rights, are exercised, or we issue additional equity or convertible securities in the future, or the underwriters exercise their option to purchase additional shares of Class A common stock, investors will incur further dilution. See the section titled “Dilution” for a further description of the dilution that will occur immediately after this offering.
Raising additional capital may cause dilution to our existing shareholders, restrict our operations, or require us to relinquish rights to our technologies or our solutions.
We may need or determine to raise additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships, and alliances and licensing arrangements. We, and indirectly, our shareholders, will bear the cost of issuing and servicing securities issued in any such transactions. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing, or nature of any future offerings. If we incur debt, debt holders would have rights senior to holders of our Class A common stock to make claims on our assets, and any debt financing we secure would result in increased fixed payment obligations and could involve restrictive and financial covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights, and other operating restrictions that could adversely impact our ability to conduct our business. If we issue additional equity securities, shareholders will experience dilution, and the new equity securities could have rights senior to those of our Class A common stock. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships, alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or our solutions, or grant licenses on terms unfavorable to us.
We have identified a material weakness in our internal control over financial reporting. If our remediation of such material weakness is not effective, or if we experience additional material weaknesses in the future or otherwise fail to develop and maintain effective internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable laws and regulations could be impaired, investors may lose confidence in our financial reporting, and the trading price of our Class A common stock may decline.
In connection with the audit of our consolidated financial statements for the year ended December 31, 2024, we identified a material weakness in our internal control over financial reporting. A material weakness, as defined by Rule 12b-2 under the Exchange Act, is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.
The material weakness identified pertained to a lack of sufficient qualified accounting resources, including those with technical expertise necessary to account for and disclose accounting transactions which require complex calculations or thorough evaluation of the accounting literature.
We have taken and will continue to take action to remediate the material weakness, including:
•
implementation of controls to enhance our review of significant accounting transactions and other new technical accounting and financial reporting issues and the preparation and review of accounting memoranda addressing these issues;
​
 
91

TABLE OF CONTENTS
 
•
implementation of controls to enable an effective and timely review of account analyses and account reconciliations; and
​
•
continued hiring of additional accounting and finance resources with public company experience and expanding the capabilities of the existing accounting and financial personnel through continuous training and education in the accounting and reporting requirements under GAAP and SEC rules and regulations.
​
Pursuant to SOX Section 404, our management will be required to report upon the effectiveness of our internal control over financial reporting beginning with the second annual report following the completion of this offering. When we lose our status as an “emerging growth company” and do not otherwise qualify as a “smaller reporting company” with less than $100.0 million in annual revenue, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for our management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we may need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our Class A common stock may decline.
We will not be able to fully remediate the material weakness until the steps detailed above have been completed and such controls have been operating effectively for a sufficient period of time. Additionally, as stated above, we have not performed an evaluation of our internal control over financial reporting as permitted under the JOBS Act; accordingly, we cannot assure you that we have identified all, or that we will not in the future have additional, material weaknesses. Material weaknesses may still exist when we report on the effectiveness of our internal control over financial reporting as required under SOX Section 404, beginning with our second annual report after the completion of this offering.
We cannot assure you that additional material weaknesses in our internal control over financial reporting will not arise in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our Class A common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.
We are an emerging growth company and the reduced disclosure requirements applicable to emerging growth companies may make our Class A common stock less attractive to investors.
We are an emerging growth company and, for so long as we remain an emerging growth company, we are permitted by SEC rules and plan to rely on exemptions from certain disclosure requirements that are applicable to other SEC-registered public companies that are not emerging growth companies. Under these exemptions, we are not required to comply with the auditor attestation requirements of SOX Section 404 or the auditor requirements to communicate critical audit matters in the auditor’s report on the financial statements, have reduced disclosure obligations regarding executive compensation, and have exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As a result, the information we provide shareholders will be different than the information that is available with respect to other public companies. We have taken advantage of reduced reporting burdens in this prospectus. In particular, in this prospectus, we have provided only two years of audited financial statements and we have not included all of the executive compensation related information that would be required if we were not an emerging growth company.
We could be an emerging growth company for up to five years following the completion of this offering. We will cease to be an emerging growth company upon the earliest of: (i) the end of the fiscal year
 
92

TABLE OF CONTENTS
 
following the fifth anniversary of this offering, (ii) the first fiscal year after our annual gross revenues are $1.235 billion or more, (iii) the date on which we have, during the previous three-year period, issued more than $1.0 billion in nonconvertible debt securities or (iv) the end of any fiscal year in which the market value of our Class A common stock held by non-affiliates exceeded $700 million as of the end of the second quarter of that fiscal year. We cannot predict whether investors will find our Class A common stock less attractive if we rely on these exemptions. If some investors find our Class A common stock less attractive as a result, there may be a less active trading market for our Class A common stock, and our stock price may be more volatile.
In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards, and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult.
Following this offering, we may become a “controlled company” within the meaning of the rules of Nasdaq. In such event, we may take advantage of the “controlled company” exemptions to the corporate governance rules of Nasdaq.
David D. Halbert, our Founder, Chairman, and Chief Executive Officer, will beneficially own shares of common stock representing approximately    % of our outstanding shares of capital stock and approximately    % of the voting power of our outstanding capital stock, assuming in each case, no exercise by the underwriters of their option to purchase additional shares of Class A common stock.
As such, we may, following this offering, become eligible to elect the “controlled company” exemptions to the corporate governance rules of Nasdaq. Under these rules, a company of which more than 50% of the voting power is held by an individual, group or another company is a “controlled company” and may elect not to comply with certain corporate governance requirements, including the requirement that:
•
a majority of our board of directors consist of “independent directors” as defined under the rules of Nasdaq;
​
•
our director nominees be selected, or recommended for our board of directors’ selection, by a nominating/governance committee comprised solely of independent directors; and
​
•
the compensation of our executive officers be determined, or recommended to our board of directors for determination, by a compensation committee comprised solely of independent directors.
​
If we choose to take advantage of controlled company status in the future, our status as a controlled company could cause our Class A common stock to be less attractive to certain investors or otherwise have an adverse effect on our trading price.
We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.
As a public company, and particularly after we are no longer an emerging growth company, we will incur significant legal, accounting, and other expenses that we did not incur as a private company. SOX Section 404, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable U.S. rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We expect that we will need to hire additional accounting, finance, and other personnel in connection with our becoming, and our efforts to comply with the requirements of being, a public company, and our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that
 
93

TABLE OF CONTENTS
 
the rules and regulations applicable to us as a public company may make it more difficult and more expensive for us to obtain director and officer liability insurance, which could make it more difficult for us to attract and retain qualified members of our board of directors. We cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.
Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
Upon the completion of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to provide reasonable assurance that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. Even if we are successful in remediating our material weaknesses, we believe that any disclosure controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.
These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.
If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our results of operations could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Class A common stock.
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue, and expenses that are not readily apparent from other sources. For example, as we adopted and implemented the new revenue accounting standard, management made judgments and assumptions based on our interpretation of the new standard. The new revenue standard is principle-based and interpretation of those principles may vary from company to company based on their unique circumstances. It is possible that interpretation, industry practice and guidance may evolve as we continue to use these new accounting standards. If our assumptions change or if actual circumstances differ from our assumptions, our results of operations may be adversely affected and could fall below our publicly announced guidance or the expectations of analysts and investors, resulting in a decline in the market price of our Class A common stock.
We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.
Our management will have broad discretion in the application of the net proceeds, including for any of the purposes described in the section titled “Use of Proceeds” in this prospectus. Our management may spend a portion or all of the net proceeds from this offering in ways that our shareholders may not desire or that may not yield a favorable return. The failure by our management to apply these funds effectively could harm our business, financial condition, and results of operations. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.
We do not intend to pay dividends for the foreseeable future. Investors in this offering may never obtain a return on their investment.
We have never declared or paid any cash dividends on our capital stock, and we do not intend to pay any cash dividends in the foreseeable future. We expect to retain all available funds and future earnings,
 
94

TABLE OF CONTENTS
 
if any, to support our operations and to finance the growth and development of our business. Any future determination to pay dividends on our capital stock will be at the discretion of our board of directors subject to applicable laws and dependent on factors our board of directors deems relevant. In addition, our ability to pay dividends on our capital stock is limited by the terms of the 2023 Term Loan Agreement and may be further restricted under the terms of any future debt or preferred securities or future credit facility. Accordingly, you must rely on the sale of your Class A common stock after price appreciation, which may never occur, as the only way to realize any future gain on your investment.
Texas law and provisions in our amended and restated certificate of formation and bylaws that will be in effect prior to the completion of this offering might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our Class A common stock.
Provisions in our amended and restated certificate of formation and bylaws that will be in effect prior to the completion of this offering may discourage, delay, or prevent a merger, acquisition, or other change in control that shareholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our Class A common stock. These provisions may also prevent or frustrate attempts by our shareholders to replace or remove our management. Therefore, these provisions could adversely affect the price of our Class A common stock. Among other things, our organizational documents will:
•
authorize our board of directors to issue shares of preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without shareholder approval;
​
•
provide that (i) from and after the date on which no shares of Class B Common Stock are outstanding (such date, the “Trigger Date”), our directors may be removed only for cause and only upon the affirmative vote of holders of at least 50% of the voting power of our then-outstanding shares of capital stock entitled to vote generally in the election of directors, (ii) vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum, or by a sole remaining director, or by the affirmative vote of at least 50% of the voting power of our then-outstanding capital stock entitled to vote generally in the election of directors, (iii) from and after the Trigger Date, any action required or permitted to be taken at an annual or special meeting of shareholders may be taken by written consent in lieu of a meeting of shareholders only with the unanimous written consent of our shareholders entitled to vote on such action, and (iv) from and after the Trigger Date, the affirmative vote of at least 662∕3% of the voting power of our then-outstanding capital stock entitled to vote thereon is required to amend our amended and restated bylaws and certain provisions of our amended and restated certificate of formation;
​
•
provide that, from and after the Trigger Date, the written request of the holders of at least 50% of the voting power of our outstanding capital stock (or the highest percentage of ownership that may be set under the Texas Business Organizations Code (the “TBOC”)) entitled to be voted at a special meeting is required for our shareholders to call a special meeting of shareholders; and
​
•
require that shareholders give advance notice to nominate directors or submit proposals for consideration at shareholder meetings.
​
Further, as a Texas corporation, we are also subject to provisions of Texas law that may impair a takeover attempt that our shareholders may find beneficial. For additional information, see “Description of Capital Stock—Anti-Takeover Effects of Certain Provisions of Our Amended and Restated Certificate of Formation.” Any provision of our amended and restated certificate of formation, bylaws, or Texas law that has the effect of delaying or preventing a change in control could limit the opportunity for our shareholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our Class A common stock.
 
95

TABLE OF CONTENTS
 
Our amended and restated certificate of formation will provide that the Business Court in the First Business Court Division of the State of Texas will be the exclusive forum for substantially all disputes between us and our shareholders (excluding claims under the federal securities laws), which could limit our shareholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
Our amended and restated certificate of formation will provide that, unless we consent in writing to the selection of an alternative forum, the Business Court in the First Business Court Division of the State of Texas will be the exclusive forum for the following types of actions or proceedings under Texas statutory or common law:
•
any derivative action or proceeding brought on our behalf;
​
•
any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees, or shareholders to us or our shareholders;
​
•
any action asserting a claim arising pursuant to any provision of the TBOC or our amended and restated certificate of formation and bylaws; and
​
•
any action asserting a claim governed by the internal affairs doctrine.
​
However, this provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Furthermore, our amended and restated certificate of formation will also provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person purchasing or otherwise acquiring or holding any interest in shares of our capital stock is deemed to have received notice of and consented to the foregoing provisions. This choice of forum provision may limit a shareholder’s ability to bring a claim in a judicial forum that it finds more favorable for disputes with us or with our directors, officers, other employees or agents, or our other shareholders, may discourage such lawsuits against us and such other persons, and may result in increased costs for a shareholder to bring a claim. Alternatively, if a court were to find this choice of forum provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition, and results of operations.
General Risk Factors
The sizes of the markets for our current and future solutions have not been established with precision, and may be smaller than we estimate.
Our estimates of the total addressable markets for our current or future solutions are based on a number of internal and third-party estimates, including, without limitation, the number of new cancer cases, the market size of oncology testing, and the number of patients with advanced stage cancer. While we believe the assumptions and the data underlying these estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting these assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, these estimates of the total addressable market for our current or future solutions may prove to be incorrect. If the actual number of patients who would benefit from our solutions, the price at which we can sell our solutions, or the annual total addressable market for our solutions is smaller than estimated, it may impair our sales growth and have an adverse impact on our business, financial condition, and results of operations.
Adverse economic or market conditions may harm our business.
Worsening economic conditions, including heightened inflation, increasing interest rates, decreasing economic activity, volatility in equity and credit markets, or other changes in the economic environment, may adversely affect our business, financial condition, and results of operations. For example, we depend on third-party manufacturers and suppliers for some of our solutions, or components and materials used in our solutions, and the suppliers of these inputs may seek to raise prices in the current inflationary economic environment. If our costs increase and we are unable to successfully pass along those increased costs to
 
96

TABLE OF CONTENTS
 
our partners and patients, our revenue and or operating profitability may be adversely affected. In addition, we may in the future raise additional debt or refinance existing debt. Our cost of borrowing in the future may be higher than it has been to date because interest rates have risen and may continue to increase. An increased cost of borrowing may adversely affect our financial condition and results of operations.
Our business is subject to economic, political, regulatory, and other risks associated with international operations.
Some of our ordering physicians and biopharma partners are located outside of the United States. While we currently have limited international operations, international expansion could also become a key component of our future business strategy. Accordingly, our future results could be harmed by a variety of factors, including:
•
challenges enforcing our contractual and intellectual property rights, especially in those foreign jurisdictions that do not respect and protect intellectual property rights to the same extent as the United States;
​
•
trade protection measures, import or export controls and licensing requirements (including possible restrictions on licensing intellectual property to certain non-U.S. persons) or other restrictive actions by U.S. or non-U.S. governments;
​
•
changes in non-U.S. laws, regulations and customs, tariffs, and trade barriers;
​
•
exchange rate risk we may face from denominating a portion of our transactions in currencies other than the U.S. dollar;
​
•
changes in a specific country’s or region’s political or economic environment, including inflation, including the United States;
​
•
logistics and regulations associated with shipping samples, including infrastructure conditions and transportation delays;
​
•
negative consequences from changes in tax laws;
​
•
negative consequences from changes in U.S. national security laws, including those governing non-U.S. investors’ ownership of U.S. biotech and other technology companies and U.S. companies’ ability to enter into joint ventures with non-U.S. entities;
​
•
compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;
​
•
compliance challenges relating to the complexity of multiple, conflicting, and changing data protection laws and international data sharing and transfer restrictions globally. For additional information, see “—Risks Related to Regulation and Legal Compliance—We are subject to stringent and evolving U.S. and foreign privacy and data security laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to privacy and data security. Our actual or perceived failure to comply with privacy and data security obligations could result in significant liability, administrative or governmental penalties, reputational harm and/or, other adverse business consequences”;
​
•
workforce uncertainty in countries where labor unrest is more common than in the United States;
​
•
adoption of new regulations, modification to existing regulations, or expiration of prior regulations that apply to the products we offer;
​
•
difficulties associated with staffing and managing international operations, including differing labor relations;
​
•
regulator and compliance risks that relate to maintaining and control over sales and distribution activities that may fall within the purview of the FCPA or comparable foreign laws;
​
 
97

TABLE OF CONTENTS
 
•
difficulties associated with the interpretation of laws and regulations in non-English speaking jurisdictions; and
​
•
business interruptions resulting from geo-political actions, including war and terrorism, pandemics, or natural disasters, including earthquakes, typhoons, floods, and fires.
​
These and other risks associated with current and future international operations may adversely affect our business and prospects.
Our business is subject to risks arising from public health crises.
Widespread public health crises may pose the risk that our company, our personnel, courier delivery services, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. For example, the COVID-19 pandemic and mitigation measures have had an adverse impact on global economic conditions. Comparable future public health crises could have similar adverse effects on our business, financial condition, and results of operations, including impairing the ability to raise capital when needed.
Government-imposed quarantines and restrictions as a result of future public health crises may also require us to temporarily terminate our clinical sites. Furthermore, if we determine that our trial participants may suffer from exposure to such diseases as a result of their participation in our clinical trials, we may voluntarily terminate certain clinical sites as a safety measure until we reasonably believe that the likelihood of exposure has subsided. As a result, our expected regulatory submissions and development timelines for our solutions may be negatively impacted. Future public health crises may materially disrupt or delay our business operations, further divert the attention and efforts of the medical community to coping with such epidemics, reduce the number of patients getting physicals and physicians potentially ordering our solutions, disrupt the clinical sites on which we depend, and/or adversely affect our operations.
Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
Our ability to utilize our net operating loss (“NOL”) and R&D credit carryforwards is subject to certain conditions. For instance, we have experienced a history of losses and a lack of future taxable income that would adversely affect our ability to utilize our NOL and R&D credit carryforwards. As of March 31, 2025, we had NOL carryforwards of $1,150.7 million for federal income tax purposes and $985.8 million for state income tax purposes. In addition, our federal NOL carryforwards generated in taxable years beginning before January 1, 2018, are permitted to be carried forward for only 20 years. Although our federal NOL carryforwards generated in taxable years beginning after December 31, 2017, may be carried forward indefinitely, they are permitted to be used in any taxable year to offset only up to 80% of taxable income, if any, in such year. For state income tax purposes, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. We also had R&D credit carryforwards of $2.8 million that will begin to expire in 2031. Our ability to use our NOL and R&D credit carryforwards also may be subject to certain limitations due to prior or future ownership changes, if any, as defined in Section 382 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) (generally a greater than 50% change, by value, in a corporation’s equity ownership over a three-year period). Under Sections 382 and 383 of the Code, and corresponding provisions of state law, if a corporation undergoes an ownership change, the corporation’s ability to use its pre-change NOL and R&D credit carryforwards to offset the corporation’s post-change income or taxes may be limited. Although we have not experienced ownership changes in the past, we may experience ownership changes as a result of this offering or subsequent shifts in our stock ownership, some of which may be outside our control. As such, there can be no assurance that we will be able to utilize our NOL and R&D credit carryforwards, and we have established valuation allowances against our NOL and R&D credit carryforwards due to the uncertainty surrounding the realization of such assets.
Changes in tax laws or regulations may have an adverse effect on our business, financial condition, and results of operations.
New tax laws, statutes, rules, regulations, or ordinances could be enacted at any time. For example, the Tax Cuts and Jobs Act, the Coronavirus Aid, Relief, and Economic Security Act, and the Inflation
 
98

TABLE OF CONTENTS
 
Reduction Act made significant changes to U.S. tax laws. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted differently, changed, repealed, or modified at any time. Any such enactment, interpretation, change, repeal, or modification could adversely affect us, possibly with retroactive effect.
We may seek acquisitions or other strategic transactions from time to time that could increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.
We may engage in various acquisitions and strategic partnerships in the future, including licensing or acquiring complementary intellectual property rights, technologies, or businesses. Any acquisition or strategic partnership may entail numerous risks, including:
•
increased operating expenses and cash requirements;
​
•
the assumption of indebtedness or contingent liabilities;
​
•
the issuance of our equity securities that would result in dilution to our shareholders;
​
•
assimilation of operations, personnel, intellectual property, and products of an acquired company;
​
•
failure to achieve any expected synergies;
​
•
retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; and
​
•
risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or candidates and regulatory approvals, and the validity and enforceability of their intellectual property.
​
In addition, as our strategy evolves, we may opt to discontinue, deprioritize, or dispose of assets, technologies, or acquired businesses.
The increasing focus on environmental, social, and governance (“ESG”) initiatives could increase our costs, harm our reputation, and adversely impact our financial results.
There has been increasing public focus by investors, patients, environmental activists, the media, and governmental and nongovernmental organizations on a variety of environmental, social, and other sustainability matters. We may experience pressure to make commitments relating to sustainability matters, including the design and implementation of specific risk mitigation strategic initiatives relating to sustainability. While we may in the future engage in various initiatives (including but not limited to voluntary disclosures, policies, or goals) to improve our ESG profile or respond to stakeholder expectations, we cannot guarantee that these initiatives will have the desired effect. If we are not effective in addressing environmental, social, and other sustainability matters affecting our business, or setting and meeting relevant sustainability goals, our reputation and financial results may suffer. In addition, even if we are effective at addressing such concerns, we may experience increased costs as a result of executing upon our sustainability goals that may not be offset by any benefit to our reputation, which could have an adverse impact on our business and financial condition.
In addition, this emphasis on ESG matters has resulted and may result in the adoption of new laws and regulations, including new reporting requirements, including with respect to climate change. ESG and sustainability-related regulation and legislation, to the extent implemented, will require us to incur significant additional costs to comply, including the implementation of significant additional internal controls, processes and procedures regarding matters that have not been subject to such controls in the past, and impose increased oversight obligations on our management and board of directors as well as impose additional disclosure obligations on us. Additionally, our suppliers, customers or other business partners may require us to provide additional climate-related information if they are also subject to additional climate-related disclosure laws or regulations in other jurisdictions. If we fail to comply with new laws, regulations or reporting requirements, or we fail to provide complete and accurate information to our suppliers, customers or other business partners, our reputation and business could be adversely impacted.
 
99

TABLE OF CONTENTS​
 
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus contains forward-looking statements. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial condition, business strategy, information solutions, technology, R&D costs, regulatory approvals, potential market opportunity, anticipated trends in our business, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.
The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would,” or the negative of these terms or other similar expressions, are intended to identify forward looking statements. Forward-looking statements contained in this prospectus include, but are not limited to, statements about:
•
developments in the precision oncology industry, including our biopharma partners’ use of molecular information and the market size for molecular information services;
​
•
our expectations as to our addressable U.S. market in oncology, future financial performance, results of operations, or other operational results or metrics;
​
•
the ability of the Caris platform to help our biopharma partners and physicians improve the efficiency and success of their therapeutic development, and clinical programs;
​
•
our ability to scale the Caris platform and develop new solutions or enhancements to existing solutions;
​
•
our ability to capture, aggregate, analyze, or otherwise utilize molecular information in novel ways;
​
•
our ability to compete with companies that are currently in, or may in the future enter, the industry in which we operate;
​
•
third-party payer reimbursement and coverage decisions;
​
•
our ability to establish, maintain, protect, and enforce our intellectual property rights of our solutions;
​
•
federal, state, and foreign regulatory requirements, including FDA regulation of our solutions;
​
•
the timing, likelihood, or conditions of regulatory filings and approvals;
​
•
our ability to hire and retain key personnel;
​
•
our anticipated cash needs and our estimates regarding our capital requirements and our needs for additional financing;
​
•
our estimates regarding our expenses, future revenue, and capital requirements;
​
•
our expectations related to the use of proceeds from this offering;
​
•
remediating the material weakness in our internal control over financial reporting; and
​
•
the volatility of the trading price of our Class A common stock.
​
These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in the section titled “Risk Factors” and elsewhere in this prospectus. Moreover, we operate in a competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
 
100

TABLE OF CONTENTS
 
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, advancements, discoveries, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations.
You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus by these cautionary statements.
 
101

TABLE OF CONTENTS​
 
MARKET AND INDUSTRY DATA
This prospectus contains estimates, projections, and other information concerning our industry, our business, and the markets for our precision medicine information solutions, including data regarding the estimated size of such markets. We obtained the industry, market, and similar data set forth in this prospectus from our internal estimates and research, including surveys and studies we have sponsored and/or conducted, and from academic and industry research, publications, surveys, and studies conducted by third parties, including governmental agencies. Information based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Forecasts and other forward-looking information with respect to industry, business, market, and other data are subject to the same qualifications and additional uncertainties regarding the other forward-looking statements in this prospectus. See the section titled “Special Note Regarding Forward-Looking Statements.”
The sources of certain industry, business, market, and other data contained in this prospectus include:
•
Nephron Research LLC, Oncology Testing TAM Analysis, March 2024, which we commissioned;
​
•
Evaluate Pharma, World Preview 2023, Outlook to 2028, August 2023;
​
•
The Centers for Disease Control and Prevention;
​
•
The American Cancer Society;
​
•
The American Lung Association;
​
•
The International Agency for Research on Cancer;
​
•
National Center for Biotechnology Information; and
​
•
The American Society of Clinical Oncology.
​
 
102

TABLE OF CONTENTS​
 
USE OF PROCEEDS
We estimate that the net proceeds from this offering will be approximately $      million (or $      million if the underwriters exercise their option to purchase additional shares of Class A common stock in full), based on an assumed initial public offering price of $      per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
Each $1.00 increase (decrease) in the assumed initial public offering price of $      per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by approximately $      million, assuming the number of shares of Class A common stock offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares of Class A common stock offered by us, as set forth on the cover page of this prospectus, would increase (decrease) our net proceeds from this offering by approximately $      million, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
The principal purposes of this offering are to increase our capitalization and financial flexibility, create a public market for our Class A common stock, and enable access to the public equity markets for us and our shareholders. As of the date of this prospectus, we have no specific plan for any significant portion of the net proceeds from this offering. However, we intend to use the net proceeds from this offering for general corporate purposes, including working capital, operating expenses, and capital expenditures. We also intend to use approximately $     of the net proceeds, together with existing cash and cash equivalents, if necessary, to satisfy our anticipated tax withholding and remittance obligations related to the RSU Net Settlement. Based on an assumed initial public offering price of $     per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and an assumed tax withholding rate of     %, we would withhold an aggregate of      shares of our common stock and use approximately $     million to satisfy such tax withholding and remittance obligations. A 1% increase (decrease) in the tax withholding rate would increase (decrease) the amount of tax withholding and remittance obligations related to the RSU Net Settlement by $     million. We may also use a portion of our net proceeds to co-develop, acquire, or invest in products, technologies, or businesses that are complementary to our business, although we do not have agreements or commitments for any material acquisitions or investments at this time.
We will have broad discretion over the uses of the net proceeds from this offering. The expected use of net proceeds from this offering represents our intentions based upon our present plans and business conditions. We cannot predict with certainty all of the particular uses for the proceeds of this offering or the amounts that we will actually spend on the uses set forth above. The timing and amount of our actual expenditures will be based on many factors, including cash flows from operations and the anticipated growth of our business. Pending the uses described above, we plan to invest the net proceeds in a variety of capital preservation investments, including short-term interest-bearing investment-grade securities, certificates of deposit, or government securities. Investors will be relying on the judgment of our management regarding the application of the net proceeds from this offering.
 
103

TABLE OF CONTENTS​
 
DIVIDEND POLICY
We have never declared or paid any cash dividends on our capital stock, and we do not currently intend to pay any cash dividends on our capital stock for the foreseeable future. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. Any future determination to pay dividends will be made at the discretion of our board of directors subject to applicable laws and will depend upon, among other factors, our results of operations, financial condition, contractual, legal, tax, and regulatory restrictions, capital requirements, and such other factors as our board of directors may deem relevant. In addition, our ability to pay cash dividends is currently restricted by the terms of the 2023 Term Loan Agreement. Our future ability to pay cash dividends on our capital stock may also be limited by the terms of any future debt or preferred securities or future credit facility.
 
104

TABLE OF CONTENTS​
 
CAPITALIZATION
The following table sets forth our cash and cash equivalents and capitalization as of March 31, 2025, as follows:
•
on an actual basis;
​
•
on a pro forma basis to give effect to (i) the Warrant Exercise, (ii) the Series E and F Issuance, (iii) the Preferred Stock Conversion, (iv) the issuance of the 2025 Convertible Notes and the related Notes Conversion, (v) the effectiveness of our amended and restated certificate of formation (which will effect the Common Stock Reclassification), and (vi) the RSU Net Settlement; and
​
•
on a pro forma as adjusted basis to give further effect to (i) our issuance and sale of      shares of Class A common stock in this offering at an assumed initial public offering price of $      per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us and (ii) the use of approximately $     million of the net proceeds from this offering, together with existing cash and cash equivalents, if necessary, to satisfy our anticipated tax withholding and remittance obligations related to the RSU Net Settlement.
​
The pro forma and pro forma as adjusted information below is illustrative only. Our capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this table in conjunction with the information contained in “Use of Proceeds” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as the consolidated financial statements and the notes thereto included elsewhere in this prospectus.
​ ​ ​
As of March 31, 2025
​
​ ​ ​
Actual
​ ​
Pro Forma
​ ​
Pro Forma
As Adjusted(1)
​
​ ​ ​
(in thousands, except share and per share data)
​
Cash and cash equivalents
​ ​ ​ $ 31,201 ​ ​ ​ ​ $          ​ ​ ​ ​ $          ​ ​
Debt (including current portion of long-term debt)(2)
​ ​ ​ $ 316,643 ​ ​ ​ ​ $ ​ ​ ​ ​ ​ $ ​ ​ ​
Redeemable convertible preferred stock, par value $0.001
per share; 787,439,505 shares authorized, 734,142,041
shares issued and outstanding, actual; and no shares
authorized, issued, or outstanding, pro forma and
pro forma as adjusted
​ ​ ​ ​ 2,246,113 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Warrants to purchase capital stock
​ ​ ​ ​ 128,691 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Shareholders’ (deficit) equity: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Preferred stock, par value $0.001 per share; no shares
authorized, issued and outstanding, actual;       
shares authorized, no shares issued and outstanding,
pro forma and pro forma as adjusted
​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Common stock, par value $0.001 per share;
1,173,000,000 shares authorized, 140,950,490 shares
issued and outstanding, actual; no shares authorized,
issued, or outstanding, pro forma and pro forma as
adjusted
​ ​ ​ ​ 145 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
 
105

TABLE OF CONTENTS
 
​ ​ ​
As of March 31, 2025
​
​ ​ ​
Actual
​ ​
Pro Forma
​ ​
Pro Forma
As Adjusted(1)
​
​ ​ ​
(in thousands, except share and per share data)
​
Class A common stock, par value $0.001 per share; no
shares authorized, issued, or outstanding, actual;
        shares authorized,            shares issued
and outstanding, pro forma; and       shares
authorized,        shares issued and outstanding,
pro forma as adjusted
​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Class B common stock, par value $0.001 per share; no shares authorized, issued, or outstanding, actual;         shares authorized,      shares issued and outstanding, pro forma and pro forma as adjusted
​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Treasury stock—6,482,550 shares of common stock, par value $0.001 per share
​ ​ ​ ​ (16,917) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Additional paid-in capital
​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Accumulated deficit
​ ​ ​ ​ (2,583,338) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Accumulated other comprehensive income
​ ​ ​ ​ 245 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Total shareholders’ (deficit) equity
​ ​ ​ ​ (2,599,865) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Total capitalization
​ ​ ​ $ 91,582 ​ ​ ​ ​ $ ​ ​ ​ ​ $ ​ ​ ​
​
​
(1)
Each $1.00 increase (decrease) in the assumed initial public offering price of $      per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, additional paid-in capital, total shareholders’ (deficit) equity, and total capitalization by approximately $      million, assuming that the number of shares of Class A common stock offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of      million shares in the number of shares of Class A common stock offered by us at the assumed initial public offering price of $      per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, additional paid-in capital, total shareholders’ (deficit) equity, and total capitalization by approximately $      million, assuming the shares of our Class A common stock offered by this prospectus are sold at the assumed initial public offering price of $      per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
​
(2)
Represents long-term indebtedness, net of debt discounts. Total debt as of March 31, 2025 consisted of approximately $400.0 million of borrowings outstanding under the 2023 Term Loan Agreement. In April 2025, we also issued 2025 Convertible Notes to certain investors in aggregate principal amount of $30.0 million. The 2025 Convertible Notes mature on January 1, 2026, accrue interest at a rate of 8% per annum (payable quarterly in cash), and will, immediately prior to and in connection with the completion of this offering, convert at a conversion price equal to 70% of the initial public offering price per share, or into        shares of our common stock, based on an assumed initial public offering price of $       per share, which is the midpoint of the price range set forth on the cover page of this prospectus. The        shares of our common stock to be issued upon conversion of the 2025 Convertible Notes based on such assumed initial public offering price will be reclassified into an equivalent number of shares of our Class B common stock in the Common Stock Reclassification. For a discussion of our long-term debt, see the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources.” Also, see our consolidated financial statements and related notes thereto included elsewhere in this prospectus, which include all recorded liabilities.
​
The number of shares of common stock in the table above excludes:
•
      shares of our Class A common stock issuable upon the exercise of options outstanding under our 2020 Plan as of March 31, 2025, at a weighted-average exercise price of $      per share;
​
 
106

TABLE OF CONTENTS
 
•
       shares of our Class A common stock issuable upon the exercise of options granted under our 2020 Plan subsequent to March 31, 2025, at a weighted-average exercise price of $       per share;
​
•
       shares of our Class A common stock issuable upon the vesting and settlement of RSUs granted under our 2020 Plan that are held by current executive officers, employees, directors, and consultants and are subject to vesting conditions that are not satisfied in connection with this offering;
​
•
      shares of our Class B common stock issuable upon the exercise of options held by David D. Halbert that were outstanding under our 2020 Plan as of March 31, 2025, at a weighted-average exercise price of $       per share;
​
•
      shares of our Class B common stock issuable upon the exercise of 2025 Warrants at an exercise price of $0.01 per share, based on an assumed initial public offering price of $       per share, which is the midpoint of the price range set forth on the cover page of this prospectus;
​
•
      shares of our Class A common stock reserved for future issuance under our 2025 Plan, which will become effective in connection with this offering, as well as shares of our Class A common stock that may be issued pursuant to provisions of our 2025 Plan that automatically increase the share reserve under our 2025 Plan; and
​
•
      shares of our Class A common stock reserved for future issuance under our ESPP, which will become effective in connection with this offering, as well as shares of our Class A common stock that may be issued pursuant to provisions in our ESPP that automatically increase the share reserve under the ESPP.
​
 
107

TABLE OF CONTENTS​
 
DILUTION
If you invest in our Class A common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the initial public offering price per share and the pro forma as adjusted net tangible book value per share of our Class A common stock immediately after this offering.
Historical net tangible book value (deficit) per share represents our total tangible assets less our liabilities and preferred stock that is not included in equity divided by the total number of shares of common stock outstanding. As of March 31, 2025, our historical net tangible book value (deficit) was approximately $      million, or $      per share. Our pro forma net tangible book value as of March 31, 2025, was approximately $      million, or $      per share, after giving effect to (i) the Warrant Exercise, (ii) the Series E and F Issuance, (iii) the Preferred Stock Conversion, (iv) the issuance of the 2025 Convertible Notes and the related Notes Conversion, (v) the Common Stock Reclassification, and (vi) RSU Net Settlement as if such events had occurred on March 31, 2025.
After giving further effect to receipt of the net proceeds of our sale of        shares of Class A common stock at an assumed initial public offering price of $      per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses, our pro forma as adjusted net tangible book value as of March 31, 2025 would have been approximately $      million, or $      per share. This represents an immediate increase in pro forma as adjusted net tangible book value of $      per share to our existing shareholders and an immediate dilution of $      per share to investors purchasing Class A common stock in this offering.
The following table illustrates this dilution to new investors on a per share basis:
​
Assumed initial public offering price per share
​ ​ ​ ​ ​ ​ ​ ​ ​ $       ​ ​
​
Historical net tangible book value (deficit) per share as of March 31, 2025
​ ​ ​ $       ​ ​ ​ ​ ​ ​ ​ ​
​
Increase per share attributable to the pro forma adjustments described above
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
Pro forma net tangible book value (deficit) per share as of March 31, 2025
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
Increase in pro forma net tangible book value per share attributable to new investors in this offering
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
Pro forma as adjusted net tangible book value per share immediately after this offering
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
Dilution per share to new investors purchasing shares in this offering
​ ​ ​ ​ ​ ​ ​ ​ ​ $ ​ ​ ​
Each $1.00 increase (decrease) in the assumed initial public offering price of $      per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted net tangible book value, by $      per share and the dilution per share to new investors by $      per share, assuming the number of shares of Class A common stock offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
We may also increase or decrease the number of shares of Class A common stock we are offering. An increase (decrease) of 1,000,000 shares in the number of shares of Class A common stock we are offering would increase (decrease) our pro forma as adjusted net tangible book value by approximately $      million, or $      per share, and the pro forma dilution per share to investors in this offering by $      per share, assuming that the assumed initial public offering price remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
If the underwriters’ option to purchase additional shares of Class A common stock in this offering is exercised in full, the pro forma as adjusted net tangible book value would be $      per share, the increase in the pro forma net tangible book value per share for existing shareholders would be $      per share, and the dilution to new investors participating in this offering would be $      per share.
The dilution information discussed above is illustrative only and will change based on the actual initial public offering price, number of shares of Class A common stock offered and other terms of this offering determined at pricing.
 
108

TABLE OF CONTENTS
 
The table below summarizes, as of March 31, 2025, on the pro forma basis described above, the number of shares of our common stock, the total consideration, and the average price per share (i) paid to us by our existing shareholders and (ii) to be paid by new investors participating in this offering at an assumed initial public offering price of $      per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.
​ ​ ​
Shares Purchased
​ ​
Total Consideration
​ ​
Weighted-
Average
Price Per
Share
​
​ ​ ​
Number
​ ​
Percent
​ ​
Amount
​ ​
Percent
​
Existing shareholders
​ ​
      
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
New investors
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Total
​ ​ ​ ​ ​ ​ ​ 100 % ​ ​ ​ ​ $       ​ ​ ​ ​ ​ ​ 100 % ​ ​ ​ ​ ​
Each $1.00 increase (decrease) in the assumed initial public offering price of $      per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) total consideration paid by new investors by $      and increase (decrease) the percent of total consideration paid by new investors by    %, assuming the number of shares of Class A common stock we are offering, as set forth on the cover page of this prospectus, remains the same, after deducting estimated underwriting discounts and commissions. We may also increase or decrease the number of shares of Class A common stock we are offering. An increase (decrease) of 1,000,000 in the number of shares of Class A common stock offered by us would increase (decrease) total consideration paid by new investors by $      , assuming that the assumed initial price to the public remains the same, and after deducting estimated underwriting discounts and commissions.
In addition, if the underwriters’ option to purchase additional shares of Class A common stock is exercised in full, the number of shares held by existing shareholders will be reduced to    % of the total number of shares of common stock to be outstanding upon the completion of this offering, and the number of shares of Class A common stock held by new investors participating in this offering will be further increased to    % of the total number of shares of common stock to be outstanding upon the completion of the offering.
The number of shares of our common stock to be outstanding after this offering is based on          shares of our Class A common stock and       shares of our Class B common stock outstanding as of March 31, 2025, after giving effect to (i) the Warrant Exercise, (ii) the Series E and F Issuance, (iii) the Preferred Stock Conversion, (iv) the issuance of the 2025 Convertible Notes and the related Notes Conversion, (v) the Common Stock Reclassification, and (vi) the RSU Net Settlement, and excludes:
•
      shares of our Class A common stock issuable upon the exercise of options outstanding under our 2020 Plan as of March 31, 2025, at a weighted-average exercise price of $      per share;
​
•
       shares of our Class A common stock issuable upon the exercise of options granted under our 2020 Plan subsequent to March 31, 2025, at a weighted-average exercise price of $       per share;
​
•
       shares of our Class A common stock issuable upon the vesting and settlement of RSUs granted under our 2020 Plan subsequent to March 31, 2025 that are held by current executive officers, employees, directors, and consultants and are subject to vesting conditions that are not satisfied in connection with this offering;
​
•
      shares of our Class B common stock issuable upon the exercise of options held by David D. Halbert that were outstanding under our 2020 Plan as of March 31, 2025, at a weighted-average exercise price of $       per share;
​
•
       shares of our Class B common stock issuable upon the exercise of 2025 Warrants at an exercise price of $0.01 per share, based on an assumed initial public offering price of $       per share, which is the midpoint of the price range set forth on the cover page of this prospectus;
​
 
109

TABLE OF CONTENTS
 
•
      shares of our Class A common stock reserved for future issuance under our 2025 Plan, which will become effective in connection with this offering, as well as shares of our Class A common stock that may be issued pursuant to provisions of our 2025 Plan that automatically increase the share reserve under our 2025 Plan; and
​
•
      shares of our Class A common stock reserved for future issuance under our ESPP, which will become effective in connection with this offering, as well as shares of our Class A common stock that may be issued pursuant to provisions in our ESPP that automatically increase the share reserve under our ESPP.
​
To the extent that any outstanding options are exercised, or new awards are granted and exercised or settled under our equity compensation plans, new investors will experience further dilution.
 
110

TABLE OF CONTENTS​
 
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes and other financial information included elsewhere in this prospectus. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under the section titled “Risk Factors” and elsewhere in this prospectus. See the section titled “Special Note Regarding Forward-Looking Statements” elsewhere in this prospectus.
Overview
We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and AI/ML algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.
We founded Caris in 2008 with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. We have spent the last 17 years developing and building our portfolio of comprehensive, proprietary molecular profiling solutions and generating what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology based on the more than 6.5 million tests we have run on over 849,000 cases, which have generated measurements of over 38 billion molecular markers. Our platform is purpose-built to leverage the convergence of NGS, AI and ML technologies, and high-performance computing. The power of our differentiated Caris platform has enabled us to develop the latest generation of advanced precision medicine diagnostic solutions designed to address the entire cancer care continuum, including early detection, MRD tracking, therapy selection, and treatment monitoring, as well as to create molecular signatures and discover and develop novel precision medicine therapeutics.
Our current commercial product portfolio consists of MI Profile, our tissue-based molecular profiling solution that has generated the majority of our revenue to date, and Caris Assure, our novel, universal blood-based molecular profiling solution that was broadly launched in the first quarter of 2024 for therapy selection. Our purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. We believe this approach best positions us to provide actionable treatment pathways from targeted therapies to drive superior clinical outcomes for patients while also generating a rich dataset to power insights and innovation. Our molecular profiling solutions and the data generated by our multi-omic technology platform also provide value to our more than 100 biopharma partners, such as Moderna, AbbVie, Xencor, and Merck KGaA, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.
We believe that our early foresight to generate comprehensive data at scale over the past many years and build a robust, foundational infrastructure have uniquely positioned Caris to leverage the benefits of biological and technological advances to deliver transformative and advanced innovations in precision medicine and patient care into the future.
 
111

TABLE OF CONTENTS
 
Since our founding, we have achieved the following significant milestones:
[MISSING IMAGE: fc_keydevelop-4c.jpg]
To our knowledge, we remain the only genomic profiling company to consistently utilize WES and WTS as standard practice on every eligible patient sample. Our in-depth profiling of patient samples has led to the creation of what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology. Our ever-expanding datasets include data generated from more than 6.5 million tests that have generated measurements of over 38 billion molecular markers from over 13 quadrillion datapoints as of March 31, 2025, as well as matched clinical outcomes for many of these patients.
Our global annual clinical case volume has been growing rapidly, with year-over-year growth of 29% in 2022, 32% in 2023, 26% in 2024, and 31% in the first quarter of 2025, primarily driven by MI Profile. With our broad commercial launch of Caris Assure for therapy selection in the first quarter of 2024 and the FDA approval of MI Cancer Seek as a companion diagnostic in the fourth quarter of 2024 followed by the broad commercial launch of MI Cancer Seek in the first quarter of 2025 as the NGS component of MI Profile, we believe that increased profiling volumes will meaningfully contribute to our growth in 2025 and beyond.
[MISSING IMAGE: bc_casevolume-4c.jpg]
 
112

TABLE OF CONTENTS
 
Our Caris platform is designed to create a virtuous cycle that can enable continued innovation and improved impact for patients and physicians. We believe our comprehensive approach to profiling will continue to drive demand for our genomic profiling capabilities, leading to further expansion of our clinico-genomic datasets, which provide additional valuable inputs to develop and enhance our solutions, with the ultimate goal of contributing to improved patient results. This continuous feedback loop enabled us to develop Caris Assure, which utilized genomic data generated by MI Profile to inform our blood-based bioinformatics algorithms, allowing us to detect previously unknown features and signals in the blood that provide advanced insights into disease development. We believe we will be able to further leverage this process to continue meaningful innovation in precision oncology as well as other chronic disease states, including cardiology, neurology, and metabolic conditions.
We have funded our operations to date principally from the sale of our stock, convertible and senior secured notes, and revenue from our molecular profiling solutions and services with biopharma companies. For the years ended December 31, 2024 and 2023, we generated total revenue of $412.3 million and $306.1 million, respectively, and incurred net losses of $281.9 million and $341.4 million, respectively. For the three months ended March 31, 2025 and 2024, we generated total revenue of $120.9 million and $80.7 million, respectively, and incurred net losses of $102.6 million and $111.0 million, respectively. Our Adjusted EBITDA was $(189.6) million and $(255.3) million for the years ended December 31, 2024 and 2023, respectively. Our Adjusted EBITDA was $(36.2) million and $(70.1) million for the three months ended March 31, 2025 and 2024, respectively. For additional information regarding Adjusted EBITDA, a non-GAAP financial measure, see “—Non-GAAP Financial Measures.” We expect to incur additional net losses in the near future, and our expenses will increase as we continue to invest in developing new solutions, expand our organization, and increase our marketing efforts to continue to drive market adoption of our solutions. These investments, together with general and administrative expenses, have resulted in negative cash flows from operations of $245.2 million, $276.1 million, $31.3 million, and $73.9 million for the years ended December 31, 2024 and 2023 and the three months ended March 31, 2025 and 2024, respectively. Our free cash flow was $(253.6) million and $(298.4) million for the years ended December 31, 2024 and 2023, respectively, and $(34.0) million and $(75.7) million for the three months ended March 31, 2025 and 2024, respectively. For additional information regarding free cash flow, a non-GAAP financial measure, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures.” Additionally, as of March 31, 2025, we had cash, cash equivalents, and short-term marketable securities of $33.4 million, and the aggregate principal amount of debt outstanding under our existing term loan was $400.0 million. For additional information regarding our liquidity and capital resources, see “—Liquidity and Capital Resources.”
Our Business Model
We generate revenue primarily from the provision of precision oncology solutions to ordering physicians utilizing MI Profile and Caris Assure. We have obtained Medicare and commercial reimbursement for MI Profile. We also have Medicare reimbursement and various levels of commercial payer adoption and/or reimbursement coverage for Caris Assure for therapy selection across the United States (other than New York State).
We also generate revenue utilizing our Caris platform to provide R&D services for biopharma partners, who we partner with to help improve the efficiency and success of their therapeutic development and clinical programs. For our biopharma partners, our profiling solutions provide prospective and retrospective testing, companion diagnostics development, data licensing, and commercial services that include identification of patients for approved therapies. In addition, our multi-modal data creates a differentiated capability to advance precision oncology research through novel target identification and discovery, translational sciences, clinical trial design solutions and patient enrollment facilitated by our right-in-time trials network, post-market label expansion, and commercialization insights. Under the strategic partnerships, targets discovered by us using our proprietary wet lab, in silico, ADAPT, proximity labeling, and surfacesome analysis can be pursued by our biopharma partners to conduct their own preclinical and clinical research, as well as the eventual development and commercialization of drug candidates. Our biopharma partners select drug targets based, among other things, on their prevalence and expression across cancer types, the uniqueness of the targets and efficacy of current treatments, and their therapeutic modality. Our biopharma partners are also able to combine their relevant technology and/or drug
 
113

TABLE OF CONTENTS
 
development capabilities, such as data analysis, in vitro studies, molecule design, and therapeutic modality, to design and manufacture potential therapies for the treatment of cancer.
We believe the market for our solutions is large and expanding. We have made significant investments in our scaled and state-of-the-art infrastructure to support our growth and our ability to address the needs of the U.S. oncology market through the provision of molecular information services across the full patient care continuum and to support biopharma drug development. We operate two precision medicine laboratories in Phoenix, Arizona, and one R&D laboratory in Tempe, Arizona. Our Arizona laboratories all utilize state-of-the-art genomic sequencing technology, including 50 NovaSeq sequencing systems, with capacity to perform more than one trillion “reads” daily. Our newest laboratory facility in Irving, Texas, near our headquarters, is continuing to be built-out and will bring our total operational capacity to over 275,000 square feet. To support our sales activity and expansion, as of March 31, 2025, we have assembled a targeted sales organization in the United States of over 270 sales team members and nearly 50 highly trained Ph.D. or M.D. MSLs who focus on physician and provider education and consultation. In addition, the Caris POA, which we established in 2015, is a growing network of leading cancer centers and research consortia across the globe that supports our academic partner engagement and research and collaboration opportunities.
Key Factors Affecting Our Performance
We believe that our operating performance and future success depend on a number of factors that present significant opportunities for us and may pose risks and challenges, including those discussed below and in the “Risk Factors” section of this prospectus.
•
Market acceptance and commercial success of our solutions.   Our success and future growth will depend on maintaining and expanding market acceptance of our molecular profiling solutions along with commercial success of these solutions across existing and new customers. Our MI Profile and Caris Assure case volumes have continued to increase over time. Such changes in our case volumes and the pricing of our solutions, however, are not impacted by the cancer type. For the years ended December 31, 2024 and 2023, the number of clinical cases was 162,862 and 128,831, respectively. For the three months ended March 31, 2025 and 2024, the number of clinical cases was 45,858 and 34,902, respectively. We commercially launched our MI Cancer Seek solution in January 2025 as the WES/WTS NGS component of MI Profile. We initiated the broad commercial launch of Caris Assure for therapy selection in the first quarter of 2024, and realizing the potential of Caris Assure across the cancer treatment continuum is a key component of our business strategy. The commercial success of Caris Assure will depend upon, among other things, additional clinical trials that demonstrate the effectiveness of Caris Assure, particularly for early detection, MCED, MRD tracking, and treatment monitoring, and the continued adoption of Caris Assure by patients, the medical community, and third-party payers. In addition, we expect that our ability to maintain and expand our sales, marketing, and distribution capabilities to support the increased adoption of our molecular profiling solutions will play a key factor in our success.
​
•
Biopharma partners.   Our revenue also depends on our ability to maintain and expand relationships with our biopharma partners and attract new biopharma partners. As we continue to develop these relationships, we expect to support a growing number of projects and continue to have opportunities to offer our platform to such customers for development and research services. For the years ended December 31, 2024 and 2023, our year-over-year growth in pharma research and development services revenue has been 131% and 37%, respectively.
​
•
Development and introduction of new solutions.   Our business success will also depend on our ability to develop and commercialize new solutions. We plan to continue to invest in the enhancement of our molecular profiling solutions, the development of new solutions to achieve meaningful innovation in precision oncology and other disease states, and the expansion of our clinico-genomic datasets to drive breakthrough science. We intend to expand the application of Caris Assure to early detection, MCED, MRD tracking, and treatment monitoring. Our ability to develop and commercialize new solutions and services could face many challenges and thus impact our future performance and results of operations. Such challenges include, but
​
 
114

TABLE OF CONTENTS
 
are not limited to, obtaining regulatory approvals; completing certain clinical development activities, validation studies, and/or clinical trials; having guidelines or recommendations for healthcare providers, administrators, payers, and patient communities relating to such solutions; and receiving favorable exposure in peer-reviewed publications and from KOLs.
•
Payer coverage and reimbursements.   Our revenue and future revenue growth will depend on our success in achieving broad coverage and adequate reimbursement for our solutions from third-party payers. Coverage and reimbursement by third-party payers, including managed care organizations, private health insurers, and government healthcare programs for the types of solutions we offer can be limited and uncertain and may depend on a number of factors, including a payer’s determination that a product is appropriate, medically necessary, and cost-effective. Each payer will make its own decision as to whether to establish a policy or enter into a contract to cover our products and the amount it will reimburse for such products. In addition, Z-Code Identifiers are used by certain payers, including under MolDX, to supplement CPT codes for our molecular diagnostics solutions. Changes to the codes used to report to payers may result in significant changes in their reimbursement. We have obtained a PMA approval from the FDA for a companion diagnostic and tumor profiling designation for MI Cancer Seek, a WES/WTS NGS assay that uses the whole exome for tumor mutational burden (“TMB”) calling along with being designed to meet the stricter requirements applicable to companion diagnostic devices. We have obtained Medicare coverage for MI Cancer Seek for CPT code 0211U, at a reimbursement rate of $8,455, under the NGS NCD. We currently market MI Cancer Seek as the WES/WTS NGS component of MI Profile. The current MolDX pricings of MI Tumor Seek Hybrid, and Caris Assure are $3,500 and $3,649, respectively. In July 2024, the AMA issued a PLA code, CPT code 0485U, for Caris Assure, with an effective date of October 1, 2024. In November 2024, CMS determined to price Caris Assure for therapy selection using the “Gapfill” method, a method used when there are no comparable existing codes available. There is no certainty regarding the pricing that we will obtain for Caris Assure during the Gapfill process. For additional information, see “—Government Regulation—​Coverage and Reimbursement—Coverage and Reimbursement in the United States.” While the average selling prices (“ASPs”) for Caris Assure and MI Cancer Seek reimbursed by a particular payer are determined by our arrangements with that payer and do not materially differ by cancer type, any fluctuation or differences in coverage and reimbursement among our third-party payers may impact our ASPs and gross margins. Moreover, if we are unable to obtain and/or maintain broad coverage and adequate reimbursement for our solutions from third-party payers, we may not be able to effectively increase our clinical case volume and our revenue would be impacted.
​
•
Scaling infrastructure to meet increasing demand.   Our financial results are also dependent upon our ability to support current and future levels of demand for our solutions, including MI Profile and Caris Assure. As and to the extent the volumes of our current and new molecular profiling solutions continue to grow, we will need to simultaneously increase our capacity for sample intake and storage, enhance our customer service, improve our billing and general processes, expand our internal quality assurance programs, incorporate new equipment, implement new technology systems and processes, expand laboratory capacity, and otherwise extend our operational capabilities to support comprehensive genomic analyses at a larger scale while retaining expected turnaround times. This may result in us purchasing additional equipment, constructing additional facilities, hiring additional qualified labor, and implementing new systems, technology, controls, and procedures. As such, our capital expenditures and cost of services may increase as we continue our efforts to expand capacity. In addition, revenue may be impacted in the event that we are not able to meet the increase in demand.
​
 
115

TABLE OF CONTENTS
 
Components of Results of Operations
Revenue
Revenue consists primarily of the following:
Molecular Profiling Services
Molecular profiling services revenue is generated from the provision of precision oncology solutions to ordering physicians utilizing MI Profile, MI Cancer Seek (NGS component of MI Profile), and Caris Assure. Revenue is recorded when performance obligations are satisfied, which is deemed to be when the results of the profiling services are provided to the ordering physicians, including certain hospitals, cancer centers, and institutions. Revenue is recorded at the amount that reflects the consideration to which we expect to be entitled from customers and third-party payers in exchange for providing such services.
Pharma Research and Development Services
Pharma research and development services revenue is generated from the provision of research and development services for biopharma partners utilizing our Caris platform. Given the nature of these services, each contract may contain multiple performance obligations, such as molecular profiling solutions, developmental services, and strategic data services. Each performance obligation is analyzed, and revenue is recognized as or when such performance obligations are satisfied. The timing and extent of revenue recognized may vary from contract to contract.
Costs and Operating Expenses
We allocate certain overhead expenses, such as rent, utilities, and depreciation to cost of services and operating expense categories based on headcount and facility usage. As a result, an overhead expense allocation is reflected in cost of services and operating expenses.
Cost of Services—Molecular Profiling Services
Cost of molecular profiling services generally consists of cost of materials, direct labor (including bonus and stock-based compensation), equipment maintenance and depreciation expenses associated with processing cases (including accessioning, sequencing, quality control analyses, and shipping charges to transport samples), and freight. Costs associated with completing the molecular profiling services are recorded as the service is performed, regardless of whether revenue is recognized with respect to the service.
Cost of Services—Pharma Research and Development Services
Cost of services for pharma research and development services generally consists of costs incurred for the performance of the services requested by our biopharma partners related to research and development services. For the development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of services. Cost of services for pharma research and development services will vary depending on the nature, timing, and scope of customer projects.
We expect cost of services to increase in absolute dollars as our revenue grows. In the short term, increases to cost of services may outpace revenue growth as we invest in expanding our laboratory capacity and implementing new processes. However, over time, the cost per clinical case is expected to decrease due to economies of scale.
Selling and Marketing Expense
Our selling and marketing expense includes costs associated with our sales organization, including our direct sales force and sales management, marketing, and business development personnel. These expenses consist principally of salaries, incentive compensation, bonuses, employee benefits, travel, and stock-based compensation, as well as marketing and educational activities. We expense all selling and marketing expenses as incurred.
 
116

TABLE OF CONTENTS
 
We believe that our marketing activities continue to drive awareness and differentiate our existing solutions and future solutions. We expect our selling and marketing expenses to continue to increase in absolute dollars as we expand our sales force and continue to grow our presence within and outside of the United States.
General and Administrative Expense
Our general and administrative expense includes costs for our executive, accounting and finance, legal, information technology, billing, and human resources functions. These expenses consist principally of salaries, bonuses, employee benefits, travel, and stock-based compensation, as well as professional services fees (such as audit and tax consulting), general corporate costs, and allocated overhead expenses. While we expect our general and administrative expenses will increase in absolute dollars as we continue to invest in our growth and operate as a public company, we expect them to decline as a percentage of revenue over time as we scale our business and leverage our investments already made.
We expect to incur additional expenses after we complete this offering, primarily due to the costs of operating as a public company, which are expected to include additional legal, accounting, corporate governance, and investor relations expenses, as well as higher directors’ and officers’ insurance premiums. In addition, as a public company, we also expect to incur increased stock-based compensation expense related to our long-term equity incentive plan.
Research and Development Expense
Our research and development expense consists of costs incurred in performing research and development activities. These expenses include direct costs for salaries and benefits, supplies used in research and development, contract services and other outside costs, costs to acquire in-process research and development projects and technologies that have no alternative future use, and allocated overhead expenses.
We expect that our overall research and development expenses will vary from period to period as a percentage of revenue, as projects and prospective trials are initiated and completed.
Other Income (Expense), Net
Interest Income
Interest income consists primarily of interest earned on our cash and cash equivalents and marketable securities.
Interest Expense
Interest expense consists primarily of contractual interest expense on our term loan, amortization of the debt discount related to our term loans, and interest expense on our finance leases.
Changes in Fair Value of Financial Instruments
Changes in fair value of financial instruments consists of changes in the fair value of the warrant liability and changes in the fair value of the derivative liability. Our warrants are classified as a liability on our consolidated balance sheets and re-measured to fair value at each balance sheet date with the corresponding changes in fair value recorded within changes in fair value of financial instruments, as the holders have the option to convert their warrants into shares of either our common stock or our Series C preferred stock. The warrants will expire upon the completion of this offering unless earlier exercised.
Other Expense, Net
Other expense, net consists of items related to foreign currency gains and losses, and other immaterial items.
 
117

TABLE OF CONTENTS
 
Results of Operations
Comparison of the Three Months Ended March 31, 2025 and 2024
The following table sets forth a summary of our results of operations for the periods presented:
​ ​ ​
Three Months Ended
March 31,
​
​ ​ ​
2025
​ ​
2024
​
​ ​ ​
(In thousands)
​
Revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Molecular profiling services
​ ​ ​ $ 114,081 ​ ​ ​ ​ $ 73,233 ​ ​
Pharma research and development services
​ ​ ​ ​ 6,834 ​ ​ ​ ​ ​ 7,444 ​ ​
Total revenue
​ ​ ​ ​ 120,915 ​ ​ ​ ​ ​ 80,677 ​ ​
Costs and operating expenses(1): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Cost of Services – Molecular Profiling Services
​ ​ ​ ​ 60,894 ​ ​ ​ ​ ​ 52,894 ​ ​
Cost of Services – Pharma Research and Development Services
​ ​ ​ ​ 2,958 ​ ​ ​ ​ ​ 1,669 ​ ​
Selling and marketing expense
​ ​ ​ ​ 39,829 ​ ​ ​ ​ ​ 39,609 ​ ​
General and administrative expense
​ ​ ​ ​ 52,119 ​ ​ ​ ​ ​ 44,354 ​ ​
Research and development expense
​ ​ ​ ​ 23,066 ​ ​ ​ ​ ​ 34,376 ​ ​
Total costs and operating expenses
​ ​ ​ ​ 178,867 ​ ​ ​ ​ ​ 172,902 ​ ​
Loss from operations
​ ​ ​ ​ (57,952) ​ ​ ​ ​ ​ (92,225) ​ ​
Other income (expense), net: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Interest income
​ ​ ​ ​ 503 ​ ​ ​ ​ ​ 1,768 ​ ​
Interest expense
​ ​ ​ ​ (12,782) ​ ​ ​ ​ ​ (9,290) ​ ​
Changes in fair value of financial instruments
​ ​ ​ ​ (32,333) ​ ​ ​ ​ ​ (11,064) ​ ​
Other expense, net
​ ​ ​ ​ (17) ​ ​ ​ ​ ​ (219) ​ ​
Total other expense, net
​ ​ ​ ​ (44,629) ​ ​ ​ ​ ​ (18,804) ​ ​
Loss before income taxes and provision for income taxes
​ ​ ​ ​ (102,581) ​ ​ ​ ​ ​ (111,028) ​ ​
Provision for (benefit from) income taxes
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​
Net loss
​ ​ ​ $ (102,581) ​ ​ ​ ​ $ (111,028) ​ ​
​
(1)
Costs and operating expenses contains the following stock-based compensation expense:
​
​ ​ ​
Three Months Ended
March 31,
​
​ ​ ​
2025
​ ​
2024
​
​ ​ ​
(In thousands)
​
Cost of services – Molecular profiling services
​ ​ ​ $ 466 ​ ​ ​ ​ $ 427 ​ ​
Cost of services – Pharma research and development services
​ ​ ​ ​ 1 ​ ​ ​ ​ ​ 2 ​ ​
Selling and marketing expense
​ ​ ​ ​ 1,243 ​ ​ ​ ​ ​ 1,118 ​ ​
General and administrative expense
​ ​ ​ ​ 10,636 ​ ​ ​ ​ ​ 1,945 ​ ​
Research and development expense
​ ​ ​ ​ 2,346 ​ ​ ​ ​ ​ 966 ​ ​
Total
​ ​ ​ $ 14,691 ​ ​ ​ ​ $ 4,458 ​ ​
 
118

TABLE OF CONTENTS
 
The following table sets forth our results of operations as a percentage of revenue for the periods presented:
​ ​ ​
Three Months Ended
March 31,
​
​ ​ ​
2025
​ ​
2024
​
Revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Molecular profiling services
​ ​ ​ ​ 94% ​ ​ ​ ​ ​ 91% ​ ​
Pharma research and development services
​ ​ ​ ​ 6% ​ ​ ​ ​ ​ 9% ​ ​
Total revenue
​ ​ ​ ​ 100% ​ ​ ​ ​ ​ 100% ​ ​
Costs and operating expenses(1): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Cost of services – Molecular profiling services
​ ​ ​ ​ 50% ​ ​ ​ ​ ​ 66% ​ ​
Cost of Services – Pharma Research and Development Services
​ ​ ​ ​ 2% ​ ​ ​ ​ ​ 2% ​ ​
Selling and marketing expense
​ ​ ​ ​ 33% ​ ​ ​ ​ ​ 49% ​ ​
General and administrative expense
​ ​ ​ ​ 43% ​ ​ ​ ​ ​ 55% ​ ​
Research and development expense
​ ​ ​ ​ 19% ​ ​ ​ ​ ​ 43% ​ ​
Total costs and operating expenses
​ ​ ​ ​ 148% ​ ​ ​ ​ ​ 214% ​ ​
Loss from operations
​ ​ ​ ​ (48)% ​ ​ ​ ​ ​ (114)% ​ ​
Other income (expense), net: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Interest income
​ ​ ​ ​ —% ​ ​ ​ ​ ​ 2% ​ ​
Interest expense
​ ​ ​ ​ (11)% ​ ​ ​ ​ ​ (12)% ​ ​
Changes in fair value of financial instruments
​ ​ ​ ​ (27)% ​ ​ ​ ​ ​ (14)% ​ ​
Other expense, net
​ ​ ​ ​ —% ​ ​ ​ ​ ​ —% ​ ​
Total other expense, net
​ ​ ​ ​ (37)% ​ ​ ​ ​ ​ (23)% ​ ​
Loss before income taxes and provision for income taxes
​ ​ ​ ​ (85)% ​ ​ ​ ​ ​ (138)% ​ ​
Provision for (benefit from) income taxes
​ ​ ​ ​ —% ​ ​ ​ ​ ​ —% ​ ​
Net loss
​ ​ ​ ​ (85)% ​ ​ ​ ​ ​ (138)% ​ ​
Revenue
​ ​ ​
Three Months Ended
March 31,
​ ​
Change
​
​ ​ ​
2025
​ ​
2024
​ ​
$
​ ​
%
​
​ ​ ​
(Dollars in thousands)
​
Molecular profiling services
​ ​ ​ $ 114,081 ​ ​ ​ ​ $ 73,233 ​ ​ ​ ​ $ 40,848 ​ ​ ​ ​ ​ 55.8% ​ ​
Pharma research and development services
​ ​ ​ ​ 6,834 ​ ​ ​ ​ ​ 7,444 ​ ​ ​ ​ ​ (610) ​ ​ ​ ​ ​ (8.2)% ​ ​
Total revenue
​ ​ ​ $ 120,915 ​ ​ ​ ​ $ 80,677 ​ ​ ​ ​ $ 40,238 ​ ​ ​ ​ ​ 49.9% ​ ​
Total revenue was $120.9 million for the three months ended March 31, 2025, compared to $80.7 million for the three months ended March 31, 2024, an increase of $40.2 million, or 49.9%.
Molecular Profiling Services Revenue
Molecular profiling services revenue increased to $114.1 million for the three months ended March 31, 2025, from $73.2 million for the three months ended March 31, 2024, an increase of $40.8 million, or 55.8%.
This increase in revenue was primarily due to the increase in clinical cases associated with MI Profile and Caris Assure for therapy selection from 33,095 and 1,807 cases, respectively, for the three months ended March 31, 2024, to 40,048 and 5,810 cases, respectively, for the three months ended March 31, 2025,
 
119

TABLE OF CONTENTS
 
a total increase of 10,956 cases, or 31.4%. We believe the growth in MI Profile clinical case volume is driven by increased market acceptance and adoption of MI Profile by ordering physicians year over year, and increased market acceptance and adoption of Caris Assure following its broad commercial launch in the first quarter of 2024.
Revenue from clinical cases for patients covered by Medicare represented approximately 54.3% and 40.5% of our molecular profiling services revenue for the three months ended March 31, 2025 and 2024, respectively due to mix.
The following table sets forth the relative impacts of clinical volume and ASP on our increase in molecular profiling services revenue.
​ ​ ​
(In thousands)
​
Molecular profiling services revenue for the three months ended March 31, 2024
​ ​ ​ $ 73,233 ​ ​
MI Profile volume increase
​ ​ ​ ​ 14,894 ​ ​
MI Profile ASP increase due to payer mix
​ ​ ​ ​ 15,704 ​ ​
Caris Assure for therapy selection
​ ​ ​ ​ 10,250 ​ ​
Molecular profiling services revenue for the three months ended March 31, 2025
​ ​ ​ $ 114,081 ​ ​
Pharma Research and Development Services Revenue
Pharma research and development services revenue decreased to $6.8 million for the three months ended March 31, 2025, from $7.4 million for the three months ended March 31, 2024, a decrease of $0.6 million, or 8.2%. The decrease is mainly driven by reduced research case volume.
Cost of Services
​ ​ ​
Three Months Ended
March 31,
​ ​
Change
​
​ ​ ​
2025
​ ​
2024
​ ​
$
​ ​
%
​
​ ​ ​
(Dollars in thousands)
​
Cost of services – Molecular profiling services
​ ​ ​ $ 60,894 ​ ​ ​ ​ $ 52,894 ​ ​ ​ ​ $ 8,000 ​ ​ ​ ​ ​ 15.1% ​ ​
Cost of services – Pharma research and development services
​ ​ ​ $ 2,958 ​ ​ ​ ​ $ 1,669 ​ ​ ​ ​ $ 1,289 ​ ​ ​ ​ ​ 77.2% ​ ​
Cost of Services—Molecular Profiling Services
Cost of services−Molecular profiling services was $60.9 million for the three months ended March 31, 2025, compared to $52.9 million for the three months ended March 31, 2024, an increase of $8.0 million, or 15.1%.
The Caris Assure laboratory contributed to the majority of the $8.0 million increase. The Caris Assure increase was primarily driven by an increase in materials and related testing costs of $5.0 million, a $1.3 million increase in utilities, rent, and allocated overhead, and an increase in labor costs of $1.1 million, due to the increased volume from broad launch in the first quarter of 2024.
Cost of Services—Pharma Research and Development Services
Cost of services−Pharma research and development services was $3.0 million for the three months ended March 31, 2025, compared to $1.7 million for the three months ended March 31, 2024, an increase of $1.3 million, or 77.2%. The increase was driven primarily by an increase within costs associated with the delivery of data licensing and target discovery services of $2.5 million, offset by a reduction in delivering research services of $1.2 million, driven by lower research volume.
Gross Profit
Gross profit, calculated as total revenue less cost of services, was $57.1 million for the three months ended March 31, 2025, compared to $26.1 million for the three months ended March 31, 2024, an increase of $30.9 million, or 118.5%, primarily due to the increase in clinical revenue.
 
120

TABLE OF CONTENTS
 
Selling and Marketing Expense
​ ​ ​
Three Months Ended
March 31,
​ ​
Change
​
​ ​ ​
2025
​ ​
2024
​ ​
$
​ ​
%
​
​ ​ ​
(Dollars in thousands)
​
Selling and marketing expense
​ ​ ​ $ 39,829 ​ ​ ​ ​ $ 39,609 ​ ​ ​ ​ $ 221 ​ ​ ​ ​ ​ 0.6% ​ ​
Selling and marketing expenses were $39.8 million for the three months ended March 31, 2025, compared to $39.6 million for the three months ended March 31, 2024, an increase of $0.2 million, or 0.6%. This increase was primarily due to a $2.1 million increase in personnel costs to support existing solutions, offset by a $1.9 million decrease in travel and marketing expenses.
General and Administrative Expense
​ ​ ​
Three Months Ended
March 31,
​ ​
Change
​
​ ​ ​
2025
​ ​
2024
​ ​
$
​ ​
%
​
​ ​ ​
(Dollars in thousands)
​
General and administrative expense
​ ​ ​ $ 52,119 ​ ​ ​ ​ $ 44,354 ​ ​ ​ ​ $ 7,765 ​ ​ ​ ​ ​ 17.5% ​ ​
General and administrative expenses were $52.1 million for the three months ended March 31, 2025, compared to $44.4 million for the three months ended March 31, 2024, an increase of $7.8 million, or 17.5%. This increase was primarily due to an increase of $11.6 million in labor costs, benefits and stock-based compensation associated with an expansion of personnel, a $1.3 million increase in consulting, audit and legal professional fees, a $1.3 million increase related to utilities and cloud computing usages, offset by a $7.2 million decrease in depreciation expense.
Research and Development Expense
​ ​ ​
Three Months Ended
March 31,
​ ​
Change
​
​ ​ ​
2025
​ ​
2024
​ ​
$
​ ​
%
​
​ ​ ​
(Dollars in thousands)
​
Research and development expense
​ ​ ​ $ 23,066 ​ ​ ​ ​ $ 34,376 ​ ​ ​ ​ $ (11,310) ​ ​ ​ ​ ​ (32.9)% ​ ​
Research and development expenses were $23.1 million for the three months ended March 31, 2025, compared to $34.4 million for the three months ended March 31, 2024, a decrease of $11.3 million, or 32.9%. The decrease was primarily driven by a reduction of $9.6 million in material and reference testing costs associated with the development of Caris Assure and FDA submission of MI Cancer Seek, a reduction of $0.8 million in labor costs, benefits and stock-based compensation, and a $0.8 million reduction in allocated overhead.
Other Income (Expense), Net
​ ​ ​
Three Months Ended
March 31,
​ ​
Change
​
​ ​ ​
2025
​ ​
2024
​ ​
$
​ ​
%
​
​ ​ ​
(Dollars in thousands)
​
Interest income
​ ​ ​ $ 503 ​ ​ ​ ​ $ 1,768 ​ ​ ​ ​ $ (1,265) ​ ​ ​ ​ ​ (71.6)% ​ ​
Interest expense
​ ​ ​ ​ (12,782) ​ ​ ​ ​ ​ (9,290) ​ ​ ​ ​ ​ (3,492) ​ ​ ​ ​ ​ 37.6% ​ ​
Changes in fair value of financial instruments
​ ​ ​ ​ (32,333) ​ ​ ​ ​ ​ (11,064) ​ ​ ​ ​ ​ (21,269) ​ ​ ​ ​ ​ 192.2% ​ ​
Other expense, net
​ ​ ​ ​ (17) ​ ​ ​ ​ ​ (219) ​ ​ ​ ​ ​ 202 ​ ​ ​ ​ ​ (92.2)% ​ ​
Total other income (expense), net
​ ​ ​ $ (44,629) ​ ​ ​ ​ $ (18,804) ​ ​ ​ ​ $ (25,825) ​ ​ ​ ​ ​ 137.3% ​ ​
 
121

TABLE OF CONTENTS
 
Interest Income
Interest income was $0.5 million for the three months ended March 31, 2025, compared to $1.8 million for the three months ended March 31, 2024, a decrease of $1.3 million, or 71.6%. This decrease was primarily due to reduced investments in marketable securities.
Interest Expense
Interest expense was $12.8 million for the three months ended March 31, 2025, compared to $9.3 million for the three months ended March 31, 2024, an increase of $3.5 million, or 37.6%. This increase was primarily due to increased interest expense associated with $200.0 million of additional borrowing under the 2023 Term Loan Agreement, which was drawn on March 5, 2024.
Changes in Fair Value of Financial Instruments
Changes in fair value of financial instruments was $32.3 million for the three months ended March 31, 2025, compared to $11.1 million for the three months ended March 31, 2024, an increase of $21.3 million, or 192.2%. This increase is mainly driven by the increase in warrant and derivative fair values during the three months ended March 31, 2025.
Other Expense, Net
Other expense, net was $17 thousand for the three months ended March 31, 2025, compared to $0.2 million for the three months ended March 31, 2024, a decrease of $0.2 million, or 92.2%. This decrease was primarily due to the undrawn fee of the 2023 Term Loan, incurred during the three months ended March 31, 2024.
 
122

TABLE OF CONTENTS
 
Comparison of the Years Ended December 31, 2024 and 2023
The following table sets forth a summary of our results of operations for the periods presented:
​ ​ ​
Years Ended December 31,
​
​ ​ ​
2024
​ ​
2023
​
​ ​ ​
(In thousands)
​
Revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Molecular profiling services
​ ​ ​ $ 349,115 ​ ​ ​ ​ $ 278,748 ​ ​
Pharma research and development services
​ ​ ​ ​ 63,145 ​ ​ ​ ​ ​ 27,380 ​ ​
Total revenue
​ ​ ​ ​ 412,260 ​ ​ ​ ​ ​ 306,128 ​ ​
Costs and operating expenses(1): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Cost of services–Molecular profiling services
​ ​ ​ ​ 223,075 ​ ​ ​ ​ ​ 207,509 ​ ​
Cost of services–Pharma research and development
services
​ ​ ​ ​ 10,403 ​ ​ ​ ​ ​ 9,309 ​ ​
Selling and marketing expense
​ ​ ​ ​ 152,602 ​ ​ ​ ​ ​ 142,925 ​ ​
General and administrative expense
​ ​ ​ ​ 169,386 ​ ​ ​ ​ ​ 149,053 ​ ​
Research and development expense
​ ​ ​ ​ 113,916 ​ ​ ​ ​ ​ 116,883 ​ ​
Total costs and operating expenses
​ ​ ​ ​ 669,382 ​ ​ ​ ​ ​ 625,679 ​ ​
Loss from operations
​ ​ ​ ​ (257,122) ​ ​ ​ ​ ​ (319,551) ​ ​
Other income (expense), net: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Interest income
​ ​ ​ ​ 7,122 ​ ​ ​ ​ ​ 11,258 ​ ​
Interest expense
​ ​ ​ ​ (50,025) ​ ​ ​ ​ ​ (31,610) ​ ​
Changes in fair value of financial instruments
​ ​ ​ ​ 18,484 ​ ​ ​ ​ ​ 11,094 ​ ​
Other expense, net
​ ​ ​ ​ (349) ​ ​ ​ ​ ​ (12,606) ​ ​
Total other expense, net
​ ​ ​ ​ (24,768) ​ ​ ​ ​ ​ (21,864) ​ ​
Loss before income taxes and provision for income taxes
​ ​ ​ ​ (281,890) ​ ​ ​ ​ ​ (341,415) ​ ​
Provision for (benefit from) income taxes
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​
Net loss
​ ​ ​ $ (281,890) ​ ​ ​ ​ $ (341,415) ​ ​
​
(1)
Costs and operating expenses contains the following stock-based compensation expense:
​
​ ​ ​
Years Ended December 31,
​
​ ​ ​
2024
​ ​
2023
​
​ ​ ​
(In thousands)
​
Cost of services–Molecular profiling services
​ ​ ​ $ 1,669 ​ ​ ​ ​ $ 1,504 ​ ​
Cost of services–Pharma research and development services
​ ​ ​ ​ 11 ​ ​ ​ ​ ​ 10 ​ ​
Selling and marketing expense
​ ​ ​ ​ 4,301 ​ ​ ​ ​ ​ 3,400 ​ ​
General and administrative expense
​ ​ ​ ​ 8,448 ​ ​ ​ ​ ​ 6,983 ​ ​
Research and development expense
​ ​ ​ ​ 4,214 ​ ​ ​ ​ ​ 3,344 ​ ​
Total
​ ​ ​ $ 18,643 ​ ​ ​ ​ $ 15,241 ​ ​
 
123

TABLE OF CONTENTS
 
The following table sets forth our results of operations as a percentage of revenue for the periods presented:
​ ​ ​
Years Ended December 31,
​
​ ​ ​
2024
​ ​
2023
​
Revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Molecular profiling services
​ ​ ​ ​ 85% ​ ​ ​ ​ ​ 91% ​ ​
Pharma research and development services
​ ​ ​ ​ 15% ​ ​ ​ ​ ​ 9% ​ ​
Total revenue
​ ​ ​ ​ 100% ​ ​ ​ ​ ​ 100% ​ ​
Costs and operating expenses(1): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Cost of services–Molecular profiling services
​ ​ ​ ​ 54% ​ ​ ​ ​ ​ 68% ​ ​
Cost of services–Pharma research and development services
​ ​ ​ ​ 3% ​ ​ ​ ​ ​ 3% ​ ​
Selling and marketing expense
​ ​ ​ ​ 37% ​ ​ ​ ​ ​ 47% ​ ​
General and administrative expense
​ ​ ​ ​ 41% ​ ​ ​ ​ ​ 49% ​ ​
Research and development expense
​ ​ ​ ​ 28% ​ ​ ​ ​ ​ 38% ​ ​
Total costs and operating expenses
​ ​ ​ ​ 162% ​ ​ ​ ​ ​ 204% ​ ​
Loss from operations
​ ​ ​ ​ (62)% ​ ​ ​ ​ ​ (104)% ​ ​
Other income (expense), net: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Interest income
​ ​ ​ ​ 2% ​ ​ ​ ​ ​ 4% ​ ​
Interest expense
​ ​ ​ ​ (12)% ​ ​ ​ ​ ​ (10)% ​ ​
Changes in fair value of financial instruments
​ ​ ​ ​ 4% ​ ​ ​ ​ ​ 4% ​ ​
Other expense, net
​ ​ ​ ​ —% ​ ​ ​ ​ ​ (4)% ​ ​
Total other expense, net
​ ​ ​ ​ (6)% ​ ​ ​ ​ ​ (7)% ​ ​
Loss before income taxes and provision for income taxes
​ ​ ​ ​ (68)% ​ ​ ​ ​ ​ (112)% ​ ​
Provision for (benefit from) income taxes
​ ​ ​ ​ —% ​ ​ ​ ​ ​ —% ​ ​
Net loss
​ ​ ​ ​ (68)% ​ ​ ​ ​ ​ (112)% ​ ​
Revenue
​ ​ ​
Years Ended December 31,
​ ​
Change
​
​ ​ ​
2024
​ ​
2023
​ ​
$
​ ​
%
​
​ ​ ​
(Dollars in thousands)
​
Molecular profiling services
​ ​ ​ $ 349,115 ​ ​ ​ ​ ​ $ 278,748 ​ ​ ​ ​ ​ $ 70,367 ​ ​ ​ ​ ​ ​ 25.2 % ​ ​
Pharma research and development services
​ ​ ​ ​ 63,145 ​ ​ ​ ​ ​ ​ 27,380 ​ ​ ​ ​ ​ ​ 35,765 ​ ​ ​ ​ ​ ​ 130.6 % ​ ​
Total revenue
​ ​ ​ $ 412,260 ​ ​ ​ ​ ​ $ 306,128 ​ ​ ​ ​ ​ $ 106,132 ​ ​ ​ ​ ​ ​ 34.7 % ​ ​
Total revenue was $412.3 million for the year ended December 31, 2024, compared to $306.1 million for the year ended December 31, 2023, an increase of $106.1 million, or 34.7%.
Molecular Profiling Services Revenue
Molecular profiling services revenue increased to $349.1 million for the year ended December 31, 2024, from $278.7 million for the year ended December 31, 2023, an increase of $70.4 million, or 25.2%.
This increase in revenue was primarily due to the increase in clinical cases associated with MI Profile and Caris Assure for therapy selection from 128,168 and 663 cases, respectively, for the year ended December 31, 2023, to 146,580 and 16,282 cases, respectively, for the year ended December 31, 2024, a total increase of 34,031 cases, or 26.4%. We believe the growth in MI Profile clinical case volume is driven by increased market acceptance and adoption of MI Profile by ordering physicians year over year, and increased market acceptance and adoption of Caris Assure following its broad commercial launch in the first quarter of 2024.
 
124

TABLE OF CONTENTS
 
For the year ended December 31, 2023, we recorded $4.4 million of revenue related to the transition of payers from “non-contract basis” to ‘‘contract basis.’’ Revenue from clinical cases for patients covered by Medicare represented approximately 39.0% and 39.3% of our molecular profiling services revenue for the years ended December 31, 2024 and 2023, respectively.
The following table sets forth the relative impacts of clinical volume and ASP on our increase in molecular profiling services revenue from 2023 to 2024.
​ ​ ​
(In thousands)
​
Molecular profiling services revenue for the year ended December 31, 2023
​ ​ ​ $ 278,748 ​ ​ ​
MI Profile volume increase
​ ​ ​ ​ 39,393 ​ ​ ​
MI Profile ASP increase due to payer mix
​ ​ ​ ​ 8,621 ​ ​ ​
Transition adjustments for MI Profile payers in 2023
​ ​ ​ ​ (4,390) ​ ​ ​
Caris Assure for therapy selection
​ ​ ​ ​ 26,743 ​ ​ ​
Molecular profiling services revenue for the year ended December 31, 2024
​ ​ ​ $ 349,115 ​ ​ ​
Pharma Research and Development Services Revenue
Pharma research and development services revenue increased to $63.1 million for the year ended December 31, 2024, from $27.4 million for the year ended December 31, 2023, an increase of $35.7 million, or 130.3%. This increase was primarily due to increased activity with our biopharma partners for our data licensing business of $35.6 million and an increase within pharma profiling services of $1.8 million. The increases were partially offset by a reduction in research revenue of $2.5 million.
Cost of Services
​ ​ ​
Years Ended December 31,
​ ​
Change
​
​ ​ ​
2024
​ ​
2023
​ ​
$
​ ​
%
​
​ ​ ​
(Dollars in thousands)
​
Cost of services–Molecular profiling services
​ ​ ​ $ 223,075 ​ ​ ​ ​ ​ $ 207,509 ​ ​ ​ ​ ​ $ 15,566 ​ ​ ​ ​ ​ ​ 7.5 % ​ ​
Cost of services–Pharma research and development services
​ ​ ​ $ 10,403 ​ ​ ​ ​ ​ $ 9,309 ​ ​ ​ ​ ​ $ 1,094 ​ ​ ​ ​ ​ ​ 11.8 % ​ ​
Cost of Services—Molecular Profiling Services
Cost of services—Molecular profiling services was $223.1 million for the year ended December 31, 2024, compared to $207.5 million for the year ended December 31, 2023, an increase of $15.6 million, or 7.5%.
The Caris Assure laboratory contributed a $20.2 million increase, which was offset by a $4.6 million decrease within the MI Profile tissue laboratory. The Caris Assure increase was primarily driven by an increase in materials and related testing costs of $15.7 million and an increase in labor costs of $2.7 million, due to the increased volume from broad launch in the first quarter of 2024. The MI Profile decrease was driven primarily by a reduction in labor costs of $2.9 million and reduced depreciation of $5.7 million, mainly from lab equipment that has been fully depreciated, offset by an increase in materials and related testing costs of $2.0 million, driven by increased case volume.
Cost of Services—Pharma Research and Development Services
Cost of services—Pharma research and development services was $10.4 million for the year ended December 31, 2024, compared to $9.3 million for the year ended December 31, 2023, an increase of $1.1 million, or 11.8%. The increase was driven primarily by an increase within costs associated with the delivery of data licensing and target discovery services, offset by a reduction in labor and materials used in pharma profiling services.
 
125

TABLE OF CONTENTS
 
Gross Profit
Gross profit, calculated as total revenue less cost of services, was $178.8 million for the year ended December 31, 2024, compared to $89.3 million for the year ended December 31, 2023, an increase of $89.5 million, or 100.2%, primarily due to the increase in the number of clinical cases and pharma research and development services revenue.
Selling and Marketing Expense
​ ​ ​
Years Ended December 31,
​ ​
Change
​
​ ​ ​
2024
​ ​
2023
​ ​
$
​ ​
%
​
​ ​ ​
(Dollars in thousands)
​
Selling and marketing expense
​ ​ ​ $ 152,602 ​ ​ ​ ​ ​ $ 142,925 ​ ​ ​ ​ ​ $ 9,677 ​ ​ ​ ​ ​ ​ 6.8 % ​ ​
Selling and marketing expenses were $152.6 million for the year ended December 31, 2024, compared to $142.9 million for the year ended December 31, 2023, an increase of $9.7 million, or 6.8%. This increase was primarily due to a $5.7 million increase in personnel costs to support existing solutions, a $1.4 million increase in professional service costs from expanded EMR integrations and consulting, and a $2.4 million increase in travel and marketing expenses.
General and Administrative Expense
​ ​ ​
Years Ended December 31,
​ ​
Change
​
​ ​ ​
2024
​ ​
2023
​ ​
$
​ ​
%
​
​ ​ ​
(Dollars in thousands)
​
General and administrative expense
​ ​ ​ $ 169,386 ​ ​ ​ ​ ​ $ 149,053 ​ ​ ​ ​ ​ $ 20,333 ​ ​ ​ ​ ​ ​ 13.6 % ​ ​
General and administrative expenses were $169.4 million for the year ended December 31, 2024, compared to $149.1 million for the year ended December 31, 2023, an increase of $20.3 million, or 13.6%. This increase was primarily due to an increase of $6.9 million in labor costs, benefits and stock-based compensation associated with an expansion of personnel, a $4.3 million increase in consulting, audit and legal professional fees, and a $6.9 million increase related to utilities and cloud computing usages.
Research and Development Expense
​ ​ ​
Years Ended December 31,
​ ​
Change
​
​ ​ ​
2024
​ ​
2023
​ ​
$
​ ​
%
​
​ ​ ​
(Dollars in thousands)
​
Research and development expense
​ ​ ​ $ 113,916 ​ ​ ​ ​ ​ $ 116,883 ​ ​ ​ ​ ​ $ (2,967) ​ ​ ​ ​ ​ ​ (2.5) % ​ ​
Research and development expenses were $113.9 million for the year ended December 31, 2024, compared to $116.9 million for the year ended December 31, 2023, a decrease of $3.0 million, or 2.5%. The decrease was primarily driven by a reduction of $8.2 million in material and reference testing costs associated with the development of Caris Assure and FDA submission of MI Cancer Seek and a reduction of $2.6 million in consulting fees, offset by an $8.0 million increase in labor costs, benefits and stock-based compensation.
 
126

TABLE OF CONTENTS
 
Other Income (Expense), Net
​ ​ ​
Years Ended December 31,
​ ​
Change
​
​ ​ ​
2024
​ ​
2023
​ ​
$
​ ​
%
​
​ ​ ​
(Dollars in thousands)
​
Interest income
​ ​ ​ $ 7,122 ​ ​ ​ ​ ​ $ 11,258 ​ ​ ​ ​ ​ $ (4,136) ​ ​ ​ ​ ​ ​ (36.7) % ​ ​
Interest expense
​ ​ ​ ​ (50,025) ​ ​ ​ ​ ​ ​ (31,610) ​ ​ ​ ​ ​ ​ (18,415) ​ ​ ​ ​ ​ ​ 58.3 % ​ ​
Changes in fair value of financial instruments
​ ​ ​ ​ 18,484 ​ ​ ​ ​ ​ ​ 11,094 ​ ​ ​ ​ ​ ​ 7,390 ​ ​ ​ ​ ​ ​ 66.6 % ​ ​
Other expense, net
​ ​ ​ ​ (349) ​ ​ ​ ​ ​ ​ (12,606) ​ ​ ​ ​ ​ ​ 12,257 ​ ​ ​ ​ ​ ​ (97.2) % ​ ​
Total other income (expense), net
​ ​ ​ $ (24,768) ​ ​ ​ ​ ​ $ (21,864) ​ ​ ​ ​ ​ $ (2,904) ​ ​ ​ ​ ​ ​ 13.3 % ​ ​
Interest Income
Interest income was $7.1 million for the year ended December 31, 2024, compared to $11.3 million for the year ended December 31, 2023, a decrease of $4.1 million, or 36.7%. This decrease was primarily due to reduced investments in marketable securities.
Interest Expense
Interest expense was $50.0 million for the year ended December 31, 2024, compared to $31.6 million for the year ended December 31, 2023, an increase of $18.4 million, or 58.3%. This increase was primarily due to increased interest expense associated with $200.0 million of additional borrowing under the 2023 Term Loan Agreement, which was drawn on March 5, 2024.
Changes in Fair Value of Financial Instruments
Changes in fair value of financial instruments was $18.5 million for the year ended December 31, 2024, compared to $11.1 million for the year ended December 31, 2023, an increase of $7.4 million, or 66.6%. This increase is mainly driven by the decrease in warrant and derivative fair values during the year ended December 31, 2024.
Other Expense, Net
Other expense, net was $0.3 million for the year ended December 31, 2024, compared to $12.6 million for the year ended December 31, 2023, a net decrease of $12.3 million, or 97.2%. This decrease was primarily due to a loss on debt extinguishment of $10.9 million in connection with our prior term loan that was recorded in January 2023.
Non-GAAP Financial Measures
We use certain non-GAAP financial measures to supplement our consolidated financial statements, which are presented in accordance with GAAP. We believe the non-GAAP financial measures we use, Adjusted EBITDA and free cash flow, are useful in evaluating our performance and liquidity. Our non-GAAP financial measures have limitations as analytical tools, however, and you should not consider them in isolation or as substitutes for analysis of our results as reported under GAAP.
Adjusted EBITDA
We define Adjusted EBITDA as net loss, adjusted to exclude interest income, interest expense, changes in fair value of financial instruments, other expense, net, the provision for (benefit from) income taxes, depreciation and amortization, and stock-based compensation expense.
We use Adjusted EBITDA in conjunction with GAAP measures as part of our overall assessment of our performance, including the preparation of our annual operating budget and quarterly forecasts, to evaluate the effectiveness of our business strategies, and to communicate with our board of directors concerning our financial performance. We believe that Adjusted EBITDA provides useful information to
 
127

TABLE OF CONTENTS
 
investors and others in understanding and evaluating our operating results in the same manner as our management team and board of directors. In addition, it provides a useful measure for period-to-period comparisons of our business, as it removes the effect of certain non-cash expenses and certain variable charges. Some of the limitations related to the use of Adjusted EBITDA as an analytical tool include:
•
it does not reflect interest income, interest expense or other non-operating gains and losses, which may represent an increase to or reduction in cash available to us;
​
•
it does not reflect recurring, non-cash expenses of depreciation of property and equipment and amortization of right-of-use assets and intangible assets, and although these are non-cash expenses, the assets being depreciated and amortized may have to be replaced in the future;
​
•
it does not reflect the impact of stock-based compensation expense, which has been, and will continue to be a part of our compensation strategy; and
​
•
it may be calculated differently than similarly titled measures used by other companies, which reduces its usefulness as a comparative measure.
​
Because of these limitations, you should consider Adjusted EBITDA alongside other financial performance measures, including net loss and our other GAAP results. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as, or similar to, some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed to imply that our future results will be unaffected by the types of items excluded from the calculation of Adjusted EBITDA.
The following table provides a reconciliation of net loss, the most directly comparable financial measure presented in accordance with GAAP, to Adjusted EBITDA for the periods presented:
​ ​ ​
Three Months
Ended March 31,
​ ​
Years Ended December 31,
​
​ ​ ​
2025
​ ​
2024
​ ​
2024
​ ​
2023
​
​ ​ ​
(In thousands)
​
Net loss
​ ​ ​ $ (102,581) ​ ​ ​ ​ $ (111,028) ​ ​ ​ ​ $ (281,890) ​ ​ ​ ​ $ (341,415) ​ ​
Interest income
​ ​ ​ ​ (503) ​ ​ ​ ​ ​ (1,768) ​ ​ ​ ​ ​ (7,122) ​ ​ ​ ​ ​ (11,258) ​ ​
Interest expense
​ ​ ​ ​ 12,782 ​ ​ ​ ​ ​ 9,290 ​ ​ ​ ​ ​ 50,025 ​ ​ ​ ​ ​ 31,610 ​ ​
Changes in fair value of financial instruments
​ ​ ​ ​ 32,333 ​ ​ ​ ​ ​ 11,064 ​ ​ ​ ​ ​ (18,484) ​ ​ ​ ​ ​ (11,094) ​ ​
Other expense, net
​ ​ ​ ​ 17 ​ ​ ​ ​ ​ 219 ​ ​ ​ ​ ​ 349 ​ ​ ​ ​ ​ 12,606 ​ ​
Depreciation and amortization expense
​ ​ ​ ​ 7,045 ​ ​ ​ ​ ​ 17,705 ​ ​ ​ ​ ​ 48,913 ​ ​ ​ ​ ​ 49,001 ​ ​
Stock-based compensation expense
​ ​ ​ ​ 14,691 ​ ​ ​ ​ ​ 4,458 ​ ​ ​ ​ ​ 18,643 ​ ​ ​ ​ ​ 15,241 ​ ​
Adjusted EBITDA
​ ​ ​ $ (36,216) ​ ​ ​ ​ $ (70,062) ​ ​ ​ ​ $ (189,566) ​ ​ ​ ​ $ (255,309) ​ ​
Free Cash Flow
We define free cash flow as net cash used in operating activities less purchases of property and equipment. We believe free cash flow is a useful measure of liquidity that provides an additional basis for assessing our ability to generate cash. Some of the limitations related to the use of free cash flow as an analytical tool include:
•
it does not reflect our future contractual commitments;
​
•
it does not represent our total residual cash flow for a given period; and
​
•
it may be calculated differently than similarly titled measures used by other companies, which reduces its usefulness as a comparative measure.
​
Because of these limitations, you should consider free cash flow alongside other financial performance measures, including net cash used in operating activities, capital expenditures, and our other GAAP results.
 
128

TABLE OF CONTENTS
 
The following table provides a reconciliation of net cash used in operating activities, the most directly comparable financial measure presented in accordance with GAAP, to free cash flow for the periods presented:
​ ​ ​
Three Months
Ended March 31,
​ ​
Years Ended December 31,
​
​ ​ ​
2025
​ ​
2024
​ ​
2024
​ ​
2023
​
​ ​ ​
(In thousands)
​
Net cash used in operating activities
​ ​ ​ $ (31,338) ​ ​ ​ ​ $ (73,925) ​ ​ ​ ​ $ (245,199) ​ ​ ​ ​ $ (276,100) ​ ​
Less: purchases of property and equipment
​ ​ ​ ​ (2,689) ​ ​ ​ ​ ​ (1,738) ​ ​ ​ ​ ​ (8,444) ​ ​ ​ ​ ​ (22,319) ​ ​
Free cash flow
​ ​ ​
$
(34,027)
​ ​ ​ ​
$
(75,663)
​ ​ ​ ​
$
(253,643)
​ ​ ​ ​
$
(298,419)
​ ​
Liquidity and Capital Resources
Sources of Liquidity
We have incurred net losses and negative cash flows from operations since inception. We expect to incur additional net losses in the near future, and our expenses will increase as we continue to invest in developing new solutions, expand our organization, and increase our marketing efforts to continue to drive market adoption of our solutions. These investments, together with general and administrative expenses, have resulted in negative cash flows from operations of $245.2 million and $276.1 million for the years ended December 31, 2024 and 2023, respectively, and an accumulated deficit of $2.6 billion as of March 31, 2025.
To date, we have funded our operations principally from the issuance of stock, term loan borrowings and convertible debt, and through revenue from molecular profiling and pharma research and development services. As of March 31, 2025, we had cash and cash equivalents of $31.2 million and short-term marketable securities of $2.2 million. We believe our existing cash and cash equivalents and anticipated cash flows from operations, together with the net proceeds from our 2025 Private Placement and this offering, will provide sufficient capital and liquidity to fund our operating expenses and capital expenditure requirements for at least the next 12 months after the completion of this offering. We will, however, continue to require additional capital to meet our operational needs. See “—Indebtedness” and “—Cash Requirements” below for additional information regarding our cash requirements and various factors that may impact our liquidity and capital resources, including the Non-conversion Amortization Payments (as defined below) in respect of our existing indebtedness.
Cash Flows
The following table summarizes our cash flows for the periods presented:
​ ​ ​
Three Months
Ended March 31,
​ ​
Years Ended December 31,
​
​ ​ ​
2025
​ ​
2024
​ ​
2024
​ ​
2023
​
​ ​ ​
(In thousands)
​
Net cash used in operating activities
​ ​ ​ $ (31,338) ​ ​ ​ ​ $ (73,925) ​ ​ ​ ​ $ (245,199) ​ ​ ​ ​ $ (276,100) ​ ​
Net cash provided by investing activities
​ ​ ​ $ (2,689) ​ ​ ​ ​ $ 59,638 ​ ​ ​ ​ $ 52,932 ​ ​ ​ ​ $ 214,774 ​ ​
Net cash provided by financing activities
​ ​ ​ $ 1,285 ​ ​ ​ ​ $ 200,107 ​ ​ ​ ​ $ 200,292 ​ ​ ​ ​ $ 10,132 ​ ​
Operating Activities
Net cash used in operating activities during the year ended December 31, 2024 was $245.2 million, which was primarily due to a net loss of $281.9 million and a net change in our operating assets and liabilities of $29.1 million, and offset by non-cash charges of $65.8 million. The net change in our operating assets and liabilities was primarily the result of a $33.8 million increase in accounts receivable, a $1.4 million increase in prepaid expenses and other current assets, offset by a $5.5 million decrease in supplies and a $0.1 million decrease in other assets. Net non-cash charges, primarily consisted of $48.9 million of
 
129

TABLE OF CONTENTS
 
depreciation and amortization expense, $18.6 million of stock-based compensation expense and $7.1 million in amortization of debt discount costs, offset by a $18.5 million gain within changes in the fair value of financial instruments.
Net cash used in operating activities during the year ended December 31, 2023 was $276.1 million, which was primarily due to a net loss of $341.4 million and a net change in our operating assets and liabilities of $7.1 million, and offset by non-cash charges, net of $72.4 million. The net change in our operating assets and liabilities was primarily the result of a $15.1 million increase in accounts receivable, and offset by a $7.2 million increase in accounts payable and a $1.3 million increase in accrued expenses and other current liabilities. Net non-cash charges primarily consisted of $49.0 million of depreciation and amortization, $15.2 million of stock-based compensation expense, $10.9 million of debt extinguishment expense, offset by a $11.1 million gain within changes in the fair value of financial instruments.
Net cash used in operating activities during the three months ended March 31, 2025 was $31.3 million, which was primarily due to a net loss of $102.6 million and a net change in our operating assets and liabilities of $13.3 million, offset by non-cash charges of $57.9 million. The net change in our operating assets and liabilities was primarily the result of a $1.7 million decrease in accounts payable, offset by a $7.9 million decrease in accounts receivable, a $2.5 million decrease in prepaid expenses and other current assets, a $2.1 million decrease in supplies, and a $2.6 million increase in accrued expenses and other liabilities. Net non-cash charges primarily consisted of $7.0 million of depreciation and amortization expense, $14.7 million of stock-based compensation expense and $1.9 million in amortization of debt discount costs, offset by a $32.3 million loss within changes in the fair value of financial instruments.
Net cash used in operating activities during the three months ended March 31, 2024 was $73.9 million, which was primarily due to a net loss of $111.0 million and a net change in our operating assets and liabilities of $1.2 million, and offset by non-cash charges of $38.3 million. The net change in our operating assets and liabilities was primarily the result of a $2.4 million increase in accounts receivable, a $0.1 million increase in prepaid expenses and other current assets, a $2.8 million decrease in accounts payable, a $0.8 million decrease in accrued expenses and other liabilities, offset by a $4.0 million decrease in supplies and a $0.3 million decrease in other assets. Net non-cash charges, primarily consisted of $17.7 million of depreciation and amortization expense, $4.5 million of stock-based compensation expense and $1.6 million in amortization of debt discount costs, offset by a $11.1 million loss within changes in the fair value of financial instruments.
Investing Activities
Net cash provided by investing activities during the year ended December 31, 2024 was $52.9 million, which was primarily due to maturities of marketable securities of $61.4 million, offset by purchases of purchases of property and equipment of $8.4 million.
Net cash provided by investing activities during the year ended December 31, 2023 was $214.8 million, which was primarily due to maturities of marketable securities of $300.5 million, offset by purchases of marketable securities of $63.4 million and purchases of property and equipment of $22.3 million.
Net cash used in investing activities during the three months ended March 31, 2025 was $2.7 million, which was primarily due to purchases of property and equipment of $2.7 million.
Net cash provided by investing activities during the three months ended March 31, 2024 was $59.6 million, which was primarily due to maturities of marketable securities of $61.4 million, offset by purchases of property and equipment of $1.7 million.
Financing Activities
Net cash provided by financing activities during the year ended December 31, 2024 was $200.3 million, which was primarily due to proceeds from issuance of additional borrowings under the 2023 Term Loan Agreement (as defined below) on March 5, 2024, net of issuance costs, of $200.0 million.
 
130

TABLE OF CONTENTS
 
Net cash provided by financing activities during the year ended December 31, 2023 was $10.1 million, which was primarily due to proceeds from issuance of the initial borrowing under the 2023 Term Loan Agreement, net of issuance costs, of $189.0 million, offset by the repayment of the prior term loans of $180.0 million.
Net cash provided by financing activities during the three months ended March 31, 2025 was $1.3 million, which was primarily due to proceeds from exercises of stock options of $1.4 million, offset by the payment of deferred offering costs of $0.1 million.
Net cash provided by financing activities during the three months ended March 31, 2024 was $200.1 million, which was primarily due to proceeds from issuance of additional borrowings under the 2023 Term Loan Agreement on March 5, 2024, net of issuance costs, of $200.0 million.
Indebtedness
In January 2023, we entered into a term loan agreement, as amended (the “2023 Term Loan Agreement”) with OrbiMed Royalty & Credit Opportunities III, LP, OrbiMed Royalty & Credit Opportunities IV, LP, and Braidwell Transaction Holdings LLC (the “Lenders”), pursuant to which we issued senior, secured promissory notes and the Lenders agreed to lend us up to an aggregate principal amount of $400.0 million (the “2023 Term Loan”), $200.0 million of which was drawn down upon issuance of the notes. Net cash proceeds to us were $189.0 million, after deducting customary debt discounts and debt issuance costs. The net proceeds were used to repay in full our then-outstanding term loans, including an aggregate principal amount of $175.0 million, a prepayment premium of $5.0 million, and accrued and unpaid interest of $1.0 million. In March 2024, we drew down the remaining $200.0 million under the 2023 Term Loan Agreement. As of March 31, 2025, we had $400.0 million of borrowings outstanding under the 2023 Term Loan Agreement.
The aggregate principal amount outstanding under the 2023 Term Loan Agreement is due and payable on January 18, 2028. If an event of default occurs and is continuing, the lenders may declare all amounts outstanding under the 2023 Term Loan Agreement to be immediately due and payable. A final payment exit fee equal to 2.0% of the amount funded under the 2023 Term Loan Agreement is due upon prepayment or maturity. Amounts borrowed pursuant to the 2023 Term Loan Agreement may be prepaid at any time. Upon prepayment, we may be subject to a prepayment penalty based on the timing of repayment.
Additionally, pursuant to the terms of the 2023 Term Loan Agreement, on the earlier to occur of (x) for dates prior to January 1, 2026, any date that the redemption rights in respect of our Series C preferred stock, Series D preferred stock, or Series E preferred stock are or may become exercisable within 90 days following such date, or (y) January 1, 2026 or the first date thereafter if, as of such date, the redemption rights in respect of our Series C preferred stock, Series D preferred stock, or Series E preferred stock are or may become exercisable on or prior to the date that is six months after the maturity date, we will be required to make a one-time payment in an amount equal to 15% of the outstanding principal amount under the 2023 Term Loan Agreement together with any applicable repayment premium and exit fee as described in the 2023 Term Loan Agreement and, commencing with the first full fiscal quarter following such payment, we will be required to repay 2.5% of the outstanding principal amount in equal quarterly installments each quarter thereafter (such payments, the “Non-conversion Amortization Payments”). The Series C preferred stock redemption rights may be exercised on or after March 31, 2026, and the Series D preferred stock and Series E preferred stock redemption rights may be exercised on or after May 11, 2026. All outstanding shares of our Series C preferred stock, Series D preferred stock, and Series E preferred stock will convert into shares of Class B common stock as part of the Preferred Stock Conversion and any redemption rights thereunder will terminate in connection with the completion of this offering and consequently, the Non-conversion Amortization Payments discussed above would not be applicable following the completion of this offering.
The aggregate principal amount under the 2023 Term Loan Agreement bears interest at a rate per annum equal to a fixed margin of 6.5% plus the greater of (a) forward-looking three-month secured overnight financing rate (“SOFR”) and (b) 2.5%. In the event of default, the fixed margin shall increase by 3.0% per annum. As of December 31, 2024, the interest rate was 11.1%. Regular quarterly payments are
 
131

TABLE OF CONTENTS
 
interest-only for the 60-month term of the 2023 Term Loan Agreement, with the principal due at maturity. The effective interest rate for the term loan is 17.0%.
Our obligations under the 2023 Term Loan Agreement are secured by a first lien security interest in substantially all of our assets and our subsidiaries’ assets. The 2023 Term Loan Agreement contains certain customary representations and warranties, affirmative and negative covenants, financial covenants, and events of default applicable to us and our subsidiaries. Additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates, and subordinated debt. As of March 31, 2025, we were in compliance with all covenants under the 2023 Term Loan Agreement.
On April 1, 2025, we closed a private financing in which we issued a combination of senior convertible notes (the “2025 Convertible Notes”), Series E convertible preferred stock and Series F convertible preferred stock, for an aggregate of $167.7 million. The 2025 Convertible Notes have an aggregate principal amount of $30.0 million. The 2025 Convertible Notes accrue interest at a rate of 8% per annum, payable quarterly in cash, and mature on January 1, 2026. In connection with this financing, we also issued warrants to acquire shares of common stock to the holders of the 2025 Convertible Notes. These warrants are not initially exercisable for any shares of common stock, but such warrants become exercisable for a specified dollar value of shares on a monthly basis commencing on June 1, 2025 if we have not completed an initial public offering by such date. Any exercisable portion of the warrants will be automatically exercised prior to the closing of the initial public offering and such warrants will terminate upon the closing of the offering.
Immediately prior to and in connection with the completion of the initial public offering, the 2025 Convertible Notes, Series E convertible preferred stock and Series F convertible preferred stock (plus an 8% accretion in connection with the preferred stocks) will convert into Class B common stock at a price equal to 70% of the initial public offering price per share.
Cash Requirements
Our primary use of cash is to fund operating expenses and capital expenditures (including leases of equipment and buildings), which consist of research and development expenditures, general and administrative expenditures, clinical and regulatory expenditures, purchases of testing equipment, and buildout of our laboratories. Cash used to fund such activities is impacted by the timing of when we pay or prepay these expenses.
The following table summarizes our material cash requirements as of December 31, 2024:
​ ​ ​
Due by
​
​ ​ ​
Total
​ ​
2025
​ ​
2026
​ ​
2027
​ ​
Thereafter
​
​ ​ ​
(In thousands)
​
Operating leases
​ ​ ​ $ 69,312 ​ ​ ​ ​ $ 10,718 ​ ​ ​ ​ $ 10,071 ​ ​ ​ ​ $ 7,082 ​ ​ ​ ​ $ 41,441 ​ ​
Finance leases
​ ​ ​ ​ 387 ​ ​ ​ ​ ​ 117 ​ ​ ​ ​ ​ 118 ​ ​ ​ ​ ​ 117 ​ ​ ​ ​ ​ 35 ​ ​
Term loans and interest(1)
​ ​ ​ ​ 516,813 ​ ​ ​ ​ ​ 97,360 ​ ​ ​ ​ ​ 36,819 ​ ​ ​ ​ ​ 36,819 ​ ​ ​ ​ ​ 345,816 ​ ​
Total material cash requirements
​ ​ ​ $ 586,512 ​ ​ ​ ​ $ 108,195 ​ ​ ​ ​ $ 47,008 ​ ​ ​ ​ $ 44,018 ​ ​ ​ ​ $ 387,292 ​ ​
​
(1)
Excludes the Non-conversion Amortization Payments described above under “—Indebtedness,” as such payment will not be required if this offering is completed prior to December 31, 2025 (the date that is 90 days prior to March 31, 2026, the first date the Series C preferred stock redemption rights may be exercised, if such rights are not earlier amended, waived, or terminated).
​
We will continue to require additional capital to fund our operations and to continue to fund investments in the development and marketing of our solutions for the foreseeable future. We may need or determine to raise additional capital through private or public equity or debt financings, through collaborative or other arrangements with corporate sources, or through other sources of financing. Requirements for additional capital will depend on many factors, including:
 
132

TABLE OF CONTENTS
 
•
the scope, timing, rate of progress and costs of our research efforts, preclinical development activities, laboratory testing, and clinical trials for our solutions;
​
•
the number and scope of clinical programs we decide to pursue;
​
•
the cost, timing, and outcome of preparing for and undergoing regulatory review of our solutions;
​
•
the scope and costs of development and commercial manufacturing activities;
​
•
the cost and timing associated with commercializing our solutions if they receive marketing approval;
​
•
the extent to which we acquire or in-license other complementary solutions or technologies;
​
•
the costs of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending intellectual property-related claims;
​
•
our ability to establish and maintain collaborations on favorable terms, if at all;
​
•
our efforts to enhance operational systems and our ability to attract, hire, and retain qualified personnel;
​
•
our success in achieving broad coverage and adequate reimbursement for our solutions from third-party payers;
​
•
our implementation of operational, financial, and management systems; and
​
•
the costs associated with being a public company.
​
A change in the outcome of any of these or other variables with respect to the development and commercialization of any of our solutions could significantly change the costs and timing associated with such development and commercialization. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans.
We may experience increased costs and be required to raise additional capital much sooner than anticipated. In April 2025, we issued the 2025 Convertible Notes. Further, if the Series C preferred stock redemption rights described above have not been amended, waived, or otherwise terminated prior to December 31, 2025 (the date that is 90 days prior to March 31, 2026, the first date on which such redemption rights would become exercisable), we will be required to make the Non-conversion Amortization Payments following such date. See “—Indebtedness” above. If this offering is not completed by such date and such early repayment and the repayment on maturity of the 2025 convertible notes are required, based on our existing assumptions and expenditures, our existing cash resources and projected operating cash flows would not be sufficient to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the date of this prospectus. These conditions indicate the existence of a material uncertainty that raises substantial doubt as to our ability to continue as a going concern. See Note 1 of our consolidated financial statements included elsewhere in this prospectus.
Critical Accounting Policies and Estimates
Our consolidated financial statements have been prepared in conformity with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”). The preparation of the consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods.
While our significant accounting policies are described in Note 2 to our consolidated financial statements included elsewhere in this prospectus, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results.
 
133

TABLE OF CONTENTS
 
Revenue
We recognize revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”).
ASC 606 provides a five-step framework through which revenue is recognized when control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract(s); (iii) determine the transaction price, including whether there are any constraints on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. At contract inception, once a contract is determined to be within the scope of ASC 606, we assess whether individual goods or services promised within each contract are distinct and, therefore, represent separate performance obligations.
Molecular Profiling Services
We recognize revenue from our molecular profiling services at the time when the results of the profiling services are delivered to ordering physicians, including certain hospitals, cancer centers, and institutions. We identify each sale of our profiling case as a single performance obligation. We estimate the transaction price based on our historical collection experience using a portfolio approach for third-party payers and patients with similar reimbursement characteristics. This includes analysis of an average reimbursement per case per portfolio and a percentage of cases reimbursed by considering the historical reimbursement data (including any refunds and recoupments) from such third-party payers and patients, current contractual and statutory requirements, patient insurance eligibility and payer reimbursement contracts, and any known or current or anticipated reimbursement trends not reflected in the historical data. We monitor the estimated amount to be collected in the portfolio at each reporting period. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to molecular profiling services in the period of change.
Pharma Research and Development Services
Contracts with biopharma partners may include multiple distinct performance obligations, such as provision of molecular profiling services, pharma research and development services, and strategic data services. For each of our contracts with biopharma partners, we evaluate the terms and conditions to identify distinct performance obligations. For each performance obligation determined, based on when and how it is delivered, we recognize revenue either when or as such obligation is delivered. Under contracts that include a performance obligation to provide molecular profiling services, to facilitate the development and regulatory approval of drugs, or to provide target discovery services, we receive payments upon the achievement of milestones, as well as provision of on-going support. We recognize pharma research and development services revenue over the period in which pharma research and development services are provided. Depending on the nature of the service, we recognize revenue using either the output or input method to measure progress, whichever provides a more faithful depiction of the transfer of goods or services. Use of an output method or input method to depict the transfer of services generally does not result in a material difference with respect to the timing of revenue recognition because most services commence and end within the same reporting period. We determine the transaction price of each performance obligation by considering the historical selling price of similar transactions, where applicable, as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of our competitors, industry publications, and current pricing practices.
Stock-Based Compensation
We have granted stock-based awards consisting primarily of stock options and RSUs to employees, consultants, and members of our board of directors. We account for stock-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation. Stock-based compensation expense is measured based on the fair value of the awards as of the grant date and is recognized as expense over the requisite service period, which is generally the vesting period.
 
134

TABLE OF CONTENTS
 
The fair value of stock option awards as of the date of the grant is estimated by applying the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based awards. These assumptions include the following:
•
Fair value per share of the underlying stock.   As our common stock is not publicly traded, the fair value of the common stock underlying our stock options is determined by our board of directors, with input from management and valuation reports prepared by third-party valuation specialists as described below under “—Common Stock Valuations.”
​
•
Expected price volatility.   As we are not a publicly traded company, the expected price volatility for our stock options is determined by using an average of historical volatilities of selected industry peers deemed to be comparable to our business and corresponding to the expected term of the awards.
​
•
Risk-free interest rate.   The risk-free interest rate is based on the U.S. treasury yield curve in effect at the time of grant for U.S. treasury notes with maturities corresponding to the expected term of the awards.
​
•
Expected term.   The expected term of stock options represents the period of time over which the options granted are expected to remain outstanding and is based on our estimate, taking into consideration vesting terms, contractual terms, and historical actual lives. Options granted have a maximum term of 10 years. Due to the lack of historical option exercise data, we utilize the simplified method for determining the expected term.
​
•
Expected dividend rate.   We have never declared or paid any cash dividends, and we do not intend to pay any cash dividends in the foreseeable future. Therefore, we use an expected dividend yield of zero percent.
​
•
Expected forfeitures.   Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is based on historical forfeitures and is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate.
​
We will continue to use judgment in evaluating the assumptions related to our stock-based compensation on a prospective basis. As we continue to accumulate additional data related to our common stock, we may refine our estimation process, which could materially impact our future stock-based compensation expense.
In connection with this offering, we expect to incur approximately $28.9 million of stock-based compensation expense related to RSUs granted through March 31, 2025, for which the performance-based vesting condition will be satisfied in connection with this offering.
Common Stock Valuations
Prior to this offering, given the absence of a public trading market for our common stock, and in accordance with the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation, our board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of fair value of our common stock at each grant date, including:
•
independent third-party valuations of our common stock;
​
•
the prices of recent issuances of convertible preferred stock by us to investors in arm’s-length transactions;
​
•
the rights, preferences, and privileges of our convertible preferred stock relative to our common stock;
​
•
our performance and market position relative to comparable publicly traded companies;
​
•
the likelihood and timing of achieving a liquidity event, such as an initial public offering or sale of our company, given prevailing market conditions;
​
 
135

TABLE OF CONTENTS
 
•
our developments and milestones;
​
•
our current business conditions and projections;
​
•
the lack of marketability inherent in our common stock; and
​
•
the general economic outlook and global economic trends.
​
In valuing our common stock, the fair value of our business, or enterprise value, was determined using the market approach and/or income approach. The market approach estimates value based on a comparison of the subject company to comparable public companies in a similar line of business. From the comparable companies, a representative market value multiple is determined and then applied to the subject company’s financial results to estimate the value of the subject company. The precedent transaction method, a form of the market approach that derives the implied equity value from the recent issuance of stock by the subject company, was also utilized when appropriate. The income approach estimates value based on the expectation of future cash flows, which are then discounted to present value.
For each valuation, the equity value, which is calculated as the enterprise value, adjusted for cash and debt, was then allocated to the common stock using the option pricing method (“OPM”) and/or the probability-weighted expected return method (“PWERM”). The OPM allocates the equity value to the various share classes based on differences in liquidation preferences, participation rights, dividend policy, and conversion rights, using a series of call options. The call right is valued using a Black-Scholes option pricing model. The PWERM employs additional information not used in the OPM, including the likelihood and potential timing of various discrete future liquidity scenarios, such as an initial public offering.
Application of these approaches involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding our expected future revenues, expenses, cash flows, discount rates and market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions, or the relationships between those assumptions, impact our valuations as of each valuation date and may have a material impact on the valuation of our common stock.
Following this offering, it will not be necessary to estimate the fair value of our common stock, as our shares of Class A common stock will be traded in the public market, and the fair value of our common stock will be based on the closing price of our Class A common stock as reported by Nasdaq.
Emerging Growth Company Status
The JOBS Act permits an “emerging growth company” such as us to delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period for complying with new or revised accounting standards and, as a result, our results of operations and financial statements may not be comparable to those of companies that have adopted the new or revised accounting standards. We will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year in which we have at least $1.235 billion in total annual gross revenue; (2) the last day of the fiscal year in which we are deemed to be a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our Class A common stock held by non-affiliates exceeded $700 million as of the last business day of the second fiscal quarter of such year; (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (4) the last day of the fiscal year ending after the fifth anniversary of the date of the completion of this offering.
Recent Accounting Pronouncements
See Note 2 of our consolidated financial statements included elsewhere in this prospectus for more information regarding recently issued accounting pronouncements.
Quantitative and Qualitative Disclosures about Market Risk
Interest Rate Risk
The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of March 31, 2025, we had cash, cash
 
136

TABLE OF CONTENTS
 
equivalents, and restricted cash of $35.3 million, and short-term marketable securities of $2.2 million, consisting of interest-bearing money market accounts, for which the fair market value would be affected by changes in the general level of United States interest rates. However, due to the short-term maturities and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash and investments.
Our borrowings under the 2023 Term Loan Agreement also subject us to market risk associated with movements in interest rates associated with forward-looking three-month SOFR. We had $400.0 million in variable rate debt outstanding as of March 31, 2025. A hypothetical 100 basis point adverse movement in the interest rate would increase our annual interest expense by $4.0 million. We hedge interest rate risk on $200.0 million of this variable rate debt with a purchased interest rate cap derivative that has a strike rate of 6.0%. We did not receive any settlement payments from the counterparty to the interest rate cap for the year ended December 31, 2024 or the three months ended March 31, 2025.
Foreign Currency Risk
Substantially all of our revenue is generated in the United States, and we do not believe we are currently subject to significant foreign currency risk. To date, foreign currency transaction gains and losses have not had a material impact on our operations, and we have not engaged in any foreign currency hedging transactions. As we expand our presence in the international market, our results of operations and cash flows are expected to increasingly be subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. We will continue to reassess our approach to manage risk relating to fluctuations in currency rates as our international operations grow.
 
137

TABLE OF CONTENTS​
 
BUSINESS
Overview
We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.
We founded Caris in 2008 with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. We have spent the last 17 years developing and building our portfolio of comprehensive, proprietary molecular profiling solutions and generating what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology based on the more than 6.5 million tests we have run on over 849,000 cases, which have generated measurements of over 38 billion molecular markers. Our platform is purpose-built to leverage the convergence of next-generation sequencing (“NGS”), artificial intelligence (“AI”) and machine learning (“ML”) technologies, and high-performance computing. The power of our differentiated Caris platform has enabled us to develop the latest generation of advanced precision medicine diagnostic solutions designed to address the entire cancer care continuum, including early detection, minimal residual disease (“MRD”) tracking, therapy selection, and treatment monitoring, as well as to create molecular signatures and discover and develop novel precision medicine therapeutics. Our current commercial product portfolio is focused on oncology and consists of MI Profile, our tissue-based molecular profiling solution that has generated the majority of our revenue to date, and Caris Assure, our novel, universal blood-based molecular profiling solution that was broadly launched in the first quarter of 2024 for therapy selection.
Dysfunctionality at the molecular level underlies every chronic disease, and this dysfunction is now measurable using techniques such as NGS. Cells are embedded within highly complex biological networks that govern all aspects of life, including how these cells grow, divide, interact, and die. These biological networks and their inherent functions, as well as dysfunctions, are controlled and directed at the molecular level. The precise molecular origins or contributors to a given biological dysfunction, however, are often unknown, and a comprehensive molecular profile is necessary to determine these origins. The central dogma of molecular biology states that genetic information flows in one direction, from DNA, to RNA, to proteins. Our approach is designed to accurately capture the full breadth of the DNA and RNA coding information in cells as well as protein expression through immunohistochemical (“IHC”) tests, constructing a fulsome mosaic of disease, and ultimately unlocking the potential for precision medicine therapeutics to guide individualized patient diagnoses and treatment.
We believe we are well-positioned to realize the full potential of our vision and optimally leverage our vast datasets due to the recent convergence of several advancements in biology, medicine, and technology: (1) the medical community’s understanding and appreciation of the molecular nature of cancer has accelerated in recent years, resulting in a continued increase in molecular profiling of different cancer types and stages; (2) NGS costs have declined, making NGS more accessible to the healthcare ecosystem; (3) cloud-computing architecture has enabled massive scalability, distributed real-time collaboration, and greater cost efficiency for the analysis of previously unmanageable amounts of data; and (4) AI and ML computational capabilities have advanced to allow more effective interrogation of large biological datasets. We believe that our early foresight to generate comprehensive data at scale over the past many years and build a robust, foundational infrastructure have uniquely positioned Caris to leverage the benefits of these biological and technological advances to deliver transformative and advanced innovations in precision medicine and patient care into the future.
Our purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. We provide whole exome sequencing (“WES”) (all 23,000 encoding DNA genes) and whole transcriptome sequencing (“WTS”) (all 61,000 RNA transcripts that encode proteins) on every eligible patient sample (a sample provided by ordering physicians that contains sufficient genetic material for profiling). Since launching our WTS solution in 2019 and WES solution in 2020, we have performed over 475,000 WES and WTS cases, which we believe is more than
 
138

TABLE OF CONTENTS
 
any other company. We sequence at a sector-leading depth of coverage, which directly correlates with increased accuracy and detection of low frequency molecular markers of relevance. MI Cancer Seek, our FDA-approved companion diagnostic assay to identify cancer patients who may benefit from treatment with targeted therapies (a component of MI Profile), consistently reaches 1,500 times depth of coverage for clinically relevant DNA genes, which is a higher sequencing depth than other assays available in the marketplace based on reported depths of coverage, and 300 times depth of coverage for the whole exome. Caris Assure features a raw average sequencing depth of 8,000 times for clinically relevant genes, similarly a higher sequencing depth than other assays available in the marketplace based on reported depths of coverage. We generate tens of billions of datapoints per clinical case to reveal an individualized molecular blueprint of the patient’s disease. We believe this approach best positions us to provide actionable treatment pathways from targeted therapies to drive superior clinical outcomes for patients while also generating a rich dataset to power insights and innovation. To our knowledge, we remain the only genomic profiling company to consistently utilize WES and WTS as standard practice on every eligible patient sample. We also evaluate protein molecular markers through an extensive menu of IHC tests performed in a tumor-type specific manner, which in combination with WES and WTS, provide a comprehensive view of a patient’s disease.
Our in-depth profiling of patient samples has led to the creation of what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology, including genomic data, clinical data, digitized slide images, and remnant tissue. As of March 31, 2025, we have run more than 6.5 million tests on over 849,000 cases, which have generated measurements of over 38 billion molecular markers. Leveraging high-powered computing and AI/ML algorithms, we, and our biopharma and research partners who use our data and bioinformatics services, analyze our datasets to determine the key molecular characteristics of a particular disease or dysfunction that drives disease, enabling signature identification and drug target discovery. As a leader in the transition to WES/WTS sequencing through our launch of a WTS solution in 2019 and a WES solution the following year, we believe we have more molecular data and information than any other company and are well-positioned to make precision medicine widely accessible. In 2018, our clinical case volume was approximately 29,000 cases, increasing to approximately 43,000 cases in 2019, approximately 60,000 cases in 2020, approximately 75,000 cases in 2021, approximately 97,000 cases in 2022, approximately 129,000 cases in 2023 and approximately 163,000 cases in 2024. Our clinical case volume for the first quarter of 2025 was approximately 45,900 cases, representing 31% year-over-year growth from approximately 34,900 clinical cases in the first quarter of 2024.
Our molecular profiling solutions and the data generated by our multi-omic technology platform provide value to our more than 100 biopharma partners, such as Moderna, AbbVie, Xencor, and Merck KGaA, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines. In addition to biopharma, we leverage our datasets to partner with outside academic centers and researchers to further advance precision oncology research. The Caris Precision Oncology Alliance (“Caris POA”), which we established in 2015, is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. As of March 31, 2025, the Caris POA was comprised of 96 members, including 45 National Cancer Institute (“NCI”)-designated comprehensive cancer centers. This academic-industry collaborative network has been exceptionally productive with over 145 peer-reviewed manuscripts published since the beginning of 2022. Close connectivity with this vast network of key opinion leaders (“KOLs”) in oncology clinical care, research, and drug development has enabled us to remain at the forefront of precision oncology and closely attuned to the key needs of the most sophisticated researchers.
Our Caris platform is designed to create a virtuous cycle that can enable continued innovation and improved impact for patients and physicians. We believe our comprehensive approach to profiling will continue to drive demand for our genomic profiling capabilities, leading to further expansion of our clinico-genomic datasets, which provide additional valuable inputs to develop and enhance our solutions, with the ultimate goal of contributing to improved patient results. This continuous feedback loop enabled us to develop Caris Assure, which utilized genomic data generated by MI Profile to inform our blood-based bioinformatics algorithms, allowing us to detect previously unknown features and signals in the blood that provide advanced insights into disease development. We believe we will be able to further leverage this process to
 
139

TABLE OF CONTENTS
 
continue meaningful innovation in precision oncology as well as other chronic disease states, including cardiology, neurology, and metabolic conditions.
Our global annual clinical case volume has been growing rapidly, with year-over-year growth of 29% in 2022, 32% in 2023, 26% in 2024, and 31% in the first quarter of 2025, primarily driven by MI Profile. With our broad commercial launch of Caris Assure for therapy selection in the first quarter of 2024 and the FDA approval of MI Cancer Seek as a companion diagnostic in the fourth quarter of 2024 followed by the broad commercial launch of MI Cancer Seek in the first quarter of 2025 as the NGS component of MI Profile, we believe that increased profiling volumes will meaningfully contribute to our growth in 2025 and beyond. For the years ended December 31, 2024 and 2023, we generated total revenue of $412.3 million and $306.1 million, respectively. For the three months ended March 31, 2025 and 2024, we generated total revenue of $120.9 million and $80.7 million, respectively. We have incurred net losses and negative cash flows from operations since inception. For the years ended December 31, 2024 and 2023, we incurred net losses of $257.1 million and $341.4 million, respectively. For the three months ended March 31, 2025 and 2024, we incurred net losses of $102.6 million and $111.0 million, respectively. Our Adjusted EBITDA was $(189.6) million and $(255.3) million for the years ended December 31, 2024 and 2023, respectively. Our Adjusted EBITDA was $(36.2) million and $(70.1) million for the three months ended March 31, 2025 and 2024, respectively. For additional information regarding Adjusted EBITDA, a non-GAAP financial measure, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures.” We expect to incur additional net losses in the near future, and our expenses will increase as we continue to invest in developing new solutions, expand our organization, and increase our marketing efforts to continue to drive market adoption of our solutions. These investments, together with general and administrative expenses, have resulted in negative cash flows from operations of $245.2 million, $276.1 million, $31.3 million, and $73.9 million for the years ended December 31, 2024 and 2023 and the three months ended March 31, 2025 and 2024, respectively. Our free cash flow was $(253.6) million and $(298.4) million for the years ended December 31, 2024 and 2023, respectively, and $(34.0) million and $(75.7) million for the three months ended March 31, 2025 and 2024, respectively. For additional information regarding free cash flow, a non-GAAP financial measure, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures.” Additionally, as of March 31, 2025, we had cash, cash equivalents, and short-term marketable securities of $33.4 million, and the aggregate principal amount of debt outstanding under our existing term loan was $400.0 million. For additional information regarding our liquidity and capital resources, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources.”
Our Industry
Cancer is a Large and Growing Disease State with a Significant Human Cost and Economic Burden on Society
Addressing the complexity of cancer remains a major challenge in healthcare and a critical area of unmet medical need, despite enormous investments in research and development (“R&D”), and the introduction of new oncology therapeutics and treatments. According to the Centers for Disease Control and Prevention, cancer is the second leading cause of death in the United States, exceeded only by heart disease. The American Cancer Society (the “ACS”) reports that in January 2022, there were more than 18 million Americans with a history of cancer and that approximately two million new cancer cases will be diagnosed in 2024 in the United States. Furthermore, approximately 611,720 Americans are expected to die of cancer in 2024. The International Agency for Research on Cancer predicts that the annual global burden of cancer will reach 35 million new cases and 18.5 million cancer deaths by 2050.
The annual burden of cancer care in the United States was more than $200 billion in 2020 and is expected to increase over the coming decades. According to an article published in JAMA Oncology, a peer-reviewed medical journal published by the American Medical Association (the “AMA”), it is estimated that the total cumulative global economic cost of cancer from 2020 to 2050 will be approximately $25 trillion. Better information and solutions are needed to detect and treat cancer earlier and more effectively to improve lives and manage healthcare costs.
 
140

TABLE OF CONTENTS
 
The Central Dogma of Biology Drives the Fundamental Need for Comprehensive Molecular Information
At its core, cancer represents the uncontrolled division and growth of the body’s cells. There are numerous biological processes in place for preventing the proliferation of cancerous cells. However, the failure of one or multiple genetic processes can lead to cancer. A cell is considered cancerous when it no longer responds to the body’s attempts to control its growth, function, and location due to abnormalities in its DNA. The central dogma of biology states that genetic information flows in one direction, from DNA, to RNA, to proteins. Thus, when present, DNA abnormalities in the exome, also referred to as genomic mutations, are transcribed into defective RNA in the transcriptome. This defective RNA, in turn, is translated into defective proteins, ultimately causing a cell to replicate uncontrollably or become cancerous.
The behavior of a specific cancer cell depends on which processes are not functioning properly. Oncogenes are genes that, when aberrantly active, cause a normal cell to become cancerous. Tumor suppressor genes must remain activated to prevent cancer; if deactivated, the cell proliferates uncontrollably. Many cancers begin with a few discreet genomic mutations, but additional mutations accumulate as the cells divide. In addition, chemical modifications to proteins post-production, known as post-translational modifications, can impact structure and function and may also result in uncontrollable cell growth. This dynamic range of potential mutations results in varying cancer types. For example, some cancer cells may simply divide and produce more cancer cells locally, while other cancer cells may invade normal tissue, enter the bloodstream, and metastasize to a remote site in the body. Given the complexity of a cancer’s origin and drivers, we believe comprehensive molecular information incorporating DNA, RNA, and protein profiles provides the most robust picture of a patient’s disease and potential treatment pathways. The below graphic depicts the central dogma of molecular biology and the profiling technology that can be used to capture the relevant molecular information at each step.
[MISSING IMAGE: fc_centraldogma-4c.jpg]
Technological Advancements have Ushered in a Molecular Revolution in Precision Oncology
The molecular revolution is upending the traditional paradigm of complex workflows of diagnosis, treatment, and monitoring of diseases, which largely uses a symptomatic, reactive approach to medicine. For example, early detection of cancer has traditionally been performed using a myriad of different non-molecular tests, including mammograms for breast cancer, colonoscopy and fecal immunochemical test for colorectal cancer, pap test for cervical cancer, and low-dose computed tomography (“CT”) scan for lung cancer. Despite these techniques, cancers can still go undetected as many of these tests can be subject to interpretative bias or risk of inaccurate results. Further, prior to the use of genetic biomarkers for the treatment of cancers, all cancer patients were treated with generic chemotherapies with a broad applicability, often resulting in lower efficacy. Comprehensive molecular profiling is augmenting these different testing modalities by introducing streamlined workflows and replacing the patchwork of tests currently in use, using a small sample of the patient’s tissue or blood.
Molecular profiling in oncology began with single-gene testing focused on individual genes in an attempt to match patients with effective targeted therapies. With the declining cost of sequencing and growing number of targeted therapies, profiling evolved to include targeted testing focused on a small number of identified gene alterations correlated with effective targeted therapies and further expanded to include profiling using 500 to 1,000 gene panels. These targeted profiling methods are now acknowledged as being inefficient in the use of limited tumor tissue, as they generate a sub-optimal and incomplete amount of
 
141

TABLE OF CONTENTS
 
molecular information. For example, a study titled “Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients” published by authors associated with Memorial Sloan Kettering Cancer Center in New York in June 2017 in the scientific journal, Nature Medicine, found that “hotspot” panels can miss 81% of actionable mutations in refractory cancers.
Over the last several decades, significant advances in genomics, proteomics, molecular technology, and computing power have enabled a comprehensive, multi-omic approach to the molecular profiling of diseases, both efficiently and at scale. Innovations in genomic sequencing and computing power have revealed deep insights into the cellular pathways and molecular nature of all types of cancer, heralding a new era of precision oncology. For example, a 2004 study published in Nature Reviews Cancer identified approximately 300 genes as being linked to cancer; a 2022 Genome Biology study identified approximately 3,350 genes were well-known or predictive drivers of cancer; and a 2022 Trends in Genetics analysis showed that of the approximately 17,300 human genes with at least one paper in PubMed, approximately 15,200 have at least one paper mentioning cancer. Precision oncology is defined as the use of molecular profiling—including analysis of DNA, RNA, and proteins—to identify a cancer’s alterations that can be targeted with specific therapies. NGS, the most advanced high-throughput sequencing method, has far surpassed other techniques used to analyze tumors and has become a cornerstone of precision oncology. This is due in large part to the genomically-driven nature of cancer, as well as the continued ongoing steep declines in the cost of sequencing over the last 30 years and technology advances in speed and accuracy, which have made NGS far more available in the clinical setting.
The treatment paradigm for oncology continues to evolve with molecular medicine practiced across the entire continuum of the disease course: from using blood-based testing to detect cancers at its earliest stages; to the determination of whether a patient is at a high-risk of relapse after completing therapy; to the advanced/metastatic setting where molecular profiling is used to guide therapy interventions. Large scale studies interrogating cancers using NGS have led to the identification of thousands of biomarkers. Oncology therapeutics are now increasingly biomarker-driven targeted therapies. Over 100 biomarker-assisted therapeutics have been approved in the United States, and numerous clinical trials are currently in progress. In addition to being predictive markers for patients likely to benefit from certain treatments, biomarkers may also be used as diagnostic indicators of the presence or type of cancer, as prognostic indicators for patient outcomes, or as tools to monitor therapy response, residual disease, or recurrence.
The information provided by comprehensive molecular profiling is driving a revolution in medicine, where molecular information is used to guide individualized patient diagnoses and treatment. Beyond oncology, this precision medicine approach has applications across a wide range of broad disease areas including cardiology, neurology, and metabolic conditions, among other chronic diseases.
The Importance of Comprehensive Molecular Profiling
Comprehensive molecular profiling provides greater clinical and economic value than traditional targeted panel testing approaches. Comprehensive molecular profiling entails evaluating thousands of potential biomarkers, including DNA, RNA, proteins, and other molecular and clinical information for characteristics unique to a particular patient’s disease.
 
142

TABLE OF CONTENTS
 
​ ​
Case Study: Advancing Cancer Treatment with Caris Molecular Profiling
​ ​
​ ​
         Caris was presented with the case of a female patient in her early 50’s with a history of Stage I endometrial cancer. Her oncologist discovered a softball-sized tumor in her ovary. After undergoing a biopsy, it was determined to be late-stage ovarian cancer, which had metastasized into surrounding tissues and her bowels. She underwent immediate surgery to remove her ovaries and 18 inches of her sigmoid colon and began a standard chemotherapy regimen.
​ ​
​ ​
         Despite the surgery and three rounds of chemotherapy, the cancer grew back within three months, now spreading into the patient’s lymph nodes. Her oncologist recognized the urgency of her situation and sent the patient’s tumor biopsy to Caris for molecular testing, noting additional rounds of chemotherapy would not be beneficial. The profiling using our MI Profile solution revealed the tumor was microsatellite instability-high, indicating responsiveness to immunotherapy and supporting her oncologists’ prior suspicion of Lynch Syndrome, also known as hereditary nonpolyposis colorectal cancer (“HNPCC”).
​ ​
​ ​
         HNPCC is caused by mutations in genes responsible for DNA mismatch repair (“MMR”), leading to an accumulation of errors in DNA replication and an increased risk of cancer development. Individuals with HNPCC have a higher lifetime risk of developing various cancers, particularly colorectal and endometrial. Identifying it in patients can help guide screening and surveillance efforts to detect cancers at an early, more treatable stage, as well as inform preventive measures to reduce cancer risk for their families.
​ ​
​ ​
         With the guidance of molecular profiling results, the patient commenced immunotherapy treatment, leading to remarkable results. Within three months, her tumor disappeared, and the cancer in her lymph nodes significantly regressed. The patient went from having no real treatment options to having multiple with the use of comprehensive profiling, and to our knowledge remains cancer-free. Additionally, the identification of Lynch Syndrome is invaluable in guiding screening and surveillance for her children and grandchildren.
​ ​
​ ​
         This transformative outcome underscores the importance of comprehensive profiling in tailoring treatment strategies based on individual genetic profiles.
​ ​
The Importance of WES/WTS
DNA
Mutations and copy number alterations (variations) can be detected using the polymerase chain reaction (“PCR”) or NGS, while DNA methylation is analyzed using PCR or pyrosequencing, which is a method for sequencing short stretches of DNA on the basis of the detection of pyrophosphate. DNA sequencing can be performed for an entire genome, exome, or, as in the case of targeted panels, within specific regions containing common cancer-associated alterations. NGS-based targeted panels are currently FDA-approved for several tumor types. These targeted panels identify known alterations in key cancer genes but do not provide a comprehensive overview of a tumor’s molecular makeup.
RNA
While mutations detected in DNA may be silent (not expressed) and therefore of little clinical relevance, those in RNA are one step closer to producing an abnormal protein. RNA is also needed to understand gene expression and splice variants through in situ hybridization and RNA sequencing. RNA sequencing provides information that DNA cannot and is superior for detecting expressed fusions.
As with DNA, RNA sequencing can be performed for one, multiple, or all transcribed genes, in either targeted areas or the full transcriptome. Transcriptome analysis using NGS generates information on splice variants and gene fusions, including fusions not previously described. This information can help define molecular signatures, stratify risk, and guide targeted therapy use. In combination with WES, WTS provides information on all expressed genes, thereby detecting alterations that can be targeted with FDA-approved therapies, standard-of-care treatments, and investigational therapies in clinical trials.
 
143

TABLE OF CONTENTS
 
​ ​
Case Study: The Importance of RNA Profiling
​ ​
​ ​
         Caris was presented with the case of a teenaged boy diagnosed with high-grade astrocytoma, a type of brain tumor. Two years prior, the patient’s oncologist had ordered DNA-only profiling from another provider who did not identify any actionable mutations in the patient’s DNA. As a result, the patient was placed on a standard chemotherapy regimen.
​ ​
​ ​
         Upon recurrence of the tumor two years later, the oncologist ordered genomic testing from the same provider, who again did not identify any actionable mutations in the DNA. The patient began radiation therapy. Despite the initial profiling attempt and results, the tumor’s recurrence necessitated further investigation, leading the patient’s healthcare team to seek out more comprehensive testing with Caris.
​ ​
​ ​
         The Caris WES/WTS report revealed a significant finding: an FGFR fusion, which is a genetic alteration that can disrupt normal cell signaling and lead to cancerous cell growth, found in the patient’s RNA. Despite the challenges posed by the tumor’s recurrence, Caris’ ability to detect this actionable variant offered hope for potential targeted therapies, including the National Cancer Institute-Children’s Oncology Group Pediatric MATCH trial* for pediatric patients with advanced, recurrent solid tumors.
​ ​
​ ​
         This case demonstrated the critical role of comprehensive molecular profiling of both the DNA and RNA. By leveraging advanced testing methodologies such as WES and WTS, the provider was able to uncover potentially life-saving treatment options for this patient facing a challenging diagnosis,high-grade astrocytoma.
​ ​
Molecular Signatures
In addition to individual gene alterations, profiling can provide information on specific patterns or combinations of molecular features that might otherwise be challenging to detect. These molecular signatures may be associated with particular cancer types, prognoses, or therapeutic responses. Examples of molecular signatures include:
•
TMB:   TMB is a measurement of the number of somatic mutations per megabase of DNA sequenced. A high TMB is used as a biomarker for the selection of certain checkpoint inhibitors to treat solid tumors. WES is the gold standard for measuring TMB as it covers the entire coding region of the genome. Measurements derived from targeted panels or comprehensive genomic profiling, on the other hand, vary significantly from panel to panel due to variable and incomplete coverage.
​
•
Microsatellite instability (“MSI”):   MSI testing measures the ability of a cell to repair mistakes in DNA replication. Defective mismatch repair caused by alterations in mismatch repair genes is associated with elevated mutation rates in areas where short DNA sequences of base pairs are repeated. These areas are referred to as microsatellites. MSI analysis can identify candidates for immunotherapy or MSI-indicated clinical trials and diagnose Lynch Syndrome in colon and endometrial cancers.
​
•
Genomic loss of heterozygosity (“gLOH”):   Loss of one copy of a genomic region, known as gLOH, may cause tumor suppressor gene inactivation, thereby promoting cancer development. gLOH is indicative of a form of defective DNA repair called homologous recombination deficiency. When a tumor exhibits DNA repair mechanism impairment, drugs targeting a secondary repair pathway can kill tumor cells without harming normal cells, a phenomenon called synthetic lethality. Thus, gLOH is a biomarker for therapeutic response to poly adenosine diphosphate-ribose polymerase (“PARP”) inhibitors which target the single-strand break DNA repair pathway.
​
•
Homologous recombination deficiency (“HRD”):   Related to gLOH, inefficient repair of damaged DNA via homologous recombination can contribute to the development of cancer. HRD often results from aberrations in key DNA repair genes, including BRCA1 and BRCA2 genes, ataxia telangiectasia mutated (“ATM”), PALB2, and CHEK2, and is associated with increased sensitivity to PARP inhibitors, as above.
​
​
*
https://www.cancer.gov/about-cancer/treatment/nci-supported/pediatric-match
​
 
144

TABLE OF CONTENTS
 
WES/WTS Offers a Complete Molecular Blueprint from the Beginning and Provides Value across the Patient Journey
WES/WTS streamlines the patient experience and clinical decision-making and offers increased value to patients, physicians, and payers. We believe WES/WTS provides the most efficient and cost-effective way to obtain the maximum information on a patient’s cancer at the start of the patient journey, potentially identifying additional mutations and expanding treatment options compared to sequential targeted panels. Through the use of WES/WTS, we believe we have significantly reduced the need for a trade-off between time and information, two valuable resources in oncology that have historically come at the expense of one another, particularly when relying on sequential targeted panels, due to cancer’s rapidly progressive nature. In a single test, we believe WES/WTS provides substantially all the relevant information needed for physicians to make the best-informed clinical decisions for their patients and does so in less time than running multiple DNA or RNA single or targeted panels sequentially. While using comparable tissue, WES/​WTS enables accurate identification of a greater number of actionable genomic alterations that can be leveraged to match patients to the most effective treatments, yielding a higher probability of response and providing comprehensive predictive and prognostic information. Furthermore, the benefits conferred by WES/​WTS have the potential to extend across the healthcare ecosystem, beyond patients and their clinicians. By supporting WES/WTS, payers can reduce waste and harm from suboptimal treatment selection and resulting over-treatment and/or misdiagnosis.
WES/WTS can also inform on acquired resistance to treatments and suggest potential synergistic therapy combinations, as well as providing substantial clinical benefit to patients with cancer of unknown origin or rare cancers. Additionally, by taking a tumor-agnostic approach compared to using tumor-specific panels, WES/WTS can detect biomarkers that have targeted therapies in other cancer types, indicating the potential to apply those drugs more broadly. Armed with these molecular insights, clinicians can identify the most suitable therapies and trials available to their patients today. Having a full molecular blueprint in silico also facilitates future use of newly approved biomarkers and therapies.
We also operate a Look Back Program that leverages our comprehensive WES/WTS to provide long-term clinical insights that help oncologists optimize patient care and identify patients that may be eligible for newly approved biomarker-driven therapies without the need for additional testing. When a novel therapy receives approval, our team reviews all of our recent clinical sequencing results to identify previously tested patients who sequencing results match the new therapy’s criteria. Through our molecular science liaisons (“MSLs”), we then contact treating physicians to ensure they are aware of these newly approved treatment options for their patients. Many clinicians may not be aware of evolving biomarker-driven therapies, and our Look Back Program bridges this gap by providing updated insights. By conducting comprehensive molecular testing upfront, the need for repeat testing is significantly reduced when new drug approvals or indications arise. This ensures timely treatment decisions, increasing the likelihood of patients receiving effective, biomarker-driven therapies. Through the Look Back Program, Caris empowers oncologists with continuous, data-driven insights that enhance patient outcomes and drive precision oncology forward. Since 2023, we have used this program to identify 556 patients that may benefit from Trastuzumab and Teucatinib for HER2+/KRAS wildtype colorectal cancer, 134 patients that may benefit from Talazoparib + Enzalutamide HRR deficient prostate cancer, 233 patients that may benefit from Reptrectinib for cancers with NTRK gene fusions, 1,737 patients that may benefit from Capivasertib for PIK3CA, AKT1 or PTEN-mutated HR+/HER2- breast cancer and 78 patients that may benefit from Zenocutuzumab for cancers with NRG1 fusions and 1,847 patients that may benefit from Trastuzumab Deruxtecan for Her2 Score 0 HR+ breast cancer. We have not broadly marketed our Look Back Program, but we use it in payer-facing materials to highlight the advantages of our WES/WTS platform.
Aside from its clinical benefits, WES/WTS is also a powerful research tool for identifying new predictive biomarkers. For example, pancreatic ductal carcinoma currently has the worst prognosis among common cancers—a situation compounded by a scarcity of predictive biomarkers and therapeutic targets. In a recent study, a comprehensive profiling approach involving WES and WTS sequencing was used to identify novel potential markers and targets for this cancer.
 
145

TABLE OF CONTENTS
 
The table below compares targeted panels with WES/WTS.
[MISSING IMAGE: tb_panels-4c.jpg]
The Convergence of NGS, AI/ML Technologies, and High-Performance Cloud Computing
NGS can generate vast amounts of genomic data. The availability of large libraries of molecular data for each individual patient is creating exciting opportunities for research in the diagnosis, treatment, and early detection of cancer, especially when paired with a patient’s clinical data.
AI can be used to mine these large volumes of data to address complex biological questions and has the potential to deliver new insights and bring precision medicine into mainstream clinical care. ML is an AI approach that focuses on applications that learn from experience and large amounts of data to improve decision-making and predictive accuracy over time. While this is a promising field of research and clinical activity, there are significant challenges to achieving the promise of AI in cancer—specifically, generating accurate and broad molecular information to underpin algorithms.
The accuracy of predictions made by AI/ML algorithms is highly dependent upon the accuracy and breadth of the underlying data used for training the AI/ML algorithms, analytically validating those algorithms, and applying the algorithms on real world data to make predictions. The accuracy of NGS-based genomic data is highly correlated to the depth of coverage of sequencing of the samples. Depth of coverage refers to the number of times a nucleotide is sequenced. A greater depth of coverage increases the confidence in the final results and allows for differentiation between sequencing errors and single nucleotide polymorphisms. A high depth of coverage is especially useful when a tumor is heterogeneous for specific mutations.
The ability to conduct research on genomic data using AI is also highly dependent on the number of genes being tested. Complex diseases are the result of multiple genomic alterations including point mutations, translocations, amplifications, and/or deletions. Cancers with more malignant properties and
 
146

TABLE OF CONTENTS
 
poorer prognosis are generally associated with larger numbers of genomic alterations. To accurately conduct research using AI, a large number of genes need to be tested and included in a given data set.
Cloud-computing architecture has enabled massive scalability and distributed real-time collaboration across industries. In addition, it has created opportunities for greater cost efficiency for the storage, processing, and analysis of previously unmanageable amounts of data.
Our Caris platform was purpose-built to leverage the convergence of NGS, AI and ML technologies, and high-performance computing.
[MISSING IMAGE: pc_unique-4c.jpg]
Limitations of Molecular Testing Today
While the molecular revolution has already changed the way cancer is being diagnosed and treated, we believe that molecular testing faces several major challenges in its current form, which have hindered broader adoption of precision oncology. These challenges include:
•
Targeted panels are subject to missing information and significant variability.   Targeted panels test for only a small portion of all cancer-associated genomic alterations. As a result, they can miss critical clinically actionable information. This information deficit can lead to suboptimal treatment decisions and/or the need for further testing, requiring increased patient sample, time, and expense. Further, the treatment landscape in oncology continues to rapidly evolve, with new agents and their cognate predictive biomarkers entering clinical trials and achieving regulatory approval. This renders targeted panels insufficient to account for newly implicated cancer genes absent re-development and validation of such panels. Using broad sequencing approaches with WES and WTS enables comprehensive identification of information to effectively treat a patient.
​
•
Lack of consistent RNA profiling.   RNA, which is transcribed from DNA, can better represent which genes are actively involved in cancer. By including both DNA and RNA
​
 
147

TABLE OF CONTENTS
 
coverage, we believe Caris captures more tumor-informed information than others in the market, leading to more accurate and comprehensive molecular profiling results for the physician and patient. This approach includes enhanced sensitivity for gene fusions with the incorporation of RNA, as well as the deployment of multi-gene signatures that use RNA to support predictive and prognostic endpoints.
•
Lack of clonal hematopoiesis derived variant subtraction technology in current blood assays.   Blood is comprised of two major components that are pertinent to patient testing: plasma and the buffy coat (a concentration of white blood cells). Most liquid biopsy providers analyze only the plasma. This is suboptimal as a plasma-only approach is unable to identify false positive mutations derived from clonal hematopoesis (“CH”) variants and that are not tumor-derived. CH mutations are common aging-related non-malignant mutations that occur in a substantial portion of the population and are not drivers of solid tumors but contribute to the formation of a genetically distinct subpopulation of blood cells. If CH mutations are not distinguished from tumor-derived mutations, it can lead to therapy selection targeted at a mutation that is present in the white blood cells instead of in the tumor, which is not beneficial for the cancer patient. Because of the prevalence of CH mutations, we believe that CH subtraction is of critical importance to optimal cancer care. Other liquid biopsy tests currently on the market cannot definitively distinguish CH mutations from tumor-derived mutations because they do not sequence the white blood cells. Caris Assure incorporates CH subtraction, resulting in fewer false positives and representing a differentiated ability to drive improved and more effectively targeted therapy selection.
​
•
Disparate data sets collected across testing modalities.   Currently, liquid biopsy providers do not offer a single blood-based testing solution across the continuum of cancer care. Instead, the use of different assay technologies across different applications and settings results in the accumulation of non-uniform data sets, which are difficult to leverage and interpret across a patient’s comprehensive care journey. We utilize a novel approach consisting of a single wet-lab test across the cancer treatment continuum, with consistently-generated uniform datasets. The elegant simplicity of a single test paired with a comprehensive assessment of the patient’s DNA and RNA allows Caris Assure to be this integrated diagnostic solution. This approach allows many more datapoints to be assessed, enabling us to select those markers that we believe provide the greatest potential for sensitivity, specificity, and overall accuracy of our test and capture the dynamic nature of biological processes.
​
•
Logistical drawbacks and sensitivity limitations of current MRD assays.   There are several limitations with current MRD approaches. Traditional tumor-informed approaches struggle with logistical drawbacks, which include needing to sequence primary tumor tissue first and experiencing long turn-around times due to the creation of a bespoke panel. Further, current tumor-informed MRD tests also limit their sensitivity by the small number of tracker mutations utilized. Because sensitivity is proportional to the numbers of tumor-derived alterations that are tracked over time, limiting to a small number of mutations artificially limits sensitivity. Currently deployed tumor-naïve approaches, while logistically superior, also limit their sensitivity by using a targeted panel of genes and do not encompass the myriad of tumor-derived signals present in the circulation.
​
•
False positives and a lack of early-stage sensitivity with current multi-cancer early detection assays.   Multi-cancer early detection (“MCED”) testing holds significant promise to make improvements in overall survival by detecting cancers at their earliest stages when they are most treatable. However, significant limitations exist with current assays. Their high rate of false positives when used in an average-risk population is notable. This leads to unneeded and costly diagnostics, such as imaging and biopsies. Also, a lack of early-stage sensitivity for many tumor types inhibits current MCED testing assays’ clinical utility. As seen in our data, the use of Caris Assure and our Assure Blood-based Cancer Detection ai (“ABCDai”) algorithm leverages detection of a wide swath of cancer-derived analytes, resulting in significantly higher Stage I/II sensitivity while mitigating false positives by maintaining high specificity.
​
As a result of these challenges, clinicians may make critical treatment decisions based on incomplete and/or inaccurate information and analytics, potentially resulting in suboptimal outcomes. We believe that
 
148

TABLE OF CONTENTS
 
our comprehensive molecular profiling solutions and the data generated by our multi-omic technology platform is well-suited to address the limitations and challenges of today’s molecular testing alternatives.
Our Market Opportunity and Vision for Leveraging Molecular Information
We believe we are well-positioned to pursue a very large market opportunity through the provision of precision medicine solutions across the entire cancer care continuum, as well as offerings to support biopharma drug discovery and development. Broad, deep, and consistent molecular information is expected to drive better clinical outcomes for patients and more efficient and effective drug discovery and development for biopharma companies. We believe our expansive multi-omic technology platform has application across multiple clinical and biopharma settings that collectively represent an estimated total addressable U.S. market of approximately $150 billion in oncology, according to a market study by Nephron Research LLC (“Nephron Research”) that we commissioned.
[MISSING IMAGE: pc_unlocking-4c.jpg]
Early Detection of Cancer in the Asymptomatic Population
The availability of an MCED blood-based profiling solution offers the potential to augment and disrupt the standard of care in preventative cancer screening. Preventative cancer screening today is limited to a small group of high prevalence cancers, including cervical, breast, colon, lung, and prostate cancers. Low adherence rates are common among patients with several of these cancers due to challenges related to socioeconomic status, age, personal attitudes and beliefs, awareness gaps, and lack of access to healthcare facilities and social support, among other factors. For example, the American Lung Association estimates that in 2021, there were approximately 14 million high-risk individuals in the United States who were eligible for lung cancer screening using low-dose CT scans yet only approximately 0.6 million screenings were completed, representing a dismal screening recommendation adherence rate of 4.5%. An MCED blood-based profiling solution that entails a minimally invasive blood draw could expand the reach of testing to more cancers and drive higher adoption in this market.
 
149

TABLE OF CONTENTS
 
We believe screening offers the greatest benefit for individuals aged 45 to 75 years given the prevalence of cancer and potential for improved outcomes and reduction in cancer mortality within the U.S. population. Based on U.S. Census Bureau data, the 45 to 75 years-old cohort who would benefit from screening for cervical, breast, colon, lung, and prostate cancers based on the recommendations of the U.S. Preventive Services Task Force (“USPSTF”), an independent body of experts that makes evidence-based recommendations for cancer screening, represents approximately 112 million people in the United States. Clinical unmet needs in this population include low patient adherence, poor performance, and lack of screening options for a majority of cancer types. Access to liquid biopsies that are reliable and can detect multiple cancer types should drive greater access and penetration of the early detection market, with early detection liquid biopsy solutions supplementing or in certain instances replacing existing screening modalities. Based on the estimated size of the cohort of individuals aged 45 to 75 years who would benefit from cancer screening per the above-referenced guidelines, and assuming pricing of at least $900 for a high-quality MCED liquid biopsy solution (based on cash pay pricing for existing available liquid biopsies), the estimated total addressable U.S. market for early detection of cancer using liquid biopsy is approximately $100 billion.
Therapy Selection for Cancer Patients
Patients with advanced and metastatic solid tumors are recommended to undergo molecular profiling to identify predictive markers for patients likely to benefit from certain approved biomarker-linked therapies. Molecular profiling of patients through either tissue biopsy or blood-based liquid biopsy allows physicians to identify a cancer’s targetable alterations. These molecular insights, particularly when generated through comprehensive molecular profiling, enable the tailoring of therapy to patients likely to benefit, while sparing exposure, toxicity, and cost for those who will not.
According to the ACS, approximately 780,000 of the two million patients in the United States who are newly diagnosed with cancer each year are found to have advanced-stage solid tumor cancers at initial diagnosis. The ACS also estimates that there are 16.5 million cancer survivors in the United States, approximately 4.3%, or 710,000, of whom are expected to relapse annually. Based on National Comprehensive Cancer Network (“NCCN”) guidelines suggesting that breast and lung cancer patients would benefit from at least two tests during therapy, and assuming that these benefits would apply to other types of solid tumors, Nephron Research estimates that approximately 520,000 newly-diagnosed advanced stage and recurrent cancer patients in the United States would benefit from repeat testing. Additionally, turnaround time for a blood test is typically shorter, but tissue tests are often more comprehensive so physicians will often order both a tissue test and a blood test. Accordingly, based on the newly-diagnosed patient, recurrent patient, and repeat testing patient cohorts described above, Nephron Research estimates that the total addressable U.S. market for therapy selection is comprised of approximately two million unique patient profiles annually and, assuming an average reimbursement of approximately $4,000 based on blended Medicare, commercial payer, and Medicaid coverage rates for various genomic profiling tests, amounts to approximately $8 billion.
According to the Nephron Research analysis, the number of annual unique patient profiles is expected to increase with clinical and payer adoption of broad molecular testing in earlier stages for newly-diagnosed cancer patients. The study also suggests that a majority of the market is currently being tested by either single gene tests or targeted testing for a low number of biomarkers recommended under NCCN guidelines and is currently approximately 30% penetrated by broad molecular testing (both tissue and blood) using broad panels (50 or more genes).
Minimal Residual Disease Tracking and Treatment Monitoring for Cancer Patients and Survivors
According to the ACS, approximately 1.3 million of the 2 million patients in the United States who are newly diagnosed with cancer each year are found to have non-metastatic cancer. We believe MRD tracking and recurrence testing is most applicable to patients within this cohort. Patients in the non-metastatic cancer cohort are expected to be monitored during their treatment journey and beyond for up to five years for recurrence, including MRD testing for patients who underwent surgery for their cancer. In addition, patients with metastatic cancer are expected to receive treatment monitoring tests during their treatment journey. According to the Nephron Research analysis, these result in a cohort of approximately 5.6 million patients being monitored at various points in their treatment journey. Assuming a range of two to
 
150

TABLE OF CONTENTS
 
three tests annually for each patient, consistent with MolDX coverage policy for MRD, pricing of $2,500 per reference test and $1,650 per follow-up blood test, in each case based on pricing for other tests available on the market, Nephron Research estimates that the total addressable U.S. market for MRD tracking tests represents approximately 16 million tests annually and amounts to approximately $28 billion.
Core Biopharma: Profiling Services for Biopharma Drug Development and Commercial Testing
Key services relevant for biopharma companies include prospective and retrospective profiling services, companion diagnostics development, and commercial services that include identification of patients for approved therapies.
According to the Nephron Research analysis, oncology testing associated with clinical trials includes approximately 250,000 cancer patients in targeted therapy clinical trials. Assuming five tests (one therapy selection test to establish cancer type and determine the therapeutic intervention(s) and four monitoring tests for follow-up consistent with typical trial designs) for each trial participant and pricing of $5,000 per therapy selection test and $1,950 per monitoring test, based on existing reimbursement rates for other tests available on the market, Nephron Research estimates that the addressable U.S. market for oncology testing in clinical trials is approximately $3.2 billion. The development of companion diagnostics tests and the identification of patients for commercial targeted therapies are both attractive opportunities for molecular information-based services. Assuming approximately 25 Phase 1b trials progress to Phase 2 each year based on recent historical data from ClinicalTrials.gov, with each trial having two partners per customary industry practice (a specialty lab and a distributable kit) and an average contract price of $10 million based on Nephron Research’s market analysis, the addressable U.S. market for the development of companion diagnostics tests is estimated to be approximately $500 million. For rare biomarkers, biopharma sponsors generally will reimburse laboratories that can help identify patients as candidates for their therapeutics. Assuming a rate of rare mutation of 4.0% within the population of newly-diagnosed cancer patients in the United States with advanced-stage solid tumor cancers, based on data from the National Institutes of Health, and an average reimbursement per patient of $10,000 based on Nephron Research’s market analysis, the addressable U.S. market for commercial services that include identification of patients for approved therapies is estimated to be approximately $300 million. Accordingly, the estimated total addressable U.S. market for core biopharma services is approximately $4.0 billion.
Data Services for Biopharma Research and Development
Matched genomic data has demonstrated use cases for biopharma applications across discovery, drug development, and clinical trial execution. Biopharma companies leverage multi-modal genomic data, including data they license, to identify key molecular characteristics of a particular disease or dysfunction that drives disease, enabling signature identification and drug target discovery. The valuable insights provided by multi-modal genomic datasets help biopharma companies identify optimal patient populations for therapeutic development and also help inform trial design, validate biomarker strategies, and assess execution feasibility of oncology clinical trials.
According to Evaluate Pharma, global spending on pharmaceutical R&D by biopharma companies grew from an estimated $145 billion in 2014 to an estimated $262 billion in 2023. According to the Nephron Research analysis, it is estimated that approximately $70 billion of the $262 billion spent in 2023 represented R&D investments in discovery, pre-trial costs, and real-world evidence, areas where matched genomic data has demonstrated use cases for biopharma applications. We expect biopharma companies to continue increasing the allocation of their total R&D investment towards multi-modal genomic data and bioinformatics services to increase efficiency and development success rates. Based on Nephron Research’s market analysis, approximately 14% of the estimated $70 billion in R&D investments in 2023 was allocated towards such data and services, resulting in an estimated total addressable U.S. market for this opportunity of approximately $10 billion.
Other Disease States Beyond Oncology
We believe there is a large market opportunity for our platform in other chronic disease states beyond oncology, including cardiology, neurology, and metabolic conditions. This begins with a fundamental premise that approaching blood-based disease detection with a comprehensive WES/WTS approach
 
151

TABLE OF CONTENTS
 
enables examination of biomarkers that go beyond oncology. It is already well known that other disease states have blood-based genomic markers that can be used for diagnostic assessment. The increasing role of CH in cardiovascular disease and neurology further buttress this approach. In cardiology, the first natural bridge exists in the field of cardio-oncology where, for example, biomarkers to predict cardiotoxicity to commonly used therapies could be implemented to help mitigate adverse events. In addition, the deployment of cardiovascular disease risk based on CH mutations could be used to augment early detection efforts. In neurology, disorders such as Alzheimer’s or Parkinson’s disease are difficult to diagnose, as the same symptoms manifest in different combinations across different disorders. Symptoms of one condition may often be similar to that of another, leading patients down the path of a “diagnostic odyssey.” The diagnosis involves tests such as CT scan, electroencephalogram, magnetic resonance imaging, electromyography, nerve conduction velocity, positron emission tomography, angiogram, spinal tap, myelogram, neurosonography, and ultrasound, among others. Personalized medicine and targeted therapies do not exist today for CNS disorders, however there is general consensus that detecting symptoms early and intervening can slow the development of disease.
The Caris Platform
We are leading a molecular revolution and developing the latest generation of advanced precision medicine information solutions that we believe have applicability across the care continuum for a broad range of conditions. The fundamental differentiation of the Caris platform and our business model is the depth, breadth, and scale of data, including how that data is integrated vertically and horizontally across our business, as well as the resulting innovation which it fuels.
Our multi-omic technology platform is built on the following pillars: (1) Caris Assure; (2) MI Profile; (3) Caris Discovery; (4) Caris Strategic Data; and (5) Caris Infrastructure. These five pillars are designed to work together to create a virtuous cycle that can enable continued innovation and improved impact for patients and physicians. We believe our comprehensive approach to profiling will continue to drive demand for our genomic profiling capabilities, leading to further expansion of our clinico-genomic datasets, which provide additional valuable inputs to develop and enhance our solutions, with the ultimate goal of contributing to improved patient results. We believe this continuing cycle will deepen our competitive advantage and allow us to achieve meaningful innovation and business success in precision oncology, while illuminating a path to precision medicine for other chronic disease states, including cardiology, neurology, and metabolic conditions.
 
152

TABLE OF CONTENTS
 
[MISSING IMAGE: pc_platform-4c.jpg]
We believe our growth and competitive differentiation are driven by the five pillars of our platform, each of which are both a product of the upstream data and a foundation to further innovation and data generation across the platform:
•
Caris Assure:   Our universal blood-based WES/WTS profiling solution is designed to deploy a single assay across the entire continuum of cancer care, including early detection, MRD tracking, therapy selection, and treatment monitoring, and generates over 42 billion datapoints, spanning 168,000 molecular markers, per clinical case. We leveraged our experience and data from MI Profile to create Caris Assure, which enables us to understand how a patient’s disease started, what therapies the tumor may be sensitive to, how the tumor is transforming to resist therapies, and how best to control or cure the disease.
​
•
MI Profile:   Our tissue-based profiling solution for therapy selection includes our comprehensive WES/WTS profiling assay and IHC protein expression testing. Our WES/WTS profiling solution generates over 28.8 billion datapoints, spanning 84,000 molecular markers, per clinical case.
​
•
Caris Discovery:   The combination of our data and our AI enables us to discover previously unknown drug targets for antibody-directed therapies (such as antibody drug conjugates, degrader-antibody conjugates, and T-cell engagers), small molecules, targeted protein degradation, synthetic lethal interactions, and cell therapy. In addition, we believe Caris Discovery is well-positioned for neoantigen discovery for personalized therapy development given our ability to detect variants, insertions, and deletions by WES and to assess gene expression and detect fusions by WTS on every patient’s tumor.
​
•
Caris Strategic Data:   As of March 31, 2025, we have run more than 6.5 million tests that have measured over 38 billion molecular markers from over 13 quadrillion datapoints. To assist us with analyzing the data we generate, we utilize over 220 AI and AI/ML tools across our clinical testing, R&D, and biopharma business. These tools include over 50 clinical sequencing
​
 
153

TABLE OF CONTENTS
 
automation and variant calling AIs, over 100 RNA expression AI signatures, approximately 20 multi-omic AI/ML therapy response predictors, two ADAPT target discovery AI/ML algorithms, 37 digital image AI/ML classifiers, and 12 AI/ML support tools. We have used our datasets to create many of these algorithms and signatures. The breadth and depth of our data assets, together with our demonstrated ability to use them to create algorithms and discover signatures, represent a deep competitive moat for us.
•
Caris Infrastructure:   We have a well-developed laboratory, R&D, and sales infrastructure that we believe is foundational to our business.
​
•
Operational Capacity.   We have substantial testing capacity, including over 275,000 square feet of space across four precision medicine laboratories with throughput capabilities of over one trillion reads per day generated by 50 NovaSeq sequencing systems. We believe this capacity provides us with ample capability to manage our current operations and future growth.
​
•
Research and Development.   We have a dedicated R&D infrastructure, including a specialized laboratory and over 200 employees dedicated to R&D efforts. In addition to our internal research, we regularly partner with outside academic centers and researchers. The Caris POA, which we established in 2015, is a growing network of leading cancer centers and research consortia across the globe that supports research partner engagement, collaboration opportunities, and the advancement of precision oncology research.
​
•
Commercial Channel.   To support our sales activity and expansion, as of March 31, 2025, we have assembled a targeted sales organization in the United States of over 270 sales team members and nearly 50 highly trained Ph.D. or M.D. MSLs who focus on physician and provider education.
​
The Caris Advantage
We believe our approach is differentiated and we have a competitive advantage because:
•
We purpose-built our Caris platform to put the patient first and make comprehensive precision medicine a reality.   Our patient-centric ethos has guided us since inception. This guiding principle underpins our belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights would realize the potential of precision medicine, driving superior patient outcomes. Our approach, which includes deep sequencing all DNA encoding genes and RNA transcripts, maximizes the molecular information generated for each clinical case and enables us to analyze and provide patients and physicians with industry-leading breadth, depth, and accuracy of multi-omic information. By providing a high-quality, individualized molecular blueprint of a patient’s disease, our platform is designed to enable the discovery, development, and application of cutting-edge precision medicine that pushes the boundaries of current science. This differentiated approach has made Caris a destination for KOLs and clinicians seeking the most complete and accurate information available for treating their patients.
​
•
We are a leading provider of tissue-based molecular profiling, including through our FDA-approved companion diagnostic tissue-based profiling solution, MI Cancer Seek.   MI Profile is a leading tissue-based molecular profiling solution for therapy selection, with over one million tests performed on approximately 146,500 clinical cases in 2024, which represents a 31.2% compound annual growth rate in clinical tissue case volume since 2018. MI Profile consists of a WES and WTS NGS component, IHC analysis, and AI/ML analysis to identify the origin of a tumor for 90 unique cancer types with approximately 95% accuracy. This comprehensive solution assists clinicians in identifying patients who may benefit from treatment with specific targeted therapies.
​
•
Our novel, universal blood-based profiling solution, Caris Assure, is unique in the market and poised for rapid adoption.   We believe our leadership in tissue molecular profiling uniquely positions us to capitalize on the increased use of blood-based profiling and adoption into
​
 
154

TABLE OF CONTENTS
 
clinical practice with Caris Assure, our novel, universal blood-based solution that is purpose-built to extend across the entire cancer care continuum and to therapeutic development by generating over 42 billion datapoints per clinical case. We built upon the data we have generated to date with MI Profile and believe our data is a significant competitive advantage in the development and clinical utility of Caris Assure. Caris Assure naturally enriches our AI/ML algorithms and transfers learning across the care continuum, yielding greater sensitivity and specificity, while continuously expanding our longitudinal patient datasets. Moreover, we believe that our single-test approach will enable us to scale our R&D infrastructure to analyze increasingly large testing volumes, process expanding datasets, and reach economies of scale in liquid biopsy. To our knowledge, we have developed and launched the most informationally rich blood-based solution in the market. We have Medicare reimbursement and various levels of commercial payer adoption and/or reimbursement coverage for Caris Assure for therapy selection across the United States (other than New York State).
•
We have built what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology.   Our proprietary oncology clinico-genomics datasets provide insights into the fundamental building blocks of disease, potentially enabling breakthroughs from targeted therapies to truly personalized medicine. Our ever-expanding datasets include data generated from more than 6.5 million tests that have generated measurements of over 38 billion molecular markers from over 13 quadrillion datapoints as of March 31, 2025, as well as matched clinical outcomes for many of these patients. Our platform generates over 111 million reads per clinical case, and each new case further expands our datasets allowing us and our biopharma partners to generate even more clinically relevant insights. We also expand and enrich our datasets through partnerships that add real-world evidence, longitudinal patient data, and clinical outcomes. The breadth and depth of our large and growing data assets represents a deep competitive moat for us, overcoming which requires significant capital investment, scaled sequencing capacity, acquisition of patient samples, and generation of corresponding clinical outcomes data. These significant data assets enable us to effectively deploy our proprietary AI/ML algorithms to analyze patient information and empower our customers to make better informed diagnoses and treatment decisions.
​
Our Caris platform is designed to create a virtuous cycle that can enable continued innovation and improved impact for patients and physicians. We believe our comprehensive approach to profiling will continue to drive demand for our genomic profiling capabilities, leading to further expansion of our clinico-genomic datasets, which provide additional valuable inputs to develop and enhance our solutions, with the ultimate goal of contributing to improved patient results. We believe this continuous feedback loop will allow us to achieve meaningful next-generation innovation in precision oncology as well as other chronic disease states.
•
Our first mover advantage, specialized commercial channel, robust infrastructure, and deep research collaborations enable our leadership and provide us with the ability to scale for future growth.   We believe we will be the first provider to achieve leadership in both solid tumor and liquid biopsy profiling solutions across the entire precision oncology care continuum. To support our sales activity and expansion, we have built a commercial organization specialized in precision oncology consisting of approximately 270 team members as of March 31, 2025, plus nearly 50 highly trained Ph.D. or M.D. MSLs, serving over 5,600 physicians in the United States across all major health systems, academic cancer institutions, and community settings. Due to the increased market acceptance of our solutions, we have achieved revenue growth and case volume growth without growing the aggregate sales headcount over the last three years.
​
Our robust infrastructure includes a team of over 60 Caris data scientists to decipher unique features from our datasets generated from millions of tests. We operate two precision medicine laboratories in Phoenix, Arizona, and one R&D laboratory in Tempe, Arizona. Our Arizona laboratories all utilize state-of-the-art genomic sequencing technology, including 50 NovaSeq sequencing systems, with capacity to perform more than one trillion “reads” daily. Our newest laboratory facility in Irving, Texas, near our headquarters, is continuing to be built-out and will bring our total operational capacity to over 275,000 square feet.
 
155

TABLE OF CONTENTS
 
Since its establishment in 2015, the Caris POA, whose members work together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients, has grown to comprise 96 members as of March 31, 2025, including 45 NCI-designated comprehensive cancer centers. This academic-industry collaborative network has been exceptionally productive with over 145 peer-reviewed manuscripts published since the beginning of 2022. Close connectivity with this vast network of KOLs in oncology clinical care, research, and drug development has enabled us to remain at the forefront of precision oncology and closely attuned to the key needs of the most sophisticated researchers.
•
We are led by a founder with significant experience building and scaling businesses in the healthcare industry and a management team with scientific expertise.   Our management team has deep domain expertise in molecular biology, oncology, artificial intelligence, data science, medicine, and genomics and have a track record of delivering innovative, high clinical utility solutions to the market. Our management team is highly entrepreneurial and has significant experience leading and operating large multi-national organizations and building innovative healthcare companies. In particular, our Founder, Chairman, and Chief Executive Officer, David D. Halbert, has successfully built and scaled profitable enterprises for approximately 40 years, including AdvancePCS Inc. (acquired by CareMark in 2004 for $7.5 billion), and Caris Diagnostics (acquired by Miraca Life Sciences in 2011 for $725 million), among others.
​
Our Strategies
As we execute on our vision, we will continue to put the patient first. Our solutions provide physicians and individual patients with actionable information throughout the disease journey, while contemporaneously generating data that can be aggregated and leveraged to unlock academic and biopharma scientific breakthroughs, which may lead to curative therapies for future generations. To achieve our goal of leading a molecular revolution and developing the next generation of precision medicine information solutions for a broad range of conditions across the care continuum, we plan to:
•
Drive the continued adoption and use of our tissue-based profiling and expand our blood-based profiling offering into early detection, MRD, and monitoring.   MI Profile continues to be one of the most comprehensive tissue-based molecular profiling solutions available. We plan to leverage our leadership with MI Profile and our proprietary clinico-genomics datasets, to drive the adoption of blood-based profiling with Caris Assure, our highly differentiated, comprehensive multi-omic liquid biopsy solution. We believe Caris Assure will address the significant unmet need across the entire cancer care continuum, with solutions for early detection, MRD tracking, therapy selection, and treatment monitoring. Broadly launched in the first quarter of 2024 for therapy selection, we have seen over 3,400 physicians from over 480 institutions order Caris Assure for therapy selection through March 31, 2025. We intend to leverage our existing commercial infrastructure, including our substantial testing capacity across two precision medicine labs and our specialized commercial channel, to support the continued launch and commercialization of Caris Assure.
​
•
Utilize the data generated by our existing solutions to develop new solutions with additional revenue using our existing sales channel.   We will leverage our clinico-genomic datasets to identify novel AI-based molecular signatures that are predictive of a patient’s clinical journey. This will allow us to reach new patient populations at earlier stages of cancer, who may not be eligible for our current solutions. We are currently using an AI/ML approach driven by H&E slide images and clinical results data from more than 10,000 breast cancer patients to develop ESPai, a new algorithm to predict the risk of disease recurrence for early-stage breast cancer patients. We have obtained the samples and clinical data from the National Surgical Adjuvant Breast and Bowel Project and the ECOG-ACRIN Cancer Research Group. We are currently in the process of creating two AI/ML models for ESPai using these samples and are working to obtain additional samples for external validation studies. We are initially creating a model for late recurrence (five to 15 years following diagnosis), but we are also in the beginning stages of creating a model for early recurrence (zero to five years following diagnosis). The ability to deliver results to patients who would otherwise require multiple tests, or for whom testing would
​
 
156

TABLE OF CONTENTS
 
not be a possibility, further differentiates us and provides significant value to patients and their physicians. This business model, possible only through our testing platform and the comprehensiveness of our underlying data, has created a new category of operational efficiency centered around patient care as shown below:
[MISSING IMAGE: pc_strategic-4c.jpg]
•
Leverage our platform to provide solutions to biopharma companies to drive advances in personalized medicine and accelerate the development of novel therapeutics.   We partner with biopharma companies to improve the efficiency and success of their therapeutic development and clinical programs by leveraging our platform. We provide prospective and retrospective profiling services, companion diagnostics development, data licensing, and commercial services that include identification of patients for approved therapies. Our biopharma business continues to gain significant momentum, with $63.1 million of revenue generated in 2024, representing a 130.3% increase compared to the prior year. A key strategy for future growth is continued pursuit of opportunities to partner with biopharma institutions to accelerate scientific breakthroughs through access to our datasets. These arrangements, such as our partnerships with Moderna, AbbVie, Xencor, and Merck KGaA include research into molecular markers and tumor-associated antigens, characterization of resistance mechanisms, and the development of personalized therapies. We believe the future of therapeutics will become more and more personalized, requiring the information that we produce to create individually tailored therapies that will have the greatest likelihood of controlling and/or curing patients of disease. Recent advances of personalized therapies that are specifically created for patients demonstrate the value of this approach.
​
•
Continue to expand and enrich our clinico-genomic datasets to drive breakthrough science and develop new solutions.   Our continued comprehensive sequencing for patients, together with our leadership in tissue-based profiling and expansion into blood-based profiling, will enable continued rapid expansion of our datasets, both with new profiling data as well as with longitudinal insights as we follow patients over time. We plan to accelerate the enrichment of
​
 
157

TABLE OF CONTENTS
 
our datasets through continuous R&D at our own laboratories, third party partnerships, and collaborative research with Caris POA members to remain at the cutting-edge of precision oncology and stay attuned to the key needs of our researchers.
•
Maximize market reach through our regulatory approval and reimbursement strategy.   A key aspect of our commercial strategy is to obtain regulatory approval and reimbursement for our solutions. In November 2024, we obtained a premarket approval (“PMA”) from the U.S. Food and Drug Administration (the “FDA”) for a companion diagnostic and tumor profiling designation for MI Cancer Seek, a WES/WTS NGS assay that uses the whole exome for TMB calling and has been designed to meet the stricter requirements applicable to companion diagnostic devices. We currently market MI Cancer Seek as the WES/WTS NGS component of MI Profile. We have secured a PLA code of 0211U from the AMA and pricing from CMS for this PLA code. We have obtained Medicare coverage for MI Cancer Seek for CPT code 0211U under the NGS NCD. For MI Tumor Seek Hybrid, we have Medicare and commercial reimbursement. For Caris Assure, we received Medicare coverage in late 2023, have secured various levels of payer adoption and/or reimbursement coverage, and will continue working to expand coverage. In July 2024, the AMA issued a PLA code, CPT code 0485U, for Caris Assure, with an effective date of October 1, 2024. In November 2024, CMS determined to price Caris Assure for therapy selection using the “Gapfill” method, a method used when there are no comparable existing codes available. There is no certainty regarding the pricing that we will obtain for Caris Assure during the Gapfill process. For additional information, see “—Government Regulation—Coverage and Reimbursement—Coverage and Reimbursement in the United States.” We plan to work closely with Medicare and private payers to continue to demonstrate the economic benefit of our platform and secure reimbursement coverage for our future offerings by leveraging our proprietary clinico-genomic datasets that contains a growing volume of corresponding clinical outcomes data. We believe this approach will lead to a differentiated reimbursement profile relative to our peers.
​
•
Capitalize on the ultimate potential of our novel, universal blood-based profiling solution, Caris Assure, and broader innovation platform in other chronic disease states beyond oncology, including in cardiology, neurology, and metabolic conditions.   We believe there is a large market opportunity to diagnose and treat chronic conditions beyond oncology through molecular information-based approaches. Beyond oncology, researchers are actively exploring the genetic and biological connections between patients and other disease states, including cardiology, neurology, and metabolic conditions. These diseases are frequently multifactorial in nature and are characterized by significant individual variability. Accordingly, a comprehensive understanding of the underlying biological pathway dysfunction is critical if we want to understand the molecular origins of disease and generate insights to bring new therapeutics to patients. As we continue to scale, we believe our solutions will drive superior clinical outcomes, leading to additional demand for our profiling solutions and further expansion of our clinico-genomic datasets, allowing us to achieve meaningful innovation in other disease states beyond oncology.
​
Our Solutions
Caris Assure—Our Universal Blood-Based Profiling Solution
Caris Assure is our novel, universal blood-based solution that is purpose-built to extend across the entire continuum of cancer treatment, including early detection, monitoring of MRD and recurrent cancers, and precision selection of molecularly targeted therapies. Caris Assure also has applications in therapeutic discovery and development. Customers for Caris Assure include treating physicians as well as researchers and biopharma companies.
Our universal approach to blood-based profiling is unique. While Caris Assure is a single wet lab test, the backend bioinformatics pipeline and analyses are adapted to where the patient may be in their cancer journey. For example, the genes, molecular alterations, and features in late-stage metastatic cancer for therapy selection will be interpreted differently than in early detection. The elegant simplicity of a single test paired with a comprehensive assessment of the patient’s DNA and RNA allows Caris Assure to be
 
158

TABLE OF CONTENTS
 
this universal diagnostic. This approach also allows many more datapoints to be assessed, enabling us to select those markers that provide the greatest potential for sensitivity, specificity, and overall accuracy of our test.
Liquid biopsies can be used across the care continuum, including for: therapy selection in the advanced/metastatic setting; MRD and monitoring in the curative/adjuvant setting; and early detection in the diagnosis setting. Because many of our competitors’ liquid biopsy assays are designed to address only a single portion of this care continuum, in order to develop products for other portions of the care continuum, our competitors must invest in the development of new wet lab assays and generate disparate datasets across the patient journey for patients, oncologists, and researchers. In contrast, Caris Assure is designed as a single test applicable across the entire patient journey. To our knowledge, there is no other assay on the market that can be applied as broadly as Caris Assure. We believe that our single-test approach will enable us to scale our R&D infrastructure to analyze increasingly larger testing volumes, process expanding datasets, and reach economies of scale in liquid biopsy across the entire cancer care continuum. The figure below shows the opportunities for blood and tissue sampling and treatment therapies within stages of the cancer care continuum. As a blood-based profiling solution designed for the entire cancer care continuum, Caris Assure has many more opportunities for testing relative to tissue-based profiling, as can be seen on the chart below.
[MISSING IMAGE: lc_oursolutions-4c.jpg]
Caris Assure is currently being offered for therapy selection as a laboratory developed test (‘‘LDT’’), and we have Medicare reimbursement and various levels of commercial payer adoption and/or reimbursement coverage for Caris Assure for therapy selection across the United States (other than New York State), at current pricing under MolDX of $3,649. We are in the process of conducting studies and analysis to internally validate and refine the assay for application to early detection, MCED, MRD tracking, and treatment monitoring, with certain validation processes and results to date described below. The commercial application of Caris Assure as an LDT to the cancer care continuum beyond therapy selection is subject to further assay development, validation, and reimbursement coverage. Further, due to the FDA’s planned phase out of its enforcement discretion policy with respect to LDTs, the marketing of Caris Assure for these applications may require marketing authorization from the FDA depending on the timing of launch. Because many of these factors are outside of our control, we are not certain regarding the timing of the availability of Caris Assure for the early detection, MCED, MRD tracking, and treatment monitoring markets.
Drawing blood is a routine medical procedure that is much less invasive than a tissue biopsy. Processing of a blood specimen, from collection to isolation, analysis, and reporting, enables faster time to results and potentially earlier start of treatment. Clinical guidelines for molecular profiling in cancer have focused on tissue as the gold standard, but with recent advances in blood-based profiling demonstrating its clinical utility, we believe that evidence and clinical guidelines support complementary usage of both tissue- and blood-based profiling across many major cancer types. We believe that one example of the benefits of blood-based profiling is that cancers frequently become resistant to new targeted therapies by developing genetic mutations that can make drugs less effective and lead to cancer recurrence. When resistance develops, clinicians need an updated molecular profile of the cancer to guide subsequent treatment strategies. At this
 
159

TABLE OF CONTENTS
 
stage in cancer progression, it is often not feasible to acquire additional tumor tissue to build the updated profile, or the amount or quality of accessible tissue is low. Small quantities or low quality of tissue from an inaccessible biopsy site can lead to a Quantity Not Sufficient (QNS) result when NGS fails for lack of input material. Without another way to generate an updated molecular profile of the patient’s tumor, the tools of precision oncology cannot be deployed. Conducting additional tissue biopsies also carries its own health risks, such as tumor seeding, which can occur when cancer cells are unintentionally deposited elsewhere in the body during the biopsy process, and infection. Liquid biopsy is a potential solution to the challenges and risks of tissue biopsies. A sample eligible for Caris Assure analysis consists of two 10 milliliter tubes of whole blood, gently inverted 10 times as is common practice in blood collection, shipped at room temperature.
Nonetheless, we believe that tissue-based profiling generally remains the gold standard for cancer therapy selection primarily because it is the most mature technology and is broadly supported by analytical validation studies. Microscopic examination of the tumor tissue is necessary for characterization of tumor type and stage and to confirm the presence of key proteins via IHCs. In blood, the variant allele frequencies of tumor biomarkers can be so low that negative results must be confirmed by tissue analysis. However, the tide is turning in clinical guidelines toward acceptance that tissue and liquid biopsy, used in combination, can improve clinical outcomes for patients. For example, the 2024 version of one of the prominent clinical guidelines for non-small cell lung cancer states that: (1) concurrent testing can improve time to test results and should be considered in the appropriate clinical situation, and (2) negative results (meaning absence of definitive driver mutation) by one method suggests the use of a complementary method.
We believe Caris Assure represents the most comprehensive blood-based solution on the market, featuring over 23,000 gene coverage at a raw average sequencing depth of coverage of 8,000 times for clinically relevant genes, as compared to other blood-based offerings in the market that only assess 500 to 1,000 genes from DNA. Caris Assure performs WES and WTS for every eligible patient blood sample. We couple this WES and WTS with advanced AI and ML technologies to offer diagnostic, prognostic, and predictive utility in a single test. Additionally, Caris Assure generates sequencing results from both the plasma and the white blood cells, or buffy coat, from each sample. This gives Caris Assure a differentiated ability to distinguish tumor variants, which are relevant for therapy selection, from both incidental germline variants and common age-related mutations that are not related to the tumor and which can confound analysis and therapy selection if not properly distinguished. For additional information regarding this capability, see “—Benefits of CH Subtraction with Caris Assure.”
Molecular features we identify using Caris Assure’s WES and WTS data include single nucleotide variants (“SNVs”), insertions/deletions (“INDELs”), structural variants, gene expression, copy number alterations (“CNAs”), TMB, and MSI. In addition, we deploy our ABCDai algorithm on Caris Assure’s WES and WTS data to address important clinical needs in early detection and monitoring of MRD and recurrent cancers. We trained ABCDai using data for over 375,000 tissue profiles and over 7,000 paired blood and tissue profiles. In a first phase, separate AI models were trained on nine feature sets representative of cancer-related and cell-free nucleic acids. In a second phase, the 500 most important features determined by us from each feature set were used to train a final ABCDai model. We engineered three ABCDai models to work in concert with Caris Assure: (i) MCED; (ii) diagnostic pathway; and (iii) MRD and monitoring.
 
160

TABLE OF CONTENTS
 
[MISSING IMAGE: fc_abcdaiassure-4c.jpg]
Caris Assure for Early Detection
We believe that one of the most promising uses for Caris Assure is for early detection, including both cancer-type-specific early detection and MCED. Our detection of cancer at very early stages would enable clinicians to treat disease sooner, which could significantly improve patient outcomes.
We trained ABCDai for MCED (“ABCDai-MCED”) using the aforementioned features on samples from 1,013 patients (507 patients with cancer and 506 individuals with no reported cancer). Performance was assessed on an independent set of 2,675 patients (526 patients with cancer and 2,149 samples from individuals with no reported cancer). ABCDai-MCED’s performance on the stratification of blood samples from the independent cohort of patients with cancer versus those with no reported cancer resulted in sensitivities for stages I-IV (n= 284, 129, 90, and 23, respectively) of 83.1% (stage I), 86.0% (stage II), 84.4% (stage III), and 95.7% (stage IV) at 99.6% specificity (n=2,149).
The chart below illustrates ABCDai-MCED’s sensitivity in detecting a range of cancer types at stages I and II, at a specificity of 99.5%
 
161

TABLE OF CONTENTS
 
[MISSING IMAGE: bc_caris-4c.jpg]
ABCDai-MCED has been shown to be useful in detecting the presence of cancer in an asymptomatic individual. Additionally, the molecular information provided by Caris Assure can assist in predicting the diagnostic pathway that can confirm the presence and tissue of origin of cancer, which knowledge is needed for proper intervention. We focused diagnostic pathway prediction on those tumor types that are most common and thus provide the most clinical utility: colonoscopy, abdominal/chest CT, endoscopy, liver ultrasound, mammograph with MRI, neck ultrasound, pelvic ultrasound, and prostate-specific antigen (“PSA”). A model to predict diagnostic pathway, ABCDai-GPS, was trained by us using the feature sets described above obtained for treatment-naïve samples from 660 patients with stage I and II cancers and 506 individuals with no reported cancer. Using 5-fold cross validation, we observed that ABCDai-GPS predicted the diagnostic pathway for 100% of the ABCDai-MCED positive calls with a top-3 accuracy of 85% for stage I and II cancers. The relationship between the proposed diagnostic pathways and tissue of origin of the cancer is shown in the following table.
Diagnostic Pathway
​ ​
Cancer Types
​
Colonoscopy ​ ​ Colorectal ​
CT Abdomen/Chest ​ ​ Pancreatic, Kidney, Bladder, Urinary tract, Lung ​
Endoscopy ​ ​ Esophageal, GIST, Gastric, Small Intestine ​
Liver ultrasound ​ ​ Cholangiocarcinoma, Liver ​
Mammograph with MRI ​ ​ Breast ​
Neck ultrasound ​ ​ Head and Neck, Thyroid ​
Pelvic ultrasound ​ ​ Uterus, Cervical, Ovarian, Female Genital Tract Malignancy ​
PSA ​ ​ Prostate ​
We are also in the early stages of developing a version of ABCDai to be used with Caris Assure for early detection of specific types of cancer. We are currently developing cancer-type-specific early detection for breast and colorectal cancers. We believe that cancer-specific early detection assays will benefit patients by providing them with clear treatment pathways. We currently intend to launch Caris Assure for early
 
162

TABLE OF CONTENTS
 
detection of breast cancer and intend to do so in a capital efficient manner, with the expectation that we will leverage either a commercial partner or our existing sales channels, however, our plans and intentions may change.
Caris Assure for Minimal Residual Disease Tracking and Treatment Monitoring
A third model was trained by us using the feature sets described above for deployment in the settings of MRD and recurrence monitoring. This model, ABCDai-M&M, was trained using samples from 3,439 patients (1,290 patients with cancer and 2,149 individuals with no reported cancer) and performance was assessed on two independent validation cohorts: 86 patients in the MRD study and 101 patients in the recurrence monitoring study. The disease-free survival of patients whose cancers were predicted by ABCDai-M&M to have an event was significantly shorter than those predicted not to have an event using a tumor naïve approach (HR=33.4, p<0.005, HR=4.39, p=.008, respectively). The ABCDai-M&M model captured 89% of MRD recurrence events with 98% NPV and 76% specificity, and 45% of recurrence monitoring events with 92.6% NPV and 83% specificity.
[MISSING IMAGE: lc_significant-4c.jpg]
The following graphic illustrates the performance of Caris Assure for CRC in the MRD setting, in our clinical validation performed on 44 patient samples.
 
163

TABLE OF CONTENTS
 
[MISSING IMAGE: lc_colorectal-4c.jpg]
Our MRD detection methodology based on ABCDai takes a tumor naive approach, and therefore does not require a bespoke panel to be created to track the recurrence of a patient’s tumor. This bespoke-free approach enables faster turn-around-time, enabling patients to be informed of additional therapy sooner to combat their disease. Additionally, because Caris Assure analyzes the entire exome, any tumor-derived alterations including those that may derive from subclones not included in the original tissue biopsy, are also detectable, thus accounting for tumor heterogeneity to help contribute to sensitivity of detection.
Benefits of CH Subtraction with Caris Assure
For therapy selection, in addition to sequencing cell-free DNA and cell-free RNA isolated from the plasma to identify somatic tumor variants, we also sequence genomic nucleic acid (gDNA and gRNA) isolated from the white blood cells, or buffy coat, from each sample. Plasma contains a mixture of cell-free variants derived from tumor, blood and other cells. These variants cannot be separated based on plasma sequencing alone. Sequencing the buffy coat separately from the plasma allows Caris Assure to identify incidental germline (inherited) mutations as well as CH mutations. CH mutations are somatic mutations that accumulate in the blood with age, occur in a substantial portion of the population, and are not cancer-derived. Caris Assure “subtracts” CH mutations in the reporting of somatic tumor variants. If CH mutations are not distinguished from tumor-derived mutations, it can confound liquid biopsy results and lead to selection of a therapy targeted at a mutation that is present in the white blood cells instead of in the tumor, which is not beneficial for the patient with cancer. Because of this, the College of American Pathologists (“CAP”) and Association for Molecular Pathology recommend that cfDNA assays should incorporate whole blood controls to differentiate CH from tumor-derived variants. Caris Assure sequencing follows this approach, thus lessening the risk of incorrectly interpreting CH or germline mutations as tumor-derived and thus result in fewer false positive diagnoses and more accurate and effective treatment recommendations.
In February 2025, we published in Clinical Cancer Research, a peer-reviewed medical journal on oncology, our validation study conducted in collaboration with leading cancer centers such as Rocky Mountain Cancer Centers, OU Health University of Oklahoma Medical Center, Hope Cancer Center of Nevada, and Texas Oncology. The study analyzed over 16,800 patients with advanced cancer across 49 cancer types and found that nearly more than four of 10 patients had at least one CH variant among reportable clinical genes. The study also found a median rate of CH variant classification of 20% for patients ranged from 65 to 69, 33% for patients aged 70 to 74, 33% for patients aged 75 to 79, and 50% for patients 80 years of age and older. High CH rates were notably detected in BRCA2, BRCA1, CHEK2, ATM and NRAS.
 
164

TABLE OF CONTENTS
 
The following graphic illustrates the study’s findings on variant classification by gDNA and plasma variant frequency, and illustrates the types of diagnostic errors that can occur when variants are not properly characterized as tumor, germline or CH mutations.
[MISSING IMAGE: lc_plasmabuffy-4c.jpg]
Because of the prevalence of CH mutations, we believe that CH subtraction is critical to optimal cancer care. As noted above, the identification of CH mutations by an assay can lead to improper therapy selection if such mutations are not shown to be from the white blood cells. By identifying and distinguishing variants that are not from the tumor itself and, therefore not relevant to therapeutic decision-making, the CH subtraction feature of Caris Assure further separates our solution from other liquid biopsy tests currently on the market that do not sequence the white blood cells and therefore cannot definitively distinguish CH mutations from tumor-derived mutations. To our knowledge, Caris Assure is the only commercially available tissue-naive blood-based profiling assay that directly accounts for CH mutations instead of using algorithmic approximations, which we believe gives Caris Assure a differentiated ability to drive improved therapy selection.
By leveraging CH subtraction, somatic mutation detection from blood collected within 30 days of matched tumor tissue showed high concordance to our tissue-based assays, with a positive percent agreement (“PPA”) of 93.8% and a positive predictive value (“PPV”) of 96.8% PPA and PPV are terms commonly used in the context of diagnostic tests and medical studies and are helpful for evaluating assay performance. PPA stands for positive percent agreement and is a measure of the agreement between a test’s positive result and the true positive status as determined by a reference standard. PPV stands for positive predictive value, which is a measure of the probability of a positive result correctly identifying a disease or condition.
 
165

TABLE OF CONTENTS
 
​ ​
Case Study: The Benefits of CH Subtraction in Therapy Selection
​ ​
​ ​
         A male in his 80’s with a history of renal cell carcinoma presented with a large osseous (bone) metastasis involving the thoracic and lumbar spine, ribs, and pelvis. Pathology was consistent with an origin in the prostate. Immunohistochemical studies performed by the outside pathology team was consistent with this diagnosis, and a liquid biopsy performed outside of Caris revealed a mutation in the ATM gene, which helps repair damaged DNA that was potentially actionable as supported by a specific FDA-approval for PARP inhibitors for patients with this mutation. This outside liquid biopsy did not specify whether the detected ATM mutation was derived from the tumor or potentially from clonal hematopoiesis.
​ ​
​ ​
         A tissue biopsy was sent to Caris for molecular profiling. Tissue molecular profiling done at Caris confirmed the diagnosis of metastatic prostate cancer with mutations in FOXA1 and MEK1, genes that play roles in regulating cell growth and behavior.
​ ​
​ ​
         The patient received palliative radiation therapy and began androgen deprivation therapy (“ADT”). The ATM mutation detected by the outside liquid biopsy also indicated potential benefit from the PARP inhibitor olaparib. After an increase in the patient’s prostate-specific antigen levels led the clinician to consider new therapy options, a blood sample was sent for Caris Assure molecular profiling.
​ ​
​ ​
         Caris Assure confirmed the previously-identified FOXA1 and MEK1 mutations, MSS, and low blood TMB consistent with low tissue TMB, but showed that the ATM mutation was CH-derived rather than tumor-derived. Therefore, ADT could continue while the patient is responsive and tolerant, but the clinician could avoid prescribing the PARP inhibitor olaparib, knowing that the ATM mutation targeted by that therapy is a false positive from CH and not a tumor biomarker.
​ ​
​ ​
         The CH subtraction capability of Caris Assure in this case provided the patient and his clinicians more accurate information about potential future treatment options, and helped the patient avoid the potential harmful side effects, time and financial cost of therapies that would likely have been ineffective.
​ ​
Caris Assure for Therapy Selection
We initiated a broad commercial launch of Caris Assure for therapy selection in the first quarter of 2024 and currently offer the solution as an LDT, which is an in vitro diagnostic (“IVD”) test intended for clinical use and designed, manufactured, and used within a single laboratory. The FDA has historically exercised enforcement discretion and not required marketing authorization for LDTs. Accordingly, we have not yet obtained FDA marketing authorization for Caris Assure. We anticipate seeking FDA marketing authorization for certain of our solutions in the future, including Caris Assure for therapy selection, in part as a result of the FDA’s planned phase out of its enforcement discretion policy with respect to LDTs. Additionally, while we currently market Caris Assure for therapy selection as an LDT, marketing authorization would be required in order for us to market Caris Assure as a companion diagnostic device for therapy selection. We do not yet have specific plans regarding the timing of a PMA or other submission, if any, for Caris Assure for therapy selection or any other indication. For additional information, see “Business—​Government Regulation—U.S. Food and Drug Administration.” We have Medicare reimbursement and various levels of commercial payer adoption and/or reimbursement coverage for Caris Assure for therapy selection across the United States. The current pricing of Caris Assure for therapy selection under MolDX is $3,649.
Caris Assure for therapy selection is available in all U.S. states (other than New York, where we intend to apply in 2025 for approval from New York State’s Clinical Laboratory Evaluation Program (“NY CLEP”)) and in Puerto Rico. We also offer Caris Assure for therapy selection internationally through distributors and direct contracts with hospital systems, where permitted by applicable regulations.
Caris Assure Profile Report
Caris Assure for therapy selection generates a personalized report that provides oncologists with the information to tailor each patient’s treatment plan. This report is built to maximize clinical utility in an easy-to interpret format. Our technology enables us to report our results for blood-based profiling even quicker than tissue-based profiling, as Caris Assure results are typically reported in approximately seven calendar days from “activation,” the time at which we receive the patient’s samples and required paperwork. A sample Caris Assure profile report is depicted below.
 
166

TABLE OF CONTENTS
 
[MISSING IMAGE: fc_miprofile02-4c.jpg]
Technical Specifications and Analytical Validation
Caris Assure analyzes all coding genes through WES (cell-free DNA) and WTS (cell-free RNA), and categorizes variants found in plasma as either tumor-derived or CH-derived and either somatic or germline. Caris Assure clinically reports SNVs, INDELs, and select fusions, as well as MSI, TMB, human leukocyte antigens, and select amplifications.
 
167

TABLE OF CONTENTS
 
[MISSING IMAGE: tb_technical-4c.jpg]
[MISSING IMAGE: bc_novelcircul-4c.jpg]
 
168

TABLE OF CONTENTS
 
Caris Assure for Biopharma
The same benefits that blood-based WES, WTS, and CH subtraction bring to patients in the clinical setting also offer significant and previously unavailable advantages to biopharma companies across the drug development continuum. Caris Assure allows biopharma companies to conduct exploration into biology and address elusive questions around response and resistance with repeat and/or longitudinal biopsies, without the restriction of earlier generation liquid biopsies. This enables biopharma companies to understand the molecular alterations responsible for resistance. In a drug development setting, the only way to get this understanding is through the WES/WTS sequencing technology underlying Caris Assure. With a typical results turn-around-time of approximately seven calendar days from activation, Caris Assure can be used in early-stage trials to identify and enroll eligible patients that meet inclusion and exclusion criteria, or more broadly to leverage this comprehensive molecular profile of patients for exploratory analyses.
Caris Assure is designed to be particularly valuable when used serially for time point studies, real-time monitoring of disease progression and treatment response, and post-treatment monitoring for recurrence. Caris Assure offers the biopharma industry the opportunity, for the first time, to incorporate complete WES and WTS interrogation at multiple timepoints throughout clinical trials in a non-invasive and easy-to-implement modality. This would enable biopharma companies to not only track changes in the mutation profile of a tumor in response to treatment, but also to assess changes in gene expression over time. Until now, different assays and analysis methods were required at different time points. Caris Assure offers biopharma companies the ability to use the same, consistent, and uniform assay across their full development program, allowing for more consistent, complete, and inter-comparable datasets across drug studies and time points. With Caris Assure, we believe biopharma companies would be able to generate more NGS data on individual clinical trial patients than has ever been possible using a blood-based assay in the history of cancer research and clinical trials.
MI Profile—Our Tissue-Based Profiling Solution
MI Profile is our tissue-based molecular profiling solution for cancer therapy selection, with over one million tests performed on approximately 146,500 clinical cases in 2024 and an additional approximately 40,000 clinical cases in the three months ended March 31, 2025. As of March 31, 2025, we have performed over 6.5 million tissue-based tests on over 790,000 clinical cases since inception. MI Profile includes our comprehensive WES/WTS NGS assay and IHC protein expression testing. Our tissue microdissection process has, to date, resulted in a high success rate in identifying actionable biomarkers in 95% of patients profiled. Eligibility of tissue samples for our MI Profile tissue profiling requires a presence of at least 20% tumor nuclei and at least 50 ng of DNA for MI Cancer Seek, and at least 25 ng for MI Tumor Seek Hybrid, and the sample must meet other requirements detailed in our requisition form used by ordering physicians. MI Cancer Seek requires formalin-fixed paraffin embedded tissue samples, but we can accept samples in different forms for MI Tumor Seek Hybrid as detailed in our requisition form.
The information generated from profiling the patient’s tissue is used to create an interpretative report based on our bioinformatics pipeline and recommend individualized therapies for cancer patients. Our goal is to maximize the information generated and corresponding clinical utility for patients from the limited available tumor tissue. The information generated, which further expands our multi-modal datasets, also provides valuable insights to aid drug discovery and development efforts. Customers for MI Profile include treating physicians as well as researchers and biopharma companies.
We have obtained Medicare and commercial reimbursement for MI Profile. MI Profile, including our MI Cancer Seek assay and our proprietary clinical molecular signatures GPSai and FOLFIRSTai are available in all U.S. states and in Puerto Rico. We also offer MI Profile internationally in over 40 countries through distributors and direct contracts with hospital systems, where permitted by applicable regulations.
We have obtained a PMA approval from the FDA for a companion diagnostic and tumor profiling designation for MI Cancer Seek, a WES/WTS NGS assay that uses the whole exome for TMB calling and for which we have obtained a Proprietary Laboratory Analyses (“PLA”) code, Current Procedural Terminology (“CPT”) code 0211U, at a reimbursement rate of $8,455. Our MI Cancer Seek solution was commercially launched in January 2025, and we currently market it as the WES/WTS NGS component of MI Profile. We have obtained Medicare coverage for MI Cancer Seek for CPT code 0211U under the NGS
 
169

TABLE OF CONTENTS
 
NCD. MI Tumor Seek Hybrid, which is a WES/WTS NGS LDT assay that we currently offer as an alternative assay in the event a specimen does not meet the requirements for MI Cancer Seek, is currently priced by MolDX at $3,500.
MI Profile Report
MI Profile generates a personalized report that provides oncologists with the information to tailor each patient’s treatment plan. The MI Profile report was built by oncologists for oncologists and is designed to maximize clinical utility in an easy-to interpret format. We generally report our results for tissue-based profiling approximately 10 calendar days from activation. A sample MI Profile report is depicted below.
[MISSING IMAGE: fc_miprofile-4c.jpg]
 
170

TABLE OF CONTENTS
 
Technical Specifications and Validation
MI Cancer Seek
The current WES/WTS NGS component of MI Profile is MI Cancer Seek, for which we have received FDA approval for use as a companion diagnostic device to identify cancer patients who may benefit from treatment with targeted therapies. The assay includes one pan-cancer and five tumor-specific indications for numerous FDA-approved therapies. To our knowledge, MI Cancer Seek is the first and only simultaneous WES and WTS-based assay with FDA-approved companion diagnostic indications for molecular profiling of solid tumors. MI Cancer Seek is available for adults and pediatric patients between the ages of one and 22.
MI Cancer Seek is a NGS-based in vitro diagnostic device using total nucleic acid isolated from formalin-fixed paraffin embedded tumor tissue specimens for the detection of SNVs, InDels, MSI, TMB in patients with previously diagnosed solid tumors, and CNA in one gene in patients with breast cancer. MI Cancer Seek is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table below, in accordance with the approved therapeutic product labeling.
[MISSING IMAGE: fc_companion-4c.jpg]
 
171

TABLE OF CONTENTS
 
[MISSING IMAGE: tb_micancer-4c.jpg]
As of March 31, 2025, MI Cancer Seek had 20 FDA-approved therapies and therapy combinations associated with its companion diagnostic indications.
Beyond the MI Cancer Seek FDA-approved indications, MI Cancer Seek reports additional sequencing-based features from DNA such as gLOH, HRD, HLA genotype, chromosomal alterations, viruses, and additional sequencing-based features from RNA such as gene expression, fusions, and variant transcripts.
 
172

TABLE OF CONTENTS
 
[MISSING IMAGE: tb_micancerseek-4c.jpg]
​
PPA and NPA are terms commonly used in the context of diagnostic tests and medical studies and are helpful for evaluating the performance of diagnostic tests:
•
PPA stands for Positive Percent Agreement. Similar to NPA, it is a measure of the agreement between a test’s positive results and the true positive status as determined by a reference standard. It reflects the test’s ability to correctly identify positive results.
​
•
NPA stands for Negative Percent Agreement. It is a measure of the agreement between a test’s negative results and the true negative status as determined by a reference standard. It reflects the test’s ability to correctly identify negative results.
​
MI Tumor Seek Hybrid
Our legacy MI Tumor Seek Hybrid profiling solution combines WES analysis of DNA for mutations, CNAs, INDELs, and genomic signatures (TMB, MSI, gLOH, and HRD) with WTS analysis for RNA fusions and variant transcripts. We have also analytically validated MI Tumor Seek Hybrid for viral detection and report HPV, MCV, and EBV presence from the WES data in the appropriate tumor context. MI Tumor Seek Hybrid achieves accurate results through high coverage depths for DNA and RNA sequencing. MI Tumor Seek Hybrid consistently reaches 1,500 times depth of coverage for clinically relevant DNA genes and 300 times depth of coverage for the whole exome. Our WTS technology allows for fusion detection, variant transcript analysis, and gene expression profiling.
AI Signatures
Our WES/WTS profiling solutions generate over 28.8 billion datapoints, spanning 84,000 molecular markers, per clinical case. To interpret this data, MI Profile utilizes an advanced, AI-powered bioinformatics pipeline. This bioinformatics pipeline includes a sophisticated rules engine, variant calling, fusion calling, copy number prediction, and expression analysis. We use over 220 AI algorithms in connection with the
 
173

TABLE OF CONTENTS
 
bioinformatic pipeline of our tissue-based sequencing. These AI algorithms assist in sample processing, quality control, biological processing, and biological interpretation. Collectively, these AI algorithms generate data on 84,000 molecular markers for each WES/WTS run.
MI Profile can also include our proprietary clinical molecular signatures, GPSai and FOLFIRSTai, which were developed by training and clinically validating AI/ML algorithms with our extensive multi-modal clinico-genomic datasets. These molecular signatures, which we currently offer as LDTs, provide clinical utility for molecular diagnosis of cancer and prediction of patient response to treatment.
•
GPSai.   Our GPSai signature is a molecular disease classifier that utilizes multiple deep neural networks and hundreds of thousands of molecular features to predict a histologic diagnosis and tumor origin directly from the DNA and RNA sequencing data. The result is a probability of the most likely diagnosis, which is then reviewed by a Caris Board-Certified Pathologist in the context of all available clinicopathologic information before report release. The primary indication for GPSai is to determine if the initial diagnosis is correct and serves as a quality control for all patients. In addition, it can be used to help identify the tissue of origin for Cancers of Unknown Primary (“CUP”), cases where the starting point of the cancer is not yet clear, which is a major unmet need in clinical oncology. This tissue of origin prediction is provided along with the comprehensive biomarker data without the need for additional specimen utilization; this tool runs on the MI Profile exome and transcriptome sequencing results. GPSai is also utilized as a quality control metric where it is run on every clinical case and the results reviewed by a pathologist. If the GPSai results do not match the outside pathologic diagnosis of the specimen, our pathologists will do additional work-up, including IHC testing, to support a new diagnosis to provide the best overall service and patient care.
​
GPSai was trained and clinically validated by us through retrospective profiling data from over 250,000 clinical cases using the outside pathologist diagnosis as the baseline. In a prospectively run clinical validation study that we conducted, GPSai demonstrated overall accuracy of 94.8% and an overall call rate of 95.1%. This clinical validation of GPSai enabled us to offer the solution as an LDT in accordance with the Clinical Laboratory Improvement Amendments of 1988’s (“CLIA”) requirement of clinical validation of a variety of performance characteristics, including accuracy, precision, specificity, sensitivity, reportable range, and reference interval before an LDT is used in clinical testing.
•
FOLFIRSTai.   Our FOLFIRSTai signature is our first clinically validated, AI-powered molecular predictor of efficacy of oxaliplatin-based chemotherapy combined with bevacizumab in patients with metastatic colorectal cancer (“mCRC”). According to estimates by the ACS, one in 23 men and one in 25 women in the United States will be diagnosed with colorectal cancer in their lifetime. FOLFOX, FOLFIRI, or FOLFOXIRI chemotherapy with bevacizumab is considered standard first-line treatment option for patients with mCRC. Some mCRC patients benefit from one combination chemotherapy regimen over the others, and identifying which patients would benefit from which regimen is a challenge for physicians. FOLFIRSTai is included for all clinical cases with completed WES results and a diagnosis of advanced stage colorectal adenocarcinoma. The FOLFIRSTai results appear in the MI Profile report as “Increased Benefit” or “Decreased Benefit” with additional detail provided about the results in the report. FOLFIRSTai is broadly accessible to patients and is covered by almost all insurance companies.
​
We clinically validated FOLFIRSTai using a real-world evidence dataset collected from the Caris POA registry, insurance claims data and samples from the TRIBE2 Phase 3 clinical trial, which compared first-line use of FOLFOXIRI and FOLFOX. In a clinical validation study that we conducted, FOLFIRSTai demonstrated that the overall survival of patients treated in a manner consistent with the FOLFIRSTai prediction was 17.5 months longer than the overall survival of patients treated counter to the prediction (representing a 71% difference). This clinical validation of FOLFIRSTai enabled us to offer the solution as an LDT in accordance with CLIA’s requirement of analytical validation of a variety of performance characteristics, including
 
174

TABLE OF CONTENTS
 
accuracy, precision, specificity, sensitivity, reportable range, and reference interval before an LDT is used in clinical testing.
​ ​
Case Study: The Power of Caris’ AI Signatures to Inform Diagnosis and Treatment
​ ​
​ ​
         Caris was presented with the case of a female patient in her early 50’s with bilateral adnexal masses (growth occurring in or near the uterus, ovaries, fallopian tubes and connecting tissues), the largest of which measured 22 cm in greatest dimension. The patient’s pathological diagnosis was ovarian adenocarcinoma based on a morphological examination under a microscope. The patient underwent total abdominal hysterectomy (surgical removal of the uterus), bilateral salpingo-oophorectomy (removal of both ovaries and fallopian tubes) with pelvic debulking of tumor (removal of as much cancerous tissue in the abdomen as possible).
​ ​
​ ​
         A representative post-surgery tissue specimen of the patient’s right adnexal lesion was sent to Caris, to help her oncologist decide the best options for therapy. Based on the patient’s comprehensive sequencing results using WES and WTS, a GPSai™ score was generated highly suggesting the colon as the malignant tissue of origin, as shown in the excerpt below:
​ ​
​ ​
[MISSING IMAGE: ph_cancercate-4c.jpg]
​ ​
​ ​
         To help further validate the GPSai™ finding, a panel of diagnostic IHCs (protein analysis) was performed that showed the tumor to be positive for colon-specific protein expression further pointing toward a diagnosis of colorectal cancer.
​ ​
​ ​
         As a result of these findings, the patient underwent colonoscopy that showed large nearly obstructive colonic lesion. This case was reviewed at the hospital tumor board and there was consensus that this patient would be best managed as metastatic colonic adenocarcinoma. As a result of the Caris GPSai™ finding, the patient’s diagnosis and course of treatment was altered based on a detailed discussion of the results with the ordering physician. Caris also provided the FOLFIRSTai result for therapy sequencing and, through NGS, generated a targeted therapy recommendation for the treating physician.
​ ​
​ ​
         This was an example of a use of Caris’ collective sequencing and proprietary AI signatures to help a patient obtain a targeted therapy recommendation and avoid the potential cost, time and side effects of ineffective therapy.
​ ​
QuantumAI Report
We also use the in-depth sequencing data generated by MI Profile to produce the QuantumAI report, a research use only description of the patient’s molecular tumor biology and characterization of their phenotype using whole exome and whole transcriptome sequencing. The QuantumAI report, which we have analytically validated but not yet clinically validated, contains various biological signatures such as DNA variants counted towards TMB across the whole exome, the Catalogue of Somatic Mutations in Cancer (COSMIC) signatures resulting from a subset of TMB variants, genomic loss of heterozygosity, genomic scar score, and copy number alterations at the chromosome band level as well as exon-level copy number alterations on over 700 genes. An enhanced eKaryotype shows copy number alterations per chromosomal band along with associated confidence intervals to highlight areas of strong or likely amplifications and deletions. RNA gene expression signatures include consensus molecular subtypes (colorectal cancer), PAM50 (breast), and purIST (pancreatic). The report also includes measurements of tumor infiltrating lymphocytes and RNA heatmap expression for hundreds of genes relative to nearly 90 distinct cancer types. An additional RNA component is a circos diagram representing all RNA fusions observed across the whole transcriptome, to help oncologists and researchers understand relationships between genetic variations, mutations, and other molecular features and to help tailor precision medicine approaches. The report also
 
175

TABLE OF CONTENTS
 
features MGMTai, an AI signature that uses both DNA and RNA features to predict response to temozolomide in glioblastoma. Anticipated future additions to the report include pancreatic, lung, and breast cancer drug therapy response predictors using AI signatures, a brain metastasis predictor using AI signatures, an image of the H&E stain used for sequencing, raw depth of coverage per genes/exons, gene expression interpretation and genetic predispositions.
IHC Testing
We leverage a broad menu of third-party IHC tests to create a customized set of tests for each patient to reveal a more complete molecular blueprint of the patient’s disease. We use IHC testing to complement our WES/WTS profiling both to inform decisions regarding therapy selection as well as to act as confirmatory testing in circumstances where our GPSai algorithm indicates a different diagnosis than that indicated in the patient record prior to our profiling or in CUP cases. We believe we have one of the broadest IHC testing menus available to patients and physicians to provide the most appropriate therapy results and diagnosis.
Testing patient specimens for protein-based biomarkers by IHC is the standard of care for both predictive and diagnostic purposes. For predictive IHCs, we run third-party companion diagnostic IHCs when available to provide therapy associations that cannot be identified through NGS testing. For example, checkpoint inhibitor therapies require IHC testing for PD-L1. We also utilize a number of third-party diagnostic IHCs to help with refining or changing a diagnosis. Most samples come to us for molecular profiling with a diagnosis in hand. However, WES and WTS provide a broad and deep data set that can help alter or refine a diagnosis. In some cases, we receive patient sample labeled as ‘Cancer of Unknown Primary,’ where it is hoped that molecular profiling will allow a more specific diagnosis to be applied. Once we evaluate the molecular data, including the results of GPSai if applicable, our pathology team will often order diagnostic IHC testing to provide additional support for a specific diagnosis.
​ ​
Case Study: Caris GPSai™ Helps Diagnose Origin of Metastatic Malignancy
​ ​
​ ​
         A woman in her early 30’s presented to her primary care physician with symptoms of abdominal distension and gastrointestinal discomfort. Imaging revealed widespread metastatic disease, including pleural effusions (excess fluid in the space between the lungs and the chest wall), pulmonary nodules (small growths in the lung), and extensive lymphadenopathy (swelling of the lymph nodes). A biopsy of a soft tissue mass in the right abdominal wall was preliminarily thought to represent carcinoma.
​ ​
​ ​
         IHC testing showed certain positive and negative markers that together led to a diagnosis by the patient’s physician of metastatic CUP. Seeking further clarity, the patient’s tissue sample was sent to Caris for molecular profiling and GPSai™ analysis.
​ ​
​ ​
         The GPSai™ result returned with a 99% probability of mesothelioma, suggesting the cancer originated from mesothelial cells, such as those lining the lungs and abdomen, rather than being a metastatic adenocarcinoma from another primary site.
​ ​
​ ​
         The integration of Caris GPSai™ into the patient’s care pathway facilitated a more precise understanding of her tumor’s origin and molecular characteristics, guiding personalized treatment decisions tailored specifically to mesothelioma. By pinpointing the precise nature of the cancer, Caris GPSai™ enabled a more targeted and effective approach to treatment, with the goal of ultimately optimizing treatment and outcomes.
​ ​
MI Profile for Biopharma
Maximizing knowledge and extracting the most information out of every patient sample on a clinical trial reduces the risk of researchers missing potential efficacy or safety signals. Sequencing the whole exome and the whole transcriptome not only yields far more biomarker data from limited specimens, but also allows for the power of such comprehensive information to be aggregated and deployed to improve patient outcomes in the future via real-world data analyses. The breadth and depth of data make our methodology fundamentally different from the currently available DNA panels, which are limited by only looking at known biomarkers. We believe that a non-comprehensive, subset panel of genes or DNA-only assay that ignores RNA is an inadequate solution for efficient and successful drug development, and represents
 
176

TABLE OF CONTENTS
 
the central underpinning for why we believe we are uniquely positioned in the marketplace to be the industry leading innovator and strategic partner of choice for biopharma companies, to jointly bring forward the next generation of novel therapies for patients with cancer. Oncology therapeutics are inevitably shifting from single driver alterations with single biomarkers to more sophisticated and complex biomarkers that can stratify patients such as novel signatures for DNA damage response repair targeting molecules and RNA-based expression for immunotherapies. Our comprehensive WES/WTS NGS assay is optimally positioned to seamlessly validate these novel biomarkers that are already included in our assay.
Molecular profiling has broad applications for our biopharma partners, including prospective screening, retrospective testing and deep translational analyses, stratification of patients for existing or future trials, and treatment monitoring. When our tissue WES/WTS assay is deployed as an integrated component of early development programs and clinical trials, that same assay can be leveraged for companion diagnostics development and commercial services that we deliver for our partners. Commitment to Caris as registration partner allows early regulatory interactions while minimizing pharma sponsor costs, maintaining flexibility to changing timelines and evolving biomarker strategies. We have obtained a PMA approval from the FDA for MI Cancer Seek as a companion diagnostic device, and we believe approval by the FDA will serve as another important inflection point for our biopharma business. Furthermore, the comprehensiveness of our WES/WTS approach creates a deep competitive moat for us.
In addition to testing of both DNA and RNA, we offer companion diagnostic partners opportunities to use samples sourced from our vast biobank of clinical specimens. This offers partners access to a large selection of fully characterized specimens of known positive and negative biomarker status. This can alleviate one of the most difficult hurdles of companion diagnostic development, namely access to enough biomarker-positive specimens across the minimum number of cancer types required to conduct FDA validation studies. For companion diagnostic projects involving a biomarker with low incidence, we offer partners a significant advantage. Beyond companion diagnostics, our biobank carries significant value for exploratory translational studies. When novel discoveries are made in silico, or based on DNA or RNA, the path to validate these findings requires tissue for proteomic assessments or targets or biomarkers. Having any tissue is valuable however, our tissue biobank is unique because of the scale due to the number of cases and tests we have completed to date, the heterogeneity of tissue types which reflects cancer prevalence, and most importantly because of the amount of WES and WTS information we have generated. In aggregate, our biobank with accompanying data and digital images provides biopharma companies with a unique and highly valuable set of research tools to help validate and derisk the next wave of oncology therapeutics.
Caris ChromoSeq
Through an exclusive license arrangement with Washington University in St. Louis (“WashU”) that we entered into in October 2024, we are developing Caris ChromoSeq, an assay that detects and analyzes hematological (blood) cancers using whole genome sequencing (“WGS”) and WTS for commercial launch. We are internally validating this assay, which is based upon the licensed assay and also includes our WTS technology, and developing it for commercial launch subject to successful validation and a successful application for reimbursement from MolDX. If successful, we believe this assay designed for genomic evaluation of patients with blood cancers would serve as a valuable complement to our existing tissue and liquid assay solutions, which are oriented towards identifying and profiling cancers of solid tumor origin, and enhance our position as a provider of choice for molecular profiling solutions. If we determine to commercialize this assay, we anticipate initially doing so as an LDT.
The licensed assay is a high coverage WGS assay currently designed and initially validated for the comprehensive genomic evaluation of patients diagnosed with acute myeloid leukemia (“AML”) or myelodysplastic syndromes (“MDS”). The licensed assay requires only 50 ng of tumor DNA (blood or bone marrow) for sequencing and is designed to identify over 600 clinically relevant chromosomal rearrangements known to be recurrent in myeloid malignancies. The licensed assay is an alternative to existing conventional diagnostic and risk assessment tools for AML and MDS, which are primarily cytogenic testing (karyotyping, or visual analysis of chromosomes), fluorescence in situ hybridization (“FISH”), or sequencing assays targeting specific genes or RNA transcripts, each of which conventional methods may provide incomplete information, have limited sensitivity, or present challenges in obtaining viable samples for testing. In a study published by WashU in 2021, the licensed assay was used to obtain genomic profiles for
 
177

TABLE OF CONTENTS
 
263 patients with myeloid cancers, including a 146 patient retrospective cohort and a 117 patient prospective cohort. Overall, the licensed assay identified 100% of the clinically significant abnormalities that had been identified by conventional cytogenic analysis and identified new clinically reportable genetic information not detected by conventional methods in 17% of the patients tested. Additionally, for 19 of the 117 patients in the prospective cohort (16%), analysis performed by the licensed assay changed their risk categorization on the basis of standard risk categories promulgated by the European Leukemia Network and the International Prognostic Scoring System—Revised. The licensed assay displayed similar performance as conventional cytogenetic analysis when predicting clinical outcomes using existing genetic risk groups (adjusted p=0.09 by log-rank test in groups identified by conventional testing; adjusted p=0.01 by log-rank test in groups identified by the licensed assay). The licensed assay was also found to stratify patients who had inconclusive results by cytogenetic analysis into risk groups in which clinical outcomes were measurably different (adjusted p=0.03 by log-rank test).
WashU has obtained Medicare coverage for patients diagnosed with AML and MDS. We believe the methods used by the licensed assay, to be modified by us, can be applied to, and we are working to expand and validate the assay’s capabilities for, hematological cancers beyond AML and MDS. In order to obtain MolDX coverage for Caris ChromoSeq, we will need to submit, and MolDX will need to approve, a technical assessment for Caris ChromoSeq.
Caris Discovery
Caris Discovery is our drug target and therapeutic discovery business. Caris Discovery leverages our profiling solutions, multi-modal clinico-genomic datasets, wet lab facilities, proprietary Adaptive Dynamic Artificial Polyligand Targeting (“ADAPT”) platform, and AI/ML-enabled in silico analyses to identify potential drug targets and develop therapeutics. We launched Caris Discovery in 2022 to partner with biopharma partners to address the lack of novel cancer-specific targets and the herding of biopharma pipelines around a discrete number of lower-risk targets. Caris Discovery is disease- and modality-agnostic and can be applied to any therapeutic modality, including antibody-directed therapies (such as antibody drug conjugates, degrader-antibody conjugates, and T-cell engagers), small molecules, targeted protein degradation, synthetic lethal interactions, cell therapy, and neoantigen discovery for personalized therapy development, among others. In addition to working with biopharma partners, Caris Discovery is developing a wholly-owned pipeline of biologics based on our platform.
An antibody-drug conjugate is a targeted cancer therapy that combines an antibody with a cytotoxic drug. The antibody specifically targets cancer cells, delivering the drug directly to them, which helps minimize the impact on healthy cells. This approach aims to increase the effectiveness of the drug while reducing side effects.
Degrader-antibody conjugates (“DACs”) are an emerging class of therapeutic agents that combine the targeting ability of antibodies with the protein degradation mechanism of degraders. DACs are designed to bind to specific proteins on the surface of cancer cells through the antibody component and then recruit the cell’s degradation machinery to eliminate the target protein inside the cell. This dual action allows for precise targeting and removal of disease-causing proteins, potentially leading to more effective treatments with fewer side effects.
T-cell engagers are a class of artificial engagers that are designed to specifically direct the body’s immune system to target cancer cells. They function by simultaneously binding to CD3 on T cells and to a specific antigen on the tumor cell, thereby bringing the T cells into close proximity with the tumor cells, which can result in the T cells attacking and killing the tumor cells.
A small molecule refers to a low molecular weight organic compound that can regulate a biological process, with a size on the order of 1 nm. In the pharmaceutical industry, small molecules can include drugs that can be orally or intravenously administered and are often used to regulate biological processes. The term contrasts with larger molecules, such as biologics.
Targeted protein degradation is a therapeutic strategy that aims to eliminate disease-causing proteins from cells. It involves the use of small molecules, known as proteolysis-targeting chimeras, or
 
178

TABLE OF CONTENTS
 
molecular glues, that can bind to specific proteins and tag them for destruction by the cell. This approach is particularly useful for targeting proteins that are difficult to inhibit with traditional drugs or for which no inhibitors exist.
Synthetic lethal interactions in drug discovery refer to a relationship between two genes where the loss of function of either gene alone is survivable by the cell, but the simultaneous loss of both is lethal. This concept is utilized in drug discovery to target cancer cells with specific genetic mutations. By inhibiting the function of a gene that is synthetically lethal to a mutated gene already present in the cancer cell, the cell can be selectively killed without harming normal cells.
Cell therapy is a form of treatment where living cells are injected into a patient to help cure a disease. In the context of cancer treatment, cell therapy can involve the use of immune cells that are either taken from the patient or from a donor, modified in a lab to enhance their ability to fight cancer, and then injected back into the patient. This approach is part of a broader category known as immunotherapy, which aims to harness the body’s immune system to combat cancer.
In addition, we believe Caris Discovery can be leveraged to discover personalized therapies for cancer. A major paradigm-shift in cancer therapy in recent years has focused on harnessing the immune system’s ability to recognize and eliminate cancer cells. One promising approach involves using personalized therapies to stimulate the immune system against tumor-specific antigens also known as neoantigens. Those neoantigens are proteins that are produced by mutations in the DNA of cancer cells and are not present in normal cells. We believe Caris Discovery is well-positioned to be able to discover personalized neoantigens for cancer therapies given our ability to detect variants and INDELs by WES and to assess gene expression and detect fusions by WTS on every patient’s tumor. We also leverage our deep proteomics expertise utilizing mass spectrometry to validate neoantigens using our biorepository of contemporaneous molecular profiled remnant patient tissue that can be predicted by deep ML from our Caris Assure blood and MI Profile tissue sequencing. Furthermore, we can predict who may or may not respond to personalized therapies and who should be excluded from personalized therapy trials due to defects in antigen presentation machinery, such as loss of major histocompatibility complex genes due to mutations or downregulation. We are working with multiple partners that have a personalized therapy in clinical development or clinical trials.
 
179

TABLE OF CONTENTS
 
Our proprietary repositories of tissue and data, each of which we believe to be at an unmatched scale, are a resource that could not have been amassed without our underlying commercial profiling business, and as such are a significant differentiator and enabler of our discovery efforts.
[MISSING IMAGE: fc_discovery-4c.jpg]
We have achieved external validation of our Caris Discovery approach through strategic partnerships with established biopharma companies, such as Merck KGaA and Xencor, to develop therapeutics against novel targets that emanate from our molecular insights and proprietary technology. Our Caris Discovery partnerships are designed to emphasize both near term revenue and the potential upside of successful therapeutics developed against novel targets identified by us, thus aligning our partners’ financial interests with our own. Our proprietary discovery proteomics and downstream target validation work is performed, by over 50 Caris scientists, in our R&D laboratory in Tempe, Arizona, a 59,000 square foot facility that includes a cell culture laboratory and state-of the-art instrumentation dedicated to drug target discovery.
In Silico Target Discovery Leveraging the Caris Clinico-genomic Dataset
Caris Discovery leverages our multi-modal clinico-genomic datasets to define clinically relevant cohorts of unmet need for drug target discovery. Stratifying cases by molecular profile, histology, and/or clinical features in silico prior to performing our proprietary proteomic work on the profiled cases in our tissue repository is extremely powerful to identify drug targets in highly relevant therapeutic areas. Once potential targets are identified, the clinico-genomic data can be integrated with our proteomics data and can be utilized to filter the initial target pool down to the targets with the highest potential value for further downstream wet-lab validation.
The proteomics work leveraging our in silico discovery work is driven by three complimentary components: (1) our ADAPT Biotargeting, (2) Proximity Labeling, and (3) the Caris Surfacesome.
•
ADAPT Biotargeting—Aptamer-Based Proteomics Discovery System.   Our ADAPT system uses a broad library of synthetically manufactured molecules called aptamers that bind to a wide range of biological targets and characterize complex biological systems, enabling the profiling
​
 
180

TABLE OF CONTENTS
 
of biological samples at a systems-wide scale coupled with affinity purification-mass spectrometry to identify the underlying target proteins. ADAPT is able to simultaneously measure millions of molecular interactions within complex biological systems in their natural states and directly from patient tissue. ADAPT is powered by real world contemporaneous patient samples, including our combined clinico-genomic datasets, thus overcoming the limitations of traditional target discovery approaches, such as comparative genetics, molecular pharmacology of variants, analysis of molecular signaling pathways, cell-based and in vivo disease models, limited panel based proteomics with a defined set of target proteins and traditional proteomics, which result in a high degree of off-target activity, false positives and bias, and lack enrichment of patient enriched cancer proteins. ADAPT allows us to make unbiased identification of unique features of disease state and allows for elucidation of novel biological mechanisms. Actionable drug targets (or molecular markers) include proteins that are present in diseased tissue but low to no detection in normal tissue. Traditional biomarker discovery tools suffer from a signal to noise challenge and require a hypothesis of where to look before being deployed. ADAPT can filter out features shared by both cancer and normal cells and enriches for features specific to cancer cells.
•
Proximity Labeling—Antibody-based Proteomics Discovery System.   We also apply proximity labeling on molecularly profiled remnant patient tissue to examine protein-protein interactions as well as to identify components that localize to discrete subcellular compartments. This approach enables us to identify actionable drug targets in patient tissue and permits the systemic analysis of spatially restricted proteomes. Applying proximity labeling on our proprietary tissue profiling data has resulted in the discovery of numerous novel drug targets potentially actionable for bispecific antibodies, dual targeting antibody modalities, and cell therapies.
​
•
Caris Surfacesome.   Cell-surface proteins are key to antibody-based therapeutics, and we have developed our own cell surfacesome comprising a database of cell surface proteins detected by mass spectrometry. This in-house database comprises genomic, transcriptomic, and proteomic data for multi-omic data analysis in addition to prepared cytosections and live cells instrumental for antibody quality control and wet-lab validation of drug targets discovered from our Aptamer and Antibody-based discovery systems.
​
Caris Strategic Data
Data and molecular information are at the core of every aspect of our business. Our team of more than 60 data scientists deploy our proprietary advanced AI/ML algorithms to decipher unique features from our resulting clinico-genomic datasets, helping us decode and further unravel the molecular complexity of disease. Our 17-year history of utilizing AI and ML algorithms, together with the breadth and depth of our clinico-genomic datasets, provide us a significant advantage in sophisticated analysis of cancer, and a foundation that we believe will have applications in additional disease states.
As of March 31, 2025, we have run more than 6.5 million tests that have measured over 38 billion molecular markers from over 13 quadrillion datapoints. To assist us with analyzing the data we generate, we utilize over 220 AI and AI/ML tools across our clinical testing, R&D, and biopharma business. These tools include over 50 clinical sequencing automation and variant calling AIs, over 100 RNA expression AI signatures, approximately 20 multi-omic AI/ML therapy response predictors, two ADAPT target discovery AI/ML algorithms, 37 digital image AI/ML classifiers, and 12 AI/ML support tools. This tremendous amount of data, which we have deidentified for research use, provides us a differentiated capability to advance precision oncology research through many business models, including training new profiling solutions and signature development, therapy development, and research into new ways to treat and cure disease, including personalized treatments.
Our goal is to develop the next generation of precision medicine tools that will allow us to transition from intuitive medicine to empirical medicine. As a leader in the transition to WES/WTS sequencing through our launch of a WTS solution in 2019 and a WES solution the following year, we believe we have more molecular data and information than any other company and are well-positioned to make precision medicine widely accessible.
 
181

TABLE OF CONTENTS
 
The Power of Big Data
With a dataset as large as ours, a key task is to reduce the dimensionality of data to those key features that are useful to understanding the systems biology while avoiding any preconceived bias in how we might expect the features to be related. We accomplish this through mathematical embedding, which we use to reduce the dimensionality of the datasets to provide powerful insights into the underlying relationships within the data. This massive amount of information, across the whole transcriptome and multiplied across hundreds of thousands of patients, then undergoes a process where features that tend to occur together more often (or clusters) are associated into a multidimensional vector space.
One example of this methodology, and how additional data drives better predictions, can be seen in the pictures below, which show the clustering of a single gene set enrichment analysis (GSEA) across increasingly large datasets, from our research into a predictive algorithm for brain metastasis. This clustering, which reflects screening through AI to reduce dimensionality and identify underlying clusters, shows that meaningful clustering groups can only be seen with larger amounts of data. The clusters become increasingly visible as the datasets grow from 1,000 to 200,000 cases.
[MISSING IMAGE: ph_powerofbigdata-4c.jpg]
In this study, once we identified the relevant clusters, we then used the coordinates of the clusters as inputs into a separate AI/ML model that would predict the likely outcome—in this case, whether a patient was more or less likely to develop a brain metastasis.
Our in-depth profiling of patient samples has led to the creation of what we believe to be one of the largest and most comprehensive multi-modal clinico-genomic datasets in oncology based on the more than 6.5 million tests we have run on over 849,000 cases, which have generated measurements of over 38 billion molecular markers. Leveraging high-powered computing and AI/ML algorithms, we, and our biopharma and research partners who use our data and bioinformatics services, analyze our datasets to determine the key molecular characteristics of a particular disease or dysfunction that drives disease, enabling signature identification and drug target discovery. We believe this wealth of data and processing power, together with whole-slide imaging, our tissue and slide repository, can help our researchers and external partners gain previously unattainable insights about specific patient populations.
A study that we recently published in Nature Communications, a peer-reviewed scientific journal, demonstrated the power of our real-world clinical and genomic dataset, augmented through agreements with external providers of clinical outcomes data, to drive clinical insights. This study evaluated real-world outcomes for patients eligible for available tissue-agnostic therapies, which are powerful “pan-cancer” therapies that target specific molecular alterations across multiple cancer types and of which several have FDA approval. The study, using the largest real-world clinical and genomic dataset of tissue-agnostic indications reported to date across more than 295,000 de-identified patients and over 50 tumor types, demonstrated that over 20% of cancer patients are candidates for a tissue-agnostic therapies based on current FDA-approved indications. Additionally, the study found that over 5% of patients lacking any tumor-specific indication were found to carry a tissue-agnostic indication and thus to be candidates for a tissue-agnostic therapy. The study also generated insights into the different outcomes produced by tissue-agnostic therapies in different tissues. We believe the datasets built by our profiling solutions help enable further development of clinical insights with therapeutic and economic implications.
This study was conducted in 2024 by our researchers using data from all patients who had undergone comprehensive tissue sequencing at our Phoenix tissue laboratory between 2015 and 2023, who had successful
 
182

TABLE OF CONTENTS
 
sequencing results, and for whom claims data was available. The study primarily measured time-on-treatment (“TOT”), determined as the interval from the initiation to the conclusion of treatment with an indicated therapy, and overall survival (“OS”), defined as the period from treatment initiation to the date of the patient’s last known clinical activity. Kaplan-Meier survival estimates were generated for patient cohorts defined by molecular characteristics. Significant p-values (generally p < .05) were seen for the following major analyses of highly clinically relevant indications: (a) poor clinical uptake of therapies targeting NTRK gene fusions, which are rare but potent drivers of tumor growth that promote cancer cell survival and proliferations; (b) differences in tissue specific outcomes in TMB-high and MSI-high settings, as well as in BRAF V600E-mutant cancers; and (c) differences in TOT and OS outcomes for non-trial patients receiving pembrolizumab and similar TOT benefit of pembrolizumab and nivolumab, two widely-used PD-1 inhibitor therapies, for patients with TMB-high tumors across various cancer types. Collectively, these analyses test the assumption that FDA-approved tissue-agnostic therapies are truly tissue-agnostic in the sense of having similar benefits across all tumor types, and demonstrate the power of large real-world datasets combining clinical data with NGS data, such as the comprehensive data generated by our solutions, to further the medical community’s understanding of cancer.
Data for Biopharma
We launched our data licensing business in late 2022. We license deidentified multi-modal datasets, components of which were generated from our clinical profiling business to external researchers, including those with biopharma companies, with the aim of generating insights directly responsible for superior clinical outcomes for patients. As the adoption of our tissue and blood-based profiling solutions continue to grow, this will result in further expansion of our multi-modal datasets, which can provide additional valuable insights to aid biopharma companies’ drug discovery and development efforts to bring innovative therapies to market. We utilize a third-party tokenization process to match deidentified data from various sources to create the multi-modal product. The linked data is then provided to the external researcher. Prior to the tokenization process, we run a series of software solutions through standardized data fields designed to remove and replace any PHI with a randomly-generated string of letters and numbers. We then use a third-party expert to certify that the data is deidentified pursuant to 45 CFR §164.514(b)(1) under HIPAA. We contractually require recipients of the data to maintain compliance with laws and regulations. The end customer takes on the contractual responsibility to properly maintain the data, not to attempt to reidentify any patient from the deidentified data set, and to obtain its own expert certification before combining the Caris data with any other data.
To further broaden the applicability and usefulness of our multi-modal datasets for biopharma companies, we have entered into agreements with clinical data partners, such as ConcertAI, Flatiron and COTA, to enable the creation of matched clinico-genomic datasets that can be licensed to biopharma companies for their use in drug discovery. These datasets generally consist of Caris molecular profiling data (and in some cases claims data), together with matched clinical data from our partners. We and our partners have entered into agreements with AbbVie, Moderna, and others to license our datasets for use in drug discovery. Together, our combined multi-modal data create a differentiated capability to advance precision oncology research through novel target identification and discovery, translational sciences, clinical trial design solutions and patient enrollment facilitated by our right-in-time trials network, post-market label expansion, and commercialization insights.
We have a rich pipeline of data opportunities that we believe will deliver new partnerships, as we continue to introduce biopharma companies to this unique data offering. In addition, many of our biopharma-related data initiatives and data partnerships allow for the flow of multi-modal data to our internal research teams, providing further synergies and enabling AI/ML powered research across the broader Caris enterprise.
Data for Clinical Research: The Caris Precision Oncology Alliance
We established the Caris POA in 2015. The Caris POA is a growing network of leading cancer centers and research consortia across the globe that supports research partner engagement, collaboration opportunities, and the advancement of precision oncology research. It consists of members that demonstrate a commitment to precision medicine and work collaboratively toward a common goal: to advance tumor
 
183

TABLE OF CONTENTS
 
profiling and establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients.
As of March 31, 2025, the Caris POA was comprised of 96 members. This represents a five-fold growth in total membership since 2017. Additionally, since 2020, we have more than doubled the number of NCI-designated comprehensive cancer centers in the Caris POA, from 20 in 2020 to 45 as of March 31, 2025.
[MISSING IMAGE: bc_carispoanet-4c.jpg]
We estimate that the members of the Caris POA have over 3,000 oncologists in over 650 locations that treat more than 650,000 new cancer patients annually. Members participate in the various activities of the Caris POA through the following:
•
profiling cancer patients using our comprehensive profiling solutions;
​
•
establishing guidelines to integrate molecular testing into cancer care and patient treatment management;
​
•
participating in research studies and clinical trials, both prospective and retrospective;
​
•
collaborating in molecular tumor boards to advance the institution and industry’s understanding of cancer and the clinical utility of profiling in clinical care;
​
•
tracking longitudinal outcomes and contribute data to the Caris POA; and
​
•
publishing novel research and clinical data.
​
As part of the Caris POA collaboration, we contribute de-identified molecular data obtained from tumor profiling of cancer patient samples, and our partners have an opportunity to contribute outcome or clinical data for use in joint research projects. Physicians and researchers across the Caris POA network are provided with information from our datasets as part of our mission to give greater access to and disseminate
 
184

TABLE OF CONTENTS
 
this data in furtherance of creating solutions for oncology. Caris POA members access our datasets through CODEai, a custom interface for our multi-modal clinico-genomic datasets that we launched in 2020. CODEai allows users to explore a cohort of over 295,000 matched datasets and clinical outcomes. CODEai users can define patient cohorts of interest and direct the underlying AI to mine the data, extract cogent information such as molecular markers that correlate with defined patient cohorts, and perform various analyses. Working with leading oncologists at Caris POA member sites, we have established a number of tumor-specific working groups comprised of key academic thought leaders and subject matter expertise to assist us in ensuring our profiling components remain clinically up-to-date with the latest important molecular markers and testing threshold criteria.
[MISSING IMAGE: lg_datacliniclogo-4c.jpg]
We also contribute to academic research to advance the understanding of molecular science and further enable the delivery of precision medicines through our collaborations with member institutions within the Caris POA. We routinely collaborate with leading cancer centers to publish and present new learnings with immediate implications on the clinical use and utility of comprehensive molecular profiling.
 
185

TABLE OF CONTENTS
 
Together with collaborators, our medical and scientific experts have authored over 380 manuscripts in peer-reviewed medical and scientific journals, and more than 660 abstracts, posters and presentations at leading industry conferences and symposiums that expound on our innovative platforms and technologies.
[MISSING IMAGE: bc_publications-4c.jpg]
Data Driving Development of New Clinical Solutions
A significant benefit of generating WES and WTS results for every eligible patient is that the resulting dataset becomes a unique and proprietary resource to fuel the development of new molecular-driven signatures, products, and profiling solution enhancements that are only possible due to the availability of large datasets. Our datasets have also been augmented through agreements with external data providers. We have leveraged our vast datasets to drive the development of AI-based signatures and other enhancements, including our ABCDai algorithm and hundreds of other AI algorithms that are used in our bioinformatics pipelines for our profiling solutions. These solutions are designed to allow us to better leverage our data to improve patient outcomes and significantly differentiate us from our competitors.
We plan to utilize our datasets and molecular profiling knowledge to continue to create proprietary molecular signatures that leverage NGS-based testing results and to utilize digital scans of tissue slides to predict the presence of certain molecular markers without the need for NGS profiling. In addition, we plan to establish patient-level prognosis and prediction of therapeutic benefit, with an initial focus on breast cancer, but that we believe will have therapeutic benefits across all cancer types.
 
186

TABLE OF CONTENTS
 
[MISSING IMAGE: tb_molecular-4c.jpg]
Caris Proprietary Molecular AI/ML Driven Signatures
We plan to utilize our datasets to continue to create proprietary molecular signatures and potentially establish patient-level prognosis and prediction of therapeutic benefit, with an initial focus on breast cancer.
In addition to our two clinically validated proprietary molecular signatures, GPSai and FOLFIRSTai, which can be ordered as part of MI Profile, we have a pipeline of proprietary molecular signatures that we are in the process of refining and validating. For example, we are developing MGMTai, a predictive signature that will help oncologists assess a patient’s risk of developing brain metastases, and other signatures in development include pancreatic cancer response predictors, a predictor of response to checkpoint inhibitor therapy for lung cancer patients, and a predictor of response to platinum-based therapies for ovarian cancer patients. Similar to our FOLFIRSTai signature, we believe these types of multi-omic, ML-driven signatures will add significant and differentiating clinical value to our solutions, positioning our profiling solutions as the most complete and comprehensive for late-stage cancer available.
We believe that whole exome and whole transcriptome data is critical to develop robust AI signatures. For example, we are using whole exome and whole transcriptome data to train two AI signatures that predict therapeutic responses. The first AI signature that we are training predicts the response of lung cancer patients to immunotherapy and chemotherapy. This model demonstrated the capability to identify, at a p-value of less than 1%, patients that would benefit from immunotherapy along with chemotherapy, versus patients for whom chemotherapy would not be expected to have a benefit. Over 60% of several hundred genes and transcripts that this model identified as the most significant features are not included in a commercially available 700-gene panel. The second AI signature that we are training predicts response of pancreatic cancer patients to FOLFIRINOX and Gemcitabine + Abraxane®. This model was shown to identify, at a p-value of less than 1%, Stage IV pancreatic patients who would have a survival benefit from FOLFIRINOX treatment but not Gemcitabine + Abraxane®, and vice versa. Of the dozens of molecular features that feed into this model, nearly half are not analyzed in a commercially available 700-gene panel. Thus, we do not believe these types of models could be replicated without whole exome and whole transcriptome data like that produced by our sequencing solutions.
Our basic strategy for molecular signature development is to utilize our proprietary WES/WTS and claims data clinical databases for initial signature creation, with validation in external datasets (when advisable), including datasets that have been developed in other prospective clinical trials. These external
 
187

TABLE OF CONTENTS
 
datasets will, in many cases, be derived from active and ongoing collaborations with cooperative oncology groups or single academic institutions, many of which are active members of the Caris POA.
Digital Pathology Innovation
We are also utilizing our datasets and AI/ML analysis to develop the ability to use digital scans of tissue slides to predict the presence of certain biomarkers without the need for NGS profiling.
We have captured more than 4.4 million images of patient tumor tissue as of March 31, 2025, including approximately 3.1 million digitized IHC images and approximately 1.4 million digitized hematoxylin and eosin (“H&E”) images, and each image is associated with the patient’s full WES/WTS profile and clinical information. The workflow for WES and WTS sequencing of patient tumor tissue requires the sectioning of a Formalin Fixed Paraffin Embedded tissue specimen, leading to the creation of a set of unstained slides containing the patient’s tumor material. We stain two slides with traditional H&E reagents, others with antibodies for downstream IHC testing, and others with Nuclear Fast Red stain to facilitate microdissection and DNA/RNA extraction for sequencing. We have implemented a fleet of seven Pramana SpectralHT next generation, robot-controlled digital slide systems (each with four scanners for 28 total scanners) to capture ultra high-definition images of all H&E and IHC slides. The images are used to drive efficient and rapid analysis and processing during the testing workflow and also provide a unique and previously unavailable rich resource to fuel new assay development and innovation based on image-driven AI.
Our data scientists are using this powerful combination of molecular and visual data together to fuel the development of new image-driven AI signatures. The goal is to use the molecular data to validate AI signatures that can predict molecular status based on the digital slide image alone. The applications of this new approach include rapid image-based diagnosis, biomarker status determination, and prognostic determinations rapidly and cost-effectively, using just the slide image.
We are currently using an AI/ML approach driven by H&E slide images and clinical results data from more than 10,000 breast cancer patients to develop ESPai, a new algorithm to predict the risk of disease recurrence for early-stage breast cancer patients. We have obtained the samples and clinical data from the National Surgical Adjuvant Breast and Bowel Project and the ECOG-ACRIN Cancer Research Group. We are currently in the process of creating two AI/ML models for ESPai using these samples and are working to obtain additional samples for external validation studies. We are initially creating a model for late recurrence (five to 15 years following diagnosis), but we are also in the beginning stages of creating a model for early recurrence (zero to five years following diagnosis).
As an additional example, we have developed an AI tool that uses the digital image of a slide that has been stained with traditional H&E reagents to predict whether a patient has an increased likelihood for being positive for a ROS1 fusion, which is a particular type of gene fusion that is associated with non-small cell lung cancer. Biopharma companies developing new ROS1-targeted therapies typically must use NGS or FISH testing to screen more than 100 patients to identify one or two positive patients, resulting in very high cost and long timelines for clinical trials. The Caris ROS1 AI signature can be used on the slide alone and identify patients who are 33 times more likely to be ROS1 positive, thereby reducing the number of patients who need to be screened by more expensive and precise methods by more than 97%. Imaged-based, low-cost AI signatures like this might also be useful in the future in countries with limited access to sequencing technology. We expect to develop more of such image-based AI signatures using the power of ML on the combined image and molecular datasets.
Our Laboratory Infrastructure
We have built substantial testing capacity with throughput capabilities of over one trillion “reads” per day. We operate two precision medicine laboratories in Phoenix, Arizona, and one R&D laboratory in Tempe, Arizona. Our Arizona laboratories all utilize state-of-the-art genomic sequencing technology, including 50 NovaSeq sequencing systems. Our newest laboratory facility in Irving, Texas, near our headquarters, is continuing to be built-out and will bring our total operational capacity to over 275,000 square feet. We believe this operational capacity provides us with ample capability to manage future growth.
 
188

TABLE OF CONTENTS
 
Our solid tissue clinical laboratory in Phoenix, Arizona is an approximately 66,000 square foot, state-of-the-art laboratory. We provide high quality, reliable molecular testing services for all stages of the drug development cycle and routine clinical use. From pre-clinical research for compound development efforts to established, commercially available therapies, we provide robust genomic and proteomic testing capabilities across a variety of specimen types and high-throughput technologies. This laboratory has the following certifications: ISO 15189, ISO 13485, CLIA: CMI 03D1019490, College of American Pathologists (“CAP”): 7195577, and New York State Department of Health.
Our blood-based clinical laboratory in Phoenix, Arizona is approximately 35,500 square feet. This laboratory started testing operations in February 2022 following the installation of liquid-handling robots and NovaSeq sequencing systems. This laboratory has the following certifications: ISO 15189, CLIA: CMI 03D2210981 and CAP: 9536852.
We also have an approximately 59,000 square foot R&D laboratory in Tempe, Arizona that is utilized for R&D and therapeutic discovery work. This laboratory has ISO 13485 certification.
We have leased an approximately 114,500 square foot facility in Irving, Texas, close to our corporate headquarters, which includes office space and will house a clinical laboratory. We expect to build out the clinical laboratory in phases in the future to coincide with product launches and provide us with additional profiling capacity as we continue to grow our business.
We test patient samples on the most powerful sequencing systems available, which are built for high throughput sequencing, scalability, and speed and allow for high throughput more economically than prior platforms. Our use of high performance NGS sequencing systems improves our throughput efficiencies and lowers our cost of sequencing. We have an installation of 50 NovaSeq sequencing systems as of March 31, 2025. In addition to NGS, we employ other technologies in our operations, including 33 liquid handling robotic systems, ultra HD digital image scanning, dynamic light scattering, flow cytometry, fragment analysis, IHC, in situ hybridization, laser capture microdissection, mass spectrometry, Sanger sequencing, pyro sequencing, quantitative polymerase chain reaction, RT-PCR, and surface plasma resonance.
Our Commercialization Strategy
The precision medicine industry is characterized by rapid changes, including technological and scientific breakthroughs, frequent new product introductions and enhancements, and evolving industry standards. Education of customers, both physicians and biopharma companies, remains one of the key barriers to higher adoption of molecular profiling. More than ever, oncologists need a trusted profiling partner to provide reliable, high-quality molecular profiling information to guide precise and individualized treatment decisions. Our relationships across key oncology stakeholders include more than 5,600 physicians and partnerships with more than 100 biopharma companies. Additionally, we have executed agreements with or recently engaged in commercial discussions with all of the top 30 pharmaceutical companies measured by market capitalization. We have optimized our systems to provide industry-leading reports, service, and turn-around-time, helping oncologists (1) navigate among therapies with potential benefit, (2) identify therapies that may not have been considered, (3) determine drugs with potential lack of benefit (avoiding unnecessary toxicities and costs), and (4) match patients to clinical trials.
In the United States, we market our solutions to clinical customers through our marketing and commercial sales organizations. Our commercial footprint consisted of nearly 300 sales team members at the end of 2021 compared to approximately 275 sales team members and approximately 25 marketing team members at the end of 2024. Since the end of 2021, the size of our sales organization has generally remained constant, though the team has grown slightly during certain periods and contracted slightly in others. Our sales team members cover the entire U.S. market, focusing on the community setting where the majority of cancer patients are treated.
In addition, as of March 31, 2025, we had nearly 50 highly trained Ph.D. or M.D. MSLs who focus on physician and provider education and consultation, enabling us to provide a personalized consultation experience for oncologists. MSLs are responsible for communicating the value of Caris to external stakeholders, such as physicians, nurses, scientists, and other interested parties. This communication primarily involves face-to-face discussions with customers. The MSLs use a variety of opportunities such as molecular
 
189

TABLE OF CONTENTS
 
tumor boards, educational seminars, and conference participation to act as a conduit of information and feedback between the medical community and us.
Decisions about which profiling services to use have become increasingly “institutionalized,” where cancer center directors and other medical leaders are adopting the approach of designating a “preferred partner” that is a technology and service leader for molecular profiling services. We believe that the Caris POA and our deep, high-quality institutional relationships provide us with an advantage in being selected as a preferred partner, and we expect this trend to continue to accelerate to further drive growth in ordering of our profiling solutions.
We market our solutions to biopharma companies through a separate Biopharma Business Development team. This team is differentiated from traditional sales organizations by recruiting professionals with a diversity of direct biopharma experience and strong scientific backgrounds and business acumen. We believe the credibility that our partnering team brings to discussions with biopharma companies has been well-received, and when combined with our profiling solutions and molecular datasets, has created a strong competitive edge.
We estimate that approximately two-thirds of our top 200 customers based on case volume were either academic medical centers or corporate physician practices.
International Distribution
Globally, we market our solutions through distributors and direct contracts with hospital systems, where permitted by the applicable regulations. Our distributors are generally obligated to obtain required in-country regulatory approvals and comply with in-country regulations. We have performed our clinical solutions to patients in over 50 countries since 2022 and are considering filing for regulatory approvals in Japan and the European Union.
EHR Integration and Electronic Ordering
We have established bi-directional electronic healthcare record (“EHR”) interfaces with individual institutions and/or specific provider locations. Test ordering can be done within the local EHR, and discrete test results can be returned to the ordering site automatically. We have integrated connections with every major EHR vendor. In addition to EHR integrations, we have a physician portal in which physicians can order testing and receive clinical reports electronically. Together, our EHR and portal ordering constituted approximately 47% of our clinical volume during 2024.
Competition
The precision oncology industry is highly competitive and subject to rapid change. An increasing awareness of the importance of genetic information to accurately understand cancer and deliver solutions for early detection, MRD tracking, therapy selection, and treatment monitoring is leading to more companies offering services in genomic profiling and sequencing.
Our competitors in tissue-based molecular profiling include Foundation Medicine (Roche) and Tempus. In addition, some academic centers, such as Memorial Sloan Kettering Cancer Center and New York Presbyterian — Weil Cornell, offer profiling to patients in their networks. Our competitors in blood-based early detection include Grail, Freenome, Guardant Health, Exact Sciences, and Delfi Diagnostics, among numerous other companies pursuing the early detection market. Our competitors in blood-based molecular profiling for therapy selection include Guardant Health and Foundation Medicine (Roche). Our competitors in blood-based molecular profiling for MRD tracking and treatment monitoring include Natera, Guardant Health, and Adaptive Biotechnologies. Our competitors in core biopharma services include Foundation Medicine (Roche), Guardant Health, Tempus, Natera, and Personalis, among others. Our competitors in offering genomic data and AI services include Tempus and Foundation Medicine (Roche). Other companies offering testing in the precision oncology industry include Illumina, NeoGenomics, Myriad Genetics, Laboratory Corporation of America, Quest Diagnostics, and BostonGene.
Some of these companies may have substantially greater financial and other resources than we have, such as larger R&D staff and more established marketing and sales forces, or may operate in
 
190

TABLE OF CONTENTS
 
jurisdictions where lower standards of evidence are required to bring products to market. In addition, other established diagnostic, medical technology, biotechnology, or pharmaceutical companies may decide in the future to invest heavily to accelerate discovery and development of similar services that could make our solutions less competitive.
We believe that we compete favorably based on the following competitive factors: our patient-first approach that includes deep sequencing all DNA encoding genes and RNA transcripts utilizing comprehensive WES and WTS, enabling us to provide patients and physicians with industry-leading breadth, depth, and accuracy of multi-omic information; our tissue-based molecular profiling solution; our novel, universal blood-based profiling solution; our large and comprehensive multi-modal clinco-genomic dataset; our specialized commercial channel, robust infrastructure, and deep research collaborations; and our highly experienced management team.
Intellectual Property
Protection of our intellectual property is fundamental to the long-term success of our business. We seek to ensure that investments made into the development of our solutions to transform healthcare through the use of comprehensive molecular information, AI/ML algorithms, and proprietary molecular technologies are protected by a combination of patents, trademarks, copyrights, trade secrets, license agreements, confidentiality agreements and procedures, employee agreements (such as proprietary information, intellectual property, restrictive covenant, and arbitration agreements), and other legal and contractual rights.
Patents
We seek patent coverage for our foundational multi-cancer, multi-purpose molecular profiling solutions for tissue and blood and for our R&D activities, including biomarker discovery using our expansive molecular profiling datasets and tumor tissue archive. Our policy is to enter into invention or patent assignment agreements with our employees and consultants that obligate these employees and consultants to assign to us any inventions they develop while working for us.
Our company-owned and in-licensed patents and applications generally fall into the following categories:
•
Patents and applications related to our molecular profiling services.   As of March 31, 2025, we owned 79 patents (including three allowances) and 75 pending applications, and had an exclusive license to one patent application, which collectively relate to our molecular profiling solutions, including claims directed to early detection of cancer, monitoring disease recurrence, identifying treatments of likely benefit or lack of benefit for cancer patients, and the use of AI and ML for prediction of response to various cancer therapies, prediction of tumor origin, and to assess other characteristics of cancers based on NGS data and/or digital pathology. The Caris-owned patents and applications are assigned to our subsidiary Caris MPI, Inc. and include 17 issued U.S. patents, 16 pending U.S. applications, 62 foreign patents (including three allowances), and 59 pending foreign applications. The in-licensed patent application is a U.S. application and is exclusively licensed to Caris MPI, Inc.
​
•
Patents and applications related to our pharma research and development services.   As of March 31, 2025, we owned 103 patents (including four allowances), and 24 pending applications, and had exclusive licenses to 43 patents and applications, which collectively relate to aptamer library screening and uses thereof, including uses in biomarker discovery, as well as cell targeting constructs and therapeutic applications thereof. The Caris-owned patents and applications are assigned to our subsidiary Caris Science, Inc. and include 16 issued U.S. patents, six pending U.S. applications, 87 foreign patents (including four allowances), and 18 pending foreign applications. The in-licensed patents and applications are exclusively licensed to Caris Science, Inc. and include two issued U.S. patents, one pending U.S. application, 36 foreign patents, and four pending foreign applications.
​
Patents and applications of particular importance within our portfolio that relate to our commercial molecular profiling services include:
 
191

TABLE OF CONTENTS
 
•
63 patents and ten pending applications directed to systems and methods for comprehensive molecular profiling for cancer patients independent of cancer type. These include 14 issued U.S. patents and one pending U.S. application, and 49 foreign patents (including two allowances) and nine pending foreign applications between Australia, Austria, Belgium, Canada, China, Denmark, Europe, Finland, France, Germany, Iceland, India, Ireland, Israel, Italy, Japan, Mexico, Luxembourg, the Netherlands, Norway, Portugal, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, and the United Kingdom. These patents and applications are Caris-owned and assigned to our subsidiary Caris MPI, Inc., and are expected to expire between 2027 and 2033;
​
•
One issued patent in Japan and 17 additional pending applications directed to AI/ML systems and methods for predicting cancer type. These include two pending U.S. applications, one PCT application, and 14 pending foreign applications between Australia, Canada, Europe, Israel, Japan, South Korea, and Mexico. These patents and applications are Caris-owned and assigned to our subsidiary Caris MPI, Inc., and are expected to expire between 2040 and 2044; and
​
•
14 patents (including one allowance) and 16 pending applications directed to AI/ML systems and methods for predicting response to platinum compounds, including FOLFOX regimens. These include three issued U.S. patents and two pending U.S. applications, and 11 foreign patents (including one allowance) and 14 pending foreign applications between Australia, Canada, Europe, France, Germany, Ireland, Israel, Japan, South Korea, Mexico, Netherlands, Switzerland, and the United Kingdom. These patents and applications are Caris-owned and assigned to our subsidiary Caris MPI, Inc., and are expected to expire between 2039 and 2040.
​
Additional patents and applications with varying levels of importance within our portfolio that relate to our commercial molecular profiling services include:
•
16 pending applications directed to AI/ML systems and methods for predicting response to various chemotherapies. These applications are Caris-owned and are expected to expire in 2041;
​
•
Six pending applications directed to AI/ML systems and methods for predicting likelihood of metastasis. These applications are Caris-owned and are expected to expire between 2041 and 2045; and
​
•
One pending application directed to profiling hematological malignancies using whole genome sequencing. This application is exclusively in-licensed and is expected to expire in 2042.
​
Additional patents and applications with varying levels of importance within our portfolio that relate to our pharma research and development services include:
•
38 patents directed to methods for use of microvesicles and microRNA as cancer biomarkers. These patents are exclusively in-licensed and are expected to expire in 2028;
​
•
47 patents and six pending applications directed to methods of sequencing aptamer libraries to detect targets of interest. These patents and applications are Caris-owned and expected to expire between 2028 and 2033;
​
•
47 patents (including two allowances) and nine pending applications directed to methods for aptamer library enrichment. These patents and applications are Caris-owned and are expected to expire between 2028 and 2038; and
​
•
Nine patents (including two allowances) and 14 pending applications directed to compositions and methods related to cell-targeting technologies. These patents and applications are either Caris-owned or exclusively in-licensed and are expected to expire between 2036 and 2044.
​
The expiration dates described above are subject to, in the case of pending applications, our continued prosecution to allowance at the applicable patent offices, and in the case of allowed, issued and granted patents, our payment of applicable issue fees, maintenance fees and annuities. Patent expiration dates are estimates and may be subject to terminal disclaimers and patent term adjustments.
 
192

TABLE OF CONTENTS
 
In some instances, we have acquired or in-licensed patent rights developed by third parties to enhance our patent portfolio and competitive advantage. For example, we have acquired patent families related to aptamer technologies and in-licensed patent applications related to cell targeting and hematological cancer assay technologies that are currently under development. Under such license agreements, we would be obligated to pay royalties for future sales in which the patents are used in the product or service sold.
Trade Secrets
In addition to patent protection, we have determined that certain technologies are better kept as trade secrets, such as aspects of our NGS methodology, bioinformatic analysis techniques, and identity of cancer biomarkers under development. We have a policy to restrict access to our trade secrets to a need-to-know basis. To further mitigate the chance of trade secret misappropriation, we enter into confidentiality agreements with parties who have access to trade secrets, such as our employees, collaborators, outside scientific collaborators, consultants, advisors, and other third parties.
Brand Protection
Our customers and partners recognize us as a leader in the molecular profiling field. Thus, just as patent and trade secret protection is essential to protecting our technology, we believe that it is equally as important for us to protect our brand and identity. We have obtained, and will continue to obtain, trademark protection for our name, logo, and solutions in countries where we operate, including our MI Profile and Caris Assure branding.
Additional Information
We will continue to pursue intellectual property protection, whether developed in-house or via third parties, that we believe will advance our business objectives. Despite our efforts and vigorous defense, our intellectual property rights in the United States and abroad may be invalidated, circumvented, or challenged in the future. In addition, the laws of various countries where our solutions are distributed may not protect our intellectual property rights to the same extent as the laws in other countries. For additional information, see the section titled “Risk Factors—Risks Related to Intellectual Property.”
Regulatory Strategy
Our regulatory strategy aligns with our overall business objectives. We believe that receiving FDA approval of our diagnostic solutions would positively impact our ability to sell our solutions and enhance our reimbursement efforts with payers, including Medicare. The current marketing status and relevant regulatory approvals obtained, planned, and/or potentially required for each of our solutions is summarized in the table below. We currently market all of our existing solutions, including Caris Assure for therapy selection, MI Tumor Seek Hybrid, GPSai, and FOLFIRSTai, as LDTs and, as required under CLIA, continue to analytically validate such solutions across a variety of performance characteristics, including accuracy, precision, specificity, sensitivity, reportable range, and reference interval. We have obtained an FDA marketing authorization for MI Cancer Seek, and we anticipate seeking FDA marketing authorization for Caris Assure for therapy selection and additional solutions in the future, including as a result of the FDA’s planned phase out of its enforcement discretion policy with respect to LDTs. Additionally, while we currently market Caris Assure for therapy selection as an LDT, marketing authorization from the FDA would be required in order for us to market Caris Assure as a companion diagnostic device for therapy selection. We do not yet have specific plans regarding the timing of a PMA or other submission, if any, for Caris Assure for therapy selection or any other indication. For additional information, see “—Government Regulation— U.S. Food and Drug Administration—Laboratory Developed Tests.”
​
Solution Name
​ ​
Marketing Status
​ ​
NY CLEP Approval
​ ​
FDA Approval/Requirements
​
​
MI Cancer Seek
​ ​ Marketed since January 2025 ​ ​ Not applicable ​ ​ PMA approval obtained in November 2024 ​
​ MI Tumor Seek Hybrid ​ ​ Marketed as an LDT since 2022 ​ ​ Approved in 2024 ​ ​ None planned, but if FDA marketing authorization is required, a PMA approval must be obtained ​
 
193

TABLE OF CONTENTS
 
​
Solution Name
​ ​
Marketing Status
​ ​
NY CLEP Approval
​ ​
FDA Approval/Requirements
​
​ Caris Assure for Therapy Selection ​ ​ Marketed as an LDT
since 2024
​ ​ Plan to submit for NY CLEP in 2025 ​ ​ Plan to submit PMA or a de novo request or 510(k) notification ​
​ FOLFIRSTai ​ ​ Marketed as an LDT
since 2020
​ ​ Approved in 2024 ​ ​ None planned, but if FDA marketing authorization is required, a de novo classification or 510(k) clearance must be obtained ​
​ GPSai ​ ​ Marketed as an LDT
since 2019
​ ​ Approved in 2024 ​ ​ None planned, but if FDA marketing authorization is required, a de novo classification or 510(k) clearance must be obtained ​
The FDA premarket review process can be long and requires significant resources to complete all of the regulatory requirements necessary for market launch of an FDA-approved prescription medical device or diagnostic product. As we work with the FDA to seek marketing authorization for our diagnostic solutions, we must accurately describe the solution in terms of its intended use, indications for use, target population of patients, functional and/or performance characteristics, labeling, and anticipated marketing claims for the device, among other things. These factors, when combined with the result of the device classification, applicable product code for the device, and whether a predicate device exists, will allow us to plan the most appropriate submission type and regulatory pathway. Determining the appropriate pathway early is crucial to setting milestones, planning necessary preclinical and clinical trials, estimating cost requirements, and creating a timeline for when the product may reach the market.
The FDA encourages participation in the FDA’s Pre-Submission Program, which allows manufacturers to seek the FDA’s feedback prior to an intended premarket submission. We have had formal pre-submission meetings with the FDA Center for Devices and Radiological Health (“CDRH”) and anticipate several more in the future to seek additional feedback from the agency on solutions that we intend to submit for premarket review. Feedback from these meetings are critical for our team to be able to put together the appropriate study designs to support a premarket submission. Though the FDA provides non-binding feedback within these discussions, obtaining this early input from CDRH can allow for necessary changes or modifications to the regulatory strategy and potentially provide long-term savings in cost and time.
We have obtained a PMA approval from the FDA for a companion diagnostic and tumor profiling designation for MI Cancer Seek, a WES/WTS NGS assay that has been designed to meet the stricter requirements applicable to companion diagnostic devices. We currently market MI Cancer Seek as the WES/WTS NGS component of MI Profile. For additional information, see “Risk Factors—Risks Related to Regulation and Legal Compliance—The marketing authorization processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and unpredictable. If we are ultimately unable to obtain any necessary or desirable marketing authorizations, or if such marketing authorizations are significantly delayed, our business will be substantially harmed.”
Government Regulation
We are subject to complex and frequently changing national, state, and local laws and regulations that govern various aspects of our business. In many jurisdictions, including the United States, the clinical laboratory and medical device industries must operate in accordance with extensive and complex legal standards, including laws and regulations related to certification, licensing, development, research, testing, manufacturing, laboratory operations, distribution, ordering and billing practices, advertising, promotion, marketing, sales and pricing practices, anti-markup practices, health information privacy and security, and consumer protection and unfair trade practices.
In the United States, the laws and regulations governing the marketing of diagnostic products are evolving, extremely complex, and in some instances, there are no significant regulatory or judicial interpretations of these laws and regulations. Clinical LDTs are regulated by the CLIA, described below, as well as by applicable state laws. In addition, the Federal Food, Drug and Cosmetic Act (“FDC Act”) defines a medical device to include any instrument, apparatus, implement, machine, contrivance, implant, in
 
194

TABLE OF CONTENTS
 
vitro reagent, or other similar or related article, including a component part, or accessory, intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals. Among other things, pursuant to the FDC Act and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, marketing and promotion, and sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. The FDA has statutory authority to assure that medical devices are safe and effective for their intended uses. While the FDA has historically exercised its enforcement discretion and not enforced certain applicable provisions of the FDC Act and implementing regulations with respect to LDTs, the FDA recently issued a final rule to phase out its enforcement discretion with respect to LDTs, which makes LDTs subject to the FDA’s medical device authority. Any solutions we develop and market would be considered by the FDA to be subject to regulation as a medical device. On March 31, 2025, the United States District Court for the Eastern District of Texas vacated the FDA’s LDT final rule.
For information on the risks we face related to the regulatory environment and other legal matters, see the section titled “Risk Factors—Risks Related to Regulation and Legal Compliance.”
Clinical Laboratory Improvement Amendments of 1988
Congress passed CLIA to establish rigorous quality standards for laboratories in the United States. Under CLIA, a laboratory is any facility that performs laboratory testing on specimens derived from human beings for the purpose of providing information for the diagnosis, prevention, or treatment of disease or the impairment or assessment of health. Such testing may also include procedures to determine, measure, or otherwise describe the presence or absence of various substances or organisms in the body.
CLIA requires that such laboratories obtain certification from the federal government and maintain compliance with various operational, personnel qualification, facilities administration, quality control and assurance, and proficiency testing requirements intended to ensure the accuracy, reliability, and timeliness of patient test results. The CMS, part of the U.S. Department of Health and Human Services (“HHS”), administers the CLIA certification program. CLIA requires that we hold a certificate that specifies the categories of testing we perform and that we comply with certain standards applicable to such tests. For every LDT used in clinical testing, CLIA requires analytical validation of a variety of performance characteristics, including accuracy, precision, specificity, sensitivity, reportable range, and reference interval. In addition, CLIA specifies certain testing categories requiring periodic proficiency testing, and certified laboratories performing these tests must enroll in an approved proficiency testing program. To demonstrate proficiency, such laboratories must test specimens received from an outside proficiency testing organization, such as CAP, and then submit the results back to that organization for evaluation. Failing to achieve a passing score on a proficiency test may lead to loss of certification to perform testing in the corresponding category. Furthermore, failure to comply with other proficiency testing regulations can result in revocation of the laboratory’s CLIA certificate, among other penalties.
We currently have two clinical laboratory facilities in Phoenix, Arizona, and we are in the process of building a laboratory in Irving, Texas. Both of the Phoenix laboratory facilities hold CAP and CLIA Accreditations. A CLIA Certificate of Accreditation is issued to a laboratory facility that performs moderate and/or high complexity testing after an accreditation organization conducts a survey and determines that the laboratory is in compliance with the CLIA regulations. Our newest laboratory facility in Irving, Texas, near our headquarters, is continuing to be built-out and will seek a CLIA Certificate of Registration from CMS, and upon required inspection, a CLIA Certificate of Accreditation. The CLIA Certificate of Registration allows the laboratory facility to begin conducting moderate and/or high complexity testing, subject to a survey to determine compliance with the CLIA regulations. After a laboratory obtains a Certificate of Registration, CLIA begins scheduling regular, routine inspections. Once the inspection process for the laboratory facility is successfully completed, the facility qualifies for a CLIA Certificate of Accreditation and thereafter is inspected every two years.
Prior to offering a new solution at our laboratories, we must also satisfy certain notification requirements to change our solution menu, such as notifications to regulatory and accrediting bodies. At their discretion, these entities may inspect our clinical laboratories at any time. CLIA accredited laboratories
 
195

TABLE OF CONTENTS
 
are subject to are required to be reviewed biannually by a CMS-approved accreditation organization (for example, CAP) and may be subject to additional random or “for cause” inspections.
If our laboratories are determined to be out of compliance with CLIA requirements at any inspection or otherwise, we may be subject to a wide range of enforcement actions and sanctions, including suspension, limitation, or revocation of the laboratory’s CLIA certificate, as well as directed plan of correction, on-site monitoring, civil monetary penalties, civil injunctive suit, or criminal penalties, as well as significant adverse publicity, all of which could have a materially adverse impact on our business.
State Laboratory Licensure Laws
In addition to the federal certification requirements for laboratories, certain states, including Maryland, Pennsylvania, New York, California, and Rhode Island require state laboratory licenses. The state laboratory licensure requirements establish standards for the day-to-day operation of a clinical laboratory, including the training and qualifications required of personnel, quality control, and proficiency testing. CLIA provides that a state may adopt laboratory regulations that are more stringent than those under federal law. A number of states have implemented their own more stringent laboratory regulatory requirements, and those states may conduct their own inspections. These states may also include reporting requirements that we must comply with in order to maintain licensure. Moreover, certain states, including New York, require approval of certain tests, including certain tests that have not been cleared or approved by the FDA (such as LDTs), through a premarket submission containing, among other information, documentation relating to device analytical and clinical performance data.
Several states require licensure of out-of-state laboratories that accept specimens from those states and/or receive specimens from laboratories in those states. Our Arizona solid tissue laboratory and our Arizona blood-based testing laboratory have obtained out-of-state licenses in states where we believe they are required, and we will file applications in additional states as applicable when we offer solutions in those states.
If a laboratory is deemed to be out of compliance with state licensing laws or regulations governing laboratories, penalties may include suspension, limitation, or revocation of the license issued by that state, disapproval of a licensure application, assessment of substantial financial penalties or fines, onsite monitoring requirements, or imposition of corrective action plans. Certain statutory or regulatory noncompliance may also result in misdemeanor charges under state law. Loss of a laboratory’s state license may also result in the inability to compliantly perform laboratory testing and receive payments from third-party payers, all of which may have a materially adverse impact on our business.
In addition to laboratory licensing, certain states, including New York and California, impose registration and/or licensing requirements on companies that manufacture medical devices. These laws can apply to a manufacturer before its products are commercialized, including when a company is evaluating its product candidates in clinical trials. Violations of these laws may result in the denial, suspension, or revocation of the registration or license, as well as other fines and penalties, including imprisonment.
Other states may adopt licensure requirements in the future, which could require us to modify, delay, or discontinue our operations in such jurisdictions. If we identify any state with such requirements or if we are contacted by a state advising us of such requirements, we intend to follow such instructions from the state regulators as to how to comply with such requirements.
U.S. Food and Drug Administration
In the United States, laboratory tests are subject to regulation by the FDA under the FDC Act and its implementing regulations, and other federal and state statutes and regulations. The laws and regulations govern, among other things, medical device development, testing, manufacture, labeling, storage, premarket clearance or approval, advertising and promotion, export, import, and product sales and distribution.
Laboratory Developed Tests
Under the FDA’s regulatory framework, IVDs are a type of medical device that can be used in the diagnosis or detection of diseases, such as cancer, or other conditions. The FDA considers LDTs to be a
 
196

TABLE OF CONTENTS
 
subset of IVDs that are intended for clinical use and are designed, manufactured, and used within a single laboratory. Until recently, the FDA has historically exercised its enforcement discretion and not enforced certain otherwise potentially applicable provisions of the FDC Act and regulations with respect to LDTs, with certain exceptions. Even under that enforcement discretion policy, the FDA has issued warning letters to, and published Medical Device Safety Communications about, manufacturers for commercializing laboratory tests that were purported to be LDTs but that the FDA alleged failed to meet the definition of an LDT or that otherwise were not subject to the FDA’s enforcement discretion policy.
The FDA has for a number of years stated its intention to modify its enforcement discretion policy with respect to LDTs and impose applicable medical device requirements to LDTs more broadly. In May 2024, the FDA finalized an amendment to its regulations via issuance of a final rule. This final rule clarifies the FDA’s historical view that LDTs are medical devices subject to the requirements applicable to other IVDs, and the FDA plans to phase in the enforcement of medical device requirements to LDTs over a period of four years. On March 31, 2025, the United States District Court for the Eastern District of Texas vacated the FDA’s LDT final rule.
In connection with the final rule, the FDA established certain new, targeted enforcement discretion policies, including, among others, for LDTs marketed as of the date of publication of the final rule on May 6, 2024, as well as for LDTs that have received approval from NY CLEP. Specifically, the FDA intends to exercise enforcement discretion and not enforce certain medical device requirements (including the requirements for marketing authorization and compliance with certain elements of the Quality System Regulation (“QSR”) with respect to LDTs that were marketed as of the date of the final rule’s publication, although such products must still comply with certain other FDA requirements, including registration and listing, portions of the QSR, medical device reporting, labeling, and corrections and removals reporting. However, where these tests are modified in certain ways from the version of the test marketed as of the final rule’s publication date, this enforcement discretion policy will no longer apply and the FDA intends to enforce all applicable FDA requirements (including premarket review and marketing authorization requirements) consistent with the phase-in policy. In addition, for LDTs that receive approval from NY CLEP, FDA intends to not enforce marketing authorization requirements when these requirements are phased in more generally at either three and a half or four years following the date of publication of the final rule. However, these tests will still be subject to the remaining medical device requirements, including registration and listing, medical device reporting, and quality system requirements, at the time that such requirements are phased in more generally.
In addition, Congress has, for over the past decade, considered a number of proposals, which if enacted, would subject LDTs to additional regulatory requirements. For example, in recent years, Congress has worked on legislation to create a novel regulatory framework governing a new category of FDA-regulated products, referred to as in vitro clinical tests (“IVCTs”), which would govern LDTs and would be separate and distinct from the existing medical device regulatory framework. For example, in March 2023, the Verifying Accurate Leading-edge IVCT Development Act of 2023 (the “VALID Act”) was introduced. The bill would establish a risk-based approach to imposing requirements related to premarket review, quality systems, and labeling requirements on all IVCTs, including LDTs, but would grandfather certain LDTs marketed before the effective date of the bill and exempt them from certain requirements. Depending on the approach adopted under any potential legislation, certain LDTs (likely those of higher risk) may be required to undergo some form of premarket review of LDTs as IVCTs, potentially with a transition period for compliance and a grandfathering provision.
FDA Classification and Premarket Review of Medical Devices
PMA Pathway.   The FDA categorizes medical devices into one of three classes—class I, II, or III—based on the risks presented by the device and the regulatory controls necessary to provide a reasonable assurance of the device’s safety and effectiveness. Class I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA’s General Controls for medical devices, which include compliance with the applicable portions of the QSR, facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising, and promotional materials. Class II devices are subject to the FDA’s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. Special
 
197

TABLE OF CONTENTS
 
controls are established by the FDA for a specific device type and often include specific labeling provisions, performance metrics, and other types of controls that mitigate risks of the device (usually incorrect results for an IVD). Devices deemed by the FDA to pose the greatest risks, such as life sustaining, life supporting or some implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, are placed in Class III, requiring approval of a PMA. Some pre-amendment devices are unclassified, but are subject to the FDA’s premarket notification and clearance process in order to be commercially distributed.
Class III devices require PMA approval before they can be marketed. Obtaining PMA approval requires the submission of “valid scientific evidence” to FDA to support a finding of a reasonable assurance of the safety and effectiveness of the device. A PMA must provide complete analytical and clinical performance data and also information about the device and its components regarding, among other things, device design, manufacturing, and labeling. Following receipt of a PMA, the FDA determines whether the application is sufficiently complete to permit a substantive review. If the FDA accepts the application for review, it has 180 days from the day of filing under the FDC Act to complete its review of a PMA, although in practice, the FDA’s review often takes significantly longer. An advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel’s recommendation. As part of the FDA’s review of a PMA, the FDA will typically inspect the manufacturer’s facilities for compliance with QSR requirements, which impose requirements related to design controls, manufacturing controls, documentation, and other quality assurance procedures. The user fee costs and the length of the FDA review time for obtaining PMA approval are significantly higher than for a 510(k) notification or a de novo classification. In addition, the FDA collects user fees for certain medical device submissions and annual fees and for medical device establishments under the Medical Device User Fee Amendments to the FDC Act, which is subject to reauthorization by Congress every five years following extensive agency and industry negotiations.
FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s). FDA may approve a PMA with post-approval conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution, and collection of long-term follow-up data from patients in the clinical study that supported PMA approval or requirements to conduct additional clinical studies post-approval. FDA may condition PMA approval on some form of post-market surveillance when deemed necessary to protect the public health or to provide additional safety and efficacy data for the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups for a number of years and to make periodic reports to FDA on the clinical status of those patients. Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the approval.
Certain changes to an approved device, such as changes in manufacturing facilities, methods, or quality control procedures, or changes in the design performance specifications, which affect the safety or effectiveness of the device, require submission of a PMA supplement. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel. Certain other changes to an approved device require the submission of a new PMA, such as when the design change causes a different intended use, mode of operation, and technical basis of operation, or when the design change is so significant that a new generation of the device will be developed, and the data that were submitted with the original PMA are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness.
510(k) Notification Pathway.   To obtain 510(k) clearance, a manufacturer must submit a premarket notification demonstrating to the FDA’s satisfaction that the proposed device is “substantially equivalent” to another legally marketed device that itself does not require PMA approval (a predicate device). A predicate device is a legally marketed device that is not subject to premarket approval, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class III to Class II or I, or a device that was found substantially equivalent
 
198

TABLE OF CONTENTS
 
through the 510(k) process. The FDA’s 510(k) clearance process usually takes from three to 12 months, but often takes longer. The FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence. In addition, the FDA collects user fees for certain medical device submissions and annual fees for medical device establishments.
If the FDA agrees that the device is substantially equivalent to a lawfully marketed predicate device, it will grant 510(k) clearance to authorize the device for commercialization. If the FDA determines that the device is “not substantially equivalent” to a previously cleared device, the device is automatically designated as a Class III device. The device sponsor must then fulfill more rigorous PMA requirements, or can request a risk-based classification determination for the device in accordance with the de novo process, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device. Once a de novo classification request is reviewed and granted, it results in the device having a Class I or II classification and future devices from the company or a competitor may use the company de novo-classified device as a 510(k) predicate.
After a device receives 510(k) clearance or de novo classification, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) clearance or, depending on the modification, PMA approval or new de novo classification. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k) or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer’s determination. Modifications that do not rise to the level of requiring a new 510(k) are accomplished through a “letter to file” in which the company documents the rationale for the change and why a new 510(k) is not required. However, if the FDA disagrees with a manufacturer’s determination, the FDA can require the manufacturer to cease marketing and/or request the recall of the modified device until new marketing authorization for the change is obtained. Also, in these circumstances, the manufacturer may be subject to significant regulatory fines or penalties.
Over the last several years, the FDA has proposed reforms to its 510(k) clearance process, and the implementation of such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products. For example, in September 2023, the FDA issued three draft guidances to strengthen and modernize the 510(k) program, and the FDA noted that in light of increasing technical complexity, clinical data are increasingly being required to support substantial equivalence determinations.
De Novo Classification Pathway.   If no legally marketed predicate can be identified for a new device to enable use of the 510(k) pathway, the device is automatically classified under the FDC Act into Class III, which generally requires PMA approval. However, the FDA can reclassify or use “de novo classification” for a device that meets the FDC Act standards for a class I or class II device, which in turn permit the device to be marketed without PMA approval. To grant such a reclassification, the FDA must determine that the FDC Act’s general controls alone, or general controls and special controls together, are sufficient to provide a reasonable assurance of the device’s safety and effectiveness. If the manufacturer seeks reclassification into Class II, the classification request must include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. The FDA may reject the classification request if it identifies a legally marketed predicate device that would be appropriate for a 510(k) notification or determines that the device is not low to moderate risk or that general controls would be inadequate to control the risks and special controls cannot be developed. The de novo classification route is generally less burdensome than the PMA approval process.
Investigational Device Exemption Process.   Clinical trials are almost always required to support a PMA and are sometimes required to support a 510(k) submission. All clinical investigations of investigational devices to determine safety and effectiveness must be conducted in accordance with the FDA’s investigational device exemption (“IDE”) regulations which govern investigational device labeling, prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a “significant risk” to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human clinical trials. A significant risk device is one that presents a potential for serious risk to the health, safety, or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or
 
199

TABLE OF CONTENTS
 
treating disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application must be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE will automatically become effective 30 days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval.
In addition, the study must be approved by, and conducted under the oversight of, an Institutional Review Board (“IRB”) for each clinical site. The IRB is responsible for the initial and continuing review of the IDE and may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and the study protocol is approved by one or more IRBs, human clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by the FDA. IDE reporting to all reviewing IRBs regarding study progress is required at regular intervals and at least annually for ongoing IDE approved studies. For a significant risk device, the progress reports must also be submitted to FDA. If the device presents a non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements. Acceptance of an IDE application for review does not guarantee that the FDA will allow the IDE to become effective and, if it does become effective, the FDA may or may not determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to, and approved by, the FDA before a sponsor or investigator may make a change to the investigational plan that may affect its scientific soundness, study plan or the rights, safety, or welfare of human subjects.
During a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping, and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators in the clinical study are also subject to FDA regulations and must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements. Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits.
Expedited Development and Review Programs.   The FDA has established programs to support and expedite the development of devices that meet criteria for Breakthrough Device designation, which can be voluntarily requested by sponsors. The program offers manufacturers of certain devices an opportunity to interact with the FDA more frequently and efficiently as they develop their products with the goal of expediting commercialization of such products to help patients have more timely access, as well as use of postmarket data collection, when scientifically appropriate, to facilitate expedited and efficient development and review of the device, opportunities for efficient and flexible clinical study design, and priority review of premarket submissions. The program is available to medical devices that meet certain eligibility criteria, including that the device provides more effective treatment or diagnosis of life threatening or irreversibly debilitating diseases or conditions, and constitutes a device (i) that represents a breakthrough technology, (ii) for which no approved or cleared alternatives exist, (iii) that offer significant advantages over existing approved or cleared alternatives, or (iv) the availability of which is in the best interest of patients.
Postmarket Regulation.   After a device is cleared or approved by the FDA for marketing, numerous and pervasive regulatory requirements continue to apply. Additionally, LDTs marketed during the phase-in period of FDA’s LDT final rule, which rule was vacated by a federal court on March 31, 2025, will become subject to certain regulatory requirements over the course of four years. These include:
•
establishment registration and device listing with the FDA;
​
•
compliance with the QSR, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation, and other quality assurance procedures during all aspects of the design and manufacturing process;
​
 
200

TABLE OF CONTENTS
 
•
labeling regulations and FDA prohibitions against the promotion of “off-label” uses of cleared or approved products;
​
•
requirements related to promotional activities;
​
•
clearance or approval of product modifications to 510(k)-cleared devices that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices, or approval of certain modifications to PMA-approved devices;
​
•
Medical Device Reporting, which requires that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;
​
•
correction, removal, and recall reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDC Act that may present a risk to health;
​
•
the FDA’s recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations; and
​
•
post-market surveillance activities and regulations, which apply to certain Class II or III devices when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device.
​
Device manufacturing processes subject to the FDA oversight are required to comply with the applicable portions of the QSR, which cover the methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation, and servicing of finished devices intended for human use. The QSR also requires, among other things, maintenance of a device master file, device history file, and complaint files. Manufacturers are subject to periodic scheduled or unscheduled inspections by the FDA. A failure to maintain compliance with the QSR requirements could result in the shut-down of, or restrictions on, manufacturing operations and the recall or seizure of products. The discovery of previously unknown problems with products, including unanticipated adverse events or adverse events of increasing severity or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician in the practice of medicine, could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory device recalls.
FDA Enforcement Powers
The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that a manufacturer has failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, including the following:
•
issuance of warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;
​
•
requesting or requiring recalls, withdrawals, or administrative detention or seizure of products;
​
•
imposing operating restrictions or partial suspension or total shutdown of production;
​
•
refusing or delaying requests for 510(k) marketing clearance, or PMA approvals of new products or modified products;
​
•
withdrawing 510(k) clearances or PMA approvals that have already been granted;
​
•
refusal to grant export approvals for products; or
​
•
criminal prosecution.
​
Healthcare Fraud and Abuse Oversight
A variety of federal and state laws prohibit fraud and abuse involving federal and state healthcare programs, as well as private insurers. These laws are interpreted broadly and actively enforced by various
 
201

TABLE OF CONTENTS
 
state and federal agencies, including CMS, the Department of Justice (“DOJ”), and the Office of Inspector General for HHS (“OIG”). While we seek to conduct our business in compliance with all federal and state fraud and abuse laws, we are unable to predict how these laws will be applied in the future or whether our arrangements will be subject to scrutiny under them by federal or state enforcement agencies. Violations of such laws may result in a range of penalties, including but not limited to significant administrative and civil fines and penalties, criminal fines and penalties, loss of licensure, disgorgement, imprisonment, exclusion from federal healthcare programs, additional reporting obligations, and oversight or other agreement to resolve allegations of non-compliance with these laws.
Federal and State Physician Self-Referral Prohibitions
We are subject to a set of federal laws aimed at preventing physician self-referral, including the federal anti self-referral law commonly known as the Stark Law. The Stark Law generally prohibits entities from billing, presenting, or causing to be presented a claim for designated health services, including laboratory services, payable by the Medicare or Medicaid programs when the physician ordering the service, or any member of such physician’s immediate family, has an ownership interest in, or compensation arrangement with, that entity, unless the arrangement meets certain delineated exceptions to the prohibition. We rely on certain exceptions to the Stark Law, and if those exceptions were to change, we could face penalties for violations. Notably, the Stark Law is a strict liability statute, which means that no proof of scienter is required to demonstrate a violation.
Sanctions for a violation of the Stark Law, among other things, include denial of payment for the services provided in violation of the prohibition, refunds of amounts collected by the entity in violation of the Stark Law, monetary penalties, and exclusion from federal healthcare program participation. In addition, violations of the Stark Law may also serve as the basis for liability under the federal False Claims Act (the “FCA”), which prohibits knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to the federal government.
Many states also have their own self-referral bans, which may extend to all self-referrals regardless of payer, with which we may have to comply unless an exception applies.
The Anti-Kickback Statute
The federal Anti-Kickback Statute (“AKS”) prohibits any person or entity, including a laboratory, from knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, in order to induce either the referral of an individual, or the furnishing, arranging for or recommending of an item or service that is reimbursable, in whole or in part, by any federal healthcare program, including the Medicare and Medicaid programs. “Remuneration” is broadly defined to include anything of value, which can include (but is not limited to) cash payments, gifts or gift cards, discounts, research opportunities, co-payment waivers or patient financial assistance, or the furnishing of services, supplies, or equipment. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The AKS can be interpreted broadly to prohibit many arrangements and practices that are lawful in businesses outside of the healthcare industry or which are innocuous or beneficial. The AKS contains statutory exceptions and regulatory safe harbors that protect certain interactions if specific requirements are met. If an arrangement meets all of the requirements of a safe harbor, it is deemed not to violate the AKS. An arrangement must fully comply with each element of an applicable safe harbor in order to qualify for protection. The failure of a transaction or arrangement to fit within a specific safe harbor, however, does not necessarily mean that the transaction or arrangement violates the statute. A violation of the AKS may result in significant penalties, including imprisonment, fines, and possible exclusion from Medicare, Medicaid, and other federal healthcare programs. Actions that violate the AKS or any similar laws may also incur liability under the FCA. Some states also have their own AKS laws and they may apply to all payers, instead of just a state healthcare program. These statutes also typically have their own safe harbor provisions, or they may cross-reference the federal AKS safe harbors.
Federal and state law enforcement authorities scrutinize arrangements between healthcare providers and potential referral sources to determine whether the arrangements were intended to induce referrals or the purchase, prescribing or ordering of products or services reimbursable by federal healthcare programs. Law enforcement authorities and the courts have also demonstrated a willingness to look behind the formalities
 
202

TABLE OF CONTENTS
 
of a transaction to determine the underlying purpose of any remuneration exchanged between healthcare providers and actual or potential referral sources. Generally, courts and federal agencies have taken the position that the AKS may be violated if even one purpose of an arrangement is to induce referrals. We rely on safe harbors to the AKS statutes in certain arrangements with potential referral sources, and those safe harbors could be revised or eliminated. In addition, the OIG periodically issues Special Fraud Alerts setting forth the agency’s view of how certain arrangements between laboratories and referring physicians implicate and potentially violate the AKS.
The penalties for violating the federal or state AKS provisions can be severe. Consequences include, among others, criminal and civil penalties, imprisonment, and possible exclusion from federal healthcare programs, among others. Moreover, claims submitted to federal healthcare programs for items or services that were the result of a violation of the AKS are deemed to be “false” for purposes of the FCA.
Eliminating Kickbacks in Recovery Act
In October 2018, Congress enacted the Eliminating Kickbacks in Recovery Act of 2018 (“EKRA”), as part of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (“SUPPORT Act”). EKRA is an all-payer anti-kickback law that criminalizes paying or offering any remuneration directly or indirectly to induce referrals to, or in exchange for, patients using the services of a recovery home, a substance use clinical treatment facility, or laboratory.
Although it appears that EKRA was intended to reach patient brokering and similar arrangements in the context of substance use recovery and treatment, the language in EKRA is broad. Moreover, although there is some overlap between EKRA’s exceptions and the AKS safe harbors, certain arrangements that are expressly protected under the AKS do not expressly receive protection under EKRA. As such, compliance with a federal AKS safe harbor does not guarantee protection under EKRA. EKRA thus potentially expands the universe of arrangements that could be subject to enforcement under federal fraud and abuse laws, as well as substantial penalties.
EKRA permits DOJ to issue regulations clarifying or expanding the statute’s exceptions, but such regulations have not yet been issued and thus there is little guidance to indicate how and to what extent it will be applied and enforced by government agencies. The relationships between laboratories and physicians, sales representatives, hospitals, and customers may be subject to scrutiny under this statute. Sanctions under the EKRA could have a negative effect on our business, if imposed.
False Claims Act
The FCA prohibits, among other things, a person from knowingly submitting (or causing to be submitted) a false claim, making a false record or statement in order to secure payment, or knowingly retaining an overpayment by the federal government. The government may assert that a claim including items and services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA. Moreover, overpayments from certain payers must be repaid within 60 days of identification unless a favorable decision is obtained on appeal, or they may be subject to reverse false claims liability. Penalties for violating the FCA include payment, among other things, of up to three times the actual damages sustained by the government, plus substantial per-claim civil penalties, as well as possible exclusion from federal healthcare programs.
Another notable feature of the FCA is that its qui tam provisions allow a private individual to bring an action on behalf of the federal government and to share in any amounts paid by the defendant to the government in connection with the action. Because the qui tam whistleblowers initially file their complaints under seal, the action may be pending for some time before the defendant is even aware of it. If the government is ultimately successful in obtaining redress in the matter or if the plaintiff succeeds in obtaining redress without the government’s involvement, then the plaintiff will receive a percentage of the recovery. It is not uncommon for qui tam lawsuits to be filed by current and former employees, as well as competitors or consultants of healthcare providers, including clinical laboratories. Several states have enacted similar laws modeled after the FCA that apply to items and services reimbursed under Medicaid and other state healthcare programs, and, in several states, such laws apply to claims submitted to any payer, including private insurers.
 
203

TABLE OF CONTENTS
 
For a discussion of such a proceeding in which we are currently involved, please see “—Legal Proceedings.”
Healthcare Fraud and False Statements
The federal healthcare fraud statute criminalizes knowingly and willfully defrauding any healthcare benefit program. A violation of this statute may result in fines, imprisonment, or exclusion from government healthcare programs. Exclusion from governmental healthcare programs also impacts the ability of the company to contract with private insurers. The false statements statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making a materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items, or services. A violation of this statute may result in fines or imprisonment. Conduct that could be considered a violation of the other healthcare related laws described herein could also form the basis of a claim under this statute.
Civil Monetary Penalties Law
The federal Civil Monetary Penalties (“CMP”) law prohibits, among other things, (i) offering or transferring remuneration to a federal healthcare program beneficiary that a person knows or should know is likely to influence the beneficiary’s decision to order or receive items or services reimbursable by a federal healthcare program from a particular provider or supplier; (ii) employing or contracting with an individual or entity that the provider knows or should know is excluded from participation in a federal healthcare program; (iii) billing for services requested by an unlicensed physician or an excluded provider; and (iv) billing for medically unnecessary services. Conduct that could be considered a violation of the FCA or the AKS can also form the basis of a CMP complaint. Penalties for violating the CMP may include exclusion from federal healthcare programs and substantial fines.
Physician Payments Sunshine Act
The federal Physician Payments Sunshine Act (“Sunshine Act”) was enacted by Congress in 2010 as part of the Affordable Care Act (“ACA”) and was amended in 2018 by the SUPPORT Act. The Sunshine Act requires certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children’s Health Insurance Program, with specific exceptions, to collect and report annually to CMS certain data on payments and other transfers of value by those manufacturers (and in some cases their distributors) to U.S. licensed physicians, teaching hospitals, and certain advanced non-physician healthcare practitioners, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives. The reporting program (known as the Open Payments program) is administered by CMS. Several states have enacted similar reporting requirements. The sale of covered medical devices triggers reporting obligations under the Sunshine Act as well as the similar state counterpart requirements.
While we intend fully to comply with applicable federal and state fraud and abuse laws, and similar laws of other states and countries as we commercialize solutions, it is possible that some of our arrangements or arrangements we may enter into in the future could become subject to regulatory scrutiny, and we cannot be certain that we will be found to be in compliance with these laws following any such regulatory review.
Other Potentially Applicable State Laws
In addition to the laws described above, states may have other fraud and abuse laws that apply to our business practices. Such laws include fee-splitting restrictions, insurance fraud laws, anti-markup laws, certain direct billing requirements, prohibitions on waiving coinsurance, copayments, deductibles, and other amounts owed by patients, and prohibitions on the provision of solutions at no or discounted cost to induce physician adoption. Other potentially applicable state laws prohibit the corporate practice of medicine, and are designed to prevent interference in the medical decision-making process by anyone who is not a licensed professional. Violation of these laws may result in a range of penalties, including civil or criminal penalties, as well as sanctions imposed against the business corporation and the professional through licensure proceedings and criminal penalties.
 
204

TABLE OF CONTENTS
 
Additional International Regulation and Product Approval
We may have to obtain or submit approvals, markings, notifications, or satisfy other premarket requirements from regulatory authorities in non-U.S. jurisdictions prior to marketing our solutions in those countries and territories. The laws and regulations in other jurisdictions vary from those in the United States and may be more difficult to satisfy, and they are subject to change, in some cases frequently. Certain regulatory authorities regulate LDTs and IVDs differently than the United States, and our solutions may need to satisfy additional requirements to be offered commercially within the jurisdictions.
European Union
In May 2017, the European Union adopted a new In Vitro Diagnostic Medical Devices Regulation 2017/746 (“IVDR”), which replaced the IVD Directive in May 2022. Under the IVDR, many more IVDs will require the involvement of a notified body in their conformity assessment procedure. Under transitional provisions, IVDs with notified body certificates issued under the IVD Directive prior to May 2022 may continue to be placed on the market for the remaining validity of the certificate, until May 2024 at the latest. After the expiry of any applicable transitional period, only IVDs that have been CE marked under the IVDR may be placed on the market in the European Union.
Other Jurisdictions
In the event we expand our business into other countries or jurisdictions around the world, we will be required to comply with such countries’ and jurisdictions’ healthcare and other laws and regulations covering comparable subject matter to that discussed in the foregoing paragraphs and that do not currently apply to us. Such laws and regulations are complex, change frequently, and vary among jurisdictions.
Coverage and Reimbursement
Reimbursement and billing for clinical laboratory services is highly complex. Laboratories must bill various payers, which may include federal healthcare programs (such as Medicare, Medicaid, and TRICARE), as well as Medicare Advantage plans, private insurers, and managed care organizations. Submitting claims to various payers is complicated because each payer may have different billing requirements. Additionally, the audit requirements laboratories must meet the ensure compliance with applicable laws and regulations, as well as internal compliance policies and procedures, add further complexity to the billing process.
We are currently pursuing and will continue to pursue payment for our solutions through a diverse and broad range of channels, including coverage and reimbursement by government healthcare programs and commercial third-party payers.
General Coverage and Reimbursement Considerations
Across jurisdictions, a decision by a payer (regardless of whether it is a governmental or private payer) to cover a solution does not guarantee that those payers will provide adequate reimbursement for that solution. Moreover, third-party payers are increasingly examining the medical necessity and cost- effectiveness of medical products and services, including clinical laboratory tests, in addition to their safety and efficacy. Furthermore, coverage and reimbursement for products, and services that utilize such products, can differ significantly from payer to payer. As a result, the coverage determination process is often time-consuming and costly and requires us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained at all.
In certain foreign markets, the government controls the coverage and pricing of many healthcare products, including clinical laboratory tests. In order to obtain coverage and reimbursement for any product that might be cleared or approved by regulators for sale, or for any procedure that utilizes such product, it may be necessary to conduct health economic studies in order to demonstrate the medical necessity and cost-effectiveness of the products. The cost of such studies would be in addition to the costs required to obtain regulatory approvals. If third-party payers do not consider a product to be cost-effective compared to
 
205

TABLE OF CONTENTS
 
other available products, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit.
The marketability of our solutions may suffer if governmental and third-party payers fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased, and we expect will continue to increase the pressure on medical products and services pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for our solutions, less favorable coverage policies and reimbursement rates may be implemented in the future.
Coverage and Reimbursement in the United States
In the United States, there is no uniform coverage for clinical laboratory tests. The extent of coverage and rate of payment for covered services varies from payer to payer. Obtaining coverage for solutions like ours that involve genomic sequencing can be particularly challenging. Medicare is the single largest healthcare payer in the United States, and a particularly significant payer for many cancer-related laboratory services given the demographics of the Medicare population, a large portion of which includes elderly individuals. Many other U.S. payers look to the Medicare policies as a benchmark and model for their own coverage and reimbursement decisions. Medicare provides two main forms of insurance coverage: traditional Medicare fee-for-service, administered by the federal government and its contractors, and Medicare Advantage, administered by private insurers that must generally follow traditional Medicare rules and guidelines.
Medicare coverage is limited to items and services that are within the scope of a Medicare benefit category that are reasonable and necessary for the diagnosis or treatment of an illness or injury. National coverage determinations are made through an evidence-based process by the CMS, with opportunities for public participation. Medicare’s National Coverage Determination (“NCD”) for NGS, first established in 2018 and subsequently updated in 2020, provides national Medicare coverage for certain molecular diagnostic tests when: (1) performed in a CLIA-certified laboratory, (2) ordered by a treating physician, (3) the patient meets certain clinical and treatment criteria, including having recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer, (4) the test is approved or cleared by the FDA as a companion IVD for an FDA approved or cleared indication for use in that patient’s cancer, and (5) results are provided to the treating physician for management of the patient using a report template to specify treatment options. The NGS NCD also states that each Medicare Administrative Contractor (“MAC”) may provide local coverage of other NGS tests for cancer patients only when the test is performed by a CLIA-certified laboratory, ordered by a treating physician and the patient meets the same clinical and treatment criteria required of nationally covered NGS tests under the NGS NCD. Palmetto GBA is the MAC responsible for administering Medicare’s MolDX, which issues local coverage determinations (“LCDs”) for molecular diagnostic tests that are not approved or cleared by the FDA. Our MAC for the Phoenix laboratory locations is Noridian, and Noridian relies on MolDX to make coverage and pricing determinations relating to molecular profiling. To achieve coverage under MolDX’s LCDs for molecular profiling, a test must demonstrate analytical and clinical validity, and clinical utility at a level that meets the Medicare reasonable and necessary requirement. Our MI Cancer Seek solution has Medicare coverage under the NGS NCD. Our MI Tumor Seek Hybrid solution and our Caris Assure solution for therapy selection are currently covered by Medicare under the MolDX Program.
On January 19, 2021, CMS released an NCD that covers future tests for colorectal cancer (“CRC”) screening if and when such screening tests have FDA approval and meet pre-specified CMS criteria. In addition, MolDX LCDs provide coverage for MRD for CRC, breast cancer, lung cancer, and other indications when applicable coverage criteria are satisfied. Amongst other items, this coverage criteria includes published literature showing the clinical validity of an assay for the intended use of the assay in the intended population. While we have had preliminary discussions with MolDX regarding coverage for Caris Assure for MRD for CRC, it is possible that MolDX will require us to complete additional publications or validation studies and timing for MolDX coverage, if any, is uncertain.
MolDX has also issued an LCD for coverage of NGS assays for myeloid malignancies where applicable coverage criteria are satisfied. Among other items, this coverage criteria includes that the assay has completed a technical assessment by MolDX for the assay’s stated indications. In order to obtain MolDX
 
206

TABLE OF CONTENTS
 
coverage for Caris ChromoSeq, we will need to submit, and MolDX will need to approve, a technical assessment for Caris ChromoSeq.
Coding plays a significant role in how our solutions are reimbursed both from commercial and governmental payers. The CPT codes, which are maintained by the AMA, are a set of codes for medical services, including profiling services. In addition to CPT codes, there are PLA codes, also maintained by the AMA, that are a set of billing codes for laboratory services that are more specific than CPT codes. New In addition to CPT and PLA codes, Z-Code Identifiers are used by certain payers, including under Medicare’s MolDX, to supplement CPT codes for molecular diagnostics tests.
A laboratory launching a new advanced diagnostic laboratory test (“ADLT”) or clinical diagnostic laboratory test (“CDLT”) can apply for a PLA code with the AMA. This process requires the laboratory to submit an application to the AMA. The AMA then makes coding methodology recommendations to CMS that could include “Crosswalk” or “Gapfill.” A Crosswalk is used if it is determined that there is an existing similar code, set of codes, or portion of a code that could be used to describe the new test. In this case, pricing would be the equivalent of the existing comparable code, the sum of multiple comparable codes, or a fraction of the comparable code. Gapfill is used when there are no comparable existing codes available. In this case, pricing is based on historical payments from other payers and/or resources required to complete the test. CMS will review the recommendation made by the AMA but will ultimately decide upon the coding methodology independently. This initial decision will be posted for public comment, and pricing will be published at the end of the public comment period. After pricing and coding is published, a request is then submitted to CMS for coverage under an existing NCD, or a request is made to create a new NCD.
In July 2020, the AMA issued a PLA code, CPT code 0211U, for our MI Cancer Seek solution with effective date October 1, 2020. CMS subsequently established national pricing for CPT code 0211U under the CLFS at $8,455. We have obtained Medicare coverage for MI Cancer Seek for CPT code 0211U under the NGS NCD. Our MI Tumor Seek Hybrid solution is reported to Medicare and to some commercial payers using unlisted molecular pathology CPT code 81479 and unique Z-Code Identifiers. In July 2024, the AMA issued a PLA code, CPT code 0485U, for Caris Assure for therapy selection, with an effective date of October 1, 2024. In November 2024, CMS determined to price Caris Assure for therapy selection using the “Gapfill” method. There is no certainty regarding the pricing that we will obtain for Caris Assure during the Gapfill process. Changes to these coverage polices or to the codes used to report to payers may result in significant changes in reimbursement.
Our early detection solution could be considered a screening test by Medicare and is not currently covered by Medicare. Medicare coverage for preventive services such as screening tests must be expressly authorized by statute or by CMS under an applicable NCD. Under CMS regulations, additional preventive services covered under an NCD must be (a) reasonable and necessary for the prevention or early detection of an illness or disability, (b) recommended with a grade of A or B by the USPSTF, which is an independent, volunteer panel of experts in the field of prevention, evidence-based medicine and primary care, and (c) appropriate for Medicare beneficiaries under Part A or Part B. None of our solutions have received such a grade or determination from USPSTF, which generally waits for FDA authorization before undertaking review of novel technology. In addition, the NCD process may take multiple years to complete, and currently, coverage decisions for preventive services are not made prior to FDA authorization. Even if we go through the lengthy NCD process, it is possible that the early detection solution will never become eligible for Medicare coverage and reimbursement.
We are evaluating opportunities for nearer-term coverage and reimbursement through Medicare Advantage plans as a supplemental benefit while generating evidence to meet the requirements of the traditional Medicare path. Medicare Advantage plans generally must cover all of the services that traditional Medicare covers (except hospice care), but they have the discretion to offer their enrollees additional, or supplemental, benefits not otherwise covered under traditional Medicare, including those benefits referred to as optional supplemental benefits, for which enrollees may elect to pay extra to receive coverage. Obtaining such coverage may, however, involve lengthy negotiations with individual Medicare Advantage plans, and there is no guarantee that we will receive such coverage.
We also intend to pursue coverage and reimbursement from private payers for our solutions. Many of these private payers must cover certain services required by federal and state laws, such as preventive
 
207

TABLE OF CONTENTS
 
health services that have received a rating of A or B by the USPSTF. Like Medicare Advantage plans, private payers have discretion to extend greater coverage than recognized under traditional Medicare but obtaining coverage from such payers may involve lengthy negotiations and there is no guarantee that we will receive such coverage. Even if we are successful in receiving coverage, the reimbursement amounts may not meet expected levels. State Medicaid programs make individual coverage decisions for diagnostic tests and have taken steps to control the cost, utilization and delivery of healthcare services meaning that, even if we receive coverage through private payers, there is no guarantee that our solutions will be covered by individual state Medicaid programs.
With respect to private health plans, the ACA mandates that such plans cover evidence-based items or services recommended by USPSTF with a grade of A or B, with certain prohibitions on cost-sharing requirements. Accordingly, if the USPSTF does not recommend use of Caris Assure or other solutions we are developing or requires a substantial amount of time to review such solutions, our business, financial condition, and results of our operations would be harmed.
The Protecting Access to Medicare Act of 2014
In April 2014, Congress passed the Protecting Access to Medicare Act of 2014 (“PAMA”), which included substantial changes to the way in which certain clinical laboratory services are paid under Medicare’s CLFS. Under PAMA (as amended by the Further Consolidated Appropriations Act in 2020 and Further Continuing Appropriations and Other Extensions Act of 2024), laboratories that receive the majority of their Medicare revenue from payments made under the CLFS and Physician Fee Schedule and receive at least $12,500 in Medicare revenues for CLFS services during a data collection period are subject to certain reporting requirements. CMS uses the data reported, including certain private payer payment rates, the volume of tests paid at each rate, and the HCPCS code associated with the test, to calculate a weighted median payment rate for each test, which is used to establish revised Medicare CLFS reimbursement rates for tests that are considered to be CDLTs. If the test falls into the category of new ADLT instead of CDLT, the test will be paid based on an actual list charge for an initial period of three quarters before being shifted to the weighted median private payer rate reported by the laboratory performing the ADLT. Laboratories offering ADLTs are subject to recoupment if the actual list charge exceeds the weighted median private payer rate by a certain amount. Accordingly, if newly developed tests receive Medicare coverage in the future, the reimbursement rate we receive for such tests may be affected by payment rates made by private payers for such tests. In addition, PAMA codified Medicare coverage rules for laboratory tests by requiring any local coverage determination to be made following the local coverage determination process. PAMA also authorizes CMS to consolidate coverage policies for clinical laboratory tests among one to four laboratory-specific MACs. These same contractors may also be designated to process claims if CMS determines that such a model is appropriate. It is unclear whether CMS will proceed with contractor consolidation under this authorization.
Congress passed legislation that delayed data reporting requirements for CDLTs that are not ADLTs, and delayed the phase-in of payment reductions under the CLFS from private payer rate implementation. The revised reimbursement methodology described above generally results in relatively lower reimbursement amounts under Medicare for clinical laboratory services than has been historically reimbursed. Any reductions to reimbursement rates resulting from the new methodology are limited to 0% in 2025 and 15% per test per year in each of 2026 through 2028.
The subsequent data reporting period for CDLTs that are not ADLTs will occur in three-year cycles, with the next cycle beginning in 2026. The pricing for our solutions may be negatively impacted by the PAMA reporting process. Given the many uncertainties built into PAMA’s price-setting process, we cannot predict how payments we receive under the CLFS, and thus our revenue, may change from year to year.
Healthcare Reform
In the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system. Changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our solutions, decrease our revenue and adversely impact sales of, and pricing of and reimbursement for, our solutions. For
 
208

TABLE OF CONTENTS
 
example, in March 2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. The ACA contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments, and fraud and abuse changes.
The implementation of the ACA in the United States, for example, has changed healthcare financing and delivery by both governmental and private insurers substantially, and affected medical device manufacturers significantly. The ACA included, among other things, provisions governing enrollment in federal and state healthcare programs, reimbursement matters, and fraud and abuse. Since its enactment, there have been judicial, U.S. Congressional and executive branch challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the “IRA”) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is unclear how other healthcare reform measures, if any, will impact our business.
In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011, among other things, resulted in reductions in payments to Medicare providers, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2032, unless additional Congressional action is taken. In addition, as a result of the American Rescue Plan Act of 2021 (“ARPA”), an additional Medicare payment reduction of up to 4% was required to take effect in January 2022; however, Congress has delayed implementation of this reduction until 2025. Additionally, the American Taxpayer Relief Act of 2012, among other things, reduced CMS payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover Medicare overpayments to providers from three to five years.
We believe that there will continue to be proposals by legislators at both the federal and state levels, regulators, and third-party payers to reduce costs while expanding individual healthcare benefits. Certain of these proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our solutions. Changes in healthcare policy could increase our costs, decrease our revenue, and impact sales of and reimbursement for our solutions.
Privacy Regulation
Data Privacy and Security Regulation
Numerous state, federal, and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health-related information. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws, including HIPAA or HITECH, and federal and state consumer protection laws and regulations (for example, Section 5 of the Federal Trade Commission Act) that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. In particular, we are a “Covered Entity” as defined under HIPAA when performing our healthcare services for customers, and also act as a “Business Associate” when performing certain services for or on behalf of Covered Entities, which requires us to develop and maintain policies with respect to the protection of, use, and disclosure of PHI, including the adoption of administrative, physical and technical safeguards to protect such information, and to provide notifications in the event of a breach of unsecured PHI. In addition, many states have also implemented healthcare privacy and genetic testing and privacy laws imposing specific patient consent requirements and protecting test results by limiting the disclosure of those results. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly
 
209

TABLE OF CONTENTS
 
evolving, may conflict with each other to make compliance efforts more challenging, and can result in investigations, proceedings, or actions that lead to significant penalties and restrictions on data processing.
As a healthcare provider, we are also subject to Section 4004 of the 21st Century Cures Act, and regulations promulgated by HHS related to patient access to electronic PHI (“EHI”), to promote interoperability and to ensure the access, exchange, or use of EHI.
Other International Privacy and Security Regulations
Our business is subject to a complex and evolving global web of laws and regulations governing data privacy, data security, cross-border data transfers, and data localization. Local, state, federal, and foreign governments are increasingly implementing or expanding their data protection regimes, resulting in additional compliance costs and risks. Many of these laws and regulations are subject to change and uncertain interpretation and could result in regulatory or litigation claims or actions, changes to our business practices, monetary penalties, increased cost of operations, declines in clinical study participation or engagement, or otherwise harm our business.
We rely on information technology systems, including third-party hosted services, to support our business processes and activities and to store personal data (including employee and patient data). Consequently, we are at risk of a cybersecurity-related attack, intrusion, or disruption, including by criminal organizations, hackers, foreign governments, and terrorists. A cybersecurity incident could result in some or all of our systems being unavailable, the loss, misuse, or unauthorized disclosure of genetic information or other personal data, negative publicity and reputational damage, exposure to risk of loss, and litigation and regulatory investigations. In the event we are a victim of a cyberattack, data breach notification laws may require us to notify regulators, affected individuals, and potentially other third parties in multiple jurisdictions. Cyber threats are constantly evolving, increasing the difficulty of detecting and successfully defending against them. Despite our security measures, we cannot guarantee that these measures will prevent all possible security breaches or attacks.
Employees and Human Capital Resources
As of March 31, 2025, we had 1,769 full-time employees. Of these employees, nearly 50 have Ph.D. or M.D. degrees and over 200 are engaged in R&D activities. None of our employees are represented by a labor union or party to a collective bargaining agreement.
Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing, and integrating our existing and new employees, advisors, and consultants. We believe our success depends on our ability to attract, retain, develop, and motivate diverse highly skilled personnel. In particular, we depend upon the personal efforts and abilities of the principal members of our senior management to partner effectively as a team and to provide strategic direction, develop our business, manage our operations, and maintain a cohesive and stable work environment. We also rely on qualified managers and skilled employees, such as scientists, engineers, and laboratory technicians, with technical expertise in operations, scientific knowledge, engineering skills, and quality management experience in order to operate our business successfully.
Our compensation program is designed to retain, motivate, and attract highly qualified personnel, including through the granting of stock-based and cash-based compensation awards, in order to increase shareholder value and the success of our Company by motivating such individuals to perform to the best of their abilities and achieve our business objectives.
Key Relationships
Supply Agreement with Illumina
In November 2022, we entered into Illumina, Inc.’s (“Illumina”) “open offer” supply agreement wherein Illumina provides products and services that we use in our laboratory operations for certain research and clinical activities, including certain sequencers, equipment, and other materials (the “Illumina Agreement”).
 
210

TABLE OF CONTENTS
 
Under the Illumina Agreement, Illumina grants non-exclusive, non-transferable, personal, non-sublicensable rights to use certain Illumina know-how and technology with Illumina products purchased under the agreement, and we granted Illumina an irrevocable, perpetual, worldwide, fully paid-up, and royalty-free license covering improvements to certain Illumina know-how and technology. The Illumina Agreement does not contain any minimum purchase requirements but provides for volume discounts and other promotions. The Illumina Agreement also contains use limitations, representations and warranties, indemnification, limitations of liability, change notification, audit rights, and other provisions.
The Illumina Agreement is irrevocable by Illumina until its expiration in August 2033. We have a unilateral right to terminate our supply relationship with Illumina at any time and for any reason without termination liability upon 90 days’ prior written notice to Illumina.
Master Supply Agreement with Roche
In July 2024, we entered into a master supply agreement with Roche Diagnostics Corporation (“Roche”), for Roche to provide sequencing probes and other testing supplies and equipment for clinical and research uses in our laboratory operations (the “Roche Agreement”). Under the Roche Agreement, we receive certain pricing levels if we purchase a specified minimum annual quantity of supplies. Under the terms of the Roche Agreement, we also agreed to make rolling forecasts of our expected needs, which forecasts currently become three- and six-month binding purchase commitments for catalog and custom products, respectively. The pricing is fixed for the initial 12 months of the agreement term described below, and subject to increase thereafter. The Roche Agreement also contains negotiated use limitations, representations and warranties, indemnification, limitations of liability, and other provisions.
The Roche Agreement has an initial term through April 2027 and will automatically renew with successive one-year terms unless either party provides 90-day advance notice of non-renewal. The agreement also provides for other customary termination rights, including in the case of material breach by, or insolvency of, either party.
Facilities
Our corporate headquarters are located in Irving, Texas, where we lease approximately 30,500 square feet pursuant to a lease expiring in 2028. We also lease office space in Arizona, Massachusetts, and New York, and in Switzerland and Japan for our international offices.
We lease an approximately 66,000 square foot solid tissue clinical laboratory facility and an approximately 35,500 square foot blood-based clinical laboratory facility in Phoenix, Arizona, with leases expiring in 2030 and 2026, respectively. We also lease an approximately 59,000 square foot R&D laboratory facility in Tempe, Arizona and an approximately 114,500 square foot laboratory facility in Irving Texas, with leases expiring in 2026 and 2035, respectively. The laboratory facility in Irving, Texas is continuing to be built-out and will bring our total operational capacity to over 275,000 square feet.
We lease an approximately 54,500 square foot customer service office and an approximately 22,550 square foot warehouse facility in Phoenix, Arizona, with leases expiring in 2030 and 2031, respectively. We also lease an approximately 23,400 square foot warehouse facility in Irving, Texas, with a lease expiring in 2032.
We do not own any real property. We believe that our facilities are adequate to meet our needs for the immediate future, and that, should it be needed, suitable additional space will be available to accommodate any such expansion of our operations.
Legal Proceedings
In March 2025, we received a Civil Investigative Demand (“CID”) from the DOJ in connection with an investigation under the FCA regarding our compliance with Medicare’s date of service rule (also referred to as the 14-day rule), particularly focused on patients of certain health care providers, and our policies, procedures, and training related to compliance with the 14-day rule. The related investigation continues to evolve and is in too early a stage to assess potential outcomes. We are cooperating with the investigation. We have implemented compliance policies, procedures, and training designed to foster
 
211

TABLE OF CONTENTS
 
compliance with the 14-day rule, but there can be no certainties regarding the outcome of the CID. In June 2022, we entered into a settlement agreement with the United States in connection with a previous investigation into our compliance with the 14-day day rule. Pursuant to this settlement agreement, under which we admitted no fault or liability, we paid approximately $2.9 million in restitution and penalties and we obtained a nationwide release from all 14-day rule claims prior to January 1, 2018.
In addition to the matter described above, we are, from time to time, party to various claims and legal proceedings arising out of our ordinary course of business, including claims or proceedings relating to, among other things, regulatory matters, intellectual property, competition, tax, and employment matters, medical malpractice, product or professional liability or other tort claims. We cannot predict with certainty the results of any claims or proceedings. We may receive unfavorable preliminary or interim rulings in the course of litigation, and there can be no assurances that favorable final outcomes will be obtained. Moreover, the existence of any claim or legal proceeding, regardless of the outcome, may adversely impact us because of diversion of management time and attention as well as the financial costs related to resolving such disputes. For additional information, see “Risk Factors—Risks Related to Regulation and Legal Compliance—We have been, are currently, and in the future may be the subject of government investigations, claims, audits, whistleblower and payer audits, overpayment and recoupment efforts and other litigation in the course of our business that could adversely affect our business and financial statements.”
 
212

TABLE OF CONTENTS​
 
MANAGEMENT
Executive Officers and Directors
Set forth below are the names, ages, and positions of our executive officers and directors as of the date of this prospectus.
Name
​ ​
Age
​ ​
Position(s)
​
Executive Officers ​ ​ ​ ​ ​ ​ ​
David D. Halbert, D.Sc. (h.c.)
​ ​
69
​ ​
Founder, Chairman, and Chief Executive Officer
​
Brian J. Brille
​ ​
64
​ ​ Vice Chairman and Executive Vice President ​
David Spetzler, M.S., Ph.D., M.B.A.
​ ​
49
​ ​ President ​
Luke Power
​ ​
44
​ ​ Senior Vice President, Chief Financial Officer,
and Chief Accounting Officer
​
J. Russel Denton
​ ​
42
​ ​ Senior Vice President, General Counsel, and Secretary ​
Non-Employee Directors ​ ​ ​ ​ ​ ​ ​
George H. Poste, D.V.M., Ph.D., D.Sc., F.R.S.
​ ​
81
​ ​ Vice Chairman ​
Jonathan Knowles, Ph.D.
​ ​
77
​ ​ Vice Chairman ​
Nathan Burns(3)
​ ​
43
​ ​ Director ​
Peter M. Castleman(1)(2)
​ ​
68
​ ​ Director ​
David Fredrickson
​ ​
50
​ ​ Director ​
Joseph E. Gilliam(1)(2)
​ ​
49
​ ​ Director ​
Jon S. Halbert
​ ​
65
​ ​ Director ​
Laura I. Johansen(2)
​ ​
59
​ ​ Director ​
Lloyd B. Minor, M.D.
​ ​
67
​ ​ Director ​
Vijay Mohan(3)
​ ​
45
​ ​ Director ​
Danny Phillips(1)
​ ​
65
​ ​ Director ​
Jeffrey Vacirca, M.D., F.A.C.P.
​ ​
56
​ ​ Director ​
​
(1)
Member of the audit committee of our board of directors.
​
(2)
Member of the compensation committee of our board of directors.
​
(3)
Messrs. Burns and Mohan have notified us that they each intend to resign from our board of directors effective as of immediately prior to the effectiveness of the registration statement of which this prospectus forms a part.
​
Executive Officers
David D. Halbert, D.Sc. (h.c.) founded our Company in 2008 and has served as our Chief Executive Officer and the Chairman of our board of directors since our inception. Mr. Halbert and his family also created and solely support the Caris Foundation, a non-profit, private foundation formed in 2002 that aids impoverished people by helping to provide for their basic needs. From 2005 to 2011, Mr. Halbert served as Chairman and Chief Executive Officer of Caris Diagnostics, a Texas-based pathology company specializing in gastrointestinal pathology, which was sold to Miraca Life Sciences in 2011. Prior to Caris Diagnostics, Mr. Halbert served as Chairman and Chief Executive Officer of AdvancePCS Inc. (“AdvancePCS”), a prescription benefit plan administrator that he founded in 1987. Mr. Halbert holds a Bachelor of Business Administration from Abilene Christian University and an honorary Doctor of Science from Abilene Christian University for his contributions to precision medicine and his global philanthropic work. We believe Mr. Halbert’s extensive knowledge of the healthcare industry, business experience, and 20 years of leadership as Caris’ Founder, Chairman, and Chief Executive Officer make him well-qualified to serve as a member of our board of directors.
 
213

TABLE OF CONTENTS
 
Brian J. Brille has served as our Vice Chairman and Executive Vice President and as a member of our board of directors since January 2018. Mr. Brille currently serves as a member of the board of trustees at the Cancer Research Institute, a non-profit organization funding cancer research. Since 2022, Mr. Brille has also served as member of the board of directors at the International Biomedical Research Alliance, a non-profit organization with a mission to support the NIH Oxford-Cambridge Scholars Program. Prior to joining Caris, Mr. Brille served in various finance-related roles for Bank of America Merrill Lynch (now BofA Securities, Inc.), a multinational investment bank and financial services company, from 1999 to 2013, including most recently as Chairman & President of Asia Pacific from 2009 to 2013, as Head of Corporate and Investment Banking from 2005 to 2008, and as Head of Healthcare Investment Banking from 1999 to 2004. Mr. Brille began his career in 1987 at Morgan Stanley & Co. LLC (“Morgan Stanley”), a multinational investment bank and financial services company, and founded Morgan Stanley’s Healthcare Services Investment Banking Group. Mr. Brille holds a Juris Doctor from Stanford Law School, a Master in Public Policy from the Harvard Kennedy School, and a Bachelor of Science in Accounting from the University of Illinois. We believe Mr. Brille’s extensive experience in the investment industry and knowledge of healthcare and technology companies make him well-qualified to serve as a member of our board of directors.
David Spetzler, M.S., Ph.D. has served as our President since November 2016. Dr. Spetzler has also served as an adjunct faculty member of the molecular cellular biology program at Arizona State University since 2007. Dr. Spetzler joined Caris in August 2009 as a Senior Scientist and has served in a variety of roles of increasing seniority during his tenure. Before Caris, Dr. Spetzler served in various research faculty roles at Arizona State University from January 2003 to August 2009. Dr. Spetzler holds a Master of Science, a Doctor of Philosophy in Molecular & Cellular Biology, and a Master of Business Administration from Arizona State University.
Luke Power has served as our Senior Vice President, Chief Financial Officer, and Chief Accounting Officer since February 2023. Mr. Power joined Caris in December 2011 as a Financial Reporting and Accounting Manager and has served in a variety of roles of increasing seniority during his tenure, including as Chief Accounting Officer from April 2017 to February 2023, Senior Director of Accounting from May 2016 to September 2016, and Director of Accounting from August 2013 to May 2016. Prior to joining Caris, Mr. Power worked as a Manager in the international assurance practice at PricewaterhouseCoopers LLP, a provider of business advisory services, from November 2002 to October 2011. Mr. Power is a certified public accountant and a fellow of Chartered Accountants Ireland. Mr. Power holds a degree in finance and accounting from Waterford Institute of Technology in Ireland.
J. Russel Denton has served as our Senior Vice President, General Counsel, and Secretary since September 2022. Prior to joining Caris, Mr. Denton served as a partner at Shearman & Sterling LLP, an international law firm, representing clients in mergers and acquisitions and equity financing transactions from March 2018 to September 2022. Prior to Shearman & Sterling LLP, Mr. Denton served as a partner at Andrews Kurth Kenyon LLP from May 2012 to February 2018. Mr. Denton began his career in September 2008 as an associate at Skadden, Arps, Slate, Meagher and Flom LLP. Mr. Denton holds a Juris Doctor from Stanford Law School and a Bachelor of Science from Duke University.
Non-Employee Directors
George H. Poste, D.V.M., Ph.D., D.Sc., F.R.S. has served as our Vice Chairman since our founding in 2008. Since February 2009, Dr. Poste has served as the Chief Scientist of the Complex Adaptive Systems Initiative at Arizona State University, a program that links expertise across the university in research on synthetic biology, ubiquitous sensing, and healthcare informatics for personalized medicine, and as the Del E. Webb Professor of Health Innovation. From May 2003 to February 2009, Dr. Poste served as Director of The Biodesign Institute at Arizona State University. Since January 2000, Dr. Poste has served as the Chief Executive Officer of Health Technology Networks, a consulting company that specializes in the application of genomic technologies and computing in healthcare. From July 1992 to December 1999, Dr. Poste was the Chief Science and Technology Officer and President, R&D, of SmithKline Beecham Corporation, a pharmaceutical company. Dr. Poste served on the Defense Science Board of the U.S. Department of Defense from January 2000 to December 2009 and is a member of the Bipartisan Commission on Biodefense as well as other U.S. government organizations to advise on national security policy on advancing defenses against bioweapons and biowarfare. Dr. Poste has served as a member of the board of directors of Exelixis,
 
214

TABLE OF CONTENTS
 
Inc., a genomics-based drug discovery company, since 2004. Previously, Dr. Poste served as a member of the board of directors of Monsanto Company, a provider of agricultural products and solutions, from 2003 to 2018, Orchid Cellmark, Inc., a DNA forensics company, from 2002 to 2009, AdvancePCS, from 2002 to 2005, Structural GenomiX, a biotechnology company, from 2000 to 2003, and Illumina, from 2000 to 2003. Dr. Poste also serves on several scientific advisory boards, including Synthetic Genomics Inc., VirBiotech, the University of Michigan Taubman Institute, and MIDAS Advanced Computing Initiative. Dr. Poste is a Fellow of the UK Royal Society, the UK Academy of Medical Sciences, American Institute for Medical and Biological Engineering. Dr. Poste is also a member of the Council for Foreign Relations and previously served as a member of the Hoover Institution, Stanford University, and has received several honorary doctorates from several universities. Dr. Poste holds a Doctor of Veterinary Medicine and a Doctor of Philosophy in Virology from the University of Bristol, England and Board Certification in Pathology from the Royal College of Pathologists. We believe Dr. Poste’s training as a scientist, knowledge of the life sciences, healthcare, and biopharma industries, and extensive service on multiple boards make him well-qualified to serve as a member of our board of directors.
Jonathan Knowles, Ph.D. has served as our Vice Chairman since 2010. Dr. Knowles served as the President of Group Research at Roche Holding AG (“Roche”), a Swiss multinational healthcare company, from September 1998 to January 2010 and as a member of its Corporate Executive Committee from January 1998 to January 2010. From January 1998 to January 2010, Dr. Knowles served as a member of the board of directors and as Chairman of the Corporate Governance Committee of Genentech, Inc., a biotechnology corporation that later became a subsidiary of Roche. From January 2007 to January 2010, Dr. Knowles served as the Chairman of the Research Directors’ Group of the European Federation of Pharmaceutical Industry Associations. He has also served on the boards of directors of various pharmaceutical companies. Dr. Knowles is a Professor Emeritus at the École Polytechnique Fédérale de Lausanne, a Distinguished Professor in Personalized Medicine at the University of Helsinki, Finland, and a visiting Professor at the University of Oxford. Dr. Knowles holds a Bachelor of Science in Molecular Genetics from the University of East Anglia and a Doctor of Philosophy in Genetics of Mitochondria from the University of Edinburgh. We believe Dr. Knowles’ extensive experience in the pharmaceutical industry and years of experience in his leadership roles as a director and executive officer make him well-qualified to serve as a member of our board of directors.
Nathan Burns has served as a member of our board of directors since August 2022. Mr. Burns is currently a Managing Director & Healthcare Portfolio Manager at Highland Capital Management, L.P., a global alternative investment manager based in Dallas, Texas. Mr. Burns joined Highland Capital Management, L.P. in July 2014 as a Director of Healthcare Absolute Return Investments. Prior to joining Highland Capital Management, L.P., Mr. Burns was a Private Equity Associate at Ripplewood Holdings, a global private equity firm, from September 2007 to December 2013. Mr. Burns began his career as an Investment Banking Analyst in the Global Technology Mergers & Acquisitions Group at Lehman Brothers, a global financial services firm, from June 2004 to June 2007. Mr. Burns holds a Bachelor of Science in Analytical Finance and Economics from Wake Forest University and Master of Business Administration from Columbia Business School. He also is a CFA charterholder. We believe Mr. Burns’ extensive experience in the investment industry and knowledge of healthcare companies make him well-qualified to serve as a member of our board of directors.
Peter M. Castleman has served as a member of our board of directors since 2008. Mr. Castleman is a private company investor and entrepreneur. Mr. Castleman is actively involved with about a dozen private companies where he is a significant owner through his family office, which he established in December 2006. Prior to establishing his family office, Mr. Castleman was the Chairman and Managing Partner of J. H. Whitney & Co., LLC, a private equity firm, from December 1992 to December 2006, where he oversaw all the firm’s activities, including the private equity investing business. Prior to joining J. H. Whitney & Co., LLC in May 1987, Mr. Castleman was with Morgan Stanley & Co. LLC in their leveraged buyout investment group. Mr. Castleman started his career at J.P. Morgan Securities LLC, where he was an international banking officer. Mr. Castleman holds a Master of Business Administration from Harvard Business School and a Bachelor of Arts from Duke University. We believe Mr. Castleman’s extensive experience in the investment industry and years of experience in his leadership roles as a director and executive officer make him well-qualified to serve as a member of our board of directors.
 
215

TABLE OF CONTENTS
 
David Fredrickson has served as a member of our board of directors since August 2024. Mr. Fredrickson currently serves as Executive Vice-President, Oncology Business Unit of AstraZeneca PLC, a position that he has held since October 2017. Previously, Mr. Fredrickson served as President of AstraZeneca K.K. in Japan, and Vice-President, Specialty Care of AstraZeneca in the United States. While in Japan, Mr. Fredrickson also served as Vice Chairman of the European Federation of Pharmaceutical Industries and Associations Japan and was a Director of the Japan Pharmaceutical Manufacturers Association. Before joining AstraZeneca, Mr. Fredrickson worked at Genentech, Inc., a biotechnology corporation that later became a subsidiary of Roche, where he served in several functions and leadership positions, including as Oncology Business Unit Manager in Spain, and in strategy, marketing, and sales roles in the United States. Prior to this, Mr. Fredrickson worked at the Monitor Group, LLC (now Monitor Deloitte Group, LLC), a global strategy consultancy firm. Mr. Fredrickson holds a Bachelor of Arts in Government from Georgetown University. We believe Mr. Fredrickson’s extensive experience in the pharmaceutical and oncology industries and years of experience in his leadership roles as a director and executive officer make him well-qualified to serve as a member of our board of directors.
Joseph E. Gilliam has served as a member of our board of directors since April 2021. Mr. Gilliam is currently the President and Chief Operating Officer at Glaukos Corporation, an ophthalmic pharmaceutical and medical device company, a position he has held since April 2022. From May 2017 to April 2022, Mr. Gilliam was Chief Financial Officer and Senior Vice President, Corporate Development at Glaukos Corporation. Prior to Glaukos Corporation, Mr. Gilliam served as a Managing Director in the Healthcare Investment Banking group at J.P. Morgan Securities LLC from 2013 to May 2017, where he led the initial public offering for Glaukos Corporation. From 2000 to 2013, Mr. Gilliam held positions of increasing responsibility at J.P. Morgan Securities LLC and its predecessor organizations, The Beacon Group and Chase Manhattan, with experience spanning mergers and acquisitions, primary and secondary public equity offerings, bank lending, bond offerings and other transactions. Mr. Gilliam started his career at PricewaterhouseCoopers LLP as an Auditor. Mr. Gilliam holds a Bachelor of Science in accounting from the Kelly School of Business at Indiana University. We believe Mr. Gilliam’s extensive experience in the investment and healthcare industries and knowledge of healthcare companies make him well-qualified to serve as a member of our board of directors.
Jon S. Halbert has served as a member of our board of directors since May 2014. Mr. Halbert currently serves as a member of the board of directors at Allegiance Group, a leading provider of fundraising services to nonprofit organizations in the United States, a position he has held since January 2023. Since August 2007, Mr. Halbert has also served as a member of the board of directors of the Pursuant Group, a nonprofit-focused marketing and fundraising organization that merged with the Allegiance Group in April 2023. Mr. Halbert also currently serves on the boards of directors of CitiSquare and Forest Forward, Dallas-based nonprofit organizations that focus on poverty and the revitalization of South Dallas, respectively. Mr. Halbert served as the Chairman of Phytel, Inc., a technology driven provider-led population health improvement company, until its merger with the International Business Machines Corporation in 2015. Prior to Phytel, Inc., Mr. Halbert co-founded and served as Vice Chairman of AdvancePCS from 1987 until its merger with CVS Caremark Corporation in 2004. Mr. Halbert holds a Bachelor of Accounting from Abilene Christian University. We believe Mr. Halbert’s extensive experience in the healthcare and technology industries and years of experience in his leadership roles as a director and executive officer make him well-qualified to serve as a member of our board of directors.
Laura I. Johansen has served as a member of our board of directors since our founding in 2008. Ms. Johansen served as our Vice Chairman until February 2012. In 2015, Ms. Johansen founded and currently serves as the President of Pence Management, a family office focused on real estate and equity investments. Ms. Johansen previously served as the President of Halbert & Associates, LLC (“Halbert & Associates”), the family office of Mr. Halbert, from 2004 to 2010. Ms. Johansen began her career at AdvancePCS as General Counsel in 1996 and served as the Senior Vice President and Corporate Secretary from 2001 until its merger with CVS Caremark Corporation in 2004. Before joining AdvancePCS, Ms. Johansen served as an Associate in the Corporate and Securities Group of Akin, Gump, Strauss, Hauer and Feld, an international law firm. Ms. Johansen holds a Bachelor of Business Administration in Marketing and a Juris Doctor from the University of Texas. We believe Ms. Johansen’s extensive experience in the healthcare industry and years of leadership experience as our Vice Chairman make her well-qualified to serve as a member of our board of directors.
 
216

TABLE OF CONTENTS
 
Lloyd B. Minor, M.D. has served as a member of our board of directors since August 2021. Dr. Minor is currently the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine, a position he has held since 2012. In addition to being the Dean of the School of Medicine, he became the Vice President for Medical Affairs at Stanford University in August 2023. Dr. Minor has also been a professor of Otolaryngology—Head and Neck Surgery and a professor of Neurobiology and Bioengineering, by courtesy, since 2012. Prior to 2012, Dr. Minor served as the Provost and Senior Vice President for Academic Affairs at Johns Hopkins University from 2009 to 2012. Dr. Minor began his career at Johns Hopkins School of Medicine in the Department of Otolaryngology—Head and Neck Surgery as a Professor from 1993 to 2003, before serving as department’s Andelot Professor and Director (Chair) from 2003 to 2009. Dr. Minor has served as a member of the board of directors of Biogen, a global pharmaceutical company, since 2024. Dr. Minor holds a Bachelor of Science in Biology and a Doctor of Medicine from Brown University. In 2012, Dr. Minor was elected to the National Academy of Medicine, formerly the Institute of Medicine. We believe Dr. Minor’s experience as a professor and knowledge of the medical and healthcare industries make him well-qualified to serve as a member of our board of directors.
Vijay Mohan has served as a member of our board of directors since August 2020. Mr. Mohan is currently a Co-Founder and Partner at Sixth Street Partners, a San Francisco-based investment firm, a position he has held since its founding in May 2009. Prior to Sixth Street Partners, Mr. Mohan was a Managing Principal at Bardin Hill Investment Partners L.P., a New York investment firm. Mr. Mohan began his career in the Technology, Media, and Telecom Group of the Investment Banking Division of Goldman Sachs & Co. LLC, a global investment banking, securities, and investment management firm. Mr. Mohan currently serves as a member of the Board of Visitors for Columbia College. He holds a Bachelor of Arts in Economics from Columbia University. We believe Mr. Mohan’s extensive experience in the investment industry and years of experience as the co-founder of Sixth Street Partners make him well-qualified to serve as a member of our board of directors.
Danny Phillips has served as a member of our board of directors since August 2015. Mr. Phillips is currently the owner of the Diamond P Longhorn Ranch in Lindale, Texas, and manages his own financial investments. Mr. Phillips currently serves as a member of the board of directors of Fortress Youth Development Center, a non-profit organization that aids the homeless community and low-income families in Fort Worth, Texas, and served as its Chairperson from 2007 to 2015. In addition, Mr. Phillips currently serves as a member of the board of directors of Mission Increase Fort Worth, a non-profit organization that offers teaching, coaching, consulting, and fundraising tools to help other non-profits grow and be successful. He also currently serves as a member of the board of directors of Texas Mutual Insurance Company, a workers’ compensation provider in Texas, a position he has held since 2012. Mr. Phillips has also previously served as a member of the board of directors of various academic organizations, such as on the board of regents at Pepperdine University and the investment board of Abilene Christian University. Mr. Phillips served in various finance-related roles at AdvancePCS for over 11 years, including as its Chief Financial Officer and Senior Executive Vice President until its sale to CVS Caremark Corporation in 2004. Prior to AdvancePCS, Mr. Phillips served various senior financial roles at Harken Energy Corporation (now HKN Inc.), a company engaged in hydrocarbon exploration in Texas, and Aloha Petroleum, Ltd., a gasoline marketer and convenience store operator in Hawaii. Mr. Phillips holds a Bachelor of Arts in Accounting from Abilene Christian University. We believe Mr. Phillips’ extensive experience in the pharmaceutical and investment industries and years of experience as a director and executive officer make him well-qualified to serve as a member of our board of directors.
Jeffrey Vacirca, M.D., F.A.C.P. has served as a member of our board of directors since November 2024. Since 2008, Dr. Vacirca has served as Chief Executive Officer and Chairman of the Board of New York Cancer & Blood Specialists, a cancer care center specializing in hematology/oncology and medical oncology. Since 2011, he has served as President and Co-Founder of National Translational Research Group, a group focusing on non-clinical research, and, from 2012 to 2023, he served as a Medical Director and Strategic Advisor for the International Oncology Network specialty group at Amerisource Bergen, a pharmaceutical products company. Since 2018, Dr. Vacirca has served as the Medical Director of the Oncology Network Development at Mount Sinai Health Network and as an associate clinical professor at Icahn School of Medicine at Mount Sinai, New York. He served as Medical Director for the Long Island Association for AIDS Care from 2008 to 2024. Dr. Vacirca also serves on the boards of directors of privately held companies Annexus Health, OneOncology (where he was a co-founder) and PatientPoint.
 
217

TABLE OF CONTENTS
 
Dr. Vacirca served as a director of Assertio Holdings, a publicly-traded pharmaceutical company, from July 2023 to November 2024, Spectrum Pharmaceuticals, a publicly-traded pharmaceutical company, from November 2018 to its July 2023 acquisition by Assertio, and BeyondSpring Inc., a publicly-traded biopharmaceutical company, from December 2020 to April 2022. Dr. Vacirca is the past president of the Community Oncology Alliance and continues to be a member of its executive committee. Dr. Vacirca also served on our Scientific Advisory Board from 2014 to 2020 and was a consultant for us from February 2022 through his election as a director. He has also been part of early funding for various companies including Cedar, Thyme Care, and Sherpa Health. Dr. Vacirca co-founded Odonate Therapeutics, a publicly held pharmaceutical company, in 2016 and served as a director until September 2019. Dr. Vacirca is the founder and Chairman of the Board of Directors of the New York Cancer Foundation, which provides financial assistance to patients undergoing treatment for cancer. Dr. Vacirca holds a Bachelor of Arts in Human Biology from the University at Albany and a Doctor of Medicine from St. George’s University. We believe that Dr. Vacirca’s extensive clinical expertise in oncology, experience in the healthcare and pharmaceutical industries, and leadership roles in cancer-focused organizations make him well-qualified to serve as a member of our board of directors.
Family Relationships
David D. Halbert, our Founder, Chairman, and Chief Executive Officer, is the brother of Jon S. Halbert, a member of our board of directors. Aside from the foregoing relationship, there are no family relationships among any of our executive officers or directors.
Composition of Our Board of Directors
Our business and affairs are managed under the direction of our board of directors. Messrs. Burns and Mohan have notified us that they each intend to resign from our board of directors effective as of immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. There have been no disagreements between us and the resigning directors on any matter relating to our operations, policies, or practices. Our board of directors upon the completion of this offering will consist of 12 members, eight of whom qualify as “independent” under the listing standards of Nasdaq. Our amended and restated certificate of formation and amended and restated bylaws, each of which will become effective immediately prior to the completion of this offering, will provide that the number of directors on our board of directors will be fixed from time to time by resolution of the board of directors.
When considering whether directors have the experience, qualifications, attributes, or skills, taken as a whole, to enable our board of directors to satisfy its oversight responsibilities effectively in light of our business and structure, the board of directors focuses primarily on each person’s background and experience as reflected in the information discussed in each of the directors’ individual biographies set forth above. We believe that our directors provide an appropriate mix of experience and skills relevant to the size and nature of our business.
Director Independence
Prior to the completion of this offering, our board of directors undertook a review of the independence of each director who is not an employee of Caris. Based on information provided by each such director concerning his or her background, employment, and affiliations, our board of directors has affirmatively determined that each of our directors, other than David D. Halbert, Brian J. Brille, George H. Poste, and Jon S. Halbert, do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is “independent” as that term is defined under the listing standards of Nasdaq. In making these determinations, our board of directors considered the current and prior relationships that each non-employee director has with our Company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director, and the transactions involving them, if any, described in the section titled “Certain Relationships and Related Party Transactions.”
Following this offering, we may become a “controlled company” as defined under the corporate governance rules of Nasdaq. The Nasdaq rules define a “controlled company” as a company of which more
 
218

TABLE OF CONTENTS
 
than 50% of the voting power for the election of directors is held by an individual, a group, or another company. In the event we become a controlled company, we may elect not to comply with certain corporate governance rules of Nasdaq. See “Risk Factors—Risks Related to This Offering and Ownership of Our Class A Common Stock—Following this offering, we may become a “controlled company” within the meaning of the rules of Nasdaq. In such event, we may take advantage of the “controlled company” exemptions to the corporate governance rules of Nasdaq.”
Lead Independent Director
David D. Halbert serves as both our Chief Executive Officer and as Chairman of our board of directors. Our board of directors has appointed Peter M. Castleman to serve as our lead independent director. As lead independent director, Mr. Castleman will preside over all meetings of the board of directors at which the Chairman of the board or directors is not present, including any executive sessions of the independent directors; call meetings or separate sessions of the independent directors; approve meeting schedules and agendas for the board of directors; approving information sent to the board of directors; acting as the liaison between the independent directors and the Chief Executive Officer and Chairman of the board of directors; and when appropriate, meeting or otherwise communicating with major shareholders or other constituencies.
Committees of the Board of Directors
Our board of directors has established an audit committee and a compensation committee, each of which will have the composition and responsibilities described below upon the completion of this offering. Members will serve on these committees until their resignation or until as otherwise determined by our board of directors. Each committee will operate under a written charter approved by our board of directors that satisfies the applicable rules of the SEC and the listing standards of Nasdaq. Upon the completion of this offering, copies of each committee’s charter will made available on our website.
We do not intend to have a standing nominating committee. In accordance with Rule 5605 of the Nasdaq rules, a majority of the independent directors may recommend a director nominee for selection by the board of directors. The board of directors believes that the independent directors can satisfactorily carry out the responsibility of properly selecting or approving director nominees without the formation of a standing nominating committee.
Audit Committee
Upon the completion of this offering, we expect our audit committee will consist of Danny Phillips, Peter M. Castleman, and Joseph E. Gilliam, with Mr. Phillips serving as Chair, and each of whom meet the requirements for independence under the listing standards of Nasdaq and SEC rules and regulations. Each member of our audit committee also meets the financial literacy and sophistication requirements of the listing standards of Nasdaq. In addition, our board of directors has determined that each member of our audit committee is an audit committee financial expert within the meaning of Item 407(d) of Regulation S-K under the Securities Act. We intend to comply with the listing requirements of Nasdaq regarding the composition of our audit committee within the transitions period for newly public companies. Following the completion of this offering, our audit committee will be responsible for, among other things:
•
the appointment, compensation, retention, and oversight of our independent registered public accounting firm;
​
•
reviewing and discussing with management and the independent registered public accounting firm our annual and quarterly financial statements and related disclosures;
​
•
reviewing and discussing with management and the independent registered public accounting firm the adequacy of our internal control over financial reporting;
​
•
establishing procedures for employees to submit concerns anonymously about questionable accounting or audit matters;
​
•
discussing our policies on risk assessment and risk management;
​
 
219

TABLE OF CONTENTS
 
•
reviewing and, if appropriate, approving related party transactions; and
​
•
pre-approving, all audit and all permissible non-audit services to be performed by the independent registered public accounting firm.
​
Compensation Committee
Upon the completion of this offering, we expect our compensation committee will consist of Peter M. Castleman, Joseph E. Gilliam, and Laura I. Johansen, with Mr. Castleman serving as Chair. Following the completion of this offering, our compensation committee will be responsible for, among other things:
•
reviewing, approving and determining, or making recommendations to our board of directors regarding, the compensation of our executive officers;
​
•
recommending compensation for non-employee directors;
​
•
administering our equity compensation plans;
​
•
reviewing and approving, or making recommendations to our board of directors, regarding incentive compensation and equity compensation plans; and
​
•
establishing and reviewing general policies relating to compensation and benefits of our employees.
​
Subject to the terms of our compensation plans, our compensation committee will have discretion to determine the amount, form, structure and implementation of compensation payable to our employees and executive officers, including, where appropriate, discretion to increase or decrease awards or to award compensation absent the attainment of performance goals and to award discretionary cash compensation outside of the parameters of our compensation plans.
Role of the Board in Risk Oversight
Our board of directors is responsible for overseeing our risk management process. Our board of directors focuses on our general risk management policies and strategy, the most significant risks facing us, and oversees the implementation of risk mitigation strategies by management. Our board of directors is also apprised of particular risk management matters in connection with its general oversight and approval of corporate matters and significant transactions.
Our board of directors does not have a standing risk management committee but intends to administer its oversight function through our audit committee, which will be responsible for overseeing enterprise risk management, including the management of financial risks and cybersecurity risks, reviewing and discussing our guidelines and policies with respect to risk assessment and risk management, and discussing with management the steps management has taken to monitor and control these exposures. In addition, the standing committees of our board of directors will address risks inherent in their respective areas of oversight. Our compensation committee will oversee risks related to our executive compensation, equity incentive plans, and other compensatory arrangements, and our will oversee risks associated with our corporate governance framework. Our board of directors intends to implement its risk oversight function both as a whole and through delegation to its committees, which will meet regularly and report back to the board of directors.
Compensation Committee Interlocks and Insider Participation
None of our executive officers currently serves, or in the past year has served, as a member of the board of directors or compensation committee (or other board committee performing equivalent functions) of any entity that has one or more of its executive officers serving on our board of directors or compensation committee.
Code of Business Conduct and Ethics
Prior to the completion of this offering, our board of directors will adopt a written code of business conduct and ethics that will apply to all of our employees, officers, and directors, including our
 
220

TABLE OF CONTENTS
 
principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions. Upon the completion of this offering, the full text of our code of business conduct and ethics will be posted on our website, www.carislifesciences.com. In addition, we intend to post on our website all disclosures that are required by law or the Nasdaq rules concerning any amendments to, or waivers from, any provision of the code of business conduct and ethics. The information on our website is deemed not to be incorporated in this prospectus or to be part of this prospectus.
Director Compensation
For 2024, we provided a $50,000 cash retainer, paid in quarterly installments, to certain non-employee directors for their service on our board of directors. We also provided additional cash retainers to committee chairs and members as follows: audit committee chair ($24,000); audit committee members ($10,000); compensation committee chair ($17,750); compensation committee members ($8,000); governance and nominating committee chair ($10,000) and governance and nominating committee members ($5,000). Dr. Minor did not receive an annual retainer but instead received a fee of $40,000 for every meeting he attended. We also reimbursed all of our directors for their out-of-pocket expenses in connection with attending board of directors and committee meetings, and our directors are eligible to obtain our solutions on the same terms and conditions available to our employees. We did not provide compensation for 2024 to our investor designee directors, Messrs. Burns and Mohan, for their services on our board of directors. David D. Halbert and Brian J. Brille, who are employees of the Company, did not receive any additional compensation for their services on our board of directors. See the section titled “Executive Compensation—​Summary Compensation Table” for the compensation received by Mr. Halbert and Mr. Brille for 2024.
The following table sets forth information regarding compensation paid to our non-employee directors for the fiscal year ended December 31, 2024.
Name
​ ​
Fees Earned or
Paid in Cash ($)
​ ​
Stock Awards ($)(1)
​ ​
Option Awards ($)(1)(2)
​ ​
All Other
Compensation ($)
​ ​
Total ($)
​
George H. Poste
​ ​ ​ ​ 55,000 ​ ​ ​ ​ ​ —(3) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 107,500(4) ​ ​ ​ ​ ​ 162,500 ​ ​
Jonathan Knowles
​ ​ ​ ​ 50,000 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 50,000 ​ ​
Nathan Burns(5)
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​
Peter M. Castleman
​ ​ ​ ​ 77,750 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 77,750 ​ ​
David Fredrickson
​ ​ ​ ​ 25,000 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 963,000 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 988,000 ​ ​
Joseph E. Gilliam
​ ​ ​ ​ 60,000 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 60,000 ​ ​
Jon S. Halbert
​ ​ ​ ​ 50,000 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 50,000 ​ ​
Laura I. Johansen
​ ​ ​ ​ 63,000 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 63,000 ​ ​
Lloyd B. Minor
​ ​ ​ ​ 160,000 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 160,000 ​ ​
Vijay Mohan(5)
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​
Danny Phillips
​ ​ ​ ​ 74,000 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 74,000 ​ ​
Jeffrey Vacirca
​ ​ ​ ​ 12,500 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 972,000 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 984,500 ​ ​
​
(1)
As of December 31, 2024, certain of our non-employee directors held outstanding options to purchase a number of shares of our common stock, as follows: Dr. Poste—700,000 shares; Dr. Knowles—10,000 shares; Mr. Fredrickson—300,000 shares; Mr. Gilliam—300,000 shares; Mr. Phillips—400,000 shares; and
Dr. Vacirca—400,000 shares. Additionally, as of December 31, 2024, Dr. Poste held a total of 874,500 restricted stock units (“RSUs”), which RSUs fully vest only upon the occurrence of an initial public offering or a change in control of the Company.
​
(2)
The amounts in this column reflect the aggregate grant date fair value of stock options granted under our 2020 Plan in 2024, as calculated in accordance with FASB ASC Topic 718 (without any reduction for risk of forfeiture) as determined based on applying the assumptions used in Note 7 to our consolidated financial statements for 2024 included elsewhere in this prospectus. Options were granted to each of Mr. Fredrickson and Dr. Vacirca in connection with their election to our board of directors.
​
(3)
Reflects the aggregate grant date fair value of RSUs granted under the 2020 Plan in 2024, as calculated in accordance with FASB ASC 718 (without any reduction for risk of forfeiture) as determined based on applying the assumptions used in Note 7 to our consolidated financial statements for 2024 included elsewhere in this prospectus. The RSUs will fully vest only upon the occurrence of a specific performance milestone (either an
​
 
221

TABLE OF CONTENTS
 
initial public offering or a change in control of the Company). Assuming the maximum performance levels are achieved, the maximum value of the RSUs would be $4,250,070. This amount may not reflect the actual value realized upon vesting or settlement, if any.
(4)
The amounts reported reflect fees received for consulting services provided to the Company and for service on the Company’s Scientific Advisory Board.
​
(5)
Messrs. Burns and Mohan have notified us that they each intend to resign from our board of directors effective as of immediately prior to the effectiveness of the registration statement of which this prospectus forms a part.
​
Compensation Paid to Employee Directors for 2024
David D. Halbert is the Chairman of our board of directors, our Founder and also serves as our Chief Executive Officer. Brian J. Brille is the Vice Chairman of our board of directors and also serves as Executive Vice President. Mr. Halbert and Mr. Brille do not receive any additional compensation for their services on our board of directors. For the compensation received by Mr. Halbert and Mr. Brille for the fiscal year ended December 31, 2024 and a description of the elements of their compensation, see the section titled “Executive Compensation.”
Non-Employee Director Compensation Policy
Effective January 1, 2025, our compensation committee adopted a Non-Employee Director Compensation Policy, pursuant to which our non-employee directors are compensated effective January 2025. Under the policy, each non-employee director will receive an annual cash retainer equal to $50,000 and an annual equity retainer consisting of time-vested RSUs with a grant date fair value equal to $300,000. The non-employee director, if any, who serves as a lead independent director will additionally receive an annual cash retainer equal to $30,000. The committee chairs of the audit committee and compensation committee, will receive annual cash retainers equal to $25,000 and $18,000, respectively. The committee members will receive the following annual cash retainers: $12,500 for service on the audit committee and $9,000 for service on the compensation committee. A non-employee director may elect to receive any cash retainer or specified portion thereof in shares of our common stock. Upon election to our board of directors, a non-employee director will receive an initial grant of RSUs with an aggregate grant date fair value of $500,000, which will vest ratably in three equal installments on the first three anniversaries of the grant date.
 
222

TABLE OF CONTENTS​
 
EXECUTIVE COMPENSATION
This section sets forth the compensation of our named executive officers (“NEOs”) for the fiscal year ended December 31, 2024. Our NEOs are our Chief Executive Officer and our two most highly compensated executive officers (as determined in accordance with SEC rules) for the fiscal year ended December 31, 2024:
•
David D. Halbert, Founder, Chairman, and Chief Executive Officer
​
•
Brian J. Brille, Vice Chairman and Executive Vice President
​
•
David Spetzler, President
​
As an emerging growth company, we have elected to take advantage of exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including reduced disclosure obligations regarding executive compensation in this prospectus and, while an emerging growth company, our future periodic reports and proxy statements, as well as exemptions from the requirements of holding nonbinding advisory votes on executive compensation.
Summary Compensation Table
The following table shows the total compensation paid to or earned by each of our NEOs for the fiscal year ended December 31, 2024.
Name and Principal Position
​ ​
Year
​ ​
Salary
($)
​ ​
Bonus
($)(1)
​ ​
Stock
Awards
($)
​ ​
Option
Awards
($)
​ ​
All Other
Compensation
($)(3)
​ ​
Total
($)
​
David D. Halbert
Chief Executive Officer
​ ​ ​ ​ 2024 ​ ​ ​ ​ ​ 750,000 ​ ​ ​ ​ ​ 1,500,000 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 2,250,000 ​ ​
Brian J. Brille
Vice Chairman and Executive
Vice President
​ ​ ​ ​ 2024 ​ ​ ​ ​ ​ 600,000 ​ ​ ​ ​ ​ 600,000 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 1,200,000 ​ ​
David Spetzler
President
​ ​ ​ ​ 2024 ​ ​ ​ ​ ​ 600,000 ​ ​ ​ ​ ​ 600,000 ​ ​ ​ ​ ​ —(2) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 13,800 ​ ​ ​ ​ ​ 1,213,800 ​ ​
​
(1)
The amounts shown in this column are the annual bonus amounts payable in respect of fiscal year 2024 to each of our NEOs. See “—Narrative to Summary Compensation Table—Annual Bonus” for a description of the terms of these bonuses.
​
(2)
Reflects the aggregate grant date fair value of RSUs granted under the 2020 Plan in 2024, as calculated in accordance with FASB ASC 718 (without any reduction for risk of forfeiture) as determined based on applying the assumptions used in Note 7 to our consolidated financial statements for 2024 included elsewhere in this prospectus. These RSUs will fully vest only upon the occurrence of a specific performance milestone (either an initial public offering or a change in control of the Company). Assuming the maximum performance levels are achieved, the value for the RSUs granted in 2024 would be $2,123,820. This amount may not reflect the actual value realized upon vesting or settlement, if any.
​
(3)
The amounts in this column represent matching contributions to the Company’s 401(k) plan.
​
Narrative Disclosure to Summary Compensation Table
Base Salary
Our NEOs each receive a base salary to compensate them for services rendered to our Company. The base salary payable to each NEO is intended to provide a fixed component of compensation reflecting the executive’s skill set, experience, role, and responsibilities. For 2024, the NEOs’ annual base salaries were as follows: Mr. Halbert—$750,000, Mr. Brille—$600,000, and Dr. Spetzler—$600,000.
Annual Bonus
We maintain an annual cash bonus program in which each of our NEOs participated for 2024. Each NEO’s target bonus is expressed as a percentage of his annual base salary. Bonuses for our NEOs are
 
223

TABLE OF CONTENTS
 
determined by the compensation committee based on a rigorous assessment of Company performance. The 2024 annual bonus targets are 200% of base salary for Mr. Halbert and 100% of base salary for each of Mr. Brille and Dr. Spetzler. In February 2025, the compensation committee determined to award two separate bonuses to Mr. Halbert: one bonus of $750,000, with respect to the first half of 2024, and another bonus of $750,000, with respect to the second half of 2024.
Equity and Long-Term Incentives
We believe that equity awards provide our executive officers with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executive officers and our shareholders. To date, we have used stock option and RSU grants for this purpose because we believe they are effective means by which to align the long-term interests of our executive officers with those of our shareholders. The use of stock options also can provide tax and other advantages to our executive officers relative to other forms of equity compensation. We believe that our equity awards are an important retention tool for our executive officers, as well as for our other employees.
We award stock options broadly to our employees. Grants to our executive officers and other employees are made at the discretion of our compensation committee and are not made at any specific time period during a year. In 2024, all of our equity incentive awards grants were made under the terms of the Caris Life Sciences, Inc. 2020 Incentive Plan, as amended and restated (the “2020 Plan”). See “—Equity Incentive Plans” for additional information on our equity plans.
In August 2024, the compensation committee approved a grant of 1,443,000 RSUs to Mr. Halbert, subject to shareholder approval that was obtained in March 2025. Such RSUs were granted in March 2025 following such approval and will fully vest upon the completion of this offering. In March 2025, the compensation committee approved a stock option grant to Dr. Spetzler with respect to 3.0 million shares at a strike price of $4.65 in order to further align his interests with those of our shareholders.
Other Benefits
Certain of our NEOs (and their guests) may use aircraft or private travel service arrangements or programs (such as car services) that we have access to for reasonable personal use and for which they bear the cost. In addition, Mr. Brille and Dr. Spetzler have certain severance rights. For further information, on Mr. Brille and Dr. Spetzler’s severance rights, see “Narrative Disclosure to Summary Compensation Table—​Employment Agreements”.
Employment Agreement with Brian Brille
We entered into an employment agreement with Mr. Brille, dated as of May 31, 2018 (the “Brille Agreement”) in connection with Mr. Brille’s “at-will” employment with us.
Pursuant to the Brille Agreement, Mr. Brille is entitled to an annual base salary of $500,000 and eligible to receive an annual target bonus equal to 100% of his salary. For the fiscal year ended December 31, 2024, Mr. Brille’s base salary was $600,000 and his annual bonus target was equal to 100% of his salary. The Brille Agreement provides that Mr. Brille is eligible to participate in the Company’s employee benefit plans and includes certain vesting rights applicable to his equity awards. Upon the termination of Mr. Brille’s employment by the Company without cause or by Mr. Brille for good reason, Mr. Brille would be entitled to the following payments and benefits, in addition to any accrued obligations: (1) a lump sum payment equal to six months of his then-current annual base salary; (2) six months of company-paid COBRA benefits; and (3) continued eligibility for consideration for any annual bonus that would otherwise be due to him with respect to the fiscal year of termination, prorated based on the number of days during the fiscal year that he was employed and payable at the same time as the bonus would have otherwise been paid had his employment not been terminated (a “Prorata Bonus”). Upon Mr. Brille’s termination of employment due to death or disability, Mr. Brille or his estate, as applicable, will be eligible to receive a Prorata Bonus, as well as any accrued obligations, and in the case of his disability, any disability benefits he is entitled to under any applicable Company plans. The Brille Agreement also includes an indefinite confidentiality covenant, as well as non-competition, customer non-solicitation and employee non-solicitation covenants that each
 
224

TABLE OF CONTENTS
 
apply for one year following Mr. Brille’s termination date and a non-interference with vendors and suppliers covenant that applies for two years following his termination date.
Invention Assignment Agreement
Mr. Brille is also party to an Inventions Assignment Agreement with us, under which he agreed to assign his right, title and interest to any inventions and related intellectual property that he may develop in the course of his employment, and is subject to confidentiality restrictions related thereto.
Employment Agreement with Dr. David Spetzler
We entered into an employment agreement with Dr. Spetzler, dated as of February 1, 2010, and an amendment to this employment agreement on July 27, 2015 (as amended, the “Spetzler Agreement”) in connection with Dr. Spetzler’s “at-will” employment with us.
Pursuant to the Spetzler Agreement, Dr. Spetzler is entitled to an annual base salary of $320,000 and eligible to receive an annual target bonus equal to 50% of his salary. For the fiscal year ended December 31, 2024, Dr. Spetzler’s base salary was $600,000 and his annual bonus target was equal to 100% of his salary. The Spetzler Agreement provides that Dr. Spetzler is eligible to participate in the Company’s employee benefit plans and, upon Dr. Spetzler’s termination of employment by the Company without cause or by Dr. Spetzler for good reason, Dr. Spetzler would be entitled to the following payments and benefits, in addition to any accrued obligations: (1) a lump sum payment equal to six months of his then-current annual base salary; (2) six months of company-paid COBRA benefits; and (3) continued eligibility for consideration for a Prorata Bonus. Upon Dr. Spetzler’s termination of employment due to death or disability, Dr. Spetzler or his estate, as applicable, will be eligible to receive a Prorata Bonus, as well as any accrued obligations, and in the case of his disability, any disability benefits he is entitled to under any applicable Company plans.
Proprietary Information, Intellectual Property, Restrictive Covenant and Arbitration Agreement
Dr. Spetzler is also party to the Company’s Proprietary Information, Intellectual Property, Restrictive Covenant and Arbitration Agreement (the “PIIA”). Under the PIIA, Dr. Spetzler is subject to an indefinite confidentiality covenant, as well as non-competition, customer non-solicitation, employee non-solicitation, non-interference with vendors and suppliers, and non-disparagement covenants that each apply for one year following Dr. Spetzler’s termination date.
 
225

TABLE OF CONTENTS
 
Outstanding Equity Awards at Fiscal Year 2024
The following table sets forth information regarding outstanding equity awards held by our NEOs as of December 31, 2024. All awards shown in this table were granted pursuant to either the Caris Life Sciences, Inc. 2012 Incentive Plan (the “2012 Plan”) or the 2020 Plan. All references to “common stock” in the table below are references to shares that will be Class A common stock (or, in the case of David D. Halbert, Class B common stock) following the completion of this offering.
​ ​ ​ ​ ​ ​ ​ ​ ​
Option Awards(1)
​ ​
Stock Awards
​
Name
​ ​
Grant Date
​ ​
Number of
Securities
Underlying
Unexercised
Options
Exercisable
(#)
​ ​
Number of
Securities
Underlying
Unexercised
Options
Unexercisable
(#)
​ ​
Option
Exercise
Price ($)
​ ​
Option
Expiration
Date
​ ​
Number of
Shares or
Units of
Stock That
Have Not
Vested (#)
​ ​
Market
Value of
Shares of
Units of
Stock That
Have Not
Vested
($)(2)
​ ​
Equity
Incentive
Plan
Awards:
Number of
Unearned
Shares,
Units or
Other
Rights
That Have
Not Vested
(#)
​ ​
Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares,
Units or
Other
Rights
That Have
Not Vested
($)(2)
​
David D.
Halbert
​ ​ ​ ​ 11/15/2018 ​ ​ ​ ​ ​ 8,000,000 ​ ​ ​ ​ ​ — ​ ​ ​ ​ $ 0.61 ​ ​ ​ ​ ​ 11/14/2028 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Brian J.
Brille(3)
​ ​ ​ ​ 1/15/2018 ​ ​ ​ ​ ​ 8,000,000 ​ ​ ​ ​ ​ — ​ ​ ​ ​ $ 0.61 ​ ​ ​ ​ ​ 1/14/2028 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ 2/27/2020 ​ ​ ​ ​ ​ 3,200,000 ​ ​ ​ ​ ​ 800,000 ​ ​ ​ ​ $ 2.00 ​ ​ ​ ​ ​ 2/26/2030 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ 8/11/2022 ​ ​ ​ ​ ​ 1,750,000(4) ​ ​ ​ ​ ​ — ​ ​ ​ ​ $ 4.05 ​ ​ ​ ​ ​ 8/11/2032 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
David
Spetzler(3)
​ ​ ​ ​ 6/24/2015 ​ ​ ​ ​ ​ 300,000 ​ ​ ​ ​ ​ — ​ ​ ​ ​ $ 0.61 ​ ​ ​ ​ ​ 6/23/2025 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ 9/12/2016 ​ ​ ​ ​ ​ 5,000,000 ​ ​ ​ ​ ​ — ​ ​ ​ ​ $ 0.61 ​ ​ ​ ​ ​ 9/12/2026 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ 4/1/2020 ​ ​ ​ ​ ​ 3,200,000 ​ ​ ​ ​ ​ 800,000 ​ ​ ​ ​ $ 2.00 ​ ​ ​ ​ ​ 4/1/2030 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ 8/11/2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 1,200,000(5) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ 5/17/2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 170,000(6) ​ ​ ​ ​ ​
​ ​ ​ ​ ​ 8/14/2024 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 437,000(6) ​ ​ ​ ​ ​
​
(1)
Except where otherwise described in these footnotes, stock option awards vest over five years, with one-fifth of the shares subject to the stock option vesting annually on each of the first five anniversaries of the grant date.
​
(2)
The market value of the restricted stock and RSUs as of December 31, 2024 is calculated by multiplying the number of unvested shares or units outstanding under the award by $        per share, which our board of directors determined equaled the fair market value of a share of our common stock as of December 31, 2024. Amounts disclosed in this column are not yet available, as our board of directors has not yet determined the market value of our common stock as of December 31, 2024. The reportable amounts will be included in an amendment to this prospectus once such determination has been made.
​
(4)
The shares of common stock subject to this option are immediately issuable pursuant to Mr. Brille’s right to early exercise this option. As of December 31, 2024, Mr. Brille had not early exercised this option. The shares underlying this option vested 20% on the date of the option grant with the remainder vesting in equal 20% installments over four years on the anniversaries of the grant date, subject to Mr. Brille’s continued services to us on each vesting date. As of December 31, 2024, 1,050,000 shares of common stock underlying this option had vested, with an unvested balance of 700,000 shares.
​
(5)
Represents shares of restricted stock acquired pursuant to Dr. Spetzler’s early exercise of an option to purchase 3,000,000 shares of common stock. The shares vested 20% on the date of the option grant with the remainder vesting in equal 20% installments over four years on the anniversaries of the grant date, subject to Dr. Spetzler’s continued services to us on each vesting date. As of December 31, 2024, 1,800,000 shares of common stock underlying this option had vested, and the remaining 1,200,000 shares were unvested.
​
 
226

TABLE OF CONTENTS
 
(6)
Represents RSUs that will vest in full in connection with this offering, subject to the RSU holders’ continuous service through the completion of the initial public offering.
​
Policies and Practices for Granting Option Awards
The Company has not granted any option awards as a reporting company. The Company does not plan to time the disclosure of material non-public information for purposes of affecting the exercise price of the options or the value of executive compensation or grant options during the four business days prior to or the one business day following the filing of a periodic report on Form 10-Q or Form 10-K, or the filing or furnishing of a Form 8-K that discloses material non-public information.
Long-Term Incentive Plans
The purpose of our equity compensation plans is to attract, retain, and motivate our employees, officers, and directors, by providing them with the opportunity to acquire a proprietary interest in the Company and to align their interests and efforts with the long-term interests of our shareholders. In connection with this offering, we expect our board of directors to adopt, and our shareholders to approve, the 2025 Plan. Under the 2025 Plan, we will have        shares of our Class A common stock reserved for issuance (plus any shares available for future grants under our 2020 Plan and any shares underlying outstanding stock awards granted under our 2020 Plan that expire or are repurchased, forfeited, canceled, or withheld).
The 2012 Plan was initially adopted by our board of directors in May 2012 and, in August 2020, was amended and restated to become the 2020 Plan. The 2020 Plan was further amended and restated in connection with this offering in order to reflect the authorization of shares of Class A common stock and Class B common stock under the 2020 Plan. Following completion of this offering, and subject to approval of the 2025 Plan by our shareholders, we will not make any additional grants under the 2020 Plan. Grants, including to our NEOs, have been and may continue to be made under the 2020 Plan prior to this offering. The material terms of the 2012 Plan and the 2020 Plan are substantially similar to the 2025 Plan, as described below. For additional information on the equity awards held by our NEOs and outstanding as of December 31, 2024 under the 2012 Plan and the 2020 Plan, see “—Outstanding Equity Awards at Fiscal Year End 2024.”
2025 Incentive Plan
Types of Awards
Our 2025 Plan provides for the grant of incentive stock options (“ISOs”), nonstatutory stock options (“NSOs”), stock appreciation rights, restricted stock awards, RSU awards, performance-based awards, and other awards. ISOs may be granted only to our employees, including our officers, and the employees of our affiliates. All other awards may be granted to our employees, including our officers, our non-employee directors and consultants, and the employees and consultants of our affiliates.
Authorized Shares
The maximum number of shares of Class A common stock that may be issued under our 2025 Plan is equal to (a) 5% of all classes of our common stock on a fully diluted basis after giving effect to this offering (including, but not limited to, all shares in respect of the Warrant Exercise, the Preferred Stock Conversion, and the Notes Conversion, shares subject to outstanding awards under the 2020 Plan, and the issuance of the Class A common stock to be sold in this offering), plus (b) the number of shares that would have returned to the share reserve of the 2020 Plan following the effectiveness of the registration statement of which this prospectus forms a part, all of which may be issued as ISOs. The 2025 Plan’s share reserve will increase on January 1 of each calendar year during the term of the 2025 Plan, beginning in 2026, by a number of shares as determined by the administrator of the 2025 Plan and in consultation with the Company, provided, that such increase (if any) will be no greater than the amount by which (y) 4% of the aggregate number of outstanding shares of all classes of our common stock as of the last day of the immediately preceding fiscal year exceeds (z) the aggregate number of shares remaining available for grant under the 2025 Plan on the last day of the immediately preceding fiscal year. Shares issued under our 2025 Plan will be
 
227

TABLE OF CONTENTS
 
authorized but unissued or reacquired shares of Class A common stock. Shares issued pursuant to awards under our 2025 Plan that we repurchase or that are forfeited, as well as shares used to pay the exercise price of an award or to satisfy the tax withholding obligations to an award, will become available for future grant under our 2025 Plan.
Plan Administration
Our board of directors, or a duly authorized committee of our board of directors, may administer our 2025 Plan. Our board of directors has delegated concurrent authority to administer our 2025 Plan to the compensation committee under the terms of the compensation committee’s charter. We sometimes refer to the board of directors, or the applicable committee with the power to administer our equity incentive plans, as the administrator. The administrator may also delegate to one or more of our officers the authority to (1) designate employees (other than officers) to receive specified awards and (2) determine the number of shares subject to such awards. The administrator has the authority to determine the terms of awards, including recipients, the exercise, purchase or strike price of awards, if any, the number of shares subject to each award, the fair market value of a share of Class A common stock, the vesting schedule applicable to the awards, together with any vesting acceleration, and the form of consideration, if any, payable upon exercise or settlement of the award and the terms of the award agreements for use under our 2025 Plan. In addition, subject to the terms of the 2025 Plan, the administrator also has the power to modify outstanding awards under our 2025 Plan, including the authority to reprice any outstanding option or stock appreciation right, cancel and re-grant any outstanding option or stock appreciation right in exchange for new stock awards, cash or other consideration, or take any other action that is treated as a repricing under generally accepted accounting principles, with the consent of any materially adversely affected participant.
Stock Options
ISOs and NSOs are granted pursuant to stock option agreements adopted by the administrator. The administrator determines the exercise price for a stock option, within the terms and conditions of the 2025 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our Class A common stock on the date of grant. Options granted under the 2025 Plan vest at the rate specified in the stock option agreement as specified in the stock option agreement by the administrator. The administrator determines the term of stock options granted under the 2025 Plan, up to a maximum of 10 years. Acceptable consideration for the purchase of Class A common stock issued upon the exercise of a stock option will be determined by the administrator and may include (1) cash, check, bank draft, or money order, (2) a broker-assisted cashless exercise, (3) the tender of shares of Class A common stock previously owned by the optionholder, (4) a net exercise of the option, and (5) other legal consideration approved by the administrator.
Unless the terms of an optionholder’s stock option agreement provide otherwise, if an optionholder’s service relationship with us, or any of our affiliates, ceases for any reason other than disability or death, the optionholder may generally exercise any vested options until the earlier of (i) the date 90 days following the termination of the optionholder’s service and (ii) the expiration of the term of the option. If an optionholder’s service relationship with us or any of our affiliates ceases due to disability or death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options until the earlier of (x) 12 months following the termination and (y) the expiration of the term of the options. In the event of a termination for cause, options generally terminate immediately upon the termination of the individual for cause. In no event may an option be exercised beyond the expiration of its term.
Tax Limitations on ISOs
The aggregate fair market value, determined at the time of grant, of Class A common stock with respect to ISOs that are exercisable for the first time by an option holder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will be treated as NSOs. No ISOs may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our parent or
 
228

TABLE OF CONTENTS
 
subsidiary corporations, unless (1) the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant and (2) the term of the ISO does not exceed five years from the date of grant.
Restricted Shares
Restricted shares may be granted to any eligible individual and made subject to such restrictions as may be determined by the administrator. Restricted shares may generally not be sold, or otherwise transferred or hypothecated, until vesting conditions are removed or expire. Except as otherwise provided in the applicable award agreement, restricted shares that remain subject to vesting conditions that have not been satisfied will not vest.
Restricted Stock Units
RSUs may be awarded to any eligible individual, typically without payment of consideration, but subject to vesting conditions based on continued employment or service or on performance criteria established by the administrator. RSUs may not typically be sold, or otherwise transferred or hypothecated, until vesting conditions are removed or expire. Stock underlying RSUs will not be issued until the RSUs have vested, and recipients of RSUs generally will have no voting or dividend rights prior to the time when vesting conditions are satisfied. Except as otherwise provided in the applicable award agreement, RSUs that remain subject to vesting conditions that have not been satisfied will not vest and will be canceled without payment to the participant therefor.
Stock Appreciation Rights
Stock appreciation rights are granted pursuant to stock appreciation right grant agreements adopted by the administrator. The administrator determines the strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of Class A common stock on the date of grant. Upon the exercise of a stock appreciation right, we will pay the participant an amount equal to the product of (1) the excess of the per share fair market value of Class A common stock on the date of exercise over the strike price, multiplied by (2) the number of shares of Class A common stock with respect to which the stock appreciation right is exercised. A stock appreciation right granted under the 2025 Plan vests at the rate specified in the stock appreciation right agreement as determined by the administrator. The administrator determines the term of stock appreciation rights granted under the 2025 Plan, up to a maximum of 10 years.
Unless the terms of a participant’s stock appreciation right agreement provide otherwise, if a participant’s service relationship with us or any of our affiliates ceases for any reason other than disability or death, the participant may generally exercise any vested stock appreciation right until the earlier of (i) the date 90 days following the termination of service and (ii) the expiration of the term of the stock appreciation right. If a participant’s service relationship with us, or any of our affiliates, ceases due to disability or death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation right until the earlier of (x) 12 months following the termination and (y) the expiration of the term of the stock appreciation right. In no event may a stock appreciation right be exercised beyond the expiration of its term.
Performance Awards
Our 2025 Plan permits the grant of performance-based stock and cash awards. The compensation committee can structure such awards so that the stock or cash will be issued or paid pursuant to such award only following the achievement of certain pre-established performance goals during a designated performance period.
Changes to Capital Structure
In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split or recapitalization, appropriate adjustments will be made to (1) the class and maximum number of shares reserved for issuance under the 2025 Plan, (2) the class and maximum number of shares by which the
 
229

TABLE OF CONTENTS
 
share reserve may increase automatically each year, (3) the class and maximum number of shares that may be issued upon the exercise of ISOs, and (4) the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding awards.
Corporate Transactions
Under the 2025 Plan, a corporate transaction is generally the consummation of (1) a sale or other disposition of all or substantially all of our assets, (2) a sale or other disposition of at least 50% of our outstanding securities, (3) a merger, consolidation, or similar transaction following which we are not the surviving corporation, or (4) a merger, consolidation, or similar transaction following which we are the surviving corporation but the shares of common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. In the event of a corporate transaction, unless otherwise provided in a participant’s award agreement or other written agreement with us or one of our affiliates or otherwise expressly provided by the administrator at the time of grant, any stock awards outstanding under the 2025 Plan may be assumed, continued, or substituted for by any surviving or acquiring corporation (or its parent company), accelerated in full or in part or canceled for or without consideration, as determined by the administrator.
Transferability
A participant may not transfer awards under our 2025 Plan other than by will, the laws of descent and distribution, or as otherwise provided under our 2025 Plan.
Plan Amendment or Termination
Our board of directors has the authority to amend, suspend, or terminate our 2025 Plan, provided that such action does not materially impair the existing rights of any participant without such participant’s written consent. Certain material amendments also require the approval of our shareholders. No ISOs may be granted after the tenth anniversary of the date our board of directors adopted our 2025 Plan. No awards may be granted under our 2025 Plan while it is suspended or after it is terminated.
2025 Employee Stock Purchase Plan
In connection with this offering, we expect our board of directors to adopt, and our shareholders to approve, the ESPP, that will be effective following the offering. The ESPP is designed to allow our eligible employees to purchase shares of our common stock, at periodic intervals, with their accumulated payroll deductions. The ESPP is intended to qualify under Section 423 of the Code. The material terms of the ESPP, as it is currently contemplated, are summarized below.
Administration
Subject to the terms and conditions of the ESPP, our board of directors, or a duly authorized committee of our board of directors, may administer the ESPP. The administrator will have the authority to administer and interpret the ESPP. All decisions made by the administrator pursuant to the ESPP will be final, binding, and conclusive on us and all participants. We will bear all expenses of administering the ESPP.
Share Reserve
The maximum number of our shares of our Class A common stock which will be authorized for sale under the ESPP is equal to 0.85% of the fully diluted shares of all classes of our common stock after giving effect to the offering (including, but not limited to, all shares in respect of the Warrant Exercise, the Preferred Stock Conversion, and the Notes Conversion, shares subject to outstanding awards under the 2020 Plan, and the issuance of the Class A common stock to be sold in this offering). The ESPP’s share reserve will automatically increase on January 1 of each calendar year during the term of the ESPP, beginning in 2026, by a number of shares equal to 1% of all classes of our common stock outstanding on the last day of the immediately preceding fiscal year, unless the administrator should decide to increase the number of shares
 
230

TABLE OF CONTENTS
 
available under the ESPP by a lesser amount. The shares reserved for issuance under the ESPP may be authorized but unissued shares or reacquired shares.
Eligibility
Employees eligible to participate in the ESPP for a given offering period generally include employees who are employed by us or one of our subsidiaries on the enrollment date of an offering period. Our employees (and, if applicable, any employees of our subsidiaries) who customarily work less than five months in a calendar year or are customarily scheduled to work less than 20 hours per week will not be eligible to participate in the ESPP. Finally, an employee who owns (directly or through attribution) 5% or more of the combined voting power or value of all our classes of stock or of one of our subsidiaries will not be allowed to participate in the ESPP.
Participation
Employees will enroll under the ESPP by completing a subscription agreement designating the percentage of their compensation to be withheld as payroll deductions during the offering period (of at least 1% of their compensation but not more than 15% of their base compensation). Such payroll deductions may be expressed as either a whole number percentage or a fixed dollar amount, and the accumulated deductions will be applied to the purchase of shares on each purchase date. However, a participant may not accrue the right to purchase shares of common stock at a rate that exceeds $25,000 in fair market value of shares of our common stock (determined at the time the option is granted) for each calendar year the option is outstanding (as determined in accordance with Section 423 of the Code).
Offering
Under the ESPP, participants are offered the option to purchase shares of our common stock at a discount during a series of successive offering periods, the duration and timing of which will be determined by the ESPP administrator. However, in no event may an offering period be longer than 27 months in length.
The option purchase price designated by the ESPP administrator will be no less than the lower of 85% of the closing trading price per share of our common stock on the first trading date of an offering period in which a participant is enrolled or 85% of the closing trading price per share on the purchase date, which will occur on the last trading day of each purchase period within an offering period.
A participant may withdraw all (but not less than all) of the payroll deductions credited to the participant’s account and not yet used to exercise the participant’s rights under the ESPP at any time by giving us written notice no later than 30 days prior to the end of the offering period. All of the participant’s payroll deductions credited to the participant’s account during an offering period will be paid to the participant as soon as reasonably practicable after receipt of notice of withdrawal. As a result, the participant’s rights for the offering period will be automatically terminated, and no further payroll deductions for the purchase of shares will be made for such offering period. If a participant withdraws from an offering period, payroll deductions will not resume at the beginning of the next offering period unless the participant timely delivers to us a new subscription agreement.
A right granted under the ESPP to a participant will not be transferable other than by will or the applicable laws of descent and distribution and is exercisable during the participant’s lifetime only by the participant. Except in the case of a participant’s death, a right under the ESPP may not be exercised to any extent except by the participant.
Adjustments upon Changes in Common Stock
Upon any reclassification, recapitalization, share split, or reverse share split; any merger, combination, consolidation, or other reorganization; any split-up, spin-off, or similar extraordinary dividend distribution in respect of the common stock; or any exchange of our common stock or other securities, or any similar, unusual or extraordinary corporate transaction in respect of the common stock; then, subject to any required action by the shareholders under applicable law, the ESPP administrator will
 
231

TABLE OF CONTENTS
 
equitably and proportionately adjust (i) the ESPP share reserve, (ii) the classes and number of shares and price per share subject to outstanding rights; and (iii) the purchase price with respect to any outstanding rights. In the event of any of the above described transactions or any unusual or nonrecurring transactions or events affecting us or our subsidiaries or our financial statements, the ESPP administrator, in its discretion, will be authorized to provide either: (i) the termination of any outstanding right in exchange for an amount of cash equal to the amount that would have been obtained upon the exercise of such right had such right been currently exercisable or the replacement of such outstanding right with other rights or property selected by the ESPP administrator in its sole discretion; (ii) to provide that outstanding rights under the ESPP will be assumed by the successor or survivor corporation or a parent or subsidiary thereof, with appropriate adjustments to the number and kind of stock and prices; (iii) to make adjustments in the number and type of shares (or other securities or property) subject to outstanding rights under the ESPP; (iv) to provide that participants’ accumulated payroll deductions may be used to purchase shares prior to the next occurring purchase date, following which the participants’ rights under the ongoing offering period will be terminated; or (v) to provide that all outstanding rights will terminate without being exercised.
Amendment and Termination
The ESPP administrator may amend, suspend, or terminate the ESPP at any time. However, no amendment will be effective unless approved by the shareholders to the extent required by applicable laws.
Additional Narrative Disclosure
Retirement and Employee Benefits Plans
All of our current NEOs are eligible to participate in our employee benefit plans, including our medical, dental, vision, life, and disability insurance plans, and may obtain our solutions, in each case on the same basis as all of our other employees. We maintain a 401(k) plan for employees. The 401(k) plan is intended to qualify under Section 401(k) of the Code so that contributions to the 401(k) plan by employees or by us, and the investment earnings thereon, are not taxable to the employees until withdrawn from the 401(k) plan, and so that contributions by us, if any, will be deductible by us when made. Under the 401(k) plan, we make a matching contribution of 100% of the first 3% of salary contributed and 50% on the next 2% of salary. The maximum match is 4% up to the IRS limit.
Change-in-Control Plan
Certain of our senior executives (including Mr. Brille and Dr. Spetzler but excluding Mr. Halbert) and non-employee directors participate in the Caris Life Sciences, Inc. Executive and Director Change in Control Plan (the “Change in Control Plan”), which is administered by our compensation committee. Under the Change in Control Plan, upon a “Change in Control” ​(as defined in the 2020 Plan) and subject to the execution of a general release of claims in our favor, all outstanding and unvested equity awards granted to a participant will automatically vest in full immediately prior to the consummation of the Change in Control. The Change in Control Plan does not contain excise tax gross-up provisions and, instead, employs a “best-net” approach under which payments and benefits are either reduced to avoid the excise tax on excess parachute payments within the meaning of Section 280G of the Code or not reduced, depending on which approach would result in the greatest after-tax amount being retained. At any time prior to a Change in Control, the Change in Control Plan may be modified, amended, or terminated by the compensation committee without notice to participants.
Clawback Policy
In connection with this offering, we will adopt a compensation recovery policy that is compliant with the listing rules of Nasdaq, as required by the Dodd-Frank Act, to be effective upon the completion of this offering.
 
232

TABLE OF CONTENTS​
 
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
The following is a description of transactions since January 1, 2022 and each currently proposed transaction in which we have been or are to be a participant and:
•
the amounts involved exceeded or will exceed $120,000; and
​
•
any of our directors, executive officers, or holders of more than 5% of our outstanding capital stock, or any immediate family member of or person sharing the household with, any of these individuals, had or will have a direct or indirect material interest.
​
Transactions with Our Founder
Guarantee of Office Lease
We lease approximately 30,500 square feet of office space in Irving, Texas for our principal executive offices pursuant to a lease expiring in April 2028. Our complete and timely performance of each obligation under the lease agreement is unconditionally and irrevocably guaranteed by David D. Halbert, the Chairman of our board of directors and our Chief Executive Officer, and his spouse, in their personal capacities. During each of the years ended December 31, 2024, 2023, and 2022, we recorded rental expense of $0.9 million in connection with this guaranteed lease.
Aircraft Charter Arrangements
In September 2017, we entered into an intercompany consulting agreement (the “Caris Air Consulting Agreement”) with Halbert & Associates and Caris Air Services, LLC (“Caris Air”), each of which is affiliated with Mr. Halbert. Pursuant to the Caris Air Consulting Agreement, we have the right to use, from time to time, an aircraft owned by Halbert & Associates and operated by Caris Air. The Caris Air Consulting Agreement has an initial term of one year and automatically renews for subsequent one-year terms on an annual basis. We only use the aircraft for business purposes and reimburse Caris Air for our usage of the aircraft based on hours of use, operating costs, and related expenses.
In September 2021, we also entered into an aircraft charter lease and services agreement (the “Aircraft Agreement”) with Caris Air, pursuant to which Caris Air dry leases from us an aircraft we own and provides chartered aircraft services, as operator of the aircraft. The Aircraft Agreement has an initial term of one year and automatically renews for subsequent one-year terms on an annual basis. Under the Aircraft Agreement, we are entitled to receive payment from Caris Air for rental of our aircraft, and we reimburse Caris Air for the chartered aircraft services it provides to us. Mr. Halbert and his family members also use our aircraft from time to time for personal use and reimburse us based on hours of use, operating costs, and related expenses.
Under the foregoing aircraft charter arrangements, we generally credit amounts owed to us by Caris Air and Mr. Halbert and his family members for rental and use of our aircraft against any amounts owed by us to Caris Air for the chartered aircraft services it provides under either the Caris Air Consulting Agreement or the Aircraft Agreement. During the years ended December 31, 2024, 2023, and 2022, we paid Caris Air aggregate net amounts of $1.6 million, $1.8 million, and $1.6 million, respectively, pursuant to these arrangements.
Convertible Loan Agreement with Sixth Street
In September 2023, pursuant to a convertible loan agreement, dated as of September 21, 2018, between us, as borrower, certain of our subsidiaries, as guarantors, and entities affiliated with Sixth Street, as lenders (as amended, the “Convertible Loan Agreement”), we issued an aggregate of 31,055,901 shares of our Series C preferred stock to the Sixth Street-affiliated lenders, TOP III Barnett Investments, LLC, TAO Barnett Investments, LLC, and Sixth Street Specialty Lending, Inc., at a conversion price of $1.61 per share, in connection with the conversion of the original aggregate principal amount of $50.0 million outstanding under the Convertible Loan Agreement. Entities affiliated with Sixth Street collectively hold more than 5% of our outstanding capital stock, and Vijay Mohan, a member of our board of directors, is a Co-Founding Partner of Sixth Street.
 
233

TABLE OF CONTENTS
 
The loans under the Convertible Loan Agreement had an interest rate of 8.0% per annum, payable in kind (“PIK”) and accretive as additional principal. Upon the issuance of shares of our Series C preferred stock and following our September 2023 cash payment of $3.0 million in respect of accrued and unpaid PIK interest under the Convertible Loan Agreement, all of our obligations under the Convertible Loan Agreement were deemed satisfied in full, and the Convertible Loan Agreement was irrevocably terminated.
Term Loan Refinancing with Sixth Street
In September 2018, we entered into a secured term loan agreement (the “Original Term Loan Agreement”) with Sixth Street Specialty Lending, Inc. and Barnett Debt Holdings, LLC, which provided us with an initial term loan of $50.0 million (the “2018 Term Loan”) and a delayed term loan draw option of $50.0 million, which we drew down in full on October 4, 2019 (the “2019 Term Loan”). In April 2020, we amended the Original Term Loan Agreement (the “Amended Term Loan Agreement”) to obtain additional term loan proceeds of $75.0 million (the “2020 Term Loan” and collectively with the 2018 Term Loan and the 2019 Term Loan, the “Original Term Loans”).
In January 2023, we entered into the 2023 Term Loan Agreement. The net cash proceeds from the 2023 Term Loan were used to repay in full the Original Term Loans (with an aggregate principal amount of $175.0 million), including a prepayment premium of $5.0 million and accrued and unpaid interest of $1.0 million. As of December 31, 2023, we have no continuing obligations associated with the Original Term Loans.
Executive Officer Promissory Notes
On September 30, 2022, David Spetzler, our President, and J. Russel Denton, our Senior Vice President, General Counsel, and Secretary, exercised their options to purchase 3,000,000 shares and 1,020,000 shares, respectively, of our common stock at an exercise price of $4.05 per share through the tender of promissory notes, each with an interest rate of 2.93% per annum. As of December 31, 2024, no principal or interest payments had been made with respect to these promissory notes. In March 2025, the full outstanding principal amount of, and accrued and unpaid interest on, each of the promissory notes was repaid by each of the executive officers in the form of stock.
Investors’ Rights Agreement
We are party to an amended and restated investors’ rights agreement (the “Investors’ Rights Agreement”), dated as of April 1, 2025, with certain holders of our capital stock, including David D. Halbert, the Chairman of our board of directors and our Chief Executive Officer, entities affiliated with Mr. Halbert, and entities affiliated with Sixth Street, J.H. Whitney VI, L.P., and Highland Capital Management, L.P., each of which are holders of more than 5% of our outstanding capital stock and/or entities with which certain of our directors are affiliated. Under the Investors’ Rights Agreement, certain holders of our capital stock have registration rights, including the right to demand that we file a registration statement or request that their shares be covered by a registration statement that we are otherwise filing. The Investors’ Rights Agreement also provides certain of these shareholders with information and observer rights, which will terminate immediately prior to the completion of this offering, and a right of first offer with regard to certain issuances of our capital stock, which right will terminate immediately following the completion of this offering. For a description of the registration rights that will continue to apply following this offering, see the section titled “Description of Capital Stock—Registration Rights.”
Voting Agreement
We are party to an amended and restated voting agreement (the “Voting Agreement”), dated as of April 1, 2025, under which certain holders of our capital stock, including David D. Halbert, the Chairman of our board of directors and our Chief Executive Officer, entities affiliated with Mr. Halbert, and entities affiliated with Sixth Street, J.H. Whitney VI, L.P., and Highland Capital Management, L.P., each of which are holders of more than 5% of our outstanding capital stock and/or entities with which certain of our directors are affiliated, have agreed as to the manner in which they will vote their shares of our capital stock on certain matters, including with respect to the election of directors. The Voting Agreement will terminate in its entirety upon the completion of this offering.
 
234

TABLE OF CONTENTS
 
Right of First Refusal and Co-Sale Agreement
We are party to an amended and restated right of first refusal and co-sale agreement (the “ROFR and Co-Sale Agreement”), dated as of April 1, 2025, with certain holders of our capital stock, including David D. Halbert, the Chairman of our board of directors and our Chief Executive Officer, entities affiliated with Mr. Halbert, and entities affiliated with Sixth Street, J.H. Whitney VI, L.P., and Highland Capital Management, L.P., each of which are holders of more than 5% of our outstanding capital stock and/or entities with which certain of our directors are affiliated. Under the ROFR and Co-Sale Agreement, we and certain holders of our capital stock have a right to purchase shares of our capital stock that shareholders propose to sell in certain circumstances to other parties. The ROFR and Co-Sale Agreement will terminate in its entirety immediately prior to the completion of this offering.
Consulting and Expert Advisory Agreements
We have entered into consulting and expert advisory agreements with George H. Poste and Jonathan Knowles, members of our board of directors, pursuant to which Dr. Poste and Dr. Knowles provide certain consulting services to us as independent contractors and serve on our Scientific Advisory Board, a team comprised of leading scientists and clinical experts who advise us on research, development, and strategy matters pertaining to precision medicine. We also entered into a consulting agreement with Jeffrey Vacirca in February 2022 pursuant to which he provided consulting services to us, which agreement was terminated upon Dr. Vacirca’s election to our board of directors in November 2024. During the years ended December 31, 2024, 2023, and 2022, we paid Dr. Poste $107,500, $137,917, and $147,083, respectively, for consulting services provided to us and for his service on our Scientific Advisory Board. During each of the years ended December 31, 2024, 2023, and 2022, we paid Dr. Knowles amounts not exceeding $120,000 for consulting services provided to us and for his service on our Scientific Advisory Board. In February 2022, we granted Dr. Vacirca an option to purchase 100,000 shares of common stock at an exercise price of $4.29 per share pursuant to his consulting agreement, and we have not paid any additional amounts under such consulting agreement. For additional information, see the section titled “Management—Director Compensation.”
Employment Agreements and Family Relationships
We are party to employment agreements with certain of our executive officers. For additional information regarding agreements with our named executive officers, see the section titled “Executive Compensation.”
In addition, Michael Halbert, our Senior Vice President, Human Resources, is the son of David D. Halbert, our Founder, Chairman, and Chief Executive Officer, and has been employed by us in various capacities since June 2011. Michael Halbert does not reside with David D. Halbert and is not one of our executive officers.
Equity Awards to Directors and Executive Officers
We have granted stock options and other equity awards to our directors and executive officers as more fully described in the sections titled “Management—Director Compensation” and “Executive Compensation.”
Director and Officer Indemnification Agreements and Insurance
Our amended and restated certificate of formation and amended and restated bylaws will provide indemnification and advancement of expenses for our directors and executive officers to the fullest extent permitted by the Texas law, subject to limited exceptions. We also have entered into separate indemnification agreements with each of our directors and executive officers, which require us to indemnify them in certain circumstances, and have purchased directors’ and officers’ liability insurance for each of our directors and executive officers. For further information, see the section titled “Description of Capital Stock—Limitations on Liability and Indemnification of Officers and Directors.”
 
235

TABLE OF CONTENTS
 
Reserved Share Program
At our request, the underwriters have reserved up to       % of the shares of Class A common stock offered by this prospectus, excluding the additional shares that the underwriters have a 30-day option to purchase, for sale, at the initial public offering price, to certain individuals identified by management, including certain of our directors, officers, employees, and certain other parties related to us. See the section titled “Underwriting—Reserved Share Program.”
Policies and Procedures for Related Person Transactions
Our board of directors recognizes the fact that transactions with related persons present a heightened risk of conflicts of interests or the perception thereof. Prior to the completion of this offering, our board of directors will adopt a written related person transaction policy setting forth the policies and procedures for the review and approval or ratification of related person transactions. This policy will cover, with certain exceptions set forth in Item 404 of Regulation S-K under the Securities Act, any transaction, arrangement, or relationship, or any series of similar transactions, arrangements, or relationships, in which we were or are to be a participant, where the amount involved exceeds $120,000 in any fiscal year, and a related person had, has, or will have a direct or indirect material interest, including without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness, and employment by us of a related person. In reviewing and approving any such transactions, our audit committee will be tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm’s length transaction and the extent of the related person’s interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this policy.
 
236

TABLE OF CONTENTS​
 
PRINCIPAL SHAREHOLDERS
The following table contains information about the beneficial ownership of our common stock as of March 31, 2025 (i) immediately prior to the completion of this offering and (ii) as adjusted to reflect the sale of shares of our Class A common stock offered by this prospectus by:
•
each individual or entity known by us to beneficially own more than 5% of our outstanding shares of Class A common stock or Class B common stock;
​
•
each of our named executive officers;
​
•
each of our directors; and
​
•
all of our directors and executive officers as a group.
​
Our calculation of the percentage of beneficial ownership prior to and after this offering is based on          shares of our Class A common stock and        shares of our Class B common stock outstanding as of March 31, 2025, after giving effect to (i) the Warrant Exercise, (ii) the Series E and F Issuance, (iii) the Preferred Stock Conversion, (iv) the issuance of the 2025 Convertible Notes and the Notes Conversion, (v) the Common Stock Reclassification, and (vi) the RSU Net Settlement. The exact number of shares of our common stock that will be withheld from a shareholder in connection with the RSU Net Settlement may differ based on the shareholder’s personal tax rates.
Beneficial ownership and percentage ownership are determined in accordance with the rules and regulations of the SEC. Under SEC rules, a person is deemed to be a “beneficial owner” of a security if that person has or shares voting power or investment power, which includes the power to dispose of or to direct the disposition of such security. A person is also deemed to be a beneficial owner of any securities of which that person has a right to acquire beneficial ownership within 60 days. Securities that can be so acquired are deemed to be outstanding for purposes of computing such person’s ownership percentage, but not for purposes of computing any other person’s percentage. Under these rules, more than one person may be deemed to be a beneficial owner of the same securities and a person may be deemed to be a beneficial owner of securities as to which such person has no economic interest. Except as indicated in the footnotes to the following table or pursuant to applicable community property laws, we believe, based on information furnished to us, that each shareholder named in the table has sole voting and investment power with respect to the shares set forth opposite such shareholder’s name.
The table below does not reflect any shares of our Class A common stock that our directors and executive officers may purchase in this offering, including through the reserved share program described under “Underwriting — Reserved Share Program.”
For further information regarding material transactions between us and certain of our shareholders, see the section titled “Certain Relationships and Related Party Transactions.”
Unless otherwise indicated in the footnotes, the address of each of the individuals named below is: c/o 750 W. John Carpenter Freeway, Suite 800, Irving, Texas 75039.
 
237

TABLE OF CONTENTS
 
​ ​ ​
Shares Beneficially Owned
Before this Offering
​ ​
% of Total
Voting Power
Before this
Offering(1)
​ ​
Shares Beneficially Owned
After this Offering
​ ​
% of Total
Voting
Power
After this
Offering(1)
​
​ ​ ​
Class A
​ ​
Class B
​ ​
Class A
​ ​
Class B
​
Name of Beneficial Owner
​ ​
Shares
​ ​
%
​ ​
Shares
​ ​
%
​ ​
Shares
​ ​
%
​ ​
Shares
​ ​
%
​
5% Shareholders:
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Entities affiliated with David D. Halbert(2)
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Entities affiliated with Sixth Street(3)
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
J.H. Whitney VI L.P.(4)
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Named Executive Officers and Directors:
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
David D. Halbert(2)
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
David Spetzler(5)
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Brian J. Brille(6)
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
George H. Poste(7)
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Jonathan Knowles(8)
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Nathan Burns
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
David Fredrickson(9)
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Peter M. Castleman(10)
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Joseph E. Gilliam(11)
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Jon S. Halbert(12)
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Laura I. Johansen(13)
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Lloyd B. Minor
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Vijay Mohan
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Danny Phillips(14)​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Jeffrey Vacirca(15)​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
All executive officers and directors as a group
(       individuals)(16)
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
*
Represents beneficial ownership of less than 1%.
​
(1)
Percentage of total voting power represents voting power with respect to all shares of our Class A common stock and Class B common stock, as a single class. The holders of our Class B common stock are entitled to 10 votes per share, and holders of our Class A common stock are entitled to one vote per share. See the section titled “Description of Capital Stock—Common Stock” for additional information about the voting rights of our Class A common stock and Class B common stock.
​
(2)
Consists of (i)           shares of Class B common stock held by David D. Halbert, of which       shares of Class B common stock are pledged as collateral to secure certain personal indebtedness of Mr. Halbert, (ii)           shares of Class B common stock underlying options to purchase Class B common stock held by Mr. Halbert that are currently exercisable or would be exercisable within 60 days of       , 2025, (iii)           shares of Class B common stock held by Caris Halbert, L.P., (iv)           shares of Class B common stock held by ADAPT I Ltd., (v)            shares of Class B common stock held by Carisome I, L.P., (vi)            shares of Class B common stock held by Caris Investment II Ltd., and (vii)            shares of Class B common stock held by Caris Investment III Ltd. (collectively with Caris Halbert, L.P., ADAPT I Ltd., Carisome I, L.P., and Caris Investment III Ltd., the “DDH Entities”). Caris Investment Management, LLC is the general partner of each of Caris Halbert, L.P., Caris Investment II Ltd., and Caris Investment III Ltd. Two family trusts are separately the general partner of ADAPT I Ltd. and the managing general partner of Carisome I, L.P., respectively. David D. Halbert, our Founder, Chairman, and Chief Executive Officer, is the managing member of Caris Investment Management, LLC and the trustee of each of the two family trusts, and in such capacities, has voting and investment power with respect to the shares held by each of the DDH Entities.
​
 
238

TABLE OF CONTENTS
 
(3)
Consists of (i)           shares of Class B common stock held by Barnett Equity Holdings, LLC (“Barnett Equity Holdings”), (ii)           shares of Class B common stock held by Barnett Equity Holdings II, LLC (“Barnett Equity Holdings II”), (iii)           shares of Class B common stock held by TOP III Barnett Investments, LLC (“TOP III Barnett”), (iv)           shares of Class B common stock held by TAO Barnett Investments, LLC (“TAO Barnett” and, together with Barnett Equity Holdings, Barnett Equity Holdings II, and TOP III Barnett, the “Barnett Holders”), and (v)       shares of Class B common stock held by Sixth Street Specialty Lending, Inc. (“SLX”).
​
TSSP Sub-Fund Holdco, LLC, a Delaware limited liability company (“Sub-Fund HoldCo”), is the sole member of each of TAO SPV GP, LLC, a Delaware limited liability company (“TAO SPV”), and Empire SPV GP, LLC, a Delaware limited liability company (“Empire SPV”). TAO SPV is the managing member of each of (i) Barnett Equity Holdings; (ii) Barnett Equity Holdings II; and (iii) TAO Barnett. Empire SPV is the managing member of TOP III Barnett.
TSSP Holdco Management, LLC, a Delaware limited liability company (“Holdco Management”), manages Sixth Street Specialty Lending Advisers Holdings, LLC, a Delaware limited liability company (“Adviser Holdings”). The business and affairs of Sixth Street Specialty Lending Advisers, LLC, a Delaware limited liability company (“Adviser”), are managed by Adviser Holdings, the sole member of Adviser. SLX is managed by Adviser.
Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman (“Mr. Waxman”). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO and Managing Partner of Holdco Management.
Because (i) of Sub-Fund HoldCo’s relationship with the Barnett Holders, Sub-Fund HoldCo may be deemed to beneficially own the shares of Class B common stock owned by the Barnett Holders; (ii) of the relationship between Mr. Waxman and the Barnett Holders, Mr. Waxman may be deemed to beneficially own the shares of Class B common stock owned by the Barnett Holders; and (iii) Mr. Waxman is a member of the board of directors of Holdco Management, he may be deemed to beneficially own the shares of Class B common stock owned by SLX. Each of Sub-Fund HoldCo and Mr. Waxman disclaims beneficial ownership of the shares of Class B common stock except to the extent of their pecuniary interest therein.
The address for each of the foregoing entities is 2100 McKinney Avenue, Suite 1500, Dallas, Texas 72501. The principal business address for Mr. Waxman is c/o Sixth Street Partners, LLC, 1 Letterman Drive, Building B, Suite B6-100, San Francisco, California 94129.
(4)
Consists of           shares of Class B common stock held by J.H. Whitney VI L.P. J.H. Whitney Equity Partners VI, L.P. is the sole general partner of J.H. Whitney VI L.P. Paul R. Vigano and Robert M. Williams, Jr., as the managing members of J.H. Whitney Equity Partners VI, L.P., share voting and investment power with respect to the shares held by J.H. Whitney VI L.P. The address for each of the foregoing entities is 212 Elm Street, Suite 1, New Canaan, Connecticut 06840.
​
(5)
Consists of (i)       shares of Class A common stock held by David Spetzler, (ii)           shares of Class A common stock underlying options to purchase Class A common stock held by Dr. Spetzler that are currently exercisable or would be exercisable within 60 days of           , 2025, and (iii)           shares of Class B common stock held by Dr. Spetzler, of which           shares of Class B common stock are pledged as collateral to secure certain personal indebtedness of Dr. Spetzler.
​
(6)
Consists of (i)           shares of Class A common stock underlying options to purchase Class A common stock held by Brian J. Brille that are currently exercisable or would be exercisable within 60 days of           , 2025, and (ii) an aggregate of           shares of Class B common stock held by five family trusts, each of which Mr. Brille serves as trustee.
​
(7)
Consists of (i)           shares of Class A common stock held by George H. Poste, (ii)          shares of Class A common stock underlying options to purchase Class A common stock held by Dr. Poste that are currently exercisable or would be exercisable within 60 days of           , 2025, (iii)      shares of Class B common stock held by Dr. Poste, and (iv)             shares of Class B common stock held by a family trust, of which Dr. Poste serves as trustee.
​
(8)
Consists of (i)     shares of Class A common stock underlying options to purchase Class A common stock held by Jonathan Knowles that are currently exercisable or would be exercisable within 60 days of           , 2025 and (ii)           shares of Class B common stock held by Dr. Knowles.
​
(9)
Consists of           shares of Class A common stock underlying options to purchase Class A common stock held by David Fredrickson that are currently exercisable or would be exercisable within 60 days of           , 2025.
​
(10)
Consists of (i)           shares of Class B common stock held by a family trust of which Peter M. Castleman serves as a trustee, (ii)       shares of Class A common stock underlying options to purchase Class A
​
 
239

TABLE OF CONTENTS
 
common stock held by Mr. Castleman that are currently exercisable or would be exercisable within 60 days of            , 2025, and (iii)        shares of Class B common stock held by CLS-PF-SPE, LLC (“CLS-PF-SPE”). CLS-PF-SPE Manager, LLC is the manager of CLS-PF-SPE. Mr. Castleman is a manager of CLS-PF-SPE Manager, LLC and in such capacity has voting and investment power with respect to the shares held by CLS-PF-SPE.
(11)
Consists of           shares of Class A common stock underlying options to purchase Class A common stock held by Joseph E. Gilliam that are currently exercisable or would be exercisable within 60 days of           , 2025.
​
(12)
Consists of (i)           shares of Class B common stock held by Jon S. Halbert, and (ii)       shares of Class B common stock held by Ke’Ohana Ventures, LLC, of which Mr. Halbert serves as the manager.
​
(13)
Consists of           shares of Class B common stock held by Laura I. Johansen.
​
(14)
Consists of           shares of Class A common stock underlying options to purchase Class A common stock held by Danny Phillips that are currently exercisable or would be exercisable within 60 days
of           , 2025.
​
(15)
Consists of           shares of Class A common stock underlying options to purchase Class A common stock held by Jeffrey Vacirca that are currently exercisable or would be exercisable within 60 days of           , 2025.
​
(16)
Consists of (i)           shares of Class A common stock held by our executive officers and directors, (ii)         shares of Class A common stock underlying options to purchase Class A common stock held by our executive officers and directors that are currently exercisable or would be exercisable within 60 days of       , 2025, (iii)         shares of Class B common stock, held by our executive officers and directors, and (iv)       shares of Class B common stock underlying options to purchase Class B common stock held by David D. Halbert that are currently exercisable or would be exercisable within 60 days of       , 2025.
​
 
240

TABLE OF CONTENTS​
 
DESCRIPTION OF CAPITAL STOCK
The following summary describes the material provisions of our capital stock and certain provisions of our amended and restated certificate of formation and our amended and restated bylaws, each of which will become effective immediately prior to the completion of this offering, and the Texas Business Organizations Code (the “TBOC”), and is qualified by reference to the amended and restated certificate of formation, the amended and restated bylaws, and the TBOC. We urge you to read our amended and restated certificate of formation and our amended and restated bylaws, which are included as exhibits to the registration statement of which this prospectus forms a part.
General
Upon the completion of this offering, our authorized capital stock will consist of        shares of Class A common stock and         shares of Class B common stock, in each case, par value $0.001 per share, and        shares of undesignated preferred stock, par value $0.001 per share.
As of March 31, 2025, after giving effect to (i) the Warrant Exercise, (ii) the Series E and F Issuance, (iii) the Preferred Stock Conversion, (iv) the issuance of the 2025 Convertible Notes and the related Notes Conversion, (v) the Common Stock Reclassification, and (vi) the RSU Net Settlement, there were        shares of our Class A common stock outstanding, held of record by                 shareholders, and         shares of our Class B common stock outstanding, held of record by        shareholders. No shares of preferred stock will be issued and outstanding immediately after completion of this offering.
Common Stock
Upon the completion of this offering, we will have two classes of authorized common stock: Class A common stock and Class B common stock. The rights of the holders of Class A common stock and Class B common stock will be identical, except with respect to voting, conversion, and transfer rights.
Voting Rights
Holders of our Class A common stock will be entitled to one vote per share of Class A common stock held, and holders of our Class B common stock will be entitled to 10 votes per share of Class B common stock held.
Holders of our Class A common stock and Class B common stock will generally vote together as a single class on all matters (or, if any holders of preferred stock are entitled to vote together with the holders of common stock, as a single class with the holders of preferred stock), submitted to a vote of our shareholders, including the election of our directors, unless otherwise provided in our amended and restated certificate of formation or required by a non-waivable provision of the TBOC. Texas law could require either holders of our Class A common stock or Class B common stock to vote separately as a single class in the following circumstances, among others:
•
if we were to seek to amend our amended and restated certificate of formation to increase or decrease the par value or the aggregate number of authorized shares of a class of our capital stock, then that class would be required to vote separately to approve the proposed amendment;
​
•
if we were to seek to amend our amended and restated certificate of formation to create a new class or increase the rights and preferences of an existing class, where in either case, the rights and preferences of such class are equal, prior, or superior to an existing class of our capital stock, then that class would be required to vote separately to approve the proposed amendment;
​
•
if we were to seek to amend our amended and restated certificate of formation to effect an exchange, reclassification, or cancellation of all or part of the shares of a class of our capital stock, then that class would be required to vote separately to approve such exchange, exchange, reclassification, or cancellation; and
​
 
241

TABLE OF CONTENTS
 
•
if we were to enter into a plan of merger or conversion under which a class of our capital stock is to be converted into or exchanged for other securities, interests, obligations, rights to acquire shares, interests, or other securities, cash, property, or any combination of the aforementioned, then that class would be required to vote separately to approve the plan of merger or conversion.
​
Dividend Rights
Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of Class A common stock and Class B common stock will be entitled to share equally, identically, and ratably, on a per share basis, with respect to any dividend or distribution of cash or property paid or distributed by us, unless different treatment of the shares of the affected class is approved by the affirmative vote of the holders of a majority of the outstanding shares of Class A common stock and Class B common stock, each voting separately as a class. See the section titled “Dividend Policy” for additional information.
Liquidation Rights
On our liquidation, dissolution, or winding-up, the holders of Class A common stock and Class B common stock will be entitled to share equally, identically, and ratably in all assets remaining after the payment of any liabilities, liquidation preferences, and accrued or declared but unpaid dividends, if any, with respect to any outstanding preferred stock, unless a different treatment is approved by the affirmative vote of the holders of a majority of the outstanding shares of Class A common stock and Class B common stock, each voting separately as a class.
No Preemptive or Similar Rights
Our Class A common stock and Class B common stock will not be entitled to preemptive rights, and will not be subject to conversion, redemption, or sinking fund provisions, except for the conversion provisions with respect to the Class B common stock described further below.
Change of Control Transactions
In the case of any distribution or payment in respect of the shares of our Class A common stock or Class B common stock upon a merger or consolidation with or into any other entity, or other substantially similar transaction, the holders of our Class A common stock and Class B common stock will be treated equally and identically with respect to shares of Class A common stock or Class B common stock owned by them, unless the only difference in the per share distribution to the holders of the Class A common stock and Class B common stock is that any securities distributed to the holder of a share of Class B common stock have 10 times the voting power of any securities distributed to the holder of a share of Class A common stock, or such merger, consolidation, or other transaction is approved by the affirmative vote of the holders of a majority of the outstanding shares of Class A common stock and Class B common stock, each voting as a separate class.
Subdivisions and Combinations
If we subdivide or combine in any manner outstanding shares of Class A common stock or Class B common stock, the outstanding shares of the other class will be subdivided or combined in the same proportion and manner, unless different treatment of the shares of each class is approved by the affirmative vote of the holders of a majority of the outstanding shares of Class A common stock and Class B common stock, each voting separately as a class.
Conversion
Each outstanding share of Class B common stock is convertible at any time at the option of its holder into one share of Class A common stock. In addition, each share of Class B common stock will convert automatically into one share of Class A common stock upon any transfer, whether or not for value, that occurs after the completion of this offering, except for certain permitted transfers set forth in our amended and restated certificate of formation, including, transfers to immediate family members, certain
 
242

TABLE OF CONTENTS
 
trusts for estate planning purposes, and entities under common control with or controlled by such holder of our Class B common stock, and transfers that are approved in advance by our board of directors as permitted transfers. Once converted into Class A common stock, the Class B common stock will be retired and cancelled and will not be reissued or available for reissuance.
All of the outstanding shares of Class B common stock will convert automatically into shares of Class A common stock upon the earliest to occur of: (i) the date fixed by our board of directors that is no less than 60 days and no more than 80 days following the date on which David D. Halbert, our Founder, Chairman, and Chief Executive Officer, dies or becomes disabled, (ii) the date fixed by our board of directors that is no less than 60 days and no more than 80 days following the date on which Mr. Halbert is no longer providing services to Caris as an executive officer or director, (iii) the date fixed by our board of directors that is no less than 60 days and no more than 80 days following the date on which Mr. Halbert, together with his affiliates and their permitted transferees, hold less than 20% of the number of shares of our capital stock that they collectively held as of the completion of this offering, or (iv) the date specified in writing by the holders of a majority of the then-oustanding shares of Class B common stock, provided that such date is no less than 10 days after such writing is delivered to us unless otherwise approved by our board of directors.
Preferred Stock
Our amended and restated certificate of formation will authorize our board of directors to establish one or more series of preferred stock (including convertible preferred stock). Unless required by law or by the TBOC, the authorized shares of preferred stock will be available for issuance without further action by our shareholders.
Our board of directors will be able to determine, with respect to any series of preferred stock, the voting powers (full or limited, or no voting powers), designations, preferences and relative, participating, optional or other special rights, and the qualifications, limitations, or restrictions thereof, of that series, including, without limitation:
•
the designation of the series;
​
•
the number of shares of the series, which our board of directors may, except where otherwise provided in the preferred stock designation, increase (but not above the total number of authorized shares of the class) or decrease (but not below the number of shares then outstanding);
​
•
whether dividends, if any, will be cumulative or non-cumulative and the dividend rate of the series;
​
•
the dates at which dividends, if any, will be payable;
​
•
the redemption rights and price or prices, if any, for shares of the series;
​
•
the terms and amounts of any sinking fund provided for the purchase or redemption of shares of the series;
​
•
the amounts payable on shares of the series in the event of any voluntary or involuntary liquidation, dissolution, or winding-up of the affairs of the Company;
​
•
whether the shares of the series will be convertible into shares of any other class or series, or any other security, of the Company or any other corporation and, if so, the specification of the other class or series or other security, the conversion price or prices or rate or rates, any rate adjustments, the date or dates as of which the shares will be convertible, and all other terms and conditions upon which the conversion may be made;
​
•
restrictions on the issuance of shares of the same series or of any other class or series; and
​
•
the voting rights, if any, of the holders of the series.
​
We will be able to issue a series of preferred stock that could, depending on the terms of the series, impede or discourage an acquisition attempt or other transaction that some, or a majority, of the holders of our common stock might believe to be in their best interests or in which the holders of our common stock
 
243

TABLE OF CONTENTS
 
might receive a premium for their common stock over the market price of the common stock. In addition, the issuance of preferred stock may adversely affect the rights of holders of our common stock by restricting dividends on the common stock, diluting the voting power of the common stock, or subordinating the liquidation rights of the common stock. As a result of these or other factors, the issuance of preferred stock may have an adverse impact on the market price of our Class A common stock.
Dividends
As a Texas corporation, we are subject to certain restrictions on dividends under the TBOC. Generally, a Texas corporation may pay dividends to its shareholders out of its surplus (the excess of its assets over its liabilities and stated capital) unless the dividend would render the corporation insolvent.
The declaration, amount, and payment of any future dividends will be at the sole discretion of our board of directors, subject to restrictions under the 2023 Term Loan Agreement, and the holders of our preferred stock we may at the time have outstanding. Our board of directors may take into account general and economic conditions, our financial condition and results of operations, our available cash and current and anticipated cash needs, capital requirements, contractual, legal, tax, and regulatory restrictions and implications on the payment of dividends by us to our shareholders or by our subsidiaries to us, including restrictions under the 2023 Term Loan Agreement and other indebtedness we may incur, and such other factors as our board of directors may deem relevant. See the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources.”
We currently expect to retain all future earnings for use in the operation and expansion of our business and have no current plans to pay dividends. See the section titled “Risk Factors—Risks Related to This Offering and Ownership of Our Class A Common Stock—We do not intend to pay dividends for the foreseeable future. Investors in this offering may never obtain a return on their investment.”
Options and RSUs
As of March 31, 2025, we had outstanding under our 2020 Plan options to purchase an aggregate of        shares of our common stock, with a weighted-average exercise price of approximately $      per share. In connection with this offering, all options outstanding under our 2020 Plan will become exercisable for                    shares of our Class A common stock and                    shares of our Class B common stock (in the case of equity awards held by David D. Halbert).
As of March 31, 2025, we had outstanding under our 2020 Plan RSUs that may be settled once vested for an aggregate of        shares of our common stock.       of these RSUs will vest in full in connection with this offering, subject to the RSU holders’ continuous service through the date of this prospectus, and will be settled in the RSU Net Settlement, where we will issue        shares of our Class A common stock and         shares of our Class B common stock, after withholding an aggregate of        shares of Class A common stock and         shares of Class B common stock, respectively, to satisfy associated estimated tax withholding and remittance obligations (based on an assumed initial offering price of $       per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assumed tax withholding rates of       % and      %, respectively). The Class B common stock issued in the RSU Net Settlement will be held by David D. Halbert.
Warrants
As of March 31, 2025, we had outstanding warrants to purchase an aggregate of up to        shares of our common stock or, at the holder’s election, Series C preferred stock, at an exercise price of $      per share. Prior to the completion of this offering, we expect that all of these warrants, which, in each case, will expire upon the completion of this offering unless earlier exercised, will be exercised in full for shares of our Series C preferred stock. The        shares of our Series C preferred stock issued upon the expected exercise of the warrants would convert into an equivalent number of shares of our common stock in the Preferred Stock Conversion and then would be reclassified into an equivalent number of shares of our Class B common stock in the Common Stock Reclassification.
In April 2025, we issued warrants to, if exercised on or after June 1, 2025, purchase at least an aggregate of       shares of our common stock, based on an assumed initial public offering price of
 
244

TABLE OF CONTENTS
 
$      per share, which is the midpoint of the price range set forth on the cover page of this prospectus, at an exercise price of $0.01 per share. All of these warrants will terminate in connection with this offering, assuming the offering will occur before June 1, 2025, the date such warrants would otherwise have initially become exercisable for shares of our common stock. If these warrants become exercisable, the shares of our common stock to be issued upon conversion of the warrants will be reclassified into an equivalent number of shares of our Class B common stock in the Common Stock Reclassification.
Convertible Notes
In April 2025, we issued the 2025 Convertible Notes to certain investors in aggregate principal amount of $30.0 million. The 2025 Convertible Notes mature on January 1, 2026 and accrue interest at a rate of 8% per annum, payable quarterly in cash. Immediately prior to and in connection with the completion of this offering, the 2025 Convertible Notes will convert at a conversion price equal to 70% of the initial public offering price per share, or into        shares of our common stock, based on an assumed initial public offering price of $      per share, which is the midpoint of the price range set forth on the cover page of this prospectus. The        shares of our common stock to be issued upon conversion of the 2025 Convertible Notes (based on such assumed initial public offering price) will be reclassified into an equivalent number of shares of our Class B common stock in the Common Stock Reclassification.
Registration Rights
Under the Investors’ Rights Agreement, following the completion of this offering, certain holders of our common stock, including, but not limited to, certain holders of more than 5% of our outstanding capital stock and entities affiliated with certain of our officers and directors, will have certain registration rights, as set forth below. Such registration rights will terminate upon the earliest of (i) the fourth anniversary of the completion of this offering and (ii) the completion of certain liquidation events. Under the Investors’ Rights Agreement, we will generally be required to pay all expenses (other than underwriting discounts and commissions and certain other expenses) related to any registration effected pursuant to the exercise of such registration rights. The Form S-1 and Form S-3 demand registration rights described below are subject to specified conditions and limitations, including the right of the underwriters to limit the number of shares of common stock included in any such registration under specified circumstances.
Form S-1 Demand Registration Rights
After the completion of this offering, the holders of up to        shares of our common stock will be entitled to certain Form S-1 demand registration rights. At any time beginning 180 days after the effective date of this registration statement, the holders of at least 20% of the shares having these rights then outstanding may request that we file a registration statement on Form S-1 to register the offer and sale of their shares. We will generally only be obligated to effect up to two such registrations. Each such request for registration must cover securities the anticipated aggregate offering price of which, net of underwriting discounts and commissions, is at least $10.0 million. If our board of directors determines that it would be materially detrimental to us and our shareholders to effect such a demand registration, we will have the right to defer such registration, not more than once in any 12-month period, for a period of up to 30 days.
Form S-3 Demand Registration Rights
After the completion of this offering, holders of up to        shares of our common stock will be entitled to certain Form S-3 demand registration rights. At any time when we are eligible to file a registration statement on Form S-3, the holders of at least 20% of the shares having these rights then outstanding will be able to request that we register the offer and sale of their shares on a registration statement on Form S-3 so long as the request covers securities the anticipated aggregate public offering price of which, net of any underwriting discounts or commissions, is at least $3.0 million. These holders may make an unlimited number of requests for registration on a registration statement on Form S-3. However, we will not be required to effect a registration on Form S-3 if we have effected three such registrations within the 12-month period preceding the date of the request. If our board of directors determines that it would be materially detrimental to us and our shareholders to effect such a demand registration, we will have the right to defer such registration, not more than once in any 12-month period, for a period of up to 30 days.
 
245

TABLE OF CONTENTS
 
Piggyback Registration Rights
After the completion of this offering, the holders of up to        shares of our common stock will be entitled to certain “piggyback” registration rights. If we propose to register shares of our common stock or other securities under the Securities Act, either for our own account or for the account of our shareholders, in connection with such offering, all holders of these shares then outstanding will be able to request that we include their shares in such registration, subject to certain marketing and other limitations. As a result, whenever we propose to file a registration statement under the Securities Act, other than with respect to (i) a registration relating solely to our stock plans, (ii) a registration relating to a corporate reorganization or other transaction covered by Rule 145 promulgated under the Securities Act, (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the shares having registration rights, or (iv) a registration relating to the offer and sale of debt securities, the holders of these shares will be entitled to notice of the registration and have the right, subject to certain limitations, to include their shares in the registration.
Anti-Takeover Effects of Certain Provisions of Our Amended and Restated Certificate of Formation, Amended and Restated Bylaws, and Texas Law
Our amended and restated certificate of formation and amended and restated bylaws will contain and the TBOC contains provisions, which are summarized in the following paragraphs, that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors. These provisions are intended to avoid costly takeover battles, reduce our vulnerability to a hostile change of control, and enhance the ability of our board of directors to maximize shareholder value in connection with any unsolicited offer to acquire us. However, these provisions may have an anti-takeover effect and may delay, deter, or prevent a merger or acquisition of us by means of a tender offer, a proxy contest, or other takeover attempt that a shareholder might consider in its best interest, including those attempts that might result in a premium over the prevailing market price for the shares of Class A common stock held by shareholders.
Dual Class Common Stock
As described above in the section titled “—Common Stock—Voting Rights,” our amended and restated certificate of formation will provide for a dual class common stock structure pursuant to which holders of our Class B common stock will have the ability to exercise significant influence over the outcome of matters requiring shareholder approval, even if they own significantly less than a majority of all outstanding shares of our common stock, including the election of directors and significant corporate transactions, such as a merger or other sale of our company or its assets for the foreseeable future. Our existing shareholders will have the ability to exercise significant influence over those matters.
Authorized but Unissued Capital Stock
Texas law does not require shareholder approval for any issuance of authorized shares. Accordingly, the authorized but unissued shares of our common stock and our preferred stock are available for future issuance without shareholder approval, subject to any limitations imposed by the listing standards of Nasdaq and restrictions under the 2023 Term Loan Agreement and other indebtedness we may incur. The listing standards of Nasdaq, which would apply if and so long as our common stock remains listed on Nasdaq, require shareholder approval of certain issuances equal to or exceeding 20% of the then outstanding voting power or then outstanding number of shares of common stock. These additional shares may be issued in the future for a variety of corporate finance transactions, acquisitions, and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger, or otherwise.
Business Combinations
We are subject to the affiliated business combinations provisions of Title 2, Chapter 21, Subchapter M of the TBOC (Sections 21.601 through 21.610), which provides that a Texas corporation may not engage in specified types of business combinations, including mergers, consolidations, and asset sales, with a
 
246

TABLE OF CONTENTS
 
person, or an affiliate or associate of that person, who is an “affiliated shareholder.” For purposes of this law, an “affiliated shareholder” is generally defined as the holder of 20% or more of the corporation’s voting shares, for a period of three years from the date that person became an affiliated shareholder. The law’s prohibitions do not apply if:
•
the business combination or the acquisition of shares by the affiliated shareholder was approved by the board of directors of the corporation before the affiliated shareholder became an affiliated shareholder; or
​
•
the business combination was approved by the affirmative vote of the holders of at least two-thirds of the outstanding voting shares of the corporation not beneficially owned by the affiliated shareholder, at a meeting of shareholders called for that purpose, not less than six months after the affiliated shareholder became an affiliated shareholder.
​
We have more than 100 shareholders and are considered to be an “issuing public corporation” for purposes of this law. The affiliated business combinations provisions of the TBOC do not apply to the following:
•
the business combination of an issuing public corporation where: (a) the corporation’s original certificate of formation or bylaws contain a provision expressly electing not to be governed by the affiliated business combinations provisions of the TBOC; or (b) the corporation adopts an amendment to its certificate of formation or bylaws, by the affirmative vote of the holders, other than affiliated shareholders, of at least two-thirds of the outstanding voting shares of the corporation, expressly electing not to be governed by the affiliated business combinations provisions of the TBOC, so long as the amendment does not take effect for 18 months following the date of the vote and does not apply to a business combination with an affiliated shareholder who became affiliated on or before the effective date of the amendment;
​
•
a business combination of an issuing public corporation with an affiliated shareholder that became an affiliated shareholder inadvertently, if the affiliated shareholder: (a) divests itself, as soon as possible, of enough shares to no longer be an affiliated shareholder; and (b) would not at any time within the three-year period preceding the announcement of the business combination have been an affiliated shareholder but for the inadvertent acquisition;
​
•
a business combination with an affiliated shareholder who became an affiliated shareholder through a transfer of shares by will or intestacy and continuously was an affiliated shareholder until the announcement date of the business combination; and
​
•
a business combination of a corporation with its wholly owned Texas subsidiary if the subsidiary is not an affiliate or associate of the affiliated shareholder other than by reason of the affiliated shareholder’s beneficial ownership of voting shares of the corporation.
​
Neither our amended and restated certificate of formation nor our amended and restated bylaws contain any provision expressly providing that we will not be subject to the affiliated business combinations provisions of the TBOC. The affiliated business combinations provisions of the TBOC may have the effect of inhibiting a non-negotiated merger or other business combination involving us, even if that event would be beneficial to our shareholders.
Vacancies
Our amended and restated certificate of formation will provide that, subject to the rights granted to one or more series of preferred stock then outstanding, and except as otherwise provided in the TBOC, any vacancies on our board of directors may only be filled by a majority of the directors then in office, although less than a quorum, or by a sole remaining director, or by the affirmative vote of a majority of the voting power of our then-outstanding capital stock entitled to vote generally in the election of directors.
No Cumulative Voting
Under Texas law, the right to vote cumulatively does not exist unless the certificate of formation specifically authorizes cumulative voting. Our amended and restated certificate of formation will not
 
247

TABLE OF CONTENTS
 
authorize cumulative voting. Therefore, shareholders holding a majority in voting power of the shares of our capital stock entitled to vote generally in the election of directors will be able to elect all of our directors.
Special Shareholder Meetings
Our amended and restated certificate of formation will provide that special meetings of our shareholders may be called at any time only by or at the direction of the board of directors, the Chairman of the board of directors, our President, our Chief Executive Officer, or from and after the date on which no shares of Class B common stock are outstanding (such date, the “Trigger Date”), by our Secretary at the written request of the holders of the greater of (a) at least 50% and (b) the highest percentage of ownership that may be set under the TBOC, of all the voting power of all of the shares of our capital stock entitled to be voted at the special meeting. Our amended and restated bylaws will prohibit the conduct of any business at a special meeting other than procedural matters or as specified in the notice for such meeting. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers, or changes in control or management of the Company.
Requirements for Advance Notification of Director Nominations and Shareholder Proposals
Our amended and restated bylaws will establish advance notice procedures with respect to shareholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. In order for any matter to be “properly brought” before a meeting, a shareholder will have to comply with advance notice requirements and provide us with certain information. Generally, to be timely, a shareholder’s notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the immediately preceding annual meeting of shareholders. Our amended and restated bylaws will also specify requirements as to the form and content of a shareholder’s notice. Our amended and restated bylaws will allow the chair of the meeting at a meeting of the shareholders to adopt rules and regulations for the conduct of meetings which may have the effect of precluding the conduct of certain business at a meeting if the rules and regulations are not followed. These provisions may also defer, delay, or discourage a potential acquiror from conducting a solicitation of proxies to elect the acquiror’s own slate of directors or otherwise attempting to influence or obtain control of us.
Shareholder Action by Written Consent
Our amended and restated certificate of formation will provide that from and after the Trigger Date, any action required or permitted to be taken at an annual or special meeting of shareholders may be taken by written consent in lieu of a meeting of shareholders only with the unanimous written consent of all holders of shares entitled to vote on such action.
Amendment of Bylaws and Certificate of Formation Provisions
Our amended and restated certificate of formation and amended and restated bylaws will provide that our board of directors is expressly authorized to adopt, amend, alter, or repeal, in whole or in part, our amended and restated bylaws without a shareholder vote in any manner not inconsistent with the laws of the State of Texas and our amended and restated certificate of formation. The shareholders may not adopt, amend, alter, or repeal our amended and restated bylaws unless such action is approved, in addition to any other vote required by our amended and restated certificate of formation, by the affirmative vote of, from and after the Trigger Date, the holders of at least 662∕3% of the voting power of all the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class.
The TBOC provides generally that the affirmative vote of the holders of at least 662∕3% of the outstanding shares entitled to vote thereon, voting together as a single class, is required to amend a corporation’s certificate of formation, unless the certificate of formation requires a greater or lesser percentage, but not less than a majority. Our amended and restated certificate of formation will provide that the affirmative vote of, from and after the Trigger Date, the holders of at least 662∕3% of the voting power of all the then-outstanding shares entitled to vote thereon, voting together as a single class, will continue to be required to amend or repeal, or adopt any provision of our amended and restated certificate of formation inconsistent with:
 
248

TABLE OF CONTENTS
 
•
the provisions providing for the election and term of our directors;
​
•
the provisions regarding resignation and removal of directors;
​
•
the provisions regarding filling vacancies on our board of directors and newly created directorships;
​
•
the provisions eliminating monetary damages for breaches of fiduciary duty by a director;
​
•
the provisions regarding shareholder action by written consent;
​
•
the provisions regarding calling special meetings of shareholders;
​
•
the provisions regarding jurisdiction and forums for proceedings;
​
•
the provisions denying preemptive rights; and
​
•
the amendment provision requiring that the above provisions be amended only with the affirmative vote of, from and after the Trigger Date, the holders of at least 662∕3% of the voting power of all the then-outstanding shares entitled to vote thereon, voting together as a single class;
​
provided, however, that for so long as any shares of Class B common stock remain outstanding, the affirmative vote of the holders of at least a majority of the voting power of the outstanding shares of Class B common stock, voting as a separate class, in addition to any other vote required by law or our amended and restated certificate of formation, shall be required to amend, alter, change, repeal, or adopt any provision inconsistent with the provisions regarding the designations and the powers, preferences, privileges, and rights, and the qualifications, limitations, or restrictions with respect to our Class A common stock and Class B common stock or the amendment provision requiring that the above bulleted provisions be amended only with the affirmative vote of, from and after the Trigger Date, the holders of at least 662∕3% of the voting power of all the then-outstanding shares entitled to vote thereon, voting together as a single class.
The combination of the lack of cumulative voting and the supermajority voting requirements will make it more difficult for shareholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Because our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing shareholders or another party to effect a change in management.
These provisions may have the effect of deterring hostile takeovers or delaying or preventing changes in control of our management or of us, such as a merger, reorganization, or tender offer. These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of our Company. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions are also intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts. Such provisions may also have the effect of preventing changes in management.
Exclusive Forum
Our amended and restated organizational documents will provide that the Business Court in the First Business Court Division of the State of Texas shall be the sole and exclusive forum for certain shareholder litigation matters, unless we consent in writing to the selection of an alternative forum or if the Business Court in the First Business Court Division of the State of Texas is not accepting filings or determines that it lacks jurisdiction, the exclusive forum will be the federal district courts in the Northern District of Texas or, if such federal district courts do not have jurisdiction, the State District Court in Dallas County, Texas; provided, however, that the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act and provided, further, that the foregoing choice of forum provision shall not apply to claims seeking to enforce
 
249

TABLE OF CONTENTS
 
any liability or duty created by the Securities Act, the Exchange Act, or any other claim for which the U.S. federal courts have exclusive jurisdiction. Although we believe this provision benefits us by providing increased consistency in the application of Texas law in the types of lawsuits to which it applies and in limiting our litigation costs, the provision may have the effect of discouraging lawsuits against our directors and officers, may result in increased costs for our shareholders to bring claims, and may limit our shareholders’ ability to obtain a favorable judicial forum for disputes with us. However, it is possible that a court could rule that this provision is unenforceable or inapplicable to a particular dispute.
Conflicts of Interest
Texas law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the corporation or its officers, directors, or shareholders. Our amended and restated certificate of formation will, to the maximum extent permitted from time to time by Texas law, renounce any interest or expectancy that we have in, or right to be offered an opportunity to participate in, specified business opportunities that are from time to time presented to our officers, directors, or shareholders or their respective affiliates, other than those officers, directors, shareholders, or affiliates who are our or our subsidiaries’ employees. Our amended and restated certificate of formation will provide that, to the fullest extent permitted by law, no director (or his or her affiliates) who is not employed by us will have any duty to refrain from (i) engaging in a corporate opportunity in the same or similar lines of business in which we or our subsidiaries from time to time are engaged or propose to engage or (ii) otherwise competing, directly or indirectly, with us or any of our subsidiaries. In addition, to the fullest extent permitted by law, in the event that any non-employee director acquires knowledge of a potential transaction or other business opportunity that may be a corporate opportunity for himself or herself or his or her affiliates or for us or our affiliates, such person will have no duty to communicate or offer such transaction or business opportunity to us or any of our subsidiaries, and they may take any such opportunity for themselves or offer it to another person or entity. Our amended and restated certificate of formation will not renounce our interest in any business opportunity that is expressly offered to a non-employee director solely in his or her capacity as a director or officer of our Company. To the fullest extent permitted by law, no business opportunity will be deemed to be a potential corporate opportunity for us unless we would be permitted to undertake the opportunity under our amended and restated certificate of formation, we have sufficient financial resources to undertake the opportunity, and the opportunity would be in line with our business.
Limitations on Liability and Indemnification of Officers and Directors
The TBOC authorizes corporations to limit or eliminate the personal liability of directors to corporations and their shareholders for monetary damages for breaches of directors’ fiduciary duties (other than breaches of the directors’ duty of loyalty to corporations or their shareholders), subject to certain exceptions. Our amended and restated certificate of formation will include a provision that eliminates the personal liability of directors for monetary damages for any breach of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the TBOC. The effect of these provisions will be to eliminate the rights of us and our shareholders, through shareholders’ derivative suits on our behalf, to recover monetary damages from a director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior. However, exculpation will not apply to any director if the director has acted in bad faith, engaged in intentional misconduct, knowingly violated the law, authorized illegal dividends or redemptions, derived an improper benefit from his or her actions as a director, or engaged in an act or omission for which the liability of the director is expressly provided by an applicable statute.
Our amended and restated bylaws will provide generally that we must indemnify and advance expenses to our directors and officers to the fullest extent authorized by the TBOC. We also have entered into separate indemnification agreements with each of our directors and executive officers and will be expressly authorized to carry directors’ and officers’ liability insurance providing indemnification for our directors, officers, and certain employees for some liabilities. We believe that these indemnification and advancement provisions and insurance will be useful to attract and retain qualified directors and officers.
These limitation of liability, indemnification, and advancement provisions may discourage shareholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions
 
250

TABLE OF CONTENTS
 
also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our shareholders. In addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.
There is currently no pending material litigation or proceeding involving any of our directors, officers, or employees for which indemnification is sought.
Dissenters’ Rights of Appraisal and Payment
Under the TBOC, with certain exceptions, our shareholders will have appraisal rights in connection with a merger, a sale of all or substantially all of our assets, an interest exchange, or a conversion. Pursuant to the TBOC, shareholders who properly request and perfect appraisal rights in connection with such merger, sale of all or substantially all of our assets, interest exchange, or conversion will have the right to receive payment of the fair value of their shares as agreed to between the shareholder and us or, if unable to reach agreement, as determined by the State District Court in Dallas County, Texas.
Shareholders’ Derivative Actions
Under the TBOC, any of our shareholders may bring an action in our name to procure a judgment in our favor, also known as a derivative action, provided that the shareholder bringing the action (i) is a holder of our shares at the time of the transaction to which the action relates or such shareholder became a shareholder by operation of law from a person that was a shareholder at the time of the transaction to which the action relates and (ii) fairly and adequately represents the interests of the Company in enforcing the right of the Company.
Listing
We have applied to list our Class A common stock on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “CAI.”
Transfer Agent and Registrar
The transfer agent and registrar for our Class A common stock will be Equiniti Trust Company, LLC. The transfer agent and registrar’s address is 48 Wall Street, 22nd Floor, New York, New York 10005.
 
251

TABLE OF CONTENTS​
 
SHARES ELIGIBLE FOR FUTURE SALE
Before this offering, there has not been a public market for shares of our Class A common stock. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal restrictions on resale. Nevertheless, future sales of substantial amounts of shares of our Class A common stock, including shares issued upon the exercise of outstanding options or upon conversion of our Class B common stock, in the public market following this offering or the possibility of these sales occurring, could cause the prevailing market price for our Class A common stock to fall or impair our ability to raise equity capital in the future.
Following this offering, we will have outstanding                shares of our Class A common stock and              shares of our Class B common stock, based on the number of shares of common stock outstanding as of March 31, 2025, after giving effect to (i) the Warrant Exercise, (ii) the Series E and F Issuance, (iii) the Preferred Stock Conversion, (iv) the issuance of the 2025 Convertible Notes and the related Notes Conversion, (v) the Common Stock Reclassification, and (vi) the RSU Net Settlement. This includes                shares of Class A common stock that we are selling in this offering, which shares may be resold in the public market immediately unless purchased by our affiliates and assumes no additional exercise of outstanding options other than as described elsewhere in this prospectus.
The remaining              shares of common stock that are not sold in this offering will be “restricted securities,” as that term is defined in Rule 144 under the Securities Act (“Rule 144”). These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rule 144 or Rule 701 under the Securities Act (“Rule 701”), which are summarized below.
As a result of the lock-up agreements and market stand-off provisions described below, and subject to the provisions of Rule 144 or Rule 701, the earliest these restricted securities may generally be available for sale in the public market is as follows:
​
Earliest Date Available for Sale in the Public Market
​ ​
Number of Shares of Common Stock
​
​            , 2025, which is                  . ​ ​ All remaining shares held by our shareholders not previously eligible for sale, subject to volume limitations applicable to “affiliates” under Rule 144 as described below. ​
In addition, pursuant to certain exceptions to the lock-up agreements, shares of our Class A common stock will be eligible for sale in the open market during the Lock-Up Period (as defined below) in sell-to-cover transactions in order to satisfy tax withholding obligations.
We expect each sell-to-cover transaction to extend over a multi-day period based on trading volumes. Because the purpose of sell-to-cover transactions is to generate proceeds sufficient to satisfy tax withholding obligations or remittance payments due as a result of the vesting or settlement of RSUs or the exercise of options that are expiring during the Lock-Up Period, the exact number of shares sold will depend on the sale prices of the Class A common stock in such transactions and our shareholders’ personal tax rates. In addition, if net settlement transactions occur on or prior to the dates set forth above, the number of shares of Class A common stock to be sold in each sell-to-cover transaction will be reduced proportionally.
Rule 144
In general, under Rule 144 as currently in effect, a person who has beneficially owned shares of our restricted common stock for at least six months would be entitled to sell their securities provided that such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a sale, and we are subject to the periodic reporting requirements of the Exchange Act, for at least 90 days before the sale. In addition, under Rule 144, any person who is not an affiliate of ours and has held their shares of common stock for at least one year, including the holding period of any prior owner other than one of our affiliates, would be entitled to sell an unlimited number of shares of common stock immediately upon the completion of this offering without regard to whether current public information about
 
252

TABLE OF CONTENTS
 
us is available. Persons who have beneficially owned shares of our restricted common stock for at least six months but who are our affiliates at the time of, or any time during the 90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the following:
•
1% of the number of shares of our capital stock then outstanding, which will equal           shares immediately after the completion of this offering, assuming no exercise by the underwriters of their option to purchase additional shares of Class A common stock; or
​
•
the average weekly trading volume of our Class A common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale,
​
provided, in each case, that we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Such sales both by affiliates and by non-affiliates must also comply with the manner of sale, current public information and notice provisions of Rule 144.
Rule 701
Any of our service providers who purchased shares under a written compensatory plan or contract prior to this offering may be entitled to rely on the resale provisions of Rule 701. Rule 701, as currently in effect, permits resales of shares, including by affiliates, in reliance upon Rule 144 but without compliance with certain restrictions, including the holding period requirement, of Rule 144. Rule 701 further provides that non-affiliates may sell such shares in reliance on Rule 144 without having to comply with the public information, volume limitation or notice provisions of Rule 144. All holders of Rule 701 shares are required to wait until 90 days after the date of this prospectus before selling such shares if such resale is pursuant to Rule 701. All Rule 701 shares are, however, subject to lock-up agreements and will only become eligible for sale upon the expiration of these lock-up agreements.
Lock-Up Agreements and Market Stand-off Provisions
In connection with this offering, our executive officers, directors, and other existing security holders have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 180 days after the date of this prospectus (the “Lock-Up Period”) without first (a) providing prior written notice to BofA Securities, Inc., J.P. Morgan Securities LLC, and Goldman Sachs & Co. LLC and (b) obtaining the written consent of BofA Securities, Inc. and either J.P. Morgan Securities LLC or Goldman Sachs & Co. LLC, who may release the securities subject to any of the lock-up agreements in whole or in part at any time. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly
•
offer, pledge, sell, or contract to sell any common stock,
​
•
sell any option or contract to purchase any common stock,
​
•
purchase any option or contract to sell any common stock,
​
•
grant any option, right, or warrant for the sale of any common stock,
​
•
lend or otherwise dispose of or transfer any common stock,
​
•
request or demand that we file or make a confidential submission of a registration statement related to the common stock, or
​
•
enter into any hedging, swap, loan, or any other agreement or transaction that transfers, in whole or in part, the economic consequence of ownership of any common stock whether any such hedging, swap, loan, or transaction is to be settled by delivery of shares or other securities, in cash or otherwise.
​
If any director, officer or shareholder is granted an early release from its obligations under any lock-up restrictions with respect to our securities in an aggregate amount in excess of one percent of our outstanding Class A common stock, then every other lock-up party automatically will be granted an equivalent early release from its obligations under their respective lock-up agreement on a pro rata basis, provided that such release shall not apply (i) if it is effected solely to permit a transfer not for consideration and the
 
253

TABLE OF CONTENTS
 
transferee has agreed in writing to be bound by the same terms described in the lock-up agreement to the extent and for the duration that such terms remain in effect at the time of the transfer and (ii) in the event of an underwritten public offering, except with respect to the lock-up party’s participation in such underwritten public offering, provided that the lock-up party shall be offered the opportunity to participate in such underwritten public offering in accordance with, and subject to, the terms of any rights agreement (including the Investors’ Rights Agreement).
The agreements of our executive officers, directors, and other existing security holders do not apply to transfers, sales or dispositions: (i) as a bona fide gift or gifts, including, without limitation, to a charitable organization or educational institution, or for bona fide estate planning purposes; (ii) by will, testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the lock-up party; (iii) (A) if the lock-up party is an individual, by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement or (B) if the lock-up party is a corporation, partnership, limited liability company or other business entity, pursuant to a merger or reorganization with or into another entity; (iv) pursuant to an order of a court or regulatory agency having jurisdiction over the lock-up party; (v) to any corporation, partnership, limited liability company or other entity controlled or managed, or under common control or management by, the lock-up party or the immediate family of the lock-up party; (vi) to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i) through (v) above; (vii) to any immediate family member or any trust, partnership, limited liability company or other entity for the direct or indirect benefit of the lock-up party or one or more immediate family members of the lock-up party, or if the lock-up party is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust; (viii) if the lock-up party is a corporation, partnership, limited liability company, trust or other business entity, (A) to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act) of the lock-up party, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control or common investment management with the lock-up party or affiliates of the lock-up party (including, for the avoidance of doubt, pursuant to a merger, acquisition or reorganization of the lock-up party and, further, where the lock-up party is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B) as part of a distribution to partners (general or limited partners), limited liability company members, shareholders or other equityholders of the lock-up party or holders of similar equity interests in the lock-up party; (ix) to us upon the lock-up party’s death, disability or termination of employment or other service relationship with us; provided that such common stock were issued to the lock-up party pursuant to an agreement or equity award granted pursuant to an employee benefit plan, option, warrant or other right disclosed in this prospectus; (x) pursuant to a bona fide third-party tender offer, or in connection with a merger, consolidation or other similar transaction, that is approved by the our board of directors, made to all holders of our capital stock involving a change of control of us (including, without limitation, entering into any lock-up, voting or similar agreement pursuant to which the lock-up party may agree to transfer, sell, tender or otherwise dispose of lock-up securities in connection with such transaction, or vote any common stock or other securities in favor of any such transaction); provided that, in the event that such tender offer, merger, consolidation or other transaction is not completed, the lock-up party’s lock-up securities shall remain subject to the restrictions set forth in this lock-up agreement; provided further that any shares of common stock not transferred, sold or otherwise disposed of in such third-party tender offer, merger, consolidation, or other similar transaction shall remain subject to the restrictions set forth in this lock-up agreement (for purposes hereof, “change of control” shall mean the transfer, sale or other disposition (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of our capital stock if, after such transaction or transactions, such person or group of affiliated persons would hold more than 50% of our outstanding voting securities (or the surviving entity)); to us in connection with the conversion or exercise of any of our outstanding equity securities into shares of common stock or in connection with the reclassification or exchange of shares of common stock, in each case as described and as contemplated in this prospectus; provided that any shares of common stock received by the lock-up party upon such conversion, exercise, reclassification, reclassification or exchange shall be subject to the restrictions set forth in this lock-up agreement; (xii) in connection with the vesting or settlement of restricted stock units or the exercise of options or other rights to purchase the shares of common stock (including, in each case, by way of “net” or “cashless” exercise), including (A) any
 
254

TABLE OF CONTENTS
 
transfer, sale or other disposition to us for the payment of exercise price, tax withholdings or remittance payments due as a result of the vesting, settlement or exercise of such restricted stock units, options or rights, and (B) any transfer, sale or other disposition of shares of common stock necessary to generate such amount of cash needed to satisfy tax withholdings or remittance payments due as a result of the vesting or settlement of restricted stock units or the exercise of options, which are expiring during the lock-up period, to purchase the shares of common stock; provided that, in each case, any such restricted stock units and options to purchase shares of common stock were granted under an equity incentive plan or other equity award plan that is described in this prospectus and provided, further, that, in each case, any such shares of common stock received by the lock-up party upon such vesting, settlement or exercise that are not so transferred, sold or otherwise disposed shall be subject to the restrictions set forth in this lock-up agreement; (xiii) up to 15% of the lock-up party’s lock-up securities, to any third-party pledgee in a bona fide transaction as collateral to secure obligations pursuant to lending or other arrangements between such third parties (or their affiliates or designees) and the lock-up party and/or its affiliates or any similar arrangement relating to a financing arrangement for the benefit of the lock-up party and/or its affiliates; and upon foreclosure of any such lending or other arrangements; (xiv) if the lock-up party is not our officer or director, in connection with a sale of the lock-up party’s shares of Class A common stock acquired (A) from the underwriters in this offering or (B) on the open market or in other transactions following this offering; or (xv) to the underwriters pursuant to the underwriting agreement.
In addition, notwithstanding the restrictions in the lock-up agreement, the lock-up party may make any demand or requests for, exercise any right with respect to, or take any action in preparation of, the registration by us under the Securities Act of the lock-up party’s lock-up securities or other securities; provided that (i) no public filing with the Securities and Exchange Commission or any other public announcement may be made during the lock-up period in relation to such registration, (ii) the representatives must have received prior written notice from us and/or the lock-up party of a confidential submission of a registration statement with the Securities and Exchange Commission during the lock-up period at least five (5) business days prior to such submission and (iii) no lock-up securities or other securities of us may be sold, distributed or exchanged during the lock-up period. Notwithstanding the foregoing, the lock-up party also may establish trading plans pursuant to Rule 10b5-1 under the Exchange Act for the transfer, sale or other disposition of lock-up securities, provided that (1) none of the securities subject to such plan may be transferred, sold or otherwise disposed of until after the expiration of the lock-up period and (2) no public announcement, report or filing under the Exchange Act, or any other public filing, report or announcement, shall be voluntarily made regarding the establishment of such plan during the lock-up period, and if any such filing, report or announcement shall be legally required during the lock-up period, such filing, report or announcement shall clearly indicate therein that none of the securities subject to such plan may be transferred, sold, or otherwise disposed pursuant to such plan until after the expiration of the lock-up period.
In the event that (i) at least 150 days have elapsed since the date of this prospectus and (ii) the end of the restricted period would fall during one of our quarterly blackout periods during which trading by certain of our employees in our securities would not be permitted under our insider trading policy then in effect (a “Blackout Period”), or within 10 trading days prior to such Blackout Period the restricted period shall end on the date that is the later of (a) 10 trading days prior to the commencement of a Blackout Period and (b) the 150th day after the date of this prospectus. For a further description of these lock-up agreements, please see “Underwriting.”
In addition to the restrictions contained in the lock-up agreements described above, the holders of outstanding equity awards and holders of outstanding common stock issued pursuant to the vesting, settlement, or exercise of equity awards, are subject to market stand-off provisions in agreements with us that impose similar restrictions on the ability of such security holders to offer, sell, or transfer our equity securities during the Lock-Up Period.
Registration Rights
After the completion of this offering, the holders of up to              shares of our common stock will, subject to the lock-up agreements referred to above, be entitled to certain rights with respect to the registration of such shares under the Securities Act. The registration of these shares of our common stock under the Securities Act would result in these shares becoming eligible for sale in the public market without
 
255

TABLE OF CONTENTS
 
restriction under the Securities Act immediately upon the effectiveness of such registration, subject to the Rule 144 limitations applicable to affiliates. See the section titled “Description of Capital Stock—Registration Rights” for a description of these registration rights.
Equity Plans
We intend to file a registration statement on Form S-8 under the Securities Act covering all of the shares of our common stock subject to options outstanding or reserved for issuance under our equity plans. We expect to file this registration statement as soon as practicable after the completion of this offering. This registration statement will become effective immediately upon filing, and shares covered by this registration statement will thereupon be eligible for sale in the public markets, subject to vesting restrictions, the lock-up agreements described above and Rule 144 limitations applicable to affiliates. For a more complete discussion of our stock plans, see the section titled “Executive Compensation—Long-Term Incentive Plans.”
 
256

TABLE OF CONTENTS​
 
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF OUR CLASS A COMMON STOCK
The following discussion is a summary of the material U.S. federal income tax consequences to Non-U.S. Holders (as defined below) of the purchase, ownership, and disposition of our Class A common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local, or non-U.S. tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended (the “Code”), Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the “IRS”), in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a Non-U.S. Holder. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the purchase, ownership, and disposition of our Class A common stock.
This discussion is limited to Non-U.S. Holders that hold our Class A common stock as a “capital asset” within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a Non-U.S. Holder’s particular circumstances, including the impact of the Medicare contribution tax on net investment income, the special tax accounting rules under Section 451(b) of the Code, and the alternative minimum tax. In addition, it does not address consequences relevant to Non-U.S. Holders subject to special rules, including, without limitation:
•
U.S. expatriates and former citizens or long-term residents of the United States;
​
•
persons holding our Class A common stock as part of a hedge, straddle, or other risk reduction strategy or as part of a conversion transaction or other integrated investment;
​
•
banks, insurance companies, and other financial institutions;
​
•
brokers, dealers, or traders in securities;
​
•
“controlled foreign corporations,” “passive foreign investment companies,” and corporations that accumulate earnings to avoid U.S. federal income tax;
​
•
partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein);
​
•
tax-exempt organizations or governmental organizations;
​
•
persons deemed to sell our Class A common stock under the constructive sale provisions of the Code;
​
•
persons who hold or receive our Class A common stock pursuant to the exercise of any employee stock option or otherwise as compensation;
​
•
tax-qualified retirement plans; and
​
•
“qualified foreign pension funds” as defined in Section 897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds.
​
If an entity treated as a partnership for U.S. federal income tax purposes holds our Class A common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, partnerships holding our Class A common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them.
THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP,
 
257

TABLE OF CONTENTS
 
AND DISPOSITION OF OUR CLASS A COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL, OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.
Definition of a Non-U.S. Holder
For purposes of this discussion, a “Non-U.S. Holder” is any beneficial owner of our Class A common stock that is neither a “U.S. person” nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following:
•
an individual who is a citizen or resident of the United States;
​
•
a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia;
​
•
an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
​
•
a trust that (1) is subject to the primary supervision of a U.S. court and the control of one or more “United States persons” ​(within the meaning of Section 7701(a)(30) of the Code), or (2) has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes.
​
Distributions
As described in the section titled “Dividend Policy,” we do not anticipate declaring or paying dividends to holders of our Class A common stock in the foreseeable future. However, if we do make distributions of cash or property on our Class A common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against and reduce a Non-U.S. Holder’s adjusted tax basis in its Class A common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under “—Sale or Other Taxable Disposition.”
Subject to the discussions below on effectively connected income, backup withholding, and FATCA (as defined below) dividends paid to a Non-U.S. Holder will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the Non-U.S. Holder furnishes a valid IRS Form W-8BEN or W-8BEN-E (or other applicable documentation) certifying qualification for the lower treaty rate). A Non-U.S. Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. Non-U.S. Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty.
If dividends paid to a Non-U.S. Holder are effectively connected with the Non-U.S. Holder’s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such dividends are attributable), the Non-U.S. Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the Non-U.S. Holder must furnish to the applicable withholding agent a valid IRS Form W-8ECI, certifying that the dividends are effectively connected with the Non-U.S. Holder’s conduct of a trade or business within the United States.
Any such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular rates in the same manner as if the Non-U.S. Holder were a resident of the United States. A Non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. Non-U.S. Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules.
 
258

TABLE OF CONTENTS
 
Sale or Other Taxable Disposition
Subject to the discussions below on backup withholding and FATCA (as defined below), a Non-U.S. Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our Class A common stock unless:
•
the gain is effectively connected with the Non-U.S. Holder’s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such gain is attributable);
​
•
the Non-U.S. Holder is a nonresident alien individual present in the United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or
​
•
our Class A common stock constitutes a U.S. real property interest (“USRPI”) by reason of our status as a U.S. real property holding corporation (“USRPHC”) for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding the disposition or the Non-U.S. Holder’s holding period for our Class A common stock.
​
Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular rates in the same manner as if the Non-U.S. Holder were a resident of the United States. A Non-U.S. Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items.
A Non-U.S. Holder described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on gain realized upon the sale or other taxable disposition of our Class A common stock, which may be offset by U.S. source capital losses of the Non-U.S. Holder (even though the individual is not considered a resident of the United States), provided the Non-U.S. Holder has timely filed U.S. federal income tax returns with respect to such losses.
With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our non-U.S. real property interests and our other business assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition of our Class A common stock by a Non-U.S. Holder will not be subject to U.S. federal income tax if our Class A common stock is “regularly traded,” as defined by applicable Treasury Regulations, on an established securities market and such Non-U.S. Holder owned, actually and constructively, 5% or less of our Class A common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the Non-U.S. Holder’s holding period.
Non-U.S. Holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules.
Information Reporting and Backup Withholding
Payments of dividends on our Class A common stock will not be subject to backup withholding, provided the applicable withholding agent does not have actual knowledge or reason to know the holder is a United States person and the holder either certifies its non-U.S. status, such as by furnishing a valid IRS Form W-8BEN, W-8BEN-E, or W-8ECI, or otherwise establishes an exemption. However, information returns are required to be filed with the IRS in connection with any distributions on our Class A common stock paid to the Non-U.S. Holder, regardless of whether such distributions constitute dividends or whether any tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our Class A common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting if the applicable withholding agent receives the certification described above and does not have actual knowledge or reason to know that such holder is a United States person or the holder otherwise establishes an exemption. Proceeds of a disposition of our
 
259

TABLE OF CONTENTS
 
Class A common stock conducted through a non-U.S. office of a non-U.S. broker generally will not be subject to backup withholding or information reporting.
Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the tax authorities of the country in which the Non-U.S. Holder resides or is established.
Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a Non-U.S. Holder’s U.S. federal income tax liability, provided the required information is timely furnished to the IRS.
Additional Withholding Tax on Payments Made to Foreign Accounts
Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax Compliance Act, or “FATCA”) on certain types of payments made to non-U.S. financial institutions and certain other non-U.S. entities. Specifically, a 30% withholding tax may be imposed on dividends on, or (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, our Class A common stock paid to a “foreign financial institution” or a “non-financial foreign entity” ​(each as defined in the Code), unless (1) the foreign financial institution undertakes certain diligence and reporting obligations, (2) the non-financial foreign entity either certifies it does not have any “substantial United States owners” ​(as defined in the Code) or furnishes identifying information regarding each substantial United States owner, or (3) the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in (1) above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain “specified United States persons” or “United States owned foreign entities” ​(each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to non-compliant foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules.
Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends on our Class A common stock. While withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition of stock on or after January 1, 2019, proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued.
Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our Class A common stock.
 
260

TABLE OF CONTENTS​
 
UNDERWRITING
BofA Securities, Inc., J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and Citigroup Global Markets Inc. are acting as representatives of each of the underwriters named below. Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the number of shares of Class A common stock set forth opposite its name below.
Underwriter
​ ​
Number
of Shares
​
BofA Securities, Inc.
​ ​
       
​
J.P. Morgan Securities LLC
​ ​ ​ ​
Goldman Sachs & Co. LLC
​ ​ ​ ​
Citigroup Global Markets Inc.
​ ​ ​ ​
TD Securities (USA) LLC
​ ​ ​ ​
Evercore Group L.L.C.
​ ​ ​ ​
Guggenheim Securities, LLC
​ ​ ​ ​
BTIG, LLC
​ ​ ​ ​
Nomura Securities International, Inc.
​ ​ ​ ​
WR Securities, LLC
​ ​ ​ ​
Total
​ ​ ​ ​
Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed, severally and not jointly, to purchase all of the shares of Class A common stock sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated.
We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities.
The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer’s certificates and legal opinions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. Sales of shares made outside of the United States may be made by affiliates of the underwriters.
Commissions and Discounts
The representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering price set forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $      per share. After the initial offering, the public offering price, concession, or any other term of the offering may be changed.
The following table shows the public offering price, underwriting discount, and proceeds before expenses to us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares of Class A common stock.
​ ​ ​
Per Share
​ ​
Without
Option
​ ​
With
Option
​
Public offering price
​ ​ ​ $ ​ ​ ​ ​ ​ $ ​ ​ ​ ​ ​ $ ​ ​ ​
Underwriting discount
​ ​ ​ $ ​ ​ ​ ​ ​ $ ​ ​ ​ ​ ​ $ ​ ​ ​
Proceeds, before expenses, to us
​ ​ ​ $ ​ ​ ​ ​ ​ $ ​ ​ ​ ​ ​ $ ​ ​ ​
 
261

TABLE OF CONTENTS
 
The expenses of the offering, not including the underwriting discount, are estimated at $       and are payable by us. We have also agreed to reimburse the underwriters for their expenses relating to clearance of this offering with the Financial Industry Regulatory Authority in an amount up to $        .
We have engaged NCMG LLC to provide certain financial advisory services in connection with this offering. The underwriters have agreed to reimburse us for such financial advisory services provided by NCMG LLC in connection with this offering.
Option to Purchase Additional Shares
We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to                 additional shares of Class A common stock at the public offering price, less the underwriting discount. If the underwriters exercise this option, each will be obligated, subject to conditions contained in the underwriting agreement, to purchase a number of additional shares of Class A common stock proportionate to that underwriter’s initial amount reflected in the above table.
No Sales of Similar Securities
We, our executive officers and directors and our other existing security holders have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 180 days (the “Lock-Up Period”) after the date of this prospectus without (a) providing prior written notice to BofA Securities, Inc., J.P. Morgan Securities LLC, and Goldman Sachs & Co. LLC and (b) first obtaining the written consent of BofA Securities, Inc. and either J.P. Morgan Securities LLC or Goldman Sachs & Co. LLC, who may release the securities subject to any of the lock-up agreements in whole or in part at any time. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly
•
offer, pledge, sell, or contract to sell any common stock,
​
•
sell any option or contract to purchase any common stock,
​
•
purchase any option or contract to sell any common stock,
​
•
grant any option, right, or warrant for the sale of any common stock,
​
•
lend or otherwise dispose of or transfer any common stock,
​
•
request or demand that we file or make a confidential submission of a registration statement related to the common stock, or
​
•
enter into any hedging, swap, loan, or any other agreement or transaction that transfers, in whole or in part, the economic consequence of ownership of any common stock whether any such hedging, swap, loan or transaction is to be settled by delivery of shares or other securities, in cash or otherwise.
​
This lock-up provision applies to common stock and to securities convertible into or exchangeable or exercisable for or repayable with common stock (collectively, the “lock-up securities”). It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power of disposition.
The agreements of our executive officers, directors, and other existing security holders do not apply to transfers, sales or dispositions: (i) as a bona fide gift or gifts, including, without limitation, to a charitable organization or educational institution, or for bona fide estate planning purposes; (ii) by will, testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the lock-up party; (iii) (A) if the lock-up party is an individual, by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement or (B) if the lock-up party is a corporation, partnership, limited liability company or other business entity, pursuant to a merger or reorganization with or into another entity; (iv) pursuant to an order of a court or regulatory agency having jurisdiction over the lock-up party; (v) to any corporation, partnership, limited liability company or other entity controlled or managed, or under common control or management by, the lock-up party or the immediate family of the lock-up party; (vi) to a nominee or custodian of a person or entity to
 
262

TABLE OF CONTENTS
 
whom a disposition or transfer would be permissible under clauses (i) through (v) above; (vii) to any immediate family member or any trust, partnership, limited liability company or other entity for the direct or indirect benefit of the lock-up party or one or more immediate family members of the lock-up party, or if the lock-up party is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust; (viii) if the lock-up party is a corporation, partnership, limited liability company, trust or other business entity, (A) to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act) of the lock-up party, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control or common investment management with the lock-up party or affiliates of the lock-up party (including, for the avoidance of doubt, pursuant to a merger, acquisition or reorganization of the lock-up party and, further, where the lock-up party is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B) as part of a distribution to partners (general or limited partners), limited liability company members, shareholders or other equityholders of the lock-up party or holders of similar equity interests in the lock-up party; (ix) to us upon the lock-up party’s death, disability or termination of employment or other service relationship with us; provided that such common stock were issued to the lock-up party pursuant to an agreement or equity award granted pursuant to an employee benefit plan, option, warrant or other right disclosed in this prospectus; (x) pursuant to a bona fide third-party tender offer, or in connection with a merger, consolidation or other similar transaction, that is approved by the our board of directors, made to all holders of our capital stock involving a change of control of us (including, without limitation, entering into any lock-up, voting or similar agreement pursuant to which the lock-up party may agree to transfer, sell, tender or otherwise dispose of lock-up securities in connection with such transaction, or vote any common stock or other securities in favor of any such transaction); provided that, in the event that such tender offer, merger, consolidation or other transaction is not completed, the lock-up party’s lock-up securities shall remain subject to the restrictions set forth in this lock-up agreement; provided further that any shares of common stock not transferred, sold or otherwise disposed of in such third-party tender offer, merger, consolidation, or other similar transaction shall remain subject to the restrictions set forth in this lock-up agreement (for purposes hereof, “change of control” shall mean the transfer, sale or other disposition (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of our capital stock if, after such transaction or transactions, such person or group of affiliated persons would hold more than 50% of our outstanding voting securities (or the surviving entity)); to us in connection with the conversion or exercise of any of our outstanding equity securities into shares of common stock or in connection with the reclassification or exchange of shares of common stock, in each case as described and as contemplated in this prospectus; provided that any shares of common stock received by the lock-up party upon such conversion, exercise, reclassification, reclassification or exchange shall be subject to the restrictions set forth in this lock-up agreement; (xii) in connection with the vesting or settlement of restricted stock units or the exercise of options or other rights to purchase the shares of common stock (including, in each case, by way of “net” or “cashless” exercise), including (A) any transfer, sale or other disposition to us for the payment of exercise price, tax withholdings or remittance payments due as a result of the vesting, settlement or exercise of such restricted stock units, options or rights, and (B) any transfer, sale or other disposition of shares of common stock necessary to generate such amount of cash needed to satisfy tax withholdings or remittance payments due as a result of the vesting or settlement of restricted stock units or the exercise of options, which are expiring during the lock-up period, to purchase the shares of common stock; provided that, in each case, any such restricted stock units and options to purchase shares of common stock were granted under an equity incentive plan or other equity award plan that is described in this prospectus and provided, further, that, in each case, any such shares of common stock received by the lock-up party upon such vesting, settlement or exercise that are not so transferred, sold or otherwise disposed shall be subject to the restrictions set forth in this lock-up agreement; (xiii) up to 15% of the lock-up party’s lock-up securities, to any third-party pledgee in a bona fide transaction as collateral to secure obligations pursuant to lending or other arrangements between such third parties (or their affiliates or designees) and the lock-up party and/or its affiliates or any similar arrangement relating to a financing arrangement for the benefit of the lock-up party and/or its affiliates; and upon foreclosure of any such lending or other arrangements; (xiv) if the lock-up party is not our officer or director, in connection with a sale of the lock-up party’s shares of Class A common stock acquired (A) from the underwriters in this offering or (B) on the open market or in other transactions following this offering; or (xv) to the underwriters pursuant to the underwriting agreement.
 
263

TABLE OF CONTENTS
 
In addition, notwithstanding the restrictions in the lock-up agreement, the lock-up party may make any demand or requests for, exercise any right with respect to, or take any action in preparation of, the registration by us under the Securities Act of the lock-up party’s lock-up securities or other securities; provided that (i) no public filing with the Securities and Exchange Commission or any other public announcement may be made during the lock-up period in relation to such registration, (ii) the representatives must have received prior written notice from us and/or the lock-up party of a confidential submission of a registration statement with the Securities and Exchange Commission during the lock-up period at least five (5) business days prior to such submission and (iii) no lock-up securities or other securities of us may be sold, distributed or exchanged during the lock-up period. Notwithstanding the foregoing, the lock-up party also may establish trading plans pursuant to Rule 10b5-1 under the Exchange Act for the transfer, sale or other disposition of lock-up securities, provided that (1) none of the securities subject to such plan may be transferred, sold or otherwise disposed of until after the expiration of the lock-up period and (2) no public announcement, report or filing under the Exchange Act, or any other public filing, report or announcement, shall be voluntarily made regarding the establishment of such plan during the lock-up period, and if any such filing, report or announcement shall be legally required during the lock-up period, such filing, report or announcement shall clearly indicate therein that none of the securities subject to such plan may be transferred, sold, or otherwise disposed pursuant to such plan until after the expiration of the lock-up period.
If any director, officer, or shareholder of the Company is granted an early release from its obligations under any lock-up restrictions with respect to our securities in an aggregate amount in excess of one percent of our outstanding Class A common stock, then every other lock-up party automatically will be granted an equivalent early release from its obligations under their respective lock-up agreement on a pro rata basis, provided that such release shall not apply (i) if it is effected solely to permit a transfer not for consideration and the transferee has agreed in writing to be bound by the same terms described in the lock-up agreement to the extent and for the duration that such terms remain in effect at the time of the transfer and (ii) in the event of an underwritten public offering, except with respect to the lock-up party’s participation in such underwritten public offering, provided that the lock-up party shall be offered the opportunity to participate in such underwritten public offering in accordance with, and subject to, the terms of any rights agreement (including the Investors’ Rights Agreement).
In the event that (i) at least 150 days have elapsed since the date of this prospectus and (ii) the end of the restricted period would fall during one of our quarterly blackout periods during which trading by certain of our employees in our securities would not be permitted under our insider trading policy then in effect (a “Blackout Period”), or within 10 trading days prior to such Blackout Period the restricted period shall end on the date that is the later of (a) 10 trading days prior to the commencement of a Blackout Period and (b) the 150th day after the date of this prospectus.
Listing
We expect the shares of Class A common stock to be approved for listing on Nasdaq under the symbol “CAI.” In order to meet the requirements for listing on that exchange, the underwriters have undertaken to sell a minimum number of shares to a minimum number of beneficial owners as required by that exchange.
Before this offering, there has been no public market for our Class A common stock. The initial public offering price will be determined through negotiations between us and the representatives. In addition to prevailing market conditions, the factors to be considered in determining the initial public offering price are:
•
the valuation multiples of publicly traded companies that the representatives believe to be comparable to us,
​
•
our financial information,
​
•
the history of, and the prospects for, our company and the industry in which we compete,
​
•
an assessment of our management, its past and present operations, and the prospects for, and timing of, our future revenues,
​
•
the present state of our development, and
​
 
264

TABLE OF CONTENTS
 
•
the above factors in relation to market values and various valuation measures of other companies engaged in activities similar to ours.
​
An active trading market for the shares may not develop. It is also possible that after the offering the shares will not trade in the public market at or above the initial public offering price.
The underwriters do not expect to sell more than 5% of the shares in the aggregate to accounts over which they exercise discretionary authority.
Price Stabilization, Short Positions and Penalty Bids
Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from bidding for and purchasing our Class A common stock. However, the representatives may engage in transactions that stabilize the price of the Class A common stock, such as bids or purchases to peg, fix, or maintain that price.
In connection with the offering, the underwriters may purchase and sell our Class A common stock in the open market. These transactions may include short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering. “Covered” short sales are sales made in an amount not greater than the underwriters’ option to purchase additional shares of Class A common stock described above. The underwriters may close out any covered short position by either exercising their option to purchase additional shares of Class A common stock or purchasing shares of Class A common stock in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option granted to them. “Naked” short sales are sales in excess of such option. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our Class A common stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of Class A common stock made by the underwriters in the open market prior to the completion of the offering.
The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions.
Similar to other purchase transactions, the underwriters’ purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our Class A common stock or preventing or retarding a decline in the market price of our Class A common stock. As a result, the price of our Class A common stock may be higher than the price that might otherwise exist in the open market. The underwriters may conduct these transactions on Nasdaq, in the over-the-counter market or otherwise.
Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our Class A common stock. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice.
Electronic Distribution
In connection with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as e-mail.
Other Relationships
Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions.
 
265

TABLE OF CONTENTS
 
In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.
“Wolfe | Nomura Alliance” is the marketing name used by Wolfe Research Securities and Nomura Securities International, Inc. in connection with certain equity capital markets activities conducted jointly by the firms. Both Nomura Securities International, Inc. and WR Securities, LLC are serving as underwriters in the offering described herein. In addition, WR Securities, LLC and certain of its affiliates may provide sales support services, investor feedback, investor education, and/or other independent equity research services in connection with this offering.
Reserved Share Program
At our request, the underwriters have reserved up to     % of the shares of Class A common stock offered by this prospectus, excluding the additional shares that the underwriters have a 30-day option to purchase, for sale, at the initial public offering price, to certain individuals identified by management. If these persons purchase reserved shares it will reduce the number of shares of Class A common stock available for sale to the general public. Any reserved shares of Class A common stock that are not so purchased will be offered by the underwriters to the general public on the same terms as the other shares of Class A common stock offered by this prospectus.
Management will provide the list of potential participants to Merrill Lynch, Pierce, Fenner & Smith Incorporated, which is an affiliate of BofA Securities, Inc., a participating underwriter, and which will administer the reserved shares program. At this time, no indications of interest will be taken. Once the preliminary prospectus has been filed, an invitation package will be made available or sent to each person identified by management, which will include the preliminary prospectus and other reserved share program documentation. An invitation to participate in the reserved share program does not guarantee that the participant will receive an allocation of Class A common stock. Accordingly, we cannot provide any assurance that any director, officer, employee, or participant will receive an invitation or an allocation in the reserved share program. If a potential participant is interested in participating, that participant will be required to complete the required documentation and will be required to return such documentation to the program administrator. The program administrator will not accept funds from any participant until after the registration statement for this offering is declared effective, this offering is priced, and the participants are notified of their final allocation and given an opportunity to confirm that they wish to purchase the shares of Class A common stock allocated to them. After the registration statement has been declared effective and this offering is priced, we and the program administrator will prepare a final approved list of allocations. The program administrator will notify each participant who has been allocated reserved shares of the number of shares of Class A common stock that have been allocated to them and the total purchase price due upon confirmation of their participation. Thereafter, participants will be required to wire or transfer their funds to the program administrator. The shares of Class A common stock under the reserved shares program will be allocated following pricing and settle in the same manner as the shares sold to the general public. If purchased by directors, officers or employees, these shares will be subject to a 180-day lock-up restriction described in this prospectus. If any potential participants purchase reserved shares, it will reduce the number of shares available for sale to the general public. Any reserved shares that are not so purchased will be offered by the underwriters to the general public on the same terms as the other shares of Class A common stock offered hereby.
European Economic Area
In relation to each Member State of the European Economic Area (each a “Relevant State”), no shares have been offered or will be offered pursuant to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in
 
266

TABLE OF CONTENTS
 
that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of shares may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation:
a.
to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
​
b.
to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent for any such offer; or
​
c.
in any other circumstances falling within Article 1(4) of the Prospectus Regulation,
​
provided that no such offer of shares shall require the Company or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.
Each person in a Relevant State who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged, and agreed to and with the Company and the underwriters that it is a qualified investor within the meaning of the Prospectus Regulation.
In the case of any shares being offered to a financial intermediary as that term is used in Article 5(1) of the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in a Relevant State to qualified investors, in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale.
The Company, the underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements, and agreements.
For the purposes of this provision, the expression an “offer to the public” in relation to any shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression “Prospectus Regulation” means Regulation (EU) 2017/1129.
The above selling restriction is in addition to any other selling restrictions set out below.
Notice to Prospective Investors in the United Kingdom
In relation to the United Kingdom (“UK”), no shares have been offered or will be offered pursuant to the public in the UK prior to the publication of a prospectus in relation to the shares which has been approved by the Financial Conduct Authority in the UK in accordance with the UK Prospectus Regulation and the FSMA, except that offers of shares may be made to the public in the UK at any time under the following exemptions under the UK Prospectus Regulation and the FSMA:
a.
to any legal entity which is a qualified investor as defined under the UK Prospectus Regulation;
​
b.
to fewer than 150 natural or legal persons (other than qualified investors as defined under the UK Prospectus Regulation), subject to obtaining the prior consent for any such offer; or
​
c.
at any time in other circumstances falling within section 86 of the FSMA,
​
provided that no such offer of shares shall require the Company or any underwriter to publish a prospectus pursuant to Section 85 of the FSMA or Article 3 of the UK Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation.
Each person in the UK who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged, and agreed to and with the Company and the underwriters that it is a qualified investor within the meaning of the UK Prospectus Regulation.
 
267

TABLE OF CONTENTS
 
In the case of any shares being offered to a financial intermediary as that term is used in Article 5(1) of the UK Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in the UK to qualified investors, in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale.
The Company, the underwriters and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements, and agreements.
For the purposes of this provision, the expression an “offer to the public” in relation to any shares in the UK means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, the expression “UK Prospectus Regulation” means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, and the expression “FSMA” means the Financial Services and Markets Act 2000.
This document is for distribution only to persons who (i) have professional experience in matters relating to investments and who qualify as investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Financial Promotion Order”), (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations etc.”) of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the FSMA) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “relevant persons”). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons.
Notice to Prospective Investors in Switzerland
The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (“SIX”) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland.
Neither this document nor any other offering or marketing material relating to the offering, the Company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (“CISA”). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares.
Notice to Prospective Investors in the Dubai International Financial Centre
This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority (“DFSA”). This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should
 
268

TABLE OF CONTENTS
 
conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should consult an authorized financial advisor.
Notice to Prospective Investors in Australia
No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission (“ASIC”), in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the “Corporations Act”), and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act.
Any offer in Australia of the shares may only be made to persons (the “Exempt Investors”) who are “sophisticated investors” ​(within the meaning of section 708(8) of the Corporations Act), “professional investors” ​(within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act.
The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian on-sale restrictions.
This prospectus contains general information only and does not take account of the investment objectives, financial situation, or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their needs, objectives, and circumstances, and, if necessary, seek expert advice on those matters.
Notice to Prospective Investors in Hong Kong
The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a) to “professional investors” as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b) in other circumstances which do not result in the document being a “prospectus” as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to the shares which are or are intended to be disposed of only to persons outside Hong Kong or only to “professional investors” as defined in the Securities and Futures Ordinance and any rules made under that Ordinance.
Notice to Prospective Investors in Japan
The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948, as amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for re-offering or resale, directly or indirectly, in Japan or to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph, “Japanese Person” shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan.
Notice to Prospective Investors in Singapore
This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, the shares were not offered or sold or caused to be made the subject of an invitation for
 
269

TABLE OF CONTENTS
 
subscription or purchase and will not be offered or sold or caused to be made the subject of an invitation for subscription or purchase, and this prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares, has not been circulated or distributed, nor will it be circulated or distributed, whether directly or indirectly, to any person in Singapore other than (i) to an institutional investor (as defined in Section 4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time (the “SFA”)) pursuant to Section 274 of the SFA, (ii) to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275 of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
Where the shares are subscribed or purchased under Section 275 of the SFA by a relevant person which is:
(a)
a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
​
(b)
a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,
​
securities or securities-based derivatives contracts (each term as defined in Section 2(1) of the SFA) of that corporation or the beneficiaries’ rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section 275 of the SFA except:
(a)
to an institutional investor or to a relevant person, or to any person arising from an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA;
​
(b)
where no consideration is or will be given for the transfer;
​
(c)
where the transfer is by operation of law; or
​
(d)
as specified in Section 276(7) of the SFA.
​
Notice to Prospective Investors in Canada
The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.
Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser’s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser’s province or territory for particulars of these rights or consult with a legal advisor.
Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of a non-Canadian jurisdiction, section 3A.4) of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.
Notice to Prospective Investors in Brazil
The offer and sale of the securities have not been and will not be registered with the Brazilian securities commission (Comissão de Valores Mobiliários, or “CVM”) and, therefore, will not be carried out by any
 
270

TABLE OF CONTENTS
 
means that would constitute a public offering in Brazil under CVM resolution no 160, dated 13 July 2022, as amended (“CVM Resolution 160”) or unauthorized distribution under Brazilian laws and regulations. The securities may only be offered to Brazilian professional investors (as defined by applicable CVM regulation), who may only acquire the securities through a non-Brazilian account, with settlement outside Brazil in non-Brazilian currency. The trading of these securities on regulated securities markets in Brazil is prohibited.
 
271

TABLE OF CONTENTS​​
 
LEGAL MATTERS
The validity of the issuance of our Class A common stock offered in this prospectus will be passed upon for us by Latham & Watkins LLP, New York, New York. Cooley LLP, New York, New York is representing the underwriters in this offering.
EXPERTS
The consolidated financial statements as of and for the year ended December 31, 2024, included in this prospectus and elsewhere in the registration statement, have been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are included in reliance upon the report of such firm given their authority as experts in accounting and auditing.
Ernst & Young LLP, an independent registered public accounting firm, has audited our consolidated financial statements at December 31, 2023 and for the year then ended as set forth in their report. We have included our financial statements in the prospectus and elsewhere in the registration statement in reliance on Ernst & Young LLP’s report, given on their authority as experts in accounting and auditing.
 
272

TABLE OF CONTENTS​
 
CHANGE IN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
On July 17, 2024, we notified Ernst & Young LLP (“EY”), which had served as our prior independent registered public accounting firm, of our intention to obtain proposals from other accounting firms to perform the audit of our consolidated financial statements as of and for the year ending December 31, 2024 (our “2024 Audit”). On July 24, 2024, EY notified the Company of its decision to decline to stand for re-election as our independent registered public accounting firm for our 2024 Audit. On September 9, 2024, the audit committee of our board of directors approved the engagement of Deloitte & Touche LLP (“Deloitte”) as our independent registered public accounting firm for our 2024 Audit, effective immediately.
The reports of EY on our consolidated financial statements as of December 31, 2023 and 2022, and for the years then ended, did not contain adverse opinions or disclaimers of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.
During the years ended December 31, 2023 and 2022 and the subsequent interim period through July 24, 2024, there were:
•
no “disagreements” ​(as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto) with EY on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of EY, would have caused EY to make reference to the subject matter of the disagreements in its report on our financial statements as of December 31, 2023 and 2022, and for the years then ended, and
​
•
no “reportable events” ​(as defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions thereto), other than the material weakness identified in our internal control over financial reporting, which pertained to the aggregation of several deficiencies reflecting ineffective control activities related to the incorrect application of generally accepted accounting principles. The audit committee of our board of directors discussed the above material weakness with EY. We have also authorized EY to respond fully to the inquiries of Deloitte concerning the subject matter of the material weakness.
​
We provided EY with a copy of the disclosure set forth in this section and requested that EY furnish us with a letter addressed to the SEC stating whether EY agrees with the statements made herein, each as required by applicable SEC rules. A copy of the letter, dated September 12, 2024, furnished by EY in response to that request, is filed as Exhibit 16.1 to the registration statement of which this prospectus is a part.
During the years ended December 31, 2023 and 2022 and the subsequent interim period through September 9, 2024, when we engaged Deloitte, we did not consult with Deloitte with respect to (i) the application of accounting principles to a specified transaction, either completed or proposed, the type of audit opinion that might be rendered on our financial statements, and neither a written report nor oral advice was provided to us that Deloitte concluded was an important factor considered by us in reaching a decision as to any accounting, auditing, or financial reporting issue, or (ii) any matter that was the subject of a “disagreement” or a “reportable event” ​(each as defined above).
 
273

TABLE OF CONTENTS​
 
WHERE YOU CAN FIND ADDITIONAL INFORMATION
We have filed with the SEC a registration statement on Form S-1 under the Securities Act, with respect to the shares of Class A common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules to the registration statement. Please refer to the registration statement and exhibits for further information with respect to the Class A common stock offered by this prospectus. Statements contained in this prospectus regarding the contents of any contract or other document are only summaries. With respect to any contract or document that is filed as an exhibit to the registration statement, you should refer to the exhibit for a copy of the contract or document, and each statement in this prospectus regarding that contract or document is qualified by reference to the exhibit. The SEC maintains an internet website that contains the registration statement of which this prospectus forms a part, as well as the exhibits thereto. These documents, along with future reports, proxy statements and other information about us, are available at the SEC’s website, www.sec.gov. The information on the SEC’s web site is not part of this prospectus, and any references to this web site or any other web site are inactive textual references only.
Upon the completion of this offering, we will become subject to the information and reporting requirements of the Exchange Act, and, in accordance with this law, will be required to file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and other information will be available on the website of the SEC referred to above. We also maintain a website at carislifesciences.com, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that can be accessed through, our website is not a part of this prospectus. Investors should not rely on any such information in deciding whether to purchase our Class A common stock. We have included our website address in this prospectus solely as an inactive textual reference.
 
274

TABLE OF CONTENTS​​
 
INDEX TO FINANCIAL STATEMENTS
Caris Life Sciences, Inc. and Subsidiaries
​ ​ ​
Page
​
Audited Consolidated Financial Statements
As of and for the Years Ended December 31, 2024 and 2023
​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ F-2 ​ ​
​ ​ ​ ​ F-4 ​ ​
​ ​ ​ ​ F-5 ​ ​
​ ​ ​ ​ F-6 ​ ​
​ ​ ​ ​ F-7 ​ ​
​ ​ ​ ​ F-8 ​ ​
Unaudited Consolidated Financial Statements
As of and for the Three Months Ended March 31, 2025 and 2024
​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ F-43 ​ ​
​ ​ ​ ​ F-44 ​ ​
​ ​ ​ ​ F-45 ​ ​
​ ​ ​ ​ F-46 ​ ​
​ ​ ​ ​ F-47 ​ ​
 
F-1

TABLE OF CONTENTS​
 
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the shareholders and the Board of Directors of Caris Life Sciences, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheet of Caris Life Sciences, Inc. and subsidiaries (the “Company”) as of December 31, 2024, the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock and shareholders’ deficit, and cash flows, for the year ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.
Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has redemptions in connection with the Series C preferred stock and debt payments in connection with the 2023 term loan and the 2025 convertible notes which raises substantial doubt about its ability to continue as a going concern. Management’s evaluation of the events and conditions and management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.
/s/ Deloitte & Touche LLP
San Jose, California
April 4, 2025
We have served as the Company’s auditor since 2024.
 
F-2

TABLE OF CONTENTS
 
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders and Board of Directors of Caris Life Sciences, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheet of Caris Life Sciences, Inc. (the Company) as of December 31, 2023, the related consolidated statements of operations and comprehensive loss, changes in redeemable convertible preferred stock and shareholders’ deficit and cash flows for the year then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023, and the results of its operations and its cash flows for the year then ended in conformity with U.S. generally accepted accounting principles.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.
/s/ Ernst & Young LLP
We served as the Company’s auditor from 2020 to 2024.
Dallas, Texas
March 18, 2024
 
F-3

TABLE OF CONTENTS​
 
Consolidated Balance Sheets
(amounts in thousands, except share data)
​ ​
As of December 31,
​
​
2024
​ ​
2023
​
Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Cash, cash equivalents, and restricted cash
​ ​ ​ $ 65,442 ​ ​ ​ ​ $ 60,007 ​ ​
Short-term marketable securities
​ ​ ​ ​ 2,201 ​ ​ ​ ​ ​ 65,184 ​ ​
Accounts receivable
​ ​ ​ ​ 88,244 ​ ​ ​ ​ ​ 55,299 ​ ​
Supplies
​ ​ ​ ​ 39,572 ​ ​ ​ ​ ​ 48,998 ​ ​
Prepaid expenses and other current assets
​ ​ ​ ​ 20,270 ​ ​ ​ ​ ​ 13,124 ​ ​
Total current assets
​ ​ ​ ​ 215,729 ​ ​ ​ ​ ​ 242,612 ​ ​
Property and equipment, net
​ ​ ​ ​ 67,817 ​ ​ ​ ​ ​ 107,088 ​ ​
Goodwill
​ ​ ​ ​ 19,344 ​ ​ ​ ​ ​ 19,344 ​ ​
Other assets
​ ​ ​ ​ 40,844 ​ ​ ​ ​ ​ 43,856 ​ ​
Total assets
​ ​ ​ $ 343,734 ​ ​ ​ ​ $ 412,900 ​ ​
Liabilities, Redeemable Convertible Preferred Stock, and Shareholders’ Deficit ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Current liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Accounts payable
​ ​ ​ $ 27,791 ​ ​ ​ ​ $ 26,680 ​ ​
Accrued expenses and other current liabilities
​ ​ ​ ​ 77,542 ​ ​ ​ ​ ​ 68,291 ​ ​
Current portion of indebtedness
​ ​ ​ ​ 60,090 ​ ​ ​ ​ ​ 167 ​ ​
Total current liabilities
​ ​ ​ ​ 165,423 ​ ​ ​ ​ ​ 95,138 ​ ​
Long-term indebtedness, net of debt discounts
​ ​ ​ ​ 319,438 ​ ​ ​ ​ ​ 166,421 ​ ​
Warrant and derivative liabilities
​ ​ ​ ​ 91,642 ​ ​ ​ ​ ​ 116,184 ​ ​
Other long-term liabilities
​ ​ ​ ​ 44,418 ​ ​ ​ ​ ​ 54,823 ​ ​
Total liabilities
​ ​ ​ ​ 620,921 ​ ​ ​ ​ ​ 432,566 ​ ​
Commitments and contingencies (see note 10) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Redeemable convertible preferred stock: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Series A preferred stock. par value $0.001: 490,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 485,795,293 shares issued and outstanding as of December 31, 2024 and December 31, 2023; and $296,335 aggregate liquidation preference as of December 31, 2024 and December 31, 2023
​ ​ ​ ​ 709,261 ​ ​ ​ ​ ​ 709,261 ​ ​
Series B preferred stock, par value $0.001: 30,000,000 shares authorized as of
December 31, 2024 and December 31, 2023; 29,629,630 shares issued and
outstanding as of December 31, 2024 and December 31, 2023; and $16,000 aggregate
liquidation preference as of December 31, 2024 and December 31, 2023
​ ​ ​ ​ 42,963 ​ ​ ​ ​ ​ 42,963 ​ ​
Series C preferred stock, par value $0.001: 142,000,000 shares authorized as of
December 31, 2024 and December 31, 2023; 116,200,835 shares issued and
outstanding as of December 31, 2024 and December 31, 2023; and $408,715 and
$381,908 aggregate liquidation preference as of December 31, 2024 and December 31,
2023, respectively
​ ​ ​ ​ 408,715 ​ ​ ​ ​ ​ 381,908 ​ ​
Series D preferred stock, par value $0.001: 102,600,000 shares authorized as of
December 31, 2024 and December 31, 2023; 102,516,283 shares issued and
outstanding as of December 31, 2024 and December 31, 2023; and $1,060,712 and
$996,458 aggregate liquidation preference as of December 31, 2024 and December 31,
2023, respectively
​ ​ ​ ​ 1,060,712 ​ ​ ​ ​ ​ 991,152 ​ ​
Total redeemable convertible preferred stock
​ ​ ​ ​ 2,221,651 ​ ​ ​ ​ ​ 2,125,284 ​ ​
Shareholders’ deficit: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Common stock $0.001 par value; 1,150,000,000 shares authorized as of December 31,
2024 and December 31, 2023; 146,747,083 and 145,790,960 shares issued as of
December 31, 2024 and December 31, 2023, respectively; 146,017,083 and
145,060,960 shares outstanding as of December 31, 2024 and December 31, 2023,
respectively; shares issued and outstanding include 2,648,000 and 3,872,000 unvested
shares subject to repurchase as of December 31, 2024 and December 31, 2023,
respectively
​ ​ ​ ​ 144 ​ ​ ​ ​ ​ 141 ​ ​
Treasury stock at cost, 730,000 shares of common stock as of December 31, 2024 and December 31, 2023
​ ​ ​ ​ (330) ​ ​ ​ ​ ​ (330) ​ ​
Additional paid-in capital
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​
Related party promissory note receivable (see note 7)
​ ​ ​ ​ (26,456) ​ ​ ​ ​ ​ (25,701) ​ ​
Accumulated deficit
​ ​ ​ ​ (2,472,406) ​ ​ ​ ​ ​ (2,119,278) ​ ​
Accumulated other comprehensive income
​ ​ ​ ​ 210 ​ ​ ​ ​ ​ 218 ​ ​
Total shareholders’ deficit
​ ​ ​ ​ (2,498,838) ​ ​ ​ ​ ​ (2,144,950) ​ ​
Total liabilities, redeemable convertible preferred stock, and shareholders’ deficit
​ ​ ​ $ 343,734 ​ ​ ​ ​ $ 412,900 ​ ​
The accompanying notes are an integral part of these consolidated financial statements
F-4

TABLE OF CONTENTS​
 
Consolidated Statements of Operations and Comprehensive Loss
(amounts in thousands, except share and per share data)
​ ​
Years Ended December 31,
​
​
2024
​ ​
2023
​
Revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Molecular profiling services
​ ​ ​ $ 349,115 ​ ​ ​ ​ $ 278,748 ​ ​
Pharma research and development services
​ ​ ​ ​ 63,145 ​ ​ ​ ​ ​ 27,380 ​ ​
Total revenue
​ ​ ​ ​ 412,260 ​ ​ ​ ​ ​ 306,128 ​ ​
Costs and operating expenses: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Cost of services–Molecular profiling services
​ ​ ​ ​ 223,075 ​ ​ ​ ​ ​ 207,509 ​ ​
Cost of services–Pharma research and development services
​ ​ ​ ​ 10,403 ​ ​ ​ ​ ​ 9,309 ​ ​
Selling and marketing expense
​ ​ ​ ​ 152,602 ​ ​ ​ ​ ​ 142,925 ​ ​
General and administrative expense (includes related party amounts of $1,869 and $2,061, for the years ended December 31, 2024 and 2023, respectively)
​ ​ ​ ​ 169,386 ​ ​ ​ ​ ​ 149,053 ​ ​
Research and development expense
​ ​ ​ ​ 113,916 ​ ​ ​ ​ ​ 116,883 ​ ​
Total costs and operating expenses
​ ​ ​ ​ 669,382 ​ ​ ​ ​ ​ 625,679 ​ ​
Loss from operations
​ ​ ​ ​ (257,122) ​ ​ ​ ​ ​ (319,551) ​ ​
Other income (expense), net: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Interest income
​ ​ ​ ​ 7,122 ​ ​ ​ ​ ​ 11,258 ​ ​
Interest expense
​ ​ ​ ​ (50,025) ​ ​ ​ ​ ​ (31,610) ​ ​
Changes in fair value of financial instruments
​ ​ ​ ​ 18,484 ​ ​ ​ ​ ​ 11,094 ​ ​
Other expense, net
​ ​ ​ ​ (349) ​ ​ ​ ​ ​ (12,606) ​ ​
Total other expense, net
​ ​ ​ ​ (24,768) ​ ​ ​ ​ ​ (21,864) ​ ​
Loss before income taxes and provision for income taxes
​ ​ ​ ​ (281,890) ​ ​ ​ ​ ​ (341,415) ​ ​
Provision for income taxes
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​
Net loss
​ ​ ​ ​ (281,890) ​ ​ ​ ​ ​ (341,415) ​ ​
Other comprehensive (loss) income, net of tax: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Unrealized (loss) gain on available-for-sale securities
​ ​ ​ ​ 7 ​ ​ ​ ​ ​ (1,660) ​ ​
Foreign currency translation adjustments
​ ​ ​ ​ (15) ​ ​ ​ ​ ​ 180 ​ ​
Comprehensive loss
​ ​ ​ ​ (281,898) ​ ​ ​ ​ ​ (342,895) ​ ​
Net loss attributable to common shareholders: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Net loss
​ ​ ​ ​ (281,890) ​ ​ ​ ​ ​ (341,415) ​ ​
Adjustments of redeemable convertible preferred stock to redemption value
​ ​ ​ ​ (96,367) ​ ​ ​ ​ ​ (121,112) ​ ​
Net loss attributable to common shareholders
​ ​ ​ $ (378,257) ​ ​ ​ ​ $ (462,527) ​ ​
Net loss per share attributable to common shareholders, basic and diluted
​ ​ ​ $ (2.66) ​ ​ ​ ​ $ (3.31) ​ ​
Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted
​ ​ ​ ​ 141,987 ​ ​ ​ ​ ​ 139,771 ​ ​
The accompanying notes are an integral part of these consolidated financial statements
F-5

TABLE OF CONTENTS​
 
Consolidated Statements of Redeemable Convertible Preferred Stock and Shareholders’ Deficit
(amounts in thousands, except share data)
​ ​
Redeemable Convertible
Preferred Stock
​ ​ ​
Common Stock
​ ​
Treasury Stock
​ ​
Additional
Paid-In
Capital
​ ​
Related
Party
Promissory
Note
Receivable
​ ​
Accumulated
Deficit
​ ​
Accumulated
Other
Comprehensive
Income
​ ​
Total
Shareholders’
Deficit
​
​
Shares
​ ​
Amount
​ ​ ​
Shares
​ ​
Amount
​ ​
Shares
​ ​
Amount
​
Balances at December 31, 2022
​ ​ ​ ​ 703,086,140 ​ ​ ​ ​ $ 1,954,172 ​ ​ ​ ​ ​ ​ 137,507,817 ​ ​ ​ ​ $ 138 ​ ​ ​ ​ ​ 730,000 ​ ​ ​ ​ $ (330) ​ ​ ​ ​ $ — ​ ​ ​ ​ $ (24,969) ​ ​ ​ ​ $ (1,678,650) ​ ​ ​ ​ $ 1,698 ​ ​ ​ ​ $ (1,702,113) ​ ​
Stock-based compensation
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 15,241 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 15,241 ​ ​
Issuance of common stock upon exercise of
stock options
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ 2,457,143 ​ ​ ​ ​ ​ 2 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 1,863 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 1,865 ​ ​
Interest income from related party promissory notes
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (732) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (732) ​ ​
Vesting of shares from early exercised stock
options
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ 1,224,000 ​ ​ ​ ​ ​ 1 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 4,957 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 4,958 ​ ​
Adjustment of redeemable convertible preferred Series C and Series D to redemption value
​ ​ ​ ​ — ​ ​ ​ ​ ​ 121,112 ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (21,899) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (99,213) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (121,112) ​ ​
Conversion of convertible note into Series C preferred stock
​ ​ ​ ​ 31,055,901 ​ ​ ​ ​ ​ 50,000 ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​
Other comprehensive loss
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (1,480) ​ ​ ​ ​ ​ (1,480) ​ ​
Net loss
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (341,415) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (341,415) ​ ​
Foreign exchange gain
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (162) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (162) ​ ​
Balances at December 31, 2023
​ ​ ​ ​ 734,142,041 ​ ​ ​ ​ $ 2,125,284 ​ ​ ​ ​ ​ ​ 141,188,960 ​ ​ ​ ​ $ 141 ​ ​ ​ ​ ​ 730,000 ​ ​ ​ ​ $ (330) ​ ​ ​ ​ $ — ​ ​ ​ ​ $ (25,701) ​ ​ ​ ​ $ (2,119,278) ​ ​ ​ ​ $ 218 ​ ​ ​ ​ $ (2,144,950) ​ ​
Stock-based compensation
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 18,643 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 18,643 ​ ​
Issuance of common stock upon exercise of
stock options
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ 956,123 ​ ​ ​ ​ ​ 1 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 1,529 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 1,530 ​ ​
Interest income from related party promissory notes
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (755) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (755) ​ ​
Vesting of shares from early exercised stock
options
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ 1,224,000 ​ ​ ​ ​ ​ 2 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 4,958 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 4,960 ​ ​
Adjustment of redeemable convertible preferred Series C and Series D to redemption value
​ ​ ​ ​ — ​ ​ ​ ​ ​ 96,367 ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (25,130) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (71,237) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (96,367) ​ ​
Other comprehensive loss
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (8) ​ ​ ​ ​ ​ (8) ​ ​
Net loss
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (281,890) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (281,890) ​ ​
Balances at December 31, 2024
​ ​ ​ ​ 734,142,041 ​ ​ ​ ​ $ 2,221,651 ​ ​ ​ ​ ​ ​ 143,369,083 ​ ​ ​ ​ $ 144 ​ ​ ​ ​ ​ 730,000 ​ ​ ​ ​ $ (330) ​ ​ ​ ​ $ — ​ ​ ​ ​ $ (26,456) ​ ​ ​ ​ $ (2,472,405) ​ ​ ​ ​ $ 210 ​ ​ ​ ​ $ (2,498,837) ​ ​
The accompanying notes are an integral part of these consolidated financial statements
F-6

TABLE OF CONTENTS​
 
Consolidated Statements of Cash Flows
(amounts in thousands)
​ ​
Years Ended December 31,
​
​
2024
​ ​
2023
​
Cash flows from operating activities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Net loss
​ ​ ​ $ (281,890) ​ ​ ​ ​ $ (341,415) ​ ​
Adjustments to reconcile net loss to net cash used in operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Depreciation and amortization
​ ​ ​ ​ 48,913 ​ ​ ​ ​ ​ 49,001 ​ ​
Stock-based compensation expense
​ ​ ​ ​ 18,643 ​ ​ ​ ​ ​ 15,241 ​ ​
Non-cash operating lease expense
​ ​ ​ ​ 5,601 ​ ​ ​ ​ ​ 4,332 ​ ​
Amortization of debt discounts
​ ​ ​ ​ 7,054 ​ ​ ​ ​ ​ 5,378 ​ ​
Changes in fair value of financial instruments
​ ​ ​ ​ (18,484) ​ ​ ​ ​ ​ (11,094) ​ ​
Loss on debt extinguishment
​ ​ ​ ​ — ​ ​ ​ ​ ​ 10,915 ​ ​
Others
​ ​ ​ ​ 4,031 ​ ​ ​ ​ ​ (1,329) ​ ​
Changes in operating assets and liabilities:
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Accounts receivable
​ ​ ​ ​ (33,816) ​ ​ ​ ​ ​ (15,081) ​ ​
Supplies
​ ​ ​ ​ 5,459 ​ ​ ​ ​ ​ (4,435) ​ ​
Prepaid expenses and other current assets
​ ​ ​ ​ (1,408) ​ ​ ​ ​ ​ 4,544 ​ ​
Other assets
​ ​ ​ ​ 121 ​ ​ ​ ​ ​ (588) ​ ​
Accounts payable
​ ​ ​ ​ (226) ​ ​ ​ ​ ​ 7,171 ​ ​
Accrued expenses and other liabilities
​ ​ ​ ​ 803 ​ ​ ​ ​ ​ 1,260 ​ ​
Net cash used in operating activities
​ ​ ​ $ (245,199) ​ ​ ​ ​ $ (276,100) ​ ​
Cash flows from investing activities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Maturities of marketable securities
​ ​ ​ ​ 61,376 ​ ​ ​ ​ ​ 300,488 ​ ​
Purchases of marketable securities
​ ​ ​ ​ — ​ ​ ​ ​ ​ (63,395) ​ ​
Purchases of property and equipment
​ ​ ​ ​ (8,444) ​ ​ ​ ​ ​ (22,319) ​ ​
Net cash provided by investing activities
​ ​ ​ $ 52,932 ​ ​ ​ ​ $ 214,774 ​ ​
Cash flows from financing activities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Payments made on finance lease obligations
​ ​ ​ ​ (157) ​ ​ ​ ​ ​ (743) ​ ​
Proceeds from exercise of stock options
​ ​ ​ ​ 1,530 ​ ​ ​ ​ ​ 1,865 ​ ​
Payment of deferred offering costs
​ ​ ​ ​ (1,059) ​ ​ ​ ​ ​ — ​ ​
Proceeds from the 2023 term loan, net of issuance costs
​ ​ ​ ​ 199,978 ​ ​ ​ ​ ​ 191,310 ​ ​
Payment of third-party debt issuance costs
​ ​ ​ ​ — ​ ​ ​ ​ ​ (2,300) ​ ​
Repayment of the Original Term Loans
​ ​ ​ ​ — ​ ​ ​ ​ ​ (180,000) ​ ​
Net cash provided by financing activities
​ ​ ​ $ 200,292 ​ ​ ​ ​ $ 10,132 ​ ​
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
​ ​ ​ ​ (4) ​ ​ ​ ​ ​ 62 ​ ​
Net decrease in cash, cash equivalents, and restricted cash
​ ​ ​ ​ 8,021 ​ ​ ​ ​ ​ (51,132) ​ ​
Cash, cash equivalents, and restricted cash at beginning of year
​ ​ ​ ​ 60,007 ​ ​ ​ ​ ​ 111,139 ​ ​
Cash, cash equivalents, and restricted cash at end of year
​ ​ ​ $ 68,028 ​ ​ ​ ​ $ 60,007 ​ ​
Supplemental disclosure of cash flow information ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Interest paid
​ ​ ​ $ 49,017 ​ ​ ​ ​ $ 15,776 ​ ​
Supplemental disclosure of non-cash activity ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Cash paid for amounts included in the measurement of lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating cash flow used for operating leases
​ ​ ​ $ 11,297 ​ ​ ​ ​ $ 12,062 ​ ​
Operating cash flow used for finance leases
​ ​ ​ $ 36 ​ ​ ​ ​ $ 78 ​ ​
Financing cash flow used for finance leases
​ ​ ​ $ 157 ​ ​ ​ ​ $ 743 ​ ​
Property and equipment included in accounts payable and accrued liabilities
​ ​ ​ $ 2,052 ​ ​ ​ ​ $ 894 ​ ​
Deferred offering costs, accrued but not yet paid
​ ​ ​ $ 3,266 ​ ​ ​ ​ $ 254 ​ ​
Conversion of convertible debt to Series C Preferred Stock
​ ​ ​ $ — ​ ​ ​ ​ $ 50,000 ​ ​
Lease liabilities arising from obtained right-of-use-assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating leases
​ ​ ​ $ 725 ​ ​ ​ ​ $ 4,782 ​ ​
Finance leases
​ ​ ​ $ 42 ​ ​ ​ ​ $ — ​ ​
The accompanying notes are an integral part of these consolidated financial statements
F-7

TABLE OF CONTENTS​
 
Notes to Consolidated Financial Statements
Note 1. Nature of the Business
Caris Life Sciences, Inc. (the “Company” or “Caris”) is a patient-centric, next-generation artificial intelligence (“AI”) TechBio company and precision medicine pioneer. The Company commercializes and develops innovative solutions to transform healthcare through the use of comprehensive molecular information, and machine learning (“ML”) algorithms.
The Company’s current molecular profiling services portfolio is focused on oncology and consists of MI Profile, a tissue-based molecular profiling solution, and Caris Assure, a novel, universal blood-based molecular profiling solution, with the aim to address the entire continuum of cancer treatment.
The Company also collaborates with biopharmaceutical companies to provide commercial services and prospective and retrospective testing, along with data and bioinformatics collaborations and novel target identification and discovery solutions.
The Company was incorporated under the laws of the Cayman Islands in November 2011 (Caris Life Sciences, Ltd.) and re-domiciled to be incorporated in Texas in July 2020 (Caris Life Sciences, Inc.) and is headquartered in Irving, Texas. The Company also has locations in Phoenix, Arizona; New York, New York; Cambridge, Massachusetts; Basel, Switzerland; and Tokyo, Japan.
Liquidity and Going Concern
As of December 31, 2024, the Company’s cash balance was approximately $64.0 million, and the short-term investments balance was $2.2 million, and the Company has a 2023 Term Loan (see Note 8) outstanding with a balance of $400.0 million.
In 2025, the Company issued the 2025 Convertible Notes (see Note 15), in the amount of $30.0 million. In connection with the Company’s Series C redeemable convertible preferred stock, the 2023 Term Loan and the 2025 Convertible Notes, the following payments may become due within 12 months of the date of the issuance of the consolidated financial statements if, the Company has not completed an initial public offering raising at least $100.0 million in gross proceeds prior to such date:
1.
The Series C redemption rights will become exercisable on March 31, 2026;
​
2.
The Company will be required to make a one-time acceleration payment on December 31, 2025 (see Note 15) in an amount equal to 15% of the outstanding principal amount under the 2023 Term Loan (or $60.0 million based on the principal amount currently outstanding) together with any applicable repayment premium and exit fee as described in the Term Loan agreement on such date; and
​
3.
The 2025 Convertible Notes of $30.0 million will come due on January 1, 2026.
​
If these payments become due, the Company’s existing cash resources and projected operating cash flows may not be sufficient to repay these amounts and continue to fund operating activities for at least the next 12 months from the issuance of the consolidated financial statements. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern.
Management intends to raise additional funding through an initial public offering raising at least $100.0 million in gross proceeds which would eliminate the requirement to make the one-time acceleration payment related to the 2023 Term Loan. Further, the initial public offering would cause the Series C redeemable convertible preferred stock and the 2025 Convertible Note to convert to common stock and thereby not be subject to redemption and repayment upon maturity on March 31, 2026 and January 1, 2026, respectively. Management may seek alternative private financing through additional debt or equity offerings that will fulfill its operating, capital and debt requirements for at least 12 months from the date of the issuance of the consolidated financial statements. However, the Company may not be able to complete such an initial public offering or otherwise secure such financing in a timely manner or on favorable terms, if at all.
 
F-8

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
Note 2. Summary of Significant Accounting Policies and Estimates
Basis of Financial Statement Presentation
The consolidated financial statements include the accounts of Caris and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
The Company’s consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”).
Use of Estimates
The preparation of the consolidated financial statements in conformity with GAAP in the United States requires the use of estimates and assumptions about future events that affect the amounts reported in the Company’s consolidated financial statements and related notes, including the amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the periods reported.
Significant estimates and assumptions are used for, but not limited to:
•
revenue recognition
​
•
fair value of stock-based awards and common stock
​
•
fair value of financial assets and liabilities
​
Future events and their effects cannot be predicted with certainty. Accordingly, the accounting estimates require the exercise of judgment. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. The accounting estimates used in the preparation of the Company’s consolidated financial statements may change as new events occur, additional information is obtained, and the operating environment changes. The Company will evaluate and update the assumptions and estimates on an ongoing basis and may employ outside experts to assist in its evaluation, as considered necessary. Actual results could materially differ from those estimates.
Reclassifications
In the preparation of the financial statements for the year ended December 31, 2024, a reclassification was made to the prior period’s financial statements to conform to the current period’s presentation. This reclassification has no impact on previously reported net income attributable to common shareholders, total assets, or total liabilities. The details of the reclassifications is as follows:
Cost of services was previously included under the caption “Cost of services” in the Consolidated Statement of Operations and Comprehensive Loss. Cost of services is now presented separately as Cost of services—Molecular profiling services and Cost of services—Pharma research and development services. The reason for the reclassification is to provide a clearer presentation of the Company’s operating expenses and enhance comparability with industry peers.
Cash, Cash Equivalents, and Restricted Cash
The Company considers all highly liquid investments with original maturities of three months or less from date of acquisition to be cash equivalents. Refer to Note 4 for information on the Company’s restricted cash.
 
F-9

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
Marketable Securities
The Company classifies its marketable securities, which mainly consist of high-grade U.S. treasury bills, as available-for-sale. High-grade U.S. Treasury Bills with original maturities from date of acquisition between three and twelve months from the balance sheet dates are classified as short-term marketable securities, while those with maturities over twelve months from the balance sheet dates are classified as long-term marketable securities. The Company records all marketable securities at fair value, with changes reflected within unrealized gain or loss on available-for-sale securities on the consolidated statements of operations and comprehensive loss. The cost of short-term investments is adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in interest income.
Foreign Currency Transactions and Translation
The Company’s operating international subsidiaries, Caris Life Sciences Switzerland Holdings GmbH and Caris K.K., use their respective local currencies as their functional currencies. Assets and liabilities for operations in local currency environments are translated to U.S. dollars at exchange rates on the last day of the reporting period. Income and expense items are translated at average rates of exchange prevailing during the reporting period. Transactions denominated in currencies other than the functional currency are remeasured based on the exchange rates at the time of the transaction. Cumulative translation adjustments are recorded as a component of accumulated other comprehensive loss. Transaction and translation gains and losses arising from intercompany balances are reported as a component of net loss and presented within the consolidated statements of operations and comprehensive loss.
Revenue Recognition
The Company recognizes revenue under ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Revenue is recognized when control of goods and services are transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services.
ASC 606 provides for a five-step model that includes:
Step 1: Identify the contract(s) with a customer.
Step 2: Identify performance obligations in the contract.
Step 3: Determine the transaction price.
Step 4: Allocate the transaction price to the performance obligations in the contract.
Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.
The Company derives revenue from two distinct channels:
•
Molecular profiling services involving the provision of precision oncology solutions utilizing MI Profile and Caris Assure.
​
•
Pharma research and development services involving delivery of laboratory, strategic data, and research services to biopharmaceutical customers.
​
Molecular Profiling Services
For the majority of its molecular profiling services, the Company recognizes revenue from the sale of its precision oncology solutions, provided to customers, including certain hospitals, institutions and patients, at the point in time when the results of the profiling services are delivered to ordering physicians. Most cases requested on behalf of customers are provided without a written agreement; however, the Company determines that an implied contract exists with its customers for whom a physician orders the case. Results from molecular profiling services are delivered via fax, electronically, or in hard copy. Shipping and handling activities are considered fulfillment activities and as such, amounts incurred are recorded within Cost of services—Molecular profiling services on the consolidated statements of operations and comprehensive loss. The Company identifies each sale of the Company’s profiling service as a distinct performance obligation
 
F-10

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
(“contract basis”). Payment terms are a function of a patient’s existing insurance benefits and applicable reimbursement contracts established between the Company and payers. Collection of consideration the Company expects to receive typically occurs within 90 to 120 days of billing. Occasionally, payers may recoup or we may refund consideration, mainly as a result of claim processing.
The total consideration to which the Company expects to be entitled in exchange for the Company’s services may be fixed or variable. Consideration includes reimbursement from patients, hospitals, and third-party commercial and governmental payers, such as insurance companies, adjusted for variable consideration related to implicit price concessions that the Company may grant. The Company estimates the variable consideration under a portfolio approach for third-party payers, hospitals and patients with similar reimbursement characteristics. This includes analysis of an average reimbursement per case per portfolio and a percentage of cases reimbursed by considering the historical reimbursement data (including any refunds and recoupments) from such third-party payers, hospitals and patients. Specifically, the Company calculates the historical average reimbursement rates for each portfolio and applies an estimated reimbursement rate, based on historical trends, to the number of cases delivered each period. The period for which historical data is drawn upon is determined on a by- portfolio basis for each payer group, taking into consideration the average collection period. Additionally, the estimate also considers current contractual and statutory requirements, patient insurance eligibility and payer reimbursement contracts, and any known current or anticipated reimbursement trends not reflected in the historical data and only recognizes revenue for variable consideration that the Company determines is probable will not result in a significant reversal in the future. The Company monitors the estimated amount to be collected at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Subsequent changes to the estimate of the transaction price are recorded as adjustments to molecular profiling services revenue in the period where such changes occur. Both the estimate and any subsequent revision are uncertain and require the use of management’s judgment in the estimation of the variable consideration and application of the constraint for such variable consideration.
For the remaining portion of its molecular profiling services, the Company has determined that collectability of the consideration to which it expects to be entitled is not probable, and thus does not recognize revenue for such services until it has provided the services to the customer and received nonrefundable consideration from the customer in exchange for the services (“non-contract basis”). The Company continually reassesses the likelihood of collection for these types of services. If collectability is deemed probable prior to receipt of consideration, then the Company recognizes revenue at the point in time that collection is deemed probable. For the year ended December 31, 2023, the Company recorded $4.4 million of revenue related to the transition of payers from non-contract basis to contract basis.
As of December 31, 2024, all payers were on the contract basis. Molecular profiling services revenue recognized by contract type for the years ended December 31, 2024 and 2023 was as follows:
​ ​ ​
Year Ended December 31,
​
​ ​ ​
2024
​ ​
2023
​
​ ​ ​
(amounts in thousands)
​
Molecular profiling services—contract basis
​ ​ ​ $ 349,115 ​ ​ ​ ​ $ 240,119 ​ ​
Molecular profiling services—non-contract basis
​ ​ ​ ​ — ​ ​ ​ ​ ​ 38,629 ​ ​
Total molecular profiling services revenue
​ ​ ​ $ 349,115 ​ ​ ​ ​ $ 278,748 ​ ​
Pharma Research and Development Services
The Company collaborates with biopharmaceutical companies to provide commercial services and prospective and retrospective testing, along with data and bioinformatics collaborations and novel target identification and discovery solutions.
Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as molecular profiling services, pharma research and development services, and strategic data services. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical
 
F-11

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
customers for proper revenue recognition, including whether services are capable of being distinct and considered distinct within the context of the contract. The performance obligations for biopharmaceutical customers vary by contract. Such contracts may include a performance obligation to provide molecular profiling services, to facilitate the development and regulatory approval of drugs, or to provide target discovery services. Under those contracts, the Company receives payments upon the achievement of milestones, as well as provision of on-going support. The transaction price of the development services contracts may include variable consideration, due to the uncertainty associated with the achievement of the milestones. In making the assessment of whether variable consideration should be included in the transaction price, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The Company recognizes pharma research and development services revenue over the period in which biopharmaceutical research and development services are provided. Depending on the nature of the service, the Company recognizes revenue using either the output or input method to measure progress, whichever provides a more faithful depiction of the transfer of goods or services. Use of an output method or input method to depict the transfer of services generally does not result in a material difference with respect to the timing of revenue recognition because most services commence and end within the same reporting period. A constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price.
Standalone Selling Price
The Company determines standalone selling prices by considering the historical selling prices of its performance obligations in similar transactions, where applicable, as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing from other vendors, industry publications, current pricing practices and management estimates.
Contract Balances
The timing of revenue recognition may differ from the timing of invoicing to customers. Accounts receivable are recorded at the invoiced amount, net of an allowance for credit losses. A receivable is recognized in the period the Company delivers goods or provides services, or when the right to consideration is unconditional. In situations where revenue recognition occurs before invoicing, an unbilled receivable is created, which represents a contract asset. As of December 31, 2024 and 2023, the unbilled receivable balance was $4.6 million and $6.6 million, respectively, which is included in accounts receivable on the consolidated balance sheets.
The Company recognizes contract liabilities primarily related to payments received in advance of satisfaction of performance obligations from contracts with customers. Contract liabilities are relieved as the Company fulfills its obligations under the contract and revenue is recognized. As of December 31, 2024 and 2023, the contract liability balance was $7.5 million and $6.2 million, respectively, which is included in accrued expenses and other current liabilities on the consolidated balance sheets.
The following table shows the changes in the contract liabilities during the period:
​ ​ ​
(amounts in thousands)
​
Balance at December 31, 2023
​ ​ ​ $ 6,190 ​ ​
Increase in contract liabilities
​ ​ ​ ​ 12,816 ​ ​
Revenue recognized during the period that was included in deferred revenues
at the beginning of the period
​ ​ ​ ​ (5,406) ​ ​
Revenue recognized from performance obligations satisfied within the same period
​ ​ ​ ​ (6,130) ​ ​
Balance at December 31, 2024
​ ​ ​ $ 7,470 ​ ​
 
F-12

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
The amount of revenue recognized during the year ended December 31, 2023 pertaining to amounts deferred as of December 31, 2022 was $0.7 million.
Transaction Price Allocated to Remaining Performance Obligations
The transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes contract liabilities and non-cancelable amounts that will be invoiced and recognized as revenue in future periods and excludes performance obligations that are subject to cancellation terms. The Company has elected not to disclose information regarding the transaction price allocated to the remaining performance obligations for which the original expected duration of the contract is one year or less. The amount of transaction price allocated to the remaining performance obligations for contracts with original expected duration over one year as of December 31, 2024 and 2023 was $5.8 million and $5.6 million, respectively. The Company expects to recognize the amounts within twelve months from the respective balance sheet dates.
Additionally, for the years ended December 31, 2024 and 2023, the Company recorded $3.9 million and $(1.9) million of adjustments to revenue related to services delivered in prior periods, which is based on variability that was subsequently resolved.
Practical Expedients and Contract Costs
Payment terms and conditions vary by contract and customer. In instances where the timing of the Company’s revenue recognition differs from the timing of its invoicing, the Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised services to the customer will be one year or less.
As a practical expedient, the Company recognizes the incremental costs of obtaining contracts, such as sales commissions, as expenses when incurred, if the amortization period of the asset that the Company otherwise would have recognized for the capitalized costs is one year or less. Sales commissions are recorded within selling and marketing expense on the consolidated statements of operations and comprehensive loss. The Company did not capitalize any sales commissions or contract fulfillment costs for the years ended December 31, 2024 and 2023.
Collaboration agreements
The Company is party to various collaboration and licensing agreements under which the Company out-licenses certain know-how and molecular data. The collaboration arrangements are intended to solidify the Company’s third-party partnerships to align oncology capabilities and create industry-leading molecular oncology research platforms to accelerate drug development and novel research. Under these collaboration arrangements, the Company generally receives a split of fees from its collaborative partners that are earned pursuant to statements of work (“SOWs”) executed with end users of the Company’s licensed molecular data.
The Company’s collaboration and licensing agreements are within the scope of ASC Topic 808, Collaborative Arrangements (“ASC 808”) and ASC 606 because the counterparty to these agreements meets the definition of a customer. As such, the Company recognizes revenue earned from the licenses of molecular data granted to the Company’s collaborative partners in accordance with ASC 606. Each license of molecular data granted by the Company to a collaborative partner represents a distinct performance obligation in the contract. The transaction price for a given arrangement is entirely variable and depends on the SOWs executed by the counterparty with end users. The amount of revenue allocated to each license is equal to the amount of revenue to which the Company expects to be entitled. The Company recognizes revenue at the point in time that it delivers the molecular data to the third-party collaborative partner. For the years ended December 31, 2024 and 2023, the Company recognized collaboration revenue of $16.2 million and $5.8 million, respectively, which is included in revenue from pharma research and development services on the consolidated statements of operations and comprehensive loss.
 
F-13

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
Cost of services—Molecular profiling services
Cost of services for molecular profiling services generally consists of cost of materials, direct labor including bonus and stock-based compensation, and equipment maintenance and depreciation expenses associated with processing cases (including accessioning, sequencing, quality control analyses and shipping charges to transport tissue samples), freight and profile results for ordering physicians. Costs associated with completing the molecular profiling services are recorded as the service is performed, regardless of when revenue is recognized with respect to the service.
Cost of services—Pharma research and development services
Cost of services for pharma research and development services generally consists of cost incurred for the performance of the services requested by the Company’s biopharmaceutical customers related to the delivery of laboratory, strategic data and research services, and will vary depending on the nature, timing, and scope of customer projects. Costs associated with delivery pharma research and development services are recorded as incurred.
Concentration of Credit Risk
Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company maintains its cash primarily with domestic financial institutions of high credit quality, with balances that exceed amounts insured by the Federal Deposit Insurance Corporation as of December 31, 2024 and 2023, respectively.
The Company invests in treasury bills issued by the U.S. Government. U.S. treasury bills with original maturities of three months or less are classified within cash equivalents. Short-term marketable securities are comprised of U.S. treasury bills with original maturities between three and twelve months. The Company believes it is not exposed to any significant credit risk on cash, cash equivalents, and marketable securities and performs periodic evaluations of the credit standing of such institutions. The goal of the Company’s investment policy is to ensure safety and preservation of the principal balance, and diversification of risk over cash balances held on deposit.
The Company is subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arise from the provision of molecular profiling services and pharma research and development services and other, primarily with biopharmaceutical companies, all of which have high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded net of allowance for credit losses, if any. Concentrations of credit risk are limited due to the number of payers and their dispersion across multiple geographic regions.
For the years ended December 31, 2024 and 2023, the Company's revenues were primarily derived from the sale of the Caris molecular profiling services. As discussed above, payment terms of the services are a function of a patient’s existing insurance benefits and applicable reimbursement contracts established between the Company and payers. Revenue associated with each payer, including its affiliated entities, as a percentage of the Company’s total revenue for the respective period, and accounts receivable balance attributable to each payer, including its affiliated entities, as a percentage of the Company’s total accounts receivable balance at the respective consolidated balance sheet date, are as follows:
​ ​ ​
% Revenue for the years
ended December 31,
​ ​
% Accounts receivable
as of December 31,
​
Major Payer
​ ​
2024
​ ​
2023
​ ​
2024
​ ​
2023
​
Payer 1
​ ​ ​ ​ 33.1% ​ ​ ​ ​ ​ 35.8% ​ ​ ​ ​ ​ 16.1% ​ ​ ​ ​ ​ 18.6% ​ ​
Payer 2
​ ​ ​ ​ * ​ ​ ​ ​ ​ 11.0% ​ ​ ​ ​ ​ * ​ ​ ​ ​ ​ 20.6% ​ ​
Payer 3
​ ​ ​ ​ 14.0% ​ ​ ​ ​ ​ 14.0% ​ ​ ​ ​ ​ 19.3% ​ ​ ​ ​ ​ * ​ ​
 
F-14

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
​
*
Represents major payers below 10.0%.
​
In addition, as of December 31, 2024, one biopharmaceutical customer represented 22.3% of total accounts receivable.
Accounts Receivable
Accounts receivable includes billed and unbilled receivables, net of an allowance for expected credit losses. Accounts receivable primarily represent receivables from biopharmaceutical customers and third-party payers. Accounts receivable for pharmaceutical services are established based on the amounts outstanding per the contractual arrangements with biopharmaceutical customers. The Company applies the current expected credit loss standard in ASC Subtopic 326-20, Financial Instruments—Credit Losses (“ASC 326-20”) and reserves a portion of the accounts receivable based on assessment of the collectability of customer accounts at the time of revenue recognition. The Company regularly reviews the reserve by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay.
Receivables deemed to be uncollectible are written-off against the allowance for credit losses at the time such receivables are deemed to be uncollectible under a specific identification or estimated method. Recoveries of accounts receivable previously written off are recorded when received. As of December 31, 2024 and 2023, the Company had an immaterial allowance for credit losses related to its accounts receivable.
Supplies
Supplies consist primarily of laboratory items and reagents used by the Company in providing services. All supplies are raw materials and are stated at the lower of cost or net realizable value on a first-in, first-out basis. The Company periodically reviews its supplies for excess or obsolescence and writes down obsolete or otherwise unmarketable supplies to their estimated net realizable value. For the years ended December 31, 2024 and 2023, the amount of write downs associated with the Company’s supplies was immaterial.
Deferred Offering Costs
Deferred offering costs consist primarily of accounting, legal, and other fees related to the Company’s proposed initial public offering (“IPO”). These costs are recorded as prepaid expenses and other current assets on the consolidated balance sheets. The deferred offering costs will be recorded against IPO proceeds upon the consummation of the IPO. In the event the planned IPO is terminated, the deferred offering costs will be expensed. The Company had $4.5 million of deferred offering costs as of December 31, 2024. Deferred offering costs were not material as of December 31, 2023.
Property and Equipment, Net
The Company reports property and equipment at cost, net of accumulated depreciation, amortization, and any asset impairments. The cost of properties held under finance leases is equal to the present value of lease payments not yet paid, adjusted for initial direct costs, prepaid lease payments and lease incentives received. Major improvements which add to productive capacity or extend the life of an asset are capitalized. Normal repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts, and any resulting gain or loss is reflected in the accompanying consolidated statements of operations and comprehensive loss for the period.
 
F-15

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
Depreciation and amortization expenses are calculated on a straight-line basis and applied to asset classes based upon the Company’s estimate of the asset class’s useful life, as summarized below:
​ ​ ​
Estimated Useful Life
​
Laboratory equipment
​ ​
3 years
​
Computer equipment and software
​ ​
3 years
​
Furniture and fixtures
​ ​
5 years
​
Aircraft
​ ​
7 years
​
Leasehold improvements/leased buildings
​ ​
Lesser of remaining lease term or useful life
​
Leased equipment
​ ​
Lesser of initial lease term or 5 years
​
Computer equipment and software includes the purchases of hardware, software and capitalized labor costs associated with internally developed software.
The Company capitalizes purchased software which is ready-for-service and capitalizes qualifying internal software development costs incurred on significant projects. Capitalization of costs begins when two criteria are met: (1) the preliminary project stage is completed, management with relevant authority authorizes and commits to funding the software project, and (2) it is probable that the software will be completed and used for its intended function. Capitalization ceases when the software is substantially complete and ready for its intended use, including the completion of all significant testing. Costs related to preliminary project activities and post-implementation operating activities are expensed as incurred.
Research and development costs and other computer software maintenance costs related to software development are expensed as incurred.
Capitalized software costs are included in property and equipment, net. These costs are amortized using the straight-line method over the estimated useful life of the underlying software, which is three years. The Company capitalized $1.1 million and $3.3 million in development costs for internal use software for the years ended December 31, 2024 and 2023, respectively.
Leases
The Company is a lessee for various types of property and equipment. The Company determines if an arrangement is or contains a lease at inception by evaluating whether the contract contains an identified asset that the Company has the right to control the use of throughout the contract term. Lease classification as either an operating or finance lease is determined at the lease commencement date when the leased assets are made available for use.
Upon lease commencement, the Company recognizes a lease liability and right-of-use (“ROU”) asset. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term, regardless of whether the lease is an operating or finance lease. Lease payments consist primarily of fixed payments under the arrangement, less tenant incentives, if any. For each lease, the Company first assesses whether the rate implicit in the lease is readily determinable. When the rate implicit in the lease is not readily determinable, the Company uses an estimate of its incremental borrowing rate (“IBR”) based on the information available at the lease commencement date in determining the present value of lease payments. In determining the appropriate IBR, the Company considers information including, but not limited to, its credit rating, the lease term, collateral and the currency in which the arrangement is denominated. ROU assets are measured based on the corresponding lease liability adjusted for (i) prepayments made to the lessor at or before the commencement date, (ii) initial direct costs the Company incurs, and (iii) tenant incentives under the lease. Certain of the Company’s leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with recognizing and measuring the ROU asset and lease liability when it is reasonably certain the Company will exercise that option.
 
F-16

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
Lease expense for operating lease payments is recognized on a straight-line basis over the lease term. Amortization expense for finance leases is recognized on a straight-line basis over the lease term, and interest expense for finance leases is recognized using the effective interest method. The Company presents operating lease payments within cash flows from operating activities on the consolidated statements of cash flows. The Company presents finance lease payments related to principal amounts within cash flows from financing activities and finance lease payments related to the interest on the lease liability within cash flows from operating activities on the consolidated statements of cash flows.
The presentation of the Company’s leases on the consolidated balance sheets depends on whether the lease is classified as an operating or finance lease. Operating lease ROU assets are included within other assets, the current portion of operating lease liabilities are included within accrued expenses and other current liabilities, and the long-term operating lease liabilities are included within other long-term liabilities. Finance lease ROU assets are included in property and equipment, net, the current portion of finance lease liabilities are included within current portion of notes payable, and long-term finance lease liabilities are included within long-term indebtedness, net of discounts.
The Company elected the practical expedient to not separate lease and non-lease components for its leases. The Company does not record leases on the consolidated balance sheet that have a lease term of twelve months or less at the lease commencement date. Refer to Note 9 for additional disclosures related to the Company’s lease arrangements.
Warrant Liability
In 2020, the Company issued warrants and amended its outstanding warrants to include a provision to allow the purchase of either common stock or its Series C redeemable convertible preferred stock upon exercise. Because the warrants may be exercised for shares of the Company’s Series C redeemable convertible preferred stock, the warrants are classified as a liability pursuant to the guidance in ASC Topic 480, Distinguishing Liabilities from Equity. The Company recognizes the liability associated with outstanding warrants within warrant and derivative liabilities on the consolidated balance sheets. The warrant liability is adjusted to fair value until such time as the warrants are no longer outstanding or the underlying securities are no longer redeemable outside the control of the Company. Changes in fair value of the warrant liability are reported within changes in fair value of financial instruments on the consolidated statements of operations and comprehensive loss. Refer to Note 8 for additional information about the warrant liability.
Fair Value Measurements
Fair value is defined as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions market participants would use in pricing an asset or liability.
The basis for these assumptions establishes a three-level fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
•
Level 1—Observable inputs such as quoted prices in active markets for identical assets and liabilities;
​
•
Level 2—Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and
​
•
Level 3—Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
​
Assets and liabilities measured at fair value are based on one or more of three valuation techniques. The three valuation techniques are as follows:
•
Market approach—Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities;
​
 
F-17

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
•
Cost approach—Amount that would be required to replace the service capacity of an asset (i.e., replacement cost); and
​
•
Income approach—Techniques to convert future amounts to a single present amount based on market expectations (including present value techniques, option-pricing models, and lattice models).
​
Financial instruments consist of cash, cash equivalents, restricted cash, short-term marketable securities, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities, debt (see Note 8), warrants, and derivative instruments.
As of December 31, 2024 and 2023, the carrying amounts of the Company’s cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate their fair value based on the short-term nature of these items. There were no transfers between Levels 1, 2 or 3 for the years ended December 31, 2024 and 2023.
The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:
​ ​ ​
As of December 31, 2024
​
​
Fair Value
​ ​
Level 1
​ ​
Level 2
​ ​
Level 3
​
​ ​ ​
(amounts in thousands)
​
Financial assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Short-term marketable securities
​ ​ ​ $ 2,201 ​ ​ ​ ​ $ 2,201 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​
Financial liabilities
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Warrant liability
​ ​ ​ $ 91,642 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​ ​ ​ $ 91,642 ​ ​
Derivative liability
​ ​ ​ $ 6,058 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​ ​ ​ $ 6,058 ​ ​
​ ​ ​
As of December 31, 2023
​
​
Fair Value
​ ​
Level 1
​ ​
Level 2
​ ​
Level 3
​
​ ​ ​
(amounts in thousands)
​
Financial assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Short-term marketable securities
​ ​ ​ $ 65,184 ​ ​ ​ ​ $ 65,184 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​
Financial liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Warrant liability
​ ​ ​ $ 98,733 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​ ​ ​ $ 98,733 ​ ​
Derivative liability
​ ​ ​ $ 17,451 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​ ​ ​ $ 17,451 ​ ​
Short-term marketable securities
The Company’s short-term marketable securities, which have maturities of less than one year, are mainly comprised of U.S. treasury bills which have observable quoted prices. There were no outstanding U.S. Treasury Bills as of December 31, 2024. The following is a summary of the Company’s available-for-sale securities as of December 31, 2023:
​ ​ ​
As of December 31, 2023
​
​
Amortized
Cost
​ ​
Gross
Unrealized
Gain
​ ​
Gross
Unrealized
(Loss)
​ ​
Estimated
Fair Value
​
​ ​ ​
(amounts in thousands)
​
U.S. treasury bills
​ ​ ​ $ 63,099 ​ ​ ​ ​ $ 5 ​ ​ ​ ​ $ (12) ​ ​ ​ ​ $ 63,092 ​ ​
 
F-18

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
Warrant liability
The Company utilized a probability-weighted scenario approach factoring in various exit strategies and the related timing of such to estimate the fair value of its warrant liability. For each scenario, the Company utilized a Black-Scholes option pricing model with the following assumptions:
•
Fair value per share of the underlying stock—The fair value of the underlying stock represents the fair value of the Company’s Series C preferred stock that the warrants are convertible into.
​
•
Volatility—The volatility is derived from historical volatilities of several unrelated publicly-listed peer companies, since the Company has no trading history. When making the selections of industry peer companies to be used in the volatility calculation, the Company considers the size, operational and economic similarities to the Company’s principal business operations.
​
•
Risk-free interest rate—The risk-free interest rate is based on U.S. treasury yield as of the measurement dates interpolated to match the maturity equal to the respective term to exit.
​
•
Dividend yield—The expected dividend assumption is based on the Company’s current expectations about the Company’s anticipated dividend policy.
​
•
Expected term (years)—Based on expected term under various exit strategies.
​
The below table summarizes the significant unobservable inputs used in the fair value measurement of the warrant liability as of December 31, 2024 and 2023:
​ ​ ​
As of December 31,
​
​ ​ ​
2024
​ ​
2023
​
​ ​ ​
2018
Warrants
​ ​
2020
Warrants
​ ​
2018
Warrants
​ ​
2020
Warrants
​
Fair value per share of the underlying stock
​ ​
$3.66–$5.65
​ ​
$3.66–$5.65
​ ​
$2.97–$8.14
​ ​
$2.97–$8.14
​
Expected volatility
​ ​
47.6%–63.0%
​ ​
61.2%–63.0%
​ ​
43.0% -55.0%
​ ​
50.0%–55.0%
​
Risk-free interest rate
​ ​
4.2%–4.3%
​ ​
4.3%
​ ​
4.4%–5.3%
​ ​
4.0%–5.3%
​
Expected dividend yield
​ ​
—%
​ ​
—%
​ ​
—%
​ ​
—%
​
Expected term (years)
​ ​
0.29–0.75
​ ​
0.29–2.25
​ ​
0.5–1.72
​ ​
0.5–3.25
​
Derivative liability
On January 18, 2023, the Company entered into a credit agreement (the “New Term Loan Agreement”) under which the Company issued senior, secured promissory notes (the “2023 Term Loan”) by which the New Term Loan lenders agreed to lend the Company up to an aggregate principal amount of $400.0 million, $200.0 million of which was received by the Company upon issuance. The Company identified certain embedded features in the 2023 Term Loan, including various contingent prepayment, compensatory payment, and default interest rate features, that are required to be bifurcated from the 2023 Term Loan and separately accounted for in the consolidated financial statements as a compound derivative liability.
Fair value of the derivative liability was estimated using the discounted cash flow method under the income approach. This approach involves significant Level 3 inputs and assumptions including an estimated probability and timing of certain contingent events, such as events of default, change of control, sale of assets, etc. The analysis also required the selection of a discount rate representative of the Company’s credit risk. The discount rate used for the initial fair value was calibrated to the transaction.
The initial fair value of the derivative liability was $28.3 million at the inception date of January 18, 2023. As of December 31, 2023, the fair value of the embedded derivative liability was $17.5 million, resulting in a remeasurement gain of $10.8 million reported within changes in fair value of financial instruments in the consolidated statements of operations and comprehensive loss.
Refer to Note 8 for additional information about the compound embedded derivative liability.
 
F-19

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
Debt
As of December 31, 2024, the estimated fair value of the 2023 Term Loan, excluding the bifurcated embedded derivative, was $380.9 million, compared to a carrying value of $373.1 million. As of December 31, 2023, the estimated fair value of the 2023 Term Loan, excluding the bifurcated embedded derivative, was $176.1 million, compared to a carrying value of $166.1 million. The Company estimated the fair value of the 2023 Term Loan as of December 31, 2024 based on a discounted cash flow analysis, and an income approach, which represented the use of Level 3 inputs in the fair value hierarchy.
Goodwill
Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities acquired through a business combination. The Company evaluates goodwill for impairment in accordance with ASC Topic 350, Intangibles—Goodwill and Other on an annual basis on October 1, or more frequently if events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, or the Company may determine to proceed directly to the quantitative impairment test.
If the Company assesses qualitative factors and concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount or if the Company determines not to use the qualitative assessment, then a quantitative impairment test is performed. The factors utilized in the qualitative assessment include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, and Company-specific events. The quantitative impairment test requires comparing the fair value of the reporting unit to its carrying value, including goodwill. The fair value of the reporting unit is determined based on the present value of estimated cash flows using available information regarding expected cash flows of each reporting unit, discount rates, and the expected long-term cash flow growth rates.
The Company has identified that its business operates as a single operating segment which is also a single reporting unit for purposes of testing goodwill for impairment. An impairment exists if the fair value of the reporting unit is lower than its carrying value. If the fair value of the reporting unit is lower than its carrying value, the Company would record an impairment loss equal to the excess of the reporting unit’s carrying value over its fair value.
There were no impairment losses for the years ended December 31, 2024 and 2023.
Research and Development Costs
Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities. The costs include direct costs for salaries and benefits, materials, contract services and other outside costs, and costs to acquire in-process research and development projects and technologies that have no alternative future use.
Advertising
The Company expenses advertising costs as incurred. The Company incurred advertising costs of $1.2 million and $0.6 million for the years ended December 31, 2024 and 2023, respectively.
Self-Insurance
The Company offers medical insurance coverage to eligible employees under a self-insured program managed by a third-party administrator, leveraging stop-loss insurance policies to mitigate risk. The Company records an estimate of its liability for medical claims, which includes the incurred claims amount plus an estimate of incurred, but not reported claims. Self-insurance liability of $1.9 million and $1.8 million for the years ended December 31, 2024 and 2023, respectively, is included within accrued expenses and other current liabilities on the consolidated balance sheets.
 
F-20

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
Comprehensive Loss
Comprehensive loss consists of net loss, unrealized gains on available-for-sale securities, foreign currency translation adjustments and gains affecting shareholders’ deficit that under GAAP are excluded from net income or loss.
Stock-Based Compensation
The Company accounts for stock-based compensation awards in accordance with ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). Stock-based compensation expense is measured based on the fair value of the stock-based awards at the grant date for all stock-based awards to employees and non-employees and is recognized as expense over the requisite service period on a straight-line basis, which is generally the vesting period. Forfeitures are estimated using historical trends. Refer to Note 7 for additional information on the Company’s stock-based compensation.
Compensated Absences
When the Company’s obligation relating to employees’ rights to receive compensation for future absences is attributable to employees’ services rendered, the obligation relates to rights that vest or accumulate, payment is probable and amount can be reasonably estimated, a liability is recorded.
Loss Contingencies
The Company accounts for liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. Refer to Note 10 for additional information on the Company’s loss contingencies.
Redeemable Convertible Preferred Stock
The Company’s redeemable convertible preferred stock is recorded outside of permanent equity because, while it is not mandatorily redeemable, it is redeemable at the option of the holders for cash upon the passage of time or the occurrence of certain events considered not solely within the Company’s control, such as a merger, acquisition, and sale of all or substantially all of the Company’s assets (each, a “deemed liquidation event”). The redeemable convertible preferred stock classified in mezzanine equity is subject to subsequent measurement under the guidance provided in the SEC Staff Announcement: Classification and Measurement of Redeemable Securities. In accordance with that guidance, the Company has elected to recognize changes in redemption value immediately as they occur through adjustments to the carrying amounts of the instruments at the end of the reporting period with the corresponding amount recorded to additional paid-in capital or, in the absence of additional paid-in-capital, accumulated deficit.
Treasury Stock
The Company records treasury stock purchases under the cost method by recording the entire cost of the acquired shares of common stock as treasury stock. In the case of re-issuance of treasury stock, amounts that exceed the acquisition cost will be recorded in additional paid-in capital. If the re-issuance price is below the treasury stock’s acquisition cost and additional paid-in capital is insufficient to cover the difference between the acquisition cost and the re-issuance price, the shortfall will be recorded in accumulated deficit.
If the Company decides to retire treasury stock, the Company will deduct the par value from common stock and reduce additional paid-in capital for any excess of cost over par value. If additional paid-in capital is insufficient, the Company reflects the shortfall in accumulated deficit.
Net Loss per Share Attributable to Common Shareholders
The Company calculates its basic and diluted net loss per share attributable to common shareholders in conformity with the two-class method required for companies with participating securities. Each series of
 
F-21

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
the Company’s redeemable convertible preferred stock is considered to be a participating security because the preferred shareholders have a right to receive dividends on a pari passu basis with the Company’s common shareholders. The two-class method determines net income (loss) per share for each class of common stock and participating security according to dividends declared or accumulated and participating rights in undistributed earnings. The two-class method requires income (loss) available to common shareholders for the period to be allocated between common and participating securities based upon the respective rights of each to share in earnings as if all income (loss) for the period had been distributed. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method between common and participating securities.
Because the Company has reported a net loss for the years ended December 31, 2024 and 2023, basic net loss per share attributable to common shareholders is calculated by dividing net loss attributable to common shareholders by the weighted-average common stock outstanding during the period, without consideration for potential common stock equivalents. Net loss attributable to common shareholders is equal to net loss, less accretion on preferred securities to their redemption value to the extent such securities are outstanding. Diluted net loss per share attributable to common shareholders is calculated by adjusting the weighted-average stock outstanding for the dilutive effect of potential common stock equivalents outstanding. For purposes of calculating the diluted net loss per share attributable to common shareholders, convertible preferred stock, convertible promissory notes, warrants, and stock options are considered to be potential common stock equivalents but are excluded from the calculation of diluted net loss per share attributable to common shareholders because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share attributable to common shareholders was the same for all periods presented.
Income Taxes
The Company accounts for income taxes under the asset and liability method as set forth in ASC 740 “Income Taxes” ​(“ASC 740”). Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The calculation of the Company’s tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across its global operations. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related taxing authority. For tax positions not meeting the more likely than not test, no tax benefit is recorded.
At December 31, 2024 and 2023, the Company has accumulated net operating loss carryforwards in both the U.S. and foreign jurisdictions, and no provision for income taxes is required. The Company’s deferred tax assets are subject to a full valuation allowance.
Recently Adopted Accounting Pronouncements
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU requires disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. The amendments require disclosure of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of the composition for other segment items to reconcile to segment profit or loss, and the title and position of the Company’s CODM. The ASU also extends certain annual disclosures to interim periods. The Company elected to early adopt this ASU for its annual reporting period ending December 31, 2023. There was no impact on the Company’s reportable segments identified and additional required disclosures have been included in Note 13.
 
F-22

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
Recently Issued Accounting Pronouncements Not Yet Adopted
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures which requires presentation of specific categories of reconciling items, as well as reconciling items that meet a quantitative threshold, in the reconciliation between the income tax provision and the income tax provision using statutory tax rates. The standard also requires disclosure of income taxes paid disaggregated by jurisdiction with separate disclosure of income taxes paid to individual jurisdictions that meet a quantitative threshold. For public business entities, the ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. For entities other than public business entities, the ASU is effective for annual periods beginning after December 15, 2025. The amendments of the ASU should be applied on a prospective basis; however, entities have the option to apply retrospectively for each period presented. The Company does not expect the adoption of this new standard in 2026 to have an impact on its consolidated financial position, results of operations, or cash flow.
In November 2024, the FASB issued ASU No. 2024-03, Income Statement- Reporting Comprehensive Income-Expense disaggregation disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. This ASU requires disclosure of specified information about certain costs and expenses in the notes to financial statements. This ASU is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Adoption of this ASU should be applied on a prospective basis. Early adoption is permitted. We are currently evaluating the impact that this guidance will have on the disclosures within our financial statements, and expect to adopt this ASU for the year ending December 31, 2027.
Note 3. Consolidated Balance Sheet and Statement of Operations and Comprehensive Loss Components
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
​ ​ ​
As of December 31,
​
​ ​ ​
2024
​ ​
2023
​
​ ​ ​
(amounts in thousands)
​
Prepaid expenses
​ ​ ​ $ 13,562 ​ ​ ​ ​ $ 11,766 ​ ​
Other current assets
​ ​ ​ ​ 6,708 ​ ​ ​ ​ ​ 1,358 ​ ​
Total prepaid expenses and other current assets
​ ​ ​ $ 20,270 ​ ​ ​ ​ $ 13,124 ​ ​
Property and Equipment, Net
Property and equipment, net consist of the following:
​ ​ ​
As of December 31,
​
​ ​ ​
2024
​ ​
2023
​
​ ​ ​
(amounts in thousands)
​
Computer equipment and software
​ ​ ​ $ 99,233 ​ ​ ​ ​ $ 95,573 ​ ​
Laboratory equipment
​ ​ ​ ​ 103,795 ​ ​ ​ ​ ​ 98,985 ​ ​
Furniture and fixtures
​ ​ ​ ​ 9,110 ​ ​ ​ ​ ​ 8,883 ​ ​
Leasehold improvements/Leased buildings
​ ​ ​ ​ 63,039 ​ ​ ​ ​ ​ 66,579 ​ ​
Aircraft and leased equipment
​ ​ ​ ​ 21,249 ​ ​ ​ ​ ​ 21,204 ​ ​
Total property and equipment
​ ​ ​ ​ 296,426 ​ ​ ​ ​ ​ 291,224 ​ ​
Less: accumulated depreciation and amortization
​ ​ ​ ​ (228,609) ​ ​ ​ ​ ​ (184,136) ​ ​
Property and equipment, net
​ ​ ​ $ 67,817 ​ ​ ​ ​ $ 107,088 ​ ​
 
F-23

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
Total depreciation and amortization expense was $48.9 million and $49.0 million for the years ended December 31, 2024 and 2023, respectively. Out of the total depreciation expense, amortization associated with finance leases was $0.1 million and $0.5 million for the years ended December 31, 2024 and 2023, respectively.
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consist of the following:
​ ​ ​
As of December 31,
​
​ ​ ​
2024
​ ​
2023
​
​ ​ ​
(amounts in thousands)
​
Trade accruals
​ ​ ​ $ 7,131 ​ ​ ​ ​ $ 7,680 ​ ​
Accrued payroll and employee medical
​ ​ ​ ​ 17,882 ​ ​ ​ ​ ​ 16,049 ​ ​
Accrued bonus
​ ​ ​ ​ 25,736 ​ ​ ​ ​ ​ 16,824 ​ ​
Current portion of early exercise stock option liability
​ ​ ​ ​ 4,957 ​ ​ ​ ​ ​ 4,957 ​ ​
Contract liability
​ ​ ​ ​ 7,470 ​ ​ ​ ​ ​ 5,676 ​ ​
Current portion of operating lease liabilities
​ ​ ​ ​ 6,080 ​ ​ ​ ​ ​ 6,420 ​ ​
Accrued interest on current portion of notes payable and convertible loan
​ ​ ​ ​ — ​ ​ ​ ​ ​ 6,332 ​ ​
Other accrued expenses
​ ​ ​ ​ 8,286 ​ ​ ​ ​ ​ 3,839 ​ ​
Total accrued expenses and other current liabilities
​ ​ ​ $ 77,542 ​ ​ ​ ​ $ 67,777 ​ ​
Other Long-Term Liabilities
Other long-term liabilities consist of the following:
​ ​ ​
As of December 31,
​
​ ​ ​
2024
​ ​
2023
​
​ ​ ​
(amounts in thousands)
​
Long-term operating lease liabilities, net of current portion
​ ​ ​ $ 38,651 ​ ​ ​ ​ $ 44,099 ​ ​
Long-term portion of early exercise stock option liability
​ ​ ​ ​ 5,767 ​ ​ ​ ​ ​ 10,724 ​ ​
Total other long-term liabilities
​ ​ ​ $ 44,418 ​ ​ ​ ​ $ 54,823 ​ ​
Other Expense, Net
Other expense, net consists of the following:
​ ​ ​
As of December 31,
​
​ ​ ​
2024
​ ​
2023
​
​ ​ ​
(amounts in thousands)
​
Loss on debt extinguishment
​ ​ ​ $ — ​ ​ ​ ​ $ (10,915) ​ ​
Other
​ ​ ​ ​ (349) ​ ​ ​ ​ ​ (1,691) ​ ​
Total other expense, net
​ ​ ​ $ (349) ​ ​ ​ ​ $ (12,606) ​ ​
Note 4. Guaranty Agreement and Restricted Cash
The Company entered into a Master Continuing Guaranty Agreement with Bank of America in 2011 to provide a guarantee for credit exposure related to the Company’s commercial bank accounts with Bank of America. The agreement was guaranteed through collateral accounts of $0.3 million as of December 31, 2024 and 2023. The agreement contains various customary affirmative and financial reporting
 
F-24

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
obligations and is considered to be restricted cash, as the account is under a security deposit agreement. All obligations are in compliance with the terms of the agreement.
The Company entered into a lease agreement with KCP NNN II Leasehold 4, LLC on July 25, 2019 to lease 114,500 square feet of space in Irving, Texas. As part of the lease agreement, the Company delivered an unconditional, irrevocable letter of credit for $3.4 million from a nationally recognized bank. The Company obtained this letter of credit and placed $3.4 million in a security deposit account. As of December 31, 2024 and 2023, amounts outstanding are $2.7 million and $3.1 million, respectively, and are included within cash, cash equivalents, and restricted cash and other assets on the consolidated balance sheets.
The remaining restricted cash amounts are not material individually.
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the amounts shown in the consolidated statements of cash flows. Restricted cash is presented within cash, cash equivalents, and restricted cash and other assets on the consolidated balance sheets.
​ ​ ​ ​ ​ ​
As of December 31,
​
​ ​ ​
Consolidated balance sheet line item
​ ​
2024
​ ​
2023
​
​ ​ ​ ​ ​ ​
(amounts in thousands)
​
Cash and cash equivalents
​ ​
Cash, cash equivalents, and restricted cash
​ ​ ​ $ 63,950 ​ ​ ​ ​ $ 56,402 ​ ​
Restricted cash – short term
​ ​
Cash, cash equivalents, and restricted cash
​ ​ ​ ​ 1,492 ​ ​ ​ ​ ​ 3,605 ​ ​
Restricted cash – long term
​ ​
Other assets
​ ​ ​ ​ 2,586 ​ ​ ​ ​ ​ — ​ ​
Total
​ ​ ​ ​ ​ ​ $ 68,028 ​ ​ ​ ​ $ 60,007 ​ ​
Note 5. Income Taxes
For financial reporting purposes, income before income taxes includes the following components:
​ ​ ​
Years Ended December 31,
​
​ ​ ​
2024
​ ​
2023
​
​ ​ ​
(amounts in thousands)
​
United States
​ ​ ​ $ (283,720) ​ ​ ​ ​ $ (339,724) ​ ​
Foreign
​ ​ ​ $ 1,830 ​ ​ ​ ​ $ (1,691) ​ ​
Total
​ ​ ​ $ (281,890) ​ ​ ​ ​ $ (341,415) ​ ​
The Company had no income tax expense or benefit for the years ended December 31, 2024 or 2023.
 
F-25

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
The difference between income taxes expected at the U.S. federal statutory income tax rate of 21% and the reported income tax benefit are summarized as follows:
​ ​ ​
Years Ended December 31,
​
​ ​ ​
2024
​ ​
2023
​
​ ​ ​
(amounts in thousands)
​
Computed statutory benefit
​ ​ ​ $ (59,197) ​ ​ ​ ​ $ (71,697) ​ ​
Change in valuation allowance
​ ​ ​ ​ 67,333 ​ ​ ​ ​ ​ 85,643 ​ ​
State taxes, net of federal benefit
​ ​ ​ ​ (10,173) ​ ​ ​ ​ ​ (15,342) ​ ​
Permanent differences
​ ​ ​ ​ 2,946 ​ ​ ​ ​ ​ 1,231 ​ ​
Permanent difference—warrant fair value adjustment
​ ​ ​ ​ (1,489) ​ ​ ​ ​ ​ (55) ​ ​
Foreign rate differential
​ ​ ​ ​ (267) ​ ​ ​ ​ ​ (5) ​ ​
Adjustments to foreign NOL’s
​ ​ ​ ​ 117 ​ ​ ​ ​ ​ 174 ​ ​
Adjustments to state NOL’s
​ ​ ​ ​ (114) ​ ​ ​ ​ ​ (522) ​ ​
Adjustments to stock-based compensation
​ ​ ​ ​ 137 ​ ​ ​ ​ ​ 671 ​ ​
Rate change
​ ​ ​ ​ (68) ​ ​ ​ ​ ​ (40) ​ ​
Other
​ ​ ​ ​ 775 ​ ​ ​ ​ ​ (58) ​ ​
Income tax benefit
​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities are as follows:
​ ​ ​
Years Ended December 31,
​
​ ​ ​
2024
​ ​
2023
​
​ ​ ​
(amounts in thousands)
​
Deferred tax assets ​ ​ ​ ​ ​ ​ ​ ​
Net operating loss carryforward
​ ​ ​ $ 290,514 ​ ​ ​ ​ $ 249,229 ​ ​
Accrued liabilities
​ ​ ​ ​ 8,449 ​ ​ ​ ​ ​ 5,854 ​ ​
Stock-based compensation
​ ​ ​ ​ 5,993 ​ ​ ​ ​ ​ 4,346 ​ ​
Interest limitation
​ ​ ​ ​ 35,614 ​ ​ ​ ​ ​ 26,727 ​ ​
Research and development credits
​ ​ ​ ​ 2,842 ​ ​ ​ ​ ​ 2,842 ​ ​
Intangibles
​ ​ ​ ​ 3,557 ​ ​ ​ ​ ​ 3,286 ​ ​
Lease obligation
​ ​ ​ ​ 11,601 ​ ​ ​ ​ ​ 13,038 ​ ​
Contractual allowances
​ ​ ​ ​ 16,867 ​ ​ ​ ​ ​ 17,543 ​ ​
Research and development costs
​ ​ ​ ​ 52,140 ​ ​ ​ ​ ​ 40,911 ​ ​
Property and equipment basis difference
​ ​ ​ ​ 4,796 ​ ​ ​ ​ ​ 1,249 ​ ​
Others
​ ​ ​ ​ 1,956 ​ ​ ​ ​ ​ 1,621 ​ ​
Total deferred tax assets
​ ​ ​ $ 434,329 ​ ​ ​ ​ $ 366,646 ​ ​
Deferred tax liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Right of use assets
​ ​ ​ ​ (9,033) ​ ​ ​ ​ ​ (10,401) ​ ​
Excess tax goodwill amortization
​ ​ ​ ​ (262) ​ ​ ​ ​ ​ (240) ​ ​
Derivative liability fair value adjustment
​ ​ ​ ​ (3,456) ​ ​ ​ ​ ​ (1,736) ​ ​
Others
​ ​ ​ ​ — ​ ​ ​ ​ ​ (24) ​ ​
Total deferred tax liabilities
​ ​ ​ ​ (12,751) ​ ​ ​ ​ ​ (12,401) ​ ​
Valuation allowance
​ ​ ​ $ (421,578) ​ ​ ​ ​ $ (354,245) ​ ​
Net deferred tax asset (liability)
​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​
 
F-26

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit the use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss over the three-year period ended December 31, 2024. Such objective evidence limits the ability to consider other subjective evidence, such as the Company’s projections for future growth. On the basis of this evaluation, as of December 31, 2024, a valuation allowance of $421.6 million has been recorded to recognize only the portion of the deferred tax assets that is more likely than not to be realized. The amount of the deferred tax assets considered realizable, however, could be adjusted if additional objectively verifiable positive evidence materializes in future reporting periods, such as a demonstrated operating profitability.
The valuation allowances increased $67.3 million and $85.6 million during the fiscal years ended December 31, 2024 and 2023, respectively, primarily due to increased U.S. federal and state net operating loss carryforwards.
The Company has gross federal, state, and foreign net operating loss carryforwards of approximately $2,152 million which expire as follows:
(amounts in thousands)
Expiration Year
​ ​
Federal
​ ​
State
​ ​
Foreign
​ ​
Total
​
2024–2030
​ ​ ​ ​ 6,338 ​ ​ ​ ​ ​ 11,630 ​ ​ ​ ​ ​ 13,736 ​ ​ ​ ​ ​ 31,704 ​ ​
2031–2040
​ ​ ​ ​ 209,538 ​ ​ ​ ​ ​ 289,839 ​ ​ ​ ​ ​ 1,913 ​ ​ ​ ​ ​ 501,290 ​ ​
2041–2045
​ ​ ​ ​ — ​ ​ ​ ​ ​ 516,068 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 516,068 ​ ​
Indefinite
​ ​ ​ $ 934,839 ​ ​ ​ ​ $ 168,226 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ 1,103,065 ​ ​
Total
​ ​ ​ $ 1,150,715 ​ ​ ​ ​ $ 985,763 ​ ​ ​ ​ $ 15,649 ​ ​ ​ ​ $ 2,152,127 ​ ​
The 2018 through 2024 net operating losses do not expire under the Tax Cuts and Jobs Act of 2017, and are subject to the 80% of taxable income limitation.
Federal tax laws impose substantial restrictions on the utilization of net operating loss and credit carryforwards in the event of an ownership change, as defined in Section 382 of the Internal Revenue Code of 1986. Accordingly, the Company’s ability to utilize these carryforwards may be limited in the event of any such ownership change. We have completed a Section 382 analysis for changes in ownership through December 31, 2023 and continue to monitor for changes that could trigger a limitation. Based on this analysis, we do not expect to have any permanent limitations on the utilization of its federal net operating losses.
The Company has U.S. federal and state tax research and development credit carryforwards of $2.8 million as of December 31, 2024 and 2023, with expiration dates through 2031 and 2026, respectively. The Company has recorded a full valuation allowance related to the credit carryforwards as of December 31, 2024.
The Company is subject to taxation in the United States and various states and foreign jurisdictions. As of December 31, 2024, all loss years remain open to examination by the taxing authorities.
The recognition and measurement of certain tax benefits includes estimates and judgment by management that inherently involve subjectivity. Changes in estimates may create volatility in the Company’s effective tax rate in future periods and may be due to the expiration of various statutes of limitations, settlements with tax authorities, or acquisition of new information about particular tax positions that may require management to change its estimates.
On December 22, 2017, the Tax Cuts and Jobs Act (TCJA) created new taxes on certain foreign earnings. Namely, U.S. shareholders are now subject to current tax on global intangible low-taxed income (“GILTI”) earned by specified foreign subsidiaries. Available guidance related to GILTI provides for an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. The Company has elected to recognize the current tax on GILTI as an expense in the period the tax is incurred. As of December 31, 2024, the Company has a GILTI tax inclusion of $2.3 million. As
 
F-27

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
of December 31, 2023, there is no GILTI tax inclusion. As of December 31, 2024 and 2023, the Company had no undistributed earnings from its foreign subsidiaries due to losses generated since inception.
Additionally, TCJA includes a requirement to capitalize and amortize research and experimental expenditures beginning in 2022. Prior to 2022, the Company expensed these costs as incurred for tax purposes. The capitalization of the research and experimental expenditures resulted in a deferred tax asset of $52.1 million and $41.9 million as of December 31, 2024 and 2023, respectively, which was offset by a valuation allowance, resulting in no significant impact to income tax expense for the years ended December 31, 2024 and 2023. This deferred tax asset will be amortized over five years for the domestic costs and fifteen years for the foreign incurred costs.
The Company accounts for uncertainty in income taxes in accordance with ASC Topic 740, Income Taxes (“ASC 740”). Through December 31, 2024, the Company has evaluated all tax positions for which the statute of limitations remained open, and the Company has not recognized any reserve for uncertain tax positions or any penalties or interest through the income statement or balance sheet as of December 31, 2024. The Company has not recorded and does not expect any material changes to the liability for uncertain tax positions during the next 12 months.
Note 6. Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock as of December 31, 2024 and 2023, consisted of the following:
​ ​ ​
As of December 31, 2024
​
(amounts in thousands, except share and per
share amounts)
​ ​
Shares
Authorized
​ ​
Shares Issued
and
Outstanding
​ ​
Original Issue
Price Per
Share
​ ​
Aggregate
Liquidation
Preference
​ ​
Net Carrying
Value
​
Series A Preferred Stock
​ ​ ​ ​ 490,000,000 ​ ​ ​ ​ ​ 485,795,293 ​ ​ ​ ​ $ 0.61 ​ ​ ​ ​ $ 296,335 ​ ​ ​ ​ $ 709,261 ​ ​
Series B Preferred Stock
​ ​ ​ ​ 30,000,000 ​ ​ ​ ​ ​ 29,629,630 ​ ​ ​ ​ $ 0.54 ​ ​ ​ ​ ​ 16,000 ​ ​ ​ ​ ​ 42,963 ​ ​
Series C Preferred Stock
​ ​ ​ ​ 142,000,000 ​ ​ ​ ​ ​ 116,200,835 ​ ​ ​ ​ $ 2.76 ​ ​ ​ ​ ​ 408,715 ​ ​ ​ ​ ​ 408,715 ​ ​
Series D Preferred Stock
​ ​ ​ ​ 102,600,000 ​ ​ ​ ​ ​ 102,516,283 ​ ​ ​ ​ $ 8.10 ​ ​ ​ ​ ​ 1,060,712 ​ ​ ​ ​ ​ 1,060,712 ​ ​
Total redeemable convertible preferred stock
​ ​ ​ ​ 764,600,000 ​ ​ ​ ​ ​ 734,142,041 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 1,781,762 ​ ​ ​ ​ $ 2,221,651 ​ ​
​ ​ ​
As of December 31, 2023
​
(amounts in thousands, except share and per
share amounts)
​ ​
Shares
Authorized
​ ​
Shares Issued
and
Outstanding
​ ​
Original Issue
Price Per
Share
​ ​
Aggregate
Liquidation
Preference
​ ​
Net Carrying
Value
​
Series A Preferred Stock
​ ​ ​ ​ 490,000,000 ​ ​ ​ ​ ​ 485,795,293 ​ ​ ​ ​ $ 0.61 ​ ​ ​ ​ $ 296,335 ​ ​ ​ ​ $ 709,261 ​ ​
Series B Preferred Stock
​ ​ ​ ​ 30,000,000 ​ ​ ​ ​ ​ 29,629,630 ​ ​ ​ ​ $ 0.54 ​ ​ ​ ​ ​ 16,000 ​ ​ ​ ​ ​ 42,963 ​ ​
Series C Preferred Stock
​ ​ ​ ​ 142,000,000 ​ ​ ​ ​ ​ 116,200,835 ​ ​ ​ ​ $ 2.76 ​ ​ ​ ​ ​ 381,908 ​ ​ ​ ​ ​ 381,908 ​ ​
Series D Preferred Stock
​ ​ ​ ​ 102,600,000 ​ ​ ​ ​ ​ 102,516,283 ​ ​ ​ ​ $ 8.10 ​ ​ ​ ​ ​ 996,458 ​ ​ ​ ​ ​ 991,152 ​ ​
Total redeemable convertible preferred stock
​ ​ ​ ​ 764,600,000 ​ ​ ​ ​ ​ 734,142,041 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 1,690,701 ​ ​ ​ ​ $ 2,125,284 ​ ​
The rights, preferences, and privileges of the redeemable convertible preferred stock are as follows:
Voting Rights
On any matter presented to the shareholders of the Company for their action or consideration at any meeting of shareholders of the Company (or by written consent of shareholders in lieu of meeting), each holder of outstanding shares of preferred stock will be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining shareholders entitled to vote on such matter.
 
F-28

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
Dividends
All classes of preferred stock are entitled to receive dividends out of any assets legally available only when, as, and if declared by the Company’s board of directors, prior to and in preference to any declaration or payment of any dividend on the common stock.
Liquidation Preference
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series C and Series D preferred stock then outstanding will be entitled to be paid out of the assets of the Company available for distribution to its shareholders at an amount per share equal to the greater of (i) the Series C and Series D original issue price, plus (A) any dividends declared but unpaid thereon and (B) a 7.0% cumulative accruing dividend, compounding annually from the date of issuance of such share of Series C and Series D preferred stock, (ii) the amount that the holder of a share of Series C and Series D preferred stock would have received upon conversion to common stock, or (iii) solely with respect to the Series D preferred stock, 1.2 times the Series D original issue price. The Series A and Series B preferred stock are then paid on a pro rata, pari passu basis an amount equal to the greater of (i) the respective original issue price plus any dividends declared but unpaid thereon, and (ii) the amount that the holder of a share of Series A or Series B preferred stock, respectively, would receive upon conversion to common stock. The remaining proceeds will be distributed to the holders of common stock.
Conversion Rights
The holders of the Company’s Series A, Series B, Series C and Series D preferred stock have the right to convert their shares into a number of fully paid and nonassessable shares of common stock as determined by dividing the respective Series A, Series B, Series C and Series D preferred stock original issue price by the conversion price in effect at the time. The initial conversion price of the Series A, Series B, Series C and Series D preferred stock was $0.61, $0.54, $2.76 and $8.10, respectively, and is subject to adjustment in accordance with anti-dilution provisions provided for in the Company’s Certificate of Formation. As of December 31, 2024, each share of Series A, Series B, Series C and Series D preferred stock was convertible into one share of common stock.
Redemption Rights
At any time on or after the fifth anniversary of the Series C and Series D original issue date, which will begin for Series C in August 2025 and for Series D in May 2026, upon written notice from the applicable shareholders, the Series C and Series D shares shall be redeemed by the Company at a price per share equal to the greater of (i) the original issue price plus (a) all declared by unpaid dividends thereon and (b) a 7.0% cumulative accruing dividend, compounding annually, or (ii) the fair market value as determined by an independent appraiser.
Anti-dilution
Subject to certain exceptions, the conversion price of the Series A and Series B preferred stock is subject to broad-based weighted average adjustment to prevent dilution in the event that the Company issues additional shares at a purchase price less than the then-applicable conversion price of the Series A and Series B preferred stock, respectively. Subject to certain exceptions, in the event the Company sells additional shares of stock at a price per share less that the Series C and Series D original issue price, the conversion price of the Series C preferred stock is adjusted to the lower price that the Company sells shares in such offering, and the conversion price of the Series D preferred stock is adjusted based on a broad-based weighted average anti-dilution formula. In the event the Company sells shares in an initial public offering, for less than 110.0% of the applicable Series C and Series D conversion price, then the Series C and Series D conversion price will be reduced (but never increased), concurrently with such issuance or deemed issuance, to 90.0% of the purchase price in such initial public offering.
 
F-29

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
Note 7. Shareholders’ Equity
Common Stock
As of December 31, 2024 and 2023, 1,150,000,000 shares of common stock with a $0.001 par value were authorized. There were 143,369,083 and 141,188,960 shares outstanding at December 31, 2024 and 2023, respectively.
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s shareholders. Common shareholders are entitled to receive dividends if and when declared by the Company’s board of directors, subject to the preferential dividend rights of any preferred stock then outstanding. No dividends have been declared or paid by the Company since its inception.
Treasury Stock
During the years ended December 31, 2024 and 2023, the Company did not repurchase any shares of common stock. Previously repurchased common stock is shown on the consolidated balance sheets and consolidated statements of redeemable convertible preferred stock and shareholders’ deficit as treasury stock. The Company had 730,000 shares of treasury stock as of December 31, 2024 and 2023. These shares have not been retired. The Company has not reissued any shares of treasury stock as of December 31, 2024 and 2023.
2020 Incentive Plan
Pursuant to the 2020 Incentive Plan (the “Plan”), the Company may grant awards of options, restricted awards, performance awards or share appreciation rights to employees, consultants, and directors of the Company. A total of 99,297,441 shares of common stock are reserved for issuance upon the exercise of all awards granted or available to be granted under the Plan as of December 31, 2024.
To the extent permitted by applicable laws or any exchange rule, any shares of common stock issued under this Plan that are issued (a) in connection with the Company’s acquisition of an unaffiliated business entity, (b) to the employees of such entity, and (c) in substitution of equity incentive awards previously issued to such employees by such entity shall not reduce the number of shares of common stock available for issuance under the Plan.
The Plan provides for a repurchase feature for vested stock-based awards at the option of the Company if the employee’s continuous service terminates for any reason, with or without cause, including death or disability. The repurchase shall be exercisable at a price equal to the fair market value of vested shares or, in the case of exercisable options, the fair market value of the common stock underlying such unexercised options less the aggregate exercise price of such options. The Company’s repurchase lapses when the Company’s common stock becomes publicly traded.
Option Activity
Under the Plan, the Company has granted incentive stock options and non-qualified stock options to its employees and other service providers (non-employees). Most of the Company’s stock options vest incrementally over five years, subject to the grantee’s continuous employment with the Company (“time-vesting options”). The Company recognizes compensation cost on a straight-line basis over the requisite service period for its time-vesting options. In addition to its time-vesting options, the Company has also granted stock options to certain non-employees for which vesting is tied to the grantee’s performance (“performance-vesting options”). The Company evaluates whether it is probable that the performance metric will be achieved for its performance-vesting options and recognizes compensation cost on a straight-line basis over the implied service period if achievement of the performance metric is deemed probable. No option shall be exercisable after the expiration of 10 years from the date it was granted. The exercise price of each option shall be not less than 100.0% of the fair market value of the common stock subject to the option on the date the option is granted.
 
F-30

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
The following table summarizes the Company’s stock option activity during the year ended December 31, 2024:
​ ​ ​
Options Outstanding
​
​ ​ ​
Number of
Options
​ ​
Weighted
Average
Exercise
Price
Per Share
​ ​
Weighted
Average
Remaining
Contract
Term
(in years)
​ ​
Aggregate
Intrinsic
Value
(in thousands)
​
Total outstanding as of December 31, 2023:
​ ​ ​ ​ 87,050,440 ​ ​ ​ ​ $ 2.00 ​ ​ ​ ​ ​ 5.78 ​ ​ ​ ​ $ 167,491 ​ ​
Granted
​ ​ ​ ​ 7,928,221 ​ ​ ​ ​ ​ 4.75 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ — ​ ​
Exercised
​ ​ ​ ​ (956,123) ​ ​ ​ ​ ​ 1.60 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2,808 ​ ​
Cancelled/forfeited
​ ​ ​ ​ (2,883,080) ​ ​ ​ ​ ​ 3.47 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 3,030 ​ ​
Expired
​ ​ ​ ​ (4,056,800) ​ ​ ​ ​ ​ 0.61 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 16,316 ​ ​
Total outstanding as of December 31, 2024
​ ​ ​ ​ 87,082,658 ​ ​ ​ ​ $ 2.27 ​ ​ ​ ​ ​ 5.40 ​ ​ ​ ​ $ 226,117 ​ ​
Total exercisable as of December 31, 2024
​ ​ ​ ​ 63,236,066 ​ ​ ​ ​ $ 1.64 ​ ​ ​ ​ ​ 4.37 ​ ​ ​ ​ $ 203,971 ​ ​
Total vested or expected to vest as of December 31, 2024
​ ​ ​ ​ 85,354,436 ​ ​ ​ ​ $ 2.22 ​ ​ ​ ​ ​ 5.31 ​ ​ ​ ​ $ 225,506 ​ ​
​ ​ ​
Unvested/Vested Activity
​
​ ​ ​
Options
​ ​
Weighted
Average
Exercise
Price
​ ​
Weighted
Average
Grant Date
Fair
Value
​ ​
Average
Remaining
Life
(in years)
​
Unvested outstanding, as of December 31, 2023
​ ​ ​ ​ 30,216,142 ​ ​ ​ ​ $ 3.44 ​ ​ ​ ​ $ 1.87 ​ ​ ​ ​ ​ 3.54 ​ ​
Granted
​ ​ ​ ​ 7,928,221 ​ ​ ​ ​ ​ 4.75 ​ ​ ​ ​ ​ 3.09 ​ ​ ​ ​ ​ ​ ​ ​
Cancelled/forfeited
​ ​ ​ ​ (2,296,469) ​ ​ ​ ​ ​ 3.68 ​ ​ ​ ​ ​ 2.15 ​ ​ ​ ​ ​ ​ ​ ​
Vested, outstanding shares
​ ​ ​ ​ (9,211,302) ​ ​ ​ ​ ​ 3.04 ​ ​ ​ ​ ​ 1.47 ​ ​ ​ ​ ​ ​ ​ ​
Unvested outstanding, as of December 31, 2024
​ ​ ​ ​ 26,636,592 ​ ​ ​ ​ ​ 3.95 ​ ​ ​ ​ ​ 2.35 ​ ​ ​ ​ ​ 3.30 ​ ​
Early exercised unvested, end of period
​ ​ ​ ​ 2,648,000 ​ ​ ​ ​ $ 4.05 ​ ​ ​ ​ $ 2.60 ​ ​ ​ ​ ​ ​ ​ ​
Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options.
The weighted average grant date fair value of options granted during the years ended December 31, 2024 and 2023 was $3.09 and $2.38 per option, respectively. The total grant date fair value of options vested during the years ended December 31, 2024 and 2023 was $13.5 million and $10.4 million, respectively. The total intrinsic value of options exercised during the years ended December 31, 2024 and 2023 was $2.8 million and $6.8 million, respectively.
Cash received for exercises of stock options during the years ended December 31, 2024 and 2023 was $1.5 million and $1.9 million, respectively.
As of December 31, 2024, total unrecognized compensation cost related to unvested stock options was $49.0 million. This amount is expected to be recognized as stock-based compensation expense in the consolidated statements of operations and comprehensive loss over a weighted average period of 3.3 years.
Modification to stock options
On November 9, 2021 and February 23, 2022, the Company granted stock options to certain executives that are exercisable upon vesting for 1,325,000 shares and 8,000,000 shares of the Company’s common stock, respectively (the “Prior Stock Options”). The Prior Stock Options vested over five years. On August 11, 2022, the Company’s Compensation Committee approved a modification to the Prior Stock Options, which was communicated to holders of the Prior Stock Options on September 1, 2022. The
 
F-31

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
modification reduced the exercise price to $4.05 and modified the vesting conditions such that 20.0% vest upon grant, while the remainder vest over the following four years. The total number of grantees affected by this modification was twelve. The modification was not mandatory, but rather could be elected by holders of the Prior Stock Options on an individual holder basis. If the holder elected to participate, the holder’s Prior Stock Options were immediately canceled, and the Company issued the holder an equivalent number of new stock options in exchange (the “New Stock Options”) which could be early exercised prior to vesting. All of the holders elected to participate in the modification and exchanged their Prior Stock Options for New Stock Options. In addition, as an alternative to paying cash, holders of the New Stock Options that elected to exercise their options were able to pay for the exercise price by executing a full recourse promissory note with the Company that is secured by the holder’s restricted shares that are issued upon early exercise. Five grantees elected to early exercise utilizing the promissory note.
The principal of each note is equal to the exercise price of the New Stock Options. Interest on the unpaid balance will compound annually and accrue at a fixed rate per annum equal to the mid-term applicable federal rate in effect on the issuance of the note. The maturity date of the notes is the earlier of (1) December 31, 2030 or (2) the occurrence of a change in control event, unless an acceleration event occurs sooner. An acceleration event would generally occur if required to ensure compliance with Section 402 of the Sarbanes-Oxley Act of 2022, the termination of the holder’s employment, the insolvency of the holder or the breach of any warranty of the holder. The holder may elect to prepay the outstanding principal and accrued interest balance of the promissory note at any time without penalty.
In addition to the outstanding balance of the note becoming due and payable immediately, upon the occurrence of an acceleration event, if the holder defaults on payment of the note, then interest will accrue at the maximum rate permitted by applicable law. The Company will have full recourse against the holder for failure to pay the note as and when due. Such promissory notes will be secured by the restricted shares issued to the holder that are underlying the note. If the note is not repaid upon an event of default or acceleration event, the Company has the right to repurchase the restricted shares issued upon the exercise of the note for fair market value, which proceeds will apply to repayment of the note (with any remaining balance remaining due).
The Company accounted for the modification as a Type I (Probable to Probable) modification under ASC 718 that does not change the classification of the award (i.e., the New Stock Options continue to be classified within equity). The Company calculated the fair value of the Prior Stock Options and New Stock Options immediately prior to and after the modification using the Black-Scholes option pricing model. The incremental fair value was added to the original unrecognized compensation cost to arrive at the new unrecognized compensation cost, to be recognized over the remaining requisite service period.
Unvested stock received from early exercises of the New Stock Options are subject to a right of repurchase at the lesser of (i) original issuance price or (ii) then-current fair market value in the event of the employee’s termination, either voluntary, or involuntary. The Company’s repurchase right with respect to these shares typically lapse over four years as the shares become vested. Early exercises of stock options are not deemed to be substantive exercises for accounting purposes and accordingly, consideration received for exercises of unvested stock options is initially recorded as a liability and subsequently reclassified into shareholders’ deficit as the related shares vest. As of December 31, 2024 and 2023, 2,648,000 and 3,872,000 shares from options exercised to date were subject to repurchase at a price of $4.05 per share. Of the amount subject to repurchase for the year ended December 31, 2024 and 2023, $5.0 million was recorded within other accrued expenses and current liabilities, respectively, and $5.8 million and $10.7 million was recorded within other long-term liabilities on the consolidated balance sheets, respectively. In addition, as the early exercise was performed via issuance of a promissory note, a corresponding debt amount, plus related interest income was recorded as contra-equity. The total amount presented as contra-equity as of December 31, 2024 and 2023 was $26.5 million and $25.7 million, respectively, which includes interest income and the impact from exercises of both the vested portion of the New Stock Options and early exercises.
 
F-32

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
Restricted Awards Activity
During the year ended December 31, 2024, the Company granted to certain of its employees restricted stock units that will be settled in shares of the Company’s common stock upon vesting.
Vesting of the restricted stock units is contingent upon the Company completing either an initial public offering of its common stock or a change of control. The Company has determined that these performance conditions are not probable of being achieved, and thus has not recognized any compensation expense associated with its restricted stock units.
The following table summarizes the Company’s restricted stock unit activity during the year ended December 31, 2024:
​ ​ ​
Number of
Restricted Stock
Units
​ ​
Weighted
Average Grant
Date Fair Value
​
Unvested as of December 31, 2023
​ ​ ​ ​ 720,500 ​ ​ ​ ​ $ 3.51 ​ ​
Granted
​ ​ ​ ​ 2,362,000 ​ ​ ​ ​ $ 4.86 ​ ​
Vested
​ ​ ​ ​ — ​ ​ ​ ​ $ — ​ ​
Cancelled/forfeited
​ ​ ​ ​ (32,500) ​ ​ ​ ​ $ 4.78 ​ ​
Unvested as of December 31, 2024
​ ​ ​ ​ 3,050,000 ​ ​ ​ ​ $ 4.55 ​ ​
The total unrecognized compensation expense related to unvested restricted stock units as of December 31, 2024 was $13.9 million, which will be recognized upon the occurrence of an initial public offering or a change of control.
Stock-Based Compensation Expense
The Company recorded stock-based compensation expense in the consolidated statements of operations and comprehensive loss as follows:
​ ​ ​
Years Ended December 31,
​
​ ​ ​
2024
​ ​
2023
​
​ ​ ​
(amounts in thousands)
​
Cost of services–Molecular profiling services
​ ​ ​ $ 1,669 ​ ​ ​ ​ $ 1,504 ​ ​
Cost of services–Pharma research and development services
​ ​ ​ ​ 11 ​ ​ ​ ​ ​ 10 ​ ​
Selling and marketing expense
​ ​ ​ ​ 4,301 ​ ​ ​ ​ ​ 3,400 ​ ​
General and administrative expense
​ ​ ​ ​ 8,448 ​ ​ ​ ​ ​ 6,983 ​ ​
Research and development expense
​ ​ ​ ​ 4,214 ​ ​ ​ ​ ​ 3,344 ​ ​
Total
​ ​ ​ $ 18,643 ​ ​ ​ ​ $ 15,240 ​ ​
There was no tax benefit associated with the above stock-based compensation expense.
Valuation of Stock-Based Awards to Employees
The Company records stock-based compensation expense for stock-based awards based on the estimated fair value of the awards on the date of the grant. The fair value of the Company’s restricted stock units is based on the fair value of the Company’s common stock at the date of grant.
The Company estimates the fair value of stock options using a Black-Scholes option pricing model. The absence of a public market for the Company’s common stock requires the Company’s board of directors to estimate the fair value of its common stock for purposes of granting options and for determining stock-based compensation expense by considering several objective and subjective factors, including contemporaneous third-party valuations, actual and forecasted operating and financial results, market
 
F-33

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
conditions and performance of comparable publicly traded companies, developments and milestones in the Company, the rights and preferences of common and convertible preferred stock, transactions involving the Company’s common stock, and assumptions for a discount for lack of marketability. The fair value of the Company’s common stock was determined in accordance with the applicable elements of the American Institute of Certified Public Accountants Accounting and Valuations Guide, Valuation of Privately Held Company Equity Securities Issued as Compensation.
The key assumptions used in determining the fair value of options granted and a summary of the methodology applied to develop each assumption are as follows:
​ ​ ​
Years Ended December 31,
​
​ ​ ​
2024
​ ​
2023
​
Expected volatility
​ ​
62.5%–68.4%
​ ​
64.3%–77.2%
​
Risk-free interest rate
​ ​
3.7%–4.6%
​ ​
3.5%–4.4%
​
Expected term (years)
​ ​
5.97–6.60
​ ​
5.90–7.50
​
Expected dividend rate
​ ​
—%
​ ​
—%
​
Expected forfeiture rate
​ ​
8.3%–8.5%
​ ​
8.4%–8.6%
​
Expected volatility.   This is a measure of the amount by which the share price has fluctuated or is expected to fluctuate. An increase in the expected price volatility will increase the fair value of the option granted and the related compensation expense. As the Company is not publicly traded, the expected price volatility for the Company’s options was determined by using an average of historical volatilities of selected industry peers deemed to be comparable to the business corresponding to the expected term of the awards.
Risk-free interest rate.   The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for U.S. Treasury notes with maturities corresponding to the expected term of the awards.
Expected term.   This is the period of time over which the options granted are expected to remain outstanding and is based on the Company’s estimate, taking into consideration vesting term, contractual term and historical actual lives. Options granted have a maximum term of ten years. An increase in the expected life will increase the fair value of the option granted and the related compensation expense. Due to the lack of historical share option exercise data, the Company utilizes the simplified method for determining the expected term.
Dividend rate.   The Company has not made any dividend payments, nor does it have plans to pay dividends in the foreseeable future. Therefore, an expected dividend yield of zero is utilized.
Forfeitures.   Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate.
 
F-34

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
Note 8. Long-Term Debt
The carrying value of debt presented within current portion of notes payable and long-term indebtedness, net of debt discounts on the consolidated balance sheets as of December 31, 2024 and 2023 includes the following components:
​ ​ ​
As of December 31,
​ ​
​ ​ ​
2024
​ ​ ​ ​ ​
2023
​ ​
​ ​ ​
(amounts in thousands)
​ ​
Term loan Initial Draw–January 18, 2023
​ ​ ​ $ 200,000 ​ ​ ​ ​ ​ ​ ​ $ 200,000 ​ ​ ​
Exit fee on term loan–January 18, 2023
​ ​ ​ ​ 2,000 ​ ​ ​ ​ ​ ​ ​ ​ 2,000 ​ ​ ​
Term loan Subsequent Draw–March 5, 2024
​ ​ ​ ​ 200,000 ​ ​ ​ ​ ​ ​ ​ ​ — ​ ​ ​
Exit fee on term loan–March 5, 2024
​ ​ ​ ​ 2,000 ​ ​ ​ ​ ​ ​ ​ ​ — ​ ​ ​
Less: Amortized debt discounts and financing costs(1)
​ ​ ​ ​ (30,863) ​ ​ ​ ​ ​ ​ ​ ​ (35,893) ​ ​ ​
Net debt
​ ​ ​
$
373,137
​ ​ ​ ​ ​ ​ ​
$
166,107
​ ​ ​
Compound bifurcated derivative liability
​ ​ ​ $ 6,058 ​ ​ ​ ​ ​ ​ ​ $ 17,451 ​ ​ ​ ​ ​
​
(1)
Includes debt discounts of $28.3 million associated with the initial carrying value of compound bifurcated derivative liability.
​
Maturities of the Company’s debt are expected to be as follows as of December 31, 2024:
​ ​ ​
Amount
​
Years Ending December 31, ​ ​ ​ ​ ​ ​ ​
2025(1) ​ ​ ​ $ 60,000 ​ ​
2026
​ ​ ​ ​ — ​ ​
2027
​ ​ ​ ​ — ​ ​
2028
​ ​ ​ ​ 340,000 ​ ​
2029
​ ​ ​ ​ — ​ ​
​
(1)
Represents 15% of the outstanding principal amount under the 2023 Term Loan Agreement, which is due on the earlier of (x) for dates prior to January 1, 2026, any date that the redemption rights in respect of our Series C preferred stock or Series D preferred stock are or may become exercisable within 90 days following such date, or (y) January 1, 2026 or the first date thereafter if, as of such date, the redemption rights in respect of our Series C preferred stock or Series D preferred stock are or may become exercisable on or prior to the date that is six months after the maturity date. The Series C preferred stock redemption rights may be exercised on or after August 14, 2025. All outstanding shares of our Series C preferred stock and Series D preferred stock will convert into shares of common stock as part of the Preferred Stock Conversion and any redemption rights thereunder will terminate in connection with the completion of this offering and consequently, the payments disclosed herein would not be applicable.
​
Term Loan Refinancing
On September 21, 2018, the Company entered into a secured term loan agreement (the “Original Term Loan Agreement”) with Sixth Street Specialty Lending, Inc. and Barnett Debt Holdings, LLC (collectively, the “Original Term Loan Lenders”), which provided the Company with an initial term loan of $50.0 million (the “2018 Term Loan”) and a delayed term loan draw option of $50.0 million, which the Company drew down in full on October 4, 2019 (the “2019 Term Loan”). On April 2, 2020, the Company amended the Original Term Loan Agreement (the “Amended Term Loan Agreement”) to obtain additional
 
F-35

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
term loan proceeds of $75.0 million (the “2020 Term Loan” and collectively with the 2018 Term Loan and the 2019 Term Loan, the “Original Term Loans”).
On January 18, 2023, the Company entered into the New Term Loan Agreement with OrbiMed Royalty & Credit Opportunities III, LP, OrbiMed Royalty & Credit Opportunities IV, LP (collectively, “OrbiMed”), and Braidwell Transaction Holdings LLC (“Braidwell”, and collectively with OrbiMed, the “New Term Loan Lenders”). Pursuant to the New Term Loan Agreement, the Company issued senior, secured promissory notes by which the New Term Loan Lenders agree to lend the Company up to an aggregate principal amount of $400.0 million, $200.0 million of which was received by the Company upon issuance (the “Initial Draw”), and the remaining $200.0 million was received by the Company in March 2024 (the “Delayed Draw”). Net cash proceeds from the 2023 Term Loan were $200.0 million and $187.0 million after deducting customary debt discounts and debt issuance costs for the years ended December 31, 2024 and 2023, respectively. The net cash proceeds in 2023 from the 2023 Term Loan were used to repay in full the Original Term Loans (with an aggregate principal amount of $175.0 million), including a prepayment premium of $5.0 million and accrued and unpaid interest of $1.0 million. A loss on debt extinguishment of $10.9 million, reflecting the difference between the cash paid to settle the Original Term Loans and the net carrying amounts of the Original Term Loans, was recognized in other expense, net on the consolidated statements of operations and comprehensive loss for the year ended December 31, 2023. As of December 31, 2023 and onwards, the Company has no continuing obligations associated with the Original Term Loans.
Until the earlier of December 31, 2024 or the date on which the 2024 Term Loan amount was fully drawn, which occurred on March 5, 2024, the undrawn balance of the New Term Loan Commitment was subject to a fee of 0.5% per annum. The outstanding principal amount of the 2023 Term Loan is due and payable on January 18, 2028. If an event of default occurs and is continuing, the New Term Loan Lenders may declare all amounts outstanding under the New Term Loan Agreement to be immediately due and payable. A final payment exit fee equal to 1.0% of the amount funded under the New Term Loan Agreement is due upon prepayment or maturity. Amounts borrowed pursuant to the New Term Loan Agreement may be prepaid at any time. Upon prepayment, the Company is subject to a prepayment penalty based on the timing of repayment.
The 2023 Term Loan bears interest at a rate per annum equal to a fixed margin of 6.5% plus the greater of (a) forward-looking three-month secured overnight financing rate (“SOFR”) and (b) 2.5%. In the event of default, the fixed margin shall increase by 3.0% per annum. As of December 31, 2024, the interest rate was 11.1%. Regular quarterly payments are interest-only for the 60-month term of the New Term Loan Agreement, with the principal due at maturity. The effective interest rate for the Initial Draw of the 2023 Term Loan is 17.0%, and the effective interest rate for the Delayed Draw of the 2023 Term Loan is 12.0%.
The Company’s obligations under the New Term Loan Agreement are secured by a first lien security interest in substantially all of the assets of the Company and its subsidiaries. The New Term Loan Agreement contains certain customary representations and warranties, affirmative and negative covenants, financial covenants, and events of default applicable to the Company and its subsidiaries. Additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt. At December 31, 2024, the Company is in compliance with all covenants.
The Company identified multiple embedded derivatives that require bifurcation from the 2023 Term Loan. They are separately accounted for in the consolidated financial statements as one compound derivative liability. Those embedded features include various contingent prepayment and compensatory payment features as well as interest rate increases upon an event of default.
Convertible Loan Conversion
In connection with the Original Term Loan Agreement dated September 21, 2018, the Company issued $50.0 million of convertible notes to the Original Term Loan Lenders pursuant to a convertible loan agreement (the “Convertible Loan Agreement”) with interest accruing at a rate of 8.0% per annum (the “2018 Convertible Loan”). The Original Term Loan Lenders had the option on each interest payment date
 
F-36

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
to receive interest in cash or in kind in the form of additional term loan principal issued pursuant to the terms of the Convertible Loan Agreement. As of December 31, 2022, the effective interest rate on the 2018 Convertible Loan was 9.4%. Following the amendment to the Convertible Loan Agreement in 2020, the Original Term Loan Lenders obtained the right to convert all or a portion of the principal amount of the 2018 Convertible Loan and any accrued but unpaid interest thereon (the “Convertible Amount”) into either Series C preferred stock or common stock at a conversion price of $1.61 per share (subject to certain anti-dilution adjustments). However, the maximum aggregate Convertible Amount that the Original Term Loan Lenders may convert without the Company’s consent is $50.0 million.
On September 20, 2023, the Original Term Loan Lenders exercised the conversion right and converted the maximum $50.0 million Convertible Amount into 31,055,901 shares of Series C preferred stock. In connection with the conversion of the 2018 Convertible Loan, the Company also paid cash of $3.0 million to the Original Term Loan Lenders in settlement of accrued but unpaid interest on the Convertible Loan.
Interest Expense
The components of interest expense associated with the Company’s long-term indebtedness, excluding finance leases, are as follows:
​ ​ ​
Years Ended December 31,
​
​ ​ ​
2024
​ ​
2023
​
​ ​ ​
(amounts in thousands)
​
Debt discount amortization
​ ​ ​ $ 7,052 ​ ​ ​ ​ $ 5,378 ​ ​
Interest expense
​ ​ ​ ​ 42,938 ​ ​ ​ ​ ​ 26,157 ​ ​
Interest expense on long-term indebtedness, excluding finance leases
​ ​ ​ $ 49,990 ​ ​ ​ ​ ​ 31,535 ​ ​
Warrant Liability
As part of the Original Term Loan Agreement, the Company issued 13,694,623 warrants with an exercise price of $1.61 (the “2018 Warrants”). In connection with the amendment to the Original Term Loan Agreement in 2020, the Company issued an additional 11,399,814 warrants with an exercise price of $1.93 (the “2020 Warrants”) and amended the 2018 Warrants. Furthermore, these amendments also permit the exercise of both the 2018 Warrants and 2020 Warrants into Series C preferred stock or common stock at the option of the holder. As a result of the amendment to permit exercise of the warrants into redeemable preferred stock, the warrants are classified as a liability pursuant to the guidance in ASC 480. Therefore, the warrants are reported at fair value within warrant and derivative liabilities on the consolidated balance sheets, with changes in fair value reported within changes in fair value of financial instruments on the consolidated statements of operations and comprehensive loss.
The following table reflects the changes in fair values associated with these warrants.
​ ​ ​
2018 Warrants
​ ​
2020 Warrants
​
Warrants granted
​ ​
13,694,623
​ ​
11,399,814
​
Exercise price
​ ​
$1.61
​ ​
$1.93
​
Exercise period
​ ​
Earlier of 7 years from the date of issuance,
or immediately after closing IPO
​
Fair value at date of issuance
​ ​
$0.8 million
​ ​
$7.9 million
​
 
F-37

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
​ ​ ​
(amounts in thousands)
​ ​ ​ ​
Fair value at December 31, 2022
​ ​ ​ $ 54,498 ​ ​ ​ ​ $ 44,498 ​ ​ ​
Increase / (decrease) in fair value
​ ​ ​ ​ 42 ​ ​ ​ ​ ​ (305) ​ ​ ​
Fair value at December 31, 2023
​ ​ ​ $ 54,540 ​ ​ ​ ​ $ 44,193 ​ ​ ​
Decrease in fair value
​ ​ ​ ​ (2,911) ​ ​ ​ ​ ​ (4,180) ​ ​ ​
Fair value at December 31, 2024
​ ​ ​ $ 51,629 ​ ​ ​ ​ $ 40,013 ​ ​ ​
Note 9. Leases
The Company enters into various building leases for office, lab and other uses. Additionally, certain of the Company’s arrangements to utilize data centers represent a lease. These leases are generally considered operating leases. The Company is obligated to make total fixed payments over the lease terms. Some of these arrangements include options to extend the leases. The Company determined that given the length of time between lease commencement and the renewal period, and the uncertainty of business and market conditions in the future, it is not reasonably certain that the renewal options will be exercised.
The Company has also entered into various information technology equipment leases. Certain of these leases are classified as operating leases and others are classified as finance leases, based on the terms of each lease arrangement.
Lease assets and liabilities are reflected in the Company’s consolidated balance sheets as follows:
​ ​ ​ ​ ​ ​
As of December 31,
​
Leases
​ ​
Consolidated balance sheet line item
​ ​
2024
​ ​
2023
​
​ ​ ​ ​ ​ ​
(amounts in thousands)
​
Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating leases
​ ​ Other assets ​ ​ ​ $ 34,950 ​ ​ ​ ​ $ 40,426 ​ ​
Finance leases
​ ​ Property and equipment, net ​ ​ ​ ​ 40 ​ ​ ​ ​ ​ 123 ​ ​
Total lease assets
​ ​ ​ ​ ​ ​ $ 34,990 ​ ​ ​ ​ $ 40,549 ​ ​
Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Current ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating leases
​ ​
Accrued expenses and other current liabilities
​ ​ ​ $ 6,080 ​ ​ ​ ​ $ 6,420 ​ ​
Finance leases
​ ​ Current portion of notes payable ​ ​ ​ ​ 90 ​ ​ ​ ​ ​ 167 ​ ​
Total current lease liabilities
​ ​ ​ ​ ​ ​ $ 6,170 ​ ​ ​ ​ $ 6,587 ​ ​
Non-current ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating leases
​ ​ Other long-term liabilities ​ ​ ​ $ 38,651 ​ ​ ​ ​ $ 44,099 ​ ​
Finance leases
​ ​
Long-term indebtedness, net of debt discounts
​ ​ ​ ​ 243 ​ ​ ​ ​ ​ 315 ​ ​
Total non-current lease liabilities
​ ​ ​ ​ ​ ​ ​ 38,894 ​ ​ ​ ​ ​ 44,414 ​ ​
Total lease liabilities
​ ​ ​ ​ ​ ​ $ 45,064 ​ ​ ​ ​ $ 51,001 ​ ​
 
F-38

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
Total lease cost reflected in the consolidated statements of operations and other comprehensive loss were as follows:
​ ​ ​
Consolidated statement of operations
and comprehensive loss line item
​ ​
As of December 31,
​
Lease cost
​ ​
2024
​ ​
2023
​
​ ​ ​ ​ ​ ​
(amounts in thousands)
​
Operating lease cost
​ ​
Cost of services–Molecular profiling services
​ ​ ​ $ 1,607 ​ ​ ​ ​ $ 1,935 ​ ​
Operating lease cost
​ ​
Cost of services–Pharma research and
development services
​ ​ ​ ​ 40 ​ ​ ​ ​ ​ 13 ​ ​
Operating lease cost
​ ​ General and administrative expense ​ ​ ​ ​ 6,738 ​ ​ ​ ​ ​ 8,037 ​ ​
Operating lease cost
​ ​ Research and development expense ​ ​ ​ ​ 2,416 ​ ​ ​ ​ ​ 2,116 ​ ​
Finance lease cost: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Amortization of ROU assets
​ ​ General and administrative expense ​ ​ ​ ​ 128 ​ ​ ​ ​ ​ 500 ​ ​
Interest on lease liabilities
​ ​ Interest expense ​ ​ ​ ​ 37 ​ ​ ​ ​ ​ 78 ​ ​
Total finance lease cost
​ ​ ​ ​ ​ ​ ​ 165.22463 ​ ​ ​ ​ ​ 578 ​ ​
The table below presents additional information related to the Company’s leases.
​ ​ ​
As of
December 31,
​
​ ​ ​
2024
​ ​
2023
​
Weighted average remaining lease terms ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating leases
​ ​
8.04 years
​ ​
8.43 years
​
Finance leases
​ ​
3.28 years
​ ​
3.49 years
​
Weighted average discount rate ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating leases
​ ​ ​ ​ 11.3% ​ ​ ​ ​ ​ 11.3% ​ ​
Finance leases
​ ​ ​ ​ 10.0% ​ ​ ​ ​ ​ 10.1% ​ ​
The Company was not party to any short-term leases, and variable lease costs were immaterial for the years ended December 31, 2024 and 2023. As of December 31, 2024 and 2023, the Company does not have any additional operating and finance leases that have not yet commenced.
The following table sets forth by year, maturities of operating and finance lease liabilities as of December 31, 2024:
(amounts in thousands)
​ ​
Operating
Leases
​ ​
Finance
Leases
​ ​
Total
​
Years Ending December 31, ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
2025
​ ​ ​ $ 10,718 ​ ​ ​ ​ $ 117 ​ ​ ​ ​ $ 10,835 ​ ​
2026
​ ​ ​ ​ 10,071 ​ ​ ​ ​ ​ 118 ​ ​ ​ ​ ​ 10,189 ​ ​
2027
​ ​ ​ ​ 7,082 ​ ​ ​ ​ ​ 117 ​ ​ ​ ​ ​ 7,199 ​ ​
2028
​ ​ ​ ​ 6,461 ​ ​ ​ ​ ​ 35 ​ ​ ​ ​ ​ 6,496 ​ ​
2029
​ ​ ​ ​ 6,309 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 6,309 ​ ​
Thereafter
​ ​ ​ ​ 28,671 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 28,671 ​ ​
Total lease payments
​ ​ ​ ​ 69,312 ​ ​ ​ ​ ​ 388 ​ ​ ​ ​ ​ 69,699 ​ ​
Less imputed interest
​ ​ ​ ​ (24,581) ​ ​ ​ ​ ​ (55) ​ ​ ​ ​ ​ (24,635) ​ ​
Present value of lease liabilities
​ ​ ​ $ 44,731 ​ ​ ​ ​ $ 333 ​ ​ ​ ​ $ 45,064 ​ ​
 
F-39

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
Note 10. Commitments and Contingencies
Purchase Obligations
The Company enters into various supply agreements that contains purchase commitments. Most of the commitments are based on a binding forecast for an agreed-upon period, which is 12-month or less. Future minimum purchase commitments under such agreements amount to $7.7 million, of which all are due in 2025. The total amount of supplies purchased during 2024 under such agreements was $32.3 million.
Additionally, in 2022, the Company entered into an arrangement for cloud computing services with non-cancellable purchase commitments for three years. The agreement was subsequently amended in 2024. For the years ended December 31, 2024 and 2023, the Company purchased cloud computing services of $9.9 million and $3.0 million, respectively, related to non-cancelable arrangements. Under the agreement, the Company has purchase obligations of $11.3 million, $12.4 million and $13.7 million for years ending December 31, 2025, 2026 and 2027.
Corporate Liability and Insurance
The Company maintains professional liability, general liability, and other customary insurance on a claims-made basis in amounts deemed appropriate by the Company’s management based upon historical claims and the nature and risks of the Company. The Company’s business may subject the Company to litigation and liability for damages. The Company believes that current insurance protection is adequate for present business operations, but there can be no assurance that the Company will be able to maintain professional and general liability insurance coverage in the future or that such insurance coverage will be available on acceptable terms or adequate to cover any or all potential product or professional liability claims. A successful liability claim in excess of insurance coverage could have a material adverse effect on the Company.
Litigation
During the ordinary course of business, the Company has become and may in the future become subject to pending and threatened legal and regulatory actions and proceedings. While it is not feasible to predict or determine the ultimate outcome of these matters, the Company believes that none of its current legal proceedings will have a material adverse effect on its financial position, results of operations, or cash flows for years ended December 31, 2024 and 2023.
Note 11. Related Parties
The Company’s officers and directors have ownership interests in certain vendors providing services to the Company. During the years ended December 31, 2024 and 2023, the Company made payments to these entities for services and expenses for $1.8 million and $2.1 million, respectively.
Note 12. Net Loss Per Share Attributable to Common shareholders
The following table sets forth the computation of the basic and diluted net loss per share attributable to common shareholders:
​ ​ ​
Years Ended December 31,
​
(amounts in thousands, except per share data)
​ ​
2024
​ ​
2023
​
Net loss
​ ​ ​ $ (281,890) ​ ​ ​ ​ $ (341,415) ​ ​
Adjustments of redeemable convertible preferred stock to redemption value
​ ​ ​ ​ (96,367) ​ ​ ​ ​ ​ (121,112) ​ ​
Net loss attributable to common shareholders
​ ​ ​ $ (378,257) ​ ​ ​ ​ $ (462,527) ​ ​
Net loss per share attributable to common shareholders, basic and diluted
​ ​ ​ $ (2.66) ​ ​ ​ ​ $ (3.31) ​ ​
Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted
​ ​ ​ ​ 141,987 ​ ​ ​ ​ ​ 139,771 ​ ​
 
F-40

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
The following common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common shareholders for the periods presented as they had an anti-dilutive effect:
​ ​ ​
Years Ended December 31,
​
​ ​ ​
2024
​ ​
2023
​
Series A preferred stock
​ ​ ​ ​ 485,795,293 ​ ​ ​ ​ ​ 485,795,293 ​ ​
Series B preferred stock
​ ​ ​ ​ 29,629,630 ​ ​ ​ ​ ​ 29,629,630 ​ ​
Series C preferred stock
​ ​ ​ ​ 116,200,835 ​ ​ ​ ​ ​ 116,200,835 ​ ​
Series D preferred stock
​ ​ ​ ​ 102,516,283 ​ ​ ​ ​ ​ 102,516,283 ​ ​
Outstanding warrants
​ ​ ​ ​ 25,094,437 ​ ​ ​ ​ ​ 25,094,437 ​ ​
Outstanding stock options
​ ​ ​ ​ 87,082,658 ​ ​ ​ ​ ​ 87,050,440 ​ ​
Unvested shares subject to repurchase
​ ​ ​ ​ 2,648,000 ​ ​ ​ ​ ​ 3,872,000 ​ ​
Total
​ ​ ​ ​ 848,967,136 ​ ​ ​ ​ ​ 850,158,918 ​ ​
Note 13. Segment and Geographic Information
The Company operates as a single operating segment. An operating segment is defined as a component of an entity for which discrete financial information is available and regularly reviewed by the entity’s chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM, its Chairman and Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance.
Net loss as reported on the consolidated statements of operations and comprehensive loss is used by the CODM to assess segment performance against management budgets and prior period operating results for the purpose of making results-driven decisions about organizational resource allocation.
Segment revenues are derived from molecular profiling, strategic data, and research services that are delivered to the Company’s biopharmaceutical and clinical customers, who are predominantly located in the United States. The Company provides these services primarily by leveraging the Company’s proprietary technologies and clinico-genomic database, which are core to the Company’s operations and are deployed similarly across the service offerings.
The table below is a summary of the segment profit or loss, including significant segment expenses:
​ ​ ​
Years Ended December 31,
​
​ ​ ​
2024
​ ​
2023
​
​ ​ ​
(amounts in thousands)
​
Revenue
​ ​ ​ $ 412,260 ​ ​ ​ ​ $ 306,128 ​ ​
Less: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Cost of services−Molecular profiling services
​ ​ ​ ​ 223,075 ​ ​ ​ ​ ​ 207,509 ​ ​
Cost of services−Pharma research and development services
​ ​ ​ ​ 10,403 ​ ​ ​ ​ ​ 9,309 ​ ​
Selling and marketing expense
​ ​ ​ ​ 152,602 ​ ​ ​ ​ ​ 142,925 ​ ​
General and administrative expense
​ ​ ​ ​ 169,386 ​ ​ ​ ​ ​ 149,053 ​ ​
Research and development expense
​ ​ ​ ​ 113,916 ​ ​ ​ ​ ​ 116,883 ​ ​
Interest income
​ ​ ​ ​ 7,122 ​ ​ ​ ​ ​ 11,258 ​ ​
Interest expense
​ ​ ​ ​ (50,025) ​ ​ ​ ​ ​ (31,610) ​ ​
Changes in fair value of financial instruments
​ ​ ​ ​ 18,484 ​ ​ ​ ​ ​ 11,094 ​ ​
Other expense, net
​ ​ ​ ​ (349) ​ ​ ​ ​ ​ (12,606) ​ ​
Segment and consolidated net loss
​ ​ ​ $ (281,890) ​ ​ ​ ​ $ (341,415) ​ ​
 
F-41

TABLE OF CONTENTS
 
Notes to Consolidated Financial Statements (Continued)
The following table sets forth the Company’s revenue by geographic areas based on the customer’s location:
​ ​ ​
Years Ended December 31,
​
​ ​ ​
2024
​ ​
2023
​
​ ​ ​
(amounts in thousands)
​
United States
​ ​ ​ $ 401,836 ​ ​ ​ ​ $ 293,408 ​ ​
International
​ ​ ​ ​ 10,424 ​ ​ ​ ​ ​ 12,720 ​ ​
Total revenue
​ ​ ​ $ 412,260 ​ ​ ​ ​ $ 306,128 ​ ​
No single country outside of the United States accounted for more than 10.0% of total revenue during each of the years ended December 31, 2024 and 2023. As of December 31, 2024 and 2023, approximately 99.0% of the Company’s total assets are located in the United States.
Note 14. Employee Benefit Plan
The Company sponsors a 401(k) plan, and pursuant to its terms, eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory maximum or 100.0% of eligible compensation on a pre-tax basis. For the years ended December 31, 2024 and 2023, the Company contributed $8.0 million and $6.8 million, respectively, to match employee contributions as permitted by the plan. The Company pays the administrative costs for the plan.
Note 15. Subsequent Events
On March 3, 2025, five grantees of the New Stock Options (see Note 7), who had previously elected to early exercise utilizing the promissory note, signed agreements to repay their notes, plus accrued interest in the form of shares of our common stock. The number of shares of common stock used in the payoff was determined using the fair value of the Company's common stock at the time of the repayment.
On March 25, 2025, in connection with the financing described above, the Company amended the terms of its certificate of formation to provide that the Series C redemption rights would not be exercisable until March 31, 2026 (from August 2025) and increased the original issue price and conversion price of its Series C convertible preferred stock used to calculate the conversion ratio of Series C preferred stock into common stock in connection with the initial public offering from $2.76 to $4.58 per share.
On April 1, 2025, the Company closed a private financing in which it issued a combination of senior convertible notes (the “2025 Convertible Notes”), Series E convertible preferred stock and Series F convertible preferred stock, for an aggregate of $167.7 million. The 2025 Convertible Notes have an aggregate principal amount of $30.0 million. The 2025 Convertible Notes accrue interest at a rate of 8% per annum, payable quarterly in cash, and mature on January 1, 2026. The Company issued 12,345,674 shares of Series E convertible preferred stock with a purchase price of $8.10 per share, for aggregate proceeds of $100.0 million. The Company also issued 4,657,401 shares of Series F convertible preferred stock with a purchase price of $8.10 per share, for aggregate proceeds of $37.7 million. In connection with this financing, the Company also issued warrants to acquire shares of common stock to the holders of the 2025 Convertible Notes. These warrants are not initially exercisable for any shares of common stock, but such warrants become exercisable for a specified dollar value of shares on a monthly basis commencing on June 1, 2025 if we have not completed an initial public offering by such date. Any exercisable portion of the warrants will be automatically exercised prior to the closing of the initial public offering and such warrants will terminate upon the closing of the offering.
Immediately prior to and in connection with the completion of the initial public offering, the 2025 Convertible Notes, Series E convertible preferred stock and Series F convertible preferred stock (plus an 8% accretion in connection with the preferred stocks) will convert into common stock at a price equal to 70% of the initial public offering price per share.
There were no other significant subsequent events identified through the date that the consolidated financial statements were issued, that could impact the financial statements.
 
F-42

TABLE OF CONTENTS​
 
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
​ ​ ​
As of March 31,
​ ​
As of December 31,
​
(amounts in thousands, except share data)
​ ​
2025
​ ​
2024
​
Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Cash, cash equivalents, and restricted cash
​ ​ ​ $ 32,704 ​ ​ ​ ​ $ 65,442 ​ ​
Short-term marketable securities
​ ​ ​ ​ 2,225 ​ ​ ​ ​ ​ 2,201 ​ ​
Accounts receivable
​ ​ ​ ​ 80,174 ​ ​ ​ ​ ​ 88,244 ​ ​
Supplies
​ ​ ​ ​ 36,552 ​ ​ ​ ​ ​ 39,572 ​ ​
Prepaid expenses and other current assets
​ ​ ​ ​ 19,578 ​ ​ ​ ​ ​ 20,270 ​ ​
Total current assets
​ ​ ​ ​ 171,233 ​ ​ ​ ​ ​ 215,729 ​ ​
Property and equipment, net
​ ​ ​ ​ 61,651 ​ ​ ​ ​ ​ 67,817 ​ ​
Goodwill
​ ​ ​ ​ 19,344 ​ ​ ​ ​ ​ 19,344 ​ ​
Other assets
​ ​ ​ ​ 39,355 ​ ​ ​ ​ ​ 40,844 ​ ​
Total assets
​ ​ ​ $ 291,583 ​ ​ ​ ​ $ 343,734 ​ ​
Liabilities, Redeemable Convertible Preferred Stock, and Shareholders’ Deficit ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Current liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Accounts payable
​ ​ ​ $ 24,226 ​ ​ ​ ​ $ 27,791 ​ ​
Accrued expenses and other current liabilities
​ ​ ​ ​ 78,235 ​ ​ ​ ​ ​ 77,542 ​ ​
Current portion of indebtedness
​ ​ ​ ​ 60,093 ​ ​ ​ ​ ​ 60,090 ​ ​
Total current liabilities
​ ​ ​ ​ 162,554 ​ ​ ​ ​ ​ 165,423 ​ ​
Long-term indebtedness, net of debt discounts
​ ​ ​ ​ 316,643 ​ ​ ​ ​ ​ 319,438 ​ ​
Warrant liabilities
​ ​ ​ ​ 128,691 ​ ​ ​ ​ ​ 91,642 ​ ​
Other long-term liabilities
​ ​ ​ ​ 37,447 ​ ​ ​ ​ ​ 44,418 ​ ​
Total liabilities
​ ​ ​ ​ 645,335 ​ ​ ​ ​ ​ 620,921 ​ ​
Commitments and contingencies (see note 9) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Redeemable convertible preferred stock: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Series A preferred stock, par value $0.001: 490,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 485,795,293 shares issued and outstanding as of March 31, 2025 and December 31, 2024; and $296,335 aggregate liquidation preference as of March 31, 2025 and December 31, 2024
​ ​ ​ ​ 709,261 ​ ​ ​ ​ ​ 709,261 ​ ​
Series B preferred stock, par value $0.001: 30,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 29,629,630 shares issued and outstanding as of March 31, 2025 and December 31, 2024; and $16,000 aggregate liquidation preference as of March 31, 2025 and December 31, 2024
​ ​ ​ ​ 42,963 ​ ​ ​ ​ ​ 42,963 ​ ​
Series C preferred stock, par value $0.001: 142,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 116,200,835 shares issued and outstanding as of March 31, 2025 and December 31, 2024; and $415,616 and $408,715 aggregate liquidation preference as of March 31, 2025 and December 31, 2024, respectively
​ ​ ​ ​ 415,616 ​ ​ ​ ​ ​ 408,715 ​ ​
Series D preferred stock, par value $0.001: 102,600,000 shares authorized as of March 31, 2025 and December 31, 2024; 102,516,283 shares issued and outstanding as of March 31, 2025 and December 31, 2024; and $1,078,273 and $1,060,712 aggregate liquidation preference as of March 31, 2025 and December 31, 2024, respectively
​ ​ ​ ​ 1,078,273 ​ ​ ​ ​ ​ 1,060,712 ​ ​
Total redeemable convertible preferred stock
​ ​ ​ ​ 2,246,113 ​ ​ ​ ​ ​ 2,221,651 ​ ​
Shareholders’ deficit: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Common stock $0.001 par value; 1,173,000,000 and 1,150,000,000 shares
authorized as of March 31, 2025 and December 31, 2024, respectively;
147,433,040 and 146,747,083 shares issued as of March 31, 2025 and
December 31, 2024, respectively; 140,950,490 and 146,017,083 shares
outstanding as of March 31, 2025 and December 31, 2024, respectively; shares
issued and outstanding include 174,412 and 2,648,000 unvested shares subject to
repurchase as of March 31, 2025 and December 31, 2024, respectively
​ ​ ​ ​ 145 ​ ​ ​ ​ ​ 144 ​ ​
Treasury stock at cost, 6,482,550 and 730,000 shares of common stock as of March 31, 2025 and December 31, 2024, respectively
​ ​ ​ ​ (16,917) ​ ​ ​ ​ ​ (330) ​ ​
Additional paid-in capital
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​
Related party promissory note receivable (see note 7)
​ ​ ​ ​ — ​ ​ ​ ​ ​ (26,456) ​ ​
Accumulated deficit
​ ​ ​ ​ (2,583,338) ​ ​ ​ ​ ​ (2,472,406) ​ ​
Accumulated other comprehensive income
​ ​ ​ ​ 245 ​ ​ ​ ​ ​ 210 ​ ​
Total shareholders’ deficit
​ ​ ​ ​ (2,599,865) ​ ​ ​ ​ ​ (2,498,838) ​ ​
Total liabilities, redeemable convertible preferred stock, and shareholders’ deficit
​ ​ ​ $ 291,583 ​ ​ ​ ​ $ 343,734 ​ ​
The accompanying notes are an integral part of these condensed consolidated financial statements
F-43

TABLE OF CONTENTS​
 
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE LOSS (UNAUDITED)
​ ​ ​
Three Months Ended March 31,
​
(amounts in thousands, except share and per share data)
​ ​
2025
​ ​
2024
​
Revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Molecular profiling services
​ ​ ​ $ 114,081 ​ ​ ​ ​ $ 73,233 ​ ​
Pharma research and development services
​ ​ ​ ​ 6,834 ​ ​ ​ ​ ​ 7,444 ​ ​
Total revenue
​ ​ ​ ​ 120,915 ​ ​ ​ ​ ​ 80,677 ​ ​
Costs and operating expenses: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Cost of Services – Molecular Profiling Services
​ ​ ​ ​ 60,894 ​ ​ ​ ​ ​ 52,894 ​ ​
Cost of Services – Pharma Research and Development Services
​ ​ ​ ​ 2,958 ​ ​ ​ ​ ​ 1,669 ​ ​
Selling and marketing expense
​ ​ ​ ​ 39,829 ​ ​ ​ ​ ​ 39,609 ​ ​
General and administrative expense (includes related party amounts of $515 and $480, for the three months ended March 31, 2025 and 2024, respectively)
​ ​ ​ ​ 52,119 ​ ​ ​ ​ ​ 44,354 ​ ​
Research and development expense
​ ​ ​ ​ 23,066 ​ ​ ​ ​ ​ 34,376 ​ ​
Total costs and operating expenses
​ ​ ​ ​ 178,867 ​ ​ ​ ​ ​ 172,902 ​ ​
Loss from operations
​ ​ ​ ​ (57,952) ​ ​ ​ ​ ​ (92,225) ​ ​
Other income (expense), net: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Interest income
​ ​ ​ ​ 503 ​ ​ ​ ​ ​ 1,768 ​ ​
Interest expense
​ ​ ​ ​ (12,782) ​ ​ ​ ​ ​ (9,290) ​ ​
Changes in fair value of financial instruments
​ ​ ​ ​ (32,333) ​ ​ ​ ​ ​ (11,064) ​ ​
Other expense, net
​ ​ ​ ​ (17) ​ ​ ​ ​ ​ (219) ​ ​
Total other expense, net
​ ​ ​ ​ (44,629) ​ ​ ​ ​ ​ (18,804) ​ ​
Loss before income taxes and provision for income taxes
​ ​ ​ ​ (102,581) ​ ​ ​ ​ ​ (111,028) ​ ​
Provision for income taxes
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​
Net loss
​ ​ ​ ​ (102,581) ​ ​ ​ ​ ​ (111,028) ​ ​
Other comprehensive (loss) income, net of tax: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Unrealized gain on available-for-sale securities
​ ​ ​ ​ — ​ ​ ​ ​ ​ 7 ​ ​
Foreign currency translation adjustments
​ ​ ​ ​ 35 ​ ​ ​ ​ ​ 8 ​ ​
Comprehensive loss
​ ​ ​ ​ (102,546) ​ ​ ​ ​ ​ (111,013) ​ ​
Net loss attributable to common shareholders: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Net loss
​ ​ ​ ​ (102,581) ​ ​ ​ ​ ​ (111,028) ​ ​
Adjustments of redeemable convertible preferred stock to redemption value
​ ​ ​ ​ (24,462) ​ ​ ​ ​ ​ (23,113) ​ ​
Net loss attributable to common shareholders
​ ​ ​ $ (127,043) ​ ​ ​ ​ $ (134,141) ​ ​
Net loss per share attributable to common shareholders, basic and diluted
​ ​ ​ $ (0.89) ​ ​ ​ ​ $ (0.95) ​ ​
Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted
​ ​ ​ ​ 142,492 ​ ​ ​ ​ ​ 141,252 ​ ​
The accompanying notes are an integral part of these condensed consolidated financial statements
F-44

TABLE OF CONTENTS​
 
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS’ DEFICIT (UNAUDITED)
​ ​ ​
Redeemable Convertible
Preferred Stock
​ ​ ​
Common Stock
​ ​
Treasury Stock
​ ​
Additional
Paid-In
Capital
​ ​
Related
Party
Promissory
Note
Receivable
​ ​
Accumulated
Deficit
​ ​
Accumulated
Other
Comprehensive
Income
​ ​
Total
Shareholders’
Deficit
​
(amounts in thousands, except share data)
​ ​
Shares
​ ​
Amount
​ ​ ​
Shares
​ ​
Amount
​ ​
Shares
​ ​
Amount
​
Balances at December 31, 2023
​ ​ ​ ​ 734,142,041 ​ ​ ​ ​ $ 2,125,284 ​ ​ ​ ​ ​ ​ 141,188,960 ​ ​ ​ ​ $ 141 ​ ​ ​ ​ ​ 730,000 ​ ​ ​ ​ $ (330) ​ ​ ​ ​ $ — ​ ​ ​ ​ $ (25,701) ​ ​ ​ ​ $ (2,119,278) ​ ​ ​ ​ $ 218 ​ ​ ​ ​ $ (2,144,950) ​ ​
Stock-based compensation
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 4,458 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 4,458 ​ ​
Issuance of common stock upon exercise of stock options
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ 157,204 ​ ​ ​ ​ ​ 1 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 209 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 210 ​ ​
Interest income from related party
promissory notes
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (186) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (186) ​ ​
Adjustment of redeemable convertible preferred Series C and Series D to redemption value
​ ​ ​ ​ — ​ ​ ​ ​ ​ 23,113 ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (4,667) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (18,446) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (23,113) ​ ​
Other comprehensive loss
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 15 ​ ​ ​ ​ ​ 15 ​ ​
Net loss
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (111,028) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (111,028) ​ ​
Balances at March 31, 2024
​ ​ ​ ​ 734,142,041 ​ ​ ​ ​ $ 2,148,397 ​ ​ ​ ​ ​ ​ 141,346,164 ​ ​ ​ ​ $ 142 ​ ​ ​ ​ ​ 730,000 ​ ​ ​ ​ $ (330) ​ ​ ​ ​ $ — ​ ​ ​ ​ $ (25,887) ​ ​ ​ ​ $ (2,248,752) ​ ​ ​ ​ $ 233 ​ ​ ​ ​ $ (2,274,594) ​ ​
Balances at December 31, 2024
​ ​ ​ ​ 734,142,041 ​ ​ ​ ​ $ 2,221,651 ​ ​ ​ ​ ​ ​ 143,369,083 ​ ​ ​ ​ $ 144 ​ ​ ​ ​ ​ 730,000 ​ ​ ​ ​ $ (330) ​ ​ ​ ​ $ — ​ ​ ​ ​ $ (26,456) ​ ​ ​ ​ $ (2,472,406) ​ ​ ​ ​ $ 210 ​ ​ ​ ​ $ (2,498,838) ​ ​
Stock-based compensation
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 14,691 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 14,691 ​ ​
Issuance of common stock upon exercise of stock options
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ 3,333,957 ​ ​ ​ ​ ​ 1 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 1,433 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 1,434 ​ ​
Interest income from related party
promissory notes
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (128) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (128) ​ ​
Payoff of related party promissory
notes
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 26,584 ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 26,584 ​ ​
Repurchases of common stock
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ (5,752,550) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 5,752,550 ​ ​ ​ ​ ​ (16,587) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (16,587) ​ ​
Adjustment of redeemable convertible preferred Series C and Series D to redemption value
​ ​ ​ ​ — ​ ​ ​ ​ ​ 24,462 ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (16,110) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (8,352) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (24,462) ​ ​
Other comprehensive loss
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (14) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 35 ​ ​ ​ ​ ​ 21 ​ ​
Net loss
​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (102,581) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ (102,581) ​ ​
Balances at March 31, 2025
​ ​ ​ ​ 734,142,041 ​ ​ ​ ​ $ 2,246,113 ​ ​ ​ ​ ​ ​ 140,950,490 ​ ​ ​ ​ $ 145 ​ ​ ​ ​ ​ 6,482,550 ​ ​ ​ ​ $ (16,917) ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​ ​ ​ $ (2,583,338) ​ ​ ​ ​ $ 245 ​ ​ ​ ​ $ (2,599,865) ​ ​
The accompanying notes are an integral part of these condensed consolidated financial statements
F-45

TABLE OF CONTENTS​
 
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
​ ​ ​
Three Months Ended March 31,
​
(amounts in thousands)
​ ​
2025
​ ​
2024
​
Cash flows from operating activities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Net loss
​ ​ ​ $ (102,581) ​ ​ ​ ​ $ (111,028) ​ ​
Adjustments to reconcile net loss to net cash used in operating activities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Depreciation and amortization
​ ​ ​ ​ 7,045 ​ ​ ​ ​ ​ 17,705 ​ ​
Stock-based compensation expense
​ ​ ​ ​ 14,691 ​ ​ ​ ​ ​ 4,458 ​ ​
Non-cash operating lease expense
​ ​ ​ ​ 1,452 ​ ​ ​ ​ ​ 1,551 ​ ​
Amortization of debt discounts
​ ​ ​ ​ 1,945 ​ ​ ​ ​ ​ 1,590 ​ ​
Changes in fair value of financial instruments
​ ​ ​ ​ 32,333 ​ ​ ​ ​ ​ 11,064 ​ ​
Other
​ ​ ​ ​ 456 ​ ​ ​ ​ ​ 1,919 ​ ​
Changes in operating assets and liabilities:
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Accounts receivable
​ ​ ​ ​ 7,913 ​ ​ ​ ​ ​ (2,378) ​ ​
Supplies
​ ​ ​ ​ 2,061 ​ ​ ​ ​ ​ 4,024 ​ ​
Prepaid expenses and other current assets
​ ​ ​ ​ 2,470 ​ ​ ​ ​ ​ (81) ​ ​
Other assets
​ ​ ​ ​ 36 ​ ​ ​ ​ ​ 326 ​ ​
Accounts payable
​ ​ ​ ​ (1,739) ​ ​ ​ ​ ​ (2,778) ​ ​
Accrued expenses and other liabilities
​ ​ ​ ​ 2,580 ​ ​ ​ ​ ​ (297) ​ ​
Net cash used in operating activities
​ ​ ​ ​ (31,338) ​ ​ ​ ​ ​ (73,925) ​ ​
Cash flows from investing activities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Maturities of marketable securities
​ ​ ​ ​ — ​ ​ ​ ​ ​ 61,376 ​ ​
Purchases of property and equipment
​ ​ ​ ​ (2,689) ​ ​ ​ ​ ​ (1,738) ​ ​
Net cash provided by (used in) investing activities
​ ​ ​ ​ (2,689) ​ ​ ​ ​ ​ 59,638 ​ ​
Cash flows from financing activities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Payments made on finance lease obligations
​ ​ ​ ​ (22) ​ ​ ​ ​ ​ (80) ​ ​
Proceeds from exercise of stock options
​ ​ ​ ​ 1,434 ​ ​ ​ ​ ​ 210 ​ ​
Payment of deferred offering costs
​ ​ ​ ​ (105) ​ ​ ​ ​ ​ — ​ ​
Proceeds from the 2023 term loan, net of issuance costs
​ ​ ​ ​ — ​ ​ ​ ​ ​ 199,978 ​ ​
Purchase of treasury stock
​ ​ ​ ​ (22) ​ ​ ​ ​ ​ — ​ ​
Net cash provided by financing activities
​ ​ ​ ​ 1,285 ​ ​ ​ ​ ​ 200,108 ​ ​
Effect of exchange rate changes on cash, cash equivalents, and restricted cash
​ ​ ​ ​ 4 ​ ​ ​ ​ ​ 1 ​ ​
Net increase (decrease) in cash, cash equivalents, and restricted cash
​ ​ ​ ​ (32,738) ​ ​ ​ ​ ​ 185,822 ​ ​
Cash, cash equivalents, and restricted cash at beginning of year
​ ​ ​ ​ 68,028 ​ ​ ​ ​ ​ 60,007 ​ ​
Cash, cash equivalents, and restricted cash at end of period
​ ​ ​ $ 35,290 ​ ​ ​ ​ $ 245,829 ​ ​
Supplemental disclosure of cash flow information ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Interest paid
​ ​ ​ $ 10,829 ​ ​ ​ ​ $ 6,080 ​ ​
Supplemental disclosure of non-cash activity ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Cash paid for amounts included in the measurement of lease liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating cash flow used for operating leases
​ ​ ​ $ 2,847 ​ ​ ​ ​ $ 2,853 ​ ​
Operating cash flow used for finance leases
​ ​ ​ $ 7 ​ ​ ​ ​ $ 11 ​ ​
Financing cash flow used for finance leases
​ ​ ​ $ 22 ​ ​ ​ ​ $ 80 ​ ​
Property and equipment included in accounts payable and accrued liabilities
​ ​ ​ $ 242 ​ ​ ​ ​ $ 2,413 ​ ​
Deferred offering costs, accrued but not paid
​ ​ ​ $ 4,420 ​ ​ ​ ​ $ 1,989 ​ ​
The accompanying notes are an integral part of these condensed consolidated financial statements
F-46

TABLE OF CONTENTS​
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Note 1. Nature of the Business
Caris Life Sciences, Inc. (the “Company” or “Caris”) is a patient-centric, next-generation artificial intelligence (“AI”) TechBio company and precision medicine pioneer. The Company commercializes and develops innovative solutions to transform healthcare through the use of comprehensive molecular information, AI, and machine learning (“ML”) algorithms.
The Company’s current molecular profiling services portfolio is focused on oncology and consists of MI Profile, a tissue-based molecular profiling solution, and Caris Assure, a novel, universal blood-based molecular profiling solution, with the aim to address the entire continuum of cancer treatment.
The Company also collaborates with biopharmaceutical companies to provide commercial services and prospective and retrospective testing, along with data and bioinformatics collaborations and novel target identification and discovery solutions.
The Company was incorporated under the laws of the Cayman Islands in November 2011 (Caris Life Sciences, Ltd.) and re-domiciled to be incorporated in Texas in July 2020 (Caris Life Sciences, Inc.) and is headquartered in Irving, Texas. The Company also has locations in Phoenix, Arizona; New York, New York; Cambridge, Massachusetts; Basel, Switzerland; and Tokyo, Japan.
Liquidity and Going Concern
As of March 31, 2025, the Company’s cash and cash equivalents balance was approximately $31.2 million, and the short-term investments balance was $2.2 million, and the Company had a 2023 Term Loan (see Note 8) outstanding with a balance of $400.0 million.
In 2025, the Company issued the 2025 Convertible Notes in the amount of $30.0 million. In connection with the Company’s Series C redeemable convertible preferred stock, the 2023 Term Loan and the 2025 Convertible Notes, the following payments may become due within 12 months of the date of the issuance of the condensed consolidated financial statements if the Company has not completed an initial public offering raising at least $100.0 million in gross proceeds prior to such due dates:
1.
The Series C redemption rights will become exercisable on March 31, 2026;
​
2.
The Company will be required to make a one-time acceleration payment on December 31, 2025 in an amount equal to 15% of the outstanding principal amount under the 2023 Term Loan (or $60.0 million based on the principal amount currently outstanding) together with any applicable repayment premium and exit fee as described in the Term Loan agreement on such date; and
​
3.
The 2025 Convertible Notes of $30.0 million will come due on January 1, 2026.
​
If these payments become due, the Company’s existing cash resources and projected operating cash flows may not be sufficient to repay these amounts and continue to fund operating activities for at least the next 12 months from the issuance of the condensed consolidated financial statements. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern.
Management intends to raise additional funding through an initial public offering raising at least $100.0 million in gross proceeds which would eliminate the requirement to make the one-time acceleration payment related to the 2023 Term Loan. Further, the initial public offering would cause the Series C redeemable convertible preferred stock and the 2025 Convertible Note to convert to common stock and thereby not be subject to redemption and repayment upon maturity on March 31, 2026 and January 1, 2026, respectively. Management may seek alternative private financing through additional debt or equity offerings that will fulfill its operating, capital and debt requirements for at least 12 months from the date of the issuance of the condensed consolidated financial statements. However, the Company may not be able to complete such an initial public offering or otherwise secure such financing in a timely manner or on favorable terms, if at all.
 
F-47

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 2. Summary of Significant Accounting Policies and Estimates
Basis of Financial Statement Presentation
The condensed consolidated financial statements include the accounts of Caris and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
The Company’s condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”).
Unaudited Interim Consolidated Financial Information
The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair statement of the Company’s financial position as of March 31, 2025 and its results of operations and cash flows for the three months ended March 31, 2025 and 2024. The results of operations for the three months ended March 31, 2025 are not necessarily indicative of the results to be expected for the year ending December 31, 2025, or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2024 included herein was derived from the audited financial statements as of that date. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted from these unaudited condensed consolidated financial statements.
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with GAAP in the United States requires the use of estimates and assumptions about future events that affect the amounts reported in the Company’s condensed consolidated financial statements and related notes, including the amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the periods reported.
Significant estimates and assumptions are used for, but not limited to:
•
revenue recognition
​
•
fair value of stock-based awards and common stock
​
•
fair value of financial assets and liabilities
​
Future events and their effects cannot be predicted with certainty. Accordingly, the accounting estimates require the exercise of judgment. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. The accounting estimates used in the preparation of the Company’s condensed consolidated financial statements may change as new events occur, additional information is obtained, and the operating environment changes. The Company will evaluate and update the assumptions and estimates on an ongoing basis and may employ outside experts to assist in its evaluation, as considered necessary. Actual results could materially differ from those estimates.
Cash, Cash Equivalents, and Restricted Cash
The Company considers all highly liquid investments with original maturities of three months or less from date of acquisition to be cash equivalents. Refer to Note 4 for information on the Company’s restricted cash.
 
F-48

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Revenue Recognition
The Company recognizes revenue under ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Revenue is recognized when control of goods and services are transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services.
ASC 606 provides for a five-step model that includes:
Step 1: Identify the contract(s) with a customer.
Step 2: Identify performance obligations in the contract.
Step 3: Determine the transaction price.
Step 4: Allocate the transaction price to the performance obligations in the contract.
Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.
The Company derives revenue from two distinct channels:
•
Molecular profiling services involving the provision of precision oncology solutions utilizing MI Profile and Caris Assure.
​
•
Pharma research and development services involving delivery of laboratory, strategic data, and research services to biopharmaceutical customers.
​
Molecular Profiling Services
For the majority of its molecular profiling services, the Company recognizes revenue from the sale of its precision oncology solutions, provided to customers, including certain hospitals, institutions and patients, at the point in time when the results of the profiling services are delivered to ordering physicians. Most cases requested on behalf of customers are provided without a written agreement; however, the Company determines that an implied contract exists with its customers for whom a physician orders the case. Results from molecular profiling services are delivered via fax, electronically, or in hard copy. Shipping and handling activities are considered fulfillment activities and as such, amounts incurred are recorded within Cost of Services—Molecular Profiling Services on the condensed consolidated statements of operations and comprehensive loss. The Company identifies each sale of the Company’s profiling service as a distinct performance obligation. Payment terms are a function of a patient’s existing insurance benefits and applicable reimbursement contracts established between the Company and payers. Collection of consideration the Company expects to receive typically occurs within 90 to 120 days of billing. Occasionally, payers may recoup or we may refund consideration, mainly as a result of claim processing.
The total consideration to which the Company expects to be entitled in exchange for the Company’s services may be fixed or variable. Consideration includes reimbursement from patients, hospitals, and third-party commercial and governmental payers, such as insurance companies, adjusted for variable consideration related to implicit price concessions that the Company may grant. The Company estimates the variable consideration under a portfolio approach for third-party payers, hospitals and patients with similar reimbursement characteristics. This includes analysis of an average reimbursement per case per portfolio and a percentage of cases reimbursed by considering the historical reimbursement data (including any refunds and recoupments) from such third-party payers, hospitals and patients. Specifically, the Company calculates the historical average reimbursement rates for each portfolio and applies an estimated reimbursement rate, based on historical trends, to the number of cases delivered each period. The period for which historical data is drawn upon is determined on a by- portfolio basis for each payer group, taking into consideration the average collection period. Additionally, the estimate also considers current contractual and statutory requirements, patient insurance eligibility and payer reimbursement contracts, and any known current or anticipated reimbursement trends not reflected in the historical data and only recognizes revenue for variable consideration that the Company determines is probable will not result in a significant reversal in the future. The Company monitors the estimated amount to be collected at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Subsequent changes to the estimate of the transaction price are recorded as adjustments to molecular profiling services revenue in the period where such changes occur. Both the estimate and any subsequent
 
F-49

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
revision are uncertain and require the use of management’s judgment in the estimation of the variable consideration and application of the constraint for such variable consideration.
Pharma Research and Development Services
The Company collaborates with biopharmaceutical companies to provide commercial services and prospective and retrospective testing, along with data and bioinformatics collaborations and novel target identification and discovery solutions.
Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as molecular profiling services, pharma research and development services, and strategic data services. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers for proper revenue recognition, including whether services are capable of being distinct and considered distinct within the context of the contract. The performance obligations for biopharmaceutical customers vary by contract. Such contracts may include a performance obligation to provide molecular profiling services, to facilitate the development and regulatory approval of drugs, or to provide target discovery services. Under those contracts, the Company receives payments upon the achievement of milestones, as well as provision of on-going support. The transaction price of the development services contracts may include variable consideration, due to the uncertainty associated with the achievement of the milestones. In making the assessment of whether variable consideration should be included in the transaction price, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The Company recognizes pharma research and development services revenue over the period in which biopharmaceutical research and development services are provided. Depending on the nature of the service, the Company recognizes revenue using either the output or input method to measure progress, whichever provides a more faithful depiction of the transfer of goods or services. Use of an output method or input method to depict the transfer of services generally does not result in a material difference with respect to the timing of revenue recognition because most services commence and end within the same reporting period. A constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price.
Standalone Selling Price
The Company determines standalone selling prices by considering the historical selling prices of its performance obligations in similar transactions, where applicable, as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing from other vendors, industry publications, current pricing practices and management estimates.
Contract Balances
The timing of revenue recognition may differ from the timing of invoicing to customers. Accounts receivable are recorded at the invoiced amount, net of an allowance for credit losses. A receivable is recognized in the period the Company delivers goods or provides services, or when the right to consideration is unconditional. In situations where revenue recognition occurs before invoicing, an unbilled receivable is created, which represents a contract asset. As of March 31, 2025 and December 31, 2024, the unbilled receivable balance was $1.6 million and $4.6 million, respectively, which is included in accounts receivable on the condensed consolidated balance sheets.
The Company recognizes contract liabilities primarily related to payments received in advance of satisfaction of performance obligations from contracts with customers. Contract liabilities are relieved as the Company fulfills its obligations under the contract and revenue is recognized. As of March 31, 2025 and December 31, 2024, the contract liability balance was $7.7 million and $7.5 million, respectively, which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets.
 
F-50

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The following table shows the changes in the contract liabilities during the period:
​ ​ ​
(amounts in
thousands)
​
Balance at December 31, 2024
​ ​ ​ $ 7,470 ​ ​
Increase in contract liabilities
​ ​ ​ ​ 3,774 ​ ​
Revenue recognized during the period that was included in deferred revenues at the beginning of the period
​ ​ ​ ​ (1,797) ​ ​
Revenue recognized from performance obligations satisfied within the same period
​ ​ ​ ​ (1,783) ​ ​
Balance at March 31, 2025
​ ​ ​ $ 7,664 ​ ​
The amount of revenue recognized during the three months ended March 31, 2024 pertaining to amounts deferred as of December 31, 2023 was $2.0 million.
Transaction Price Allocated to Remaining Performance Obligations
The transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes contract liabilities and non-cancelable amounts that will be invoiced and recognized as revenue in future periods and excludes performance obligations that are subject to cancellation terms. The Company has elected not to disclose information regarding the transaction price allocated to the remaining performance obligations for which the original expected duration of the contract is one year or less. The amount of transaction price allocated to the remaining performance obligations for contracts with original expected duration over one year as of March 31, 2025 was $7.1 million. The Company expects to recognize the amounts within twelve months from the respective balance sheet dates.
Additionally, for the three months ended March 31, 2025 and 2024, the Company recorded $3.9 million and $(3.9) million of adjustments to revenue related to services delivered in prior periods, respectively, which is based on variability that was subsequently resolved.
Practical Expedients and Contract Costs
Payment terms and conditions vary by contract and customer. In instances where the timing of the Company’s revenue recognition differs from the timing of its invoicing, the Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised services to the customer will be one year or less.
As a practical expedient, the Company recognizes the incremental costs of obtaining contracts, such as sales commissions, as expenses when incurred, if the amortization period of the asset that the Company otherwise would have recognized for the capitalized costs is one year or less. Sales commissions are recorded within selling and marketing expense on the condensed consolidated statements of operations and comprehensive loss. The Company did not capitalize any sales commissions or contract fulfillment costs for the periods ended March 31, 2025 and December 31, 2024.
Collaboration agreements
The Company is party to various collaboration and licensing agreements under which the Company out-licenses certain know-how and molecular data. The collaboration arrangements are intended to solidify the Company’s third-party partnerships to align oncology capabilities and create industry-leading molecular oncology research platforms to accelerate drug development and novel research. Under these collaboration arrangements, the Company generally receives a split of fees from its collaborative partners that are earned pursuant to statements of work (“SOWs”) executed with end users of the Company’s licensed molecular data.
 
F-51

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The Company’s collaboration and licensing agreements are within the scope of ASC Topic 808, Collaborative Arrangements (“ASC 808”) and ASC 606 because the counterparty to these agreements meets the definition of a customer. As such, the Company recognizes revenue earned from the licenses of molecular data granted to the Company’s collaborative partners in accordance with ASC 606. Each license of molecular data granted by the Company to a collaborative partner represents a distinct performance obligation in the contract. The transaction price for a given arrangement is entirely variable and depends on the SOWs executed by the counterparty with end users. The amount of revenue allocated to each license is equal to the amount of revenue to which the Company expects to be entitled. The Company recognizes revenue at the point in time that it delivers the molecular data to the third-party collaborative partner. For the three months ended March 31, 2025 and 2024, the Company recognized collaboration revenue of $1.3 million and $1.4 million, respectively, which is included in revenue from pharma research and development services on the condensed consolidated statements of operations and comprehensive loss.
Cost of Services—Molecular Profiling Services
Cost of services for molecular profiling services generally consists of cost of materials, direct labor including bonus and stock-based compensation, and equipment maintenance and depreciation expenses associated with processing cases (including accessioning, sequencing, quality control analyses and shipping charges to transport tissue samples), freight and profile results for ordering physicians. Costs associated with completing the molecular profiling services are recorded as the service is performed, regardless of when revenue is recognized with respect to the service.
Cost of Services—Pharma Research and Development Services
Cost of services for pharma research and development services generally consists of cost incurred for the performance of the services requested by the Company’s biopharmaceutical customers related to the delivery of laboratory, strategic data and research services, and will vary depending on the nature, timing, and scope of customer projects. Costs associated with delivering pharma research and development services are recorded as incurred.
Concentration of Credit Risk
Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company maintains its cash primarily with domestic financial institutions of high credit quality, with balances that exceed amounts insured by the Federal Deposit Insurance Corporation as of March 31, 2025 and December 31, 2024, respectively.
The Company invests in treasury bills issued by the U.S. Government. U.S. treasury bills with original maturities of three months or less are classified within cash equivalents. Short-term marketable securities are comprised of U.S. treasury bills with original maturities between three and twelve months. The Company believes it is not exposed to any significant credit risk on cash, cash equivalents, and marketable securities and performs periodic evaluations of the credit standing of such institutions. The goal of the Company’s investment policy is to ensure safety and preservation of the principal balance, and diversification of risk over cash balances held on deposit.
The Company is subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arise from the provision of molecular profiling services and pharma research and development services and other, primarily with biopharmaceutical companies, all of which have high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded net of allowance for credit losses, if any. Concentrations of credit risk are limited due to the number of payers and their dispersion across multiple geographic regions.
For the three months ended March 31, 2025 and 2024, the Company’s revenues were primarily derived from the sale of the Caris molecular profiling services. As discussed above, payment terms of the
 
F-52

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
services are a function of a patient’s existing insurance benefits and applicable reimbursement contracts established between the Company and payers. Revenue associated with each payer, including its affiliated entities, as a percentage of the Company’s total revenue for the respective period, and accounts receivable balance attributable to each payer, including its affiliated entities, as a percentage of the Company’s total accounts receivable balance at the respective condensed consolidated balance sheet date, are as follows:
​ ​ ​
% Revenue for the
three months ended March 31,
​ ​
% Accounts
receivable as of
​
Major Payer
​ ​
2025
​ ​
2024
​ ​
March 31,
2025
​ ​
December 31,
2024
​
Payer 1
​ ​ ​ ​ 51.2% ​ ​ ​ ​ ​ 36.8% ​ ​ ​ ​ ​ 64.3% ​ ​ ​ ​ ​ 16.1% ​ ​
Payer 2
​ ​ ​ ​ 13.5% ​ ​ ​ ​ ​ 13.6% ​ ​ ​ ​ ​ 10.0% ​ ​ ​ ​ ​ 19.3% ​ ​
Payer 3
​ ​ ​ ​ * ​ ​ ​ ​ ​ * ​ ​ ​ ​ ​ 11.5% ​ ​ ​ ​ ​ * ​ ​
​
*
Represents major payers below 10.0%.
​
Accounts Receivable
Accounts receivable includes billed and unbilled receivables, net of an allowance for expected credit losses. Accounts receivable primarily represent receivables from biopharmaceutical customers and third-party payers. Accounts receivable for pharmaceutical services are established based on the amounts outstanding per the contractual arrangements with biopharmaceutical customers. The Company applies the current expected credit loss standard in ASC Subtopic 326-20, Financial Instruments—Credit Losses (“ASC 326‑20”) and reserves a portion of the accounts receivable based on assessment of the collectability of customer accounts at the time of revenue recognition. The Company regularly reviews the reserve by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay.
Receivables deemed to be uncollectible are written-off against the allowance for credit losses at the time such receivables are deemed to be uncollectible under a specific identification or estimated method. Recoveries of accounts receivable previously written off are recorded when received. As of March 31, 2025 and December 31, 2024, the Company had an immaterial allowance for credit losses related to its accounts receivable.
Supplies
Supplies consist primarily of laboratory items and reagents used by the Company in providing services. All supplies are raw materials and are stated at the lower of cost or net realizable value on a first-in, first-out basis. The Company periodically reviews its supplies for excess or obsolescence and writes down obsolete or otherwise unmarketable supplies to their estimated net realizable value. As of March 31, 2025 and December 31, 2024, the amount of write downs associated with the Company’s supplies was immaterial.
Deferred Offering Costs
Deferred offering costs consist primarily of accounting, legal, and other fees related to the Company’s proposed initial public offering (“IPO”). These costs are recorded as prepaid expenses and other current assets on the condensed consolidated balance sheets. The deferred offering costs will be recorded against IPO proceeds upon the consummation of the IPO. In the event the planned IPO is terminated, the deferred offering costs will be expensed. The Company had $5.8 million and $4.5 million of deferred offering costs as of March 31, 2025 and December 31, 2024, respectively.
Property and Equipment, Net
The Company reports property and equipment at cost, net of accumulated depreciation, amortization, and any asset impairments. The cost of properties held under finance leases is equal to the
 
F-53

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
present value of lease payments not yet paid, adjusted for initial direct costs, prepaid lease payments and lease incentives received. Major improvements which add to productive capacity or extend the life of an asset are capitalized. Normal repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts, and any resulting gain or loss is reflected in the accompanying condensed consolidated statements of operations and comprehensive loss for the period.
Depreciation and amortization expenses are calculated on a straight-line basis and applied to asset classes based upon the Company’s estimate of the asset class’s useful life, as summarized below:
​ ​ ​
Estimated Useful Life
​
Laboratory equipment
​ ​
3 years
​
Computer equipment and software
​ ​
3 years
​
Furniture and fixtures
​ ​
5 years
​
Aircraft
​ ​
15 years
​
Leasehold improvements/leased buildings
​ ​
Lesser of remaining lease term or useful life
​
Leased equipment
​ ​
Lesser of initial lease term or 5 years
​
Computer equipment and software includes the purchases of hardware, software and capitalized labor costs associated with internally developed software.
The Company capitalizes purchased software which is ready-for-service and capitalizes qualifying internal software development costs incurred on significant projects. Capitalization of costs begins when two criteria are met: (1) the preliminary project stage is completed, management with relevant authority authorizes and commits to funding the software project, and (2) it is probable that the software will be completed and used for its intended function. Capitalization ceases when the software is substantially complete and ready for its intended use, including the completion of all significant testing. Costs related to preliminary project activities and post-implementation operating activities are expensed as incurred.
Research and development costs and other computer software maintenance costs related to software development are expensed as incurred.
Capitalized software costs are included in property and equipment, net. These costs are amortized using the straight-line method over the estimated useful life of the underlying software, which is three years.
Fair Value Measurements
Fair value is defined as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions market participants would use in pricing an asset or liability.
The basis for these assumptions establishes a three-level fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
•
Level 1—Observable inputs such as quoted prices in active markets for identical assets and liabilities;
​
•
Level 2—Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and
​
•
Level 3—Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
​
Assets and liabilities measured at fair value are based on one or more of three valuation techniques. The three valuation techniques are as follows:
 
F-54

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
•
Market approach—Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities;
​
•
Cost approach—Amount that would be required to replace the service capacity of an asset (i.e., replacement cost); and
​
•
Income approach—Techniques to convert future amounts to a single present amount based on market expectations (including present value techniques, option-pricing models, and lattice models).
​
Financial instruments consist of cash, cash equivalents, restricted cash, short-term marketable securities, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities, debt, warrants, and derivative instruments.
As of March 31, 2025 and December 31, 2024, the carrying amounts of the Company’s cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities approximate their fair value based on the short-term nature of these items. There were no transfers between Levels 1, 2 or 3 for the periods ended March 31, 2025 and December 31, 2024.
The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:
​ ​ ​
As of March 31, 2025
​
​ ​ ​
Fair Value
​ ​
Level 1
​ ​
Level 2
​ ​
Level 3
​
​ ​ ​
(amounts in thousands)
​
Financial assets ​ ​ ​ ​ ​
Short-term marketable securities
​ ​ ​ $ 2,225 ​ ​ ​ ​ $ 2,225 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​
Financial liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Warrant liability
​ ​ ​ $ 128,691 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​ ​ ​ $ 128,691 ​ ​
Derivative liability
​ ​ ​ $ 1,342 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​ ​ ​ $ 1,342 ​ ​
​ ​ ​
As of December 31, 2024
​
​ ​ ​
Fair Value
​ ​
Level 1
​ ​
Level 2
​ ​
Level 3
​
​ ​ ​
(amounts in thousands)
​
Financial assets ​ ​ ​ ​ ​
Short-term marketable securities
​ ​ ​ $ 2,201 ​ ​ ​ ​ $ 2,201 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​
Financial liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Warrant liability
​ ​ ​ $ 91,642 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​ ​ ​ $ 91,642 ​ ​
Derivative liability
​ ​ ​ $ 6,058 ​ ​ ​ ​ $ — ​ ​ ​ ​ $ — ​ ​ ​ ​ $ 6,058 ​ ​
Warrant liability
The Company utilized a probability-weighted scenario approach factoring in various exit strategies and the related timing of such to estimate the fair value of its warrant liability. For each scenario, the Company utilized a Black-Scholes option pricing model with the following assumptions:
•
Fair value per share of the underlying stock—The fair value of the underlying stock represents the fair value of the Company’s Series C preferred stock that the warrants are convertible into.
​
•
Volatility—The volatility is derived from historical volatilities of several unrelated publicly-listed peer companies, since the Company has no trading history. When making the selections of industry peer companies to be used in the volatility calculation, the Company considers the size, operational and economic similarities to the Company’s principal business operations.
​
 
F-55

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
•
Risk-free interest rate—The risk-free interest rate is based on U.S. treasury yield as of the measurement dates interpolated to match the maturity equal to the respective term to exit.
​
•
Dividend yield—The expected dividend assumption is based on the Company’s current expectations about the Company’s anticipated dividend policy.
​
•
Expected term (years)—Based on expected term under various exit strategies.
​
The below table summarizes the significant unobservable inputs used in the fair value measurement of the warrant liability as of March 31, 2025 and December 31, 2024:
​ ​ ​
As of March 31, 2025
​ ​
As of December 31, 2024
​
​ ​ ​
2018 Warrants
​ ​
2020 Warrants
​ ​
2018 Warrants
​ ​
2020 Warrants
​
Fair value per share of the underlying stock
​ ​
$4.76–$7.43
​ ​
$4.76–$7.43
​ ​
$3.66–$5.65
​ ​
$3.66–$5.65
​
Expected volatility
​ ​
46.0%–62.0%
​ ​
59.4%–62.0%
​ ​
47.6%–63.0%
​ ​
61.2%–63.0%
​
Risk-free interest rate
​ ​
4.2%–4.3%
​ ​
3.9%–4.3%
​ ​
4.2%–4.3%
​ ​
4.3%
​
Expected dividend yield
​ ​
—%
​ ​
—%
​ ​
—%
​ ​
—%
​
Expected term (years)
​ ​
0.19–0.50
​ ​
0.19–2.75
​ ​
0.29–0.75
​ ​
0.29–2.25
​
Derivative liability
On January 18, 2023, the Company entered into a credit agreement (the “New Term Loan Agreement”) under which the Company issued senior, secured promissory notes (the “2023 Term Loan”) by which the New Term Loan lenders agreed to lend the Company up to an aggregate principal amount of $400.0 million, $200.0 million of which was received by the Company upon issuance, and $200.0 was drawn down in March 2024. The Company identified certain embedded features in the 2023 Term Loan, including various contingent prepayment, compensatory payment, and default interest rate features, that are required to be bifurcated from the 2023 Term Loan and separately accounted for in the condensed consolidated financial statements as a compound derivative liability.
Fair value of the derivative liability was estimated using the discounted cash flow method under the income approach. This approach involves significant Level 3 inputs and assumptions including an estimated probability and timing of certain contingent events, such as events of default, change of control, sale of assets, etc. The analysis also required the selection of a discount rate representative of the Company’s credit risk. The discount rate used for the initial fair value was calibrated to the transaction.
Refer to Note 8 for additional information about the compound embedded derivative liability.
Debt
As of March 31, 2025, the estimated fair value of the 2023 Term Loan, excluding the bifurcated embedded derivative, was $377.8 million, compared to a carrying value of $375.1 million. As of December 31, 2024, the estimated fair value of the 2023 Term Loan, excluding the bifurcated embedded derivative, was $380.9 million, compared to a carrying value of $373.1 million. The Company estimated the fair value of the 2023 Term Loan as of based on a discounted cash flow analysis, and an income approach, which represented the use of Level 3 inputs in the fair value hierarchy.
Goodwill
Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities acquired through a business combination. The Company evaluates goodwill for impairment in accordance with ASC Topic 350, Intangibles—Goodwill and Other on an annual basis on October 1, or more frequently if events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, or the Company may determine to proceed directly to the quantitative impairment test.
 
F-56

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
If the Company assesses qualitative factors and concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount or if the Company determines not to use the qualitative assessment, then a quantitative impairment test is performed. The factors utilized in the qualitative assessment include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, and Company-specific events. The quantitative impairment test requires comparing the fair value of the reporting unit to its carrying value, including goodwill. The fair value of the reporting unit is determined based on the present value of estimated cash flows using available information regarding expected cash flows of each reporting unit, discount rates, and the expected long-term cash flow growth rates.
The Company has identified that its business operates as a single operating segment which is also a single reporting unit for purposes of testing goodwill for impairment. An impairment exists if the fair value of the reporting unit is lower than its carrying value. If the fair value of the reporting unit is lower than its carrying value, the Company would record an impairment loss equal to the excess of the reporting unit’s carrying value over its fair value.
There were no impairment losses for the periods ended March 31, 2025 and 2024.
Research and Development Costs
Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities. The costs include direct costs for salaries and benefits, materials, contract services and other outside costs, and costs to acquire in-process research and development projects and technologies that have no alternative future use.
Advertising
The Company expenses advertising costs as incurred. The Company incurred advertising costs of $0.1 million and $0.2 million for the three months ended March 31, 2025 and 2024, respectively.
Self-Insurance
The Company offers medical insurance coverage to eligible employees under a self-insured program managed by a third-party administrator, leveraging stop-loss insurance policies to mitigate risk. The Company records an estimate of its liability for medical claims, which includes the incurred claims amount plus an estimate of incurred, but not reported claims. Self-insurance liability of $2.0 million and $1.9 million for the periods ended March 31, 2025 and December 31, 2024, respectively, is included within accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Net Loss per Share Attributable to Common Shareholders
The Company calculates its basic and diluted net loss per share attributable to common shareholders in conformity with the two-class method required for companies with participating securities. Each series of the Company’s redeemable convertible preferred stock is considered to be a participating security because the preferred shareholders have a right to receive dividends on a pari passu basis with the Company’s common shareholders. The two-class method determines net income (loss) per share for each class of common stock and participating security according to dividends declared or accumulated and participating rights in undistributed earnings. The two-class method requires income (loss) available to common shareholders for the period to be allocated between common and participating securities based upon the respective rights of each to share in earnings as if all income (loss) for the period had been distributed. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method between common and participating securities.
Because the Company has reported a net loss for the three months ended March 31, 2025 and 2024, basic net loss per share attributable to common shareholders is calculated by dividing net loss attributable to common shareholders by the weighted-average common stock outstanding during the period, without
 
F-57

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
consideration for potential common stock equivalents. Net loss attributable to common shareholders is equal to net loss, less accretion on preferred securities to their redemption value to the extent such securities are outstanding. Diluted net loss per share attributable to common shareholders is calculated by adjusting the weighted-average stock outstanding for the dilutive effect of potential common stock equivalents outstanding. For purposes of calculating the diluted net loss per share attributable to common shareholders, convertible preferred stock, convertible promissory notes, warrants, and stock options are considered to be potential common stock equivalents but are excluded from the calculation of diluted net loss per share attributable to common shareholders because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share attributable to common shareholders was the same for all periods presented.
Income Taxes
The Company accounts for income taxes under the asset and liability method as set forth in ASC 740 “Income Taxes” ​(“ASC 740”). Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.
The calculation of the Company’s tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across its global operations. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related taxing authority. For tax positions not meeting the more likely than not test, no tax benefit is recorded.
At March 31, 2025 and December 31, 2024, the Company has accumulated net operating loss carryforwards in both the U.S. and foreign jurisdictions, and no provision for income taxes is required. The Company’s deferred tax assets are subject to a full valuation allowance.
Recently Issued Accounting Pronouncements Not Yet Adopted
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures which requires presentation of specific categories of reconciling items, as well as reconciling items that meet a quantitative threshold, in the reconciliation between the income tax provision and the income tax provision using statutory tax rates. The standard also requires disclosure of income taxes paid disaggregated by jurisdiction with separate disclosure of income taxes paid to individual jurisdictions that meet a quantitative threshold. For public business entities, the ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. For entities other than public business entities, the ASU is effective for annual periods beginning after December 15, 2025. The amendments of the ASU should be applied on a prospective basis; however, entities have the option to apply retrospectively for each period presented. The Company does not expect the adoption of this new standard in 2026 to have an impact on its condensed consolidated financial position, results of operations, or cash flow.
In November 2024, the FASB issued ASU No. 2024-03, Income Statement- Reporting Comprehensive Income-Expense disaggregation disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. This ASU requires disclosure of specified information about certain costs and expenses in the notes to financial statements. This ASU is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Adoption of this ASU should be applied on a prospective basis. Early adoption is permitted. We are currently evaluating the impact that this guidance will have on the disclosures within our financial statements, and expect to adopt this ASU for the year ending December 31, 2027.
 
F-58

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 3. Condensed Consolidated Balance Sheet and Statement of Operations and Comprehensive Loss Components
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
​ ​ ​
As of March 31,
2025
​ ​
As of December 31,
2024
​
​ ​ ​
(amounts in thousands)
​
Prepaid expenses
​ ​ ​ $ 11,924 ​ ​ ​ ​ $ 13,562 ​ ​
Other current assets
​ ​ ​ ​ 7,654 ​ ​ ​ ​ ​ 6,708 ​ ​
Total prepaid expenses and other current assets
​ ​ ​ $ 19,578 ​ ​ ​ ​ $ 20,270 ​ ​
Property and Equipment, Net
Property and equipment, net consist of the following:
​ ​ ​
As of March 31,
2025
​ ​
As of December 31,
2024
​
​ ​ ​
(amounts in thousands)
​
Computer equipment and software
​ ​ ​ $ 77,118 ​ ​ ​ ​ $ 73,312 ​ ​
Capitalized software
​ ​ ​ ​ 22,622 ​ ​ ​ ​ ​ 25,921 ​ ​
Laboratory equipment
​ ​ ​ ​ 103,900 ​ ​ ​ ​ ​ 103,795 ​ ​
Furniture and fixtures
​ ​ ​ ​ 9,110 ​ ​ ​ ​ ​ 9,110 ​ ​
Leasehold improvements/Leased buildings
​ ​ ​ ​ 63,290 ​ ​ ​ ​ ​ 63,039 ​ ​
Aircraft and leased equipment
​ ​ ​ ​ 21,249 ​ ​ ​ ​ ​ 21,249 ​ ​
Total property and equipment
​ ​ ​ ​ 297,289 ​ ​ ​ ​ ​ 296,426 ​ ​
Less: accumulated depreciation and amortization
​ ​ ​ ​ (235,638) ​ ​ ​ ​ ​ (228,609) ​ ​
Property and equipment, net
​ ​ ​ $ 61,651 ​ ​ ​ ​ $ 67,817 ​ ​
Total depreciation and amortization expense was $7.0 million and $17.7 million for the three months ended March 31, 2025 and 2024, respectively.
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consist of the following:
​ ​ ​
As of March 31,
2025
​ ​
As of December 31,
2024
​
​ ​ ​
(amounts in thousands)
​
Trade accruals
​ ​ ​ $ 5,470 ​ ​ ​ ​ $ 7,131 ​ ​
Accrued payroll and employee medical
​ ​ ​ ​ 14,264 ​ ​ ​ ​ ​ 17,882 ​ ​
Accrued bonus
​ ​ ​ ​ 33,150 ​ ​ ​ ​ ​ 25,736 ​ ​
Current portion of early exercise stock option liability
​ ​ ​ ​ 327 ​ ​ ​ ​ ​ 4,957 ​ ​
Contract liability
​ ​ ​ ​ 7,664 ​ ​ ​ ​ ​ 7,470 ​ ​
Current portion of operating lease liabilities
​ ​ ​ ​ 6,023 ​ ​ ​ ​ ​ 6,080 ​ ​
Other accrued expenses
​ ​ ​ ​ 11,337 ​ ​ ​ ​ ​ 8,286 ​ ​
Total accrued expenses and other current liabilities
​ ​ ​ $ 78,235 ​ ​ ​ ​ $ 77,542 ​ ​
 
F-59

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Other Long-Term Liabilities
Other long-term liabilities consist of the following:
​ ​ ​
As of March 31,
2025
​ ​
As of December 31,
2024
​
​ ​ ​
(amounts in thousands)
​
Long-term operating lease liabilities, net of current portion
​ ​ ​ $ 37,067 ​ ​ ​ ​ $ 38,651 ​ ​
Long-term portion of early exercise stock option liability
​ ​ ​ ​ 380 ​ ​ ​ ​ ​ 5,767 ​ ​
Total other long-term liabilities
​ ​ ​ $ 37,447 ​ ​ ​ ​ $ 44,418 ​ ​
Note 4. Guaranty Agreement and Restricted Cash
The Company entered into a lease agreement with KCP NNN II Leasehold 4, LLC on July 25, 2019 to lease 114,500 square feet of space in Irving, Texas. As part of the lease agreement, the Company delivered an unconditional, irrevocable letter of credit for $3.4 million from a nationally recognized bank. The Company obtained this letter of credit and placed $3.4 million in a security deposit account. As of March 31, 2025 and December 31, 2024, amounts outstanding are $2.7 million and are included within cash, cash equivalents, and restricted cash and other assets on the condensed consolidated balance sheets.
The remaining restricted cash amounts are not material individually.
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheet that sum to the total of the amounts shown in the condensed consolidated statements of cash flows. Restricted cash is presented within cash, cash equivalents, and restricted cash and other assets on the condensed consolidated balance sheets.
​ ​ ​
Condensed consolidated balance sheet line item
​ ​
As of March 31,
2025
​ ​
As of December 31,
2024
​
​ ​ ​ ​ ​ ​
(amounts in thousands)
​
Cash and cash equivalents
​ ​
Cash, cash equivalents, and restricted cash
​ ​ ​ $ 31,201 ​ ​ ​ ​ $ 63,950 ​ ​
Restricted cash−short-term
​ ​
Cash, cash equivalents, and restricted cash
​ ​ ​ ​ 1,503 ​ ​ ​ ​ ​ 1,492 ​ ​
Restricted cash−long-term
​ ​
Other assets
​ ​ ​ ​ 2,586 ​ ​ ​ ​ ​ 2,586 ​ ​
Total
​ ​ ​ ​ ​ ​ $ 35,290 ​ ​ ​ ​ $ 68,028 ​ ​
Note 5. Income Taxes
The Company is subject to tax liabilities imposed by multiple jurisdictions. The Company determines our best estimate of the annual effective tax rate at each interim period using expected annual pre-tax earnings, statutory tax rates, and available tax planning opportunities. Certain significant or unusual items are separately recognized in the quarter in which they occur, which can cause variability in the effective tax rate from quarter to quarter. The Company recognizes interest and penalties related to uncertain tax positions, if any, as an income tax expense.
The effective tax rate on income for the three months ended March 31, 2025 and 2024 is 0%. For the three months ended March 31, 2025 and 2024, the tax rates differed from the U.S. federal statutory rate of 21.0% primarily due to the impact of net operating losses and valuation allowances.
The Company is subject to taxation in the United States and various states and foreign jurisdictions. As of March 31, 2025, all loss years remain open to examination by the taxing authorities.
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for temporary differences between the financial reporting bases and tax bases of assets and liabilities based on enacted tax rates expected to be in effect when such amounts are realized or settled. However, deferred tax assets are recognized only to the extent that it is more likely than not that they
 
F-60

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
will be realized based upon consideration of available evidence, including future reversals of existing taxable temporary differences, future projected taxable income, the length of the tax asset carryforward periods and tax planning strategies. The effects of remeasurement of deferred tax assets and liabilities resulting from changes in tax rates are recognized in income in the period of enactment.
Note 6. Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock as of March 31, 2025 and December 31, 2024, consisted of the following:
​ ​ ​
As of March 31, 2025
​
(amounts in thousands, except share and per
share amounts)
​ ​
Shares
Authorized
​ ​
Shares Issued
and
Outstanding
​ ​
Original
Issue Price
Per Share
​ ​
Aggregate
Liquidation
Preference
​ ​
Net
Carrying
Value
​
Series A Preferred Stock
​ ​ ​ ​ 490,000,000 ​ ​ ​ ​ ​ 485,795,293 ​ ​ ​ ​ $ 0.61 ​ ​ ​ ​ $ 296,335 ​ ​ ​ ​ $ 709,261 ​ ​
Series B Preferred Stock
​ ​ ​ ​ 30,000,000 ​ ​ ​ ​ ​ 29,629,630 ​ ​ ​ ​ $ 0.54 ​ ​ ​ ​ ​ 16,000 ​ ​ ​ ​ ​ 42,963 ​ ​
Series C Preferred Stock
​ ​ ​ ​ 142,000,000 ​ ​ ​ ​ ​ 116,200,835 ​ ​ ​ ​ $ 2.76 ​ ​ ​ ​ ​ 415,616 ​ ​ ​ ​ ​ 415,616 ​ ​
Series D Preferred Stock
​ ​ ​ ​ 102,600,000 ​ ​ ​ ​ ​ 102,516,283 ​ ​ ​ ​ $ 8.10 ​ ​ ​ ​ ​ 1,078,273 ​ ​ ​ ​ ​ 1,078,273 ​ ​
Total redeemable convertible preferred
stock
​ ​ ​ ​ 764,600,000 ​ ​ ​ ​ ​ 734,142,041 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 1,806,224 ​ ​ ​ ​ $ 2,246,113 ​ ​
​ ​ ​
As of December 31, 2024
​
(amounts in thousands, except share and per
share amounts)
​ ​
Shares
Authorized
​ ​
Shares Issued
and
Outstanding
​ ​
Original
Issue Price
Per Share
​ ​
Aggregate
Liquidation
Preference
​ ​
Net
Carrying
Value
​
Series A Preferred Stock
​ ​ ​ ​ 490,000,000 ​ ​ ​ ​ ​ 485,795,293 ​ ​ ​ ​ $ 0.61 ​ ​ ​ ​ $ 296,335 ​ ​ ​ ​ $ 709,261 ​ ​
Series B Preferred Stock
​ ​ ​ ​ 30,000,000 ​ ​ ​ ​ ​ 29,629,630 ​ ​ ​ ​ $ 0.54 ​ ​ ​ ​ ​ 16,000 ​ ​ ​ ​ ​ 42,963 ​ ​
Series C Preferred Stock
​ ​ ​ ​ 142,000,000 ​ ​ ​ ​ ​ 116,200,835 ​ ​ ​ ​ $ 2.76 ​ ​ ​ ​ ​ 408,715 ​ ​ ​ ​ ​ 408,715 ​ ​
Series D Preferred Stock
​ ​ ​ ​ 102,600,000 ​ ​ ​ ​ ​ 102,516,283 ​ ​ ​ ​ $ 8.10 ​ ​ ​ ​ ​ 1,060,712 ​ ​ ​ ​ ​ 1,060,712 ​ ​
Total redeemable convertible preferred
stock
​ ​ ​ ​ 764,600,000 ​ ​ ​ ​ ​ 734,142,041 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $ 1,781,762 ​ ​ ​ ​ $ 2,221,651 ​ ​
The rights, preferences, and privileges of the redeemable convertible preferred stock are as follows:
Voting Rights
On any matter presented to the shareholders of the Company for their action or consideration at any meeting of shareholders of the Company (or by written consent of shareholders in lieu of meeting), each holder of outstanding shares of preferred stock will be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining shareholders entitled to vote on such matter.
Dividends
All classes of preferred stock are entitled to receive dividends out of any assets legally available only when, as, and if declared by the Company’s board of directors, prior to and in preference to any declaration or payment of any dividend on the common stock.
Liquidation Preference
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series C and Series D preferred stock then outstanding will be entitled to be paid out of the assets of the Company available for distribution to its shareholders at an amount per share equal to the greater of (i) the Series C and Series D original issue price, plus (A) any dividends declared but
 
F-61

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
unpaid thereon and (B) a 7.0% cumulative accruing dividend, compounding annually from the date of issuance of such share of Series C and Series D preferred stock, (ii) the amount that the holder of a share of Series C and Series D preferred stock would have received upon conversion to common stock, or (iii) solely with respect to the Series D preferred stock, 1.2 times the Series D original issue price. The Series A and Series B preferred stock are then paid on a pro rata, pari passu basis an amount equal to the greater of (i) the respective original issue price plus any dividends declared but unpaid thereon, and (ii) the amount that the holder of a share of Series A or Series B preferred stock, respectively, would receive upon conversion to common stock. The remaining proceeds will be distributed to the holders of common stock.
Conversion Rights
The holders of the Company’s Series A, Series B, Series C and Series D preferred stock have the right to convert their shares into a number of fully paid and nonassessable shares of common stock as determined by dividing the respective Series A, Series B, Series C and Series D preferred stock original issue price by the conversion price in effect at the time. The initial conversion price of the Series A, Series B, Series C and Series D preferred stock was $0.61, $0.54, $2.76 and $8.10, respectively, and is subject to adjustment in accordance with anti-dilution provisions provided for in the Company’s Certificate of Formation. The Company’s Certificate of Formation also specifies that, solely with respect to the calculation of the conversion of the Series C preferred stock in connection with an initial public offering, the original issue price and the initial conversion price of the Series C preferred stock are both equal to $4.58. As of March 31, 2025, each share of Series A, Series B, Series C and Series D preferred stock was convertible into one share of common stock.
Redemption Rights
At any time on or after the fifth anniversary of the Series C and Series D original issue date, which will begin for Series C in March 2026 and for Series D in May 2026, upon written notice from the applicable shareholders, the Series C and Series D shares shall be redeemed by the Company at a price per share equal to the greater of (i) the original issue price plus (a) all declared by unpaid dividends thereon and (b) a 7.0% cumulative accruing dividend, compounding annually, or (ii) the fair market value as determined by an independent appraiser.
Anti-dilution
Subject to certain exceptions, the conversion price of the Series A and Series B preferred stock is subject to broad-based weighted average adjustment to prevent dilution in the event that the Company issues additional shares at a purchase price less than the then-applicable conversion price of the Series A and Series B preferred stock, respectively. Subject to certain exceptions, in the event the Company sells additional shares of stock at a price per share less than the Series C and Series D original issue price, the conversion price of the Series C preferred stock is adjusted to the lower price that the Company sells shares in such offering, and the conversion price of the Series D preferred stock is adjusted based on a broad-based weighted average anti-dilution formula. In the event the Company sells shares in an initial public offering for less than 1.11111 times the applicable Series C conversion price, then the Series C conversion price will be reduced (but never increased), concurrently with such issuance to 90.0% of the purchase price in such initial public offering. In the event the Company sells shares in an initial public offering for less than 110.0% of the applicable Series D conversion price, then the series D conversion price will be reduced (but never increased), concurrently with such issuance to 90.0% of the purchase price in such initial public offering.
Note 7. Shareholders’ Equity
Common Stock
As of March 31, 2025 and December 31, 2024, 1,173,000,000 and 1,150,000,000 shares of common stock with a $0.001 par value were authorized, respectively. There were 140,950,490 and 143,369,083 shares outstanding at March 31, 2025 and December 31, 2024, respectively.
 
F-62

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s shareholders. Common shareholders are entitled to receive dividends if and when declared by the Company’s board of directors, subject to the preferential dividend rights of any preferred stock then outstanding. No dividends have been declared or paid by the Company since its inception.
Treasury Stock
During the three months ended March 31, 2025, the Company repurchased 5,752,550 shares of common stock for an amount of $16.6 million, mainly associated with previously early-exercised options. Refer to below for further details. No common shares were repurchased during the year ended December 31, 2024. Repurchased common stock is shown on the condensed consolidated balance sheets and condensed consolidated statements of redeemable convertible preferred stock and shareholders’ deficit as treasury stock. The Company had 6,482,550 and 730,000 shares of treasury stock as of March 31, 2025 and December 31, 2024, respectively. These shares have not been retired. The Company has not reissued any shares of treasury stock as of March 31, 2025 and December 31, 2024.
2020 Incentive Plan
Pursuant to the 2020 Incentive Plan (the “Plan”), the Company may grant awards of options, restricted awards, performance awards or share appreciation rights to employees, consultants, and directors of the Company. A total of 104,364,034 shares of common stock are reserved for issuance upon the exercise of all awards granted or available to be granted under the Plan as of March 31, 2025.
To the extent permitted by applicable laws or any exchange rule, any shares of common stock issued under this Plan that are issued (a) in connection with the Company’s acquisition of an unaffiliated business entity, (b) to the employees of such entity, and (c) in substitution of equity incentive awards previously issued to such employees by such entity shall not reduce the number of shares of common stock available for issuance under the Plan.
The Plan provides for a repurchase feature for vested stock-based awards at the option of the Company if the employee’s continuous service terminates for any reason, with or without cause, including death or disability. The repurchase shall be exercisable at a price equal to the fair market value of vested shares or, in the case of exercisable options, the fair market value of the common stock underlying such unexercised options less the aggregate exercise price of such options. The Company’s repurchase lapses when the Company’s common stock becomes publicly traded.
Option Activity
Under the Plan, the Company has granted incentive stock options and non-qualified stock options to its employees and other service providers (non-employees). Most of the Company’s stock options vest incrementally over five years, subject to the grantee’s continuous employment with the Company (“time-vesting options”). The Company recognizes compensation cost on a straight-line basis over the requisite service period for its time-vesting options. In addition to its time-vesting options, the Company has also granted stock options to certain non-employees for which vesting is tied to the grantee’s performance (“performance-vesting options”). The Company evaluates whether it is probable that the performance metric will be achieved for its performance-vesting options and recognizes compensation cost on a straight-line basis over the implied service period if achievement of the performance metric is deemed probable. No option shall be exercisable after the expiration of 10 years from the date it was granted. The exercise price of each option shall be not less than 100.0% of the fair market value of the common stock subject to the option on the date the option is granted.
The following tables summarize the Company’s stock option activity during the three months ended March 31, 2025:
 
F-63

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
​ ​ ​
Options Outstanding
​
​ ​ ​
Number of
Options
​ ​
Weighted
Average
Exercise
Price
Per Share
​ ​
Weighted
Average
Remaining
Contract
Term
(in years)
​ ​
Aggregate
Intrinsic
Value
(in thousands)
​
Total outstanding as of December 31, 2024:
​ ​ ​ ​ 87,082,658 ​ ​ ​ ​ $ 2.27 ​ ​ ​ ​ ​ 5.40 ​ ​ ​ ​ $ 226,117 ​ ​
Granted
​ ​ ​ ​ 11,341,559 ​ ​ ​ ​ ​ 4.65 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ — ​ ​
Exercised
​ ​ ​ ​ (685,957) ​ ​ ​ ​ ​ 2.08 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 1,766 ​ ​
Cancelled/forfeited
​ ​ ​ ​ (1,282,283) ​ ​ ​ ​ ​ 2.45 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2,839 ​ ​
Total outstanding as of March 31, 2025
​ ​ ​ ​ 96,455,977 ​ ​ ​ ​ $ 2.55 ​ ​ ​ ​ ​ 5.71 ​ ​ ​ ​ $ 361,193 ​ ​
Total exercisable as of March 31, 2025
​ ​ ​ ​ 67,399,410 ​ ​ ​ ​ $ 1.80 ​ ​ ​ ​ ​ 4.44 ​ ​ ​ ​ $ 302,635 ​ ​
Total vested or expected to vest as of March 31, 2025
​ ​ ​ ​ 91,901,836 ​ ​ ​ ​ $ 2.45 ​ ​ ​ ​ ​ 5.56 ​ ​ ​ ​ $ 352,524 ​ ​
​ ​ ​
Unvested/Vested Activity
​
​ ​ ​
Options
​ ​
Weighted
Average
Exercise
Price
​ ​
Weighted
Average
Grant Date
Fair
Value
​ ​
Average
Remaining
Life
(in years)
​
Unvested outstanding, as of December 31, 2024
​ ​ ​ ​ 26,636,592 ​ ​ ​ ​ $ 3.95 ​ ​ ​ ​ $ 2.35 ​ ​ ​ ​ ​ 3.30 ​ ​
Granted
​ ​ ​ ​ 11,341,559 ​ ​ ​ ​ ​ 4.65 ​ ​ ​ ​ ​ 3.89 ​ ​ ​ ​ ​ ​ ​ ​
Cancelled/forfeited
​ ​ ​ ​ (142,927) ​ ​ ​ ​ ​ 4.19 ​ ​ ​ ​ ​ 2.63 ​ ​ ​ ​ ​ ​ ​ ​
Vested, outstanding shares
​ ​ ​ ​ (5,988,657) ​ ​ ​ ​ ​ 3.64 ​ ​ ​ ​ ​ 2.40 ​ ​ ​ ​ ​ ​ ​ ​
Unvested outstanding, as of March 31, 2025
​ ​ ​ ​ 31,846,567 ​ ​ ​ ​ ​ 4.26 ​ ​ ​ ​ ​ 2.89 ​ ​ ​ ​ ​ 3.41 ​ ​
Early exercised unvested, end of period
​ ​ ​ ​ 174,412 ​ ​ ​ ​ $ 4.05 ​ ​ ​ ​ $ 2.60 ​ ​ ​ ​ ​ ​ ​ ​
Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options.
The weighted average grant date fair value of options granted during the three months ended March 31, 2025 was $3.89 per option. The total grant date fair value of options vested during the three months ended March 31, 2025 and 2024 was $14.4 million and $5.9 million, respectively. The total intrinsic value of options exercised during the three months ended March 31, 2025 and 2024 was $1.8 million and $0.4 million, respectively.
Modification to stock options
On November 9, 2021 and February 23, 2022, the Company granted stock options to certain executives that are exercisable upon vesting for 1,325,000 shares and 8,000,000 shares of the Company’s common stock, respectively (the “Prior Stock Options”). The Prior Stock Options vested over five years. On August 11, 2022, the Company’s Compensation Committee approved a modification to the Prior Stock Options, which was communicated to holders of the Prior Stock Options on September 1, 2022. The modification reduced the exercise price to $4.05 and modified the vesting conditions such that 20.0% vest upon grant, while the remainder vest over the following four years. The total number of grantees affected by this modification was twelve. The modification was not mandatory, but rather could be elected by holders of the Prior Stock Options on an individual holder basis. If the holder elected to participate, the holder’s Prior Stock Options were immediately canceled, and the Company issued the holder an equivalent number of new stock options in exchange (the “New Stock Options”) which could be early exercised prior to vesting. All of the holders elected to participate in the modification and exchanged their Prior Stock Options for New Stock Options. In addition, as an alternative to paying cash, holders of the New Stock Options that elected to exercise their options were able to pay for the exercise price by executing a full recourse promissory
 
F-64

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
note with the Company that is secured by the holder’s restricted shares that are issued upon early exercise. Five grantees elected to early exercise 6,120,000 options utilizing the promissory note.
The principal of each note is equal to the exercise price of the New Stock Options. Interest on the unpaid balance will compound annually and accrue at a fixed rate per annum equal to the mid-term applicable federal rate in effect on the issuance of the note. The maturity date of the notes is the earlier of (1) December 31, 2030 or (2) the occurrence of a change in control event, unless an acceleration event occurs sooner. An acceleration event would generally occur if required to ensure compliance with Section 402 of the Sarbanes-Oxley Act of 2022, the termination of the holder’s employment, the insolvency of the holder or the breach of any warranty of the holder. The holder may elect to prepay the outstanding principal and accrued interest balance of the promissory note at any time without penalty.
In addition to the outstanding balance of the note becoming due and payable immediately, upon the occurrence of an acceleration event, if the holder defaults on payment of the note, then interest will accrue at the maximum rate permitted by applicable law. The Company will have full recourse against the holder for failure to pay the note as and when due. Such promissory notes will be secured by the restricted shares issued to the holder that are underlying the note. If the note is not repaid upon an event of default or acceleration event, the Company has the right to repurchase the restricted shares issued upon the exercise of the note for fair market value, which proceeds will apply to repayment of the note (with any remaining balance remaining due).
The Company accounted for the modification as a Type I (Probable to Probable) modification under ASC 718 that does not change the classification of the award (i.e., the New Stock Options continue to be classified within equity). The Company calculated the fair value of the Prior Stock Options and New Stock Options immediately prior to and after the modification using the Black-Scholes option pricing model. The incremental fair value was added to the original unrecognized compensation cost to arrive at the new unrecognized compensation cost, to be recognized over the remaining requisite service period.
Unvested stock received from early exercises of the New Stock Options are subject to a right of repurchase at the lesser of (i) original issuance price or (ii) then-current fair market value in the event of the employee’s termination, either voluntary, or involuntary. The Company’s repurchase right with respect to these shares typically lapse over four years as the shares become vested. Early exercises of stock options are not deemed to be substantive exercises for accounting purposes and accordingly, consideration received for exercises of unvested stock options is initially recorded as a liability and subsequently reclassified into shareholders’ deficit as the related shares vest. As of March 31, 2025 and December 31, 2024, 174,412 and 2,648,000 shares from options exercised to date were subject to repurchase at a price of $4.05 per share. Of the amount subject to repurchase as of March 31, 2025 and December 31, 2024, $0.3 million and $5.0 million was recorded within other accrued expenses and current liabilities, respectively, and $0.4 million and $5.8 million was recorded within other long-term liabilities on the condensed consolidated balance sheets, respectively. In addition, as the early exercise was performed via issuance of a promissory note, a corresponding debt amount, plus related interest income was recorded as contra-equity. The total amount presented as contra-equity as of December 31, 2024 $26.5 million, which includes interest income and the impact from exercises of both the vested portion of the New Stock Options and early exercises.
On March 3, 2025, the Company repurchased 5,716,850 common stock shares issued upon early exercise of stock options at $4.65 per share and proceeds were used to pay off the promissory notes and accrued interests. Repurchased common stock shares included 3,243,262 and 2,473,588 common stock shares, respectively, that were for options vested and unvested at the time of the repurchase, respectively. On the same day, the Company granted 6,120,000 new stock options to the same employees. New options were issued at an exercise price of $4.65 per share, have the same vesting status as cancelled options and are not early exercisable. The other terms of the new options are substantially the same as the original options.
The Company accounted for the repurchase of the shares and grant of the new options as a Type I (Probable to Probable) modification under ASC 718. The Company calculated the fair value of the original options and new options immediately prior to and after the modification using the Black-Scholes option pricing model based on the following assumptions: risk-free interest rate of 3.93% – 3.99%; dividend yield
 
F-65

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
of 0.00%; stock price volatility of 68.96% – 69.48%; and an expected life of 5.0 – 5.3 years. The total incremental fair value was $15.1 million, of which $8.6 million corresponding to the vested options was immediately recognized as compensation expense, with the remaining $6.5 million and the original unrecognized compensation cost of $5.7 million being recognized over the remaining requisite service period.
Restricted Awards Activity
The Company grants restricted stock units that will be settled in shares of the Company’s common stock upon vesting to its employees and non-employee directors.
Vesting of the restricted stock units is contingent upon the Company completing either an initial public offering of its common stock or a change of control. The Company has determined that these performance conditions are not probable of being achieved, and thus has not recognized any compensation expense associated with its restricted stock units.
The following table summarizes the Company’s restricted stock unit activity for the three months ended March 31, 2025:
​ ​ ​
Number of
Restricted Stock
Units
​ ​
Weighted
Average Grant
Date Fair Value
​
Unvested as of December 31, 2024
​ ​ ​ ​ 3,050,000 ​ ​ ​ ​ $ 4.55 ​ ​
Granted
​ ​ ​ ​ 2,088,160 ​ ​ ​ ​ $ 4.65 ​ ​
Unvested as of March 31, 2025
​ ​ ​ ​ 5,138,160 ​ ​ ​ ​ $ 4.59 ​ ​
Stock-Based Compensation Expense
The Company recorded stock-based compensation expense in the condensed consolidated statements of operations and comprehensive loss as follows:
​ ​ ​
Three Months Ended March 31,
​
​ ​ ​
2025
​ ​
2024
​
​ ​ ​
(amounts in thousands)
​
Cost of services–Molecular profiling services
​ ​ ​ $ 466 ​ ​ ​ ​ $ 427 ​ ​
Cost of services–Pharma research and development services
​ ​ ​ ​ 1 ​ ​ ​ ​ ​ 2 ​ ​
Selling and marketing expense
​ ​ ​ ​ 1,243 ​ ​ ​ ​ ​ 1,118 ​ ​
General and administrative expense
​ ​ ​ ​ 10,636 ​ ​ ​ ​ ​ 1,945 ​ ​
Research and development expense
​ ​ ​ ​ 2,346 ​ ​ ​ ​ ​ 966 ​ ​
Total
​ ​ ​ $ 14,691 ​ ​ ​ ​ $ 4,458 ​ ​
There was no tax benefit associated with the above stock-based compensation expense.
Valuation of Stock-Based Awards to Employees
The Company records stock-based compensation expense for stock-based awards based on the estimated fair value of the awards on the date of the grant. The fair value of the Company’s restricted stock units is based on the fair value of the Company’s common stock at the date of grant.
The Company estimates the fair value of stock options using a Black-Scholes option pricing model. The absence of a public market for the Company’s common stock requires the Company’s board of directors to estimate the fair value of its common stock for purposes of granting options and for determining stock-based compensation expense by considering several objective and subjective factors, including contemporaneous third-party valuations, actual and forecasted operating and financial results, market
 
F-66

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
conditions and performance of comparable publicly traded companies, developments and milestones in the Company, the rights and preferences of common and convertible preferred stock, transactions involving the Company’s common stock, and assumptions for a discount for lack of marketability. The fair value of the Company’s common stock was determined in accordance with the applicable elements of the American Institute of Certified Public Accountants Accounting and Valuations Guide, Valuation of Privately Held Company Equity Securities Issued as Compensation.
The key assumptions used in determining the fair value of options granted and a summary of the methodology applied to develop each assumption are as follows:
​ ​ ​
Three Months Ended
March 31,
2025
​
Expected volatility
​ ​
69.0%–69.5%
​
Risk-free interest rate
​ ​
3.9%–4.1%
​
Expected term (years)
​ ​
5.00–6.55
​
Expected dividend rate
​ ​
—%
​
Expected forfeiture rate
​ ​
0.0%–8.3%
​
No awards were granted during the three months ended March 31, 2024.
Expected volatility.   This is a measure of the amount by which the share price has fluctuated or is expected to fluctuate. An increase in the expected price volatility will increase the fair value of the option granted and the related compensation expense. As the Company is not publicly traded, the expected price volatility for the Company’s options was determined by using an average of historical volatilities of selected industry peers deemed to be comparable to the business corresponding to the expected term of the awards.
Risk-free interest rate.   The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for U.S. Treasury notes with maturities corresponding to the expected term of the awards.
Expected term.   This is the period of time over which the options granted are expected to remain outstanding and is based on the Company’s estimate, taking into consideration vesting term, contractual term and historical actual lives. Options granted have a maximum term of ten years. An increase in the expected life will increase the fair value of the option granted and the related compensation expense. Due to the lack of historical share option exercise data, the Company utilizes the simplified method for determining the expected term.
Dividend rate.   The Company has not made any dividend payments, nor does it have plans to pay dividends in the foreseeable future. Therefore, an expected dividend yield of zero is utilized.
Forfeitures.   Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate.
 
F-67

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 8. Long-Term Debt
The carrying value of debt presented within current portion of notes payable and long-term indebtedness, net of debt discounts on the condensed consolidated balance sheets as of March 31, 2025 and December 31, 2024 includes the following components:
​ ​ ​
As of March 31,
2025
​ ​
As of December 31,
2024
​
​ ​ ​
(amounts in thousands)
​
Term loan Initial Draw–January 18, 2023
​ ​ ​ $ 200,000 ​ ​ ​ ​ $ 200,000 ​ ​
Exit fee on term loan–January 18, 2023
​ ​ ​ ​ 2,000 ​ ​ ​ ​ ​ 2,000 ​ ​
Term loan Subsequent Draw–March 5, 2024
​ ​ ​ ​ 200,000 ​ ​ ​ ​ ​ 200,000 ​ ​
Exit fee on term loan–March 5, 2024
​ ​ ​ ​ 2,000 ​ ​ ​ ​ ​ 2,000 ​ ​
Less: Amortized debt discounts and financing costs(1)
​ ​ ​ ​ (28,918) ​ ​ ​ ​ ​ (30,863) ​ ​
Net debt
​ ​ ​
$
375,082
​ ​ ​ ​
$
373,137
​ ​
Compound bifurcated derivative liability
​ ​ ​ $ 1,342 ​ ​ ​ ​ $ 6,058 ​ ​
​
(1)
Includes debt discounts of $28.3 million associated with the initial carrying value of compound bifurcated derivative liability.
​
Maturities of the Company’s debt are expected to be as follows as of March 31, 2025:
​ ​ ​
Amount
​
Years Ending December 31, ​ ​ ​ ​ ​ ​ ​
Remainder of 2025(1)
​ ​ ​ $ 60,000 ​ ​
2026
​ ​ ​ ​ — ​ ​
2027
​ ​ ​ ​ — ​ ​
2028
​ ​ ​ ​ 340,000 ​ ​
2029
​ ​ ​ ​ — ​ ​
​
(1)
Represents 15% of the outstanding principal amount under the 2023 Term Loan Agreement, which is due on the earlier of (x) for dates prior to January 1, 2026, any date that the redemption rights in respect of our Series C preferred stock or Series D preferred stock are or may become exercisable within 90 days following such date, or (y) January 1, 2026 or the first date thereafter if, as of such date, the redemption rights in respect of our Series C preferred stock or Series D preferred stock are or may become exercisable on or prior to the date that is six months after the maturity date. The Series C preferred stock redemption rights may be exercised on or after March 31, 2026. All outstanding shares of our Series C preferred stock and Series D preferred stock will convert into shares of common stock as part of the Preferred Stock Conversion and any redemption rights thereunder will terminate in connection with the completion of this offering and consequently, the payments disclosed herein would not be applicable.
​
Term Loan Refinancing
On September 21, 2018, the Company entered into a secured term loan agreement (the “Original Term Loan Agreement”) with Sixth Street Specialty Lending, Inc. and Barnett Debt Holdings, LLC (collectively, the “Original Term Loan Lenders”), which provided the Company with an initial term loan of $50.0 million (the “2018 Term Loan”) and a delayed term loan draw option of $50.0 million, which the Company drew down in full on October 4, 2019 (the “2019 Term Loan”). On April 2, 2020, the Company amended the Original Term Loan Agreement (the “Amended Term Loan Agreement”) to obtain additional term loan proceeds of $75.0 million (the “2020 Term Loan” and collectively with the 2018 Term Loan and the 2019 Term Loan, the “Original Term Loans”).
 
F-68

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
On January 18, 2023, the Company entered into the New Term Loan Agreement with OrbiMed Royalty & Credit Opportunities III, LP, OrbiMed Royalty & Credit Opportunities IV, LP (collectively, “OrbiMed”), and Braidwell Transaction Holdings LLC (“Braidwell”, and collectively with OrbiMed, the “New Term Loan Lenders”). Pursuant to the New Term Loan Agreement, the Company issued senior, secured promissory notes by which the New Term Loan Lenders agree to lend the Company up to an aggregate principal amount of $400.0 million, $200.0 million of which was received by the Company upon issuance (the “Initial Draw”), and the remaining $200.0 million was received by the Company in March 2024 (the “Delayed Draw”).
Until the earlier of December 31, 2024 or the date on which the 2024 Term Loan amount was fully drawn, which occurred on March 5, 2024, the undrawn balance of the New Term Loan Commitment was subject to a fee of 0.5% per annum. The outstanding principal amount of the 2023 Term Loan is due and payable on January 18, 2028. If an event of default occurs and is continuing, the New Term Loan Lenders may declare all amounts outstanding under the New Term Loan Agreement to be immediately due and payable. A final payment exit fee equal to 1.0% of the amount funded under the New Term Loan Agreement is due upon prepayment or maturity. Amounts borrowed pursuant to the New Term Loan Agreement may be prepaid at any time. Upon prepayment, the Company is subject to a prepayment penalty based on the timing of repayment.
The 2023 Term Loan bears interest at a rate per annum equal to a fixed margin of 6.5% plus the greater of (a) forward-looking three-month secured overnight financing rate (“SOFR”) and (b) 2.5%. In the event of default, the fixed margin shall increase by 3.0% per annum. As of March 31, 2025, the interest rate was 10.8%. Regular quarterly payments are interest-only for the 60-month term of the New Term Loan Agreement, with the principal due at maturity. The effective interest rate for the Initial Draw of the 2023 Term Loan is 17.0%, and the effective interest rate for the Delayed Draw of the 2023 Term Loan is 12.0%.
The Company’s obligations under the New Term Loan Agreement are secured by a first lien security interest in substantially all of the assets of the Company and its subsidiaries. The New Term Loan Agreement contains certain customary representations and warranties, affirmative and negative covenants, financial covenants, and events of default applicable to the Company and its subsidiaries. Additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt. At March 31, 2025, the Company is in compliance with all covenants.
The Company identified multiple embedded derivatives that require bifurcation from the 2023 Term Loan. They are separately accounted for in the condensed consolidated financial statements as one compound derivative liability. Those embedded features include various contingent prepayment and compensatory payment features as well as interest rate increases upon an event of default.
Interest Expense
The components of interest expense associated with the Company’s long-term indebtedness, excluding finance leases, are as follows:
​ ​ ​
Three Months Ended March 31,
​
​ ​ ​
2025
​ ​
2024
​
​ ​ ​
(amounts in thousands)
​
Debt discount amortization
​ ​ ​ $ 1,945 ​ ​ ​ ​ $ 1,589 ​ ​
Interest expense
​ ​ ​ ​ 10,829 ​ ​ ​ ​ ​ 7,690 ​ ​
Interest expense on long-term indebtedness, excluding finance leases
​ ​ ​ $ 12,774 ​ ​ ​ ​ ​ 9,279 ​ ​
Warrant Liability
As part of the Original Term Loan Agreement, the Company issued 13,694,623 warrants with an exercise price of $1.61 (the “2018 Warrants”). In connection with the amendment to the Original Term
 
F-69

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Loan Agreement in 2020, the Company issued an additional 11,399,814 warrants with an exercise price of $1.93 (the “2020 Warrants”) and amended the 2018 Warrants. Furthermore, these amendments also permit the exercise of both the 2018 Warrants and 2020 Warrants into Series C preferred stock or common stock at the option of the holder. As a result of the amendment to permit exercise of the warrants into redeemable preferred stock, the warrants are classified as a liability pursuant to the guidance in ASC 480. Therefore, the warrants are reported at fair value within warrant liabilities on the condensed consolidated balance sheets, with changes in fair value reported within changes in fair value of financial instruments on the condensed consolidated statements of operations and comprehensive loss.
The following table reflects the changes in fair values associated with these warrants.
​ ​ ​
2018 Warrants
​ ​
2020 Warrants
​
Warrants granted
​ ​
13,694,623
​ ​
11,399,814
​
Exercise price
​ ​
$1.61
​ ​
$1.93
​
Exercise period
​ ​
Earlier of 7 years from the date of issuance,
or immediately after closing IPO
​
Fair value at date of issuance
​ ​
$0.8 million
​ ​
$7.9 million
​
​ ​ ​
(amounts in thousands)
​
Fair value at December 31, 2023
​ ​ ​ $ 54,540 ​ ​ ​ ​ $ 44,193 ​ ​
Decrease in fair value
​ ​ ​ ​ (2,911) ​ ​ ​ ​ ​ (4,180) ​ ​
Fair value at December 31, 2024
​ ​ ​ $ 51,629 ​ ​ ​ ​ $ 40,013 ​ ​
Increase in fair value
​ ​ ​ ​ 20,405 ​ ​ ​ ​ ​ 16,644 ​ ​
Fair value at March 31, 2025
​ ​ ​ $ 72,034 ​ ​ ​ ​ $ 56,657 ​ ​
Note 9. Commitments and Contingencies
Purchase Obligations
The Company enters into various supply agreements that contains purchase commitments. Most of the commitments are based on a binding forecast for an agreed-upon period, which is 12-month or less.
Corporate Liability and Insurance
The Company maintains professional liability, general liability, and other customary insurance on a claims-made basis in amounts deemed appropriate by the Company’s management based upon historical claims and the nature and risks of the Company. The Company’s business may subject the Company to litigation and liability for damages. The Company believes that current insurance protection is adequate for present business operations, but there can be no assurance that the Company will be able to maintain professional and general liability insurance coverage in the future or that such insurance coverage will be available on acceptable terms or adequate to cover any or all potential product or professional liability claims. A successful liability claim in excess of insurance coverage could have a material adverse effect on the Company.
Litigation
During the ordinary course of business, the Company has become and may in the future become subject to pending and threatened legal and regulatory actions and proceedings. While it is not feasible to predict or determine the ultimate outcome of these matters, the Company believes that none of its current legal proceedings will have a material adverse effect on its financial position, results of operations, or cash flows for the periods ended March 31, 2025 and December 31, 2024.
 
F-70

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Note 10. Related Parties
The Company’s officers and directors have ownership interests in certain vendors providing services to the Company. During the three months ended March 31, 2025 and 2024, the Company made payments to these entities for services and expenses for $0.7 million and $0.5 million, respectively.
Note 11. Net Loss Per Share Attributable to Common shareholders
The following table sets forth the computation of the basic and diluted net loss per share attributable to common shareholders:
​ ​ ​
Three Months Ended March 31,
​
(amounts in thousands, except per share data)
​ ​
2025
​ ​
2024
​
Net loss
​ ​ ​ $ (102,581) ​ ​ ​ ​ $ (111,028) ​ ​
Adjustments of redeemable convertible preferred stock to redemption value
​ ​ ​ ​ (24,462) ​ ​ ​ ​ ​ (23,113) ​ ​
Net loss attributable to common shareholders
​ ​ ​ $ (127,043) ​ ​ ​ ​ $ (134,141) ​ ​
Net loss per share attributable to common shareholders, basic and diluted
​ ​ ​ $ (0.89) ​ ​ ​ ​ $ (0.95) ​ ​
Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted
​ ​ ​ ​ 142,492 ​ ​ ​ ​ ​ 141,252 ​ ​
The following common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common shareholders for the periods presented as they had an anti-dilutive effect:
​ ​ ​
Three Months Ended March 31,
​
​ ​ ​
2025
​ ​
2024
​
Series A preferred stock
​ ​ ​ ​ 485,795,293 ​ ​ ​ ​ ​ 485,795,293 ​ ​
Series B preferred stock
​ ​ ​ ​ 29,629,630 ​ ​ ​ ​ ​ 29,629,630 ​ ​
Series C preferred stock
​ ​ ​ ​ 116,200,835 ​ ​ ​ ​ ​ 116,200,835 ​ ​
Series D preferred stock
​ ​ ​ ​ 102,516,283 ​ ​ ​ ​ ​ 102,516,283 ​ ​
Outstanding warrants
​ ​ ​ ​ 25,094,437 ​ ​ ​ ​ ​ 25,094,437 ​ ​
Outstanding stock options
​ ​ ​ ​ 96,455,977 ​ ​ ​ ​ ​ 86,008,216 ​ ​
Unvested shares subject to repurchase
​ ​ ​ ​ 174,412 ​ ​ ​ ​ ​ 3,872,000 ​ ​
Total
​ ​ ​ ​ 855,866,867 ​ ​ ​ ​ ​ 849,116,694 ​ ​
Note 12. Segment and Geographic Information
The Company operates as a single operating segment. An operating segment is defined as a component of an entity for which discrete financial information is available and regularly reviewed by the entity’s chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM, its Chairman and Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance.
Net loss as reported on the condensed consolidated statements of operations and comprehensive loss is used by the CODM to assess segment performance against management budgets and prior period operating results for the purpose of making results-driven decisions about organizational resource allocation.
Segment revenues are derived from molecular profiling, strategic data, and research services that are delivered to the Company’s biopharmaceutical and clinical customers, who are predominantly located in the United States. The Company provides these services primarily by leveraging the Company’s proprietary technologies and clinico-genomic database, which are core to the Company’s operations and are deployed similarly across the service offerings.
 
F-71

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The table below is a summary of the segment profit or loss, including significant segment expenses:
​ ​ ​
Three Months Ended March 31,
​
​ ​ ​
2025
​ ​
2024
​
​ ​ ​
(amounts in thousands)
​
Revenue
​ ​ ​ $ 120,915 ​ ​ ​ ​ $ 80,677 ​ ​
Less: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Cost of services−Molecular profiling services
​ ​ ​ ​ 60,894 ​ ​ ​ ​ ​ 52,894 ​ ​
Cost of services−Pharma research and development services
​ ​ ​ ​ 2,958 ​ ​ ​ ​ ​ 1,669 ​ ​
Selling and marketing expense
​ ​ ​ ​ 39,829 ​ ​ ​ ​ ​ 39,609 ​ ​
General and administrative expense
​ ​ ​ ​ 52,119 ​ ​ ​ ​ ​ 44,354 ​ ​
Research and development expense
​ ​ ​ ​ 23,066 ​ ​ ​ ​ ​ 34,376 ​ ​
Interest income
​ ​ ​ ​ 503 ​ ​ ​ ​ ​ 1,768 ​ ​
Interest expense
​ ​ ​ ​ (12,782) ​ ​ ​ ​ ​ (9,290) ​ ​
Changes in fair value of financial instruments
​ ​ ​ ​ (32,333) ​ ​ ​ ​ ​ (11,064) ​ ​
Other expense, net
​ ​ ​ ​ (17) ​ ​ ​ ​ ​ (219) ​ ​
Segment and consolidated net loss
​ ​ ​ $ (102,581) ​ ​ ​ ​ $ (111,028) ​ ​
The following table sets forth the Company’s revenue by geographic areas based on the customer’s location:
​ ​ ​
Three Months Ended March 31,
​
​ ​ ​
2025
​ ​
2024
​
​ ​ ​
(amounts in thousands)
​
United States
​ ​ ​ $ 118,432 ​ ​ ​ ​ $ 78,430 ​ ​
International
​ ​ ​ ​ 2,483 ​ ​ ​ ​ ​ 2,247 ​ ​
Total revenue
​ ​ ​ $ 120,915 ​ ​ ​ ​ $ 80,677 ​ ​
No single country outside of the United States accounted for more than 10.0% of total revenue during each of the three months ended March 31, 2025 and 2024. As of March 31, 2025 and December 31, 2024, approximately 99.0% of the Company’s total assets are located in the United States.
Note 13. Employee Benefit Plan
The Company sponsors a 401(k) plan, and pursuant to its terms, eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory maximum or 100.0% of eligible compensation on a pre-tax basis. For the three months ended March 31, 2025 and 2024, the Company contributed $1.9 million and $2.2 million, respectively, to match employee contributions as permitted by the plan. The Company pays the administrative costs for the plan.
Note 14. Subsequent Events
On April 1, 2025, the Company closed a private financing in which it issued a combination of senior convertible notes (the “2025 Convertible Notes”), Series E convertible preferred stock and Series F convertible preferred stock, for an aggregate of $167.7 million. The 2025 Convertible Notes have an aggregate principal amount of $30.0 million. The 2025 Convertible Notes accrue interest at a rate of 8% per annum, payable quarterly in cash, and mature on January 1, 2026. The Company issued 12,345,674 shares of Series E convertible preferred stock with a purchase price of $8.10 per share, for aggregate proceeds of $100.0 million. The Company also issued 4,657,401 shares of Series F convertible preferred stock with a purchase price of $8.10 per share, for aggregate proceeds of $37.7 million. In connection with this financing, the Company also issued warrants to acquire shares of common stock to the holders of the 2025 Convertible Notes.
 
F-72

TABLE OF CONTENTS
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)
These warrants are not initially exercisable for any shares of common stock, but such warrants become exercisable for a specified dollar value of shares on a monthly basis commencing on June 1, 2025 if we have not completed an initial public offering by such date. Any exercisable portion of the warrants will be automatically exercised prior to the closing of the initial public offering and such warrants will terminate upon the closing of the offering.
Immediately prior to and in connection with the completion of the initial public offering, the 2025 Convertible Notes, Series E convertible preferred stock and Series F convertible preferred stock (plus an 8% accretion in connection with the preferred stocks) will convert into common stock at a price equal to 70% of the initial public offering price per share.
There were no other significant subsequent events identified through the date that the condensed consolidated financial statements were issued, that could impact the financial statements.
 
F-73

TABLE OF CONTENTS
​
​
Through and including           , 2025 (the 25th day after the date of this prospectus), all dealers effecting transactions in the Class A common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealer’s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.
       Shares
[MISSING IMAGE: lg_carislifesciences-pn.jpg]
Class A Common Stock
​
P R O S P E C T U S
​
BofA Securities
J.P. Morgan
Goldman Sachs & Co. LLC
Citigroup
TD Cowen
Evercore ISI
Guggenheim Securities
BTIG
Wolfe | Nomura Alliance
          , 2025
​
​

TABLE OF CONTENTS
 
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 13.   Other Expenses of Issuance and Distribution
The following table presents the costs and expenses, other than underwriting discounts and commissions, payable in connection with this offering. All amounts are estimates except the SEC registration fee, the FINRA filing fee, and Nasdaq listing fee. Except as otherwise noted, all the expenses below will be paid by us.
​
SEC registration fee
​ ​ ​ $ 15,310 ​ ​
​
FINRA filing fee
​ ​ ​ ​ 15,500 ​ ​
​
Nasdaq listing fee
​ ​ ​ ​ * ​ ​
​
Printing and engraving expenses
​ ​ ​ ​ * ​ ​
​
Legal fees and expenses
​ ​ ​ ​ * ​ ​
​
Accounting fees and expenses
​ ​ ​ ​ * ​ ​
​
Transfer agent and registrar fees
​ ​ ​ ​ * ​ ​
​
Miscellaneous fees and expenses
​ ​ ​ ​ * ​ ​
​
Total
​ ​ ​ $ * ​ ​
​
*
To be completed by amendment.
​
Item 14.   Indemnification of Directors and Officers
Caris Life Sciences, Inc. was incorporated under the laws of Texas.
The Texas Business Organizations Code (the “TBOC”) permits a corporation to indemnify a director who was, is or is threatened to be a named defendant or respondent in a proceeding as a result of the performance of his or her duties if such person acted in good faith and, in the case of conduct in the person’s official capacity as a director, in a manner he or she reasonably believed to be in the best interests of the corporation and, in all other cases, that the person reasonably believed his or her conduct was not opposed to the best interests of the corporation and with respect to any criminal action or proceeding, that such person had no reasonable cause to believe his or her conduct was unlawful. Subject to certain exceptions, the TBOC further permits a corporation to eliminate in its charter all monetary liability of the corporation’s directors to the corporation or its shareholders for conduct in performance of such director’s duties, but not for a breach of the director’s duty of loyalty or receipt of an improper benefit. Our amended and restated certificate of formation will provide that a director of the corporation will not be liable to the corporation or its shareholders for monetary damages for any act or omission by the director in the performance of his or her duties, except that there will be no limitation of liability to the extent the director has been found liable under applicable law for: (i) breach of the director’s duty of loyalty owed to the corporation or its shareholders; (ii) an act or omission not in good faith that constitutes a breach of duty of the director to the corporation or that involves intentional misconduct or a knowing violation of the law; (iii) a transaction from which the director received an improper benefit, regardless of whether the benefit resulted from an action taken within the scope of the director’s duties; or (iv) an act or omission for which the liability of the director is expressly provided for by an applicable statute.
Sections 8.101 and 8.103 of the TBOC provide that a corporation may indemnify a person who was, is or is threatened to be a named defendant or respondent in a proceeding because the person is or was a director only if a determination is made that such indemnification is permissible under the TBOC: (i) by a majority vote of the directors who at the time of the vote are disinterested and independent, regardless of whether such directors constitute a quorum; (ii) by a majority vote of a board committee designated by a majority of disinterested and independent directors and consisting solely of disinterested and independent directors; (iii) by special legal counsel selected by the board of directors or a committee of the board of
 
II-1

TABLE OF CONTENTS
 
directors as set forth in (i) or (ii); (iv) by the shareholders in a vote that excludes the shares held by directors who are not disinterested and independent; or (v) by a unanimous vote of the shareholders.
Section 8.104 of the TBOC provides that the corporation may pay or reimburse, in advance of the final disposition of the proceeding, reasonable expenses incurred by a present director who was, is or is threatened to be made a named defendant or respondent in a proceeding after the corporation receives a written affirmation by the director of his or her good faith belief that he or she has met the standard of conduct necessary for indemnification under Section 8.101 and a written undertaking by or on behalf of the director to repay the amount paid or reimbursed if it is ultimately determined that he or she has not met that standard or if it is ultimately determined that indemnification of the director is not otherwise permitted under the TBOC. Section 8.105 also provides that reasonable expenses incurred by a former director, or a present or former employee, agent, or officer of the corporation, who was, is or is threatened to be made a named defendant or respondent in a proceeding may be paid or reimbursed by the corporation, in advance of the final disposition of the action, as the corporation considers appropriate.
Section 8.105 of the TBOC provides that, subject to restrictions in its certificate of formation and to the extent consistent with other law, a corporation may indemnify and advance expenses to a person who is not a director, including an officer, employee, or agent of the corporation as provided by: (i) the corporation’s governing documents; (ii) an action by the corporation’s governing authority; (iii) resolution by the shareholders; (iv) contract; or (v) common law. As consistent with Section 8.105, persons who are not directors may seek indemnification and advancement of expenses from a corporation to the same extent that directors may seek indemnification and advancement of expenses from a corporation.
Further, our amended and restated certificate of formation and amended and restated bylaws will provide that we must indemnify our directors and officers to the fullest extent authorized by law. We are also expressly required to advance certain expenses to our directors and officers, except for claims brought by us, and carry directors’ and officers’ insurance providing indemnification for our directors and officers for some liabilities. We believe that these indemnification provisions and the directors’ and officers’ insurance are useful to attract and retain qualified directors and executive officers.
We have also entered into, or will enter into prior to the completion of this offering, indemnification agreements with each of our directors and executive officers. The indemnification agreements provide, or will provide, among other things, for indemnification to the fullest extent permitted by the TBOC and our amended and restated certificate of formation and amended and restated bylaws against (i) any and all direct and indirect liabilities and reasonable expenses, including judgments, fines, penalties, interest and amounts paid in settlement of any claim with our approval and reasonable counsel fees and disbursements and (ii) any liabilities incurred as a result of serving as a director, officer, employee, or agent (including as a trustee, fiduciary, partner, or manager or in a similar capacity) of another enterprise or an employee benefit plan at our request. The indemnification agreements also provide for, or will provide for, the advancement or payment of expenses to the indemnitee and for reimbursement to us if it is found that such indemnitee is not entitled to such indemnification under applicable law and our amended and restated certificate of formation and amended and restated bylaws or the terms of the indemnification agreements.
We expect to maintain standard policies of insurance that provide coverage (i) to our directors and officers against loss rising from claims made by reason of breach of duty or other wrongful act and (ii) to us with respect to indemnification payments that we may make to such directors and officers. The underwriting agreement provides for indemnification by the underwriters of us and our officers and directors, and by us of the underwriters, for certain liabilities arising under the Securities Act or otherwise in connection with this offering.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, or persons controlling us under any of the foregoing provisions, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.
Item 15.   Recent Sales of Unregistered Securities
The following sets forth information regarding all unregistered securities sold by us since January 1, 2022:
 
II-2

TABLE OF CONTENTS
 
Convertible Notes Issuances
In April 2025, we issued convertible notes in the aggregate principal amount of $30.0 million to 12 accredited investors.
Preferred Stock Issuances
In September 2023, we issued an aggregate of 31,055,901 shares of our Series C preferred stock, par value $0.001 per share, to three lenders at a conversion price of $1.61 per share, in connection with the conversion of the original aggregate principal amount of $50,000,000 outstanding under a convertible loan agreement with such lenders. Upon such conversion and following our cash payment of $3,002,567.25 in respect of accrued and unpaid pay-in-kind interest under the convertible loan agreement, all of our obligations under the convertible loan agreement were deemed satisfied in full, and the agreement irrevocably terminated.
In April 2025, we issued an aggregate of 12,345,674 shares of our Series E preferred stock, par value $0.001 per share, to 12 accredited investors at a purchase price of $8.10 per share, for an aggregate purchase price of $99,999,959.40.
In April 2025, we issued an aggregate of 4,657,401 shares of our Series F preferred stock, par value $0.001 per share, to 11 accredited investors at a purchase price of $8.10 per share, for an aggregate purchase price of $37,724,948.10.
Warrant Issuances
In April 2025, we issued warrants to, if exercised on or after June 1, 2025, purchase at least an aggregate of        shares of our common stock, based on an assumed initial public offering price of $      per share, which is the midpoint of the price range set forth on the cover page of this prospectus, at an exercise price of $0.01 per share. All of these warrants will terminate in connection with this offering, assuming the offering will occur before June 1, 2025, the date such warrants would otherwise have initially become exercisable for shares of our common stock.
Equity Plan-Related Issuances
From January 1, 2022 through the date of this registration statement, we granted to our employees, officers, and directors options to purchase an aggregate of 60,361,187 shares of our common stock at per share exercise prices ranging from $4.05 to $6.28, and restricted stock units representing an aggregate of 5,170,660 shares of our common stock, under our 2020 Incentive Plan. From January 1, 2022 through the date of this registration statement, we issued an aggregate of 16,534,809 shares of common stock at per share purchase prices ranging from $0.61 to $5.60 pursuant to the exercise of options by our employees, officers, and directors.
The issuances of the securities in the transactions described above were deemed to be exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act and/or Rule 506, Rule 701, or Regulation S promulgated thereunder. The securities were issued directly by us and did not involve a public offering or general solicitation. The recipients of such securities represented their intentions to acquire the securities for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof.
None of the transactions set forth in Item 15 involved any underwriters, underwriting discounts or commissions, or any public offering. All recipients had adequate access, through their relationships with us, to information about us.
 
II-3

TABLE OF CONTENTS
 
Item 16.   Exhibits and Financial Statement Schedules
(a)
Exhibits. The following exhibits are included herein or incorporated herein by reference:
​
​
Exhibit
Number
​ ​
Description
​
​ 1.1* ​ ​ Form of Underwriting Agreement. ​
​  3.1 ​ ​ ​
​  3.2 ​ ​ ​
​  3.3 ​ ​ ​
​  3.4 ​ ​ ​
​  4.1* ​ ​ Form of Registrant’s Class A common stock certificate. ​
​  4.2+ ​ ​ ​
​  5.1* ​ ​ Opinion of Latham & Watkins LLP. ​
​ 10.1(a)+ ​ ​ ​
​ 10.1(b)+ ​ ​ First Amendment to Credit Agreement, dated as of April 1, 2025, among the Registrant, the lenders party thereto, and Wilmington Trust, National Association, as administrative agent and collateral agent. ​
​ 10.2(a)+§ ​ ​ ​
​ 10.2(b)+§ ​ ​ ​
​ 10.3(a)+§ ​ ​ ​
​ 10.3(b)+§ ​ ​ ​
​ 10.3(c)+§ ​ ​ ​
​ 10.4(a)† ​ ​ ​
​ 10.4(b)† ​ ​ ​
​ 10.4(c)† ​ ​ ​
​ 10.4(d)† ​ ​ ​
​ 10.4(e)† ​ ​ ​
​ 10.4(f)† ​ ​ ​
​ 10.4(g)† ​ ​ ​
​ 10.5† ​ ​ ​
​ 10.6† ​ ​ ​
​ 10.7†§ ​ ​ ​
 
II-4

TABLE OF CONTENTS
 
​
Exhibit
Number
​ ​
Description
​
​ 10.8† ​ ​ ​
​ 10.9†§ ​ ​ ​
​ 10.10† ​ ​ ​
​ 10.11† ​ ​ ​
​ 10.12 ​ ​ ​
​ 16.1 ​ ​ ​
​ 21.1* ​ ​ Subsidiaries of the Registrant. ​
​ 23.1 ​ ​ ​
​ 23.2 ​ ​ ​
​ 23.3* ​ ​ Consent of Latham & Watkins LLP (contained in Exhibit 5.1). ​
​ 23.4 ​ ​ ​
​ 24.1 ​ ​ ​
​ 107 ​ ​ ​
​
*
To be filed by amendment.
​
†
Indicates a management contract or compensatory plan or arrangement.
​
+
Certain of the schedules and attachments to this exhibit have been omitted pursuant to Regulation S-K, Item 601(a)(5). The registrant hereby undertakes to provide further information regarding such omitted materials to the SEC upon request.
​
§
Certain portions of this exhibit (indicated by “[***]”) have been redacted pursuant to Regulation S-K, Item 601(a)(6).
​
(b)
Financial Statement Schedules. All schedules have been omitted because the information required to be presented in them is not applicable or is shown in the consolidated financial statements or related notes.
​
Item 17.   Undertakings
The undersigned registrant hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreements certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser.
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
The undersigned registrant hereby undertakes that:
(1)   For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.
 
II-5

TABLE OF CONTENTS
 
(2)   For the purpose of determining any liability under the Securities Act of 1933, as amended, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
 
II-6

TABLE OF CONTENTS​
 
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Irving, Texas, on this 23rd day of May, 2025.
CARIS LIFE SCIENCES, INC.
/s/ David D. Halbert
​
David D. Halbert
Founder, Chairman, and Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints David D. Halbert and Luke Power, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments) and any registration statement related thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought, and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
​
Signature
​ ​
Title
​ ​
Date
​
​
/s/ David D. Halbert
​
David D. Halbert
​ ​ Founder, Chairman, and Chief Executive Officer
(Principal Executive Officer)
​ ​
May 23, 2025
​
​
/s/ Luke Power
​
Luke Power
​ ​ Senior Vice President, Chief Financial Officer, and Chief Accounting Officer
(Principal Financial and Accounting Officer)
​ ​
May 23, 2025
​
​
/s/ George H. Poste
​
George H. Poste
​ ​ Vice Chairman ​ ​
May 23, 2025
​
​
/s/ Jonathan Knowles
​
Jonathan Knowles
​ ​ Vice Chairman ​ ​
May 23, 2025
​
​
/s/ Brian J. Brille
​
Brian J. Brille
​ ​ Vice Chairman and Executive Vice President ​ ​
May 23, 2025
​
​
/s/ Peter M. Castleman
​
Peter M. Castleman
​ ​ Director ​ ​
May 23, 2025
​
​
/s/ David Fredrickson
​
David Fredrickson
​ ​ Director ​ ​
May 23, 2025
​
 
II-7

TABLE OF CONTENTS
 
​
Signature
​ ​
Title
​ ​
Date
​
​
/s/ Joseph E. Gilliam
​
Joseph E. Gilliam
​ ​ Director ​ ​
May 23, 2025
​
​
/s/ Jon S. Halbert
​
Jon S. Halbert
​ ​ Director ​ ​
May 23, 2025
​
​
/s/ Laura I. Johansen
​
Laura I. Johansen
​ ​ Director ​ ​
May 23, 2025
​
​
/s/ Lloyd B. Minor
​
Lloyd B. Minor
​ ​ Director ​ ​
May 23, 2025
​
​
/s/ Danny Phillips
​
Danny Phillips
​ ​ Director ​ ​
May 23, 2025
​
​
/s/ Jeffrey Vacirca
​
Jeffrey Vacirca
​ ​ Director ​ ​
May 23, 2025
​
 
II-8

 

Exhibit 3.1

 

AMENDED AND RESTATED
CERTIFICATE OF
FORMATION
OF
CARIS LIFE SCIENCES, INC.

 

Caris Life Sciences, Inc. (the “Corporation”), a for-profit corporation organized and existing under and by virtue of the provisions of the Texas Business Organizations Code, as amended from time to time (the “TBOC”), does hereby certify:

 

First: The name of the filing entity is Caris Life Sciences, Inc.

 

Second: The Corporation was formed as a Texas for-profit corporation pursuant to the TBOC on July 17, 2020, and issued file number 803691720 by the Secretary of State of the State of Texas (“Secretary of State”).

 

Third: Each new amendment has been made in accordance with the provisions of the TBOC. The amendments to the certificate of formation and the Restated Certificate (as defined below) have been approved in the manner required by the TBOC and by the governing documents of the entity.

 

Fourth: The Amended and Restated Certificate of Formation in the form attached hereto as Exhibit A (the “Restated Certificate”), accurately states the text of the certificate of formation being restated, and each amendment to the certificate of formation being restated that is in effect, and as further amended by the Restated Certificate. The Restated Certificate does not contain any other change in the certificate of formation being restated except for the information permitted to be omitted by the provisions of the TBOC applicable to the filing entity.

 

The undersigned affirms that the person designated as registered agent in the Restated Certificate has consented to the appointment. The undersigned signs this document subject to the penalties imposed by law for the submission of a materially false or fraudulent instrument and certifies under penalty of perjury that the undersigned is authorized under the provisions of law governing the entity to execute the filing instrument.

 

  CARIS LIFE SCIENCES, INC.
     
  By: /s/ David D. Halbert
  Name: David D. Halbert
  Title: Chief Executive Officer 
     
  Date: March 24, 2025

 

 

 

 

AMENDED AND RESTATED
CERTIFICATE OF FORMATION

OF
CARIS LIFE SCIENCES, INC.

 

First: The name of this corporation is Caris Life Sciences, Inc. (the “Corporation”).

 

Second: The address of the registered office of the Corporation in the State of Texas is 1999 Bryan Street, Suite 900, Dallas, Texas 75201 and the name of the registered agent at that address is CT Corporation System.

 

Third: The purpose of the Corporation is to engage in any lawful business for which business corporations may be organized under the TBOC.

 

Fourth: The total number of shares of all classes of stock which the Corporation will have authority to issue is (i) 1,173,000,000 shares of Common Stock, $0.001 par value per share (“Common Stock”) and (ii) 830,600,000 shares of Preferred Stock, $0.001 par value per share (“Preferred Stock”).

 

The following is a statement of the designations and the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation.

 

A.            COMMON STOCK

 

1.                  General. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock set forth herein.

 

2.                  Voting. The holders of the Common Stock are entitled to one vote for each share of Common Stock held at all meetings of shareholders (and written actions in lieu of meetings); provided, however, that, except as otherwise required by law, holders of Common Stock, as such, will not be entitled to vote on any amendment to this Amended and Restated Certificate of Formation (“Restated Certificate”) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to this Restated Certificate or pursuant to the TBOC. There will be no cumulative voting. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Preferred Stock that may be required by the terms of this Restated Certificate) the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section 21.364(d) of the TBOC.

 

-2-

 

 

B.            PREFERRED STOCK

 

(i) 490,000,000 shares of the authorized Preferred Stock of the Corporation are hereby designated “Series A Preferred Stock”; (ii) 30,000,000 shares of the authorized Preferred Stock of the Corporation are hereby designated “Series B Preferred Stock”; (iii) 142,000,000 shares of the authorized Preferred Stock of the Corporation are hereby designated “Series C Preferred Stock”; (iv) 102,600,000 shares of the authorized Preferred Stock of the Corporation are hereby designated “Series D Preferred Stock”; (v) 12,345,678 shares of the authorized Preferred Stock of the Corporation are hereby designated “Series E Preferred Stock”; and (vi) 10,493,827 shares of the authorized Preferred Stock of the Corporation are hereby designated “Series F Preferred Stock”; each with the following rights, preferences, powers, privileges and restrictions, qualifications and limitations. Subject to compliance with Section 3.3, Section 3.4 Section 3.5, and Section 3.6, the Board of Directors (the “Board”) is hereby expressly authorized to provide, out of the authorized but unissued shares of Preferred Stock, for one or more new series of Preferred Stock and, with respect to each such series, to fix the number of shares constituting such series and the designation of such series, the voting powers, if any, of the shares of such series, and the preferences and relative, participating, optional, or other special rights, if any, and any qualifications, limitations, or restrictions thereof, of the shares of such series without shareholder action in accordance with Section 21.155 of the TBOC. The powers, preferences and relative, participating, optional and other special rights of each series of Preferred Stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding. Unless otherwise indicated, references to “sections” or “subsections” in this Part B of this Article Fourth refer to sections and subsections of Part B of this Article Fourth.

 

1.             Dividends.

 

The Corporation will not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in this Restated Certificate) the holders of the Preferred Stock then outstanding will first receive, or simultaneously receive, on a pari passu basis, a dividend on each outstanding share of Preferred Stock in an amount at least equal to (i) in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Preferred Stock as would equal the product of (A) the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into Common Stock and (B) the number of shares of Common Stock issuable upon conversion of a share of Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (ii) in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Preferred Stock determined by (A) dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to such class or series) and (B) multiplying such fraction by an amount equal to the applicable Original Issue Price (as defined below); provided that, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Corporation, the dividend payable to the holders of Preferred Stock pursuant to this Section 1 will be calculated based upon the dividend on the class or series of capital stock that would result in the highest Preferred Stock dividend. The “Series A Original Issue Price” will mean $0.61 per share, subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to the Series A Preferred Stock; the “Series B Original Issue Price” will mean $0.54 per share, subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to the Series B Preferred Stock; the “Series C Original Issue Price” will mean $2.76 per share, subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to the Series C Preferred Stock; the “Series D Original Issue Price” will mean $8.10 per share, subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to the Series D Preferred Stock; the “Series E Original Issue Price” will mean $8.10 per share, subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to the Series E Preferred Stock; and the “Series F Original Issue Price” will mean $8.10 per share, subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to the Series F Preferred Stock. Notwithstanding anything to the contrary herein, solely with respect to dividends declared on the Preferred Stock, such dividends shall not be paid in the form of stock; provided, that, the foregoing shall not restrict the payment of dividends in the form of stock in connection with a dividend declared on the Common Stock or pursuant to Sections 2 or 5.

 

-3-

 

 

2.             Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales.

 

2.1          Preferential Payments to Holders of Series E Preferred Stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of shares of Series E Preferred Stock then outstanding will be entitled to be paid out of the assets of the Corporation available for distribution to its shareholders, and in the event of a Deemed Liquidation Event (as defined below), the holders of shares of Series E Preferred Stock then outstanding will be entitled to be paid out of the consideration payable to shareholders in such Deemed Liquidation Event or out of the Available Proceeds (as defined below), as applicable, before any payment will be made to the holders of Series F Preferred Stock, Series D Preferred Stock, Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock or Common Stock by reason of their ownership thereof, the following amounts per share: an amount per share equal to the greater of (i) the Series E Original Issue Price, plus (A) any dividends declared but unpaid thereon and (B) a 7% cumulative accruing dividend, compounding annually from the date of issuance of such share of Series E Preferred Stock, or (ii)  such amount per share as would have been payable had all shares of Series E Preferred Stock been converted into Common Stock pursuant to Section 4 immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (the amount payable pursuant to this sentence is hereinafter referred to as the “Series E Liquidation Amount”). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its shareholders will be insufficient to pay the holders of shares of Series E Preferred Stock the full amounts to which they will be entitled under this Section 2.1, the holders of shares of Series E Preferred Stock will share ratably, on a pari passu basis, in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.

 

2.2          Preferential Payments to Holders of Series D Preferred Stock and Series C Preferred Stock. Subject to the prior right of the holders of the Series E Preferred Stock provided in Section 2.1, in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of shares of Series D Preferred Stock and Series C Preferred Stock then outstanding will be entitled to be paid, pro rata on a pari passu basis out of the assets of the Corporation available for distribution to its shareholders, and in the event of a Deemed Liquidation Event (as defined below), the holders of shares of Series D Preferred Stock and Series C Preferred Stock then outstanding will be entitled to be paid, pro rata on a pari passu basis, out of the consideration payable to shareholders in such Deemed Liquidation Event or out of the Available Proceeds (as defined below), as applicable, before any payment will be made to the holders of Series F Preferred Stock, Series B Preferred Stock, Series A Preferred Stock or Common Stock by reason of their ownership thereof, the following amounts per share: (a) in respect of the Series D Preferred Stock, an amount per share equal to the greater of (i) the Series D Original Issue Price, plus (A) any dividends declared but unpaid thereon and (B) a 7% cumulative accruing dividend, compounding annually from the date of issuance of such share of Series D Preferred Stock, (ii)  such amount per share as would have been payable had all shares of Series D Preferred Stock been converted into Common Stock pursuant to Section 4 immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event, or (iii) 1.2 times the Series D Original Issue Price for each share of Series D Preferred Stock (the amount payable pursuant to this sentence is hereinafter referred to as the “Series D Liquidation Amount”); provided that, without the prior written consent of the Requisite Series D Holders (as defined below), the Series D Liquidation Amount shall consist, with respect to each share of Series D Preferred Stock, of an amount of cash equal to at least 1.2 times (subject to reduction in accordance with the following sentence) the Series D Original Issue Price for each such share; and (b) in respect of the Series C Preferred Stock, an amount per share equal to the greater of (i) the Series C Original Issue Price, plus (A) any dividends declared but unpaid thereon and (B) a 7% cumulative accruing dividend, compounding annually from the date of issuance of such share of Series C Preferred Stock, or (ii)  such amount per share as would have been payable had all shares of Series C Preferred Stock been converted into Common Stock pursuant to Section 4 immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (the amount payable pursuant to this sentence is hereinafter referred to as the “Series C Liquidation Amount”). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its shareholders will be insufficient to pay the holders of shares of Series D Preferred Stock and Series C Preferred Stock the full amounts to which they will be entitled under this Section 2.2, the holders of shares of Series D Preferred Stock and Series C Preferred Stock will share ratably, on a pari passu basis, in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.

 

-4-

 

 

2.3           Preferential Payments to Holders of Series F Preferred Stock. Subject to the prior right of the holders of the Series E Preferred Stock, Series D Preferred Stock and Series C Preferred Stock provided in Sections 2.1 and 2.2, in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of shares of Series F Preferred Stock then outstanding will be entitled to be paid out of the assets of the Corporation available for distribution to its shareholders, and in the event of a Deemed Liquidation Event (as defined below), the holders of shares of Series F Preferred Stock then outstanding will be entitled to be paid out of the consideration payable to shareholders in such Deemed Liquidation Event or out of the Available Proceeds (as defined below), as applicable, before any payment will be made to the holders of Series B Preferred Stock, Series A Preferred Stock and Common Stock by reason of their ownership thereof, an amount per share equal to the greater of (i) the Series F Original Issue Price, plus (A) any dividends declared but unpaid thereon, and (B) 8% cumulative accruing dividend, compounding annually from the date of issuance of such share of Series F Preferred Stock, (ii) 1.5 times the Series F Original Issue Price for each share of Series F Preferred Stock or (iii) such amount per share as would have been payable had all shares of Series F Preferred Stock been converted into Common Stock pursuant to Section 4 immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (the amount payable pursuant to this sentence is hereinafter referred to as the “Series F Liquidation Amount”). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its shareholders will be insufficient to pay the holders of shares of the Series F Preferred Stock the full amount to which they will be entitled under this Section 2.3, the holders of shares of the Series F Preferred Stock will share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.

 

2.4           Preferential Payments to Holders of Series B Preferred Stock and Series A Preferred Stock. Subject to the prior right of the holders of the Series E Preferred Stock, Series D Preferred Stock, Series C Preferred Stock and Series F Preferred Stock provided in Sections 2.1, 2.2 and 2.3, in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of shares of Series B Preferred Stock and Series A Preferred Stock (together, the “Existing Preferred Stock”) then outstanding will be entitled to be paid, pro rata on a pari passu basis out of the assets of the Corporation available for distribution to its shareholders, and in the event of a Deemed Liquidation Event (as defined below), the holders of shares of Existing Preferred Stock then outstanding will be entitled to be paid, pro rata on a pari passu basis, out of the consideration payable to shareholders in such Deemed Liquidation Event or out of the Available Proceeds (as defined below), as applicable, before any payment will be made to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the greater of (i) the applicable Original Issue Price, plus any dividends declared but unpaid thereon, or (ii) such amount per share as would have been payable had all shares of Existing Preferred Stock been converted into Common Stock pursuant to Section 4 immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (the amount payable pursuant to this sentence is hereinafter referred to as the “Existing Preferred Liquidation Amount” and, together with the Series E Liquidation Amount, Series D Liquidation Amount, Series C Liquidation Amount, and Series F Liquidation Amount, the “Liquidation Amount”). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its shareholders will be insufficient to pay the holders of shares of the Existing Preferred Stock the full amount to which they will be entitled under this Section 2.4, the holders of shares of the Existing Preferred Stock will share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.

 

2.5           Payments to Holders of Common Stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, after the payment in full of all Liquidation Amounts required to be paid to the holders of shares of Preferred Stock, the remaining assets of the Corporation available for distribution to its shareholders or, in the case of a Deemed Liquidation Event, the consideration not payable to the holders of shares of Preferred Stock pursuant to Sections 2.1, 2.2, 2.3 and 2.4 or the remaining Available Proceeds, as the case may be, will be distributed among the holders of shares of Common Stock, pro rata based on the number of shares held by each such holder.

 

-5-

 

 

2.6           Deemed Liquidation Events.

 

2.6.1        Definition. Each of the following events will be considered a “Deemed Liquidation Event” unless the holders of a majority of the outstanding shares of Preferred Stock, voting together as a single class on an as-converted basis (the “Requisite Holders”), elect otherwise by written notice sent to the Corporation at least 10 days prior to the effective date of any such event; provided, however, that if the price to be paid per share of Series C Preferred Stock in connection with such Deemed Liquidation Event is less than the Series C Original Issue Price, the consent of the holders of a majority of the outstanding shares of Series C Preferred Stock (including in such majority SH Caris Life US, LLC (“Stonebridge-Highland”)), so long as Stonebridge-Highland and its Affiliates (as defined in that certain Amended and Restated Investors’ Rights Agreement to be entered into in connection with the issuance of the Series E Preferred Stock (as amended, restated or modified from time to time the “Investors’ Rights Agreement”) which are permitted assigns under the Investors’ Rights Agreement hold at least 13,586,957 shares of Series C Preferred Stock (subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to the Series C Preferred Stock)) voting as a separate class (the “Requisite Series C Holders”), will be required for such waiver; provided further, that if the price to be paid per share of Series D Preferred Stock in connection with such Deemed Liquidation Event is less than the Series D Original Issue Price, the consent of the holders of a majority of the outstanding shares of Series D Preferred Stock (including in such majority the holders of a majority of the shares of Series D Preferred Stock held by “Sixth Street” (which shall mean Barnett Equity Holdings II, LLC, Sixth Street Specialty Lending, Inc. and their Affiliates which are permitted assigns under the Investors’ Rights Agreement), so long as Sixth Street holds at least 18,518,518 shares of Series D Preferred Stock (subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to the Series D Preferred Stock)) voting as a separate class (the “Requisite Series D Holders”), will be required for such waiver; provided further, that if the price to be paid per share of Series E Preferred Stock in connection with such Deemed Liquidation Event is less than the Series E Original Issue Price, the consent of the holders of a majority of the outstanding shares of Series E Preferred Stock (including in such majority (i) “Braidwell” (which shall mean Braidwell Transaction Holdings LLC – Series 11, a Delaware limited liability company and its Affiliates which are permitted assigns under the Investors’ Rights Agreement) for so long as Braidwell holds the lesser of (x) 8.75% of the shares of Series E Preferred Stock then outstanding (or Common Stock issued upon conversion thereof) and (y) 25% of the Series E Preferred Stock sold to Braidwell pursuant to that certain Series E/F Preferred Stock Purchase Agreement, dated on or about the date hereof and (ii) additional holders of Series E Preferred Stock that (x) are not affiliated with Braidwell and (y) collectively hold at least 4% of the shares of Series E Preferred Stock then outstanding, voting as a separate class (the “Requisite Series E Holders”), will be required for such waiver:

 

(a)           a merger or consolidation in which

 

(i)the Corporation is a constituent party or

 

(ii)a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock pursuant to such merger or consolidation,

 

-6-

 

 

except any such merger or consolidation involving the Corporation or a subsidiary in which the shares of capital stock of the Corporation outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of (1) the surviving or resulting corporation; or (2) if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation. In the event the Requisite Holders elect to not treat an event referred to in Section 2.6.1(a) as a Deemed Liquidation Event by sending a written notice to the Corporation as set forth in Section 2.6.1, the Corporation will send written notice to each holder of Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock, and each such holder will have its shares of Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and/or Series F Preferred Stock, as applicable, redeemed by the Corporation at a cash redemption price per share equal to the Series C Liquidation Amount, Series D Liquidation Amount, Series E Liquidation Amount or Series F Liquidation Amount, as applicable, unless such holder opts out of such redemption within 15 days following receipt of such written notice, subject to the Available Proceeds as defined in Section 2.6.2(b). The Corporation will use commercially reasonable efforts to obtain financing to permit the Corporation to redeem the Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock as required by this Section 2.6.1(a);

 

(b)           (1) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken as a whole, or (2) the sale or disposition (whether by merger, consolidation or otherwise, and whether in a single transaction or a series of related transactions) of one or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation. In the event the Requisite Holders elect to not treat an event referred to in Section 2.6.1(b) as a Deemed Liquidation Event by sending a written notice to the Corporation as set forth in Section 2.6.1, the Corporation will send written notice to each holder of Series F Preferred Stock, Series E Preferred Stock, Series D Preferred Stock, and Series C Preferred Stock, and each such holder will have its shares of Series F Preferred Stock, Series E Preferred Stock, Series D Preferred Stock, and/or Series C Preferred Stock, as applicable, redeemed by the Corporation at a cash redemption price per share equal to the Series F Liquidation Amount, Series E Liquidation Amount, Series D Liquidation Amount, or the Series C Liquidation Amount, as applicable, unless such holder opts out of such redemption within 15 days following receipt of such written notice, subject to the Available Proceeds as defined in Section 2.6.2(b). The Corporation will use commercially reasonable efforts to obtain financing to permit the Corporation to redeem the Series F Preferred Stock, Series E Preferred Stock, Series D Preferred Stock, and Series C Preferred Stock as required by this Section 2.6.1(b); or

 

-7-

 

 

(c)           a sale or transfer of the majority of the total outstanding voting power of the Corporation to a person or entity (other than a person or entity that was (or whose affiliates or family members were) a shareholder of the Corporation or direct or indirect beneficial owners of a shareholder of the Corporation prior to such transactions or series of related transactions) by means of any transaction or series of related transactions to which the Corporation, or any subsidiary of the Corporation, is a party (including, without limitation, a stock acquisition or other corporate reorganization), other than a public offering of the Corporation’s capital stock or a sale or transfer in which the holders (together with their affiliates, family members and direct and indirect beneficial owners) of a majority of the outstanding shares of capital stock, by voting power, of the Corporation outstanding immediately prior to such sale or transfer continue to hold (together with their affiliates, family members and direct and indirect beneficial owners) shares of capital stock that represent, immediately following such sale or transfer, at least a majority, by voting power, of the capital stock of (1) the Corporation; (2) the surviving or resulting corporation; or (3) if the Corporation or the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such sale or transfer, the parent corporation of such surviving or resulting corporation. In the event the Requisite Holders elect to not treat an event referred to in Section 2.6.1(c) as a Deemed Liquidation Event by sending a written notice to the Corporation as set forth in Section 2.6.1, the Corporation will send written notice to each holder of Series F Preferred Stock, Series E Preferred Stock, Series D Preferred Stock, and Series C Preferred Stock and each such holder will have its shares of Series F Preferred Stock, Series E Preferred Stock, Series D Preferred Stock, and/or Series C Preferred Stock, as applicable, redeemed by the Corporation at a cash redemption price per share equal to the Series F Liquidation Amount, Series E Liquidation Amount, Series D Liquidation Amount or the Series C Liquidation Amount, as applicable, unless such holder opts out of such redemption within 15 days following receipt of such written notice, subject to the Available Proceeds as defined in Section 2.6.2(b). The Corporation will use commercially reasonable efforts to obtain financing to permit the Corporation to redeem the Series F Preferred Stock, Series E Preferred Stock, Series D Preferred Stock, and Series C Preferred Stock as required by this Section 2.6.1(c). For the avoidance of doubt, any transaction that qualifies as a Deemed Liquidation Event pursuant to Section 2.6.1(a) and Section 2.6.1(c) shall be treated as a Deemed Liquidation Event under Section 2.6.1(a) only.

 

(d)          Notwithstanding the other provisions of this Section 2.6.1, a merger, consolidation or other business combination transaction between the Corporation and any of its subsidiaries on one hand and a SPAC (as defined below) on the other hand shall not constitute a Deemed Liquidation Event so long as the shares of capital stock of the Corporation outstanding immediately prior to such merger, consolidation or other business combination transaction continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger, consolidation or other business combination transaction, at least a majority, by voting power, of the capital stock of the surviving or resulting corporation. “SPAC” means (1) a special purpose acquisition corporation, (2) a blank check company, (3) any similar development stage company, and, in the case that any of the entities identified in clauses (1)-(3) was newly-formed for the purpose of raising capital and completing a business combination transaction with another entity which does not have material business operations or hold material assets other than cash, or (4) any subsidiary of any of the entities identified in clauses (1)-(3), and (5) in the case of clauses (1)-(3), the equity securities of such entity that are publicly listed on the New York Stock Exchange or Nasdaq.

 

-8-

 

 

2.6.2        Effecting a Deemed Liquidation Event.

 

(a)           The Corporation will not have the power to effect a Deemed Liquidation Event referred to in Section 2.6.1(a)(i) unless the agreement or plan of merger or consolidation for such transaction (the “Merger Agreement”) provides that the consideration payable to the shareholders of the Corporation in such Deemed Liquidation Event will be paid to the holders of capital stock of the Corporation in accordance with Section 2.1 through Section 2.5.

 

(b)          In the event of a Deemed Liquidation Event referred to in Section 2.6.1(a)(ii), Section 2.6.1(b) or Section 2.6.1(c), if the Corporation does not effect a dissolution of the Corporation under the TBOC within ninety (90) days after such Deemed Liquidation Event, then (i) the Corporation will send a written notice to each holder of Preferred Stock no later than the ninetieth (90th) day after the Deemed Liquidation Event advising such holders of their right (and the requirements to be met to secure such right) pursuant to the terms of the following clause to require the redemption of such shares of Preferred Stock, and (ii) if (A) with respect to the Series A Preferred Stock, the Requisite Series A Holders (as defined herein), (B) with respect to the Series B Preferred Stock, the Requisite Series B Holders, (C) with respect to the Series C Preferred Stock, the Requisite Series C Holders, (D) with respect to the Series D Preferred Stock, the Requisite Series D Holders, (E) with respect to the Series E Preferred Stock, the Requisite Series E Holders, or (F) with respect to the Series F Preferred Stock, the Requisite Series F Holders (as defined below), as applicable, so request in a written instrument delivered to the Corporation not later than one hundred twenty (120) days after such Deemed Liquidation Event, the Corporation will use the consideration received by the Corporation for such Deemed Liquidation Event (net of any retained liabilities associated with the assets sold or technology licensed, as determined in good faith by the Board), together with any other assets of the Corporation available for distribution to its shareholders, all to the extent permitted by Texas law governing distributions to shareholders (the “Available Proceeds”), on the one hundred fiftieth (150th) day after such Deemed Liquidation Event, to redeem all outstanding shares of such series of Preferred Stock that have elected to be redeemed, excluding those of holders of any Preferred Stock who elect not to be redeemed, at a price per share equal to the applicable Liquidation Amount. Notwithstanding the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not sufficient to redeem all outstanding shares of Preferred Stock, the Corporation will first redeem a pro rata portion of each holder’s shares of (1) Series E Preferred Stock, then (2) Series D Preferred Stock and Series C Preferred Stock on a pari passu basis, then (3) the Series F Preferred Stock, then (4) the Existing Preferred Stock, and lastly (5) the Common Stock to the fullest extent of such Available Proceeds, based on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the Available Proceeds were sufficient to redeem all such shares, and will redeem the remaining shares as soon as it may lawfully do so under Texas law governing distributions to shareholders. The provisions of Section 6 will apply, with such necessary changes in the details thereof as are necessitated by the context, to the redemption of the Preferred Stock pursuant to this Section 2.6.2(b). Prior to the distribution or redemption provided for in this Section 2.6.2(b), the Corporation will not expend or dissipate the consideration received for such Deemed Liquidation Event, except to discharge expenses incurred in connection with such Deemed Liquidation Event.

 

-9-

 

 

2.6.3        Amount Deemed Paid or Distributed. The amount deemed paid or distributed to the holders of capital stock of the Corporation upon any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption will be the cash or the value of the property, rights or securities to be paid or distributed to such holders pursuant to such Deemed Liquidation Event.

 

2.6.4        Allocation of Escrow and Contingent Consideration. In the event of a Deemed Liquidation Event pursuant to Section 2.6.1(a)(i), if any portion of the consideration payable to the shareholders of the Corporation is payable only upon satisfaction of contingencies (the “Additional Consideration”), the Merger Agreement will provide that (a) the portion of such consideration that is not Additional Consideration (such portion, the “Initial Consideration”) will be allocated among the holders of capital stock of the Corporation in accordance with Section 2.1 through Section 2.5 as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event; and (b) any Additional Consideration which becomes payable to the shareholders of the Corporation upon satisfaction of such contingencies will be allocated among the holders of capital stock of the Corporation in accordance with Section 2.1 through Section 2.5 after taking into account the previous payment of the Initial Consideration as part of the same transaction. For the purposes of this Section 2.6.4, consideration placed into escrow or retained as a holdback to be available for satisfaction of indemnification or similar obligations in connection with such Deemed Liquidation Event will be deemed to be Initial Consideration.

 

2.6.5        Valuation of Non-Cash Consideration. If any property, rights, securities or assets of the Corporation to be paid or distributed to stockholders in connection with a Deemed Liquidation Event are other than cash, then the value of such property, rights, securities or assets shall be their fair market value as determined in good faith by the Board, except that any publicly traded securities to be distributed to stockholders in Deemed Liquidation Event shall be valued as follows:

 

(a)           if the securities are then traded on a national securities exchange, then the value of the securities shall be deemed to be the volume-weighted average of the closing prices of the securities on such exchange over the ten (10) trading day period ending five (5) trading days prior to the distribution, as such amounts are determined using the preceding methodology in good faith by the Board; and

 

(b)           if the securities are actively traded over the counter, then the value of the securities shall be deemed to be the volume-weighted average of the closing bid prices of the securities over the ten (10) trading day period ending five (5) trading days prior to the distribution, as such amounts are determined using the preceding methodology in good faith by the Board.

 

For the purposes of this Section 2.6.5, “trading day” shall mean any day which the exchange or system on which the securities to be distributed are traded is open, “volume-weighted average” means the average of the averages calculated by weighting the applicable closing prices by the volume of securities traded for each applicable trading day, and “closing prices” or “closing bid prices” shall be deemed to be: (i) for securities traded primarily on the New York Stock Exchange or a Nasdaq market, the last reported trade price or sale price, as the case may be, at 4:00 p.m., New York time, on that day and (ii) for securities listed or traded on other exchanges, markets and systems, the market price as of the end of the regular hours trading period that is generally accepted as such for such exchange, market or system. If, after the date hereof, the benchmark times generally accepted in the securities industry for determining the market price of a stock as of a given trading day shall change from those set forth above, the fair market value shall be determined as of such other generally accepted benchmark times.

 

-10-

 

 

3.             Voting.

 

3.1           General. On any matter presented to the shareholders of the Corporation for their action or consideration at any meeting of shareholders of the Corporation (or by written consent of shareholders in lieu of meeting), each holder of outstanding shares of Preferred Stock will be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining shareholders entitled to vote on such matter. Except as provided by law or by the other provisions of this Restated Certificate, holders of Preferred Stock will vote together with the holders of Common Stock as a single class and on an as-converted to Common Stock basis.

 

3.2          Election of Directors. Subject to any rights granted to holders of indebtedness, the holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Preferred Stock), exclusively and voting together as a single class on an as-converted basis, shall be entitled to elect the total number of directors of the Corporation. For so long as the holders of Series C Preferred Stock hold at least 5,579,710 shares of Series C Preferred Stock (subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to the Series C Preferred Stock), the holders of Series C Preferred Stock, together as a single class on an as-converted to Common Stock basis, will be entitled to elect one (1) director of the Corporation (the “Series C Director”). At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the class or series entitled to elect such director will constitute a quorum for the purpose of electing such director. Except as otherwise provided in this Section  3.2 or any shareholder agreement, a vacancy in any directorship filled by the holders of any class or series will be filled only by vote or written consent in lieu of a meeting of the holders of such class or series or by any remaining director or directors elected by the holders of such class or series pursuant to this Section 3.2 or any shareholder agreement.

 

3.3          Series C Preferred Stock Protective Provisions. Only for so long as at least 5,579,710 shares of Series C Preferred Stock (subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to the Series C Preferred Stock) are outstanding, the Corporation will not, either directly or indirectly by amendment, merger, consolidation or otherwise, do or allow any subsidiary to do any of the following without (in addition to any other vote required by law or this Restated Certificate) the written consent or affirmative vote of the Requisite Series C Holders given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class, and any such act or transaction entered into without such consent or vote will be null and void ab initio, and of no force or effect: 

 

3.3.1        liquidate, dissolve or wind-up the business and affairs of the Corporation, or effect any merger or consolidation that would not qualify as a Deemed Liquidation Event or a Qualified SPAC Transaction, if such merger or consolidation would result in the cancellation or conversion of the Series C Preferred Stock and the holders of the Series C Preferred Stock would receive an amount less than the Series C Liquidation Amount;

 

-11-

 

 

3.3.2        amend, alter or repeal any provision of this Restated Certificate or Bylaws of the Corporation (the “Bylaws”) in a manner that adversely affects the powers, preferences or rights of the Series C Preferred Stock, it being understood that amendments or alterations to create Permitted Preferred Stock (as defined below) with rights and obligations that are (A) permitted by the definition of Permitted Preferred Stock, (B) shared pro rata with the Preferred Stock, or (C) specific to the Permitted Preferred Stock, in each instance of clauses (A), (B) or (C), do not adversely affect the powers, preferences or rights of the Series C Preferred Stock;

 

3.3.3        create, or authorize the creation of, or issue or obligate itself to issue shares of, any other securities convertible into or exercisable for any equity securities, having rights, preferences or privileges pari passu or senior to the Series C Preferred Stock (provided that the creation, authorization or issuance of Permitted Preferred Stock will not require the consent of the Requisite Series C Holders);

 

3.3.4        purchase or redeem any capital stock or pay any dividend on any capital stock prior to the Series C Preferred Stock other than (A) dividends or distributions on the Preferred Stock, (B) dividends or other distributions payable on the Common Stock solely in the form of additional shares of Common Stock, (C) redemptions of Preferred Stock pursuant to Section 6, or (D) repurchases of shares from former employees, independent directors, officers or consultants or other persons who performed services for the Corporation (other than the founder, the founder’s family members and directors appointed by specific investors) in each instance in an aggregate amount for each individual less than 1.5% of the Corporation’s equity securities calculated on a fully-diluted basis in connection with the cessation of such employment or service;

 

3.3.5        amend the rights, preferences or privileges of any existing security that is junior to the Series C Preferred Stock in a manner that would render such existing security pari passu or senior to the Series C Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption;

 

3.3.6        enter into any transaction after the Series D Original Issue Date (as defined below) with an affiliate, shareholder or director of the Corporation unless such transaction (A) in the case of a director or employee of the Corporation, involves standard employee benefits generally made available to all employees, (B) in the case of a director or officer of the Corporation, involves standard director and officer indemnification agreements approved by the Board, (C) involves aggregate per transaction consideration of less than $1,000,000, (D) is an issuance of equity to which the rights granted to the Series C Preferred Stock pursuant to Section 4 of the Investors’ Rights Agreement are applicable and/or validly waived, (E) applies to all similarly situated shareholders in the same manner, or (F) involves an affiliate, shareholder or director of the Corporation who holds less than 5% of the Corporation’s equity securities on a fully diluted basis and has been approved by a majority of the disinterested members of the Board;

 

3.3.7        enter into any merger, consolidation or other similar business combination transaction with a SPAC, other than a Qualified SPAC Transaction; or

 

3.3.8        except pursuant to a Deemed Liquidation Event, Qualified SPAC Transaction or a merger, consolidation or reorganization in which the holders of Series C Preferred Stock receive securities with substantially similar rights as the Series C Preferred Stock, convert any Series C Preferred Stock into any other security other than as expressly contemplated in Sections 4 and 5 of this Restated Certificate.

 

-12-

 

 

“Permitted Preferred Stock” means Preferred Stock that: (i) in the case of Preferred Stock having rights, preferences or privileges senior to the Series D Preferred Stock or Series C Preferred Stock, has the following characteristics: (A) votes separately from each of the Series D Preferred Stock and Series C Preferred Stock on any series-specific vote of the Series D Preferred Stock or Series C Preferred Stock (as applicable), (B) does not have a redemption right exercisable prior to the Series D Preferred Stock’s or the Series C Preferred Stock’s respective redemption rights pursuant to Section 6 hereof; provided, that if the right to request a redemption of such Preferred Stock is permitted to be exercised on the same day as the right to request a redemption of the Series D Preferred Stock or Series C Preferred Stock, such Preferred Stock may have a preference in seniority of payment on redemption to the Series D Preferred Stock or Series C Preferred Stock (as applicable) to the extent the right to request redemption is exercised within ninety (90) days of the date the Series D Preferred Stock or Series C Preferred Stock (as applicable) exercises their respective right to request redemption, and (C) has a method for calculating aggregate senior liquidation preference on a liquidation, dissolution, winding up or Deemed Liquidation Event (including any dividends) not more favorable to the holders thereof than the method for calculating the Series D Liquidation Amount or Series C Liquidation Amount (as applicable); and (ii) in the case of Preferred Stock that does not have rights, preferences or privileges senior to either the Series D Preferred Stock or the Series C Preferred Stock (as applicable); has the following characteristics: (A) votes separately from each of the Series D Preferred Stock and Series C Preferred Stock on any series-specific vote of the Series D Preferred Stock or Series C Preferred Stock, (B) does not have a redemption right exercisable prior to the Series D Preferred Stock’s or the Series C Preferred Stock’s respective redemption right pursuant to Section 6 hereof and to the extent the right to request redemption is exercised within thirty (30) days of the date the Series D Preferred Stock or Series C Preferred Stock (as applicable) exercises their respective right to request redemption, is redeemed pro rata, and (C) has a method for calculating aggregate preference on a liquidation, dissolution, winding up or Deemed Liquidation Event (including any dividends) not more favorable to the holders thereof than the method for calculating the Series D Liquidation Amount or Series C Liquidation Amount (as applicable); and (iii) the aggregate original purchase price of such Preferred Stock described in the preceding clauses (i) and (ii) shall not exceed $100,000,000.00.

 

The Series E Preferred Stock shall constitute Permitted Preferred Stock and sales of Series E Preferred Stock shall decrease the aggregate original price of Permitted Preferred Stock permitted to be issued by the Corporation in accordance with this Restated Certificate.

 

3.4          Series D Preferred Stock Protective Provisions. Only for so long as at least 32,796,296 shares of Series D Preferred Stock (subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to the Series D Preferred Stock) are outstanding, the Corporation will not, either directly or indirectly by amendment, merger, consolidation or otherwise, do or allow any subsidiary to do any of the following without (in addition to any other vote required by law or this Restated Certificate) the written consent or affirmative vote of the Requisite Series D Holders given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class, and any such act or transaction entered into without such consent or vote will be null and void ab initio, and of no force or effect:

 

-13-

 

 

3.4.1        liquidate, dissolve or wind-up the business and affairs of the Corporation, or effect any merger or consolidation that would not qualify as a Deemed Liquidation Event or a Qualified SPAC Transaction, if such merger or consolidation would result in the cancellation or conversion of the Series D Preferred Stock and the holders of the Series D Preferred Stock would receive an amount less than the Series D Liquidation Amount;

 

3.4.2        amend, alter or repeal any provision of this Restated Certificate or the Bylaws in a manner that adversely affects the powers, preferences or rights of the Series D Preferred Stock, it being understood that amendments or alterations to create Permitted Preferred Stock (as defined above) with rights and obligations that are (A) permitted by the definition of Permitted Preferred Stock, (B) shared pro rata with the Preferred Stock, or (C) specific to the Permitted Preferred Stock, in each instance of clauses (A), (B) or (C), do not adversely affect the powers, preferences or rights of the Series D Preferred Stock;

 

3.4.3        create, or authorize the creation of, or issue or obligate itself to issue shares of, any other securities convertible into or exercisable for any equity securities, having rights, preferences or privileges pari passu or senior to the Series D Preferred Stock (provided that the creation, authorization or issuance of Permitted Preferred Stock will not require the consent of the Requisite Series D Holders);

 

3.4.4        purchase or redeem any capital stock or pay any dividend on any capital stock prior to the Series D Preferred Stock other than (A) dividends or distributions on the Preferred Stock, (B) dividends or other distributions payable on the Common Stock solely in the form of additional shares of Common Stock, (C) redemptions of Preferred Stock pursuant to Section 6, or (D) repurchases of shares from former employees, independent directors, officers or consultants or other persons who performed services for the Corporation (other than the founder, the founder’s family members and directors appointed by specific investors) in each instance in an aggregate amount for each individual less than 1.5% of the Corporation’s equity securities calculated on a fully-diluted basis in connection with the cessation of such employment or service;

 

3.4.5        amend the rights, preferences or privileges of any existing security that is junior to the Series D Preferred Stock in a manner that would render such existing security pari passu or senior to the Series D Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption;

 

3.4.6        enter into any transaction after the Series D Original Issue Date (as defined below) with an affiliate, shareholder or director of the Corporation unless such transaction (A) in the case of a director or employee of the Corporation, involves standard employee benefits generally made available to all employees, (B) in the case of a director or officer of the Corporation, involves standard director and officer indemnification agreements approved by the Board, (C) involves aggregate per transaction consideration of less than $1,000,000, (D) is an issuance of equity to which the rights granted to the Series D Preferred Stock pursuant to Section 4 of the Investors’ Rights Agreement are applicable and/or validly waived, (E) applies to all similarly situated shareholders in the same manner, or (F) involves an affiliate, shareholder or director of the Corporation who holds less than 5% of the Corporation’s equity securities on a fully diluted basis and has been approved by a majority of the disinterested members of the Board;

 

-14-

 

 

3.4.7        enter into any merger, consolidation or other similar business combination transaction with a SPAC, other than a Qualified SPAC Transaction; or

 

3.4.8       except pursuant to a Deemed Liquidation Event, Qualified SPAC Transaction or a merger, consolidation or reorganization in which the holders of Series D Preferred Stock receive securities with substantially similar rights as the Series D Preferred Stock, convert any Series D Preferred Stock into any other security other than as expressly contemplated in Sections 4 and 5 of this Restated Certificate.

 

3.5           Series E Preferred Stock Protective Provisions. Only for so long as at least 3,703,703 shares of Series E Preferred Stock (subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to the Series E Preferred Stock) are outstanding, the Corporation will not, either directly or indirectly by amendment, merger, consolidation or otherwise, do or allow any subsidiary to do any of the following without (in addition to any other vote required by law or this Restated Certificate) the written consent or affirmative vote of the Requisite Series E Holders given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class, and any such act or transaction entered into without such consent or vote will be null and void ab initio, and of no force or effect:

 

3.5.1        liquidate, dissolve or wind-up the business and affairs of the Corporation, or effect any merger or consolidation that would not qualify as a Deemed Liquidation Event or a Qualified SPAC Transaction, if such merger or consolidation would result in the cancellation or conversion of the Series E Preferred Stock and the holders of the Series E Preferred Stock would receive an amount less than the Series E Liquidation Amount;

 

3.5.2        amend, alter or repeal any provision of this Restated Certificate or the Bylaws in a manner that adversely affects the powers, preferences or rights of the Series E Preferred Stock;

 

3.5.3        create, or authorize the creation of, or issue or obligate itself to issue shares of, any other securities convertible into or exercisable for any equity securities, having rights, preferences or privileges pari passu or senior to the Series E Preferred Stock;

 

3.5.4        purchase or redeem any capital stock or pay any dividend on any capital stock prior to the Series E Preferred Stock other than (A) dividends or distributions on the Preferred Stock, (B) dividends or other distributions payable on the Common Stock solely in the form of additional shares of Common Stock, (C) redemptions of Preferred Stock pursuant to Section 6 or (D) repurchases of shares from former employees, independent directors, officers or consultants or other persons who performed services for the Corporation (other than the founder, the founder’s family members and directors appointed by specific investors) in each instance in an aggregate amount for each individual less than 1.5% of the Corporation’s equity securities calculated on a fully-diluted basis in connection with the cessation of such employment or service;

 

3.5.5        amend the rights, preferences or privileges of any existing security that is junior to the Series E Preferred Stock in a manner that would render such existing security pari passu or senior to the Series E Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption;

 

-15-

 

 

3.5.6        enter into any transaction after the Series E Original Issue Date with an affiliate, shareholder or director of the Corporation unless such transaction (A) in the case of a director or employee of the Corporation, involves standard employee benefits generally made available to all employees, (B) in the case of a director or officer of the Corporation, involves standard director and officer indemnification agreements approved by the Board, (C) involves aggregate per transaction consideration of less than $1,000,000, (D) is an issuance of equity to which the rights granted to the Series E Preferred Stock pursuant to Section 4 of the Investors’ Rights Agreement are applicable and/or validly waived, (E) applies to all similarly situated shareholders in the same manner, or (F) involves an affiliate, shareholder or director of the Corporation who holds less than 5% of the Corporation’s equity securities on a fully diluted basis and has been approved by a majority of the disinterested members of the Board;

 

3.5.7        enter into any merger, consolidation or other similar business combination transaction with a SPAC, other than a Qualified SPAC Transaction; or

 

3.5.8        except pursuant to a Deemed Liquidation Event, Qualified SPAC Transaction or a merger, consolidation or reorganization in which the holders of Series E Preferred Stock receive securities with substantially similar rights as the Series E Preferred Stock, convert any Series E Preferred Stock into any other security other than as expressly contemplated in Sections 4 and 5 of this Restated Certificate.

 

3.6           Series F Preferred Stock Protective Provisions. Only for so long as at least 3,148,148 shares of Series F Preferred Stock (subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to the Series F Preferred Stock) are outstanding, the Corporation will not, either directly or indirectly by amendment, merger, consolidation or otherwise, do or allow any subsidiary to do any of the following without (in addition to any other vote required by law or this Restated Certificate) the written consent or affirmative vote of the Requisite Series F Holders (as defined below) given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class, and any such act or transaction entered into without such consent or vote will be null and void ab initio, and of no force or effect:

 

3.6.1        amend, alter or repeal any provision of this Restated Certificate or the Bylaws in a manner that adversely affects the powers, preferences or rights of the Series F Preferred Stock.

 

4.             Optional Conversion.

 

The holders of the Preferred Stock will have conversion rights as follows (the “Conversion Rights”):

 

4.1            Right to Convert.

 

4.1.1        Conversion Ratio. Each share of Preferred Stock will be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing the applicable Original Issue Price, by the applicable Conversion Price (as defined below) in effect at the time of conversion. The “Series A Conversion Price” will initially be equal to $0.61, the “Series B Conversion Price” will initially be equal to $0.54, the “Series C Conversion Price” will initially be equal to $2.76, the “Series D Conversion Price” will initially be equal to $8.10, the “Series E Conversion Price” will initially be equal to $8.10, and the “Series F Conversion Price” will initially be equal to $8.10. Each such initial Conversion Price, and the rate at which shares of Preferred Stock may be converted into shares of Common Stock, will be subject to adjustment as provided below. Notwithstanding anything herein to the contrary, solely for the purposes of Sections 4.4.4(b) and 4.4.4(c) only, (i) the Series C Original Issue Price will be equal to $4.58 per share, subject to appropriate adjustment in the event of any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to the Series C Preferred Stock and (ii) the Series C Conversion Price will initially be equal to $4.58 per share, subject to adjustment as provided below.

 

-16-

 

 

4.1.2        Termination of Conversion Rights. In the event of a notice of redemption of any shares of Series E Preferred Stock, Series D Preferred Stock, or Series C Preferred Stock pursuant to Section 6, the Conversion Rights of the shares designated for redemption will terminate at the close of business on the last full day preceding the date fixed for redemption, unless the applicable Redemption Price is not fully paid on such Redemption Date, in which case the Conversion Rights for such shares will continue until such price is paid in full. In the event of a liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event described in Section 2.6.1(a)(i), the Conversion Rights will terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts distributable on such event to the holders of Preferred Stock; provided that the foregoing termination of Conversion Rights shall not affect the amount(s) otherwise paid or payable in accordance with Section 2 to holders of Preferred Stock pursuant to such liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event (including without limitation the Series E Liquidation Amount, Series D Liquidation Amount, and the Series C Liquidation Amount).

 

4.2           Fractional Shares. No fractional shares of Common Stock will be issued upon conversion of the Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation will pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Board. Whether or not fractional shares would be issuable upon such conversion will be determined on the basis of the total number of shares of Preferred Stock the holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion.

 

4.3           Mechanics of Conversion.

 

4.3.1        Notice of Conversion. In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares of Common Stock, such holder will (a) provide written notice to the Corporation’s transfer agent at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent) that such holder elects to convert all or any number of such holder’s shares of Preferred Stock and, if applicable, any event on which such conversion is contingent and (b), if such holder’s shares are certificated, surrender the certificate or certificates for such shares of Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent). Such notice will state such holder’s name or the names of the nominees in which such holder wishes the shares of Common Stock to be issued. If required by the Corporation, any certificates surrendered for conversion will be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or his, her or its attorney duly authorized in writing. The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of such notice and, if applicable, certificates (or lost certificate affidavit and agreement) will be the time of conversion (the “Conversion Time”), and the shares of Common Stock issuable upon conversion of the specified shares will be deemed to be outstanding of record as of such date. The Corporation will, as soon as practicable after the Conversion Time (i) issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof and a certificate for the number (if any) of the shares of Preferred Stock represented by the surrendered certificate that were not converted into Common Stock, (ii) pay in cash such amount as provided in Section 4.2 in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and (iii) pay all declared but unpaid dividends on the shares of Preferred Stock converted.

 

-17-

 

 

4.3.2        Reservation of Shares. The Corporation will at all times when the Preferred Stock is outstanding, reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized shares of Common Stock as will from time to time be sufficient to effect the conversion of all outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock will not be sufficient to effect the conversion of all then outstanding shares of the Preferred Stock, the Corporation will take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as will be sufficient for such purposes, including, without limitation, engaging in best efforts to obtain the requisite shareholder approval of any necessary amendment to this Restated Certificate. Before taking any action which would cause an adjustment reducing the Conversion Price below the then par value of the shares of Common Stock issuable upon conversion of the Preferred Stock, the Corporation will take any corporate action which may, in the opinion of its counsel, be necessary in order that the Corporation may validly and legally issue fully paid and non-assessable shares of Common Stock at such adjusted Conversion Price.

 

4.3.3        Effect of Conversion. All shares of Preferred Stock which will have been surrendered for conversion as herein provided will no longer be deemed to be outstanding and all rights with respect to such shares will immediately cease and terminate at the Conversion Time, except only the right of the holders thereof to receive shares of Common Stock in exchange therefor, to receive payment in lieu of any fraction of a share otherwise issuable upon such conversion as provided in Section 4.2 and to receive payment of any dividends declared but unpaid thereon. Any shares of Preferred Stock so converted will be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for shareholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly.

 

4.3.4        No Further Adjustment. Upon any such conversion, no adjustment to the Conversion Price will be made for any declared but unpaid dividends on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion.

 

-18-

 

 

4.3.5        Taxes. The Corporation will pay any and all issue and other similar taxes (excluding, for the avoidance of doubt, any income or withholding taxes of the holder) that may be payable in respect of any issuance or delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this Section 4. The Corporation will not, however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance or delivery will be made unless and until the person or entity requesting such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid.

 

4.4           Adjustments to Conversion Price for Diluting Issues.

 

4.4.1        Special Definitions. For purposes of this Article Fourth, the following definitions will apply:

 

(a)          “Option” means rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities.

 

(b)          “Series E Original Issue Date” means the date on which the first share of Series E Preferred Stock was issued.

 

(c)           “Series D Original Issue Date” means May 11, 2021.

 

(d)          “Convertible Securities” means any evidences of indebtedness, shares or other securities directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options.

 

(e)          “Additional Shares of Common Stock” means all shares of Common Stock issued (or, pursuant to Section  4.4.3 below, deemed to be issued) by the Corporation after the Series E Original Issue Date, other than (1) the following shares of Common Stock and (2) shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (clauses (1) and (2), collectively, “Exempted Securities”):

 

(i)shares of Common Stock, Options or Convertible Securities issued or issuable upon conversion of any of the Preferred Stock;

 

(ii)shares of Common Stock or Options issued to officers, directors or employees of, or consultants or advisors to, the Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board;

 

(iii)shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, split-up or other distribution on shares of Common Stock that is covered by Section 4.5, 4.6, 4.7 or 4.8;

 

-19-

 

 

(iv)shares of Common Stock, Options or Convertible Securities issued as acquisition consideration pursuant to the acquisition of another corporate entity by the Corporation by merger, purchase of substantially all of the assets or other reorganization or to a joint venture agreement, provided that such issuances are approved by the Board and which is not for the principal purpose of raising money;

 

(v)shares of Common Stock or Convertible Securities actually issued upon exercise of Options or shares of Common Stock actually issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security approved by the Board;

 

(vi)shares of Common Stock, Options or Convertible Securities issued to third-party banks, equipment lessors or other financial institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction approved by the Board;

 

(vii)shares of Common Stock issued or issuable in connection with a strategic alliance or licensing of technology or intellectual property, research, development, collaboration or other OEM, marketing, or vendor/supplier arrangement approved by the Board;

 

(viii)shares of Common Stock issued upon conversion of Series E Preferred Stock and Series F Preferred Stock issued in connection with an IPO;

 

(ix)the Senior Convertible Notes issued pursuant to that certain Convertible Note Purchase Agreement, dated on or about the date hereof (as may be amended or restated from time to time, the “Note Purchase Agreement”) and shares of Common Stock issued upon conversion of any Senior Convertible Notes issued pursuant to the Note Purchase Agreement; or

 

(x)the Warrants to Purchase Common Stock issued pursuant to the Note Purchase Agreement and shares of Common Stock issued upon exercise of any Warrant to Purchase Common Stock issued pursuant to the Note Purchase Agreement.

 

-20-

 

 

4.4.2        No Adjustment of Conversion Price. No adjustment in the Series E Conversion Price will be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Requisite Series E Holders agreeing that no such adjustment will be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock. No adjustment in the Series D Conversion Price will be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Requisite Series D Holders agreeing that no such adjustment will be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock. No adjustment in the Series C Conversion Price will be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Requisite Series C Holders agreeing that no such adjustment will be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock. No adjustment in the Series F Conversion Price will be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of a majority of the outstanding shares of Series F Preferred Stock, voting together as a single class on an as-converted basis (the “Requisite Series F Holders”) agreeing that no such adjustment will be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock. No adjustment in the Series B Conversion Price will be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of a majority of the outstanding shares of Series B Preferred Stock, voting together as a single class on an as-converted basis (the “Requisite Series B Holders”) agreeing that no such adjustment will be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock. No adjustment in the Series A Conversion Price will be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of a majority of the outstanding shares of Series A Preferred Stock, voting together as a single class on an as-converted basis (the “Requisite Series A Holders”) agreeing that no such adjustment will be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock.

 

4.4.3        Deemed Issue of Additional Shares of Common Stock.

 

(a)           If the Corporation at any time or from time to time after the Series E Original Issue Date issues any Options or Convertible Securities (excluding Options or Convertible Securities which are themselves Exempted Securities) or fixes a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability but without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, will be deemed to be Additional Shares of Common Stock issued as of the time of such issue or, in case such a record date has been fixed, as of the close of business on such record date.

 

-21-

 

 

(b)           If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the Series C Conversion Price pursuant to the terms of Section  4.4.4 or the Series A Conversion Price, Series B Conversion Price, Series D Conversion Price, Series E Conversion Price, or Series F Conversion Price pursuant to the terms of Section 4.4.5, are revised as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1) any increase or decrease in the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any such Option or Convertible Security or (2) any increase or decrease in the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then, effective upon such increase or decrease becoming effective, the applicable Conversion Price computed upon the original issue of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) will be readjusted to such applicable Conversion Price as would have obtained had such revised terms been in effect upon the original date of issuance of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this clause (b) will have the effect of increasing the applicable Conversion Price to an amount which exceeds the lower of (i) applicable Conversion Price in effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or (ii) the applicable Conversion Price that would have resulted from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security) between the original adjustment date and such readjustment date.

 

(c)           If the terms of any Option or Convertible Security (excluding Options or Convertible Securities which are themselves Exempted Securities), the issuance of which did not result in an adjustment to the Series C Conversion Price pursuant to the terms of Section 4.4.4 or the Series A Conversion Price, Series B Conversion Price, Series D Conversion Price, Series E Conversion Price, or Series F Conversion Price pursuant to the terms of Section 4.4.5 (either because the consideration per share (determined pursuant to Section  4.4.6) of the Additional Shares of Common Stock subject thereto was equal to or greater than the applicable Conversion Price then in effect, or because such Option or Convertible Security was issued before the Series E Original Issue Date), are revised after the Series E Original Issue Date as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1) any increase in the number of shares of Common Stock issuable upon the exercise, conversion or exchange of any such Option or Convertible Security or (2) any decrease in the consideration payable to the Corporation upon such exercise, conversion or exchange, then such Option or Convertible Security, as so amended or adjusted, and the Additional Shares of Common Stock subject thereto (determined in the manner provided in Section 4.4.3(a)) will be deemed to have been issued effective upon such increase or decrease becoming effective.

 

-22-

 

 

(d)          Upon the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof) which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the Series C Conversion Price pursuant to the terms of Section 4.4.4 or the Series A Conversion Price, Series B Conversion Price, Series D Conversion Price, Series E Conversion Price, or Series F Conversion Price pursuant to the terms of Section 4.4.5, the applicable Conversion Price will be readjusted to such applicable Conversion Price as would have obtained had such Option or Convertible Security (or portion thereof) never been issued.

 

(e)           If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or Convertible Security is issued or amended but is subject to adjustment based upon subsequent events, any adjustment to the applicable Conversion Price provided for in this Section 4.4.3 will be effected at the time of such issuance or amendment based on such number of shares or amount of consideration without regard to any provisions for subsequent adjustments (and any subsequent adjustments will be treated as provided in clauses (b) and (c) of this Section 4.4.3). If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, cannot be calculated at all at the time such Option or Convertible Security is issued or amended, any adjustment to the applicable Conversion Price that would result under the terms of this Section 4.4.3 at the time of such issuance or amendment will instead be effected at the time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming for purposes of calculating such adjustment to the applicable Conversion Price that such issuance or amendment took place at the time such calculation can first be made.

 

4.4.4        Adjustment of Series C Conversion Price Upon Issuance of Additional Shares of Common Stock.

 

(a)           In the event the Corporation at any time after the Series E Original Issue Date issues Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to Section 4.4.3, but excluding, for the avoidance of doubt, any Additional Shares of Common Stock deemed to be issued pursuant to this Section 4.4.4 or Section 4.4.5) other than in an initial public offering, without consideration or for a consideration per share less than the applicable Series C Conversion Price in effect immediately prior to such issuance or deemed issuance, then the Series C Conversion Price will be reduced, concurrently with such issuance or deemed issuance, to the price at which the Additional Shares of Common Stock are issued; provided that if such issuance or deemed issuance was without consideration, then the Corporation will be deemed to have received an aggregate of $0.001 of consideration for all such Additional Shares of Common Stock issued or deemed to be issued. For the avoidance of doubt, there will be no adjustment to the Series C Conversion Price pursuant to this Section 4.4.4(a) in the events described under Section 4.4.4(b) or Section 4.4.4(c).

 

(b)           Solely with respect to shares of Series C Preferred Stock, in the event of the issuance of Additional Shares of Common Stock in an initial public offering by the Corporation in which the final offering price per share of Common Stock to the public (the “IPO Price”) is less than 1.11111 times the Series C Original Issue Price, the Series C Conversion Price shall be automatically reduced (concurrently with the closing of such initial public offering) to a price per share equal to ninety percent (90%) of the IPO Price; provided that, the adjustments set forth in this Section 4.4.4(b) shall be applicable in the event of, and apply to, any direct listing of the Corporation's Common Stock.

 

-23-

 

 

(c)           Solely with respect to shares of Series C Preferred Stock, in the event of a Qualified SPAC Transaction (as defined in Section 5) in which the SPAC Price (as defined below) is less than 1.2 times the Series C Original Issue Price, the Series C Conversion Price shall be automatically reduced (concurrently with such Qualified SPAC Transaction and such that such reduction is given effect in connection with the mandatory conversion of the Series C Preferred Stock in connection with the Qualified SPAC Transaction) to a price per share equal to eighty percent (80%) of the SPAC Price. The “SPAC Price” means the per share consideration payable in respect of each issued and outstanding share of Common Stock in a Qualified SPAC Transaction (with such per share consideration determined on the basis of the terms of the definitive agreement for the merger or combination of the Corporation or its subsidiary, as applicable, with the SPAC and the volume-weighted average of the closing prices of the securities to be received in connection with the Qualified SPAC Transaction on such exchange over the ten (10) trading day period ending five (5) trading days prior to the consummation of such Qualified SPAC Transaction).

 

4.4.5        Adjustment of Series A Conversion Price, Series B Conversion Price, Series D Conversion Price, Series E Conversion Price, and Series F Conversion Price Upon Issuance of Additional Shares of Common Stock.

 

(a)           In the event the Corporation at any time after the Series E Original Issue Date issues Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to Section 4.4.3), without consideration or for a consideration per share less than the Conversion Price for the Series A Preferred Stock, Series B Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, or Series F Preferred Stock in effect immediately prior to such issuance or deemed issuance, then the Conversion Price for the Series A Preferred Stock, Series B Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, or Series F Preferred Stock, as the case may be, will be reduced, concurrently with such issue, to a price (calculated to the nearest one-hundredth of a cent) determined in accordance with the following formula after the application of the adjustment set forth in this Section 4.4.5(a):

 

CP2 = CP1*(A + B) ÷ (A + C).

 

For purposes of the foregoing formula, the following definitions will apply:

 

(i)“CP2” means the applicable Conversion Price in effect immediately after such issuance or deemed issuance of Additional Shares of Common Stock;

 

(ii)“CP1” means the applicable Conversion Price in effect immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock;

 

-24-

 

 

(iii)“A” means the number of shares of Common Stock outstanding immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issuance or deemed issuance or upon conversion or exchange of Convertible Securities (including the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue);

 

(iv)“B” means the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had been issued or deemed issued at a price per share equal to CP1 (determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP1); and

 

(v)“C” means the number of such Additional Shares of Common Stock issued in such transaction, including pursuant to Section 4.4.4.

 

(b)          Solely with respect to shares of Series D Preferred Stock, in the event of a Qualified IPO (as defined in Section 5) in which the IPO Price is less than 1.1 times the Series D Original Issue Price, the Series D Conversion Price shall be automatically reduced (concurrently with the closing of such Qualified IPO and such that such reduction is given effect in connection with the mandatory conversion of the Series D Preferred Stock in connection with the Qualified IPO) to a price per share equal to ninety percent (90%) of the IPO Price; provided that, the adjustments set forth in this Section 4.4.5(b) shall be applicable in the event of, and apply to, any direct listing of the Corporation's Common Stock.

 

(c)           Solely with respect to shares of Series D Preferred Stock, in the event of a Qualified SPAC Transaction (as defined in Section 5) in which the SPAC Price is less than 1.2 times the Series D Original Issue Price, the Series D Conversion Price shall be automatically reduced (concurrently with such Qualified SPAC Transaction and such that such reduction is given effect in connection with the mandatory conversion of the Series D Preferred Stock in connection with the Qualified SPAC Transaction) to a price per share equal to eighty percent (80%) of the SPAC Price.

 

-25-

 

 

(d)          Solely with respect to shares of Series E Preferred Stock, in the event of a Qualified IPO, the Series E Conversion Price shall be automatically reduced (concurrently with the closing of such Qualified IPO and such that such reduction is given effect in connection with the mandatory conversion of the Series E Preferred Stock in connection with the Qualified IPO) to a price per share equal to seventy percent (70%) of the IPO Price; provided, that, notwithstanding anything in this Restated Certificate to the contrary, solely for the purposes of this Section 4.4.5(d), each share of Series E Preferred Stock will convert into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing (i) the sum of (x) the Series E Original Issue Price plus (y) an additional amount which shall accrue at the rate of 8% of the Series E Original Issue Price, compounded monthly from the issuance of such share of Series E Preferred Stock, by (ii) the Series E Conversion Price; provided that, the adjustments set forth in this Section 4.4.5(d) shall be applicable in the event of, and apply to, any direct listing of the Corporation's Common Stock.

 

(e)           Solely with respect to shares of Series E Preferred Stock, in the event of a Qualified SPAC Transaction (as defined in Section 5) the Series E Conversion Price shall be automatically reduced (concurrently with such Qualified SPAC Transaction and such that such reduction is given effect in connection with the mandatory conversion of the Series E Preferred Stock in connection with the Qualified SPAC Transaction) to a price per share equal to seventy percent (70%) of the SPAC Price; provided, that, notwithstanding anything in Section 4.1.1 to the contrary, solely for the purposes of this Section 4.4.5(e), each share of Series E Preferred Stock will convert into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing (i) the sum of (x) the Series E Original Issue Price plus (y) an additional amount which shall accrue at the rate of 8% of the Series E Original Issue Price, compounded monthly from the issuance of such share of Series E Preferred Stock, by (ii) the Series E Conversion Price.

 

(f)           Solely with respect to shares of Series F Preferred Stock, in the event of a Qualified IPO the Series F Conversion Price shall be automatically reduced (concurrently with the closing of such Qualified IPO and such that such reduction is given effect in connection with the mandatory conversion of the Series F Preferred Stock in connection with the Qualified IPO) to a price per share equal to seventy percent (70%) of the IPO Price; provided, that, notwithstanding anything in Section 4.1.1 to the contrary, solely for the purposes of this Section 4.4.5(f), each share of Series F Preferred Stock will convert into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing (i) the sum of (x) the Series F Original Issue Price plus (y) an additional amount which shall accrue at the rate of 8% of the Series F Original Issue Price, compounded monthly from the issuance of such share of Series F Preferred Stock, by (ii) the Series F Conversion Price; provided that, the adjustments set forth in this Section 4.4.5(f) shall be applicable in the event of, and apply to, any direct listing of the Corporation's Common Stock.

 

(g)          Solely with respect to shares of Series F Preferred Stock, in the event of a Qualified SPAC Transaction (as defined in Section 5) the Series F Conversion Price shall be automatically reduced (concurrently with such Qualified SPAC Transaction and such that such reduction is given effect in connection with the mandatory conversion of the Series F Preferred Stock in connection with the Qualified SPAC Transaction) to a price per share equal to seventy percent (70%) of the SPAC Price; provided, that, notwithstanding anything in Section 4.1.1 to the contrary, solely for the purposes of this Section 4.4.5(g), each share of Series F Preferred Stock will convert into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing (i) the sum of (x) the Series F Original Issue Price plus (y) an additional amount which shall accrue at the rate of 8% of the Series F Original Issue Price, compounded monthly from the issuance of such share of Series F Preferred Stock, by (ii) the Series F Conversion Price.

 

-26-

 

 

4.4.6        Determination of Consideration. For purposes of this Section  4.4, the consideration received by the Corporation for the issuance or deemed issuance of any Additional Shares of Common Stock will be computed as follows:

 

(a)           Cash and Property: Such consideration will:

 

(i)insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation, excluding amounts paid or payable for accrued interest;

 

(ii)insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of such issue, as determined in good faith by the Board; and

 

(iii)in the event Additional Shares of Common Stock are issued together with other shares or securities or other assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in clauses (i) and (ii) above, as determined in good faith by the Board.

 

(b)         Options and Convertible Securities. The consideration per share received by the Corporation for Additional Shares of Common Stock deemed to have been issued pursuant to Section 4.4.3, relating to Options and Convertible Securities, will be determined by dividing:

 

(i)The total amount, if any, received or receivable by the Corporation as consideration for the issue of such Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration) payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities, by

 

-27-

 

 

(ii)the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities.

 

4.4.7        Multiple Closing Dates. In the event the Corporation issues on more than one date Additional Shares of Common Stock that are a part of one transaction or a series of related transactions and that would result in an adjustment to the Conversion Price of a series of Preferred Stock pursuant to the terms of Section 4.4.4 or 4.4.5, then, upon the final such issuance, such Conversion Price will be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and without giving effect to any additional adjustments as a result of any such subsequent issuances within such period).

 

4.5           Adjustment for Stock Splits and Combinations. If the Corporation at any time or from time to time after the Series E Original Issue Date effects a subdivision of the outstanding Common Stock, the applicable Conversion Price in effect immediately before that subdivision will be proportionately decreased so that the number of shares of Common Stock issuable on conversion of each share of such series will be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding. If the Corporation at any time or from time to time after the Series E Original Issue Date combines the outstanding shares of Common Stock, the applicable Conversion Price in effect immediately before the combination will be proportionately increased so that the number of shares of Common Stock issuable on conversion of each share of such series will be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. Any adjustment under this section will become effective at the close of business on the date the subdivision or combination becomes effective.

 

4.6          Adjustment for Certain Dividends and Distributions. In the event the Corporation at any time or from time to time after the Series E Original Issue Date makes or issues, or fixes a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable on the Common Stock in additional shares of Common Stock, then and in each such event the applicable Conversion Price in effect immediately before such event will be decreased as of the time of such issuance or, in the event such a record date will have been fixed, as of the close of business on such record date, by multiplying the applicable Conversion Price then in effect by a fraction:

 

(1)           the numerator of which will be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date, and

 

-28-

 

 

(2)            the denominator of which will be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution.

 

Notwithstanding the foregoing (a) if such record date has been fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed therefor, the applicable Conversion Price will be recomputed accordingly as of the close of business on such record date and thereafter the applicable Conversion Price will be adjusted pursuant to this section as of the time of actual payment of such dividends or distributions; and (b) that no such adjustment will be made if the holders of such series of Preferred Stock simultaneously receive a dividend or other distribution of shares of Common Stock in a number equal to the number of shares of Common Stock as they would have received if all outstanding shares of such series of Preferred Stock had been converted into Common Stock on the date of such event.

 

4.7          Adjustments for Other Dividends and Distributions. In the event the Corporation at any time or from time to time after the Series E Original Issue Date makes or issues, or fixes a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation (other than a distribution of shares of Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of Section 1 do not apply to such dividend or distribution, then and in each such event the holders of Preferred Stock will receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such securities or other property as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event.

 

4.8          Adjustment for Merger or Reorganization, etc. Subject to the provisions of Section  2.6 and Section 5, if there occurs any reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not the Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a transaction covered by Section 4.4, 4.6, 4.7 or Section 5), then, following any such reorganization, recapitalization, reclassification, consolidation or merger, each share of Preferred Stock will thereafter be convertible in lieu of the Common Stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the Corporation issuable upon conversion of one share of Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as determined in good faith by the Board) will be made in the application of the provisions in this Section 4 with respect to the rights and interests thereafter of the holders of the Preferred Stock, to the end that the provisions set forth in this Section 4 (including provisions with respect to changes in and other adjustments of the applicable Conversion Price) will thereafter be applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable upon the conversion of the Preferred Stock.

 

-29-

 

 

4.9           Certificate as to Adjustments. Upon the occurrence of each adjustment or readjustment of any Conversion Price pursuant to this Section 4, the Corporation at its expense will, as promptly as reasonably practicable but in any event not later than ten (10) days thereafter, compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property into which the Preferred Stock is convertible) and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation will, as promptly as reasonably practicable after the written request at any time of any holder of Preferred Stock (but in any event not later than ten (10) days thereafter), furnish or cause to be furnished to such holder a certificate setting forth (i) the applicable Conversion Price then in effect, and (ii) the number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of Preferred Stock.

 

4.10         Notice of Record Date. In the event:

 

(a)               the Corporation will take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or any other securities, or to receive any other security; or

 

(b)               of any capital reorganization of the Corporation, any reclassification of the Common Stock of the Corporation, or any Deemed Liquidation Event; or

 

(c)                of the voluntary or involuntary dissolution, liquidation or winding-up of the Corporation,

 

then, and in each such case, the Corporation will send or cause to be sent to the holders of the Preferred Stock a notice specifying, as the case may be, (i) the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii) the effective date on which such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up is proposed to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the Preferred Stock) will be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up, and the amount per share and character of such exchange applicable to the Preferred Stock and the Common Stock. Such notice will be sent at least ten (10) days prior to the record date or effective date for the event specified in such notice.

 

-30-

 

 

5.             Mandatory Conversion.

 

5.1           Trigger Events. Upon (a) the closing of the sale of shares of Common Stock to the public in a firm-commitment underwritten initial public offering, pursuant to an effective registration statement under the Securities Act of 1933, as amended, (an “IPO”) in which (i) the gross cash proceeds to the Corporation are equal to or greater than $100,000,000.00 (it being understood that stockholders of the Corporation may also sell shares of Common Stock in such IPO in addition to the shares of Common Stock sold by the Corporation), and (ii) the Common Stock is listed for trading on the New York Stock Exchange or the Nasdaq Stock Market (an IPO meeting the requirements of both of the foregoing clauses, a “Qualified IPO”), (b) the consummation of a merger or combination of the Corporation or its subsidiary, as applicable, with a SPAC and in which the SPAC consummates a concurrent private placement of its equity securities resulting in gross cash proceeds to the SPAC of at least $450,000,000.00 (such transaction, a “Qualified SPAC Transaction”), or (c) the date and time, or the occurrence of an event, specified by vote or written consent of: (i) with respect to the Series A Preferred Stock, the Requisite Series A Holders; (ii) with respect to the Series B Preferred Stock, the Requisite Series B Holders; (iii) with respect to the Series C Preferred Stock, the Requisite Series C Holders; (iv) with respect to the Series D Preferred Stock, the Requisite Series D Holders; (v) with respect to the Series E Preferred Stock, the Requisite Series E Holders, and (vi) with respect to the Series F Preferred Stock, the Requisite Series F Holders (the time of such closing or the date and time specified or the time of the event specified in such vote or written consent is referred to herein as the “Mandatory Conversion Time”), then (i) all outstanding shares of such series of Preferred Stock will automatically be converted into shares of Common Stock, at the then effective conversion rate as calculated pursuant to Section 4.1.1, and (ii) such shares may not be reissued by the Corporation.

 

5.2           Procedural Requirements. All holders of record of shares of Preferred Stock will be sent written notice of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this Section 5. Such notice need not be sent in advance of the occurrence of the Mandatory Conversion Time. Upon receipt of such notice, each holder of shares of Preferred Stock in certificated form will surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, any certificates surrendered for conversion will be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Preferred Stock converted pursuant to Section 5, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender any certificates at or prior to such time), except only the rights of the holders thereof, upon surrender of any certificate or certificates of such holders (or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this Section 5.2. As soon as practicable after the Mandatory Conversion Time and, if applicable, the surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation will (a) issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof and (b) pay cash as provided in Section 4.2 in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends on the shares of Preferred Stock converted. Such converted Preferred Stock will be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for shareholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly.

 

-31-

 

 

6.             Redemption.

 

6.1           General. Unless prohibited by Texas law governing distributions to shareholders or by an agreement entered into by the Corporation in connection with bona fide third-party indebtedness existing as of the Series D Original Issue Date (including any refinancing of such existing indebtedness so long as such refinancing does not extend the maturity date of such indebtedness), at any time on or after March 31, 2026 in respect of shares of Series C Preferred Stock or the fifth (5th) anniversary of the Series D Original Issue Date in respect of shares of Series D Preferred Stock and Series E Preferred Stock, upon receipt of a written notice (the “Redemption Request”) from the Requisite Series C Holders requesting redemption of the shares of Series C Preferred Stock, the Requisite Series D Holders requesting redemption of the shares of Series D Preferred Stock, or the Requisite Series E Holders requesting redemption of the shares of Series E Preferred Stock (as applicable) and designating the Redemption Majority Representative (as defined below), shares of Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock (as applicable), in each case, other than Excluded Shares (as defined below), will be redeemed by the Corporation (x) in respect of the Series C Preferred Stock, at a price per share equal to the greater of (i) the Series C Original Issue Price, plus (A) all declared but unpaid dividends thereon and (B) a 7% cumulative accruing dividend, compounding annually from the date of issuance of such share of Series C Preferred Stock, and (ii) the Fair Market Value (determined in the manner set forth below) of a single share of Series C Preferred Stock as of the date of the Corporation’s receipt of the Redemption Request (the “Series C Redemption Price”); (y) in respect of the Series D Preferred Stock, at a price per share equal to the greater of (i) the Series D Original Issue Price, plus (A) all declared but unpaid dividends thereon and (B) a 7% cumulative accruing dividend, compounding annually from the date of issuance of such share of Series D Preferred Stock, and (ii) the Fair Market Value (determined in the manner set forth below) of a single share of Series D Preferred Stock as of the date of the Corporation’s receipt of the Redemption Request (the “Series D Redemption Price”); and (z) in respect of the Series E Preferred Stock, at a price per share equal to the greater of (i) the Series E Original Issue Price, plus (A) all declared but unpaid dividends thereon and (B) a 7% cumulative accruing dividend, compounding annually from the date of issuance of such share of Series E Preferred Stock and (ii) the Fair Market Value (determined in the manner set forth below) of a single share of Series E Preferred Stock as of the date of the Corporation’s receipt of the Redemption Request (the “Series E Redemption Price”). The Series C Redemption Price, the Series D Redemption Price or the Series E Redemption Price (as applicable) will be paid or the Series C Preferred Stock, the Series D Preferred Stock and the Series E Preferred Stock (as applicable) will be redeemed not more than the later of sixty (60) days after the final determination of the applicable fair market value (as determined below, “Fair Market Value”). For purposes of this Section 6.1, the Fair Market Value of a single share of Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock shall be determined by the Corporation within ten (10) business days upon receipt of a Redemption Notice (as defined below) and communicated in writing to a representative (the “Redemption Majority Representative”) of the holders of a majority of the outstanding shares of Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock (as applicable) that have elected to have their shares redeemed in a written notice sent by the Corporation stating in reasonable detail the facts upon which such calculation was based (the “FMV Notice”). Upon request of the Redemption Majority Representative, the Corporation shall, as promptly as possible, provide to such Redemption Majority Representative documentation supporting the method of calculation of the determination of the Board, the facts upon which such calculation was based and all other information or documents reasonably requested by the Redemption Majority Representative in a reasonably prompt manner. Upon the Redemption Majority Representative’s receipt of the FMV Notice and any documentation that may be reasonably requested by the Redemption Majority Representative, the Redemption Majority Representative shall have ten (10) business days following the receipt of the FMV Notice to either accept the Corporation’s determination of the Fair Market Value or send to the Corporation a written notice (a “Dispute Notice”) setting forth in reasonable detail the Redemption Majority Representative’s proposed alternative calculation of the Fair Market Value as of such date. The proposed Fair Market Value set forth in any FMV Notice shall become final, conclusive and binding on the parties unless the Redemption Majority Representative provides a Dispute Notice pursuant to this Section. The Corporation and the Redemption Majority Representative will attempt to promptly resolve the matters raised in any Dispute Notice. If the Corporation and the Redemption Majority Representative cannot agree on the Fair Market Value within ten (10) business days of delivery of such Dispute Notice, either the Corporation or the Redemption Majority Representative may elect to engage, at the Corporation’s expense, a nationally recognized public accounting firm to be mutually agreed upon by the parties (the “Independent Appraiser”) to determine the Fair Market Value. If the Corporation and the Redemption Majority Representative cannot agree on an Independent Appraiser, each shall select a nationally recognized public accounting firm within twenty-five (25) days of delivery of the Dispute Notice and those two firms at the Corporation’s expense will agree on a third nationally recognized public accounting firm to be the Independent Appraiser within fifteen (15) days of their appointment to determine the Fair Market Value at the Corporation’s expense. The Independent Appraiser’s determination of such Fair Market Value shall be rendered with a written decision as to its determination of the Fair Market Value which shall include a statement in reasonable detail of the basis for its determination. The Independent Appraiser shall consult with the Corporation and the Redemption Majority Representative concerning the proposed Fair Market Value. In no event shall the determination of the Independent Appraiser provide for a calculation of Fair Market Value that is less than the lower value proposed, or greater than the higher value proposed, in each case by the Corporation or the Redemption Majority Representative. The determination of the Independent Appraiser with respect to the disputed Fair Market Value submitted to it will be final, conclusive and binding on the parties. The Corporation and the Redemption Majority Representative shall use their commercially reasonable efforts to cooperate with the Independent Appraiser (including by executing a customary engagement letter reasonably acceptable to it) and to cause any determination by the Independent Appraiser to be made within three (3) business days after commencement of the Independent Appraiser’s engagement. The date provided in the Redemption Notice (as defined below) is referred to as a “Redemption Date.” On the Redemption Date, the Corporation will redeem, on a pro rata basis in accordance with the number of shares of Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock (as applicable) owned by each holder, the number of outstanding shares of Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock (as applicable); provided, however, that Excluded Shares (as such term is defined in Section 6.2) will not be redeemed and will be excluded from the calculations set forth in this sentence. If the Requisite Series E Holders exercise a Redemption Request within thirty (30) days of the exercise of the redemption rights of the Requisite Series D Holders or the Requisite Series D Holders exercise a Redemption Request within thirty (30) days of the exercise of the redemption rights of the Requisite Series E Holders, the Corporation will (x) promptly (and in any event within five (5) business days) provide notice to each holder of record of Series E Preferred and Series D Preferred that both classes of Preferred Stock will be redeemed (provided that the failure to provide such notice shall not give rise to any claim or liability against the Corporation) and (y) redeem shares of Series D Preferred Stock and Series E Preferred Stock on a pro rata basis. If, on the applicable Redemption Date, Texas law governing distributions to shareholders prevents the Corporation from redeeming all shares of Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock (as applicable) to be redeemed, the Corporation will ratably redeem the maximum number of shares that it may redeem consistent with such law, and will redeem the remaining shares as soon as it may lawfully do so under such law. The Corporation will use commercially reasonable efforts to obtain financing to permit the Corporation to redeem the Series C Preferred Stock, Series D Preferred Stock, and Series E Preferred Stock as required by this Section 6.

 

-32-

 

 

6.2          Redemption Notice. Without limiting any notice required by Section 6.1, the Corporation will send written notice of the mandatory redemption (the “Redemption Notice”) to each holder of record of Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock (as applicable) not less than thirty (30) days after the final determination of the Fair Market Value as set forth in Section 6.1. The Redemption Notice will state:

 

(a)               the number of shares of Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock (as applicable) held by the holder that the Corporation will redeem on the Redemption Date specified in the Redemption Notice;

 

(b)               the Redemption Date (which will be no more than thirty (30) days following the determination of the applicable Redemption Price) and the applicable Redemption Price;

 

(c)               the date upon which the holder’s right to convert such shares terminates (as determined in accordance with Section  4.1.2); and

 

(d)               for holders of shares in certificated form, that the holder is to surrender to the Corporation, in the manner and at the place designated, his, her or its certificate or certificates representing the shares of Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock (as applicable) to be redeemed.

 

If the Corporation receives, on or prior to the fifteenth (15th) day after the date of delivery of the Redemption Notice to a holder of Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock, written notice from such holder that such holder elects to be excluded from the redemption provided in this Section 6, then the shares of Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock registered on the books of the Corporation in the name of such holder at the time of the Corporation’s receipt of such notice will thereafter be “Excluded Shares.” Excluded Shares will not be redeemed or redeemable pursuant to this Section 6, whether on such Redemption Date or thereafter.

 

6.3           Surrender of Certificates; Payment. On or before the applicable Redemption Date, each holder of shares of Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock to be redeemed on such Redemption Date, unless such holder has exercised his, her or its right to convert such shares as provided in Section 4, will, if a holder of shares in certificated form, surrender the certificate or certificates representing such shares (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation, in the manner and at the place designated in the Redemption Notice, and thereupon the applicable Redemption Price for such shares will be payable to the order of the person whose name appears on such certificate or certificates as the owner thereof. In the event less than all of the shares of Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock represented by a certificate are redeemed, a new certificate, instrument, or book entry representing the unredeemed shares of Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock will promptly be issued to such holder.

 

-33-

 

 

6.4           Rights Subsequent to Redemption. If the Redemption Notice has been duly given, and if on the applicable Redemption Date, the applicable Redemption Price payable upon redemption of the shares of Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock to be redeemed on such Redemption Date is paid or tendered for payment or deposited with an independent payment agent so as to be available therefor in a timely manner, then notwithstanding that any certificates evidencing any of the shares of Series C Preferred Stock or Series D Preferred Stock so called for redemption has not been surrendered, dividends with respect to such shares of Series C Preferred Stock or Series D Preferred Stock will cease to accrue after such Redemption Date and all rights with respect to such shares will forthwith after the Redemption Date terminate, except only the right of the holders to receive the applicable Redemption Price without interest upon surrender of any such certificate or certificates therefor.

 

7.             Redeemed or Otherwise Acquired Shares. Any shares of Preferred Stock that are redeemed or otherwise acquired by the Corporation or any of its subsidiaries will be automatically and immediately cancelled and retired and will not be reissued, sold or transferred. Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the holders of Preferred Stock following redemption.

 

8.             Waiver. Any of the rights, powers, preferences and other terms of the Preferred Stock set forth herein may be waived on behalf of all holders of Preferred Stock by the Requisite Holders; provided, however, that any waiver that adversely affects the powers, rights and preferences of the Series F Preferred Stock will require the consent of the Requisite Series F Holders; provided, further, that any waiver that adversely affects the powers, rights and preferences of the Series E Preferred Stock will require the consent of the Requisite Series E Holders; provided further, that any waiver that adversely affects the powers, rights and preferences of the Series D Preferred Stock will require the consent of the Requisite Series D Holders; provided further, that any waiver that adversely affects the powers, rights and preferences of the Series C Preferred Stock will require the consent of the Requisite Series C Holders; provided further that any waiver that adversely affects the powers, rights and preferences of the Series B Preferred Stock will require the consent of the Requisite Series B Holders; provided further that any waiver that adversely affects the powers, rights and preferences of the Series A Preferred Stock will require the consent of the Requisite Series A Holders. For the avoidance of doubt, the right of a particular holder of (x) Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock, as applicable, to be excluded from the redemption of the Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock pursuant to Sections 2.6.1(a), 2.6.1(b) or 2.6.1(c), (y) the applicable series of Preferred Stock to be excluded from the redemption of the applicable series of Preferred Stock following the request of the Requisite Series A Holders, Requisite Series B Holders, Requisite Series C Holders, Requisite Series D Holders, Requisite Series E Holders, or Requisite Series F Holders, as applicable, to redeem the applicable series of Preferred Stock pursuant to Section 2.6.2(b), or (z) Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock as applicable, to be to be excluded from redemption of the Series C Preferred Stock, Series D Preferred Stock, or Series E Preferred Stock following receipt of a Redemption Request pursuant to Section 6, can be waived without the consent of such holder.

 

-34-

 

 

9.                  Notices. Any notice required or permitted by the provisions of this Article Fourth to be given to a holder of shares of Preferred Stock will be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication in compliance with the provisions of the TBOC, and will be deemed sent upon such mailing or electronic transmission.

 

Fifth: The number constituting the Board is fourteen (14), and the name and address of the initial director(s) who are to serve as the director(s) until the next annual meeting of shareholders, or until their respective successors are elected and qualified, is as follows:

 

NAME ADDRESS

David D. Halbert

c/o Caris Life Sciences, Inc.
750 W John Carpenter Fwy
Suite 800
Irving, TX 75039

Laura I. Johansen

Peter Castleman

George Poste

Jonathan Knowles

Jon S. Halbert

Danny Phillips

Brian Brille

Vijay Mohan

Joseph E. Gilliam

Nathan Burns

Dave Fredrickson

Lloyd B. Minor

Jeffrey Vacirca

 

 

Sixth: Subject to any additional vote required by this Restated Certificate, the number of directors of the Corporation will be determined in the manner set forth in the Bylaws. Each director will be entitled to one vote on each matter presented to the Board.

 

-35-

 

 

Seventh: Elections of directors need not be by written ballot unless the Bylaws will so provide.

 

Eighth: Meetings of shareholders may be held within or without the State of Texas, as the Bylaws may provide. The books of the Corporation may be kept outside the State of Texas at such place or places as may be designated from time to time by the Board or in the Bylaws.

 

Ninth: A director of the Corporation will not be personally liable to the Corporation or its shareholders for monetary damages for an act or omission in the director’s capacity as a director, except for liability (i) for any breach of the director’s duty of loyalty to the Corporation or its shareholders, (ii) for acts or omissions not in good faith which constitute a breach of duty to the Corporation or involve intentional misconduct or a knowing violation of law, (iii) for any transaction from which the director derived any improper personal benefit, regardless of whether the benefit resulted from an action taken within the scope of such person’s duties or (iv) for an act or omission for which the liability of the director is expressly provided for by statute. If the TBOC is amended hereafter to authorize the further limitation of the liability of directors, then the limitation on personal liability provided in this Article will, without the necessity of further action by the Corporation or the Board, be modified to provide such limitation to the fullest extent permitted by the TBOC as so amended.

 

The Corporation will indemnify, and provide advancement of expenses to, any person who was or is a party or is threatened to be made a party to any threatened, pending, or completed action or other proceeding (whether civil, criminal, administrative, arbitrative, or investigative), including any appeal thereof, or any inquiry or investigation that could lead to such an action or proceeding (any of the foregoing to be referred to hereafter as a “proceeding”) by reason of the fact that the person (1) is or was a director or officer of the Corporation; (2) is or was serving at the request of a director or officer of the Corporation as an agent of the Corporation; or (3) while a director, officer or agent of the Corporation, is or was serving at the request of the Corporation as a partner, director, officer, venturer, proprietor, trustee, employee, administrator, or agent of another entity, organization, or an employee benefit plan (each such person in (3) to be referred to hereafter as a “delegate” and, together with each such person in (1) and (2), a “covered person”) to the fullest extent permitted by the TBOC, as the same now exists or may hereafter be amended, substituted, or replaced (but, in the case of any such amendment, substitution, or replacement, only to the extent that such amendment, substitution, or replacement permits the Corporation to provide broader indemnification rights and advancement of expenses than the TBOC permitted the Corporation to provide prior to such amendment, substitution, or replacement), against all judgments (including arbitration awards), court costs, penalties, settlements, fines, excise, and other similar taxes and reasonable attorneys’ fees actually incurred by the covered person in connection with such proceeding. The right to indemnification in this paragraph will continue as to a covered person who has ceased to be a director, officer, agent or delegate and will inure to his or her heirs, executors, or administrators.

 

Any amendment, repeal or modification of the foregoing provisions of this Article Ninth will not adversely affect any right or protection of a director, officer, agent, or other person existing at the time of, or increase the liability of any director, office or agent of the Corporation with respect to any acts or omissions of such director, officer or agent occurring prior to, such amendment, repeal or modification.

 

-36-

 

 

Tenth: Special meetings of the shareholders may be called by the holders of at least fifty percent (50%) of all the shares entitled to vote at the proposed special meeting. Any action required by statute to be taken at any annual or special meeting of shareholders, or any action which may be taken at any annual or special meeting of shareholders, may be taken without a meeting, without prior notice, and, as authorized by Section 6.202 of the TBOC, without a vote, if a consent or consents in writing, setting forth the action so taken, will be signed by the holder or holders of shares having not less than the minimum number of votes that would be necessary to take such action at a meeting at which the holders of all shares entitled to vote on the action were present and voted. As authorized by Section 21.365 of the TBOC, in lieu of the vote required by Section 21.364 of the TBOC, unless otherwise stated in this Restated Certificate, the shareholders by Majority Vote (as defined below) will approve (a) any “fundamental action” as defined in Section 21.364 of the TBOC, (b) the sale, transfer, or disposition of all or substantially all of the assets of the Corporation, or (c) any reorganization, merger, interest exchange, or conversion. “Majority Vote” means the affirmative vote of the holders of a majority of the shares entitled to vote on the matter at a shareholder’s meeting.

 

Eleventh: The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in being offered an opportunity to participate in, any Excluded Opportunity. An “Excluded Opportunity” is any matter, transaction or interest that is presented to, or acquired by, or which otherwise comes into the possession of (i) any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii) any holder of Preferred Stock or any partner, member, director, shareholder, employee, affiliate or agent of any such holder, other than someone who is an employee of the Corporation or any of its subsidiaries (collectively, the persons referred to in clauses (i) and (ii) are “Covered Persons”), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person’s capacity as a director of the Corporation while such Covered Person is performing services in such capacity. Any repeal or modification of this Article Eleventh will only be prospective and will not affect the rights under this Article Eleventh in effect at the time of the occurrence of any actions or omissions to act giving rise to liability. Notwithstanding anything to the contrary contained elsewhere in this Restated Certificate, the affirmative vote of the Requisite Holders, the Requisite Series D Holders and the Requisite Series C Holders, voting as a separate class, will be required to amend, repeal or adopt any provisions inconsistent with this Article Eleventh.

 

-37-

 

 

Twelfth: Unless the Corporation consents in writing to the selection of an alternative forum, the state courts in Dallas County, Texas (the “Court”) shall be the sole and exclusive forum for any shareholder (including a beneficial owner) to bring (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation’s shareholders, (iii) any action asserting a claim against the Corporation, its directors, officers or employees arising pursuant to any provision of the TBOC or this Restated Certificate or Bylaws, or (iv) any action asserting a claim against the Corporation, its directors, officers or employees governed by the internal affairs doctrine, except for, as to each of (i) through (iv) above, any claim as to which the Court determines that there is an indispensable party not subject to the jurisdiction of the Court (and the indispensable party does not consent to the personal jurisdiction of the Court within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court, or for which the Court does not have subject matter jurisdiction. If any provision or provisions of this Article Twelfth is held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Article Twelfth (including, without limitation, each portion of any sentence of this Article Twelfth containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances will not in any way be affected or impaired thereby. Any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Article Twelfth.

 

Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. Any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Article Twelfth.

 

Thirteenth: The shareholders do not have statutory preemptive rights.

 

Fourteenth: Except as otherwise provided in this Restated Certificate, in furtherance and not in limitation of the powers conferred by statute, the Board is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws.

 

* * *

 

-38-

 

Exhibit 3.2

 

AMENDED AND RESTATED
CERTIFICATE OF FORMATION

OF
CARIS LIFE SCIENCES, INC.

 

Caris Life Sciences, Inc. (the “Corporation”), a for-profit corporation organized and existing under and by virtue of the provisions of the Texas Business Organizations Code, as amended from time to time (the “TBOC”), does hereby certify:

 

First: The name of the filing entity is Caris Life Sciences, Inc.

 

Second: The Corporation was formed as a Texas for-profit corporation pursuant to the TBOC on July 17, 2020, and issued file number 803691720 by the Secretary of State of the State of Texas.

 

Third: Each new amendment has been made in accordance with the provisions of the TBOC. The amendments to the certificate of formation and the Restated Certificate (as defined below) have been approved in the manner required by the TBOC and by the governing documents of the entity.

 

Fourth: The Amended and Restated Certificate of Formation in the form attached hereto as Exhibit A (the “Restated Certificate”), accurately states the text of the certificate of formation being restated, and each amendment to the certificate of formation being restated that is in effect, as further amended by the Restated Certificate. The Restated Certificate does not contain any other change in the certificate of formation being restated except for the information permitted to be omitted by the provisions of the TBOC applicable to the filing entity.

 

Fifth: The Restated Certificate takes effect upon the occurrence of a future event or fact, other than the passage of time. The event or fact that will cause the document to take effect is the closing of the initial public offering of the Corporation. The 90th day after the date of signing is         , 2025.

 

The undersigned affirms that the person designated as registered agent in the Restated Certificate has consented to the appointment. The undersigned signs this document subject to the penalties imposed by law for the submission of a materially false or fraudulent instrument and certifies under penalty of perjury that the undersigned is authorized to execute the filing instrument.

 

  CARIS LIFE SCIENCES, INC.
   
  By:  
  Name: David D. Halbert     
  Title:  Chief Executive Officer 
  Date:         , 2025

 

 

 

 

EXHIBIT A

 

Article I

 

The name of this corporation is Caris Life Sciences, Inc. (the “Corporation”).

 

Article II

 

The address of the registered office of the Corporation in the State of Texas is 1999 Bryan Street, Suite 900, Dallas, Texas 75201, and the name of the registered agent at that address is CT Corporation System.

 

Article III

 

The purpose of the Corporation is to engage in any lawful business for which business corporations may be organized under the Texas Business Organizations Code (the “TBOC”) as it now exists or may hereafter be amended and supplemented.

 

Article IV

 

The total number of shares of all classes of capital stock which the Corporation will have authority to issue is          shares, consisting of (i)          shares of Common Stock, $0.001 par value per share (the “Common Stock”), of which (a)         shares shall be a series designated as Class A Common Stock (“Class A Common Stock”) and (b)          shares shall be a series designated as Class B Common Stock (“Class B Common Stock”), and (ii)          shares of Preferred Stock, $0.001 par value per share (“Preferred Stock”).

 

Subject to the rights of any holders of Preferred Stock then outstanding, the number of authorized shares of Class A Common Stock, Class B Common Stock or Preferred Stock may be increased or decreased (but not below (i) the number of shares thereof then outstanding and (ii) with respect to the Class A Common Stock, the number of shares of Class A Common Stock reserved pursuant to Section 8 of Part A of this Article IV) by the affirmative vote of the holders of capital stock representing a majority of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote thereon, and no vote of the holders of the Class A Common Stock, the Class B Common Stock or the Preferred Stock voting separately as a class shall be required therefor, to the extent permitted by Section 21.364(d) of the TBOC.

 

Upon the effectiveness of this Amended and Restated Certificate of Formation (such certificate, the “Restated Certificate” and such time, the “Effective Time”), (i) each share of Common Stock (as defined in the Corporation’s certificate of formation heretofore in effect (the “Prior Certificate”)) issued and outstanding or held in treasury immediately prior to the Effective Time shall, automatically and without further action by any shareholder, be reclassified as, and shall become, one (1) share of Class B Common Stock (the “Reclassification”) and (ii) any stock certificate that, immediately prior to the Effective Time, represented one or more shares of Common Stock (as defined in the Prior Certificate), shall, from and after the Effective Time, automatically and without the necessity of presenting the same for surrender or exchange, represent the same number of shares of Class B Common Stock.

 

The designations and the powers, preferences, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation are as follows:

 

-2-

 

 

A.            Common Stock.

 

1.            Equal Status; General. Except as otherwise provided herein or required by law, shares of Class A Common Stock and Class B Common Stock shall have the same rights, privileges, preferences and powers, rank equally (including as to dividends and distributions, and upon any liquidation, dissolution, distribution of assets or winding up of the Corporation), share ratably and be identical in all respects and as to all matters. The voting, dividend, liquidation and other rights, powers and preferences of the holders of Common Stock are subject to, and qualified by, the rights, powers and preferences of any series of Preferred Stock as may be designated by the Board of Directors of the Corporation (the “Board”) and outstanding from time to time.

 

2.            Quorum; Voting. Except as otherwise provided by applicable law, this Certificate of Formation or the Bylaws, the presence, in person or by proxy, at a shareholders meeting of the holders of shares of outstanding capital stock of the Corporation representing a majority of the voting power of all outstanding shares of capital stock of the Corporation entitled to vote at such meeting and not less than one-third of the outstanding shares of the Corporation entitled to vote at such meeting shall constitute a quorum for the transaction of business at such meeting, except that when specified business is to be voted on by a class or series of stock voting as a class, the holders of shares representing a majority of the voting power of the outstanding shares of such class or series entitled to vote at such meeting and not less than one-third of the outstanding shares of such class or series entitled to vote at such meeting shall constitute a quorum of such class or series for the transaction of such business. Except as otherwise provided herein or expressly required by a nonwaivable provision of the TBOC, at all meetings of shareholders and on all matters submitted to a vote of shareholders of the Corporation generally, (i) each holder of Class A Common Stock, as such, shall have one (1) vote per share of Class A Common Stock held of record by such holder, and (ii) each holder of Class B Common Stock, as such, shall have ten (10) votes per share of Class B Common Stock held of record by such holder; provided, however, that, except as otherwise required by law, holders of Class A Common Stock and Class B Common Stock, as such, shall not be entitled to vote on any amendment to this Restated Certificate that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to this Restated Certificate (including any Certificate of Designation (as defined below)) or pursuant to the TBOC. Except as otherwise provided herein or required by a nonwaivable provision of the TBOC, the holders of shares of Class A Common Stock and Class B Common Stock shall at all times vote together as a single class on all matters (or, if any holders of Preferred Stock are entitled to vote together with the holders of Common Stock, as a single class with the holders of Preferred Stock), including the election of directors, submitted to a vote of the shareholders of the Corporation generally. There shall be no cumulative voting. As authorized by Section 21.365 of the TBOC, in lieu of the vote required by Section 21.457 or Section 21.364 of the TBOC, unless otherwise stated in this Restated Certificate, the shareholders by the affirmative vote of the holders of capital stock representing a majority of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote thereon will approve (i) any “fundamental action” as defined in Section 21.364 of the TBOC or (ii) any “fundamental business transaction” as defined in Section 1.002 of the TBOC. To the extent permitted by Section 21.365(b) of the TBOC, notwithstanding any other provision of the TBOC, except as otherwise provided in this Restated Certificate, all classes or series of stock shall only be entitled to vote as a single class or series, and separate voting by class or series is not required, for the purpose of approving any matter, including in connection with any “fundamental action” as defined in Section 21.364 of the TBOC or a “fundamental business transaction” as defined in Section 1.002 of the TBOC; provided that, if a class or series of shares is nevertheless entitled to vote as a class or series on any “fundamental action” as defined in Section 21.364 of the TBOC, then unless otherwise stated in this Restated Certificate, the shareholders by the affirmative vote of the holders of capital stock representing a majority of the voting power of all of the then outstanding shares of capital stock of the Corporation of such class or series shall approve such “fundamental action”.

 

-3-

 

 

3.            Dividends. Subject to the preferential or other rights of any holders of any then-outstanding shares of Preferred Stock, shares of Class A Common Stock and Class B Common Stock shall be treated equally, identically and ratably, on a per share basis, with respect to any distributions or share dividends as may be declared and paid from time to time by the Board out of any assets of the Corporation legally available therefor; provided, however, that in the event a share dividend is paid in the form of shares of Class A Common Stock or Class B Common Stock (or rights to acquire, or securities convertible into or exchangeable for, such shares), then holders of Class A Common Stock shall be entitled to receive shares of Class A Common Stock (or rights to acquire, or securities convertible into or exchangeable for, such shares, as the case may be) and holders of Class B Common Stock shall be entitled to receive shares of Class B Common Stock (or rights to acquire, or securities convertible into or exchangeable for, such shares, as the case may be), with holders of shares of Class A Common Stock and Class B Common Stock receiving, on a per share basis, an identical number of shares of Class A Common Stock or Class B Common Stock (or rights to acquire, or securities convertible into or exchangeable for, such shares, as the case may be), as applicable. Notwithstanding the foregoing, the Board may pay or make a disparate distribution or share dividend per share of Class A Common Stock or Class B Common Stock (whether in the amount of such dividend payable per share, the form in which such dividend is payable, the timing of the payment, or otherwise) if such disparate distribution or share dividend is approved by the affirmative vote of the holders of a majority of the outstanding shares of Class A Common Stock and Class B Common Stock, each voting separately as a series.

 

4.            Subdivisions, Combinations or Reclassifications. Shares of Class A Common Stock or Class B Common Stock may not be subdivided, combined or reclassified unless the shares of the other class of Common Stock are concurrently therewith proportionately subdivided, combined or reclassified in a manner that maintains the same proportionate equity ownership among the holders of the outstanding Class A Common Stock and Class B Common Stock on the record date for such subdivision, combination or reclassification; provided, however, that shares of one such series may be subdivided, combined or reclassified in a different or disproportionate manner if such subdivision, combination or reclassification is approved by the affirmative vote of the holders of a majority of the outstanding shares of Class A Common Stock and Class B Common Stock, each voting separately as a series.

 

5.            Liquidation, Dissolution or Winding Up. Subject to the preferential or other rights of any holders of Preferred Stock then outstanding, upon the dissolution, distribution of assets, liquidation or winding up of the Corporation, whether voluntary or involuntary, holders of Class A Common Stock and Class B Common Stock will be entitled to receive ratably all assets of the Corporation available for distribution to its shareholders in proportion to the number of shares held by each such shareholder, unless disparate or different treatment of the shares of each such series with respect to distributions upon any such liquidation, dissolution, distribution of assets or winding up is approved by the affirmative vote of the holders of a majority of the outstanding shares of Class A Common Stock and Class B Common Stock, each voting separately as a series.

 

-4-

 

 

6.            Merger, Consolidation or Similar Transaction. In the case of any distribution or payment in respect of the shares of Common Stock, or any consideration into which such shares are converted, upon the merger or consolidation of the Corporation with or into any other entity, or in the case of any other transaction having an effect on shareholders substantially similar to that resulting from a merger or consolidation of the Corporation with or into any other entity, such distribution, payment or consideration that the holders of shares of Common Stock have the right to receive, or the right to elect to receive, shall be made ratably on a per share basis among the holders of the Class A Common Stock and Class B Common Stock as a single class; provided, however, that shares of each such series may (but shall not be required to) receive, or have the right to elect to receive, different or disproportionate consideration in connection with such merger, consolidation or other transaction if (i) the only difference in the per share consideration to the holders of the Class A Common Stock and Class B Common Stock is that any securities distributed to the holder of, or issuable upon the conversion of, a share of Class B Common Stock have ten (10) times the voting power of any securities distributed to the holder of, or issuable upon the conversion of, a share of Class A Common Stock, or (ii) such merger, consolidation, or other transaction is approved by the affirmative vote of the holders of a majority of the then outstanding shares of Class A Common Stock and Class B Common Stock, each voting separately as a series. For the avoidance of doubt, any distribution, payment or consideration for purposes of this Section 6 of Part A of Article IV shall not be deemed to include (i) any amount or consideration to be paid to or received by a holder of Common Stock pursuant to any indemnification, employment, consulting, severance or similar services arrangement, whether or not entered into in connection with a transaction described in this Section or (ii) a negotiated agreement between a holder of Common Stock with any counterparty (or Affiliate (as defined below) thereof) to a transaction described in this Section wherein such holder is contributing, selling, transferring or otherwise disposing of shares of the Corporation’s capital stock to such counterparty (or Affiliate thereof) as part of a “rollover” or similar transaction that is in connection with such transaction.

 

7.            Conversion of Class B Common Stock.

 

7.1            Optional Conversion. Each share of Class B Common Stock shall be convertible into one (1) fully paid and nonassessable share of Class A Common Stock at the option of the holder thereof at any time upon written notice to the Corporation, subject to the provisions of Subsection 7.4 of Part A of Article IV.

 

7.2            Automatic Conversion Upon Certain Transfers. With respect to each holder of Class B Common Stock, upon the occurrence of a Transfer (as defined below), other than a Permitted Transfer (as defined below), of shares of Class B Common Stock held by such holder, each share subject to such Transfer shall automatically, without further action by the Corporation or the holder thereof, convert into one (1) fully paid and nonassessable share of Class A Common Stock.

 

-5-

 

 

7.3            Final Conversion of All Shares. Each outstanding share of Class B Common Stock shall automatically, without further action by the Corporation or any holder thereof, convert into one (1) fully paid and nonassessable share of Class A Common Stock at the Final Conversion Time (as defined below).

 

7.4            Mechanics of Conversion.

 

7.4.1            Before any holder of Class B Common Stock shall be entitled to convert any shares of Class B Common Stock into shares of Class A Common Stock pursuant to Subsection 7.1 of Part A of Article IV, such holder shall surrender the certificate or certificates therefor (if any), duly endorsed, at the principal corporate office of the Corporation or of any transfer agent for the Class B Common Stock, and shall provide written notice to the Corporation, at its principal corporate office, of such conversion election and shall state therein the name or names (i) in which the certificate or certificates representing the shares of Class A Common Stock into which the shares of Class B Common Stock are so converted are to be issued (if such shares of Class A Common Stock will be certificated) or (ii) in which such shares of Class A Common Stock are to be registered in book-entry form (if such shares of Class A Common Stock will be uncertificated). If the shares of Class A Common Stock into which the shares of Class B Common Stock are to be converted are to be issued in a name or names other than the name of the holder of the shares of Class B Common Stock being converted, such notice shall be accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the holder. The Corporation shall, as soon as practicable thereafter, issue and deliver at such office to such holder, or to the nominee or nominees of such holder, a certificate or certificates representing the number of shares of Class A Common Stock to which such holder shall be entitled upon such conversion (if such shares of Class A Common Stock are certificated) or shall register such shares of Class A Common Stock in book-entry form (if such shares of Class A Common Stock are uncertificated). Such conversion shall be deemed to be effective immediately prior to the close of business (i) with respect to certificated shares, on the date of such surrender of the certificate or certificates representing the shares of Class B Common Stock to be converted or (ii) with respect to shares that are uncertificated, immediately prior to the close of business on the date that the holder delivers notice of such conversion election as required by this Subsection to the Corporation or its transfer agent, and, in each case, the shares of Class A Common Stock issuable upon such conversion shall be deemed to be outstanding as of such time, and the person or persons entitled to receive the shares of Class A Common Stock issuable upon such conversion shall be deemed to be the record holder or holders of such shares of Class A Common Stock as of such time. Notwithstanding anything herein to the contrary, shares of Class B Common Stock represented by a lost, stolen or destroyed stock certificate may be converted pursuant to Subsection 7.1 of Part A of Article IV if the holder thereof notifies the Corporation or its transfer agent that such certificate has been lost, stolen or destroyed, provides an affidavit of that fact acceptable to the Corporation and executes an agreement acceptable to the Corporation (and, if required by the Corporation, posts a bond in such amount as the Corporation may determine is reasonably necessary) to indemnify the Corporation from any loss incurred by it in connection with such certificate.

 

-6-

 

 

7.4.2            Each outstanding stock certificate (if shares are in certificated form) that, immediately prior to the occurrence of a conversion pursuant to Subsections 7.2 and 7.3 of Part A of Article IV represented one or more shares of Class B Common Stock subject to such conversion shall, upon such conversion, be deemed to represent an equal number of shares of Class A Common Stock, without the need for surrender or exchange thereof. The Corporation shall, upon the request of any holder whose shares of Class B Common Stock have been converted into shares of Class A Common Stock as a result of any conversion pursuant to Subsections 7.2 or 7.3 of Part A of Article IV, and upon surrender by such holder to the Corporation of the outstanding certificate(s) formerly representing such holder’s shares of Class B Common Stock, if any (or, in the case of any lost, stolen or destroyed certificate, upon such holder providing an affidavit of that fact acceptable to the Corporation and executing an agreement acceptable to the Corporation (and, if required by the Corporation, posting a bond in such amount as the Corporation may determine is reasonably necessary) to indemnify the Corporation from any loss incurred by it in connection with such certificate), issue and deliver to such holder’s transferee(s) or such holder, as applicable, certificate(s) representing the shares of Class A Common Stock into which such holder’s shares of Class B Common Stock were converted as a result of such conversion (if such shares are certificated) or, if such shares are uncertificated, register such shares in book-entry form.

 

7.4.3            Each share of Class B Common Stock that is converted pursuant to Subsections 7.1, 7.2 or 7.3 of Part A of Article IV shall thereupon automatically be retired and cancelled in accordance with the applicable provisions of the TBOC, and shall not be available for reissuance. Upon the retirement and cancellation of all shares of Class B Common Stock, all references to Class B Common Stock in this Restated Certificate shall be eliminated.

 

7.4.4            The Corporation may, from time to time, establish such policies and procedures, not in violation of applicable law or the other provisions of this Restated Certificate or the Bylaws of the Corporation, relating to the conversion of the Class B Common Stock into Class A Common Stock and the general administration of this dual series of Common Stock structure, as it may deem necessary or advisable in connection therewith. If the Corporation has reason to believe that any circumstance giving rise to a conversion of shares of Class B Common Stock into Class A Common Stock in accordance with the provisions of this Section 7 of Part A of Article IV has occurred but has not theretofore been reflected on the books and records of the Corporation (or in book-entry as maintained by the transfer agent of the Corporation), the Corporation may request that the holder of such shares furnish affidavits or other evidence to the Corporation as the Corporation deems necessary to determine whether a conversion of shares of Class B Common Stock to Class A Common Stock has occurred, and if such holder does not within ten (10) days after the date of such request furnish sufficient evidence to the Corporation (in the manner provided in the request) to enable the Corporation to determine that no such conversion has occurred, any such shares of Class B Common Stock, to the extent not previously converted, shall be automatically converted into shares of Class A Common Stock and the same shall thereupon be registered on the books and records of the Corporation (or in book-entry as maintained by the transfer agent of the Corporation). In connection with any action of shareholders taken at a meeting, the stock ledger of the Corporation (or in book-entry as maintained by the transfer agent of the Corporation) shall be presumptive evidence as to who are the shareholders entitled to vote in person or by proxy at any meeting of shareholders and the class or classes or series of shares held by each such shareholder and the number of shares of each class or classes or series held by such shareholder.

 

-7-

 

 

8.            Reservation of Stock. The Corporation shall at all times reserve and keep available out of its authorized but unissued shares of Class A Common Stock, solely for the purpose of effecting the conversion of the shares of Class B Common Stock, such number of shares of Class A Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding shares of Class B Common Stock into shares of Class A Common Stock; and if at any time the number of authorized but unissued shares of Class A Common Stock will not be sufficient to effect the conversion of all the then outstanding shares of Class B Common Stock, the Corporation will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Class A Common Stock to such number of shares as will be sufficient for such purpose.

 

9.            Definitions.

 

9.1            “Affiliate” means, with respect to any person, an “affiliate” of such person as defined in Rule 405 of the Securities Act (as defined below).

 

9.2            “Code” means Internal Revenue Code of 1986, as amended.

 

9.3            “Disability” means, with respect to the Founder (as defined below), the permanent and total disability of the Founder such that the Founder is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death within twelve (12) months or which has lasted or can be expected to last for a continuous period of not less than twelve (12) months, in each case, as determined by a licensed medical practitioner jointly selected by a majority of the disinterested members of the Board and the Founder; provided that, if the Founder is incapable of selecting a licensed physician, then the Founder’s spouse shall make the selection on behalf of the Founder, or in the absence or incapacity of the Founder’s spouse, the Founder’s adult children by majority vote shall make the selection on behalf of the Founder. In the event that (i) a dispute exists as to whether the Founder has suffered a Disability or (ii) neither the Founder’s spouse nor his adult children, as applicable, are able to select a licensed physician on behalf of the Founder, no Disability of the Founder shall be deemed to have occurred unless and until an affirmative ruling regarding such Disability has been made by a court of competent jurisdiction, and such ruling has become final and nonappealable.

 

9.4            “Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

9.5            “Family Member” means with respect to any natural person, the spouse, widow, widower, domestic partner, parents, grandparents, lineal descendants, siblings and lineal descendants of siblings (in each case whether by blood relation, adoption, marriage or domestic partnership) of such person.

 

9.6            “Final Conversion Time” means 4:00 p.m. in Dallas, Texas on the earliest to occur of (i) the date fixed by the Board that is no less than sixty (60) days and no more than one hundred eighty (180) days following the death or determination of Disability of the Founder, (ii) the date fixed by the Board that is no less than sixty (60) days and no more than one hundred eighty (180) days following the date that the Founder is no longer providing services to the Corporation as an executive officer or director, (iii) the date fixed by the Board that is no less than sixty (60) days and no more than one hundred eighty (180) days following the date on which the Founder, his Permitted Entities (as defined below) and any of their Permitted Transferees (as defined below) cease to hold or control the vote of, in the aggregate, at least twenty percent (20%) of the shares of Class B Common Stock held by or subject to the Voting Control (as defined below) of them as of the completion of the Corporation’s IPO (as defined below) (as appropriately adjusted for any stock split, stock dividend, reorganization, stock combination or similar transaction with respect to the Class B Common Stock), or (iv) the date specified in writing by the holders of a majority of the then-outstanding shares of Class B Common Stock, provided that in the case of clause (iv), such specified date is at least ten (10) days after such writing is delivered to the Corporation unless otherwise approved by the Board.

 

-8-

 

 

9.7            “Founder” means David D. Halbert.

 

9.8            “IPO” means the sale of shares of Class A Common Stock to the public in a firm-commitment underwritten initial public offering, pursuant to an effective registration statement under the Securities Act.

 

9.9            “Permitted Entity” means, with respect to any Qualified Shareholder (as defined below):

 

(i) any Affiliate of, or corporation, general partnership, limited partnership, limited liability company, private limited company or other entity that directly or indirectly controls, is controlled by, or is under common control with, such Qualified Shareholder, one or more Family Members of such Qualified Shareholder or any other Permitted Entity of such Qualified Shareholder;

 

(ii) any Permitted Trust (as defined below) primarily for the benefit of (a) such Qualified Shareholder, (b) one or more Family Members of such Qualified Shareholder and/or (c) any other Permitted Entity of such Qualified Shareholder;

 

(iii) any organization that is tax-exempt under Section 501(c)(3) of the Code, so long as such Qualified Shareholder and/or one or more Family Members of such Qualified Shareholder have exclusive Voting Control with respect to the shares of Class B Common Stock held by such organization;

 

(iv) any organization that is tax-exempt under Section 501(c)(3) of the Code and is a Qualified Shareholder as of the Effective Time; and

 

(v) any Individual Retirement Account, as defined in Section 408(a) of the Code, or a pension, profit sharing, stock bonus or other type of plan or trust of which such Qualified Shareholder is a participant or beneficiary and which satisfies the requirements for qualification under Section 401 of the Code; provided that in each case such Qualified Shareholder or such Qualified Shareholder’s Permitted Transferees have exclusive Voting Control with respect to the shares of Class B Common Stock held in such account, plan or trust.

 

-9-

 

 

9.10          “Permitted Transfer” shall mean, and be restricted to, any Transfer of a share of Class B Common Stock:

 

(i)            by a Qualified Shareholder to (a) one or more Family Members of such Qualified Shareholder or (b) any Permitted Entity of such Qualified Shareholder;

 

(ii)            by a Permitted Entity of a Qualified Shareholder to (a) such Qualified Shareholder, (b) one or more Family Members of such Qualified Shareholder, or (c) any other Permitted Entity of such Qualified Shareholder;

 

(iii)            to a broker or other nominee so long as the transferor of such share of Class B Common Stock, immediately following such Transfer, retains (a) Voting Control over such share and (b) control over the disposition of such share; or

 

(iv)            that is approved in advance by the Board as a “Permitted Transfer.”

 

9.11          “Permitted Transferee” means a transferee of shares of Class B Common Stock received in a Permitted Transfer.

 

9.12          “Permitted Trust” means a bona fide trust where each trustee is (i) a Qualified Shareholder, (ii) a Family Member of such Qualified Shareholder, (iii) a professional in the business of providing trustee services, including private professional fiduciaries, trust companies and bank trust departments, or (iv) an individual who may be removed and replaced at the sole discretion of a Qualified Shareholder or a Family Member of such Qualified Shareholder.

 

9.13            “Qualified Shareholder” means (i) the record holder of a share of Class B Common Stock as of the Effective Time; (ii) the initial record holder of any shares of Class B Common Stock that are originally issued by the Corporation after the Effective Time pursuant to the exercise, settlement, conversion or exchange of any option, restricted stock unit, warrant or convertible security that, in each case, was outstanding as of the Effective Time; (iii) each natural person who, prior to the Effective Time, transferred shares of capital stock of the Corporation to a Permitted Entity that is a Qualified Shareholder as of the Effective Time pursuant to clause (i); (iv) each natural person who, prior to the Effective Time, transferred equity awards granted to such person by the Corporation to a Permitted Entity that is a Qualified Shareholder as of the Effective Time pursuant to clause (i) or becomes a Qualified Shareholder pursuant to clause (ii); (v) a Permitted Transferee; and (vi) the Founder.

 

9.14          “Securities Act” means the Securities Act of 1933, as amended.

 

9.15          “Transfer” means any direct or indirect sale, exchange, redemption, assignment, distribution, encumbrance, hypothecation, gift, pledge, retirement, transfer, conveyance or other disposition or alienation in any way (whether or not for value and whether voluntarily, involuntarily or by operation of law), including, without limitation: (i) any assignment or distribution resulting from death, incompetency, bankruptcy, liquidation and dissolution; (ii) any transfer to a broker or other nominee (regardless of whether there is a corresponding change in beneficial ownership); and (iii) any transfer of, or entering into a binding agreement with respect to the transfer of, Voting Control; provided, however, that the following shall not be considered a “Transfer” within the meaning of this Section 9 of Part A of Article IV:

 

(i)            the granting of a revocable proxy to officers or directors of the Corporation at the request of the Board in connection with actions to be taken at an annual or special meeting of shareholders or any other action of the shareholders permitted by this Restated Certificate;

 

-10-

 

 

(ii)            the entering into a voting trust, agreement or arrangement (with or without granting a proxy) to which the Founder and/or the Founder’s Permitted Transferees are party that (a) the Corporation is aware as of the Effective Time or (b) is disclosed either in a Schedule 13D filed with the Securities and Exchange Commission or in writing to the Secretary of the Corporation;

 

(iii)            the entering into a voting trust, agreement or arrangement (with or without granting a proxy) pursuant to a written agreement to which the Corporation is a party or that has been approved by the Board;

 

(iv)            the entering into, or reaching an agreement, arrangement or understanding regarding, a support, voting, tender or similar agreement or arrangement (with or without a proxy) in connection with a merger, asset transfer, asset acquisition or similar transaction approved by the Board;

 

(v)            (a) the pledge of shares of Class B Common Stock by a shareholder that creates a mere security interest in such shares pursuant to a bona fide loan or other financing transaction, including, without limitation, any form of margin loan, or (b) a bona fide hedging or other derivative transaction (including without limitation a swap, option or forward transaction (or combination thereof) and any related pledge), in each case, for so long as such shareholder continues to exercise Voting Control over such shares; provided, however, that each of (x) a foreclosure on such shares or other similar action by the pledgee and (y) the settlement of any hedging or derivative transaction by delivery of shares of Class B Common Stock shall constitute a Transfer; and

 

(vi)            the entering into a trading plan pursuant to Rule 10b5-1 under the Exchange Act, with a broker or other nominee; provided, however, that a sale of such shares of Class B Common Stock pursuant to such plan shall constitute a “Transfer” at the time of such sale.

 

9.16          “Voting Control” means, with respect to a share of Class B Common Stock, the power (whether exclusive or shared) to vote or direct the voting of such share by proxy, voting agreement or otherwise.

 

B.            Preferred Stock.

 

Shares of Preferred Stock may be issued from time to time in one or more series, each of such series to have such terms as stated or expressed herein and in the resolution or resolutions providing for the creation and issuance of such series adopted by the Board as hereinafter provided. Any shares of Preferred Stock which may be redeemed, purchased or acquired by the Corporation may be reissued except as otherwise provided by law.

 

In accordance with Section 21.155 of the TBOC, authority is hereby expressly granted to the Board from time to time to issue the Preferred Stock in one or more series, to establish the number of shares to be included in each such series and to determine and fix the voting powers, full or limited, or no voting powers, and such designations, preferences and relative, participating, optional or other special rights of each such series and such qualifications, limitations or restrictions thereof, as shall be stated and expressed in such resolution or resolutions adopted by the Board providing for the establishment and issuance of such series of Preferred Stock, all to the fullest extent now or hereafter permitted by the TBOC. The Board is also expressly authorized to increase or decrease (but not below the number of shares of such series issued as of the time of such decrease) the number of shares of any series of Preferred Stock established by the Board pursuant to Section 21.155 of the TBOC. Without limiting the generality of the foregoing, the resolution or resolutions providing for the designation and issuance of any series of Preferred Stock may provide that such series shall be superior or rank equally or be junior to any other series of Preferred Stock to the extent permitted by law and this Restated Certificate (including any certificate of designation filed with respect to any series of Preferred Stock (a “Certificate of Designation”)). Except as otherwise required by law, holders of any series of Preferred Stock shall be entitled only to such voting rights, if any, as shall expressly be granted thereto by this Restated Certificate (including any Certificate of Designation).

 

-11-

 

 

Article V

 

For the management of the business and for the conduct of the affairs of the Corporation it is further provided that:

 

A.            General Powers. The business and affairs of the Corporation will be managed by or under the direction of the Board.

 

B.            Number of Directors; Initial Directors; Election of Directors. As of the Effective Time, the number of directors of the Corporation constituting the initial Board is twelve (12), and the names and addresses of the initial directors of the Corporation are as follows:

 

NAME ADDRESS

David D. Halbert

c/o Caris Life Sciences, Inc.
750 W John Carpenter Fwy
Suite 800
Irving, TX 75039

Laura I. Johansen

Peter M. Castleman

George H. Poste

Jonathan Knowles

Jon S. Halbert

Danny Phillips

Brian Brille

Joseph E. Gilliam

Lloyd B. Minor

David Fredrickson

Jeffrey Vacirca

 

Subject to the rights of the holders of any series of Preferred Stock to elect directors, the number of directors that constitutes the entire Board shall be fixed solely in the manner set forth in the Bylaws of the Corporation. Each director will be entitled to one vote on each matter presented to the Board.

 

-12-

 

 

C.            Term and Removal. Subject to the rights of the holders of any series of Preferred Stock to elect directors, each director shall hold office until the annual meeting at which such director’s term expires and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation, disqualification or removal. No decrease in the number of directors shall shorten the term of any incumbent director. Subject to the rights of the holders of any series of Preferred Stock to elect directors, the Board or any individual director may be removed from office at any time with or without cause by the affirmative vote of the holders of capital stock representing a majority of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class; provided, however, that from and after the date on which no shares of Class B Common Stock shall be outstanding (such date, the “Trigger Date”), the Board or any individual director may be removed from office at any time and only for cause by the affirmative vote of the holders of capital stock representing a majority of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class.

 

D.            Vacancies and Newly Created Directorships. Subject to the rights of the holders of any series of Preferred Stock to elect directors, and except as otherwise provided in the TBOC, any newly created directorship that results from an increase in the number of directors or any vacancy on the Board that results from the death, disability, resignation, disqualification or removal of any director or from any other cause shall be filled solely by (i) the affirmative vote of a majority of the total number of directors then in office, even if less than a quorum, or by a sole remaining director, or (ii) the affirmative vote of the holders of capital stock representing a majority of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, at an annual or special meeting of shareholders called for that purpose. Any director elected to fill a newly created directorship or vacancy in accordance with this Part D of Article V shall hold office until the next annual meeting of shareholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation, retirement, disqualification, or removal. Notwithstanding the foregoing, except as may be permitted under the TBOC, during a period between two successive annual meetings of shareholders, the Board may not fill more than two vacancies created by an increase in the number of directors.

 

E.            Preferred Stock Directors. Whenever the holders of any series of Preferred Stock issued by the Corporation shall have the right as provided for herein (including any Certificate of Designation), voting separately as a series or separately as a class with one or more such other series, to elect directors, the election, term of office, removal and other features of such directorships shall be governed by the terms of this Restated Certificate (including any Certificate of Designation). Notwithstanding anything to the contrary in this Part E of this Article V, during the period when the holders of any series of Preferred Stock issued by the Corporation shall have the right to elect additional directors, the number of directors to be elected by the holders of any such series of Preferred Stock shall be in addition to the number fixed pursuant to Part B of this Article V, and the total number of directors constituting the entire Board shall be automatically increased by such number of directors to be elected by the holders of any such series of Preferred Stock and each such additional director shall serve until such director’s successor shall have been duly elected and qualified, or until such director’s right to hold such office terminates pursuant to said provisions, whichever occurs earlier, subject to his or her earlier death, resignation, disqualification, or removal. Except as otherwise provided in the Certificate of Designation(s) in respect of any series of Preferred Stock, whenever the holders of any series of Preferred Stock having such right to elect additional directors are divested of such right pursuant to the provisions of this Restated Certificate (including any Certificate of Designation), the terms of office of all such additional directors elected by the holders of such series of Preferred Stock, or elected to fill any vacancies resulting from the death, resignation, disqualification or removal of such additional directors, shall forthwith terminate (in which case each such director thereupon shall cease to be qualified as, and shall cease to be, a director) and the total authorized number of directors of the Corporation shall automatically be reduced accordingly.

 

-13-

 

 

Article VI

 

A.            Limitation of Personal Liability. To the fullest extent permitted by the TBOC, a director of the Corporation will not be personally liable to the Corporation or its shareholders for monetary damages for an act or omission in the director’s capacity as a director, except for liability for (i) any breach of the director’s duty of loyalty to the Corporation or its shareholders, (ii) acts or omissions not in good faith that constitute a breach of duty to the Corporation or involve intentional misconduct or a knowing violation of law, (iii) any transaction from which the director derived any improper benefit, regardless of whether the benefit resulted from an action taken within the scope of such person’s duties or (iv) an act or omission for which the liability of the director is expressly provided for by an applicable statute. If the TBOC is amended hereafter to authorize the further limitation of the personal liability of directors, then the limitation on personal liability provided in this Article VI will, without the necessity of further action by the Corporation or the Board, be modified to provide such limitation to the fullest extent permitted by the TBOC as so amended.

 

B.            Indemnification. To the fullest extent permitted by the TBOC, as the same now exists or may hereafter be amended, substituted, or replaced, the Corporation is authorized to indemnify, and provide advancement of expenses to, its directors, officers, employees and agents (and any other persons to which the TBOC permits the Corporation to provide indemnification) through provisions in the Bylaws of the Corporation, agreements with such directors, officers, employees, agents or other persons, the vote of shareholders or disinterested directors or otherwise.

 

C.            Amendments to Article VI. Any amendment, repeal or modification of the foregoing provisions of this Article VI will not adversely affect any right or protection of a director, officer, employee, agent, or other person existing at the time of, or increase the liability of any director, officer, employee, agent or other person of the Corporation with respect to, any acts or omissions of such director, officer, employee, agent or other person occurring prior to, such amendment, repeal or modification.

 

Article VII

 

Meetings of shareholders may be held within or without the State of Texas, as the Bylaws of the Corporation may provide. To the extent permitted by the TBOC, the books of the Corporation may be kept outside the State of Texas at such place or places as may be designated from time to time by the Board or in the Bylaws of the Corporation.

 

-14-

 

 

Article VIII

 

A.            Consent of Shareholders in Lieu of Meeting. Prior to the Trigger Date, any action required or permitted by the TBOC to be taken by the shareholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of the outstanding capital stock of the Corporation representing not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. From and after the Trigger Date, any action required or permitted by the TBOC to be taken at any annual or special meeting of shareholders may be taken without a meeting, without prior notice and without a vote, only if a consent or consents in writing, setting forth the action so taken, shall be signed by all holders of shares entitled to vote on such action. Any such action taken by written consent pursuant to this Part A of Article VIII shall be delivered to the Corporation at its principal office.

 

B.            Special Meetings. Except as otherwise expressly provided by the terms of any series of Preferred Stock permitting the holders of such series of Preferred Stock to call a special meeting of the holders of such series, special meetings of the shareholders of the Corporation may be called, for any purpose or purposes, at any time only by or at the direction of (i) the Board, (ii) the Chair of the Board, (iii) the President, (iv) the Chief Executive Officer, (v) from and after the Trigger Date, the Secretary of the Corporation at the request of the holders of the greater of (a) at least fifty percent (50%) and (b) the highest percentage of ownership that may be set under the TBOC without the necessity of further action by the Corporation or the Board, of the voting power of all the shares of capital stock of the Corporation entitled to vote at the proposed special meeting or (v) prior to the Trigger Date, the Secretary of the Corporation at the request of the holders of capital stock representing (a) at least fifty percent (50%) of the voting power of all of the shares of capital stock of the Corporation entitled to vote at the proposed special meeting and (b) at least ten percent (10%) of all of the shares of capital stock of the Corporation entitled to vote at the proposed special meeting.

 

C.            Advance Notice. Advance notice of shareholder nominations for the election of directors and of other business proposed to be brought by shareholders before any meeting of shareholders of the Corporation shall be given in the manner provided in the Bylaws of the Corporation.

 

Article IX

 

Unless the Corporation consents in writing to the selection of an alternative forum, (i) the Business Court in the First Business Court Division of the State of Texas (the “Business Court”) located in Dallas, Texas (or, in the event that the Business Court is not then accepting filings or determines that it lacks jurisdiction, the United States District Court for the Northern District of Texas (the “Federal Court”) or, if the Federal Court lacks jurisdiction, the state district courts of Dallas County, Texas) shall be the sole and exclusive forum for any shareholder (including a beneficial owner) to bring (a) any derivative action or proceeding brought on behalf of the Corporation, (b) any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation’s shareholders, including a claim alleging the aiding and abetting of such a breach of fiduciary duty, (c) any action asserting a claim against the Corporation, its directors, officers or employees arising pursuant to any provision of the TBOC, this Restated Certificate or the Bylaws of the Corporation (in each case, as they may be amended from time to time), (d) any action asserting a claim against the Corporation, its directors, officers or employees governed by the internal affairs doctrine or (e) any action asserting an “internal entity claim” as that term is defined in Section 2.115 of the TBOC; and (ii) subject to the preceding provisions of this Article IX, the Federal Court shall be the exclusive forum for the resolution of any complaint asserting a cause or causes of action arising under the Securities Act or the Exchange Act, including all causes of action asserted against any defendant to such complaint. If any action, the subject matter of which is within the scope of this Article IX, is filed in a court other than, in the case of clause (i), the courts located in the State of Texas, and in the case of clause (ii), the Federal Court (a “Foreign Action”) in the name of any shareholder, such shareholder shall be deemed to have consented to (x) the personal jurisdiction of the state and federal courts in the State of Texas in connection with any action brought in any such court to enforce the provisions of this Article IX and (y) having service of process made upon such shareholder in any such action by service upon such shareholder’s counsel in the Foreign Action as agent for such shareholder.

 

-15-

 

 

To the fullest extent permitted by law, any person purchasing or otherwise acquiring or holding any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Article IX. This Article IX is intended to benefit and may be enforced by the Corporation, its officers and directors, the underwriters of, or financial advisors in connection with, any offering giving rise to such complaint, and any other professional or entity whose profession gives authority to a statement made by that person and who has prepared or certified any part of the documents underlying the offering.

 

Article X

 

The shareholders do not have statutory preemptive rights.

 

Article XI

 

A.            Amendment of the Certificate of Formation. The Corporation reserves the right to amend, alter, change, adopt or repeal any provision contained in this Restated Certificate, in the manner now or hereafter prescribed by this Restated Certificate and the TBOC, and all rights conferred upon shareholders herein are granted subject to this reservation; provided, however, that, notwithstanding any other provision of this Restated Certificate or any provision of law that might otherwise permit a lesser vote or no vote, but in addition to any vote of the holders of shares of any class or series of capital stock of the Corporation required by law or by this Restated Certificate, the affirmative vote of the holders of (a) prior to the Trigger Date, at least a majority of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class, and (b) from and after the Trigger Date, at least 66 2/3% of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class, in each case with any shares of a class or series that does not otherwise have a right to vote under this Certificate of Formation being treated as having no votes in the vote as a single class to the greatest extent permitted by applicable law, shall be required to amend or repeal, or adopt any provision of this Restated Certificate inconsistent with Articles V, VI, VIII, IX, X, this Article XI and Article XII; provided, however, for so long as any shares of Class B Common Stock remain outstanding, the Corporation shall not, without the prior affirmative vote of the holders of at least a majority of the voting power of the outstanding shares of Class B Common Stock, voting as a separate class, in addition to any other vote required by law or this Restated Certificate, directly or indirectly, amend, alter, change, repeal or adopt any provision inconsistent with Part A of Article IV or this proviso of this Part A of Article XI.

 

-16-

 

 

B.            Amendment of Bylaws. Except as otherwise provided in this Restated Certificate, in furtherance and not in limitation of the powers conferred upon it by the TBOC, the Board is expressly authorized to adopt, amend, alter or repeal any or all of the Bylaws of the Corporation. The shareholders may not adopt, amend, alter or repeal the Bylaws of the Corporation unless such action is approved, in addition to any other vote required by this Certificate of Incorporation, by the affirmative vote of the holders of (a) prior to the Trigger Date, at least a majority of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class, and (b) from and after the Trigger Date, at least 66 2/3% of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class.

 

C.            Severability. If any provision or provisions of this Restated Certificate, including, without limitation, Article IX, is held to be invalid, illegal or unenforceable as applied to any person or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, (i) the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Restated Certificate (including, without limitation, each portion of any paragraph of this Restated Certificate containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances will not in any way be affected or impaired thereby and (ii) the provisions of this Restated Certificate (including, without limitation, each portion of any paragraph of this Restated Certificate containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) will be construed so as to permit the Corporation to protect its directors, officers, employees and agents from personal liability in respect of their good faith service to or for the benefit of the Corporation to the fullest extent permitted by law.

 

Article XII

 

The right to a jury trial concerning any “internal entity claim” as that term is defined in Section 2.115 of the TBOC, to the fullest extent permitted by the TBOC and applicable law, shall be waived. Without limiting the foregoing, to the fullest extent permitted by the TBOC and applicable law, any person purchasing or otherwise acquiring or holding any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Article XII.

 

* * *

 

-17-

 

 

Exhibit 3.3

 

AMENDED AND RESTATED BYLAWS OF

CARIS LIFE SCIENCES, INC.

ADOPTED ON JULY 28, 2020

 

ARTICLE I

OFFICES

 

Section 1.01    REGISTERED OFFICE AND AGENT. The registered office and registered agent of Caris Life Sciences, Inc. (the “Corporation”) will be as set forth in the Corporation’s Certificate of Formation (the “Certificate”). The registered office or registered agent may be changed by resolution of the Board of Directors (the “Board”), upon making the appropriate filing with the Secretary of State.

 

Section 1.02    PRINCIPAL OFFICE. The principal office of the Corporation will be located at such place within or without the State of Texas as will be fixed from time to time by the Board.

 

Section 1.03    OTHER OFFICES. The Corporation may also have other offices at any places, within or without the State of Texas, as the Board may designate, or as the business of the Corporation may require or as may be desirable.

 

Section 1.04 BOOKS AND RECORDS. All records maintained by the Corporation in the regular course of its business, including its share transfer ledger, books of account, and minute books, may be maintained in written paper form or another form capable of being converted to written paper form within a reasonable time. The Corporation will convert any records so kept upon the request of any person entitled to inspect the records pursuant to applicable law.

 

ARTICLE II

SHAREHOLDERS

 

Section 2.01    PLACE OF MEETING. All meetings of the shareholders will be held either at the principal office of the Corporation or at any other place, either within or without the State of Texas, as will be designated in the notice of the meeting or duly executed waiver of notice. The Board may, in its discretion, determine that the meeting may be held solely by means of remote communication as set out in Section 2.02 below.

 

Section 2.02    MEETINGS OF SHAREHOLDERS BY REMOTE COMMUNICATION. If authorized by the Board, and subject to any guidelines and procedures adopted by the Board, shareholders not physically present at a shareholders' meeting may participate in the meeting by means of remote communication and may be considered present in person and may vote at the meeting, whether held at a designated place or solely by means of remote communication, subject to the conditions imposed by applicable law.

 

Section 2.03    ANNUAL MEETING. An annual meeting of shareholders will be held on the date and time set by the Board and stated in the notice of the meeting for the purpose of electing directors and transacting any other business as may be brought properly before the meeting. Failure to hold the annual meeting at the designated time does not result in the winding up or termination of the Corporation. If the Board fails to call the annual meeting, any shareholder may make written demand to any officer of the Corporation that an annual meeting be held.

 

 

 

Section 2.04    SPECIAL SHAREHOLDERS' MEETINGS. Special meetings of the shareholders may be called by the President, the Board, or by the holders of at least fifty percent (50%) of all the shares entitled to vote at the proposed special meeting. The record date for determining shareholders entitled to call a special meeting is the date the first shareholder signs the notice of that meeting. Only business within the purpose or purposes described in the notice or executed waiver of notice may be conducted at a special meeting of the shareholders.

 

Section 2.05    FIXING THE RECORD DATE. For the purpose of determining shareholders entitled to notice of or to vote at any meeting of shareholders or any adjournment thereof, the Board may fix a date, not more than sixty (60) days or less than ten (10) days before the meeting, as the record date for such determination.

 

Whenever action by shareholders is proposed to be taken by consent in writing without a meeting of shareholders, the Board may fix a record date for the purpose of determining shareholders entitled to consent to that action, which record date will not precede, and will not be more than ten (10) days after, the date upon which the resolution fixing the record date is adopted by the Board.

 

If no record date has been fixed as provided in this Section 2.05, then (a) the record date for determining shareholders entitled to notice of or to vote at any meeting of shareholders or any adjournment thereof will be the date on which notice of the meeting is mailed, (b) the record date for determining shareholders entitled to give written consent to action taken without a meeting, where no prior Board action is required to be taken by the Texas Business Organizations Code (the “TBOC”), will be the date on which a signed written consent is first delivered to the Corporation, and (c) the record date for determining shareholders entitled to give written consent to action taken without a meeting, where prior Board action is required to be taken by the TBOC, will be the close of business on the date on which the Board adopts a resolution taking such prior action.

 

Section 2.06    NOTICE OF SHAREHOLDERS’ MEETING. Written notice stating the place, day, and hour of the meeting, the means of any remote communications by which shareholders may be considered present and may vote at the meeting, and, in case of a special meeting, the purpose or purposes for which the meeting is called, will be given not less than ten (10) days and not more than sixty (60) days before the date of the meeting, personally, by electronic transmission, or by mail, by or at the direction of the President, the Secretary, or the officer or person calling the meeting, to each shareholder entitled to vote at the meeting. If mailed, the notice will be deemed to be given when deposited in the United States mail addressed to the shareholder at the shareholder's address as it appears on the share transfer records of the Corporation, with postage prepaid.

 

2

 

 

Notwithstanding the preceding paragraph, notice of a shareholder meeting regarding a fundamental business transaction (as defined by Texas law) must be given to each shareholder of the Corporation not later than twenty-one (21) days prior to the meeting, regardless of the shareholder’s right to vote on the matter. Notice of such action will comply with any other requirements set by law.

 

A shareholder entitled to notice of a meeting may sign a written waiver of notice either before or after the time of the meeting. The participation or attendance of a shareholder at a meeting constitutes waiver of notice, unless the shareholder participates in or attends the meeting solely to object to the transaction of business on the ground that the meeting was not lawfully called or convened.

 

Notice may be given to the shareholder by electronic transmission. The shareholder may specify the form of electronic transmission to be used to communicate notice. The shareholder may revoke this consent by written notice to the Corporation.

 

Notice by electronic transmission is deemed given when the notice is:

 

(a)Transmitted to a fax number provided by the shareholder.

 

(b)Transmitted to an email address provided by the shareholder.

 

 (c)Posted on an electronic network and a message is sent to the shareholder at the address provided by the shareholder.

 

(d)Communicated to the shareholder by any other form of electronic transmission.

 

Section 2.07    VOTING LISTS. The officer or agent in charge of the share transfer records of the Corporation will prepare, at least eleven (11) days before each meeting of shareholders, a complete list of the shareholders entitled to vote at the meeting or any adjournment thereof, arranged in alphabetical order, with (a) the address of each shareholder, (b) the type of shares held by each shareholder, (c) the number of shares held by each shareholder, and (d) the number of votes that each shareholder is entitled to if different than the number of shares held.

 

The list will be kept on file at the registered office or principal place of business of the Corporation and will be subject to inspection by any shareholder at any time during usual business hours for a period of ten (10) days prior to the meeting. The list will also be produced and kept open at the meeting and will be subject to the inspection of any shareholder during the meeting. The original share transfer records will be prima-facie evidence of the shareholders entitled to examine the list and to vote at any meeting of shareholders.

 

Section 2.08    QUORUM OF SHAREHOLDERS. The presence in person or by proxy of the holders of a majority of the shares entitled to vote constitutes a quorum for a meeting of the shareholders. Unless otherwise required by the TBOC, the Certificate, or these Bylaws:

 

3

 

 

(a)            The affirmative vote of the holders of a majority of the shares represented at a meeting at which a quorum is present will be the act of the shareholders.

 

(b)            The shareholders represented in person or by proxy at a meeting at which a quorum is present may conduct any business properly brought before the meeting until adjournment, and the subsequent withdrawal from the meeting of any shareholder or the refusal of any shareholder represented in person or by proxy to vote will not affect the presence of a quorum at the meeting.

 

If a quorum is not present, the shareholders represented in person or by proxy may adjourn the meeting until a time and place determined by a vote of the holders of a majority of the shares represented in person or by proxy at that meeting. At such adjourned meeting at which the required number of voting shares will be present or represented, any business may be transacted which might have been transacted at the meeting as originally noticed.

 

Section 2.09    CONDUCT OF MEETINGS. The Board may adopt by resolution rules and regulations for the conduct of meetings of the shareholders as it will deem appropriate. At every meeting of the shareholders, a director or officer designated by the Board will act as chairman of, and preside at, the meeting. The Secretary or, in his or her absence or inability to act, the person whom the chairman of the meeting will appoint secretary of the meeting, will act as secretary of the meeting and keep the minutes thereof.

 

Section 2.10    VOTING OF SHARES. Each outstanding share, regardless of class or series, will be entitled to one vote on each matter submitted to a vote at a meeting of shareholders, except to the extent that the Certificate provides for more or less than one vote per share or limits or denies voting rights to the holders of the shares of any class or series. Unless otherwise required by the TBOC, the Certificate, or these Bylaws, any matter, other than the election of directors, brought before any meeting of shareholders at which a quorum is present will be decided by the affirmative vote of the holders of the majority of shares present in person or represented by proxy at the meeting and entitled to vote on the matter.

 

Unless otherwise required by the Certificate, the election of directors will be decided by a plurality of the votes cast by the holders of shares entitled to vote in the election at a meeting of the shareholders at which a quorum is present.

 

Shareholders are prohibited from cumulating their votes in any election of directors of the Corporation.

 

Any vote may be taken by voice or show of hands unless a shareholder entitled to vote, either in person or by proxy, objects, in which case written ballots will be used.

 

Section 2.11    VOTING BY PROXY OR NOMINEE. Shares of the Corporation owned by the Corporation itself or by another corporation or entity, the majority of the voting shares or interest of which is owned or controlled by the Corporation, will not be voted, directly or indirectly, at any meeting, and will not be counted in determining the total number of outstanding shares at any given time. Nothing in this section will be construed as limiting the right of the Corporation or any domestic or foreign corporation or other entity to vote shares, held or controlled by it in a fiduciary capacity, or with respect to which it otherwise exercises voting power in a fiduciary capacity.

 

4

 

 

Any shareholder may vote either in person or by proxy executed in writing by the shareholder. No proxy will be valid after eleven (11) months from the date of its execution unless otherwise provided in the proxy. A proxy will be revocable unless the proxy form conspicuously states that the proxy is irrevocable and the proxy is coupled with an interest. Proxies coupled with an interest include the appointment as proxy of (a) a pledgee; (b) a person who purchased or agreed to purchase, or who owns or holds an option to purchase, the shares subject to the proxy; (c) a creditor of the Corporation who extended the Corporation credit under terms requiring the appointment; (d) an employee of the Corporation whose employment contract requires the appointment; or (e) a party to a voting agreement or shareholders’ agreement created under the TBOC.

 

Shares owned by another corporation, domestic or foreign, may be voted by any officer, agent, or proxy as the bylaws of that corporation may authorize or, in the absence of authorization, as the board of directors of that corporation may determine.

 

An administrator, executor, guardian, or conservator may vote shares held in that fiduciary capacity if the shares forming a part of an estate are in the possession and forming a part of the estate being served by the fiduciary, either in person or by proxy, without a transfer of the shares into the fiduciary’s name. A trustee may vote shares standing in the trustee’s name, either in person or by proxy, but no trustee will be entitled to vote shares held by him or her without a transfer of the shares into his or her name as trustee.

 

A receiver may vote shares standing in the name of a receiver and may vote shares held by or under the control of a receiver without the transfer thereof into the receiver’s name if authority to do so is contained in an appropriate order of the court by which the receiver was appointed.

 

A shareholder whose shares are pledged will be entitled to vote the shares until the shares have been transferred into the name of the pledgee, and thereafter the pledgee will be entitled to vote the shares transferred, subject to any agreements containing restrictions on the hypothecation, assignment, pledge, or voluntary or involuntary transfer of shares.

 

The Board may establish a procedure by which a shareholder may file a statement with the Corporation that all or a portion of the shares registered in the name of the shareholder are held for the account of a specified person to be recognized by the Corporation as the shareholder. The procedure must determine the extent of the Corporation’s recognition of the specified person as a shareholder and may include any provisions that the Board deems necessary, including, but not limited to, any of the following:

 

(a)The types of nominee shareholders who may file a statement.

 

 (b)The rights or privileges of the beneficial owner to be recognized by the Corporation upon filing of a statement.

 

(c)The information to be included in the statement.

 

5

 

 

 (d)The timeframe within which the statement must be received for the statement to be effective as to an upcoming meeting or vote.

 

 (e)The time period for which the statement filed will be recognized by the Corporation.

 

Section 2.12    WRITTEN CONSENT OF SHAREHOLDERS WITHOUT A MEETING. Any action required by the TBOC to be taken at any annual or special meeting of shareholders, or any action which may be taken at any annual or special meeting of shareholders, may be taken without a meeting, without prior notice, and without a vote, if a consent or consents in writing, setting forth the action so taken, will have been signed by the holder or holders of shares having not less than the minimum number of votes that would be necessary to take the action at a meeting at which holders of all shares entitled to vote on the action were present and voted. Prompt notice of the taking of any action by shareholders without a meeting by less than unanimous written consent will be given to those shareholders who did not consent in writing to the action.

 

ARTICLE III

DIRECTORS

 

Section 3.01    BOARD. The business and affairs of the Corporation will be managed under the direction of the Board. Directors need not be residents of the State of Texas or shareholders of the Corporation.

 

Section 3.02    NUMBER OF DIRECTORS. The number of directors will be one (1), provided that the number may be increased or decreased from time to time by an amendment to these Bylaws or by resolution adopted by the Board. No decrease in the number of Directors will have the effect of shortening the term of any incumbent director.

 

Section 3.03    TERM OF OFFICE. At the first annual meeting of shareholders and at each annual meeting thereafter, the holders of shares entitled to vote in the election of directors will elect directors, each of whom will hold office until a successor is duly elected and qualified or until the director’s earlier death, resignation, disqualification, or removal.

 

Section 3.04    VACANCIES AND NEWLY CREATED DIRECTORSHIPS. Any vacancy occurring in the Board may be filled by election at an annual or special meeting of shareholders called for that purpose, or may be filled by the affirmative vote of a majority of the remaining directors even when the majority of the remaining directors is less than a quorum of the total number of directors specified in the Certificate or the Bylaws. A director elected to fill a vacancy will be elected for the unexpired term of his or her predecessor in office.

 

A directorship to be filled by reason of an increase in the number of directors may be filled by election at an annual or special meeting of shareholders called for that purpose, or may be filled by the Board for a term of office continuing only until the next election of one or more directors by the shareholders; provided that the Board may not fill more than two (2) directorships during the period between any two (2) successive annual meetings of shareholders.

 

6

 

 

Section 3.05    REMOVAL. Any director or the entire Board may be removed, with or without cause, by a vote of the holders of a majority of the shares then entitled to vote at an election of the director or directors, at any meeting of shareholders called expressly for that purpose.

 

Section 3.06    RESIGNATION. A director may resign by providing written notice to the Corporation. The resignation will be effective upon the later of the date of receipt of the notice of resignation or the effective date specified in the notice. Acceptance of the resignation will not be required to make the resignation effective.

 

Section 3.07    REGULAR MEETINGS OF DIRECTORS. A regular meeting of the newly-elected Board will be held without other notice immediately following each annual meeting of shareholders, at which the board will elect officers and transact any other business as will come before the meeting. The board may designate a time and place for additional regular meetings, by resolution, without notice other than the resolution.

 

Section 3.08    SPECIAL MEETINGS OF DIRECTORS. The Chairman may call a special meeting of the Board at a time or place determined by the Chairman. The Chairman will call a special meeting at the written request of two (2) or more directors.

 

Section 3.09    NOTICE OF DIRECTORS’ MEETINGS. All special meetings of the Board will be held upon not less than two (2) days’ written notice stating the date, place, and time of the meeting delivered to each director either personally or by mail. Notice of a regular or special meeting of the Board may be provided to a director by electronic transmission on consent of the director. The director may specify the form of electronic transmission to be used to communicate notice.

 

A written waiver of the required notice signed by a director entitled to the notice, before or after the meeting, is the equivalent of giving notice to the director who signs the waiver. A director’s attendance at any meeting will constitute a waiver of notice of the meeting, except where the directors attends a meeting for the express purpose of objecting to the transaction of any business on the grounds that the meeting is not lawfully called or convened.

 

Section 3.10    QUORUM AND ACTION BY DIRECTORS. A majority of the number of directors will constitute a quorum for the transaction of business. The act of the majority of the directors present at a meeting at which a quorum is present at the time of the act will be the act of the Board, unless the act of a greater number is required by law, the Certificate, or these Bylaws. The directors at a meeting for which a quorum is not present may adjourn the meeting until a time and place as may be determined by a vote of the directors present at that meeting.

 

Section 3.11    COMPENSATION. Directors, as such, will not receive any stated salary for their services, but by resolution of the Board a fixed sum and expenses of attendance, if any, may be allowed for attendance at any meeting of the Board or committee thereof. A director will not be precluded from serving the Corporation in any other capacity and receiving compensation for services in that capacity.

 

7

 

 

Section 3.12    ACTION BY DIRECTORS WITHOUT A MEETING. Unless otherwise restricted by the Certificate or these Bylaws, any action required or permitted to be taken at a meeting of the Board or any committee may be taken without a meeting if all members of the Board or committee consent in writing or by electronic transmission and the writings or electronic transmissions are filed with the minutes of the proceedings of the Board.

 

Section 3.13    COMMITTEES OF THE BOARD. The Board, by resolution adopted by a majority of the Board, may designate one or more directors to constitute one or more committees, to exercise the authority of the Board to the extent provided in the resolution of the Board and allowed under the TBOC.

 

No committee of the Board will have the authority to authorize a distribution or to authorize the issuance of shares of the Corporation unless the resolution designating a particular committee expressly so provides.

 

The designation of a committee of the Board and the delegation thereto of authority will not operate to relieve the Board, or any member thereof, of any responsibility imposed by law.

 

ARTICLE IV

OFFICERS

 

Section 4.01    POSITIONS AND ELECTION. The officers of the Corporation will be elected by the Board and will be a Chief Executive Officer, President and a Secretary and any other officers, including assistant officers and agents, as may be deemed necessary by the Board. Any two (2) or more offices may be held by the same person.

 

Each officer will serve until a successor is elected and qualified or until the earlier death, resignation, or removal of that officer. Vacancies or new offices will be filled at the next regular or special meeting of the Board.

 

Section 4.02    REMOVAL. Any officer elected or appointed by the Board may be removed with or without cause by the affirmative vote of the majority of the Board. Removal will be without prejudice to the contract rights, if any, of the officer so removed.

 

Section 4.03    CHAIRMAN AND VICE CHAIRMAN. The Chairman of the Board (the “Chairman”), if any, will preside at all meetings of the Board and of the shareholders at which the Chairman will be present. The Chairman will have and may exercise such powers as are, from time to time, assigned to the Chairman by the Board and as may be provided by law. In the absence of the Chairman, the Vice Chairman of the Board (the “Vice Chairman”), if any, will preside at all meetings of the Board and of the shareholders at which the Vice Chairman will be present. The Vice Chairman will have and may exercise such powers as are, from time to time, assigned to such person by the Board and as may be provided by law.

 

Section 4.04    CHIEF EXECUTIVE OFFICER. In the absence of a Chairman and/or Vice Chairman, the Chief Executive Officer will preside as the chairman of meetings of the shareholders and the Board. The Chief Executive Officer will, subject to the control of the Board, have general and active management of the business of the Corporation and will see that all orders and resolutions of the Board are carried into effect. All other officers, officials, employees and agents will report directly or indirectly to the Chief Executive Officer. The Chief Executive Officer, President or any executive Vice President will execute bonds, mortgages and other contracts on behalf of the Corporation, except where required or permitted by law to be otherwise signed and executed and except where the signing and execution thereof will be expressly delegated by the Board to some other officer or agent of the Corporation.

 

8

 

 

Section 4.05    PRESIDENT. In the absence or disability of the Chief Executive Officer, the President will perform all the duties of the Chief Executive Officer. When acting as the Chief Executive Officer, the President will have all the powers of, and be subject to all the restrictions upon, the Chief Executive Officer. The President will have such other powers and perform such other duties as from time to time may be prescribed by the Board, these Bylaws, the Chief Executive Officer or the Chairman.

 

Section 4.06    VICE PRESIDENTS. Each Vice President may be designated by such title as the Board may determine, and each Vice President in order of their rank as designated by the Board will, in the absence or disability of the President, or at his or her request, perform the duties and exercise the powers of the President and will perform other duties as the Board will assign.

 

Section 4.07    SECRETARY AND ASSISTANT SECRETARIES. The Secretary will attend all meetings of the Board and of the shareholders, and will record all votes and the minutes of all proceedings and will perform like duties for the standing committees when required. The Secretary will give or cause to be given notice of all meetings of the Board and of the shareholders, and will perform other duties as may be prescribed by the Board. The Secretary will be the custodian of the records and of the seal of the Corporation, and will affix the seal to all documents and attest to it when duly authorized by the Board.

 

Each Assistant Secretary may, in the absence or disability of the Secretary, or at his or her request or the request of the President, perform the duties and exercise the powers of the Secretary, and will perform other duties as the Board will assign.

 

In the absence of the Secretary or an Assistant Secretary, the minutes of all meetings of the board and of the shareholders will be recorded by the person designated by the President or by the Board.

 

Section 4.08    THE TREASURER AND ASSISTANT TREASURERS. The Treasurer will be the principal financial officer of the Corporation, will have the custody of the corporate funds and securities, will keep full and accurate accounts of receipts and disbursements of the Corporation, will deposit all moneys and other valuable effects in the name and to the credit of the Corporation in the depositories designated by the Board, and in general will perform all the duties incident to the office of Treasurer and such other duties as the Board may assign from time to time.

 

The Treasurer will disburse the funds of the Corporation as may be ordered by the Board, taking proper vouchers for the disbursements. The Treasurer will keep and maintain the Corporation’s books of account and will render to the President and directors an account of all of his or her transactions as Treasurer and of the financial condition of the Corporation and exhibit the books, records, and accounts to the President or directors at any time.

 

9

 

 

If required by the Board, the Treasurer will give the Corporation a bond in a sum and with a surety or sureties satisfactory to the Board for the faithful performance of the duties of the office and for the restoration to the Corporation, in case of death, resignation, retirement, or removal from office, of all books, papers, vouchers, money, and other property of whatever kind in the incumbent’s possession or under the incumbent’s control belonging to the Corporation.

 

Each Assistant Treasurer may, in the absence or disability of the Treasurer, or at his or her request or the request of the President, perform the duties and exercise the powers of the Treasurer, and will perform other duties as the Board will assign.

 

Section 4.09    AUTHORITY TO EXECUTE AGREEMENTS. All agreements of the Corporation will be executed on behalf of the Corporation by (a) the President or any Vice President, (b) such other officer or employee of the Corporation authorized in writing by the President, with such limitations or restrictions on such authority as the President deems appropriate or (c) such other person as may be authorized by the Board.

 

ARTICLE V

UNCERTIFICATED SHARES AND TRANSFER

 

Section 5.01    UNCERTIFICATED SHARES.

 

The shares of the Corporation will be uncertificated, provided, that any holder of uncertificated shares, upon request, will be entitled to have a certificate for shares of the Corporation so held in which case the Corporation will issue a certificate for such shares to such holder. Any certificates representing shares of the Corporation will be signed by the Chief Executive Officer, the President or a Vice President of the Corporation and either the Secretary or an Assistant Secretary of the Corporation. The signature of any such officer on any such share certificate may be a facsimile. In case any officer who has signed or whose facsimile signature has been placed on any such share certificate will have ceased to be such officer before such certificate is issued, it may be issued by the Corporation with the same effect as if he or she were such officer at the date of its issuance. Within a reasonable time after the issuance or transfer of uncertificated shares, the Corporation will send to the registered owner of the uncertificated shares a written notice that sets forth all of the information required by Section 3.205 the Texas Business Organizations Code.

 

Except as otherwise expressly provided by law, the rights and obligations of the holders of uncertificated shares and the rights and obligations of the holders of certificates representing shares, if any, of the same class and series will be identical. No share will be issued until the consideration therefor, fixed as provided by law, has been fully paid.

 

No requirement of the TBOC with respect to matters to be set forth on certificates representing shares of the Corporation will apply to or affect certificates outstanding when the requirement first becomes applicable to the certificates; but the requirements will apply to all certificates thereafter issued whether in connection with an original issue of shares, a transfer of shares, or otherwise.

 

10

 

 

Section 5.02    TRANSFERS OF SHARES. Shares of the Corporation will be transferable in the manner prescribed by law and in these Bylaws. Transfers of shares will be made on the books of the Corporation only by the holder of record thereof or by such other person as may under law be authorized to endorse such shares for transfer or by such shareholder’s attorney lawfully constituted in writing. Except as otherwise provided by law, upon surrender to the Corporation or its transfer agent of a certificate for shares duly endorsed or accompanied by proper evidence of succession, assignment, or authority to transfer, the Corporation will issue a new certificate to the person entitled thereto, cancel the old certificate, and record the transaction upon its books. No transfer of shares will be valid as against the Corporation for any purpose until it will have been entered in the share transfer records of the Corporation by an entry showing from and to what person those shares were transferred.

 

Section 5.03    REGISTERED SHAREHOLDERS. The Corporation will be entitled to treat the holder of record of any shares issued by the Corporation as the holder in fact thereof for all purposes, including voting those shares, receiving dividends or distributions thereon or notices in respect thereof, transferring those shares, exercising rights of dissent with respect to those shares, exercising or waiving any preemptive right with respect to those shares, entering into agreements with respect to those shares in accordance with Texas law, or giving proxies with respect to those shares.

 

Neither the Corporation nor any of its officers, directors, employees, or agents will be liable for regarding that person as the owner of those shares at that time for those purposes, regardless of whether that person possesses a certificate for those shares, and will not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person, whether or not it will have express or other notice of such claim or interest, except as otherwise provided by Texas law.

 

Section 5.04    LOST CERTIFICATES. The Board may direct a new certificate or certificates to be issued in place of any certificate or certificates previously issued by the Corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate is lost, stolen, or destroyed. When authorizing the issue of a new certificate or certificates, the Board, in its discretion and as a condition precedent to the issuance thereof, may require the owner of the lost, stolen, or destroyed certificate or certificates or his or her legal representative to give the Corporation a bond with surety in a sum as it may direct, as indemnity against any claim that may be made against the Corporation on account of the alleged loss, theft, or destruction of any such certificate or the issuance of such new certificate.

 

ARTICLE VI

DISTRIBUTIONS AND DIVIDENDS

 

Section 6.01    DECLARATION. The Board may authorize distributions on the outstanding shares in cash, property, or in the shares of the Corporation at any annual, regular, or special meeting of the Board to the extent permitted by, and subject to the provisions of, the laws of the State of Texas. The Board may by resolution create a reserve or reserves out of the Corporation’s surplus or allocate any part or all of surplus in any manner for any proper purpose or purposes, and may increase, decrease, or abolish any such reserve, designation, or allocation in the same manner, after first obtaining the written approval of a majority of the shareholders.

 

11

 

 

Section 6.02    FIXING RECORD DATES FOR DISTRIBUTIONS AND DIVIDENDS. For the purpose of determining shareholders entitled to receive a distribution by the Corporation (other than a distribution involving a purchase or redemption by the Corporation of any of its own shares) or a share dividend, the Board may, at the time of declaring the distribution or dividend, set a date no more than sixty (60) days prior to the date of the distribution or dividend. If no record date is fixed for the determination of shareholders entitled to receive a distribution (other than a distribution involving a purchase or redemption by the Corporation of any of its own shares) or a share dividend, the date on which the resolution of the Board declaring the distribution or share dividend is adopted will be the record date for the determination of shareholders.

 

ARTICLE VII

INDEMNIFICATION

 

Section 7.01    INDEMNIFICATION OF EXISTING AND FORMER DIRECTORS AND OFFICERS. The Corporation will indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending, or completed action or other proceeding (whether civil, criminal, administrative, arbitrative, or investigative), including any appeal thereof, or any inquiry or investigation that could lead to such an action or proceeding (any of the foregoing to be referred to hereafter as a “proceeding”) by reason of the fact that the person (1) is or was a director or officer of the Corporation; or (2) while a director or officer of the Corporation, is or was serving at the request of the Corporation as a partner, director, officer, venturer, proprietor, trustee, employee, administrator, or agent of another entity, organization, or an employee benefit plan (each such person in (2) to be referred to hereafter as a “delegate” and, together with each such person in (1), a “covered person”) to the fullest extent permitted by the TBOC, as the same now exists or may hereafter be amended, substituted, or replaced (but, in the case of any such amendment, substitution, or replacement, only to the extent that such amendment, substitution, or replacement permits the Corporation to provide broader indemnification rights than the TBOC permitted the Corporation to provide prior to such amendment, substitution, or replacement), against all judgments (including arbitration awards), court costs, penalties, settlements, fines, excise, and other similar taxes and reasonable attorneys’ fees (all of the foregoing to be referred to hereafter as “expenses”) actually incurred by the covered person in connection with such proceeding. The right to indemnification in this Section 7.01 will continue as to a covered person who has ceased to be a director, officer, or delegate and will inure to his or her heirs, executors, or administrators.

 

Section 7.02    ADVANCEMENT OF EXPENSES. The Corporation will pay or reimburse reasonable expenses incurred by a covered person currently serving as a director, officer, or delegate of the Corporation who was or is a party or is threatened to be made a party to any proceeding in advance of the final disposition of the proceeding, without any determination as to the covered person’s entitlement to indemnification, if the Corporation receives the following before any such advancement of expenses:

 

12

 

 

(a)            A written affirmation by the covered person of the covered person’s good faith belief that he or she has met the standard of conduct necessary for indemnification under the TBOC.

 

(b)            A written undertaking by or on behalf of the covered person to repay the amount so advanced if the final determination is that the covered person has not met the required standard of conduct set forth in the TBOC or that indemnification is prohibited by the TBOC.

 

Section 7.03    INDEMNIFICATION OF AND ADVANCEMENT OF EXPENSES TO OTHER PERSONS. Notwithstanding any other provision of this ARTICLE VII, the Corporation may indemnify and advance expenses to persons other than covered persons, including advisory directors, non-executive officers, employees, and agents of the Corporation, to the extent and in the manner provided by the TBOC and these Bylaws.

 

Section 7.04    INDEMNIFICATION RIGHTS NOT EXCLUSIVE. The rights provided pursuant to this ARTICLE VII will not be exclusive of any other rights to which a person may be entitled by applicable law, the Corporation’s Certificate, action or resolution of the Corporation’s shareholders or disinterested directors or contract.

 

Section 7.05    INSURANCE. The Corporation may purchase and maintain insurance or another arrangement to indemnify any covered person against any liability asserted against and incurred by the covered person in that capacity or arising out of the covered person’s status in that capacity, regardless of whether the Corporation would have the power to indemnify the covered person against that liability under applicable law.

 

Section 7.06    REPORTS OF INDEMNIFICATION AND ADVANCES. No later than one (1) year from the date that the Corporation indemnifies or advances expenses to a director, it will give a written report of such indemnification or advancement to the shareholders, which report must be made with or before the notice or waiver of notice of the next shareholders’ meeting or the next submission to the shareholders of a written consent without a meeting.

 

ARTICLE VIII

MISCELLANEOUS

 

Section 8.01    SEAL. The Corporation may adopt a corporate seal in a form approved by the Board. The Corporation will not be required to use the corporate seal and the lack of the corporate seal will not affect an otherwise valid contract or other instrument executed by the Corporation.

 

Section 8.02    CHECKS, DRAFTS, ETC. All checks, drafts or other instruments for payment of money or notes of the Corporation will be signed by an officer or officers or any other person or persons as will be determined from time to time by resolution of the Board.

 

Section 8.03    FISCAL YEAR. The fiscal year of the Corporation will be as determined by the Board.

 

13

 

 

Section 8.04    INVALID PROVISIONS. If any one or more of the provisions of these Bylaws, or the applicability of any provision to a specific situation, will be held invalid or unenforceable, the provision will be modified to the minimum extent necessary to make it or its application valid and enforceable, and the validity and enforceability of all other provisions of these Bylaws and all other applications of any provision will not be affected thereby.

 

Section 8.05    CONFLICT WITH APPLICABLE LAW OR CERTIFICATE. These Bylaws are adopted subject to any applicable law and the Certificate. Whenever these Bylaws may conflict with any applicable law or the Certificate, such conflict will be resolved in favor of such law or the Certificate.

 

ARTICLE IX

AMENDMENT OF BYLAWS

 

Section 9.01    AMENDMENT OF BYLAWS. The Board may amend, alter, change, and repeal these Bylaws or adopt new bylaws. The shareholders may make additional bylaws and may alter and repeal any bylaws whether such bylaws were originally adopted by them or otherwise.

 

14

 

 

Exhibit 3.4

 

AMENDED AND RESTATED BYLAWS
OF
CARIS LIFE SCIENCES, INC.
(AS OF         , 2025)

 

Article I
OFFICES

 

Section 1.1.        Registered Office. The address of the registered office of Caris Life Sciences, Inc. (the “Corporation”) in the State of Texas, and the name of its registered agent at such address, shall be as set forth in the Corporation’s certificate of formation, as the same may be amended and/or restated from time to time (the “Certificate of Formation”).

 

Section 1.2.        Additional Offices. The Corporation may, in addition to its registered office in the State of Texas, have such other offices and places of business, both within and outside the State of Texas, as the Board of Directors of the Corporation (the “Board”) may from time to time determine or as the business and affairs of the Corporation may require.

 

Article II
MEETINGS OF SHAREHOLDERS

 

Section 2.1.        Place of Meetings. Meetings of shareholders shall be held at any place within or outside the State of Texas, designated by the Board. The Board may, in its sole discretion, determine that a meeting of shareholders shall not be held at any place, but may instead be held solely by means of remote communication pursuant to Section 9.5(a) of these Bylaws. In the absence of any such designation or determination, shareholders meetings shall be held at the Corporation’s principal executive office.

 

Section 2.2.        Annual Meetings. The Board shall designate the date and time of the annual meeting of shareholders. At the annual meeting of shareholders, directors shall be elected and other business properly brought before the meeting in accordance with Section 2.8 of these Bylaws may be transacted. The Board may postpone, adjourn, reschedule or cancel any previously scheduled annual meeting of shareholders (for any reason or no reason).

 

Section 2.3.        Special Meetings.

 

(a)            Subject to the rights of the holders of any outstanding series of the preferred stock of the Corporation (“Preferred Stock”), and to the requirements of applicable law, special meetings of shareholders may be called only by such persons and only in such manner as set forth in the Certificate of Formation. Other than procedural matters, no business may be transacted at any special meeting of shareholders other than the business specified in the notice of such meeting. The Board may postpone, adjourn, reschedule or cancel (to the extent permitted under the TBOC) any previously scheduled special meeting of shareholders (for any reason or no reason).

 

(b)           A special meeting requested by one or more shareholders holding the requisite percentage specified in the Certificate of Formation (the “Requisite Percentage”) pursuant to the Certificate of Formation (a “Shareholder Requested Meeting”) shall be called by the Secretary only if the shareholders requesting such meeting provide the information set forth in Section 2.3(c) of these Bylaws below and otherwise comply with this Section 2.3, as determined by the Board. For purposes of these Bylaws, any determination to be made by the Board may be made by the Board, a committee of the Board or any officer of the Corporation designated by the Board or a committee of the Board, and any such determination shall be final and binding on the Corporation, its shareholders and any other person so long as made in good faith (without any further requirements).

 

(c)            In order for a Shareholder Requested Meeting to be called by the Secretary pursuant to Section 2.3(b) of these Bylaws, one or more written requests for a special meeting (individually or collectively, a “Special Meeting Request”) signed and dated by the shareholder(s) that Own(s) (as defined below) the Requisite Percentage (or its or their respective duly authorized agent) must be delivered to the Secretary at the principal executive office of the Corporation and must be accompanied by:

 

 

 

(i)          in the case of any Shareholder Requested Meeting at which director nominations are proposed to be presented, the information and documentation required by Section 3.4 of these Bylaws, including any updates or supplements thereto required pursuant to Section 3.4 of these Bylaws, if applicable;

 

(ii)         in the case of any Shareholder Requested Meeting at which any business other than director nominations is proposed to be presented, the information and documentation required by Section 2.8(a)(ii) of these Bylaws (as though such provision were applicable to special meetings), as well as any updates or supplements thereto required pursuant to Section 2.8(a)(ii) of these Bylaws, if applicable; and

 

(i)          as to each shareholder of the Corporation signing such request, or if such shareholder is a nominee or custodian, the beneficial owner(s) on whose behalf such request is signed, an affidavit by each such person (A) stating the class or series and number of shares of capital stock of the Corporation that he, she, or it Owns as of the date such request was signed; and (B) agreeing to (1) update and supplement such affidavit as of the record date for the Shareholder Requested Meeting (and such update and supplement shall be delivered to the Secretary at the principal executive office of the Corporation not later than five (5) Business Days (as defined below) after the record date for such Shareholder Requested Meeting) and as of the date that is ten (10) Business Days prior to the date of the Shareholder Requested Meeting (and such update and supplement shall be delivered to the Secretary at the principal executive office of the Corporation not later than seven (7) Business Days prior to the date of such Shareholder Requested Meeting) and (2) notify the Corporation promptly (and in any event within forty-eight (48) hours) in writing to the Secretary at the principal executive office of the Corporation of any disposition after the record date for such Shareholder Requested Meeting, but prior to the date of the Shareholder Requested Meeting. For purposes of these Bylaws, “Business Day” shall mean any day other than a Saturday, a Sunday or a day on which banking institutions in the State of Texas are authorized or obligated by law or executive order to close.

 

(d)            One or more written requests for a special meeting delivered to the Secretary shall constitute a valid Special Meeting Request only if each such written request satisfies the requirements of this Section 2.3 and has been dated and delivered to the Secretary within sixty (60) days of the earliest dated of such requests. Any requesting shareholder may revoke his, her, or its Special Meeting Request at any time by written revocation delivered to the Secretary at the principal executive office of the Corporation; provided, however, that if following such revocation, the unrevoked valid Special Meeting Requests represent in the aggregate less than the Requisite Percentage, there shall be no requirement to hold a Shareholder Requested Meeting. Except as otherwise provided by applicable law or except to the extent previously determined by the Board in connection with a Special Meeting Request, the chair of the Shareholder Requested Meeting shall have the power and duty (i) to determine whether any business proposed to be brought before the meeting was made in accordance with the procedures set forth in this Section 2.3 and applicable law and (ii) if any proposed business was not made or proposed in compliance with this Section 2.3 and applicable law, to declare that such proposed business shall not be transacted.

 

(e)            If none of the shareholders who submitted the Special Meeting Request, or their qualified representatives, appears at the Shareholder Requested Meeting and presents the matters to be presented for consideration that were specified in the Special Meeting Request, the Corporation need not present such matters for a vote at such meeting (notwithstanding that ballots or proxies in respect of such matter may have been received by the Corporation). For purposes of these Bylaws, to be considered a qualified representative of a shareholder, (i) a person must be a duly authorized officer, manager, or partner of such shareholder or must be authorized by a writing executed by such shareholder stating that such person is authorized to act for such shareholder as proxy at the meeting of shareholders; and (ii) prior to the presentation of such matters at the meeting of shareholders, such person must produce a valid government-issued photo identification, as well as either (A) proof that he, she, or it is a duly authorized officer, manager, or partner of such shareholder or (B) such writing (or a reliable reproduction or electronic transmission of the writing).

 

2

 

 

(f)            For purposes of these Bylaws, a shareholder or beneficial owner shall be deemed to “Own” only those outstanding shares of the Corporation’s capital stock as to which such person possesses both: (i) the full voting and investment rights pertaining to such shares and (ii) the full economic interest in (including the opportunity for profit from and the risk of loss on) such shares; provided that the number of shares calculated in accordance with clauses (i) and (ii) shall not include any shares (A) purchased by such person or any of its Affiliates (as defined below) in any transaction that has not been settled or closed; (B) sold short by such person or any of its Affiliates; (C) borrowed by such person or any of its Affiliates for any purpose or purchased by such person or any of its Affiliates pursuant to an agreement to resell or subject to any other obligation to resell to another person; or (D) subject to any option, warrant, forward contract, swap, contract of sale, or other derivative or similar agreement entered into by such person or any of its Affiliates, whether any such instrument or agreement is to be settled with shares or with cash based on the notional amount or value of shares of outstanding capital stock of the Corporation, in any such case which instrument or agreement has, or is intended to have, or if exercised would have the purpose or effect of (1) reducing in any manner, to any extent, or at any time in the future, such person’s or any of its Affiliates’ full right to vote or direct the voting of any such shares, or (2) hedging, offsetting or altering to any degree any gain or loss arising from the full economic ownership of such shares by such person or any of its Affiliates. For purposes of these Bylaws, a shareholder or beneficial owner shall Own shares held in the name of a nominee or other intermediary so long as the person retains the right to instruct how the shares are voted with respect to the election of directors and possesses the full economic interest in the shares. For purposes of these Bylaws, a person shall be deemed to continue to Own shares during any period in which the person has delegated any voting power by means of a proxy, power of attorney, or other instrument or arrangement that is revocable at any time by the person. For purposes of these Bylaws, a person shall also be deemed to continue to Own shares during any period in which the person has loaned such shares provided that the person has the power to recall such loaned shares on no more than five (5) Business Days’ notice, the person recalls the loaned shares no later than five (5) Business Days after being notified that the Shareholder Requested Meeting will be held, and the person holds the recalled shares through the date of the Shareholder Requested Meeting. The determination of the extent to which a shareholder or beneficial owner “Owns” any shares of capital stock of the Corporation for these purposes shall be made by the Board. The terms “Owned,” “Owning” and “Ownership” and other variations of the word “Own” shall have correlative meanings in these Bylaws. For purposes of these Bylaws, the term “Affiliates” shall have the meaning given in Rule 12b-2 under the Exchange Act (as defined below).

 

Section 2.4.        Notices. Written notice of each shareholders meeting stating the place, if any, date, and time of the meeting, and the means of remote communication, if any, by which shareholders and proxy holders may be deemed to be present in person and vote at such meeting and the record date for determining the shareholders entitled to vote at the meeting, if such date is different from the record date for determining shareholders entitled to notice of the meeting, shall be given in the manner permitted by Section 9.3 of these Bylaws to each shareholder entitled to vote thereat as of the record date for determining the shareholders entitled to notice of the meeting, by the Corporation not less than ten (10) nor more than sixty (60) days before the date of the meeting unless otherwise required by Section 21.353 of the Texas Business Organizations Code (the “TBOC”). If said notice is for a special meeting of shareholders, it shall in addition state the purpose or purposes for which the meeting is called, and the business transacted at such meeting shall be limited to the matters so stated in the Corporation’s notice of meeting (or any supplement thereto). Any meeting of shareholders as to which notice has been given may be postponed, and any meeting of shareholders as to which notice has been given may be cancelled (to the extent permitted by the TBOC), by the Board upon public announcement (as defined in Section 2.8(c) of these Bylaws) given before the date previously scheduled for such meeting.

 

Section 2.5.        Quorum. Except as otherwise provided by applicable law, the Certificate of Formation or these Bylaws, the presence, in person or by proxy, at a shareholders meeting of the holders of shares of outstanding capital stock of the Corporation representing a majority of the voting power of all outstanding shares of capital stock of the Corporation entitled to vote at such meeting and not less than one-third of the outstanding shares of the Corporation entitled to vote at such meeting shall constitute a quorum for the transaction of business at such meeting, except that when specified business is to be voted on by a class or series of stock voting as a class, the holders of shares representing a majority of the voting power of the outstanding shares of such class or series entitled to vote at such meeting and not less than one-third of the outstanding shares of such class or series entitled to vote at such meeting shall constitute a quorum of such class or series for the transaction of such business. If a quorum shall not be present or represented by proxy at any meeting of the shareholders of the Corporation, the chair of the meeting may adjourn the meeting from time to time in the manner provided in Section 2.7 of these Bylaws until a quorum shall attend in person or be represented by proxy. The shareholders present at a duly convened meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough shareholders to leave less than a quorum. Shares of its own stock belonging to the Corporation or to another corporation, if a majority of the voting power of the shares entitled to vote in the election of directors of such other corporation is held, directly or indirectly, by the Corporation, shall neither be entitled to vote nor be counted for quorum purposes; provided, however, that the foregoing shall not limit the right of the Corporation or any such other corporation to vote shares held by it in a fiduciary capacity.

 

3

 

 

Section 2.6.        Voting of Shares.

 

(a)            Voting Lists. The Corporation shall prepare, no later than the eleventh (11th) day before each meeting of shareholders, a complete list of the shareholders entitled to vote at the meeting (provided, however, that if the record date for determining the shareholders entitled to vote is less than eleven (11) days before the date of the meeting, the list shall reflect the shareholders entitled to vote as of the eleventh (11th) day before the meeting date), arranged in alphabetical order, and showing the address of each shareholder, the number and class or series of shares registered in the name of each shareholder and the number of votes to which each shareholder is entitled. The Corporation shall not be required to include electronic mail addresses or other electronic contact information on such list. Subject to the last sentence of this Section 2.6(a), such list shall be open to the examination of any shareholder, for any purpose germane to the meeting for a period of at least ten (10) days before the meeting date: (i) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (ii) during ordinary business hours, at the Corporation’s principal executive office. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to shareholders of the Corporation. Such list shall presumptively determine the identity of the shareholders entitled to vote at the meeting and the number and class or series of shares held by each of them. Failure to comply with the foregoing requirements of this Section 2.6(a) shall not affect the validity of any action taken at a meeting of the shareholders of the Corporation. Except as otherwise provided by law, the stock ledger shall be the only evidence as to who are the shareholders entitled to examine the list of shareholders required by this Section 2.6(a) or to vote in person or by proxy at any meeting of shareholders.

 

(b)            Manner of Voting. At any shareholders meeting, every shareholder entitled to vote may vote in person or by proxy. If authorized by the Board, the voting by shareholders or proxy holders at any meeting conducted by remote communication may be effected by a ballot submitted by electronic transmission (as defined in Section 9.3 of these Bylaws), provided that any such electronic transmission must either set forth or be submitted with information from which the Corporation can determine that the electronic transmission was authorized by the shareholder or proxy holder. The Board, in its discretion, or the chair of the meeting of shareholders, in such person’s discretion, may require that any votes cast at such meeting shall be cast by written ballot.

 

(c)            Proxies. Each shareholder entitled to vote at a meeting of shareholders may authorize another person or persons to act for such shareholder by proxy authorized by an instrument in writing or by a transmission permitted by law, including Rule 14a-19 promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), filed in accordance with the procedure established for the meeting, provided that no such proxy shall be valid after eleven (11) months after the date of its execution, unless the proxy provides for a longer period. The revocability of a proxy that states on its face that it is irrevocable shall be governed by the provisions of Section 21.369 of the TBOC. A proxy may be in the form of an electronic transmission that sets forth or is submitted with information from which it can be determined that the transmission was authorized by the shareholder. Any shareholder directly or indirectly soliciting proxies from other shareholders must use a proxy card color other than white, which shall be reserved for the exclusive use by the Board.

 

(d)            Required Vote. Subject to the rights of the holders of any series of Preferred Stock, voting separately by class or series, to elect directors pursuant to the terms of any series of Preferred Stock, at all meetings of shareholders at which a quorum is present, the election of directors shall be determined by a plurality of the votes cast by the shareholders present in person or represented by proxy at the meeting and entitled to vote thereon. All other matters presented to the shareholders at a meeting at which a quorum is present shall be determined by the vote of a majority of the votes cast for or against by the shareholders present in person or represented by proxy at the meeting and entitled to vote thereon, unless the matter is one upon which, by a provision of applicable law, the Certificate of Formation, these Bylaws or applicable stock exchange rules, a different vote is required, in which case such provision shall govern and control the decision of such matter.

 

(e)            Inspectors of Election. The Board may, and shall if required by law, in advance of any meeting of shareholders, appoint one or more persons as inspectors of election, who may be employees of the Corporation or otherwise serve the Corporation in other capacities, to act at such meeting of shareholders or any adjournment thereof and to make a written report thereof. The Board may appoint one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspectors of election or alternates are appointed by the Board, the chair of the meeting may appoint one or more inspectors to act at the meeting. If applicable, each inspector, before discharging his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. If applicable, the inspectors shall ascertain and report the number of outstanding shares and the voting power of each; determine the number of shares present in person or represented by proxy at the meeting and the validity of proxies and ballots; count all votes and ballots and report the results; determine and retain for a reasonable period a record of the disposition of any challenges made to any determination by the inspectors; and certify their determination of the number of shares represented at the meeting and their count of all votes and ballots. No person who is a candidate for an office at an election may serve as an inspector at such election. Any report of an inspector shall be in writing and signed by the inspector or by a majority of them if there is more than one inspector acting at such meeting. If there is more than one inspector, the report of a majority shall be the report of the inspectors.

 

4

 

 

Section 2.7.        Adjournments. Any meeting of shareholders, annual or special, may be adjourned by the chair of the meeting, from time to time, whether or not there is a quorum, to reconvene at the same or some other place. Unless these Bylaws otherwise require, notice need not be given of any such adjourned meeting if the date, time, and place, if any, thereof, and the means of remote communication, if any, by which shareholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken. At the adjourned meeting the shareholders, or the holders of any class or series of stock entitled to vote separately as a class, as the case may be, may transact any business that might have been transacted at the original meeting. If the adjournment is for more than thirty (30) days, notice of the adjourned meeting shall be given to each shareholder of record entitled to vote at the meeting. If after the adjournment a new record date for shareholders entitled to vote is fixed for the adjourned meeting, the Board shall fix a new record date for notice of such adjourned meeting in accordance with Section 9.2 of these Bylaws, and shall give notice of the adjourned meeting to each shareholder of record entitled to vote at such adjourned meeting as of the record date fixed for notice of such adjourned meeting. To the extent permitted by the TBOC, shareholders shall not be entitled to adjourn a meeting of shareholders, whether or not a quorum is present.

 

Section 2.8.        Advance Notice for Business.

 

(a)            Annual Meetings of Shareholders. No business may be transacted at an annual meeting of shareholders, other than business that is either (i) specified in the Corporation’s notice of meeting (or any supplement thereto) given by or at the direction of the Board, (ii) otherwise properly brought before the annual meeting by or at the direction of the Board or (iii) otherwise properly brought before the annual meeting by any shareholder of the Corporation (x) who is a shareholder of record entitled to vote at such annual meeting on the date of the giving of the notice provided for in this Section 2.8(a), on the record date for the determination of shareholders entitled to vote at such annual meeting and on the date of the annual meeting and (y) who complies with the notice procedures set forth in this Section 2.8(a). Notwithstanding anything in this Section 2.8(a) to the contrary, only persons nominated for election as a director to fill any term of a directorship that expires on the date of the annual meeting pursuant to Section 3.4 of these Bylaws will be considered for election at such meeting.

 

(i)          In addition to any other applicable requirements, for business (other than director nominations) to be properly brought before an annual meeting by a shareholder, such shareholder must have given timely notice thereof in proper written form to the Secretary and such business must otherwise be a proper matter for shareholder action. Subject to Section 2.8(a)(iii) of these Bylaws , a shareholder’s notice to the Secretary with respect to such business, to be timely, must be received by the Secretary at the principal executive office of the Corporation not earlier than the close of business on the one hundred twentieth (120th) day nor later than the close of business on the ninetieth (90th) day before the anniversary date of the immediately preceding annual meeting of shareholders; provided, however, that in the event that the annual meeting is more than thirty (30) days before or more than sixty (60) days after such anniversary date (or if there has been no prior annual meeting), notice by the shareholder to be timely must be so delivered not earlier than the close of business on the one hundred twentieth (120th) day before the meeting and not later than the later of (x) the close of business on the ninetieth (90th) day before the meeting and (y) the close of business on the tenth (10th) day following the day on which public announcement of the date of the annual meeting is first made by the Corporation. The public announcement of an adjournment, recess, rescheduling or postponement of an annual meeting shall not commence a new time period (or extend any time period) for the giving of a shareholder’s notice as described in this Section 2.8(a).

 

5

 

 

(ii)         To be in proper written form, a shareholder’s notice to the Secretary with respect to any business (other than director nominations) to bring before any annual meeting of shareholders must set forth as to each such matter such shareholder proposes to bring before the annual meeting (A) a brief description of the business desired to be brought before the annual meeting, the text of the proposal or business (including the text of any resolutions proposed for consideration and in the event such business includes a proposal to amend these Bylaws, the language of the proposed amendment) and the reasons for conducting such business at the annual meeting, (B) the name and record address of such shareholder and the name and address of the beneficial owner, if any, on whose behalf the proposal is made, (C) the class or series and number of shares of capital stock of the Corporation that are owned beneficially and of record by such shareholder and by the beneficial owner, if any, on whose behalf the proposal is made, (D) a description of all agreements, arrangements or understandings (whether written or oral) between or among such shareholder and the beneficial owner, if any, on whose behalf the proposal is made and any other person or persons (including their names and addresses) in connection with the proposal of such business by such shareholder, (E) any material interest, direct or indirect, of such shareholder and the beneficial owner, if any, on whose behalf the proposal is made in such business, other than an interest arising from the ownership of Corporation securities where such shareholder or such beneficial owner receives no extra or special benefit not shared on a pro rata basis by all other holders of the same class or series, and (F) a representation that such shareholder (or a qualified representative of such shareholder) intends to appear in person or by proxy at the annual meeting to bring such business before the meeting. As to the shareholder giving the notice and each beneficial owner, if any, on whose behalf the proposal is made (including any Affiliate or Associate (as defined below)), such shareholder’s notice must set forth: (I) the name and address of the shareholder proposing such business as they appear on the Corporation’s books as of the date of the notice and the name and address of such beneficial owner, if any; (II) the class or series and number of shares of the Corporation that are, directly or indirectly, owned beneficially or of record (within the meaning of Rule 13d-3 under the Exchange Act) by such shareholder and such beneficial owner, if any (except that any such person shall in all events be deemed to beneficially own any shares of any class or series of the Corporation as to which such person has a right to acquire beneficial ownership at any time in the future); (III) a description of any agreement, arrangement, understanding, or relationship with respect to the proposal between or among such shareholder or such beneficial owner and any of their respective Affiliates or Associates; (IV) a description of any proxy, contract, agreement, arrangement, understanding, or relationship pursuant to which such shareholder and such beneficial owner, if any, has a right to vote any shares of any security of the Corporation; (V) a description of any agreement, arrangement, understanding, or relationship (including any hedging transactions and any derivative or short positions, profit interests, options, warrants, convertible securities, stock appreciation or similar rights, and borrowed or loaned shares (a “Derivative Instrument”)) directly or indirectly owned beneficially by such shareholder and such beneficial owner, if any, whether or not such instrument or right shall be subject to settlement in underlying shares of capital stock of the Corporation, the effect or intent of which is to mitigate loss to, manage risk, or benefit from share price changes for, or increase or decrease the voting power of, such shareholder or such beneficial owner, with respect to securities of the Corporation; (VI) any proportionate interest in shares of the Corporation or Derivative Instruments held, directly or indirectly, by a general or limited partnership in which such shareholder or beneficial owner, if any, is a general partner or, directly or indirectly, beneficially owns an interest in a general partner; (VII) any performance-related fees (other than an asset-based fee) that such shareholder or beneficial owner, if any, is entitled to based on any increase or decrease in the value of shares of the Corporation or Derivative Instruments, if any, as of the date of such notice, including, without limitation, any such interests held by members of such shareholder’s or beneficial owner’s immediate family sharing the same household; (VIII) any rights to distributions or dividends on the shares of the Corporation owned beneficially by such shareholder or beneficial owner, if any, that are separated or separable from the underlying shares of the Corporation; (IX) a representation as to whether such shareholder or such beneficial owner, if any, intends or is part of a group that intends to (1) deliver a proxy statement and form of proxy to the Corporation’s shareholders or (2) otherwise solicit proxies or votes from shareholders in support of such proposal; and (X) any other information relating to such shareholder and such beneficial owner, if any, required to be disclosed in a proxy statement required to be made in connection with a contested solicitation of proxies for the proposal pursuant to and in accordance with Section 14 of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of these Bylaws, the term “Associates” shall have the meaning given in Rule 12b-2 under the Exchange Act. A shareholder providing notice of any business proposed to be brought before a meeting shall further update and supplement such notice, if necessary, so that the information provided or required to be provided in such notice pursuant to this Section 2.8 shall be true and correct in all material respects as of the record date for the meeting and as of the date that is ten (10) Business Days prior to the meeting or any adjournment, recess, rescheduling, or postponement thereof. Such update and supplement shall be delivered to, or mailed and received by, the Secretary at the principal executive office of the Corporation (i) not later than five (5) Business Days after the record date for the meeting (in the case of the update and supplement required to be made as of the record date), and (ii) not later than seven (7) Business Days prior to the date for the meeting or any adjournment, recess, rescheduling, or postponement thereof (in the case of the update and supplement required to be made as of ten (10) Business Days prior to the meeting or any adjournment, recess, rescheduling, or postponement thereof).

 

6

 

 

(iii)        The foregoing notice requirements of this Section 2.8(a) shall be deemed satisfied by a shareholder as to any proposal (other than nominations) if the shareholder has notified the Corporation of such shareholder’s intention to present such proposal at an annual meeting in compliance with Rule 14a-8 (or any successor thereof) of the Exchange Act, and such shareholder has complied with the requirements of such Rule for inclusion of such proposal in a proxy statement prepared by the Corporation to solicit proxies for such annual meeting. If the Board or the chair of the annual meeting determines that any shareholder proposal was not made in accordance with the provisions of this Section 2.8(a) or that the information provided in a shareholder’s notice does not satisfy the information requirements of this Section 2.8(a), such proposal shall not be presented for action at the annual meeting. Further, the Board may, in its discretion, exclude from any proxy materials sent to shareholders any matters that may properly be excluded under the Exchange Act, Securities and Exchange Commission rules, or other applicable laws. Notwithstanding the foregoing provisions of this Section 2.8(a), if the shareholder (or a qualified representative of the shareholder) does not appear at the annual meeting of shareholders of the Corporation to present the proposed business, such proposed business shall not be transacted, notwithstanding that proxies in respect of such matter may have been received by the Corporation.

 

(iv)        In addition to the provisions of this Section 2.8(a), a shareholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth herein. Nothing in this Section 2.8(a) shall be deemed to affect any rights of shareholders to request inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 under the Exchange Act.

 

(b)           Special Meetings of Shareholders. Other than procedural matters, only such business shall be conducted at a special meeting of shareholders as shall have been brought before the meeting pursuant to the Corporation’s notice of meeting. Nominations of persons for election to the Board may be made at a special meeting of shareholders at which directors are to be elected pursuant to the Corporation’s notice of meeting only pursuant to Section 3.4 of these Bylaws.

 

(c)            Public Announcement. For purposes of these Bylaws, “public announcement” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed or furnished by the Corporation with the Securities and Exchange Commission pursuant to Sections 13, 14 or 15(d) of the Exchange Act (or any successor thereto).

 

7

 

 

Section 2.9.        Conduct of Meetings. The chair of each annual and special meeting of shareholders shall be the Chair of the Board or, in the absence (or inability or refusal to act) of the Chair of the Board, such other person as shall be appointed by the Board. The date and time of the opening and the closing of the polls for each matter upon which the shareholders will vote at a meeting shall be determined and announced at the meeting by the chair of the meeting, and after the polls close, no ballots, proxies or votes or any revocations or changes thereto may be accepted. The Board may adopt by resolution such rules and regulations for the conduct of the meeting of shareholders as it shall deem appropriate. Except to the extent inconsistent with these Bylaws or such rules and regulations as adopted by the Board, the chair of any meeting of shareholders shall have the right and authority to convene and (for any or no reason) to recess and/or adjourn the meeting, to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chair, are appropriate for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the Board or prescribed by the chair of the meeting, may include, without limitation, the following: (a) the establishment of an agenda or order of business for the meeting; (b) rules and procedures for maintaining order at the meeting and the safety of those present (including, without limitation, rules and procedures regarding the manner of voting, conduct of discussion or removal of disruptive persons from the meeting); (c) limitations on attendance at or participation in the meeting to shareholders of record of the Corporation, their duly authorized and constituted proxies or such other persons as the chair of the meeting shall determine; (d) restrictions on entry to the meeting after the time fixed for the commencement thereof; (e) limitations on the time allotted to questions or comments by participants or to the number of questions or comments by an individual participant; and (f) restrictions on the use of cellphones, audio or video recording devices or other electronic devices at the meeting. Unless and to the extent determined by the Board or the chair of the meeting, meetings of shareholders shall not be required to be held in accordance with the rules of parliamentary procedure. The chair of the meeting may, if the facts warrant, determine and declare to the meeting that a matter, nomination or other business was not properly brought before the meeting. If the chair of the meeting should so determine, the chair of the meeting shall so declare to the meeting, and any such matter, nomination or other business declared not to be properly brought before the meeting shall not be transacted or considered. The secretary of each annual and special meeting of shareholders shall be the Secretary or, in the absence (or inability or refusal to act) of the Secretary, an Assistant Secretary. In the absence (or inability or refusal to act) of the Secretary and all Assistant Secretaries, the chair of the meeting may appoint any person to act as secretary of the meeting.

 

Article III
DIRECTORS

 

Section 3.1.        Powers. The business and affairs of the Corporation shall be managed by or under the direction of the Board, subject to any limitation imposed by applicable law, the Certificate of Formation, or these Bylaws.

 

Section 3.2.        Number of Directors. Subject to the Certificate of Formation, the total number of directors constituting the Board shall be determined from time to time by resolution of the Board. No reduction of the authorized number of directors shall have the effect of removing any director before that director’s term of office expires.

 

Section 3.3.        Chair and Vice Chair of the Board. The Chair of the Board, if any, will preside at all meetings of the Board and of the shareholders at which the Chair will be present. The Chair of the Board will have and may exercise such powers as are, from time to time, assigned to the Chair by the Board and as may be provided by law. . The Vice Chair of the Board, if any, will have and may exercise such powers as are, from time to time, assigned to such person by the Board and as may be provided by law.

 

Section 3.4.        Advance Notice for Nomination of Directors.

 

(a)            Only persons who are nominated in accordance with the following procedures shall be eligible for election as directors of the Corporation, except as may be otherwise provided by the terms of one or more series of Preferred Stock with respect to the rights of holders of one or more series of Preferred Stock to elect directors. Nominations of persons for election to the Board at any annual meeting of shareholders, or at any special meeting of shareholders called for the purpose of electing directors as set forth in the Corporation’s notice of such special meeting, may be made (i) by or at the direction of the Board or (ii) by any shareholder of the Corporation (x) who is a shareholder of record entitled to vote in the election of directors on the date of the giving of the notice provided for in this Section 3.4, on the record date for the determination of shareholders entitled to vote at such meeting and at the time of such meeting and (y) who complies with the notice procedures and other requirements set forth in this Section 3.4 and with applicable law.

 

(b)            In addition to any other applicable requirements, for a nomination to be made by a shareholder, such shareholder must have given timely notice thereof in proper written form to the Secretary. To be timely, a shareholder’s notice to the Secretary must be received by the Secretary at the principal executive office of the Corporation (i) in the case of an annual meeting, not earlier than the close of business on the one hundred twentieth (120th) day nor later than the close of business on the ninetieth (90th) day before the anniversary date of the immediately preceding annual meeting of shareholders; provided, however, that in the event that the annual meeting is more than thirty (30) days before or more than sixty (60) days after such anniversary date (or if there has been no prior annual meeting), notice by the shareholder to be timely must be so received not earlier than the close of business on the one hundred twentieth (120th) day before the meeting and not later than the later of (x) the close of business on the ninetieth (90th) day before the meeting and (y) the close of business on the tenth (10th) day following the day on which public announcement of the date of the annual meeting was first made by the Corporation; and (ii) in the case of a special meeting of shareholders called for the purpose of electing directors, not later than the close of business on the tenth (10th) day following the day on which public announcement of the date of the special meeting is first made by the Corporation. In no event shall the public announcement of an adjournment, recess, rescheduling or postponement of an annual meeting or special meeting commence a new time period (or extend any time period) for the giving of a shareholder’s notice as described in this Section 3.4.

 

8

 

 

(c)            Notwithstanding anything in paragraph (b) to the contrary, in the event that the number of directors to be elected to the Board at an annual meeting is greater than the number of directors whose terms expire on the date of the annual meeting and there is no public announcement by the Corporation naming all of the nominees for the additional directors to be elected or specifying the size of the increased Board before the close of business on the ninetieth (90th) day prior to the anniversary date of the immediately preceding annual meeting of shareholders, a shareholder’s notice required by this Section 3.4 shall also be considered timely, but only with respect to nominees for the additional directorships created by such increase that are to be filled by election at such annual meeting, if it shall be received by the Secretary at the principal executive office of the Corporation not later than the close of business on the tenth (10th) day following the date on which such public announcement was first made by the Corporation.

 

(d)            To be in proper written form, a shareholder’s notice to the Secretary must (i) set forth as to each person whom the shareholder proposes to nominate for election as a director (A) the name, age, business address and residence address of the person, (B) the principal occupation or employment of the person, (C) the class or series and number of shares of capital stock of the Corporation that are owned beneficially or of record by the person, (D) any other information relating to the person that would be required to be disclosed in a proxy statement required to be made in connection with solicitations of proxies in an election contest pursuant to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder and (E) a complete and accurate description of all direct and indirect compensation and other material monetary agreements, arrangements, and understandings (whether written or oral) during the past three (3) years, and any other material relationships between or among such shareholder and beneficial owner, if any, and their respective Affiliates and Associates, on the one hand, and each proposed nominee, and his or her respective Affiliates and Associates, on the other hand, including, without limitation, all information that would be required to be disclosed pursuant to Rule 404 promulgated under Regulation S-K of the Securities Act of 1933 if the shareholder making the nomination and any beneficial owner on whose behalf the nomination is made, if any, or any Affiliate or Associate thereof, were the “registrant” for purposes of such rule and the nominee were a director or executive officer of such registrant; and (ii) be accompanied by (A) a written consent of each proposed nominee to being named as a nominee and to serve as a director if elected and (B) a completed signed questionnaire and written representation and agreement, as required by Section 3.4(h) of these Bylaws. The Corporation may require any proposed nominee to furnish such other information as the Corporation may reasonably require to determine the eligibility of such proposed nominee to serve as a director of the Corporation and that the Corporation believes could be material to a reasonable shareholder’s understanding of the independence (both from management and from the shareholder and beneficial owner, if any) and qualifications of such proposed nominee. As to the shareholder giving the notice and each beneficial owner, if any, on whose behalf the nomination is made (including any Affiliate or Associate), such shareholder’s notice must set forth: (I) the information required by Section 2.8(a)(ii)(I) through (II) and (IV) through (VIII) of these Bylaws, (II) a description of all arrangements or understandings relating to the nomination to be made by such shareholder among such shareholder, the beneficial owner, if any, on whose behalf the nomination is made, and any of their respective Affiliates or Associates, each proposed nominee and any other person or persons (including their names), (III) a representation that such shareholder (or a qualified representative of such shareholder) intends to appear in person or by proxy at the meeting to nominate the persons named in its notice and a representation that such beneficial owner, if any, is the beneficial owner of stock of the Corporation and (IV) any other information relating to such shareholder and the beneficial owner, if any, on whose behalf the nomination is made that would be required to be disclosed in a proxy statement required to be made in connection with solicitations of proxies in an election contest pursuant to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder. A shareholder providing notice of any nomination proposed to be brought before a meeting shall further update and supplement such notice, if necessary, so that the information provided or required to be provided in such notice pursuant to this Section 3.4(d) shall be true and correct in all material respects as of the record date for the meeting and as of the date that is ten (10) Business Days prior to the meeting or any adjournment, recess, rescheduling, or postponement thereof. Such update and supplement shall be delivered to, or mailed and received by, the Secretary at the principal executive office of the Corporation (i) not later than five (5) Business Days after the record date for the meeting (in the case of the update and supplement required to be made as of the record date) and (ii) not later than seven (7) Business Days prior to the date for the meeting or any adjournment, recess, rescheduling, or postponement thereof (in the case of the update and supplement required to be made as of ten (10) Business Days prior to the meeting or any adjournment, recess, rescheduling, or postponement thereof).

 

9

 

 

(e)            If the Board or the chair of the meeting of shareholders determines that any nomination was not made in accordance with the provisions of this Section 3.4, or that the information provided in a shareholder’s notice does not satisfy the information requirements of this Section 3.4, then such nomination shall not be considered at the meeting in question. Notwithstanding the foregoing provisions of this Section 3.4, if the shareholder (or a qualified representative of the shareholder) does not appear at the meeting of shareholders of the Corporation to present the nomination, such nomination shall be disregarded, notwithstanding that proxies in respect of such nomination may have been received by the Corporation.

 

(f)            In addition to the provisions of this Section 3.4, a shareholder shall also comply with all of the applicable requirements of state law and of the Exchange Act and the rules and regulations thereunder related to the submission of director nominations and related solicitation of proxies. Nothing in this Section 3.4 shall be deemed to affect any rights of the holders of Preferred Stock to elect directors pursuant to the Certificate of Formation.

 

(g)            These Bylaws shall not be deemed to require inclusion in the Corporation’s proxy statement of nominations or proposals of shareholders which the Corporation is not otherwise required to include in its proxy statement.

 

(h)            To be eligible to be a nominee for election or reelection as a director of the Corporation pursuant to this Section 3.4, a proposed nominee must deliver (in accordance with the time periods prescribed for delivery of notice under these Bylaws and applicable law) to the Secretary at the principal executive office of the Corporation (i) a written questionnaire (in the form provided by the Secretary upon written request by a stockholder of record) with respect to the background and qualification of such person and the background of any other person or entity on whose behalf the nomination is being made and (ii) a written representation and agreement (in the form provided by the Secretary upon written request by a stockholder of record) that such person (A) is not and will not become a party to (I) any agreement, arrangement, or understanding (whether written or oral) with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a director of the Corporation, will act or vote in such capacity on any issue or question (a “Voting Commitment”) that has not been disclosed to the Corporation or (II) any Voting Commitment that could limit or interfere with such person’s ability to comply, if elected as a director of the Corporation, with such person’s fiduciary duties under applicable law; (B) is not and will not become a party to any agreement, arrangement, or understanding (whether written or oral) with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement, or indemnification in connection with such person’s nomination, candidacy, service, or action as a director of the Corporation that has not been disclosed to the Corporation; and (C) would be in compliance, if elected as a director of the Corporation, and will comply with all applicable law, applicable stock exchange rules, the Corporation’s Code of Business Conduct and Ethics, and any other policies and guidelines of the Corporation applicable to members of the Board and any applicable Board committee(s).

 

(i)            Notwithstanding anything herein to the contrary, if (A) any shareholder providing notice pursuant to this Section 3.4 or each beneficial owner, if any, on whose behalf the nomination is made (including any Affiliate or Associate) provides notice pursuant to Rule 14a-19(b) under the Exchange Act with respect to any proposed nominee and (B) (I) such person subsequently either (1) notifies the Corporation that such person no longer intends to solicit proxies in support of the election or reelection of such proposed nominee in accordance with Rule 14a-19(b) under the Exchange Act or (2) fails to comply with the requirements of Rule 14a-19(a)(2) or Rule 14a-19(a)(3) under the Exchange Act (or fails to timely provide reasonable evidence sufficient to satisfy the Corporation that such person has met the requirements of Rule 14a-19(a)(3) under the Exchange Act in accordance with the following sentence) and (II) no other shareholder that has provided notice pursuant to this Section 3.4 or any beneficial owner, if any, on whose behalf the nomination was made (including any Affiliate or Associate) has provided notice pursuant to Rule 14a-19(b) under the Exchange Act with respect to such proposed nominee (x) to the Corporation’s knowledge based on information provided pursuant to Rule 14a-19 under the Exchange Act or these Bylaws, still intends to solicit proxies in support of the election or reelection of such proposed nominee in accordance with Rule 14a-19(b) under the Exchange Act and (y) has complied with the requirements of Rule 14a-19(a)(2) and Rule 14a-19(a)(3) under the Exchange Act and the requirements set forth in the following sentence, then the nomination of such proposed nominee shall be disregarded and no vote on the election of such proposed nominee shall occur (notwithstanding that proxies in respect of such vote may have been received by the Corporation). Upon request by the Corporation, if any shareholder providing notice pursuant to this Section 3.4 or each beneficial owner, if any, on whose behalf the nomination is made (including any Affiliate or Associate) provides notice pursuant to Rule 14a-19(b) under the Exchange Act, such person shall deliver to the Secretary, no later than five (5) Business Days prior to the applicable meeting date, reasonable evidence that the requirements of Rule 14a-19(a)(3) under the Exchange Act have been satisfied.

 

10

 

 

Section 3.5.        Compensation. Unless otherwise restricted by the Certificate of Formation or these Bylaws, the Board shall have the authority to fix the compensation of directors, including for service on a committee of the Board, and may be paid either a fixed sum for attendance at each meeting of the Board or other compensation as director. The directors may be reimbursed their expenses, if any, for attendance at each meeting of the Board. No such payment shall preclude any director from serving the Corporation in any other capacity and receiving compensation therefor. Members or chairs of committees of the Board may be allowed reimbursement of expenses and additional compensation for service on or chairing the committee.

 

Article IV
BOARD MEETINGS

 

Section 4.1.        Regular Meetings. Regularly scheduled, periodic meetings of the Board may be held without notice at such times, dates and places (within or without the State of Texas) as shall from time to time be determined by the Board.

 

Section 4.2.        Special Meetings. Special meetings of the Board (a) may be called by the Chair of the Board and (b) shall be called by the Chair of the Board or Secretary on the written request of at least a majority of directors then in office, or the sole director, as the case may be, and shall be held at such time, date and place (within or without the State of Texas) as may be determined by the person calling the meeting or, if called upon the request of directors or the sole director, as specified in such written request. Notice of each special meeting of the Board shall be given, as provided in Section 9.3 of these Bylaws, to each director (i) at least twenty four (24) hours before the meeting if such notice is oral notice given personally or by telephone or written notice given by hand delivery or by means of a form of electronic transmission and delivery; (ii) at least two (2) days before the meeting if such notice is sent by a nationally recognized overnight delivery service; and (iii) at least five (5) days before the meeting if such notice is sent through the United States mail. If the Secretary shall fail or refuse to give such notice, then the notice may be given by the officer who called the meeting or the directors who requested the meeting. Any and all business that may be transacted at a regular meeting of the Board may be transacted at a special meeting. Except as may be otherwise expressly provided by applicable law, the Certificate of Formation, or these Bylaws, neither the business to be transacted at, nor the purpose of, any special meeting need be specified in the notice or waiver of notice of such meeting. A special meeting may be held at any time without notice if all the directors are present or if those not present waive notice of the meeting in accordance with Section 9.4 of these Bylaws.

 

Section 4.3.        Quorum; Required Vote. A majority of the Board shall constitute a quorum for the transaction of business at any meeting of the Board, and the act of a majority of the directors present at any meeting at which there is a quorum shall be the act of the Board, except as may be otherwise specifically provided by applicable law, the Certificate of Formation or these Bylaws. If a quorum shall not be present at any meeting, a majority of the directors present may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present.

 

Section 4.4.        Consent In Lieu of Meeting. Unless otherwise restricted by the Certificate of Formation or these Bylaws, any action required or permitted to be taken at any meeting of the Board or any committee thereof may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions (or paper reproductions thereof) are filed with the minutes of proceedings of the Board or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

 

11

 

 

Section 4.5.        Organization. The chair of each meeting of the Board shall be the Chair of the Board or, in the absence (or inability or refusal to act) of the Chair of the Board, a chair elected from the directors present. The Secretary shall act as secretary of all meetings of the Board. In the absence (or inability or refusal to act) of the Secretary, an Assistant Secretary shall perform the duties of the Secretary at such meeting. In the absence (or inability or refusal to act) of the Secretary and all Assistant Secretaries, the chair of the meeting may appoint any person to act as secretary of the meeting.

 

Article V
COMMITTEES OF DIRECTORS

 

Section 5.1.        Establishment. The Board may by resolution designate one or more committees, each committee to consist of one or more of the directors of the Corporation. Each committee shall keep regular minutes of its meetings and report the same to the Board when required by the resolution designating such committee. The Board shall have the power at any time to fill vacancies in, to change the membership of, or to dissolve any such committee.

 

Section 5.2.        Available Powers. Any committee established pursuant to Section 5.1 of these Bylaws, to the extent permitted by applicable law and by resolution of the Board, shall have and may exercise all of the powers and authority of the Board in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers that may require it.

 

Section 5.3.        Alternate Members. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of such committee. In the absence or disqualification of a member of the committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he, she or they constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in place of any such absent or disqualified member.

 

Section 5.4.        Procedures. Unless the Board otherwise provides, the time, date, place, if any, and notice of meetings of a committee shall be determined by such committee. At meetings of a committee, a majority of the number of members of the committee (but not including any alternate member, unless such alternate member has replaced any absent or disqualified member at the time of, or in connection with, such meeting) shall constitute a quorum for the transaction of business. The act of a majority of the members present at any meeting at which a quorum is present shall be the act of the committee, except as otherwise specifically provided by applicable law, the Certificate of Formation, these Bylaws or the Board. If a quorum is not present at a meeting of a committee, the members present may adjourn the meeting from time to time, without notice other than an announcement at the meeting, until a quorum is present. Unless the Board otherwise provides and except as provided in these Bylaws, each committee designated by the Board may make, alter, amend and repeal rules for the conduct of its business. In the absence of such rules each committee shall conduct its business in the same manner as the Board is authorized to conduct its business pursuant to Article III and Article IV of these Bylaws.

 

Section 5.5.        Subcommittees. Unless otherwise provided in the Certificate of Formation, these Bylaws or the resolutions of the Board designating the committee, a committee may create one or more subcommittees, each subcommittee to consist of one or more members of the committee, and delegate to a subcommittee any or all of the powers and authority of the committee.

 

Article VI
OFFICERS

 

Section 6.1.        Officers. The officers of the Corporation elected by the Board shall be a Chief Executive Officer, a President, a Secretary and such other officers (including without limitation, a Chair of the Board, a Vice Chair of the Board, Vice Presidents, Assistant Secretaries, a Treasurer and Assistant Treasurers) as the Board from time to time may determine. Officers elected by the Board shall each have such powers and duties as generally pertain to their respective offices, subject to the specific provisions of this Article VI. Such officers shall also have such powers and duties as from time to time may be conferred by the Board. The Chief Executive Officer may also appoint such other officers (including without limitation one or more Vice Presidents) as may be necessary or desirable for the conduct of the business of the Corporation. Such other officers shall have such powers and duties and shall hold their offices for such terms as may be provided in these Bylaws or as may be prescribed by the Board or, if such officer has been appointed by the Chief Executive Officer, as may be prescribed by the Chief Executive Officer.

 

12

 

 

(a)            Chief Executive Officer. The Chief Executive Officer will, subject to the control of the Board, have general and active management of the business of the Corporation and will see that all orders and resolutions of the Board are carried into effect. All other officers, officials, employees and agents will report directly or indirectly to the Chief Executive Officer. The Chief Executive Officer, President or any Vice President will execute bonds, mortgages and other contracts on behalf of the Corporation, except where required or permitted by law to be otherwise signed and executed and except where the signing and execution thereof will be expressly delegated by the Board to some other officer or agent of the Corporation.

 

(b)            President. In the absence or disability of the Chief Executive Officer, the President will perform all the duties of the Chief Executive Officer. When acting as the Chief Executive Officer, the President will have all the powers of, and be subject to all the restrictions upon, the Chief Executive Officer. The President will have, subject to the supervision, direction and control of the Board and the Chief Executive Officer, the general powers and duties of supervision, direction and management of the affairs and business of the Corporation customarily and usually associated with the position of President. The President will have such other powers and perform such other duties as from time to time may be prescribed by the Board, these Bylaws, the Chief Executive Officer or the Chair.

 

(c)            Vice Presidents. Each Vice President will perform other duties as the Board, the Chief Executive Officer or the President may assign.

 

(d)            Secretary. The Secretary will attend all meetings of the Board and of the shareholders, and will record all votes and the minutes of all proceedings and will perform like duties for the standing committees when required. The Secretary will give or cause to be given notice of all meetings of the Board and of the shareholders, will have all such further powers and duties as are customarily and usually associated with the position of Secretary, and will perform other duties as may be prescribed by the Board, the Chief Executive Officer or the President. .

 

(e)            Assistant Secretaries. Each Assistant Secretary may, in the absence or disability of the Secretary, or at his or her request or the request of the Chief Executive Officer or the President, perform the duties and exercise the powers of the Secretary, and will perform other duties as the Board, the Chief Executive Officer, the President, or the Secretary may assign. In the absence of the Secretary or an Assistant Secretary, the minutes of all meetings of the Board and of the shareholders will be recorded by the person designated by the Chief Executive Officer, the President or by the Board.

 

(f)            Treasurer.

 

(i)          The Treasurer will have the custody of the corporate funds and securities, will keep full and accurate accounts of receipts and disbursements of the Corporation, will deposit all moneys and other valuable effects in the name and to the credit of the Corporation in the depositories designated by the Board, and in general will have all such further powers and duties as are customarily and usually associated with the position of Treasurer and such other duties as the Board, the Chief Executive Officer, or the President may assign from time to time.

 

(ii)         Each Assistant Treasurer may, in the absence or disability of the Treasurer, or at his or her request or the request of the Chief Executive Officer or the President, perform the duties and exercise the powers of the Treasurer, and will perform other duties as the Board, the Chief Executive Officer, the President, or the Treasurer may assign.

 

Section 6.2.        Removal; Vacancies. Any officer may be removed, with or without cause, at any time by the Board. Any officer appointed by the Chief Executive Officer may also be removed, with or without cause, by the Chief Executive Officer unless the Board otherwise provides. Any vacancy occurring in any elected office of the Corporation may be filled by the Board. Any vacancy occurring in any office appointed by the Chief Executive Officer may be filled by the Chief Executive Officer unless the Board then determines that such office shall thereupon be elected by the Board, in which case the Board shall elect such officer.

 

13

 

 

Section 6.3.        Multiple Officeholders. Any number of offices may be held by the same person.

 

Section 6.4.        Representation of Shares of Other Corporations.        The Chair of the Board, the Chief Executive Officer, or the President of the Corporation, or any other person authorized by the Board, the Chief Executive Officer or the President, is authorized to vote, represent and exercise on behalf of the Corporation all rights incident to any and all shares or voting securities of any other corporation or other person standing in the name of the Corporation. The authority granted herein may be exercised either by such person directly or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the authority.

 

Article VII
SHARES

 

Section 7.1.        Uncertificated Shares. The shares of the Corporation will be uncertificated, provided, that any holder of uncertificated shares, upon written request to the transfer agent or registrar of the Corporation, will be entitled to a certificate for shares of the Corporation so held in which case the Corporation will issue a certificate for such shares to such holder. Any certificates representing shares of the Corporation shall be in such form as shall be approved by the Board of Directors and will be signed by the Chief Executive Officer, the President or a Vice President of the Corporation and either the Secretary or an Assistant Secretary of the Corporation. The signature of any such officer on any such share certificate may be a facsimile. In case any officer who has signed or whose facsimile signature has been placed on any such share certificate will have ceased to be such officer before such certificate is issued, it may be issued by the Corporation with the same effect as if he or she were such officer at the date of its issuance. Within a reasonable time after the issuance or transfer of uncertificated shares, the Corporation will send to the registered owner of the uncertificated shares a written notice that sets forth all of the information required by Section 3.205 of the TBOC. Except as otherwise expressly provided by law, the rights and obligations of the holders of uncertificated shares and the rights and obligations of the holders of certificates representing shares, if any, of the same class and series will be identical. No requirement of the TBOC with respect to matters to be set forth on certificates representing shares of the Corporation will apply to or affect certificates outstanding when the requirement first becomes applicable to the certificates; but the requirements will apply to all certificates thereafter issued whether in connection with an original issue of shares, a transfer of shares, or otherwise.

 

Section 7.2.        Multiple Classes and/or Series of Stock. If the Corporation shall be authorized to issue more than one class of stock or more than one series of any class of stock, the Corporation shall (a) cause the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights to be set forth in full or summarized on the face or back of any certificate that the Corporation issues to represent shares of such class or series of stock or (b) in the case of uncertificated shares, within a reasonable time after the issuance or transfer of such shares, send to the registered owner thereof a written notice containing the information required to be set forth on certificates as specified in clause (a) above; provided, however, that, except as otherwise provided by applicable law, in lieu of the foregoing requirements, there may be set forth on the face or back of such certificate or, in the case of uncertificated shares, on such written notice a statement that the Corporation will furnish without charge to each shareholder who so requests the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences or rights.

 

Section 7.3.        Signatures. Each certificate representing capital stock of the Corporation shall be signed by or in the name of the Corporation by (a) the Chair of the Board, the Chief Executive Officer, the President or a Vice President and (b) the Treasurer, an Assistant Treasurer, the Secretary or an Assistant Secretary of the Corporation. Any or all the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, such certificate may be issued by the Corporation with the same effect as if such person were such officer, transfer agent or registrar on the date of issue.

 

Section 7.4.        Consideration and Payment for Shares.

 

(a)            Subject to applicable law and the Certificate of Formation, shares of stock may be issued for such consideration, having in the case of shares with par value a value not less than the par value thereof, and to such persons, as determined from time to time by the Board. The consideration may consist of any tangible or intangible property or any benefit to the Corporation including cash, promissory notes, services performed, contracts for services to be performed, securities of the Corporation or any other organization or any other property of any kind or nature, or any combination thereof.

 

(b)            Subject to applicable law and the Certificate of Formation, shares may not be issued until the full amount of the consideration has been paid.

 

14

 

 

Section 7.5.        Lost, Destroyed or Wrongfully Taken Certificates.

 

(a)            If an owner of a certificate representing shares claims that such certificate has been lost, stolen or destroyed, the Corporation shall issue a new certificate representing such shares or such shares in uncertificated form if the owner notifies the Corporation or its transfer agent that such certificate has been lost, stolen or destroyed, provides an affidavit of that fact acceptable to the Corporation and executes an agreement acceptable to the Corporation (and, if required by the Corporation, posts a bond in such amount as the Corporation may determine is reasonably necessary) to indemnify the Corporation from any loss incurred by it in connection with such certificate.

 

(b)            If a certificate representing shares has been lost, apparently destroyed or stolen, and the owner fails to notify the Corporation of that fact within a reasonable time after the owner has notice of such loss, apparent destruction or stealing and the Corporation registers a transfer of such shares before receiving notification, the owner shall be precluded from asserting against the Corporation any claim for registering such transfer or a claim to a new certificate representing such shares or such shares in uncertificated form.

 

Section 7.6.        Transfer of Shares. Shares of the Corporation will be transferable in the manner prescribed by law, in the Certificate of Formation, these Bylaws or an agreement between the Corporation and one or more shareholders. Transfers of shares will be made on the books of the Corporation only by the holder of record thereof or by such other person as may under law be authorized to endorse such shares for transfer or by such shareholder’s attorney lawfully constituted in writing. Except as otherwise provided by law, upon surrender to the Corporation or its transfer agent of a certificate for shares duly endorsed or accompanied by proper evidence of succession, assignment, or authority to transfer, the Corporation will issue a new certificate to the person entitled thereto, cancel the old certificate, and record the transaction upon its books. No transfer of shares will be valid as against the Corporation for any purpose until it will have been entered in the share transfer records of the Corporation by an entry showing from and to what person those shares were transferred.

 

Section 7.7.        Registered Shareholders. Before due presentment for registration of transfer of a certificate representing shares of the Corporation or of an instruction requesting registration of transfer of uncertificated shares, the Corporation may treat the registered owner as the person exclusively entitled to inspect for any proper purpose the stock ledger and the other books and records of the Corporation, vote such shares, receive distributions or dividends or notifications with respect to such shares and otherwise exercise all the rights and powers of the owner of such shares, except that a person who is the beneficial owner of such shares (if held in a voting trust or by a nominee on behalf of such person) may, upon providing documentary evidence of beneficial ownership of such shares and satisfying such other conditions as are provided under applicable law, may also so inspect the books and records of the Corporation.

 

Section 7.8.        Regulations. The Board shall have power and authority to make such additional rules and regulations, subject to any applicable requirement of law, as the Board may deem necessary and appropriate with respect to the issue, transfer or registration of transfer of shares of stock or certificates representing shares. The Board may appoint one or more transfer agents or registrars and may require for the validity thereof that certificates representing shares bear the signature of any transfer agent or registrar so appointed.

 

15

 

 

Article VIII
INDEMNIFICATION

 

Section 8.1.        Right to Indemnification. To the fullest extent permitted by applicable law, as the same exists or may hereafter be amended, the Corporation shall indemnify and hold harmless each person who was or is made a party or is threatened to be made a party to or is otherwise involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter a “proceeding”), by reason of the fact that he or she is or was a director or officer of the Corporation or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, other enterprise or nonprofit entity, including service with respect to an employee benefit plan (hereinafter an “Indemnitee”), whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent, or in any other capacity while serving as a director, officer, employee or agent, against all liability and loss suffered and expenses (including, without limitation, attorneys’ fees, judgments, fines, ERISA excise taxes and penalties and amounts paid in settlement) reasonably incurred by such Indemnitee in connection with such proceeding; provided, however, that, except as provided in Section 8.3 of these Bylaws with respect to proceedings to enforce rights to indemnification, the Corporation shall indemnify an Indemnitee in connection with a proceeding (or part thereof) initiated by such Indemnitee only if such proceeding (or part thereof) was authorized by the Board.

 

Section 8.2.        Right to Advancement of Expenses. In addition to the right to indemnification conferred in Section 8.1 of these Bylaws, an Indemnitee shall also have the right to be paid by the Corporation to the fullest extent not prohibited by applicable law the expenses (including, without limitation, attorneys’ fees) incurred in defending or otherwise participating in any such proceeding in advance of its final disposition (hereinafter an “advancement of expenses”); provided, however, that, if the TBOC requires, an advancement of expenses incurred by an Indemnitee in his or her capacity as a director or officer of the Corporation (and not in any other capacity in which service was or is rendered by such Indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon the Corporation’s receipt of an undertaking (hereinafter an “undertaking”), by or on behalf of such Indemnitee, to repay all amounts so advanced if it shall ultimately be determined that such Indemnitee is not entitled to be indemnified under this Article VIII or otherwise and a written affirmation by such Indemnitee of the Indemnitee’s good faith belief that such Indemnitee has met the standard of conduct necessary for indemnification under Chapter 8 of the TBOC.

 

Section 8.3.        Right of Indemnitee to Bring Suit. If a claim under Section 8.1 or Section 8.2 of these Bylaws is not paid in full by the Corporation within sixty (60) days after a written claim therefor has been received by the Corporation, except in the case of a claim for an advancement of expenses, in which case the applicable period shall be twenty (20) days, the Indemnitee may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim. If successful in whole or in part in any such suit, or in a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Indemnitee shall also be entitled to be paid the expense of prosecuting or defending such suit. In (a) any suit brought by the Indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by an Indemnitee to enforce a right to an advancement of expenses) it shall be a defense that, and (b) in any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final judicial decision from which there is no further right to appeal (hereinafter a “final adjudication”) that, the Indemnitee has not met any applicable standard for indemnification set forth in the TBOC. Neither the failure of the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel, or its shareholders) to have made a determination prior to the commencement of such suit that indemnification of the Indemnitee is proper in the circumstances because the Indemnitee has met the applicable standard of conduct set forth in the TBOC, nor an actual determination by the Corporation (including a determination by its directors who are not parties to such action, a committee of such directors, independent legal counsel, or its shareholders) that the Indemnitee has not met such applicable standard of conduct, shall create a presumption that the Indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by the Indemnitee, shall be a defense to such suit. In any suit brought by the Indemnitee to enforce a right to indemnification or to an advancement of expenses hereunder, or by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the Indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this Article VIII or otherwise shall be on the Corporation.

 

Section 8.4.        Non-Exclusivity of Rights. The rights provided to any Indemnitee pursuant to this Article VIII shall not be exclusive of any other right, which such Indemnitee may have or hereafter acquire under applicable law, the Certificate of Formation, these Bylaws, an agreement, a vote of shareholders or disinterested directors, or otherwise.

 

16

 

 

Section 8.5.        Insurance. The Corporation may maintain insurance, at its expense, to protect itself and/or any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the TBOC.

 

Section 8.6.        Indemnification of Other Persons. This Article VIII shall not limit the right of the Corporation to the extent and in the manner authorized or permitted by law to indemnify and to advance expenses to persons other than Indemnitees. Without limiting the foregoing, the Corporation may, to the extent authorized from time to time by the Board and to the extent permitted by the TBOC, grant rights to indemnification and to the advancement of expenses to any employee or agent of the Corporation and to any other person who is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan, to the fullest extent of the provisions of this Article VIII with respect to the indemnification and advancement of expenses of Indemnitees under this Article VIII.

 

Section 8.7.        Amendments. Any repeal or amendment of this Article VIII by the Board or the shareholders of the Corporation or by changes in applicable law, or the adoption of any other provision of these Bylaws inconsistent with this Article VIII, will, to the extent permitted by applicable law, be prospective only (except to the extent such amendment or change in applicable law permits the Corporation to provide broader indemnification rights to Indemnitees on a retroactive basis than permitted prior thereto), and will not in any way diminish or adversely affect any right or protection existing hereunder in respect of any act or omission occurring prior to such repeal or amendment or adoption of such inconsistent provision; provided, however, that amendments or repeals of this Article VIII shall require the affirmative vote of the shareholders holding at least 66 2/3% of the voting power of all outstanding shares of capital stock of the Corporation.

 

Section 8.8.        Certain Definitions. For purposes of this Article VIII, (a) references to “other enterprise” shall include any employee benefit plan; (b) references to “fines” shall include any excise taxes assessed on a person with respect to an employee benefit plan; (c) references to “serving at the request of the Corporation” shall include any service that imposes duties on, or involves services by, a person with respect to any employee benefit plan, its participants, or beneficiaries; and (d) a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner not opposed to the best interest of the Corporation for purposes of Section 21.401 of the TBOC.

 

Section 8.9.        Contract Rights. The rights provided to Indemnitees pursuant to this Article VIII shall be contract rights and such rights shall continue as to an Indemnitee who has ceased to be a director, officer, agent or employee and shall inure to the benefit of the Indemnitee’s heirs, executors and administrators.

 

Section 8.10.        Severability. If any provision or provisions of this Article VIII shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Article VIII shall not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of this Article VIII (including, without limitation, each such portion of this Article VIII containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.

 

Article IX
MISCELLANEOUS

 

Section 9.1.        Place of Meetings. If the place of any meeting of shareholders, the Board or committee of the Board for which notice is required under these Bylaws is not designated in the notice of such meeting, such meeting shall be held at the principal executive office of the Corporation; provided, however, if the Board has, in its sole discretion, determined that a meeting shall not be held at any place, but instead shall be held by means of remote communication pursuant to Section 9.5 of these Bylaws , then such meeting shall not be held at any place.

 

17

 

 

Section 9.2.        Fixing Record Dates.

 

(a)            In order that the Corporation may determine the shareholders entitled to notice of any meeting of shareholders or any adjournment thereof, the Board may fix a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the Board, and which record date shall not be more than sixty (60) nor less than ten (10) days before the date of such meeting. If the Board so fixes a date, such date shall also be the record date for determining the shareholders entitled to vote at such meeting unless the Board determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board, the record date for determining shareholders entitled to notice of and to vote at a meeting of shareholders shall be at the close of business on the Business Day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the Business Day next preceding the day on which the meeting is held. A determination of shareholders of record entitled to notice of or to vote at a meeting of shareholders shall apply to any adjournment of the meeting; provided, however, that the Board may fix a new record date for the adjourned meeting, and in such case shall also fix as the record date for shareholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of shareholders entitled to vote in accordance with the foregoing provisions of this Section 9.2(a) of these Bylaws at the adjourned meeting.

 

(b)            In order that the Corporation may determine the shareholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the shareholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than sixty (60) days prior to such action. If no record date is fixed, the record date for determining shareholders for any such purpose shall be at the close of business on the day on which the Board adopts the resolution relating thereto.

 

Section 9.3.        Means of Giving Notice.

 

(a)            Notice to Directors. Whenever under applicable law, the Certificate of Formation or these Bylaws notice is required to be given to any director, such notice shall be given either (i) in writing and sent by mail, or by a nationally recognized delivery service, (ii) by means of facsimile telecommunication or other form of electronic transmission, or (iii) by oral notice given personally or by telephone. A notice to a director will be deemed given as follows: (i) if given by hand delivery, orally, or by telephone, when actually received by the director, (ii) if sent through the United States mail, when deposited in the United States mail, with postage and fees thereon prepaid, addressed to the director at the director’s address appearing on the records of the Corporation, (iii) if sent for next day delivery by a nationally recognized overnight delivery service, when deposited with such service, with fees thereon prepaid, addressed to the director at the director’s address appearing on the records of the Corporation, (iv) if sent by facsimile telecommunication, when sent to the facsimile transmission number for such director appearing on the records of the Corporation, (v) if sent by electronic mail, when sent to the electronic mail address for such director appearing on the records of the Corporation, or (vi) if sent by any other form of electronic transmission, when sent to the address, location or number (as applicable) for such director appearing on the records of the Corporation.

 

(b)            Notice to Shareholders. Whenever under applicable law, the Certificate of Formation or these Bylaws notice is required to be given to any shareholder, such notice may be given (i) in writing and sent either by hand delivery, through the United States mail, or by a nationally recognized overnight delivery service for next day delivery, or (ii) by means of a form of electronic transmission consented to by the shareholder, to the extent permitted by the TBOC. A notice to a shareholder shall be deemed given as follows: (i) if given by hand delivery, when actually received by the shareholder, (ii) if sent through the United States mail, when deposited in the United States mail, with postage and fees thereon prepaid, addressed to the shareholder at the shareholder’s address appearing on the stock ledger of the Corporation, (iii) if sent for next day delivery by a nationally recognized overnight delivery service, when deposited with such service, with fees thereon prepaid, addressed to the shareholder at the shareholder’s address appearing on the stock ledger of the Corporation, and (iv) if given by a form of electronic transmission consented to by the shareholder to whom the notice is given and otherwise meeting the requirements set forth above, (A) if by facsimile transmission, when directed to a number at which the shareholder has consented to receive notice, (B) if by electronic mail, when directed to an electronic mail address at which the shareholder has consented to receive notice, (C) if by a posting on an electronic network together with separate notice to the shareholder of such specified posting, upon the later of (1) such posting and (2) the giving of such separate notice, and (D) if by any other form of electronic transmission, when directed to the shareholder. A shareholder may revoke such shareholder’s consent to receiving notice by means of electronic communication by giving written notice of such revocation to the Corporation. Any such consent shall be deemed revoked if (1) the Corporation is unable to deliver by electronic transmission two consecutive notices given by the Corporation in accordance with such consent and (2) such inability becomes known to the Secretary or an Assistant Secretary or to the Corporation’s transfer agent, or other person responsible for the giving of notice; provided, however, the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action.

 

18

 

 

(c)            Electronic Transmission. “Electronic transmission” means any form of communication, not directly involving the physical transmission of paper, that creates a record that may be retained, retrieved and reviewed by a recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process.

 

(d)            Notice to Shareholders Sharing Same Address. To the extent permitted under the TBOC, without limiting the manner by which notice otherwise may be given effectively by the Corporation to shareholders, any notice to shareholders given by the Corporation under any provision of the TBOC, the Certificate of Formation or these Bylaws shall be effective if given by a single written notice to shareholders who share an address if consented to by the shareholders at that address to whom such notice is given. A shareholder may revoke such shareholder’s consent by delivering written notice of such revocation to the Corporation. Any shareholder who fails to object in writing to the Corporation within sixty (60) days of having been given written notice by the Corporation of its intention to send such a single written notice shall be deemed to have consented to receiving such single written notice.

 

(e)            Exceptions to Notice Requirements. Whenever notice is required to be given by the Corporation, under any provision of the TBOC, the Certificate of Formation or these Bylaws, to any shareholder to whom (1) notice of two consecutive annual meetings of shareholders and all notices of shareholder meetings or of the taking of action by written consent of shareholders without a meeting to such shareholder during the period between such two consecutive annual meetings, or (2) all, and at least two payments (if sent by first-class mail) of distributions or interest on securities during a 12-month period, have been mailed by first class mail addressed to such shareholder at such shareholder’s address as shown on the ownership records of the Corporation and have been returned undeliverable, the giving of such notice to such shareholder shall not be required. To the extent permitted by the TBOC, notice of a meeting is not required to be given to a shareholder entitled to notice under the any provision of the TBOC, the Certificate of Formation or these Bylaws if the person entitled to notice of the meeting is considered a lost securityholder under the Exchange Act and the regulations adopted under the Exchange Act. Any action or meeting that shall be taken or held without notice to any such shareholder shall have the same force and effect as if such notice had been duly given to any such shareholder. If any such shareholder shall deliver to the Corporation a written notice setting forth such shareholder’s then current address, the requirement that notice be given to such shareholder shall be reinstated. In the event that the action taken by the Corporation is such as to require the filing of a certificate or other document with the Secretary of State of Texas or otherwise, the certificate or other document need not state that notice was not given to persons to whom notice was not required to be given pursuant to the TBOC.

 

Section 9.4.        Waiver of Notice. Whenever any notice is required to be given under applicable law, the Certificate of Formation, or these Bylaws, a written waiver of such notice, signed by the person or persons entitled to said notice, or a waiver by electronic transmission by the person entitled to said notice, whether before or after the time stated therein, shall be deemed equivalent to such required notice. All such waivers shall be kept with the books of the Corporation. Attendance at a meeting shall constitute a waiver of notice of such meeting, except where a person attends for the express purpose of objecting to the transaction of any business on the ground that the meeting was not lawfully called or convened.

 

Section 9.5.        Meeting Attendance via Remote Communication Equipment.

 

(a)            Shareholder Meetings. If authorized by the Board in its sole discretion, and subject to such guidelines and procedures as the Board may adopt, shareholders entitled to vote at such meeting and proxy holders not physically present at a meeting of shareholders may, by means of remote communication:

 

(i)            participate in a meeting of shareholders; and

 

19

 

 

(ii)            be deemed present in person and vote at a meeting of shareholders, whether such meeting is to be held at a designated place or solely by means of remote communication, provided that (A) the Corporation shall implement reasonable measures to verify that each person deemed present and permitted to vote at the meeting by means of remote communication is a shareholder or proxy holder, (B) the Corporation shall implement reasonable measures to provide such shareholders and proxy holders a reasonable opportunity to participate in the meeting and, if entitled to vote, to vote on matters submitted to the applicable shareholders, including an opportunity to read or hear the proceedings of the meeting substantially concurrently with such proceedings, and (C) if any shareholder or proxy holder votes or takes other action at the meeting by means of remote communication, a record of such votes or other action shall be maintained by the Corporation.

 

(b)            Board Meetings. Unless otherwise restricted by applicable law, the Certificate of Formation or these Bylaws, members of the Board or any committee thereof may participate in a meeting of the Board or any committee thereof by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other. Such participation in a meeting shall constitute presence in person at the meeting, except where a person participates in the meeting for the express purpose of objecting to the transaction of any business on the ground that the meeting was not lawfully called or convened.

 

Section 9.6.        Distributions and Dividends. The Board may from time to time declare, and the Corporation may pay, distributions or dividends (payable in cash, property or shares of the Corporation’s capital stock) on the Corporation’s outstanding shares of capital stock, subject to applicable law and the Certificate of Formation.

 

Section 9.7.        Reserves. The Board may set apart out of the funds of the Corporation available for distributions or dividends a reserve or reserves for any proper purpose and may abolish any such reserve.

 

Section 9.8.        Contracts and Negotiable Instruments. Except as otherwise provided by applicable law, the Certificate of Formation or these Bylaws, any contract, bond, deed, lease, mortgage or other instrument may be executed and delivered in the name and on behalf of the Corporation by such officer or officers or other employee or employees of the Corporation as the Board may from time to time authorize. Such authority may be general or confined to specific instances as the Board may determine. Unless so authorized or ratified by the board of directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.

 

Section 9.9.        Fiscal Year. The fiscal year of the Corporation shall be fixed by the Board.

 

Section 9.10.      Seal. The Board may adopt a corporate seal, which shall be in such form as the Board determines. The seal may be used by causing it or a facsimile thereof to be impressed, affixed or otherwise reproduced.

 

Section 9.11.      Books and Records. The books and records of the Corporation may be kept within or outside the State of Texas at such place or places as may from time to time be designated by the Board.

 

Section 9.12.      Resignation. Any director, committee member or officer may resign by giving notice thereof in writing or by electronic transmission to the Corporation. The resignation shall take effect at the time it is delivered unless the resignation specifies a later effective date or an effective date determined upon the happening of an event or events. Unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective. Any resignation is without prejudice to the rights, if any, of the Corporation under any contract to which the officer is a party.

 

Section 9.13.      Amendments. The Board shall have the power to adopt, amend, alter or repeal these Bylaws. The affirmative vote of a majority of the Board shall be required to adopt, amend, alter or repeal these Bylaws. These Bylaws also may be adopted, amended, altered or repealed by the shareholders; provided, however, that in addition to any vote required by applicable law or the Certificate of Formation, the affirmative vote of the holders of (a) prior to the Trigger Date (as defined below), at least a majority of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class (except as otherwise provided in Section 8.7 of these Bylaws), and (b) from and after the Trigger Date, at least 66 2/3% of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote thereon, voting together as a single class, shall be required for the shareholders to adopt, amend, alter or repeal these Bylaws. For purposes of these Bylaws, the “Trigger Date” means the date on which no shares of Class B Common Stock shall be outstanding.

 

20

 

 

 Exhibit 4.2

 

AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT

 

 

 

 

TABLE OF CONTENTS

 

Page

 

1.Definitions 1
    
2.Registration Rights 6
2.1Demand Registration 6
2.2Company Registration 8
2.3Underwriting Requirements 8
2.4Obligations of the Company 9
2.5Furnish Information 11
2.6Expenses of Registration 11
2.7Delay of Registration 11
2.8Indemnification 11
2.9Reports Under Exchange Act 14
2.10Limitations on Subsequent Registration Rights 14
2.11“Market Stand-off” Agreement 15
2.12Restrictions on Transfer 15
2.13Termination of Registration Rights 16
2.14Qualified SPAC Transaction 16
     
3.Information and Observer Rights 17
3.1Delivery of Financial Statements 17
3.2Inspection 18
3.3Observer Rights 18
3.4Termination of Information and Observer Rights 19
3.5Confidentiality 19
3.6Material Non-Public Information 20
     
4.Rights to Future Stock Issuances 20
4.1Right of First Offer 20
4.2Termination 23
     
5.Additional Covenants 23
5.1Matters Requiring Series C Director Approval 23
5.2Right to Conduct Activities 23
5.3Permitted Issuances of Series E Preferred Stock, Series D Preferred Stock, and Series C Preferred Stock 23
5.4Termination of Covenants 24
     
6.Miscellaneous 24
6.1Successors and Assigns 24
6.2Governing Law 25

 

i

 

 

 6.3Counterparts 25
6.4Titles and Subtitles 25
6.5Notices 25
6.6Amendments and Waivers 26
6.7Severability 27
6.8Aggregation of Stock 27
6.9Additional Investors 27
6.10Entire Agreement 27
6.11Dispute Resolution 27
6.12WAIVER OF JURY TRIAL 28
6.13Delays or Omissions 28
6.14Massachusetts Business Trust 28

 

Schedule A  - Schedule of Investors
Schedule B - Investment Management Entities
Schedule C  - Material Non-Public Information Contacts

 

ii

 

 

AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT

  

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 1st day of April, 2025, by and among Caris Life Sciences, Inc., a Texas corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.

 

RECITALS

  

WHEREAS, certain of the Investors hold shares of Common Stock, Preferred Stock and/or shares of Common Stock issued upon conversion thereof;

 

WHEREAS, the Company and certain of the Investors are parties to that certain Series E/F Preferred Stock Purchase Agreement of even date herewith (the “Purchase Agreement”) providing for the sale of shares of the Series E Preferred Stock, par value $0.001 per share (the “Series E Preferred Stock”) and Series F Preferred Stock, par value $0.001 per share (the “Series F Preferred Stock”);

 

WHEREAS, the Company and certain of the Investors are parties to that certain Amended and Restated Investors’ Rights Agreement, dated as of May 11, 2021 (the “Existing Agreement”), and such Investors have the power and authority to amend and restate the Existing Agreement pursuant to the provisions of Section 6.6 thereof; and 

 

WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to induce certain of the Investors to invest funds in the Company pursuant to the Purchase Agreement, the Investors and the Company hereby agree that this Agreement will amend and restate the Existing Agreement in its entirety and that this Agreement will govern the rights of the Investors to cause the Company to register shares of Common Stock issuable to the Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company, and will govern certain other matters as set forth in this Agreement. 

 

NOW, THEREFORE, the parties hereby agree as follows: 

 

1.            Definitions. For purposes of this Agreement: 

 

1.1            “Affiliate” means, (a) with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer, director or trustee of such Person, or any venture capital fund or registered investment company or other investment fund now or hereafter existing that is controlled by one or more general partners, managing members or investment adviser of, or shares the same management company or investment adviser with, such Person; and (b) in the case of a Fidelity Investor, also an investment company registered under the Investment Company Act of 1940 advised or sub-advised by Fidelity or any affiliated investment advisor of Fidelity, one or more mutual funds, pension funds, pooled investment vehicles or institutional clients advised or sub-advised by Fidelity or any affiliated investment advisor of Fidelity, in each case, registered under the Investment Advisors Act of 1940, as amended.

 

 

 

 

1.2            “Board” means the board of directors of the Company.

 

1.3            “Braidwell” means Braidwell Transaction Holdings LLC – Series 11. 

 

1.4            “Certificate” means the Company’s Amended and Restated Certificate of Formation, as amended and/or restated from time to time.

 

1.5            “Common Stock” means shares of the Company’s common stock, par value $0.001 per share.

 

1.6            “Competitor” means a Person engaged, directly or indirectly (including through any partnership, limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in therapeutic development, drug delivery, diagnostics and disease monitoring and that is materially competitive with any material portion of the business of the Company as determined in good faith by the Board (including through ownership of any portfolio company), but does not include any financial investment firm or collective investment vehicle that, together with its Affiliates, holds (i) less than a majority of the outstanding equity or securities exchangeable for or convertible into equity of any Competitor or (ii) any indebtedness of any Competitor and does not, nor do any of its Affiliates, have a right to directly or indirectly, control any Competitor, it being agreed that equity ownership of less than 20% of a publicly traded company, in and of itself, does not constitute control over such company. The parties agree that the investment management entities set forth on Schedule B (which schedule may be updated by the Company to add additional Investors from time to time) and their affiliated investment management and/or sub-advisory clients are not Competitors as of the date of this Agreement and any existing or future debt or equity holding (“Portfolio Company”) by affiliated investment management and/or sub-advisory clients of such investment management entity will not be aggregated to determine whether such investment management entity becomes a Competitor; provided that such Portfolio Company does not receive any confidential information and does not acquire any ownership interest in the Company.

 

1.7            “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law.

 

2

 

 

1.8            “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants.

 

1.9            “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

1.10            “Excluded Registration” means (i) a registration relating to the sale or grant of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, equity incentive or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered.

 

1.11            “Existing Preferred Stock” means, collectively, shares of the Company’s Series A Preferred Stock and Series B Preferred Stock.

 

1.12            “Fidelity” means Fidelity Management & Research Company.

 

1.13            “Fidelity Investor” means any Investor advised or sub-advised by Fidelity. 

 

1.14            “Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC.

 

1.15            “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits forward incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

1.16            “GAAP” means generally accepted accounting principles in the United States as in effect from time to time. 

 

1.17            “Highland” means Highland Capital Management, L.P. 

 

1.18            “Holder” means any holder of Registrable Securities (including any Affiliate of an Investor) who is a party to this Agreement. 

 

1.19            “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a natural person referred to herein.

 

1.20            “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

 

3

 

 

1.21            “IPO” means (i) the Company’s first underwritten public offering of its Common Stock under the Securities Act or (ii) the Company’s direct listing on the New York Stock Exchange or Nasdaq.

 

1.22            “Major Investor” means any Investor.

 

1.23            “New Securities” means, collectively, equity securities of the Company and any of its wholly owned subsidiaries, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities; provided, however, that securities of the Company’s subsidiaries that are to be issued to the Company or another direct or indirect subsidiary of the Company shall not be “New Securities” for purposes of this Agreement.

  

1.24            “Note Purchase Agreement” means that certain Convertible Note Purchase Agreement, dated as of the date hereof, by and among the Company and the other parties thereto, , as may be amended and/or restated from time to time.

  

1.25            “OrbiMed” means, collectively, OrbiMed Partners Master Fund Limited, Worldwide Healthcare Trust PLC and OrbiMed Genesis Master Fund, L.P.

  

1.26            “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 

1.27            “Preferred Stock” means, collectively, shares of the Company’s Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock.

 

1.28            “Qualified SPAC Transaction” has the meaning assigned to such term in the Certificate.

 

1.29            “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other debt or equity securities of the Company, or other debt or equity instruments or other similar agreements or arrangements, held by the Investors or their Affiliates; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Section 2.13 of this Agreement.

 

1.30            “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities.

 

4

 

 

1.31            “Restricted Securities” means the securities of the Company required to be notated with the legend set forth in Section 2.12(b) hereof.

 

1.32            “Right of First Refusal & Co-Sale Agreement” means that certain Amended and Restated Right of First Refusal and Co-Sale Agreement of even date herewith by and among the Company and the Shareholders (as defined therein), as may be amended and/or restated from time to time.

 

1.33            “SEC” means the Securities and Exchange Commission.

 

1.34            “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act.

  

1.35            “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.

 

1.36            “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

1.37            “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Section 2.6.

 

1.38            “Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.001 per share.

  

1.39            “Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.001 per share.

  

1.40            “Series C Director” has the meaning assigned to such term in the Voting Agreement.

 

1.41            “Series C Preferred Stock” means shares of the Company’s Series C Preferred Stock, par value $0.001 per share.

 

1.42            “Series D Preferred Stock” means shares of the Company’s Series D Preferred Stock, par value $0.001 per share.

 

1.43            “Series D Purchase Agreement” means that certain Series D Preferred Stock Purchase Agreement, dated May 11, 2021 by and among the Company and the investors party thereto.

 

1.44            “Sixth Street” means Sixth Street Specialty Lending, Inc., TAO Barnett Investments, LLC, TOP III Barnett Investments, LLC, Barnett Equity Holdings, LLC and Barnett Equity Holdings II, LLC.

 

5

 

 

1.45            “Stonebridge-Highland” means SH Caris Life US, LLC.

 

1.46            “Stonebridge” means Stonebridge Capital, Inc.

 

1.47            “Voting Agreement” means that certain Amended and Restated Voting Agreement of even date herewith by and among the Company and the Shareholders (as defined therein), as may be amended and/or restated from time to time.

 

2.            Registration Rights. The Company covenants and agrees as follows:

 

2.1            Demand Registration.

 

(a)            Form S-1 Demand. If at any time after one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from any of (i) Holders of twenty percent (20%) of the Registrable Securities issued upon conversion of the Series C Preferred Stock, (ii) Holders of twenty percent (20%) of the Registrable Securities issued upon conversion of the Series D Preferred Stock, (iii) Holders of twenty percent (20%) of the Registrable Securities issued upon conversion of the Series E Preferred Stock, or (iv) Holders of twenty percent (20%) of the Registrable Securities issued upon conversion of the Existing Preferred Stock, that the Company file a Form S-1 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $10 million, then the Company will (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and, in each case, subject to the limitations of Sections 2.1(c) and 2.3.

 

(b)            Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from any of: (i) Holders of twenty percent (20%) of the Registrable Securities issued upon conversion of the Series C Preferred Stock, (ii) Holders of twenty percent (20%) of the Registrable Securities issued upon conversion of the Series D Preferred Stock, (iii) Holders of twenty percent (20%) of the Registrable Securities issued upon conversion of the Series E Preferred Stock, or (iv) Holders of twenty percent (20%) of the Registrable Securities issued upon conversion of the Existing Preferred Stock that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $3 million, then the Company will (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and 2.3.

 

6

 

 

(c)            Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board it would be materially detrimental to the Company and its shareholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company will have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof will be tolled correspondingly, for a period of not more than thirty (30) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period.

 

(d)            The Company will not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(a): (i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b); (iii) with respect to Section 2.1(a)(i), after the Company has effected two registrations pursuant to Section 2.1(a)(i); (iv) with respect to Section 2.1(a)(ii), after the Company has effected two registrations pursuant to Section 2.1(a)(ii); or (v) with respect to Section 2.1(a)(iii), after the Company has effected two registrations pursuant to Section 2.1(a)(iii). The Company will not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b): (i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected three registrations pursuant to Section 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration will not be counted as “effected” for purposes of this Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration statement will be counted as “effected” for purposes of this Section 2.1(d); provided, that if such withdrawal is during a period the Company has deferred taking action pursuant to Section 2.1(c) or follows an event or series of events that would reasonably be expected to have a material adverse effect on the business, assets, (including intangible assets), financial condition, or results of operations of the Company and its subsidiaries, taken as a whole, then the Initiating Holders may withdraw their request for registration and such registration will not be counted as “effected” for purposes of this Section 2.1(d).

 

7

 

 

2.2            Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for shareholders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company will, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company will, subject to the provisions of Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company will have the right to terminate or withdraw any registration initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration will be borne by the Company in accordance with Section 2.6.

 

2.3            Underwriting Requirements.

 

(a)            If pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they will so advise the Company as a part of their request made pursuant to Section 2.1, and the Company will include such information in the Demand Notice. The underwriter(s) will be selected by the Board and will be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration will be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting will (together with the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Section 2.3, if the underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders will so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting will be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as will mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting will not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares.

 

8

 

 

(b)            In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Section 2.2, the Company will not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by shareholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company will be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering will be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as will mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event will the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering. For purposes of the provision in this Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, shareholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, will be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” will be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence.

 

(c)            For purposes of Section 2.1, a registration will not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Section 2.3(a), fewer than one hundred percent (100%) of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually included.

 

2.4            Obligations of the Company. Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company will, as expeditiously as reasonably possible:

 

(a)            prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period will be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period will be extended for up to thirty (30) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold;

 

9

 

 

(b)            prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement;

 

(c)            furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate the disposition of their Registrable Securities;

  

(d)            use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or blue-sky laws of such jurisdictions as are reasonably requested by the selling Holders; provided that the Company will not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act;

 

(e)            in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering;

 

(f)            use its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed;

 

(g)            provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration;

 

(h)            promptly make available for inspection by the selling Holders, any underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith;

 

(i)            notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and

 

10

 

 

(j)            after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus.

 

In addition, the Company will ensure that at all times after any registration statement covering a public offering of securities of the Company under the Securities Act will have become effective, its insider trading policy will provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.

 

2.5            Furnish Information. It will be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder will furnish to the Company, upon reasonable notice, such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities.

 

2.6            Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company, and the reasonable fees and disbursements, not to exceed $75,000, of one counsel (and any reasonably necessary local counsel) for the selling Holders (“Selling Holder Counsel”), will be borne and paid by the Company; provided, however, that the Company will not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders will bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders will not be required to pay any of such expenses and will not forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 will be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf.

 

2.7            Delay of Registration. No Holder will have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2.

 

2.8            Indemnification. If any Registrable Securities are included in a registration statement under this Section 2:

 

11

 

 

(a)            To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, investment advisors and shareholders of each such Holder, legal counsel and accountants for each such Holder, any underwriter (as defined in the Securities Act) for each such Holder, and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(a) will not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent will not be unreasonably withheld, nor will the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration.

 

(b)            To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) will not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent will not be unreasonably withheld; and provided further that in no event will the aggregate amounts payable by any Holder by way of indemnity or contribution under Sections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder.

 

(c)            Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party will have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) will have the right to retain one (1) separate counsel, with the fees and expenses to be paid by the indemnifying party, if the representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action will relieve such indemnifying party of any liability to the indemnified party under this Section 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.8.

 

12

 

 

(d)            To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party will be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event will a Holder’s liability pursuant to this Section 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder.

 

(e)            Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement will control.

 

(f)            Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of the Company and Holders under this Section 2.8 will survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise will survive the termination of this Agreement. 

 

13

 

 

2.9            Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company will:

 

(a)            make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO or the closing of a Qualified SPAC Transaction;

 

(b)            use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements);

 

(c)            furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO or one (1) year after the closing of a Qualified SPAC Transaction), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form); and

 

(d)            take such further reasonable action as any Holder may reasonably request from time to time to enable such Holder (i) to remove any restrictive legends from such Holder’s Registrable Securities and transfer such Holder’s Registrable Securities to a brokerage account and (ii) to sell such Holder’s Registrable Securities without registration under the Securities Act and within the limitations of the exemptions provided by SEC Rule 144 or any similar rule or regulation hereafter adopted by the SEC; provided that, notwithstanding anything to the contrary, the Company shall not be required to provide a legal opinion or determination to any third party with regards to the “affiliate” status of any Holder under SEC Rule 144 as part of its obligations under this Section 2.9(d).

 

2.10            Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company will not, without the prior written consent of (x) the holders of a majority of the Series E Preferred Stock then outstanding (including in such majority (i) Braidwell for so long as Braidwell and its Affiliates which are permitted assigns under this Agreement hold the lesser of (A) 8.75% of the shares of Series E Preferred Stock then outstanding (or Common Stock issued upon conversion thereof) and (B) 25% of the Series E Preferred Stock sold to Braidwell pursuant to the Purchase Agreement and (ii) additional holders of Series E Preferred Stock that (A) are not Affiliated with Braidwell and (B) collectively hold at least 4% of the shares of Series E Preferred Stock then outstanding (the “Requisite Series E Holders”); (y) the holders of a majority of the Series D Preferred Stock then outstanding (including in such majority Sixth Street for so long as Sixth Street and its Affiliates which are permitted assigns under this Agreement hold at least 18,518,518 shares of Series D Preferred Stock (or Common Stock issued upon conversion thereof) (as adjusted for any stock split, stock dividend, reorganization, stock combination, or similar transaction effected after the date hereof)) (the “Requisite Series D Holders”); and (z) the holders of a majority of the Series C Preferred Stock then outstanding (including in such majority Stonebridge-Highland for so long as Stonebridge-Highland and its Affiliates which are permitted assigns under this Agreement hold at least 13,586,957 shares of Series C Preferred Stock (as adjusted for any stock split, stock dividend, reorganization, stock combination, or similar transaction effected after the date hereof)) (the “Requisite Series C Holders”), enter into any agreement with any holder or prospective holder of any securities of the Company that would (i) provide to such holder or prospective holder the right to include securities in any registration on other than either a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders have had the opportunity to include in the registration and offering all shares of Registrable Securities that they wish to so include; or (ii) allow such holder or prospective holder to vote with the holders of Series E Preferred Stock, Series D Preferred Stock, or Series C Preferred Stock to initiate a demand for registration of any securities held by such holder or prospective holder; provided that this limitation will not apply to Registrable Securities acquired by any additional Investor that becomes a party to this Agreement in accordance with Section 6.9.

 

14

 

  

2.11            “Market Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the IPO, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days in the case of the IPO, or such other period as may be required by law to accommodate regulatory restrictions on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in applicable FINRA rules, or any successor provisions or amendments thereto), (i) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right, or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock in each instance held immediately before the effective date of the registration statement for the IPO (which for clarification excludes securities acquired in the related offering); or (ii) enter into any swap, derivative security, or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities held immediately before the effective date of the registration statement for the IPO, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Section 2.11 will not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder; provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein; and provided further that any such transfer will not involve a disposition for value, and the foregoing provisions of this Section 2.11 will be applicable to the Holders only if all officers and directors are subject to the same restrictions and the Company obtains similar agreements from shareholders owning, in the aggregate, more than ninety-two percent (92%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock). For the avoidance of doubt, the restrictions described in this Section 2.11 shall not apply to the sale of any shares acquired in the IPO or in the open market following the IPO. The underwriters in connection with such registration are intended third-party beneficiaries of this Section 2.11 and will have the right, power, and authority to enforce the provisions hereof as though they were a party hereto, subject to the terms and conditions hereof. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary to give further effect thereto. If any of the obligations described in this Section 2.11 are waived or terminated with respect to any of the securities of any Holder, officer, director, or other Company stockholder (in any such case, the “Released Securities”), (X) the Company shall provide notice to each Holder within two (2) Business Days (provided that the failure to provide such notice shall not give rise to any claim or liability against the Company) and (Y) the foregoing provisions shall be waived or terminated, as applicable, to the same extent and with respect to the same percentage of securities held by each Holder as the percentage of the Released Securities represents with respect to the securities held by the applicable Holder, officer, director, or other stockholder.

 

2.12            Restrictions on Transfer.

 

(a)            The Preferred Stock and the Registrable Securities will not be sold, pledged, or otherwise transferred, and the Company will not recognize and will issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the IPO, SEC Rule 144, in each case, to be bound by the terms of this Section 2.12.

 

(b)            Each certificate, instrument, or book-entry representing (i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, reorganization, stock combination, or similar transaction, will (unless otherwise permitted by the provisions of Section 2.12(c)) be notated with a legend substantially in the following form:

 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT.

 

15

 

 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE SHAREHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.

 

The Holders consent to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12.

 

(c)            The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction or following the IPO, the transfer is made pursuant to SEC Rule 144, the, Holder thereof will give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice will describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, will be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who will, and whose legal opinion will, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities will be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144, or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Section 2.12. Each certificate, instrument, or book-entry representing the Restricted Securities transferred as above provided will be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Section 2.12(b), except that such certificate instrument, or book-entry will not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act.

 

2.13            Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Sections 2.1 or 2.2 will terminate upon the earlier of (a) closing of a Deemed Liquidation Event, as such term is defined in the Certificate, other than a Deemed Liquidation Event under clause (c) of the definition of Deemed Liquidation Event in circumstances where the Investors continue to own shares of the Company, or (b) the fourth anniversary of the IPO.

 

2.14            Qualified SPAC Transaction. Upon the closing of any Qualified SPAC Transaction, the Company will use reasonable best efforts to cause the rights of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Sections 2.1, Section 2.2, Section 2.3, Section 2.4, Section 2.5, Section 2.6, Section 2.7, Section 2.8, Section 2.9, or Section 2.10 to apply mutatis mutandis to the stock of the publicly traded corporation from such Qualified SPAC Transaction as if it was an IPO hereunder.

 

16

 

 

3.            Information and Observer Rights.

 

3.1            Delivery of Financial Statements. The Company will deliver to each Major Investor, provided that the Board has not reasonably determined that such recipient is a Competitor of the Company:

 

(a)            as soon as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and a comparison between (x) the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as defined in Section 3.1(e)) for such year, and (iii) a statement of shareholders’ equity as of the end of such year, all such financial statements audited and certified by independent public accountants of nationally recognized standing selected by the Company;

 

(b)            as soon as practicable, but in any event within sixty (60) days after the end of each fiscal quarter of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of shareholders’ equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

 

(c)            as soon as practicable, but in any event within sixty (60) days after the end of each fiscal quarter of each fiscal year, a capitalization table showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company;

 

(d)            such other information relating to the business of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Section 3.1(d) to provide any such requested information more than once a fiscal quarter to any Major Investor or provide information (i) that the Company determines in its sole discretion to be a trade secret, confidential information, or competitively sensitive; (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel; or (iii) that is financial in nature; and

 

17

 

 

(e)            as soon as practicable, but in any event within thirty (30) days following the end of each fiscal year, a budget and business plan for the next fiscal year approved by the Board (collectively, the “Budget”).

 

If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections will be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries.

 

Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this Section 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 will be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective.

 

3.2            Inspection. The Company shall permit the Major Investors (provided that the Board has not reasonably determined that any such Major Investor is a Competitor), once a fiscal quarter upon at least seven (7) days’ advance notice, to visit the Company’s properties, discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investors; provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to information that it, in its sole discretion, considers to be a trade secret, confidential information, or competitively sensitive or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. The Major Investors collectively may only exercise their inspection rights pursuant to this Section 3.2 one (1) time per fiscal quarter, but the Company will give the Major Investors reasonably prompt notice of an exercise of these rights and make reasonable arrangements to offer all Major Investors the opportunity to participate with one representative of such Major Investor. Any information obtained during such inspection shall be treated as confidential information pursuant to Section 3.5 hereof.

 

3.3            Observer Rights. (a) Unless the Series C Director is serving on the Board and is an employee, consultant or advisor of Stonebridge-Highland, Stonebridge, or Highland or their respective Affiliates, for as long as Stonebridge-Highland owns at least 13,586,957 shares of Series C Preferred Stock (or Common Stock issued upon conversion thereof) (as adjusted for any stock split, stock dividend, reorganization, stock combination, or similar transaction effected after the date hereof), the Company will invite a representative of Stonebridge-Highland reasonably acceptable to the Company (which will initially be Nate Burns) to attend all meetings of the Board in a nonvoting observer capacity; (b) unless the Series C Director is serving on the Board and is an employee, consultant or advisor of Coatue US 21 LLC or its Affiliates (“Coatue”), for as long as Coatue owns at least 13,586,957 shares of Series C Preferred Stock (or Common Stock issued upon conversion thereof) (as adjusted for any stock split, stock dividend, reorganization, stock combination or similar transaction effected after the date hereof), the Company will invite a representative of Coatue reasonably acceptable to the Company (the “Coatue Observer”) to attend all meetings of the Board in a nonvoting observer capacity; and (c) for as long as OrbiMed owns at least 8,152,175 shares of Series C Preferred Stock (or Common Stock issued upon conversion thereof) (as adjusted for any stock split, stock dividend, reorganization, stock combination, or similar transaction effected after the date hereof), the Company will invite a representative of OrbiMed reasonably acceptable to the Company (the “OrbiMed Observer”) to attend all meetings of the Board in a nonvoting observer capacity, and in this respect, will give such representatives copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors (with respect to Stonebridge Highland’s observer, without following the procedures in Section 3.6); provided, however, that such representatives will agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided and will not disclose such information to any other persons; and provided further, that the Company reserves the right to withhold any information and to exclude such representatives from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representatives is a Competitor of the Company.

 

18

 

 

3.4            Termination of Information and Observer Rights. The covenants set forth in Section 3.1, Section 3.2, and Section 3.3 will terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, (iii) upon the closing of a Qualified SPAC Transaction, or (iv) upon the closing of a Deemed Liquidation Event, as such term is defined in the Certificate, other than a Deemed Liquidation Event under clause (c) of the definition of Deemed Liquidation Event in circumstances where the Investors continue to own shares of the Company, whichever event occurs first.

 

3.5            Confidentiality. Each Investor, other than Sixth Street, agrees that such Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company or its representatives (including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.5 by such Investor), (b) is or has been independently developed or conceived by such Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to such Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose (i) confidential information to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; provided that such Person is subject to an obligation of confidentiality; (ii) high-level summaries that only describe the Company’s business and high-level general financial information without reference to business plans, intellectual property, trade secrets, or other confidential information of the Company to prospective limited partners or members of such Investor; (iii) general financial information and high-level summaries that only describe the Company’s business without reference to business plans, intellectual property, trade secrets, or other confidential information of the Company to limited partners or members of such Investor (but not prospective limited partners or members); provided that such recipient is subject to an obligation of confidentiality with respect to the information received; (iv) confidential information to bona fide prospective purchasers of an Investor’s capital stock of the Company; provided that (A) such prospective purchaser is not a Competitor, (B) such prospective purchaser enters into a confidentiality agreement with the Investor that is consistent with and on terms no less restrictive than this Section 3.5 that provides that the Company is a third-party beneficiary and entitled to enforce such confidentiality agreement against such prospective purchaser, and (C) the Investor making such disclosure to such prospective purchaser shall be liable under this Agreement for any disclosure or use of confidential information by such prospective purchaser that would be a breach of this Agreement as if such prospective purchaser were an Investor under this Agreement; (iv) to the extent required in connection with any routine or periodic examination, audit or similar process by any regulatory or self-regulatory body or authority not specifically directed at the Company or the confidential information obtained from the Company pursuant to the terms of the Agreement, including, without limitation, quarterly or annual reports; or (v) as may otherwise be required by law, regulation, rule, court order, or subpoena; provided that such Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. The Company acknowledges and agrees that in no event shall an Investor’s confidentiality and non-use obligations hereunder in any manner be deemed or construed as an outright restriction on such Investor’s or its representatives’ (or any of their respective Affiliates) ability to trade any securities of a company that is publicly traded; provided, however, that each Investor acknowledges its obligations to comply with applicable securities laws, including those that prohibit Persons from purchasing or selling securities while in possession of relevant material non-public information. For the avoidance of doubt, Sixth Street shall not be subject to any of the restrictions set forth in this Section 3.5.

 

19

 

 

3.6            Material Non-Public Information. The Company understands and acknowledges that in the regular course of the Investors’ businesses, certain Investors may invest in companies that have issued securities that are publicly traded (each, a “Public Company”). Accordingly, if the Company has identified material non-public information in its possession relating to a Public Company, the Company will not share such material non-public information with the Investors. The Company will use commercially reasonable efforts to identify the material non-public information about a Public Company (“Public Company Information”) and will contact the Investors who have a contact set forth on Schedule C (the “Restricted Investors”). In the event that the Company seeks an exception to the prohibition on providing material non-public information on a Public Company to the Restricted Investors, the Company shall provide prior written notice (which may include e-mail) describing such information to and receive prior written approval (which may include e-mail) from such contact set forth on Schedule C. The Company will be permitted to disclose agreements entered into with Public Companies in the ordinary course of business, such as routine customer, supplier, advertising, and publishing agreements without such written authorization. Each Investor acknowledges and agrees that this Section 3.6 shall not apply to any Public Company Information that is disclosed during discussions at any meeting of the Board (or any committee thereof), which, with respect to all Restricted Investors other than Braidwell, excludes disclosure in materials prepared for the board.

 

4.            Rights to Future Stock Issuances. 

 

4.1            Right of First Offer. Subject to the terms and conditions of this Section 4.1 and applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company will first offer such New Securities to each Major Investor. A Major Investor may apportion the right of first offer hereby granted to it in such proportions as such Major Investor deems appropriate, among (i) itself and (ii) its Affiliates (other than portfolio companies or operating companies); provided that each such Affiliate (x) is not a Competitor, (y) agrees to enter into this Agreement and each of the Voting Agreement and Right of First Refusal and Co-Sale Agreement, as an “Investor” and “Shareholder” under the Voting Agreement and an Other Holder under the Right of First Refusal and Co-Sale Agreement, and (z) the participation of such Affiliate in such offering would not require the Company or such Affiliate to make any regulatory filing with any governmental authority (other than filings required in accordance with the U.S. Corporate Transparency Act or any similar regulatory filings). It is understood and agreed that only funds jointly managed by Highland and Stonebridge will be deemed Affiliates of Stonebridge-Highland for purposes of this Section 4.1 prior to (x) the Company’s first IPO or (y) a concurrent private placement in connection with a Qualified SPAC Transaction (clauses (x) and (y) together, a “Public Offering”), and with respect to a Public Offering, Affiliates of each of Highland and Stonebridge will be deemed Affiliates of Stonebridge-Highland for purposes of this Section 4.1.

 

20

 

 

(a)            The Company will give notice (the “Offer Notice”) to each Major Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities; provided, that in the case of a Public Offering, the Company will only be required to provide notice of the expected size of the offering (but will not be required to provide information regarding the expected price of the offering).

 

(b)            By notification to the Company within twenty (20) days (or ten (10) days in connection with a Public Offering) after the Offer Notice is given, each Major Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor (including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and any other Derivative Securities then outstanding). At the expiration of such twenty (20) day period (or ten (10) day period in connection with a Public Offering), the Company will promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. During the ten (10) day period (or three (3) day period in connection with a Public Offering) commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Section 4.1(b) will occur within the later of one hundred twenty (120) days of the date that the Offer Notice is given and the date of the initial sale of New Securities pursuant to Section 4.1(c); provided, that in connection with a Public Offering, such closing will occur pursuant to the terms of such Public Offering.

 

21

 

 

(c)            If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Section 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Section 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice; provided, that in connection with a Public Offering, the Company will not be restricted regarding the aggregate size of the offering or the price per share. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within sixty (60) days of the execution thereof, the right provided hereunder will be deemed to be revived and such New Securities may not be offered unless first reoffered to the Major Investors in accordance with this Section 4.1.

 

(d)            The right of first offer in this Section 4.1 will not be applicable to (i) Exempted Securities (as defined in the Certificate); (ii) the issuance of shares of Series E Preferred Stock and/or shares of Series F Preferred Stock to Additional Purchasers pursuant to Section 1.3 of the Purchase Agreement; provided, that, (x) with respect to the Series E Preferred Stock, such shares shall have an aggregate original purchase price of no greater than $100,000,000.00, less the aggregate original purchase price of the shares of Series E Preferred Stock sold at the Initial Closing (as defined in the Purchase Agreement) and (y) with respect to the Series F Preferred Stock, such shares shall have an aggregate original purchase price of no greater than $85,000,000.00, less the aggregate original purchase price of the shares of Series F Preferred Stock sold at the Initial Closing; (iii) the issuance of Additional Notes (as defined in the Note Purchase Agreement) to Additional Purchasers (as defined in the Note Purchase Agreement) pursuant to Section 1.2.4 of the Note Purchase Agreement, so long as such Additional Notes are issued pursuant to the Note Purchase Agreement in effect as of the Initial Closing (as defined in the Note Purchase Agreement) without giving effect to any material amendments of the Note Purchase Agreement after the Initial Closing (as defined in the Note Purchase Agreement) or (iv) the issuance of the Warrants (as defined in the Note Purchase Agreement) pursuant to Section 6.1.3 of the Note Purchase Agreement, so long as such Warrants are issued pursuant to the Note Purchase Agreement in effect as of the Initial Closing (as defined in the Note Purchase Agreement) on the terms set forth in the form of Warrant attached thereto without giving effect to any material amendments of the Note Purchase Agreement, the form of Warrant or any Warrants issued pursuant to the Note Purchase Agreement, in each case after the Initial Closing (as defined in the Note Purchase Agreement).

 

(e)            Notwithstanding any provision hereof to the contrary, in lieu of complying with the provisions of this Section 4.1 except for New Securities to be issued in connection with a Public Offering, the Company may elect to give notice to the Major Investors within thirty (30) days after the issuance of New Securities. Such notice will describe the type, price, and terms of the New Securities. Each Major Investor will have twenty (20) days from the date notice is given to elect to purchase up to the number of New Securities that would, if purchased by such Major Investor, maintain such Major Investor’s percentage-ownership position, calculated as set forth in Section 4.1(b) before giving effect to the issuance of such New Securities.

 

22

 

 

4.2            Termination. The covenants set forth in Section 4.1 will terminate and be of no further force or effect (i) immediately following the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, (iii) upon the closing of a Qualified SPAC Transaction, or (iv) upon the closing of a Deemed Liquidation Event, as such term is defined in the Certificate, other than a Deemed Liquidation Event under clause (c) of the definition of Deemed Liquidation Event in circumstances where the Investors continue to own shares of the Company, whichever event occurs first.

 

5.            Additional Covenants.

 

5.1            Matters Requiring Series C Director Approval. In the event the holders of Series C Preferred Stock are entitled to designate the Series C Director as set forth in the Certificate, the Company hereby covenants and agrees with each of the Investors that it will not, without the approval of the Board, which approval must include the affirmative vote of the Series C Director:

 

(a)            incur more than $30 million of additional indebtedness for borrowed money (beyond the principal amount of any indebtedness for borrowed money that exists as of the appointment of the Series C Director to the Board) after the date of appointment of the Series C Director; or

 

(b)            change the principal business of the Company or enter into a new line of business, in each case outside the life sciences sector, which for clarification does not include the sale or licensing of data gathered from businesses within the life sciences sector.

 

5.2            Right to Conduct Activities. The Company hereby agrees and acknowledges that each Major Investor (together with their respective Affiliates) is a professional investment organization and as such reviews the business plans and related proprietary information of many enterprises, some of which may compete directly or indirectly with the Company’s business (as currently conducted or as currently propose to be conducted).  The Company hereby agrees that, to the extent permitted under applicable law, no Major Investor (or its Affiliates) will be liable to the Company for any claim arising out of, or based upon, (i) the investment by such Major Investor (or its Affiliates) in any entity competitive with the Company, or (ii) actions taken by any partner, officer, employee, or other representative of such Major Investor (or its Affiliates) to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing will not relieve (x) any of the Investors from liability associated with the unauthorized disclosure or use of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company.

 

5.3            Permitted Issuances of Series E Preferred Stock, Series D Preferred Stock, and Series C Preferred Stock.

 

23

 

 

(a)            The Company hereby agrees and acknowledges that unless the Requisite Series E Holders give their prior written consent, the Company will not issue shares of Series E Preferred Stock other than pursuant to the Purchase Agreement.

 

(b)            The Company hereby agrees and acknowledges that unless the Requisite Series D Holders give their prior written consent, the Company will not issue shares of Series D Preferred Stock other than pursuant to the Series D Purchase Agreement.

 

(c)            The Company hereby agrees and acknowledges that unless the Requisite Series C Holders give their prior written consent, the Company will not issue shares of Series C Preferred Stock other than pursuant to: (i) warrants issued to Sixth Street Specialty Lending, Inc., and Barnett Equity Holdings, LLC disclosed on the Disclosure Schedules to the Purchase Agreement; and (ii) that certain Convertible Loan Agreement, dated as of September 21, 2018, by and among Caris Life Sciences, Ltd., certain subsidiaries of Caris Life Sciences, Ltd. from time to time and TPG Specialty Lending, Inc., as amended by that certain Amendment No. 1 to Convertible Loan Agreement, dated as of April 2, 2020, by and among Caris Life Sciences, Ltd., Caris Molecular Diagnostics, Inc., Caris Science, Inc., Caris MPI, Inc., Caris Pharmatech, Inc., Caris Therapeutics, Inc., TAO Barnett Investments, LLC, Top III Barnett Investments, LLC, and TPG Specialty Lending, Inc., as each such agreement may be further amended or restated from time to time.

 

5.4            Termination of Covenants. The covenants set forth in Section 5.1 and Section 5.3 will terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, (iii) upon the closing of a Qualified SPAC Transaction, or (iv) upon the closing of a Deemed Liquidation Event, as such term is defined in the Certificate, other than a Deemed Liquidation Event under clause (c) of the definition of Deemed Liquidation Event in circumstances where the Investors continue to own shares of the Company, whichever event occurs first. 

 

6.            Miscellaneous. 

 

6.1            Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder, (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members, or (iii) after such transfer, holds at least 2,000,000 shares of Registrable Securities (or such lesser amount of Registrable Securities constituting all of such Investor’s Registrable Securities) (subject to appropriate adjustments for any stock split, stock dividend, reorganization, stock combination, or similar transaction effected after the date hereof); provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including, without limitation, the provisions of Section 2.11 and Section 3.5; provided, further that such Affiliate or Immediate Family Member is not either (x) a Competitor of the Company or (y) Person of the type described in Rule 506(d)(1) of the Securities Act of 1933, as amended. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or shareholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member will be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights will, as a condition to the applicable transfer, establish a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided herein. No assignment shall relieve any party of its obligations under Section 3.5.

 

24

 

 

6.2            Governing Law. This Agreement will be governed by the internal law of the State of Texas, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Texas.

 

6.3            Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

6.4            Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement.

 

6.5            Notices. All notices and other communications given or made pursuant to this Agreement will be in writing and will be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications will be sent to the respective parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address or address as subsequently modified by written notice given in accordance with this Section 6.5. If notice is given to the Company, a copy will also be sent to GC@carisls.com and to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Attn: Nathan Ajiashvili, Email: Nathan.Ajiashvili@lw.com, if notice is given to Braidwell, a copy will also be given to Gibson, Dunn & Crutcher LLP, One Embarcadero Center, # 2600, San Francisco, CA 94111, Attn: Ryan Murr, Email: RMurr@gibsondunn.com, Stonebridge-Highland, a copy will also be given to Squire Patton Boggs (US) LLP, 1801 California St., Suite 4900, Denver, CO 80202, Attn: Thomas Reems, Email: thomas.reems@squirepb.com, and if notice is given to Sixth Street, a copy will also be given to Ropes & Gray LLP, 32nd Floor, 191 North Wacker Drive, Chicago, IL 60606, Attn: Matthew J. Richards; Email: Matthew.Richards@ropesgray.com.

 

25

 

 

6.6            Amendments and Waivers. Any term of this Agreement may be amended, modified or terminated and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of (i) the Company, (ii) the Principal Holders (as defined in the Right of First Refusal and Co-Sale Agreement), (iii) the Requisite Series C Holders, (iv) the Requisite Series D Holders, and (v) the Requisite Series E Holders (unless this Agreement is to be amended in connection with the authorization, creation, issuance, and/or sale of Permitted Preferred Stock (as defined in the Certificate), to (A) add the purchaser(s) of Permitted Preferred Stock as Investor(s) or Major Investor(s) for purposes of this Agreement, including Sections 3 and 4, (B) create a list of transactions which require the consent of a director appointed solely by the purchasers of Permitted Preferred Stock, (C) grant such purchaser(s) registration rights that may be granted in compliance with Section 2.10 and (D) grant such purchaser(s) rights that would not adversely modify the rights of the holders of the Series C Preferred Stock, the holders of the Series D Preferred Stock or the holders of the Series E Preferred Stock (beyond any modification associated with the addition of additional Investors, holders of Permitted Preferred Stock or Major Investors) (for purposes of this clause (D) the Investors holding Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock agree that granting rights to the holder(s) of Permitted Preferred Stock on a subject matter when the holders of Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock, as applicable, are not granted rights on that subject matter does not adversely modify the rights of the holders of Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock, as applicable), it being understood that any such amendment described in this parenthetical shall not require the consent of the Requisite Series C Holders, the Requisite Series D Holders or the Requisite Series E Holders); provided that the Company may in its sole discretion waive compliance with Section 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Section 2.12(c) will be deemed to be a waiver); provided further that this Agreement may not be amended, modified, terminated, or waived to adversely modify the rights granted to J.H. Whitney VI, L.P. disproportionately to the effect on the rights of the other Investors without the written consent of J.H. Whitney VI, L.P. Notwithstanding the foregoing, Section 1.1, Section 1.5, Section 1.21, Schedule B, Section 3.1, Section 3.2, Section 3.5(iii), Section 6.8 and this sentence of Section 6.6 shall not be amended, modified, terminated (other than as provided in Section 3.4) or waived in a manner that would adversely affect the rights of an Investor that is a mutual fund, pension fund, separately managed account or other pooled investment vehicle, in each case managed by an investment advisor registered under the Investment Advisers Act of 1940, as amended (an “Advisory Investor”), without either (i) the consent of such Advisory Investor, or (ii) providing such Advisory Investor the rights in such sections in a separate letter agreement.

 

Notwithstanding the foregoing, Section 3.1, Section 4, and any other section of this Agreement applicable to the Major Investors (including this clause of this Section 6.6) may not be amended, modified, terminated or waived without the written consent of the Company and the holders of at least a majority of the Registrable Securities then outstanding and held by the Major Investors. Notwithstanding the foregoing, Schedule A, Schedule B, and Schedule C hereto may be amended by the Company from time to time to add transferees of any Registrable Securities in compliance with the terms of this Agreement without the consent of the other parties; and Schedule A, Schedule B, and Schedule C hereto may also be amended by the Company after the date of this Agreement without the consent of the other parties to add information regarding any additional Investor who becomes a party to this Agreement in accordance with Section 6.9. The Company will give prompt notice of any amendment, modification, or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, modification, termination, or waiver. Any amendment, modification, termination, or waiver effected in accordance with this Section 6.6 will be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, will be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision.

 

26

 

 

6.7            Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability will not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision will be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law.

 

6.8            Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates will be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

 

6.9            Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the Company’s Series E Preferred Stock and/or shares of Series F Preferred Stock after the date hereof pursuant to the Purchase Agreement, any purchaser of such shares may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter will be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors will be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder.

 

6.10            Entire Agreement. This Agreement (including any Schedules and Exhibits hereto), the Side Letters (as defined in the Series D Purchase Agreement) and any side letters entered into in connection with the Purchase Agreement constitute the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled (including the Existing Agreement, which this Agreement amends and restates in its entirety).

 

6.11            Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Texas or to the jurisdiction of the United States District Court for the Northern District of Texas, in each case located in Dallas County, Texas, for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Dallas County, Texas or the United States District Court for the Northern District of Texas, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action, or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action, or proceeding is brought in an inconvenient forum, that the venue of the suit, action, or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.

 

27

 

 

6.12            WAIVER OF JURY TRIAL. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION AGREEMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.

 

6.13            Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, will impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor will it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor will any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, will be cumulative and not alternative.

 

6.14            Massachusetts Business Trust. A copy of the Declaration of Trust of each Fidelity Investor or any Affiliate thereof is on file with the Secretary of State of the Commonwealth of Massachusetts and notice is hereby given that this Agreement has been executed on behalf of the trustees of such Fidelity Investor or any Affiliate thereof as trustees and not individually and that the obligations of this Agreement are not binding on any of the trustees, officers or stockholders of such Fidelity Investor or any Affiliate thereof individually but are binding only upon such Fidelity Investor or any Affiliate thereof and its assets and property.

 

[Remainder of Page Intentionally Left Blank]

 

28

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  CARIS LIFE SCIENCES, INC.
     
  By: /s/ David D. Halbert
  Name: David D. Halbert
  Title: Chief Executive Officer

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

  CARIS HALBERT, L.P.
  By: Caris Investment Management, LLC, its General Partner
     
  By: /s/ David D. Halbert
  Name: David D. Halbert
  Title: Managing Member

 

  ADAPT I LTD.
 

By: DDH Adapt Trust, its General Partner

     
  By: /s/ David D. Halbert
  Name: David D. Halbert
  Title: Trustee
     
  CARISOME I, L.P.
  By: DDH Carisome Trust, its Managing General Partner
     
  By: /s/ David D. Halbert
  Name: David D. Halbert
  Title: Trustee
     
  CARIS INVESTMENT III LTD.
  By: Caris Investment Management, LLC, its General Partner
     
  By: /s/ David D. Halbert
  Name: David D. Halbert
  Title: Managing Member

 

 Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  CARIS INVESTMENT II LTD.
  By: Caris Investment Management, LLC, its General Partner
   
  By: /s/ David D. Halbert
Name: David D. Halbert
Title: Managing Member
   
  /s/ David. D. Halbert
  DAVID D. HALBERT

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above. 

 

  SH CARIS LIFE US, LLC
   
  By: /s/ Jun Park
  Name: Jun Park
  Title: Authorizd Officer
   
  SH CARIS LIFE US 2, LLC
   
  By: /s/ Jun Park
  Name: Jun Park
  Title: Authorizd Officer
   
  SH CARIS LIFE US 3, LLC
   
  By: /s/ Jun Park
  Name: Jun Park
  Title: Authorizd Officer

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  SIXTH STREET SPECIALTY LENDING, INC.
   
  By: /s/ Joshua Peck
  Name: Joshua Peck
  Title: Vice President
   
  TAO BARNETT INVESTMENTS, LLC
   
  By: /s/ Joshua Peck
  Name: Joshua Peck
  Title: Vice President
   
  TOP III BARNETT INVESTMENTS, LLC
   
  By: /s/ Joshua Peck
  Name: Joshua Peck
  Title: Vice President
     
  BARNETT EQUITY HOLDINGS, LLC
     
  By: /s/ Joshua Peck
  Name: Joshua Peck
  Title: Vice President
     
  BARNETT EQUITY HOLDINGS II, LLC
   
  By: /s/ Joshua Peck
  Name: Joshua Peck
  Title: Vice President

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  T. ROWE PRICE NEW HORIZONS FUND, INC.
  T. ROWE PRICE U.S. EQUITIES TRUST
  MASSMUTUAL SELECT FUNDS -
  MASSMUTUAL SELECT T. ROWE PRICE
  SMALL AND MID CAP BLEND FUND
   
  Each account, severally and not jointly
   
  By: T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable
     
  By: /s/ Nicholas Garifo
  Name: Nicholas Garifo
  Title: Vice President, Senior Legal Counsel

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  T. ROWE PRICE HEALTH SCIENCES FUND, INC.
  TD MUTUAL FUNDS - TD HEALTH SCIENCES FUND
  T ROWE PRICE HEALTH SCIENCES PORTFOLIO
   
  Each account, severally and not jointly
   
  By: T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable
     
  By: /s/ Nicholas Garifo
  Name: Nicholas Garifo
  Title: Vice President, Senior Legal Counsel

  

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  T. ROWE PRICE SMALL-CAP STOCK FUND, INC.
 

T. ROWE PRICE INSTITUTIONAL SMALL-CAP STOCK FUND

 

T. ROWE PRICE SPECTRUM CONSERVATIVE ALLOCATION FUND

  T. ROWE PRICE SPECTRUM MODERATE ALLOCATION FUND
  T. ROWE PRICE SPECTRUM MODERATE GROWTH ALLOCATION FUND
  T. ROWE PRICE MODERATE ALLOCATION PORTFOLIO
  U.S. SMALL-CAP STOCK TRUST
  VALIC COMPANY I - SMALL CAP FUND
  TD MUTUAL FUNDS - TD U.S. SMALL-CAP EQUITY FUND
  T. ROWE PRICE U.S. SMALL-CAP CORE EQUITY TRUST
  MINNESOTA LIFE INSURANCE COMPANY
  COSTCO 401(K) RETIREMENT PLAN
  MASSMUTUAL SELECT FUNDS - MASSMUTUAL
 

SELECT T. ROWE PRICE SMALL AND MID CAP BLEND FUND

   
  Each account, severally and not jointly
   
  By: T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable
     
  By: /s/ Nicholas Garifo
  Name: Nicholas Garifo
  Title: Vice President, Senior Legal Counsel

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  T. ROWE PRICE MID-CAP GROWTH FUND, INC.
  T. ROWE PRICE INSTITUTIONAL MID-CAP EQUITY GROWTH FUND
  T. ROWE PRICE MID-CAP GROWTH PORTFOLIO
  T. ROWE PRICE U.S. EQUITIES TRUST
  TD MUTUAL FUNDS - TD U.S. MID-CAP GROWTH
  FUND
  MASSMUTUAL SELECT FUNDS - MASSMUTUAL
  SELECT MID CAP GROWTH FUND
  MML SERIES INVESTMENT FUND - MML MID CAP GROWTH FUND
  BRIGHTHOUSE FUNDS TRUST I - T. ROWE PRICE MID CAP GROWTH PORTFOLIO
  T. ROWE PRICE U.S. MID-CAP GROWTH EQUITY
  TRUST
  COSTCO 401(K) RETIREMENT PLAN
  MASSMUTUAL SELECT FUNDS - MASSMUTUAL
  SELECT T. ROWE PRICE SMALL AND MID CAP
  BLEND FUND

 

  Each account, severally and not jointly
   
  By: T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable
     
  By: /s/ Nicholas Garifo
  Name: Nicholas Garifo
  Title: Vice President, Senior Legal Counsel

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  T. ROWE PRICE DIVERSIFIED MID-CAP GROWTH FUND, INC. 
  T. ROWE PRICE TAX-EFFICIENT EQUITY FUND
  JEFFREY LLC
  LINCOLN VARIABLE INSURANCE
  PRODUCTS TRUST - LVIP T. ROWE PRICE STRUCTURED
  MID-CAP GROWTH FUND 
  VOYA PARTNERS, INC. - VY T. ROWE PRICE
  DIVERSIFIED MID CAP GROWTH PORTFOLIO
  LINCOLN VARIABLE INSURANCE PRODUCTS
  TRUST – LVIP BLENDED MID CAP MANAGED
  VOLATILITY FUND

 

  Each account, severally and not jointly
   
  By: T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable
     
  By: /s/ Nicholas Garifo
  Name: Nicholas Garifo
  Title: Vice President, Senior Legal Counsel

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  T. ROWE PRICE ALL-CAP OPPORTUNITIES FUND 
  T. ROWE PRICE ALL-CAP OPPORTUNITIES
  PORTFOLIO
  T. ROWE PRICE GLOBAL ALLOCATION FUND, INC.

 

  Each account, severally and not jointly
   
  By: T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable
     
  By: /s/ Nicholas Garifo
  Name: Nicholas Garifo
  Title: Vice President, Senior Legal Counsel

 

  T. ROWE PRICE NEW HORIZONS TRUST
   
  By: T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable
     
  By: /s/ Nicholas Garifo
  Name: Nicholas Garifo
  Title: Vice President, Senior Legal Counsel

  

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  FIDELITY SECURITIES FUND: FIDELITY SMALL CAP GROWTH FUND 
   
  By: /s/ Chris Maher
  Name:  Chris Maher
  Title: Authorized Signatory 
   
  FIDELITY SECURITIES FUND: FIDELITY SMALL CAP GROWTH K6 FUND
   
  By: /s/ Chris Maher
  Name:  Chris Maher
  Title:  Authorized Signatory
   
  FMR CAPITAL, INC. – FLEX PILOT PORTFOLIO
  BY: FIDELITY MANAGEMENT & RESEARCH COMPANY LLC, AS INVESTMENT ADVISOR
   
  By: /s/ Chris Maher
  Name: Chris Maher
  Title:  Authorized Signatory
   
  FIDELITY MT. VERNON STREET TRUST: FIDELITY SERIES GROWTH COMPANY FUND 
   
  By: /s/ Chris Maher
  Name:  Chris Maher
  Title:  Authorized Signatory

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

 

FIDELITY MT. VERNON STREET TRUST:

FIDELITY GROWTH COMPANY FUND 

   
  By: /s/ Chris Maher
  Name: Chris Maher
  Title: Authorized Signatory
   
  FIDELITY GROWTH COMPANY COMMINGLED POOL 
   
  By: Fidelity Management Trust Company, as Trustee 
   
  By: /s/ Chris Maher
  Name: Chris Maher
  Title: Authorized Signatory
   
  FIDELITY MT. VERNON STREET TRUST: FIDELITY GROWTH COMPANY K6 FUND 
   
  By: /s/ Chris Maher
  Name:  Chris Maher
  Title: Authorized Signatory
   
  FIDELITY SELECT PORTFOLIOS: HEALTH
  CARE PORTFOLIO
   
   
  By: /s/ Chris Maher
  Name:  Chris Maher
  Title: Authorized Signatory

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

  

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  FIDELITY ADVISOR SERIES VII: FIDELITY
  ADVISOR HEALTH CARE FUND 
   
  By: /s/ Chris Maher
  Name:  Chris Maher
  Title:  Authorized Signatory
   
  FIDELITY CENTRAL INVESTMENT
  PORTFOLIOS LLC: FIDELITY U.S. EQUITY
  CENTRAL FUND - HEALTH CARE SUB 
   
  By: /s/ Chris Maher
  Name:  Chris Maher
  Title:  Authorized Signatory
   
  VARIABLE INSURANCE PRODUCTS FUND
  IV: HEALTH CARE PORTFOLIO
   
  By: /s/ Chris Maher
  Name:  Chris Maher
  Title:  Authorized Signatory
   
  FIDELITY SELECT PORTFOLIOS: SELECT
  MEDICAL TECHNOLOGY AND DEVICES 
  PORTFOLIO 
   
  By: /s/ Chris Maher
  Name:  Chris Maher
  Title:  Authorized Signatory

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  COATUE US 21 LLC
   
  By: /s/ Brent Duddie
  Name: Brent Duddie
  Title: Authorized Signatory
     
  Date: March 24, 2025
   
  COATUE US 44 LLC
 
  By: /s/ Brent Duddie
  Name: Brent Duddie
  Title: Authorized Signatory
     
  Date: March 24, 2025

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  SLP CHROME AGGREGATOR, L.P.
   
  By: SLP VI Aggregator GP, L.L.C., its general partner
  By: Silver Lake Technology Associates VI, L.P., its managing member
  By: STLA VI (GP) L.L.C., its general partner
  By: Silver Lake Group, L.L.C., its managing member
   
  By: /s/ Andrew Schader
  Name:  Andrew Schader
  Title:  Managing Director

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above. 

 

  ORBIMED PARTNERS MASTER FUND LIMITED
  By: OrbiMed Capital LLC, solely in its capacity as Investment Advisor 
   
  By: /s/ C. Scotland Stevens 
  Name: C. Scotland Stevens
  Title: Member
   
  WORLDWIDE HEALTHCARE TRUST PLC 
  By: OrbiMed Capital LLC, solely in its capacity as Portfolio Manager 
   
  By: /s/ C. Scotland Stevens 
  Name: C. Scotland Stevens
  Title: Member
   
  ORBIMED GENESIS MASTER FUND, L.P.
  By: OrbiMed Genesis GP LLC,
        its General Partner 
   
  By: OrbiMed Advisors LLC,
         its Managing Member
   
  By: /s/ C. Scotland Stevens 
  Name: C. Scotland Stevens
  Title: Member

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  ORBIMED PARTNERS SPV, LTD 
  By: OrbiMed Capital LLC, solely in its capacity as Investment Advisor
   
  By: /s/ C. Scotland Stevens
  Name: C. Scotland Stevens
  Title: Member

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  Neuberger berman principal strategies prima fund lp 
   
  By: Neuberger Berman Investment Advisers LLC, its investment manager 
   
  By: /s/ Gabe Cahill
  Name: Gabe Cahill
  Title: Managing Director 
   
  Neuberger berman principal strategies Co-invest fund I lp
   
  By: Neuberger Berman Investment Advisers LLC, its investment manager
   
  By: /s/ Gabe Cahill 
  Name: Gabe Cahill
  Title: Managing Director 
   
  Neuberger berman principal strategies Co-invest fund I-B lp 
   
  By: Neuberger Berman Investment Advisers LLC, its investment manager
   
  By: /s/ Gabe Cahill 
  Name: Gabe Cahill
  Title: Managing Director

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  J.H. WHITNEY VI L.P. 
   
  By: J.H. Whitney Equity Partners VI, L.P. 
  its General Partner 
   
  By: /s/ Paul R. Vigano
  Name: Paul R. Vigano
  Title: Managing Member

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  CPP INVESTMENT BOARD PMI-3 INC. 
   
  By: /s/ Thomas Kalvik
  Name: Thomas Kalvik
  Title: Authorized Signatory 
   
  Date: March 26th, 2025
   
  By: /s/ Bruce Hogg
  Name: Bruce Hogg
  Title: Authorized Signatory
   
  Date: March 26th, 2025

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  ROCK SPRINGS CAPITAL MASTER FUND
  LP 
   
  By: Rock Springs General Partner LLC, its General Partner
   
  By: /s/ Kris Jenner
  Name: Kris Jenner
  Title: Member

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  BRAIDWELL TRANSACTION HOLDINGS LLC – SERIES 11
   
  By: Braidwell LP, its Investment Manager 
   
  By: /s/ Colin Bettison 
  Name: Colin Bettison 
  Title: Authorized Signatory

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  GHISALLO FUND MASTER LTD
   
  By: /s/ Michael Germino
  Name: Michael Germino
  Title: Director

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD. 
   
  By: Perceptive Advisors, LLC
   
  By: /s/ James H. Mannix
  Name: James H. Mannix 
  Title: COO

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  SteelMill Master Fund LP
   
  By: PointState Holdings LLC, its General Partner
   
  By: /s/ Alfred J. Barbagallo
  Name: Alfred J. Barbagallo
  Title: Authorized Signatory

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  WOODLINE MASTER FUND LP
   
  By: /s/ Erin Mullen
  Name: Erin Mullen
  Title: Authorized Signatory

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  FIRST LIGHT FOCUS FUND, LP
   
  By: First Light Asset Management LLC, its investment advisor
   
  By: /s/ Mathew Arens
  Name: Mathew Arens
  Title: CEO

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  EATON VANCE WORLDWIDE 
  HEALTH SCIENCES FUND 
   
  By: Eaton Vance Management, as its investment adviser 
   
  By: /s/ Jason Kritzer
  Name:  Jason Kritzer
  Title: Vice President

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  Longaeva Private Growth I L.P.
   
  By: Longaeva Partners L.P., its investment manager 
   
  By: /s/ Dannia Altemimei
  Name:  Dannia Altemimei
  Title: Authorized Signatory 
   
  By: /s/ Matthew Siclari
  Name: Matthew Siclari
  Title: Authorized Signatory

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  AEF Plus Privates Fund, LLC 
   
  By: Balyasny Asset Management L.P., its Manager 
   
  By: /s/ Dannia Altemimei
  Name:  Dannia Altemimei
  Title:  Authorized Signatory
   
  By: /s/ Matthew Siclari
  Name: Matthew Siclari
  Title: Authorized Signatory

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  RIVERVIEW GROUP LLC 
   
  By: Integrated Holding Group LP, 
       its Managing Member 
   
           By: Millennium Management LLC,
           its General Partner
   

  By: /s/ Mark Meskin 
  Name: Mark Meskin
  Title: Chief Strategic Development Officer

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  PATRICK MCBRIEN
   
  By: /s/ Patrick McBrien
  Name: Patrick McBrien

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

  JEREMY ABELSON
   
  By: /s/ Jeremy Abelson
  Name:  Jeremy Abelson

 

Signature Page to Amended and Restated Investors’ Rights Agreement

 

 

 

 

Schedule A

 

Investors

 

SCHEDULE A - 1

 

 

Schedule B

  

Investment Management Entities 

 

SCHEDULE B - 1

 

 

Schedule C

 

Material Non-Public Information Contacts

 

SCHEDULE C - 1

 

Exhibit 10.1(a)

 

 

CREDIT AGREEMENT

 

dated as of January 18, 2023

 

among

 

CARIS LIFE SCIENCES, INC.,

 

as the Borrower,

 

THE LENDERS FROM TIME TO TIME PARTY HERETO

 

and

 

WILMINGTON TRUST, NATIONAL ASSOCIATION,

 

as the Administrative Agent

 

 

 

 

 

 

TABLE OF CONTENTS

 

ARTICLE I DEFINITIONS AND ACCOUNTING TERMS 1
   
SECTION 1.1 Defined Terms 1
SECTION 1.2 Use of Defined Terms 34
SECTION 1.3 Cross-References 34
SECTION 1.4 Accounting and Financial Determinations 34
SECTION 1.5 Other Interpretive Provisions 35
   
ARTICLE II COMMITMENT AND BORROWING PROCEDURES 35
   
SECTION 2.1 Commitment 35
SECTION 2.2 Borrowing Procedure 35
SECTION 2.3 Funding 36
SECTION 2.4 Reduction of the Commitment Amounts 36
   
ARTICLE III REPAYMENTS, PREPAYMENTS, INTEREST AND FEES 36
   
SECTION 3.1 Repayments and Prepayments 36
SECTION 3.2 Amortization; Repayments and Prepayments 36
SECTION 3.3 Application 38
SECTION 3.4 Interest Rate 38
SECTION 3.5 Default Rate 38
SECTION 3.6 Payment Dates 38
SECTION 3.7 Fee Letters 38
SECTION 3.8 Payments Generally 39
SECTION 3.9 Undrawn Fee 39
   
ARTICLE IV SOFR RATE AND OTHER PROVISIONS 39
   
SECTION 4.1 Increased Costs, Etc 39
SECTION 4.2 Increased Capital Costs 40
SECTION 4.3 Taxes 40
SECTION 4.4 Payments, Computations; Proceeds of Collateral, Etc 45
SECTION 4.5 Setoff 46
SECTION 4.6 SOFR Rate Not Determinable 46
SECTION 4.7 Defaulting Lenders 47
   
ARTICLE V CONDITIONS TO MAKING THE LOANS 49
   
SECTION 5.1 Credit Extensions 49
SECTION 5.2 Secretary’s Certificate, Etc 49
SECTION 5.3 Closing Date Certificates 49
SECTION 5.4 Payment of Outstanding Indebtedness, Etc 50
SECTION 5.5 Delivery of Note 50
SECTION 5.6 Financial Information, Etc. 50
SECTION 5.7  Compliance Certificate 50
SECTION 5.8 Solvency, Etc. 51
SECTION 5.9 Guarantee 51

 

 

 

SECTION 5.10 Security Agreement 51
SECTION 5.11 Intellectual Property Security Agreements 51
SECTION 5.12 Opinion of Counsel 52
SECTION 5.13 Insurance 52
SECTION 5.14 Closing Fees, Expenses, Etc. 52
SECTION 5.15 Anti-Terrorism Laws 52
SECTION 5.16 Loan Documents 52
SECTION 5.17 Satisfactory Legal Form 52
SECTION 5.18 No Material Adverse Effect 52
SECTION 5.19 Revenue Base 52
SECTION 5.20 Disclosure Schedules 52
   
ARTICLE VI REPRESENTATIONS AND WARRANTIES 53
   
SECTION 6.1 Organization, Etc. 53
SECTION 6.2 Due Authorization, Non-Contravention, Etc. 53
SECTION 6.3 Government Approval, Regulation, Etc. 53
SECTION 6.4 Validity, Etc. 54
SECTION 6.5 Financial Information 54
SECTION 6.6 No Material Adverse Effect 54
SECTION 6.7 Litigation, Labor Matters and Environmental Matters 54
SECTION 6.8 Subsidiaries 55
SECTION 6.9 Ownership of Properties 55
SECTION 6.10 Taxes 55
SECTION 6.11 Benefit Plans, Etc. 55
SECTION 6.12 Accuracy of Information 56
SECTION 6.13 Regulations U and X 56
SECTION 6.14 Solvency 56
SECTION 6.15 Intellectual Property 56
SECTION 6.16 Material Agreements 59
SECTION 6.17 Permits 59
SECTION 6.18 Regulatory Matters 59
SECTION 6.19 Transactions with Affiliates 63
SECTION 6.20 Investment Company Act 63
SECTION 6.21 OFAC 63
SECTION 6.22 Deposit and Disbursement Accounts 63
SECTION 6.23 Data Privacy and Information Security 64
SECTION 6.24 HIPAA 65
SECTION 6.25 No Side Arrangements or Other Fees 66
   
ARTICLE VII AFFIRMATIVE COVENANTS 66
   
SECTION 7.1 Financial Information, Reports, Notices, Etc. 66
SECTION 7.2 Maintenance of Existence; Compliance with Contracts, Laws, Etc. 70
SECTION 7.3 Maintenance of Properties 70
SECTION 7.4 Insurance 71
SECTION 7.5 Books and Records 71
SECTION 7.6 Environmental Law Covenant 72

 

- ii -

 

 

SECTION 7.7 Use of Proceeds 72
SECTION 7.8 Future Guarantors, Security, Etc. 72
SECTION 7.9 Obtaining of Permits, Etc. 73
SECTION 7.10 [Reserved] 73
SECTION 7.11 Maintenance of Regulatory Authorizations, Contracts, Intellectual Property, Etc. 73
SECTION 7.12 [Reserved] 75
SECTION 7.13 Cash Management 75
SECTION 7.14 Excluded Subsidiaries 77
SECTION 7.15 Post-Closing Deliverables 78
SECTION 7.16 Parent HoldCo Reorganization 79
   
ARTICLE VIII NEGATIVE COVENANTS 80
   
SECTION 8.1 Business Activities 80
SECTION 8.2 Indebtedness 80
SECTION 8.3 Liens 83
SECTION 8.4 Financial Covenants 86
SECTION 8.5 Investments 88
SECTION 8.6 Restricted Payments, Etc. 90
SECTION 8.7 Consolidation, Merger; Permitted Acquisitions, Etc. 92
SECTION 8.8 Permitted Dispositions 93
SECTION 8.9 Modification of Certain Agreements 94
SECTION 8.10 Transactions with Affiliates 94
SECTION 8.11 Restrictive Agreements, Etc. 95
SECTION 8.12 Sale and Leaseback 95
SECTION 8.13 [Reserved] 96
SECTION 8.14 Change in Name, Location, Executive Office or Executive Management; Change in Fiscal Year 96
SECTION 8.15 Benefit Plans and Agreements 96
   
ARTICLE IX EVENTS OF DEFAULT 96
   
SECTION 9.1 Listing of Events of Default 96
SECTION 9.2 Action if Bankruptcy 99
SECTION 9.3 Action if Other Event of Default 99
SECTION 9.4 Right to Cure 100
SECTION 9.5 Application of Funds 100
   
ARTICLE X MISCELLANEOUS PROVISIONS 101
   
SECTION 10.1 Waivers, Amendments, Etc. 101
SECTION 10.2 Notices; Time; Inside Information 102
SECTION 10.3 Payment of Costs and Expenses 105
SECTION 10.4 Indemnification; Expenses; and Damage Waiver 106
SECTION 10.5 Survival 107
SECTION 10.6 Severability 107
SECTION 10.7 Headings 107
SECTION 10.8 Execution in Counterparts, Effectiveness, Etc. 108

 

- iii -

 

 

SECTION 10.9 Governing Law; Entire Agreement 108
SECTION 10.10 Successors and Assigns 108
SECTION 10.11 Other Transactions 111
SECTION 10.12 Forum Selection and Consent to Jurisdiction 111
SECTION 10.13 Waiver of Jury Trial 112
SECTION 10.14 Confidential Information 112
SECTION 10.15 Exceptions to Confidentiality 113
SECTION 10.16 No Waiver; Cumulative Remedies; Enforcement 113
SECTION 10.17 Payments Set Aside 114
SECTION 10.18 Electronic Execution of Assignments and Certain Other Documents 114
SECTION 10.19 Independent Nature of Lenders 115
SECTION 10.20 No Fiduciary Relationship 115
   
ARTICLE XI ADMINISTRATIVE AGENT 115
   
SECTION 11.1 Appointment and Authority 115
SECTION 11.2 Rights as a Lender 116
SECTION 11.3 Exculpatory Provisions 117
SECTION 11.4 Reliance by the Administrative Agent 119
SECTION 11.5 Delegation of Duties 119
SECTION 11.6 Resignation or Removal of the Administrative Agent 120
SECTION 11.7 Non-Reliance on the Administrative Agent and Other Lenders 120
SECTION 11.8 Administrative Agent May File Proofs of Claim 121
SECTION 11.9 Collateral and Guarantee Matters 122
SECTION 11.10 Erroneous Payments 123

 

- iv -

 

 

 

SCHEDULES:
   
Schedule 2.1 Commitments and Applicable Percentages
Schedule 6.7(a) Litigation
Schedule 6.7(b) Labor Matters
Schedule 6.8 Existing Subsidiaries
Schedule 6.11 Benefit Plans, Etc.
Schedule 6.15(a)(1) Intellectual Property (Registrations and Applications)
Schedule 6.15(a)(2) Intellectual Property (In-Bound Licenses and Sub-Licenses)
Schedule 6.15(f) Proceedings Challenging Owned Intellectual Property
Schedule 6.15(g) Validity of Owned and Licensed Intellectual Property
Schedule 6.15(j)(1) Infringement Notices
Schedule 6.15(j)(2) Infringement of Third Party Intellectual Property
Schedule 6.16 Material Agreements
Schedule 6.18(i) Violation of Fraud and Abuse Laws
Schedule 6.18(l) Health Program-Related Offenses
Schedule 6.19 Transactions with Permitted Holders
Schedule 6.22 Deposit and Disbursement Accounts
Schedule 6.24(d) HIPAA
Schedule 8.2(b) Indebtedness to be Paid
Schedule 8.2(c) Existing Indebtedness
Schedule 8.3(c) Existing Liens
Schedule 8.5(a) Investments
Schedule 8.10 Transactions with Affiliates
Schedule 8.11 Restrictive Agreements
Schedule 10.2 Notice Information

 

EXHIBITS:
     
Exhibit A - Form of Promissory Note
Exhibit B - Form of Loan Request
Exhibit C - Form of Compliance Certificate
Exhibit D - Form of Guarantee
Exhibit E - Form of Security Agreement
Exhibit F - Form of Assignment and Assumption
Exhibit G - Form of Solvency Certificate

 

- v -

 

 

CREDIT AGREEMENT

 

THIS CREDIT AGREEMENT dated as of January 18, 2023 (as amended, supplemented or otherwise modified from time to time, this “Agreement”), is among CARIS LIFE SCIENCES, INC., a Texas corporation (the “Borrower”), the Lenders (defined herein) and Wilmington Trust, National Association (together with its Affiliates, successors, transferees and assignees), as Administrative Agent. The Borrower, the Administrative Agent and each Lender are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

 

W I T N E S S E T H:

 

WHEREAS, the Borrower has requested that the Lenders provide a senior term loan facility to the Borrower in an aggregate principal amount of $400,000,000 (with $200,000,000 available on the Closing Date, an additional $200,000,000 available in minimum increments of $100,000,000 on or prior to the Delayed Draw Unavailability Date), subject to the terms and conditions set forth herein; and

 

WHEREAS, the Lenders are willing, on the terms and subject to the conditions hereinafter set forth, to extend the Commitment and make the Loans to the Borrower;

 

NOW, THEREFORE, the parties hereto agree as follows.

 

ARTICLE I
DEFINITIONS AND ACCOUNTING TERMS

 

SECTION 1.1 Defined Terms. The following terms (whether or not underscored) when used in this Agreement, including its preamble and recitals, shall, except where the context otherwise requires, have the following meanings (such meanings to be equally applicable to the singular and plural forms thereof):

 

“2020 Incentive Plan” means the Caris Life Sciences, Inc. 2020 Incentive Plan, as amended, restated, supplemented or otherwise modified from time to time.

 

“2023 Convertible Loan Agreement” means that certain Convertible Loan Agreement, dated as of September 21, 2018, among the Borrower (as successor to Caris Life Sciences, Ltd.), certain subsidiaries of the Borrower party thereto, the lenders from time to time party thereto and Sixth Street Specialty Lending, Inc. (f/k/a TPG Specialty Lending, Inc.), as administrative agent for the lenders (as supplemented or amended prior to the Closing Date and as further supplemented or amended from time to time in accordance with the terms of this Agreement).

 

“2023 Convertible Loan Documents” means the “Loan Documents” (as defined in the 2023 Convertible Loan Agreement).

 

“2023 Convertible Loan Repayment” means the conversion, repurchase, redemption, repayment or other retirement of all or a portion of the 2023 Convertible Loans, including any accrued and unpaid interest and premium thereon.

 

 

 

 

“2023 Convertible Loans” means those certain 8.00% unsecured convertible senior loans in an aggregate original principal amount of $50,000,000 due on September 21, 2023, issued by the Borrower and governed by the terms of the 2023 Convertible Loan Agreement.

 

“ADAPT Biotargeting System” means the Loan Parties’ technology platform for profiling the molecular composition of cells, tissues, and circulating microvesicles/exosomes, including but not limited to the use of aptamer-based testing technology to develop assays for diagnosis, prognosis, and theranostics of cancer and other diseases.

 

“Administration Fee” has the meaning set forth in the Fee Letter.

 

“Administrative Agent” means Wilmington Trust, National Association, in its capacity as administrative agent under any of the Loan Documents, or any successor administrative agent.

 

“Administrative Agent’s Office” means the Administrative Agent’s address and, as appropriate, account as set forth on Schedule 10.2 or such other address or account as the Administrative Agent may from time to time notify the Borrower and the Lenders.

 

“Affiliate” of any Person means any other Person which, directly or indirectly, Controls, is Controlled by or is under common Control with such Person. “Control” (and its correlatives) by any Person means (a) the power of such Person, directly or indirectly, (i) to vote 15% or more of the Voting Securities (determined on a fully diluted basis) of another Person or (ii) to direct or cause the direction of the management and policies of such other Person (whether by contract or otherwise), or (b) the ownership by such Person of 15% or more of the Capital Securities of another Person.

 

“Agency Fee Letter” means the fee letter, dated as of the Closing Date, between the Borrower and the Administrative Agent.

 

“Agreement” is defined in the preamble.

 

“Amortization Termination Date” is defined in Section 3.2.

 

“Applicable Margin” means 6.50%.

 

“Applicable Percentage” means, with respect to any Lender at any time, (a) with respect to such Lender’s portion of the outstanding Loans at any time, the percentage of the outstanding principal amount of the Loans held by such Lender at such time and (b) with respect to such Lender’s portion of the outstanding Commitments at any time, the percentage of the Commitment Amount held by such Lender at such time. The initial Applicable Percentage of each Lender is set forth opposite the name of such Lender on Schedule 2.1 or in the Assignment and Assumption pursuant to which such Lender becomes a party hereto, as applicable.

 

“Approved Fund” means any Fund that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers or manages a Lender.

 

-2-

 

 

“Assignment and Assumption” means an assignment and assumption entered into by a Lender and an Eligible Assignee (with the consent of any party whose consent is required by Section 10.10(b)), and accepted by the Administrative Agent, in substantially the form of Exhibit F hereto.

 

“Assignment Effective Date” is defined in Section 10.10(a).

 

“Attributable Debt” means, with respect to any Sale/Leaseback Transaction that does not result in a Capitalized Lease Liability, the present value (computed in accordance with GAAP) of the total obligations of the lessee for rental payments during the remaining term of the lease included in such Sale/Leaseback Transaction (including any period for which such lease has been extended). In the case of any lease which is terminable by the lessee upon payment of a penalty, the Attributable Debt shall be the lesser of (i) the Attributable Debt determined assuming termination upon the first date such lease may be terminated (in which case the Attributable Debt shall also include the amount of the penalty, but no rent shall be considered as required to be paid under such lease subsequent to the first date upon which it may be so terminated) and (ii) the Attributable Debt determined assuming no such termination.

 

“Authorized Officer” means, as applied to any Person, any individual holding the position of chairman of the board (if an officer), chief executive officer, president or one of its vice presidents (or the equivalent thereof), such Person’s chief financial officer or treasurer or other similar officer or Person performing similar functions of such Loan Party and, solely for purposes of notices given pursuant to Article II hereof, any other officer or employee of the applicable Loan Party so designated by any of the foregoing officers in a notice to the Administrative Agent or the Required Lenders or any other officer or employee of the applicable Loan Party designated in or pursuant to an agreement between the applicable Loan Party and the Administrative Agent or the Required Lenders and, as to any document delivered on the Closing Date, any secretary or assistant secretary of a Loan Party, in each such case, whose signatures and incumbency shall have been certified to the Administrative Agent and the Lenders. Unless otherwise specified, all references herein to an “Authorized Officer” shall refer to an Authorized Officer of the Borrower.

 

“Benefit Plan” means any employee benefit plan, as defined in section 3(3) of ERISA, that is either (i) a Multiemployer Plan, (ii) subject to section 412 of the Code, section 302 of ERISA or Title IV of ERISA or (iii) has assets that are invested in Capital Securities of the Borrower or any Subsidiaries or any of their respective ERISA Affiliates.

 

“Bona Fide Lending Affiliate” means any bona fide debt fund, investment vehicle, regulated banking entity, non-regulated lending entity or other similar entity (in each case, other than a Person that is explicitly excluded pursuant to clause (a) of the definition of “Disqualified Institution”) that is primarily engaged in commercial loans and similar extensions of credit in the ordinary course of business.

 

“Borrower” is defined in the preamble.

 

“Borrower Materials” means information, reports, financial statements and other materials delivered by the Borrower to the Administrative Agent and the Lenders hereunder, as well as other reports and information provided by the Administrative Agent to the Lenders.

 

-3-

 

 

“Borrower’s Charter” means that certain Amended and Restated Certificate of Formation of the Borrower, dated as of May 3, 2021, and as may be amended, restated, amended and restated, supplemented or otherwise modified from time to time after the Closing Date to the extent permitted by Section 8.9(a).

 

“Braidwell” means, collectively, Braidwell Transaction Holdings LLC – Series 2 and its Affiliates and Approved Funds.

 

“Business Associate” has the same meaning as the term “business associate” in 45 C.F.R. § 160.103.

 

“Business Day” means any day which is neither a Saturday or Sunday nor a legal holiday on which banks are authorized or required to be closed in New York, New York.

 

“Capital Securities” means, with respect to any Person, all shares of, interests or participations in, or other equivalents in respect of (in each case however designated, whether voting or non-voting), of such Person’s capital stock, and any warrants, options or other rights entitling the holder thereof to purchase or acquire any such capital stock, in each case, whether now outstanding or issued on or after the Closing Date. Notwithstanding the foregoing, neither Post-IPO Convertible Indebtedness, any other convertible Indebtedness permitted by this Agreement nor Permitted Call Spread Swap Agreements shall constitute Capital Securities unless and until so converted into Capital Securities.

 

“Capitalized Lease Liabilities” means, with respect to any Person, all monetary obligations of such Person and its Subsidiaries under any leasing or similar arrangement which have been (or, in accordance with GAAP, should be) classified as finance leases, and for purposes of each Loan Document the amount of such obligations shall be the capitalized amount thereof, determined in accordance with GAAP, and the stated maturity thereof shall be the date of the last payment of rent or any other amount due under such lease prior to the first date upon which such lease may be terminated by the lessee without payment of a premium or a penalty.

 

“Caris Discovery” means the Loan Parties’ drug target or therapeutic target discovery platform, including the ADAPT Biotargeting System.

 

“Caris Molecular Intelligence” means the Loan Parties’ profiling business operated under the current names MI Tumor Seek (or variations thereof), MI Profile and Caris Assure and any future name, which relates to: (i) the profiling of patient samples (whether tissue or blood), including but not limited to immunohistochemistry, in situ hybridization, next-generation sequencing of DNA and/or RNA, Sanger sequencing, pyrosequencing, and gene fusions, variant transcripts and fragment analysis, (ii) the analysis and performance of bioinformatics, and any other analysis (including FOLFIRSTai, and GPSai) related to tumors and (iii) reporting, consultations, treatment recommendations (including companion diagnostics) or other end product related tumor profiling and the analysis therein.

 

“Caris Strategic Data” means the Loan Parties’ data platform and business relating to molecular and clinical outcomes data and molecular signatures.

 

“Cash Equivalent Investment” means, at any time:

 

-4-

 

 

(a)            any direct obligation of (or unconditionally guaranteed by) the United States (or any agency or political subdivision thereof, to the extent such obligations are supported by the full faith and credit of the United States) maturing not more than one year after such time;

 

(b)            commercial paper maturing not more than one year from the date of issue, which is issued by a corporation (other than an Affiliate of the Borrower or any of its Subsidiaries) organized under the laws of any state of the United States or of the District of Columbia and rated A-1 or higher by S&P or P-1 or higher by Moody’s; or

 

(c)            any certificate of deposit, demand or time deposit or bankers’ acceptance, maturing not more than 180 days after its date of issuance, which is issued by or placed with any bank or trust company organized under the laws of the United States (or any state thereof) and which has (x) a credit rating of A2 or higher from Moody’s or A or higher from S&P and (y) a combined capital and surplus greater than $500,000,000; or

 

(d)            investments in money market mutual funds at least 95% of the assets of which are comprised of securities of the types described in clauses (a) through (c) of this definition.

 

“Casualty Event” means the damage, destruction or condemnation, as the case may be, of property of any Person or any of its Subsidiaries.

 

“CFC” means a “controlled foreign corporation” within the meaning of Section 957 of the Code.

 

“Change in Control” means and shall be deemed to have occurred if

 

(i)prior to the consummation of a Direct Listing, Qualified IPO or a Qualified SPAC Transaction, (A) the Permitted Holders shall at any time not own, in the aggregate, directly or indirectly, beneficially and of record, at least 40% of the Voting Securities of the Borrower (calculated without giving effect to the issuance or deemed issuance of any shares of Common Stock issued or deemed issued as a result of any adjustment to the Series C Conversion Price or Series D Conversion Price (each as defined in the Borrower’s Charter) in accordance with the Borrower’s Charter following the Closing Date) and the right to elect or designate for election at least a majority of the board of directors (or equivalent) of the Borrower or (B) any “person” or “group” (within the meaning of Rule 13d-5 of the Exchange Act), other than Permitted Holders, shall own, directly or indirectly, beneficially or of record, determined on a fully diluted basis, more than 35% of the Voting Securities of the Borrower (calculated without giving effect to the issuance or deemed issuance of any shares of Common Stock after the Closing Date to any Sixth Street Entity as a result of any adjustment to the Series C Conversion Price or Series D Conversion Price (each as defined in the Borrower’s Charter) in accordance with the Borrower’s Charter);

 

-5-

 

 

(ii)upon and after the consummation of a Direct Listing, Qualified IPO or a Qualified SPAC Transaction, any “person” or “group” (within the meaning of Rule 13d-5 of the Exchange Act), other than Permitted Holders, shall own, directly or indirectly, beneficially or of record, determined on a fully diluted basis, more than 35% of the Voting Securities of the Borrower (calculated without giving effect to the issuance or deemed issuance of any shares of Common Stock after the Closing Date to any Sixth Street Entity as a result of any adjustment to the Series C Conversion Price or Series D Conversion Price (each as defined in the Borrower’s Charter) in accordance with the Borrower’s Charter);

 

(iii)a majority of the seats (other than vacant seats) on the board of directors (or equivalent) of the Borrower shall at any time be occupied by persons (x) who were not members of such board of directors (or equivalent) on the first day of such period, (y) whose election or nomination to such board was not approved by either the Permitted Holders or by individuals referred to in clause (x) above constituting at the time of such election or nomination at least a majority of such board or (z) whose election or nomination to such board was not approved by the Permitted Holders or by individuals referred to in clauses (x) and (y) above;

 

(iv)the Borrower shall cease to own, directly or indirectly through other Wholly Owned Subsidiaries, beneficially and of record, 100% of the issued and outstanding Capital Securities of the Loan Parties, except as otherwise permitted by this Agreement or, after the occurrence of a Parent HoldCo Reorganization, any Parent HoldCo shall cease to own, directly or indirectly through another Parent HoldCo, beneficially and of record, 100% of the issued and outstanding Capital Securities of the Borrower;

 

provided that the occurrence of a Direct Listing, a Qualified IPO or a Qualified SPAC Transaction (including any change in board membership as a result thereof) shall not be deemed a Change in Control;

 

provided, further, that from and after a Parent HoldCo Reorganization, each reference to “the Borrower” in the foregoing clauses (i), (ii) or (iii) shall be deemed to be a reference to Parent HoldCo.

 

“Change in Law” means the occurrence, after the date of this Agreement, of any of the following: (i) the adoption or taking effect of any law, rule, regulation or treaty, (ii) any change in any law, rule, regulation or treaty or in the administration, interpretation, implementation or application thereof by any Governmental Authority or (iii) the making or issuance of any request, rule, guideline or directive (whether or not having the force of law) by any Governmental Authority; provided that, notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a “Change in Law”, regardless of the date enacted, adopted or issued.

 

-6-

 

 

“CLIA” means the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. § 263a, et. seq.), together with implementing regulations (42 C.F.R. § 493) and interpretative guidelines issued by CMS.

 

“Closing Date” means the date of this Agreement.

 

“Closing Date Certificate” means a closing date certificate executed and delivered by an Authorized Officer of the Borrower in form and substance reasonably satisfactory to the Administrative Agent and the Required Lenders.

 

“Closing Date Transactions” means, collectively, (a) the execution and delivery of the Loan Documents on the Closing Date and the funding of the Initial Loans hereunder on the Closing Date, (b) the consummation of the Existing Debt Refinancing and (c) the payment of all fees, premiums, expenses and other transaction costs incurred in connection therewith.

 

“CMS” means the U.S. Centers for Medicare and Medicaid Services.

 

“Code” means the Internal Revenue Code of 1986, as amended from time to time.

 

“Collateral” has the meaning set forth in the Security Agreement.

 

“Commitment” means, as to each Lender, such Lender’s obligation (if any) to make Loans hereunder.

 

“Commitment Amount” means the Initial Commitment Amount plus the Delayed Draw Commitment Amount. The aggregate principal amount of the Commitment Amount of all of the Lenders as in effect on the Closing Date is $400,000,000.

 

“Company Competitor” means any Person that competes with the business of the Borrower and its Subsidiaries from time to time.

 

“Compliance Certificate” means a certificate duly completed and executed by an Authorized Officer of the Borrower, substantially in the form of Exhibit C hereto.

 

“Confidential Business Information” means, whether patentable or unpatentable and whether or not reduced to practice, confidential business information, including trade secrets, proprietary information, technical data, laboratory notebooks, clinical data, know-how, inventions, manufacturing processes and techniques, financial, marketing and business data, pricing and cost information, business, finance and marketing plans, customer and prospective customer lists and information, and supplier and prospective supplier lists and information, research and development information, data and other information included in or supporting Regulatory Authorizations.

 

“Confidential Information” means any and all non-public information or material (whether written or oral, or in electronic or other form) that, at any time before, on or after the Closing Date, has been or is provided or communicated to the Receiving Party by or on behalf of the Disclosing Party pursuant to this Agreement or in connection with the transactions contemplated hereby.

 

-7-

 

 

“Contingent Liability” means any agreement, undertaking or arrangement by which any Person guarantees, endorses or otherwise becomes or is contingently liable upon (by direct or indirect agreement, contingent or otherwise, to provide funds for payment, to supply funds to, or otherwise to invest in, a debtor, or otherwise to assure a creditor against loss) the Indebtedness of any other Person (other than by endorsements of instruments in the course of collection), or guarantees the payment of dividends or other distributions upon the Capital Securities of any other Person. The amount of any Person’s obligation under any Contingent Liability shall (subject to any limitation set forth therein) be deemed to be the outstanding amount of the debt, obligation or other liability guaranteed thereby.

 

“Control” is defined within the definition of “Affiliate”.

 

“Controlled Account” is defined in Section 7.13.

 

“Controlled Investment Affiliate” means, as to any Person, any other Person that (a)  directly or indirectly, is in Control of, is Controlled by, or is under common Control with, such Person and (b) is organized by such Person primarily for the purpose of making equity or debt investments in one or more companies, in each case, including any trust or other holding, investment or estate planning vehicles Controlled directly or indirectly by or organized by such Person.

 

“Copyright Security Agreement” means any Copyright Security Agreement executed and delivered to the Administrative Agent by the Borrower or any of the Guarantors in substantially the form of Exhibit C to the Security Agreement, as amended, supplemented, amended and restated or otherwise modified from time to time.

 

“Copyrights” means all registered and unregistered copyrights, whether statutory or common law, along with any and all (i) renewals, revisions, extensions, derivative works, enhancements, modifications, updates and new releases thereof, (ii) rights in works of authorship, including all rights of authorship of any type and in all forms of media, use, publication, reproduction, distribution, performance, preparation of derivative works, transformation, moral and economic rights of authors, design rights and registered designs and (iii) foreign copyrights and any other rights corresponding thereto throughout the world.

 

“Core Assets” means all rights, interest and title of the Borrower and its Subsidiaries in any Intellectual Property or other proprietary products, services, data or processes that directly relate to Caris Molecular Intelligence or Caris Strategic Data.

 

“Covered Entity” has the same meaning as the term “covered entity” in 45 C.F.R. § 160.103.

 

“Cure Right” is defined in Section 9.4.

 

“Data Processors” means any Third Party service providers, software developers, outsourcers, or others to which Borrower or its Subsidiaries engage and allow access to Personal Data or IT Assets (solely with respect to all Personal Data stored or contained therein or transmitted thereby).

 

-8-

 

 

“Debtor Relief Laws” means the Bankruptcy Code of the United States and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief laws of the United States or other applicable jurisdictions from time to time in effect.

 

“Default” means any Event of Default or any condition, occurrence or event which, after notice or lapse of time or both, would constitute an Event of Default.

 

“Defaulting Lender” means, subject to Section 4.7(b), any Lender that (i) has refused or failed to (a) fund all or any portion of its Loans, which refusal or failure is not cured within one Business Day of the date such Loans were required to be funded hereunder unless such Lender notifies the Administrative Agent and the Borrower in writing that such failure is the result of such Lender’s determination that one or more conditions precedent to funding (each of which conditions precedent, together with any applicable default, shall be specifically identified in such writing) has not been satisfied or waived, or (b) pay to the Administrative Agent or any other Lender any other amount required to be paid by it hereunder within one Business Day of the date when due, (ii) has notified the Borrower or the Administrative Agent in writing that it does not intend to comply with its funding obligations hereunder, or has made a public statement to that effect (unless such writing or public statement relates to such Lender’s obligation to fund a Loan hereunder and states that such position is based on such Lender’s determination that a condition precedent to funding (which condition precedent, together with any applicable default, shall be specifically identified in such writing or public statement) cannot be satisfied), (iii) has failed to confirm in a manner reasonably satisfactory to the Administrative Agent that it will comply with its funding obligations under this Agreement, or (iv) has, or has a direct or indirect parent company that has, (a) become the subject of a proceeding under any Debtor Relief Law, or (b) had appointed for it a receiver, custodian, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its business or assets, including the Federal Deposit Insurance Corporation or any other state or federal regulatory authority acting in such a capacity; provided, a Lender shall not be a Defaulting Lender solely by virtue of the ownership or acquisition of any equity interest in such Lender or any direct or indirect parent company thereof by a Governmental Authority so long as such ownership interest does not result in or provide such Lender with immunity from the jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on its assets or permit such Lender (or such Governmental Authority or instrumentality) to reject, repudiate, disavow or disaffirm any contracts or agreements made with such Lender. Any determination by the Administrative Agent that a Lender is a Defaulting Lender under clauses (i) through (iv) above shall be conclusive and binding absent manifest error, and such Lender shall be deemed to be a Defaulting Lender (subject to Section 4.7(b)) upon delivery of written notice of such determination to the Borrower and each Lender.

 

“Delayed Draw Closing Date” means each (or any) of the First Delayed Draw Closing Date and the Second Delayed Draw Closing Date.

 

-9-

 

 

“Delayed Draw Commitment Amount” as to each Lender, means its obligation to make Delayed Draw Loans to the Borrower pursuant to Section 2.1 in the principal amount equal to such Lender’s Applicable Percentage of Delayed Draw Loans requested by the Borrower in the Loan Request delivered in accordance with Section 2.2. The aggregate principal amount of the Delayed Draw Commitment Amount of all of the Lenders as in effect on the Closing Date (after giving effect to the making of the Initial Loans) is $200,000,000; provided that (i) upon the making of the Delayed Draw Loans on the First Delayed Draw Closing Date, the Delayed Draw Commitment Amount shall be reduced by the aggregate principal amount of Delayed Draw Loans made on such date and (ii) on and subject to the occurrence of the Second Delayed Draw Closing Date, the Delayed Draw Commitment Amount shall be reduced to $0; provided, further, that the Delayed Draw Commitment Amount shall be reduced to $0 pursuant to and in accordance with Section 2.4.

 

“Delayed Draw Commitment Termination Date” means the earliest to occur of (i) the Second Delayed Draw Closing Date or, if the Delayed Draw Commitment Amount is equal to $0 after the First Delayed Draw Closing Date, the First Delayed Draw Closing Date (in either case, immediately after the making of the Delayed Draw Loans on such date), (ii) the Delayed Draw Unavailability Date and (iii) the date upon which the Delayed Draw Commitment Amount is terminated or otherwise reduced to $0 pursuant to and in accordance with Section 2.4(b).

 

“Delayed Draw Loan” is defined in Section 2.1.

 

“Delayed Draw Unavailability Date” means December 31, 2024.

 

“Designated Jurisdiction” means, at any time, a country or territory that is itself the target of comprehensive Sanctions (as of the Closing Date, Cuba, Iran, North Korea, Syria, the Crimea region of Ukraine, the so-called Donetsk People’s Republic, and the so-called Luhansk People’s Republic).

 

“Determination Date” is defined in Section 3.2.

 

“Direct Listing” means, with respect to any Person, the direct listing of such Person’s Capital Securities on the New York Stock Exchange or the NASDAQ Stock Market. Unless otherwise specified, a Direct Listing shall mean a Direct Listing of the Borrower’s Capital Securities.

 

“Disclosing Party” means the Borrower or any of its Subsidiaries that is a Party disclosing Confidential Information.

 

“Disposition” (or similar words such as “Dispose”) means any sale, transfer, lease, license, contribution or other conveyance (including by way of merger) of, or the granting of options, warrants or other rights to, any of the Borrower’s or the Subsidiaries’ assets (including accounts receivable and Capital Securities of Subsidiaries) to any other Person (other than to the Borrower or any of its Subsidiaries) in a single transaction or series of transactions. For the avoidance of doubt, the issuance of any Capital Securities by the Borrower (or by a Subsidiary to the Borrower or another Wholly Owned Subsidiary of the Borrower) shall not constitute a “Disposition” for any purpose under this Agreement.

 

“Disqualified Capital Securities” means any Capital Securities that, by their terms (or by the terms of any security or other Capital Securities into which they are convertible or for which they are exchangeable) or upon the happening of any event or condition, (a) mature or are mandatorily redeemable (other than solely for Qualified Capital Securities), pursuant to a sinking fund obligation or otherwise (except as a result of a Change in Control or asset sale so long as any rights of the holders thereof upon the occurrence of a Change in Control or asset sale event shall be subject to the prior repayment in full of the Loans and all other Obligations that are accrued and payable and the termination of the Commitment), (b) are redeemable at the option of the holder thereof (other than solely for Qualified Capital Securities) (except as a result of a Change in Control or asset sale so long as any rights of the holders thereof upon the occurrence of a Change in Control or asset sale event shall be subject to the prior repayment in full of the Loans and all other Obligations that are accrued and payable and the termination of the Commitment), in whole or in part, (c) provide for the scheduled payment of dividends in cash or (d) are or become convertible into or exchangeable for Indebtedness or any other Capital Securities that would constitute Disqualified Capital Securities, in each case, prior to the date that is ninety-one (91) days after the Maturity Date; provided that if such Capital Securities are issued pursuant to a plan for the benefit of employees of the Borrower or any of its Subsidiaries, or by any such plan to such employees, such Capital Securities shall not constitute Disqualified Capital Securities solely because they may be required to be repurchased by the Borrower or its Subsidiaries in order to satisfy applicable statutory or regulatory obligations.

 

-10-

 

 

“Disqualified Institution” means, on any date, (a)(i) any Company Competitor or (ii) other Person (including any financial institution), in each case identified on the list delivered to the Administrative Agent by the Borrower prior to the Closing Date, (b) any Company Competitor that is designated by the Borrower as a Disqualified Institution by prior notice to the Administrative Agent after the Closing Date and approved by the Required Lenders (such approval not to be unreasonably withheld or delayed) in their sole discretion acting reasonably (such designation will become effective three (3) Business Days after approval by the Required Lenders and will not apply retroactively to disqualify the transfer of, or agreement to transfer, an interest in the Commitments or Loans, as applicable, that was effective prior to the effective date of such supplement), and (c) any Disqualified Institution’s known Affiliates or Affiliates identified in writing to the Administrative Agent from time to time or otherwise readily identifiable as such by name. Notwithstanding the foregoing, in no event will a Bona Fide Lending Affiliate be a Disqualified Institution, unless such Bona Fide Lending Affiliate is explicitly identified under clause (a) of the definition of “Disqualified Institution” above. The Administrative Agent shall not (x) be obligated to ascertain, monitor or inquire as to whether any Lender or participant or prospective Lender or participant is a Disqualified Institution or (y) have any liability with respect to or arising out of any assignment or participation of Loans, or disclosure of Confidential Information, to any Disqualified Institution, except to the extent resulting from the Administrative Agent’s own gross negligence or willful misconduct as determined by a final non-appealable judgment by a court of competent jurisdiction.

 

“Division/Series Transaction” means, with respect to any Person that is a limited liability company organized under the Laws of the State of Delaware, that any such Person (a) divides into two or more Persons (whether or not the original Person survives such division) or (b) creates, or reorganizes into, one or more series, in each case, as contemplated under the Laws of the State of Delaware.

 

“Eligible Assignee” means any Person that meets the requirements to be an assignee under Section 10.10(b)(iii) and (v) (subject to such consents, if any, as may be required under Section 10.10(b)(iii)); provided that no Defaulting Lender or Disqualified Institution shall be an Eligible Assignee (in the case of (x) a Company Competitor that has been designated as a Disqualified Institution under the definition thereof, only to the extent that no Event of Default arising under Section 9.1(a) or Section 9.1(h) has occurred and is continuing at the time of such assignment and (y) any other Disqualified Institution, only to the extent that no Event of Default has occurred and is continuing at the time of such assignment).

 

-11-

 

 

“EMA” means the European Medicines Agency or any successor entity.

 

“Environmental Laws” means all federal, state, local or international laws, statutes, rules, regulations, codes, directives, treaties, requirements, ordinances, orders, decrees, judgments, injunctions, notices or binding agreements issued, promulgated or entered into by any Governmental Authority, relating in any way to the environment, natural resources, Hazardous Material or health and safety matters.

 

“Environmental Liability” means any liability, loss, claim, suit, action, investigation, proceeding, damage, commitment or obligation, contingent or otherwise (including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), of or affecting the Borrower or any Subsidiary directly or indirectly arising from, in connection with or based upon (i) any Environmental Law or Environmental Permit, (ii) the generation, use, handling, transportation, storage, treatment, recycling, presence, disposal, Release or threatened Release of, or exposure to, any Hazardous Materials, or (iii) any contract, agreement, penalty, order, decree, settlement, injunction or other arrangement (including operation of law) pursuant to which liability is assumed, entered into, inherited or imposed with respect to any of the foregoing.

 

“Environmental Permit” is defined in Section 6.7.

 

“ERISA” means the Employee Retirement Income Security Act of 1974, as amended from time to time.

 

“ERISA Affiliate” means, as applied to any Person, (i) any corporation that is a member of a controlled group of corporations within the meaning of section 414(b) of the Code of which that Person is a member, (ii) any trade or business (whether or not incorporated) that is a member of a group of trades or businesses under common control within the meaning of section 414(c) of the Code of which that Person is a member, or (iii) any member of an affiliated service group within the meaning of section 414(m) or 414(o) of the Code of which that Person, any corporation described in clause (i) above or any trade or business described in clause (ii) above is a member.

 

“ERISA Event” means: (a) a “reportable event” within the meaning of Section 4043 of ERISA and the regulations issued thereunder with respect to any Pension Plan (excluding those for which the provision for thirty day notice to the PBGC has been waived by regulation); (b) the failure to meet the minimum funding standard Section 412 or 430 of the Code with respect to any Pension Plan or the failure to make any required contribution (including any installment) to a Multiemployer Plan; (c) the provision by the administrator of any Pension Plan pursuant to Section 4041(a)(2) of ERISA of a notice of intent to terminate such plan in a distress termination described in Section 4041(c) of ERISA; (d) the withdrawal by any Loan Party or any ERISA Affiliate from any Pension Plan with two or more contributing sponsors or the termination of any such Pension Plan resulting in liability to the Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates pursuant to Section 4063 or 4064 of ERISA; (e) the institution by the PBGC of proceedings to terminate any Pension Plan, or the appointment of a trustee to administer any Pension Plan; (f) the imposition of liability on the Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates pursuant to Section 4062(e) or 4069 of ERISA or by application of Section 4212(c) of ERISA; (g) the withdrawal of any ERISA Affiliate in a complete or partial withdrawal (within the meaning of Sections 4203 and 4205 of ERISA) from any Multiemployer Plan; or (h) the imposition of a Lien pursuant to the Code or ERISA on any Loan Party of its Subsidiaries with respect to any Pension Plan or Multiemployer Plan.

 

-12-

 

 

“Erroneous Payment” is defined in Section 11.10(a).

 

“Event of Default” is defined in Section 9.1.

 

“Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

“Excluded Accounts” is defined in Section 7.13.

 

“Excluded Assets” has the meaning set forth in the Security Agreement.

 

“Excluded Subsidiary” means (A) any Foreign Subsidiary or Foreign Subsidiary Holding Company that: (i) does not hold any exclusive right, title or interest in any material Core Asset or any other material Intellectual Property, (ii) does not hold or maintain any material Regulatory Authorization, whether now in effect or hereafter issued by any Regulatory Agency, including any Key Permits received from the FDA, (iii) is not party to any Material Agreement, other than ordinary course contracts or agreements (including leases of or licenses to use real property) that are not material to the business of the Borrower and the Guarantors (taken as a whole), (iv) does not, individually or together with all Excluded Subsidiaries except for Excluded Subsidiaries excluded pursuant to clause (C) of this definition, have cash or Cash Equivalent Investments exceeding $5,000,000 in the aggregate at any time, (v) as of the last day of the most recent Fiscal Quarter for which financial statements have been delivered pursuant to Section 7.1(b) or Section 7.1(c) (or, if prior to the date of the delivery of the first financial statements to be delivered pursuant to Section 7.1(b) or Section 7.1(c), the most recent financial statements referred to in Section 5.6), for the period of four consecutive Fiscal Quarters then ended, individually contributed less than 5.0% of Revenue for such period and, together with all other Excluded Subsidiaries except for Excluded Subsidiaries excluded pursuant to clause (C) of this definition, contributed less than 10.0% of Revenue for such period, and (vi) as of the last day of the most recent Fiscal Quarter for which financial statements have been delivered pursuant to Section 7.1(b) or Section 7.1(c) (or, if prior to the date of the delivery of the first financial statements to be delivered pursuant to Section 7.1(b) or Section 7.1(c), the most recent financial statements referred to in Section 5.6), for the period of four consecutive Fiscal Quarters then ended, individually contributed less than 5.0% of the consolidated total assets of the Borrower and its Subsidiaries for such period, and together with all other Excluded Subsidiaries except for Excluded Subsidiaries excluded pursuant to clause (C) of this definition, contributed less than 10.0% of the consolidated total assets of the Borrower and its Subsidiaries for such period, (B) any other Foreign Subsidiary or Foreign Subsidiary Holding Company if the Borrower in good faith after consulting with its tax or other relevant advisors and subject to the Required Lenders’ consent (not to be unreasonably withheld, conditioned or delayed) determines that the burden or cost (including any adverse tax consequences to the Borrower or any of its Subsidiaries, which are not de minimis) of providing a guarantee by such Foreign Subsidiary or Foreign Subsidiary Holding Company will outweigh the benefits to be obtained by the Lenders therefrom, including by taking into account the overall collateral package under the Loan Documents and the amount of the Loans, (C) any not-for-profit Subsidiary (which as of the Closing Date shall include, for the avoidance of doubt, Caris Molecular Pathology, a Texas not-for-profit corporation), (D) any captive insurance Subsidiary, (E)(i) any newly acquired non-Wholly Owned Subsidiary that is prohibited by its Organic Documents or contractual obligations in existence at the time of acquisition (but not entered into in contemplation thereof) for so long as such prohibition or contractual obligation remains in effect or (ii) any Foreign Subsidiary prohibited by the requirement of any Laws, in each case of the foregoing clauses (i) and (ii) of this clause (E), from guaranteeing, or granting Liens to secure, the Obligations, or if guaranteeing or granting Liens to secure the Obligations would require governmental (including regulatory) consent, approval, license or authorization unless and until such consent, approval, license or authorization has been received, (F) any Subsidiary that is a special purpose vehicle (or similar entity) established and used solely for the purposes of receivables factoring or any other permitted receivables securitization or (G) subject to compliance with Section 7.14(c), Caris Research Institute, Inc.

 

-13-

 

 

“Existing Debt Refinancing” is defined in Section 5.4.

 

“Exit Fee” has the meaning set forth in the Fee Letter.

 

“Family Member” means, with respect to any individual, any other individual having a relationship by blood (to the second degree of consanguinity), marriage, or adoption to such individual.

 

“FATCA” means Sections 1471 through 1474 of the Code, as of the Closing Date (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof and any agreements entered into pursuant to Section 1471(b)(1) of the Code and any fiscal or regulatory legislation, rules, or practices adopted pursuant to any intergovernmental agreement, treaty, or convention among Governmental Authorities and implementing such sections of the Code.

 

“FD&C Act” means the U.S. Federal Food, Drug, and Cosmetic Act (or any successor thereto), as amended from time to time, 21 U.S.C. Section 301 et. seq. and regulations promulgated thereunder.

 

“FDA” means the U.S. Food and Drug Administration and any successor entity.

 

“Federal Funds Rate” means, for any day, the rate per annum equal to the weighted average of the rates on overnight federal funds transactions with members of the Federal Reserve System arranged by federal funds brokers on such day, as published by the Federal Reserve Bank of New York on the Business Day next succeeding such day; provided that if such day is not a Business Day, the Federal Funds Rate for such day shall be such rate on such transactions on the next preceding Business Day as so published on the next succeeding Business Day.

 

“Fee Letter” means the Fee Letter, dated as of the Closing Date, among the Borrower, the Lenders and the Administrative Agent.

 

-14-

 

 

“First Delayed Draw Closing Date” means the first date upon which any Delayed Draw Loans are made hereunder, which shall (i) consist of Delayed Draw Loans in a minimum aggregate principal amount of $100,000,000 and (ii) occur no later than the Delayed Draw Unavailability Date.

 

“Fiscal Quarter” means a quarter ending on the last day of March, June, September or December.

 

“Fiscal Year” means any period of twelve consecutive calendar months ending on December 31; references to a Fiscal Year with a number corresponding to any calendar year (e.g., the “2022 Fiscal Year”) refer to the Fiscal Year ending on December 31 of such calendar year.

 

“Fixture Locations” means (i) the locations set forth in sub-clauses (iii)-(vi) of Section 7.15(b) and (ii) each other owned or leased location of any Loan Party after the Closing Date in which Collateral (other than any Collateral consisting of aircraft) in excess of $10,000,000 is located.

 

“Foreign Lender” means a Lender that is organized under the laws of a jurisdiction outside of the United States.

 

“Foreign Subsidiary” means a Subsidiary of the Borrower that is not organized under the laws of the United States, any state thereof, or the District of Columbia.

 

“Foreign Subsidiary Holding Company” means any Subsidiary that is not a Foreign Subsidiary that owns (directly or through one or more entities that are disregarded for U.S. federal income tax purposes) no material assets other than equity interests of one or more Foreign Subsidiaries that are CFCs.

 

“Fund” means any Person (other than a natural Person) that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its activities.

 

“GAAP” means generally accepted accounting principles in the United States.

 

“GCP” means the Good Clinical Practices that establish the national and international ethical, regulatory and scientific quality standards for designing, conducting, recording and reporting clinical trials that are enforced by the FDA (including 21 CFR Parts 50, 54, 56 and 312) and by comparable foreign Governmental Authorities.

 

“GLP” means the Good Clinical Laboratory Practices and regulatory requirements for or concerning the conduct of nonclinical research that are enforced by the FDA (including 21 CFR Part 58) and by comparable foreign Governmental Authorities.

 

“Governmental Authority” means any national, supranational, federal, state, county, provincial, local, municipal or other government or political subdivision thereof (including any Regulatory Agency), whether domestic or foreign, and any agency, authority, commission, ministry, instrumentality, regulatory body, court, tribunal, arbitrator, central bank or other Person exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to any such government.

 

-15-

 

 

“Governmental Payor” means Medicare, Medicaid, TRICARE, CHAMPVA, any state health plan adopted pursuant to Title XIX or Title XXI of the Social Security Act any other state or federal health care program and any other Governmental Authority which presently or in the future maintains a third party payor program, as well as any fiscal intermediary, contractor or similar claims processing and payment agent acting on behalf of the foregoing programs.

 

“Guarantee” means the guarantee executed and delivered by an Authorized Officer of each Guarantor, substantially in the form of Exhibit D hereto, as amended, supplemented, amended and restated or otherwise modified from time to time.

 

“Guarantors” means each existing and each subsequently acquired or organized Subsidiary (other than any Excluded Subsidiary) that shall have executed the Guarantee pursuant to Section 7.8.

 

“Hazardous Material” means any material, substance, chemical, mixture or waste which is capable of damaging or causing harm to any living organism, the environment or natural resources, including all explosive, special, hazardous, polluting, toxic, industrial, dangerous, biohazardous, medical, infectious or radioactive substances, materials or wastes, noise, odor, electricity or heat, and including petroleum or petroleum products, byproducts or distillates, asbestos or asbestos-containing materials, urea formaldehyde, polychlorinated biphenyls, radon gas, ozone-depleting substances, greenhouse gases, and all other substances or wastes of any nature regulated pursuant to any Environmental Law or as to which any Governmental Authority requires investigation, reporting or remedial action.

 

“Hedging Obligations” means, with respect to any Person, all liabilities of such Person under currency exchange agreements, interest rate swap agreements, interest rate cap agreements and interest rate collar agreements, and all other agreements or arrangements designed to protect such Person against fluctuations in interest rates or currency exchange rates.

 

“herein”, “hereof”, “hereto”, “hereunder” and similar terms contained in any Loan Document refer to such Loan Document as a whole and not to any particular Section, paragraph or provision of such Loan Document.

 

“HIPAA” means, collectively, the Health Insurance Portability and Accountability Act of 1996, Public Law 104-191, as amended by the Health Information Technology for Economic and Clinical Health Act, enacted as Title XIII of the American Recovery and Reinvestment Act of 2009, Public Law 111-5, and their implementing regulations, including but not limited to, the Standards for Privacy of Individually Identifiable Health Information at 45 C.F.R. Parts 160 and 164, Subparts A and E, the Security Standards for the Protection of Electronic Protected Health Information at 45 C.F.R. Parts 160 and 164, Subparts A and C, and the Notification of Breach of Unsecured Protected Health Information requirements at 45 C.F.R. Part 160 and 164, Subparts A and D.

 

“Impermissible Qualification” means any qualification or exception to the opinion or certification of any independent public accountant as to any financial statement of the Borrower or any Subsidiary (i) which is of a “going concern” or similar nature other than any such qualification that is related solely to (I)(A) the occurrence of the Maturity Date as a result of the Loans maturing during such Fiscal Year or (B) the occurrence of any upcoming date where redemption rights in respect of the Series C Preferred Stock and/or Series D Preferred Stock are or may become exercisable or (II) any prospective or actual inability to satisfy any financial maintenance covenant included in the Loan Documents on a future date in a future period, (ii) which relates to the limited scope of examination of matters relevant to such financial statement or (iii) which relates to the treatment or classification of any item in such financial statement and which, as a condition to its removal, would require an adjustment to such item the effect of which would be to cause the Borrower to be in Default.

 

-16-

 

 

“including” and “include” means including without limiting the generality of any description preceding such term, and, for purposes of each Loan Document, the parties hereto agree that the rule of ejusdem generis shall not be applicable to limit a general statement, which is followed by or referable to an enumeration of specific matters, to matters similar to the matters specifically mentioned.

 

“Indebtedness” of any Person means:

 

(a)            all obligations of such Person for borrowed money or advances and all obligations of such Person evidenced by bonds, debentures, notes or similar instruments;

 

(b)            all obligations relative to the face amount of all letters of credit, whether or not drawn, and banker’s acceptances issued for the account of such Person;

 

(c)            all Capitalized Lease Liabilities of such Person, all obligations of such Person arising under Synthetic Leases and all Attributable Debt of such Person;

 

(d)            net Hedging Obligations of such Person to the extent such obligations would appear as a net liability on a balance sheet of such Person (other than in the footnotes) prepared in accordance with GAAP;

 

(e)            all obligations of such Person in respect of Disqualified Capital Securities;

 

(f)            whether or not so included as liabilities in accordance with GAAP, all obligations of such Person to pay the deferred purchase price of property or services, including any earn-outs or other deferred payment obligations in connection with an acquisition (excluding (i) any purchase price adjustment, royalty, earn-out, contingent payment or deferred payment of a similar nature incurred in connection with an acquisition that are paid within 60 days after the conditions to such payment (other than any conditions that are simply the passage of time) are met, and (ii) trade accounts payable in the ordinary course of business that are not overdue for a period of more than 90 days or, if overdue for more than 90 days, as to which a dispute exists and adequate reserves in conformity with GAAP have been established on the books of such Person), and indebtedness secured by (or for which the holder of such indebtedness has an existing right, contingent or otherwise, to be secured by) a Lien on property owned or being acquired by such Person (including indebtedness arising under conditional sales or other title retention agreements), whether or not such indebtedness shall have been assumed by such Person or is limited in recourse; and

 

-17-

 

 

(g)            all Contingent Liabilities of such Person in respect of any of the foregoing.

 

The Indebtedness of any Person shall include the Indebtedness of any other Person (including any partnership in which such Person is a general partner) to the extent such Person is liable therefor as a result of such Person’s ownership interest in or other relationship with such Person, except to the extent the terms of such Indebtedness provide that such Person is not liable therefor. For the avoidance of doubt, Indebtedness shall not include any bona fide royalty obligations payable by a Loan Party or any Subsidiary in respect of any in-license or acquisition of Intellectual Property by any Loan Party or Subsidiary in connection with the Caris Discovery line of business.

 

“Indemnified Liabilities” is defined in Section 10.4.

 

“Indemnified Parties” is defined in Section 10.4.

 

“Infringement” and “Infringes” mean the infringement, misappropriation or other violation of know-how, trade secrets, confidential information, or Intellectual Property.

 

“Initial Commitment Amount” as to each Lender, means its obligation to make Initial Loans to the Borrower on the Closing Date pursuant to Section 2.1 in the principal amount equal to such Lender’s Applicable Percentage of Initial Loans. The aggregate principal amount of the Initial Commitment Amount of all of the Lenders as in effect on the Closing Date is $200,000,000.

 

“Initial Commitment Termination Date” means the Closing Date (immediately after the making of the Initial Loans on such date).

 

“Initial Loan” is defined in Section 2.1.

 

“Insolvency Event” is defined in Section 9.1(h)(iv).

 

“Intellectual Property” means all intellectual property and other proprietary rights of any kind or nature, in any jurisdiction in the world, whether registered or unregistered and whether registrable or not, protected, created or arising under any law, including any and all rights in: (i) Patents; (ii) Trademarks; (iii) Copyrights; (iv) computer software, databases, data, compilations of data, and documentation; (v) Confidential Business Information; and (vi) rights to sue for past, present and future Infringements of any of the foregoing.

 

“Interest Period” means, (a) initially, the period beginning on (and including) the date on which the Initial Loans are made hereunder pursuant to Section 2.3 and ending on (but not including) the last day of such Fiscal Quarter, and (b) thereafter, the period beginning on (and including) the last day of the immediately preceding Fiscal Quarter and ending on the earlier of (x) (but not including) the last day of such succeeding Fiscal Quarter thereafter and (y) (and including) the Maturity Date.

 

“Investment” means, relative to any Person, (i) any loan, advance or extension of credit made by such Person to any other Person, including the purchase by such Person of any bonds, notes, debentures or other debt securities of any other Person, (ii) Contingent Liabilities in favor of any other Person, and (iii) any Capital Securities held by such Person in any other Person. The amount of any Investment shall be the original principal or capital amount thereof less all returns of principal or equity thereon and shall, if made by the transfer or exchange of property other than cash, be deemed to have been made in an original principal or capital amount equal to the fair market value of such property at the time of such Investment.

 

-18-

 

 

“IT Assets” means the computers and other information technology infrastructure and assets used by the Borrower or any of the Subsidiaries in the conduct of their business as currently operated.

 

“Key Permits” means all Permits relating to the Products, including all Regulatory Authorizations.

 

“knowledge” of the Borrower means the knowledge of any executive officer or senior vice president of the Borrower or any Subsidiary.

 

“Laws” means all applicable U.S. federal, state, local or foreign laws, statutes, ordinances, rules, regulations, judgments, orders, injunctions, decrees, arbitration awards issued by any Governmental Authority, including Privacy Laws.

 

“LDT” means a laboratory developed test that is designed, developed, validated and performed by a single clinical laboratory authorized to perform high complexity testing under CLIA. The parties acknowledge that, as of the Closing Date, the FDA’s regulation of LDTs has evolved considerably over time, and that the FDA has not historically required LDTs to be the subject of medical device clearances or approvals, even when the FDA has asserted that the requirements for such premarket review apply as a matter of Law.

 

“Lender” means each Person identified as a “Lender” on the signature pages hereto and its successors and permitted assigns.

 

“Licensed Intellectual Property” means all Intellectual Property that is licensed to, or otherwise authorized for use by, the Borrower or any Subsidiary.

 

“Lien” means any security interest, mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or otherwise), charge against or interest in property, or other priority or preferential arrangement of any kind or nature whatsoever, to secure payment of a debt or performance of an obligation. For the avoidance of doubt, Liens shall not include any bona fide royalty obligations payable by a Loan Party or any Subsidiary in respect of any in-license or acquisition of Intellectual Property by any Loan Party or Subsidiary in connection with the Caris Discovery line of business.

 

“Liquidity” means, at any time, an amount determined by the Borrower equal to the sum of unrestricted cash-on-hand and Cash Equivalent Investments of the Borrower and the Guarantors, and, subject to Section 7.15, to the extent held in a Controlled Account located in the United States.

 

-19-

 

 

“Loan Documents” means, collectively, this Agreement, the Notes, the Security Agreement, the Fee Letter, the Agency Fee Letter, each other agreement pursuant to which the Secured Parties are granted a Lien in the Collateral to secure the Obligations (including any mortgages entered into pursuant to Section 7.8), the Guarantee and each other agreement, certificate, document or instrument expressly delivered in connection with any Loan Document, whether or not specifically mentioned herein or therein. For the avoidance of doubt, neither the Organic Documents nor any shareholders or similar agreement of the Borrower or any Subsidiary shall constitute “Loan Documents”.

 

“Loan Party” means, collectively, the Borrower and the Guarantors.

 

“Loan Request” means a Loan request and certificate duly executed by an Authorized Officer of the Borrower substantially in the form of Exhibit B hereto.

 

“Loans” means the Initial Loan and the Delayed Draw Loans.

 

“Material Adverse Effect” means a material adverse effect on (i) the business, financial condition, operations, performance or properties of the Borrower and the Subsidiaries taken as a whole, (ii) the rights and remedies of the Secured Parties under any Loan Document or (iii) the ability of the Borrower and the Guarantors to perform their Obligations under any Loan Document.

 

“Material Agreements” means (i) the 2023 Convertible Loan Documents, (ii) each contract or agreement to which the Borrower or any Subsidiary is a party involving aggregate payments in the immediately preceding calendar year of more than $15,000,000, whether such payments are being made by the Borrower or any Subsidiary to a non-Affiliated Person, or by a non-Affiliated Person to the Borrower or any Subsidiary, and (iii) all other contracts or agreements the termination of which could reasonably be expected to result in a Material Adverse Effect. Notwithstanding anything contained in this Agreement to the contrary, nothing contained herein shall limit the Borrower or its Subsidiaries’ ability to terminate any Material Agreement (and, for the avoidance of doubt, upon such termination such contract or agreement shall no longer constitute a “Material Agreement” for any purpose under this Agreement and the other Loan Documents).

 

“Material Real Property” means any individual real property in the United States that is owned in fee by any Loan Party with a fair market value (as reasonably determined by the Borrower) in excess of $10,000,000.

 

“Maturity Date” means January 18, 2028.

 

“Moody’s” means Moody’s Investors Service, Inc.

 

“Multiemployer Plan” means a Benefit Plan that is a “multiemployer plan” as defined in Section 4001(a)(3) of ERISA.

 

“Net Asset Sales Proceeds” means, with respect to a Disposition pursuant to Section 8.8(vii) or (xiii) after the Closing Date by the Borrower or any Subsidiary to any Person of any assets of the Borrower or any Subsidiary, the excess of gross cash proceeds received by the Borrower or any Subsidiary from such Disposition in excess of $1,000,000, in each case individually or in the aggregate in any Fiscal Year (in each case net of all reasonable and customary costs and expenses, and including Taxes payable by the recipient of such proceeds, incurred in connection with such Disposition which have not been paid to Affiliates of the Borrower in connection therewith); provided, that so long as (i) the Borrower has delivered Administrative Agent prior written notice of its intention to apply such monies (the “Reinvestment Amounts”) to the costs of purchase of other assets useful in the business of the Borrower and its Subsidiaries and (ii) the Borrower or any Subsidiary completes such purchase within 180 days (or, in the case of a binding commitment in respect of the application of such Reinvestment Amounts within such 180 days, 270 days) after the initial receipt of such monies, the Borrower or any Subsidiary shall have the option to apply such monies to the costs of purchase of other assets useful in the business of the Borrower or such Subsidiary, unless and to the extent that such applicable period shall have expired without such purchase being made or completed, in which case, any amounts remaining shall be paid to Administrative Agent and applied in accordance with Section 3.3.

 

-20-

 

 

“Net Casualty Proceeds” means, with respect to any Casualty Event, the amount of any insurance proceeds or condemnation awards received by the Borrower or any of the Subsidiaries in connection with such Casualty Event, other than proceeds that are used to repair or replace the assets subject to such Casualty Event within 180 days of receipt of such proceeds with respect to such Casualty Event with like or similar assets (or, in the case of a binding commitment in respect of the application of such amounts within such 180 days, 270 days), in excess of $1,000,000 individually or in the aggregate in any Fiscal Year (in each case net of all reasonable and customary collection expenses thereof), but excluding any proceeds or awards required to be paid to a creditor (other than to the Lenders) which holds a first priority Lien permitted by Section 8.3(e) on the property which is the subject of such Casualty Event (it being understood and agreed that the Borrower or such Subsidiary may retain such insurance proceeds or condemnation awards pending such reinvestment).

 

“Non-Defaulting Lender” means, at any time, each Lender that is not a Defaulting Lender at such time.

 

“Non-Excluded Taxes” means any Taxes other than (a) Taxes imposed on or measured by a Person’s net income, and franchise Taxes, in both cases with respect to any Lender and imposed by any Governmental Authority under the laws of which such Lender is organized or in which it maintains its applicable lending office or that are Other Connection Taxes, (b) branch profits taxes imposed by the United States or any similar tax imposed by any other jurisdiction described in clause (a) above, (c) any withholding tax that is imposed by the United States on amounts payable to a Lender at the time such Lender first becomes a party to this Agreement (other than pursuant to an assignment requested by the Borrower under Section 4.3(h)) or designates a new lending office, except to the extent that such Lender’s assignor (or such Lender in case of the designation of a new lending office) was entitled, immediately before the assignment (or designation of a new lending office), to receive additional amounts from the Borrower with respect to such withholding tax pursuant to Section 4.3(a), (d) Taxes attributable to a recipient’s failure to comply with Section 4.3(e), and (e) any withholding Taxes or other amounts imposed or payable under FATCA.

 

“Note” means a promissory note of the Borrower payable to a Lender, in the form of Exhibit A hereto (as such promissory note may be amended, endorsed or otherwise modified from time to time), evidencing the aggregate Indebtedness of the Borrower to such Lender resulting from the outstanding amount of the Loans, and also means all other promissory notes accepted from time to time in substitution therefor or renewal thereof.

 

-21-

 

 

“Obligations” means all obligations (monetary or otherwise, whether absolute or contingent, matured or unmatured) of the Borrower and each Guarantor arising under or in connection with a Loan Document and the principal of and premium, if any, and interest (including interest accruing during the pendency of any proceeding of the type described in Section 9.1(h), whether or not allowed in such proceeding) on the Loans.

 

“OFAC” means the Office of Foreign Assets Control of the United States Department of the Treasury.

 

“OrbiMed” means, collectively, OrbiMed Royalty & Credit Opportunities III, LP and OrbiMed Royalty & Credit Opportunities IV, LP and their respective Affiliates and Approved Funds.

 

“Organic Document” means, relative to the Borrower or any Subsidiary, its certificate of incorporation, by-laws, certificate of partnership, partnership agreement, certificate of formation, limited liability agreement, operating agreement and all shareholder agreements, voting trusts and similar arrangements applicable to the Borrower’s or any Subsidiary’s Capital Securities; provided, that “Organic Documents” shall not include any side letters executed by the Borrower and any of its shareholders.

 

“Other Administrative Proceeding” means any administrative proceeding relating to a dispute involving a patent office, trademark office, copyright office or other relevant intellectual property registry which relates to validity, opposition, revocation, ownership or enforceability of the relevant Intellectual Property.

 

“Other Connection Taxes” means, with respect to any recipient, Taxes imposed as a result of a present or former connection between such recipient and the jurisdiction imposing such Tax (other than connections arising solely from such recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).

 

“Other Taxes” means any and all stamp, documentary or similar Taxes, or any other property Taxes or similar levies that arise on account of any payment made or required to be made under any Loan Document or from the execution, delivery, registration, recording or enforcement of, or otherwise with respect to, any Loan Document (excluding, for the avoidance of doubt, Taxes described in the definition of Non-Excluded Taxes), except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section 4.3(h)).

 

“Outside Counsel” means, in respect of any Lender, such Lender’s outside counsel as may be designated from time to time by such Lender for purposes hereof and the other Loan Documents (including, to the extent applicable, receiving notices and communications hereunder and under the other Loan Documents).

 

-22-

 

 

“Owned Intellectual Property” means all Intellectual Property that is owned (solely or jointly with others) by the Borrower or any Subsidiary.

 

“Parent HoldCo” means a company organized in the United States, any state thereof or in the District of Columbia, that directly or indirectly owns 100% of the Capital Securities of the Borrower as a result of a Parent HoldCo Reorganization and that complies with the requirements under Section 7.16.

 

“Parent HoldCo Reorganization” means any transaction or series of transactions consummated in connection with or in anticipation of a Direct Listing, a Qualified IPO or a Qualified SPAC Transaction in which Borrower becomes a direct or indirect Wholly Owned Subsidiary of Parent HoldCo.

 

“Party” and “Parties” have the meanings set forth in the preamble.

 

“Patent” means any issued national, regional and international patent and any application or invention disclosure therefor (whether provisional applications, non-provisional applications, divisionals, continuations, continuations in-part, and continued prosecution applications), and which for purposes of this Agreement, shall be deemed to include any substitutions, reissues, reexaminations, renewals, extensions, adjustments, restorations, supplemental protection certificates and patent rights in any form in connection therewith, whether in or related to the United States or any foreign country or other jurisdiction.

 

“Patent Security Agreement” means any Patent Security Agreement executed and delivered to the Administrative Agent by the Borrower or any of the Guarantors in substantially the form of Exhibit A to the Security Agreement, as amended, supplemented, amended and restated or otherwise modified from time to time.

 

“Payment Recipient” is defined in Section 11.10(a).

 

“PBGC” means the Pension Benefit Guaranty Corporation or any successor thereto.

 

“Pension Plan” means any Benefit Plan, other than a Multiemployer Plan, which is subject to Section 412 of the Code or Section 302 of ERISA.

 

“Permits” means all permits, licenses, registrations, certificates, orders, approvals, authorizations, consents, clearances, waivers, franchises, variances and similar rights issued by or obtained from any Governmental Authority or any other Person, including, without limitation, those relating to Environmental Laws and Regulatory Authorizations or to clinical laboratory certification or accreditation.

 

“Permitted Acquisition” means the purchase or other acquisition of all of the Capital Securities (other than qualifying directors’ shares) in any, or all or substantially all of the property of, or all or substantially all of any business, business or product line, unit or division of, any Person (other than any joint venture owned by another Person that is purchased or acquired) that, upon the consummation thereof, will be owned by a direct or indirect Wholly Owned Subsidiary of the Borrower (including as a result of a merger or consolidation); provided that, with respect to each Permitted Acquisition:

 

-23-

 

 

(a)            the Borrower and its Subsidiaries (including any newly acquired or acquired Subsidiary in such Permitted Acquisition) shall comply with the requirements of Section 7.8 to the extent required thereunder; provided that the aggregate amount of consideration for all newly-created or acquired Subsidiaries that are Excluded Subsidiaries and all assets acquired in Permitted Acquisition that are not directly owned by one or more Loan Parties and included in the Collateral shall not exceed $20,000,000 in the aggregate (and to be measured without duplication);

 

(b)            the lines of business of the Person to be (or the property of which is to be) so purchased or otherwise acquired shall be permitted pursuant to Section 8.1;

 

(c)            in the case of a purchase or other acquisition of the Capital Securities of another Person, the board of directors (or other comparable governing body) of such other Person shall have duly approved such purchase or other acquisition;

 

(d)            immediately before and after giving effect to any such purchase or other acquisition, no Event of Default, shall exist or result therefrom; provided that, at the Borrower’s election, this clause (d) shall be satisfied if there is no Default or Event of Default in existence at the time of execution and effectiveness of the definitive documentation for such purchase or acquisition, so long as the closing thereof occurs no more than 180 days after the execution and effectiveness of such definitive documentation;

 

(e)            immediately before and after giving effect to any such purchase or other acquisition, the Borrower shall be in pro forma compliance with the financial covenants set forth in Section 8.4; and

 

(f)            the Borrower shall have delivered to the Administrative Agent and the Lenders, at least five (5) Business Days prior to the date on which any such purchase or other acquisition is to be consummated (or such shorter period of time as agreed by the Required Lenders in their reasonable discretion), a written notice describing such transaction, and thereafter, if requested by the Required Lenders for any such individual transaction involving consideration in excess of $15,000,000, to the extent available, (i) historical financial statements of or related to the Person or assets to be acquired (for the avoidance of doubt, no financial statements shall be required with respect to any Person, business or product line, unit or division for which no financial statements are available), (ii) twelve month projections for such Person or assets to be acquired and for the Borrower after giving effect to such transaction, and (iii) material documentation and other information relating to such transaction and reasonably requested by the Required Lenders.

 

“Permitted Call Spread Swap Agreements” means (a) any Swap Agreement (including, but not limited to, any bond hedge transaction or capped call transaction) pursuant to which the Borrower acquires an option requiring the counterparty thereto to deliver to the Borrower shares of common stock of the Borrower, the cash value of such shares or a combination thereof from time to time upon exercise of such option and (b) any Swap Agreement pursuant to which the Borrower issues to the counterparty thereto warrants to acquire common stock of the Borrower (whether such warrant is settled in shares, cash or a combination thereof), in each case of clauses (a) and (b) entered into by the Borrower in connection with the issuance of Post-IPO Convertible Indebtedness; provided that (i) the terms, conditions and covenants of each such Swap Agreement shall be such as are customary for Swap Agreements of such type (as determined by the Borrower in good faith) and (ii) in the case of clause (b) above, such Swap Agreement would be classified as an equity instrument in accordance with GAAP, and the settlement of such Swap Agreement does not require the Borrower to make any payment in cash or cash equivalents that would disqualify such Swap Agreement from so being classified as an equity instrument.

 

-24-

 

 

“Permitted Cure Securities” means the Capital Securities of the Borrower or other equity securities thereof that do not constitute Disqualified Capital Securities that are utilized to cure any breach by the Borrower or any of its Subsidiaries of their obligations under Section 8.4(b) pursuant to Section 9.4.

 

“Permitted Holders” means David D. Halbert, his heirs and other Family Members and any trusts or other holding, investment or estate planning vehicles for the benefit of any of the foregoing and any Controlled Investment Affiliate thereof.

 

“Permitted Receivables Indebtedness” means Indebtedness with respect to an accounts receivables facility; provided that (i) the financing terms, covenants, termination events and other provisions thereof shall be market terms for similar facilities of reasonably similar size, including the provision of a customary “borrowing base” concept, and (ii) such Indebtedness shall not to exceed, in an aggregate amount at any time outstanding (in each case, measured solely at the time of incurrence thereof), the applicable amounts set forth below based on the average Revenue of the Borrower and the Subsidiaries for the two most recently ended Fiscal Quarters for which financial statements have been delivered pursuant to Section 7.1(b) or Section 7.1(c) (or, if prior to the date of the delivery of the first financial statements to be delivered pursuant to Section 7.1(b) or Section 7.1(c), the most recent financial statements referred to in Section 5.6):

 

Revenue (Average) Aggregate Amount of Permitted
Receivables Indebtedness
Less than $25,000,000 per Fiscal Quarter $0
Equal to or greater than $25,000,000 but less than $37,500,000 per Fiscal Quarter $10,000,000
Equal to or greater than $37,500,000 but less than $50,000,000 per Fiscal Quarter $15,000,000
Equal to or greater than $50,000,000 but less than $62,500,000 per Fiscal Quarter $20,000,000
Equal to or greater than $62,500,000 but less than $75,000,000 per Fiscal Quarter $25,000,000
Equal to or greater than $75,000,000 but less than $87,500,000 per Fiscal Quarter $30,000,000
Equal to or greater than $87,500,000 but less than $100,000,000 per Fiscal Quarter $35,000,000
Equal to or greater than $100,000,000 but less than $112,500,000 per Fiscal Quarter $40,000,000
Equal to or greater than $112,500,000 but less than $125,000,000 per Fiscal Quarter $45,000,000
Equal to or greater than $125,000,000 per Fiscal Quarter $50,000,000

 

-25-

 

 

“Permitted Refinancing” means, with respect to any Indebtedness, any extensions, renewals, refinancings and replacements of such Indebtedness; provided that such extension, renewal, refinancing or replacement (a) shall not increase the outstanding principal amount of such Indebtedness, except by an amount equal to unpaid accrued interest and premium (including tender premiums) thereon plus other reasonable amounts paid (including original issue discount and upfront fees), and fees and expenses reasonably incurred, in connection with such renewals, refinancing or replacement and by an amount equal to any existing commitments unutilized thereunder, (b) contains terms (i) relating to outstanding principal amount, amortization, maturity, collateral (if any) and subordination (if any) taken as a whole no less favorable in any material respect to the Borrower and its Subsidiaries or the Secured Parties than such terms of any agreement or instrument governing such existing Indebtedness or (ii) otherwise on customary market terms (taken as a whole as determined by the Borrower in its reasonable judgment), including with respect to high yield debt securities to the extent applicable, (c) [reserved], (d) shall not contain any new requirement to grant any lien or security or to give any guarantee that was not an existing requirement of such Indebtedness, except with respect to any new Subsidiary or assets acquired on or after the date such Indebtedness is incurred that is also Collateral under the Loan Documents, (e) to the extent such modification, extension, renewal, refinancing and replacement concerns Indebtedness that is subordinated in right of payment to the Obligations, shall require that such Indebtedness be subordinated in right of payment to the Obligations on terms at least as favorable to the Lenders as those contained in the documentation governing the Indebtedness being modified, extended, renewed, refinance or replaced, and (f) to the extent such modification, extension, renewal, refinancing and replacement concerns Indebtedness that is subordinated to the Liens securing the Obligations, shall require that such Indebtedness be unsecured or secured by Liens that are subordinated to the Liens securing the Obligations on terms at least as favorable to the Lenders as those contained in the documentation (including any intercreditor or similar agreements) governing the Indebtedness being modified, extended, renewed, refinance or replaced.

 

“Permitted Subordinated Indebtedness” means Indebtedness incurred after the Closing Date by the Borrower or the Subsidiaries that is (i) subordinated to the Obligations and all other Indebtedness owing from the Borrower or the Subsidiaries to the Secured Parties pursuant to a written subordination agreement satisfactory to the Administrative Agent and the Required Lenders in their sole discretion and (ii) in an amount and on terms approved by the Administrative Agent and the Required Lenders in their sole discretion.

 

-26-

 

 

“Person” means any natural person, corporation, limited liability company, partnership, joint venture, association, trust or unincorporated organization, Governmental Authority or any other legal entity, whether acting in an individual, fiduciary or other capacity.

 

“Personal Data” means data that constitutes personal information that identifies a natural person or that is otherwise considered personally identifiable information, personal data, nonpublic personal information or any term substantially equivalent to any of the foregoing under applicable Law, including Protected Health Information.

 

“Plan Asset Regulation” means 29 C.F.R. §2510.3-101, as modified by Section 3(42) of ERISA.

 

“Plan Assets” means “plan assets” as defined in the Plan Asset Regulation.

 

“Platform” is defined in Section 10.2(c).

 

“Post-IPO Convertible Indebtedness” means Indebtedness that is convertible at the option of the holders thereof into common stock of the Borrower incurred by the Borrower after the occurrence of a Qualified Direct Listing Event or the consummation of a Qualified IPO or Qualified SPAC Transaction in an aggregate amount not to exceed the product of (x) the Revenue Base for the most recently ended Test Period and (y) 1.75; provided, however, that (a) such Indebtedness shall be unsecured, (b) such Indebtedness shall not be guaranteed by any Subsidiary of the Borrower, (c) such Indebtedness shall bear interest at a rate per annum as is customary in the market for public companies at such time, as determined by the Borrower in its reasonable commercial judgment, (d) such Indebtedness shall not include covenants and defaults (other than covenants and defaults customary for convertible indebtedness but not customary for loans for public company issuers, as determined by the Borrower in its good faith judgment) that are, taken as a whole, more restrictive on the Loan Parties than the provisions of this Agreement (as determined by the Borrower in its good faith judgment), (e) immediately prior to and after giving effect to the incurrence of such Indebtedness, no Event of Default shall have occurred and be continuing or could reasonably be expected to occur as a result therefrom and (f) such Indebtedness shall not (i) mature or be mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, (ii) be redeemable at the option of the holder thereof, in whole or in part or (iii) provide for the scheduled payment of dividends or distributions (other than scheduled cash interest payments) in cash, in each case of the foregoing sub-clauses (i), (ii) and (iii), prior to the date that is 6 months after the Maturity Date (it being understood, for the avoidance of doubt, that (w) a redemption right of the Borrower in respect of such Indebtedness, (x) conversion rights of holders in respect of such Indebtedness, (y) acceleration rights of holders of such Indebtedness upon the occurrence of an event of default specified in the agreement governing such Indebtedness and (z) the obligation to pay customary amounts to holders of such Indebtedness in connection with an asset disposition, casualty event, “change of control” or “fundamental change”, in each case, shall not be considered in connection with the determination of scheduled maturity date for purposes of this clause (f)).

 

-27-

 

 

“Prime Rate” means (a) the rate of interest last quoted by The Wall Street Journal as the “Prime Rate” in the U.S. or, if The Wall Street Journal ceases to quote such rate, the per annum interest rate published by the Federal Reserve Board in Federal Reserve Statistical Release H.15 (519) (Selected Interest Rates) as the “bank prime loan” rate or, if such rate is no longer quoted therein, any similar rate quoted therein (as determined by the Administrative Agent) or any similar release by the Federal Reserve Board (as determined by the Administrative Agent), minus (b) 1.00%; provided that if the Prime Rate shall be less than 2.50%, such rate shall be deemed to be 2.50% for the purposes of this Agreement.

 

“Privacy Laws” mean each Law applicable to privacy and the protection and security of Personal Data, including HIPAA, Laws related to localization of Personal Data, Laws related to online behavioral advertising, Laws related to consumer privacy with respect to direct marketing such as the Telephone Consumer Protection Act (TCPA) and CAN-SPAM, and rules under the Payment Card Industry Data Security Standards, in each case, solely to the extent applicable to the business of the Borrower or its Subsidiaries.

 

“Product” means (i) Caris Molecular Intelligence, (ii) Caris Discovery (it being understood and agreed that any targets developed by the Loan Parties within the Caris Discovery line of business and licensed to a third party (to the extent not otherwise commercialized or developed by any Loan Party) as permitted by and in accordance with this Agreement will not be considered to be Products), (iii) Caris Strategic Data and (iv) any current or future service or product (including LDTs and software products and services and data products and services) researched, designed, developed, manufactured, licensed, marketed, offered, sold, performed, distributed or otherwise commercialized by the Loan Parties and their Subsidiaries, including any such product in development or which may be developed.

 

“Product Authorizations” means any and all approvals, exemptions, licenses, notifications, registrations, listings, clearances or authorizations or other Permits granted by, submitted to, obtained from or filed with any Governmental Authority necessary for the testing, manufacture, performing, marketing, or sale of a Product in any country or jurisdiction.

 

“Product Development and Commercialization Activities” means, with respect to any Product, any combination of research, development, manufacture, import, use, sale, importation, storage, labeling, marketing, promotion, supply, distribution, testing, packaging, purchasing or other commercialization activities, receipt of payment in respect of any of the foregoing, or like activities the purpose of which is to commercially exploit such Product.

 

“Protected Health Information” has the same meaning as “protected health information” in 45 C.F.R. § 160.103.

 

“Public Lender” has the meaning set forth in Section 7.1.

 

“Purchase Money Indebtedness” means Indebtedness incurred to finance the acquisition, repair, replacement, construction or improvement of fixed or capital assets, where the amount of such Indebtedness does not exceed the greater of (a) the cost of the assets being financed and the cost of such repair, replacement, construction or improvement, as applicable, and (b) the fair market value of such assets; provided, however, that such Indebtedness is incurred concurrently with or within one-hundred and eighty days after or prior to such acquisition, repair, replacement, construction or improvement of the applicable assets.

 

-28-

 

 

“Qualified Capital Securities” means any Capital Securities that are not Disqualified Capital Securities.

 

“Qualified Direct Listing Event” means the time after a Direct Listing at which the issuance of Capital Securities of the Borrower after the Direct Listing has generated gross cash proceeds of at least $100,000,000 to the Borrower.

 

“Qualified IPO” has the meaning assigned to such term in the Borrower’s Charter.

 

“Qualified SPAC Transaction” has the meaning assigned to such term in the Borrower’s Charter.

 

“Receiving Party” means any Lender that is a Party receiving Confidential Information.

 

“Recipient” is defined in Section 10.14.

 

“Register” is defined in Section 10.10(c).

 

“Regulatory Agencies” means any Governmental Authority that is concerned with the use, control, safety, efficacy, reliability, manufacturing, testing, marketing, distribution, sale or other Product Development and Commercialization Activities relating to any Product of the Borrower or any of the Subsidiaries, including CMS, FDA, and all similar agencies in other jurisdictions, including non-United States jurisdictions.

 

“Regulatory Authorizations” means all approvals, clearances, notifications, authorizations, orders, exemptions, registrations, listings, certifications, licenses and Permits granted by, submitted to, obtained from, or filed with any Regulatory Agencies, including all Product Authorizations.

 

“Reinvestment Amounts” has the meaning assigned to such term in the definition of “Net Asset Sales Proceeds”.

 

“Related Parties” means the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of the Borrower and the Subsidiaries.

 

“Release” means any releasing, disposing, discharging, injecting, spilling, leaking, leaching, pumping, pouring, dumping, depositing, emitting, escaping, emptying, seeping, dispersal, migrating or placing, including movement through, into or upon the environment or any natural or man-made structure.

 

“Repayment Premium” has the meaning set forth in the Fee Letter.

 

“Required Lenders” means Non-Defaulting Lenders having Total Credit Exposures representing more than 50% of the Total Credit Exposures of all Non-Defaulting Lenders; provided, to the extent there are any Significant Lenders, “Required Lenders” shall also include each Significant Lender.

 

 

-29-

 

 

“Required Revenue” is defined in Section 8.4(b).

 

“Restricted Payment” means (i) the declaration or payment of any dividend on, or the making of any payment or distribution on account of, or setting apart assets for a sinking or other analogous fund for the purchase, redemption, defeasance, retirement or other acquisition of, any class of Capital Securities of the Borrower or any Subsidiary or any warrants, options or other right or obligation to purchase or acquire any such Capital Securities, whether now or hereafter outstanding, (ii) the making of any other distribution in respect of such Capital Securities, in each case either directly or indirectly, whether in cash, property or obligations of the Borrower or any Subsidiary or otherwise or (iii) the payment of any management fees, transaction fees, expense reimbursement or other indemnities to any holder (or Affiliate thereof) of the Capital Securities of the Borrower or any Subsidiary or any warrants, options or other right or obligation to purchase or acquire any such Capital Securities in respect of such Capital Securities or in respect of management, sponsoring, structuring, arranging or other services. Notwithstanding the foregoing, and for the avoidance of doubt, (i) the conversion of (including any cash payment or fractional shares upon conversion), or payment of any principal or premium on, or payment of any interest with respect to, the 2023 Convertible Loans, any Post-IPO Convertible Indebtedness or other permitted convertible Indebtedness under this Agreement shall not constitute a Restricted Payment and (ii) any payment with respect to, or early unwind or settlement of, any Permitted Call Spread Swap Agreement shall not constitute a Restricted Payment.

 

“Revenue” means total consolidated revenue of the Borrower and its Subsidiaries, as determined in accordance with GAAP. Revenue shall be determined in a manner consistent with the methodologies, practices and procedures used in developing the Borrower’s audited financial statements.

 

“Revenue Base” means, with respect to any period, the Revenues for such period.

 

“Revenue Deficiency” means, for any Test Period, the amount by which the Required Revenue for the trailing four quarter period ending on the last day of the applicable Test Period exceeds the Revenue Base for such trailing four quarter period ending on the last day of such Test Period.

 

“S&P” means S&P Global Ratings, a S&P Financial Services LLC business, and any successor thereto.

 

“Sale/Leaseback Transaction” is defined in Section 8.12.

 

“Sanctions” means any international economic sanction administered or enforced by the United States Government (including, without limitation, OFAC), the United Nations Security Council, the European Union or His Majesty’s Treasury.

 

“SEC” means the United States Securities and Exchange Commission.

 

- 30 -

 

 

“Second Delayed Draw Closing Date” means the second date upon which Delayed Draw Loans are made hereunder, which shall (i) occur after and subject the occurrence of the First Delayed Draw Closing Date (so long as the Delayed Draw Commitment Amount is greater than $0 after the making of the Delayed Draw Loans on the First Delayed Draw Closing Date), (ii) consist of Delayed Draw Loans in a minimum aggregate principal amount equal to the Delayed Draw Commitment Amount outstanding after the First Delayed Draw Closing Date and (iii) occur no later than the Delayed Draw Unavailability Date.

 

“Secured Parties” means the Lenders and the Administrative Agent.

 

“Security Agreement” means the Pledge and Security Agreement executed and delivered by each of the parties thereto, substantially in the form of Exhibit E hereto, as amended, supplemented, amended and restated or otherwise modified from time to time.

 

“Series C Preferred Stock” means the Series C Preferred Stock of the Borrower issued pursuant to the Borrower’s Charter.

 

“Series D Preferred Stock” means the Series D Preferred Stock of the Borrower issued pursuant to the Borrower’s Charter.

 

“Significant Lender” means (x) OrbiMed (in its capacity as a Lender hereunder), so long as (i) OrbiMed is a Non-Defaulting Lender and (ii) OrbiMed’s Total Credit Exposure represents more than 33.33% of the Total Credit Exposures of all Non-Defaulting Lenders and (y) Braidwell (in its capacity as a Lender hereunder), so long as (i) Braidwell is a Non-Defaulting Lender and (ii) Braidwell’s Total Credit Exposure represents more than 33.33% of the Total Credit Exposures of all Non-Defaulting Lenders.

 

“Sixth Street Entity” means each of Sixth Street Specialty Lending, Inc., TAO Barnett Investments, LLC, TOP III Barnett Investments, LLC, Barnett Equity Holdings, LLC, Barnett Equity Holdings II, LLC, and any Affiliate of each of the foregoing.

 

“SOFR Administrator” means the CME Group Benchmark Administration Limited (CBA) (or a successor administrator of the secured overnight financing rate).

 

“SOFR Administrator’s Website” means the website of the SOFR Administrator, currently at https://www.cmegroup.com/market-data/cme-group-benchmark-administration.html, or any successor source for the secured overnight financing rate identified as such by the SOFR Administrator from time to time.

 

“SOFR Rate” means, for any Interest Period, the forward-looking three-month term rate based on the secured overnight financing rate on the day (such day, the “SOFR Rate Determination Date”) that is two (2) Business Days prior to the first day of any Interest Period, with the rate, or methodology for this rate, and conventions for this rate being established by the Administrative Agent in accordance with the “3 Month CME Term SOFR” published on the SOFR Administrator’s Website (as calculated by the Administrative Agent and rounded upwards, if necessary, to the nearest 1/1,000 of 1%); provided that if as of 5:00 p.m. (New York City time) on any SOFR Rate Determination Date, such 3 Month CME Term SOFR has not been published on the SOFR Administrator’s Website, then the SOFR Rate for the related Interest Period will be the 3 Month CME Term SOFR as published on the SOFR Administrator’s Website on the first preceding Business Day for which 3 Month CME Term SOFR was published on the SOFR Administrator’s Website so long as such first preceding Business Day is not more than three (3) Business Days prior to such SOFR Rate Determination Date.

 

- 31 -

 

 

“SOFR Rate Determination Date” is defined within the definition of “SOFR Rate”.

 

“Solvent” and “Solvency” mean, with respect to any Person on a particular date, that on such date (i) the fair value of the property of such Person is greater than the total amount of liabilities, including Contingent Liabilities, of such Person, (ii) the present fair saleable value of the assets of such Person is not less than the amount that will be required to pay the probable liability of such Person on its debts as they become absolute and matured, (iii) such Person does not intend to, and does not believe that it will, incur debts or liabilities beyond its ability to pay as such debts and liabilities mature, (iv) such Person is not engaged in a business or a transaction, and is not about to engage in a business or a transaction, for which the property of such Person would constitute an unreasonably small capital and (v) such Person has not executed this Agreement or any other Loan Document, or made any transfer or incurred any Obligations hereunder or thereunder, with actual intent to hinder, delay or defraud either present or future creditors. The amount of Contingent Liabilities at any time shall be computed as the amount that, in light of all the facts and circumstances existing at such time, would reasonably be expected to become an actual or matured liability.

 

“Specified Events of Default” means an Event of Default arising under Section 9.1(a) or Section 9.1(h) or an Event of Default arising under Section 9.1(c) solely due to the Loan Parties’ default in the due performance or observance of any of its obligations under Section 8.4.

 

“Specified Letter” means that certain letter agreement, dated as of the Closing Date, by and among the Borrower, Sixth Street Specialty Lending, Inc., Barnett Equity Holdings, LLC, Barnett Equity Holdings II, LLC and SH Caris Life US, LLC.

 

“Subsidiary” means, with respect to any Person, any other Person of which more than 50% of the outstanding Voting Securities of such other Person (irrespective of whether at the time Capital Securities of any other class or classes of such other Person shall or might have voting power upon the occurrence of any contingency) is at the time directly or indirectly owned or controlled by such Person, by such Person and one or more other Subsidiaries of such Person, or by one or more other Subsidiaries of such Person. Unless the context otherwise specifically requires, the term “Subsidiary” shall be a reference to a Subsidiary of the Borrower.

 

“Swap Agreement” means any agreement with respect to any swap, forward, spot, future, credit default or derivative transaction or option or similar agreement involving, or settled by reference to, one or more rates, currencies, commodities, equity or debt instruments or securities, or economic, financial or pricing indices or measures of economic, financial or pricing risk or value or any similar transaction or any combination of these transactions; provided that no phantom stock or similar plan providing for payments only on account of services provided by current or former directors, officers, employees or consultants of the Borrower or the Subsidiaries shall be a Swap Agreement.

 

- 32 -

 

 

“Synthetic Lease” means, as applied to any Person, any lease (including leases that may be terminated by the lessee at any time) of any property (whether real, personal or mixed) (i) that is not a finance lease in accordance with GAAP and (ii) in respect of which the lessee retains or obtains ownership of the property so leased for federal income tax purposes, other than any such lease under which that Person is the lessor.

  

“Taxes” means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.

 

“Termination Date” means the date on which all Obligations (other than contingent indemnification and expense reimbursement obligations for which no claim has been made) have been paid in full in cash and all of the Commitments shall have terminated.

 

“Test Period” in effect at any time means the most recent period of four consecutive Fiscal Quarters of the Borrower ended on or prior to such time (taken as one accounting period) in respect of which financial statements for each Fiscal Quarter or Fiscal Year in such period have been or are required to be delivered pursuant to Section 7.1(b) or (c), as applicable; provided that, prior to the first date that financial statements have been or are required to be delivered pursuant to Section 7.1(b) or (c), the Test Period in effect shall be the period of four consecutive fiscal quarters of the Borrower ended September 30, 2022.

 

“Third Party” means any Person other than the Borrower or any of its Subsidiaries.

 

“Total Credit Exposure” means, as to any Lender on any date, (i) the aggregate outstanding principal amount of the Loans of such Lender after giving effect to any borrowings and prepayments or repayments of any Loans occurring on such date, plus (ii) the unfunded amount of such Lender’s Commitments that remains outstanding under this Agreement.

 

“Trademark” means any trademark, service mark, trade name, logo, symbol, trade dress, domain name, corporate name or other indicator of source or origin, and all applications, registrations and renewals therefor, together with all of the goodwill associated therewith.

 

“Trademark Security Agreement” means any Trademark Security Agreement executed and delivered to the Administrative Agent by the Borrower or any of the Guarantors substantially in the form of Exhibit B to any Security Agreement, as amended, supplemented, amended and restated or otherwise modified from time to time.

 

“UCC” means the Uniform Commercial Code as in effect from time to time in the State of New York; provided that, if, with respect to any financing statement or by reason of any provisions of law, the perfection or the effect of perfection or non-perfection of the security interests granted to any Secured Party pursuant to the applicable Loan Document is governed by the Uniform Commercial Code as in effect in a jurisdiction of the United States other than New York, then “UCC” means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions of each Loan Document and any financing statement relating to such perfection or effect of perfection or non-perfection.

 

“Undrawn Fee” is defined in Section 3.9.

 

- 33 -

 

 

“United States” or “U.S.” means the United States of America, its fifty states and the District of Columbia.

  

“Voting Securities” means, with respect to any Person, Capital Securities of any class or kind ordinarily having the power to vote for the election of directors, managers or other voting members of the governing body of such Person.

 

“Warrants” means, collectively, (a) Caris Life Sciences, Ltd. Warrant to Purchase Ordinary Shares, dated September 21, 2018, by and between the Borrower (f/k/a Caris Life Sciences, Ltd.) and Barnett Equity Holdings, LLC, as amended by (i) that certain Amendment of Warrant, dated as of April 2, 2020, by and between the Borrower (f/k/a Caris Life Sciences, Ltd.) and Barnett Equity Holdings, LLC and (ii) that certain Omnibus Amendment of Warrants, by and among the Borrower (as successor to Caris Life Sciences, LLC), Barnett Equity Holdings, LLC and Sixth Street Specialty Lending, Inc. (f/k/a TPG Specialty Lending, Inc.) (“SSSL”), dated as of August 4, 2020 (the “Omnibus Amendment”); (b) Caris Life Sciences, Ltd. Warrant to Purchase Ordinary Shares, dated September 21, 2018, by and between the Borrower (f/k/a Caris Life Sciences, Ltd.) and SSSL, as amended by (i) that certain Amendment of Warrant, dated as of April 2, 2020, by and between the Borrower (f/k/a Caris Life Sciences, Ltd.), and SSSL and (ii) the Omnibus Amendment; (c) Caris Life Sciences, Ltd. Warrant to Purchase Shares, issued April 2, 2020 by the Borrower (f/k/a Caris Life Sciences, Ltd.) to Barnett Equity Holdings, LLC, as amended by the Omnibus Amendment; and (d) Caris Life Sciences, Ltd. Warrant to Purchase Shares, issued April 2, 2020 by the Borrower (f/k/a Caris Life Sciences, Ltd.) to SSSL, as amended by the Omnibus Amendment, in each case of the foregoing clauses (a) through (d), as in effect on the Closing Date and as may be amended, restated, amended and restated, supplemented or otherwise modified from time to time after the Closing Date to the extent permitted by Section 8.9(a).

 

“Wholly Owned Subsidiary” means any direct or indirect Subsidiaries of the Borrower, all of the outstanding Capital Securities of which (other than any director’s qualifying shares or investments by foreign nationals mandated by applicable laws) is owned directly or indirectly by the Borrower.

 

SECTION 1.2 Use of Defined Terms. Unless otherwise defined or the context otherwise requires, terms for which meanings are provided in this Agreement shall have such meanings when used in each other Loan Document and the schedules attached hereto.

 

SECTION 1.3 Cross-References. Unless otherwise specified, references in a Loan Document to any Article or Section are references to such Article or Section of such Loan Document, and references in any Article, Section or definition to any clause are references to such clause of such Article, Section or definition.

 

SECTION 1.4 Accounting and Financial Determinations. Unless otherwise specified, all accounting terms used in each Loan Document shall be interpreted, and all accounting determinations and computations thereunder (including under Section 8.4 and the definitions used in such calculations) shall be made, in accordance with GAAP, as in effect from time to time; provided that, if either the Borrower or the Required Lenders request an amendment to any provision hereof to eliminate the effect of any change occurring after the Closing Date in GAAP or the application thereof on the operation of such provision, regardless of whether any such notice is given before or after such change in GAAP or the application thereof, then such provision shall be interpreted on the basis of GAAP in effect and applied immediately before such change shall have become effective until such request shall have been withdrawn or such provision amended in accordance herewith. Unless otherwise expressly provided, all financial covenants and defined financial terms shall be computed on a consolidated basis for the Borrower and the Subsidiaries, in each case without duplication.

 

- 34 -

 

 

SECTION 1.5 Other Interpretive Provisions. Except as otherwise specified or limited herein, references to any Person include the permitted successors and assigns of such Person. References “from” or “through” any date mean, unless otherwise specified, “from and including” or “through and including”, respectively. References to any statute or act shall include all related current regulations and all amendments and any successor statutes, acts and regulations. References to any agreement, instrument or document shall include all schedules, exhibits, annexes and other attachments thereto. References to capitalized terms that are not defined herein, but are defined in the UCC, shall have the meanings given them in the UCC.

 

ARTICLE II
COMMITMENT AND BORROWING PROCEDURES

 

SECTION 2.1 Commitment. On the terms and subject to the conditions of this Agreement, each Lender severally agrees to make its portion of a term loan (the “Initial Loan”) to the Borrower on the Closing Date in an amount equal to (but not less than) the Initial Commitment Amount. On the terms and subject to the conditions of this Agreement, each Lender agrees to make its portion of term loans (the “Delayed Draw Loans”) to the Borrower (i) on the First Delayed Draw Closing Date in the aggregate amount set forth on the Loan Request delivered pursuant to Section 2.2 below (which aggregate amount must be in an amount (A) equal to or greater than $100,000,000 (and an integral multiple of $50,000,000 in excess thereof) and (B) not to exceed the Delayed Draw Commitment Amount) and (ii) on the Second Delayed Draw Closing Date in the aggregate amount set forth on the Loan Request delivered pursuant to Section 2.2 below (which aggregate amount must be in an amount equal to the remaining Delayed Draw Commitment Amount); provided that (i) upon the funding of the Delayed Draw Loans on the First Delayed Draw Closing Date, the Delayed Draw Commitment Amount shall be reduced by the aggregate principal amount of Delayed Draw Loans made on such date and (ii) upon the funding of the Delayed Draw Loans on the Second Delayed Draw Closing Date, the Delayed Draw Commitment Amount shall be reduced to $0. No amounts paid or prepaid with respect to the Loans may be reborrowed.

 

SECTION 2.2 Borrowing Procedure. The Borrower may irrevocably request that the Initial Loans be made by delivering to the Administrative Agent a Loan Request on or before 11:00 a.m. (New York City time) on a Business Day at least three (3) Business Days prior to the proposed Closing Date (or such shorter period as the Administrative Agent and the Required Lenders may agree in their discretion). The Borrower may irrevocably request that the Delayed Draw Loans be made by delivering to the Administrative Agent a Loan Request on or before 11:00 a.m. (New York City time) on a Business Day at least twelve (12) Business Days (or such shorter period as the Administrative Agent and each Lender may agree in their sole discretion) prior to the proposed Delayed Draw Closing Date.

 

- 35 -

 

 

SECTION 2.3 Funding. After receipt of the Loan Request in accordance with Section 2.2 for the Initial Loans, the Administrative Agent shall promptly notify each Lender of the amount of such Lender’s portion of the Initial Loans. Each Lender shall, on the Closing Date, and subject to the terms and conditions hereof, make the requested proceeds of such Lender’s portion of the Initial Loans available to or as instructed by the Administrative Agent. After receipt of the Loan Request in accordance with Section 2.2 for the Delayed Draw Loans, the Administrative Agent shall promptly notify each Lender of the amount of such Lender’s portion of the Delayed Draw Loans requested pursuant to such Loan Request and subject to the terms and conditions hereof. Each Lender shall, on the applicable Delayed Draw Closing Date, and subject to the terms and conditions hereof, make the requested proceeds of such Lender’s portion of the Delayed Draw Loans requested pursuant to such Loan Request available to or as instructed by the Administrative Agent. Upon satisfaction or waiver of the applicable conditions set forth in Article V, in each case, the Administrative Agent shall make all funds so received available to the Borrower by wire transfer to the account the Borrower shall have specified in its applicable Loan Request in an amount equal to (but not less than) the Lenders’ applicable Commitment Amount. It is understood that (i) no Lender shall be responsible for any default by any other Lender in its obligation to make Loans hereunder and that each Lender severally but not jointly shall be obligated to make the Loans provided to be made by it hereunder, regardless of the failure of any other Lender to fulfill its commitments hereunder and (ii) other than as expressly provided herein with respect to a Defaulting Lender, failure by a Lender to perform any of its obligations under any of the Loan Documents shall not release any Person from performance of its obligation under any Loan Document.

  

SECTION 2.4 Reduction of the Commitment Amounts.

 

(a)            Mandatory. The Initial Commitment Amount shall automatically and permanently be reduced to zero on the Initial Commitment Termination Date (immediately after the making of the Initial Loan on such date). The Delayed Draw Commitment Amount shall automatically and permanently be reduced to zero on the Delayed Draw Commitment Termination Date.

 

(b)            Optional. The Borrower may, upon written notice to the Administrative Agent at least five (5) Business Days (or such shorter period as the Administrative Agent and the Required Lenders may agree in their sole discretion) prior to the date of termination, terminate the unused Delayed Draw Commitment Amount.

 

ARTICLE III
REPAYMENTS, PREPAYMENTS, INTEREST AND FEES

 

SECTION 3.1 Repayments and Prepayments. The Borrower agrees that the Loans, and any fees or interest accrued or accruing thereon, shall be repaid and prepaid solely in U.S. dollars pursuant to the terms of this Article III.

 

SECTION 3.2 Amortization; Repayments and Prepayments. On the earlier to occur of (x) for dates prior to January 1, 2026, any date that the redemption rights in respect of the Series C Preferred Stock or the Series D Preferred Stock are or may become exercisable within 90 days following such date, or (y) January 1, 2026 or the first date thereafter if, as of such date, the redemption rights in respect of the Series C Preferred Stock or the Series D Preferred Stock are or may become exercisable on or prior to the date that is 6 months after the Maturity Date (such earlier applicable date (if any) or, if such day is not a Business Day, the next succeeding Business Day, the “Determination Date”), the Borrower shall provide written notice to the Administrative Agent at least five (5) Business Days prior to the likely occurrence of the Determination Date and, on the Determination Date, make a one-time amortization payment in an amount equal to 15% of the outstanding principal amount of the Loans outstanding on the Determination Date, together with the applicable Repayment Premium and Exit Fee. Following the occurrence of a Determination Date, commencing with the first full Fiscal Quarter following such Determination Date and ending on the Amortization Termination Date (as defined below), the Borrower shall repay the outstanding principal amount of the Loans on the last day of each Fiscal Quarter (provided that if such day is not a Business Day, then such repayment shall be made on the next succeeding Business Day), in equal quarterly installments equal to 2.5% of the outstanding principal balance of the Loan on the applicable Determination Date, together with the applicable Repayment Premium and Exit Fee, unless sooner required to be repaid pursuant to the terms of this Agreement. “Amortization Termination Date” shall mean the earliest to occur of (A) the Maturity Date, (B) the waiver or amendment of the terms of the Series C Preferred Stock and the Series D Preferred Stock to cause the put rights thereunder to not be exercisable on or prior to the date that is 6 months after the Maturity Date, (C) the redemption in full of all of the outstanding Series C Preferred Stock and the Series D Preferred Stock and (D) the conversion of all of the outstanding Series C Preferred Stock and Series D Preferred Stock into common stock of the Borrower.

 

- 36 -

 

 

The Borrower shall also repay in full the unpaid principal amount of the Loans on the Maturity Date; provided that, at any time prior to the Maturity Date, payments and prepayments of the Loans shall also be made as set forth below:

 

(a)            The Borrower shall have the right, with at least three (3) Business Days’ (or such shorter period as the Administrative Agent and the Required Lenders may agree in their sole discretion) notice to the Administrative Agent, at any time and from time to time to prepay any unpaid principal amount of the Loans, in whole or in part, together with the applicable Repayment Premium and the Exit Fee.

 

(b)            Within three Business Days of receipt by the Borrower or any Subsidiary of any (i) Net Casualty Proceeds or (ii) Net Asset Sales Proceeds, the Borrower shall notify the Administrative Agent thereof. The Borrower shall within three (3) Business Days of such notice make a mandatory prepayment of the Loans (provided that a Lender may elect to waive such prepayment with respect to its Loans upon written notice to the Borrower and the Administrative Agent prior to the required prepayment date) in an amount equal to 100% of such proceeds (or such lesser amount as the Required Lenders may specify on the date of such request), in each case, together with the applicable Repayment Premium and the Exit Fee, to be applied as set forth in Section 3.3.

 

(c)            The Borrower shall repay the Loans in full immediately upon any acceleration of the Maturity Date thereof pursuant to Section 9.2 or Section 9.3, unless, pursuant to Section 9.3, only a portion of the Loans is so accelerated (in which case the portion so accelerated shall be so repaid), in each case together with the applicable Repayment Premium and the Exit Fee.

 

- 37 -

 

 

SECTION 3.3 Application. Amounts repaid or prepaid in respect of the outstanding principal amount of the Loans pursuant to clauses (a), (b) or (c) of Section 3.2 shall be applied first (and subject to the occurrence of a Determination Date), pro rata among the remaining principal payments due in respect of the Loans (if any), and thereafter, pro rata to the Initial Loan and the Delayed Draw Loan.

 

SECTION 3.4 Interest Rate.

 

(a)            During each Interest Period, interest payable in cash by the Borrower shall accrue on the Loans during such Interest Period at a rate per annum equal to the greater of (x) the SOFR Rate for such Interest Period and (y) 2.50%, plus, in either case, the Applicable Margin.

 

(b)            The interest rate shall be recalculated and, if necessary, adjusted for each Interest Period, in each case pursuant to the terms hereof.

 

SECTION 3.5 Default Rate. At all times commencing upon the date any Event of Default occurs, and continuing until such Event of Default is no longer continuing, at the election of the Required Lenders (except to the extent provided below), the Applicable Margin shall be increased by 3.00% per annum (with such increase applied from and after the date on which such Event of Default initially occurred); provided, that no election or notice of the imposition of the default rate specified in this Section 3.5 shall be required in the case of any Specified Event of Default.

 

SECTION 3.6 Payment Dates. Interest accrued on the Loans shall be payable in cash, without duplication:

 

(a)            on the Maturity Date therefor;

 

(b)            on the date of any payment or prepayment, in whole or in part, of principal outstanding on such Loan on the principal amount so paid or prepaid;

 

(c)            on the last day of each Interest Period; provided that if such day is not a Business Day, then such payment shall be made on the next succeeding Business Day; and

 

(d)            on that portion of the Loans that is accelerated pursuant to Section 9.2 or Section 9.3, immediately upon such acceleration.

 

Interest accrued on the Loans or other monetary Obligations after the date such amount is due and payable (whether on the Maturity Date, upon acceleration or otherwise) shall be payable upon demand.

 

SECTION 3.7 Fee Letters. The Borrower shall pay to (i) the Administrative Agent such fees in the amounts and at such times specified under the Agency Fee Letter, (ii) the Lenders (or to the Administrative Agent, for the account of the applicable Lenders) such fees in the amounts and at such times specified under the Fee Letter and (iii) OrbiMed the Administration Fee in the amounts and at such times specified under the Fee Letter.

 

- 38 -

 

 

SECTION 3.8 Payments Generally. Subject to Section 9.3, all payments of principal, interest, fees and any Repayment Premium on the Loans and all other Obligations payable by the Borrower or any Guarantor under the Loan Documents shall be due, without any presentment thereof, to the Administrative Agent, at the Administrative Agent’s Office. The Administrative Agent shall distribute any such payments received by it for the account of any other Person to the appropriate recipient promptly following receipt. Except as otherwise set forth herein, all repayments and prepayments under the Loan Documents shall be made to the Lenders on a pro rata basis in accordance with their respective Applicable Percentages. If any payment is scheduled to be made on a day that is not a Business Day, then such payment shall be made on the next succeeding Business Day.

 

SECTION 3.9 Undrawn Fee. Prior to the Delayed Draw Commitment Termination Date, on the last day of each Fiscal Quarter (provided that if such day is not a Business Day, then such payment shall be made on the next succeeding Business Day) until the Delayed Draw Commitment Termination Date (and if the Delayed Draw Commitment Termination Date occurs on a date that is not the last day of a Fiscal Quarter, the amount of the fee for the corresponding Fiscal Quarter shall be a prorated amount for the portion of such Fiscal Quarter ending on the Delayed Draw Commitment Termination Date and shall be paid on such date), the Borrower shall pay to the Administrative Agent for the ratable account of each Lender, in cash, a fee (the “Undrawn Fee”) in an amount equal to (x) 0.50% per annum multiplied by (y) the undrawn Delayed Draw Commitment Amount. For purposes of this Section 3.9, the Undrawn Fee shall be calculated on a daily basis. The Undrawn Fee shall be fully earned and nonrefundable under any circumstances and in addition to, and not creditable against, any other fee, cost or expense payable under the Loan Documents.

 

ARTICLE IV
SOFR RATE AND OTHER PROVISIONS

 

SECTION 4.1 Increased Costs, Etc. The Borrower agrees to reimburse the Lenders for any increase in the cost to the Lenders of, or any reduction in the amount of any sum receivable by the Lenders in respect of, the Lenders’ Commitments and the making, continuation or maintaining of the Loans hereunder that may arise in connection with any Change in Law, except for such changes with respect to increased capital costs and Taxes which are governed by Section 4.2 and Section 4.3, respectively. The Administrative Agent shall notify the Borrower in writing of the occurrence of any such event, stating the reasons therefor and setting forth in reasonable detail the additional amount required fully to compensate the Lenders for such increased cost. Such additional amounts shall be payable by the Borrower directly to the Administrative Agent for the accounts of the Lenders within ten (10) Business Days of its receipt of such notice, and such notice shall, in the absence of manifest error, be conclusive and binding on the Borrower. The Borrower shall not be required to compensate any Lender for any amount claimed under this Section 4.1 that was incurred more than 180 days prior to the date that such Lender (or the Administrative Agent on its behalf) notifies the Borrower of the event that gives rise to such claim and that such Lender has determined to request such compensation; provided that if the circumstance giving rise to such increased cost is retroactive, then such 180-day period referred to above shall be extended to include the period of retroactive effect thereof.

 

- 39 -

 

 

SECTION 4.2 Increased Capital Costs. If any Change in Law affects or would affect the amount of capital required or expected to be maintained by any Lender or any Person controlling such Lender, and such Lender determines (in good faith but in its sole and absolute discretion) that the rate of return on its or such controlling Person’s capital as a consequence of the Commitments or the Loans made by it hereunder is reduced to a level below that which such Lender or such controlling Person could have achieved but for the occurrence of any such circumstance, then such Lender shall notify the Borrower in writing of such Lender’s claim for compensation, stating the reasons therefor and setting forth in reasonable detail the additional amount required fully to compensate such Lender for such reduction in rate of return. The Borrower shall within ten (10) Business Days following receipt of such notice pay directly to the Administrative Agent for the account of such Lender additional amounts sufficient to compensate such Lender or such controlling Person for such reduction in rate of return. A statement of such Lender as to any such additional amount or amounts shall, in the absence of manifest error, be conclusive and binding on the Borrower. In determining such amount, such Lender may use any method of averaging and attribution that it (in its sole and absolute discretion) shall deem applicable. The Borrower shall not be required to compensate any Lender for any amount claimed under this Section 4.2 that was incurred more than 180 days prior to the date that such Lender (or the Administrative Agent on its behalf) notifies the Borrower of the event that gives rise to such claim and that such Lender has determined to request such compensation; provided that if the circumstance giving rise to such reduction in rate of return is retroactive, then such 180-day period referred to above shall be extended to include the period of retroactive effect thereof.

 

SECTION 4.3 Taxes. The Borrower covenants and agrees as follows with respect to Taxes.

 

(a)            Except as required by applicable Law, any and all payments by the Borrower or any Guarantor under each Loan Document shall be made without setoff, counterclaim or other defense, and free and clear of, and without deduction or withholding for or on account of, any Taxes. In the event that any Taxes are imposed and required to be deducted or withheld from any payment required to be made by the Borrower or any of the Guarantors to or on behalf of the Lenders under any Loan Document (as determined in the good faith discretion of the applicable withholding agent), then:

 

(i)            if such Taxes are Non-Excluded Taxes or Other Taxes, the amount of such payment shall be increased as may be necessary so that such payment is made, after the withholding or deduction for or on account of such Taxes (including such deductions and withholdings applicable to additional sums payable under this Section 4.3), in an amount that is not less than the amount provided for in such Loan Document; and

 

(ii)           the Borrower or such Guarantor shall withhold or deduct the full amount of such Taxes from such payment (as increased pursuant to clause (a)(i)) and shall timely pay such amount to the Governmental Authority imposing such Taxes in accordance with applicable Law or at the option of the Administrative Agent timely reimburse it for the payment of any Other Taxes.

 

- 40 -

 

 

(b)            In addition, without duplication of Section 4.3(a), the Borrower shall timely pay all Other Taxes imposed to the relevant Governmental Authority imposing such Other Taxes in accordance with applicable Law.

 

(c)            As promptly as practicable after the payment of any Taxes or Other Taxes required to be paid by the Borrower under Section 4.3(a) or (b), and in any event within 45 days of any such payment being due, the Borrower shall furnish to the Administrative Agent a copy of an official receipt (or a certified copy thereof) evidencing the payment of such Taxes or Other Taxes.

 

(d)            The Loan Parties shall indemnify the Administrative Agent and each Lender, within 10 days after demand therefor, for any Non-Excluded Taxes and Other Taxes levied, imposed or assessed on (and whether or not paid directly by) by the Administrative Agent or such Lender whether or not such Non-Excluded Taxes or Other Taxes are correctly or legally asserted by the relevant Governmental Authority. Promptly upon having knowledge that any such Non-Excluded Taxes or Other Taxes have been levied, imposed or assessed, and promptly upon notice thereof by such Lender, the Borrower shall pay such Non-Excluded Taxes or Other Taxes directly to the relevant Governmental Authority (provided that, such Lender shall not be under any obligation to provide any such notice to the Borrower). The Borrower acknowledges that any payment made to any Lender or to any Governmental Authority in respect of the indemnification obligations of the Borrower provided in this clause (d) shall constitute a payment in respect of which the provisions of clause (a) and this clause (d) shall apply.

 

(e)            Status of Lenders. (i) Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower and the Administrative Agent, at the time or times reasonably requested by the Borrower or the Administrative Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by the Borrower or the Administrative Agent, shall deliver such other documentation prescribed by applicable Law or reasonably requested by the Borrower or the Administrative Agent as will enable the Borrower or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in paragraphs (e)(ii)(1), (e)(ii)(2) and (e)(iv) of this Section) shall not be required if in the Lender’s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.

 

- 41 -

 

 

(ii)            Without limiting the generality of the foregoing, in the event that the Borrower is a U.S. Borrower,

  

(1)            any Lender that is a U.S. Person shall deliver to the Borrower and the Administrative Agent on or about the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed copies of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax;

 

(2)            any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or about the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), whichever of the following is applicable;

 

(3)            in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “interest” article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “business profits” or “other income” article of such tax treaty;

 

(4)            executed copies of IRS Form W-8ECI;

 

(5)            in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate to the effect that such Foreign Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Code, a “10 percent shareholder” of the Borrower within the meaning of Section 871(h)(3)(B) of the Code, or a “controlled foreign corporation” related to the Borrower as described in Section 881(c)(3)(C) of the Code (a “U.S. Tax Compliance Certificate”) and (y) executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E; or

 

(6)            to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN, IRS Form W 8BEN-E, a U.S. Tax Compliance Certificate substantially in the form of Exhibit B-2 or Exhibit B-3, IRS Form W-9, and/or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit B-4 on behalf of each such direct and indirect partner;

 

- 42 -

 

 

(iii)          any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or about the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed copies of any other form prescribed by applicable Law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable Law to permit the Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and

 

(iv)          if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and the Administrative Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Administrative Agent such documentation prescribed by applicable Law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Administrative Agent as may be necessary for the Borrower and the Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment. Solely for purposes of this clause (iv), “FATCA” shall include any amendments made to FATCA after the date of this Agreement.

 

(v)           On or before the Closing Date (and on or before the date any successor or replacement Administrative Agent becomes the Administrative Agent hereunder), to the extent copies thereof have not previously been so delivered, the Administrative Agent shall deliver to the Borrower duly completed and executed copies of either (i) IRS Form W-9 (or any subsequent versions thereof or successors thereto) or (ii) (A) IRS Form W-8IMY (or any subsequent versions thereof or successors thereto) certifying that it is a “U.S. branch” of a foreign bank and evidencing its agreement with the Borrower to be treated as a U.S. person with respect to payments made to it by the Loan Parties such that the Administrative Agent assumes primary withholding and reporting responsibilities and (B) IRS Form W-8ECI with respect to any amount payable to the Administrative Agent for its own account.

 

- 43 -

 

 

Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Administrative Agent in writing of its legal inability to do so.

 

(f)            If any party determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section (including by the payment of additional amounts pursuant to this Section), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under this Section with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this paragraph (f) (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this paragraph (f), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this paragraph (f) the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This paragraph shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.

 

(g)            Each party’s obligations under this Section 4.3 shall survive the resignation or replacement of the Administrative Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Commitments and the repayment, satisfaction or discharge of all other Obligations.

 

(h)            If any Lender requests compensation under Sections 4.1, 4.2 or 4.3, or requires Borrower to pay any Non-Excluded Taxes, Other Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 4.3, then such Lender (at the request of the Borrower) will, to the extent not inconsistent with the internal policies of such Lender and any applicable legal or regulatory restrictions, use reasonable efforts to (a) make, issue, fund or maintain its Loans through another office of such Lender, or (b) take such other measures as such Lender may deem reasonable, if as a result thereof the additional amounts which would otherwise be required to be paid to such Lender pursuant to Sections 4.1, 4.2 or 4.3 would be materially reduced and if, as determined by such Lender in its sole discretion, the making, issuing, funding or maintaining of such Loans through such other office or in accordance with such other measures, as the case may be, would not otherwise adversely affect such Loans or the interests of such Lender; provided, such Lender will not be obligated to utilize such other office pursuant to this Section 4.3(h) unless Borrower agrees to pay all incremental expenses incurred by such Lender as a result of utilizing such other office as described above and such designation or assignment would eliminate or reduce amounts payable pursuant to Sections 4.1, 4.2 or 4.3, as the case may be, in the future. A certificate as to the amount of any such expenses payable by Borrowers pursuant to this Section 4.3(h) (setting forth in reasonable detail the basis for requesting such amount) submitted by such Lender to Borrower (with a copy to Administrative Agent) shall be conclusive absent manifest error.

 

- 44 -

 

 

(i)            The Loans are deemed to be made with original issue discount for U.S. federal income tax purposes. Requests for information regarding the issue price, amount of original issue discount, issue date, and yield to maturity on the Loans shall be directed to the Borrower care of Luke Power, Corporate Vice President, Interim Chief Financial Officer and Treasurer at ### or ###.

 

SECTION 4.4 Payments, Computations; Proceeds of Collateral, Etc.

 

(a)            Unless otherwise expressly provided in a Loan Document, all payments by the Borrower pursuant to each Loan Document shall be made without setoff, deduction or counterclaim not later than 12:00 p.m. (New York City time) on the date due in same day or immediately available funds, marked for attention as indicated, or in such other manner or to such other account as the Administrative Agent may from time to time direct in writing. Funds received after 12:00 p.m. (New York City time) on any day shall be deemed to have been received by the Administrative Agent on the next succeeding Business Day and any applicable interest or fee shall continue to accrue. All interest and fees shall be computed on the basis of the actual number of days occurring during the period for which such interest or fee is payable over a year comprised of 360 days. Payments due on other than a Business Day shall be made on the next succeeding Business Day and such extension of time shall be included in computing interest and fees in connection with that payment.

 

(b)            All amounts received as a result of the exercise of remedies under the Loan Documents (including from the proceeds of collateral securing the Obligations) or under applicable Law shall be applied upon receipt to the Obligations in accordance with Section 9.5.

 

(c)            The obligations of the Lenders hereunder to make Loans and to make payments pursuant to Section 10.4(c) are several and not joint. The failure of any Lender to make any Loan or to make any payment under Section 10.4(c) on any date required hereunder shall not relieve any other Lender of its corresponding obligation to do so on such date, and no Lender shall be responsible for the failure of any other Lender to so make its Loan or to make its payment under Section 10.4(c).

 

(d)            Nothing herein shall be deemed to obligate any Lender to obtain the funds for any Loan in any particular place or manner or to constitute a representation by any Lender that it has obtained or will obtain the funds for any Loan in any particular place or manner.

 

- 45 -

 

 

(e)            If any Lender shall, by exercising any right of setoff or otherwise, obtain payment in respect of any principal of or interest on its portion of any of the Loans, any Exit Fee or any Repayment Premium in connection therewith resulting in such Lender’s receiving payment of a proportion of the aggregate amount of the Loans and accrued interest thereon and any Exit Fee or Repayment Premium in connection therewith greater than its Applicable Percentage thereof as provided herein, then such Lender shall (x) notify the Administrative Agent of such fact and (y) purchase (for cash at face value) participations in the portions of the Loans of the other Lenders, or make such other adjustments as shall be equitable, so that the benefit of all such payments shall be shared by the Lenders ratably in accordance with the aggregate amount of principal of, accrued interest on and any Exit Fee or Repayment Premium in connection with their respective portions of the Loans and other amounts owing them; provided that:

  

(i)            if any such participations are purchased and all or any portion of the payment giving rise thereto is recovered, such participations shall be rescinded and the purchase price restored to the extent of such recovery, without interest; and

 

(ii)            the provisions of this Section 4.4(e) shall not be construed to apply to (x) any payment made by or on behalf of the Borrower pursuant to and in accordance with the express terms of this Agreement or (y) any payment obtained by a Lender as consideration for the assignment of or sale of a participation in any of its portion of the Loans to any assignee or participant, other than an assignment to a Borrower or any Guarantor (as to which the provisions of this Section shall apply).

 

The Borrower, on behalf of itself and the Guarantors, hereby consents to the foregoing and agrees, to the extent it may effectively do so under applicable Law, that any Lender acquiring a participation pursuant to the foregoing arrangements may exercise against the Borrower or such Guarantor rights of setoff and counterclaim with respect to such participation as fully as if such Lender were a direct creditor of the Borrower or such Guarantor in the amount of such participation.

 

SECTION 4.5 Setoff. Each Lender shall, upon the occurrence and during the continuance of any Event of Default, have the right to appropriate and apply to the payment of the Obligations owing to it (whether or not then due), and (as security for such Obligations) the Borrower hereby grants to each Lender a continuing security interest in, any and all balances, credits, deposits, accounts or moneys of the Borrower then or thereafter maintained with or on behalf of such Lender. Each Lender agrees promptly to notify the Borrower after any such appropriation and application made by such Lender; provided that, the failure to give such notice shall not affect the validity of such setoff and application. The rights of each Lender under this Section 4.5 are in addition to other rights and remedies (including other rights of setoff under applicable law or otherwise) which such Lender may have.

 

SECTION 4.6 SOFR Rate Not Determinable.

 

(a)            If prior to the commencement of any Interest Period for a Loan, the Administrative Agent determines (which determination shall be conclusive absent manifest error), or the Required Lenders notify the Administrative Agent that they have determined, that adequate and reasonable means do not exist for ascertaining the SOFR Rate for such Interest Period, then the Administrative Agent shall give notice thereof to the Borrower as promptly as practicable and, until the Administrative Agent notifies (if applicable, upon the instruction of the Required Lenders) the Borrower that the circumstances giving rise to such notice no longer exist, (i) the Loans shall bear interest calculated pursuant to Section 3.4 but using the Prime Rate instead of the SOFR Rate and (ii) the continuation of any outstanding Loan or the extension of a new Loan hereunder shall be made with interest calculated pursuant to Section 3.4 but using the Prime Rate instead of the SOFR Rate.

 

- 46 -

 

 

(b)            If at any time the Administrative Agent determines (which determination shall be conclusive absent manifest error), or the Required Lenders notify the Administrative Agent that they have determined, that (i) the circumstances set forth in Section 4.6(a) have arisen and such circumstances are unlikely to be temporary or (ii) the circumstances set forth in Section 4.6(a) have not arisen but the supervisor for the administrator of the SOFR Rate has made a public statement identifying a specific date after which the SOFR Rate shall no longer be used for determining interest rates for loans, then the Administrative Agent (at the direction of the Required Lenders) shall (in consultation with the Borrower) establish an alternate rate of interest to that based on the SOFR Rate that gives due consideration to the then-prevailing market convention for determining a rate of interest for loans in the United States at such time, and the Required Lenders and the Borrower shall enter into an amendment to this Agreement to reflect such alternate rate of interest and such other related changes as the Borrower and the Required Lenders may determine to be appropriate. Until an alternate rate of interest shall be determined in accordance with this Section 4.6(b) (but, in the case of the circumstances described in clause (ii) of the first sentence of this Section 4.6(b), only to the extent the SOFR Rate for such Interest Period is not available or published at such time on a current basis), Section 4.6(a) shall be applicable.

 

SECTION 4.7 Defaulting Lenders.

 

(a)            Adjustments. Notwithstanding anything to the contrary contained in this Agreement, if any Lender becomes a Defaulting Lender, then, until such time as such Lender is no longer a Defaulting Lender, to the extent permitted by applicable Law:

 

(i)            Waivers and Amendments.  Such Defaulting Lender’s right to approve or disapprove any amendment, waiver or consent with respect to this Agreement shall be restricted as set forth in the definition of Required Lenders and Section 10.1.

 

(ii)            Defaulting Lender Waterfall.  Any payment of principal, interest, fees or other amounts received by the Administrative Agent for the account of such Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to Article IX or otherwise) or received by the Administrative Agent from a Defaulting Lender pursuant to Section 10.17 shall be applied at such time or times as may be determined by the Administrative Agent as follows: first, to the payment of any amounts owing by such Defaulting Lender to the Administrative Agent hereunder; second, as the Borrower may request (so long as no Default or Event of Default shall have occurred and be continuing), to the funding of any Loan in respect of which such Defaulting Lender has failed to fund its portion thereof as required by this Agreement, as determined by the Administrative Agent; third, if so determined by the Administrative Agent and the Borrower, to be held in a deposit account and released pro rata in order to satisfy such Defaulting Lender’s potential future funding obligations with respect to Loans under this Agreement; fourth, to the payment of any amounts owing to the Lenders as a result of any judgment of a court of competent jurisdiction obtained by any Lender against such Defaulting Lender as a result of such Defaulting Lender’s breach of its obligations under this Agreement; fifth, so long as no Default or Event of Default has occurred and is continuing, to the payment of any amounts owing to the Borrower as a result of any judgment of a court of competent jurisdiction obtained by such Borrower against such Defaulting Lender as a result of such Defaulting Lender's breach of its obligations under this Agreement and sixth, to such Defaulting Lender or as otherwise directed by a court of competent jurisdiction; provided that if (x) such payment is a payment of the principal amount of any Loans in respect of which such Defaulting Lender has not fully funded its appropriate share, and (y) such Loans were made at a time when the conditions set forth in Article V were satisfied or waived, such payment shall be applied solely to pay the Loans of all Non-Defaulting Lenders on a pro rata basis prior to being applied to the payment of any Loans of such Defaulting Lender until such time as all Loans are held by the Lenders pro rata in accordance with the Commitments hereunder.  Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender shall be deemed paid to and redirected by such Defaulting Lender, and each Lender irrevocably consents hereto.

 

- 47 -

 

  

(iii)          Certain Fees. No Defaulting Lender shall be entitled to receive any fees payable under Section 3.9 for any period during which such Lender is a Defaulting Lender (and the Borrower shall not be required to pay any such fee that otherwise would have been required to have been paid to that Defaulting Lender).

 

(b)            Defaulting Lender Cure. If the Borrower and the Administrative Agent agree in writing that a Lender is no longer a Defaulting Lender, the Administrative Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set forth therein, that Lender will, to the extent applicable, purchase at par that portion of outstanding Loans of the other Lenders or take such other actions as the Administrative Agent may determine to be necessary to cause the Loans to be held on a pro rata basis by the Lenders in accordance with their Commitments, whereupon such Lender will cease to be a Defaulting Lender; provided that no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrower while that Lender was a Defaulting Lender; and provided, further, that except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lender’s having been a Defaulting Lender.

 

- 48 -

 

 

ARTICLE V
CONDITIONS TO MAKING THE LOANS

 

SECTION 5.1 Credit Extensions. The obligation of each Lender to make its portion of the Initial Loans shall be subject to the execution and delivery of this Agreement by the parties hereto, the delivery of a Loan Request as requested pursuant to Section 2.2, and the satisfaction of each of the conditions precedent set forth below in this Article V (other than Sections 5.19 and 5.20). The obligation of each Lender to make its portion of the Delayed Draw Loans on the First Delayed Draw Closing Date shall be subject to the prior making of the Initial Loan, the delivery of a Loan Request pursuant to Section 2.2, and the satisfaction of each of the conditions precedent set forth below in Sections 5.3, 5.8, 5.19 and 5.20. The obligation of each Lender to make its portion of the Delayed Draw Loans on the Second Delayed Draw Closing Date shall be subject to the prior occurrence of the First Delayed Draw Closing Date, the delivery of a Loan Request as requested pursuant to Section 2.2, and the satisfaction of each of the conditions precedent set forth below in Sections 5.3, 5.8, 5.19 and 5.20.

 

SECTION 5.2 Secretary’s Certificate, Etc. The Administrative Agent and each Lender shall have received from the Borrower and each Guarantor, (i) a copy of a good standing certificate, dated a date reasonably close to the Closing Date, for each such Person and (ii) a certificate, dated as of the Closing Date, duly executed and delivered by such Person’s Secretary or Assistant Secretary, managing member or general partner, or other Authorized Officer, as applicable, as to:

 

(a)            resolutions of each such Person’s board of directors (or other managing body, in the case of a Person other than a corporation) and any other corporate resolutions required by applicable Law or pursuant to such Person’s Organic Documents, each of which shall be then in full force and effect, authorizing the execution, delivery and performance of each Loan Document to be executed by such Person and the transactions contemplated hereby and thereby;

 

(b)            the incumbency and signatures of those of its officers, managers, managing member or general partner, as applicable, authorized to act with respect to each Loan Document to be executed by such Person; and

 

(c)            the full force and validity of each Organic Document of such Person and copies thereof;

 

upon which certificates the Administrative Agent and each Lender may conclusively rely until it shall have received a further certificate of the Secretary, Assistant Secretary, managing member or general partner, as applicable, of any such Person canceling or amending the prior certificate of such Person.

 

SECTION 5.3 Closing Date Certificates. The Administrative Agent and each Lender shall have received a Closing Date Certificate, dated as of the Closing Date, the First Delayed Draw Closing Date and the Second Delayed Draw Closing Date, as the case may be, and duly executed and delivered by an Authorized Officer of the Borrower, in which the Borrower shall certify that (i) the representations and warranties set forth in each Loan Document shall, in each case, be true and correct in all material respects (except with respect to any representation or warranty qualified by materiality or Material Adverse Effect, each of which representation or warranty is true and correct in all respects) as of such date (except to the extent that they relate specifically to an earlier specified date, in which case they are true and correct in all material respects (except with respect to any representation or warranty qualified by materiality or Material Adverse Effect, each of which representation or warranty is true and correct in all respects) on and as of such earlier date), (ii) no Default of Event of Default shall have then occurred and be continuing, or would result from the Loans to be advanced on the Closing Date, the First Delayed Draw Closing Date or the Second Delayed Draw Closing Date, as the case may be, and (iii) all of the conditions set forth in this Article V required to be satisfied by the Loan Parties on such date have been satisfied, except for those conditions expressly and specifically waived by the Required Lenders in writing, and as of such date as such certificate is delivered, such certifications by the Borrower shall in fact be true and correct. All documents and agreements required to be appended to the Closing Date Certificate, if any, shall be in form and substance reasonably satisfactory to the Administrative Agent and OrbiMed, shall have been executed and delivered by the requisite parties, and shall be in full force and effect.

 

- 49 -

 

 

SECTION 5.4 Payment of Outstanding Indebtedness, Etc. All Indebtedness identified in Schedule 8.2(b), together with all interest, all prepayment premiums and all other amounts due and payable with respect thereto, shall have been paid in full from the proceeds of the Loans and the commitments in respect of such Indebtedness shall have been terminated, and all Liens securing payment of any such Indebtedness shall have been released and the Administrative Agent and each Lender shall have received all Uniform Commercial Code Form UCC-3 termination statements or other instruments (including customary payoff letters) as may be reasonably required in connection therewith (collectively, the “Existing Debt Refinancing”).

 

SECTION 5.5 Delivery of Note. Each Lender shall have received a Note duly executed and delivered by an Authorized Officer of the Borrower.

 

SECTION 5.6 Financial Information, Etc. The Administrative Agent and each Lender shall have received:

 

(a)            audited consolidated financial statements of the Borrower and the Subsidiaries for each of the Fiscal Years ended December 31, 2020 and December 31, 2021; and

 

(b)            unaudited consolidated balance sheets of the Borrower and the Subsidiaries for the Fiscal Quarters ended March 31, 2022, June 30, 2022 and September 30, 2022, together with the related consolidated statements of income, stockholders’ equity and cash flows for the twelve months then ended.

 

SECTION 5.7 Compliance Certificate. The Lenders and the Administrative Agent shall have received an initial Compliance Certificate on a pro forma basis as if the Loans had been made as of September 30, 2022 and as to such items therein as the Administrative Agent and OrbiMed reasonably requests, dated the Closing Date, duly executed (and with all schedules thereto duly completed) and delivered by the chief financial or accounting Authorized Officer of the Borrower.

 

- 50 -

 

 

SECTION 5.8 Solvency, Etc. The Lenders and the Administrative Agent shall have received a solvency certificate as to the Solvency of the Borrower and its Subsidiaries on a consolidated basis, after giving effect to the incurrence of the applicable Loans, and the use of proceeds of such Loans, duly executed and delivered by the chief financial or accounting Authorized Officer of the Borrower, dated as of the Closing Date, First Delayed Draw Closing Date or the Second Delayed Draw Closing Date, as the case may be, in the form attached as Exhibit G.

 

SECTION 5.9 Guarantee. The Lenders and the Administrative Agent shall have received executed counterparts of the Guarantee, dated as of the Closing Date, duly executed and delivered by each Guarantor.

 

SECTION 5.10 Security Agreement. The Lenders and the Administrative Agent shall have received executed counterparts of the Security Agreement, dated as of the Closing Date, duly executed and delivered by the Borrower and each Guarantor, together with:

 

(a)            certificates (in the case of Capital Securities that are securities (as defined in the UCC)) evidencing all of the issued and outstanding Capital Securities directly owned by the Borrower or any Guarantor (including with respect to the Capital Securities of any Excluded Subsidiary (other than Excluded Assets)), which certificates in each case shall be accompanied by undated instruments of transfer duly executed in blank, or, in the case of Capital Securities that are uncertificated securities (as defined in the UCC), confirmation and evidence satisfactory to the Administrative Agent and the Lenders that the security interest therein has been granted to and perfected by the Administrative Agent for the benefit of the Secured Parties in accordance with Articles 8 and 9 of the UCC and all Laws otherwise applicable to the perfection of the pledge of such Capital Securities;

 

(b)            subject to Section 7.15, UCC financing statements suitable in form for naming the Borrower and each Guarantor as a debtor and the Administrative Agent as the secured party, or other similar instruments or documents to be filed under the UCC of all jurisdictions as may be necessary or, in the opinion of the Required Lenders, desirable to perfect the security interests of the Administrative Agent, on behalf of the Secured Parties, pursuant to the Security Agreement; and

 

(c)            subject to Section 7.15, evidence that all deposit accounts, lockboxes, disbursement accounts, investment accounts or other similar accounts of the Borrower and each Guarantor are Controlled Accounts (other than Excluded Accounts).

 

SECTION 5.11 Intellectual Property Security Agreements. The Administrative Agent and the Lenders shall have received a Patent Security Agreement, a Copyright Security Agreement and a Trademark Security Agreement, as applicable, each dated as of the Closing Date, duly executed and delivered by the Borrower or any Guarantor that, pursuant to the Security Agreement, is required to provide such intellectual property security agreements to the Administrative Agent for the benefit of the Secured Parties.

 

- 51 -

 

 

SECTION 5.12 Opinion of Counsel. The Administrative Agent and the Lenders shall have received customary opinions, dated the Closing Date and addressed to the Secured Parties, from Shearman & Sterling LLP, counsel to the Loan Parties, in form and substance reasonably satisfactory to the Administrative Agent and the Lenders.

 

SECTION 5.13 Insurance. Subject to Section 7.15, the Administrative Agent and the Lenders shall have received insurance certificates and endorsements from one or more insurance companies satisfactory to the Administrative Agent and the Lenders, evidencing coverage required to be maintained pursuant to each Loan Document, with the Administrative Agent named as loss payee or additional insured, as applicable.

 

SECTION 5.14 Closing Fees, Expenses, Etc. Each Lender and the Administrative Agent, as applicable, shall have received for its own account (i) all fees, costs and expenses due and payable pursuant to Section 10.3 and 10.4 and (ii) all fees due and payable on the Closing Date pursuant to this Agreement, the Agency Fee Letter and the Fee Letter.

 

SECTION 5.15 Anti-Terrorism Laws. Each Lender and the Administrative Agent shall have received, as applicable, all documentation and other information required by bank regulatory authorities under applicable “know your customer” and anti-money laundering rules and regulations, including the U.S.A. Patriot Act.

 

SECTION 5.16 Loan Documents. The Administrative Agent shall have received executed counterparts of this Agreement and the other Loan Documents, properly executed by an Authorized Officer of each of the Borrower and each other signing Guarantor and by each Lender party to such Loan Documents.

 

SECTION 5.17 Satisfactory Legal Form. All documents executed or submitted pursuant hereto by or on behalf of the Borrower or any Guarantor shall be reasonably satisfactory in form and substance to the Administrative Agent and the Lenders, and the Administrative Agent and the Lenders shall have received all information, approvals, resolutions, opinions, documents or instruments as the Administrative Agent or such Lender may reasonably request.

 

SECTION 5.18 No Material Adverse Effect. Since December 31, 2021, there has not been a Material Adverse Effect.

 

SECTION 5.19 Revenue Base. Solely as a condition precedent to the First Delayed Draw Closing Date and the Second Delayed Draw Closing Date, as the case may be, the Administrative Agent and the Lenders shall be satisfied that the Revenue Base for the most recently ended Test Period prior to such Delayed Draw Closing Date was at least $300,000,000.

 

SECTION 5.20 Disclosure Schedules. Immediately prior to each Delayed Draw Closing Date, the Borrower shall deliver to the Administrative Agent and the Lenders updates to Schedules 6.15(a)(1), 6.15(j)(1) and 6.22, each such updated Schedule to be complete and accurate in all material respects as of such Delayed Draw Closing Date.

 

- 52 -

 

 

ARTICLE VI
REPRESENTATIONS AND WARRANTIES

  

In order to induce the Lenders and the Administrative Agent to enter into this Agreement and to make the Loans hereunder, the Borrower represents and warrants to the Lenders and the Administrative Agent that:

 

SECTION 6.1 Organization, Etc. The Borrower and each Subsidiary (a) (i) is validly organized and existing and in good standing (to the extent such concept exists in such jurisdiction) under the laws of the jurisdiction of its incorporation or organization, and (ii) is duly qualified to do business and is in good standing as a foreign entity (to the extent such concept exists in such jurisdiction) in each jurisdiction where the nature of its business requires such qualification (in the case of this clause (a)(ii), unless the failure to so qualify as a foreign entity would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect); and (b) except, as of the Closing Date, required approvals contemplated by the Specified Letter and required board approvals in each case with respect to the borrowing of any Delayed Draw Term Loan on the applicable Delayed Draw Closing Date, , has full power and authority and holds all requisite governmental licenses, permits, clearances and other approvals required (i) in the case of the Loan Parties, to enter into and perform its obligations under each Loan Document to which it is a party, and (ii) to own and hold under lease its property and to conduct its business substantially as currently conducted by it (in the case of this clause (b)(ii), except to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect).

 

SECTION 6.2 Due Authorization, Non-Contravention, Etc. The execution, delivery and performance by the Borrower and each Guarantor of each Loan Document executed or to be executed by it are in each case within such Person’s corporate or organizational powers, except, as of the Closing Date, required approvals contemplated by the Specified Letter and required board approvals in each case with respect to the borrowing of any Delayed Draw Term Loan on the applicable Delayed Draw Closing Date, have been duly authorized by all necessary corporate or organizational action, and do not:

 

(a)            contravene (i) the Borrower’s or any Guarantor’s Organic Documents, (ii) in any material respect, any court decree or order binding on or affecting the Borrower or any Guarantor or (iii) in any material respect, any Law or governmental regulation binding on or affecting the Borrower or any Guarantor; or

 

(b)            result in (i) or require the creation or imposition of any Lien on the Borrower’s or any Guarantor’s properties (except as permitted by this Agreement) or (ii) a material default under any material contract, agreement, or instrument binding on or affecting the Borrower or any Guarantor.

 

SECTION 6.3 Government Approval, Regulation, Etc. No authorization, approval, clearance or other action by, and no notice to or filing with, any Governmental Authority or other Person (other than (i) those that have been, or on the Closing Date will be, duly obtained or made and which are, or on the Closing Date will be, in full force and effect, and (ii) recordings, filings and other perfection actions in connection with the Liens granted to the Administrative Agent under this Agreement or any other Loan Document) is required for the due execution, delivery or performance by the Borrower or any Guarantor of any Loan Document to which it is a party.

 

- 53 -

 

 

SECTION 6.4 Validity, Etc. Each Loan Document to which the Borrower or any Guarantor is a party constitutes the legal, valid and binding obligations of such Person enforceable against such Person in accordance with its respective terms (except, in any case, as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally and by principles of equity).

 

SECTION 6.5 Financial Information. The consolidated financial statements of the Borrower and the Subsidiaries furnished to the Administrative Agent and the Lenders pursuant to Sections 5.6 and 7.1 have been prepared in accordance with GAAP, consistently applied, and present fairly in all material respects the consolidated financial condition of the Persons covered thereby as at the dates thereof and the results of their operations for the periods then ended, subject, in the case of unaudited financial statements, to the absence of footnote disclosure and normal and recurring year-end adjustments.

 

SECTION 6.6 No Material Adverse Effect. Since December 31, 2021 to the Closing Date, there has been no Material Adverse Effect. As of any Delayed Draw Closing Date, no Material Adverse Effect has occurred and is continuing.

 

SECTION 6.7 Litigation, Labor Matters and Environmental Matters.

 

(a)            Except as described on Schedule 6.7(a), there are no actions, suits or proceedings by or before any arbitrator or Governmental Authority (other than any actions, suits or proceedings commenced under seal that have not been disclosed to the Borrower) pending against, threatened in writing against, or, to the knowledge of the Borrower, otherwise threatened against or affecting the Borrower or any Subsidiary (i) as to which there is a reasonable likelihood of an adverse determination and that, if adversely determined, would reasonably be expected, individually or in the aggregate, to (A) on the Closing Date, result in liabilities in excess of $5,000,000 or (B) on any Delayed Draw Closing Date, have or result in a Material Adverse Effect that is continuing or (ii) that would reasonably be likely to adversely affect this Agreement or the transactions contemplated hereby.

 

(b)            Except as described on Schedule 6.7(b), there are no labor controversies pending against, threatened in writing against, or, to the knowledge of the Borrower, otherwise threatened against or affecting the Borrower or any Subsidiary (i) that would reasonably be expected, individually or in the aggregate, to (A) on the Closing Date, result in liabilities in excess of $5,000,000 or (B) on any Delayed Draw Closing Date, have or result in a Material Adverse Effect that is continuing or (ii) that would reasonably be likely to adversely affect this Agreement or the transactions contemplated hereby.

 

(c)            Neither the Borrower nor any Subsidiary (i) has failed to comply with any Environmental Law or to obtain, maintain or comply with any Permit under or in connection with any Environmental Law (“Environmental Permit”), (ii) is or has been subject to any Environmental Liability, (iii) has received notice of any Environmental Liability, or (iv) knows of any basis for any Environmental Liability, in each case of clauses (i) through (iv) above, which would reasonably be expected to result in a Material Adverse Effect.

 

- 54 -

 

 

SECTION 6.8 Subsidiaries. As of the Closing Date, the Borrower has no Subsidiaries except those Subsidiaries which are identified in Schedule 6.8 (which Schedule also identifies the direct and indirect owners of the Capital Securities of such Subsidiaries).

 

SECTION 6.9 Ownership of Properties. Each of the Borrower and each Subsidiary owns (i) in the case of owned real property, good and marketable fee title to, and (ii) in the case of owned personal property, good and valid title to, or, in the case of leased real or personal property, valid and enforceable leasehold interests (as the case may be) in, all of its properties and assets, tangible and intangible, of any nature whatsoever, that are reasonably necessary in the ordinary conduct of the business of the Borrower and its Subsidiaries, free and clear in each case of all Liens or claims, except for Liens permitted pursuant to Section 8.3, unless the failure to own any such property, interests or assets would not, taken as a whole, be reasonably expected to result in a Material Adverse Effect.

 

SECTION 6.10 Taxes. Each of the Borrower and each Subsidiary has filed all federal and material foreign, state and local tax returns and reports required by Law to have been filed by it and has paid all material Taxes due and owing, except any such Taxes which are being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP shall have been set aside on its books.

 

SECTION 6.11 Benefit Plans, Etc. Except as set forth on Schedule 6.11, as of the Closing Date, none of the Borrower or any of the Subsidiaries or any of their respective ERISA Affiliates sponsors, maintains, contributes to, is required to contribute to, or has any actual or potential liability with respect to, any Benefit Plan. As of the Closing Date, none of the Borrower or any of the Subsidiaries is a party to any collective bargaining agreement and none of the employees of the Borrower or any of the Subsidiaries are subject to any collective bargaining agreement with respect to their employment with Borrower or any of its Subsidiaries. Except as would not, individually or in the aggregate, result in any Material Adverse Effect, (i) each “employee benefit plan,” as defined in Section 3(3) of ERISA, that provides retirement benefits, is sponsored by the Borrower or any of their ERISA Affiliates and is intended to be tax qualified under section 401 of the Code is so qualified and no assets of any such plan are invested in Capital Securities of the Borrower and (ii) each employee benefit plan, program or arrangement that is sponsored, maintained, contributed to or required to be contributed to by the Borrower or any Subsidiary has complied, both in form and in operation, in all respects with its terms and applicable Law. No ERISA Event has occurred or is reasonably expected to occur that could reasonably be expected to result in a Material Adverse Effect. The underlying assets of the Borrower and its Subsidiaries do not constitute Plan Assets and, to the knowledge of the Borrower and its Subsidiaries the execution, delivery and performance of this Agreement and the other Loan Documents do not and will not constitute a non-exempt prohibited transaction under Section 406 of ERISA or Section 4975 of the Code.

 

- 55 -

 

 

SECTION 6.12 Accuracy of Information. None of the written information (other than any projections, estimates and pro forma financial information and any general economic or specific industry information) heretofore or contemporaneously furnished in writing to the Administrative Agent or any Lender by or on behalf of the Borrower or any Subsidiary in connection with any Loan Document or any transaction contemplated hereby when furnished and when taken as a whole, contains any untrue statement of a material fact, or omits to state any material fact necessary to make any such information not misleading in a material respect in light of the circumstances under which such statements were made. All financial projections and pro forma financial information delivered to the Administrative Agent and the Lenders by the Borrower (or its agents) have been prepared on the basis of good faith estimates and assumptions believed by the Borrower to be fair and reasonable in light of current business conditions as of the date thereof; provided, however, that such projections are subject to uncertainties and contingencies, that no assurances can be given that any particular projections will be attained and that actual results during the period or periods covered by such financial information may differ significantly from the projected results set forth therein and that such differences may be material.

  

SECTION 6.13 Regulations U and X. None of the Borrower or any Subsidiary is engaged principally, or as one of its important activities, in the business of extending credit for the purpose, whether immediate, incidental or ultimate, of buying or carrying margin stock, and no part of the proceeds of the Loans will be used to buy or carry any margin stock in violation of the Federal Reserve Board’s Regulation U or Regulation X. Terms for which meanings are provided in such Regulation U or Regulation X, as from time to time in effect, are used in this Section with such meanings.

 

SECTION 6.14 Solvency. On the Closing Date, the First Delayed Draw Closing Date and the Second Delayed Draw Closing Date, as applicable, after giving effect to the incurrence of the Initial Loans and the applicable Delayed Draw Loans, respectively, and the use of proceeds of such Loans, the Borrower and the Subsidiaries taken as a whole, on a consolidated basis, both before and after giving effect to the Loans, are Solvent.

 

SECTION 6.15 Intellectual Property.

 

(a)            Schedule 6.15(a)(1) sets forth a complete and accurate list as of the Closing Date or any relevant Delayed Draw Closing Date, as the case may be, of all (x) Patents, including any Patent applications, (y) registered Trademarks (including domain names) and any pending registrations or applications for Trademarks, and (z) registered Copyrights and any applications for Copyright registration, in each case of clauses (x) through (z), owned by the Borrower or any Subsidiary. Schedule 6.15(a)(2) sets forth a complete and accurate list as of the Closing Date of all material in-bound license or sublicense agreements with respect to any Intellectual Property owned by a Third Party that is used in and material to the conduct of the business of the Borrower and the Subsidiaries as currently conducted (but excluding inbound licenses of over-the-counter or “open source” software that is commercially available to the public or licenses to other Intellectual Property licensed or otherwise made available pursuant to a click-wrap, shrink wrap or similar agreement or on a subscription basis). For each item of Intellectual Property listed on Schedule 6.15(a)(1), the Borrower has, where relevant, indicated (A) the countries in which such item is registered, (B) the application numbers, (C) the registration or patent numbers, and (D) the owner of such item of Intellectual Property.

 

- 56 -

 

 

(b)            To the knowledge of the Borrower, the Owned Intellectual Property and Licensed Intellectual Property together constitute all Intellectual Property reasonably necessary for the operation of the business of the Borrower and the Subsidiaries as currently conducted and as currently proposed to be conducted, except in each case, on the relevant Delayed Draw Closing Date, as would not reasonably be expected to have a Material Adverse Effect.

 

(c)            Each of the Borrower and each Subsidiary owns, or has a valid license or rights in any other form, as applicable, to all rights associated with the Owned Intellectual Property and the Licensed Intellectual Property (i) on the Closing Date, in all material respects, and (ii) on the relevant Delayed Draw Closing Date, except as would not reasonably be expected to cause a Material Adverse Effect. The Owned Intellectual Property and the agreements associated with the Licensed Intellectual Property are free and clear of any and all Liens other than Liens permitted pursuant to Section 8.3. This Section 6.15(c) shall not be construed as a representation that the Borrower or any Subsidiary is Infringing any Intellectual Property of any Person.

 

(d)            The Borrower or a Subsidiary, as applicable, is the sole and exclusive owner of all right, title and interest in and to all of its Owned Intellectual Property and has possession of a proper chain of title from each inventor of any technology claimed in any Patent or Patent application assigning full unconditional ownership to each of the Borrower or such Subsidiary, as applicable, in each case of the foregoing, (i) on the Closing Date, in all material respects and (ii) on the relevant Delayed Draw Closing Date, except as would not reasonably be expected to cause a Material Adverse Effect. All such Owned Intellectual Property is subsisting and has not expired, lapsed or been forfeited, cancelled or abandoned unless permitted hereunder, except, on the relevant Delayed Draw Closing Date, where such event or circumstance is not reasonably expected to cause a Material Adverse Effect.

 

(e)            Each of the Borrower and each Subsidiary, as applicable, has taken commercially reasonable actions to maintain and protect all Owned Intellectual Property, including by timely paying all registration, maintenance, renewal and annuity fees, as applicable, except where the failure to take such action would not reasonably be expected to cause a Material Adverse Effect.

 

(f)             Except as set forth on Schedule 6.15(f), (i) there is no proceeding challenging the ownership, inventorship validity or enforceability of any Owned Intellectual Property, (ii) neither the Borrower nor any of the Subsidiaries is involved in any proceeding where it is challenging the ownership, validity or enforceability of any Intellectual Property of any other Person, and (iii) none of the Owned Intellectual Property is the subject of any material Other Administrative Proceeding, except in each case, on the relevant Delayed Draw Closing Date, where such challenge is not reasonably expected to have a Material Adverse Effect, except for prosecution of pending Intellectual Property applications.

 

- 57 -

 

 

(g)            Except as set forth on Schedule 6.15(g), to the knowledge of the Borrower, (A) all Owned Intellectual Property and the Licensed Intellectual Property is valid, enforceable and subsisting, and (B) no event has occurred, and nothing has been done or omitted to have been done, that would affect the validity or enforceability of any Owned Intellectual Property or Licensed Intellectual Property, except where such event is not reasonably expected to have a Material Adverse Effect.

  

(h)            There are no claims pending or threatened in writing that have been brought by the Borrower or any of the Subsidiaries against any Person alleging Infringement of any Owned Intellectual Property or Licensed Intellectual Property, except for, on any Delayed Draw Closing Date, any claims that would not reasonably be expected to have a Material Adverse Effect. To the knowledge of the Borrower, no Third Party is committing any act of Infringement of any Owned Intellectual Property or Licensed Intellectual Property, except where such Infringement is not reasonably expected to have a Material Adverse Effect.

 

(i)             As of the Closing Date, with respect to each license agreement listed on Schedule 6.15(a)(2), such license agreement (i) is in full force and effect and is binding upon and enforceable against the Borrower and the Subsidiaries to the extent party thereto and, to the knowledge of the Borrower, all other parties thereto in accordance with its terms, (ii) has not been amended or otherwise modified, except as set forth on Schedule 6.15(a)(2), and (iii) has not suffered a default or breach thereunder (with respect to defaults or breaches of parties other than the Borrower and the Subsidiaries, to the knowledge of the Borrower) except, in each of the foregoing clauses (i) through (iii), to the extent as would not reasonably be expected to have a Material Adverse Effect.

  

(j)             As of the Closing Date, the First Delayed Draw Closing Date and the Second Delayed Draw Closing Date, as the case may be, except as set forth on Schedule 6.15(j)(1) and as would not reasonably be expected to have a Material Adverse Effect, neither the Borrower nor any of the Subsidiaries has received written notice or, to the knowledge of the Borrower, any other communications from any Third Party: (i) alleging that the conduct of the business of the Borrower or any of the Subsidiaries (including the development, manufacture, use, sale or other commercialization of any Product) Infringes any Intellectual Property of that or any other Third Party or (ii) challenging the validity or enforceability of any of Patent owned by the Borrower or any Subsidiary. To the knowledge of the Borrower, except as set forth on Schedule 6.15(j)(2), the conduct of its respective business and the business of the Subsidiaries (including the development, manufacture, use, sale or other commercialization of any Product) does not Infringe any Intellectual Property of any Third Party, except as would not reasonably be expected to have a Material Adverse Effect.

 

(k)            The Borrower and the Subsidiaries have used commercially reasonable efforts and precautions to protect their (i) rights in, and with respect to, Confidential Business Information, and maintain the confidentiality of, their respective Owned Intellectual Property and (ii) respective commercially significant unregistered Intellectual Property, in each of the foregoing clauses (i) and (ii), (A) on the Closing Date, in all material respects and (B) on the relevant Delayed Draw Closing Date, except as would not reasonably be expected to have a Material Adverse Effect.

 

- 58 -

 

 

(l)             (i) All current and former employees of the Borrower and each Subsidiary, and all other Persons with access to any Confidential Business Information, are subject to written agreements that include customary confidentiality and restriction on use terms sufficient to maintain the confidential status and limit the use of such Confidential Business Information, and (ii) no trade secret of the Borrower or any of its Subsidiaries with respect to any Product has been published or disclosed by the Borrower or any of its Subsidiaries to any Person, except pursuant to a written agreement requiring such Person to keep such trade secret confidential, in each case of the foregoing clauses (i) and (ii), (A) on the Closing Date, in all material respects, and (B) on the relevant Delayed Draw Closing Date, except as would not reasonably be expected to have a Material Adverse Effect.

 

(m)           This Section 6.15 sets forth the sole representations and warranties of the Borrower with respect to the Infringement of any Intellectual Property of any Person.

 

SECTION 6.16 Material Agreements. Set forth on Schedule 6.16 is a complete and accurate list as of the Closing Date, of all Material Agreements of the Borrower and the Subsidiaries, including any amendments and modifications thereto. Except to the extent otherwise terminated as contemplated by the definition thereof, each Material Agreement is in full force and effect and the legal, valid and binding obligation of (x) the Borrower or the Subsidiary party thereto and, (y) to the knowledge of the Borrower, the other parties thereto, enforceable against the Borrower and the Subsidiaries party thereto and all other parties thereto in accordance with its terms (except, in any case, as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally and by principles of equity), except, in each of the foregoing clauses (x) and (y), as would not reasonably be expected to have a Material Adverse Effect. (A) Neither the Borrower nor any of the Subsidiaries is in breach or in default under any Material Agreement, nor has the Borrower or any of the Subsidiaries taken any action that would permit any other Person party to any Material Agreement to have, and no such Person otherwise has, any defenses, counterclaims or rights of setoff thereunder and (B) to the knowledge of the Borrower, no such other Person party to such Material Agreement is in breach or in default thereunder, except, in each of the foregoing clauses (A) and (B), as would not reasonably be expected to have a Material Adverse Effect.

 

SECTION 6.17 Permits. The Borrower and the Subsidiaries have all Permits, including Key Permits and Environmental Permits required for the ownership, operation and conduct of their business, including their testing and distribution of the Products, except as would not reasonably be expected to have a Material Adverse Effect, it being understood and agreed that, as of the Closing Date, the Borrower and its Subsidiaries do not have medical device clearances or approvals from the FDA for its LDTs. All such Permits are validly held and there are no defaults thereunder, except as could not reasonably be expected to have a Material Adverse Effect.

 

SECTION 6.18 Regulatory Matters.

 

- 59 -

 

 

(a)            All Permits held by the Borrower and the Subsidiaries are (i) legally and beneficially owned exclusively by the Borrower or such Subsidiary, free and clear of all Liens other than Liens permitted pursuant to Section 8.3, and (ii) validly registered and on file with the applicable Governmental Authority, in compliance with all filing and maintenance requirements (including any fee requirements) thereof, and are in good standing, valid and enforceable with the applicable Governmental Authority, it being understood and agreed that, as of the Closing Date, the Borrower and its Subsidiaries do not have medical device clearances or approvals from the FDA for its LDTs. All required notices, registrations and listings, supplemental applications or notifications, reports and other required filings with respect to the Products have been filed with applicable Governmental Authorities, except where the failure to file the same would not, whether individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

  

(b)            Except in each case as would not reasonably be expected to have a Material Adverse Effect, since January 1, 2019, (i) the Products, as well as the business of the Borrower and the Subsidiaries, comply with (A) all applicable Laws, including, without limitation, applicable requirements of CLIA and the FD&C Act (it being understood and agreed that, as of the Closing Date, the Borrower and its Subsidiaries do not have medical device clearances or approvals from the FDA for its LDTs), and (B) the terms of all Product Authorizations and other Permits; (ii) all laboratory testing services have been conducted in compliance with CLIA and all federal and state laws regarding laboratory testing services; (iii) all LDTs have been designed, developed, validated, and performed in compliance with CLIA, the FD&C Act, and all federal and state laws regarding laboratory testing services; (iv) none of the Borrower and the Subsidiaries, or, to the knowledge of the Borrower, their respective suppliers, have received any inspection reports, warning letters, untitled letters or similar documents with respect to any Product and/or with respect to the business of the Borrower and/or the Subsidiaries, from any Governmental Authority that assert lack of compliance with any applicable Laws (other than inspection reports that do not contain material findings or that have been remedied); (v) none of the Borrower or any of the Subsidiaries has received any written notice of, or otherwise have knowledge of, any pending regulatory enforcement action, investigation, or inquiry against the Borrower or any of the Subsidiaries or, to the knowledge of the Borrower, any of their respective suppliers, with respect to the Products; (vi) to the knowledge of the Borrower, there have been no Product recalls, safety alerts, withdrawals, clinical holds, marketing suspensions, removals, seizures, injunctions or the like conducted, undertaken or issued by any Person, whether or not at the request, demand or order of any Governmental Authority or otherwise, with respect to any Product nor, to the knowledge of the Borrower, has any such action been requested, demanded, or ordered by any Governmental Authority; (vii) to the knowledge of the Borrower, none of the Borrower or any of the Subsidiaries has received any written notice of (A) any criminal, injunctive, seizure, detention or civil penalty actions that have at any time been commenced or threatened in writing by any Governmental Authority with respect to or in connection with any Products, or (B) any consent decrees (including plea agreements) which relate to any Products; and (viii) to the knowledge of the Borrower, there is no basis for commencement of any criminal, injunctive, seizure, detention, or civil penalty actions by any Governmental Authority relating to the Products or for issuance of any consent decrees. To the knowledge of the Borrower, none of the Borrower or any of the Subsidiaries is employing or utilizing the services of any individual who has been debarred or suspended under any applicable Law since January 1, 2019, other than, with respect to a Delayed Draw Closing Date, any employee or service provider that has been terminated by the Borrower reasonably promptly following the Borrower or its Subsidiaries becoming aware of such suspension or debarment.

 

- 60 -

 

 

(c)            As of the Closing Date (and, except as would not reasonably be expected to result in a Material Adverse Effect, as of each Delayed Draw Closing Date), none of the Borrower or the Subsidiaries has received any written notice from, any Governmental Authority or an institutional review board or ethics committee alleging any material non-compliance with applicable laws or GCPs or otherwise requiring the termination or suspension any clinical trial (in-whole or in-part) conducted, or being conducted, by or on behalf of the Borrower and the Subsidiaries with respect to any Product. Except as would not reasonably be expected to have a Material Adverse Effect, no clinical trial conducted, or being conducted, by or on behalf of the Borrower, and/or the Subsidiaries with respect to any Product has used, or is using, any clinical investigator who has been disqualified from conducting clinical investigations by FDA or other Governmental Authority.

 

(d)            Except in each case as would not reasonably be expected to have a Material Adverse Effect, with respect to the Products, since January 1, 2019: (i) all activities (including, without limitation, testing, validating, performing, marketing, sale, recordkeeping) by the Borrower or any of the Subsidiaries and, to the knowledge of the Borrower, their respective suppliers relating to the Products have been conducted, and are currently being conducted, in compliance with the applicable requirements of CLIA, the FD&C Act, other applicable requirements of Governmental Authorities, and (ii) none of the Borrower or any of the Subsidiaries, or, to the knowledge of the Borrower, any of their respective suppliers, has received written notice or threat of commencement of action by any Governmental Authority to withdraw its approval of any Product, to enjoin or prevent the performance of any LDT or otherwise prevent Borrower or any of its Subsidiaries from performing laboratory services, or to otherwise disrupt the business of the Borrower and the Subsidiaries, in each case, it being understood and agreed that, as of the Closing Date, the Borrower and its Subsidiaries do not have medical device clearances or approvals from the FDA for its LDTs.

 

(e)            [Reserved].

 

(f)            [Reserved].

 

(g)            Except as would not have a Material Adverse Effect, all studies, tests and preclinical and clinical trials relating to the Products conducted by or on behalf of the Borrower or any of the Subsidiaries have been conducted, and are currently being conducted, in compliance with all applicable Laws, including, but not limited to, applicable provisions of the CLIA and the FD&C Act, including applicable GCPs and applicable GLPs, it being understood and agreed that, as of the Closing Date, the Borrower and its Subsidiaries do not have medical device clearances or approvals from the FDA for its LDTs.

 

- 61 -

 

 

(h)            To the Borrower’s knowledge, there has been no untrue statement of fact and no fraudulent statement made by the Borrower or any of the Subsidiaries at the time such statements were made, or to the knowledge of the Borrower, any of their respective agents or representatives (when acting in such capacity) in any filing with the CMS, the FDA or any other Governmental Authority, and there has been no failure to disclose any fact required to be disclosed to any Regulatory Agency, in each case, except where the failure to do so would not reasonably be expected to result in a Material Adverse Effect.

 

(i)             Except as set forth on Schedule 6.18(i), as of the Closing Date (and, except as would not reasonably be expected to result in a Material Adverse Effect, as of each Delayed Draw Closing Date), the Borrower and the Subsidiaries are in material compliance with federal and state fraud and abuse laws, including the federal Anti-Kickback Statute, the False Claims Act, the Foreign Corrupt Practices Act, and similar applicable state, federal or foreign laws. Except as set forth on Schedule 6.18(i), from January 1, 2019 to the Closing Date (and, except as would not reasonably be expected to result in a Material Adverse Effect, from January 1, 2019 to each Delayed Draw Closing Date), none of the Borrower or any of the Subsidiaries has received any written notice from the United States Department of Justice, any U.S. Attorney, any State Attorney General, or any other similar Governmental Authority alleging any violation of any such laws in any material respect. The Borrower and its Subsidiaries have established and implemented a compliance program designed to ensure material compliance with federal and state fraud and abuse laws, including the federal Anti-Kickback Statute, the False Claims Act, the Foreign Corrupt Practices Act, and similar applicable state, federal or foreign laws.

 

(j)            The transactions contemplated by the Loan Documents (or contemplated by the conditions to effectiveness of any Loan Document) will not materially impair the Borrower’s or any of the Subsidiaries’ ownership of or rights under (or the license or other right to use, as the case may be) any Key Permits relating to the Products.

 

(k)            [Reserved].

 

(l)            Except as set forth on Schedule 6.18(l), since January 1, 2019, none of the Borrower or any of the Subsidiaries, nor, to the Borrower’s knowledge, any individual who is an officer, director, manager or employee of the Borrower or any of the Subsidiaries has been convicted of or, to the Borrower’s knowledge, charged with or investigated for any federal or state health program-related offense or any other offense related to healthcare or been excluded or suspended from participation in any such program, except, as of any Delayed Draw Closing Date, for any such individuals who have been promptly terminated by the Borrower or its Subsidiaries following such conviction or charge or as would not reasonably be expected to result in a Material Adverse Effect. Except as set forth on Schedule 6.18(l), since January 1, 2019, none of the Borrower or any of the Subsidiaries, nor, to the Borrower’s knowledge, any individual who is an officer or director of the Borrower or any of the Subsidiaries has been convicted of any crime that has resulted or would reasonably be expected to result in a debarment or exclusion under (i) 21 U.S.C. Section 335a or (ii) any similar applicable Law, except, as of any Delayed Draw Closing Date, for any such individuals who have been promptly terminated by the Borrower or its Subsidiaries following such conviction or charge or as would not reasonably be expected to result in a Material Adverse Effect. Except as set forth on Schedule 6.18(l), from January 1, 2019 through the Closing Date (and, except as would not reasonably be expected to result in a Material Adverse Effect, from January 1, 2019 through each Delayed Draw Closing Date), no debarment proceedings or investigations in respect of the business of the Borrower or any of the Subsidiaries are pending or, to the Borrower’s knowledge, threatened against the Borrower, any of the Subsidiaries or any individual who is an officer, director, manager or employee of the Borrower or any of the Subsidiaries.

 

- 62 -

 

 

SECTION 6.19 Transactions with Affiliates. Except as set forth on Schedule 6.19, none of the Borrower or any Subsidiary has entered into, renewed, extended or been a party to, any transaction (including the purchase, sale, lease, transfer or exchange of property or assets of any kind or the rendering of services of any kind) with the Permitted Holders, in each case as in effect on the Closing Date, except for (a) employment arrangements (including employee benefits, compensation, equity awards and director/officer indemnification agreements) that have been approved by the Borrower’s Board of Directors or a committee thereof and (b) equity investments in the Borrower (including any related stockholders’ agreements).

 

SECTION 6.20 Investment Company Act. None of the Borrower or any Subsidiary is required to register as an “investment company” as such terms are defined in, or subject to regulation under, the Investment Company Act of 1940, as amended.

 

SECTION 6.21 OFAC. None of the Borrower, any Subsidiary or, to the knowledge of the Borrower, any Related Party (a) is currently the subject of any Sanctions, (b) is located, organized or residing in any Designated Jurisdiction, or (c) is or has been (within the previous five (5) years) engaged in any transaction with any Person who is now or was then the subject of Sanctions or who is located, organized or residing in any Designated Jurisdiction. No Loan, nor the proceeds from any Loan, has been or will be used, directly or indirectly, to lend, contribute or provide to, or has been or will be otherwise made available to fund, any activity or business in any Designated Jurisdiction or to fund any activity or business of any Person located, organized or residing in any Designated Jurisdiction or who is the subject of any Sanctions, or in any other manner that will result in any violation by any Person (including the Administrative Agent, any Lender and any of their respective Affiliates) of Sanctions.

 

SECTION 6.22 Deposit and Disbursement Accounts. Set forth on Schedule 6.22 is a complete and accurate list as of the Closing Date or any Delayed Draw Closing Date of all banks and other financial institutions at which the Borrower or any Guarantor maintains deposit accounts, lockboxes, disbursement accounts, investment accounts or other similar accounts, such Schedule correctly identifies the name, address and telephone number of each bank or financial institution, the name in which each such account is held, the type of each such account, and the complete account number for each such account, and each such account (other than Excluded Accounts) is a Controlled Account to the extent required pursuant to Section 7.13.

 

- 63 -

 

 

SECTION 6.23 Data Privacy and Information Security.

 

(a)            The Borrower and its Subsidiaries maintain data and privacy security policies, processes, and controls, all of which meet or exceed any requirements of applicable Law, except as would not reasonably be expected to have a Material Adverse Effect. To the knowledge of the Borrower, none of the Borrower’s or any Subsidiary’s privacy statements or disclosures have been or are misleading or deceptive, and the contemplated transactions to be consummated hereunder as of the Closing Date or any Delayed Draw Closing Date will not violate any privacy statements, other consumer facing disclosures or Laws, in each case, except as would not reasonably be expected to have a Material Adverse Effect. There is not currently pending and there has not been in the past five (5) years any action, proceeding, suit or claim against the Borrower or its Subsidiaries with respect to privacy or data security, except as would not reasonably be expected to have a Material Adverse Effect. To the knowledge of the Borrower, except as would not reasonably be expected to have a Material Adverse Effect, neither the Borrower nor any Subsidiary, nor any Products, have experienced in the past five (5) years any security incident in which an unauthorized party accessed or acquired Personal Data stored by the Borrower or any Subsidiary, Confidential Business Information stored by the Borrower or any Subsidiary or IT Assets.

 

(b)            Except as would not reasonably be expected to have a Material Adverse Effect, the Borrower and its Subsidiaries have used commercially reasonable efforts to cause all Data Processors that process Personal Data on behalf of the Borrower or any of its Subsidiaries to protect the Personal Data of the Borrower and its Subsidiaries, including without limitation (i) compliance with applicable Privacy Laws and (ii) implementation of a commercially reasonable information security program to protect the applicable Personal Data.

 

(c)            As of the Closing Date and any Delayed Draw Closing Date, except as would not reasonably be expected to have a Material Adverse Effect, the IT Assets are sufficient to conduct the business of the Borrower and the Subsidiaries as currently conducted by the Borrower and the Subsidiaries. To the knowledge of the Borrower, except as would not reasonably be expected to have a Material Adverse Effect, neither the IT Assets nor any Products contain any “virus,” “spyware,” “malware,” “worm,” “Trojan horse” (as such terms are commonly understood in the software industry), disabling codes or instructions, or other similar code or software routines or components (collectively, “Malicious Code”) that are designed or intended to delete, destroy, disable, interfere with, perform unauthorized modifications to, or provide unauthorized access to any data, files, software, system, network, or other device. Except as would not reasonably be expected to have a Material Adverse Effect, the Borrower and its Subsidiaries have established, implemented and tested commercially reasonable backup and disaster recovery policies, procedures and systems sufficient to reasonably maintain the operation of the business of the Borrower and the Subsidiaries as currently conducted.

 

- 64 -

 

 

 

  

(d)            The Borrower, its Subsidiaries and, to the knowledge of the Borrower, any Data Processors have, in all material respects, implemented and maintained reasonable technical measures consistent with generally accepted industry standards to protect the operation, confidentiality, integrity, and security, as applicable, of all Confidential Business Information stored by the Borrower and its Subsidiaries, Personal Data, and IT Assets (including, for clarity, all information and transactions stored or contained therein or transmitted thereby) against unauthorized access, acquisition, interruption, alternation, modification, or use, as applicable.

 

(e)            Except as would not reasonably be expected to have a Material Adverse Effect, the Borrower and its Subsidiaries have taken or caused to be taken commercially reasonable actions designed to ensure that all IT Assets (i) are free from any defect, bug, Malicious Code or programming, design or documentation error or corruption or other defect, and (ii) are fully functional and operate and run in a commercially reasonable manner. Except as would not reasonably be expected to have a Material Adverse Effect, none of the IT Assets have malfunctioned or failed or have experienced any breakdowns or continued substandard performance in the past 24 months that has caused disruption or interruption in the Borrower’s or any Subsidiary’s use thereof or to the business of the Borrower and the Subsidiaries.

 

SECTION 6.24 HIPAA.

 

(a)            Except as would not reasonably be expected to have a Material Adverse Effect, in each instance where the Borrower or any Subsidiary acts as a Covered Entity, such entity is in compliance with HIPAA. The Borrower, and each Subsidiary that acts as a Covered Entity, has implemented reasonable and adequate policies, procedures and training designed to assure continued compliance and to detect non-compliance, except where the failure to implement such policies, procedures, and training would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. Except as would not reasonably be expected to have a Material Adverse Effect, the Borrower, and each Subsidiary that acts as a Covered Entity, has provided all requisite notices, obtained all required consents, and satisfied all other requirements (i) for its use and disclosure of Protected Health Information and (ii) as necessary for the conduct of business as currently conducted and in connection with this Agreement. Except as would not reasonably be expected to have a Material Adverse Effect, the Borrower, and each Subsidiary that acts as a Covered Entity, has entered into business associate agreements with Subsidiaries and Data Processors in all situations where required by 45 C.F.R. §§ 164.502(e) and 164.504(e).

 

(b)            In each instance where Borrower or any Subsidiary acts as a Business Associate, such entity has entered into a Business Associate agreement that is in material compliance with 45 C.F.R. § 164.504(e) with each such Covered Entity, as required by 45 C.F.R. § 164.502(e)(2), except where failure to have entered into a Business Associate agreement would not have a Material Adverse Effect. Except as would not reasonably be expected to have a Material Adverse Effect, in those instances where the Borrower or any Subsidiary acts as a Business Associate on behalf of Covered Entities, each of the Borrower and such Subsidiary is, and has been, in compliance with all applicable Business Associate agreements and those portions of HIPAA applicable to Business Associates.

 

- 65 -

 

 

(c)            Except as would not reasonably be expected to have a Material Adverse Effect, the Borrower, and each Subsidiary that acts as a Covered Entity or Business Associate, has implemented a comprehensive written information security program that complies with 45 C.F.R. Part 164, Subpart C. Except as would not reasonably be expected to have a Material Adverse Effect, the Borrower, and each Subsidiary that acts as a Covered Entity or Business Associate, have addressed and fully remediated all identified threats and deficiencies to the security of Protected Health Information maintained by such entity consistent with applicable Laws, including HIPAA.

 

(d)            As of the Closing Date, except as set forth on Schedule 6.24(d), to the knowledge of the Borrower, for the past three (3) years, there has been no material security incident or material breach of any Protected Health Information held by the Borrower or any Subsidiary. As of the Closing Date, except as set forth on Schedule 6.24(d), the Borrower has not, nor has any Subsidiary or other third party acting on Borrower’s behalf, notified, or been required to notify, any person of any security incident, including any loss or unauthorized access, use or disclosure, of Protected Health Information that would constitute a breach for which notification to individuals, the media, or the U.S. Department of Health and Human Services is required under 45 C.F.R. Part 164, Subpart D.

 

SECTION 6.25 No Side Arrangements or Other Fees. As of the Closing Date, (i) there are no agreements or arrangements with any Lender or an Affiliate of a Lender relating to the Loans, Commitments, the Loan Documents or the facilities contemplated by the Loan Documents that have not been disclosed to each Significant Lender on or prior to the Closing Date or (ii) there are no fees payable to any Lender or an Affiliate of a Lender in connection with the Loans, Commitments, the Loan Documents or the facilities contemplated by the Loan Documents other than as expressly set forth in this Agreement, the Fee Letter and Agency Fee Letter.

 

ARTICLE VII
AFFIRMATIVE COVENANTS

 

The Borrower covenants and agrees with the Administrative Agent and the Lenders that until the Termination Date has occurred, the Borrower will, and will cause the Subsidiaries to, perform or cause to be performed the obligations set forth below.

 

SECTION 7.1 Financial Information, Reports, Notices, Etc.. The Borrower will (or, solely in the case of clause (l) below, will use commercially reasonable efforts to) furnish the Administrative Agent for further delivery to the Lenders (or, solely in the case of clause (i) below, furnish the Significant Lenders upon request by any Significant Lender) copies of the following financial statements, reports, notices and information:

 

(a)            prior to the consummation of a Direct Listing, Qualified IPO or Qualified SPAC Transaction, concurrently with the delivery of the financial information pursuant to Section 7.1(b) (solely with respect to the Fiscal Quarter ending June 30 and December 31 of each Fiscal Year), the Borrower shall (x) identify to the Administrative Agent each Material Agreement then in effect and (y) provide a copy of the “Payer Revenue Per Case” file previously provided to the Lenders containing updated information as of the last day of such applicable Fiscal Quarter;

 

- 66 -

 

 

(b)            (i) as soon as available and in any event within 60 days after the end of each Fiscal Quarter of each Fiscal Year beginning with the fiscal quarter ended December 31, 2022, an unaudited consolidated balance sheet of the Borrower and the Subsidiaries as of the end of such Fiscal Quarter and related consolidated statements of income, stockholders’ equity and cash flows of the Borrower and the Subsidiaries for such Fiscal Quarter and for the period commencing at the end of the previous Fiscal Year and ending with the end of such Fiscal Quarter, and including (in each case) in comparative form the figures for the corresponding Fiscal Quarter in the immediately preceding Fiscal Year, and (ii) as soon as available and in any event within 60 days after the end of each Fiscal Quarter of each Fiscal Year, the Revenue Base for such Fiscal Quarter and for the twelve-month period ending with the end of such Fiscal Quarter and including (in each case) in comparative form the figures for the corresponding Fiscal Quarter in the immediately preceding Fiscal Year and the corresponding twelve-month period immediately preceding such twelve-month period, certified as complete and correct by the chief financial or accounting Authorized Officer of the Borrower (subject to normal year-end audit adjustments and the absence of footnotes);

 

(c)            as soon as available and in any event within 120 days after the end of each Fiscal Year beginning with the Fiscal Year ended December 31, 2022, (i) a copy of the consolidated balance sheet of the Borrower and the Subsidiaries, and the related consolidated statements of income, stockholders’ equity and cash flows of the Borrower and the Subsidiaries for such Fiscal Year, setting forth in comparative form the figures for the immediately preceding Fiscal Year, audited (without any Impermissible Qualification) by independent public accountants acceptable to the Required Lenders (it being understood that Ernst & Young LLP or any other “Big Four” accounting firm are reasonably acceptable to the Required Lenders); and (ii) a report of the Revenue Base for the Fiscal Quarter then ending and such Fiscal Year and including in comparative form the figures for the corresponding Fiscal Quarter in the immediately preceding Fiscal Year and the immediately preceding Fiscal Year;

 

(d)            concurrently with the delivery of the financial information pursuant to clauses (b) (solely with respect to the first three Fiscal Quarters of each Fiscal Year) and (c), a Compliance Certificate, executed by the chief financial or accounting Authorized Officer of the Borrower, (i) showing compliance with the financial covenants set forth in Section 8.4 and stating that no Default has occurred and is continuing (or, if a Default has occurred, specifying the details of such Default and the action that the Borrower or any of the Subsidiaries has taken or proposes to take with respect thereto), (ii) stating that no Subsidiary has been formed or acquired since the delivery of the last Compliance Certificate (or, if such Subsidiary has been formed or acquired since the delivery of the last Compliance Certificate, a statement that such Subsidiary has complied with Section 7.8 to the extent required thereunder) and (iii) stating that no Material Real Property has been acquired by any Loan Party or any of the Subsidiaries since the delivery of the last Compliance Certificate (or, if any Material Real Property has been acquired since the delivery of the last Compliance Certificate, a statement that the Loan Parties have complied with Section 7.8 with respect to any such real property);

 

- 67 -

 

 

(e)            as soon as possible and in any event within five (5) Business Days after the Borrower obtains knowledge of the occurrence of a Default, a statement of an Authorized Officer of the Borrower setting forth details of such Default and the action which the Borrower or any of the Subsidiaries has taken or proposes to take with respect thereto;

 

(f)             as soon as possible and in any event within five (5)  Business Days after the Borrower obtains knowledge of (i) the occurrence of any material adverse development with respect to any litigation, action, proceeding or labor controversy described in Schedule 6.7(a) or (ii) the commencement of any litigation, action, proceeding or labor controversy of the type and materiality described in Section 6.7, notice thereof and, to the extent any Lender requests, copies of all documentation reasonably requested by such Lender relating thereto (excluding any documentation subject to attorney-client privilege);

 

(g)            reasonably promptly after the commencement thereof, notice of any adverse proceeding commenced by the Borrower or any Loan Party against any non-Affiliated Person and involving an amount in controversy in excess of $10,000,000;

 

(h)            as soon as possible and in any event within three days after the Borrower obtains knowledge of: (i) any claim that the Borrower, any of the Subsidiaries or one of their ERISA Affiliates has actual or potential liability under a Benefit Plan (including the occurrence of any ERISA Event) that, individually or in the aggregate, would reasonably be expected to result in a Material Adverse Effect, (ii) any effort to unionize the employees of the Borrower or any Subsidiary that, individually or in the aggregate, would reasonably be expected to result in a Material Adverse Effect, or (iii) material, non-routine correspondence with the Internal Revenue Service regarding the qualification of a retirement plan under section 401(a) of the Code that would reasonably be expected to result in liabilities to the Borrower or any of the Subsidiaries in excess of $5,000,000;

 

(i)             prior to the consummation of a Direct Listing, Qualified IPO or Qualified SPAC Transaction, promptly upon request by a Significant Lender, to such Significant Lender and to each other Significant Lender all notices and any materials delivered to the board of directors (or equivalent) of the Borrower or any committees thereof in connection with a meeting of such board or committee, or with any action to be taken by written consent, including drafts of any material resolutions or actions proposed to be adopted by written consent; provided that the Borrower reserves the right to withhold any information if access to such information could adversely affect the attorney-client privilege between the Borrower and its counsel or result in disclosure of trade secrets or a conflict of interest or to the extent that the board of directors (or equivalent) of the Borrower in the exercise of its fiduciary obligations and with the advice of counsel determines that (A) it is in the best interest of the Borrower to do so because any Lender or any of its respective Affiliates has an interest in the subject matter under discussion or (B) doing so is necessary to discharge the directors’ fiduciary duties;

 

- 68 -

 

  

(j)             promptly upon receipt thereof, copies of all “management letters” (or equivalent) submitted to the Borrower or any of the Subsidiaries by the independent public accountants referred to in clause (c) in connection with each audit made by such accountants;

 

(k)            promptly upon receipt thereof (or in the case of updates to previously disclosed matters under this clause (k), promptly upon request by the Required Lenders), copies of all subpoenas, requests for information and other notices regarding any active or potential investigation of, or claim or litigation against, the Borrower or any of the Subsidiaries by any Governmental Authority, and the results of any inspections of any manufacturing facilities of the Borrower or any of the Subsidiaries or, where the results are known by the Borrower, any Third Party suppliers of the Borrower or any of the Subsidiaries by any Governmental Authority (including any Form FDA 483s), in each case, to the extent that such investigation, claim or litigation, or the results of any such inspection, could reasonably be expected to result in liability in excess of $7,500,000 or have or result in a Material Adverse Effect;

 

(l)             prior to the consummation of a Direct Listing, Qualified IPO or Qualified SPAC Transaction, promptly, after the Administrative Agent or any Significant Lender so requests, copies of any Material Agreement and information reasonably requested by the Administrative Agent or such Significant Lender in connection with the listing of Material Agreements provided by the Borrower pursuant to Section 7.1(a)(i);

 

(m)           following the consummation of a Direct Listing, a Qualified IPO or a Qualified SPAC Transaction, after the sending or filing thereof, copies of all reports, notices, prospectuses and registration statements which the Borrower or any of the Subsidiaries files with the SEC or any national securities exchange;

 

(n)            as soon as available, but in any event not later than February 28 of each calendar year, the Borrower’s financial and business projections and budget for such year, as approved by the Borrower’s board of directors (or equivalent); and

 

(o)            such other financial and other information as any Lender or the Administrative Agent may from time to time reasonably request (including information and reports in such detail as such Lender or the Administrative Agent may reasonably request with respect to the terms of and information provided pursuant to the Compliance Certificate).

 

- 69 -

 

 

The Borrower hereby acknowledges that (a) the Administrative Agent will make available to the Lenders the Borrower Materials (for the avoidance of doubt, other than any material required to be furnished pursuant to Section 7.1(i) hereof) by posting the Borrower Materials on the Platform and (b) certain of the Lenders may be “public-side” Lenders (i.e., any Lender that has selected the “Private-Side Information” or similar designation on the content declaration screen of the Platform in order to enable such Lender to make reference to information that is not made available through the “Public-Side Information” portion of the Platform and that may contain material non-public information with respect to the Borrower or its securities) (each, a “Public Lender”). The Borrower hereby agrees that (w) it will ensure that all Borrower Materials that are to be made available to Public Lenders shall be clearly and conspicuously marked “PUBLIC” which, at a minimum, shall mean that the word “PUBLIC” shall appear prominently on the first page thereof, (x) by marking Borrower Materials “PUBLIC,” the Borrower shall be deemed to have authorized the Administrative Agent and the Lenders to treat the Borrower Materials as either information that would be made publicly available if the Borrower was a public company or not material information (although it may be sensitive and proprietary) with respect to the Borrower for purposes of United States Federal and state securities laws; provided that to the extent such Borrower Materials constitute Confidential Information, the same shall be treated as set forth in Section 10.14, (y) all Borrower Materials marked “PUBLIC” are permitted to be made available through a portion of the Platform designated “Public Lender” and (z) the Administrative Agent shall treat the Borrower Materials that are not marked “PUBLIC” as being suitable only for posting on a portion of the Platform designated “Private Lender.” Notwithstanding the foregoing, subject to Section 10.2, the Borrower shall not be under any obligation to make any Borrower Materials public.

 

To the extent applicable, documents required to be delivered pursuant to clauses (b), (c) and (m) of this Section 7.1 shall be deemed to have been delivered on the date on which such documents are filed for public availability on the SEC’s Electronic Data Gathering and Retrieval System.

 

SECTION 7.2 Maintenance of Existence; Compliance with Contracts, Laws, Etc.. The Borrower and each Subsidiary will (a) preserve and maintain its legal existence (except as otherwise permitted by Section 8.7) in its jurisdiction of organization and each other jurisdiction in which they are it is qualified to do business other than any such jurisdiction (other than its jurisdiction of organization) where the failure to be so qualified or in good standing would not reasonably be expected to have a Material Adverse Effect; (b) perform in all material respects its obligations under Material Agreements, except where the failure to do so would not reasonably be expected to have a Material Adverse Effect; (c) comply in all material respects with all applicable Laws, rules, regulations and orders, except where the failure to do so would not reasonably be expected to have a Material Adverse Effect; and (d) pay (before the same become delinquent) all material Taxes, imposed upon the Borrower or any of the Subsidiaries or upon their property except to the extent being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP have been set aside on the books of the Borrower or any of the Subsidiaries, as applicable.

 

SECTION 7.3 Maintenance of Properties. Except as would not reasonably be expected to result in a Material Adverse Effect, the Borrower and the Subsidiaries will maintain, preserve, protect and keep its and their respective properties in good repair, working order and condition (ordinary wear and tear excepted), and make reasonably necessary repairs, renewals and replacements so that the business carried on by the Borrower or any of the Subsidiaries may be conducted at all times.

 

- 70 -

 

 

SECTION 7.4 Insurance. The Borrower and each of the Subsidiaries will maintain:

 

(a)            insurance on its property with financially sound and reputable insurance companies against business interruption, loss and damage in at least the amounts (and with only those deductibles) customarily maintained, and against such risks as are typically insured against in the same general area, by Persons of comparable size engaged in the same or similar business as the Borrower and the Subsidiaries; and

 

(b)            all worker’s compensation, employer’s liability insurance or similar insurance as may be required under the laws of any state or jurisdiction in which it may be engaged in business.

 

Without limiting the foregoing, the Loan Parties shall deliver to the Administrative Agent endorsements to the property/casualty insurance and liability insurance policies in form and substance reasonably acceptable to the Administrative Agent and the Required Lenders that: (i) (x) in the case of property/casualty insurance, name the Administrative Agent as mortgagee (if applicable) and lender loss payee, and (y) in the case of liability insurance, name the Administrative Agent as additional insured; and (ii) provide that no cancellation or modification as to the amount or scope of coverage of such property/casualty and liability policies will be made without at least thirty (30) days’ prior written notice thereof (or ten (10) days’ prior written notice thereof in the case of cancellation due to non-payment of premiums) to the Administrative Agent; provided that the requirement in the foregoing clause (ii) shall not apply to any policy renewals providing for the same or greater coverage.

 

SECTION 7.5 Books and Records. The Borrower and each of the Subsidiaries will keep books and records in accordance with GAAP which accurately reflect all of its business affairs and transactions and permit the Administrative Agent, any Lender or any of their respective representatives, at reasonable times and intervals upon reasonable notice to the Borrower, to visit the Borrower’s or any of the Subsidiaries’ offices during normal business hours, to discuss the Borrower’s or any of the Subsidiaries’ financial or other matters with its officers and employees, and its independent public accountants (the Borrower shall be given the opportunity to participate in any discussions with the Borrower’s independent public accounts, but the Borrower hereby authorizes such independent public accountant to discuss the Borrower’s and any of the Subsidiaries’ financial and other matters with the Administrative Agent, any Lender or their respective representatives whether or not any representative of the Borrower or any of the Subsidiaries is present) and to examine any of its books and records; provided that excluding any such visits and inspections during the continuation of any Event of Default, no more than one such visit during any calendar year shall be at the Borrower’s expense. The Borrower shall pay any fees of such independent public accountant incurred in connection with the Administrative Agent’s or any Lender’s exercise of its rights pursuant to this Section. Notwithstanding anything to the contrary in this Section 7.5, none of the Borrower or any of the Subsidiaries will be required to disclose, permit the inspection, examination or making copies or abstracts of, or discussion of, any document, information or other matter that (a) constitutes non-financial trade secrets or non-financial proprietary information, (b) in respect of which disclosure to the Administrative Agent or any Lender (or their respective representatives) is prohibited by law or any binding agreement or (c) is subject to attorney-client or similar privilege or constitutes attorney work product. In any event, the inspections described in this Section 7.5 shall be conducted in a manner that will not unreasonably interfere with the business operations of the Borrower and the Subsidiaries.

 

- 71 -

 

 

SECTION 7.6 Environmental Law Covenant. The Borrower and each of the Subsidiaries will (i) use and operate all of its and their businesses, facilities and properties in material compliance with all Environmental Laws, and keep and maintain all Environmental Permits and remain in compliance therewith, except as could not reasonably be expected to have a Material Adverse Effect, and (ii) promptly notify the Administrative Agent of, and provide the Administrative Agent with copies of all material claims, complaints, notices or inquiries relating to, any actual or alleged non-compliance with any Environmental Laws or Environmental Permits or any actual or alleged Environmental Liabilities. The Borrower and each of the Subsidiaries will promptly resolve, remedy and mitigate any such non-compliance or Environmental Liabilities, except as could not reasonably be expected to have a Material Adverse Effect.

 

SECTION 7.7 Use of Proceeds. The Borrower will use the proceeds of the Loans for general corporate purposes, to consummate the Existing Debt Refinancing and to pay fees and expenses associated with the Closing Date Transactions and the other transactions contemplated hereby and thereby.

 

SECTION 7.8 Future Guarantors, Security, Etc. The Loan Parties will execute any documents, financing statements, agreements and instruments, and take all further action that may be required under applicable Law, or that the Administrative Agent or the Required Lenders may reasonably request, in order to effectuate the transactions contemplated by the Loan Documents and in order to grant, preserve, protect and perfect the validity (subject to Liens permitted by Section 8.3 and any exceptions and limitations expressly permitted by the Loan Documents) of the Liens created or intended to be created by the Loan Documents. The Borrower will cause (a) (i) any subsequently acquired Subsidiary (other than any Excluded Subsidiary), within twenty (20) Business Days (or such later date as agreed by the Required Lenders in their reasonable discretion) of its acquisition, and (ii) any subsequently organized Subsidiary (other than any Excluded Subsidiary), within ten (10) Business Days (or such later date as agreed by the Required Lenders in their reasonable discretion) of its formation, to execute a supplement (in form and substance reasonably satisfactory to the Administrative Agent and the Required Lenders) to the Guarantee and each other applicable Loan Document in favor of the Administrative Agent for the benefit of the Secured Parties, to cause such Subsidiary to become compliant with the terms of the Security Agreement, and take such other actions as may be required or reasonably requested by the Administrative Agent for the benefit of the Secured Parties to have a valid Lien with the priority intended to be created on, and security interest in, substantially all of the assets of such Subsidiary (other than any Excluded Assets), subject to no other Liens (other than Liens permitted by Section 8.3) and the limitations set forth below and (b) except to the extent constituting (or intended to constitute) Excluded Assets, all of the presently existing or thereafter arising issued and outstanding shares of Capital Securities of any Subsidiary (other than any Excluded Subsidiary) to be pledged to the Administrative Agent for the benefit of the Secured Parties pursuant to one or more pledge agreements or other documents reasonably acceptable to the Administrative Agent. The Borrower will promptly notify the Administrative Agent of any subsequently acquired ownership interest in Material Real Property and will provide the Administrative Agent with a description of such Material Real Property, the acquisition date thereof and the purchase price therefor. In addition, from time to time, each of the Loan Parties will, at its cost and expense, reasonably promptly take such actions as shall be necessary to secure the Obligations by pledging or creating, or causing to be pledged or created, perfected Liens with respect to such assets and properties as the Administrative Agent or the Required Lenders shall designate (other than any Excluded Assets and fee-owned real property that does not qualify as Material Real Property), it being agreed that it is the intent of the parties that the Obligations shall be secured by, among other things, substantially all the assets of the Loan Parties (including Material Real Property and personal property acquired subsequent to the Closing Date but excluding any Excluded Assets and fee-owned real property that does not qualify as Material Real Property). Such Liens will be created under the Loan Documents in form and substance reasonably satisfactory to the Administrative Agent and the Required Lenders, and the Loan Parties shall deliver or cause to be delivered to the Administrative Agent all such instruments and documents (including mortgages, legal opinions, title insurance policies and lien searches) as the Administrative Agent or the Required Lenders shall reasonably request to evidence compliance with this Section.

 

- 72 -

 

 

SECTION 7.9 Obtaining of Permits, Etc. With respect to Products, the Borrower and each of the Subsidiaries will obtain, maintain and preserve, and take all necessary action to timely renew all Permits and accreditations which are necessary in the proper conduct of its business.

 

SECTION 7.10 [Reserved].

 

SECTION 7.11 Maintenance of Regulatory Authorizations, Contracts, Intellectual Property, Etc.

 

(a)            With respect to the Products, each of the Borrower and each of the Subsidiaries will, in all material respects, (i) maintain in full force and effect all Regulatory Authorizations, contract rights, or other rights necessary for the operations of its business; (ii) pursue the prosecution of and pay all costs and expenses relating to, all Owned Intellectual Property and all Material Agreements, except in the case of each of the foregoing in the event that the Borrower or any of the Subsidiaries determines in its reasonable commercial judgment not to do so; (iii) notify the Administrative Agent (which shall furnish such notice to the Lenders), promptly after commencing such legal action, of any legal action that is material to the Borrower and its Subsidiaries brought by the Borrower or any of its Subsidiaries alleging Infringement by any Person of any Owned Intellectual Property and pursue any such legal action, except in any specific circumstances where the Borrower reasonably determines it is not commercially reasonable to do so or where providing such notice could reasonably compromise attorney-client privilege or otherwise adversely affect Borrower or its Subsidiaries ability to effectively enforce any Owned Intellectual Property or otherwise pursue such legal action; (iv) use commercially reasonable efforts to pursue and maintain in full force and effect legal protection for, and protect against Infringement with respect to, all Owned Intellectual Property and all Licensed Intellectual Property for which Borrower or any Subsidiary has the right to enforce, except in the event that the Borrower or any of the Subsidiaries determines in its reasonable commercial judgment not to do so; (v) notify the Administrative Agent (which shall furnish such notice to the Lenders), where it is permissible to do so and promptly after learning thereof, of (1) any legal action filed by any Third Party with a Governmental Authority, or any written notice, allegation, or other communication from any Third Party, alleging that the conduct of the business of Borrower or any of the Subsidiaries (including the development, manufacture, use, sale or other commercialization of any Product) Infringes any Intellectual Property of that or any other Third Party in any material respect or challenging the validity or enforceability of any material Owned Intellectual Property or any material Licensed Intellectual Property, except where (1) it is not commercially reasonable to provide such notice or (2) where providing such notice could reasonably compromise attorney-client privilege or otherwise adversely affect Borrower or its Subsidiaries ability to effectively defend against any claims of Infringement, invalidity, or unenforceability and Borrower will use commercially reasonable efforts to resolve any such claim(s), except where the Borrower or any of its Subsidiaries determines in its reasonable commercial judgment not to do so; and (vi) maintain an appropriate information security program with organizational, physical, administrative and technical measures to protect the operation, confidentiality, integrity, and security, as applicable, of all Confidential Business Information of the Borrower or any Subsidiary, Personal Data stored by the Borrower or any Subsidiary and material IT Assets against unauthorized access, acquisition, interruption, alteration, modification, or use, as applicable, in each case of the foregoing clauses (i), (ii), (iv) and (vi), except where the failure to do so would not reasonably be expected to have a Material Adverse Effect.

 

- 73 -

 

 

(b)            Each of the Borrower and its Subsidiaries will furnish to the Administrative Agent (which shall furnish such notice to the Lenders) prompt written notice of the following, and, with respect to clauses (i) and (ii) below, copies of any notices from, or responses to, any Governmental Authority:

 

(i)            any written notice that any Governmental Authority is limiting, suspending or revoking any Regulatory Authorization, changing the market classification or labeling of or otherwise materially restricting the marketing of the Products of the Borrower or any of its Subsidiaries;

 

(ii)           the Borrower or any of its Subsidiaries receiving written notice from CMS, FDA or another Governmental Authority of (A) such Person becoming subject to any warning letter, untitled letter, notice of violation letter, or similar notification, (B) a material shut-down or suspension of testing services at any laboratory operated by the Borrower or any of its Subsidiaries; or (C) any Product of the Borrower or any of its Subsidiaries being seized, withdrawn, recalled, detained, or subject to a suspension of manufacturing or import alert, or the commencement of any proceedings in the United States or any other jurisdiction seeking the withdrawal, recall, suspension, import detention or refusal, or seizure of any Product are pending or threatened against the Borrower or any of its Subsidiaries; or

 

(iii)          copies of any written recommendation from any Governmental Authority or other regulatory body that the Borrower or any of its Subsidiaries, or any obligor (to the extent received by the Borrower) to which the Borrower or any of its Subsidiaries provides services that are material to the Borrower and its Subsidiaries, taken as a whole, should have any material licensure, clearance(s), provider or supplier number, or accreditation suspended or revoked, or any material penalties or sanctions imposed.

 

- 74 -

 

 

(c)            Each of the Borrower and the Subsidiaries will promptly notify the Administrative Agent (which shall furnish such notice to the Lenders) as soon as possible and in any event within five (5) days of learning of a notification by the FDA, or any comparable foreign Governmental Authority, that a Product that is an LDT must affirmatively be approved or cleared as a medical device to continue to be marketed, and is not subject to an exercise of enforcement discretion, it being understood and agreed that, as of the Closing Date, the Borrower and its Subsidiaries do not have medical device clearances or approvals from the FDA for its LDTs.

 

SECTION 7.12 [Reserved].

 

SECTION 7.13 Cash Management. The Loan Parties will:

 

(a)            (i) maintain a current and complete list of all accounts (of the type initially set forth on Schedule 6.22) of the Loan Parties (other than (A) any accounts exclusively used for payroll, payroll taxes and other employee wage and benefit programs to or for the benefit of the Borrower’s or a Subsidiary’s employees, which shall in no event hold in the aggregate more than the amount generally maintained in such accounts in the ordinary course of business, (B) accounts of the Borrower and the Guarantors constituting trust, fiduciary and escrow accounts, (C) accounts of the Borrower and the Guarantors that solely secure obligations in respect of letters of credit, credit cards and other obligations which are permitted by clauses (m), (n) and (o) of Section 8.2, (D) accounts of the Borrower and the Guarantors located outside the United States, in which, in the case of this clause (D), there is not maintained at any point in time funds on deposit, together with funds on deposit in accounts of Excluded Subsidiaries in compliance with clause (iv) of the definition of “Excluded Subsidiary”, greater than $5,000,000 in the aggregate for all such accounts under such clauses, (E) any accounts consisting solely of withheld income taxes and federal, state or local employment taxes in such amounts as are required in the reasonable judgment of the Loan Party in the ordinary course of business to be paid to the Internal Revenue Service or state or local government agencies with respect to current or former employees of any of the Loan Parties, (F) any accounts consisting solely of amounts required to be paid over to an employee benefit plan pursuant to DOL Reg. Sec. 2510.3-102 on behalf of or for the benefit of employees of one or more Loan Parties and (G) zero balance accounts so long as the balance in such account is zero at the end of each Business Day (provided that any accounts pursuant to this clause (G) shall remain zero balance accounts for such purpose during the term of this Agreement and shall be subject to a sweep agreement reasonably satisfactory to the Administrative Agent and the Required Lenders, and the Borrower shall use commercially reasonable efforts to require that the depositary bank thereunder provide ten (10) days’ prior notice to the Administrative Agent and the Lenders prior to any change to the terms of the daily sweep of such account(s)) (clauses (A) through (G), collectively, the “Excluded Accounts”)) and promptly deliver any updates to such list to the Administrative Agent; and (ii) in addition to complying with clause (c) below and subject to Section 7.15 hereof, as applicable, execute and maintain a “springing” account control agreement for each such account (other than Excluded Accounts) in form and substance reasonably acceptable to the Administrative Agent and the Required Lenders (each such account, a “Controlled Account”);

 

- 75 -

 

 

(b)            deposit promptly after the date of receipt thereof in accordance with prudent business practices all cash, checks, drafts or other similar items of payment relating to or constituting payments made in respect of any and all accounts and other rights and interests into Controlled Accounts except to the extent permitted to be kept in Excluded Accounts;

 

(c)            in order to perfect Administrative Agent’s security interest in funds received from Governmental Payors making payments under Medicare, Medicaid or any other federal or state healthcare program and other account debtors, the Loan Parties will create and maintain an account into which all deposits from existing accounts which contain funds received from Governmental Payors and other account debtors shall be swept on a daily basis, which account shall be a Controlled Account; provided, that, for the avoidance of doubt, no breach of this Section 7.13(c) shall be deemed to have occurred and the Loan Parties shall be deemed compliant with this Section 7.13(c) if any such funds shall not be swept on a daily basis in accordance with the foregoing provisions in this Section 7.13(c) solely due to the account bank’s failure to perform its obligations under the applicable account documentation and not due to any action by the Loan Parties or any failure of the Loan Parties to perform their respective obligations hereunder or under any account documentation; and

 

(d)            at any time after the occurrence and during the continuance of an Event of Default, at the request of the Administrative Agent (acting at the direction of the Required Lenders), promptly cause all payments constituting proceeds of accounts to be directed into lockbox accounts under agreements in form and substance reasonably satisfactory to the Required Lenders.

 

- 76 -

 

 

SECTION 7.14 Excluded Subsidiaries.

 

(a)            If at any time (x) the aggregate cash or Cash Equivalent Investments attributable to all Excluded Subsidiaries except for Excluded Subsidiaries excluded pursuant to clause (C) of the definition of “Excluded Subsidiary” exceeds $5,000,000, the Borrower shall (i) designate sufficient applicable Subsidiaries as “Guarantors” to eliminate such excess, and such designated Subsidiaries shall for all purposes of this Agreement constitute Guarantors and be subject to the provisions of Section 7.8, or (ii) immediately repatriate cash and/or Cash Equivalent Investments in an aggregate amount sufficient to eliminate such excess, (y) the aggregate portion of the Revenue attributable to (I) an Excluded Subsidiary exceeds 5.0% of the Revenue of the Borrower and its Subsidiaries or (II) all Excluded Subsidiaries except for Excluded Subsidiaries excluded pursuant to clause (C) of the definition of “Excluded Subsidiary” exceeds 10.0% of the Revenue of the Borrower and its Subsidiaries, as applicable, in each case for any period of four consecutive Fiscal Quarters (determined as of the last day of the most recent Fiscal Quarter for which financial statements have been delivered pursuant to Section 7.1(b) or Section 7.1(c) (or, if prior to the date of the delivery of the first financial statements to be delivered pursuant to Section 7.1(b) or Section 7.1(c), the most recent financial statements referred to in Section 5.6)), the Borrower shall designate such applicable Excluded Subsidiary or sufficient applicable Subsidiaries as “Guarantors” to eliminate such excess, and such designated Subsidiaries shall for all purposes of this Agreement constitute Guarantors and be subject to the provisions of Section 7.8 or (z) the aggregate portion of total assets attributable to (I) an Excluded Subsidiary exceeds 5.0% of the consolidated total assets of the Borrower and its Subsidiaries or (II) all Excluded Subsidiaries except for Excluded Subsidiaries excluded pursuant to clause (C) of the definition of “Excluded Subsidiary” exceeds 10.0% of the consolidated total assets of the Borrower and its Subsidiaries, as applicable, in each case for any period of four consecutive Fiscal Quarters (determined as of the last day of the most recent Fiscal Quarter for which financial statements have been delivered pursuant to Section 7.1(b) or Section 7.1(c) (or, if prior to the date of the delivery of the first financial statements to be delivered pursuant to Section 7.1(b) or Section 7.1(c), the most recent financial statements referred to in Section 5.6)), the Borrower shall designate such applicable Excluded Subsidiary or sufficient applicable Subsidiaries as “Guarantors” to eliminate such excess, and such designated Subsidiaries shall for all purposes of this Agreement constitute Guarantors and be subject to the provisions of Section 7.8.

 

(b)            Should (x) an Excluded Subsidiary cease to meet the criteria set forth in clauses (i), (ii) or (iii) of clause (A) of the definition thereof, (y) an Excluded Subsidiary hold any exclusive right, title or interest in any material Core Asset or (z) should any not-for-profit Subsidiary (including Caris Molecular Pathology) no longer constitute or be qualified as a “non-for-profit” Person in its jurisdiction of organization, in each case, the Borrower shall designate such Subsidiary as a “Guarantor”, and such Subsidiary shall for all purposes of this Agreement constitute a Guarantor and be subject to the provisions of Section 7.8.

 

(c)            On or prior to the date that is 90 days after the Closing Date or such longer period as the Administrative Agent and the Required Lenders may agree in their sole discretion, the Borrower shall cause Caris Research Institute, Inc. to comply with the requirements of Section 7.8 or to be dissolved. From the Closing Date until Caris Research Institute, Inc. either dissolves or complies with the requirements of Section 7.8, it shall be a dormant company with no operations, no assets and no liabilities.

 

- 77 -

 

 

SECTION 7.15 Post-Closing Deliverables. Notwithstanding anything to the contrary herein or in the other Loan Documents (it being understood that to the extent that the existence of any of the following post-closing obligations that is not overdue would otherwise cause any representation, warranty, covenant, default or event of default in this Agreement or any other Loan Document to be in breach, the Lenders hereby waive such breach for the period from the Closing Date until the first date on which such condition is required to be fulfilled (giving effect to any extensions thereof) pursuant to this Section 7.15), the Borrower shall deliver or cause to be delivered the following items to the Administrative Agent, or take or cause to be taken the following actions, in each case, no later than the dates set forth below (or such later date agreed to by Required Lenders in their sole discretion), and each deliverable shall be in form and substance reasonably satisfactory to the Required Lenders:

 

(a)            Within thirty (30) days after the Closing Date, all endorsements to insurance policies required to be maintained pursuant to the Loan Documents in favor of the Administrative Agent required under the Loan Documents;

 

(b)            Borrower shall use commercially reasonable efforts (in consultation with the Significant Lenders and giving consideration to the interests of the Lenders) to deliver landlord access agreements and bailee letters in form and substance reasonably satisfactory to the Required Lenders from the landlords at the following locations within ninety (90) days after the Closing Date, or as promptly as reasonably practicable thereafter:

 

(i)            750 West John Carpenter Freeway, Suite 800, Irving, Texas 75039;

 

(ii)           4415 Cotton Ctr Blvd., Suite 100, Phoenix, Arizona;

 

(iii)          4610 S 44th Pl., Bldg 16 (BDO), Phoenix, Arizona;

 

(iv)          4025 E Cotton Ctr Blvd., Suite 200, Phoenix, Arizona;

 

(v)           350 W Washington St., 4th Floor, Tempe, Arizona;

 

(vi)          3600 West Royal Lane, Irving, Texas 75063;

 

(vii)         3680 West Royal Lane, Suite 115, Irving, Texas 75063; and

 

(viii)        2221 Alliance Boulevard, Suite 100, Fort Worth, Texas 76177;

 

(c)            Within ninety (90) days after the Closing Date, evidence that all deposit accounts, lockboxes, disbursement accounts, investment accounts or other similar accounts of the Borrower and each Guarantor are Controlled Accounts (other than Excluded Accounts);

 

(d)            Within sixty (60) days after the Closing Date, the Borrower shall have filed for recordation with the Federal Aviation Administration a security agreement to perfect the Administrative Agent’s security interest in the Gulfstream model G280 aircraft (bearing U.S. registration mark N213GA and manufacturer’s serial number 2213) registered to Caris Science, Inc., together with any other filings or registrations related thereto; and

 

- 78 -

 

 

(e)            The Loan Parties shall use commercially reasonable efforts (in consultation with the Significant Lenders and giving consideration to the interests of the Lenders) to deliver UCC “fixture filing” financing statements suitable in form for naming the applicable Loan Party as a debtor and the Administrative Agent as the secured party, or other similar instruments or documents to be filed under the UCC of all jurisdictions as may be necessary or, in the opinion of the Required Lenders, desirable to perfect the security interests of the Administrative Agent, on behalf of the Secured Parties, in the Collateral located at each location described under clause (i) of the definition of “Fixture Location”, in each case within ninety (90) days after the Closing Date, or as promptly as reasonably practicable thereafter; and

 

(f)             Within ninety (90) days of the Closing Date, the Borrower shall have delivered (or caused its applicable Subsidiary to deliver) to the Administrative Agent: (i) a joinder (which may be effectuated pursuant to counterpart signatures) to the intercompany note contemplated by Section 8.2(k)(i), duly executed by each applicable Subsidiary of the Borrower, (ii) to the extent constituting Collateral, the original stock certificate for Caris Life Sciences (Gibraltar) Limited, together with the related executed stock power, and (iii) a duly executed “authenticated record” as contemplated by Section 4.1.2(b) of the Security Agreement, in relation to the Capital Securities of Caris KK (solely to the extent constituting Collateral).

 

SECTION 7.16 Parent HoldCo Reorganization. Upon the consummation of a Parent HoldCo Reorganization, (i) each Parent HoldCo shall become a Loan Party under this Agreement and the other Loan Documents and comply with the requirements under Section 7.8, (ii) each reference in this Agreement to “the Borrower and its Subsidiaries” shall be deemed to be a reference to “each Parent HoldCo, the Borrower and its Subsidiaries” and each reference in this Agreement to “the Borrower or its Subsidiaries” or to “the Borrower or any of its Subsidiaries” shall be deemed to be a reference to “any of Parent HoldCo, the Borrower or its Subsidiaries”. At all times after the consummation of a Parent HoldCo Reorganization, each Parent HoldCo shall be a passive holding company with no operations, no assets and no liabilities, other than:

 

(a)            acting as a holding company for, and owning the Capital Securities of the Borrower or any other Parent HoldCo and activities and assets incidental thereto,

 

(b)            maintenance and administration of stock option and stock ownership plans and activities incidental thereto,

 

(c)            the receipt and making of Restricted Payments to the extent permitted by Section 8.6,

 

(d)            concurrently with the issuance of Capital Securities (other than Disqualified Capital Securities), the redemption, purchase or retirement of any Capital Securities of such Parent HoldCo using the proceeds of, or conversion or exchange of any Capital Securities of such Parent HoldCo for, such Capital Securities,

 

(e)            the obtainment of, and the payment of any fees and expenses for, management, consulting, investment banking and advisory services to the extent otherwise permitted by this Agreement,

 

(f)             in connection with, and following the completion of, a Direct Listing, Qualified IPO or Qualified SPAC Transaction, activities necessary or reasonably advisable for or incidental to the initial registration and listing of such Parent HoldCo (or any of its parent company’s) common stock and the continued existence of such Parent HoldCo (or any of its parent company) as a public company,

 

- 79 -

 

 

 

(g)            providing indemnification to officers and directors;

 

(h)            participation in tax, accounting and other administrative activities as a member of the consolidated group of companies, if applicable,

 

(i)             [reserved],

 

(j)             liabilities and activities to comply with requirements of applicable Law,

 

(k)            authorizing, executing and performing its obligations under this Agreement and each other Loan Document to which it is a party,

 

(l)             preserving and keeping in full force and effect its existence, and

 

(m)           activities incidental to the businesses of activities described in clauses (a) through (k) of this Section 7.16.

 

ARTICLE VIII
NEGATIVE COVENANTS

 

The Borrower covenants and agrees with the Administrative Agent and the Lenders that until the Termination Date has occurred, the Borrower and the Subsidiaries will perform or cause to be performed the obligations set forth below.

 

SECTION 8.1 Business Activities. None of the Borrower or any of the Subsidiaries will engage in any business activity except those business activities engaged in on the date of this Agreement and activities reasonably incidental or ancillary thereto.

 

SECTION 8.2 Indebtedness. None of the Borrower or any of the Subsidiaries will create, incur, assume or permit to exist any Indebtedness, other than:

 

(a)            Indebtedness in respect of the Obligations;

 

(b)            Indebtedness incurred in connection with Permitted Acquisitions or other Investment permitted by Section 8.5 (including existing Indebtedness of a Person acquired in connection with a Permitted Acquisition or any such permitted Investment, provided such Indebtedness was not incurred in anticipation of such acquisition); provided, however, that the aggregate amount of all such Indebtedness, at any one time outstanding, shall not exceed $75,000,000; provided, further, that the obligors in respect of any such Indebtedness assumed in connection with a Permitted Acquisition or other Investment permitted by Section 8.5 shall be solely the entities acquired in such Permitted Acquisition or such permitted Investment; provided, further, that any such Indebtedness incurred (rather than assumed) in connection with Permitted Acquisitions or other Investment permitted by Section 8.5 shall be solely Indebtedness of the Loan Parties (including any entities that will become Loan Parties in connection with such Permitted Acquisition or such permitted Investment) and shall be unsecured and subordinated to the Obligations in a manner satisfactory to Administrative Agent and the Required Lenders;

 

- 80 -

 

 

(c)            Indebtedness existing as of the Closing Date which is identified in Schedule 8.2(c) and Permitted Refinancings thereof;

 

(d)            Indebtedness incurred by Borrower or any of its Subsidiaries arising from agreements providing for indemnification or from guaranties or letters of credit, surety bonds or performance bonds securing the performance of Borrower or any such Subsidiary pursuant to such agreements and Indebtedness which may be deemed to exist pursuant to any guaranties, performance, surety, statutory, appeal or similar obligations incurred in the ordinary course of business and Indebtedness constituting guaranties in the ordinary course of business of the obligations of suppliers, customers, franchisees and licensees of Borrower and its Subsidiaries;

 

(e)            Purchase Money Indebtedness, Capitalized Lease Liabilities and Attributable Debt in a principal amount not to exceed $70,000,000 in the aggregate outstanding at any time and Permitted Refinancings thereof; provided that Attributable Debt under this clause (e) shall not exceed $10,000,000 in the aggregate outstanding at any time;

 

(f)             Permitted Subordinated Indebtedness and Permitted Refinancings thereof;

 

(g)            Indebtedness in respect of the 2023 Convertible Loans and Permitted Refinancings thereof;

 

(h)            Hedging Obligations (including the Permitted Call Spread Swap Agreements); provided, however, that such obligations are (or were) entered into by a Loan Party or a Subsidiary for the purpose of directly mitigating risks associated with liabilities, commitments, investments, assets, or property held or reasonably anticipated by such Person and not for purposes of speculation;

 

(i)             Indebtedness of any Guarantor or the Borrower owing to the Borrower or any Guarantor;

 

(j)             other Indebtedness of the Borrower and the Subsidiaries in an aggregate amount at any time outstanding not to exceed $25,000,000;

 

(k)            Indebtedness of (i) the Borrower or any Guarantor owing to an Excluded Subsidiary; provided that all of such Indebtedness shall be subordinated to the Obligations pursuant to an intercompany debt subordination agreement in a form approved by the Administrative Agent and the Required Lenders in their reasonable discretion, (ii) any Excluded Subsidiaries owing to the Borrower or any Guarantor in an aggregate principal amount at any time outstanding not to exceed $20,000,000, and (iii) any Excluded Subsidiaries owing to any other Excluded Subsidiary;

 

- 81 -

 

 

(l)             Indebtedness owed to any Person providing property, casualty, liability, or other insurance to the Loan Parties, including to finance insurance premiums, so long as the amount of such Indebtedness is not in excess of the amount of the unpaid cost of, and shall be incurred only to defer the cost of, such insurance for the policy year in which such Indebtedness is incurred and such Indebtedness is outstanding only during such policy year;

 

(m)           Indebtedness incurred in the ordinary course of business in connection with credit cards (including commercial cards (including so-called “purchase cards”, “procurement cards” or “p-cards”)), credit card processing services, debit cards, stored value cards, and cash management or related services, including treasury, depository, return items, overdraft, controlled disbursement, merchant store value cards, e-payables services, electronic funds transfer, interstate depository network, automatic clearing house transfer (including the Automated Clearing House processing of electronic funds transfers through the direct Federal Reserve Fedline system) and other customary cash management arrangements incurred in the ordinary course of business in an aggregate amount not to exceed $10,000,000 at any time outstanding;

 

(n)            Indebtedness in respect of letters of credit incurred in the ordinary course of business in an aggregate amount not to exceed $10,000,000 issued at any time and any Permitted Refinancing thereof; provided that any Indebtedness under this clause (n) may be cash collateralized;

 

(o)            Indebtedness with respect to warehouse receipts, surety and appeal bonds, performance bonds, customs bonds or similar instruments issued to support performance obligations incurred in the ordinary course of business;

 

(p)            Indebtedness in respect of netting services, overdraft protections and other like services, in each case incurred in the ordinary course of business;

 

(q)            other Indebtedness of the Subsidiaries in an aggregate amount at any time not to exceed $10,000,000;

 

(r)             other unsecured Indebtedness (which, for the avoidance of doubt, may be pari passu with or subordinated to the Obligations in right of payment) of the Borrower in an aggregate amount at any time outstanding equal to the product of (i) the Revenue Base for the most recently ended Test Period and (ii) 1.50; provided that (A) such Indebtedness does not require or incur cash interest payments, (B) such Indebtedness shall not be guaranteed by any Subsidiary of the Borrower, (C) such Indebtedness shall not include covenants and defaults that are, taken as a whole, more restrictive on the Loan Parties than the provisions of this Agreement (as determined by the Borrower in its good faith judgment), and (D) such Indebtedness shall not (i) mature or be mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, (ii) be redeemable at the option of the holder thereof, in whole or in part or (iii) provide for any payments of principal or other cash payments, in each case of the foregoing sub-clauses (i), (ii) and (iii), prior to the date that is 6 months after the Maturity Date (it being understood, for the avoidance of doubt, that (w) a redemption right of the Borrower in respect of such Indebtedness, (x) conversion rights of holders in respect of such Indebtedness, (y) acceleration rights of holders of such Indebtedness upon the occurrence of an event of default specified in the agreement governing such Indebtedness and (z) the obligation to pay customary amounts to holders of such Indebtedness in connection with an asset disposition, casualty event, “change of control” or “fundamental change”, in each case, shall not be considered in connection with the determination of scheduled maturity date for purposes of this clause (D));

 

- 82 -

 

 

(s)            unsecured Indebtedness in respect of any judgment or order for the payment of money rendered against the Borrower or its Subsidiaries, individually or in the aggregate, in an amount that would not result in an Event of Default under Section 9.1(f);

 

(t)             Permitted Receivables Indebtedness;

 

(u)            Post-IPO Convertible Indebtedness;

 

(v)            Indebtedness arising from agreements of the Borrower or any Subsidiary providing for indemnification, adjustment of purchase or acquisition price or similar obligations (including earn-outs or similar permitted Investments), in each case, incurred or assumed in connection with any Permitted Acquisition or other Investment permitted by Section 8.5; and

 

(w)           to the extent constituting Indebtedness, the Series C Preferred Stock, the Series D Preferred Stock and the Warrants;

 

provided that, no Indebtedness otherwise permitted by clauses (f), (j), (q), (r), (u) and (v) shall be assumed, created or otherwise incurred if any Specified Event of Default has occurred and is then continuing or would result therefrom.

 

SECTION 8.3 Liens. None of the Borrower or any of the Subsidiaries will create, incur, assume or permit to exist any Lien upon any of its property (including Capital Securities of any Person), revenues or assets, whether now owned or hereafter acquired, except:

 

(a)            Liens securing payment of the Obligations;

 

(b)            any Lien existing on any property or asset prior to the acquisition thereof by a Loan Party or existing on any property or asset of any Person that becomes a Subsidiary after the Closing Date prior to the time such Person becomes a Subsidiary, in each case, in connection with a Permitted Acquisition or other Investment permitted by Section 8.5; provided that (1) such Lien is not created in contemplation of or in connection with such acquisition or such Person becoming a Subsidiary, as the case may be, (2) such Lien shall not apply to any other property or assets of the Loan Parties (other than the proceeds and products thereof, accessions thereto and improvements thereon), and (3) such Liens existing pursuant to this clause (b) shall only secure Indebtedness in the aggregate not to exceed $15,000,000;

 

- 83 -

 

 

(c)            Liens existing as of the Closing Date and disclosed in Schedule 8.3(c) securing Indebtedness described in Section 8.2(c), and Permitted Refinancings thereof; provided that, no such Lien shall encumber any additional property and the amount of Indebtedness secured by such Lien is not increased from that existing on the Closing Date or any Permitted Refinancings thereof;

 

(d)            Liens securing payment of Permitted Subordinated Indebtedness that are (i) subordinate to the Liens securing payment of the Obligations and all other Indebtedness owing from the Borrower or the Subsidiaries to the Secured Parties and (ii) subject to a written subordination agreement satisfactory to the Required Lenders in their sole discretion;

 

(e)            Liens securing Indebtedness of the Borrower or the Subsidiaries permitted pursuant to Section 8.2(e) (provided that (i) such Liens shall be created substantially simultaneously with, or within one-hundred and eighty days of, the acquisition, repair, replacement, construction or improvement of the assets financed with such Indebtedness and (ii) such Liens do not at any time encumber any property other than the property so financed);

 

(f)             carriers’, warehousemen’s, mechanics’, materialmen’s, landlords’ and like Liens arising in the ordinary course of business for amounts not overdue for more than 60 days or being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP shall have been set aside on its books;

 

(g)            Liens incurred or deposits made in the ordinary course of business in connection with worker’s compensation, unemployment insurance or other forms of governmental insurance or benefits, or to secure performance of tenders, statutory obligations, bids, leases or other similar obligations (other than for borrowed money) entered into in the ordinary course of business or to secure obligations on surety and appeal bonds or performance bonds;

 

(h)            judgment Liens in existence for less than 45 days after the entry thereof or with respect to which execution has been stayed or the payment of which is covered in full (subject to a customary deductible) by insurance maintained with responsible insurance companies and which do not otherwise result in an Event of Default under Section 9.1(f);

 

(i)             easements, rights-of-way, zoning restrictions, minor defects or irregularities in title and other similar encumbrances not interfering in any material respect with the value or use of the property to which such Lien is attached;

 

(j)             Liens for Taxes not at the time delinquent or thereafter payable without penalty or being diligently contested in good faith by appropriate proceedings and for which adequate reserves in accordance with GAAP shall have been set aside on its books;

 

- 84 -

 

 

(k)            licenses and/or sublicenses of Intellectual Property otherwise permitted under this Agreement or the other Loan Documents, and restrictions under licenses of Intellectual Property entered into in the ordinary course of business pursuant to which the Borrower or any Subsidiary is a licensee;

 

(l)             banker’s liens, rights of setoff and similar non-consensual Liens in favor of financial institutions incurred in the ordinary course of business arising in connection with the Borrower’s or any Subsidiary’s deposit accounts or securities accounts held at such institutions to secure solely payment of fees and similar costs and expenses; provided such accounts are maintained in compliance with Section 7.13(a);

 

(m)           Liens in favor of customs and revenue authorities arising as a matter of Law to secure payment of customs duties in connection with the importation of goods in the ordinary course of business;

 

(n)            Liens granted in the ordinary course of business on the unearned portion of insurance premiums securing the financing of insurance premiums to the extent the financing is permitted by Section 8.2(l);

 

(o)            Liens on cash and Cash Equivalent Investments (i) securing letters of credit to the extent permitted by Section 8.2(n) or (ii) securing Indebtedness permitted by Section 8.2(m);

 

(p)            (x) Liens on cash and Cash Equivalent Investments securing Hedging Obligations permitted by Section 8.2(h) in an aggregate amount not to exceed $10,000,000 and (y) Liens on cash and Cash Equivalent Investments securing Permitted Call Spread Swap Agreements permitted by Section 8.2(h);

 

(q)            Liens on accounts receivable and related assets securing Permitted Receivables Indebtedness; provided that the lender under the facility governing such Permitted Receivables Indebtedness shall have entered into a customary intercreditor agreement with the Administrative Agent in form and substance reasonably satisfactory to the Administrative Agent and the Required Lenders;

 

(r)             any interest or title of a lessor or sublessor under any lease of real estate permitted hereunder;

 

(s)            Liens solely on any cash earnest money deposits made by the Borrower or any of its Subsidiaries in connection with any letter of intent or purchase agreement with respect to any acquisition or investment permitted hereunder;

 

(t)             purported Liens evidenced by the filing of precautionary UCC financing statements relating solely to operating leases of personal property entered into in the ordinary course of business;

 

(u)            leases and subleases of assets (excluding Intellectual Property) granted to third parties in the ordinary course of business;

 

- 85 -

 

 

(v)            Liens in the nature of the right of setoff in favor of counterparties to contractual agreements with the Borrower or its Subsidiaries in the ordinary course of business; and

 

(w)           other Liens that secure obligations permitted under this Agreement not exceeding $20,000,000 in the aggregate at any one time outstanding.

 

Each Secured Party agrees to execute and deliver such collateral subordination agreements and related documents as reasonably requested of it to confirm the priority of the Liens permitted pursuant to Section 8.3(e).

 

SECTION 8.4 Financial Covenants.

 

(a)            Minimum Liquidity. The Liquidity of the Borrower shall not at any time be less than $20,000,000; provided that if the Borrower redeems or repurchases for cash all or any portion of the Series C Preferred Stock or the Series D Preferred Stock (except for any redemption or repurchase made using the proceeds of an issuance of Capital Securities, so long as such proceeds are escrowed solely for the purpose of effectuating such repurchase or redemption of Series C Preferred Stock or Series D Preferred Stock or such issuance is consummated substantially concurrently with such repurchase or redemption), from and after the date of such repurchase or redemption, the Liquidity of the Borrower shall not at any time be less than the outstanding principal amount of the Loans at such time (as such amount may be decreased from time to time); provided, further, that if all of the outstanding Series C Preferred Stock and Series D Preferred Stock are converted into common stock of the Borrower following the occurrence of a Qualified Direct Listing Event or consummation of a Qualified IPO or a Qualified SPAC Transaction, the Liquidity of the Borrower shall not at any time be less than $20,000,000. The Borrower shall maintain an aggregate amount equal to the then applicable amount required under this Section 8.4(a), along with its other cash and Cash Equivalent Investments, in a Controlled Account as required pursuant to Section 7.13(a).

 

- 86 -

 

 

(b)            Minimum Revenue Base. Subject to Section 9.4, the Revenue Base for the last day of a Test Period shall not be less than (i) prior to the First Delayed Draw Closing Date, the amount set forth in the second column below for the Test Period ending on such applicable date and (ii) on and after the occurrence of the First Delayed Draw Closing Date, the amount set forth in the third column below for the Test Period ending on such applicable date (each such amount for each applicable period, the “Required Revenue”):

  

Test Period Ending

Prior to the First Delayed Draw
Closing Date –
Minimum Revenue Base

If the First Delayed Draw Closing Date has
occurred–
Minimum Revenue Base

December 31, 2022 $200,000,000 $270,000,000
March 31, 2023 $202,000,000 $272,000,000
June 30, 2023 $205,000,000 $275,000,000
September 30, 2023 $207,000,000 $275,000,000
December 31, 2023 $210,000,000 $275,000,000
March 31, 2024 $212,000,000 $275,000,000
June 30, 2024 $215,000,000 $280,000,000
September 30, 2024 $217,000,000 $285,000,000
December 31, 2024 $220,000,000 $290,000,000
March 31, 2025 $222,000,000 $295,000,000
June 30, 2025 $225,000,000 $300,000,000
September 30, 2025 $227,000,000 $305,000,000
December 31, 2025 $230,000,000 $312,500,000
March 31, 2026 $232,000,000 $320,000,000
June 30, 2026 $235,000,000 $327,500,000
September 30, 2026 $237,000,000 $335,000,000
December 31, 2026 $240,000,000 $342,500,000
March 31, 2027 $242,000,000 $350,000,000
June 30, 2027 $245,000,000 $357,500,000
September 30, 2027 $247,000,000 $365,000,000
December 31, 2027 $250,000,000 $372,500,000

 

- 87 -

 

 

SECTION 8.5 Investments. None of the Borrower or any of the Subsidiaries will purchase, make, incur, assume or permit to exist any Investment in any other Person, except:

 

(a)            (i) Investments among the Loan Parties existing on the Closing Date and among the non-Loan Parties existing on the Closing Date, (ii) Investments between a Loan Party and a Subsidiary of the Borrower that is not a Loan Party existing as of November 30, 2022 and, other than Investments consisting of a Loan Party’s equity interests in a Wholly Owned Subsidiary, identified in Schedule 8.5(a), and (iii) other Investments existing on the Closing Date and identified in Schedule 8.5(a), and any modification, replacement, renewal or extension of the Investments identified in the foregoing clause (i) through (iii) otherwise permitted by the terms of this Agreement; provided that, the amount of the original Investment is not increased except pursuant to a contractual requirement to increase the amount of such Investment as in effect on the Closing Date, which requirement exists on the Closing Date and is described on Schedule 8.5(a);

 

(b)            Cash Equivalent Investments;

 

(c)            Investments received in connection with the bankruptcy or reorganization of, or settlement of delinquent accounts and disputes with, customers and suppliers, in each case in the ordinary course of business;

 

(d)            Investments consisting of any deferred portion of the sales price received by the Borrower or any of the Subsidiaries in connection with any Disposition permitted under Section 8.8;

 

(e)            Investments constituting (i) accounts receivable arising, (ii) trade debt granted, or (iii) deposits made, in each case of clauses (i) through (iii) in connection with the purchase price of goods or services, in each case in the ordinary course of business;

 

(f)             Permitted Acquisitions;

 

(g)            Investments by (i) the Borrower or any Guarantor in the Borrower or any Guarantor, (ii) any Excluded Subsidiary in the Borrower or any Guarantor and (iii) any Excluded Subsidiary in any other Excluded Subsidiary;

 

(h)            Investments by the Borrower or any Guarantor in any Excluded Subsidiary in an aggregate amount at any time outstanding not to exceed $20,000,000 and subject to the limitations set forth in Section 7.13(a)(i)(D);

 

(i)             Investments in an amount not to exceed cash proceeds contributed as equity to the capital of the Borrower from a Person that is not a Subsidiary of the Borrower, in each case contributed on or during the 6 months preceding the date on which such Investment is made;

 

(j)             Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business;

 

(k)            Investments consisting of travel advances and employee relocation loans and other similar employee loans and advances in the ordinary course of business not to exceed $1,000,000 at any time;

 

(l)             the granting of Liens permitted by Section 8.3;

 

(m)            to the extent constituting Investments, Indebtedness permitted pursuant to Section 8.2(i) or Section 8.2(k);

 

- 88 -

 

 

(n)            transfers of rights with respect to one or more targets identified in the Caris Discovery line of business to joint ventures with third parties or to other entities where the Borrower or its applicable Subsidiary retains the right to acquire such joint ventures or other entities or otherwise repurchase such targets at nominal consideration upon the termination of such joint venture or other entity; provided that no transfer of exclusive rights with respect to any Core Asset for the Caris Molecular Intelligence line of business is permitted;

 

(o)            Investments in joint ventures and acquisitions of Capital Securities that would constitute Permitted Acquisitions but for the fact that such joint ventures and the Persons in which such Capital Securities are acquired do not become Wholly Owned Subsidiaries of a Loan Party; provided that (i) the aggregate amount of such Investments shall not exceed $5,000,000 at any time outstanding and (ii) no Investment in any joint venture pursuant to this clause (o) may be comprised of any transfer of exclusive rights with respect to any Core Asset for the Caris Molecular Intelligence line of business;

 

(p)            Investments made to redeem or purchase the unvested portion of an award from a given service provider (or his/her successors, heirs, descendants and/or estates);

 

(q)            (i) Permitted Call Spread Swap Agreements and (ii) Hedging Obligations permitted by Section 8.2;

 

(r)             prepayments and deposits to suppliers in the ordinary course of business;

 

(s)            (i) guarantees permitted by Section 8.2 and (ii) guarantees by Borrower or any Subsidiary of operating leases or of other obligations that do not constitute Indebtedness entered into in the ordinary course of business;

 

(t)            [Reserved];

 

(u)            Investments received as non-cash consideration in a Disposition permitted hereunder;

 

(v)            Investments of any Person (or any Subsidiary of such Person) in existence at the time such Person (or any Subsidiary of such Person) becomes a Subsidiary of Borrower; provided that, such Investments were not made in connection with or anticipation of such Person becoming a Subsidiary;

 

(w)            loans and advances to service providers, including officers, directors and employees, of the Borrower and its Subsidiaries solely to fund such Person’s purchase of Capital Securities of the Borrower in connection with the exercise or settlement by such Person of options or other equity awards issued pursuant to the 2020 Incentive Plan, so long as no cash is advanced by the Borrower or its Subsidiaries in connection with such loan or advance; and

 

(x)            other Investments, other than Investments by the Borrower or any Guarantor in any Excluded Subsidiary, in an aggregate amount not to exceed $25,000,000 over the term of this Agreement.

 

- 89 -

 

 

SECTION 8.6 Restricted Payments, Etc. None of the Borrower or any of the Subsidiaries will declare or make a Restricted Payment, make any deposit for any Restricted Payment, or make a payment or prepayment of principal of, premium, if any, interest, fees, redemption, exchange, purchase, retirement, defeasance, sinking fund or similar payment with respect to any Permitted Subordinated Indebtedness, Post-IPO Convertible Indebtedness, Indebtedness permitted pursuant to Sections 8.2(r) (with respect to cash interest) or Indebtedness in respect of the 2023 Convertible Loans, except:

 

(a)            Restricted Payments made by the Borrower or any Subsidiaries to any Loan Party;

 

(b)            payments on Permitted Subordinated Indebtedness expressly permitted to be paid under the subordination agreement relating to such Permitted Subordinated Indebtedness;

 

(c)            any 2023 Convertible Loan Repayment;

 

(d)            (i) payments of interest on any applicable Indebtedness as required by and in accordance with the definitive documentation governing such applicable Indebtedness, (ii) required payments of principal, and any accrued interest, premium and fees thereon, at the scheduled maturity date of such applicable Indebtedness and (iii) the issuance of Capital Securities in connection with or as part of the conversion, redemption, retirement, payment, repurchase, exchange or cancellation of any such applicable Indebtedness;

 

(e)            redemption, repurchases, retirement or other acquisition or retirement for value of Capital Securities of the Borrower held by any future, present or former service provider, including consultants, employees, directors or officers (or any Affiliates, spouses, former spouses, other immediate family members, successors, executors, administrators, heirs, distributees, descendants or estates of any of the foregoing) so long as any Specified Event of Default does not exist at the time of such redemption, repurchase, retirement or other acquisition or retirement or value and would not exist after giving effect thereto; provided, that the amount of such redemption, repurchases, retirement or other acquisition or retirement for value (not including the amount of Capital Securities withheld from equity awards to satisfy tax withholding obligations) does not exceed $15,000,000 in the aggregate in any Fiscal Year (or, after the occurrence of a Qualified Direct Listing Event or the consummation of a Qualified IPO or a Qualified SPAC Transaction, $30,000,000 in the aggregate in any Fiscal Year) (provided, that any unused portion for any Fiscal Year may be carried forward to the immediately succeeding Fiscal Year);

 

(f)             redemption or repurchase on a cashless basis (by netting amounts owed under promissory notes owed to the Borrower) of the unvested portion of any award from any former service provider, including consultants, employees, directors or officers (or any Affiliates, spouses, former spouses, other immediate family members, successors, executors, administrators, heirs, distributees, descendants or estates of the foregoing); provided, that the amount of any such redemptions or repurchases shall not exceed the lesser of (x) the amount previously paid by such Person to the Borrower to purchase such award and (y) the fair market value of such award at the time such award becomes eligible for redemption or repurchase by the Borrower;

 

- 90 -

 

 

(g)            Payments and distributions to fund the redemption or repurchase of the Series C Preferred Stock and/or Series D Preferred Stock, subject to the Borrower’s compliance with the terms and conditions set forth in Sections 3.2 and 8.4(a);

 

(h)            Restricted Payments payable solely in the Capital Securities (other than Disqualified Capital Securities) of such Person;

 

(i)             cashless repurchases of Capital Securities of the Borrower deemed to occur upon exercise of stock options or warrants if such Capital Securities represent a portion of the exercise price of such options or warrants;

 

(j)             cash payments in lieu of the issuance of fractional shares;

 

(k)            the payment of customary fees and reasonable out of pocket expenses to directors of the Borrower and its Subsidiaries not to exceed $3,000,000 in the aggregate per calendar year and indemnities provided on behalf of directors and officers of the Borrower and its Subsidiaries, in each case, in the ordinary course of business to the extent attributable to the operation of the Borrower and its Subsidiaries;

 

(l)             any purchase, redemption, repurchase or defeasance of the 2023 Convertible Loans or any Permitted Subordinated Indebtedness (to the extent permitted by the applicable subordination agreement) made by exchange for, or out of the proceeds of, Indebtedness incurred in compliance with Section 8.2;

 

(m)           the repurchase of Capital Securities of the Borrower (or the payment of a dividend to a direct or indirect parent of the Borrower to fund such repurchase) upon vesting of restricted stock, restricted stock units, performance shares units or similar equity incentives to satisfy tax withholding or similar tax obligations with respect thereto; and

 

(n)            other Restricted Payments in an amount not to exceed $5,000,000 over the term of this Agreement.

 

For the avoidance of doubt, nothing contained in this Section 8.6 shall prohibit or otherwise limit (A) any payment or prepayment that is (i) expressly permitted to be paid under the applicable subordination agreement related to any Indebtedness permitted under Section 8.2 or (ii) scheduled interest payments and required payments of principal, and any accrued interest, premium and fees thereon, at the scheduled maturity date of such Indebtedness or (B) the entry into, exercise of its rights under, and performance by the Borrower or any applicable Subsidiary of its respective payment and other obligations under the Permitted Call Spread Swap Agreements.

 

- 91 -

 

 

Notwithstanding the foregoing, the Borrower may repurchase, exchange or induce the conversion of Post-IPO Convertible Indebtedness or other convertible Indebtedness permitted by this Agreement by delivery of shares of the Borrower’s common stock and/or a different series of Post-IPO Convertible Indebtedness or such other permitted convertible Indebtedness (which series matures after, and does not require any scheduled amortization or other scheduled payments of principal prior to, the analogous date under the indenture or other definitive agreement governing the Post-IPO Convertible Indebtedness or such other permitted convertible Indebtedness, as the case may be, that is so repurchased, exchanged or converted) (any such series of Post-IPO Convertible Indebtedness, so long as it complies with the conditions of such definition, “Refinancing Convertible Debt”) and/or by payment of cash (x) in lieu of any fractional shares, (y) in respect of accrued and unpaid interest of such Post-IPO Convertible Indebtedness or such other permitted convertible Indebtedness and (z) additional cash in an amount that does not exceed the proceeds received by the Borrower from the substantially concurrent issuance of shares of the Borrower’s common stock and/or a Refinancing Convertible Debt plus the net cash proceeds, if any, received by the Borrower pursuant to the related exercise or early unwinding or termination of the related Permitted Call Spread Swap Agreements pursuant to the immediately following proviso; provided that, substantially concurrently with, or a commercially reasonable period of time before or after, the related settlement date for the Post-IPO Convertible Indebtedness or such other permitted convertible Indebtedness, as the case may be, that is so repurchased, exchanged or converted, the Borrower shall (and, for the avoidance of doubt, shall be permitted under this Section 8.6 to) exercise or unwind or terminate early (whether in cash, shares or any combination thereof) the portion of the Permitted Call Spread Swap Agreements, if any, corresponding to such Post-IPO Convertible Indebtedness or other permitted convertible Indebtedness that is so repurchased, exchanged or converted.

 

SECTION 8.7 Consolidation, Merger; Permitted Acquisitions, Etc. None of the Borrower or any of the Subsidiaries will (a) liquidate or dissolve, consolidate with, or merge into or with, any other Person, or (b) purchase or otherwise acquire all or substantially all of the assets of any Person (or any division, business unit, product or line of business thereof, including any geographic subset thereof), other than, in the case of clause (b), to consummate a Permitted Acquisition or other Investment permitted by Section 8.5, except that, in the case of clauses (a) and (b), so long as no Event of Default has occurred and is continuing (or would occur), any Subsidiary may liquidate or dissolve voluntarily into, and may merge with and into, the Borrower or any Subsidiary; provided that, in connection with any Permitted Acquisition or other Investment permitted by Section 8.5, the Borrower or any Subsidiary may merge into or consolidate with any other Person or permit any other Person to merge into or consolidate with it, so long as (i) the Person surviving such merger with any Subsidiary shall be a direct or indirect Wholly Owned Subsidiary of the Borrower and a Guarantor (unless it is otherwise an Excluded Subsidiary) and (ii) in the case of any such merger to which the Borrower is a party, the Borrower is the surviving Person.

 

- 92 -

 

 

SECTION 8.8 Permitted Dispositions. None of the Borrower or any of the Subsidiaries will Dispose of any of its assets (including accounts receivable and Capital Securities of the Borrower or the Subsidiaries) to any Person in one transaction or series of transactions unless such Disposition (i) is of inventory or obsolete, damaged, worn out or surplus property Disposed of in the ordinary course of its business; (ii) is permitted by Section 8.5, Section 8.6 or Section 8.7; (iii) constitutes the lapse, abandonment, cancellation, non-renewal or discontinuance of use of non-material Owned Intellectual Property of the Borrower or any Subsidiary, or non-exclusive licenses of Licensed Intellectual Property thereof that the Borrower reasonably determines in good faith is no longer necessary or desirable in the conduct of the Borrower’s or any Subsidiary’s business, or the lapse, abandonment, cancellation, non-renewal or other discontinuance of any of any Owned Intellectual Property that the Borrower or any Subsidiary reasonably believes will not be allowed to issue or register by any Governmental Authority that needs to be issued or registered to be of value to the Borrower and its Subsidiaries; (iv) (A) is a Disposition by a Loan Party to another Loan Party, (B) is a Disposition by any Loan Party to an Excluded Subsidiary in an amount not to exceed $20,000,000 in the aggregate for all such Dispositions, or (C) is a Disposition by any Excluded Subsidiary to another Excluded Subsidiary; (v) constitutes the sale, forgiveness or discounting, on a non-recourse basis and in the ordinary course of business, of past due accounts in connection with the collection or compromise thereof or the settlement of delinquent accounts or in connection with the bankruptcy or reorganization of suppliers or customers in accordance with the applicable terms of this Agreement; (vi) to the extent constituting Dispositions, constitutes the granting of Liens permitted by Section 8.3 and any mergers, consolidations, dispositions, dissolutions and liquidations permitted pursuant to Section 8.7; (vii) constitutes Dispositions in which (I) the assets subject to such Disposition are sold for fair value, as determined by the Borrower in good faith, (II) at least 75% of the consideration therefor is cash or Cash Equivalent Investments, (III) no Specified Event of Default has occurred and is continuing or would result from the making of such Disposition and (IV) the amount of assets Disposed of pursuant to this clause (vii) does not exceed $20,000,000 in the aggregate in any Fiscal Year (provided, that any unused portion pursuant to this clause (vii) for any Fiscal Year may be carried forward to the immediately succeeding Fiscal Year); (viii) constitutes the cancellation, termination or surrender by any Loan Party or any Subsidiary of any Loan Party of any lease in the ordinary course of business; (ix) constitutes the unwinding of any Hedging Obligation in accordance with its terms; (x) constitutes (i) a lease or sublease of property (other than of Intellectual Property) to other Persons or (ii) a non-exclusive license or non-exclusive sublicense to suppliers, customers and distributors in connection with the commercialization of Products, in each case of this clause (x), in the ordinary course of business not materially interfering with the business of Borrower and its Subsidiaries taken as a whole; (xi) subject to compliance with Section 3.2(b), constitutes a Disposition of property as a result of a casualty event involving such property or any disposition of real property to a Governmental Authority as a result of a condemnation of such real property; (xii) constitutes a Disposition of Investments in joint ventures, to the extent required by, or made pursuant to buy/sell arrangements between the joint venture parties set forth in joint venture arrangements and similar binding arrangements; provided that, the consideration received shall be in an amount at least equal to the fair market value thereof (as determined by the Borrower in good faith); (xiii) constitutes a Disposition the proceeds of which do not exceed $1,000,000 in the aggregate in any Fiscal Year; (xiv) constitutes the issuance of Capital Securities by a Subsidiary that represents all or a portion of the consideration paid by Borrower or a Subsidiary in connection with any Investment permitted by this Agreement, including in connection with the formation of a joint venture with a Person other than a Subsidiary; (xv) constitutes (A) a Disposition of Capital Securities (I) deemed to occur upon the exercise of stock options, warrants or other equity derivatives or settlement of convertible securities if such Capital Securities represents (1) a portion of the exercise price thereof or (2) withholding incurred in connection with such exercise, or (II) upon the exercise of any warrant; or (B) a Disposition deemed to occur upon cancellation or forgiveness of loans and advances constituting Investments permitted by this Agreement; (xvi) in connection with the enforcement and/or settlement of litigation, the non-exclusive licensing of patents owned by Borrower and its Subsidiaries which do not impair Borrower’s ability to carry out its business and do not impact the projected revenues of the Borrower and its Subsidiaries, in any material respect; and (xvii) constitutes a non-exclusive license or other grant of rights to use Intellectual Property in the ordinary course of business (or, (x) with respect to targets identified in the Caris Discovery line of business, any exclusive or non-exclusive license or other grant of rights to use such Intellectual Property (but not, for the avoidance of doubt, any Core Assets) and (y) with respect to prescribed data sets in the Caris Strategic Data line of business, any exclusive or non-exclusive license or other grant of rights to use such Intellectual Property (but not, for the avoidance of doubt, any Core Asset for the Caris Molecular Intelligence line of business)), in each case granted by the Borrower or any Subsidiary.

 

- 93 -

 

 

SECTION 8.9 Modification of Certain Agreements. None of the Borrower or any of the Subsidiaries will consent to any amendment, supplement, waiver or other modification of, or enter into any forbearance from exercising any rights with respect to, the terms or provisions contained in (a) any Organic Documents of the Borrower or any of the Subsidiaries, if the result would have an adverse effect in any material respect on the Administrative Agent or the Lenders or their rights or remedies under this Agreement or any Loan Document, (b) any agreement governing any Permitted Subordinated Indebtedness, if the result would shorten the maturity date thereof or advance the date on which any cash payment is required to be made thereon or would otherwise change any terms thereof in a manner adverse in any material respect to the Administrative Agent or the Lenders, (c) the 2023 Convertible Loan Documents, if the result could reasonably be expected to have an adverse effect in any material respect on the Administrative Agent or the Lenders, (d) the definitive documentation governing the Post-IPO Convertible Indebtedness, if the result could reasonably be expected to have an adverse effect in any material respect on the Administrative Agent or the Lenders, or (e) the definitive documentation governing any Permitted Receivables Indebtedness, if the result could reasonably be expected to have an adverse effect in any material respect on the Administrative Agent or the Lenders; provided, that in each of the foregoing clauses (b), (c), (d) and (e), nothing contained in this Section 8.9 shall prohibit or otherwise limit the Borrower or any of its Subsidiary from consummating a Permitted Refinancing with respect to the applicable Indebtedness or replacing such Indebtedness with other Permitted Indebtedness.

 

SECTION 8.10 Transactions with Affiliates. None of the Borrower nor any of the Subsidiaries will enter into or cause or permit to exist any arrangement, transaction or contract (including for the purchase, lease or exchange of property or the rendering of services) involving aggregate payments (x) per transaction or series of related transactions in excess of $2,500,000 per Fiscal Year and (y) in the aggregate over the term of this Agreement, in excess of $10,000,000 for such transaction or series of related transactions, in each case with any of its Affiliates, unless such arrangement, transaction or contract is on fair and reasonable terms no less favorable to the Borrower or any Subsidiary than it could obtain in an arm’s-length transaction with a Person that is not one of its Affiliates, except for (a) compensation and other employment agreements or arrangements with David D. Halbert (including employee benefits, compensation, equity awards and director/officer indemnification agreements), that are approved by the Borrower’s Board of Directors or a committee thereof, (b) equity investments in the Borrower (including any related stockholders’ agreements), (c) transactions of the type set forth on Schedule 8.10 and continuations thereof on substantially consistent terms and other similar servicing arrangements entered into in the ordinary course of business from time to time, (d) any Restricted Payments permitted pursuant to Section 8.6 or any Investments permitted pursuant to clauses (c), (k), (p) or (w) of Section 8.5, (e) any transaction between or among the Loan Parties and their Wholly Owned Subsidiaries to the extent otherwise permitted under this Agreement, (f) compensation and other employment agreements and arrangements (including employee benefits, compensation, equity awards and director/officer indemnification agreements and Dispositions permitted by Section 8.8(xv)) for service providers, including officers, directors and employees, of the Borrower and its Subsidiaries entered into in the ordinary course of business or that are approved by the Borrower’s Board of Directors or a committee thereof, (g) sales or issuances of Capital Securities of the Borrower to Affiliates of the Borrower which are otherwise permitted or not restricted by the Loan Documents (including any related stockholders’ agreements); and (h) any agreement between any Person and an Affiliate of such Person existing at the time such Person is acquired by or merged into Borrower or its Subsidiaries pursuant to the terms of this Agreement; provided that, such agreement was not entered into in contemplation of such acquisition or merger and such Affiliate of such Person was not an Affiliate of the Borrower prior to such acquisition or merger.

 

- 94 -

 

 

SECTION 8.11 Restrictive Agreements, Etc. None of the Borrower or any of the Subsidiaries will enter into any agreement prohibiting (i) the creation or assumption of any Lien to secure the Obligations upon its properties, revenues or assets, whether now owned or hereafter acquired, (ii) the ability of the Borrower or any of the Guarantors to amend or otherwise modify any Loan Document, or (iii) pay dividends or make any other distributions on any of the Borrower’s or any Subsidiary’s Capital Securities owned by the Borrower or any Subsidiary. The foregoing prohibitions shall not apply to restrictions (A) contained in any Loan Document (including any applicable intercreditor or subordination agreement) or in the 2023 Convertible Loan Documents, (B) in the case of clause (i), contained in any agreement governing any Indebtedness permitted by Section 8.2(e) as to the assets financed with the proceeds of such Indebtedness, (C) in the case of clause (iii), contained in the definitive documentation governing any Permitted Receivables Indebtedness, (D) in the case of clause (i), by reason of customary provisions restricting assignments, subletting or other transfers contained in leases, licenses, joint venture agreements and similar agreements entered into in the ordinary course of business, (E) in the case of clause (iii), that are or were created by virtue of any transfer or option or right with respect to any property, assets or Capital Securities not otherwise prohibited under this Agreement, (F) existing on the Closing Date identified on Schedule 8.11, (G) in the case of clause (i) or (iii), in agreements relating to Indebtedness of any Subsidiary that does not become a Loan Party in existence at the time such Subsidiary became a Subsidiary of Borrower and any amendments or modifications thereof that do not materially expand the scope of any such restriction; provided that, such restriction apply only to such Subsidiary, (H) in the case of clause (i) or (iii), arising under or in connection with any agreement or instrument of any joint venture that is not a Loan Party (including with respect to Capital Securities therein), (I) in the case of clause (iii), in any agreement governing Indebtedness permitted by Section 8.2; provided that such restrictions are no more restrictive, taken as a whole, than the comparable restrictions set forth in this Agreement as determined in the good faith judgment of Borrower and (K) imposed by any amendments, modifications, restatements, renewals, increases, supplements, refundings, replacements or refinancings of the contracts, instruments or obligations referred to in clauses (A) through (I) of this Section 8.11; provided that they are permitted hereunder and do not expand the scope of any such restriction.

 

SECTION 8.12 Sale and Leaseback. None of the Borrower or any of the Subsidiaries will directly or indirectly enter into any agreement or arrangement providing for the sale or transfer by it of any property (now owned or hereafter acquired) to a Person and the subsequent lease or rental of such property or other similar property from such Person (such agreement or arrangement, a “Sale/Leaseback Transaction”), unless (a) the sale or transfer of property thereunder is permitted by Section 8.7 and Section 8.8, (b) any Capitalized Lease Liabilities or Attributable Debt arising in connection therewith are permitted by Section 8.2(e), and (c) any Liens arising in connection therewith (including Liens deemed to arise in connection with any such Capitalized Lease Liabilities or Attributable Debt) are permitted by Section 8.3.

 

- 95 -

 

 

SECTION 8.13 [Reserved].

 

SECTION 8.14 Change in Name, Location, Executive Office or Executive Management; Change in Fiscal Year. None of the Borrower or any of the Subsidiaries will: (a) without 20 days’ prior written notice to the Administrative Agent, (i) change in its legal name or any trade name used to identify it in the conduct of its business or ownership of its properties, (ii) change its jurisdiction of incorporation, formation or organization or change its legal form in a manner that would result in an adverse effect in any material respect on the Administrative Agent or the Lenders or their rights and remedies under this Agreement or any Loan Document, (iii) relocate its chief executive office, principal place of business or any office in which it maintains books or records relating to its business (including the establishment of any new office or facility) or (iv) change in its federal taxpayer identification number or organizational number (or equivalent); (b) terminate the employment of or replace its chief executive officer, chief scientific officer or chief financial officer without written notification (which may be by email) to the Administrative Agent within 30 days thereafter; (c) change its Fiscal Year or any of its Fiscal Quarters; or (d) enter into any Division/Series Transaction, or permit any of its Subsidiaries to enter into any Division/Series Transaction (it being understood that none of the provisions in this Agreement nor any other Loan Document shall be deemed to permit any Division/Series Transaction).

 

SECTION 8.15 Benefit Plans and Agreements. Except as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, none of the Borrower or any Subsidiary will (i) become the sponsor of, incur any responsibility to contribute to or otherwise incur actual or potential liability with respect to, any Benefit Plan, (ii) allow any “employee benefit plan,” as defined in section 3(3) of ERISA, that provides retirement benefits, is sponsored by the Borrower, any Subsidiary, or any of their ERISA Affiliates and is intended to be tax qualified under section 401 of the Code to cease to be tax qualified or (iii) allow the assets of any tax qualified retirement plan sponsored by the Borrower, any Subsidiary, or any of their ERISA Affiliates to become invested in Capital Securities of the Borrower or any Subsidiary.

 

ARTICLE IX
EVENTS OF DEFAULT

 

SECTION 9.1 Listing of Events of Default. Each of the following events or occurrences described in this Article IX shall constitute an “Event of Default”.

 

(a)            Non-Payment of Obligations. The Borrower shall default in the payment or prepayment when due of (i) any principal of or interest on any Loan, or (ii) any fee described in Article III or any other monetary Obligation, and in the case of clause (ii) such default shall continue unremedied for a period of three Business Days after such amount was due.

 

- 96 -

 

 

(b)            Breach of Warranty. Any representation or warranty made or deemed to be made by any Loan Party in any Loan Document (including any certificates delivered pursuant to Article V) is or shall be incorrect in any material respect when made or deemed to have been made.

 

(c)            Non-Performance of Certain Covenants and Obligations. Any Loan Party shall default in the due performance or observance of any of its obligations under Section 7.1, Section 7.7, Section 7.13(a)(ii), Section 7.13(c), Section 7.15 or Article VIII.

 

(d)            Non-Performance of Other Covenants and Obligations. Any Loan Party shall default in the due performance and observance of any other covenant, obligation or agreement contained in any Loan Document executed by it, and such default shall continue unremedied for a period of 30 days after the earlier to occur of (i) notice thereof given to the Borrower by the Lenders or (ii) the date on which the Borrower or any Subsidiary has knowledge of such default.

 

(e)            Default on Other Indebtedness. (i) (x) Following the occurrence of an “Event of Default” (as defined in the 2023 Convertible Loan Agreement), the exercise of any rights of acceleration under the 2023 Convertible Loan Agreement in accordance with the terms thereof or (y) a default shall occur in the payment of any amount when due (subject to any applicable grace period), whether by acceleration or otherwise, of any principal or stated amount of, or interest or fees on, the 2023 Convertible Loan Agreement; provided, this clause (i) shall be inoperative and the Indebtedness under the 2023 Convertible Loan Agreement shall instead be subject to the immediately succeeding clause (ii) if the “Maturity Date” (as defined in the 2023 Convertible Loan Agreement) is extended to a date beyond September 21, 2023, and (ii) with respect to any Indebtedness (other than Indebtedness under the 2023 Convertible Loan Agreement) of the Borrower or any of the Subsidiaries (and, to the extent clause (i) above becomes inoperative pursuant to the proviso thereto, Indebtedness of the Borrower and Subsidiaries under the 2023 Convertible Loan Agreement), a default shall occur in the payment of any amount when due (subject to any applicable grace period), whether by acceleration or otherwise, of any principal or stated amount of, or interest or fees on, any such Indebtedness having a principal or stated amount, individually or in the aggregate, in excess of $25,000,000 or a default shall occur in the performance or observance of any obligation or condition with respect to such Indebtedness if the effect of such default is to accelerate the maturity of any such Indebtedness or such default shall continue unremedied for any applicable period of time sufficient to permit the holder or holders of such Indebtedness, or any trustee or agent for such holders, to cause or declare such Indebtedness to become due and payable or to require such Indebtedness to be prepaid, redeemed, purchased or defeased, or require an offer to purchase or defease such Indebtedness to be made, prior to its expressed maturity. For the avoidance of doubt and without limiting the generality of the foregoing clauses (i) and (ii), the foregoing shall not apply to any early payment requirement or unwinding or termination with respect to any Permitted Call Spread Swap Agreement.

 

- 97 -

 

 

(f)             Judgments. Any judgment or order for the payment of money individually or in the aggregate in excess of $25,000,000 (exclusive of any amounts fully covered by insurance (less any applicable deductible) and as to which the insurer has acknowledged its responsibility to cover such judgment or order) shall be rendered against the Borrower or any of the Subsidiaries and such judgment shall not have been vacated or discharged or stayed or bonded pending appeal within 30 days after the entry thereof or enforcement proceedings shall have been commenced by any creditor upon such judgment or order.

 

(g)            Change in Control. Any Change in Control shall occur.

 

(h)            Bankruptcy, Insolvency, Etc. The Borrower or (except as permitted pursuant to Section 8.7) any of the Subsidiaries shall:

 

(i)            become insolvent or generally fail to pay, or admit in writing its inability or unwillingness generally to pay, debts as they become due;

 

(ii)           apply for, consent to, or acquiesce in the appointment of a trustee, receiver, sequestrator or other custodian for any substantial part of the property of any thereof, or make a general assignment for the benefit of creditors;

 

(iii)          in the absence of such application, consent or acquiescence in or permit or suffer to exist the appointment of a trustee, receiver, sequestrator or other custodian for a substantial part of the property of any thereof, and such trustee, receiver, sequestrator or other custodian shall not be discharged within 60 days; provided that, the Borrower and each Subsidiary hereby expressly authorizes the Administrative Agent and the Lenders to appear in any court conducting any relevant proceeding during such 60-day period to preserve, protect and defend its rights under the Loan Documents;

 

(iv)          permit or suffer to exist the commencement of any bankruptcy, insolvency, reorganization, debt arrangement, arrangement (including any plan of compromise or arrangement or other corporate proceeding involving or affecting its creditors) or other case or proceeding under any bankruptcy or insolvency law or any dissolution, winding up or liquidation proceeding, in respect thereof (each, an “Insolvency Event”), and, if any such case or proceeding is not commenced by the Borrower or any Subsidiary, such case or proceeding shall be consented to or acquiesced in by the Borrower or such Subsidiary, as the case may be, or shall result in the entry of an order for relief or shall remain for 60 days undismissed; provided that the Borrower and each Subsidiary hereby expressly authorizes the Administrative Agent and the Lenders to appear in any court conducting any such case or proceeding during such 60-day period to preserve, protect and defend its rights under the Loan Documents; or

 

(v)            take any action authorizing, or in furtherance of, any of the foregoing.

 

- 98 -

 

 

(i)             Impairment of Security, Etc. Any Loan Document or any Lien granted thereunder in any portion of the Collateral of a value of $10,000,000 or more shall (except in accordance with its terms), in whole or in part, terminate, cease to be effective or cease to be the legally valid, binding and enforceable obligation of the Borrower or any Guarantor party thereto; the Borrower, any Guarantor or any other party shall, directly or indirectly, contest in any manner such effectiveness, validity, binding nature or enforceability; or, except as permitted under any Loan Document, any Lien on any portion of the Collateral of a value of $10,000,000 or more securing any Obligation shall cease to be a perfected Lien.

 

(j)             [Reserved].

 

(k)            Regulatory Matters. If any of the following occurs and has had or would reasonably be expected to have or result in a Material Adverse Effect: (i) subject to the next sentence of this Section 9.1(k), the FDA, CMS, EMA or any other Governmental Authority (A) issues a letter or other communication asserting that any Product lacks a required Regulatory Authorization or (B) initiates enforcement action against, or issues a warning letter or takes any other action with respect to, the Borrower or any of the Subsidiaries, or any of their Products or the manufacturing facilities therefor, that in either case of the foregoing clauses (A) or (B), causes the Borrower or such Subsidiary to discontinue or suspend marketing or withdraw any of its Products, which discontinuance, suspension or withdrawal would reasonably be expected to last for more than 90 days; (ii) the Borrower or any of the Subsidiaries enters into a settlement agreement with the FDA, CMS, EMA or any other similar Governmental Authority; or (iii) a recall or similar event which could reasonably be expected to result in liability to the Borrower and its Subsidiaries. For the avoidance of doubt, the failure to obtain an FDA approval for the Borrower’s LDTs shall not, in and of itself, constitute a Default or an Event of Default under this Section 9.1(k) unless such failure results in any event described in the preceding sentence of this Section 9.1(k).

 

(l)            Sweep of Governmental Payor Accounts. The Loan Parties or any Subsidiary instructs the depository bank of any zero balance account referenced in Section 7.13(a)(i)(G) to discontinue the daily sweep of funds in such account into a Controlled Account, or otherwise revokes instructions under the sweep agreement governing such account regarding the daily sweep of funds into a Controlled Account.

 

SECTION 9.2 Action if Bankruptcy. If any Event of Default described in clauses (i) through (iv) of Section 9.1(h) with respect to the Borrower shall occur, the Commitments (if not theretofore terminated) shall automatically terminate and the outstanding principal amount of the Loans and all other Obligations shall automatically be and become immediately due and payable, without notice or demand to any Person.

 

SECTION 9.3 Action if Other Event of Default. If any Event of Default (other than any Event of Default described in clauses (i) through (iv) of Section 9.1(h)) shall occur for any reason, whether voluntary or involuntary, and be continuing, the Administrative Agent may, and shall at the direction of the Required Lenders or OrbiMed (so long as OrbiMed holds Total Credit Exposures representing more than 50% of the Total Credit Exposures of all Lenders), by notice to the Borrower declare all or any portion of the outstanding principal amount of the Loans and other Obligations to be due and payable and/or the Commitments (if not theretofore terminated) to be terminated, whereupon the full unpaid amount of the Loans and other Obligations which shall be so declared due and payable shall be and become immediately due and payable, without further notice, demand or presentment, and the Commitments shall terminate.

 

- 99 -

 

 

 

SECTION 9.4 Right to Cure. Notwithstanding anything to the contrary otherwise contained in this Article IX, in the event of any Event of Default arising under Section 9.1(c) due to any Loan Party’s default in the due performance or observance of any of its obligations under Section 8.4(b), the Borrower shall have the right (the “Cure Right”) within 45 days of the end of the respective Test Period to apply cash proceeds from the issuance of Permitted Cure Securities to prepay the Loans (including any Repayment Premium and Exit Fee); provided that, the Cure Right shall not be exercised (x) more than once in any period of two (2) consecutive Fiscal Quarters, (y) more than twice during any period of four (4) consecutive Fiscal Quarters or (z) more than three times during the term of this Agreement. After giving effect to the foregoing prepayment, the Borrower’s Revenue Base shall be deemed (solely for purposes of measuring compliance with Section 8.4(b)) to be increased with respect to such Test Period (and for all future Test Periods that include all or any part of such Test Period) for all purposes under this Agreement by an amount equal to the lesser of (x) 100% of the proceeds so applied and (y) the Revenue Deficiency for such Test Period. If, after giving effect to the foregoing pro forma adjustment, the Borrower and its Subsidiaries are in compliance with the financial covenant set forth in Section 8.4(b), the requirements of such Section 8.4(b) shall be deemed to be satisfied as of the relevant date of determination with the same effect as though there had been no failure to comply on such date, and the applicable breach or default of such Section 8.4(b) that had occurred shall be deemed cured for purposes of this Agreement.

 

SECTION 9.5 Application of Funds. After the exercise of remedies provided for in Section 9.3 (or after the Loans have automatically become immediately due and payable as set forth in Section 9.2), any amounts received by any Lender or the Administrative Agent on account of the Obligations shall be applied in the following order:

 

First, to payment of that portion of the Obligations constituting fees, indemnities, expenses and other amounts (including fees, charges and disbursements of counsel to the Administrative Agent and amounts payable under Article III) payable to the Administrative Agent in its capacity as such;

 

Second, to payment of that portion of the Obligations constituting fees, indemnities and other amounts (other than principal, interest and any amount payable under the Fee Letter) payable to the Lenders (including fees, charges and disbursements of counsel to the respective Lenders) arising under the Loan Documents and amounts payable under Section 4.3, ratably among them in proportion to the respective amounts described in this clause Second payable to them;

 

Third, to payment of that portion of the Obligations constituting accrued and unpaid interest on the Loans and amounts payable under the Fee Letter, ratably among the Lenders in proportion to the respective amounts described in this clause Third held by them;

 

 - 100 - 

 

 

Fourth, to payment of that portion of the Obligations constituting accrued and unpaid principal of the Loans, ratably among the Lenders in proportion to the respective amounts described in this clause Fourth held by them; and

 

Last, the balance, if any, after all of the Obligations have been paid in full, to the Borrower or as otherwise required by law.

 

ARTICLE X
MISCELLANEOUS PROVISIONS

 

SECTION 10.1 Waivers, Amendments, Etc. No amendment or waiver of any provision of this Agreement or any other Loan Document, and no consent to any departure by the Borrower or any Guarantor therefrom, shall be effective unless in writing signed by the Required Lenders and by the Borrower or the applicable Guarantor, as the case may be, and acknowledged by the Administrative Agent, and each such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given; provided, further, that:

 

(a)            no such amendment, waiver or consent shall:

 

(i)            extend or increase the Commitment of a Lender (or reinstate any Commitment terminated pursuant to Section 9.2) without the written consent of such Lender whose Commitment is being extended or increased (it being understood and agreed that a waiver of any condition precedent set forth in Article V or a waiver of any Default or a mandatory reduction in Commitments is not considered an extension or increase in Commitments of any Lender);

 

(ii)            postpone any date fixed by this Agreement or any other Loan Document for any payment of principal (excluding mandatory prepayments or scheduled amortization and related amounts payable in connection therewith), interest, Repayment Premiums, fees or other amounts due to the Lenders (or any of them) without the written consent of each Lender entitled to receive such payment (it being understood that a waiver of any Default or Event of Default (or of any related default interest payable pursuant to Section 3.5) shall not constitute such a postponement);

 

(iii)           reduce the principal of, the rate of interest specified herein on or any Repayment Premium specified herein on any Loan, or any fees or other amounts payable hereunder or under any other Loan Document (including, for the avoidance of doubt, the Exit Fee) without the written consent of each Lender entitled to receive such payment of principal, interest, fees or other amounts (other than any such reduction in connection with a waiver of any Default, Event of Default (including, for the avoidance of doubt, any default interest payable pursuant to Section 3.5), mandatory prepayment, amortization payment or amendment to any financial covenant);

 

(iv)           (x) amend or waive any provision of Section 9.5, or (y) amend or waive any provision providing for the pro rata treatment of the Lenders, in each case, without the written consent of each Lender directly affected thereby;

 

 - 101 - 

 

 

(v)           change any provision of this Section 10.1(a) or the definition of “Required Lenders” without the written consent of all the Lenders; or

 

(vi)          consent to the assignment or transfer by the Borrower of any of its rights and obligations under this Agreement and the other Loan Documents, or release all or substantially all of the Collateral or release all or substantially all of the Guarantors from their obligations under the Guarantee, in each case, without the written consent of all the Lenders;

 

(vii)         (x) amend, waive or modify Section 11.6 hereof, without the consent of the Required Lenders; and

 

(b)            unless also signed by the Administrative Agent, no amendment, waiver or consent shall affect the rights, duties, benefits, privileges, protections, indemnities or immunities of the Administrative Agent under this Agreement or any other Loan Document;

 

provided, however, that notwithstanding anything to the contrary herein, (i) each Lender is entitled to vote as such Lender sees fit on any bankruptcy reorganization plan that affects the Loans, and each Lender acknowledges that the provisions of Section 1126(c) of the Bankruptcy Code of the United States supersedes the unanimous consent provisions set forth herein and (ii) the Required Lenders shall determine whether or not to allow the Borrower or any Guarantor to use cash collateral in the context of a bankruptcy or insolvency proceeding and such determination shall be binding on all of the Lenders.

 

Notwithstanding anything to the contrary herein, no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder, except (x) that the Commitments of such Lender may not be increased or extended without the consent of such Lender and (y) for any such amendment, waiver or consent that treats such Defaulting Lender disproportionately and adversely from the other Lenders (other than because of its status as a Defaulting Lender).

 

Subject to Section 4.7, any payments, fees or other consideration (other than reimbursements for out-of-pocket expenses) received by or on behalf of the Administrative Agent or any of the Lenders in respect of any amendment, waiver or consent under the Loan Documents shall be distributed to the Lenders on a pro rata basis.

 

SECTION 10.2 Notices; Time; Inside Information.

 

(a)            All notices and other communications provided under any Loan Document shall be in writing (including by email) and addressed, delivered or transmitted, if to the Administrative Agent, the Borrower or the Lenders, to the applicable Person at its physical address or email address set forth on Schedule 10.2 hereto, or at such other physical address or email address as may be designated by such party in a notice to the other parties. Any notice, if mailed and properly addressed with postage prepaid or if properly addressed and sent by pre-paid courier service, shall be deemed given when received; any notice, if transmitted by email, shall be deemed given upon the earlier of (x) confirmation of receipt by the recipient and (y) the opening of business on the next Business Day for the recipient. Unless otherwise indicated, all references to the time of a day in a Loan Document shall refer to New York City time.

 

 - 102 - 

 

 

(b)            The Administrative Agent and the Lenders shall be entitled to rely and act upon any notices (including telephonic or electronic loan notices) purportedly given by or on behalf of the Borrower or any Guarantor even if (i) such notices were not made in a manner specified herein, were incomplete or were not preceded or followed by any other form of notice specified herein, or (ii) the terms thereof, as understood by the recipient, varied from any confirmation thereof. The Borrower and each Guarantor shall indemnify the Administrative Agent, each Lender and their respective the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives from all losses, costs, expenses and liabilities resulting from the reliance by such Person on each notice purportedly given by or on behalf of the Borrower and each Guarantor; provided that such indemnity shall not, as to any Person be available to the extent that such losses, costs, expenses or liabilities are determined by a court of competent jurisdiction by final and non-appealable judgment to have resulted from the gross negligence or willful misconduct of such Person. All telephonic notices to and other telephonic communications with the Administrative Agent may be recorded by the Administrative Agent, and each of the parties hereto hereby consents to such recording.

 

(c)            Borrower Materials may be delivered pursuant to procedures approved by the Administrative Agent, including electronic delivery (if possible) upon request by the Administrative Agent to an electronic system maintained by the Administrative Agent (the “Platform”). The Borrower shall notify the Administrative Agent of each posting of Borrower Materials on the Platform and the materials shall be deemed received by the Administrative Agent only upon its receipt of such notice. Borrower Materials and other information relating to this credit facility may be made available to Lenders on the Platform. The Platform is provided “as is” and “as available.” The Administrative Agent does not warrant the accuracy or completeness of any information on the Platform nor the adequacy or functioning of the Platform, and expressly disclaims liability for any errors or omissions in the Borrower Materials or any issues involving the Platform, except to the extent resulting from the Administrative Agent’s own gross negligence or willful misconduct as determined by a final non-appealable judgment by a court of competent jurisdiction. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF THIRD PARTY RIGHTS, OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY ADMINISTRATIVE AGENT WITH RESPECT TO BORROWER MATERIALS OR THE PLATFORM. None of the Administrative Agent nor any of its Affiliates, partners, directors, officers, employees, agents, trustees, administrators, managers or advisors, nor any of the partners, directors, officers, employees, agents, trustees, administrators, managers or advisors of its Affiliates shall have any liability to the Loan Parties, Lenders or any other Person for losses, claims, damages, liabilities or expenses of any kind (whether in tort, contract or otherwise) relating to use by any Person of the Platform or delivery of Borrower Materials and other information through the Platform except to the extent any thereof result from the applicable Person’s own gross negligence or willful misconduct as determined by a final non appealable judgment by a court of competent jurisdiction.

 

 - 103 - 

 

 

(d)            From and after the occurrence of a Direct Listing, a Qualified IPO or a Qualified SPAC Transaction each Loan Party shall not, and shall cause each of its Related Parties to not, provide any Lender, attorneys, agents or representatives with any material nonpublic information regarding the Borrower or its Subsidiaries, the Borrower’s securities, any of the Borrower’s Affiliates or any other Person (collectively, “Inside Information”) without the express prior written consent of such Lender.

 

(e)            From and after the occurrence of a Direct Listing, a Qualified IPO or a Qualified SPAC Transaction, notwithstanding the foregoing clause (d), to the extent the Borrower reasonably and in good faith determines that it is necessary to disclose Inside Information to a Lender for purposes relating to this Agreement or any other Loan Document (a “Necessary Disclosure”), the Borrower shall inform Outside Counsel to such Lender of such determination without disclosing the applicable Inside Information, and the Borrower and such Outside Counsel on behalf of the applicable Lender shall endeavor to agree upon a process for making such Necessary Disclosure to the applicable Lender or its representatives that is mutually acceptable to such Lender and the Borrower (an “Agreed Disclosure Process”). Thereafter, the Borrower shall be permitted to make such Necessary Disclosure (only) in accordance with the Agreed Disclosure Process.

 

(f)            From and after the occurrence of a Direct Listing, a Qualified IPO or a Qualified SPAC Transaction, neither the Administrative Agent nor any Affiliates thereof shall provide any Inside Information to any Lender without complying with the processes set forth in clauses (d) and (e) of this Section 10.2 as if the Administrative Agent were the Borrower for the purposes thereof.

 

(g)            From and after the occurrence of a Direct Listing, a Qualified IPO or a Qualified SPAC Transaction, at or prior to 9:00 a.m. (New York City time) on the second (2nd) Business Day following each of the First Delayed Draw Closing Date and the Second Delayed Draw Closing Date, the Borrower shall file a Form 8-K with the SEC or furnish a Form 8-K to the SEC describing the terms of the borrowing occurring on such date and any other material transactions occurring in connection therewith. At or prior to 9:00 a.m. (New York City time) on the fourth (4th) Business Day following Borrower’s delivery of a notice of termination of any unfunded Commitments or notice of any repayment, prepayment, redemption or payment in full of the outstanding principal amounts of the Loans, the Borrower shall file a Form 8-K with the SEC or furnish a Form 8-K to the SEC describing such termination, repayment, prepayment, redemption or payment (as applicable) and any other material transactions occurring in connection therewith.

 

 - 104 - 

 

 

SECTION 10.3 Payment of Costs and Expenses. The Borrower agrees to pay on demand all reasonable documented expenses of the Administrative Agent and the Lenders (limited, in the case of attorneys’ fees and legal expenses, to the reasonable and documented fees and out-of-pocket expenses of Covington & Burling LLP, counsel to the Administrative Agent and the Lenders, specialist counsel, if any, relating to any applicable legal subject matter who may be retained by or on behalf of the Administrative Agent and the Lenders, and of local counsel, if any, in any applicable jurisdiction who may be retained by or on behalf of the Administrative Agent and the Lenders) in connection with:

 

(a)            the negotiation, preparation, execution and delivery of each Loan Document, including schedules and exhibits, and any amendments, waivers, consents, supplements or other modifications to any Loan Document as may from time to time hereafter be required, whether or not the transactions contemplated hereby are consummated;

 

(b)            the filing or recording of any Loan Document (including any financing statements) and all amendments, supplements, amendment and restatements and other modifications to any thereof, searches made following the Closing Date in jurisdictions where financing statements (or other documents evidencing Liens in favor of the Secured Parties) have been recorded and any and all other documents or instruments of further assurance required to be filed or recorded by the terms of any Loan Document;

 

(c)            the preparation and review of the form of any document or instrument relevant to any Loan Document; and

 

(d)            reasonable legal diligence, consulting and other advice in connection with the Borrower, the Subsidiaries and any of their Related Parties;

 

provided, that, unless otherwise agreed by the Borrower in writing, the fees and expenses of OrbiMed (other than those fees and expenses incurred by or on behalf of OrbiMed in connection with the syndication of the Loans) reimbursable by the Borrower on the Closing Date as contemplated by this Section 10.3 shall not exceed $500,000 in the aggregate (with such amount to be inclusive of the Expense Deposit (as defined below)).

 

OrbiMed shall apply the $100,000 expense deposit (the “Expense Deposit”) that the Borrower furnished to OrbiMed prior to the Closing Date to the documented fees and expenses that are payable or reimbursable in accordance with the foregoing sentence. The Borrower also agrees to reimburse the Lenders upon demand for all reasonable out-of-pocket expenses (limited, in the case of attorneys’ fees and legal expenses, to reasonable fees and expenses of counsel to the Administrative Agent and the Lenders) incurred by the Administrative Agent and each Lender in connection with (x) the negotiation of any restructuring or “work-out” with the Borrower, whether or not consummated, of any Obligations and (y) the enforcement of any Obligations.

 

 - 105 - 

 

 

SECTION 10.4 Indemnification; Expenses; and Damage Waiver.

 

(a)            In consideration of the execution and delivery of this Agreement by the Lenders and the Administrative Agent, the Borrower hereby indemnifies, agrees to defend, exonerates and holds each Lender and the Administrative Agent (and any sub-agent thereof) and each of the respective partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of any of the foregoing Persons (collectively, the “Indemnified Parties”) free and harmless from and against any and all actions, causes of action, suits, losses, costs, liabilities, obligations and damages, claims and expenses incurred in connection therewith (irrespective of whether any such Indemnified Party is a party to the action for which indemnification hereunder is sought), reasonable attorneys’ and professionals’ fees and disbursements (limited, in the case of attorneys’ fees and legal expenses, to one primary external counsel to each of (x) (i) the Administrative Agent and (ii) the Required Lenders and local counsel to each of (y) (i) the Administrative Agent and (ii) the Required Lenders in each relevant jurisdiction), whether incurred in connection with actions between the parties hereto or the parties hereto and third parties (collectively, the “Indemnified Liabilities”), arising out of or in connection with the Loan Documents, including, without limitation, Indemnified Liabilities arising out of or relating to (i) the entering into, administration, performance and enforcement of any Loan Document by any of the Indemnified Parties (including any action brought by or on behalf of the Borrower as the result of any determination by any Lender pursuant to Article V not to fund any Loan), and (ii) any Environmental Liability; provided that the foregoing indemnity will not, as to any Indemnified Party, apply to losses, claims, damages, liabilities or related expenses to the extent that they have resulted from (i) the willful misconduct or gross negligence of such Indemnified Party (or any of its Related Parties) (as determined by a court of competent jurisdiction in a final and non-appealable decision) or (ii) disputes solely among the Indemnified Parties that are not arising out of any act or omission by the Borrower or any Affiliate of the Borrower, other than claims against the Administrative Agent in such capacity. If and to the extent that the foregoing indemnification may be unenforceable for any reason, the Borrower agrees to make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable Law. This Section 10.4(a) shall not apply with respect to Taxes other than any Taxes that represent losses, claims and damages arising from any non-Tax claim.

 

(b)            [Reserved].

 

(c)            Reimbursement by Lenders. To the extent that the Borrower and the Guarantors for any reason fail to pay any amount required under subsection (a) of this Section 10.4 to be paid by them to the Administrative Agent (or any sub-agent thereof) or any of their respective partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives, each Lender severally agrees to pay to the Administrative Agent (or any such sub-agent) or such partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of such Person, as the case may be, such Lender’s pro rata share (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought based on each Lender’s share of the Total Credit Exposure at such time) of such unpaid amount (including any such unpaid amount in respect of a claim asserted by such Lender), such payment to be made severally among them based on such Lenders’ Applicable Percentages (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought); provided, further, that the unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Administrative Agent (or any such sub-agent), or against any of their respective partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives acting for the Administrative Agent (or any such sub-agent) in connection with such capacity.

 

 - 106 - 

 

 

(d)            Waiver of Consequential Damages, Etc. To the fullest extent permitted by applicable Law, no Party hereto shall assert, and each Party hereto hereby waives, and acknowledges that no other Person shall have, any claim against any Indemnified Party, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement, any other Loan Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any Loan or the use of the proceeds thereof. No Indemnified Party referred to in Section 10.4(a) above shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby.

 

(e)            Payments. All amounts due under this Section 10.4 shall be payable not later than 10 Business Days after demand therefor.

 

SECTION 10.5 Survival. The obligations of the Borrower under Section 4.1, Section 4.2, Section 4.3, Section 10.3 and Section 10.4, shall in each case survive any assignment by any Lender and the occurrence of the Termination Date. The agreements in this Section 10.5 and the indemnity provisions of Section 10.4(c) shall survive the resignation or replacement of the Administrative Agent, any assignment by any Lender, the termination of the Commitments and the repayment, satisfaction or discharge of all the other Obligations. All representations and warranties made by the Borrower or any Guarantor hereunder and in each other Loan Document or other document delivered pursuant hereto or thereto or in connection herewith or therewith shall survive the execution and delivery hereof and thereof. Such representations and warranties have been or will be relied upon by the Administrative Agent and each Lender, regardless of any investigation made by the Administrative Agent or any Lender or on their behalf and notwithstanding that the Administrative Agent or any Lender may have had notice or knowledge of any Default at the time of any borrowing.

 

SECTION 10.6 Severability. Any provision of any Loan Document which is prohibited or unenforceable in any jurisdiction shall, as to such provision and such jurisdiction, be ineffective only to the extent of such prohibition or unenforceability without invalidating the remaining provisions of such Loan Document affecting the validity or enforceability of such provision in any other jurisdiction.

 

SECTION 10.7 Headings. The various headings of each Loan Document are inserted for convenience only and shall not affect the meaning or interpretation of such Loan Document or any provisions thereof.

 

 - 107 - 

 

 

SECTION 10.8 Execution in Counterparts, Effectiveness, Etc. This Agreement may be executed by the parties hereto in several counterparts, each of which shall be an original and all of which shall constitute together but one and the same agreement. This Agreement shall become effective when counterparts hereof executed on behalf of the Borrower and the Lenders, shall have been received by the Administrative Agent. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g., “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement.

 

SECTION 10.9 Governing Law; Entire Agreement. EACH LOAN DOCUMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT CONTEMPLATED HEREBY AND THEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). The Loan Documents constitute the entire understanding among the parties hereto with respect to the subject matter thereof and supersede any prior agreements, written or oral, with respect thereto.

 

SECTION 10.10 Successors and Assigns.

 

(a)            Successors and Assigns Generally. The provisions of this Agreement and the other Loan Documents shall be binding upon and inure to the benefit of the Parties hereto and thereto and their respective successors and assigns permitted hereby, except that the Borrower may not assign or otherwise transfer any of its rights or obligations hereunder or thereunder without the prior written consent of the Administrative Agent and each Lender and no Lender may assign or otherwise transfer any of its rights or obligations hereunder except (i) to an Eligible Assignee in accordance with the provisions of Section 10.10(b), or (ii) by way of pledge or assignment of a security interest subject to the restrictions of Section 10.10(d) (and any other attempted assignment or transfer by any party hereto shall be null and void). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby and, to the extent expressly contemplated hereby, the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of each of the Administrative Agent and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement. No assignment or transfer of any Commitment or Loan shall be effective until receipt and acceptance into the Register by the Administrative Agent of a fully executed Assignment and Assumption effecting the assignment or transfer thereof, together with the required forms and certificates regarding tax matters and any fees payable in connection with such assignment, in each case, as provided in Section 10.10(b). The date of such assignment shall be referred to herein as the “Assignment Effective Date.”

 

(b)            Assignments by Lenders. Any Lender may at any time assign to one or more Eligible Assignees all or a portion of its rights and obligations under this Agreement and the other Loan Documents (including all or a portion of its Commitment and the Loans at the time owing to it); provided that any such assignment shall be subject to the following conditions:

 

 - 108 - 

 

 

(i)            Minimum Amounts.

 

A.            in the case of an assignment of the entire remaining amount of the assigning Lender’s Commitment and/or the Loans at the time owing to it or contemporaneous assignments to related Approved Funds that equal at least the amount specified in Section 10.10(b)(i)(B) in the aggregate or in the case of an assignment to a Lender, an Affiliate of a Lender or an Approved Fund, no minimum amount need be assigned; and

 

B.            in any case not described in Section 10.10(b)(i)(A), the aggregate amount of the Commitment (which for this purpose includes applicable Loans outstanding thereunder) or, if the applicable Commitment is not then in effect, the principal outstanding balance of the applicable Loans of the assigning Lender subject to each such assignment, determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent or, if “Trade Date” is specified in the Assignment and Assumption, as of the Trade Date, shall not be less than $1,000,000 (and in addition shall be subject to clause (b)(iii) below) unless each of the Administrative Agent and, so long as no Event of Default has occurred and is continuing, the Borrower otherwise consents (each such consent not to be unreasonably withheld or delayed);

 

(ii)            Proportionate Amounts. Each partial assignment shall be made as an assignment of a proportionate part of all of the assigning Lender’s rights and obligations under this Agreement with respect to the Loans or the Commitment assigned;

 

(iii)           Required Consents. No consent shall be required for any assignment, except to the extent required by Section 10.10(b)(i)(B) and, in addition, (x) the consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed) shall be required for assignments to a Person that is not a Lender, an Affiliate of a Lender or an Approved Fund and (y) the consent of the Borrower (such consent not to be unreasonably withheld, conditioned or delayed, and which consent shall be deemed to have been provided if the Borrower shall not have responded to a written request for such consent within ten (10) Business Days) shall be required for any assignment of Loans and/or Commitments in an aggregate principal amount of less than $40,000,000 to a Person that is not a Lender, an Affiliate of a Lender or an Approved Fund so long as no Event of Default has occurred and is continuing; provided, however, in the event that, after giving effect to any assignment, OrbiMed would have Total Credit Exposures representing less than 50.1% of the Total Credit Exposures of all Lenders, the consent of the Borrower (such consent not to be unreasonably withheld, conditioned or delayed, and which consent shall be deemed to have been provided if the Borrower shall not have responded to a written request for such consent within ten (10) Business Days) shall be required for any assignment (regardless of the amount assigned) so long as no Event of Default has occurred and is continuing;

 

 - 109 - 

 

 

(iv)           Assignment and Assumption. Assignments and assumptions of Loans and Commitments by Lenders shall be effected by manual execution and delivery to the Administrative Agent of an Assignment and Assumption. Assignments made pursuant to the foregoing provision shall be effective as of the Assignment Effective Date, subject to acceptance and recording thereof in the Register by the Administrative Agent pursuant to Section 10.10(c). In connection with all assignments there shall be delivered to the Administrative Agent such forms, certificates or other evidence, if any, with respect to United States federal income tax withholding matters as the assignee under such Assignment and Assumption may be required to deliver pursuant to Section 4.3, together with payment to the Administrative Agent of a registration and processing fee of $3,500, (which shall not be required for assignments from a Lender to an Affiliate of such Lender) and may otherwise be waived or reduced at the sole discretion of the Administrative Agent.

 

(v)            No Assignment to Certain Persons. No such assignment shall be made to the Borrower or any Guarantor or any Affiliate or Subsidiary of the Borrower or any Guarantor, or any Person who, upon becoming a Lender hereunder, would constitute any of the foregoing Persons (other than to the Lenders on the Closing Date and their respective Affiliates).

 

(vi)           Subject to acceptance and recording thereof by the Administrative Agent pursuant to Section 10.10(c), from and after the effective date specified in each Assignment and Assumption, the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under this Agreement, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the assigning Lender’s rights and obligations under this Agreement, such Lender shall cease to be a party hereto) but shall continue to be entitled to the benefits of Sections 4.3, 10.3 and 10.4 with respect to facts and circumstances occurring prior to the effective date of such assignment. Upon request, the Borrower (at its expense) shall execute and deliver a Note to the assignee Lender.

 

 - 110 - 

 

 

(c)            Register. The Administrative Agent, acting solely for this purpose as an agent of the Borrower, shall maintain at the Administrative Agent’s Office a copy of each Assignment and Assumption delivered to it (or the equivalent thereof in electronic form) and a register for the recordation of the names and addresses of the Lenders, and the Commitments of, and principal amounts (and stated interest) of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be conclusive absent manifest error, and the Borrower, the Administrative Agent and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement. The Register shall be available for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice. The parties intend that any interest in or with respect to the Loans under this Agreement be treated as being issued and maintained in “registered form” within the meaning of Sections 163(f), 871(h)(2), and 881(c)(2) of the Code and any regulations thereunder (and any successor provisions), including without limitation under United States Treasury Regulations Section 5f.103-1(c) and Proposed Regulations Section 1.163-5 (and any successor provisions), and the provisions of this Agreement shall be construed in a manner that gives effect to such intent.

 

(d)            Certain Pledges. Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement (including under its Note, if any) to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank; provided that no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.

 

(e)            Administrative Agent. Any corporation or association into which the Administrative Agent may be converted or merged, or with which it may be consolidated, or to which it may sell or transfer all or substantially all of its corporate trust business and assets as a whole or substantially as a whole, or any corporation or association resulting from any such conversion, sale, merger, consolidation or transfer to which the Administrative Agent is a party, will be and become the successor to the Administrative Agent under this Agreement and will have and succeed to the rights, powers, duties, immunities and privileges as its predecessor, without the execution or filing of any instrument or paper or the performance of any further act.

 

SECTION 10.11 Other Transactions. Nothing contained herein shall preclude any Lender or any of its Affiliates from engaging in any transaction, in addition to those contemplated by the Loan Documents, with the Borrower or any of its Affiliates in which the Borrower or such Affiliate is not restricted hereby from engaging with any other Person.

 

SECTION 10.12 Forum Selection and Consent to Jurisdiction. EACH OF THE PARTIES HERETO HEREBY AGREES THAT ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, ANY LOAN DOCUMENT, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE ADMINISTRATIVE AGENT, ANY LENDER OR THE BORROWER IN CONNECTION HEREWITH OR THEREWITH SHALL BE BROUGHT AND MAINTAINED IN THE COURTS OF THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK IN THE STATE OF NEW YORK OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK; PROVIDED THAT ANY SUIT SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT THE ADMINISTRATIVE AGENT’S OR THE LENDERS’ OPTION, IN THE COURTS OF ANY JURISDICTION WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, OR BY PERSONAL SERVICE WITHIN OR WITHOUT THE STATE OF NEW YORK AT ITS ADDRESS FOR NOTICES SPECIFIED IN SECTION 10.2. EACH OF THE PARTIES HERETO HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY HAVE OR HEREAFTER MAY HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. TO THE EXTENT THAT ANY PARTY HERETO HAS OR HEREAFTER MAY ACQUIRE ANY IMMUNITY FROM JURISDICTION OF ANY COURT OR FROM ANY LEGAL PROCESS (WHETHER THROUGH SERVICE OR NOTICE, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID OF EXECUTION OR OTHERWISE) WITH RESPECT TO ITSELF OR ITS PROPERTY, EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, SUCH IMMUNITY IN RESPECT OF ITS OBLIGATIONS UNDER THE LOAN DOCUMENTS.

 

 - 111 - 

 

 

SECTION 10.13 Waiver of Jury Trial. THE ADMINISTRATIVE AGENT, THE LENDERS AND THE BORROWER HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE TO THE FULLEST EXTENT PERMITTED BY LAW ANY RIGHTS THEY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, EACH LOAN DOCUMENT, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE ADMINISTRATIVE AGENT, ANY LENDER OR THE BORROWER IN CONNECTION THEREWITH. EACH OF THE PARTIES HERETO ACKNOWLEDGES AND AGREES THAT IT HAS RECEIVED FULL AND SUFFICIENT CONSIDERATION FOR THIS PROVISION (AND EACH OTHER PROVISION OF EACH OTHER LOAN DOCUMENT TO WHICH IT IS A PARTY) AND THAT THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE PARTIES ENTERING INTO THE LOAN DOCUMENTS.

 

SECTION 10.14 Confidential Information. Subject to the provisions of Section 10.15, at all times prior to the Termination Date, the Receiving Party shall keep confidential and shall not publish or otherwise disclose any Confidential Information furnished to it by the Disclosing Party, except to those of the Receiving Party’s employees, advisors or consultants who have a need to know such information to assist such Receiving Party in the performance of such Receiving Party’s obligations or in the exercise of such Receiving Party’s rights hereunder and who are subject to reasonable obligations of confidentiality consistent with this Section 10.14 (collectively, “Recipients”); provided that the Receiving Party shall remain liable for any breach of this Section 10.14 by any of its Recipients. Notwithstanding anything to the contrary set forth herein, any Lender may disclose Confidential Information received from or on behalf of the Borrower and its Subsidiaries related hereto, to (i) its Affiliates, (ii) other than with respect to any information provided pursuant to Section 7.1(i) hereof, potential and actual assignees of any of such Lender’s rights hereunder and (iii) other than with respect to any information provided pursuant to Section 7.1(i) hereof, potential and actual investors in, or lenders to, such Lender (including, in each of the foregoing cases, such Person’s employees, advisors or consultants); provided that in each case, each such Person referred to in clauses (i) through (iii) shall be subject to reasonable obligations of confidentiality and provided, further, that such Lender shall remain liable for any breach of this Section 10.14 by any such Person referred to in clause (i) through (iii) to whom such Lender disclosed such Confidential Information. In addition to the foregoing, the Receiving Party may disclose Confidential Information belonging to the Disclosing Party to the extent (and only to the extent) such disclosure is reasonably necessary in order to comply with applicable Laws (including any securities law or regulation or the rules of a securities exchange) and with judicial process, if in the reasonable opinion of the Receiving Party, such disclosure is necessary for such compliance, provided that the Receiving Party (x) will only disclose those portions of the Confidential Information that are necessary or required to be so disclosed, and (y) to the extent legally permissible, will notify the Disclosing Party of the Receiving Party’s intent to make any disclosure pursuant thereto sufficiently prior to making such disclosure so as to allow the Disclosing Party time to take whatever action it may deem appropriate to protect the confidentiality of the information to be disclosed.

 

 - 112 - 

 

 

SECTION 10.15 Exceptions to Confidentiality. The Receiving Party’s obligations set forth in this Agreement shall not extend to any Confidential Information of the Disclosing Party:

 

(a)            that is or hereafter becomes part of the public domain (other than as a result of a disclosure by the Receiving Party or its Recipients in violation of this Agreement);

 

(b)            that is received from a Third Party without restriction on disclosure and without, to the knowledge of the Receiving Party, breach of any agreement between such Third Party and the Disclosing Party;

 

(c)            that the Receiving Party can demonstrate by competent evidence was already in its possession without any limitation on disclosure prior to its receipt from the Disclosing Party;

 

(d)            that is generally made available to Third Parties by the Disclosing Party without restriction on disclosure; or

 

(e)            that the Receiving Party can demonstrate by competent evidence was independently developed by the Receiving Party without use of or reference to the Confidential Information.

 

SECTION 10.16 No Waiver; Cumulative Remedies; Enforcement. No failure by any Lender or the Administrative Agent to exercise, and no delay by any such Person in exercising, any right, remedy, power or privilege hereunder or under any other Loan Document shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. The rights, remedies, powers and privileges herein provided, and provided under each other Loan Document, are cumulative and not exclusive of any rights, remedies, powers and privileges provided by Law.

 

 - 113 - 

 

 

Notwithstanding anything to the contrary contained herein or in any other Loan Document, the authority to enforce rights and remedies hereunder and under the other Loan Documents against the Borrower and the Guarantors or any of them shall be vested exclusively in, and all actions and proceedings at law in connection with such enforcement shall be instituted and maintained exclusively by, the Administrative Agent in accordance with Section 11.1 for the benefit of all the Lenders; provided, however, that the foregoing shall not prohibit (a) the Administrative Agent from exercising on its own behalf the rights and remedies that inure to its benefit (solely in its capacity as Administrative Agent) hereunder and under the other Loan Documents, (b) any Lender from exercising setoff rights in accordance with Section 4.5 (subject to the terms of Section 4.4(e)), or (c) any Lender from filing proofs of claim or appearing and filing pleadings on its own behalf during the pendency of a proceeding relative to the Borrower or any Guarantor under any Debtor Relief Law or any proceedings arising out of or in connection with an Insolvency Event; and provided, further, that if at any time there is no Person acting as Administrative Agent hereunder and under the other Loan Documents, then (i) the Required Lenders shall have the rights otherwise ascribed to the Administrative Agent pursuant to Section 11.1 and (ii) in addition to the matters set forth in clauses (b) and (c) of the preceding proviso and subject to Section 4.4(e), any Lender may, with the consent of the Required Lenders, enforce any rights and remedies available to it and as authorized by the Required Lenders.

 

SECTION 10.17 Payments Set Aside. To the extent that any payment by or on behalf of the Borrower or any Guarantor is made to the Administrative Agent or any Lender, or the Administrative Agent or any Lender exercises its right of setoff, and such payment or the proceeds of such setoff or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by the Administrative Agent or such Lender in its discretion) to be repaid to a trustee, receiver, receiver, manager, monitor or any other party, in connection with any proceeding under any Debtor Relief Law, any proceedings arising out of or in connection with an Insolvency Event or otherwise, then (a) to the extent of such recovery, the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such setoff had not occurred, and (b) each Lender severally agrees to pay to the Administrative Agent upon demand its applicable share (without duplication) of any amount so recovered from or repaid by the Administrative Agent, plus interest thereon from the date of such demand to the date such payment is made at a rate per annum equal to the Federal Funds Rate from time to time in effect. The obligations of the Lenders under clause (b) of the preceding sentence shall survive the payment in full of the Obligations and the termination of this Agreement.

 

SECTION 10.18 Electronic Execution of Assignments and Certain Other Documents. The words “execute,” “execution,” “signed,” “signature” and words of like import in this Agreement, any Assignment and Assumption or in any amendment or other modification hereof (including waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Administrative Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

 

 - 114 - 

 

 

SECTION 10.19 Independent Nature of Lenders. The obligations of each Lender under this Agreement and each of the other Loan Documents are several and not joint with the obligations of any other Lender, and no Lender shall be responsible in any way for the performance of the obligations of any other Lender under this Agreement or any other Loan Document. Each Lender shall be responsible only for its own representations, warranties, agreements and covenants hereunder and under the other Loan Documents. Nothing contained in this Agreement or any other Loan Document, and no action taken by any Lender pursuant hereto or thereto, shall be deemed to constitute the Lenders as, and the Borrower and the Guarantors acknowledge and agree that the Lenders do not thereby constitute, a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Lenders are in any way acting in concert or as a group with respect to the Obligations or the transactions contemplated by this Agreement or any other Loan Document, and the Borrower and the Guarantors shall not assert any contrary position.

 

SECTION 10.20 No Fiduciary Relationship. Each of the Borrower and the Guarantors acknowledge and agree that (a) each Lender is acting at arm’s length from the Borrower and the Guarantors with respect to this Agreement and the Borrower and the Guarantors and the transactions contemplated hereby and thereby; (b) no Lender will, solely by virtue of this Agreement or any of the Loan Documents or any transaction contemplated hereby or thereby, become an Affiliate of, or have any agency, tenancy or joint venture relationship with, any of the Borrower and the Guarantors; (c) no Lender has acted, or is or will be acting, as a financial advisor to, or fiduciary (or in any similar capacity) of, or has any fiduciary or similar duty to, any of the Borrower and the Guarantors with respect to, or in connection with, this Agreement and the other Loan Documents and the transactions contemplated hereby and thereby, and each of the Borrower and the Guarantors agree not to assert, and hereby waives, any claim that any Lender has any fiduciary duty to any of the Borrower and the Guarantors; (d) any advice given by a Lender or any of its representatives or agents in connection with this Agreement and the other Loan Documents and the transactions contemplated hereby and thereby is merely incidental to such Lender’s performance of its obligations hereunder and thereunder; and (e) each of the Borrower’s and the Guarantors’ decision to enter into this Agreement and the other Loan Documents has been based solely on the independent evaluation by the Borrower, the Guarantors and their representatives.

 

ARTICLE XI
ADMINISTRATIVE AGENT

 

SECTION 11.1 Appointment and Authority.

 

(a)            Each of the Lenders hereby irrevocably appoints Wilmington Trust, National Association, to act on its behalf as the Administrative Agent hereunder and under the other Loan Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof or thereof, together with such actions and powers as are incidental thereto. The provisions of this Article are solely for the benefit of the Administrative Agent and the Lenders, and neither the Borrower nor any Guarantor shall have rights as a third party beneficiary of any of such provisions. It is understood and agreed that the use of the term “agent” herein or in any other Loan Documents (or any other similar term) with reference to the Administrative Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable law. Instead such term is used as a matter of market custom, and is intended to create or reflect only an administrative relationship between contracting parties.

 

 - 115 - 

 

 

(b)            The Administrative Agent shall also act as the “collateral agent” under the Loan Documents, and each of the Lenders hereby irrevocably appoints and authorizes the Administrative Agent to act as the agent of such Lender for purposes of acquiring, holding and enforcing any and all Liens on Collateral granted by any of the Borrower and the Guarantors to secure any of the Obligations, together with such powers and discretion as are incidental thereto. In this connection, the Administrative Agent, as “collateral agent” (and any co-agents, sub-agents and attorneys-in-fact appointed by the Administrative Agent pursuant to Section 11.5 for purposes of holding or enforcing any Lien on the Collateral (or any portion thereof) granted under the Security Agreement, or for exercising any rights and remedies thereunder at the direction of the Administrative Agent), shall be entitled to the benefits of all provisions of Article X (including Section 10.4(c)), as though such co-agents, sub-agents and attorneys-in-fact were the “collateral agent” under the Loan Documents and this Article XI as if set forth in full herein with respect thereto.

 

(c)            Each of the Lenders authorizes the Administrative Agent to perform the duties, obligations and responsibilities and to exercise the rights, powers, authorities and discretions specifically given to the Administrative Agent under or in connection with the Loan Documents together with any other incidental rights, powers, authorities and discretions.

 

(d)            At the direction of the Required Lenders, the Administrative Agent is hereby authorized to enter into any usual and customary intercreditor agreement and/or subordination agreement to the extent contemplated by the terms hereof, and the Lenders acknowledge that each such intercreditor agreement and/or subordination agreement is binding upon them. Each Lender (a) hereby agrees that it will be bound by and will take no actions contrary to the provisions of any such intercreditor agreement or subordination agreement and (b) in connection therewith agrees that, to the extent contemplated thereby, the Liens on the Collateral may be subject to the provisions thereof. In addition, but in conformance with the terms hereof, at the direction of the Required Lenders the Administrative Agent shall enter into (i) any amendments to any intercreditor agreements or subordination agreements, as the case may be, and (ii) any other intercreditor arrangements, in the case of clauses (i) and (ii), to the extent required to give effect to the establishment of intercreditor rights and privileges as contemplated and required by of this Agreement. Each Lender waives any conflict of interest, now contemplated or arising hereafter, in connection therewith and agrees not to assert against the Administrative Agent or any of its affiliates any claims, causes of action, damages or liabilities of whatever kind or nature relating thereto.

 

SECTION 11.2 Rights as a Lender. The Person serving as the Administrative Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Administrative Agent and the term “Lender” or “Lenders” shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity. Such Person and its Affiliates may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of business with the Borrower, any Guarantor or any Affiliate thereof as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Lenders.

 

 - 116 - 

 

 

SECTION 11.3 Exculpatory Provisions. The Administrative Agent shall not have any duties or obligations except those expressly set forth herein and in the other Loan Documents, and its duties hereunder shall be administrative in nature. Without limiting the generality of the foregoing, the Administrative Agent:

 

(a)            shall not be subject to any fiduciary or other implied duties, regardless of whether a Default or Event of Default has occurred and is continuing;

 

(b)            shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise as directed in writing by the Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in the other Loan Documents), provided that the Administrative Agent shall not be required to take any action or to exercise any of the rights or powers vested in it by this Agreement at the request or direction of the Lenders, pursuant to the provisions of this Agreement, unless such Lenders shall have offered to the Administrative Agent security or indemnity (satisfactory to the Administrative Agent in its sole and absolute discretion) against the costs, expenses and liabilities which may be incurred by it in compliance with such request or direction, or that, in its opinion or the opinion of its counsel, may expose the Administrative Agent to liability or that is contrary to any Loan Document or applicable Law, including for the avoidance of doubt any action that may be in violation of the automatic stay under any Debtor Relief Law or that may effect a forfeiture, modification or termination of property of a Defaulting Lender in violation of any Debtor Relief Law; and

 

(c)            shall not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to any Borrower and any of the Subsidiaries that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity.

 

The Administrative Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Required Lenders or (ii) in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and non-appealable judgment. Subject to the proviso in Section 11.3(b), with respect to any discretion, consent, approval or similar such action to be made, taken, omitted to be taken or determined by the Administrative Agent hereunder or under any other Loan Document (each an “Agent Determination”), such Agent Determination shall be made by the Administrative Agent at the written direction of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith shall be necessary under the circumstances). The Administrative Agent shall be deemed not to have knowledge of any Default or Event of Default unless and until notice describing such Default or Event of Default is given in writing to the Administrative Agent by the Borrower, or a Lender.

 

 - 117 - 

 

 

The Administrative Agent shall have the right to request instructions from the Required Lenders or, as required, each of the Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith shall be necessary under the circumstances). If the Administrative Agent shall request instructions from the Required Lenders or each of the Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith shall be necessary under the circumstances), as the case may be, with respect to any act or action (including the failure to act) in connection with this Agreement or any other Loan Document, the Administrative Agent shall be entitled to refrain from such act or taking such action unless and until the Administrative Agent shall have received instructions from the Required Lenders or such other number or percentage of the Lenders, as the case may be, and the Administrative Agent shall not incur any liability to any Person by reason of so refraining. The Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default or Event of Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in Article V or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent.

 

The Administrative Agent shall have no liability for any action taken, or errors in judgment made, in good faith by it or any of its officers, employees or agents, unless it shall have been negligent in ascertaining the pertinent facts. The permissive rights of the Administrative Agent to do things enumerated in this Agreement shall not be construed as a duty and, with respect to such permissive rights, the Administrative Agent shall not be answerable in respect thereof other than for its gross negligence or willful misconduct. Nothing in this Agreement shall require the Administrative Agent to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties or in the exercise of any of its rights or powers hereunder.

 

Neither the Administrative Agent nor any of its directors, officers, employees, agents or affiliates shall be responsible for nor have any duty to monitor the performance or any action of the Borrower or any Guarantor, or any of their directors, members, officers, agents, affiliates or employee, nor shall it have any liability in connection with the malfeasance or nonfeasance by such party. The Administrative Agent may assume performance by all such Persons of their respective obligations. The Administrative Agent shall have no enforcement or notification obligations relating to breaches of representations or warranties of any other Person.

 

The Administrative Agent shall not be responsible or liable for any failure or delay in the performance of its obligations under this Agreement arising out of or caused, directly or indirectly, by circumstances beyond its control, including without limitation, any act or provision of any present or future law or regulation or governmental authority; acts of God; earthquakes; fires; floods; wars; terrorism; civil or military disturbances; sabotage; epidemics; riots; interruptions, loss or malfunctions of utilities, computer (hardware or software) or communications service; accidents; labor disputes; acts of civil or military authority or governmental actions; or the unavailability of the Federal Reserve Bank wire or telex or other wire or communication facility.

 

 - 118 - 

 

 

SECTION 11.4 Reliance by the Administrative Agent.

 

(a)            The Administrative Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of a Loan, that by its terms must be fulfilled to the satisfaction of a Lender, the Administrative Agent may presume that such condition is satisfactory to such Lender unless the Administrative Agent shall have received notice to the contrary from such Lender prior to the making of such Loan. The Administrative Agent may consult with legal counsel (who may be counsel for the Borrower or the Subsidiaries), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.

 

(b)            Reliance by the Administrative Agent and Lenders. The Administrative Agent and the Lenders shall be entitled to rely and act upon any notices (including telephonic or electronic loan notices) purportedly given by or on behalf of the Borrower or any of the Guarantors even if (i) such notices were not made in a manner specified herein, were incomplete or were not preceded or followed by any other form of notice specified herein, or (ii) the terms thereof, as understood by the recipient, varied from any confirmation thereof. The Borrower and the Guarantors shall indemnify the Administrative Agent, each Lender and their respective partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives from all losses, costs, expenses and liabilities resulting from the reliance by such Person on each notice purportedly given by or on behalf of the Borrower or any Guarantor; provided that such indemnity shall not, as to any Person be available to the extent that such losses, costs, expenses or liabilities are determined by a court of competent jurisdiction by final and non-appealable judgment to have resulted from the gross negligence or willful misconduct of such Person. All telephonic notices to and other telephonic communications with the Administrative Agent may be recorded by the Administrative Agent, and each of the parties hereto hereby consents to such recording.

 

SECTION 11.5 Delegation of Duties. The Administrative Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Administrative Agent. The Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives. The rights, benefits and privileges (including the exculpatory and indemnification provisions) of Article X and this Article XI shall apply to any such sub-agent and to the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of the Administrative Agent and any such sub-agent, and shall apply to their respective activities in connection with the syndication of the credit facilities provided for herein as well as activities as Administrative Agent. The Administrative Agent shall not be responsible for the negligence or misconduct of any sub-agents except to the extent that a court of competent jurisdiction determines in a final and non-appealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such sub-agents. Notwithstanding anything herein to the contrary, with respect to each sub-agent appointed by the Administrative Agent, (i) such sub-agent shall be a third party beneficiary under this Agreement with respect to all such rights, benefits and privileges (including exculpatory rights and rights to indemnification) and shall have all of the rights and benefits of a third party beneficiary, including an independent right of action to enforce such rights, benefits and privileges (including exculpatory rights and rights to indemnification) directly, without the consent or joinder of any other Person, against any or all of the Borrower, the Guarantors and the Lenders, (ii) any modification to such rights, benefits and privileges (including exculpatory rights and rights to indemnification) shall not be effective as against such sub-agent without its written consent thereto, and (iii) such sub-agent shall only have obligations to the Administrative Agent and not to the Borrower or any Guarantor, Lender or any other Person and none of the Borrower, the Guarantors, the Lenders or any other Person shall have any rights, directly or indirectly, as a third party beneficiary or otherwise, against such subagent.

 

 - 119 - 

 

 

SECTION 11.6 Resignation or Removal of the Administrative Agent. The Administrative Agent may resign as the Administrative Agent at any time by giving thirty (30) days advance notice thereof to the Lenders and the Borrower and, thereafter, the retiring Administrative Agent shall be discharged from its duties and obligations hereunder. Upon any such resignation, the Required Lenders shall have the right to appoint a successor Administrative Agent. No less than thirty (30) days following the delivery of such written notice, the Required Lenders shall have the right with the consent of the Borrower (such consent not to be unreasonably withheld, conditioned or delayed; provided, that no consent of the Borrower shall be required if an Event of Default has occurred and is continuing) to appoint a successor Administrative Agent, which shall be a bank with an office in the United States, or an Affiliate of any such bank with an office in the United States, with whom the Lenders shall be dealing on an arm’s length basis. Upon the acceptance of any appointment as the Administrative Agent hereunder by a successor Administrative Agent, such successor Administrative Agent shall thereupon succeed to and become vested with all rights, powers, privileges and duties of the retiring Administrative Agent. After any retiring Administrative Agent’s resignation hereunder as the Administrative Agent or upon a removal of the Administrative Agent upon the written request of the Required Lenders, the provisions of this Section 11.6 shall continue in effect for its benefit in respect of any actions taken or omitted to be taken by it while it was acting as the Administrative Agent. If no successor has accepted appointment as the Administrative Agent by the date which is thirty (30) days following delivery of written notice of resignation or removal, the retiring Administrative Agent’s resignation or removal shall nevertheless thereupon become effective and the Required Lenders shall perform all of the duties of the Administrative Agent hereunder until such time, if any, as the Required Lenders appoint a successor agent as provided for above. For the avoidance of doubt, in no event shall any such successor Administrative Agent be a Defaulting Lender or Disqualified Institution.

 

SECTION 11.7 Non-Reliance on the Administrative Agent and Other Lenders. Each Lender acknowledges that it has, independently and without reliance upon the Administrative Agent or any other Lender or any of their respective partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Lender also acknowledges that it will, independently and without reliance upon the Administrative Agent or any other Lender or any of their respective partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder.

 

 - 120 - 

 

 

SECTION 11.8 Administrative Agent May File Proofs of Claim. In case of the pendency of any receivership, insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or other judicial proceeding relative to the Borrower or any Guarantor, the Administrative Agent (irrespective of whether the principal of any Loan shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent shall have made any demand on the Borrower) shall be entitled and empowered, by intervention in such proceeding or otherwise:

 

(a)            to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans and all other Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders and the Administrative Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders and the Administrative Agent under Section 10.4) allowed in such judicial proceeding; and

 

(b)            to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same;

 

and any custodian, receiver, receiver-manager, monitor, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the making of such payments directly to the Lenders, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due the Administrative Agent under Section 10.4.

 

 - 121 - 

 

 

In addition, the Lenders hereby irrevocably authorize the Administrative Agent, based upon the written instruction of the Required Lenders, to (a) credit bid and in such manner purchase (either directly or through one or more acquisition vehicles) all or any portion of the Collateral at any sale thereof conducted under the provisions of the Debtor Relief Laws, including under Section 363 of the Bankruptcy Code of the United States or any similar laws in any other jurisdictions to which the Borrower or any Guarantor is subject, or (b) credit bid and in such manner purchase (either directly or through one or more acquisition vehicles) all or any portion of the Collateral at any other sale or foreclosure conducted by (or with the consent or at the direction of) the Administrative Agent (whether by judicial action or otherwise) in accordance with applicable Law. In connection with any such credit bid and purchase, the Obligations owed to the Lenders shall be entitled to be, and shall be, credit bid on a ratable basis (with Obligations with respect to contingent or unliquidated claims being estimated for such purpose if the fixing or liquidation thereof would not unduly delay the ability of the Administrative Agent to credit bid and purchase at such sale or other disposition of the Collateral and, if such claims cannot be estimated without unduly delaying the ability of the Administrative Agent to credit bid, then such claims shall be disregarded, not credit bid, and not entitled to any interest in the asset or assets purchased by means of such credit bid) and the Lenders whose Obligations are credit bid shall be entitled to receive interests (ratably based upon the proportion of their Obligations credit bid in relation to the aggregate amount of Obligations so credit bid) in the asset or assets so purchased (or in the Capital Securities of the acquisition vehicle or vehicles that are used to consummate such purchase). Except as provided above and otherwise expressly provided for herein or in the other Loan Documents, the Administrative Agent will not execute or deliver a release of any Lien on any Collateral. Upon request by the Administrative Agent at any time, the Lenders will confirm in writing the Administrative Agent’s authority to release any such Liens on particular types or items of Collateral pursuant to, and in accordance with, this Section. Each Secured Party whose Obligations are credit bid under this Section shall be entitled to receive interests in the Collateral or any other asset acquired in connection with such credit bid (or in the Capital Securities of the acquisition vehicle or vehicles that are used to consummate such acquisition) on a ratable basis in accordance with the percentage obtained by dividing (y) the amount of Obligations of such Secured Party that were credit bid in such credit bid by (z) the aggregate amount of all Obligations that were credit bid in such credit bid.

 

Nothing contained herein shall be deemed to authorize the Administrative Agent to authorize or consent to or accept or adopt on behalf of any Lender any plan of reorganization, arrangement, adjustment or composition affecting the Obligations or the rights of any Lender or to authorize the Administrative Agent to vote in respect of the claim of any Lender in any such proceeding.

 

SECTION 11.9 Collateral and Guarantee Matters. The Lenders irrevocably authorize the Administrative Agent:

 

(a)            to release any Lien on any Collateral granted to or held by the Administrative Agent under any Loan Document (i) upon the Termination Date, (ii) that is sold or otherwise disposed of to a Person that is not the Borrower or any Guarantor as part of or in connection with any sale or other Disposition permitted hereunder and under the other Loan Documents or any Casualty Event, (iii) owned by a Guarantor upon release of such Guarantor from its obligations under its Guarantee pursuant to Section 11.9(b) or (iv) as approved in accordance with Section 10.1;

 

(b)            to release any Guarantor from its obligations under the Guarantee (i) upon the Termination Date or (ii) if such Person ceases to be a Subsidiary as a result of a transaction permitted under the Loan Documents; and

 

(c)            to subordinate any Lien on any Collateral relating to customary “ABL Priority Collateral” related to accounts receivable in connection with the entering into of an intercreditor agreement in relation to Permitted Receivables Indebtedness.

 

Upon request by the Administrative Agent at any time, the Required Lenders will confirm in writing the Administrative Agent’s authority to release its interest in particular types or items of property, or to release any Guarantor from its obligations under the Guarantee, pursuant to this Section 11.9.

 

 - 122 - 

 

 

In the event that any Collateral shall be attached, garnished or levied upon by any court order, or the delivery thereof shall be stayed or enjoined by an order of a court, or any order, judgment or decree shall be made or entered by any court order affecting the Collateral, the Administrative Agent is hereby expressly authorized, in its sole discretion, to respond as it deems appropriate or to comply with all writs, orders or decrees so entered or issued, or which it is advised by legal counsel of its own choosing is binding upon it, whether with or without jurisdiction. In the event that the Administrative Agent obeys or complies with any such writ, order or decree it shall not be liable to any of the Parties or to any other person, firm or corporation, should, by reason of such compliance notwithstanding, such writ, order or decree be subsequently reversed, modified, annulled, set aside or vacated.

 

The Administrative Agent shall have no obligation to give, execute, deliver, file, record, authorize or obtain any financing statements, notices, instruments, documents, agreements, consents or other papers as shall be necessary to (i) create, preserve, perfect or validate any security interest granted to the Administrative Agent pursuant to the Loan Documents or (ii) enable the Administrative Agent to exercise and enforce its rights under the Loan Documents with respect to any such pledge and security interest. The Administrative Agent shall not be responsible for or have a duty to ascertain or inquire into any representation or warranty regarding the existence, value or collectability of the Collateral, the existence, priority or perfection of the Administrative Agent’s Lien thereon, or any certificate prepared by the Borrower or any Guarantor in connection therewith, nor shall the Administrative Agent be responsible or liable to the Lenders for any failure to monitor or maintain any portion of the Collateral.

 

SECTION 11.10 Erroneous Payments.

 

(a)            If the Administrative Agent notifies a Lender, or any Person who has received funds on behalf of a Lender (any such Lender or other recipient, a “Payment Recipient”), that the Administrative Agent has determined in its sole discretion (whether or not after receipt of any notice under immediately succeeding clause (b)) that any funds (as set forth in such notice from the Administrative Agent) received by such Payment Recipient from the Administrative Agent or any of its Affiliates were erroneously or mistakenly transmitted to, or otherwise erroneously or mistakenly received by, such Payment Recipient (whether or not known to such Lender or other Payment Recipient on its behalf) (any such funds, whether transmitted or received as a payment, prepayment or repayment of principal, interest, fees, distribution or otherwise, individually and collectively, an “Erroneous Payment”) and demands in writing the return of such Erroneous Payment (or a portion thereof), such Erroneous Payment shall at all times remain the property of the Administrative Agent pending its return or repayment as contemplated below in this Section 11.10 and shall be segregated by the Payment Recipient and held in trust for the benefit of the Administrative Agent, and such Lender shall (or, with respect to any Payment Recipient who received such funds on its behalf, shall cause such Payment Recipient to) promptly, but in no event later than two Business Days thereafter, return to the Administrative Agent the amount of any such Erroneous Payment (or portion thereof) as to which such a demand was made, in same day funds (in the currency so received), together with interest thereon in respect of each day from and including the date such Erroneous Payment (or portion thereof) was received by such Payment Recipient to the date such amount is repaid to the Administrative Agent in same day funds at the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation from time to time in effect. A notice of the Administrative Agent to any Payment Recipient under this clause (a) shall be conclusive, absent manifest error.

 

 - 123 - 

 

 

(b)            Without limiting immediately preceding clause (a), each Lender, or any Person who has received funds on behalf of a Lender, hereby further agrees that if it receives a payment, prepayment or repayment (whether received as a payment, prepayment or repayment of principal, interest, fees, distribution or otherwise) from the Administrative Agent (or any of its Affiliates) (x) that is in a different amount than, or on a different date from, that specified in this Agreement or in a notice of payment, prepayment or repayment sent by the Administrative Agent (or any of its Affiliates) with respect to such payment, prepayment or repayment, (y) that was not preceded or accompanied by a notice of payment, prepayment or repayment sent by the Administrative Agent (or any of its Affiliates), or (z) that such Lender, or other such recipient, otherwise becomes aware was transmitted, or received, in error or by mistake (in whole or in part), then in each such case:

 

(i)it acknowledges and agrees that (A) in the case of immediately preceding clauses (x) or (y), an error or mistake shall be presumed to have been made (absent written confirmation from the Administrative Agent to the contrary) or (B) an error and mistake has been made (in the case of immediately preceding clause (z)), in each case, with respect to such payment, prepayment or repayment; and

 

(ii)such Lender shall (and shall cause any other recipient that receives funds on its respective behalf to) promptly (and, in all events, within one Business Day of its knowledge of the occurrence of any of the circumstances described in immediately preceding clauses (x), (y) and (z)) notify the Administrative Agent of its receipt of such payment, prepayment or repayment, the details thereof (in reasonable detail) and that it is so notifying the Administrative Agent pursuant to this Section 11.10(b)(ii).

 

(c)            Each Lender hereby authorizes the Administrative Agent to set off, net and apply any and all amounts at any time owing to such Lender under any Loan Document, or otherwise payable or distributable by the Administrative Agent to such Lender under any Loan Document with respect to any payment of principal, interest, fees or other amounts, against any amount that the Administrative Agent has demanded to be returned under immediately preceding clause (a).

 

(d)            [Reserved].

 

 - 124 - 

 

 

(e)            The parties hereto agree that (x) irrespective of whether the Administrative Agent may be equitably subrogated, in the event that an Erroneous Payment (or portion thereof) is not recovered from any Payment Recipient that has received such Erroneous Payment (or portion thereof) for any reason, the Administrative Agent shall be subrogated to all the rights and interests of such Payment Recipient (and, in the case of any Payment Recipient who has received funds on behalf of a Lender or Secured Party, to the rights and interests of such Lender or Secured Party, as the case may be) under the Loan Documents with respect to such amount and (y) an Erroneous Payment shall not pay, prepay, repay, discharge or otherwise satisfy any Obligations owed by the Borrower or any Guarantor; provided that this Section 11.10 shall not be interpreted to increase (or accelerate the due date for), or have the effect of increasing (or accelerating the due date for), the Obligations of the Borrower relative to the amount (and/or timing for payment) of the Obligations that would have been payable had such Erroneous Payment not been made by the Administrative Agent; provided, further, that for the avoidance of doubt, immediately preceding clauses (x) and (y) shall not apply to the extent any Erroneous Payment is, and solely with respect to the amount of such Erroneous Payment that is, comprised of funds received by the Administrative Agent from the Borrower or any Guarantor for the purpose of making such Erroneous Payment.

 

(f)            To the extent permitted by applicable law, no Payment Recipient shall assert any right or claim to an Erroneous Payment, and hereby waives, and is deemed to waive, any claim, counterclaim, defense or right of set-off or recoupment with respect to any demand, claim or counterclaim by the Administrative Agent for the return of any Erroneous Payment received, including, without limitation, any defense based on “discharge for value” or any similar doctrine.

 

(g)            Each party’s obligations, agreements and waivers under this Section 11.10 shall survive the resignation or replacement of the Administrative Agent, any transfer of rights or obligations by, or the replacement of, a Lender, the termination of the Commitments and/or the repayment, satisfaction or discharge of all Obligations (or any portion thereof) under any Loan Document.

 

[Signature Page Follows]

 

 - 125 - 

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective officers thereunto duly authorized as of the day and year first above written.

 

 

CARIS LIFE SCIENCES, INC.
as the Borrower

 

  By: /s/ David D. Halbert
    Name: David D. Halbert
    Title: Chairman & Chief Executive Officer

 

Signature Page to Credit Agreement

 

 

 

 

  WILMINGTON TRUST, NATIONAL ASSOCIATION,
as the Administrative Agent
 

  By: /s/ Jessica A. Jankiewicz
    Name: Jessica A. Jankiewicz
    Title: Vice President

 

Signature Page to Credit Agreement

 

 

 

 

  ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP,
as a Lender
   
  By OrbiMed ROF III LLC,
its General Partner
   
   By OrbiMed Advisors LLC,
its Managing Member
   
  By: /s/ Matthew Rizzo
    Name: Matthew Rizzo
    Title: Member

 

 

  ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP,
as a Lender
   
  By OrbiMed ROF IV LLC,
its General Partner
   
  By OrbiMed Advisors LLC,
its Managing Member
   
  By: /s/ Matthew Rizzo
    Name: Matthew Rizzo
    Title: Member

 

Signature Page to Credit Agreement

 

 

 

 

  BRAIDWELL TRANSACTION HOLDINGS LLC –
SERIES 2, as a Lender
       
  By: Braidwell LP
  its Investment Manager
       
  By: /s/ Manish K. Mital
    Name: Manish K. Mital
    Title: Chief Operating Officer & General Counsel
       
  By: /s/ Colin Bettison
    Name: Colin Bettison
    Title: Head of Finance & Operations

 

 

Signature Page to Credit Agreement

 

 

 

 

Schedule 2.1

Commitments and Applicable Percentages

 

Page 1 | Schedules to Credit Agreement

Schedule 2.1 (Commitments and Applicable Percentages)

 

 

 

 

Schedule 6.7(a)

Litigation

 

Page 2 | Schedules to Credit Agreement

Schedule 6.7(a) (Litigation)

 

 

 

 

Schedule 6.7(b)

Labor Matters

 

Page 3 | Schedules to Credit Agreement

Schedule 6.7(b) (Labor Matters) 

 

 

 

 

Schedule 6.8

Existing Subsidiaries 

 

Page 4 | Schedules to Credit Agreement

Schedule 6.8 (Existing Subsidiaries)

 

 

 

 

Schedule 6.11

Benefit Plans; Etc.

 

Page 5 | Schedules to Credit Agreement

Schedule 6.11 (Benefit Plans, Etc.)

 

 

 

 

Schedule 6.15(a)(1)

Intellectual Property (Registrations and Applications)

 

Page 6 | Schedules to Credit Agreement

Schedule 6.15(a)(1) (Intellectual Property (Registrations and Applications))

 

 

 

 

Schedule 6.15(a)(2)

Intellectual Property (In-Bound Licenses and Sub-Licenses)

 

 

Page 7 | Schedules to Credit Agreement

Schedule 6.15(a)(2) (Intellectual Property (Registration and Applications))

 

 

 

 

Schedule 6.15(f)

Proceedings Challenging Owned Intellectual Property

 

Page 8 | Schedules to Credit Agreement

Schedule 6.15(f) (Proceedings Challenging Ownwed Intellectual Property)

 

 

 

 

Schedule 6.15(g)

Validity of Owned and Licensed Intellectual Property 

 

Page 9 | Schedules to Credit Agreement

Schedule 6.15(g) (Validity of Owned and Licensed Intellectual Property)

 

 

 

 

Schedule 6.15(j)(1)

Infringement Notices

 

Page 10 | Schedules to Credit Agreement

Schedule 6.15(j)(1) (Infringement Notices)

 

 

 

 

Schedule 6.15(j)(2)

Infringement of Third Party Intellectual Property

 

Page 11 | Schedules to Credit Agreement

Schedule 6.15(j)(2) (Infringement of Third Party Intellectual Property)

 

 

 

 

Schedule 6.16

Material Agreements

 

Page 12 | Schedules to Credit Agreement

Schedule 6.16 (Material Agreements)

 

 

 

 

Schedule 6.18(i)

Violation of Fraud and Abuse Laws

 

Page 13 | Schedules to Credit Agreement

Schedule 6.18(i) (Violations of Fraud and Abuse Laws)

 

 

 

 

Schedule 6.18(l)

Health Program-Related Offenses

 

Page 14 | Schedules to Credit Agreement

Schedule 6.18(l) (Health Program-Related Offenses)

 

 

 

 

Schedule 6.19

Transactions with Permitted Holders

 

Page 15 | Schedules to Credit Agreement

Schedule 6.19 (Transactions with Permitted Holders) 

 

 

 

 

Schedule 6.22

Deposit and Disbursement Accounts 

 

Page 16 | Schedules to Credit Agreement

Schedule 6.22 (Deposit and Disbursement Accounts)

 

 

 

 

Section 6.24(d)

HIPAA

 

Page 17 | Schedules to Credit Agreement

Schedule 6.24(d) (HIPAA)

 

 

 

 

Schedule 8.2(b)

Indebtedness to be Paid

 

Page 18 | Schedules to Credit Agreement

Schedule 8.2(b) (Indebtedness to be Paid)

 

 

 

 

Schedule 8.2(c)

Existing Indebtedness

 

Page 19 | Schedules to Credit Agreement

Schedule 8.2(c) (Existing Indebtedness)

 

 

 

 

Schedule 8.3(c)

Existing Liens

 

Page 20 | Schedules to Credit Agreement

Schedule 8.3(c) (Existing Liens)

 

 

 

 

Schedule 8.5(a)

Investments

 

Page 21 | Schedules to Credit Agreement

Schedule 8.5(a) (Existing Investments)

 

 

 

 

Schedule 8.10

Affiliate Transactions 

 

Page 22 | Schedules to Credit Agreement

Schedule 8.10 (Affiliate Transactions)

 

 

 

 

Schedule 8.11

Restrictive Agreements 

 

Page 23 | Schedules to Credit Agreement

Schedule 8.11 (Restrictive Agreements)

 

 

 

 

Schedule 10.2

Notice Information

 

Page 24 | Schedules to Credit Agreement

Schedule 10.2 (Notice Information)

 

 

 

 

 

EXHIBIT A

FORM OF PROMISSORY NOTE

 

Up to $[__] January 18, 2023

 

FOR VALUE RECEIVED, CARIS LIFE SCIENCES, INC., a Texas corporation (the “Borrower”), hereby promises to pay to the order of [name of lender], a [__] (the “ Lender”) on the Maturity Date or as otherwise required from time to time in accordance with the terms of the Credit Agreement (as defined below) at the Administrative Agent’s Office, the principal sum of [__] DOLLARS ($[__]), or, if less, the aggregate unpaid principal amount of the Loans (and any continuation thereof) made (or, without duplication, continued) by the Lender pursuant to the Credit Agreement, dated as of January 18, 2023 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), by and among the Borrower, the Lenders party thereto and Wilmington Trust, National Association, as the Administrative Agent. Unless otherwise defined herein or the context otherwise requires, capitalized terms used in this Note have the meanings provided in the Credit Agreement.

 

The Borrower also promises to pay interest on the unpaid principal amount hereof from time to time outstanding from the date hereof until maturity (whether by acceleration or otherwise) and, after maturity upon demand, until paid in full, at the rates per annum and on the dates specified in the Credit Agreement, as well as any other amounts due at maturity to the Lender in respect of the Loans.

 

Pursuant to, and in accordance with, Section 3.2, Section 3.4 and Section 3.6 of the Credit Agreement, payments of both principal and interest are to be made in U.S. Dollars in same day or immediately available funds to the Administrative Agent for the account of the Lender at the Administrative Agent’s Office in accordance with the Credit Agreement.

 

This Note is referred to in, and evidences Indebtedness incurred under, the Credit Agreement, to which reference is made for a description of the security and guarantee for this Note and for a statement of the terms and conditions on which the Borrower is permitted and required to make prepayments and repayments of the unpaid principal amount of the Indebtedness evidenced by this Note and on which such Indebtedness may be declared to be immediately due and payable. Any prepaid principal of this Note may not be reborrowed.

 

All parties hereto, whether as makers, endorsers or otherwise, severally waive presentment for payment, demand, protest and notice of dishonor to the fullest extent possible in accordance with applicable Law.

 

THIS NOTE HAS BEEN ISSUED WITH ORIGINAL ISSUE DISCOUNT FOR U.S. FEDERAL INCOME TAX PURPOSES. REQUESTS FOR INFORMATION REGARDING THE ISSUE PRICE, AMOUNT OF ORIGINAL ISSUE DISCOUNT, ISSUE DATE AND YIELD TO MATURITY WITH RESPECT TO THIS NOTE MAY BE DIRECTED TO THE BORROWER CARE OF LUKE POWER, CORPORATE VICE PRESIDENT, INTERIM CHIEF FINANCIAL OFFICER AND TREASURER AT ### OR ###.

 

 

 

 

THIS NOTE HAS BEEN DELIVERED IN NEW YORK, NEW YORK, AND SHALL BE DEEMED TO BE A CONTRACT MADE UNDER AND GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK).

 

[Signature Page Follows]

 

2

 

 

  CARIS LIFE SCIENCES, INC.
   
  By:  
    Name:
    Title:

 

[Signature Page to Promissory Note]

 

 

 

 

EXHIBIT B

 

FORM OF LOAN REQUEST

 

__________ ___, 20__

 

Wilmington Trust, National Association

50 South Sixth Street, Suite 1290

Minneapolis, MN 55402

Attn: Caris Life Sciences Loan Administrator

Email: ###

Telephone: ###

 

Ladies and Gentlemen:

 

Reference is hereby made to that certain Credit Agreement, [to be dated on or about]1 [dated as of]2 January 18, 2023 (as amended, supplemented or otherwise modified from time to time and in effect on the date hereof, the “Credit Agreement”), by and among Caris Life Sciences, Inc., a Texas corporation (the “Borrower”), the Lenders party thereto and Wilmington Trust, National Association, as administrative agent (together with its Affiliates, successors, transferees and assignees, the “Administrative Agent”).

 

Unless otherwise defined herein or the context otherwise requires, terms used herein have the meanings provided in the Credit Agreement.

 

Pursuant to the provisions of Section 2.2 of the Credit Agreement, the Borrower hereby requests [the Initial] [a Delayed Draw] Loan of $_________3 to be made on _____________, 20__ (the “Proposed Disbursement Date”) in accordance with the bank account details and wire transfer instructions for disbursement of the proceeds of the proposed Loans as set forth on Schedule A hereto, which Loans shall be evidenced by those certain Promissory Notes dated as of [__], 2023 issued to the Lenders in the aggregate original principal amount of up to $400,000,000.00.

 

[The undersigned hereby represents and warrants to the Administrative Agent, for the benefit of the Secured Parties, that:

 

(a) no Default or Event of Default has occurred and is continuing or would result from the proposed Loans; and

 

 

1Note: Use for the request for the Initial Loan.

 

2Note: Use for the request of any Delayed Draw Loan.

 

3 Note: For the Initial Loan, requested amount shall not be less than the Initial Commitment Amount. For Delayed Draw Loans requested on the First Delayed Draw Closing Date, requested amount shall not be less than $100,000,000 (and integral multiples of $50,000,000 in excess thereof). For Delayed Draw Loans requested on the Second Delayed Draw Closing Date, requested amount shall not be less than the remaining Delayed Draw Commitment Amount.

 

 

 

 

(b) the representations and warranties contained in Article VI of the Credit Agreement and in the other Loan Documents are true and correct in all material respects (except with respect to any representation or warranty qualified by materiality or Material Adverse Effect, each of which representation or warranty is true and correct in all respects), before and after giving effect to the making of the proposed Loan and to the application of the proceeds thereof, as though made on and as of the date hereof, except to the extent that they relate specifically to an earlier specified date, in which case they are true and correct in all material respects (except to the extent that they relate specifically to an earlier specified date, in which case they are true and correct in all material respects (except with respect to any representation or warranty qualified by materiality or Material Adverse Effect, each of which representation or warranty is true and correct in all respects) on and as of such earlier date).]4

 

The officer signing below is an Authorized Officer of the Borrower and is authorized to request the Loans contemplated hereby and issue this Loan Request on behalf of the Borrower.

 

[Signature Page Follows]

 

 

4 Note: Include for the request for any Delayed Draw Loan.

 

2

 

 

  Very truly yours,
   
  CARIS LIFE SCIENCES, INC.,
  as the Borrower
   
  By:  
    Name:
    Title:

 

[Signature Page to Loan Request]

 

 

 

 

Schedule A

 

Disbursement / Wire Instructions

 

 

 

 

EXHIBIT C

 

FORM OF COMPLIANCE CERTIFICATE

 

CARIS LIFE SCIENCES, INC.

 

COMPUTATION DATE: _____________ __, 20__

 

This Compliance Certificate (this “Certificate”) is delivered pursuant to [Section 5.7]1 [Section 7.1(d)]2 of the Credit Agreement, dated as of January 18, 2023 (the “Credit Agreement”), by and among Caris Life Sciences, Inc., a Texas corporation (the “Borrower”), the Lenders party thereto and Wilmington Trust, National Association, as administrative agent (together with its Affiliates, successors, transferees and assignees, the “Administrative Agent”). Unless otherwise defined herein or the context otherwise requires, terms used in this Certificate have the meanings provided in the Credit Agreement.

 

This Certificate relates to the [Fiscal Quarter] [Fiscal Year] commencing on _____________, 20__ and ending on ____________ __, 20__ (such latter date being the “Computation Date”).

 

The undersigned, the chief financial or accounting Authorized Officer of the Borrower, is duly authorized to execute and deliver this Certificate on behalf of the Borrower. By executing this Certificate, the undersigned hereby certifies to the Administrative Agent and each Lender that as of the Computation Date:

 

(a) [Attached hereto as Annex I are (i) an unaudited consolidated balance sheet of the Borrower and the Subsidiaries as of the end of such Fiscal Quarter and related consolidated statements of income, stockholders’ equity and cash flows of the Borrower and the Subsidiaries for such Fiscal Quarter and for the period commencing at the end of the previous Fiscal Year and ending with the end of such Fiscal Quarter, including (in each case) in comparative form the figures for the corresponding Fiscal Quarter in the immediately preceding Fiscal Year and (ii) a report of the Revenue Base for such Fiscal Quarter and for the twelve-month period ending with the end of such Fiscal Quarter and including (in each case) in comparative form the figures for the corresponding Fiscal Quarter in the immediately preceding Fiscal Year and the corresponding twelve-month period immediately preceding such twelve-month period (subject to normal year-end audit adjustments and the absence of footnotes).]3

 

 

1 Use for the delivery on the Closing Date.
2 Use for the delivery after the Closing Date.
3 Use for the delivery of quarterly financial statements.

 

 

 

 

[Attached hereto as Annex I are (i) the consolidated balance sheet of the Borrower and the Subsidiaries and the related consolidated statements of income, stockholders’ equity and cash flows of the Borrower and the Subsidiaries for such Fiscal Year, setting forth in comparative form the figures for the immediately preceding Fiscal Year, audited (without any Impermissible Qualification) by independent public accountants acceptable to the Required Lenders (it being understood that Ernst & Young LLP or any other “Big Four” accounting firm are reasonably acceptable to the Required Lenders); and (ii) a report of the Revenue Base for the Fiscal Quarter then ending and such Fiscal Year and including in comparative form the figures for the corresponding Fiscal Quarter in the immediately preceding Fiscal Year and the immediately preceding Fiscal Year.]4

 

(b)            The financial statements or reports, as applicable, delivered with this Certificate in accordance with [Section 7.1(b)]5 [Section 7.1(c)]6 of the Credit Agreement have been prepared in accordance with GAAP, consistently applied, and present fairly in all material aspects the consolidated financial condition of the Borrower and the Subsidiaries and the results of operations [(subject to normal year-end audit adjustments and the absence of footnotes in the case of unaudited financial statements)]7.

 

(c)            During such [Fiscal Quarter] [Fiscal Year] and as of the Computation Date, the Borrower and the Subsidiaries have at all times been in compliance in all respects with the financial covenant set forth in Section 8.4(a) of the Credit Agreement. As of the Computation Date (for the applicable Test Period ending on such Computation Date), the Borrower and the Subsidiaries are in compliance in all respects with the financial covenant set forth in Section 8.4(b) of the Credit Agreement. Set forth on Attachment 1 hereto are calculations showing compliance with the financial covenant set forth in Section 8.4(a) of the Credit Agreement as of the Computation Date. Set forth on Attachment 2 hereto are calculations showing compliance with the financial covenant set forth in Section 8.4(b) as of the Computation Date.

 

(d)            No Default has occurred and is continuing [except as set forth on Attachment 3 hereto, which includes a description of the nature and period of existence of such Default and what action the Borrower or any of the Subsidiaries has taken, is taking or proposes to take with respect thereto].

 

(e)            Subsequent to the date of the most recent Compliance Certificate submitted by the undersigned pursuant to Section 7.1(d) of the Credit Agreement prior to the date hereof, neither the Borrower nor any Subsidiary has formed or acquired any new Subsidiary [except as set forth on Attachment 4 hereto, in which case such new Subsidiary has complied with the requirements of Section 7.8 of the Credit Agreement to the extent required thereunder].

 

(f)            Subsequent to the date of the most recent Compliance Certificate submitted by the undersigned pursuant to Section 7.1(d) of the Credit Agreement prior to the date hereof, neither the Borrower nor any Subsidiary has acquired any Material Real Property [except as set forth on Attachment 5 hereto, in which case the Loan Parties have complied with the requirements of Section 7.8 of the Credit Agreement with respect to such real property, to the extent required thereunder].

 

 

4 Use for the delivery of annual financial statements.
5 Use for the delivery of quarterly financial statements.
6 Use for the delivery of annual financial statements.
7 Include for the delivery of quarterly financial statements.

 

 

 

 

(g)            [Attached hereto as Attachment 6 is a report listing all published applications for the registration of any Intellectual Property with the United States Patent and Trademark Office filed during such Fiscal Quarter.]

 

(h)            [Attached hereto as Attachment 7 [is] [are (x)] a list of each Material Agreement in effect on the last day of such Fiscal Quarter [and (y)] a copy of the “Payer Revenue Per Case” file [dated as of a date not later than the last day] of such Fiscal Quarter.8]

 

[Signature Page Follows]

 

 

8 Include only, (x) as applicable, prior to the consummation of a Direct Listing, Qualified IPO or Qualified SPAC Transaction and (y) with the delivery of any quarterly financial statements required pursuant to Section 7.1(b) of the Credit Agreement (solely with respect to the Fiscal Quarter ending June 30 and December 31 of each Fiscal Year).

 

 

 

 

IN WITNESS WHEREOF, the undersigned has caused this Certificate to be executed and delivered, and the certification and warranties contained herein to be made, by its chief financial or accounting Authorized Officer as of the date first above written.

 

  CARIS LIFE SCIENCES, INC.
   
  By:  
    Name:
    Title:

 

[Signature Page to Compliance Certificate]

 

 

 

 

Annex I

 

[Quarterly or Annual Deliverables]

 

 

 

 

Attachment 1    
     
Financial Covenant (Minimum Liquidity) Calculation    
Section 8.4(a) - Liquidity (as of the Computation Date)    
     
A.1 Unrestricted cash-on-hand of the Borrower and the Guarantors in a    
Controlled Account (subject to Section 7.15) located in the United    
States
  $
A.2 Cash Equivalent Investments of the Borrower and the Guarantors    
in a Controlled Account (subject to Section 7.15) located in the United    
States $  
     
Total Liquidity Amount (A.1 + A.2) $  
     
Applicable Liquidity Requirement1 $  
     
Compliance [Yes/No]

 

 

1 The Liquidity of the Borrower shall not at any time be less than $20,000,000; provided that if the Borrower redeems or repurchases for cash all or any portion of the Series C Preferred Stock or the Series D Preferred Stock (except for any redemption or repurchase made using the proceeds of an issuance of Capital Securities, so long as such proceeds are escrowed solely for the purpose of effectuating such repurchase or redemption of Series C Preferred Stock or Series D Preferred Stock or such issuance is consummated substantially concurrently with such repurchase or redemption), from and after the date of such repurchase or redemption, the Liquidity of the Borrower shall not at any time be less than the outstanding principal amount of the Loans at such time (as such amount may be decreased from time to time); provided, further, that if all of the outstanding Series C Preferred Stock and Series D Preferred Stock are converted into common stock of the Borrower following the occurrence of a Qualified Direct Listing Event or the consummation of a Qualified IPO or a Qualified SPAC Transaction, the Liquidity of the Borrower shall not at any time be less than $20,000,000.

 

 

 

 

Attachment 2

 

Financial Covenant (Minimum Revenue Base) Calculation

 

Section 8.4(b) – Revenue Base (as of the Computation Date)

 

Revenue Base is calculated as follows:  
   
total consolidated revenue of the Borrower and its Subsidiaries, as determined in accordance with GAAP, for the Test Period ending on the Computation Date;  
   
Applicable Minimum Revenue Base requirement:1  
   
Compliance [Yes/No]

 

 

1 Subject to Section 9.4 of the Credit Agreement, the Revenue Base for the last day of a Test Period shall not be less than (i) prior to the First Delayed Draw Closing Date, the amount set forth in the second column below for the Test Period ending on such applicable date and (ii) on and after the occurrence of the First Delayed Draw Closing Date, the amount set forth in the third column below for the Test Period ending on such applicable date:

 

    Prior to the First Delayed Draw   If the First Delayed Draw Closing Date 
    Closing Date –   has occurred– 
Test Period Ending   Minimum Revenue Base   Minimum Revenue Base 
December 31, 2022   $200,000,000   $270,000,000 
March 31, 2023   $202,000,000   $272,000,000 
June 30, 2023   $205,000,000   $275,000,000 
September 30, 2023   $207,000,000   $275,000,000 
December 31, 2023   $210,000,000   $275,000,000 
March 31, 2024   $212,000,000   $275,000,000 
June 30, 2024   $215,000,000   $280,000,000 
September 30, 2024   $217,000,000   $285,000,000 
December 31, 2024   $220,000,000   $290,000,000 
March 31, 2025   $222,000,000   $295,000,000 
June 30, 2025   $225,000,000   $300,000,000 
September 30, 2025   $227,000,000   $305,000,000 
December 31, 2025   $230,000,000   $312,500,000 
March 31, 2026   $232,000,000   $320,000,000 
June 30, 2026   $235,000,000   $327,500,000 
September 30, 2026   $237,000,000   $335,000,000 
December 31, 2026   $240,000,000   $342,500,000 
March 31, 2027   $242,000,000   $350,000,000 
June 30, 2027   $245,000,000   $357,500,000 
September 30, 2027   $247,000,000   $365,000,000 
December 31, 2027   $250,000,000   $372,500,000 

 

 

 

 

Attachment 3

 

[Description of Default] [Intentionally omitted.]

 

 

 

 

Attachment 4

 

[Formation or Acquisition of New Subsidiaries] [Intentionally omitted.]

 

 

 

 

Attachment 5

 

[Material Real Property] [Intentionally omitted.]

 

 

 

 

Attachment 6

 

[Intellectual Property] [Intentionally omitted.]

 

 

 

 

Attachment 7

 

[Material Agreements and “Payer Revenue Per Case” File] [Intentionally omitted.]

 

 

 

 

EXHIBIT D

 

FORM OF GUARANTEE

 

This GUARANTEE, dated as of January 18, 2023 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, this “Guarantee”), is made by the entities listed on Schedule I hereto (together with any additional Persons named pursuant to Section 5.5 below, each, a “Guarantor”, and collectively, the “Guarantors”), in favor of WILMINGTON TRUST, NATIONAL ASSOCIATION, as administrative agent (together with its successors, transferees and assignees, in such capacity, the “Administrative Agent”), for the benefit of itself and the other Secured Parties (as defined below).

 

W I T N E S S E T H:

 

WHEREAS, pursuant to the Credit Agreement, dated as of January 18, 2023 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), by and among CARIS LIFE SCIENCES, INC., a Texas corporation (the “Borrower”), the Lenders party thereto and the Administrative Agent, the Lenders have extended Commitments to make Loans to the Borrower from time to time; and

 

WHEREAS, as a condition precedent to the making of the Loans and in order to induce the Lenders to make or continue to make, as the case may be, the Loans under the Credit Agreement, the Guarantors are required to execute and deliver this Guarantee;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and in order to induce the Lenders to make the Loans to the Borrower, each Guarantor hereby agrees, for the benefit of the Secured Parties, as follows.

 

ARTICLE I

DEFINITIONS

 

SECTION 1.1. Certain Terms. The following terms (whether or not underscored) when used in this Guarantee, including its preamble and recitals, shall have the following meanings (such definitions to be equally applicable to the singular and plural forms thereof):

 

“Administrative Agent” is defined in the preamble.

 

“Borrower” is defined in the first recital.

 

“Credit Agreement” is defined in the first recital.

 

“Guarantee” is defined in the preamble.

 

“Guarantor” is defined in the preamble.

 

“Obligor” means the Borrower and the Guarantors.

 

 

 

 

SECTION 1.2. Credit Agreement Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Guarantee, including its preamble and recitals, have the meanings provided in the Credit Agreement.

 

ARTICLE II

GUARANTEE PROVISIONS

 

SECTION 2.1. Guarantee. Subject to the limitations expressly set forth herein, each Guarantor jointly and severally, absolutely, unconditionally and irrevocably guarantees the full and punctual payment when due, whether at stated maturity, by required prepayment, declaration, acceleration, demand or otherwise, and performance of all Obligations of the Borrower and each Guarantor now or hereafter existing, whether for principal, interest (including interest accruing at the then applicable Default rate as provided in Section 3.5 of the Credit Agreement, whether or not a claim for post-filing or post-petition interest is allowed under applicable Law following the institution of a proceeding under bankruptcy, insolvency or similar Laws), fees, expenses or otherwise (including all such amounts which would become due but for the operation of the automatic stay under Section 362(a) of the United States Bankruptcy Code, 11 U.S.C. §362(a), and the operation of Sections 502(b) and 506(b) of the United States Bankruptcy Code, 11 U.S.C. §502(b) and §506(b)) (the “ Guaranteed Obligations”); provided that each Guarantor shall only be liable under this Guarantee for the maximum amount of such liability (after giving effect to any indemnification, contribution or similar rights) that can be hereby incurred without rendering this Guarantee, as it relates to such Guarantor, voidable under applicable Law relating to fraudulent conveyance or fraudulent transfer, and not for any greater amount. This Guarantee constitutes a guarantee of payment when due and not of collection, and each Guarantor specifically agrees that it shall not be necessary or required that the Administrative Agent for the benefit of itself and the other Secured Parties exercise any right, assert any claim or demand or enforce any remedy whatsoever against such Guarantor or any other Person before or as a condition to the obligations of such Guarantor becoming due hereunder. Section 10.4 of the Credit Agreement is hereby incorporated by reference with respect to each Guarantor mutatis mutandis.

 

SECTION 2.2. Reinstatement, Etc. Each Guarantor agrees that this Guarantee shall continue to be effective or be reinstated (including on or after the Termination Date), as the case may be, if at any time any payment (in whole or in part) of any of the Guaranteed Obligations is invalidated, declared to be fraudulent or preferential, set aside, rescinded or must otherwise be restored by any Secured Party, including upon the occurrence of any Event of Default set forth in Section 9.1(h) of the Credit Agreement or otherwise, all as though such payment had not been made.

 

SECTION 2.3. Guarantee Absolute, Etc. Subject to the limitations expressly set forth herein, this Guarantee shall in all respects be a continuing, absolute, unconditional and irrevocable guarantee of payment, and shall remain in full force and effect until (unless reinstated pursuant to Section 2.2 above) the payment in full in cash in immediately available funds of the Guaranteed Obligations or, with respect to the Guarantee of any Guarantor, the release of such Guarantor in accordance with Section 5.14 hereof. Subject to the limitations expressly set forth herein, the liability of each Guarantor under this Guarantee shall, to the fullest extent possible in accordance with applicable Law, be absolute, unconditional and irrevocable irrespective of:

 

2

 

 

(a) any lack of validity, legality or enforceability of any Loan Document;

 

(b) the failure of any Secured Party (i) to assert any claim or demand or to enforce any right or remedy against such Guarantor or any other Person (including any other guarantor) under the provisions of any Loan Document or otherwise, or (ii) to exercise any right or remedy against any other guarantor (including such Guarantor and any other Guarantor) of, or collateral securing, any Guaranteed Obligations;

 

(c) any change in the time, manner or place of payment of, or in any other term of, all or any part of the Guaranteed Obligations, or any other extension, compromise or renewal of any Guaranteed Obligation, or any amendment to, rescission, waiver, or other modification of, or any consent to or departure from, any of the terms of any Loan Document;

 

(d) any reduction, limitation, impairment or termination of any Guaranteed Obligations for any reason, including any claim of waiver, release, surrender, alteration or compromise, and shall not be subject to (and, to the fullest extent possible in accordance with applicable Law, each Guarantor hereby waives any right to or claim of) any defense or setoff, counterclaim, recoupment or termination whatsoever by reason of the invalidity, illegality, irregularity, compromise, unenforceability of, or any other event or occurrence affecting, any Guaranteed Obligations or otherwise (other than, in each case, a defense of payment in full in cash of the Guaranteed Obligations);

 

(e) any addition, exchange or release of any collateral or of any Person that is (or will become) a guarantor of the Guaranteed Obligations, or any surrender or non-perfection of any collateral, or any amendment to, or waiver or release of, or addition to, or consent to or departure from, any other guarantee held by the Secured Parties securing any of the Guaranteed Obligations; or

 

(f) any other circumstance which might otherwise constitute a defense available to, or a legal or equitable discharge of, any Obligor, any surety or any guarantor (including any Guarantor) (other than the defense of payment in full of cash).

 

SECTION 2.4. Setoff. Each Guarantor hereby irrevocably authorizes the Administrative Agent on behalf of the Secured Parties, without the requirement that any notice be given to such Guarantor (such notice being expressly waived by such Guarantor, to the extent permitted by applicable Law), upon the occurrence and solely during the continuance of any Event of Default, to appropriate and apply to the payment of the Guaranteed Obligations owing to it (whether or not then due), any and all balances, credits, deposits, accounts or moneys of such Guarantor then or thereafter maintained with or on behalf of any Secured Party. By acceptance of this Guarantee, the Administrative Agent agrees to notify such Guarantor after any such set-off and application made by the Administrative Agent on behalf of such Secured Party; provided that the failure to give such notice shall not affect the validity of such setoff and application. The rights of the Secured Parties under this Section 2.4 are in addition to other rights and remedies (including other rights of setoff under applicable Law or otherwise) which the Secured Parties may have.

 

SECTION 2.5. Waiver, Etc. To the extent permitted by applicable Law, each Guarantor waives promptness, diligence, notice of acceptance and any other notice with respect to any of the Guaranteed Obligations and this Guarantee and any requirement that the Secured Parties protect, secure, perfect or insure any Lien, or any property subject thereto, or exhaust any right or take any action against any Obligor or any other Person (including any Guarantor) or entity or any collateral securing the Guaranteed Obligations, as the case may be.

 

3 

 

 

SECTION 2.6. Postponement of Subrogation, Etc. Each Guarantor agrees that it will not exercise any rights which it may acquire by way of rights of subrogation under any Loan Document to which it is a party, nor shall such Guarantor seek or be entitled to seek any contribution or reimbursement from the Borrower or any other Obligor, in respect of any payment made under any Loan Document or otherwise, until following the payment in full in cash in immediately available funds of the Guaranteed Obligations. Any amount paid to such Guarantor on account of any such subrogation rights prior to the payment in full in cash in immediately available funds of the Guaranteed Obligations shall be held in trust for the benefit of the Secured Parties and shall immediately be paid and turned over to the Administrative Agent, for the benefit of itself and the other Secured Parties, in the exact form received by such Guarantor (duly endorsed in favor of the Administrative Agent, if required), to be credited and applied against the Guaranteed Obligations, whether matured or unmatured, in accordance with Section 2.7; provided that, if such Guarantor has made payment to the Administrative Agent of all or any part of the Guaranteed Obligations and the Guaranteed Obligations have been paid in full in cash in immediately available funds, then, at such Guarantor’s request, the Administrative Agent will, at the expense of such Guarantor, execute and deliver to such Guarantor appropriate documents (without recourse and without representation or warranty) necessary to evidence the transfer by subrogation to such Guarantor of an interest in the Guaranteed Obligations resulting from such payment. In furtherance of the foregoing, at all times prior to the payment in full in cash in immediately available funds of the Guaranteed Obligations, such Guarantor shall refrain from taking any action or commencing any proceeding against the Borrower or any other Obligor or Guarantor (or their successors or assigns, whether in connection with a bankruptcy proceeding or otherwise) to recover any amounts in respect of payments made under this Guarantee to the Administrative Agent.

 

SECTION 2.7. Payments; Application. Each Guarantor agrees that all obligations of such Guarantor hereunder shall be paid solely in U.S. Dollars to the Administrative Agent for the benefit of itself and the other Secured Parties in immediately available funds, without set-off, counterclaim or other defense and applied in accordance with the Credit Agreement, including Article III, Article IV and Article X thereof, free and clear of and without deduction for any Taxes unless required by applicable Law and subject to the obligation to pay additional amounts in accordance with Section 4.3 of the Credit Agreement, such Guarantor hereby agreeing to comply with and be bound by the provisions of the Credit Agreement, including Article III, Article IV and Article X thereof, in respect of all payments and application of such payments made by it hereunder and the provisions of which Articles and Sections are hereby incorporated into and made a part of this Guarantee by this reference as if set forth herein; provided that references to the “Borrower” in such Articles and Sections shall be deemed to be references to such Guarantor, and references to “this Agreement” in such Articles and Sections shall be deemed to be references to this Guarantee.

 

4 

 

 

ARTICLE III

REPRESENTATIONS AND WARRANTIES

 

In order to induce the Secured Parties to enter into the Credit Agreement and make the Loans thereunder, each Guarantor represents and warrants to the Administrative Agent, for the benefit of itself and the other Secured Parties, as set forth below.

 

SECTION 3.1. Credit Agreement Representations and Warranties. The representations and warranties contained in Article VI of the Credit Agreement, insofar as the representations and warranties contained therein are applicable to such Guarantor and its properties, are true and correct in all material respects, except for any representation and warranty that is qualified by materiality or reference to Material Adverse Effect, which such representation and warranty shall be true and correct in all respects (except in the case of any representation and warranty which expressly relates to a given date or period, which representation and warranty was true and correct in all material respects (and in all respects if qualified by materiality or reference to Material Adverse Effect)) as of the Closing Date, with each such representation and warranty set forth in Article VI of the Credit Agreement (insofar as applicable as aforesaid) and all other terms of the Credit Agreement to which reference is made therein, together with all related definitions and ancillary provisions, being hereby incorporated into this Guarantee by this reference as though specifically set forth in this Article III.

 

SECTION 3.2. Financial Condition, Etc. Each Guarantor has knowledge of the Borrower’s and each other Guarantor’s financial condition and affairs and has adequate means to obtain from each such Person on an ongoing basis information relating thereto and to each such Person’s ability to pay and perform the Guaranteed Obligations. Each Guarantor acknowledges and agrees that the Secured Parties shall have no obligation to investigate the financial condition or affairs of the Borrower or any other Guarantor for the benefit of such Guarantor nor to advise such Guarantor of any fact respecting, or any change in, the financial condition or affairs of each such Person that might become known to the Secured Parties at any time, whether or not the Secured Parties know or believe or have reason to know or believe that any such fact or change is unknown to such Guarantor, or might (or does) materially increase the risk of such Guarantor as guarantor, or might (or would) affect the willingness of such Guarantor to continue as a guarantor of the Guaranteed Obligations.

 

SECTION 3.3. Best Interests. It is in the best interests of each Guarantor to execute this Guarantee inasmuch as each Guarantor will, as a result of being an Affiliate of the Borrower, derive substantial direct and indirect benefits from the Loans made to the Borrower by the Lenders pursuant to the Credit Agreement, and each Guarantor agrees that the Lenders are relying on this representation in agreeing to make the Loans to the Borrower.

 

5 

 

 

ARTICLE IV

COVENANTS, ETC.

 

SECTION 4.1. Covenants. Each Guarantor covenants and agrees that, at all times prior to the earlier of (x) the release of such Guarantor in accordance with Section 5.14 hereof and (y) the payment in full in cash in immediately available funds of the Guaranteed Obligations, it will perform, comply with and be bound by all of the agreements, covenants and obligations contained in the Credit Agreement (including Articles VII and VIII of the Credit Agreement) which are applicable to such Guarantor or its properties, and each such agreement, covenant and obligation contained in the Credit Agreement and all other terms of the Credit Agreement to which reference is made in this Article IV, together with all related definitions and ancillary provisions, is hereby incorporated into this Guarantee by this reference as though specifically set forth in this Article IV.

 

SECTION 4.2. Contribution and Subrogation. Each Guarantor (a “Contributing Guarantor”) agrees (subject to the Section 4.3) that, in the event a payment shall be made by any other Guarantor hereunder in respect of any Guaranteed Obligation, or assets of any other Guarantor shall be sold pursuant to the Security Agreement or any other security document to satisfy any Guaranteed Obligation owed to any Secured Party, and such other Guarantor (the “Claiming Guarantor”) shall not have been fully indemnified by the Borrower, the Contributing Guarantor shall indemnify the Claiming Guarantor in an amount equal to (i) the amount of such payment or (ii) the greater of the book value or the fair market value of such assets, as the case may be, in each case multiplied by a fraction of which the numerator shall be the net worth of the Contributing Guarantor on the date hereof and the denominator shall be the aggregate net worth of all the Guarantors now or hereafter existing.

 

SECTION 4.3. Subordination. (a) Notwithstanding any provision of this Agreement to the contrary, all rights of the Guarantors under Sections 4.2 and all other rights of indemnity, contribution or subrogation under applicable law or otherwise shall be fully subordinated to the indefeasible payment in full in cash of the Guaranteed Obligations. No failure on the part of the Borrower or any Guarantor to make the payments required by Section 4.2 (or any other payments required under applicable law or otherwise) shall in any respect limit the obligations and liabilities of any Guarantor with respect to its obligations hereunder, and each Guarantor shall remain liable for the full amount of its obligations hereunder.

 

ARTICLE V

MISCELLANEOUS PROVISIONS

 

SECTION 5.1. Loan Document. This Guarantee is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Section 1.5 and Article X thereof.

 

SECTION 5.2. Binding on Successors, Transferees and Assigns; Assignment. This Guarantee shall (a) remain in full force and effect until the payment in full in cash in immediately available funds of the Guaranteed Obligations or, with respect to a Guarantor, the release of such Guarantor in accordance with Section 5.14 hereof, (b) be binding upon each Guarantor and its successors, transferees and assigns and (c) inure to the benefit of and be enforceable by the Secured Parties; provided that such Guarantor may not (unless otherwise permitted under the terms of the Credit Agreement) assign any of its obligations hereunder unless expressly permitted by the Credit Agreement or with such consents required by Section 10.1 of the Credit Agreement.

 

6 

 

 

SECTION 5.3. Amendments, Etc. No amendment to or waiver of any provision of this Guarantee, nor consent to any departure by any Guarantor from its obligations under this Guarantee, shall in any event be effective except in accordance with Section 10.1 of the Credit Agreement.

 

SECTION 5.4. Notices; Agency of Borrower for Guarantors. All notices and other communications provided for hereunder shall be given or made as set forth in Section 10.2 of the Credit Agreement.

 

SECTION 5.5. Additional Guarantors. Upon the execution and delivery by any other Person of a supplement in the form of Annex I hereto, such Person shall become a “Guarantor” hereunder as of the date of such supplement with the same force and effect as if it were originally a party to this Guarantee and named as a “Guarantor” hereunder. The execution and delivery of such supplement shall not require the consent of any other Guarantor hereunder, and the rights and obligations of each Guarantor hereunder shall remain in full force and effect notwithstanding the addition of any new Guarantor as a party to this Guarantee.

 

SECTION 5.6. No Waiver; Remedies. In addition to, and not in limitation of, Section 2.3 and Section 2.5, no failure on the part of any Secured Party to exercise, and no delay in exercising, any right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any right hereunder preclude any other or further exercise thereof or the exercise of any other right. The remedies herein provided are cumulative and not exclusive of any remedies provided by Law.

 

SECTION 5.7. [Reserved].

 

SECTION 5.8. Section Captions. Section captions used in this Guarantee are for convenience of reference only and shall not affect the construction of this Guarantee.

 

SECTION 5.9. Severability. Any provision of this Guarantee which is prohibited or unenforceable in any jurisdiction shall, as to such provision and such jurisdiction, be ineffective only to the extent of such prohibition or unenforceability without invalidating the remaining provisions of this Guarantee or affecting the validity or enforceability of such provision in any other jurisdiction.

 

SECTION 5.10. Governing Law, Entire Agreement, Etc. THIS GUARANTEE AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS GUARANTEE OR ANY OTHER LOAN DOCUMENT CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Guarantee, along with the other Loan Documents, constitutes the entire understanding among the parties hereto with respect to the subject matter hereof and supersedes any prior agreements, written or oral, with respect hereto.

 

7 

 

 

SECTION 5.11. Forum Selection and Consent to Jurisdiction. ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, THIS GUARANTEE, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF THE SECURED PARTIES OR ANY GUARANTOR IN CONNECTION HEREWITH SHALL BE BROUGHT AND MAINTAINED IN THE COURTS OF THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK IN THE STATE OF NEW YORK OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK; PROVIDED THAT ANY SUIT SEEKING ENFORCEMENT AGAINST ANY COLLATERAL OR OTHER PROPERTY MAY BE BROUGHT, AT THE ADMINISTRATIVE AGENT’S OR THE LENDERS’ OPTION, IN THE COURTS OF ANY JURISDICTION WHERE SUCH COLLATERAL OR OTHER PROPERTY MAY BE FOUND. THE SECURED PARTIES, BY ACCEPTANCE OF THIS GUARANTEE, AND EACH GUARANTOR IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS BY REGISTERED MAIL, POSTAGE PREPAID, OR BY PERSONAL SERVICE WITHIN OR WITHOUT THE STATE OF NEW YORK AT THE ADDRESS FOR NOTICES SPECIFIED IN SECTION 10.2 OF THE CREDIT AGREEMENT. THE SECURED PARTIES, BY ACCEPTANCE OF THIS GUARANTEE, AND EACH GUARANTOR HEREBY EXPRESSLY AND IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY OBJECTION WHICH IT MAY HAVE OR HEREAFTER MAY HAVE TO THE LAYING OF VENUE OF ANY SUCH LITIGATION BROUGHT IN ANY SUCH COURT REFERRED TO ABOVE AND ANY CLAIM THAT ANY SUCH LITIGATION HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. TO THE EXTENT THAT THE SECURED PARTIES, BY ACCEPTANCE OF THIS GUARANTEE, OR ANY GUARANTOR HAS OR HEREAFTER MAY ACQUIRE ANY IMMUNITY FROM JURISDICTION OF ANY COURT OR FROM ANY LEGAL PROCESS (WHETHER THROUGH SERVICE OR NOTICE, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID OF EXECUTION OR OTHERWISE) WITH RESPECT TO ITSELF OR ITS PROPERTY, THE SECURED PARTIES, BY ACCEPTANCE OF THIS GUARANTEE, AND SUCH GUARANTOR, EACH ON ITS OWN BEHALF, HEREBY IRREVOCABLY WAIVES TO THE FULLEST EXTENT PERMITTED BY LAW SUCH IMMUNITY IN RESPECT OF ITS OBLIGATIONS UNDER THIS GUARANTEE.

 

SECTION 5.12. Counterparts. This Guarantee may be executed by the parties hereto in several counterparts, each of which shall be an original and all of which shall constitute together but one and the same agreement. This Guarantee shall become effective when counterparts hereof executed on behalf of each Guarantor shall have been received by the Administrative Agent, on behalf of the Secured Parties. Delivery of an executed counterpart of a signature page to this Guarantee by email (e.g., “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Guarantee. The words “execution,” “signed,” “signature,” and words of like import this Guarantee or any amendment or other modification hereof (including waivers and consents) shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

 

8 

 

 

SECTION 5.13. Waiver of Jury Trial. THE ADMINISTRATIVE AGENT FOR THE BENEFIT OF ITSELF AND THE OTHER SECURED PARTIES, BY ACCEPTANCE OF THIS GUARANTEE, AND EACH GUARANTOR HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE TO THE FULLEST EXTENT PERMITTED BY LAW ANY RIGHTS THEY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH, THIS GUARANTEE, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN) OR ACTIONS OF ANY SECURED PARTY OR ANY GUARANTOR IN CONNECTION HEREWITH. EACH GUARANTOR ACKNOWLEDGES AND AGREES THAT IT HAS RECEIVED FULL AND SUFFICIENT CONSIDERATION FOR THIS PROVISION (AND EACH OTHER PROVISION OF EACH OTHER LOAN DOCUMENT TO WHICH IT IS A PARTY) AND THAT THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE SECURED PARTIES TO ENTER INTO THE LOAN DOCUMENTS.

 

SECTION 5.14. Termination; Release. This Guarantee shall terminate with respect to all Guaranteed Obligations upon the payment in full in cash in immediately available funds of all such Guaranteed Obligations. A Guarantor shall be automatically released from its obligations hereunder in accordance with Section 11.9(b) of the Credit Agreement. In connection with the termination or release, upon the reasonable request and at the sole expense of such Guarantor, the Administrative Agent shall execute and deliver, without any representations, warranties or recourse of any kind whatsoever, all agreements and instruments to evidence the termination or such release.

 

[Signature Page Follows]

 

9 

 

 

IN WITNESS WHEREOF, each Guarantor and Administrative Agent have caused this Guarantee to be duly executed and delivered by its Authorized Officer as of the date first above written.

 

  CARIS SCIENCE, INC.
  CARIS MPI, INC.
  CARIS PHARMATECH, INC.
  CARIS THERAPEUTICS, INC.
   
  By:  
    Name:
    Title:

 

[Signature Page to Guarantee]

 

 

 

 

 

WILMINGTON TRUST, NATIONAL

ASSOCIATION,

  as the Administrative Agent
   
  By:  
    Name:
    Title:

 

[Signature Page to Guarantee]

 

 

 

 

Schedule I

 

CARIS SCIENCE, INC.

CARIS MPI, INC.

CARIS PHARMATECH, INC.

CARIS THERAPEUTICS, INC.

 

[Schedule I to Guarantee]

 

 

 

ANNEX I
to Guarantee

 

SUPPLEMENT TO

GUARANTEE

 

This SUPPLEMENT, dated as of [__] (this “ Supplement”), is to the Guarantee, dated as of January 18, 2023 (as amended, supplemented or otherwise modified from time to time, the “Guarantee”), by the Guarantors (such term, and other terms used in this Supplement, to have the meanings set forth in Article I of the Guarantee, unless otherwise defined herein or if the context otherwise requires) from time to time party thereto, in favor of the Secured Parties (as defined in the Guarantee).

 

W I T N E S S E T H:

 

WHEREAS, pursuant to a Credit Agreement, dated as of January 18, 2023 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), by and among Caris Life Sciences, Inc., a Texas Corporation (the “Borrower”), the Lenders party thereto and WILMINGTON TRUST, NATIONAL ASSOCIATION, as administrative agent (together with its Affiliates, successors, transferees and assignees, the “Administrative Agent”), the Lenders have extended Commitments to make the Loans to the Borrower; and

 

WHEREAS, pursuant to the provisions of Section 5.5 of the Guarantee, each of the undersigned is becoming a Guarantor under the Guarantee; and

 

WHEREAS, each of the undersigned desires to become a “Guarantor” under the Guarantee in order to induce the Lenders to continue to extend the Loans under the Credit Agreement;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, each of the undersigned agrees, for the benefit of the Secured Parties, as follows.

 

SECTION 1. Party to Guarantee, Etc. In accordance with the terms of the Guarantee, by its signature below, each of the undersigned hereby irrevocably agrees to become a Guarantor under the Guarantee with the same force and effect as if it were an original signatory thereto and each of the undersigned hereby (a) agrees to be bound by and comply with all of the terms and provisions of the Guarantee applicable to it as a Guarantor and (b) represents and warrants that the representations and warranties made by it as a Guarantor thereunder are true and correct in all material respects, except for any representation and warranty that is qualified by materiality or reference to Material Adverse Effect, which such representation and warranty shall be true and correct in all respects (except in the case of any representation and warranty which expressly relates to a given date or period, which representation and warranty was true and correct in all material respects (and in all respects if qualified by materiality or reference to Material Adverse Effect) as of the respective date or for the respective period, as the case may be). In furtherance of the foregoing, each reference to a “Guarantor” and/or “Guarantors” in the Guarantee shall be deemed to include each of the undersigned.

 

[Annex I to Guarantee – Form of Supplement]

 

 

 

 

SECTION 2. Representations. Each of the undersigned Guarantors hereby represents and warrants that this Supplement has been duly authorized, executed and delivered by it and that this Supplement and the Guarantee constitute its legal, valid and binding obligation, enforceable against it in accordance with its terms (except, in any case, as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally and principles of equity).

 

SECTION 3. Full Force of Guarantee. Except as expressly supplemented hereby, the Guarantee shall remain in full force and effect in accordance with its terms.

 

SECTION 4. Severability. Wherever possible each provision of this Supplement shall be interpreted in such manner as to be effective and valid under applicable Law, but if any provision of this Supplement shall be prohibited by or invalid under such Law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Supplement or the Guarantee.

 

SECTION 5. Governing Law, Entire Agreement, Etc. THIS SUPPLEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS SUPPLEMENT OR ANY DOCUMENT CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Supplement, along with the other Loan Documents, constitutes the entire understanding among the parties hereto with respect to the subject matter thereof and supersedes any prior agreements, written or oral, with respect thereto.

 

SECTION 6. Effectiveness. This Supplement shall become effective when a counterpart hereof executed by each undersigned Guarantor shall have been received by the Administrative Agent, on behalf of the Secured Parties. Delivery of an executed counterpart of a signature page to this Supplement by email (e.g., “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Supplement. The words “execution,” “signed,” “signature,” and words of like import this Supplement or any amendment or other modification hereof (including waivers and consents) shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

 

[Signature Page Follows]

 

[Annex I to Guarantee – Form of Supplement]

 

2 

 

 

IN WITNESS WHEREOF, each of the parties hereto has caused this Supplement to be duly executed and delivered by its Authorized Officer as of the date first above written.

 

  [NAME OF ADDITIONAL GUARANTOR]
   
  By:  
    Name:
    Title:
   
  [NAME OF ADDITIONAL GUARANTOR]
   
  By:  
    Name:
    Title:

 

[Signature Page to Guarantee Supplement]

[Annex I to Guarantee – Form of Supplement]

 

 

 

 

EXHIBIT E

 

FORM OF PLEDGE AND SECURITY AGREEMENT

 

This PLEDGE AND SECURITY AGREEMENT, dated as of January 18, 2023 (as amended, restated, amended or restated, supplemented or otherwise modified from time to time, this “Security Agreement”), is made by CARIS LIFE SCIENCES, INC., a Texas corporation (the “Borrower”), and the other entities listed on Annex A hereto (together with the Borrower and any other entity that may become a party hereto as provided herein, each a “Grantor” and, collectively, the “Grantors”), in favor of WILMINGTON TRUST, NATIONAL ASSOCIATION, a national banking association organized and existing under the laws of the United States of America, as administrative agent (together with its successors, transferees and assignees, in such capacity, the “Administrative Agent”) for the Secured Parties (defined below).

 

W I T N E S S E T H :

 

WHEREAS, pursuant to the Credit Agreement, dated as of January 18, 2023 (as amended, restated, amended or restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), by and among the Borrower, the Lenders party thereto and the Administrative Agent, the Lenders have extended Commitments to make Loans to the Borrower from time to time;

 

WHEREAS, in order to induce the Lenders to make or continue to make, as the case may be, the Loans under the Credit Agreement, each Grantor is required to execute and deliver this Security Agreement; and

 

WHEREAS, it is required under the terms of the Credit Agreement that the Grantors shall have granted, pledged and assigned the security interests and undertaken the obligations contemplated by this Security Agreement.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor agrees, for the benefit of the Secured Parties, as follows:

 

ARTICLE I

DEFINITIONS

 

SECTION 1.1. Certain Terms. The following terms (whether or not underscored) when used in this Security Agreement, including its preamble and recitals, shall have the following meanings (such definitions to be equally applicable to the singular and plural forms thereof):

 

“Administrative Agent” is defined in the preamble.

 

“Borrower” is defined in the preamble.

 

“Collateral” is defined in Section 2.1.

 

“Collateral Accounts” is defined in Section 4.3(b).

 

 

 

 

“Control Agreement” means a “springing” control agreement, in form and substance reasonably satisfactory to the Administrative Agent and the Required Lenders, executed and delivered by a Loan Party, the Administrative Agent, and the applicable securities intermediary (with respect to a Securities Account) or bank (with respect to a Deposit Account), which provides for “control” (as defined in the UCC) by Administrative Agent with respect to the applicable account and certain Collateral related thereto.

 

“Copyright Collateral” means (a) all Copyrights owned by a Grantor, including the Copyright registrations and applications referred to in Schedule V, (b) the rights of a Grantor to sue for past, present and future infringements of any of the foregoing, all rights corresponding thereto, all extensions and renewals of any thereof, (c) all Proceeds of a Grantor of any of the foregoing, including royalties, income, payments, claims, damages and Proceeds of suit, and (d) all Copyright licenses to which a Grantor is a party.

 

“Credit Agreement” is defined in the first recital.

 

“Distributions” means all dividends paid on Capital Securities, liquidating dividends paid on Capital Securities, shares (or other designations) of Capital Securities resulting from (or in connection with the exercise of) stock splits, reclassifications, warrants, options, non-cash dividends, mergers, consolidations, and all other distributions (whether similar or dissimilar to the foregoing) on or with respect to any Capital Securities constituting Collateral.

 

“Excluded Assets” is defined in Section 2.1.

 

“Excluded Securities” means (a) Capital Securities in newly acquired or created non-wholly owned Subsidiaries or in newly acquired or created entities where a Grantor holds 50% or less of the outstanding Capital Securities of such entity, to the extent (i) a pledge of such Capital Securities is prohibited by the Organic Documents or agreements with the other equity holders of such entity in existence at the time of such acquisition (but not entered into in contemplation thereof), (ii) where, despite the commercially reasonable efforts of the Grantors to obtain a consent under such Organic Documents or agreements with other equity holders to permit the pledge of such Capital Securities to Administrative Agent, such consent cannot be obtained and (iii) such Capital Securities have not been pledged to any other Person and (b) Capital Securities in excess of 65% of the total combined voting power of all classes of Capital Securities of any first- tier Foreign Subsidiaries; provided that if any such Foreign Subsidiary shall become a Loan Party, the exclusion for Capital Securities of such Foreign Subsidiary in this clause (b) shall not apply.

 

“Financing Statements” is defined in Section 3.7(b).

 

“General Intangibles” means all “general intangibles” and all “payment intangibles”, each as defined in the UCC and shall include all interest rate or currency protection or hedging arrangements, all tax refunds, all licenses, permits, concessions and authorizations and all Intellectual Property Collateral (in each case, regardless of whether characterized as general intangibles under the UCC).

 

“Grantor” and “Grantors” are defined in the preamble.

 

2

 

 

“Intellectual Property Collateral” means, collectively, the Copyright Collateral, the Patent Collateral, the Trademark Collateral and the Trade Secrets Collateral.

 

“Intercompany Note” means any promissory note evidencing loans made by any Grantor to any other Grantor or Subsidiary of a Grantor, as the case may be.

 

“Investment Property” means, collectively, (a) all “investment property” as such term is defined in Section 9-102(a)(49) of the UCC and (b) whether or not constituting “investment property” as so defined, all Pledged Notes.

 

“Margin Stock” means “margin stock” as such term is defined in Regulation T, U or X of the Board of Governors of the Federal Reserve System.

 

“Patent Collateral” means:

 

(a)            all of the Patents throughout the world owned by a Grantor, including each issued Patent and Patent application referred to in Schedule III;

 

(b)            all Proceeds of the foregoing (including royalties income, payments, claims, damages and Proceeds of infringement suits) and the right to sue third parties for past, present or future infringements of any Patent or Patent application and for breach or enforcement of any Patent license; and

 

(c)            all Patent licenses providing any Grantor with the right to use any items of the type referred to in clause (a) above.

 

“Permitted Liens” means all Liens permitted by Section 8.3 of the Credit Agreement.

 

“Pledged Notes” means all promissory notes listed on Item J of Schedule II (as such schedule may be amended or supplemented from time to time), all Intercompany Notes at any time issued to any Grantor and all other promissory notes issued to or held by any Grantor.

 

“Secured Parties” means, collectively, the Administrative Agent and the Lenders and “Secured Party” means any one of them.

 

“Securities Act” is defined in Section 6.2(a).

 

“Security Agreement” is defined in the preamble.

 

“Specified Notes” means, collectively, (i) each of the five (5) Full Recourse Promissory Note, dated as of September 30, 2022, by and between each maker thereof and the Borrower, in connection with each Nonqualified Stock Option Exercise Agreement, dated as of September 30, 2022, by and between such maker and the Borrower, and (ii) any promissory note evidencing Investments permitted under Section 8.5(w) of the Credit Agreement, in each case of the foregoing clauses (i) and (ii), as amended, restated, amended and restated, supplemented, replaced, refinanced or otherwise modified from time to time.

 

3

 

 

“Trade Secrets” of a Person means all of such Person’s common law and statutory trade secrets.

 

“Trade Secrets Collateral” means all of the Trade Secrets owned by the Grantors, whether or not such Trade Secret has been reduced to a writing or other tangible form and including the right to sue for and to enjoin and to collect damages for the actual or threatened misappropriation of any Trade Secret and for the breach or enforcement of any such Trade Secret license and all Trade Secret licenses to which a Grantor is a party.

 

“Trademark Collateral” means:

 

(a)            (i) all of the Trademarks owned by the Grantors and all goodwill of the business associated therewith, now existing or hereafter adopted or acquired including those Trademark registrations and applications referred to in Schedule IV, whether currently in use or not, including registrations, recordings and applications in the United States Patent and Trademark Office or in any office or agency of the United States of America, or any state thereof or any other country or political subdivision thereof or otherwise, and all common-law rights relating to the foregoing, and (ii) the right to obtain all reissues, extensions or renewals of the foregoing;

 

(b)            the right to sue third parties for past, present and future infringements of any Trademark Collateral described in clause (a);

 

(c)            all Proceeds of the foregoing, including any claim by any Grantor against third parties for past, present or future infringement or dilution of any Trademark, or for any injury to the goodwill associated with the use of any such Trademark; and

 

(d)            all Trademark licenses for the grant by or to any Grantors of any right to use any Trademark.

 

SECTION 1.2. Credit Agreement Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Security Agreement, including its preamble and recitals, have the meanings provided in the Credit Agreement.

 

SECTION 1.3. UCC Definitions. When used herein the terms “Account”, “Certificated Securities”, “Chattel Paper”, “Commercial Tort Claim”, “Commodity Account”, “Commodity Contract”, “Deposit Account”, “Document”, “Electronic Chattel Paper”, “Equipment”, “Goods”, “Instrument”, “Inventory”, “Letter-of-Credit Rights”, “Payment Intangibles”, “Proceeds”, “Promissory Notes”, “Securities Account”, “Security Entitlement”, “Supporting Obligations” and “Uncertificated Securities” have the meaning provided in Article 8 or Article 9, as applicable, of the UCC. “Letters of Credit” has the meaning provided in Section 5-102 of the UCC.

 

4

 

 

ARTICLE II

SECURITY INTEREST

 

SECTION 2.1. Grant of Security Interest. Each Grantor hereby grants to the Administrative Agent, for the benefit of the Secured Parties, a continuing security interest in all of such Grantor’s right, title and interest in and to the following property, whether now or hereafter existing, owned or acquired by such Grantor, and wherever located (collectively, the “Collateral”):

 

(a)Accounts;

 

(b)Chattel Paper;

 

(c)Commercial Tort Claims, including those listed on Item I of Schedule II (as such schedule may be amended or supplemented from time to time);

 

(d)Deposit Accounts;

 

(e)Documents;

 

(f)General Intangibles;

 

(g)Goods (including Goods held on consignment with third parties);

 

(h)Instruments;

 

(i)Investment Property;

 

(j)Letter-of-Credit Rights and Letters of Credit;

 

(k)Supporting Obligations;

 

(l)all books, records, writings, databases, information and other personal property relating to, used or useful in connection with, evidencing, embodying, incorporating or referring to, any of the foregoing in this Section 2.1;

 

(m)all Proceeds of any of the foregoing and, to the extent not otherwise included, all payments under insurance (whether or not the Administrative Agent is the loss payee thereof) in respect of Collateral; and

 

(n)all other property and rights of every kind and description and interests therein.

 

Notwithstanding anything to the contrary contained herein or in any other Loan Document, the term “Collateral” shall not include:

 

(i)any General Intangibles or other rights or interests, in each case arising under any contracts, instruments, leases, licenses, permits, letters of credit, purchase money arrangements, instruments or other documents as to which the grant of a security interest would (A) constitute or result in the unenforceability of any of the foregoing documents, (B) give any other party to such contract, instrument, lease, license, permit, letter of credit, purchase money arrangement, instrument or other document the right to terminate its obligations thereunder or (C) otherwise require consent thereunder (other than from any Grantor);

 

5

 

 

(ii)           Trademark applications filed in the United States Patent and Trademark Office on the basis of such Grantor’s “intent to use” such trademark, unless and until acceptable evidence of use of the Trademark has been filed with the United States Patent and Trademark Office pursuant to Section 1(c) or Section 1(d) of the Lanham Act (15 U.S.C. 1051, et seq.), to the extent that granting a Lien in such Trademark application prior to such filing would adversely affect the enforceability or validity of such Trademark application;

 

(iii)          any asset or portion of any asset, the granting of a security interest in which (A) would be void or illegal under any applicable Law, (B) would cause the destruction, invalidation or abandonment of such asset or portion of asset under applicable Law, (C) would require any governmental or third party consent, approval, license or authorization (unless such consent, approval license or authorization has been obtained), or (D) pursuant thereto would result in, or permit the termination of, such asset or portion of asset;

 

(iv)         acquired property (including property acquired through acquisition or merger of another entity) if at the time of such acquisition the granting of a security interest therein or the pledge thereof is prohibited by any contract or other agreement (in each case, not created in contemplation thereof) to the extent and for so long as such contract or other agreement prohibits such security interest or pledge;

 

(v)           any asset subject to a Permitted Lien (other than Liens in favor of the Secured Parties) securing obligations permitted under the Credit Agreement to the extent that the grant of other Liens on such asset (A) would result in a breach, violation or invalidation of, or constitute a default under, the agreement or instrument governing such Permitted Lien, (B) would result in the loss of use of such asset or (C) would require the consent of the holder of such Permitted Lien or permit the holder of such Permitted Lien to terminate the Grantor’s use of such asset;

 

(vi)the Excluded Accounts;

 

(vii)         any particular asset where the Borrower in good faith after consulting with its tax or other relevant advisors and subject to the Required Lenders’ consent (not to be unreasonably withheld, conditioned or delayed) that the burden or cost (including any adverse tax consequences to the Borrower or any of its Subsidiaries, which are not de minimis) of providing a pledge thereof or a security interest therein will outweigh the benefits to be obtained by the Lenders therefrom, including by taking into account the overall collateral package and the amount of the Loans;

 

(viii)Margin Stock;

 

(ix)[reserved];

 

(x)[reserved];

 

(xi)          any governmental licenses or state or local franchises, charters and authorizations, to the extent a security interest in any such license, franchise, charter or authorization is prohibited or restricted thereby;

 

6

 

 

(xii)any Excluded Securities;

 

(xiii)any Specified Notes;

 

(xiv)Leasehold interests in real property;

 

(xv)any fee-owned real property other than Material Real Property;

 

(xvi)[reserved]; and

 

(xvii)       motor vehicles and other assets subject to certificates of title (other than aircraft), except to the extent a security interest therein can be perfected by the filing of a UCC financing statement;

 

provided that the property described in each of clauses (i), (iii), (iv), (v) and (xi) above shall only be excluded from the term “Collateral” to the extent the conditions stated in such clauses are not rendered ineffective pursuant to Sections 9-406, 9-407, 9-408 or 9-409 of the UCC or any other applicable Law; provided further that the property described in each of clauses (i) through (xvii) above shall not include any Proceeds, products, substitutions or replacements thereof (unless such Proceeds, products, substitutions or replacements would otherwise constitute property described in any of clauses (i) through (xvii) above) (all such assets excluded from “Collateral” pursuant to the foregoing clauses (i) through (xvii) above and the provisos contained in this paragraph, the “Excluded Assets”).

 

SECTION 2.2. Security for Obligations. This Security Agreement and the Collateral in which the Administrative Agent, for the benefit of the Secured Parties, is granted a security interest hereunder by the Grantors secure the payment and performance of all of the Obligations.

 

SECTION 2.3. Grantors Remain Liable. Anything herein to the contrary notwithstanding:

 

(a)           the Grantors will remain liable under the contracts and agreements included in the Collateral to the extent set forth therein;

 

(b)           the exercise by any Secured Party of any of its rights hereunder will not release any Grantor from any of its duties or obligations under any such contracts or agreements included in the Collateral; and

 

(c)           the Secured Parties will not have any obligation or liability under any contracts or agreements included in the Collateral by reason of this Security Agreement, nor will the Secured Parties be obligated to perform any of the obligations or duties of any Grantor thereunder or to take any action to collect or enforce any claim for payment assigned hereunder.

 

SECTION 2.4. Distributions on Capital Securities; Payments on Pledged Notes. In the event that any (a) Distribution with respect to any Capital Securities or (b) payment with respect to any Pledged Notes, in each case pledged hereunder, is not prohibited under Section 8.6 of the Credit Agreement, such Distribution or payment may be paid directly to the applicable Grantor. If any Distribution or payment is made in contravention of Sections 8.5 or 8.6 of the Credit Agreement, such Grantor shall hold the same segregated and in trust for the Administrative Agent, for the benefit of the Secured Parties, until paid to the Administrative Agent in accordance with Section 4.1.5.

 

7

 

 

SECTION 2.5. Security Interest Absolute, Etc. Subject to Section 7.5 hereof and to the other limitations expressly set forth herein and in the other Loan Documents, this Security Agreement shall in all respects be a continuing, absolute, unconditional and irrevocable grant of security interest, and shall remain in full force and effect until the Termination Date. Subject to the limitations expressly set forth herein and in the other Loan Documents, all rights of the Secured Parties and the security interests granted to the Administrative Agent, for the benefit of the Secured Parties, hereunder, and all obligations of the Grantors hereunder, shall, to the fullest extent permitted by applicable Law, in each case, be absolute, unconditional and irrevocable irrespective of:

 

(a)           any lack of validity, legality or enforceability of any Loan Document (other than this Security Agreement);

 

(b)           the failure of any Secured Party (i) to assert any claim or demand or to enforce any right or remedy against the Borrower or any of the Subsidiaries or any other Person (including any other Grantor) under the provisions of any Loan Document or otherwise, or (ii) to exercise any right or remedy against any other guarantor (including any other Grantor) of, or Collateral securing, any Obligations;

 

(c)           any change in the time, manner or place of payment of, or in any other term of, all or any part of the Obligations, or any other extension, compromise or renewal of any Obligations;

 

(d)           any reduction, limitation, impairment or termination of any Obligations for any reason, including any claim of waiver, release, surrender, alteration or compromise and shall not be subject to (and each Grantor hereby waives, until payment of all Obligations, any right to or claim of) any defense or setoff, counterclaim, recoupment or termination whatsoever by reason of the invalidity, illegality, nongenuineness, irregularity, compromise, unenforceability of, or any other event or occurrence affecting, any Obligations or otherwise;

 

(e)           any amendment to, rescission, waiver, or other modification of, or any consent to or departure from, any of the terms of any Loan Document;

 

(f)            any addition, exchange or release of any Collateral or of any Person that is (or will become) a Grantor (including the Grantors hereunder), or any surrender or non-perfection of any Collateral, or any amendment to or waiver or release or addition to, or consent to or departure from, any other guaranty held by the Administrative Agent, for the benefit of the Secured Parties, securing any of the Obligations; or

 

(g)           other than payment in full of the Obligations, any other circumstance which might otherwise constitute a defense available to, or a legal or equitable discharge of the Borrower or any of the Subsidiaries, any surety or any guarantor.

 

8

 

 

SECTION 2.6. Postponement of Subrogation. Each Grantor agrees that it will not exercise any rights against another Grantor which it may acquire by way of rights of subrogation under any Loan Document to which it is a party until following the Termination Date. No Grantor shall seek or be entitled to seek any contribution or reimbursement from the Borrower or any other Grantor, in respect of any payment made by such Grantor under any Loan Document or otherwise, until following the Termination Date. Any amount paid to any Grantor on account of any such subrogation rights prior to the Termination Date shall be held in trust for the benefit of the Secured Parties and shall immediately be paid and turned over to the Administrative Agent, for the benefit of the Secured Parties, in the exact form received by such Grantor (duly endorsed in favor of the Administrative Agent, if required), to be credited and applied against the Obligations then due and payable in accordance with Section 6.1(b); provided that, if such Grantor has made payment to the Administrative Agent of all or any part of the Obligations and the Termination Date has occurred, then at such Grantor’s written request, the Administrative Agent will, at the expense of such Grantor, execute and deliver to such Grantor appropriate documents (without recourse and without representation or warranty) necessary to evidence the transfer by subrogation to such Grantor of an interest in the Obligations resulting from such payment. In furtherance of the foregoing, at all times prior to the Termination Date, such Grantor shall refrain from taking any action or commencing any proceeding against the Borrower or any other Grantor (or their successors or assigns, whether in connection with a bankruptcy proceeding or otherwise) to recover any amounts in respect of payments made under this Security Agreement to the Administrative Agent or any other Secured Party.

 

ARTICLE III

REPRESENTATIONS AND WARRANTIES

 

In order to induce the Secured Parties to enter into the Credit Agreement and make the Loans thereunder, each Grantor represents and warrants to the Administrative Agent, for the benefit of the Secured Parties, as set forth below.

 

SECTION 3.1. As to Capital Securities of the Subsidiaries, Investment Property.

 

(a)           With respect to any Subsidiary organized in the United States of such Grantor that is:

 

(i)            a corporation, business trust, joint stock company or similar Person, all Capital Securities issued by such Subsidiary, to the extent constituting Collateral, are duly authorized and validly issued, fully paid and non-assessable, and represented by a certificate or certificates; and

 

(ii)            a partnership or limited liability company, no Capital Securities issued by such Subsidiary, to the extent constituting Collateral, (A) is dealt in or traded on securities exchanges or in securities markets, (B) if constituting Uncertificated Securities, expressly provides that such Capital Securities is a security governed by Article 8 of the UCC or (C) is held in a Securities Account. Each Grantor party hereto that is an issuer of any Uncertificated Securities constituting Collateral agrees that, at any time after the occurrence and during the continuation of an Event of Default, it will comply with the instructions with respect to such Uncertificated Securities originated by Administrative Agent without the consent of any other Grantor

 

9

 

 

(b)           Each Grantor has delivered to the Administrative Agent all Certificated Securities constituting Collateral held by such Grantor in a Subsidiary on or substantially concurrent with the Closing Date (or such later date as may be applicable pursuant to the Credit Agreement), or, solely with respect to a Grantor that becomes a party to this Security Agreement after the Closing Date, the date such Grantor becomes a party to this Security Agreement or such other date agreed to by the Required Lenders) to the Administrative Agent, together with duly executed undated blank stock powers, or other equivalent instruments of transfer acceptable to the Administrative Agent.

 

(c)           With respect to Uncertificated Securities constituting Collateral owned by any Grantor in a Subsidiary that is not a Grantor party hereunder on the Closing Date (or, solely with respect to a Grantor that becomes a party to this Security Agreement after the Closing Date, the date such Grantor becomes a party to this Security Agreement or such other date agreed to by the Required Lenders), such Grantor has caused the issuer thereof to agree in an authenticated record with such Grantor and the Administrative Agent that such issuer will comply with instructions with respect to such security originated by the Administrative Agent given in accordance with this Security Agreement at any time after the occurrence and during the continuation of an Event of Default without further consent of such Grantor.

 

(d)           The percentage of the issued and outstanding Capital Securities of each Subsidiary of a Grantor pledged on the Closing Date (or, solely with respect to a Grantor that becomes a party to this Security Agreement after the Closing Date, the date such Grantor becomes a party to this Security Agreement) by each Grantor hereunder is as set forth on Schedule I. All shares of such Capital Securities have been duly and validly issued and are fully paid and nonassessable.

 

(e)           Each of the Intercompany Notes, to the extent constituting Collateral, constitutes the legal, valid and binding obligation of the obligor with respect thereto, enforceable in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar Laws relating to or affecting creditors’ rights generally, general equitable principles (whether considered in a proceeding in equity or at Law) and an implied covenant of good faith and fair dealing.

 

SECTION 3.2. Grantor Name, Location, Etc. In each case as of the Closing Date (or, solely with respect to a Grantor that becomes a party to this Security Agreement after the Closing Date, on the date such Grantor becomes a party to this Security Agreement):

 

(a)           (i) The jurisdiction in which each Grantor is located for purposes of Sections 9-301 and 9-307 of the UCC and (ii) the address of each Grantor’s executive office and principal place of business is set forth in Item A of Schedule II.

 

(b)           The Grantors do not have any trade names other than those set forth in Item C of Schedule II.

 

(c)           During the 12 months preceding the date hereof (or, solely with respect to a Grantor that becomes a party to this Security Agreement after the Closing Date, preceding the date such Grantor becomes a party to this Security Agreement), no Grantor has been known by any legal name different from the one set forth on the signature page hereto, nor has such Grantor been the subject of any merger or other corporate reorganization, except as set forth in Item D of Schedule II.

 

10

 

 

(d)           Each Grantor’s federal taxpayer identification number (or foreign equivalent) is set forth in Item E of Schedule II hereto.

 

(e)Reserved.

 

(f)            No Grantor maintains any Deposit Accounts, Securities Accounts or Commodity Accounts with any Person, in each case, other than any Excluded Account and except as set forth on Item G of Schedule II.

 

(g)           No Grantor is the beneficiary of any Letters of Credit with a face amount exceeding $5,000,000 individually, except as set forth on Item H of Schedule II.

 

(h)           No Grantor has Commercial Tort Claims in favor of such Grantor in excess of $5,000,000, except as set forth on Item I of Schedule II.

 

(i)            The name set forth on the signature page attached hereto (or the signature page of the supplement hereto by which such Grantor has become a party to this Security Agreement, as applicable) is the true and correct legal name (as defined in the UCC) of each Grantor (but without giving effect to capitalization).

 

SECTION 3.3. No Liens, Etc. No effective UCC financing statement or other filing similar in effect covering all or any part of the Collateral is on file in any recording office, except those filed in favor of the Administrative Agent relating to this Security Agreement, Permitted Liens or as to which a duly authorized termination statement relating to such UCC financing statement or other instrument has been delivered to the Administrative Agent on the Closing Date.

 

SECTION 3.4. Possession of Inventory, Control, Etc.

 

(a)           Each Grantor has, and agrees that it will maintain, exclusive possession of its Documents, Instruments, Promissory Notes, Goods, Equipment and Inventory, in each case to the extent constituting Collateral, other than (i) Equipment, Goods or Inventory that is in transit in the ordinary course of business, (ii) Equipment, Goods or Inventory that in the ordinary course of business is in the possession or control of a warehouseman, bailee agent, employee, contractor or other Person, (iii) Inventory that is in the possession of a consignee in the ordinary course of business and (iv) Instruments or Promissory Notes that have been delivered to the Administrative Agent pursuant to Section 3.5. With respect to any locations where Collateral in excess of $10,000,000 is located, each Grantor shall use commercially reasonable efforts (in consultation with the Significant Lenders and giving consideration to the interests of the Lenders) to furnish to the Administrative Agent landlord access agreements, bailee waivers or similar agreements, in form and substance satisfactory to the Administrative Agent and the Required Lenders, from each landlord, lessor or warehouseman to such Grantor after the date hereof, in each case subject to Section 7.15 of the Credit Agreement.

 

11

 

 

(b)           Each Grantor is the sole entitlement holder of each of its Deposit Accounts to the extent constituting Collateral, and no other Person (other than the Administrative Agent pursuant to this Security Agreement, the applicable depositary institution or any other Person with respect to Permitted Liens) has control or possession of, or any other interest in, any of its Deposit Accounts or any other securities or property credited thereto, in each case, except as otherwise expressly permitted under the Credit Agreement.

 

SECTION 3.5. Negotiable Documents, Instruments and Chattel Paper. Each Grantor has delivered to the Administrative Agent possession of all originals of all Documents, Instruments, Promissory Notes and tangible Chattel Paper (other than any Document, Instrument, Promissory Note or tangible Chattel Paper (x) not constituting Collateral or (y) not exceeding $1,500,000 in principal amount individually or $5,000,000 in principal amount in the aggregate) owned or held by such Grantor on the Closing Date (or, solely with respect to a Grantor that becomes a party to this Security Agreement after the Closing Date, the date such Grantor becomes a party to this Security Agreement).

 

SECTION 3.6. Intellectual Property Collateral. With respect to any Intellectual Property Collateral:

 

(a)           no settlement or consents, covenants not to sue, nonassertion assurances, or releases have been entered into by any Grantor or to which such Grantor is bound that adversely affects its rights to own or use any Intellectual Property to the extent that it would materially prevent such Grantor from carrying out its business operations as currently conducted;

 

(b)           such Grantor has not granted a security interest or pledged as collateral any of its Intellectual Property that has not been terminated or released except as permitted under the Credit Agreement;

 

(c)           such Grantor has executed and delivered to the Administrative Agent Intellectual Property Collateral security agreements accordance with Section 4.5 for all registrations and applications of Copyrights, Patents and Trademarks owned by such Grantor, including all registrations and applications of Copyrights, Patents and Trademarks on Schedules III through VI (as such schedules may be amended or supplemented from time to time by notice by such Grantor to the Administrative Agent); and

 

(d)           such Grantor uses commercially reasonable efforts designed to ensure the reasonable quality of the manufacture, distribution and sale of all products sold by such Grantor and in the provision of all services rendered by such Grantor, in each case, under or in connection with all Trademarks owned by such Grantor.

 

SECTION 3.7. Validity, Etc.

 

(a)           This Security Agreement creates a valid security interest in the Collateral securing the payment of the Obligations to the extent such security interest may be created pursuant to Article 9 of the UCC.

 

(b)           As of the Closing Date (or the date such Grantor becomes a party to this Security Agreement, as applicable), each Grantor has filed or caused to be filed all UCC-1 financing statements in the filing office for each Grantor’s jurisdiction of organization listed in Item A of Schedule II (collectively, the “Financing Statements”) (or has delivered to the Administrative Agent (or its designee) the Financing Statements suitable for timely and proper filing in such offices) and has taken all other actions necessary for the Administrative Agent to obtain control of the Collateral as provided in Sections 9-104, 9-105, 9-106 and 9-107 of the UCC to the extent required by the Loan Documents.

 

12

 

 

(c)           Upon the filing of the Financing Statements with the appropriate agencies therefor, the security interests created under this Security Agreement shall constitute a perfected security interest in the Collateral described on such Financing Statements in favor of the Administrative Agent to the extent that a security interest therein may be perfected by filing a financing statement pursuant to the relevant UCC, prior to all other Liens, except for Permitted Liens.

 

SECTION 3.8. Authorization, Approval, Etc. Except as have been obtained or made and are in full force and effect, no authorization, approval or other action by, and no notice to or filing with, any Governmental Authority or any other third party is required either:

 

(a)           for the perfection or maintenance of the security interests hereunder, including the first priority nature (subject to Permitted Liens) of such security interest to the extent required hereunder or under any other Loan Document (to the extent same can be achieved by the filing of Financing Statements or, with respect to Intellectual Property Collateral, the recordation of any agreements with the United States Patent and Trademark Office or the United States Copyright Office or, with respect to foreign Intellectual Property Collateral of a Grantor to the extent (i) such foreign Intellectual Property Collateral is registered in a foreign Law jurisdiction in which any Grantor has entered into a security agreement or such other agreements governed by such foreign Law to create and perfect the security interests granted by such Loan Party (any such jurisdiction, a “Foreign Grantor Jurisdiction”) and (ii) the Administrative Agent (at the direction of the Required Lenders) has requested that the applicable Grantor take such action, the taking of appropriate action under such Foreign Grantor Jurisdictions, and, with respect to after-acquired Intellectual Property Collateral, any subsequent filings in such applicable intellectual property offices); provided, that the Grantors shall not have any obligation to perfect any security interest or lien in any Intellectual Property Collateral in any jurisdiction other than the United States of America, and will not be required hereunder to make any filings in any intellectual property offices or registrars other than the United States Patent and Trademark Office or the United States Copyright Office, if such Grantor determines in good faith and subject to the Required Lenders’ consent (not to be unreasonably withheld, conditioned or delayed) that the burden or cost of taking such action will outweigh the benefits to be obtained by the Lenders therefrom, including by taking into account the overall collateral package and the amount of the Loans.

 

(b)           for the exercise by the Administrative Agent of the voting or other rights and remedies provided for in this Security Agreement, except (i) with respect to any securities issued by a Subsidiary of the Grantors, as may be required in connection with a disposition of such securities by Laws affecting the offering and sale of securities generally, the remedies in respect of the Collateral pursuant to this Security Agreement and (ii) any “change of control” or similar filings required by state licensing agencies.

 

13

 

 

SECTION 3.9. Best Interests. It is in the best interests of each Grantor (other than the Borrower) to execute this Security Agreement inasmuch as such Grantor will, as a result of being an Affiliate of the Borrower, derive substantial direct and indirect benefits from the Loans made to the Borrower by the Lenders pursuant to the Credit Agreement, and each Grantor agrees that the Lenders are relying on this representation in agreeing to make such Loans pursuant to the Credit Agreement to the Borrower.

 

ARTICLE IV

COVENANTS

 

Each Grantor covenants and agrees that, until the Termination Date, such Grantor will perform, comply with and be bound by the obligations set forth below.

 

SECTION 4.1. As to Investment Property, Etc.

 

SECTION 4.1.1. Capital Securities of Subsidiaries. No Grantor will allow any of its Subsidiaries that is organized in the United States, in each case (to the extent applicable) solely with respect to the Collateral:

 

(a)            that is a corporation, business trust, joint stock company or similar Person, to issue Uncertificated Securities;

 

(b)            that is a partnership or limited liability company, to (i) issue Capital Securities that are to be dealt in or traded on securities exchanges or in securities markets, (ii) expressly provide in its Organic Documents that its Capital Securities are securities governed by Article 8 of the UCC (unless its Capital Securities are Certificated Securities and the Grantors have complied with Section 4.1.3 to the extent applicable) and except to the extent any Subsidiary acquired after the date hereof has provided for such in its Organic Documents (and such election to do so was not implemented in contemplation of such acquisition, in which event the applicable Grantor will notify the Administrative Agent in writing thereof and such Grantor shall comply with all perfection steps required hereunder with respect to such Capital Securities), or (iii) place such Subsidiary’s Capital Securities in a Securities Account; or

 

(c)           to issue Capital Securities in addition to or in substitution for the Capital Securities pledged hereunder, except to such Grantor (so long as such Capital Securities are promptly pledged and delivered to the Administrative Agent pursuant to the terms of this Security Agreement).

 

SECTION 4.1.2. Investment Property (other than Certificated Securities).

 

(a)           With respect to any Deposit Accounts, Securities Accounts, Commodity Accounts, Commodity Contracts or Security Entitlements constituting Investment Property owned or held by any Grantor, such Grantor will cause (except for Excluded Accounts) the intermediary maintaining such Investment Property or other assets to execute a Control Agreement relating to such Investment Property or other assets in compliance with Section 7.13 and Section 7.15 of the Credit Agreement.

 

14

 

 

(b)           With respect to any Uncertificated Securities (other than Uncertificated Securities credited to a Securities Account) constituting Collateral owned or held by any Grantor, such Grantor will cause the issuer of such securities that is not a party hereto to either (i) to agree in an authenticated record with such Grantor and the Administrative Agent that such issuer will comply with instructions with respect to such security originated by the Administrative Agent given in accordance with this Security Agreement at any time after the occurrence and during the continuation of an Event of Default without further consent of such Grantor or (ii) execute a Control Agreement relating to such Investment Property in compliance with Section 7.13 and Section 7.15 of the Credit Agreement.

 

(c)           Except as otherwise permitted under the Credit Agreement, no Grantor shall cause or permit any Person other than the Administrative Agent or the Secured Parties or the financial institution maintaining such Investment Property to have “control” (as defined in Section 9-104, 9-105, 9-106 and 9-107 of the UCC) any Investment Property constituting part of the Collateral.

 

SECTION 4.1.3. Certificated Securities (Stock Powers). Each Grantor agrees that all Certificated Securities constituting Collateral, including the Capital Securities delivered by such Grantor pursuant to this Security Agreement, will be accompanied by duly executed undated blank stock powers, or other equivalent instruments of transfer reasonably acceptable to the Administrative Agent.

 

SECTION 4.1.4. Continuous Pledge. Each Grantor will (subject to the terms hereof and the terms of the Credit Agreement): (a) deliver to the Administrative Agent all Investment Property and all Payment Intangibles, in each case constituting Collateral to the extent that such Investment Property or Payment Intangibles are evidenced by a Document, Instrument, Promissory Note or Chattel Paper (other than any Document, Instrument, Promissory Note or Chattel Paper not exceeding $1,500,000 in principal amount individually or $5,000,000 in principal amount in the aggregate), and (b) to the extent constituting Collateral, at all times keep pledged to the Administrative Agent pursuant hereto, on a perfected basis, a security interest therein and in all interest and principal with respect to such Payment Intangibles, and all Proceeds and rights from time to time received by or distributable to such Grantor in respect of any of the foregoing Collateral. Each Grantor agrees that it will, promptly following receipt thereof, deliver to the Administrative Agent possession of all originals of negotiable Documents, Instruments, Promissory Notes and Chattel Paper constituting Collateral that it acquires following the Closing Date (other than any Document, Instrument, Promissory Note or Chattel Paper not exceeding $1,500,000 in principal amount individually or $5,000,000 in principal amount in the aggregate).

 

SECTION 4.1.5. Voting Rights, Dividends, Etc. Each Grantor agrees:

 

(a)           upon receipt of notice of the occurrence and continuance of an Event of Default from the Administrative Agent and without any request therefor by the Administrative Agent, so long as such Event of Default shall continue, to deliver (properly endorsed where required hereby or requested by the Administrative Agent) to the Administrative Agent all dividends and Distributions with respect to Investment Property constituting Collateral; all interest, principal, other cash payments on Payment Intangibles constituting Collateral; and all Proceeds of the Collateral, in each case thereafter received by such Grantor, all of which shall be held by the Administrative Agent as additional Collateral, except for payments made in accordance with Section 8.6 of the Credit Agreement; and

 

15

 

 

(b)           immediately upon the occurrence and during the continuance of an Event of Default and so long as the Administrative Agent has notified such Grantor in writing of the Administrative Agent’s intention to exercise its voting power under this clause (b),

 

(i)            the Administrative Agent may exercise (to the exclusion of such Grantor) the voting power and all other incidental rights of ownership with respect to any Investment Property constituting Collateral, and such Grantor hereby grants the Administrative Agent an irrevocable proxy, exercisable solely upon the occurrence and during the continuation of an Event of Default, to vote such Investment Property; and

 

(ii)            upon the request by the Administrative Agent, such Grantor shall promptly deliver to the Administrative Agent such additional proxies and other documents as may be necessary to allow the Administrative Agent to exercise such voting power.

 

All dividends, Distributions, interest, principal, cash payments, Payment Intangibles and Proceeds constituting Collateral and that may at any time and from time to time be held by such Grantor, but which such Grantor is then obligated to deliver to the Administrative Agent pursuant to the terms hereof, shall, until delivery to the Administrative Agent, be held by such Grantor separate and apart from its other property in trust for the Administrative Agent. The Administrative Agent agrees that unless an Event of Default shall have occurred and be continuing and the Administrative Agent shall have given the notice referred to in clause (b) above, such Grantor will have the exclusive voting power with respect to any Investment Property and the Administrative Agent will, upon the written request of such Grantor, promptly deliver such proxies and other documents, if any, as shall be reasonably requested by such Grantor which are necessary to allow such Grantor to exercise that voting power; provided that no vote shall be cast, or consent, waiver or ratification given, or action taken by such Grantor that would impair in any material respect any such Collateral or violate any provision of any Loan Document.

 

SECTION 4.1.6. Margin Stock. If at any time the Investment Property of a Grantor or any part thereof consists of Margin Stock, such Grantor shall promptly so notify the Administrative Agent and deliver to the Administrative Agent a duly executed and completed Form U-1 and such other instruments and documents reasonably requested by the Administrative Agent that are necessary to demonstrate conformity therewith in form and substance satisfactory to the Administrative Agent.

 

SECTION 4.2. Change of Name, Etc. No Grantor will change its name or place of incorporation or organization or federal taxpayer identification number except as otherwise permitted by the Credit Agreement.

 

16

 

 

 

 

SECTION 4.3. As to Accounts.

 

(a)        Each Grantor shall have the right to collect all Accounts so long as no Event of Default shall have occurred and be continuing.

 

(b)        Upon (i) the occurrence and continuance of an Event of Default and (ii) the delivery of notice by the Administrative Agent to each Grantor, all Proceeds of Collateral received by such Grantor shall be delivered in kind to the Administrative Agent for deposit in a Deposit Account of such Grantor maintained with the Administrative Agent or that otherwise is a Controlled Account (together with any other Deposit Accounts or Controlled Accounts pursuant to which any portion of the Collateral is deposited with the Administrative Agent after the occurrence and during the continuation of an Event of Default, the “Collateral Accounts”), and such Grantor shall not commingle any such Proceeds, and shall hold separate and apart from all other property, all such Proceeds in express trust for the benefit of the Administrative Agent until delivery thereof is made to the Administrative Agent.

 

(c)        Following the delivery of notice pursuant to clause (b)(ii) above and for so long as an Event of Default is continuing, the Administrative Agent shall have the right to apply any amount in any Collateral Account to the payment of any Obligations which are then due and payable in accordance with Section 4.4(b) of the Credit Agreement.

 

(d)        With respect to each of the Collateral Accounts, it is hereby confirmed and agreed that (i) deposits in such Collateral Account are subject to a security interest as contemplated hereby, (ii) such Collateral Account shall be under the control of the Administrative Agent and (iii) following the delivery of notice pursuant to clause (b)(ii) above and for so long as an Event of Default is continuing, the Administrative Agent shall have the sole right of withdrawal over such Collateral Account.

 

SECTION 4.4.    As to Grantors’ Use of Collateral.

 

(a)        Subject to clause (b) below, each Grantor: (i) will, at its own expense, endeavor to collect in the ordinary course consistent with its past practice all amounts due with respect to any of the Collateral, including the taking of such action with respect to such collection as the Administrative Agent may reasonably request following the occurrence and during the continuance of an Event of Default or, in the absence of such request, as such Grantor may deem advisable, (ii) may grant, in the ordinary course of business, to any party obligated on any of the Collateral, any rebate, refund or allowance to which such party may be lawfully entitled, and may accept, in connection therewith, the return of Goods, the sale or lease of which shall have given rise to such Collateral, and (iii) may make Dispositions and take such other actions permitted under the Credit Agreement.

 

(b)        At any time following the occurrence and solely during the continuance of an Event of Default, whether before or after the maturity of any of the Obligations, the Administrative Agent may (i) revoke any or all of the rights of each Grantor set forth in clause (a) above, (ii) notify any parties obligated on any of the Collateral to make payment to the Administrative Agent of any amounts due or to become due thereunder and (iii) enforce collection of any of the Collateral by suit or otherwise and surrender, release or exchange all or any part thereof, or compromise or extend or renew for any period (whether or not longer than the original period) any indebtedness thereunder or evidenced thereby.

 

17

 

 

(c)        Upon the request of the Administrative Agent following the occurrence and solely during the continuance of an Event of Default, each Grantor will, at its own expense, notify any parties obligated on any of the Collateral to make payment to the Administrative Agent of any amounts due or to become due thereunder.

 

(d)        At any time following the occurrence and solely during the continuance of an Event of Default, the Administrative Agent may endorse, in the name of such Grantor, any item, howsoever received by the Administrative Agent, representing any payment on or other Proceeds of any of the Collateral.

 

SECTION 4.5.   As to Intellectual Property Collateral. Without prejudice to the Credit Agreement, each Grantor covenants and agrees to comply with the following provisions as such provisions relate to any Intellectual Property constituting Collateral that is material to the operations or business of such Grantor:

 

(a)        such Grantor will deliver, concurrently with the delivery of any Compliance Certificate in accordance with Section 7.1(d) of the Credit Agreement, a report listing all published applications for the registration of any Intellectual Property with the United States Patent and Trademark Office filed during such quarter and, upon the request of the Administrative Agent (subject to the terms of the Credit Agreement and this Security Agreement), such Grantor shall execute and deliver a customary Intellectual Property security agreement as the Administrative Agent may reasonably request to evidence the Administrative Agent’s security interest in such Intellectual Property; and

 

(b)        such Grantor will execute and deliver to the Administrative Agent, upon the Administrative Agent’s written request, a Patent Security Agreement, Trademark Security Agreement and/or Copyright Security Agreement, as the case may be, in the forms of Exhibit A, Exhibit B and Exhibit C hereto, respectively, following its obtaining an ownership interest in any such Patent, Trademark or Copyright that is issued, registered, or applied for with the U.S. Patent and Trademark Office or the U.S. Copyright Office, and shall execute and deliver to the Administrative Agent any other document reasonably requested by the Administrative Agent, in writing, to evidence the Administrative Agent’s interest in any part of such item of Intellectual Property that is Collateral unless such Grantor determines, in each case, in good faith (with the consent of the Required Lenders) that any such Intellectual Property is either (i) of negligible economic value to such Grantor or (ii) not material to such Grantor’s business.

 

SECTION 4.6. As to Letter-of-Credit Rights.

 

(a)        Each Grantor, by granting a security interest in its Letter of Credit Rights to the Administrative Agent, intends to (and hereby does) collaterally assign to the Administrative Agent its rights (including its contingent rights thereunder) to the Proceeds of all Letter-of-Credit Rights of which it is or hereafter becomes a beneficiary or assignee.

 

(b)        Upon the occurrence and solely during the continuation of an Event of Default, such Grantor will, promptly upon request by the Administrative Agent, (i) notify (and such Grantor hereby authorizes the Administrative Agent to notify) the issuer and each nominated Person with respect to each of the Letters of Credit of such Grantor with value in excess of $5,000,000 that the Proceeds thereof have been assigned to the Administrative Agent hereunder and any payments due or to become due in respect thereof are to be made directly to the Administrative Agent and (ii) arrange for the Administrative Agent to become the transferee beneficiary of each such Letter of Credit.

 

18

 

 

SECTION 4.7. As to Commercial Tort Claims. Each Grantor covenants and agrees that, until the Termination Date, with respect to any Commercial Tort Claim with value in excess of $5,000,000 hereafter arising, it shall reasonably promptly deliver to the Administrative Agent a supplement in form and substance reasonably satisfactory to the Administrative Agent and the Required Lenders, together with all supplements to schedules thereto, identifying such new Commercial Tort Claim.

 

SECTION 4.8. Electronic Chattel Paper and Transferable Records. If any Grantor at any time holds or acquires an interest in any Electronic Chattel Paper or any “transferable record,” as that term is defined in Section 201 of the U.S. Federal Electronic Signatures in Global and National Commerce Act or in Section 16 of the U.S. Uniform Electronic Transactions Act, as in effect in any relevant jurisdiction, constituting Collateral and with a value in excess of $1,500,000 in principal amount individually or $5,000,000 in principal amount in the aggregate, such Grantor shall promptly notify the Administrative Agent thereof and, at the request of the Administrative Agent, shall take such action as the Administrative Agent may reasonably request to vest in the Administrative Agent control under Section 9-105 of the UCC of such Electronic Chattel Paper or control under Section 201 of the Federal Electronic Signatures in Global and National Commerce Act or, as the case may be, Section 16 of the Uniform Electronic Transactions Act, as so in effect in such jurisdiction, of such transferable record. The Administrative Agent agrees with such Grantor that the Administrative Agent will arrange, pursuant to procedures reasonably satisfactory to the Administrative Agent and so long as such procedures will not result in the Administrative Agent’s loss of control, for the Grantor to make alterations to the Electronic Chattel Paper or transferable record permitted under Section 9-105 of the UCC or, as the case may be, Section 201 of the U.S. Federal Electronic Signatures in Global and National Commerce Act or Section 16 of the U.S. Uniform Electronic Transactions Act for a party in control to allow without loss of control, unless an Event of Default has occurred and is continuing or would occur after taking into account any action by such Grantor with respect to such Electronic Chattel Paper or transferable record.

 

SECTION 4.9. Certain Limitations. Notwithstanding anything to the contrary set forth herein or in any other Loan Document:

 

(a)        the Grantors shall not be required to provide any notice or obtain the consent of any governmental authorities under the Federal Assignment of Claims Act (or any state equivalent thereof);

 

(b)        other than with respect to any fixture affixed to any real property located at any Fixture Location, the Grantors shall not be required to file any fixture filing or take any action other than the filing of a UCC financing statement with respect to any security interest in Fixtures affixed to or attached to any other real property;

 

19

 

 

(c)        other than actions to be taken by the Grantors at the request of the Administrative Agent (at the direction of the Required Lenders) pursuant to Section 3.8(a), the Grantors that are not Foreign Subsidiaries shall not be required to take any action (other than filings pursuant to the UCC in the office of the secretary of state (or similar central filing office) of the relevant state(s)) (A) with respect to any assets located outside of the United States, (B) in any non-U.S. jurisdiction, or (C) required by the laws of any non-U.S. jurisdiction to create, perfect or maintain any security interest or otherwise (it being understood that there shall be no security agreements or pledge agreements governed by the laws of any non-U.S. jurisdiction), in each case of the foregoing clauses (A) through (C), other than the delivery of any pledged Capital Securities of a Foreign Subsidiary of any Grantor and subject to the Required Lenders’ consent (not to be unreasonably withheld, conditioned or delayed) that the burden or cost of taking such action will outweigh the benefits to be obtained by the Lenders therefrom, including by taking into account the overall collateral package and the amount of the Loans; provided, that no Grantor shall be required to take any action for the perfection or maintenance of any security interest hereunder with respect to Intellectual Property Collateral in any non-U.S. jurisdiction other than pursuant to Section 3.8(a);

 

(d)        to send notices to account debtors or other contractual third parties other than during the occurrence of an Event of Default; or

 

(e)        to take any action with respect to a security interest in Letter-of-Credit Rights except the filing of a UCC financing statement and such actions set forth in Section 4.6.

 

SECTION 4.10. Further Assurances, Etc. Each Grantor agrees that, from time to time at its own expense, it will, subject to the terms of this Security Agreement and the other Loan Documents, promptly execute and deliver all further instruments and documents, and take all further action, that may be necessary or that the Administrative Agent may reasonably request, in order to perfect, preserve and protect any security interest granted or purported to be granted hereby or to enable the Administrative Agent to exercise and enforce its rights and remedies hereunder with respect to any Collateral. Without limiting the generality of the foregoing, such Grantor will:

 

(a)        from time to time upon the request of the Administrative Agent, promptly deliver to the Administrative Agent such stock powers, instruments and similar documents, reasonably satisfactory in form and substance to the Administrative Agent, with respect to such Collateral as the Administrative Agent may request and will, from time to time upon the request of the Administrative Agent, after the occurrence and solely during the continuance of any Event of Default, promptly transfer any securities constituting Collateral into the name of any nominee designated by the Administrative Agent; if any Collateral shall be evidenced by an Instrument, negotiable Document, Promissory Note or tangible Chattel Paper, deliver and pledge to the Administrative Agent hereunder such Instrument, negotiable Document, Promissory Note or tangible Chattel Paper (other than Instruments, negotiable Documents, Promissory Notes or tangible Chattel Papers in principal amount less than $1,500,000 individually or $ 5,000,000 in the aggregate) duly endorsed and accompanied by duly executed instruments of transfer or assignment, all in form and substance reasonably satisfactory to the Administrative Agent;

 

20

 

 

(b)        file (and such Grantor hereby authorizes the Administrative Agent to file) such Financing Statements or continuation statements, or amendments thereto, and such other instruments or notices, as may be necessary and that the Administrative Agent may reasonably request in order to perfect and preserve the security interests and other rights granted or purported to be granted to the Administrative Agent, for the benefit of the Secured Parties, hereby;

 

(c)        at all times keep pledged to the Administrative Agent, for the benefit of the Secured Parties, pursuant hereto, on a first-priority (except for Permitted Liens), perfected basis, all Investment Property constituting Collateral, all dividends and Distributions with respect thereto, and all interest and principal with respect to Promissory Notes constituting Collateral, and all Proceeds and rights from time to time received by or distributable to such Grantor in respect of any of the foregoing Collateral, in each case, to the extent required hereunder or under any other Loan Document;

 

(d)        not take or omit to take any action the taking or the omission of which would result in the impairment or alteration of the obligations owing under any Payment Intangible or other Instrument constituting Collateral in any material respect, except as provided in Section 4.4;

 

(e)       not create any tangible Chattel Paper, with a value in excess of $1,500,000 individually or $5,000,000 in the aggregate, without, at the request of the Administrative Agent, placing a legend on such tangible Chattel Paper reasonably acceptable to the Administrative Agent indicating that the Administrative Agent has a security interest in such Chattel Paper;

 

(f)        furnish to the Administrative Agent, from time to time at the Administrative Agent’s reasonable request, statements and schedules further identifying and describing the Collateral and such other reports in connection with the Collateral, all in reasonable detail; and

 

(g)        do all things reasonably requested by the Administrative Agent in accordance with and subject to the terms and conditions of this Security Agreement and the other Loan Documents in order to enable the Administrative Agent to have and maintain control over the Collateral consisting of Investment Property, Deposit Accounts (other than Excluded Accounts), Letter-of-Credit Rights and Electronic Chattel Paper.

 

With respect to the foregoing and the grant of the security interest hereunder, each Grantor hereby authorizes the Administrative Agent to file one or more financing or continuation statements, and amendments thereto, relative to all or any part of the Collateral. Each Grantor agrees that a carbon, photographic or other reproduction of this Security Agreement or any UCC financing statement covering the Collateral or any part thereof shall be sufficient as a UCC financing statement where permitted by Law. Each Grantor hereby authorizes the Administrative Agent to file financing statements describing as the collateral covered thereby “all of the debtor’s personal property or assets” or words to that effect, notwithstanding that such wording may be broader in scope than the Collateral described in this Security Agreement.

 

Notwithstanding anything else herein, the Administrative Agent shall not be liable for the preparation, filing or maintenance of any UCC or other applicable financing statements or instruments.

 

21

 

 

ARTICLE V

THE ADMINISTRATIVE AGENT

 

SECTION 5.1. Agent Appointed Attorney-in-Fact. Each Grantor hereby irrevocably designates and appoints the Administrative Agent, on behalf of the Secured Parties, as its attorney-in-fact, with full authority in the place and stead of such Grantor and in the name of such Grantor or otherwise, from time to time in the Administrative Agent’s discretion, solely following the occurrence and during the continuance of an Event of Default, to take any action and to execute any instrument in accordance with applicable Law which the Administrative Agent may deem reasonably necessary or advisable to accomplish the purposes of this Security Agreement, and, subject to and in furtherance of the foregoing,:

 

(a)         to demand, collect, settle, compromise and adjust, and give discharges and releases concerning the Collateral, all as the Administrative Agent may deem reasonably appropriate;

 

(b)         to commence and prosecute any actions at any court for the purposes of collecting any of the Collateral and enforcing any other right in respect thereof;

 

(c)         to defend, settle or compromise any action brought in respect of the Collateral and, in connection therewith, give such discharge or release as the Administrative Agent may deem reasonably appropriate;

 

(d)        to pay or discharge taxes, liens, security interests or other encumbrances levied or placed on or threatened against the Collateral;

 

(e)         to direct any parties liable for any payment in connection with any of the Collateral to make payment of any and all monies due and to become due thereunder directly to the Administrative Agent or as the Administrative Agent shall direct;

 

(f)         to receive payment of and receipt for any and all monies, claims, and other amounts due and to become due at any time in respect of or arising out of any Collateral;

 

(g)         to sign and endorse any drafts, assignments, proxies, stock powers, verifications, notices and other documents relating to the Collateral;

 

(h)        to execute and deliver all assignments, conveyances, statements, financing statements, renewal financing statements, security and pledge agreements, affidavits, notices and other agreements, instruments and documents that the Administrative Agent may deem reasonably appropriate in order to perfect and maintain the security interests and liens granted in this Security Agreement and in order to fully consummate all of the transactions contemplated herein;

 

(i)         to exchange any of the Collateral or other property upon any merger, consolidation, reorganization, recapitalization or other readjustment of the issuer thereof and, in connection therewith, deposit any of the Collateral with any committee, depository, transfer agent, registrar or other designated agency upon such terms as the Administrative Agent may deem reasonably appropriate;

 

22

 

 

(j)         upon delivery of notice in accordance with Section 4.1.5(b), to vote for a shareholder or member resolution, or to sign an instrument in writing, sanctioning the transfer of any or all of the Collateral into the name of the Administrative Agent (or its designee) or one or more of the Secured Parties or into the name of any transferee to whom the Collateral or any part thereof may be sold pursuant to Article VI hereof; and

 

(k)        to perform the affirmative obligations of such Grantor hereunder.

 

Each Grantor hereby acknowledges, consents and agrees that the power of attorney granted pursuant to this Section 5.1 is irrevocable until the Termination Date and coupled with an interest.

 

SECTION 5.2. Assignment by the Administrative Agent. The Administrative Agent may from time to time assign its security interest in the Collateral and any portion thereof to a successor agent in accordance with the Credit Agreement, and the assignee shall be entitled to all of the rights and remedies of the Administrative Agent under this Security Agreement in relation thereto.

 

SECTION 5.3. Administrative Agent May Perform. Upon the occurrence and solely during the continuation of any Event of Default, if any Grantor fails to perform any agreement contained herein, the Administrative Agent, on behalf of the Secured Parties, may (but shall not be obligated to), with written notice to such Grantor (which notice may be delivered to such Grantor after the Administrative Agent has taken such actions as described in this Section 5.3), itself perform, or cause performance of, such agreement, that the Administrative Agent deems necessary for the maintenance, preservation or protection of any of the Collateral or of its security interest therein to the extent provided for herein, and the expenses of the Administrative Agent incurred in connection therewith shall be payable by such Grantor pursuant to Sections 10.3 and 10.4 of the Credit Agreement.

 

SECTION 5.4. Administrative Agent Has No Duty. The powers conferred on the Administrative Agent hereunder are solely to protect its interest in the Collateral and shall not impose any duty on it to exercise any such powers. Except for reasonable care of any Collateral in its possession and the accounting for moneys actually received by it hereunder, the Administrative Agent shall have no duty as to any Collateral or responsibility for:

 

(a)            ascertaining or taking action with respect to calls, conversions, exchanges, maturities, tenders or other matters relative to any Investment Property, whether or not the Administrative Agent has or is deemed to have knowledge of such matters, or

 

(b)            taking any necessary steps to preserve rights against prior parties or any other rights pertaining to any Collateral.

 

The provisions of Article XI of the Credit Agreement, including the rights, privileges, protections, benefits, indemnities and immunities of the Administrative Agent are incorporated herein, mutatis mutandis, as if a part hereof, and shall also apply to the Administrative Agent acting under or in connection with this Security Agreement.

 

SECTION 5.5. Reasonable Care. The Administrative Agent is required to exercise reasonable care in the custody and preservation of any of the Collateral in its possession; provided that the Administrative Agent shall be deemed to have exercised reasonable care in the custody and preservation of any of the Collateral, if such Collateral is accorded treatment substantially equal to that which the Administrative Agent accords its own property.

 

23

 

 

SECTION 5.6. Release of Collateral. Without limiting the effects of Section 7.5, the Administrative Agent, upon the direction of the Required Lenders or otherwise in accordance with the Credit Agreement, may release any of the Collateral from this Security Agreement or may substitute any of the Collateral for other Collateral without altering, varying or diminishing in any way the force, effect, Lien, pledge or security interest of this Security Agreement as to any Collateral not expressly released or substituted, and this Security Agreement shall continue as a first priority Lien (subject to Permitted Liens) on all Collateral not expressly released or substituted.

 

ARTICLE VI

REMEDIES

 

SECTION 6.1. Certain Remedies.

 

(a)        Upon the occurrence and solely during the continuation of any Event of Default, the Administrative Agent may exercise in respect of the Collateral, in addition to other rights and remedies provided for herein or otherwise available to it, all the rights and remedies of the Administrative Agent on default under the UCC and, subject to and in furtherance of the foregoing, in accordance with applicable Law the Administrative Agent also may:

 

(i)        take possession of any Collateral not already in its possession without demand and without legal process;

 

(ii)      require each Grantor to, and each Grantor hereby agrees that it will, at its expense and upon request of the Administrative Agent forthwith, assemble all or part of the Collateral as directed by the Administrative Agent and make it available to the Administrative Agent at a place to be designated by the Administrative Agent that is reasonably convenient to both the Administrative Agent and such Grantor;

 

(iii)     enter onto the property where any Collateral is located and take possession thereof without demand and without legal process; and

 

(iv)      without notice except as specified below, lease, license, sell or otherwise dispose of the Collateral or any part thereof in one or more parcels at any public or private sale, at any of the Administrative Agent’s offices or elsewhere, for cash, on credit or for future delivery, and upon such other terms as the Administrative Agent may deem commercially reasonable. Each Grantor agrees that, to the extent notice of sale shall be required by Law, at least 10 days’ prior notice to such Grantor of the time and place of any public sale or the time after which any private sale is to be made shall constitute reasonable notification. The Administrative Agent shall not be obligated to make any sale of Collateral regardless of notice of sale having been given. The Administrative Agent may adjourn any public or private sale from time to time by announcement at the time and place fixed therefor, and such sale may, without further notice, be made at the time and place to which it was so adjourned.

 

24

 

 

(b)        Upon the occurrence and solely during the continuation of any Event of Default, all cash Proceeds received by the Administrative Agent in respect of any sale of, collection from, or other realization upon, all or any part of the Collateral shall be applied by the Administrative Agent against all or any part of the Obligations as set forth in Section 4.4(b) of the Credit Agreement.

 

(c)        Upon the occurrence and solely during the continuation of any Event of Default, the Administrative Agent may:

 

(i)        transfer all or any part of the Collateral into the name of the Administrative Agent or its nominee, with or without disclosing that such Collateral is subject to the Lien hereunder;

 

(ii)       notify the parties obligated on any of the Collateral to make payment to the Administrative Agent of any amount due or to become due thereunder;

 

(iii)      withdraw, or cause or direct the withdrawal, of all funds with respect to any Collateral Account;

 

(iv)     enforce collection of any of the Collateral by suit or otherwise, and surrender, release or exchange all or any part thereof, or compromise or extend or renew for any period (whether or not longer than the original period) any obligations of any nature of any party with respect thereto;

 

(v)      endorse any checks, drafts, or other writings in any Grantor’s name to allow collection of the Collateral;

 

(vi)     take control of any Proceeds of the Collateral; and

 

(vii)    execute (in the name, place and stead of any Grantor) endorsements, assignments, stock powers and other instruments of conveyance or transfer with respect to all or any of the Collateral.

 

SECTION 6.2. [Reserved].

 

SECTION 6.3. Compliance with Restrictions. Each Grantor agrees that in any sale of any of the Collateral whenever an Event of Default shall have occurred and be continuing, the Administrative Agent is hereby authorized to comply with any limitation or restriction in connection with such sale as it may be advised by counsel is necessary in order to avoid any violation of applicable Law (including compliance with such procedures as may restrict the number of prospective bidders and purchasers, require that such prospective bidders and purchasers have certain qualifications, and restrict such prospective bidders and purchasers to Persons who will represent and agree that they are purchasing for their own account for investment and not with a view to the distribution or resale of such Collateral), or in order to obtain any required approval of the sale or of the purchaser by any Governmental Authority or official, and such Grantor further agrees that such compliance shall not result in such sale being considered or deemed not to have been made in a commercially reasonable manner, nor shall the Administrative Agent be liable nor accountable to such Grantor for any discount allowed by the reason of the fact that such Collateral is sold in compliance with any such limitation or restriction.

 

25

 

 

ARTICLE VII

MISCELLANEOUS PROVISIONS

 

SECTION 7.1. Loan Document. This Security Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Section 1.5 and Article X thereof.

 

SECTION 7.2. Binding on Successors, Transferees and Assigns; Assignment. This Security Agreement shall remain in full force and effect until the Termination Date has occurred, shall be binding upon the Grantors and their successors, permitted transferees and permitted assigns and shall inure to the benefit of and be enforceable by the Administrative Agent and the Secured Parties; provided that no Grantor may assign or transfer any of its rights or obligations hereunder without the prior consent of the Required Lenders.

 

SECTION 7.3. Amendments, Etc. No amendment or modification to or waiver of any provision of this Security Agreement, nor consent to any departure by any Grantor from its obligations under this Security Agreement, shall in any event be effective unless the same shall be in writing and signed by the Administrative Agent and the Grantors and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.

 

SECTION 7.4. Notices. All notices and other communications provided for hereunder shall be delivered or made as provided in Section 10.2 of the Credit Agreement.

 

SECTION 7.5. Release of Liens.

 

(a)            This Security Agreement and all security interests granted hereunder shall terminate with respect to all Obligations upon the Termination Date.

 

(b)            The security interest granted hereunder in any Collateral shall be released in accordance with Section 11.9(a) of the Credit Agreement.

 

(c)            Any Grantor (other than the Borrower) shall be released from its obligations hereunder and the security interest granted hereunder in the Collateral of such Grantor shall be released in accordance with Section 11.9(b) of the Credit Agreement.

 

Upon the occurrence of the Termination Date or any event specified in subclauses (i), (ii) and (iii) of Section 11.9(a) of the Credit Agreement, the security interest granted herein with respect to each applicable Grantor or any applicable property shall be deemed to be automatically released and such property shall automatically revert to the applicable Grantor with no further action on the part of any Person. In connection with any termination or release pursuant to paragraph (a), (b) or (c) of this Section 7.5, the Administrative Agent shall, at the Grantors’ sole expense, deliver to the Grantors, without any representations, warranties or recourse of any kind whatsoever, all such Collateral held by the Administrative Agent hereunder, and execute and deliver to, and authorize the filing by, the Grantors such documents as the Grantors shall reasonably request to evidence such termination or release.

 

26

 

 

SECTION 7.6. Additional Grantors. Upon the execution and delivery by any other Person of a supplement in the form of Annex I hereto, such Person shall become a “Grantor” hereunder with the same force and effect as if it were originally a party to this Security Agreement and named as a “Grantor” hereunder. The execution and delivery of such supplement shall not require the consent of any other Grantor hereunder, and the rights and obligations of each Grantor hereunder shall remain in full force and effect notwithstanding the addition of any new Grantor as a party to this Security Agreement. Any schedules delivered by any additional Grantor pursuant to such supplement shall supplement the relevant schedules to this Security Agreement.

 

SECTION 7.7. No Waiver; Remedies. In addition to, and not in limitation of Section 2.5, no failure on the part of the Administrative Agent to exercise, and no delay in exercising, any right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any right hereunder preclude any other or further exercise thereof or the exercise of any other right. The remedies herein provided are cumulative and not exclusive of any remedies provided by Law.

 

SECTION 7.8. Severability. Any provision of this Security Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such provision and such jurisdiction, be ineffective only to the extent of such prohibition or unenforceability without invalidating the remaining provisions of this Security Agreement or affecting the validity or enforceability of such provision in any other jurisdiction.

 

SECTION 7.9. Governing Law, Entire Agreement, Etc. THIS SECURITY AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS SECURITY AGREEMENT OR ANY DOCUMENT CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Security Agreement, along with the other Loan Documents, constitutes the entire understanding among the parties hereto with respect to the subject matter thereof and supersedes any prior agreements, written or oral, with respect thereto.

 

SECTION 7.10. Counterparts. This Security Agreement may be executed by the parties hereto in several counterparts, each of which shall be an original and all of which shall constitute together but one and the same agreement. This Security Agreement shall become effective when counterparts hereof executed on behalf of all of the signatories hereto, shall have been received by the Administrative Agent. The words “execute,” “execution,” “signed,” “signature” and words of like import in this Agreement or in any amendment or other modification hereof (including waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Administrative Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

 

27

 

 

SECTION 7.11. Rights of Required Lenders. If the Administrative Agent has a right to take or omit to take any action hereunder, it shall exercise such right if so instructed by the Required Lenders. With respect to any discretion, consent, approval or similar such action to be made, taken, omitted to be taken or determined by the Administrative Agent under this Agreement (each, an “Agent Determination”), such Agent Determination shall be made by the Administrative Agent at the direction of the Required Lenders. If the Administrative Agent has resigned and no successor agent has been appointed pursuant to Section 10.10 of the Credit Agreement, all rights of the Administrative Agent hereunder may be exercised by the Required Lenders (acting jointly and not severally).

 

[Signature Page Follows]

 

28

 

 

IN WITNESS WHEREOF, each of the parties hereto has caused this Security Agreement to be duly executed and delivered by its Authorized Officer as of the date first above written.

 

  CARIS LIFE SCIENCES, INC.
CARIS SCIENCE, INC. CARIS MPI, INC.
  CARIS PHARMATECH, INC.
CARIS THERAPEUTICS, INC.
each, as a Grantor
   
  By:  
    Name:
    Title:

 

[Signature Page to Security Agreement]

 

 

 

 

  WILMINGTN TRUST, NATIONAL ASSOCIATION
  as the Administrative Agent
   
  By:  
    Name:
    Title:

 

[Signature Page to Security Agreement]

 

 

 

 

ANNEX A

 

CARIS SCIENCE, INC., a Texas corporation

CARIS MPI, INC., a Texas corporation

CARIS PHARMATECH, INC., a Texas corporation

CARIS THERAPEUTICS, INC., a Texas corporation

 

[Annex A to Security Agreement]

 

 

 

 

SCHEDULE I

to Security Agreement

 

[Schedules to Security Agreement]

32

 

 

SCHEDULE II

to Security Agreement

 

[Schedules to Security Agreement]

33

 

 

SCHEDULE III

to Security Agreement

 

[Schedules to Security Agreement]

34

 

 

SCHEDULE IV

to Security Agreement

 

[Schedules to Security Agreement]

35

 

 

EXHIBIT A

TO SECURITY AGREEMENT

 

PATENT SECURITY AGREEMENT

 

This PATENT SECURITY AGREEMENT, dated as of ________ __, 20__ (this “Agreement”), is made by [NAME OF GRANTOR], a ________ _______ (the “Grantor”), in favor of WILMINGTON TRUST, NATIONAL ASSOCIATION, a national banking association organized and existing under the laws of the United States of America (together with its Affiliates, successors, transferees and assignees, the “Administrative Agent”), as Administrative Agent for the Secured Parties.

 

W I T N E S S E T H :

 

WHEREAS, pursuant to the Credit Agreement, dated as of January 18, 2023 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), by and among Caris Life Sciences, Inc., a Texas corporation (the “Borrower”), the Lenders (as defined therein) and the Administrative Agent, the Lenders have extended Commitments to make Loans to the Borrower;

 

WHEREAS, in connection with the Credit Agreement, the Grantor and its Affiliates have executed and delivered a Pledge and Security Agreement in favor of the Administrative Agent, for the benefit of the Secured Parties, dated as of January 18, 2023 (as amended, supplemented or otherwise modified from time to time, the “Security Agreement”);

 

WHEREAS, pursuant to the Credit Agreement and pursuant to clause (b) of Section 4.5 of the Security Agreement, the Grantor is required to execute and deliver this Security Agreement and to grant to the Administrative Agent, for the benefit of the Secured Parties, a continuing security interest in all of the Patent Collateral (as defined below) to secure all of the Obligations; and

 

WHEREAS, the Grantor has duly authorized the execution, delivery and performance of this Security Agreement;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees, for the benefit of the Secured Parties, as follows:

 

SECTION 1. Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Security Agreement, including its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement.

 

SECTION 2. Grant of Security Interest. The Grantor hereby grants to the Administrative Agent, for the benefit of the Secured Parties, a continuing security interest in all of the Grantor’s right, title and interest in and to each issued Patent and Patent application referred to in Schedule I attached hereto (the “Patent Collateral”).

 

 

 

 

SECTION 3. Security Agreement. This Agreement has been executed and delivered by the Grantor for the purpose of registering the security interest of the Administrative Agent in the Patent Collateral with the United States Patent and Trademark Office. The security interest granted hereby has been granted in furtherance of, and not in limitation of, the security interest granted to the Administrative Agent for the benefit of the Secured Parties under the Security Agreement. The Security Agreement (and all rights and remedies of the Secured Parties thereunder) shall remain in full force and effect in accordance with its terms.

 

SECTION 4. Release of Liens. The security interests granted herein in such Patent Collateral shall terminate and be released in accordance with Section 7.5 of the Security Agreement.

 

SECTION 5. Acknowledgment. The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Secured Parties with respect to the security interest in the Patent Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein.

 

SECTION 6. Loan Document. This Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article X thereof.

 

SECTION 7. Effectiveness. This Agreement shall become effective when a counterpart hereof executed by the Grantor, shall have been received by the Administrative Agent. Delivery of an executed counterpart of a signature page to this Security Agreement by email (e.g., “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Security Agreement.

 

[Signature Page Follows]

 

2 

 

 

IN WITNESS WHEREOF, the Grantor hereto has caused this Agreement to be duly executed and delivered by its Authorized Officer as of the date first above written.

 

  [NAME OF GRANTOR]
   
  By:  
    Name:
    Title:

 

[Signature Page to Patent Security Agreement]

 

 

 

 

SCHEDULE I

TO PATENT SECURITY AGREEMENT

 

Issued Patents

 

Country Patent No. Issue Date Inventor(s) Title

 

Pending Patent Applications

 

Country Serial No. Filing Date Inventor(s) Title

 

[Schedule I to Patent Security Agreement]

 

1 

 

 

EXHIBIT B

TO SECURITY AGREEMENT

 

TRADEMARK SECURITY AGREEMENT

 

This TRADEMARK SECURITY AGREEMENT, dated as of ________ __, 20__ (this “Agreement”), is made by [NAME OF GRANTOR], a ________ _______ (the “Grantor”), in favor of WILMINGTON TRUST, NATIONAL ASSOCIATION, a national banking association organized and existing under the laws of the United States of America (together with its Affiliates, successors, transferees and assignees, the “Administrative Agent”), as Administrative Agent for the Secured Parties.

 

W I T N E S S E T H :

 

WHEREAS, pursuant to the Credit Agreement, dated as of January 18, 2023 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), by and among Caris Life Sciences, Inc., a Texas corporation (the “Borrower”), the Lenders (as defined therein) and the Administrative Agent, the Lenders have extended Commitments to make Loans to the Borrower;

 

WHEREAS, in connection with the Credit Agreement, the Grantor and its Affiliates have executed and delivered a Pledge and Security Agreement in favor of the Administrative Agent, for the benefit of the Secured Parties, dated as of January 18, 2023 (as amended, supplemented or otherwise modified from time to time, the “Security Agreement”);

 

WHEREAS, pursuant to the Credit Agreement and pursuant to clause (b) of Section 4.5 of the Security Agreement, the Grantor is required to execute and deliver this Security Agreement and to grant to the Administrative Agent, for the benefit of the Secured Parties, a continuing security interest in all of the Trademark Collateral (as defined below) to secure all of the Obligations; and

 

WHEREAS, the Grantor has duly authorized the execution, delivery and performance of this Security Agreement;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees, for the benefit of the Secured Parties, as follows:

 

SECTION 1. Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Security Agreement, including its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement.

 

SECTION 2. Grant of Security Interest. The Grantor hereby grants to the Administrative Agent, for the benefit of the Secured Parties, a continuing security interest in all of Grantor’s right, title and interest in and to the Trademark registrations and applications referred to in Schedule I attached hereto, excluding Trademark applications filed in the United States Patent and Trademark Office on the basis of such Grantor’s “intent to use” such trademark, unless and until acceptable evidence of use of the Trademark has been filed with the United States Patent and Trademark Office pursuant to Section 1(c) or Section 1(d) of the Lanham Act (15 U.S.C. 1051, et seq.), (the “Trademark Collateral”).

 

[Exhibit B to Security Agreement]

 

1 

 

 

SECTION 3. Security Agreement. This Agreement has been executed and delivered by the Grantor for the purpose of registering the security interest of the Administrative Agent in the Trademark Collateral with the United States Patent and Trademark Office. The security interest granted hereby has been granted in furtherance of, and not in limitation of, the security interest granted to the Administrative Agent for the benefit of the Secured Parties under the Security Agreement. The Security Agreement (and all rights and remedies of the Secured Parties thereunder) shall remain in full force and effect in accordance with its terms.

 

SECTION 4. Release of Liens. The security interests granted herein in such Trademark Collateral shall terminate and be released in accordance with Section 7.5 of the Security Agreement.

 

SECTION 5. Acknowledgment. The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Secured Parties with respect to the security interest in the Trademark Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein.

 

SECTION 6. Loan Document. This Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article X thereof.

 

SECTION 7. Effectiveness. This Agreement shall become effective when a counterpart hereof executed by the Grantor, shall have been received by the Administrative Agent. Delivery of an executed counterpart of a signature page to this Security Agreement by email (e.g., “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Security Agreement.

 

[Signature Page Follows]

 

[Exhibit B to Security Agreement]

 

2 

 

 

IN WITNESS WHEREOF, the Grantor hereto has caused this Agreement to be duly executed and delivered by its Authorized Officer as of the date first above written.

 

  [NAME OF GRANTOR]
   
  By:  
    Name:
    Title:

 

[Signature Page to Trademark Security Agreement]

 

 

 

 

SCHEDULE I

TO TRADEMARK SECURITY AGREEMENT

 

Registered Trademarks

 

Country Trademark Registration No. Registration Date

 

Pending Trademark Applications

 

Country Trademark Serial No. Filing Date

 

[Schedule I to Trademark Security Agreement]

 

1 

 

 

EXHIBIT C

TO SECURITY AGREEMENT

 

COPYRIGHT SECURITY AGREEMENT

 

This COPYRIGHT SECURITY AGREEMENT, dated as of ________ __, 20__ (this “Agreement”), is made by [NAME OF GRANTOR], a ________ _______ (the “Grantor”), in favor of WILMINGTON TRUST, NATIONAL ASSOCIATION, a national banking association organized and existing under the laws of the United States of America (together with its Affiliates, successors, transferees and assignees, the “Administrative Agent”), as Administrative Agent for the Secured Parties.

 

W I T N E S S E T H :

 

WHEREAS, pursuant to the Credit Agreement, dated as of January 18, 2023 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), by and among Caris Life Sciences, Inc., a Texas corporation (the “Borrower”), the Lenders (as defined therein) and the Administrative Agent, the Lenders have extended Commitments to make Loans to the Borrower;

 

WHEREAS, in connection with the Credit Agreement, the Grantor and its Affiliates have executed and delivered a Pledge and Security Agreement in favor of the Administrative Agent, for the benefit of the Secured Parties, dated as of January 18, 2023 (as amended, supplemented or otherwise modified from time to time, the “Security Agreement”);

 

WHEREAS, pursuant to the Credit Agreement and pursuant to clause (b) of Section 4.5 of the Security Agreement, the Grantor is required to execute and deliver this Security Agreement and to grant to the Administrative Agent, for the benefit of the Secured Parties, a continuing security interest in all of the Copyright Collateral (as defined below) to secure all of the Obligations; and

 

WHEREAS, the Grantor has duly authorized the execution, delivery and performance of this Security Agreement;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantor agrees, for the benefit of the Secured Parties, as follows:

 

SECTION 1. Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Security Agreement, including its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement.

 

SECTION 2. Grant of Security Interest. The Grantor hereby grants to the Administrative Agent, for the benefit of the Secured Parties, a continuing security interest in all of the Grantor’s right, title and interest in and to the Copyright registrations and applications referred to in Schedule I attached hereto (the “Copyright Collateral”).

 

[Exhibit C to Security Agreement – Copyright Security Agreement]

 

1 

 

 

SECTION 3. Security Agreement. This Agreement has been executed and delivered by the Grantor for the purpose of registering the security interest of the Administrative Agent in the Copyright Collateral with the United States Copyright Office. The security interest granted hereby has been granted in furtherance of, and not in limitation of, the security interest granted to the Administrative Agent for the benefit of the Secured Parties under the Security Agreement. The Security Agreement (and all rights and remedies of the Secured Parties thereunder) shall remain in full force and effect in accordance with its terms.

 

SECTION 4. Release of Liens. The security interests granted herein in such Copyright Collateral shall terminate and be released in accordance with Section 7.5 of the Security Agreement.

 

SECTION 5. Acknowledgment. The Grantor does hereby further acknowledge and affirm that the rights and remedies of the Secured Parties with respect to the security interest in the Copyright Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein.

 

SECTION 6. Loan Document. This Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article X thereof.

 

SECTION 7. Effectiveness. This Agreement shall become effective when a counterpart hereof executed by the Grantor, shall have been received by the Administrative Agent. Delivery of an executed counterpart of a signature page to this Security Agreement by email (e.g., “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Security Agreement.

 

[Signature Page Follows]

 

[Exhibit C to Security Agreement – Copyright Security Agreement]

 

2 

 

 

IN WITNESS WHEREOF, the Grantor hereto has caused this Agreement to be duly executed and delivered by its Authorized Officer as of the date first above written.

 

  [NAME OF GRANTOR]
   
  By:  
    Name:
    Title:

 

[Signature Page to Copyright Security Agreement]

 

 

 

 

SCHEDULE I

TO COPYRIGHT SECURITY AGREEMENT

 

Registered Copyrights

 

Country Registration No. Registration Date Author(s) Title

 

Copyright Pending Registration Applications

 

Country Serial No. Filing Date Author(s) Title

 

[Schedule I to Copyright Security Agreement]

 

1 

 

 

ANNEX I

TO SECURITY AGREEMENT

 

SUPPLEMENT TO

PLEDGE AND SECURITY AGREEMENT

 

This SUPPLEMENT, dated as of __, 20__ (this “Supplement”), is to the Pledge and Security Agreement, dated as of January 18, 2023 (as amended, supplemented or otherwise modified from time to time, the “Security Agreement”), among the Grantors (such term, and other terms used in this Supplement, to have the meanings set forth in Article I of the Security Agreement, unless otherwise defined herein or if the context otherwise requires) from time to time party thereto, in favor of WILMINGTON TRUST, NATIONAL ASSOCIATION, a national banking association organized and existing under the laws of the United States of America (together with its Affiliates, successors, transferees and assignees, the “Administrative Agent”), as Administrative Agent for the Secured Parties.

 

W I T N E S S E T H :

 

WHEREAS, pursuant to the Credit Agreement, dated as of January 18, 2023 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), by and among Caris Life Sciences, Inc., a Texas corporation (the “Borrower”), the Lenders (as defined therein) and the Administrative Agent, the Lenders have extended Commitments to make Loans to the Borrower;

 

WHEREAS, pursuant to the provisions of Section 7.6 of the Security Agreement, each of the undersigned is becoming a Grantor under the Security Agreement; and

 

WHEREAS, each of the undersigned desires to become a “Grantor” under the Security Agreement in order to induce the Lenders to continue to extend Loans under the Credit Agreement;

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, each of the undersigned agrees, for the benefit of the Secured Parties, as follows.

 

SECTION 1. Party to Security Agreement, Etc. In accordance with the terms of the Security Agreement, by its signature below, each of the undersigned hereby irrevocably agrees to become a Grantor under the Security Agreement with the same force and effect as if it were an original signatory thereto and each of the undersigned hereby (a) agrees to be bound by and comply with all of the terms and provisions of the Security Agreement applicable to it as a Grantor and (b) represents and warrants that the representations and warranties made by it as a Grantor thereunder are true and correct in all material respects as of the date hereof, except for any representation and warranty that is qualified by materiality or reference to Material Adverse Effect, which such representation and warranty shall be true and correct in all respects (except in the case of any representation and warranty which expressly relates to a given date or period, which representation and warranty was true and correct in all material respects (and in all respects if qualified by materiality or reference to Material Adverse Effect) as of the respective date or for the respective period, as the case may be). In furtherance of the foregoing, each reference to a “Grantor” and/or “Grantors” in the Security Agreement shall be deemed to include each of the undersigned.

 

 

 

 

SECTION 2. Schedules. Each of the undersigned Grantors hereby authorizes the Administrative Agent to add the information set forth on the Schedules to this Supplement to the correlative Schedules attached to the Security Agreement.

 

SECTION 3. Representations. Each of the undersigned Grantors hereby represents and warrants that this Supplement has been duly authorized, executed and delivered by it and that this Supplement and the Security Agreement constitute its legal, valid and binding obligation, enforceable against it in accordance with its terms (except, in any case, as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally and by principles of equity).

 

SECTION 4. Full Force of Security Agreement. Except as expressly supplemented hereby, the Security Agreement shall remain in full force and effect in accordance with its terms.

 

SECTION 5. Severability. Wherever possible each provision of this Supplement shall be interpreted in such manner as to be effective and valid under applicable Law, but if any provision of this Supplement shall be prohibited by or invalid under such Law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Supplement or the Security Agreement.

 

SECTION 6. Governing Law, Entire Agreement, Etc. THIS SUPPLEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS SUPPLEMENT OR ANY DOCUMENT CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Supplement, along with the other Loan Documents, constitutes the entire understanding among the parties hereto with respect to the subject matter thereof and supersedes any prior agreements, written or oral, with respect thereto.

 

SECTION 7. Effectiveness. This Supplement shall become effective when a counterpart hereof executed by each undersigned Grantor shall have been received by the Administrative Agent. The words “execute,” “execution,” “signed,” “signature” and words of like import in this Supplement or in any amendment or other modification hereof (including waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Administrative Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

 

[Signature Page Follows]

 

[Schedule II to Security Agreement Supplement]

 

2

 

 

IN WITNESS WHEREOF, each of the parties hereto has caused this Supplement to be duly executed and delivered by its Authorized Officer as of the date first above written.

 

  [NAME OF ADDITIONAL GRANTOR]
   
  By:  
    Name:
    Title:

 

  [NAME OF ADDITIONAL GRANTOR]
   
  By:  
    Name:
    Title:

 

[Signature Page to Security Agreement Supplement]

 

 

 

 

SCHEDULE I

TO SECURITY AGREEMENT SUPPLEMENT

 

Subsidiary Name of Grantor Interest Percentage

 

[Schedule I to Security Agreement Supplement]

 

1 

 

 

SCHEDULE II

TO SECURITY AGREEMENT SUPPLEMENT

 

Item A. Location of each Grantor.

 

Name of Grantor:
  
Location   for   purposes   of   UCC (executive office / principal place of business):
   

 

Item B. Filing locations (last five years).

 

Item C. Trade names.

 

Name of Grantor: Trade Names:
   

 

Item D. Merger or other corporate reorganization.

 

Item E. Grantor's federal taxpayer ID numbers.

 

Name of Grantor: Taxpayer ID number:
   

 

Item F. [Reserved].

 

Item G. Deposit Accounts, Securities Accounts and Commodities Accounts.

 

Name of Grantor: Description of Deposit Accounts, Securities Accounts and Commodities Accounts:
 

 

Item H. Letter-of-Credit Rights.

 

[Schedule II to Security Agreement Supplement]

 

1 

 

 

Item I. Commercial Tort Claims.

 

Item J. Pledged Notes.

 

Name of Grantor: Description of Pledged Notes:
   

 

[Schedule II to Security Agreement Supplement]

 

2 

 

 

SCHEDULE III

TO SECURITY AGREEMENT SUPPLEMENT

 

Patents.

 

[Schedule III to Security Agreement Supplement]

 

1 

 

 

SCHEDULE IV

TO SECURITY AGREEMENT SUPPLEMENT

 

Trademarks.

 

[Schedule IV to Security Agreement Supplement]

 

1 

 

 

SCHEDULE V

TO SECURITY AGREEMENT SUPPLEMENT

 

Copyrights.

 

[Schedule V to Security Agreement Supplement]

 

1 

 

 

EXHIBIT F

FORM OF ASSIGNMENT AND ASSUMPTION

 

This Assignment and Assumption (the “Assignment and Assumption”) is dated as of the Effective Date set forth below and is entered into by and between [the][each]1 Assignor identified in item 1 below ([the][each, an] “Assignor”) and [the][each]2 Assignee identified in item 2 below ([the][each, an] “Assignee”). [It is understood and agreed that the rights and obligations of [the Assignors][the Assignees]3 hereunder are several and not joint.]4 Capitalized terms used but not defined herein shall have the meanings given to them in the Credit Agreement identified below (as amended, restated, amended and restated, supplemented or otherwise modified in writing from time to time, the “Credit Agreement”), receipt of a copy of which is hereby acknowledged by [the][each] Assignee. The Standard Terms and Conditions set forth in Annex 1 attached hereto are hereby agreed to and incorporated herein by reference and made a part of this Assignment and Assumption as if set forth herein in full.

 

For an agreed consideration, [the][each] Assignor hereby irrevocably sells and assigns to [the Assignee][the respective Assignees], and [the][each] Assignee hereby irrevocably purchases and assumes from [the Assignor][the respective Assignors], subject to and in accordance with the Standard Terms and Conditions and the Credit Agreement, as of the Effective Date inserted by the Administrative Agent as contemplated below (i) all of [the Assignor’s][the respective Assignors’] rights and obligations in [its capacity as a Lender][their respective capacities as Lenders] under the Credit Agreement and any other documents or instruments delivered pursuant thereto to the extent related to the amount and percentage interest identified below of all of such outstanding rights and obligations of [the Assignor][the respective Assignors] and (ii) to the extent permitted to be assigned under applicable Law, all claims, suits, causes of action and any other right of [the Assignor (in its capacity as a Lender)][the respective Assignors (in their respective capacities as Lenders)] against any Person, whether known or unknown, arising under or in connection with the Credit Agreement, any other documents or instruments delivered pursuant thereto or the loan transactions governed thereby or in any way based on or related to any of the foregoing, including, but not limited to, contract claims, tort claims, malpractice claims, statutory claims and all other claims at law or in equity related to the rights and obligations sold and assigned pursuant to clause (i) above (the rights and obligations sold and assigned by [the][any] Assignor to [the][any] Assignee pursuant to clauses (i) and (ii) above being referred to herein collectively as [the][an] “Assigned Interest”). Each such sale and assignment is without recourse to [the][any] Assignor and, except as expressly provided in this Assignment and Assumption, without representation or warranty by [the][any] Assignor.

 

 

1 For bracketed language here and elsewhere in this form relating to the Assignor(s), if the assignment is from a single Assignor, choose the first bracketed language. If the assignment is from multiple Assignors, choose the second bracketed language.

2 For bracketed language here and elsewhere in this form relating to the Assignee(s), if the assignment is to a single Assignee, choose the first bracketed language. If the assignment is to multiple Assignees, choose the second bracketed language.

3 Select as appropriate.

4 Include bracketed language if there are either multiple Assignors or multiple Assignees.

 

 

 

 

1.Assignor[s]:    
      
   [Assignor [is][is not] a Defaulting Lender]  

 

2.Assignee[s]:    
      

[for each Assignee, indicate [Affiliate][Approved Fund] of [identify Lender]]

 

3.Borrower(s): Caris Life Sciences, Inc.

 

4.Administrative Agent: Wilmington Trust, National Association, as the Administrative Agent under the Credit Agreement

 

5.Credit Agreement: Credit Agreement, dated as of January 18, 2023 by and among Caris Life Sciences, Inc., a Texas corporation (the “Borrower”), the Lenders party thereto and Wilmington Trust, National Association, as administrative agent (together with its Affiliates, successors, transferees and assignees, the “Administrative Agent”)

 

6.Assigned Interest[s]:

 

        Aggregate          
        Amount of   Amount of   Percentage Assigned  
Assignor[s]5   Assignee[s]6   [Initial][Delayed   [Initial][Delayed   of [Initial][Delayed  
    Draw]   Draw]   Draw] Commitment/  
        Commitment/Loans Commitment/Loans   Loans8  
        for all Lenders7   Assigned      
                   
        $   $   %  
        $   $   %  
        $   $   %  

 

 

5 List each Assignor, as appropriate.

6 List each Assignee, as appropriate.

7 Amounts in this column and in the column immediately to the right to be adjusted by the counterparties to take into account any payments or prepayments made between the Trade Date and the Effective Date. Set forth the type of Commitment/Loan to be assigned.

8 Set forth, to at least 9 decimals, as a percentage of the applicable Commitments/Loans of all Lenders thereunder.

 

2 

 

 

[7.      Trade Date:                                         ]9

 

Effective Date:                                       , 20         [TO BE INSERTED BY ADMINISTRATIVE AGENT AND WHICH SHALL BE THE EFFECTIVE DATE OF RECORDATION OF TRANSFER IN THE REGISTER THEREFOR.]

 

[SIGNATURE PAGES FOLLOW]

 

 

9 To be completed if the Assignor(s) and the Assignee(s) intend that the minimum assignment amount is to be determined as of the Trade Date.

 

3 

 

 

The terms set forth in this Assignment and Assumption are hereby agreed to:

 

  ASSIGNOR [NAME OF ASSIGNOR]
   
  By:  
    Name:
    Title:

 

  ASSIGNEE [NAME OF ASSIGNEE]
   
  By:  
    Name:
    Title:

 

[Signature Page to Assignment and Assumption]

 

 

 

 

Consented to:10

 

Wilmington Trust, National Association,

as Administrative Agent

 

By:    
  Name:  
  Title:  

 

[Consented to:11

 

Caris Life Sciences, Inc., as the

Borrower]

 

By:    
  Name:  
  Title:  

 

 

10 To be added only if the consent of the Administrative Agent is required by the terms of the Credit Agreement.

11 To be added only if the consent of the Borrower is required by the terms of the Credit Agreement.

 

[Signature Page to Assignment and Assumption]

 

 

 

 

ANNEX 1 TO ASSIGNMENT AND ASSUMPTION

 

STANDARD TERMS AND CONDITIONS FOR

 

ASSIGNMENT AND ASSUMPTION

 

1.            Representations and Warranties.

 

1.1.         Assignor[s]. [The][Each] Assignor (a) represents and warrants that (i) it is the legal and beneficial owner of [the][the relevant] Assigned Interest, (ii) [the][such] Assigned Interest is free and clear of any lien, encumbrance or other adverse claim, (iii) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby and (iv) it is [not] a Defaulting Lender; and (b) assumes no responsibility with respect to (i) any statements, warranties or representations made in or in connection with the Credit Agreement or any other Loan Document, (ii) the execution, legality, validity, enforceability, genuineness, sufficiency or value of the Loan Documents or any collateral thereunder, (iii) the financial condition of the Borrower, any of its Subsidiaries or Affiliates or any other Person obligated in respect of any Loan Document or (iv) the performance or observance by the Borrower, any of its Subsidiaries or Affiliates or any other Person of any of their respective obligations under any Loan Document.

 

1.2.         Assignee[s]. [The][Each] Assignee (a) represents and warrants that (i) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby and to become a Lender under the Credit Agreement, (ii) it meets all the requirements to be an assignee under Section 10.10(b) of the Credit Agreement (subject to such consents, if any, as may be required under Section 10.10(b)(i)(B) and Section 10.10(b)(iii) of the Credit Agreement, or pursuant to any other applicable section of the Credit Agreement), (iii) from and after the Effective Date, it shall be bound by the provisions of the Credit Agreement and the other Loan Documents as a Lender thereunder and, to the extent of [the][the relevant] Assigned Interest, shall have the obligations of a Lender thereunder, (iv) it is sophisticated with respect to decisions to acquire assets of the type represented by [the][such] Assigned Interest and either it, or the Person exercising discretion in making its decision to acquire [the][such] Assigned Interest, is experienced in acquiring assets of such type, (v) it has received a copy of the Credit Agreement, and has received or has been accorded the opportunity to receive copies of the most recent financial statements delivered pursuant to Section 7.1 thereof, as applicable, and such other documents and information as it deems appropriate to make its own credit analysis and decision to enter into this Assignment and Assumption and to purchase [the][such] Assigned Interest and (vi) it has, independently and without reliance upon the Administrative Agent or any other Lender and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Assignment and Assumption and to purchase [the][such] Assigned Interest; and (b) agrees that (i) it will, independently and without reliance upon the Administrative Agent, [the][any] Assignor or any other Lender, and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Loan Documents, and (ii) it will perform in accordance with their terms all of the obligations which by the terms of the Loan Documents are required to be performed by it as a Lender.

 

 

 

 

2.            Payments. From and after the Effective Date, the Administrative Agent shall make all payments in respect of [the][each] Assigned Interest (including payments of principal, interest, fees and other amounts) to [the][the relevant] Assignor for amounts which have accrued to but excluding the Effective Date and to [the][the relevant] Assignee for amounts which have accrued from and after the Effective Date.

 

3.            General Provisions. This Assignment and Assumption shall be binding upon, and inure to the benefit of, the parties hereto and their respective successors and permitted assigns. This Assignment and Assumption may be executed in any number of counterparts, which together shall constitute one instrument. Delivery of an executed counterpart of a signature page of this Assignment and Assumption by telecopy shall be effective as delivery of a manually executed counterpart of this Assignment and Assumption. This Assignment and Assumption shall be governed by, and construed in accordance with, the law of the State of New York.

 

 

 

 

EXHIBIT G

 

FORM OF SOLVENCY CERTIFICATE

 

Date: [_____], 20[_]

 

To the Administrative Agent and each of the Lenders

party to the Credit Agreement referred to below:

 

Pursuant to Section 5.8 of the Credit Agreement, dated as of January 18, 2023 (the “Credit Agreement”), by and among Caris Life Sciences, Inc., a Texas corporation (the “Borrower”), the Lenders party thereto and Wilmington Trust, National Association, as administrative agent (together with its Affiliates, successors, transferees and assignees, the “Administrative Agent”), the undersigned, solely in the undersigned’s capacity as [chief financial officer][ specify other chief financial or accounting Authorized Officer] of the Borrower, hereby certifies, on behalf of the Borrower and not in the undersigned’s individual or personal capacity and without personal liability, that, to his or her knowledge, as of the [[First][Second] Delayed Draw] Closing Date, after giving effect to the incurrence of the applicable Loans under the Credit Agreement on such date and the use of proceeds of such Loans:

 

(a)the fair value of the property of the Borrower and its Subsidiaries, on a consolidated basis, is greater than the total amount of liabilities, including Contingent Liabilities, of the Borrower and its Subsidiaries, on a consolidated basis;

 

(b)the present fair saleable value of the assets of the Borrower and its Subsidiaries, on a consolidated basis, is not less than the amount that will be required to pay the probable liabilities of the Borrower and its Subsidiaries, on a consolidated basis, on their debts as they become absolute and matured;

 

(c)the Borrower and its Subsidiaries, on a consolidated basis, do not intend to, and do not believe that they will, incur debts or liabilities beyond their ability to pay as such debts and liabilities mature;

 

(d)the Borrower and its Subsidiaries, on a consolidated basis, are not engaged in a business or a transaction, and are not about to engage in a business or a transaction, for which the property of the Borrower and its Subsidiaries, on a consolidated basis, would constitute an unreasonably small capital; and

 

(e)the Borrower and its Subsidiaries, on a consolidated basis, have not executed the Credit Agreement or any other Loan Document, or made any transfer or incurred any Obligations thereunder, with actual intent to hinder, delay or defraud either present or future creditors.

 

For purposes of this Solvency Certificate, the amount of any Contingent Liability at any time will be computed as the amount that, in light of all the facts and circumstances existing at such time, would reasonably be expected to become an actual or matured liability. Capitalized terms used but not otherwise defined herein have the meanings assigned to them in the Credit Agreement.

 

The undersigned is familiar with the business and financial position of the Borrower and its Subsidiaries. In reaching the conclusions set forth in this Solvency Certificate, the undersigned has made such investigations and inquiries as the undersigned has deemed appropriate, having taken into account the nature of the business currently conducted or currently proposed to be conducted by the Borrower and its Subsidiaries.

 

[Signature Page Follows]

 

 

 

 

IN WITNESS WHEREOF, the undersigned has executed this Solvency Certificate, solely in the undersigned’s capacity as [chief financial officer][specify other chief financial or accounting Authorized Officer] of the Borrower, on behalf of the Borrower and not in the undersigned’s individual or personal capacity and without personal liability, as of the date first stated above.

 

  CARIS LIFE SCIENCES, INC.
     
  By:  
    Name:
    Title:

 

[Signature Page to Solvency Certificate]

 

 

 

 

 

 

Exhibit 10.1(b)

Execution Version

 

FIRST AMENDMENT TO CREDIT AGREEMENT

 

This FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of April 1, 2025 by and among CARIS LIFE SCIENCES, INC., a Texas corporation (the “Borrower”), the Lenders party hereto (the “Lenders”), and WILMINGTON TRUST, NATIONAL ASSOCIATION, as administrative agent for the Lenders (together with its Affiliates, successors, transferees and assignees, the “Administrative Agent”).

 

WHEREAS, the Borrower, the Lenders and the Administrative Agent entered into a Credit Agreement, dated as of January 18, 2023 (the “Credit Agreement”), pursuant to which the Lenders have extended credit to the Borrower on the terms set forth therein;

 

WHEREAS, pursuant to Section 10.1 of the Credit Agreement, the Credit Agreement may be amended by an instrument in writing signed by the Borrower and the Required Lenders and acknowledged by the Administrative Agent;

 

WHEREAS, the Lenders constitute the Required Lenders under the Credit Agreement; and

 

WHEREAS, the Borrower and the Lenders desire to amend certain provisions of the Credit Agreement as provided in this Amendment.

 

NOW, THEREFORE, in consideration of the mutual agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.             Definitions; Loan Document. Capitalized terms used herein without definition shall have the meanings assigned to such terms in the Credit Agreement. This Amendment shall constitute a Loan Document for all purposes of the Credit Agreement and the other Loan Documents.

 

2.             Amendments to Schedules. The Schedules to the Credit Agreement are hereby supplemented by adding new Schedule 8.6(f) thereto in the appropriate numeric order, in the form attached hereto as Exhibit A.

 

3.             Amendments to Section 1.1.

 

(a)               Section 1.1 of the Credit Agreement is hereby amended by inserting the following new defined terms therein in the proper alphabetical order:

 

“2025 Convertible Note Collateral Agent” means Wilmington Trust, National Association, in its capacity as collateral agent under the 2025 Convertible Note Purchase Agreement.

 

“2025 Convertible Note Purchase Agreement” means that certain Convertible Note Purchase Agreement, dated as of April 1, 2025, among the Borrower, certain subsidiaries of the Borrower party thereto, the 2025 Convertible Note Collateral Agent, and the purchasers from time to time party thereto.

 

 

 

“2025 Convertible Note Documents” means the “Transaction Agreements” (as defined in the 2025 Convertible Note Purchase Agreement).

 

“2025 Convertible Note Intercreditor Agreement” means that certain Intercreditor Agreement, dated as of April 1, 2025, among the Administrative Agent, the 2025 Convertible Note Collateral Agent, the Borrower and the other Loan Parties.

 

“2025 Convertible Note Maturity Date” means January 1, 2026 (or such later date as the Borrower and the purchasers party to the 2025 Convertible Note Purchase Agreement may agree so long as such extension of the 2025 Convertible Note Maturity Date by the purchasers is not made in exchange for a fee or other compensation).

 

“2025 Convertible Notes” means those certain 8.00% senior convertible notes in an aggregate original principal amount of up to $30,000,000 due on the 2025 Convertible Note Maturity Date, issued by the Borrower and governed by the terms of the 2025 Convertible Note Documents.

 

“First Amendment” means the First Amendment to the Agreement, dated as of the First Amendment Effective Date, among the Borrower, the Lenders party thereto and the Administrative Agent.

 

“First Amendment Effective Date” means April 1, 2025.

 

“Series E Preferred Stock” means the Series E Preferred Stock of the Borrower issued pursuant to the Borrower’s Charter.

 

(b)               The definition of “Borrower’s Charter” in Section 1.1 of the Credit Agreement is hereby amended and restated in its entirety as follows:

 

“Borrower’s Charter” means that certain Second Amended and Restated Certificate of Formation of the Borrower, dated as of March 24, 2025, and as may be amended, restated, amended and restated, supplemented or otherwise modified from time to time after the Closing Date to the extent permitted by Section 8.9(a).

 

(c)               The definition of “Change of Control” in Section 1.1 of the Credit Agreement is hereby amended by replacing each instance of the phrase “Series C Conversion Price or Series D Conversion Price (each as defined in the Borrower’s Charter)” therein with the phrase “Series C Conversion Price, Series D Conversion Price or Series E Conversion Price (each as defined in the Borrower’s Charter)”.

 

-2-

 

 

(d)               The definition of “Impermissible Qualification” in Section 1.1 of the Credit Agreement is hereby amended and restated in its entirety as follows:

 

    “Impermissible Qualification” means any qualification or exception to the opinion or certification of any independent public accountant as to any financial statement of the Borrower or any Subsidiary (i) which is of a “going concern” or similar nature other than any such qualification that is related solely to any or a combination of (I)(A) the occurrence of the Maturity Date as a result of the Loans maturing during such Fiscal Year or (B) in the case of sub-clauses (x), (y) and (z) of this clause (I)(B), for the Fiscal Year ending December 31, 2024 only, the occurrence of (w) any upcoming date where redemption rights in respect of the Series C Preferred Stock, Series D Preferred Stock and/or Series E Preferred Stock are or may become exercisable, (x) any upcoming date on which the Loans may become subject to amortization as contemplated by Section 3.2 as a result of the occurrence of any of the events specified in the foregoing clause (I)(B)(x), (y) any upcoming date on which the principal obligations under the 2025 Convertible Note Documents would mature or otherwise become mandatorily payable or redeemable in whole or in part or (z) any increase above $20,000,000 to the minimum amount of Liquidity required to be maintained by the Borrower pursuant to Section 8.4(a), or (II) any prospective or actual inability to satisfy any financial maintenance covenant included in the Loan Documents on a future date in a future period, (ii) which relates to the limited scope of examination of matters relevant to such financial statement or (iii) which relates to the treatment or classification of any item in such financial statement and which, as a condition to its removal, would require an adjustment to such item the effect of which would be to cause the Borrower to be in Default.

 

(e)               The definition of “Loan Documents” in Section 1.1 of the Credit Agreement is hereby amended by inserting “the First Amendment, the 2025 Convertible Note Intercreditor Agreement,” immediately after the phrase “the Agency Fee Letter,”.

 

(f)                The definition of “Material Agreements” in Section 1.1 of the Credit Agreement is hereby amended by inserting “(ii) the 2025 Convertible Note Documents,” immediately after clause (i) thereof and renumbering each successive clause therein.

 

(g)               The definition of “Restricted Payment” in Section 1.1 of the Credit Agreement is hereby amended by amending and restating the last sentence thereof in its entirety to read as follows: “Notwithstanding the foregoing, and for the avoidance of doubt, (i) the conversion of (including any cash payment or fractional shares upon conversion), or payment of any principal or premium on, or payment of any interest with respect to, or payment of any fees, expenses or other similar amounts in respect of or in relation to, the 2023 Convertible Loans, the 2025 Convertible Notes, any Post-IPO Convertible Indebtedness or other permitted convertible Indebtedness under this Agreement shall not constitute a Restricted Payment and (ii) any payment with respect to, or early unwind or settlement of, any Permitted Call Spread Swap Agreement shall not constitute a Restricted Payment.”

 

-3-

 

 

4.              Amendments to Section 3.2. Section 3.2 of the Credit Agreement is hereby amended by (i) replacing each instance of the phrase “the Series C Preferred Stock or the Series D Preferred Stock” therein with the phrase “the Series C Preferred Stock, Series D Preferred Stock or the Series E Preferred Stock”, (ii) replacing each instance of the phrase “the Series C Preferred Stock and the Series D Preferred Stock” therein with the phrase “the Series C Preferred Stock, the Series D Preferred Stock and the Series E Preferred Stock” and (iii) adding a new sentence at the end of the first paragraph thereof to read as follows: “For the avoidance of doubt, there shall be only one “Determination Date” under this Section 3.2 and the amortization payment in an amount equal to 15% of the outstanding principal amount of the Loans contemplated by this paragraph shall in all events be required to be made (if at all) solely on a one-time basis.”

 

5.              Amendments to Section 8.2.

 

(a)Section 8.2 of the Credit Agreement is hereby amended by inserting a new clause (x) immediately after clause (w) thereof, as follows:

 

“ and (x) Indebtedness in respect of the 2025 Convertible Notes;”

 

(b)Section 8.2 of the Credit Agreement is hereby amended by inserting the phrase “, the Series E Preferred Stock” immediately after the phrase “the Series D Preferred Stock” in clause (w) thereof.

 

6.              Amendments to Section 8.3. Section 8.3 of the Credit Agreement is hereby amended by inserting a new clause (x) immediately after clause (w) thereof, as follows:

 

“and (x) Liens securing Indebtedness of the Borrower or the Subsidiaries permitted pursuant to Section 8.2(x).”

 

7.              Amendments to Section 8.4. Section 8.4(a) of the Credit Agreement is hereby amended and restated in its entirety as follows:

 

(a)            Minimum Liquidity. The Liquidity of the Borrower shall not at any time be less than $20,000,000; provided that (x) if the Borrower redeems or repurchases for cash all or any portion of the Series C Preferred Stock or the Series D Preferred Stock (except for any redemption or repurchase made using the proceeds of an issuance of Capital Securities, so long as such proceeds are escrowed solely for the purpose of effectuating such repurchase or redemption of Series C Preferred Stock or Series D Preferred Stock or such issuance is consummated substantially concurrently with such repurchase or redemption), from and after the date of such repurchase or redemption, the Liquidity of the Borrower shall not at any time be less than the outstanding principal amount of the Loans at such time (as such amount may be decreased from time to time) (provided, further, that if all of the outstanding Series C Preferred Stock and Series D Preferred Stock are converted into common stock of the Borrower following the occurrence of a Qualified Direct Listing Event or consummation of a Qualified IPO or a Qualified SPAC Transaction, the Liquidity of the Borrower shall not at any time be less than $20,000,000) and (y) if the Borrower pays any principal under the 2025 Convertible Notes (excluding (i) any principal paid solely in common stock of the Borrower and cash payments made in lieu of fractional shares of common stock of the Borrower and (ii) common stock of the Borrower issued as a result of any conversion of the 2025 Convertible Notes in accordance with their terms), from and after the date of such repayment (giving effect to such repayment), the Liquidity of the Borrower shall not at any time be less than $50,000,000. The Borrower shall maintain an aggregate amount equal to the then applicable amount required under this Section 8.4(a), along with its other cash and Cash Equivalent Investments, in a Controlled Account as required pursuant to Section 7.13(a).

 

-4-

 

 

8.              Amendments to Section 8.6.

 

(a)Section 8.6 of the Credit Agreement is hereby amended by inserting the phrase “, Indebtedness in respect of the 2025 Convertible Notes” immediately after the phrase “(with respect to cash interest)”.

 

(b)Section 8.6 of the Credit Agreement is hereby amended by replacing the phrase “the Series C Preferred Stock and/or Series D Preferred Stock” in clause (g) therein with the phrase “the Series C Preferred Stock, the Series D Preferred Stock and/or the Series E Preferred Stock”.

 

(c)Section 8.6(f) of the Credit Agreement is hereby amended and restated in its entirety as follows

 

“ (f) transactions described on Schedule 8.6(f), completed prior to the First Amendment Effective Date;”

 

(d)Section 8.6(m) of the Credit Agreement is hereby amended and restated in its entirety as follows:

 

“ (m) the repurchase of Capital Securities of the Borrower (or the payment of a dividend to a direct or indirect parent of the Borrower to fund such repurchase) upon (x) vesting of restricted stock, restricted stock units, performance shares units or similar equity incentives or (y) upon the vesting or exercise of any stock options or other equity awards, in each case under this clause (m) to satisfy tax withholding or similar tax obligations with respect thereto; ”

 

(e)Section 8.6 of the Credit Agreement is hereby amended by replacing the period and the end of clause (n) with “; and” and inserting a new clause (o) immediately after clause (n) thereof, as follows:

 

“ (o) payments of scheduled interest on, or (so long as there is no Event of Default then existing or would result therefrom) principal at the stated maturity of, Indebtedness under the 2025 Convertible Notes.”

 

-5-

 

 

9.              Amendments to Section 8.9.

 

(a)Section 8.9 of the Credit Agreement is hereby amended by inserting a new clause (f) immediately after clause (e) thereof, as follows:

 

“or (f) the 2025 Convertible Note Documents, if the result could reasonably be expected to have an adverse effect in any material respect on the Administrative Agent or the Lenders;”

 

10.           Amendments to Section 8.11. Section 8.11 of the Credit Agreement is hereby amended by inserting the phrase “, in the 2025 Convertible Note Documents” immediately before the phrase “or in the 2023 Convertible Loan Documents” in clause (A) of the second sentence thereof.

 

11.           Amendments to Section 9.1.

 

(a)Section 9.1 of the Credit Agreement is hereby amended by inserting the following sentence at the end of clause (e) of such section:

 

“Notwithstanding the foregoing, this Section 9.1(e) shall not apply to any “Event of Default” (as defined in the 2025 Convertible Note Documents) or to any Indebtedness or other obligations under the 2025 Convertible Note Documents (which shall instead be subject to Section 9.1(m) below).”

 

(b)Section 9.1 of the Credit Agreement is hereby amended by inserting the following new clause (m) at the end of such Section:

 

“(m) 2025 Convertible Notes. (i) Any “Event of Default” (as defined in the 2025 Convertible Note Documents) shall occur and be continuing under the 2025 Convertible Note Documents or (ii) a default shall occur in the payment of any amount when due (subject to any applicable grace period), whether by acceleration or otherwise, of any principal or stated amount of, or interest or fees on, any Indebtedness under the 2025 Convertible Notes. If any “Event of Default” (as defined in the 2025 Convertible Note Documents) under clause (m)(i) hereof shall exist solely as a consequence of the occurrence of a default or Event of Default under the Loan Documents (in such case, a “Predicate Default”), and such Predicate Default shall cease to exist under the Loan Documents, it is understood and agreed that the Event of Default under this Section 9.1(m) as a result of an “Event of Default” under the 2025 Convertible Note Documents caused by such Predicate Default shall be deemed to no longer exist.”

 

12.           Conditions to Effectiveness of Amendment. This Amendment shall become effective upon receipt:

 

(a)by the Lenders, the Administrative Agent and the Borrower of a counterpart signature of the other to this Amendment duly executed and delivered by each of the Lenders, the Administrative Agent and the Borrower;

 

-6-

 

 

(b)by the Lenders and the Administrative Agent of a certificate, dated as of the First Amendment Effective Date, duly executed and delivered by an Authorized Officer of the Borrower, as to:

 

(i)                resolutions of the Borrower’s board of directors and any other corporate resolutions required by applicable Law or pursuant to the Borrower’s Organic Documents, each of which shall be then in full force and effect, authorizing the execution, delivery and performance of this Amendment and the transactions contemplated hereby; and

 

(ii)               the full force and validity of each Organic Document of the Borrower and copies thereof;

 

(c)by the Lenders and the Administrative Agent of duly executed copies of the 2025 Convertible Note Documents and the 2025 Convertible Note Intercreditor Agreement; and

 

(d)by the Administrative Agent, for the ratable account of each Lender, a fee in an aggregate amount equal to one percent (1.00%) of the aggregate Loans outstanding on the First Amendment Effective Date.

 

The Borrower agrees that the fee payable under clause (d) above shall be (i) paid in U.S. Dollars, (ii) fully earned upon the First Amendment Effective Date, (iii) nonrefundable and (iv) in addition to, and not creditable against, any other fee, cost or expense payable under the Loan Documents.

 

13.           Expenses. The Borrower agrees to pay on demand all expenses of the Administrative Agent and the Lenders (including, without limitation, the fees and out-of-pocket expenses of Seward & Kissel LLP, counsel to the Administrative Agent and Covington & Burling LLP, counsel to OrbiMed and Gibson, Dunn & Crutcher LLP, counsel to Braidwell) incurred in connection with the negotiation, preparation, execution and delivery of this Amendment.

 

14.          Representations and Warranties. The Borrower represents and warrants to the Lenders, as of the effective date of this Amendment, as follows:

 

(a)           The representations and warranties of the Borrower and the Subsidiaries contained in the Credit Agreement or any other Loan Document are true and correct in all material respects as of the date hereof (except (i) with respect to representations and warranties expressly made as of an earlier date, in which case such representations and warranties are true and correct in all material respects as of such earlier date and (ii) if any such representation or warranty contains any materiality qualifier, such representation or warranty is true and correct in all respects).

 

(b)           No Default or Event of Default under the Credit Agreement has occurred and is continuing or would result from the effectiveness of this Amendment.

 

-7-

 

 

15.           No Implied Amendment or Waiver. Except as expressly set forth in this Amendment, this Amendment shall not, by implication or otherwise, limit, impair, constitute a waiver of or otherwise affect any rights or remedies of the Administrative Agent and the Lenders under the Credit Agreement or the other Loan Documents, or alter, modify, amend or in any way affect any of the terms, obligations or covenants contained in the Credit Agreement or the other Loan Documents, all of which shall continue in full force and effect. Nothing in this Amendment shall be construed to imply any willingness on the part of the Administrative Agent or any Lender to agree to or grant any similar or future amendment, consent or waiver of any of the terms and conditions of the Credit Agreement or the other Loan Documents.

 

16.           Waiver and Release. TO INDUCE THE ADMINISTRATIVE AGENT AND THE LENDERS TO AGREE TO THE TERMS OF THIS AMENDMENT, THE BORROWER AND ITS AFFILIATES (COLLECTIVELY, THE “RELEASING PARTIES”) REPRESENT AND WARRANT THAT, AS OF THE DATE HEREOF, THERE ARE NO CLAIMS OR OFFSETS AGAINST, OR RIGHTS OF RECOUPMENT WITH RESPECT TO, OR DISPUTES OF, OR DEFENSES OR COUNTERCLAIMS TO, THEIR OBLIGATIONS UNDER THE LOAN DOCUMENTS, AND IN ACCORDANCE THEREWITH THE RELEASING PARIES:

 

(a)            WAIVE ANY AND ALL SUCH CLAIMS, OFFSETS, RIGHTS OF RECOUPMENT, DISPUTES, DEFENSES AND COUNTERCLAIMS, WHETHER KNOWN OR UNKNOWN, ARISING PRIOR TO THE DATE HEREOF.

 

(b)           FOREVER RELEASE, RELIEVE, AND DISCHARGE THE ADMINISTRATIVE AGENT, THE LENDERS, THEIR AFFILIATES AND THEIR RESPECTIVE OFFICERS, DIRECTORS, SHAREHOLDERS, MEMBERS, PARTNERS, PREDECESSORS, SUCCESSORS, ASSIGNS, ATTORNEYS, ACCOUNTANTS, AGENTS, EMPLOYEES, AND REPRESENTATIVES (COLLECTIVELY, THE “RELEASED PARTIES”), AND EACH OF THEM, FROM ANY AND ALL CLAIMS, LIABILITIES, DEMANDS, CAUSES OF ACTION, DEBTS, OBLIGATIONS, PROMISES, ACTS, AGREEMENTS, AND DAMAGES, OF WHATEVER KIND OR NATURE, WHETHER KNOWN OR UNKNOWN, SUSPECTED OR UNSUSPECTED, CONTINGENT OR FIXED, LIQUIDATED OR UNLIQUIDATED, MATURED OR UNMATURED, WHETHER AT LAW OR IN EQUITY, WHICH THE RELEASING PARTIES EVER HAD, NOW HAVE, OR MAY, SHALL, OR CAN HEREAFTER HAVE, DIRECTLY OR INDIRECTLY ARISING OUT OF OR BASED UPON ANY OF THE LOAN DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREBY (EXCLUDING, FOR CLARITY, TRANSACTIONS CONCERNING THE 2025 CONVERTIBLE NOTES OR THE BORROWER’S CAPITAL SECURITIES) AT ANY TIME FROM THE BEGINNING OF THE WORLD THROUGH AND INCLUDING THE DATE HEREOF.

 

(c)           IN CONNECTION WITH THE RELEASE CONTAINED HEREIN, ACKNOWLEDGE THAT THEY ARE AWARE THAT THEY MAY HEREAFTER DISCOVER CLAIMS PRESENTLY UNKNOWN OR UNSUSPECTED, OR FACTS IN ADDITION TO OR DIFFERENT FROM THOSE WHICH THEY KNOW OR BELIEVE TO BE TRUE, WITH RESPECT TO THE MATTERS RELEASED HEREIN. NEVERTHELESS, IT IS THE INTENTION OF THE RELEASING PARTIES, THROUGH THIS AMENDMENT AND WITH ADVICE OF COUNSEL, FULLY, FINALLY, AND FOREVER TO RELEASE ALL SUCH MATTERS, AND ALL CLAIMS RELATED THERETO, WHICH DO NOW EXIST, OR HERETOFORE HAVE EXISTED. IN FURTHERANCE OF SUCH INTENTION, THE RELEASES HEREIN GIVEN SHALL BE AND REMAIN IN EFFECT AS A FULL AND COMPLETE RELEASE OR WITHDRAWAL OF SUCH MATTERS NOTWITHSTANDING THE DISCOVERY OR EXISTENCE OF ANY SUCH ADDITIONAL OR DIFFERENT CLAIMS OR FACTS RELATED THERETO.

 

-8-

 

 

(d)           COVENANT AND AGREE NOT TO BRING ANY CLAIM, ACTION, SUIT, OR PROCEEDING AGAINST THE RELEASED PARTIES, DIRECTLY OR INDIRECTLY, REGARDING OR RELATED IN ANY MANNER TO THE MATTERS RELEASED HEREBY (FOR THE AVOIDANCE OF DOUBT, IN RELATION TO THE LOAN DOCUMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED THEREBY (EXCLUDING FOR CLARITY, TRANSACTIONS CONCERNING THE 2025 CONVERTIBLE NOTES OR THE BORROWER’S CAPITAL SECURITIES)), AND FURTHER COVENANT AND AGREE THAT THIS AMENDMENT IS A BAR TO ANY SUCH CLAIM, ACTION, SUIT, OR PROCEEDING.

 

(e)          REPRESENT AND WARRANT TO THE RELEASED PARTIES THAT THEY HAVE NOT HERETOFORE ASSIGNED OR TRANSFERRED, OR PURPORTED TO ASSIGN OR TRANSFER, TO ANY PERSON OR ENTITY ANY CLAIMS OR OTHER MATTERS HEREIN RELEASED.

 

(f)           ACKNOWLEDGE THAT THEY HAVE HAD THE BENEFIT OF INDEPENDENT LEGAL ADVICE WITH RESPECT TO THE ADVISABILITY OF ENTERING INTO THIS RELEASE AND HEREBY KNOWINGLY, AND UPON SUCH ADVICE OF COUNSEL, WAIVE ANY AND ALL APPLICABLE RIGHTS AND BENEFITS UNDER, AND PROTECTIONS OF, CALIFORNIA CIVIL CODE SECTION 1542, AND ANY AND ALL STATUTES AND DOCTRINES OF SIMILAR EFFECT. CALIFORNIA CIVIL CODE SECTION 1542 PROVIDES AS FOLLOWS:

 

A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release, and that if known by him or her, would have materially affected his or her settlement with the debtor or released party.

 

17.           Counterparts; Governing Law. This Amendment may be executed by the parties hereto in several counterparts, each of which shall be an original and all of which shall constitute together but one and the same agreement. Delivery of an executed counterpart of a signature page to this Amendment by email (e.g., “pdf” or “tiff”) or telecopy shall be effective as delivery of a manually executed counterpart of this Amendment. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK).

 

-9-

 

 

18.           Agent Authorization. Each of the Lenders party hereto, constituting the Required Lenders, hereby authorizes and directs the Administrative Agent to execute and deliver the acknowledgment to this Amendment.

 

[Remainder of Page Intentionally Left Blank]

 

-10-

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their respective officers thereunto duly authorized as of the day and year first above written.

 

CARIS LIFE SCIENCES, INC.
 as the Borrower
  
  
 By: /s/ Luke Power
 Name: Luke Power
 Title: Senior Vice President, Chief Financial Officer, and Chief Accounting Officer

 

[Signature Page to First Amendment to Credit Agreement]

 

 

 

ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP,
 as a Lender
  
 By: OrbiMed ROF III LLC,
   its General Partner
  
   By: OrbiMed Advisors LLC,
     its Managing Member
  
  
 By: /s/ Matthew Rizzo
 Name: Matthew Rizzo
 Title: Member
  
  
 ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP,
 as a Lender
  
 By: OrbiMed ROF IV LLC,
   its General Partner
  
   By: OrbiMed Advisors LLC,
     its Managing Member
  
  
 By: /s/ Matthew Rizzo
 Name: Matthew Rizzo
 Title: Member
  
  
 ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV OFFSHORE, LP,
 as a Lender
  
 By: OrbiMed ROF IV LLC,
   its General Partner
  
   By: OrbiMed Advisors LLC,
     its Managing Member
  
  
 By: /s/ Matthew Rizzo
 Name: Matthew Rizzo
 Title: Member

 

[Signature Page to First Amendment to Credit Agreement]

 

 

 

 BRAIDWELL TRANSACTION HOLDINGS LLC – SERIES 2,
 as a Lender
  
 By: Braidwell LP,
   its Investment Manager
  
  
 By: /s/ Colin Bettison
 Name: Colin Bettison
 Title: Authorized Signatory

 

ACKNOWLEDGED BY: 
  
WILMINGTON TRUST, NATIONAL ASSOCIATION 
as the Administrative Agent 
  
  
By: /s/ Jessica A. Jankiewicz 
Name: Jessica A. Jankiewicz 
Title: Vice President 

 

[Signature Page to First Amendment to Credit Agreement]

 

 

 

EXHIBIT A

 

Schedule 8.6(f)

 

Certain Restricted Payments

 

 

 

Exhibit 10.2(a)

 

Certain confidential information contained in this document, marked by “[***]”, has been omitted because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.

 

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
tel 858.202.4500
fax 858.202.4545
www.illumina.com

 

David D. Halbert  March 29, 2021

Chief Executive Officer

Caris MPI, Inc.

750 West John Carpenter Freeway

Suite 800

Irving, Texas 75039

 

Dear Mr. Halbert:

 

In connection with Illumina Inc.’s proposed acquisition of GRAIL, Inc. (the “Transaction”), Illumina is irrevocably offering to Caris MPI Inc. (“Caris”) the terms enclosed in Exhibit A (the “Supply Agreement”) and Exhibit B (the “IVD Test Kit Agreement Terms”) to allay any concerns relating to the Transaction, including that Illumina would disadvantage GRAIL’s potential competitors after the Transaction by increasing their sequencing prices or by withholding access to Illumina’s latest innovations in Next-Generation Sequencing (“NGS”). To address these concerns, these terms will be offered to any existing or new customer of Illumina that purchases NGS products for developing and/or commercializing oncology tests and will remain open for six (6) years from the closing of the Transaction (the “Open Term”). You may accept this offer and the attendant terms in this letter and attached hereto any time from today until expiration of the Open Term by signing and returning this letter to the undersigned.

 

The Supply Agreement shall not be effective unless and until the Transaction closes. The Supply Agreement shall be effective for twelve (12) years from the closing of the Transaction, regardless of when this offer is accepted. This irrevocable offer is binding on Illumina. This offer to enter into the Supply Agreement during the Open Term shall be governed by, and construed in accordance with, the laws of the State of New York, without giving effect to the conflicts-of-law principles thereof.

 

In addition, Caris may enter into, at any time from today until expiration of the Open Term, an agreement with Illumina (i.e., an “IVD Test Kit Agreement”) under which Caris may develop and commercialize in-vitro diagnostic (“IVD”) distributable test kits that may be used by third-party laboratories for use on Illumina’s diagnostic sequencing platforms that have received FDA marketing authorization (e.g., the NextSeq550Dx sequencing platform). Specifically, under the terms specified in Exhibit B, Caris may enter into an IVD Test Kit Agreement to develop an IVD distributable test kit on the NextSeq550Dx sequencing platform or any future Illumina diagnostic sequencing platform that receives FDA authorization. An agreement under Exhibit B to develop an IVD distributable test kit on any Illumina diagnostic sequencing platform would be effective for fifteen (15) years from the date the Transaction closes. The IVD Test Kit Agreement shall not be effective unless and until the Transaction closes. Caris may also choose to enter into an IVD Test Kit Agreement for a single Illumina diagnostic sequencing platform, either the NextSeq550Dx platform or any subsequent diagnostic platform, once it receives regulatory approval, under the terms specified in Exhibit B. This irrevocable offer is binding on Illumina. This offer to enter into the IVD Test Kit Agreement during the Open Term shall be governed by, and construed in accordance with, the laws of the State of New York, without giving effect to the conflicts-of-law principles thereof.

 

There will be no change or disruption to Illumina’s supply of NGS products to you irrespective of your execution of the Supply Agreement or the IVD Test Kit Agreement. Illumina remains fully committed to enabling the innovation and exciting work that Caris is doing on Illumina’s next-generation sequencing platforms.

 

 

 

 

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
tel 858.202.4500
fax 858.202.4545
www.illumina.com

 

Please contact me if you have any questions.

 

  Sincerely,
   
  /s/ Nicole Berry
  Nicole Berry
  SVP and General Manager, Americas
       
  Accepted and Agreed:
   
  Caris MPI, Inc.  
   
  /s/ David D. Halbert
  Name: David D. Halbert
  Title: CEO
  Date: 9/21/2022

 

 

 

 

Exhibit A – Supply Agreement

 

1.DEFINITIONS

 

“Affiliate(s)” means with respect to a party, any entity that, directly or indirectly, controls, is controlled by or is under common control with such Party for so long as such control exists. For purposes of this definition, an entity has control of another entity if it has the direct or indirect ability or power to direct or cause the direction of management policies of such other entity or otherwise direct the affairs of such other entity, whether through ownership of the voting securities of such other entity, by contract or otherwise.

 

“Application Specific IP” means the Illumina Intellectual Property Rights that pertain to the Supplied Product (and use thereof) only with regard to specific field(s) or specific application(s). Application Specific IP excludes all Core IP. By way of non-limiting example, Illumina Intellectual Property Rights for NIPT, for specific forensic methods, or for specific nucleic acid biomarkers, sequences, or combinations of biomarkers or sequences are examples of Application Specific IP.

 

“Core IP” means Illumina Intellectual Property Rights that pertain to or cover aspects or features of any Supplied Product (or use thereof), or software embedded in or installed on Illumina hardware (or use thereof), or software that Illumina hardware is designed to communicate or interact with (or use thereof), that are common to such Supplied Product in all applications and all fields of use. To avoid any doubt, and without limitation, Core IP specifically excludes any and all Intellectual Property Rights relating to NIPT.

 

“Customer” means the For-Profit Entity that enters into this Supply Agreement with Illumina.

 

“Customer Use” means use in all fields of use, specifically excluding any use that (i) is not in accordance with the product’s specifications or documentation (it being understood that specifications and documentation shall not undermine or limit Customer’s rights under this Supply Agreement), (ii) is a re-use of a previously used consumable, (iii) is the disassembling, reverse-engineering, reverse-compiling, or reverse-assembling of the Supplied Product, (iv) is the separation, extraction, or isolation of components of consumables or other unauthorized analysis of the consumables, (v) gains access to or determines the methods of operation of the Supplied Product, or (vi) is the transfer to a third party of, or sub-licensing of, software or third-party software.

 

“Equivalent” means, with respect to the comparison of Customer to another customer, that (a) the aggregate volume of all Supplied Products purchased by such other customer from Illumina in the immediately preceding year (measured in U.S. dollars) is not more than 10% greater than the volume purchased by Customer in prior year, (b) such other customer is a For-Profit Entity, and (c) such other customer is not currently receiving Grandfathered Pricing.

 

“For-Profit Entity” means a for-profit company in the United States that purchases Supplied Products for performing sequencing for liquid biopsy cancer screening or diagnostic tests for clinical oncology purposes, on human samples received from, and delivered to, unaffiliated health care professionals, health care organizations or other laboratories for clinical oncology purposes. A For-Profit Entity excludes governments, government agencies, hospitals, research institutes, academic institutions, non-profits and Illumina Affiliates (including GRAIL).

 

 

 

 

“GRAIL” means GRAIL, Inc. for so long as it is an Affiliate of Illumina, or any successor to GRAIL, Inc. or any substantial part of the business of GRAIL, Inc. that in either case is Illumina or an Affiliate of Illumina.

 

“Grandfathered Pricing” means any pricing (either under a quote of duration longer than 30 days or a supply agreement) that is operative for the Customer for use of the Supplied Products at the time that the Transaction closes, provided that this pricing is for ongoing, ordinary course purchases of Supplied Products.

 

“Illumina Intellectual Property Rights” means all Intellectual Property Rights owned or controlled by Illumina or Affiliates of Illumina during the Term of this Agreement. Application Specific IP and Core IP are separate, non-overlapping, subsets within the Illumina Intellectual Property Rights.

 

“Intellectual Property Right(s)” means all rights in patent, copyrights (including rights in computer software), trade secrets, know-how, trademark, service mark and trade dress rights and other industrial or intellectual property rights under the laws of any jurisdiction, whether registered or not and including all applications therefor and registrations thereto.

 

“Pre-Release Sequencing Product” means Illumina sequencing hardware or Sequencing Consumables that are not available for purchase in Illumina’s product catalogue. Such sequencing hardware or Sequencing Consumables shall include any re-designed or modified products made available to any For-Profit Entity or to GRAIL that optimize, in any material respect, a product’s interoperability, capabilities, or performance.

 

“Sequencing Consumables” means those consumables intended by Illumina to be used to perform a sequencing process on Illumina’s NextSeq, NextSeqDx and NovaSeq instruments and any future sequencing hardware launched by Illumina or its Affiliates, and includes core consumables that are (i) commercialized or otherwise made available by Illumina to customers or Affiliates of Illumina and (ii) intended by Illumina to be used to perform a sequencing process on any such system. Sequencing Consumables do not include products that were at the “end of life” or “end of sale” or were announced (before January 1, 2021) to customers as a planned “end of life” or “end of sale”. Sequencing Consumables are limited to products that are shipped to and used in the United States.

 

“Short Term Project” means a project or circumstance giving rise to a discrete purchase of Sequencing Consumables outside of ongoing ordinary course of purchases made by a For-Profit Entity. The duration of a Short Term Project is no more than two years.

 

“Supplied Product(s)” means Illumina’s NextSeq, NextSeqDx and NovaSeq instruments, and any future sequencing instruments launched by Illumina or its Affiliates, or Sequencing Consumables,1 that are purchased by Customer for any Customer Use pursuant to the Supply Agreement. Supplied Products do not include products that were at the “end of life” or “end of sale” or were announced (before January 1, 2021) to customers as a planned “end of life” or “end of sale”. Supplied Products are limited to products that are shipped to and used in the United States.

 

 

1 The NextSeq and NovaSeq instruments and associated Sequencing Consumables are labeled “For Research Use Only. Not for use in diagnostic procedures.” They are subject to laws and regulations applicable to products with that label (e.g., 21 C.F.R. § 809.10(c)(2)(i)).

 

The NextSeqDx is an FDA-regulated device intended for targeted sequencing of DNA libraries from human genomic DNA extracted from peripheral whole blood or formalin-fixed, paraffin-embedded (FFPE) tissue, when used for in vitro diagnostic (IVD) assays performed on the instrument. The NextSeq 550Dx instrument is not intended for whole genome or de novo sequencing. The NextSeq 550Dx

 

2

 

 

“Transaction” means Illumina Inc.’s proposed acquisition of GRAIL, Inc. pursuant to the Agreement and Plan of Merger, dated September 20, 2020 (as amended on February 4, 2021 by the Amendment to the Agreement and Plan of Merger, the “Merger Agreement”), among Illumina, Grail, SDG Ops, Inc., a Delaware corporation and direct, wholly owned subsidiary of Illumina, and SDG Ops, LLC, a Delaware limited liability company and direct, wholly owned subsidiary of Illumina.

 

“Volume-Based Net Price” means the actual list price of a Supplied Product less the applicable discount for a customer’s volume under a volume-based discount schedule.

 

2.TERM

 

This Supply Agreement shall not be effective unless and until the Transaction closes, regardless of the date of signing. Once the Supply Agreement is effective, it shall be effective for twelve (12) years from the closing of the Transaction, regardless of the date either party signs this Supply Agreement (the “Term”).

 

3.TERMS & CONDITIONS

 

This Supply Agreement is subject to compliance with the terms and conditions herein and applicable law. Unless otherwise agreed with Customer, Illumina’s standard Terms & Conditions, as available in the below links, apply to the extent they do not conflict with this Exhibit A, and in the event of a conflict, the terms of Exhibit A supersede.

 

a.Terms and Conditions of Sale – Research Use Products:
 https://www.illumina.com/content/dam/illumina-marketing/documents/terms-
conditions/united-states/usa-terms-and-conditions-of-sale-general.pdf
   
b.Terms and Conditions of Sale – Illumina Advantage Products:
https://www.illumina.com/content/dam/illumina-marketing/documents/terms-
conditions/worldwide/terms-conditions-ai-products.pdf
   
c.Terms and Conditions of Sale – IVD Products:
  https://www.illumina.com/content/dam/illumina-marketing/documents/terms-
conditions/united-states/usa-terms-and-conditions-of-sale-ivd.pdf

 

 

instrument is to be used with registered and listed, cleared or approved, IVD reagents and analytical software.

 

3

 

 

4.ACCESS TO SUPPLIED PRODUCTS

 

a.            Access to Services. Customer shall have access to the same product services and support services for purchase relating to the Supplied Products to which GRAIL or any For-Profit Entity has access, or which Customer had access before the Transaction.

 

b.            Access to Supplied Products. Customer shall have access to the Supplied Products for purchase that GRAIL or any For-Profit Entity has access within 45 days of when GRAIL or such For-Profit Entity, as applicable, is offered such access (if not earlier) for purchase.

 

c.            Access to Pre-Release Sequencing Products. Customer shall have access for purchase to any Pre-Release Sequencing Product to which GRAIL or any For-Profit Entity is offered access within 45 days of when GRAIL or such For-Profit Entity, as applicable, is offered such access (if not earlier), and for the same categories of uses, specifically: (i) feedback to Illumina for development of NGS products, including through alpha or beta testing; (ii) for clinical trials; (iii) for clinical validation; (iv) for pre-commercial test development not relating to clinical trials; or (v) for a commercialized product developed by Customer. Customer’s purchase of any Pre-Release Sequencing Product is subject to the pricing terms in Section 5 in this Supply Agreement. This provision does not apply to Pre-Release Sequencing Products that are developed by Illumina for a specific For-Profit Entity pursuant to a development agreement under 4.d. with such For-Profit Entity.

 

d.            Development Agreement. Illumina shall enter into, upon Customer request, a separate development agreement with Customer on commercially reasonable terms, relating to the design or modification of any Supplied Product, in a manner that optimizes interoperability with Customer’s tests, including, without limitation, capabilities, performance, speed, efficiency, cost, convenience, accuracy, specificity, precision, ease of use and user experience.

 

e.            No Obsolescence. Illumina shall not discontinue any Supplied Product so long as Customer continues to purchase that Supplied Product. Illumina may discontinue a Supplied Product that Customer has not purchased in more than one year.

 

5.PRICING

 

Under the pricing protections in this section, Customer will be able to select one of two options for each Supplied Product that they purchase under this Supply Agreement. Customer may elect to receive the Grandfathered Pricing that Customer received before the close of the Transaction under 5.a. Because all of the Supplied Products that Customer currently purchases will remain available under 4.e, Customer may maintain its current pricing for the Term. A Customer who has elected Grandfathered Pricing under 5.a will also receive the benefit of the No Price Increases term in 5.c, the New Product Pricing under 5.d and Short Term Projects under 5.h.

 

Alternatively, Customer may elect to switch over to receiving Universal Pricing under 5.b, under which Customer purchases each Supplied Product under the pricing in Appendix 1. Under Universal Pricing, Customer will also receive the benefit of the No Price Increases provision for the Term of the Supply Agreement under 5.c. Customer will also receive pricing protections for new versions of existing Supplied Products under 5.d. As described in 5.d., Illumina also commits to certain lower pricing for Suppled Products. Under the Universal Pricing option, pursuant to 5.e and 5.f, Customer will also receive the benefit of any lower pricing offered to an Equivalent customer or to GRAIL, for any Supplied Product, and Customer will be notified of such triggering lower pricing under 5.g.

 

4

 

 

Finally, under either Grandfathered Pricing or Universal Pricing, Customer will also have access to pricing for Short Term Projects under 5.h.

 

a.            Grandfathered Pricing. Customer may continue to receive the benefit of any Grandfathered Pricing for the Term. If Customer elects to receive Grandfathered Pricing for a Supplied Product Customer shall not receive the benefit of the terms in sections 5.b and 5.e–5.g for that Supplied Product, but will receive the benefit of the terms in sections 5.c, 5.d and 5.h for that Supplied Product.

 

b.            Universal Pricing. If Customer is not receiving Grandfathered Pricing for a Supplied Product, Customer shall receive the Volume-Based Net Price for that Supplied Product in accordance with Appendix 1. The universal pricing grid in Appendix 1 contains all currently available universal pricing, including list prices and volume-based discount tiers, for currently available Supplied Products, and such Appendix 1 will be updated as additional pricing tiers or new Supplied Products (including new versions of existing Supplied Products) become available.

 

c.            No Price Increases. The inflation-adjusted (based on the Bureau of Labor Statistics’ Analytical Laboratory Instrument Manufacturing Index in the Producer Price Index (“PPI”)) Volume-Based Net Price (under Appendix 1) that Customer has access to for each Supplied Product purchased under this Supply Agreement over the twelve (12) year term of this Supply Agreement shall not increase. To the extent Illumina’s costs of goods sold for a Supplied Product materially increase due to factors beyond Illumina’s control, then the Volume-Based Net Price (under Appendix 1) may increase solely to reflect that cost increase and solely for the duration of that cost increase.

 

d.            New Product Pricing. To the extent that Illumina launches a new version of any Supplied Product (e.g., a sequencing instrument of similar throughput, or a Sequencing Consumable of the same sequencing read length and similar number of sequencing reads per flow cell), the inflation-adjusted (based on the PPI) Volume-Based Net Price per gigabase of sequencing shall not be higher as compared to the Volume-Based Net Price of the prior version of the Supplied Product, provided that the new version of the Supplied Product does not result in any material improvements in performance or capability. In addition, by 2025, Illumina commits that, under this Supply Agreement, the Volume-Based Net Price (under Appendix 1) to Customer per gigabase of sequencing using the highest throughput Illumina instrument then available, with the highest throughput, best-performance flow cell and kit then available, at full capacity, will be at least 43% lower than the inflation-adjusted (based on the PPI) Volume-Based Net Price (under Appendix 1 as of March 26, 2021), per gigabase of sequencing using the NovaSeq instrument, with an S4 300 flow cell, at full capacity. For the avoidance of doubt, holding volume constant, every customer (regardless of their application, or whether they are in oncology screening) using the highest throughput instrument and best-performance flow cell would observe by 2025 a reduction in price, under the Universal Pricing option, per gigabase of sequencing, of 43%. By way of example, for a customer at the highest volume discount tier today, the per gigabase sequencing price is $4, using a NovaSeq instrument with an S4 300 flow cell. Under this commitment, the per gigabase of sequencing price for that customer at the same volume discount tier in 2025 would be no greater than $2.26 (inflation-adjusted based on the PPI) using the highest throughput Illumina instrument then available, with the highest-throughput, best-performance flow cell and kit then available. To the extent Illumina’s costs of goods sold for a Supplied Product materially increase due to factors beyond Illumina’s control, then the Volume-Based Net Price (under Appendix 1) may increase solely to reflect that cost increase and solely for the duration of that cost increase.

 

5

 

 

e.            Equivalent Customer. If Customer is not receiving Grandfathered Pricing for Supplied Product, without limiting Section 5.f, Customer shall have access to Volume-Based Net Prices (under Appendix 1) for that Supplied Product that are no less favorable (i.e., the same or better) than the Volume-Based Net Prices provided by Illumina to an Equivalent customer after the date the Transaction closes, for that Supplied Product.

 

f.            GRAIL. If Customer is not currently receiving Grandfathered Pricing for Supplied Product, Customer shall have access to Volume-Based Net Prices (under Appendix 1) for that Supplied Product that are no less favorable (i.e., the same or better) than the Volume-Based Net Prices provided to GRAIL (including of transfer pricing, portability fees, and royalties), after the date the Transaction closes, for that Supplied Product.

 

g.            Notification and Refund. In the event that Sections 5.e or 5.f are triggered, Illumina will notify Customer promptly, and no later than 45 days after the end of the applicable Illumina fiscal quarter, and the pricing made available to Customer for the applicable Supplied Products will be reduced, effective as of the date on which GRAIL or the Equivalent customer received the triggering pricing, and Customer will receive such reduced pricing for the period of time that the triggering pricing is available to GRAIL or the Equivalent customer. With respect to units of Supplied Product ordered and invoiced pursuant to a Purchase Order accepted after the date the triggering purchase was made, and for which Customer has paid the applicable invoice, Illumina will refund to Customer the difference between the pricing made available to Customer and the triggering pricing, multiplied by the number of affected units of Supplied Product.

 

h.           Short Term Projects. Customer shall have access to Short Term Project pricing that is no less favorable (i.e., the same or better) than pricing extended to Equivalent customer or GRAIL for a Short Term Project of substantially similar size (i.e., using between 90% and 110% of the volume of Sequencing Consumables) and duration (i.e., for a period of not more than 3 months longer than the other Short Term Project), provided that Customer has requested such pricing. If Illumina offers GRAIL pricing for a Short Term Project under this section, Illumina shall make Customer aware of such pricing promptly, but in no event later than 45 days after the end of the applicable Illumina fiscal quarter. No customer, including GRAIL, may receive Short Term Project pricing for more than two consecutive years. No customer, including GRAIL, may use Short Term Project pricing for ongoing ordinary course purchases, including for its standard commercial testing. Pricing for Short Term Projects will not be considered as triggering with respect to the obligations in Sections 5.e and 5.f.

 

6.FDA

 

Customer may enter into, at any time from today, effective as of the closing of the Transaction, until the sixth anniversary of the closing of the Transaction, an agreement with Illumina under which Customer may develop and commercialize in-vitro diagnostic (“IVD”) test kits for use on Illumina’s diagnostic (“Dx”) sequencing platforms. Illumina will provide standard terms for Customer to enter into a stand-alone agreement to enable Customer to develop and commercialize IVD test kits on one or all of Illumina’s Dx sequencing platforms. Illumina shall provide any documentation or information reasonably required for Customer to seek FDA approval or FDA marketing authorization to sell a for-profit, clinical test using the Supplied Products.

 

6

 

 

7.PURCHASE ORDERS

 

This Supply Agreement is not contingent on any purchase commitments by Customer, nor does it affect Customer’s existing unilateral right to terminate its supply relationship with Illumina at any time and for any reason. Written purchase orders (“Purchase Orders”) submitted in accordance with this Supply Agreement, Illumina’s Terms and Conditions, or an operative supply agreement may be rejected by Illumina only if Illumina does not have sufficient supply of the applicable Supplied Product to fulfill the order or if the Purchase Order is not in accordance with standard lead times for the applicable Supplied Product.

 

8.SHORT SUPPLY

 

In the event Illumina is experiencing a supply shortage of the applicable Supplied Product (or components therein), Illumina will allocate the existing supply in an equitable manner among its customers (including Affiliates) based on expiring lots, and which shall not favor Affiliates over other customers.

 

9.INTELLECTUAL PROPERTY

 

a.            Core IP Rights. Customer’s purchase of Supplied Products under this Supply Agreement confers upon Customer the non-exclusive, non-transferable, personal, non-sublicensable right solely under Illumina’s Core IP to use the Supplied Products, only with Illumina hardware and software, and only in Customer facilities. Except as expressly stated in this Section 9 with respect to Core IP, no right or license under any Illumina Intellectual Property Rights is granted, expressly, by implication, or by estoppel, to Customer under this Supply Agreement.

 

b.            IP Infringement. In no event will Illumina have the right to cease shipping of the Supplied Product solely on the basis of any alleged claim of infringement of any intellectual property rights of Illumina.

 

10.CONFIDENTIAL INFORMATION

 

a.            Confidentiality. To the extent that Illumina may have access to confidential information (“Confidential Information”) of Customer in connection with this Supply Agreement or the provision of Supplied Products by Illumina to Customer, Illumina shall in no event share such Confidential Information of Customer with GRAIL or any subsidiary of GRAIL, or any employees who work within GRAIL. Any Confidential Information received shall be used by Illumina only (i) to perform Illumina’s product supply obligations, service or obligations under any agreement to Customer, or (ii) for performance of general business practices by non-technical functions (e.g., accounting, customer service) within Illumina, which functions shall have access to such information only on a need-to-know basis, and Illumina shall not use such Confidential Information for any other purpose, expressly including without limitation, for any of its own or Affiliates’ internal purposes. All employees who may receive Confidential Information will be advised of these confidentiality obligations and use restrictions. Illumina shall continue its practice of maintaining all Confidential Information of Customer confidential as to any other entity.

 

b.            GRAIL Firewall. Illumina shall establish a firewall designed to prevent any GRAIL personnel (and any Illumina personnel carrying out activities with respect to the GRAIL business or products) from accessing any Confidential Information obtained by or made available to Illumina relating to Customer or its business or products, whether pursuant to this Supply Agreement or otherwise.

 

7

 

 

11.TERMINATION

 

Customer has a unilateral right to terminate its supply relationship with Illumina at any time and for any reason without termination liability upon ninety (90) days’ prior written notice to Illumina, provided, however, that Customer shall honor all invoices, which invoices shall be issued upon shipment, for Supplied Products ordered under a Purchase Order that was accepted by Illumina prior to the termination date. Illumina cannot terminate this Supply Agreement for convenience during the Term. If either party materially breaches this Supply Agreement and fails to cure such breach within 60 days after receiving written notice of the breach, the non-breaching party shall have the right to terminate this Supply Agreement by providing written notice to the other party; provided, however, that if such breach is curable, but not reasonably curable within such 60-day period, and the breaching Party is using commercially reasonable efforts to cure the breach, then such cure period will be extended to not longer than 180 days. Notwithstanding anything to the contrary herein, this Supply Agreement may not be terminated based solely on a claim relating to infringement of any Illumina Intellectual Property Rights pursuant to Section 9.b.

 

12.ENFORCEMENT

 

a.            Audit. Illumina agrees to conduct an annual audit by an independent third-party auditor selected by Illumina from among the “Big 4” accounting firms to audit Illumina’s compliance with the commitments set forth herein. Illumina will provide Customers with a written report (with reasonable redactions) confirming compliance with the commitments set forth herein. Illumina shall provide cooperation, including access to necessary books and records, in support of any audit conducted. To the extent Customer has a good faith basis for alleging that Illumina is in breach of a commitment contained herein, Illumina shall engage an auditor to assess Customer’s allegation separate from and in addition to Illumina’s annual audit.

 

b.            Arbitration. If any dispute arises from or relates to this Supply Agreement, including as a result of a dispute over terms in a separate agreement that incorporates the terms herein (the “Dispute”), other than claims involving infringement, validity, or enforceability of Intellectual Property Rights (whether Illumina’s or Customer’s), or about the scope of Intellectual Property Rights in an agreement, Illumina and Customer (each a “party” and together the “parties”) shall submit the matter to confidential binding arbitration to determine final terms and conditions of the supply agreement, or to settle the dispute as to the terms of a supply agreement.

 

i.            Prior to submitting any matter to arbitration, Illumina and Customer shall each designate a contact having the proper authorization to resolve the Dispute in a final and binding fashion, who shall meet in person or by telephone for a period of thirty (30) days (or such other period of time as Illumina and the Customer shall mutually agree) in an attempt to resolve the Dispute in good faith.

 

ii.           The arbitration proceeding shall be conducted in accordance with the Commercial Arbitration Rules of the AAA and as otherwise described in this Section 12.b.

 

iii.          The location of the arbitration proceeding will be mutually agreed by the parties. In the event there is no agreement as to location, the arbitration proceeding will take place in New York City, NY.

 

8

 

 

iv.            Within five business days of the commencement of an arbitration, Customer and Illumina each shall furnish a legally binding writing to the other committing to maintain the confidentiality of the arbitration and of any written statement and discovery materials exchanged during the arbitration, and to limit the use of any such materials to the arbitration.

 

v.            Upon written request by either party to the other party, the parties shall promptly negotiate in good faith to appoint an appropriate Arbitrator. If the parties are not able to agree within ten (10) days after the receipt by a party of the written request in the immediately preceding sentence, the AAA shall be responsible for selecting an Arbitrator with relevant experience related to the dispute of at least ten (10) years and to do so within fifteen (15) days of being approached by a party. The fees and costs of the Arbitrator and the AAA shall be shared equally (50%/50%) by the parties. Each party to the arbitration shall bear its own legal fees and expenses.

 

vi.            Within twenty (20) days after the designation of the Arbitrator, the parties shall each simultaneously submit to the Arbitrator and one another a written statement of their respective positions on such Dispute. Each party shall have fifteen (15) days from receipt of the other party’s submission to submit a written response thereto. The Arbitrator shall have the right to meet with the parties, either alone or together, as necessary to make a determination. Further, the Arbitrator shall have the right to request information and materials and to require and facilitate discovery as it shall determine is appropriate in the circumstances, taking into account the needs of the parties and the desirability of making discovery expeditious and cost-effective determinations. In reaching a decision, the Arbitrator may consider only documents exchanged in discovery between the parties, testimony explaining the documents and the parties’ written statements and other materials submitted and arguments made by counsel.

 

vii.            No later than thirty (30) days after the parties each submit their written statements to the Arbitrator, or as otherwise agreed by the parties, the Arbitrator shall make a determination by selecting the resolution proposed by one of the parties that as a whole is the most consistent with this Agreement and the most fair and reasonable to the parties in light of the totality of the circumstances. The Arbitrator shall provide the parties with a written statement setting forth the basis of the determination in connection therewith, provided that the Arbitrator shall not have the authority to alter any explicit provision of the Supply Agreement. The decision of the Arbitrator shall be final, binding and conclusive, absent manifest error; judgment on the award may be entered in any court having jurisdiction. Neither party may disclose the existence, content, or results of any arbitration without the prior written consent of both parties, unless required by law.

 

viii.            The parties may, by agreement, modify any time periods specified in this Section 12.b. At any time after the commencement of arbitration, the parties may agree to suspend the arbitration, for periods not to exceed fourteen (14) days in the aggregate, to attempt to resolve their dispute through negotiation. The parties shall effectuate such suspension through a joint writing filed with the AAA. Either party may terminate the suspension at any time by filing with the AAA a writing calling for the arbitration to resume.

 

c.            Choice of Law. This Supply Agreement shall be governed by, and construed in accordance with, the laws of the State of New York, without giving effect to the conflicts-of-law principles thereof.

 

9

 

 

Appendix 1 to Exhibit A – Universal Consumables and Instruments Discount Schedules and List Price Catalogue

 

10

 

Exhibit B – IVD Test Kit Agreement Terms

 

In connection with Illumina Inc.’s proposed acquisition of GRAIL, Inc. (the “Transaction”), Illumina is offering to Caris the following terms. Caris may select from the terms below for any of three types of IVD Test Kit Agreements: An “All Platforms” Agreement described in the leftmost column, a “NextSeq” Agreement described in the middle column, or a “NovaSeq” Agreement, described in the rightmost column. Caris is referred to as “Customer” in Exhibit B. Any IVD Test Kit Agreement under the terms offered in this Exhibit B shall not be effective unless and until the Transaction closes, regardless of the date of signing.

 

Platform All Platforms NextSeq NovaSeq
Objectives and Applicable Instruments  

·      The parties would enter into an IVD Test Kit Agreement (the “Agreement”) to enable Customer to develop and commercialize distributable in-vitro diagnostic (IVD) test kits (“IVD Test Kits”) for use on Illumina’s NextSeq 550Dx and future Illumina regulatory approved Dx sequencing platforms, including the expected NovaSeqDx (“IVD Hardware”). 

 

·      Illumina does not guarantee that NovaSeqDx or any future platforms will receive regulatory approval in any jurisdiction.2

·      The parties would enter into an IVD Test Kit Agreement (the “Agreement”) to enable Customer to develop and commercialize distributable in-vitro diagnostic (IVD) test kits (“IVD Test Kits”) for use on Illumina’s NextSeq 550Dx sequencing platform (the “NextSeqDx”).    

·     The parties would enter into an IVD Test Kit Agreement (the “Agreement”) to enable Customer to develop and commercialize distributable in-vitro diagnostic (IVD) test kits (“IVD Test Kits”) for use on an Illumina platform for diagnostic purposes that is currently under development that is similar to the NovaSeq (the “NovaSeqDx”).

 

·      Illumina does not guarantee that NovaSeqDx will receive regulatory approval in any jurisdiction.3  

Number of IVD Test Kits ·      Unlimited ·      Up to three (3) ·     Up to three (3)
Territory ·      Worldwide, in jurisdictions where the applicable IVD Hardware has regulatory approval.

 

 

2 Illumina does not guarantee that the NovaSeqDx or any future platforms will be listed pursuant to applicable regulations in any jurisdiction.

 

 

 

 

Platform All Platforms NextSeq NovaSeq

Term

 

 

·      Term of Agreement (during which time Customer could sell IVD Test Kits) would be 15 years from the date the Transaction closes. Customer could enter into new IVD Plans for IVD Test Kit development during the first 10 years (the “Development Term”).

   

·      Continued Commercialization: After expiration of the Term, Customer may continue commercializing IVD Test Kits that were launched before expiration of the Term for so long as Illumina is still commercializing the applicable Sequencing Consumables and servicing and supporting the applicable IVD Hardware in the applicable Territory.

·      10 years from the date the Transaction closes.

   

·      Continued Commercialization: After the expiration of the Term, Customer may continue commercializing IVD Test Kits that were launched before the expiration of the Term for so long as Illumina is still commercializing the applicable Sequencing Consumables and servicing and supporting the NextSeqDx in the applicable Territory.

·      10 years from the later of (i) the date the Transaction closes or (ii) the date NovaSeqDx is listed with FDA in the U.S. pursuant to applicable law.

   

·      Continued Commercialization: After the expiration of the Term, Customer may continue commercializing IVD Test Kits that were launched before the expiration of the Term for so long as Illumina is still commercializing the applicable Sequencing Consumables and servicing and supporting the NovaSeqDx in the applicable Territory.

Financial Considerations

 

 

·      Tech Access Fee: [***]

 

·      Development Milestone Payments: [***]

   

·      Tech Access Fee: [***]

   

·      Development Milestone Payments: [***]

·      Tech Access Fee: [***]

   

·      Development Milestone Payments: [***]

 

2

 

 

Platform All Platforms NextSeq NovaSeq
  ·      Revenue Share: [***] ·      Revenue Share: [***] ·      Revenue Share: [***]
Governance for All Platforms Agreement ·      A Joint Steering Committee (“JSC”) composed of an equal number of representatives from each party would oversee the collaboration. ·      N/A ·      N/A
Additional End- User Technical Support for All Platforms Agreement

·      The parties would enter into one or more IVD Support Schedule(s) that would specify:

 

·      cross-training activities to facilitate customer support

 

·      a customer triage mechanism, including turnaround time requirements and an Information Transfer Form to facilitate customer hand-offs

·      N/A ·      N/A

 

3

 

 

Platform All Platforms NextSeq NovaSeq

 

 

 

·      timing and mechanism for review of customer support cases and quality/safety metrics

 

·      escalation procedures and adverse event reporting mechanisms

 

·      mechanism for discussing potential cross-product replacement processes

   
Additional Commercial Support for All Platforms Agreement ·      Upon Customer’s request, the parties would establish a joint commercialization committee (JCC) to discuss potential opportunities to collaborate commercially, including co-marketing and co-promotion opportunities, commercialization cross-training opportunities, lead generation joint campaigns, etc.  ·      N/A ·     N/A

 

 

·      Illumina would provide marketing materials concerning the IVD

Hardware and Sequencing Consumables for Customer’s use in commercializing the IVD Test Kits.

 

 

 

 

  ·      Customer would have the right to reference the name and catalogue number of the IVD Hardware and Sequencing Consumables used in an IVD System in marketing materials for the IVD Test Kit and to reference the Illumina-provided information concerning the Illumina sales organization or channel partner responsible for selling the IVD Hardware and Sequencing Consumables for a given country.    

 

4

 

 

Platform All Platforms NextSeq NovaSeq
 

·      On a semi-annual basis Illumina would share the following information concerning Illumina’s IVD Hardware install base to support Customer’s commercialization of IVD Test Kits:  

 

·      Total IVD Hardware instrument placements by Illumina in the Territory by region and by country  

 

·      Total IVD Hardware instrument placements by Illumina, sorted by Illumina-designated customer segment (e.g., academic medical center labs, IDN/regional hospital labs, community hospital labs, etc.)  

 

·      Total number of Customer sites who have purchased IVD Hardware from Illumina by customer segment

   

 

5

 

 

Platform All Platforms NextSeq NovaSeq
 

·      The Agreement would contain a mechanism for agreeing upon Commercial Plans for support of IVD Test Kit commercialization, including:

 

·      jurisdiction-specific commercialization planning, including connecting responsible Customer representatives and Illumina affiliates and channel partners who would operate in a particular jurisdiction

 

·      assistance with enabling third-party laboratories to perform pre-launch verification studies to ensure commercial readiness of the IVD Test Kit

 

·      mechanisms for providing assistance and documentation with respect to requests for public tender offers marketing materials Illumina would provide concerning the IVD Hardware and Sequencing Consumables for Customer’s use in commercializing the IVD Test Kits

   

 

6

 

 

Platform All Platforms NextSeq NovaSeq
         
Field ·     Field: Oncology, including risk assessment, screening, diagnosis, staging, prognosis, monitoring, and treatment selection.
  ·     Exclusion: Whole genome sequencing (“WGS”), meaning an assay that sequences all or substantially all of the genome to a depth greater than 10x and reports information concerning nucleotide base calls or variants in nucleotide sequence, structure, or copy number; provided, however, that WGS does not include any such assay that reports only genome-wide signals such as (a) DNA fragmentation patterns or (b) nucleotide base modification such as methylations.
  ·     For clarity, the field would not include forensic testing, non-invasive prenatal testing, pre-implantation genetic screening of embryos or pre-implantation genetic diagnosis of embryos, or human leukocyte antigen testing in connection with transplantation.
Exclusivity ·     Non-exclusive
IVD Systems and IVD Test Kits ·     Each IVD system (“IVD System”) would consist of, for the applicable agreement:
    ·      the IVD Hardware/the NextSeqDx/the NovaSeqDx
    ·      the associated core sequencing consumables used in the sequencing process (“Sequencing Consumables”)
    ·      an LRM software module (or software having similar functionality for use with NovaSeqDx or other future IVD Hardware) developed by Illumina to run the IVD Test Kit on the applicable IVD Hardware/the NextSeqDx/the NovaSeqDx (the “LRM Software Module”)
    ·      the IVD Test Kit
  ·     The IVD Test Kits would contain all reagents needed for the workflow (other than Sequencing Consumables) and Customer’s analysis software.
  ·     Customer would supply the IVD Test Kits and LRM Software Modules to end-users.
  ·     Illumina would supply the Sequencing Consumables and IVD Hardware/NextSeqDx/NovaSeqDx to end-users.
  ·     Each party would be responsible for development (other than Illumina developing the LRM Software Modules for Customer), regulatory approval, quality control, and commercialization of their products.
IVD Plans ·     Each IVD Test Kit, and the parties’ specific development obligations and timelines with respect to each IVD Test Kit, would be described in a development plan to be negotiated in good faith (each, an “IVD Plan”).

 

7

 

 

Platform All Platforms NextSeq NovaSeq
 

·      Customer would propose potential IVD Plans. Illumina may not unreasonably reject any proposed IVD Plan.

 

·      It would be deemed reasonable for Illumina to reject any proposed IVD Plan that: (a) is reasonably likely to cause Illumina or its Affiliate not to comply with Law, or result in a breach of any agreement or other arrangement to which Illumina or its Affiliate is a party; (b) would result in an IVD Test Kit that is reasonably likely to be used in a manner that is contrary to ethical guidelines promulgated by established national and international ethical bodies; (c) is reasonably likely to require Illumina to engage in any development activities after expiration of the Development Term (in the case of the all-platforms Agreement) or the Term (in the case of the NextSeqDx or NovaSeqDx Agreement); (d) is not technologically feasible or would require IVD Hardware/NextSeqDx/NovaSeqDx or Sequencing Consumables to be used in a manner outside standard, published, specifications or Illumina’s standard terms and conditions of sale; (e) is reasonably likely to result in an IVD Test Kit that violates or infringes upon the IP of a third party; or (f) requires Illumina to perform activities not specified in this Exhibit B or the Agreement.

Customer Responsibilities Development

·      Develop and obtain regulatory approval for the IVD Test Kits (including all related testing, studies, and regulatory submissions). IVD Hardware/NextSeqDx/NovaSeqDx instruments and Sequencing Consumables required for development would be purchased from Illumina under the terms and conditions specified in the Supply Agreement. Customer may enter into the Supply Agreement provided in Exhibit A to the Open Offer during the Open Offer Period.

 

·      Validate and obtain regulatory approval for the LRM Software Modules (including all related testing, studies, and regulatory submissions, other than the LRM Software Module verification done by Illumina).

 

Commercialization 

·      Manufacture and sell the IVD Test Kits and distribute the LRM Software Modules to end-users.

 

·      Maintain reasonable quality systems, consistent with industry standards and applicable legal requirements.

 

·      Provide reasonable product support and technical support, consistent with industry standards, for the IVD Test Kits and LRM Software Modules.

 

·      Refer to Illumina all support inquiries which Customer has reasonably determined to be caused by the IVD Hardware or Sequencing Consumables.

Illumina

Responsibilities

Development Development Development
     

 

8

 

 

Platform All Platforms NextSeq NovaSeq
 

·      Develop and verify the LRM Software Modules for the IVD Test Kits.

   

·      Supply Customer the IVD Hardware and Sequencing Consumables needed for development and testing of the IVD Test Kits.

   

·      Provide reasonable consultation in connection with Customer seeking, obtaining, and maintaining regulatory approvals for each IVD Test Kit and LRM Software Module.

   

·      Provide reasonable consultation with respect to performance optimization of IVD Test Kits with the IVD Hardware and Sequencing Consumables (which consultation would not involve technical development or testing).

   

·      Once per calendar year during the Development Term, the Illumina JSC members would provide the Partner JSC members with a general, high-level, presentation concerning Illumina’s in vitro diagnostic sequencing instrument pipeline, including a general description of instruments for which Illumina intends to seek Regulatory Approval during the following calendar year.

·      Develop and verify the LRM Software Modules for the IVD Test Kits.

   

·      Supply Customer the NextSeqDx and Sequencing Consumables needed for development and testing of the IVD Test Kits.

   

·      Provide reasonable consultation in connection with Customer seeking, obtaining, and maintaining regulatory approvals for each IVD Test Kit and LRM Software Module.

   

·      Provide reasonable consultation with respect to performance optimization of IVD Test Kits with the NextSeqDx and Sequencing Consumables (which consultation would not involve technical development or testing).

 

·      Illumina would not be required to obtain any regulatory approvals for the NextSeqDx or Sequencing Consumables or to otherwise expand or modify any regulatory approval for Sequencing Consumables or IVD Hardware (including any expanded sample type claim or additional regulatory approval in any jurisdiction(s)).

 

Commercialization

·      Develop and verify the LRM Software Modules for the IVD Test Kits.

   

·      Supply Customer the NovaSeqDx and Sequencing Consumables needed for development and testing of the IVD Test Kits.

   

·      Provide reasonable consultation in connection with Customer seeking, obtaining, and maintaining regulatory approvals for each IVD Test Kit and LRM Software Module.

   

·      Provide reasonable consultation with respect to performance optimization of IVD Test Kits with the NovaSeqDx and Sequencing Consumables (which consultation would not involve technical development or testing).

   

·      Illumina would not be required to obtain any regulatory approvals for the NovaSeqDx or Sequencing Consumables or to otherwise expand or modify any regulatory approval for Sequencing Consumables or IVD Hardware (including any expanded sample type claim or additional regulatory approval in any jurisdiction(s)).

 

Commercialization

       

 

9

 

 

Platform All Platforms NextSeq NovaSeq
 

·      Illumina would not be required to obtain any regulatory approvals for the IVD Hardware or Sequencing Consumables or to otherwise expand or modify any regulatory approval for Sequencing Consumables or IVD Hardware (including any expanded sample type claim or additional regulatory approval in any jurisdiction(s)).

   

·      Illumina would not be required to obtain any regulatory approvals for the IVD Hardware or Sequencing Consumables or to otherwise expand or modify any regulatory approval for Sequencing Consumables or IVD Hardware (including any expanded sample type claim or additional regulatory approval in any jurisdiction(s)).

   

Commercialization

 

·      Sell the IVD Hardware and Sequencing Consumables to end-users throughout the Change Period and use commercially reasonable efforts to sell Sequencing Consumables for an additional 5 years after the Change Period.

   

·      Provide product support and technical support to end-users for the IVD Hardware and Sequencing Consumables.

   

·      Refer to Customer all support inquiries which Illumina has reasonably determined to be caused by an IVD Test Kit or LRM Software Module.

·      Sell the NextSeqDx and Sequencing Consumables to end-users throughout the Change Period and use commercially reasonable efforts to sell Sequencing Consumables for an additional 5 years after the Change Period.

   

·      Provide product support and technical support to end-users for the NextSeqDx and Sequencing Consumables. 

   

·      Refer to Customer all support inquiries which Illumina has reasonably determined to be caused by an IVD Test Kit or LRM Software Module.

   

·      Provide second-tier product and technical support for the LRM Software Modules to Customer.

   

·      Provide Customer with the right to engage in quality audits to the extent required by applicable law and regulatory requirements.

 

·      Use commercially reasonable efforts to maintain existing regulatory approvals for the NextSeqDx and related Sequencing Consumables throughout the Change Period and for five years thereafter.

·      Sell the NovaSeqDx and Sequencing Consumables to end-users throughout the Change Period and use commercially reasonable efforts to sell Sequencing Consumables for an additional 5 years after the Change Period.

   

·      Provide product support and technical support to end-users for the NovaSeqDx and Sequencing Consumables.

 

·      Refer to Customer all support inquiries which Illumina has reasonably determined to be caused by an IVD Test Kit or LRM Software Module.

   

·      Provide second-tier product and technical support for the LRM Software Modules to Customer.

   

·      Provide Customer with the right to engage in quality audits to the extent required by applicable law and regulatory requirements.

 

·      Use commercially reasonable efforts to maintain regulatory approvals (once obtained) for the NovaSeqDx and related Sequencing Consumables throughout the Change Period and for five years thereafter.

 

10

 

 

Platform All Platforms NextSeq NovaSeq
 

·      Provide second-tier product and technical support for the LRM Software Modules to Customer.

   

·      Provide Customer with the right to engage in quality audits to the extent required by applicable law and regulatory requirements.

   

·      Use commercially reasonable efforts to maintain existing and new regulatory approvals (once obtained) for the IVD Hardware and related Sequencing Consumables throughout the Change Period and for five years thereafter.

   

·      During the Change Period for each IVD Hardware, Illumina would (a) provide at least 6 months’ notice for major, planned changes to the platform (IVD Hardware, Sequencing Consumables, or LRM Software Modules) and (b) notify Customer as soon as reasonably practicable of any major, unplanned changes to IVD Hardware, Sequencing Consumables, or LRM Software Modules. A major change is a change that Illumina reasonably expects to require Customer to make a filing or submission to any regulatory authority in connection with obtaining or maintaining regulatory approval for an IVD Test Kit.

During the Change Period, Illumina would (a) provide at least 6 months’ notice for major, planned changes to the platform (NextSeqDx, Sequencing Consumables, or LRM Software Modules) and (b) notify Customer as soon as reasonably practicable of any major, unplanned changes to the NextSeqDx, Sequencing Consumables, or LRM Software Modules. A major change is a change that Illumina reasonably expects to require Customer to make a filing or submission to any regulatory authority in connection with obtaining or maintaining regulatory approval for an IVD Test Kit.

 

During the Change Period, Illumina would (a) provide at least 6 months’ notice for major, planned changes to the platform (NovaSeqDx, Sequencing Consumables, or LRM Software Modules) and (b) notify Customer as soon as reasonably practicable of any major, unplanned changes to the NovaSeqDx, Sequencing Consumables, or LRM Software Modules. A major change is a change that Illumina reasonably expects to require Customer to make a filing or submission to any regulatory authority in connection with obtaining or maintaining regulatory approval for an IVD Test Kit.

 

 

11

 

 

Platform All Platforms NextSeq NovaSeq
 

·      Following a notice under (a) or (b) above, upon Customer’s reasonable request, Illumina would discuss with Customer the steps necessary to transition to modified or successor instruments, core consumables, or LRM software modules, if any, and Illumina would use commercially reasonable efforts to assist Customer with such transition.

   

Change Period

 

·      The “Change Period” for the NextSeqDx and its related Sequencing Consumables and LRM Software Modules would end no earlier than ten years from the date the Transaction closes.

 

·      For the NovaSeqDx and any other future IVD Hardware and their related Sequencing Consumables and LRM Software Modules, the Change Period would end no earlier than ten years from the date the Transaction closes. Illumina would ensure that all customers with IVD development agreements have the same Change Period for the applicable IVD Hardware, including any extensions to the Change Period Illumina may make from time to time.

Rights Grants

  

·      Illumina would grant Customer, by exhaustion, the right under Illumina core sequencing IP (but not any application-specific IP) to use the IVD Hardware and Sequencing Consumables purchased from Illumina under the Agreement to develop the IVD Test Kits.

 

·      Illumina would grant Customer a right to refer to the device listing for the IVD Hardware and Sequencing Consumables in support of seeking Regulatory Approval for the IVD Test Kits and to incorporate the information contained in the device listings into the submissions for the IVD Test Kits and LRM Software Modules by reference.

 

·      Illumina would grant a non-exclusive license to enable Customer to distribute the LRM Software Modules in executable object code to end-users. Customer would not receive access to the source code.

 

12

 

 

Platform All Platforms NextSeq NovaSeq

Sublicensing and Assignment ·      All rights and licenses granted to Customer would be personal, non-sublicensable, and non-transferable. The IVD Test Kits could be commercialized only under a Customer-owned brand and not as a private label or “white label” for any person other than Customer or under any original equipment manufacturer (OEM) arrangement. Customer would not have the right to assign or transfer the Agreement or any rights or obligations under the Agreement without the prior written consent of Illumina (which restriction would not apply to acquisitions of Customer where the Customer entity that is party to the Agreement does not change).
Change of Control

·      If Customer undergoes a Change of Control, Customer would notify Illumina within 5 business days.

 

·      Under any Change of Control, Customer would pay Illumina a $2M change of control fee.

Press Release ·      Any press release announcing the Agreement would be reviewed and approved by both parties.
GRAIL Firewall ·      Illumina shall establish a firewall designed to prevent any GRAIL personnel (and any Illumina personnel carrying out activities with respect to the GRAIL business or products) from accessing any Confidential Information obtained by or made available to Illumina relating to Customer or its business or products, whether pursuant to this Supply Agreement or otherwise.
Arbitration ·      If any dispute arises from or relates to an Agreement as to the terms set forth above, other than claims involving infringement, validity, or enforceability of intellectual property rights (whether Illumina’s or Customer’s), or about the scope of intellectual property rights in an Agreement, the Parties shall submit the dispute to confidential binding arbitration.
Additional Provisions ·      This document contains a high-level summary of certain terms of the Agreement. Additional standard provisions, such as confidentiality, compliance requirements, representations and warranties, indemnification, termination rights, revenue share reporting and audit rights, limitations on liability, force majeure, etc. would be included in the Agreement.
Choice of Law ·      This IVD Test Kit Agreement shall be governed by, and construed in accordance with, the laws of the State of New York, without giving effect to the conflicts-of-law principles thereof.

 

13

 

 

 

 

  Illumina, Inc.
5200 Illumina Way
San Diego, CA 92122
tel 858.202.4500
fax 858.202.4545
www.illumina.com

 

David D. Halbert  September 8, 2021

Chief Executive Officer
Caris MPI, Inc.
750 West John Carpenter Freeway
Suite 800
Irving, Texas 70539

 

Re: Additional Terms – Addendum to Supply Agreement

 

Dear Mr. Halbert:

 

With reference to the standard contract terms Illumina, Inc. (“Illumina”) made available to any U.S. oncology customer on March 30, 2021, specifically, Exhibit A to Illumina’s letter dated March 29, 2021 (“Exhibit A”), Illumina is irrevocably offering additional terms to further allay any concerns relating to Illumina’s August 18, 2021 acquisition (the “Tr hereafter as “GRAIL”).

 

Any terms used but not otherwise defined herein shall have the meanings ascribed to them in the March 29, 2021 Letter, including Exhibit A. T he terms of this addendum may be accepted any time from today until expiration of the Open Term for Exhibit A. The terms of this addendum shall become effective immediately upon Customer’s acceptance of these terms, and shall remain in effect during the Term for as long as GRAIL is an Affiliate of Illumina.

 

Under this addendum, each of the terms and conditions set forth in the Exhibit A shall continue to apply, in addition to or as modified by the supplemental terms provided in Exhibit C to this letter (together with Exhibit A, the “Supply Agreement”).

 

  Sincerely,
   
  /s/ Francis deSouza
  Francis deSouza
  Chief Executive Officer
       
  Accepted and Agreed:
   
  Caris /s/ David D. Halbert
   
  Name: David D. Halbert
  Title: CEO
  Date: 9/21/2022

 

 

 

Exhibit C – Additional Supply Agreement Terms

 

1.The following underlined text is hereby added to Section 4(a) of Exhibit A:

 

·“a. Access to Services. Customer shall have access to the same product services and support services for purchase relating to the Supplied Products to which GRAIL or any For-Profit Entity has access, or which Customer had access before the Transaction. For such services, Customer shall have access to the same volume-based pricing that GRAIL has access to for the equivalent level of service, or to which Customer had access before the transaction, at the Customer’s option.”

 

2.In Section 4(b) of Exhibit A, the clause “45 days of when GRAIL or such For-Profit Entity” is replaced with “5 days of when GRAIL or such For-Profit Entity”, such that the section reads:

 

·“b. Access to Supplied Products. Customer shall have access to the Supplied Products for purchase that GRAIL or any For-Profit Entity has access, within 5 days of when GRAIL or such For-Profit Entity, as applicable, is offered such access (if not earlier) for purchase.”

 

3.In Section 4(c) of Exhibit A, the clause “45 days of when GRAIL or such For-Profit Entity” is replaced with “5 days of when GRAIL or such For-Profit Entity”, such that the section reads:

 

·“c. Access to Pre-Release Sequencing Products. Customer shall have access for purchase to any Pre-Release Sequencing Product to which GRAIL or any For-Profit Entity is offered access within 5 days of when GRAIL or such For-Profit Entity, as applicable, is offered such access (if not earlier), and for the same categories of uses, specifically: (i) feedback to Illumina for development of NGS products, including through alpha or beta testing; (ii) for clinical trials; (iii) for clinical validation; (iv) for pre-commercial test development not relating to clinical trials; or (v) for a commercialized product developed by Customer. Customer’s purchase of any Pre- Release Sequencing Product is subject to the pricing terms in Section 5 in this Supply Agreement. This provision does not apply to Pre-Release Sequencing Products that are developed by Illumina for a specific For-Profit Entity pursuant to a development agreement under 4.d. with such For-Profit Entity.”

 

4.Section 4 of Exhibit A is hereby amended by adding the following Section 4(f) at the end thereof:

 

·“f. Access to Information. Customer shall have access to the same information about final product specifications of any new Supplied Product, any new version of a Supplied Product or any Pre-Release Sequencing Product within 5 days of when GRAIL is provided such information.”

 

5.Section 4 of Exhibit A is hereby amended by adding the following Section 4(g) at the end thereof:

 

·“g. GRAIL Purchases and Services. Illumina shall publish, on the “Oncology Contract Terms” website, (i) the Supplied Products, by SKU, that GRAIL is purchasing; (ii) the service plans, by SKU, that GRAIL is purchasing; and (iii) the pricing grid for both products and services under which GRAIL is purchasing Supplied Products and services. To the extent necessary, Illumina shall update this website within 5 days of entry of any purchase order for Supplied Products or any service contract relating to the Supplied Products by GRAIL. ”

 

1

 

 

6.Section 5(d) of Exhibit A is hereby amended by adding the following text at the end thereof:

 

·“The price for a new Supplied Product or a new version of a materially improved Supplied Product must be commercially reasonable. For any materially improved Supplied Product, the price of the new version must take into account the value of the improvement. For avoidance of doubt, in any arbitration in which the price of a new version of a Supplied Product or a new Supplied Product is disputed, the arbitrator is empowered to determine the reasonableness of the price, including the value of the any improvement in performance or capability, and to require that Illumina charge a price that is commensurate with the improvement, as well as require any associated refunds to Customer."

 

7.Section 12(a) of Exhibit A is hereby amended by:

 

·Replacing both instances of the term “annual” with the term “bi-annual (every 6 months)”; and

 

·Adding the following text at the end thereof: “In addition to providing the written report, in the event of any finding of potential noncompliance with Illumina’s performance under the Supply Agreement, Customer shall be notified within 10 days of identifying such a finding of potential noncompliance.”

 

8.Section 12(b) of Exhibit A is hereby amended by adding the following Section 12(b)(ix) at the end thereof:

 

·“ix. If the Arbitrator determines that Illumina has breached any provision of the Supply Agreement, the Arbitrator may order any relief necessary to restore the status quo prior to Illumina’s breach, including monetary and/or injunctive relief. In resolving any dispute under the Supply Agreement, the Arbitrator shall take into account, and the Arbitrator’s decision shall reflect, that the purpose of the Supply Agreement is to allay any concerns relating to the Transaction, including that Illumina would disadvantage GRAIL’s potential competitors after the Transaction by increasing their sequencing prices or by withholding access to Illumina’s latest innovations in NGS.”

 

2

 

 

Appendix 1 to Exhibit A – Universal Consumables and Instruments Discount Schedules and List Price Catalogue

 

 

 

Exhibit 10.2(b)

 

Certain confidential information contained in this document, marked by “[***]”, has been omitted because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.

 

MASTER SUPPLY AGREEMENT

 

This Master Supply Agreement is entered into and effective as of April 1, 2024 (the “Effective Date”) by and between Roche Diagnostics Corporation, an Indiana corporation with its principal offices at 9115 Hague Road, Indianapolis IN 46250 (“Roche”) and Caris MPI, Inc., a Texas corporation with its principal offices at 750 West John Carpenter Freeway, Suite 800, Irving, Texas 75039 (“Customer”). This Master Agreement sets forth the terms and conditions under which Customer agrees to purchase and/or use, equipment, products and/or services from the Roche Sequencing division that may be identified on the attached schedules and exhibits (“Schedules”) that are agreed upon by the Parties pursuant to this Master Agreement.

 

A.DEFINITIONS

 

For purposes of this Agreement, capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in this Article A.

 

1.    “Affiliate” means (a) an organization, which directly or indirectly controls a Party to this Agreement; (b) an organization, which is directly or indirectly controlled by a Party to this Agreement; or (c) an organization, which is controlled, directly or indirectly, by the ultimate parent company of a Party. Control as per (a) to (c) is defined as owning more than fifty percent of the voting stock of a company or having otherwise the power to govern the financial and the operating policies or to appoint the management of an organization. With respect to Roche, the term “Affiliate” shall not include Chugai Pharmaceutical Co. Ltd., 1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku Tokyo, 103-8324, Japan (“Chugai”) and Foundation Medicine, Inc., 150 Second Street, Cambridge, MA 02141, USA (“FMI”) and their respective subsidiaries, unless Roche opts for such inclusion of Chugai and/or FMI and their respective subsidiaries by obtaining prior written consent from Customer.

 

2.“Agreement” or “Master Agreement” means this Master Supply Agreement, including all Schedules, between Roche and Customer.

 

3.    “Calendar Year” means for any given year the period beginning on January 1 and ending on December 31.

 

4.    “Confidential Information” means any and all of the following information of Roche (and/or its Affiliates) or Customer (and/or its Affiliates) (each, a “Disclosing Party”) that may be hereafter disclosed by or on behalf of a Disclosing Party in any form, whether in writing, orally, electronically or otherwise, or otherwise made available by observation, inspection or otherwise by such Disclosing Party to the other Party (the “Receiving Party”): (a) all information that is a trade secret under applicable trade secret law or other legal principles; (b) all information concerning product specifications, formulations, and other specific and proprietary product information, including pricing; and (c) all information concerning the business and affairs of the Disclosing Party that is marked as confidential, or a reasonable person would consider to be confidential. For purposes of this Master Agreement, “Roche Confidential Information” shall mean Confidential Information that is disclosed hereunder by or on behalf of Roche and/or its Affiliates, and “Customer Confidential Information” shall mean Confidential Information that is disclosed hereunder by or on behalf of Customer and/or its Affiliates.

 

THIS AGREEMENT HAS BEEN APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT.
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.

 

Page 1 of 13

 

 

5.    “Party” or “Parties” means Roche and Customer, which are collectively referred to as “Parties” and each individually as a “Party.”

 

6.    “Product(s)” means the products, raw materials, and reagents detailed in each Schedule to this Master Agreement.

 

7.    “Purchase Order” means the firm, written orders (whether verbal, hard copy or electronic form) for the purchase, manufacturing and/or delivery of the Product(s) submitted by Customer to Roche.

 

8.    “Quality Claim” means a written notice delivered by Customer to Roche alleging that Products delivered to Customer (a) have suffered damage in transit, (b) do not match the quantities ordered, (c) fail to meet Specifications upon completion of Quality Testing, or (d) contain a Latent Defect.

 

9.    “Schedule” means each Schedule attached to this Master Agreement, including any and all attachments and exhibits thereto.

 

10. “Specifications” means the Roche description of the characteristics of a certain Product as set forth in the Certificate of Analysis (“CoA”) unless otherwise noted in the applicable Schedule or Exhibit.

 

B.GENERAL TERMS AND CONDITIONS

 

1.SCOPE OF MASTER AGREEMENT AND APPLICATION TO SCHEDULES. The terms and conditions contained in this Master Agreement shall govern each Schedule entered into by the Parties, unless a Schedule specifically provides otherwise.

 

2.PURCHASE ORDERS AND SHIPMENTS. Once a Purchase Order has been delivered to Roche, Roche will review each such Purchase Order, and such Purchase Order is presumed approved, unless Roche rejects such Purchase Order within forty-five (45) days. Each Purchase Order, once approved, shall constitute a binding obligation upon Customer and Roche. Roche will ship the Products specified to the facility specified by Customer in the applicable Purchase Order, which shall be located in the continental United States (the “Designated Facility”). Shipment dates shall be subject to standard lead times as set forth in the applicable Schedule. Customer is responsible for insurance on and damage to the Products immediately upon delivery to Customer’s Designated Facility. All freight, shipping, processing and special delivery charges shall be included on Roche’s invoices to Customer, and Customer agrees to pay same.

 

THIS AGREEMENT HAS BEEN APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT.
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.

 

Page 2 of 13

 

 

3.PRICING. The price for each Product is set forth in the applicable Schedule. Pricing is firm for the initial [***] of the Term. Thereafter, Roche reserves the right to increase pricing up to [***] per year. Price decreases may be considered with increased minimum order quantities as agreed upon by the Parties in this Agreement.

 

4.MINIMUM ORDER QUANTITIES: The Products can only be ordered in the minimum quantities specified in the applicable Schedule.

 

5.FORECASTS. [***].

 

6.PRODUCT QUALITY.

 

a.After delivery of a shipment of Products to Customer’s Designated Facility, Customer shall have (i) five (5) business days to determine whether the Products have been damaged in transit or fail to meet the quantities of Products ordered and submit a Quality Claim based thereon, and (ii) thirty (30) days to determine whether the Products conform to Specifications by undertaking visual inspections and commercially reasonable testing to determine conformity (“Quality Testing”) and submit a Quality Claim based thereon. After thirty (30) days have passed following delivery of Products to Customer’s Designated Facility without receipt of a Quality Claim, the Products shall be deemed to meet the Specifications, unless a Latent Defect (as defined below) is discovered. Thereafter, if a defect is discovered which causes Product(s) not to be in conformance with the Specifications which was not reasonably discoverable upon Quality Testing by Customer and was in no way caused by Customer (“Latent Defect”), Customer shall submit a Quality Claim to notify Roche of this Latent Defect. Any Quality Claims shall indicate in reasonable specificity the non-conforming characteristics of the Products. As promptly as possible after a submission of a Quality Claim by Customer, the Parties will work together cooperatively and in good faith to investigate and determine whether the Product meets the Roche Specifications, not any Customer specific requirements. Customer shall have no obligation to pay for the Products that are subject to the Quality Claims pending resolution of this investigation.

 

THIS AGREEMENT HAS BEEN APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT.
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.

 

Page 3 of 13

 

 

b.If this joint investigation confirms (i) the stated Quality Claim, and (ii) that the stated Quality Claim is Roche’s responsibility (a “Confirmed Claim”), then Roche shall, at Roche’s option: (1) if payment has already been made by Customer, provide Customer with a refund of the full amount paid by Customer for the non-conforming Products or issue Customer a credit against future billings equal to the full amount paid by Customer for the non-conforming Products, or (2) replace such defective or non- conforming Products with Products that conform to Specifications. The foregoing shall be Roche’s sole and exclusive liability, and Customer’s sole and exclusive remedies with respect to Products determined to be Confirmed Claims. If the stated Quality Claim either is determined not to be valid or is determined not to be Roche’s responsibility, then Customer shall accept and pay for the Products that were subject to the Quality Claim, and shall pay Roche’s reasonable costs of such joint investigation. If the stated Quality Claim is determined to be valid and Roche’s responsibility, then Roche shall pay Customer’s reasonable costs of such joint investigation.

 

c.Roche, at its option, may require that Customer return Products that are Confirmed Claims to Roche or dispose, in accordance with all applicable laws, of Products that are Confirmed Claims. Roche shall pay for all shipping costs of returning Products that are Confirmed Claims, or for all disposal costs incurred by Customer in connection with the disposal of Products that are Confirmed Claims. In the event Roche requests that Products that are Confirmed Claims be returned to Roche, Roche shall bear the risk of loss for such Products from the time such Products are picked up at Customer’s premises for return delivery.

 

7.FAILURE TO SUPPLY. In the event either Party anticipates that a disruption, shortfall, or cessation in supply of Product by Roche is likely to occur for any reason, such Party shall promptly notify the other Party, and the Parties shall discuss in good faith appropriate steps to alleviate such a shortfall. If Roche fails, for any reason, to deliver at least one hundred percent (100%) of the Product ordered by Customer on the agreed upon delivery date at Customer’s designated facility, and fails to cure such failure within forty-five (45) days (a “Failure to Supply”), Customer shall have the right to cancel all or any part of the corresponding Purchase Order.

 

8.PAYMENT TERMS. All payments are due thirty (30) days from the Roche invoice date.

 

9.TAXES. All sales taxes, value added taxes, duties, levies, surcharges or other similar charges and any penalties levied thereon that relate to any amounts paid for the Products hereunder shall be the responsibility of, and paid by, Customer. If Roche is required to pay any of these amounts, Customer shall reimburse Roche therefor or provide Roche at the time the order is submitted an exemption certificate or other document acceptable to the authority that is imposing the payment.

 

THIS AGREEMENT HAS BEEN APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT.
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.

 

Page 4 of 13

 

 

10.WARRANTY. Any and all warranties which may be provided with respect to any particular Product are detailed in the applicable Schedule and/or on the Product packaging/labeling, except that all warranties shall be voided upon any reformulation or chemical or other alteration or any other improper use or storage of a Product by Customer or its Affiliates or representatives. Any warranty provided with respect to any Product will begin on the date of shipment for that Product. CUSTOMER EXPRESSLY ACKNOWLEDGES AND AGREES THAT ROCHE MAKES NO OTHER REPRESENTATIONS GUARANTEES OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, REPRESENTATIONS, GUARANTEES OR WARRANTIES AS TO THE MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF PRODUCTS. Each Party further warrants that it will comply with all applicable laws and regulations with respect to its duties and obligations under this Agreement.

 

11.FIELD OF USE AND LIMITATIONS ON RESALE [B2C] Resale of Products are prohibited. All Products are intended for use solely by Customer. Products may not in any circumstances be resold by Customer without the prior written consent of Roche.

 

12.REGULATORY REQUIREMENTS. Unless explicitly stated otherwise in the Product labeling, Customer acknowledges that the Products under this Agreement are manufactured for “Research Use Only,” and are intended solely for use in basic or applied laboratory research, including the evaluation of the design, limited-scale performance, or usability of the product. Customer acknowledges that the Products are not intended to be used in clinical diagnostic, prognostic, or therapeutic indications. Customer's acknowledgment in the previous sentences recognizes the regulatory requirements of Roche, but it is not intended to limit the rights and obligations of Customer under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 and its subsequent amendments, as well as any other state and local requirements. Notwithstanding the foregoing, Customer is solely responsible for obtaining all requisite regulatory approvals and clearances and any other approvals, consents or other authorizations necessary for using such Products for any diagnostics purposes.

 

13.LABELING. Products (both kit and kit components) will be provided with standard label design and content unless otherwise noted in the applicable Schedule.

 

14.PACKAGING. Roche will design Product packaging configuration of best fit unless otherwise noted in the applicable Schedule.

 

15.QUALITY TESTING AND CERTIFICATE OF ANALYSIS. Products will be subject to standard functional and contamination testing and accompanied by a standard Certificate of Analysis unless otherwise noted in the applicable Schedule.

 

THIS AGREEMENT HAS BEEN APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT.
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.

 

Page 5 of 13

 

 

16.INTELLECTUAL PROPERTY.

 

a.Background IP. Subject only to the rights expressly granted under this Agreement, each Party shall retain all rights, title and interests in and to its Background IP, where “Background IP” means all intellectual property or intellectual property rights: (i) developed, owned or controlled by a Party as of the Effective Date of this Agreement; and/ or (ii) any additional feature or functionality, or any enhancement, refinement or advancement of any existing or additional feature or functionality of a Party’s Background IP to the extent such subsection (ii) intellectual property or intellectual property rights are solely developed by or for such Party and do not arise from or include Confidential Information of the other Party.

 

b.Improvements. Each of the Parties acknowledges and agrees that (i) ownership of improvements in and to the Products shall be determined in accordance with inventorship according to United States patent laws (each a “Product Improvement”); and (ii) any such Product Improvements to Products, and any modifications or improvements to workflows using Products, whether made by or on behalf of Customer, solely or jointly, shall remain exclusive to Customer, and shall constitute Customer Confidential Information (each, a “Customer Improvement”).

 

c.No Other Rights – Roche. Unless specifically granted otherwise, nothing contained in this Agreement shall be construed to grant Customer a license or in any way give ownership to any Roche-owned intellectual property or intellectual property rights, or any intellectual property or intellectual property rights owned by any Roche Affiliate or any third party.

 

d.No Other Rights – Customer. Unless specifically granted otherwise, nothing contained in this Agreement shall be construed to grant Roche a license or in any way give ownership to any Customer-owned intellectual property or intellectual property rights, or any intellectual property or intellectual property rights owned by any Customer Affiliate or any third party.

 

17.DEFAULT. A Party is in default under this Master Agreement if: (a) such Party does not perform any of its material obligations under the Master Agreement and this failure continues for forty-five (45) days after written notification of such failure; (b) such Party notifies the other Party that it does not intend to perform its obligations under this Master Agreement; (c) Customer or any Customer Affiliate offers Products for resale other than as allowed by this agreement; or (d) Roche’s disclosure of any Customer Improvement to a third party without Customer’s prior written consent to such disclosure.

 

18.REMEDIES.

 

a.Default by Roche. In the event of a default by Roche, Customer may (1) terminate this Master Agreement, with Roche remaining liable for all obligations which have not yet been met under the Master Agreement or any Schedule, and (2) exercise any and all other remedies available at law or in equity. Customer agrees that it will remain obligated to pay all sums owed to Roche prior to the date of termination and for any deliveries/fulfillment of obligations after the date of termination.

 

THIS AGREEMENT HAS BEEN APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT.
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.

 

Page 6 of 13

 

 

b.Default by Customer. In the event of a default by Customer, Roche may (1) terminate the Master Agreement and all Schedules, and collect all amounts owing or that become due under the Master Agreement and Schedules, including a late payment charge of [***] per month or the highest rate permitted by law, whichever is less; (2) if Products purchased during the then-current period are subject to tiered pricing based on Customer’s purchase volumes, retroactively bill Customer for Products to reflect actual Customer purchase volumes during such period; (3) require Customer to pay immediately the greater of (i) the difference between the applicable Annual Commitment and the amount of Products actually purchased by Customer and invoiced by Roche during such period, or (ii) the difference between the amount of Products subject to binding forecasts and the amount of Products actually purchased by Customer and invoiced by Roche during such period, if any; and (4) exercise any and all other remedies available at law or in equity.

 

c.Cumulative Rights. All of the remedies available are cumulative and may be exercised in any order.

 

d.Other Expenses. The defaulting Party agrees to reimburse the non-defaulting Party for all costs, expenses and damages, including reasonable attorney’s fees and all other expenses of collection incurred by the non-defaulting Party.

 

19.INDEMNITY / LIMITATION OF LIABILITY.

 

a.Indemnification by Roche. Roche agrees to indemnify and hold Customer, its directors, officers, employees, agents, successors and assigns harmless from all liabilities, including reasonable attorneys’ fees, arising out of any claim by a third party to the extent resulting from one or more of the following: (i) Roche’s gross negligence or willful misconduct, (ii) Roche’s breach of its warranties set forth herein, or (iii) Roche’s material failure to perform its duties or obligations as set forth in this Master Agreement or any Schedule, except, in each case, to the extent related to Customer’s negligence or willful misconduct.

 

b.Indemnification by Customer. Customer agrees to indemnify and hold Roche and its Affiliates, and their respective directors, officers, employees, agents, successors and assigns harmless from all liabilities, including reasonable attorneys’ fees, arising out of any claim by a third party to the extent resulting from one or more of the following: (1) Customer’s gross negligence or willful misconduct, (ii) Customer’s material failure to perform its duties or obligations as set forth in this Master Agreement or any Schedule, or (iii) the misuse, alteration or improper storage or handling of any Product(s) provided under this Master Agreement or any Schedule by Customer, or any Affiliate or representative of Customer, except, in each case, to the extent related to Roche’s negligence or willful misconduct. Additionally Customer agrees to indemnify and hold Roche harmless from all liabilities, including reasonable attorneys’ fees, to the extent arising as a result of use of non-Roche products, provided that the foregoing indemnification obligation will not apply to the extent such use of non-Roche products is authorized by Roche, is specified in Roche product manuals or literature, or is reasonably expected given the advertised or expected uses of the Product/s.

 

THIS AGREEMENT HAS BEEN APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT.
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.

 

Page 7 of 13

 

 

c.Third Party Claim of Infringement. If a claim of patent infringement or misappropriation or wrongful use of a trade secret or other proprietary right is brought against a Party hereto in any country by reason of any act conducted in the furtherance of this Master Agreement or any of its Schedules, or if a Party becomes aware of any act potentially infringing a patent or other proprietary right owned by a third party in any country related to the subject matter of this Master Agreement or any of its Schedules, such Party shall promptly give notice thereof to the other Party. Each Party shall indemnify, defend and hold harmless the other Party and its Affiliates, directors, officers, employees, agents, successors and assignees against any damages, costs, expenses and liabilities (including reasonable attorneys’ fees and expenses) arising out of a third party claim of patent infringement or misappropriation or wrongful use of a trade secret or other proprietary right to the extent that such damages, costs, expenses or liabilities are caused by the indemnifying Party’s products or actions in the furtherance of this Master Agreement or any of its Schedules. Notwithstanding the foregoing, Roche shall not be required to indemnify, defend or hold harmless any person under this paragraph with respect to the Products to the extent such claim is related to any combination, modification or other alteration made or action taken after delivery of the Products,

 

d.Indemnity Procedures. In any claim for indemnification (an “Indemnity Claim”), the indemnified Party agrees to give the indemnifying Party prompt written notice of any matter upon which such indemnified Party intends to base such a claim under this Agreement. Counsel shall be selected by the indemnifying Party. The indemnified Party may, at its sole option and expense, participate in such defense with counsel of its own selection, and further agrees to fully cooperate in the conduct of any such defense. With respect to any Indemnity Claim relating solely to the payment of money damages and which could not result in the indemnified Party’s becoming subject to injunctive or other equitable relief or otherwise adversely affect the business of the indemnified Party in any commercially significant manner, and as to which the indemnifying Party shall have acknowledged in writing the obligation to indemnify the indemnified Party hereunder, the indemnifying Party shall have the sole right to defend, settle or otherwise dispose of such Indemnity Claim, on such terms as the indemnifying Party, in its sole discretion, shall deem appropriate; provided that the indemnifying Party shall provide reasonable evidence of its ability to pay any damages claimed and with respect to any such settlement shall obtain the written release of the indemnified Party from the Indemnity Claim. The indemnifying Party shall obtain the written consent of the indemnified Party, such consent not to be unreasonably withheld, prior to ceasing to defend, settling or otherwise disposing of any Indemnity Claim if as a result thereof the indemnified Party would become subject to injunctive or other equitable relief or the business of the indemnified Party would be adversely affected in any manner. In the event that any such indemnity obligation shall be apportioned greater than 50% to any Party, that Party shall have the right to control the Indemnity Claim, subject to the participation and involvement of the other Party. EXCEPT FOR A BREACH OF ARTICLE B.23, CONFIDENTIALITY, AND WITHOUT LIMITING EACH PARTY’S INDEMNIFICATION OBLIGATIONS UNDER THIS SECTION, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

 

THIS AGREEMENT HAS BEEN APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT.
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.

 

Page 8 of 13

 

 

20.TERM AND TERMINATION. The initial term (“Term”) of this Agreement shall begin on the Effective Date and shall continue until the third anniversary of the Effective Date. Thereafter, this Agreement shall automatically renew for successive one (1) year terms (each a “Renewal Term”), unless earlier terminated as provided below in this Section, or unless one Party notifies the other in writing of its election not to renew no less than ninety (90) days prior to the end of the Term or the then current Renewal Term, as the case may be.

 

a.This Agreement may be terminated at any time upon the mutual agreement of both Parties in writing.

 

b.In the event of a Default under this Master Agreement or any Schedule, by either Party, as provided in Article B.18, Default, then the other Party may terminate this Agreement.

 

c.This Agreement shall terminate automatically if such Party becomes insolvent, dissolves or is dissolved, assigns its assets for the benefit of creditors or enters voluntarily into any bankruptcy or reorganization proceeding (or has failed for a period of at least sixty (60) days to dismiss any bankruptcy or reorganization proceeding that was filed against such Party involuntarily) or admits in writing its inability to pay its debts.

 

Termination of this Agreement, for any reason, shall not release any Party from any liability or any obligation which, at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination. In addition, termination of this Agreement shall not preclude either Party from pursuing any rights and remedies it may have hereunder at law or in equity, subject to any limitations set forth herein.

 

21.ASSIGNMENT. Neither this Agreement nor any of the rights, interests nor obligations hereunder may be assigned by either Party without the prior written consent of the other Party, which consent shall not be unreasonably withheld; provided that either Party may assign or otherwise transfer this Agreement to any Affiliate or to any to a successor who purchases all or substantially all of such Party’s business, whether by merger, purchase of assets or stock or other transaction or series of transactions without consent, and agrees to be bound by the terms and conditions of this Agreement on a going-forward basis. Such assigning or transferring Party shall give the other Party prompt written notice of such assignment or other transfer, and shall remain liable to the other Party for compliance with the terms and conditions of this Agreement prior to the effective date of such assignment or other transfer. Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective successors and permitted assignees, and no other person shall have any right, benefit or obligation under this Agreement as a third-party beneficiary or otherwise. Any assignment in violation of this Section is void.

 

THIS AGREEMENT HAS BEEN APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT.
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.

 

Page 9 of 13

 

 

22.CREDIT INFORMATION. Customer agrees to provide Roche with complete and accurate financial statements and other financial information that Roche reasonably requests from time to time, and Customer understands that Roche will obtain credit bureau reports and make credit inquiries as necessary. All financial information provided to Roche will be treated as confidential.

 

23.CONFIDENTIALITY. In the event that the Parties exchange Confidential Information, the following terms shall govern:

 

a.Confidentiality and Restricted Use. Each Receiving Party of Confidential Information hereunder acknowledges the confidential and proprietary nature of the Confidential Information of the Disclosing Party and agrees that, for a period of five (5) years following the expiration or termination of this Agreement, such Confidential Information (i) shall be kept confidential by the Receiving Party; (ii) shall not be used for any reason or purpose other than in furtherance of such Party’s performance of its obligations hereunder; and (iii) without limiting the foregoing, shall not be disclosed by the Receiving Party to any person or entity, except (1) in each case as otherwise expressly permitted by the terms of this Agreement, (2) with the prior written consent of an authorized representative of the Disclosing Party, or (3) its employees, officers, directors, managers, and professional advisors who have a need to know such information to perform such Party’s obligations under this Agreement and who are bound by a legal, ethical or contractual obligation at least as stringent as those contained herein to not use and keep confidential such Confidential Information.

 

b.Exceptions. The restrictions set forth above do not apply to that part of the Confidential Information of a Disclosing Party that the Receiving Party demonstrates (i) was, is or becomes generally available to the public other than as a result of a breach of this paragraph by the Receiving Party or its Affiliates or other representatives; (ii) was or is developed by or for the Receiving Party independently of and without reference to any Confidential Information of the Disclosing Party; or (iii) was, is or becomes available to the Receiving Party on a non-confidential basis from a third party not bound by a confidentiality agreement or any legal, fiduciary, or other obligation restricting disclosure.

 

THIS AGREEMENT HAS BEEN APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT.
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.

 

Page 10 of 13

 

 

c.Legal Proceedings. If the Receiving Party becomes compelled in any legal proceeding or is requested by a governmental body having the requisite legal or regulatory jurisdiction and authority, the Receiving Party shall provide the applicable Disclosing Party with prompt notice of such compulsion or request (if permitted by law) so that it may seek an appropriate remedy or waive compliance with the provisions of this paragraph. In the absence of a protective order or other remedy, the Receiving Party may disclose that portion (and only that portion) of the Confidential Information of the Disclosing Party that, based upon advice of the Receiving Party’s counsel, the Receiving Party is legally compelled to disclose or that has been requested by such governmental body; provided, however, that the Receiving Party shall use reasonable efforts to obtain reliable assurance that confidential treatment will be accorded by any person, entity or governmental body to whom any Confidential Information is so disclosed. The provisions of this paragraph do not apply to any legal proceedings between the Parties to this Agreement.

 

d.Return or Destruction of Confidential Information. Upon expiration or earlier termination of this Agreement, the Receiving Party shall promptly deliver to the Disclosing Party all Confidential Information of the Disclosing Party, together with all copies thereof, in the possession, custody or control of the Receiving Party or, alternatively, with the written consent of the Disclosing Party, destroy all such Confidential Information and certify such destruction in writing to the Disclosing Party; provided, however, that the Receiving Party may retain one copy of such Confidential Information in its legal department solely to facilitate the resolution of any controversies after the Disclosing Party’s Confidential Information is returned.

 

24.GOVERNING LAW, VENUE, and RIGHT TO JURY TRIAL. Customer agrees that the internal laws of the State of New York, without regard to choice of law principles, will govern this Master Agreement and all Schedules hereto, and any disputes concerning the subject matter addressed herein, and Customer consents to the exclusive jurisdiction of and venue in any state or federal court located within the State of New York. Each Party expressly waives its rights to trial by jury.

 

25.FORCE MAJEURE. Either Party’s obligations under this Agreement shall be suspended in the event that Party is hindered or prevented from complying with its obligations because of labor disturbances, wars, acts of domestic or international terrorism, fires, storms, earthquakes, accidents, floods, droughts, global health emergencies or pandemics (including the COVID-19 global pandemic), interferences or any other cause beyond its reasonable control.

 

26.ENTIRE AGREEMENT. Customer agrees that the terms and conditions in this Master Agreement and each Schedule (together with any attachments or exhibits thereto), if any, make up the entire agreement between Customer and Roche with respect to the subject matter hereof. In the event of a conflict between the terms of this Master Agreement and any Schedule (or any attachments or exhibits to a Schedule), the terms of the applicable Schedule shall control. The terms and conditions contained in any Purchase Order sent by Customer shall not apply.

 

THIS AGREEMENT HAS BEEN APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT.
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.

 

Page 11 of 13

 

 

27.NOTICES. All notices, consents, waivers and other communications required or permitted by this Agreement shall be in writing and shall specifically refer to this Agreement. Notices shall be sent via one of the following means and will be effective (a) on the date of delivery, when delivered in person or by nationally recognized overnight courier service (costs prepaid); (b) on the date of receipt, if sent by a PDF image sent by email or other electronic transmission (with delivery confirmed); or (c) on the date received or rejected by the addressee, if sent by first class certified mail, return receipt requested (or its equivalent). Notices shall be sent to the other Party receiving the notice at its address shown on the face of this Master Agreement.

 

28.USE OF TRADEMARK AND NAME. Customer may not use Roche’s or its Affiliates’ names or trademarks, or refer to or disclose the existence of this Agreement or the obligations performed hereunder, directly or indirectly, without the prior written consent of Roche’s Corporate Communications department, except as may be required by law or government regulation.

 

29.NON-WAIVER. No term or provision hereof shall be deemed waived and no breach excused unless such waiver or consent shall be in writing and signed by a duly authorized representative of the Party claimed to have waived or consented.

 

30.MISCELLANEOUS. The titles and headings used in this Agreement are for convenience only and shall not be used to interpret the terms and conditions of this Agreement. This Master Agreement is not binding on Roche until signed by an authorized representative of Roche. If either Party delays or fails to enforce any of its rights under this Master Agreement or any Schedule, such Party will be able to enforce its rights at a later time. The terms of this Master Agreement and all Schedules are Confidential Information and shall not be disclosed by either Party to any third party, except as may be required by law or government regulation.

 

31.BUSINESS REVIEWS. During the Term, Customer and Roche will meet quarterly at a mutually agreeable time and place or by telephone to review and discuss, in good faith, Customer’s next pending Purchase Order, as well the Parties’ performance and any issues or concerns arising under this Agreement.

 

[SIGNATURE PAGE TO FOLLOW]

 

THIS AGREEMENT HAS BEEN APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT.
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.

 

Page 12 of 13

 

 

THE UNDERSIGNED, BEING DULY AUTHORIZED SIGNATORIES, AGREE TO ALL TERMS AND CONDITIONS SET FORTH HEREIN AND THEY HEREBY EXECUTE THIS MASTER AGREEMENT.

 

Caris MPI, Inc. Roche Diagnostics Corporation
   
/s/ David D. Halbert /s/ Lyndsi Matthews
Signature Signature
   
David D. Halbert  
Printed Printed
   
CEO Franchise Manager
Title Title
   
6/25/2024 07/08/2024
Date Date

 

THIS AGREEMENT HAS BEEN APPROVED BY THE ROCHE DIAGNOSTICS LEGAL DEPARTMENT.
ANY CHANGE TO THE AGREEMENT REQUIRES LEGAL DEPARTMENT APPROVAL.

 

Page 13 of 13

 

 

SCHEDULE [Quote 5696054220]

 

EXHIBIT A: PRODUCTS AND PRICING

 

 

 

 

SCHEDULE [5696054220]

 

EXHIBIT B: FORECAST FOR FIRST TWELVE MONTHS

 

 

 

 

Exhibit 10.3(a)

 

LEASE AGREEMENT

 

WPT LAND 2 LP,

as Landlord

 

AND

 

23andMe, Inc.,

a Delaware corporation as
Tenant

 

AT

 

Workspace Cotton Center – Building 5

  

4415 Cotton Center Boulevard - Suite 100

Phoenix, Arizona 85040

 

 

 

 

LEASE AGREEMENT

 

INDEX

 

§ Section Page
     
1. Basic Lease Terms and Definitions 3
2. Premises 5
3. Use 5
4. Term; Option to Renew; Option of Early Termination; Possession 8
5. Rent; Taxes 11
6. Operating Expenses 12
7. Utilities; Services 15
8. Insurance; Waivers; Indemnification 19
9. Maintenance and Repairs 23
10. Compliance 24
11. Signs 27
12. Alterations 28
13. Mechanics’ Liens 30
14. Landlord’s Rights 30
15. Damage by Fire or Other Casualty 32
16. Condemnation 32
17. Quiet Enjoyment 32
18. Assignment and Subletting 33
19. Subordination; Mortgagee’s Rights 35
20. Tenant’s Certificate; Financial Information; Confidentiality 36
21. Surrender 37
22. Defaults - Remedies 38
23. Tenant’s Authority; OFAC 42
24. Liability of Landlord 43
25. Notices 43
26. Security Deposit 44
27. Broker 46
28. Mortgagee Approval 46
29. Tenant Improvements 46
30. Right of First Refusal 50
31. Miscellaneous 51

 

i

 

 

THIS LEASE AGREEMENT dated March 1, 2019, is made by and between WPT LAND 2 LP, a Delaware limited partnership (“Landlord”), and 23andMe, Inc., a Delaware corporation (“Tenant”).

 

For good and valuable consideration of the rents and covenants hereinafter set forth, the receipt and sufficiency of which are acknowledged, and the promises set forth herein, intending to be legally bound, Landlord hereby leases to Tenant, and Tenant hereby rents from Landlord, the following described Premises (as defined below) upon the following terms and conditions. Accordingly, Landlord and Tenant agree as follows:

 

1.Basic Lease Terms and Definitions.

 

(a)Premises: Suite 100, consisting of 21,001 rentable square feet of space on the first floor, as shown on Exhibit “A”.

 

(b)Building: Workspace Cotton Center Building 5, 4415 Cotton Center Boulevard, Phoenix, Maricopa County, Arizona 85040, consisting of 35,463 rentable square feet of space, being Tax Parcel No. 123-06-058.

 

(c)Term: Eighty-eight (88) consecutive months commencing on the Commencement Date.

 

(d)Commencement Date: The date Landlord delivers possession of the Premises to Tenant. If the Commencement Date occurs on a date other than the first day of a calendar month, there shall be added to the first Lease Year, the number of days comprising the remainder of the calendar month following the Commencement Date, and all annual increases in Minimum Annual Rent shall occur as of the anniversary of the first day of the first full month following the Commencement Date.

 

(e)Expiration Date: The last day of the Term.

 

(f)Minimum Annual Rent: Payable in monthly installments as follows:

 

  Dollar/Square       
Lease Month  Foot per Year   Annual   Monthly 
*1 - 16  $13.50   $283,514.00   $23,626.13 
17- 28  $13.91   $292,019.00   $24,334.91 
29 - 40  $14.32   $300,779.00   $25,064.96 
41 - 52  $14.75   $309,803.00   $25,816.90 
53 - 64  $15.19   $319,097.00   $26,591.41 
65 - 76  $15.65   $328,670.00   $27,389.15 
77 - 88  $16.12   $338,530.00   $28,210.83 

 

* Except as set forth in the next succeeding sentence, Monthly Rent based on the Minimum Annual Rent but not Annual Operating Expense (as defined below), payments (or the Management Fee which is a part of Operating Expenses and shall be calculated as if such monthly Minimum Annual Rent is being paid in full) or Additional Taxes (as defined below) payments, shall be abated (the “Abatement”) for the first three (3) full calendar months following the Commencement Date. Should this Lease be terminated during the initial Term by Landlord as a result of an uncured Event of Default (as defined below) by Tenant under this Lease, Landlord shall be entitled to recover from Tenant (in addition to all other rights and remedies available to Landlord) such Abatement.

 

3

 

 

(g)Annual Operating Expenses: Landlord’s good faith estimate of Annual Operating Expenses for 2019 is $4.60 per rentable square foot of space per year which amount excludes utilities and janitorial and trash removal expenses to be paid directly be Tenant as set forth in Section 7 below. Accordingly, from and after the Commencement Date, estimated Annual Operating Expenses shall be $92,004.60, payable in equal monthly installments of $7,667.05, subject to adjustment and reconciliation as provided in this Lease.

 

(h)Tenant’s Share: 59.20%, obtained by dividing the rentable square feet of the Premises by the rentable square feet of the Building.

 

(i)Use: General office, research and development laboratory, CLIA laboratory and life science production, warehousing, shipping and receiving, and uses incidental thereto.

 

(j)Security Deposit: One Hundred Thousand Dollars ($100,000.00).

 

(k)Addresses for Notices:

 

  If to Landlord:
    With a copy to:
     
  c/o Workspace Property Trust  
  700 Dresher Road McCausland Keen + Buckman
  Suite 150 80 W. Lancaster Avenue
  Horsham, PA 19044 4th Floor
  Attention: Anthony A. Nichols, Jr., Devon, PA 19333
  Senior Vice-President Attention: Stephan K. Pahides, Esq.
  E-mail: [***] Email: [***]

 

If to Tenant:

 

23andMe, Inc.

899 W. Evelyn Avenue

Mountain View, CA 94041

Attn: Chief Legal and Regulatory Officer

Email: [***]

Phone: [***]

 

4

 

 

(l)Brokers: Cushman + Wakefield, as Tenant’s broker, and CBRE, as Landlord’s broker.

 

(m)Guarantor: Not Applicable.

 

(n)Contents: The following are attached to and made a part of this Lease:

 

Exhibits:“A” - Plan Showing Premises “B” - Building Rules
    “C” – Payment Rider
    “D” – Parking Area Plan
    “E” - Tenant Estoppel Certificate Form
    “F” –Tenant Improvement Plans and Specifications
    “G”- Hazardous Materials List
    “H”- Sign Plans and Specifications
    “I”- Intentionally omitted

 

2.     Premises. Landlord leases to Tenant and Tenant leases from Landlord the Premises, together with the right in common with others to use the Common Areas. Tenant accepts the Premises, Building and Common Areas in their “AS IS” “WHERE IS” condition, without relying on any representation, covenant or warranty by Landlord other than as expressly set forth in this Lease. Notwithstanding the above, Landlord agrees to perform Landlord’s Work (as defined herein) and to deliver the Premises to Tenant with all Building Systems (as defined herein) in good working order and repair. Landlord and Tenant stipulate and agree to the rentable square footages set forth in Sections 1(a) and (b) above for all purposes with respect to this Lease. Following the Commencement Date, Tenant shall have access to the Premises twenty-four (24) hours per day, seven (7) days per week, fifty-two (52) weeks per year, subject to events beyond the reasonable control of Landlord and closures of the Premises permitted under this Lease. “Common Areas” means all areas and facilities as provided by Landlord from time to time for the use or enjoyment of all tenants in the Building or Property, including, if applicable and without limitation, lobbies, public hallways, public restrooms, fire stairs, elevators, driveways, sidewalks, parking, loading areas, landscaped areas, mechanical and fan rooms, janitor closets, electrical and telephone closets, pipe and elevator shafts, vertical ducts, structural components of the Building excluding the Building Structure (as defined below), and all other general Building or Property components, facilities, and fixtures that serve or are available to more than one (1) tenant at the Property. “Land” means the lot or plot of land on which the Building is situated or the portion thereof allocated by Landlord to the Building. “Property” means the Land, the Building, adjoining parking areas, sidewalks, driveways, landscaping and additional buildings situate thereon if applicable, and the Common Areas.

 

3.Use.

 

(a)               Tenant shall occupy and use the Premises only for the Use specified in Section l above, and pursuant to the Building Rules (as defined hereunder). Without limited the generality of the foregoing, Tenant shall not use the Premises for any on-site retail sales. Tenant waives any implied warranty of Landlord that the Premises is suitable for Tenant’s intended commercial purpose or Tenant’s permitted Use or for any other purpose under any and all applicable zoning ordinances or regulations. Tenant shall not permit any conduct or condition which may endanger, disturb or otherwise interfere with any other Building occupant’s normal operations or with the management of the Building. Tenant may use all Common Areas only for their intended purposes. Subject to Tenant’s use of the Common Areas and the terms of this Lease, Landlord shall have exclusive control of all Common Areas at all times. “Building Rules” means the rules and regulations attached to this Lease as Exhibit “B” as they may be amended from time to time. In the event of any conflict between the Building Rules and this Lease, this Lease shall control. Tenant shall be responsible, at its sole cost and expense, to obtain all required permits, approvals, zoning change or variance required by the City of Phoenix for Tenant’s Use including, without limitation, the operation of its business and the completion of Tenant’s Improvements (as defined below) and of any Alterations (as defined below) installed by or on behalf of Tenant to the Premises for the conduct of its business, but the failure of Tenant to obtain any or all such permits and approvals shall not affect the validity of this Lease. Tenant understands, agrees and acknowledges that neither Landlord nor its Agents have made any representation or warranty that Tenant’s intended Use is permitted under the City of Phoenix zoning ordinance applicable to the Property.

 

5

 

 

(b)               Tenant shall have the right, at Tenant’s sole risk and responsibility, and pursuant to the Building Rules, to use, on a non-exclusive basis in common with other tenants and visitors of the Building, forty-eight (48) unreserved, uncovered parking spaces on the Property and twelve (12) reserved canopy parking spaces (the “Covered Parking Spaces”) on the Property at the location, all as shown on Exhibit “D”, attached hereto and made a part hereof (the “Parking Area”). Tenant will have exclusive parking rights to the twelve (12) Covered Parking Space in the Parking Area identified as “Tenant’s Reserved Parking Area” as depicted on Exhibit “D”. Tenant will, upon request, promptly furnish to Landlord the license numbers of the cars operated by Tenant and its subtenants, invitees, concessionaires, licensees and their respective officers, agents and employees and which are expected to be parked at the Property from time to time. Notwithstanding the foregoing, Landlord is under no obligation to enforce Tenant’s parking rights granted hereunder and Landlord shall have no liability to Tenant for any unauthorized parking of any vehicles within the Parking Area. The Parking Area provided for herein is provided as a license solely for the accommodation of Tenant and other Building occupants or invitees, and Landlord assumes no responsibility or liability of any kind whatsoever from whatever cause with respect to the automobile Parking Areas, including adjoining streets, sidewalks and passageways, or the use thereof by Tenant or tenant’s employees, customers, agents, contractors or invitees. Tenant may not assign, transfer, sublease or otherwise alienate the use of the Parking Area without Landlord’s prior written consent except in connection with an assignment, transfer or sublease of this Lease approved by Landlord or permitted under Section 18(b) below. The Covered Parking Spaces shall be subject to a charge of Thirty-Five Dollars ($35.00) per Covered Parking Space per month during the Term, payable in same manner and time as Minimum Annual Rent. Landlord shall have the right to relocate all or any of the surface parking spaces of the Covered Parking Spaces to areas within reasonably close proximity to the Leased Premises. Any such relocation of the Covered Parking Spaces shall be at Landlord’s sole cost, and the relocated covered parking spaces shall be covered. Such relocated covered parking spaces may, but are not required to, be located within a structured parking facility. Landlord acknowledges that Tenant may be parking at the Property twenty-four hours a days, seven days a week, and such parking may include Tenant’s trucks.

 

6

 

 

(c)               Without the prior written consent of Landlord, and except as required under applicable Laws (as defined below) or regulatory agency rules (including those of the SEC), Tenant shall not Publicize (as defined hereunder) in any medium this Lease or the negotiations for, or the terms, conditions or provisions included in it, provided, however, that Tenant may announce the fact that this Lease has been signed and the size of the Premises. “Publicize” as used in the preceding sentence means public dissemination of information for marketing or promotional purposes, whether by press release, in printed or digital marketing materials, on a website, or otherwise. Landlord shall not have the right to use or Publicize any trademark, trade name, trade dress or any name, picture or logo which is commonly identified with Tenant, and shall have no right to use any rights in or to any such trademark, trade name, trade dress or any name, picture or logo of Tenant. Landlord may also: (i) include Tenant’s name in any description of this Lease in any offering materials related to the sale or other transfer of the Building; (ii) disclose the details of this Lease to prospective lenders, purchasers or other transferees of Landlord’s interest in the Property; (iii) photograph the Premises, which images may include Tenant’s trademark, trade name, trade dress or any name, picture or logo which is commonly identified with Tenant, for Landlord’s use in its website or printed promotional and marketing materials; and, (iv) publicize this Lease (without naming Tenant unless Tenant consents) after the Commencement Date. Any press release issued by either party regarding this Lease shall be subject to the prior approval of both parties, which approval shall not be unreasonably withheld, delayed or conditioned.

 

(d)               Landlord hereby discloses to Tenant that the Premises and Building are a portion of a larger development known as Cotton Center, and that Cotton Center consists of certain improvements for the benefit of all owners and occupants in Cotton Center, in accordance with, and under and subject to that certain Declaration of Covenants, Conditions, Easements and Restrictions dated December 24, 1998, recorded in Instrument No. 98-1169019, as amended from time-to-time (collectively, the “Cotton Center CC&Rs”). Pursuant to the Cotton Center CC&Rs, residents of Cotton Center are assessed association fees and other charges, which cover, among other items, repair and maintenance of improvements within Cotton Center, such as sidewalks, curbs, landscape areas, fountains and lighting and such charges are part of Tenant’s Share of Operating Expenses. This Lease is subject to all terms and conditions of such Cotton Center CC&Rs. Landlord acknowledges that Tenant’s proposed use of the Premises is for establishing a clinical testing laboratory. Laboratory will be licensed in accordance with Clinical Laboratory Improvement Act (CLIA). The principle specimen type will be non-infectious saliva and the testing performed will be genotyping DNA extracted from the specimen.

 

(e)               Landlord hereby discloses to Tenant that the Premises and Building are also part of a development known as Allred Cotton Center, within Cotton Center, and that Allred Cotton Center consists of certain improvements for the benefit of all owners and occupants in Allred Cotton Center, in accordance with, and under and subject to that certain Declaration of Covenants, Conditions and Restrictions and Grant of Easements dated November 3, 2000, recorded in Instrument No. 2000-0862293, as amended from time-to-time (collectively, the “Allred CC&Rs”). Pursuant to the Allred CC&Rs, residents of Allred Cotton Center are assessed association fees and other charges, which cover, among other items, repair and maintenance of improvements within Allred Cotton Center, such as sidewalks, curbs, landscape areas, fountains and lighting and such charges are part of Tenant’s Share of Operating Expenses. This Lease is subject to all terms and conditions of such Allred CC&Rs.

 

7

 

 

4.Term; Option to Renew; Option of Early Termination; Possession.

 

(a)               The Term of this Lease shall commence on the Commencement Date and shall end on the Expiration Date, unless sooner terminated in accordance with this Lease. If Landlord is delayed in delivering possession of all or any portion of the Premises to Tenant as of the Commencement Date, this Lease will not be void or voidable, nor will Landlord be liable to Tenant for any loss or damage resulting therefrom, but in that event, the Term will commence on the date Landlord delivers possession of the Premises to Tenant in the condition required herein, which date will then become the Commencement Date (and the Expiration Date will be extended so that the length of the Term remains unaffected by such delay) and the Monthly Rent due for any partial month shall be prorated on a per diem basis. Tenant acknowledges that neither Landlord nor its Agents (as defined below) have agreed to undertake any alterations or construct any Tenant improvements to the Premises except as expressly set forth in Section 29 below. Within five (5) days after receipt of a request from Landlord, Tenant shall execute and deliver a certificate in form and substance reasonably required by Landlord confirming the Commencement Date and the Expiration Date, but the failure to do so shall not alter the terms of this Lease, and in such event, Landlord’s determination of such dates shall be deemed accepted. For purposes of this Lease, the term “Lease Year” means the period from the Commencement Date through the succeeding twelve (12) full calendar months (including for the first Lease Year any partial month from the Commencement Date until the first day of the first full calendar month) and each successive twelve (12) month period thereafter during the Term, and any Renewal Term (as defined hereunder).

 

(b)               Landlord shall not be liable for any loss or damage to Tenant resulting from any delay in delivering possession of the Premises to Tenant due to the holdover of any existing tenant, other circumstances outside of Landlord’s reasonable control, any event of Force Majeure (as defined below), or any event or act by, or caused by Tenant or Tenant’s Agents (as defined below) (collectively, an “Excused Delay”), nor shall any delays affect the continuation or validity of this Lease. For purposes of this Lease, “Agents” of a party means such party’s employees, agents, servants, representatives, independent contractors, subcontractors, designees, licensees or invitees and in the case of Landlord only, shall include without limitation, Workspace Property Management, L.P., Workspace Property Trust, L.P., and any other associated or affiliated entity.

 

(c)               Provided that (i) there then exists no Event of Default by Tenant under this Lease, and (ii) Tenant, its Strategic Partners, and its Permitted Transferees (as such terms are defined below) occupy at least 50% of the Premises, Tenant shall have the right and option to extend the Term of this Lease for one (1) additional sixty (60) month period (the “Renewal Term”), commencing as of the date immediately following the Expiration Date on the same terms and conditions as are in effect on the last day of the Term except that no Abatement or Tenant Improvement Allowance shall be continued, and the Minimum Annual Rent shall be the FMV (as defined below), as determined by Landlord and Tenant using the standard set forth in Section 4(c)(ii) of this Lease (the “Renewal Option”).

 

(i)               The Renewal Option is exercisable by Tenant giving Landlord prior written notice of Tenant’s election to extend the Term (“Renewal Notice”), on or prior to the date which is twelve (12) months prior to the Expiration Date; it being agreed that time is of the essence with respect to the Renewal Notice. If and when the Renewal Term is in effect, all references to the Term of this Lease, shall be deemed to mean the Renewal Term. This Renewal Option is personal to Tenant and is non-transferable to any assignee, subtenant (regardless of whether any such assignment or sublease was made with or without Landlord’s consent) or other party, other than Permitted Transferee. Within thirty (30) days after Landlord receives notice of Tenant’s Renewal Notice, but in no event prior to the date that is more than twelve (12) months prior to the Expiration Date, Landlord will give notice to Tenant (the “Rent Notice”) of Landlord’s opinion of the FMV and comparing the FMV to the Minimum Annual Rent payable in the immediately preceding Lease Year. If Tenant does not respond to the Rent Notice within thirty (30) days after receiving it, Landlord’s opinion of the FMV shall be deemed accepted as the Minimum Annual Rent due for each Lease Year of the Renewal Term. If, during such thirty (30) day period, Tenant gives Landlord notice that Tenant contests Landlord’s determination of the FMV (an “Objection Notice”), which notice must contain therein Tenant’s opinion of the FMV, the parties may then negotiate to determine a FMV acceptable to both parties to arrive at a mutually agreeable Minimum Annual Rent for each Lease Year of the Renewal Term. When the parties come to an agreement, they will both execute an amendment to this Lease, establishing the Minimum Annual Rent for each Lease Year of such Renewal Term. Following the exercise of this Renewal Option, Tenant shall not have any further renewal rights. If, within twenty (20) days after Landlord’s receipt of the Objection Notice the parties have not signed such an amendment to this Lease, the parties agree to submit the determination of Minimum Annual Rent applicable to the Renewal Term to arbitration as set forth in Section 4(c)(iii) of this Lease below (the “Arbitration Election”).

 

8

 

 

(ii)               “FMV” shall mean, for the purposes of this Section 4(c)(ii), as of the date in question, the fair market value of the then current annual rental charge, including provisions for subsequent increases and other adjustments for leases or agreements to lease then currently being negotiated, or executed in comparable space located in the Building, the office/laboratory park of which the Building is a part, and leases or agreements to lease then currently being negotiated or executed for comparable class A office/laboratory space located elsewhere in office/laboratory buildings located in the City of Phoenix, Arizona sub-market, for a term commencing on or about the Expiration Date. In determining FMV, the following factors, among others, shall be taken into account and given effect: size, location of premises, lease term, condition of the building, condition of the premises, economic strength of the tenant, pass-throughs paid by tenants, commissions payable in connection with the leasing, economic concessions (including free rent, tenant improvements being performed by landlords for tenants, or tenant improvement allowances being granted by landlords to tenants), then being granted by landlords to tenants and services provided by landlords. The value of any Tenant Improvements or Alterations installed by Tenant at its own expense and not using any of the Tenant Improvement Allowance shall not be taken into account in determining FMV.

 

(iii)               If the parties submit to the Arbitration Election, FMV shall be determined by impartial arbitrators, one (1) to be chosen by the Landlord, one (1) to be chosen by Tenant, and a third (3rd) to be selected, if necessary, as below provided. The unanimous written decision of the two (2) first chosen, without selection and participation of a third (3rd) arbitrator, or otherwise, the written decision of a majority of three (3) arbitrators chosen and selected as aforesaid, shall be conclusive and binding upon Landlord and Tenant. Landlord and Tenant shall each notify the other of its chosen arbitrator within ten (10) business days following the Arbitration Election and, unless such two (2) arbitrators shall have reached a unanimous decision within thirty (30) days after their designation, they shall so notify the then President of the Maricopa County or City of Phoenix Board of Realtors (or such organization as may succeed to said Maricopa or City of Phoenix County Board of Realtors) and request him/her to select an impartial third (3rd) arbitrator, who shall be an office/laboratory building owner, a real estate counselor or a broker familiar with similar types of office /laboratory space properties, to determine FMV as herein defined. Such third (3rd) arbitrator and the first two (2) chosen shall, subject to commercial arbitration rules of the American Arbitration Association, hear the parties and their evidence and render their decision within thirty (30) days following the conclusion of such hearing and notify Landlord and Tenant thereof. All arbitrators shall not have been employed or retained by either Landlord or Tenant or any affiliate of either for a period of at least five (5) years prior to appointment pursuant hereto. Landlord and Tenant shall bear the expense of the third (3rd) arbitrator (if any) equally. The arbitrators shall be real estate brokers with at least ten (10) years full-time commercial brokerage experience who are familiar with the FMV of first-class office/laboratory space in the Phoenix area. If the dispute between the parties as to a FMV has not been resolved before the commencement of Tenant’s obligation to pay Rent based upon such FMV, then Tenant shall pay Minimum Annual Rent and other charges under the Lease for the Premises based upon the FMV designated by Landlord until either the agreement of the parties as to the FMV, or the decision of the arbitrators, as the case may be, at which time Tenant shall pay any underpayment of Rent and other charges to Landlord, or Landlord shall refund any overpayment of Rent and other charges to Tenant.

 

9

 

 

(d)               Tenant shall have the one-time right and option (the “Termination Option”), exercisable by giving Landlord a minimum of twelve (12) months prior written notice thereof, to terminate this Lease as of the end of the thirty-sixth (36th) month after the Commencement Date, stating that Tenant is exercising its limited right of early termination (the “Early Termination Notice”), provided that (i) this Lease is then in effect, and (ii) no Event of Default has occurred and is continuing prior to such Early Termination Notice date. The date Tenant actually terminates this Lease shall be known as the “Early Termination Date”. This limited early termination right is personal to Tenant and is non-transferable to any assignee, subtenant (regardless of whether any such assignment or sublease was made with or without Landlord’s consent), or other party, other than a Permitted Transferee. Any assignment or sublease under this Lease then in effect shall likewise terminate on the Early Termination Date. At the time of providing such Early Termination Notice, and as a condition to such early termination, Tenant must concurrently deliver to Landlord payment in an amount equal to the aggregate of: (a) six (6) full month’s Minimum Annual Rent at the then current or applicable rental rate; and (b) the Unamortized Transaction Costs (as hereinafter defined) (the “Early Termination Payment”). Tenant shall pay all Rent under the Lease and abide by all of the terms and conditions of the Lease through and including such Early Termination Date. If the Early Termination Notice is not accompanied by such Early Termination Payment, the Early Termination Notice shall be deemed null and void and this Lease shall continue in full force and effect. The term “Unamortized Transaction Costs” shall mean: (1) the unamortized amount of the Tenant Improvement Allowance or any part thereof issued to Tenant; (2) the unamortized amount of commissions, if any, that shall have been paid or shall become payable to the Broker in connection with this Lease; (3) the unamortized amount of actual legal, engineering and other consultant fees that shall have been paid by Landlord in connection with this Lease; and (4) if applicable the unamortized amount of the Additional Tenant Allowance or any part thereof issued to Tenant. The term “unamortized amount” means the balance of the amount remaining on the Early Termination Date after amortizing the amounts in clauses (1), (2) and (3) of this Section 4(d), based upon an amortization term equal to the Term, using a hypothetical interest rate of 9.0% per annum, and the amounts in clause (3) of this Section 4(d), based upon an amortization term equal to the Term, using a hypothetical interest rate of eleven percent (11%) per annum, compounded monthly, with payments in arrears, on a level-payment, monthly payment, declining balance basis. Promptly following receipt of request from Tenant at any time during the Term, Landlord shall provide a calculation of the Early Termination Payment. Nothing herein contained shall afford Tenant the right to cure the failure to pay the Early Termination Payment, or to cure the failure to give the Early Termination Notice when and as provided under this Lease, and any failure of Tenant to make such payment or give such notice at the time set forth in this Section 4(d) shall render Tenant’s right to exercise the Termination Option void and of no further force and effect.

 

10

 

 

5.     Rent; Taxes. This is a “triple net” lease, and the Minimum Annual Rent payments due from Tenant do not include any Annual Operating Expenses, other additional Rent, or utilities and services, which amounts are Tenant’s responsibility as set forth herein. Notwithstanding the foregoing, Minimum Annual Rent does not include any applicable Arizona privilege, sales, excise, rental and other taxes (except income taxes) imposed now or hereafter imposed by any governmental authority upon the Minimum Annual Rent provided to be paid by Tenant to, or on behalf of, Landlord (collectively, “Additional Taxes”), which applicable Additional Taxes shall be considered additional Rent under this Lease and shall be paid by Tenant in addition to the above noted Minimum Annual Rent, together with each installment of Minimum Annual Rent payments, Operating Expenses (as defined hereunder) payments or other additional Rent payments made by Tenant. Accordingly, Tenant agrees to pay to Landlord, without demand, deduction or offset, Minimum Annual Rent, Annual Operating Expenses, Additional Taxes, and other additional Rent for the Term, in advance, on the first (1st) day of each calendar month during the Term (collectively, the “Monthly Rent”), to Landlord’s address set forth on the “Payment Rider” attached hereto as Exhibit “C” (unless Landlord designates otherwise) or if required by Landlord to an account selected by Landlord by direct payment, in which event Tenant shall execute and deliver a direct payment authorization within five (5) days after receipt of Landlord’s notice; provided that Monthly Rent for the fourth (4th) full month shall be paid at the signing of this Lease. If the Commencement Date is not the first (1st) day of the month, the monthly installment of Minimum Annual Rent for that partial month shall be apportioned on a per diem basis and shall be paid on or before the Commencement Date, and the Abatement shall commence as of the first day of the first full calendar month following the Commencement Date. Tenant shall pay Landlord a service and handling charge equal to five percent (5%) of any Rent not paid within five (5) days after the date due, which amount shall be considered part of Tenant’s Rent obligation. In addition, any Rent, including such charge, not paid within five (5) days after the due date will bear interest at the at the rate of One and One-Half Percent (1½%) per month (the “Interest Rate”) from the date due to the date paid, which amount shall be considered part of Tenant’s Rent obligation. The payment of interest on such amounts will not extend the due date of any amount owed. Tenant shall pay before delinquent all taxes or other charges levied or assessed upon, measured by, or arising from: (a) the conduct of Tenant’s business; (b) Tenant’s leasehold estate; or (c) Tenant’s property. Additionally, Tenant shall pay to Landlord all sales, use, transaction privilege, or other excise tax that may at any time be levied or imposed upon, or measured by, any amount payable by Tenant under this Lease. For purposes of this Lease, “Rent” means the Minimum Annual Rent, Annual Operating Expenses, Additional Taxes, and any other additional amounts of money payable by Tenant to Landlord under this Lease.

 

11

 

 

6.     Operating Expenses. The amount and percentage of the Annual Operating Expenses set forth in Section 1(g) and Section 1(h) above represents Tenant’s Share of the estimated Operating Expenses for the calendar year in which the Term commences, and includes the cost of utilities and services for the Common Areas, and the cost of water, and other utilities and services supplied to the Premises, except as set forth below but excludes the costs of electricity and other utilities and services that are separately metered to the Premises or which are Tenant’s responsibility, which shall be paid by Tenant directly to the utility or service provider(s) as set forth in Section 7 of this Lease, except as otherwise provided herein. As part of Landlord’s Work, Landlord shall cause a submeter to be installed for the electric service to the Premises, and Tenant shall timely pay all electric utility charges directly to Landlord. Landlord shall provide annually prior to January 1 of each calendar year a reasonable estimate of the Annual Operating Expenses due for such calendar year, and Tenant shall pay Tenant’s Share of such estimate in equal installments on a monthly basis as part of Rent. Landlord may adjust such amount from time to time if the estimated Annual Operating Expenses increase or decrease. Landlord may also invoice Tenant separately from time to time for Tenant’s Share of any extraordinary or unanticipated Operating Expenses. By April 30th of each calendar year (and as soon as practical after the expiration or termination of this Lease or, at Landlord’s option, after a sale of the Property), Landlord shall provide Tenant with a statement of actual Operating Expenses representing Tenant’s Share for the preceding calendar year or part thereof. Within thirty (30) days after delivery of the statement to Tenant, Landlord or Tenant shall pay to the other the amount of any overpayment or deficiency then due from one to the other or, at Landlord’s option, Landlord may credit Tenant’s account for any overpayment. If Tenant does not give Landlord notice within ninety (90) days after receiving Landlord’s statement that Tenant disagrees with the statement and specifying the items and amounts in dispute, Tenant shall be deemed to have waived the right to contest the statement. Landlord’s and Tenant’s obligation to pay any overpayment or deficiency due the other pursuant to this Section 6 shall survive the expiration or termination of this Lease. Notwithstanding any other provision of this Lease to the contrary, Landlord may, in its reasonable discretion, determine from time to time the method of computing and allocating Operating Expenses, including the method of allocating Operating Expenses to various types of space within the Building to reflect any disparate levels of services provided to different types of space. If the Building is not fully occupied during any period, Landlord may make a reasonable adjustment based on occupancy in computing the Operating Expenses for such period so that Operating Expenses are computed as though the Building had been fully occupied.

 

(a)               “Operating Expenses” means all costs, fees, charges and expenses incurred or charged by Landlord in connection with the ownership, operation, maintenance and repair of, and services provided to, the Property, including, but not limited to, and to the extent not otherwise payable by Tenant pursuant to this Lease, (i) the charges at standard retail rates for any services provided to Tenant and other occupants of the Building by Landlord pursuant to Section 7 of this Lease, (ii) the cost of insurance carried by Landlord pursuant to Section 8 of this Lease together with the cost of any deductible paid by Landlord in connection with an insured loss (subject to the amortization of any permitted capital expenditures), (iii) Landlord’s cost to Maintain (as defined hereunder) the Property pursuant to Section 9 of this Lease, including without limitation, fire protection, trash collection, janitorial services pursuant to Section 7(b) below, water, sewer, heating, ventilation and air conditioning (“HVAC”) systems, roof maintenance, elevator maintenance, interior and exterior landscaping, snow and ice removal, and Common Area cleaning and exterminating, (iv) a non-reconcilable amount equal to the charges incurred by Landlord for personnel, vehicles, and supplies used or attributable to the Premises a fixed amount of Eighteen Cents ($0.18) per rentable square foot of the Premises per year, (v) all levies, taxes (including real estate taxes, sales taxes and gross receipt taxes), assessments, liens, license and permit fees, together with the reasonable cost of contesting any of the foregoing, which are applicable to the Term, and which are imposed by any authority or under any Law, or pursuant to any recorded covenants or agreements, upon or with respect to the Property pursuant to Section 5 of this Lease, or any improvements thereto, or directly upon this Lease or the Rent or upon amounts payable by any subtenants or other occupants of the Premises, or against Landlord because of Landlord’s estate or interest in the Property, (vi) the annual amortization (over their estimated economic useful life or payback period, whichever is shorter) of the costs (including reasonable financing charges) of capital improvements or replacements (a) required by any Laws coming into effect after the Commencement Date, (b) made for the purpose of reducing Operating Expenses, or (c) made for the purpose of directly enhancing the safety of tenants in the Building, and (vii) a management and administrative fee equal to five percent (5%) of gross rents (i.e. Minimum Annual Rent, Annual Operating Expenses, Additional Taxes and any additional Rent other than the management fee) from the Property.

 

12

 

 

(b)               The foregoing notwithstanding, Operating Expenses will not include: (i) depreciation on the Building, (ii) financing and refinancing costs (except as provided above), interest on debt or amortization payments on any Mortgage (as defined hereunder), or rental under any ground or underlying lease, (iii) leasing commissions, advertising expenses, tenant improvements or allowances, or other costs directly related to the leasing of the Property, (iv) income, excess profits or corporate capital stock tax imposed or assessed upon Landlord, unless such tax or any similar tax is levied or assessed in lieu of all or any part of any taxes includable in Operating Expenses above, (v) any bad debt loss, rent loss, or reserves for bad debt or rent loss or future expenses; (vi) costs associated with operation of the business of the ownership of the Building or entity that constitutes Landlord or Landlord’s property manager, as distinguished from the cost of Building operations, including the costs of partnership or corporate accounting and legal matters; defending or prosecuting any lawsuit with any mortgagee, lender, ground lessor, broker, tenant, occupant, or prospective tenant or occupant; selling or syndicating any of Landlord’s interest in the Building; and disputes between Landlord and Landlord’s property manager; (vii) costs of services or other benefits of a type that are not available to Tenant but that are available to other tenants or occupants of the Building, and costs for which Landlord is reimbursed including reimbursements by other tenants or occupants of the Building other than through payment of tenants’ shares of Operating Expenses; and (viii) fees paid to any affiliate or party related to Landlord to the extent such fees exceed the charges for comparable services rendered by unaffiliated third parties of comparable skill, stature and reputation in the same market;. If Landlord elects to prepay real estate taxes during any discount period, Tenant shall be entitled to the benefit of any such prepayment. Landlord shall have the right to directly perform (by itself or through an affiliate) any services provided under this Lease provided that the Landlord’s charges included in Operating Expenses for any such services shall not exceed competitive market rates for comparable services.

 

13

 

 

(c)               If Tenant provides written notice to Landlord within the ninety (90) day period following delivery of the annual reconciliation statement that Tenant disagrees with such statement for Operating Expenses, and specifies the items and amounts in dispute, Tenant shall, (i) pending the resolution of such dispute, nonetheless pay all of Tenant’s Share of Annual Operating Expenses in accordance with the statement furnished by Landlord, and Tenant shall have the right, at its sole cost and expense, to examine Landlord’s books and records relating to the determination of Operating Expenses for such calendar year, and commence and diligently complete an audit of such charges (an “Audit”); provided, however, that (1) Tenant shall give Landlord a minimum of five (5) business days’ prior written notice of its intent to exercise such right, (2) the inspection may not take place outside of normal business hours at Landlord’s corporate offices, at Tenant’s sole cost, (3) Tenant shall use reasonable efforts to not interfere with Landlord’s normal business activities, taking into account the workload of Landlord’s employees involved in responding to the Audit request; and (4) an Event of Default under this Lease has not occurred and is then continuing. The Audit of Landlord’s records may be conducted by Tenant’s accounting staff or only a certified public accountant, subject to Landlord’s approval, which approval shall not be unreasonably withheld. Any accounting firm selected by Tenant in connection with the Audit (a) shall be a reputable independent nationally or regionally recognized certified public accounting firm which has previous experience in auditing financial operating records of landlords of office /laboratory buildings; (b) shall not already be providing accounting and/or lease administration service to Tenant and shall not have provided accounting and/or lease administration service to Tenant in the past three (3) years; (c) shall not be retained by Tenant on a contingency fee basis (i.e. Tenant must be billed based on the actual time and materials that are incurred by the accounting firm in the performance of the Audit, and a statement signed by an officer of Tenant confirming such agreement between Tenant and auditor, shall be provided to Landlord prior to the commencement of the Audit); and (d) at Landlord’s option, both Tenant and its agent shall be required to execute a commercially reasonable confidentially agreement prepared by Landlord. The foregoing Audit shall be completed, and the results delivered to Landlord, within ninety (90) days after the date Tenant delivers its Audit notice (subject to delay due to any event caused by or inaction of Landlord or Landlord’s Agents), or Tenant shall be deemed to have waived the right to contest the statement. Landlord and Tenant shall work together in good faith to resolve any issues raised in Tenant’s Audit. In the event Tenant timely completes its Audit and it reveals an overpayment by Tenant of Tenant’s Share of Annual Operating Expenses (an “Overcharge”), and Landlord in good faith agrees with such determination, the amount due Tenant (if any) shall be credited against no more than fifty percent (50%) of Tenant’s monthly Minimum Annual Rent next coming due for each month following the determination of such Overcharge until such time as Tenant is reimbursed in full, and if the Audit reveals that Tenant was undercharged during any given year (an “Undercharge”), Tenant shall promptly pay to Landlord the amount of such Undercharge. Landlord shall additionally reimburse Tenant in the event of an Overcharge of greater than five percent (5%), and Tenant shall additionally reimburse Landlord, in the event of an Undercharge of greater than five percent (5%), for the out of pocket costs incurred in connection with such Audit in an amount not to exceed Five Thousand Dollars ($5,000). If the parties are unable to resolve the dispute within thirty (30) days after completion of Tenant’s Audit, then, at Tenant’s request, a certified public accounting firm selected by Landlord and subject to requirements (a), (b), and (c) above as to Landlord, and reasonably approved by Tenant, shall, at Tenant’s cost, conduct an audit of the relevant Operating Expenses (the “Neutral Audit”). The parties shall split all costs and expenses of the Neutral Audit unless the final determination in such Neutral Audit is that Landlord Overcharged Tenant for Tenant’s Share of Operating Expenses in the statement for the year being audited by more than five percent (5%) in which case Landlord shall pay all costs and expenses of the Neutral Audit in an amount not to exceed Five Thousand Dollars ($5,000). In any event, Landlord will reimburse or provide a credit for any Overcharge of Operating Expenses and Tenant shall pay to Landlord any Undercharge of Operating Expenses.

 

14

 

 

(d)              The parties agree that Tenant’s Share reflects and will be continually adjusted to reflect the ratio of the gross square feet of the area rented to Tenant (including, if applicable, an allocable share of all Common Areas) as the numerator, as compared with the total number of gross square feet of the entire Building (or additional buildings that are or may be constructed within the Property), as the denominator, measured outside wall to outside wall, but excluding therefrom any storage areas. Notwithstanding anything to the contrary set forth in this Section 8, with respect to water only, Tenant’s share of charges for water shall be 100% until such time as another tenant occupies any portion of the Building. Landlord shall have the right to make changes or revisions in the Common Areas of the Building or the Land so as to provide additional leasing area. Landlord shall also have the right to construct additional buildings in the Property for such purposes as Landlord may deem appropriate, and subdivide the lands for that purpose if necessary, and upon so doing, the Property shall become the subdivided lot on which the Building in which the Premises is located. However, if any service provided for in Section 6(b) above is separately billed or separately metered within the Building, then the square footage so billed or metered shall be subtracted from the denominator and the Tenant’s Share for such service and/or utility shall be separately computed, and the Annual Operating Expenses for such item shall not include any charges attributable to said square footage.

 

7.Utilities; Services.

 

(a)               With the exception of Tenant’s Share of any utilities and services expressly included as part of the Operating Expenses in Section 6(b) above, Tenant shall directly pay for electricity, power, telephone, internet and other communication services and any other utilities or services supplied to the Premises commencing on the Commencement Date. Except to the extent Landlord elects to provide any such services and invoice Tenant for the cost or include the cost in Operating Expenses, Tenant shall obtain such service in its own name and timely pay all charges directly to the provider(s). As part of Landlord’s Work, Landlord shall either install a separate dedicated electricity meter, or install a submeter allocated between various occupants of the Building to measure Tenant electricity usage at the Premises. If such submeter is utilized, the cost of such actual measured amount shall be billed by Landlord directly to Tenant as a charge separate and distinct from Tenant’s Share of Operating Expenses. If such separate dedicated meter is installed, Tenant shall pay all charges incurred directly to the applicable utility service provider. Landlord shall not be responsible or liable for any interruption in such services, nor shall such interruption affect the continuation or validity of, or constitute a Landlord default under, this Lease. Landlord shall have the exclusive right to select, and to change, the companies providing such services to the Building or Premises. Any wiring, cabling or other equipment necessary to connect Tenant’s telecommunications equipment shall be Tenant’s responsibility, and shall be installed by Tenant in a manner approved by Landlord. If because of Tenant’s density, use, equipment or other Tenant circumstances, Tenant’s consumption of any utility or other service included as part of Landlord’s Operating Expenses or demands on the Building Systems (as defined hereunder) are excessive when compared with other occupants of the Property, or cause extraordinary maintenance and repair issues beyond those customarily and routinely incurred by Landlord to operate the Building Systems, Landlord may install supplemental equipment and meters at Tenant’s expense, and may invoice Tenant separately for, and Tenant shall pay on demand, the cost of Tenant’s excessive consumption or use, or such additional equipment, as reasonably determined by Landlord. Landlord shall have the option, at any time during the Term or extension thereof, to exclude any utility service from Operating Expenses, in which case, Landlord may either: (i) provide any such services and invoice Tenant for the cost; or (ii) require Tenant to obtain service in its own name and timely pay all charges directly to the provider.

 

15

 

 

(b)              Landlord will furnish the following services for the normal use and occupancy of the Premises for Tenant’s Use, the costs of which are included as part of Operating Expenses: (i) electricity, or normal lighting of Common Areas; (ii) HVAC; (iii) water, (iv) sanitary sewer, (v) Common Area janitorial and litter removal, and (vi) such other services Landlord reasonably determines are appropriate or necessary, all in a manner comparable to that of similar buildings in the area. If Tenant requests, and if Landlord is able to furnish services in addition to those identified above, Tenant shall pay Landlord’s reasonable charge for such supplemental services. Tenant acknowledges that Landlord has no obligation to provide any additional services in or about the Premises or the Building, its parking or access areas, or in or about the Land.

 

(c)               Landlord shall have no obligation to provide surveillance or security systems in or about the Premises or the Building, the Parking Area, or access areas, or in or about the Land, and Landlord shall have no liability and Tenant hereby waives all claims in connection with the decision whether or not to provide such services, or the failure of any security personnel, mechanical surveillance or other security or surveillance measures to prevent the occurrence of any theft, vandalism or any other criminal or like causes (or the failure to apprehend the perpetrators of such acts), whether provided by Tenant or Landlord. Subject to the provisions of Section 8(f) below, Tenant shall defend, indemnify, and hold Landlord harmless from any such claims made by any of Tenant’s or Tenant’s Agent’s employee, licensee, invitee, contractor, agent or other person whose presence in, on or about the Premises or the Building is attendant to the business of Tenant. Tenant shall have the right, at its sole cost and expense and only after providing written notice to Landlord, to install, maintain, operate, repair, update and replace its own security system on the Premises, including without limitation, card access readers, and interior and exterior cameras (collectively, the “Security System”), subject to Landlord’s approval of the location and installation methods of such Security System, not to be unreasonably withheld. Any such installation of Tenant’s Security System shall be an Alteration (as defined hereunder) and shall be subject to all applicable provisions of Sections 12 and 13 of this Lease. Tenant shall provide to Landlord card access readers, keys or combinations, as the case may be, to permit Landlord to access all part of the Premises, subject to the terms of this Lease and Tenant’s security, safety, and clean-room procedures. Upon the expiration or earlier termination of this Lease, Landlord, at its option, may either require Tenant to leave the Security System in place, in good working order, and transfer ownership thereof to Landlord, or remove the Security System and repair any damage resulting therefrom (which determination by Landlord shall be made and delivered to Tenant at the same time as the approval of Tenant’s Security System).

 

16

 

 

(d)              Tenant, at Tenant’s sole cost and expense, shall have the right to install one 600 k.w. generator, together with one generator pad and a sound attenuation house (not to exceed 480 contiguous useable square feet of ground area and 11’4” feet in height), reasonably necessary for Tenant’s business operations in the Premises for emergency, electrical back-up purposes, including one above-ground diesel fuel tank with a capacity of up to 350 gallons, a conduit (no greater than six inches (6”) in diameter) and wires running within the said conduit to connect the generator to Tenant’s equipment in the Building, a muffler with a sound/noise level not to exceed sixty (60) decibels of a distance of not more than twenty (20) feet from the equipment (the sixty (60) decibels maximum sound level applies to all equipment noise, including HVAC), and all related equipment and apparatus (the “Generator”), strictly under and subject to the following conditions:

 

(i)              Before beginning the installation of the Generator, which Tenant shall perform in a good and workmanlike manner and in compliance with the following standards, Tenant shall first obtain Landlord’s written approval, not to be unreasonably withheld, and in connection therewith Tenant shall provide to Landlord final plans and specifications prepared by an engineer approved by Landlord and setting forth in detail the design, location, size, method of installation, screening and all related equipment and apparatus for Landlord’s review and written approval, together with evidence reasonably satisfactory to Landlord that all Laws and industry standards have been satisfied. Landlord’s approval shall not constitute a representation or warranty by Landlord that Tenant’s plans and specifications comply with any Laws or industry standards as such compliance shall be the sole responsibility of Tenant. Landlord, at Landlord’s sole and reasonable discretion, shall determine the type of screening required to be maintained around the generator and the places and method of penetrating the exterior of the Building to connect the Generator to the Premises, at Tenant’s sole cost and expense;

 

(ii)              At least three (3) business days prior to the Generator installation, Tenant shall notify Landlord of the date and time of the installation and such installation shall be fully coordinated with Landlord. Such installation shall not damage the Building or materially interfere with the use of any portion of the Building during Normal Business Hours while such installation is taking place;

 

(iii)              Tenant shall have the obligation to perform and shall pay all costs and expenses in connection with, arising out of, or related to the Generator including without limitation the installation, use, operation, insurance, maintenance, repair, tangible personal property taxes, and, to the extent necessary and appropriate, replacement, as may be needed to keep the Generator in a safe, good, orderly condition and repair. In connection with the Generator, Tenant shall reimburse Landlord for the reasonable costs and expenses of Landlord’s consultants, architects, engineers, contractors and attorneys upon invoice;

 

(iv)              Tenant shall properly fuel and immediately notify Landlord verbally and in writing and remove from the area and otherwise remediate any spills or other leaks of fluid from the Generator or otherwise connected therewith and shall otherwise comply with all Environmental Laws (as defined hereunder), industry standards and Building Rules, as reasonably imposed by Landlord. All testing of the Generator shall be performed after Normal Business Hours and in accordance with a schedule to be submitted in advance to and approved in writing by Landlord. Landlord shall have the right, during the Term, to relocate the Generator, at Landlord’s sole cost and expense. Landlord shall have the right, during the Term, to require Tenant to modify the Generator sound attenuation housing and exhaust system if, in Landlord’s reasonable discretion, noise or exhaust fumes are interfering with other tenants and occupants in the Building or the Property;

 

17

 

 

(v)              During the Term, the Generator shall remain the personal property of Tenant, but at the expiration or earlier termination of this Lease, the Generator shall become the sole and exclusive property of Landlord without any payment to Tenant, subject to the provisions of Section 21(a) below; and,

 

(vi)              All applicable terms and conditions of this Lease shall apply to the Generator, except that the Generator area shall not be included within the rentable area calculation of the Premises.

 

(e)               Landlord manages the roof access from the Building and Tenant shall abide by Landlord’s roof access procedures, as set forth in this Section 7(e). Tenant shall have the right to install, maintain, and repair a satellite business terminal system and its components for Tenant’s business operations (hereinafter the “Satellite System”), consisting of an outdoor satellite antenna and electronic unit on the roof of the Building, indoor electronics unit within the Premises and IFL or other signal cables under a non-exclusive license from Landlord, under and subject to the following conditions: (i) Tenant shall comply with all Laws and industry standards with respect to the Satellite System; (ii) Tenant shall obtain Landlord’s prior approval of the Satellite System for aesthetics, sound consideration and of the location of the Satellite System on the roof of the Building and all roof penetrations required for the installation of the Satellite System, which approval shall not be unreasonably conditioned, withheld, or delayed; (iii) if Landlord approves installation of the Satellite System on the roof of the Building, Tenant agrees to consult with Landlord’s roofing contractor prior to installation and strictly to comply with the roofing contractor’s recommendations and requirements; and (iv) Tenant shall pay all costs incurred by Landlord in connection with the Satellite System including, without limitation, all architectural, engineering, contractors’ and legal fees, any charges incurred by Landlord’s roofing contractor and other consultants, and any and all damage, repairs and restoration resulting from the installation, operation, maintenance, repair, replacement, relocation and removal of the Satellite System. Access to the roof of the Building shall be restricted by Landlord at all times. Accordingly, Tenant shall notify Landlord at least three (3) business days prior to the installation of the Satellite System and Tenant, utilizing Landlord’s roofing contractor, shall install the Satellite System only if Landlord, its agent, or its roofing contractor is present. Tenant shall maintain the Satellite System in a safe, good, and orderly condition. The installation, maintenance, repair, and removal of the Satellite System shall be performed by Landlord’s roofing contractor at Tenant’s sole cost and expense in a manner which will not impair the integrity of, damage, or adversely affect the warranty applicable to, the roof or any other portion of the Building. The Satellite System shall not cause interference with any other existing telecommunications systems of Landlord or other tenants or occupants of the Building. The Satellite System shall be used solely by Tenant in the ordinary course of its business for its Use, and Tenant shall not allow any parties other than Tenant, its contractors, sublessees, licensees, and invitees within the Premises to use the Satellite System. If any work to the Building or the Property by Landlord or its contractors necessitates removing or relocating the Satellite System or any Satellite System components, Landlord shall, at Landlord’s sole cost and expense, remove and reinstall or relocate same to a new location designated by Landlord, as applicable. Tenant hereby waives all claims for recovery against Landlord for any and all loss or damage which may be inflicted upon the Satellite System and its operation by Landlord or its Agents or other tenants in the Building or from any other cause. Landlord shall not be responsible or liable for any interruption in connection with the Satellite System, nor shall such interruption affect the continuation or validity of this Lease. Tenant shall retain ownership of the Satellite System. Accordingly, no later than the expiration or earlier termination of this Lease, at Tenant’s sole expense, Tenant, utilizing Landlord’s roofing contractor, shall remove the Satellite System and repair any resulting damage, ordinary wear and tear, damage by casualty, and repairs that are Landlord’s responsibility excepted, all in accordance with the terms of Section 12 below.

 

18

 

 

8.Insurance; Waivers; Indemnification.

 

(a)               Landlord will at all times during the Term carry a policy of insurance which insures the Building, including the Premises, if any, against loss or damage by fire or other casualty (namely, the perils against which insurance is afforded by a standard fire insurance policy); provided, however, that Landlord will not be responsible for, and will not be obligated to insure against, any loss of or damage to any personal property or trade fixtures of Tenant or any alterations which Tenant may make to the Premises or any loss suffered by Tenant due to business interruption. All insurance maintained by Landlord pursuant to this Section 8 may be effected by blanket insurance policies.

 

(b)              Prior to Tenant’s entry onto the Premises, Tenant will obtain and have and thereafter keep in full force and effect at all times until the expiration of the Term of this Lease, insurance coverage as follows:

 

(i)              Commercial general liability insurance policy on an ISO CG 00 01 form, on an occurrence basis, providing coverage for claims for bodily injury, personal injury and property damage occurring on, in or about the Premises with a per occurrence/per offense limit of at least Three Million and 00/100 Dollars ($3,000,000.00) with no deductible or self-insured retention unless specifically approved by Landlord. Defense costs shall be in addition to the policy limits. Such insurance shall provide coverage for all of Tenant’s operations and shall include contractual liability coverage, including coverage applicable to the Tenant’s indemnity requirements herein, and shall include an endorsement naming Landlord, Workspace Property Management, L.P., Workspace Property Trust, L.P. and each of their respective directors, officers, shareholders, members, employees, associated and affiliated entities, ground lessors, any Mortgagees(s) (as defined hereunder), and any other party as designated by Landlord (hereinafter “Landlord Additional Insureds”) as additional insureds on a primary and non-contributory basis for all liability, claims, costs, damages, and expenses arising out or resulting from Tenant’s acts, omissions, operations, occupancy, use, control, and/or tenancy of the Premises. This insurance may be effected by a combination of a primary general liability policy and an excess liability policy provided the limit of the primary general liability policy is not less than One Million and 00/100 Dollars ($1,000,000.00) per occurrence and the excess liability policy follows form. Any aggregate under the policy(ies) shall apply separately to the Premises. Such policy(ies) shall include a severability of interest condition or clause providing coverage to each insured as if such insured was the only insured under the policy.

 

19

 

 

(ii)              Workers’ compensation insurance in statutory amounts and in accordance with the laws of the state in which the Premises are located and employers’ liability insurance with limits not less than Five Hundred Thousand and 00/100 Dollars ($500,000.00) bodily injury by accident and bodily injury by disease. Such insurance shall cover all individuals employed at or retained on behalf of Tenant with respect to the Premises. Such insurance shall include a waiver of subrogation against Landlord Additional Insureds.

 

(iii)              All risk property insurance upon property of every description and kind owned by Tenant and/or under Tenant’s care, custody or control and/or for which Tenant is responsible located at the Premises or for which Tenant is legally liable or installed by or on behalf of Tenant. Such insurance shall be in an amount equal to the full replacement cost thereof. Such policy shall also include coverage for business interruption and extra expense in an amount and with coverage adequate to indemnify Tenant for its loss of business and costs of operations for a period of at least twelve (12) months. The deductible under such policy shall not exceed Five Thousand and 00/100 Dollars ($5,000.00) unless specifically approved by Landlord.

 

(iv)              Environmental liability insurance covering the Generator and all other operations in the Premises with limits of not less than $2,000,000.00 combined single limit.

 

(v)              Insurance for such other hazards and in such amounts as Landlord may reasonably require and as at the time are commonly insured against with respect to property similar in character, general location and use and occupancy to the Premises or as required by any Mortgagee in amounts reasonably determined by Landlord. If, by reason of changed economic conditions, the insurance amounts referred to in this Section 8(b) become inadequate, Tenant agrees to increase the amounts of such insurance at its next renewal date upon Landlord’s reasonable request. If the forms of policies, endorsements, certificates, or evidence of insurance required by this Section 8(b) are superseded or discontinued, Landlord may require other equivalent or better forms.

 

All of Tenant’s insurance policies shall be issued by insurers authorized to issue such insurance, licensed to do business and admitted in the state in which the Property is located and rated at least A-VIII in the most current edition of Best’s Insurance Reports, shall be in a form and with terms and conditions acceptable to Landlord, all property insurance policies shall include a waiver of subrogation against Landlord Additional Insureds, to the extent permitted by law, and, if commercially available, shall provide an undertaking by the insurers to provide at least thirty (30) days prior written notice to Landlord and Landlord’s Mortgagee prior to any material change, reduction in coverage or cancellation of any of the insurance policies required herein (ten (10) days in the event of non-payment of premium). Tenant shall deliver to Landlord, within five (5) days after the date of this Lease or any earlier date on which Tenant accesses the Premises, and at least five (5) days prior to the date of each policy renewal, a certificate of insurance, in a form acceptable to Landlord, evidencing such coverage and including all policy forms and endorsements requested by Landlord. Tenant shall provide complete copies of its insurance policies to Landlord within fifteen (15) days of Landlord’s request. It is understood and agreed that Tenant’s insurance policies shall be primary to any separate coverage carried by any Landlord Additional Insured. Any other insurance carried by Landlord Additional Insureds shall be excess of and non-contributory with Tenant’s insurance. The minimum limits of Tenant’s liability insurance and other requirements designated in this Section 8 shall in no way limit or diminish Tenant’s liability including Tenant’s indemnification obligations under this Lease. Acceptance by Landlord of delivery of any certificates of insurance does not constitute approval or agreement by Landlord that the insurance requirements in this Section 8(b) have been met, and failure of Landlord to demand such evidence of full compliance with these insurance requirements or failure of Landlord to identify a deficiency from certificates or evidence provided will not be construed as a waiver of Tenant’s obligation to maintain such insurance.

 

20

 

 

Tenant’s insurance obligations set forth herein shall continue in effect throughout the Term and after the Term as long as Tenant, or anyone claiming by, through or under Tenant, occupies all or any part of the Premises.

 

(c)               Tenant will not do or allow anything to be done on the Premises which will increase the rate of insurance on the Building from that of a general office/laboratory building. If any use of the Premises by Tenant results in an increase in the insurance rate(s) for the Building, Tenant will pay Landlord, as additional Rent, within thirty (30) days after being billed, any resulting increase in premiums irrespective of whether Landlord shall have consented to Tenant’s act. If Tenant installs, or causes the installation of, any electrical equipment which overloads the electrical lines, Tenant shall, at its own expense, make all changes to its Premises and install any fire extinguishing equipment and/or other safeguards that Landlord’s insurance underwriters or applicable fire, safety and building codes and regulations may require. Nothing herein contained shall be deemed to constitute Landlord’s consent to such overloading.

 

(d)              Tenant’s insurance may be maintained through blanket policies of insurance with Tenant and Tenant’s affiliates provided such policies provide coverage at least as broad and with limits for this location not less than a separate policy, for this location only, would provide. In the event Tenant has a net worth of not less than $200,000,000 and Tenant provides financial records documenting same, in a format acceptable to Landlord, and at all times as requested by Landlord, Tenant shall be permitted to self-insure for the general liability and property insurance required herein, up to a limit agreed to by Landlord, provided all of the following terms are met: (a) Tenant shall have the same obligations, duties, and responsibilities to all of the Landlord Additional Insureds as would an insurance company to its insureds if the insurance required herein was maintained by Tenant on a first dollar (no deductible or self-insured retention) basis, including, but not limited to, the obligation and duty to defend and indemnify all of the Landlord Additional Insureds and the duty of fair claims handling practices; (b) Tenant agrees that such self-insurance shall be the primary insurance coverage for any occurrence or event arising out of, occurring, or resulting from Tenant’s operations or use or occupancy of the Premises and shall be deemed insurance for purposes of any other insurance maintained directly by all of the Landlord Additional Insureds; (c) Tenant agrees that any insurance maintained by all of the Landlord Additional Insureds shall be in excess of and non-contributory with Tenant’s self-insurance; (d) Tenant waives all claims and its rights of recovery against all of the Landlord Additional Insureds to the same extent as the waiver of subrogation in the insurance policy, if maintained on a first dollar basis, would have applied; (e) Tenant maintains appropriate loss reserves which are actuarially derived in accordance with accepted standards of the insurance industry and accrued (i.e. charged against earnings) or otherwise funded; (f) Tenant shall pay any amounts due in lieu of insurance proceeds because of any self-insurance or retentions, which amounts shall be treated as insurance proceeds for all purposes under this Lease; and (g) all amounts which Tenant pays or is required to pay and all loss or damages resulting from risks for which Tenant has elected to self-insure or have self-insured retentions, shall not limit Tenant’s indemnification obligations under this Lease.

 

21

 

 

(e)            Notwithstanding anything to the contrary set forth in this Lease, Tenant shall waive and release Landlord Additional Insureds for any loss or damage to the property, and any resulting loss of use of such property, arising out of fire or other casualty coverable by a standard “Causes of Loss-Special Form” property insurance policy with such endorsements and additional coverages as are considered good business practice in Tenant’s business, even if such loss or damage shall be brought about by the fault or negligence of any of the Landlord Additional Insured or their respective Agents. Notwithstanding anything to the contrary set forth in this Lease, Landlord shall waive and release Tenant for any loss or damage to its property arising out of fire or other casualty coverable by a standard “Causes of Loss-Special Form” property insurance policy. This waiver and release is effective regardless of whether the releasing party actually maintains the insurance described above in this subsection and is not limited to the amount of insurance actually carried, or to the actual proceeds received after a loss. Each party shall have its insurance company that issues its property coverage waive any rights of subrogation, and shall have the insurance company include an endorsement acknowledging this waiver, if necessary. Tenant assumes all risk of damage of Tenant’s property within or at the Property and any resulting loss of use or business interruption, including, but not limited to, any loss or damage caused by water leakage, fire, windstorm, explosion, theft, act of any other tenant, or other cause. Landlord and Tenant acknowledge that the insurance requirements of this Lease reflect their mutual recognition and agreement that each party will look to its own insurance and that each can best insure against loss to its property and business no matter what the cause.

 

(f)             Subject to subsection 8(e) above, and except to the extent caused by the active negligence or willful misconduct of any of the Landlord Additional Insureds or their Agents, Tenant will indemnify, defend, and hold harmless such Landlord Additional Insureds and their Agents from and against any and all claims, actions, damages, proceedings, costs, liability and expense (including reasonable fees of attorneys, investigators and experts) which may be asserted against, imposed upon, or incurred by any of the Landlord Additional Insureds or their Agents and arising out of or in connection with loss of life, personal injury or damage to property (i)   in or about the Premises during the Term or (ii) arising out of the occupancy or use of the Property by Tenant or its Agents, whether in contract or tort, occasioned wholly or in part by any active negligence or willful misconduct of Tenant or its Agents, whether prior to, during or after the Term. Tenant’s obligations pursuant to this subsection 8(f) shall survive the expiration or termination of this Lease with respect to occurrences during the Term. In case any action or proceeding be brought against any of the Landlord Additional Insureds or their Agents by reason of any such claim, Tenant, upon notice from any of the Landlord Additional Insureds or their Agents, will, at Tenant’s expense, resist and defend such action or proceeding with counsel acceptable to such Landlord Additional Insureds and their Agents.

 

 22

 

 

(g)            Subject to subsection 8(e) above, and except to the extent caused by the active negligence or willful misconduct of any of the Tenant or its Agents, Landlord will indemnify, defend, and hold harmless such Tenant and its Agents from and against any and all claims, actions, damages, proceedings, costs, liability and expense (including reasonable fees of attorneys, investigators and experts) which may be asserted against, imposed upon, or incurred by Tenant or its Agents and arising out of or in connection with loss of life, personal injury or damage to property, whether in contract or tort, occasioned wholly or in part by any active negligence or willful misconduct of any Landlord Additional Insured or their Agents, whether prior to, during or after the Term. Landlord’s obligations pursuant to this subsection 8(g) shall survive the expiration or termination of this Lease with respect to occurrences during the Term. In case any action or proceeding be brought against Tenant or its Agents by reason of any such claim, Landlord , upon notice from Tenant or its Agents, will, at Tenant’s expense, resist and defend such action or proceeding with counsel acceptable to Tenant or its their Agents.

 

9.   Maintenance and Repairs.

 

(a)            Landlord shall Maintain the Building footings, foundation, structural steel columns and girders (the “Building Structure”) at Landlord’s sole expense. Subject to reimbursement as an Operating Expense, Landlord shall Maintain: (i) the exterior utility lines and facilities to the point of connection to/distribution within the Building (unless maintained by the applicable utility company); (ii) the Building (including the roof but excluding the Building Structure), including the Premises (except to the extent of Tenant’s obligations set forth in Section 9(b) hereof); (iii) the Building Systems; (iv) the Common Areas; and, (v) any other improvements owned by Landlord located on the Property. If Tenant becomes aware of any condition that is Landlord’s responsibility to repair, replace or maintain, Tenant shall promptly notify Landlord of such condition. Moreover, regardless of who bears responsibility for any repair, replacement or maintenance, Tenant shall immediately notify Landlord if Tenant becomes aware of any areas of water intrusion or mold growth in or about the Premises. The cost of repairs to the Common Areas will be included as an Operating Expenses, except where the repair has been made necessary by misuse or neglect by Tenant or Tenant’s Agents, in which event Landlord will nevertheless make the repair but Tenant will pay to Landlord, as additional Rent, upon demand, the cost incurred by Landlord to complete such repairs. “Maintain” means to provide such maintenance, repair and, to the extent necessary and appropriate, replacement, as may be needed to keep the subject property in good working order or condition. Maintenance also includes utilizing such building-performance assessment tools and energy-optimizing practices that Landlord in its discretion reasonably deems necessary and appropriate for planning, designing, installing, testing, operating and maintaining the Building Systems and Common Areas in an energy efficient manner and providing a safe and comfortable work environment, with a view toward achieving improved overall Building performance and minimizing the Building’s impact on the environment. “Building Systems” means any electrical, mechanical, structural, plumbing, HVAC, sprinkler, life safety or security systems serving the Building. Notwithstanding anything to the contrary set forth in this Section 9(a), if any part of the Building’s roof or structure or any Building Systems requires repair or replacement during the eighteen (18) months commencing on the Commencement Date, Landlord shall cause such repair or replacement to be made at its cost and expense and not as an Operating Expense. Landlord may engage a HVAC service contractor at Landlord’s sole discretion, to perform routine maintenance of all Building HVAC units, including those serving the Premises, the cost of which is subject to reimbursement by Tenant as an Operating Expense.

 

 23

 

 

(b)             Except as provided in subsection 9(a) above, Tenant, at its sole cost and expense, shall Maintain the Premises and all fixtures and equipment in the Premises. Tenant, at its sole expense, shall keep the Premises in a neat and orderly condition. Alterations (as defined hereunder), repairs and replacements to the Property, including the Premises, made necessary because of Tenant’s Improvements, Alterations or installations, any use or circumstances special or particular to Tenant, or any act or omission of Tenant or its Agents shall be made at the sole expense of Tenant to the extent not covered by any applicable insurance proceeds paid to Landlord.

 

10.  Compliance.

 

(a)            Tenant will, at its expense, promptly comply with all Laws now or subsequently pertaining to Tenant’s use or occupancy of the Premises including, without limitation, those relating to ADA. Tenant will pay any taxes or other charges by any authority on Tenant’s property or trade fixtures or relating to Tenant’s use of the Premises. Neither Tenant nor its Agents shall use the Premises in any manner that under any Law would require Landlord to make any alteration to or in the Building or Common Areas (without limiting the foregoing, Tenant shall not use the Premises in any manner that would cause the Premises or the Property to be deemed a “place of public accommodation” under the ADA if such use would require any such Alteration). Landlord shall be responsible for compliance with the ADA, and any other Laws regarding accessibility, with respect to the Common Areas. Tenant shall be responsible for compliance with the ADA, and any other Laws regarding accessibility, with respect to the Premises. “ADA” means the Americans with Disabilities Act of 1990 (42 U.S.C. § 1201 et seq.), as amended and supplemented from time to time. As used herein, “Laws” means any and all present or future federal, state, municipal, county and other local laws, statutes, ordinances, rules, orders, regulations, directives, subdivisions, guidelines, common law, and any and all governmental, quasi-governmental, judicial or administrative orders, directives, decrees, judgments, injunctions, and agreements, and any and all other requirements of federal, state or local governmental authorities, bureaus, agencies, or offices having jurisdiction over the Property, or of any private association or contained in any restrictive covenants or other declarations or agreements, now or subsequently pertaining to the Property or the use and occupation of the Property.

 

(b)            Tenant will comply, and will cause its Agents to comply, with the Building Rules. Landlord may adopt, and Tenant shall comply with, reasonable rules and regulations to promote energy efficiency, sustainability and environmental standards for the Property, as the same may be changed from time to time upon reasonable notice to Tenant.

 

 24

 

 

(c)            Landlord represents to Tenant that to Landlord’s actual knowledge, there are not Hazardous Materials (as defined hereunder) located in the Premises or the Building that require any remediation. Tenant agrees that (i) no activity will be conducted on the Premises that will use or produce any Hazardous Materials, except for activities which are part of the ordinary course of Tenant’s business and are conducted in accordance with all Environmental Laws (as defined hereunder) (“Permitted Activities”); (ii) the Premises will not be used for storage of any Hazardous Materials, except for materials used in the Permitted Activities which are properly stored in a manner and location complying with all Environmental Laws; (iii) no portion of the Premises or Property will be used by Tenant or Tenant’s Agents for disposal of Hazardous Materials; (iv) Tenant will deliver to Landlord copies of all Material Safety Data Sheets and other written information prepared by manufacturers, importers or suppliers of any chemical; (v) Tenant will immediately notify Landlord of any violation by Tenant or Tenant’s Agents of any Environmental Laws or the release or suspected release of Hazardous Materials in, under or about the Premises, and Tenant shall immediately deliver to Landlord a copy of any notice, filing or permit sent or received by Tenant with respect to the foregoing; and (vi) Tenant will cooperate with Landlord, any Mortgagee or any purchaser of the Property in their environmental assessments of the Property, including without limitation, participation in interviews regarding the uses and environmental conditions at or affecting the Property, and providing reasonable access to the Premises. “Environmental Laws” means all present or future federal, state or local laws, ordinances, rules or regulations (including the rules and regulations of the federal Environmental Protection Agency and comparable state agency) relating to the protection of human health or the environment. “Hazardous Materials” means pollutants, contaminants, toxic or hazardous wastes or other materials the removal of which is required or the use of which is regulated, restricted, or prohibited by any Environmental Law. If at any time during or after the Term, any portion of the Property is found to be contaminated by Tenant or Tenant’s Agents or subject to conditions prohibited in this Lease caused by Tenant or Tenant’s Agents, Tenant will indemnify, defend and hold Landlord harmless from all claims, demands, actions, liabilities, costs, expenses, attorneys’ fees, damages and obligations of any nature arising from or as a result thereof, and Landlord shall have the right to direct remediation activities, all of which shall be performed at Tenant’s cost. Tenant’s obligations pursuant to this subsection shall survive the expiration or termination of this Lease.

 

(d)            Landlord acknowledges that it is not the intent of this Section 10 to prohibit Tenant from using the Premises for the Permitted Use. Tenant may operate its business according to prudent industry practices so long as the use or presence of Hazardous Materials is strictly and property monitored according to all then applicable Environmental Laws and the terms of this Lease. As a material inducement to Landlord to allow Tenant to use Hazardous Materials in connection with its business, Tenant agrees to deliver to Landlord prior to the Commencement Date a list identifying each type of Hazardous Materials to be brought upon, kept, used, stored, handled, treated, generated on, or released or disposed of from, the Premises and setting forth any and all governmental approvals or permits required in connection with the presence, use, storage, handling, treatment, generation, release or disposal of such Hazardous Materials on or from the Premises (“Hazardous Materials List”). The initial Hazardous Materials List is attached hereto as Exhibit “G”. Tenant shall deliver to Landlord an updated Hazardous Materials List at least once a year and shall also deliver an updated list before any new Hazardous Material is brought onto, kept, used, stored, handled, treated, generated on, or released or disposed of from, the Premises. Tenant shall deliver to Landlord true and correct copies of the following documents (“Haz Mat Documents”) relating to the use, storage, handling, treatment, generation, release or disposal of Hazardous Materials prior to the Commencement Date, or if unavailable at that time, concurrent with the receipt from or submission to a Governmental Authority: permits; approvals; reports and correspondence; storage and management plans, notice of violations of any Laws; plans relating to the installation of any storage tanks to be installed in or under the Project (provided, said installation of tanks shall only be permitted after Landlord has given Tenant its written consent to do so, which consent may be withheld in Landlord’s sole and absolute discretion); all closure plans or any other documents required by any and all federal, state and local Governmental Authorities for any storage tanks installed in or on the Premises for the closure of any such tanks; and a Surrender Plan. Tenant is not required, however, to provide Landlord with any portion(s) of the Haz Mat Documents containing information of a proprietary nature which, in and of themselves, do not contain a reference to any Hazardous Materials or hazardous activities. It is not the intent of this Section to provide Landlord with information which could be detrimental to Tenant’s business should such information become possessed by Tenant’s competitors.

 

 25

 

 

(e)            In addition, Tenant shall, at Tenant’s sole expense, comply in all respects with all Laws applicable now or in the future to the handling, transportation, generation, management, disposal, processing, treatment, storage and use of (i) “chemotherapeutic waste” and “infectious waste” as each term in defined under all laws applicable now or in the future, (ii) “radioactive waste” as defined under all Laws applicable now or in the future, (iii) human corpses, remains and anatomical parts that are donated and used for scientific or medical education, research or treatment, (iv) body fluids or biologicals which are being stored at a laboratory prior to laboratory testing, (v) similar laboratory wastes and materials, or (vi) discarded sharps used in patient care, medical research or laboratories, including but not limited to hypodermic, intravenous, and other medical needles and syringes, scalpel blades, blood vials and glassware in contact with infectious waste, including slides and cover slips at the Premises (“Regulated Waste”). Tenant solely is responsible for obtaining, at Tenant’s expense, any and all governmental permits or approval (“Permits”) required to handle, transport, generate, manage, dispose, process, treat, store or use Regulated Waste at the Premises. Tenant shall comply in all respects with all terms and conditions of such Permits. Under no circumstances shall Tenant be permitted under this Lease to accept at the Premises for processing, treatment, storage, use, or disposal any radioactive, infectious or chemotherapeutic waste generated by any other entity or facility. This Section should not be interpreted to abridge or to modify Tenant’s obligation under this Lease to comply with any other provision of any Law including, without limitation, Tenant’s responsibility to comply with Environmental Laws governing Hazardous Materials. Tenant, at its expense, shall defend, indemnify and hold harmless Landlord, Landlord’s Affiliates and Landlord’s Affiliated Officers from and against any claims, damages, liabilities, losses, actions, and/or lawsuits, including, without limitation, personal injury or property damage, arising from or related to (i) Tenant’s breach of its covenants contained in this Section, (ii) Tenant’s handling, transportation, generation, management, disposal, processing, treatment, storage and/or use of Regulated Waste, or (iii) the presence of any Regulated Waste at the Premises as a result of the activities of Tenant or any of its Agents.

 

(f)             Without limiting any of the foregoing, Tenant shall have the obligation and liability to treat, handle or dispose of its Regulated Waste at its sole cost and expense and accordingly shall obtain its own Regulated Waste disposal vendor. Notwithstanding the foregoing, Tenant shall be permitted to store its Regulated Waste in a location designated within the Premises by Tenant for such purpose and in an appropriate container.

 

 26

 

 

11. Signs. (a) Landlord will furnish Tenant Building standard identification signage on or beside the main entrance door to the Premises in accordance with Landlord’s standard graphics program for the Building and in accordance with all applicable State, Municipal and County Laws and regulations, including without limitation, the requirements of the City of Phoenix and the Cotton Center CCR’s and the Allred CC&Rs. Except as expressly permitted in this Section 11, Tenant shall not place any signs, graphics, notice, picture, placard or poster, or any advertising matter whatsoever on the exterior of the Premises, Building, or the Property, or make or permit any changes in or to Tenant’s signage, without the prior consent of Landlord, in its sole discretion, other than signs that are located wholly within the interior of the Premises and not visible from the exterior of the Premises. Tenant shall maintain all signs installed by Tenant in good condition. Tenant shall remove its signs at the termination of this Lease, shall repair any resulting damage, and shall restore the Premises and/or the Property to its condition existing prior to the installation of Tenant’s signs. Landlord shall have the right to install and maintain signs on the exterior and interior of the Building, provided any such signs for other tenants are not above Tenant’s window lines, and do not materially interfere with Tenant’s signage rights herein. In the event Tenant leases the Expansion Space, as defined in Section 30 below, then Tenant’s signage rights shall be exclusive. Tenant will not have the right to have additional names placed on the Building directory without Landlord’s prior written consent. Tenant shall bear the cost of any additional names placed on the Building directory approved by Landlord or any changes required to any existing sign due to a name change by Tenant. In the event that Tenant desires to change its name on the Building directory or on any sign, Tenant shall provide an explanation to Landlord of the circumstances prompting the need for such name change. If any sign for which this Lease requires Landlord’s approval has not been approved by Landlord is displayed, then Landlord shall, upon reasonable prior notice to Tenant, have the right to remove such sign at Tenant’s expense or to require Tenant to do the same.

 

(b)            Notwithstanding the restriction in Section 11(a) and subject to compliance with all applicable state, municipal and county regulations, and any other applicable covenants, so long as Tenant or a Permitted Transferee leases more rentable square feet of the Building than any other tenant, then Tenant shall, subject to the terms of this Section 11 and at Tenant’s sole cost and expense, have the right to install one (1) building mounted identification sign (“Building Mounted Sign”) in a location along the facade of the Building that is the exterior to the Premises, as long as such location is approved by Landlord, and in compliance with all applicable Laws, and in a size and design consistent with the location, size, terms, conditions, and restrictions set forth in Exhibit “H”, attached hereto, identifying Tenant’s name. The size of such Building Mounted Sign shall be equal to the maximum size of exterior signage permitted by applicable Maricopa County / City of Phoenix regulation or any other applicable Law (which maximum size may also be limited by monument and directional signage in the complex), provided such sign does not exceed the size of the sign ban, cover any applicable window or otherwise exceed the parameters set forth in Exhibit “H”. Landlord shall have the right to allow other tenants to install such signs on any portion of the of the Building on the exterior to the premises leased by such tenants and Landlord shall have the right in Landlord’s reasonable discretion to cause Tenant, at Tenant’s expense, to change the size and location of Tenant’s Building Mounted Sign so that Tenant’s exterior sign does not exceed fifty-seven percent (57%) of the maximum sign of exterior signage permitted by applicable Maricopa County / City of Phoenix regulation or any other applicable Law (which maximum size may also be limited by monument and directional signage in the complex) as Landlord determines reasonably necessary to allow for additional exterior signs.

 

 27

 

 

(c)            The conditions of Tenant’s right to install such Building Mounted Sign are and shall be that (i) Tenant shall be responsible for obtaining all necessary zoning and code approvals from Maricopa County / City of Phoenix, as well as any other governmental approvals at Tenant’s sole cost and expense, provided that Landlord shall use reasonable efforts to cooperate with Tenant in obtaining such approvals, (ii) Tenant shall, at its sole cost and expense, be responsible for obtaining all approvals, if any, required under protective covenants applicable to the Building, provided that Landlord shall use reasonable efforts to cooperate with Tenant in obtaining such approvals, (iii) the method of mounting the sign on the Building shall be subject to the prior written approval of Landlord, which is hereby granted to the extent such sign is depicted on Exhibit “H”, (iv) the final location of such sign shall be subject to Landlord’s prior written approval, (v) Tenant shall pay the cost of mounting and installing such sign, using a contractor approved in advance by Landlord, (vi) Tenant shall be solely responsible for the electrical supply necessary to light the sign, if applicable, and for obtaining a separate meter from the appropriate utility provider for such sign, (vii) if at any time after the Commencement Date has occurred, Tenant, its Permitted Transferees and Strategic Partners occupy less than fifty percent (50%) of the rentable square feet in the Building and Tenant is not leasing a premises larger than any other tenant of the Building, Landlord shall have the right to require Tenant to remove the Building Mounted Sign at Tenant’s expense upon thirty (30) days’ prior written notice to Tenant, (viii) if at any time an Event of Default shall have occurred and be continuing, then in addition to any other remedies Landlord may have under this Lease, Landlord shall have the right to remove Tenant’s Building Mounted Sign and restore the exterior of the Building at Tenant’s cost and expense, and (ix) upon the expiration or earlier termination of this Lease, Tenant shall remove and bear the cost of removal of the Tenant’s Building Mounted Sign, and shall pay, within thirty (30) days after request therefor (together with reasonable evidence supporting such cost) for the restoration of the exterior of the Building if exterior is damaged by such removal. Notwithstanding anything to the contrary contained herein, Tenant shall have the right to transfer its signage rights to an approved Transferee.

 

(d)             If any sign for which this Lease requires Landlord’s approval has not been approved by Landlord is displayed, then Landlord shall, upon reasonable prior notice to Tenant, have the right to remove such sign at Tenant’s expense or to require Tenant to do the same. Landlord reserves the right to install and display signs, advertisements and notices on any part of the exterior or interior of the Building; provided, however, that Landlord shall only affix, install, or display signs on the interior of the Premises which pertain to the management or operation of the Building.

 

12. Alterations.

 

(a)            Except for non-structural Alterations that (i) do not exceed One Hundred Thousand and 00/100 Dollars ($100,000.00), (ii) are not visible from the exterior of the Premises, (iii) do not affect any Building System, the roof, or the structural strength of the Building (iv) do not require penetrations into the floor, ceiling or walls, and (v) do not require work within the walls, below the floor or above the ceiling, Tenant shall not make or permit any Alterations in or to the Premises without first obtaining Landlord’s consent, and unless such alterations affect the structural elements of the Building, the Common Areas or Building Systems, or would otherwise require a building permit. With respect to any Alterations made by or on behalf of Tenant (whether or not the Alteration requires Landlord’s consent): (i) not less than ten (10) days prior to commencing any Alteration, Tenant shall deliver to Landlord for Landlord’s review and approval the plans, specifications and necessary permits for the Alterations (the “Alteration Plans”), together with certificates evidencing that Tenant’s contractors and subcontractors have adequate insurance coverage naming the Landlord Additional Insureds, as their interests may appear, as additional insureds; (ii) Tenant shall obtain Landlord’s prior written approval of any contractor or subcontractor, which such approval shall not be unreasonably withheld, conditioned or delayed; (iii) the Alteration shall be constructed with new materials, in a good and workmanlike manner, and in compliance with all Laws and the plans and specifications delivered to, and, if required above, approved by Landlord; (iv) the Alteration shall be performed in accordance with Landlord’s reasonable requirements relating to sustainability and energy efficiency; and (v) upon Landlord’s request Tenant shall, prior to commencing any Alteration, provide Landlord reasonable security against liens arising out of such construction. “Alteration(s)” means any addition, alteration or improvement to the Premises or Property including Tenant’s Improvements and FFE (as defined below). Any Alteration by Tenant shall be the property of Tenant until the expiration or termination of this Lease; at that time without payment by Landlord the Alteration shall remain on the Property and become the property of Landlord unless Landlord gives notice to Tenant at the time Landlord approves such Alteration or if Landlord’s approval is not required at least four (4) months prior to the Expiration Date, provided that if this Lease is terminated earlier then no advance notice is required, to remove any of such Alterations, in which event Tenant will remove them, will repair any resulting damage and will restore the Premises to the condition existing prior to Tenant’s installation of such Alteration(s), all in accordance with the terms of Section 21(a) below.

 

 28

 

 

(b)            Landlord’s review or approval of any Alterations or plans or specifications therefor shall not be a representation or warranty of Landlord that such Alterations, plans or specifications are fit for any use or comply with any Laws, and Tenant shall have no right to rely upon any review or approval. Landlord shall have no liability to Tenant or any third party by reason of such review or approval, and any such review and approval shall be for Landlord’s own benefit.

 

(c)            All workmen and mechanics performing any Alterations must work in harmony and not interfere with labor employed by Landlord, Landlord’s contractors or labor employed by any other tenants or their contractors. If at any time during the course of the installation of any Alterations, any workmen or mechanics performing the Alterations are unable to work in harmony, or interfere, with labor employed by Landlord, Landlord’s contractors or by any other tenants or their contractors, then the approval granted by Landlord to Tenant for the subject Alterations may be withdrawn by Landlord upon forty eight (48) hours’ written notice to Tenant, and Tenant shall thereafter cause the Alterations to cease, and shall at Landlord’s sole option restore the Premises to the condition that existed prior to the commencement of such Alteration. Tenant shall indemnify, defend and hold Landlord and its Agents harmless from and against any claim, liability or other losses in any way arising from labor disharmony in connection with any Alterations or any other contractors or employees of Tenant, its subtenants, successors or assigns. Landlord reserves the right to require Tenant to use contractors designated by Landlord, in its sole discretion, for Alterations that are performed in secure areas of the Building or other portions of the Building outside of the Premises or which impact any Building Systems.

 

 29

 

 

13.  Mechanics’ Liens. Except to the extent contracted for by Landlord, the interest of Landlord in the Premises and the Property shall not be subject in any way to any liens, including real estate commission liens and construction liens for improvements to or other work performed by or on behalf of Tenant. Tenant promptly shall pay for any labor, services, materials, supplies or equipment furnished to Tenant in or about the Premises. Tenant shall keep the Premises and the Property free from any liens arising out of any labor, services, materials, supplies or equipment furnished or alleged to have been furnished to Tenant. Tenant shall take all steps permitted by law in order to avoid the imposition of any such liens including a written provision in all construction contracts for suppliers of labor, services, materials and equipment, approved in writing by Landlord prior to execution, that this Lease prohibits mechanics/construction liens against the Premises and the Property. Should any such lien or notice of such lien be filed against the Premises or the Property, Tenant shall discharge the same by satisfying or bonding over such lien within fifteen (15) days after Tenant has notice that the lien or claim is filed regardless of the validity of such lien or claim. It is further understood and agreed that under no circumstance is the Tenant to be deemed the agent of Landlord for any Alteration, repair, or construction within the Premises, the same being done at the sole expense and request of Tenant and not as an express or implied agent of Landlord. All contractors, materialmen, suppliers, mechanics, and laborers are hereby charged with notice that they must look only to Tenant for the payment of any charge for work done or materials furnished upon the Premises in connection with any Tenant Improvements, Alterations, repair or construction by Tenant within the Premises during the Term.

 

14. Landlord’s Rights.

 

(a)            Tenant shall permit Landlord and its Agents to enter the Premises at all reasonable times following reasonable notice (but in no event less than one business day except in an emergency) to inspect, perform any work to Maintain, or make alterations to the Premises or the Property, to exhibit the Premises for the purpose of sale or financing, and, during the last twelve (12) months of the Term, to exhibit the Premises to any prospective tenant for the Premises. Except in the event of an emergency, Landlord shall adhere to Tenant’s safety and cleanliness procedures and policies, including any of Tenant’s ‘advertised gown guidelines’ for entering into any laboratory areas, and Tenant shall have the right to require Landlord to be escorted by an employee or representative of Tenant. Landlord will make reasonable efforts not to inconvenience Tenant in exercising such rights. Tenant will provide Landlord or its designees free and unfettered access to any mechanical or utility rooms, conduits, risers or the like located within the Premises.

 

 30

 

 

(b)            In addition to any other rights provided for herein and provided Landlord uses commercially reasonable efforts to limit any interference with Tenant’s use of or access to the Premises, Landlord reserves the following rights, exercisable without liability to Tenant for damage or injury to property, person, or business and without effecting an eviction, constructive or actual, or disturbance of Tenant’s use or possession or giving rise to any claim: (i) to name the Building and to change the name or street address of the Building or the roads leading to and from the Building or the Land; (ii) to relocate various facilities within the Building and on the Land, including, without limitation, lobby areas, mechanical areas, entrances or passageways, doors or doorways, corridors, elevators, stairs, toilets or other Common Areas; access to and from the Building; or the configuration of the parking areas; (iii) to install vending machines of all kinds in the Building (but not the Premises) and to receive all of the revenue derived therefrom; (iv) when reasonably necessary to temporarily close the Parking Area or any part thereof, walkways, drives, entrances, doors, corridors, elevators or other facilities; (v) to subdivide the Property; (vi) to subject all or any part of the Property to a condominium regime; (vii)   to pursue, or allow any tenant or prospective Property purchaser to pursue, any variance or other zoning relief which Landlord shall, in its good faith judgment, determine to be advisable; (viii)  to unilaterally alter Tenant’s ingress and egress to the Building or make any change in operating conditions to restrict pedestrian, vehicular or delivery ingress and egress to a particular location, or at any time close temporarily any Common Areas to make repairs or changes therein or to effect construction, repairs or changes within the Building or on the Land on which the Building is located, or to discourage non-tenant parking, and may do such other acts in and to the Common Areas as in Landlord’s sole judgment may be desirable to improve their convenience; (ix)  to use and/or allow others to use the roof of the Building or any portion of the Land on which the Building is located; (x) to limit the space on the directory of the Building to be allotted to Tenant; and, (xi) to grant to anyone the right to conduct any particular business or undertaking in the Building.

 

(c)            No rights, easements or licenses are acquired in the Property or any land adjacent to the Property by Tenant by implication or otherwise except as expressly set forth in this Lease. Any diminution or shutting off of light air or view by any structure which may be erected on lands adjacent to the Building shall in no way effect this Lease or impose any liability on Landlord.

 

(d)            If Tenant breaches any covenant or condition of this Lease, in addition to all other remedies available to Landlord under this Lease, Landlord may, on prior notice to Tenant (except that no notice need be given in case of emergency), cure such breach at the expense of Tenant, and the reasonable amount of all expenses, including attorney’s fees, incurred by Landlord in so doing (whether paid by Landlord or not) will be deemed payable on demand as additional Rent.

 

 31

 

 

15. Damage by Fire or Other Casualty.

 

(a)            If the Premises or Common Areas shall be damaged or destroyed by fire or other casualty, Tenant shall promptly notify Landlord, and Landlord, subject to the conditions set forth in this Section 15, shall repair such damage and restore the Premises or Common Areas to substantially the same condition in which they were immediately prior to such damage or destruction, but not including the repair, restoration or replacement of the Tenant Improvements, FFE or any Alterations installed by or on behalf of Tenant. Landlord shall notify Tenant, within thirty (30) days after the date of the casualty, if Landlord anticipates that the restoration will take more than one hundred eighty (180) days from the date of the casualty to complete; in such event, either Landlord or Tenant (unless the damage was caused by Tenant) may terminate this Lease effective as of the date of casualty by giving notice to the other within ten (10) days after Landlord’s notice. If a casualty occurs during the last twelve (12) months of the Term that materially affects Tenant’s use of or access to the Premises, either Tenant Landlord may terminate this Lease; provided that if Landlord exercises such termination right and Tenant has the right to extend the Term for at least three (3) more years and does so within thirty (30) days after the date of the casualty, such termination shall not be effective. Moreover, Landlord may terminate this Lease if the loss is not substantially covered by the insurance maintained or required to be maintained by Landlord under this Lease or if any holder of a Mortgage on the Land or Building does not permit or release a substantial portion of the insurance proceeds for such repair or restoration. Tenant will receive an abatement of Minimum Annual Rent and Annual Operating Expenses and Additional Taxes to the extent the Premises are rendered untenantable as a result of the casualty.

 

(b)            Tenant hereby expressly waives the benefit of A.R.S. §33-343 or any other or statute now or hereafter in effect which would otherwise afford Tenant the right to terminate this Lease or its obligations hereunder due to damage to or destruction of the Premises and agrees that the terms of this Lease shall govern the effect of any damage and destruction thereof.

 

16.  Condemnation. If (a) all of the Premises are Taken (as defined hereunder), (b) any part of the Premises is Taken and the remainder is insufficient in Landlord’s opinion for the reasonable operation of Tenant’s business, or (c) any of the Property is Taken, and, in Tenant or Landlord’s opinion, it would be impractical or the condemnation proceeds are insufficient to restore the remainder, then this Lease shall terminate as of the date the condemning authority takes possession. If this Lease is not terminated, to the extent that proceeds are paid to Landlord and made available by the holder of a Mortgage on the Land or the Building, Landlord shall restore the Building to a condition as near as reasonably possible to the condition prior to the Taking, the Minimum Annual Rent shall be abated for the period of time all or a part of the Premises is untenantable in proportion to the square foot area untenantable, and this Lease shall be amended appropriately. The compensation awarded for a Taking shall belong to Landlord. Except for any relocation benefits to which Tenant may be entitled, Tenant hereby assigns all claims against the condemning authority to Landlord, including, but not limited to, any claim relating to Tenant’s leasehold estate. “Taken” or “Taking” means acquisition by a public authority having the power of eminent domain by condemnation or conveyance in lieu of condemnation.

 

17. Quiet Enjoyment. Landlord covenants that Tenant, upon performing all of its covenants,agreements and conditions of this Lease, shall have quiet and peaceful possession of the Premises as against anyone claiming by or through Landlord, subject, however, to the terms of this Lease.

 

 32

 

 

18. Assignment and Subletting.

 

(a)            Except as provided in Section 18(b) below, Tenant shall not enter into nor permit any Transfer (as defined hereunder) voluntarily or by operation of law, without the prior consent of Landlord. Without limitation, Tenant agrees that Landlord’s consent shall not be considered unreasonably withheld if (i) the business, business reputation, or creditworthiness of the proposed transferee is unacceptable to Landlord, in Landlord’s sole discretion, (ii) Landlord or an affiliate of Landlord has comparable space (including without limitation comparable size, finishes, function, parking and location) available for lease by the proposed transferee, the intention being that Tenant shall not compete with Landlord in the leasing market, (iii) the proposed transferee is a governmental agency or a quasi-governmental entity or any other person or entity entitled, directly or indirectly, to diplomatic or sovereign immunity, regardless of whether the proposed transferee agrees to waive such diplomatic or sovereign immunity, or shall not be subject to the service of process in, or the jurisdiction of the courts of, the State of Arizona; or (iv) an Event of Default (as defined below) exists, or Tenant is in default under this Lease or any act or omission has occurred which would constitute a default with the giving of notice and/or the passage of time. A consent to one Transfer shall not be deemed to be a consent to any subsequent Transfer. In no event shall any Transfer relieve Tenant from any obligation under this Lease. Landlord’s acceptance of Rent from any person shall not be deemed to be a waiver by Landlord of any provision of this Lease or to be a consent to any Transfer. Any Transfer not in conformity with this Section 18 shall be void at the option of Landlord or its Mortgagee. “Transfer” means (i) any assignment, transfer, pledge or other encumbrance of all or a portion of Tenant’s interest in this Lease, (ii) any sublease, license or concession of all or a portion of Tenant’s interest in the Premises, or (iii) any transfer of a controlling interest in Tenant, other than as part of an initial public offering of stock in Tenant on a national stock exchange. For the purpose of this definition, “transfer of a controlling interest of Tenant” means either (i) ownership or voting control, directly or indirectly, or at least fifty (50%) percent of all equity or other beneficial interest or (ii) the power to direct the management and policies of such entity.

 

(b)             Notwithstanding the provisions of Section 18(a) above, Landlord’s consent shall not be required, and Sections 18 (c) and (d) shall not apply, in the event of any Transfer by Tenant to an Affiliate (as defined hereunder) provided that (i) the Affiliate has a tangible net worth at least equal to that of Tenant as of the Commencement Date of this Lease, (ii) Tenant provides Landlord notice of the Transfer at least fifteen (15) days prior to the effective date of the Transfer, together with current financial statements of the Affiliate certified by an executive officer of the Affiliate and a copy of the proposed Transfer documents, and (iii) in the case of an assignment or sublease, Tenant delivers to Landlord an assumption agreement or a sublease (as applicable) reasonably acceptable to Landlord executed by Tenant and the Affiliate, together with a certificate of insurance and appropriate endorsements evidencing the Affiliate’s compliance with the insurance requirements of Tenant under this Lease. “Affiliate” means (x) any entity controlling, controlled by, or under common control of, Tenant, (y) any successor to Tenant by merger, consolidation or reorganization, or (z) any purchaser of all or substantially all of the assets or equity of Tenant as a going concern. The term “Permitted Transferee” shall mean an Affiliate that meets the conditions set form in subsections 15(b)(i) through (iii) above. Further, Landlord’s consent, shall not be required but notice shall be provided to Landlord prior to the commencement of occupancy, and Sections 18 (c) and (d) shall not apply to any occupancy of less than 2,000 rentable square feet by any “Strategic Partners” of Tenant on a short term or specific project basis. A Strategic Partner means a non-affiliated company with whom Tenant or a Tenant Affiliate is participating in ongoing research and development, testing, marketing, or consulting relating to the business of Tenant. Tenant shall be responsible for any and all actions or inactions of any Strategic Partner (and its employees, agents and invitees) in, on or about the Premises or Building.

 

 33

 

 

(c)            The provisions of subsection 18(a) above notwithstanding, if Tenant proposes to Transfer all of the Premises (other than to an Affiliate) for all or substantially all the then remaining Term, Landlord may terminate this Lease, either conditioned on execution of a new lease between Landlord and the proposed transferee or without that condition. If this Lease is not so terminated , Tenant shall pay to Landlord, immediately upon receipt, fifty percent (50%) of the excess of (i) all compensation received by Tenant for the Transfer over (ii) the Rent allocable to the Premises and Term transferred, after Tenant has recouped from such excess all brokers’ commissions, legal fees, and tenant improvement costs and allowances incurred by Tenant in connection with such Transfer and the unamortized portion of Tenant’s investment in Tenant Improvements and Alterations.

 

(d)             If Tenant requests Landlord’s consent to a Transfer, Tenant shall provide Landlord, at least fifteen (15) days prior to the proposed Transfer, current financial statements of the transferee certified by an executive officer of the transferee, a complete copy of the proposed Transfer documents, and any other information Landlord reasonably requests. If Landlord fails to approve such Transfer within fifteen (15) days after Landlord’s receipt of all requested materials, Landlord’s consent to such Transfer shall be deemed rejected. Immediately following any approved assignment or sublease, Tenant shall deliver to Landlord an assumption agreement or a sublease (as applicable) reasonably acceptable to Landlord executed by Tenant and the transferee, together with a certificate of insurance evidencing the transferee’s compliance with the insurance requirements of Tenant under this Lease. Each sublease will provide that such sublessee’s rights will be no greater than those of Tenant, and that the sublease is subject and subordinate to this Lease and to the matters to which this Lease is or will be subordinate, and that upon an Event of Default, Landlord may, at its option, have such sublessee attorn to Landlord or require that such sublessee pay its rent due to Tenant directly to Landlord, provided, however, in such case Landlord will not (i) be liable for any previous act or omission of Tenant under such sublease or, (ii) be subject to any offset not expressly provided for in this Lease or by any previous prepayment of more than one month’s rent. Landlord shall apply any amounts received from the Transferee as rent to Tenant’s obligations under this Lease. The liability of Tenant and each assignee or sublessee will be joint, several and primary for the observance of all the provisions, obligations and undertakings of this Lease, including the payment of Rent through the entire Term, as the same may be renewed, extended or otherwise modified. The proposed assignee or subtenant may use the Premises for the permitted Use only.

 

(e)            Tenant acknowledges that Landlord will incur costs in connection with any Transfer under this Lease. Accordingly, Tenant shall promptly pay to Landlord the amount (“Transfer Charge”) of all costs (including, without limitation, Landlord’s reasonable attorney’s fees) actually incurred by Landlord in connection with any Transfer, not to exceed $2.500 without Tenant’s prior approval. Tenant shall pay the Transfer Charge even in the event that a proposed Transfer is not effectuated.

 

 34

 

 

19. Subordination; Mortgagee’s Rights.

 

(a)            Tenant accepts this Lease subject and subordinate to any Mortgage of the entire Building and/or Land affecting the Premises, which may now or in the future be secured upon the Building and/or Land, and to all renewals, modifications, consolidations, replacements and extensions thereof, provided that Tenant’s right of possession of the Premises shall not be disturbed by the Mortgagee so long as an Event of Default does not exist. This clause shall be self-operative, and although no instrument or act on the part of Tenant will be necessary to effectuate such subordination, Tenant will, nevertheless, in confirmation of such subordination, within ten (10) business days after request, execute and deliver any further instruments confirming the subordination of this Lease and any further instruments of attornment that the Mortgagee may reasonably request. However, any Mortgagee may at any time subordinate its Mortgage to this Lease, without Tenant’s consent, by giving notice to Tenant, and this Lease shall then be deemed prior to such Mortgage without regard to their respective dates of execution and delivery; provided that such subordination shall not affect any Mortgagee’s rights with respect to condemnation awards, casualty insurance proceeds, intervening liens or any right which shall arise between the recording of such Mortgage and the execution of this Lease. Notwithstanding the foregoing, the party holding the instrument to which this Lease is subordinate shall have the right to recognize and preserve this Lease in the event of any foreclosure sale or possessory action, and in such case this Lease shall continue in full force and effect at the option of the party holding the superior lien and Tenant shall attorn to such party and shall execute, acknowledge and deliver any instrument that has for its purpose and effect the confirmation of such attornment within ten (10) business days after request. Tenant waives the protection of any statute or rule of law that gives or purports to give Tenant any right to terminate this Lease or surrender possession of the Premises upon the transfer of Landlord’s interest. “Mortgage” means any mortgage, deed of trust or other lien or encumbrance on Landlord’s interest in the Property or any portion thereof, including without limitation any ground or master lease if Landlord’s interest is or becomes a leasehold estate. “Mortgagee” means the holder of any Mortgage, including any ground or master lessor if Landlord’s interest is or becomes a leasehold estate. Notwithstanding the foregoing, Landlord will use commercially reasonable efforts to obtain a non-disturbance, subordination and attornment agreement from Landlord’s current Mortgagee on such Mortgagee’s current standard form of agreement or such other commerically reasonable form as is acceptable to such Mortgagee. Landlord shall not be required to incur any cost, expense or liability to obtain such agreement, it being agreed that Tenant shall be responsible for any fee or review costs charged by the Mortgagee. Upon request of Landlord and provided such form is commerically reasonable, Tenant will execute the Mortgagee’s form of non-disturbance, subordination and attornment agreement or such other agreed to form and return the same to Landlord for execution by the Mortgagee. Landlord’s inability to obtain a non-disturbance, subordination and attornment agreement for Tenant shall have no effect on the rights, obligations and liabilities of Landlord and Tenant or be considered to be a default by Landlord hereunder.

 

 35

 

 

(b)            No Mortgagee shall be (i) liable for any previous act or omission of a prior landlord, (ii) subject to any rental offsets or defenses hereunder because of any act or omission of any prior landlord, (iii) bound by any amendment of this Lease made without its written consent, (iv) bound by payment of Monthly Rent more than one month in advance or liable for any other funds paid by Tenant to Landlord unless such funds actually have been transferred to the Mortgagee by Landlord, or (v) liable for any security not actually received by it. Subject to the foregoing, the provisions hereof shall be binding upon and inure to the benefit of the successors and assigns of Landlord.

 

(c)            The provisions of Section 15 and Section 16 above notwithstanding, Landlord’s obligation to restore the Premises after a casualty or condemnation shall be subject to the consent and prior rights of any Mortgagee.

 

(d)            Tenant shall send to each Mortgagee of any Mortgage covering the Property or any part thereof (after notification of the identity of such mortgagee and the mailing address thereof) copies of all notices of default, termination, or renewal that Tenant sends to Landlord; such notices to said Mortgagee shall be sent in the same manner and time as notices are required to be sent pursuant to Section 25 hereof. Tenant will accept performance of any provision of this Lease by such Mortgagee as performance by, and with the same force and effect as though performed by, Landlord.

 

20. Tenant’s Certificate; Financial Information; Confidentiality.

 

(a)            Within ten (10) business days after Landlord’s request from time to time, (i) Tenant shall execute, acknowledge and deliver to Landlord, for the benefit of Landlord, Mortgagee, any prospective Mortgagee, and any prospective purchaser of Landlord’s interest in the Property, an estoppel certificate in the form of attached as Exhibit “E” (or other commercially reasonable form requested by Landlord), modified as necessary to accurately state the facts represented, and (ii) Tenant shall furnish to Landlord, Landlord’s Mortgagee, prospective Mortgagee and/or prospective purchaser reasonably requested financial information. Landlord agrees to keep any private financial information provided to it by Tenant confidential (except for disclosure to the parties listed in this subsection (ii), and any Mortgagee, prospective Mortgagee and/or prospective purchaser with which Landlord shares such information shall be informed by Landlord of the obligation to keep such information confidential.

 

(b)            Tenant agrees not to disclose the terms, covenants, conditions or other facts with respect to this Lease, including the Minimum Annual Rent and additional Rent, to any person, corporation, partnership, association, newspaper, periodical or other entity, except to Tenant’s accountants or attorneys (who shall also be required to keep the terms of this Lease confidential) or as required by law. This non-disclosure and confidentiality agreement will be binding upon Tenant without limitation as to time, and a breach of this Section 20(b) will constitute a material breach under this Lease. In addition, Tenant’s employees, contractors, etc. shall keep any of the terms and conditions of this Lease, including any billing statements and/or any backup supporting those statements, confidential.

 

 36

 

 

21. Surrender.

 

(a)            On the date on which this Lease expires or terminates, Tenant shall return possession of the Premises to Landlord in good condition, except for ordinary wear and tear, and except for casualty damage or other conditions that Tenant is not required to remedy under this Lease. Notwithstanding anything to the contrary contained in this Lease, and subject to the terms of this Section 21(a), prior to the expiration or earlier termination of this Lease, Tenant shall remove from the Premises all Tenant Improvements (subject to Section 29(c) below), Alterations (subject to Section 12(a) above), the Satellite System (subject to Section 7(e) above), the Building Mounted Sign (subject to Section 11(b) above), and its FFE, partitions, and all other personal property installed by Tenant or its assignees or subtenants. Tenant shall also cap or terminate all telephone, computer and data connections at service entry panels in accordance with all applicable Laws. With respect to the Generator, or any Tenant Improvements or Alterations Tenant is otherwise required to remove hereunder, Landlord agrees that Tenant shall be required to remove the same only if Landlord provides notice to Tenant to remove such items at least three (3) months prior to the Expiration Date, unless this Lease is terminated following an Event of Default in which case no notice shall be required. Tenant shall repair any damage resulting from any and all such removal and shall restore the Premises to good order and the condition existing prior to Tenant’s installation of any Tenant Improvements or Alterations the Satellite System, or the Building Mounted Sign required to be removed pursuant to the terms of this Lease. Any of the Tenant FFE or the Satellite System, or the Building Mounted Sign or Tenant’s personal property not removed or restored as required herein shall be deemed abandoned, and Landlord, at Tenant’s expense, may remove, store, sell or otherwise dispose of such property in such manner as Landlord may see fit and retain such property as its property or sell such property and keep the proceeds. If Tenant does not return possession of the Premises to Landlord in the condition required under this Lease, Tenant shall pay Landlord all resulting actual damages Landlord may incur. Tenant’s failure to comply with the terms and conditions of this Section 21(a) shall also be deemed an Event of Default by the Tenant under this Lease, entitling Landlord to exercise all legal and equitable remedies available to Landlord.

 

(b)            Upon the expiration of the Term or earlier termination of Tenant’s right of possession, Tenant shall surrender the Premises to Landlord free of Hazardous Materials brought upon, kept, used, stored, handled, treated, generated in, or released or disposed of from, the Premises (collectively, “Tenant HazMat Operations”) and released of all Hazardous Materials Clearances, broom clean, ordinary wear and tear and casualty loss and condemnation covered by Sections 15 and 16 excepted. At least 3 months prior to the surrender of the Premises, Tenant shall deliver to Landlord a narrative description of the actions proposed (or required under any Law) to be taken by Tenant in order to surrender the Premises (including any Alterations permitted by Landlord to remain in the Premises) at the expiration or earlier termination of the Term, free from any residual impact from the Tenant HazMat Operations and otherwise released or unrestricted use and occupancy (“Surrender Plans”). Such Surrender Plan shall be accompanied by a current listing of (i) all Hazardous Materials licenses and permits held by or on behalf of any Tenant Agent with respect to the Premises, and (ii) all Hazardous Materials used, stored, handled, treated, generated, released or disposed of from the Premises, and shall be subject to the review and approval of Landlord’s environmental consultant. In connection with the review and approval of the Surrender Plan, upon the request of Landlord, Tenant shall deliver to Landlord or its consultant such additional non-proprietary information concerning Tenant HazMat Operations as Landlord shall request. On or before such surrender, Tenant shall deliver to Landlord evidence that the approved Surrender Plan shall have been satisfactorily completed and Landlord shall have the right, subject to reimbursement at Tenant’s expense as set forth below, to cause Landlord’s environmental consultant to inspect the Premises and perform such additional procedures as may be deemed reasonably necessary to confirm that the Premises are, as of the effective date of such surrender or early termination of this Lease, free from any residual impact from Tenant HazMat Operations. Tenant shall reimburse Landlord, as Additional Rent, for the actual out-of-pocket expense incurred by Landlord for Landlord’s environmental consultant to review and approve the Surrender Plan and to visit the Premises and verify satisfactory completion of the same, which cost shall not exceed $5,000. Landlord shall have the unrestricted right to deliver such Surrender Plan and any report by Landlord’s environmental consultant with respect to the surrender of the Premises to third parties.

 

 37

 

 

(c)             If Tenant remains in possession of the Premises or any part thereof after the expiration or termination of this Lease (“Holdover”), without the written consent of Landlord, Tenant’s occupancy of the Premises shall be that of a tenancy at sufferance. Tenant’s occupancy during any Holdover period shall otherwise be subject to the provisions of this Lease (unless clearly inapplicable), except that the Monthly Rent shall be one hundred seventy-five percent (175%) of the Monthly Rent payable for the last full month immediately preceding the Holdover, plus all other charges payable hereunder, and upon all the terms hereof applicable to such a tenancy at sufferance. No Holdover or payment by Tenant after the expiration or termination of this Lease shall operate to extend the Term or prevent Landlord from immediate recovery of possession of the Premises by summary proceedings or otherwise. Nothing contained herein shall be deemed to authorize Tenant to remain in occupancy of the Premises after the Expiration Date or sooner termination of the Term. Any provision in this Lease to the contrary notwithstanding, any Holdover by Tenant shall constitute an Event of Default entitling Landlord to exercise, without obligation to provide Tenant any notice or cure period, all of the remedies available to Landlord upon an Event of Default, and Tenant shall be liable for, and agrees to hold Landlord harmless from and against, all liabilities, obligations, damages, penalties, claims, costs, charges and expenses, including attorneys’ fees and consequential damages, that Landlord suffers as a result of the Holdover, including any claims made by any succeeding tenant based on such delay. Notwithstanding anything to the contrary set forth in this Section 21(c), Tenant shall have the one-time right to elect to extend the Term for a period of three (3) months upon providing to Landlord notice of such election at least nine (9) months prior to the Expiration Date (the “Extended Term”). During the Extended Term the Minimum Annual Rent shall be equal to 150% of the Minimum Annual Rent applicable at the last month of the Term, and all of the other terms of provisions of this Lease shall apply, except that Tenant shall not have any right to make any Alterations or any Transfers, expand the Premises, or extend the Term.

 

(d)            During the last ninety (90) days prior to the Expiration Date, if Tenant has vacated the Premises, Landlord may decorate, remodel, repair, alter or otherwise prepare the Premises for occupancy, without affecting Tenant’s obligation to pay Rent for the Premises, however, Tenant’s indemnification obligations shall not apply to any acts, omissions or events within the Premises that arise on and after Landlord’s entry for such purposes.

 

22. Defaults - Remedies.

 

(a)            It shall be an “Event of Default” following the expiration of all applicable notice and cure periods set forth below:

 

 (i)           If Tenant does not pay in full when due any and all Rent, and such failure continues for more than five (5) business days following notice of delinquency from Landlord; provided, however, that Landlord shall not be obligated to provide written notice of monetary default more than one (1) time in any twelve-month period, and each subsequent monetary default during such twelve-month period shall be an Event of Default if not received on the date due hereunder;

 

 38

 

 

(ii)          If Tenant enters into or permits any Transfer in violation of Section 18 above;

 

(iii)         If Tenant fails to observe and perform or otherwise breaches any other provision of this Lease, and, except as provided in Section 22(d) below, Tenant fails to cure the default on or before the date that is ten (10) business days after Landlord gives Tenant notice of default; provided, however, if the default cannot reasonably be cured within ten (10) business days following Landlord’s giving of notice, Tenant shall be afforded additional reasonable time (not to exceed thirty (30) days following Landlord’s notice) to cure the default if Tenant begins to cure the default within ten (10) business days following Landlord’s notice and continues diligently in good faith to completely cure the default; or

 

(iv)         If Tenant becomes insolvent or makes a general assignment for the benefit of creditors or offers a settlement to creditors, or if a petition in bankruptcy or for reorganization or for an arrangement with creditors under any federal or state law is filed by or against Tenant, or a bill in equity or other proceeding for the appointment of a receiver for any of Tenant’s assets is commenced, or if any of the real or personal property of Tenant shall be levied upon; provided that any proceeding brought by anyone other than Landlord or Tenant under any bankruptcy, insolvency, receivership or similar law shall not constitute an Event of Default until such proceeding has continued unstayed for more than sixty (60) consecutive days.

 

Any notice periods provided for in this Lease shall run concurrently with any statutory notice periods and any notice given hereunder may be given simultaneously with or incorporated into any such statutory notice.

 

(b)            If an Event of Default occurs, Landlord shall, at any time thereafter, with or without notice or demand and without limiting Landlord in the exercise of any other right or remedy which Landlord may have by reason of such default (with such remedies being cumulative and not exclusive), have the following rights and remedies:

 

(i)           Landlord, without any obligation to do so, may elect to cure the default on behalf of Tenant, in which event Tenant shall reimburse Landlord upon demand for any sums paid or costs incurred by Landlord (together with an administrative fee of fifteen percent (15%) thereof) in curing the default, plus interest at the Interest Rate from the respective dates of Landlord’s incurring such costs, which sums and costs together with interest at the Interest Rate shall be deemed additional Rent;

 

(ii)          To exercise all rights and remedies under ARS§§33-361 and 362 including, without limitation, to enter, re-enter and repossess the Premises, by breaking open locked doors if necessary, without terminating this Lease, and remove all persons and all or any property from the Premises, by action at law or otherwise, without being liable for prosecution or damages, in which case Landlord shall be entitled to enforce all of Landlord’s rights and remedies under this Lease, including the right to recover the Rent and all other amounts due hereunder as they become due. Landlord may, at Landlord’s option, make Alterations and repairs in order to relet the Premises and relet all or any part(s) of the Premises for Tenant’s account. Tenant agrees to pay to Landlord within thirty (30) days any deficiency (taking into account all reasonable costs incurred by Landlord) that may arise by reason of such reletting. In the event of reletting without termination of this Lease, Landlord may at any time thereafter elect to terminate this Lease for such previous breach. No re-entry or taking possession of the Premises by Landlord pursuant to this Section 22(b)(ii) or other action on Landlord’s part shall be construed as an election to terminate this Lease unless a written notice of such intention is given to Tenant or unless the termination hereof is decreed by a court of competent jurisdiction. Landlord’s election not to terminate this Lease pursuant to this Section 22(b)(ii) or pursuant to any other provision of this Lease shall not preclude Landlord from subsequently electing to terminate this Lease or pursuing any of its other remedies;

 

 39

 

 

(iii)        To accelerate the whole or any part of the Rent for the balance of the Term as provided in Section 22(b)(iv) below, along with all sums past due, and declare the same to be immediately due and payable, which sums shall be discounted to present value at the discount rate of the Federal Reserve Bank of San Francisco at the time of award plus one percent (1%). In determining the amount of any future payments due Landlord as a result of increases in Annual Operating Expenses and Additional Taxes, Landlord may make such determination based upon the amount of Annual Operating Expenses and Additional Taxes paid by Tenant for the full year immediately prior to such Event of Default;

 

(iv)          To terminate this Lease and the Term by any lawful means without any right on the part of Tenant to save the forfeiture by payment of any sum due or by other performance of any condition, term or covenant broken, in which case Tenant shall promptly surrender possession of the Premises to Landlord. In such event, Landlord shall be entitled to recover from Tenant all damages incurred by Landlord by reason of Tenant’s default including, but not limited to, the cost of recovering possession of the Premises; expenses of re-letting, including necessary renovation and alteration of the Premises, reasonable attorneys’ fees, and any real estate commission actually paid; the “worth at the time of award” established by the court having jurisdiction thereof of the amount by which the unpaid rent and other charges due for the balance of the Term after the time of Tenant’s default exceeds the amount of such rental loss for the same period that Tenant proves by clear and convincing evidence could have been reasonably avoided; and that portion of any leasing commission paid by Landlord applicable to the unexpired Term of this Lease (which shall be calculated based on the assumption that any leasing commission applicable to the Term would have been evenly and equally amortized in monthly payments over the number of months contained in the Term at an interest rate of seven percent (7%) per annum). For purposes of this Section 22(b)(iv), “worth at the time of award” of the amount referred to above shall be computed by discounting each amount by a rate equal to the Prime Rate at the time of the award plus three percent (3%), but in no event more than an annual rate of ten percent (10%). As used herein, the “Prime Rate” means the then current prime rate published in the Western Edition of the Wall Street Journal provided, however, if the Western Edition of the Wall Street Journal no publishes a prime rate then the Prime Rate shall be an equivalent rate established by a financial institution or financial publication designated by Landlord;

 

 40

 

 

(v)           Maintain Tenant’s right to possession, in which case this Lease shall continue in effect, whether or not Tenant shall have abandoned the Premises. In such event Landlord shall be entitled to enforce all of Landlord’s rights and remedies under this Lease, including the right to recover the Rent and all other amounts due hereunder as they become due;

 

(vi)         Landlord may immediately proceed to collect or bring action for the whole Rent or such part thereof as aforesaid, as well as for liquidated damages provided for hereinafter, as being rent in arrears, or may enter judgment therefor in an amicable action as herein elsewhere provided for in case of rent in arrears, or may file a Proof of Claim in any bankruptcy or insolvency proceeding for such rent, or Landlord may institute any other proceedings, whether similar to the foregoing or not, to enforce payment thereof;

 

(vii)        Landlord shall have the right of injunction, in the event of a breach or threatened breach by Tenant of any of the agreements, conditions, covenants, or terms hereof, to restrain the same and the right to invoke any remedy allowed by law or in equity, whether or not other remedies, indemnity or reimbursements are herein provided. The rights and remedies given to Landlord in this Lease are distinct, separate, and cumulative remedies, and no one of them, whether or not exercised by Landlord, shall be deemed to be in exclusion of any of the others; and,

 

(viii)       Pursue any other remedy now or hereafter available under the laws or judicial decisions of the state wherein the Premises are located. The expiration or termination of this Lease and/or the termination of Tenant’s right to possession shall not relieve Tenant from liability under any indemnity provisions of this Lease as to matters occurring or accruing during the Term hereof or by reason of Tenant’s occupancy of the Premises.

 

(c)            Any provision to the contrary in this Section 22 notwithstanding, (i) Landlord shall not be required to give Tenant the notice and opportunity to cure provided in Section 22(a)(iii) above more than twice in any consecutive twelve (12) month period, and thereafter Landlord may declare an Event of Default without affording Tenant any of the notice and cure rights provided under this Lease, and (ii) Landlord shall not be required to give such notice prior to exercising its rights if Tenant fails to comply with the provisions of Sections 8, 13, 18, 20, or 26 of this Lease or in an emergency.

 

(d)            No waiver by Landlord of any breach by Tenant shall be a waiver of any subsequent breach, nor shall any forbearance by Landlord to seek a remedy for any breach by Tenant be a waiver by Landlord of any rights and remedies with respect to such or any subsequent breach. Efforts by Landlord to mitigate the damages caused by Tenant’s default shall not constitute a waiver of Landlord’s right to recover damages hereunder. No right or remedy herein conferred upon or reserved to Landlord is intended to be exclusive of any other right or remedy provided herein or by law, but each shall be cumulative and in addition to every other right or remedy given herein or now or hereafter existing at law or in equity. No payment by Tenant or receipt or acceptance by Landlord (or payment into a lock-box account) of a lesser amount than the total amount due Landlord under this Lease shall be deemed to be other than on account, nor shall any endorsement or statement on any check or payment be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord’s right to recover the balance of Rent due, or Landlord’s right to pursue any other available remedy.

 

 41

 

 

(e)            If either party commences an action or proceeding against the other party arising out of or in connection with this Lease, the prevailing party shall be entitled to have and recover from the other party attorneys’ fees, costs of suit, investigation expenses and discovery costs, including costs of appeal.

 

(f)             IN ANY CIVIL ACTION, COUNTERCLAIM, OR PROCEEDING, WHETHER AT LAW OR IN EQUITY, WHICH ARISES OUT OF, CONCERNS, OR RELATES TO THIS LEASE, ANY AND ALL TRANSACTIONS CONTEMPLATED BY THIS LEASE, THE PERFORMANCE OF THIS LEASE, OR THE RELATIONSHIP CREATED BY THIS LEASE, WHETHER SOUNDING IN CONTRACT, TORT, STRICT LIABILITY, OR OTHERWISE, TRIAL SHALL BE TO A COURT OF COMPETENT JURISDICTION AND NOT TO A JURY. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY.

 

(g)            Landlord shall not be deemed to be in default under this Lease unless Tenant gives Landlord notice specifying the default and Landlord fails to cure the default within a reasonable period following Tenant’s notice. Further, and after the giving of two (2) written notices to Landlord of the applicable Landlord default describing with specificity the nature of the default, and Landlord’s failure to commence to cure such default within a reasonable period following Landlord’s receipt of such notice), Tenant may, unless Landlord disputes the specifics of such default, perform such obligation of Landlord, in which instance Landlord shall be obligated to reimburse Tenant for its actual costs expenses, and disbursements incurred in such performance which, if due and in Landlord’s sole discretion, may be paid as a credit against no more than fifty percent of (50%) of Tenant’s monthly Minimum Annual Rent next coming due for each month following the date such costs and expenses were incurred by Tenant, until such time as Tenant is reimbursed in full (provided Tenant shall not be permitted to offset such costs or expenses against its payment of any Annual Minimum Rent, Operating Expenses or any other Rent due hereunder). The provisions of this Section 22(g) shall survive the expiration or earlier termination of this Lease.

 

23. Tenant’s Authority; OFAC. Tenant represents and warrants to Landlord that: (a) Tenant is duly formed, validly existing and in good standing under the laws of the state under which Tenant is organized, and qualified to do business in the state in which the Property is located, and (b) the person(s) signing this Lease are duly authorized to execute and deliver this Lease on behalf of Tenant, and if Tenant is a corporation, partnership, joint venture, limited liability company, or other type of organization (each, an “Entity”), Tenant will, within fifteen (15) days after Landlord’s request, provide Landlord with a resolution confirming the authorization. Tenant represents and warrants to Landlord (i) that neither Tenant nor any person or Entity that directly owns a ten percent (10%) or greater equity interest in Tenant nor any of its officers, directors or managing members (collectively, “Tenant and Others in Interest”) is a person or Entity with whom U.S. persons or Entities are restricted from doing business under regulations of the Office of Foreign Asset Control (“OFAC”) of the Department of the Treasury (including those named on OFAC’s Specially Designated and Blocked Persons List) or under any statute, executive order (including Executive Order 13224 signed on September 24, 2001 (the “Executive Order”) and entitled “Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism”), or other governmental action, (ii) that Tenant and Others in Interest’s activities do not violate the International Money Laundering Abatement and Financial Anti-Terrorism Act of 2001 or the regulations or orders promulgated thereunder (as amended from time to time, the “Money Laundering Act”), and (iii) that throughout the Term Tenant will comply with the Executive Order and the Money Laundering Act. Tenant certifies that it is not engaged in this transaction, directly or indirectly on behalf of, or instigating or facilitating this transaction, directly or indirectly on behalf of, any such person, group, entity, or nation. Tenant hereby agrees to defend, indemnify, and hold harmless Landlord from and against any and all claims, damages, losses, risks, liabilities, and expenses (including attorney’s fees and costs) arising from or related to any breach of the foregoing certification.

 

 42

 

 

24.  Liability of Landlord. The word “Landlord” in this Lease includes the Landlord executing this Lease as well as its successors and assigns, each of which shall have the same rights, remedies, powers, authorities and privileges as it would have had it originally signed this Lease as Landlord. Any such person or entity, whether or not named in this Lease, shall have no liability under this Lease after it ceases to hold title to the Premises except for obligations already accrued (and, as to any unapplied portion of Tenant’s Security Deposit, if applicable, Landlord shall be relieved of all liability upon transfer of such portion to its successor in interest). Tenant shall look solely to Landlord’s successor in interest for the performance of the covenants and obligations of the Landlord hereunder which subsequently accrue. Landlord shall not be deemed to be in default under this Lease unless Tenant gives Landlord notice specifying the default and Landlord fails to cure the default within a reasonable period following Tenant’s notice. In no event shall Landlord be liable to Tenant for any loss of business or profits of Tenant or for consequential, punitive or special damages of any kind. Anything in this Lease to the contrary notwithstanding, covenants, undertakings and agreements herein made on the part of Landlord are made and intended not as personal covenants, undertakings and agreements or for the purpose of binding Landlord personally or the assets of Landlord, except Landlord’s interest in the Property (including rental, sales, financing and insurance proceeds arising from the Property), but are made and intended for the purpose of binding only Landlord’s interest in the Property, as the same may from time to time be encumbered. Neither Landlord nor any principal of Landlord nor any owner of the Property, nor any of their respective partners, officers, employees, heirs, legal representatives, successors, and assigns, whether disclosed or undisclosed, shall have any personal liability with respect to any of the provisions of this Lease or the Premises; Tenant shall look solely to the equity of Landlord in the Property and any available insurance proceeds for the satisfaction of any claim by Tenant against Landlord.

 

25.  Notices. Any notice, consent or other communication under this Lease shall be in writing and addressed to Landlord or Tenant at their respective addresses specified in Section 1 above (or to such other address as either may designate by notice to the other) with a copy to any Mortgagee or other party designated by Landlord. Each notice or other communication shall be deemed given if sent by prepaid overnight delivery service or by certified mail, return receipt requested, postage prepaid or in any other manner, with delivery in any case evidenced by a receipt, and shall be deemed to have been given on the day of actual delivery to the intended recipient or on the business day delivery is refused. The giving of notice by Landlord’s attorneys, representatives and Agents under this Section 25 shall be deemed to be the acts of Landlord. If a party refuses or fails to accept delivery of a notice, such notice shall be deem to have been given upon attempted delivery thereof. Tenant consents to the receipt of electronic messages from Landlord, its Affiliates or legal counsel sent to the email address set forth in Section 1.

 

 43

 

 

26. Security Deposit.

 

(a)            At the time of signing this Lease, Tenant shall deposit with Landlord the Security Deposit to be retained by Landlord as cash security for the faithful performance and observance by Tenant of the provisions of this Lease. Tenant shall not be entitled to any interest on the Security Deposit. Landlord shall have the right to commingle the Security Deposit with its other funds. Landlord may use the whole or any part of the Security Deposit for the payment of any amount as to which Tenant is in default or to compensate Landlord for any loss or damage it may suffer by reason of Tenant’s default under this Lease. If Landlord uses all or any portion of the Security Deposit as herein provided, within ten (10) days after demand, Tenant shall pay Landlord cash in an amount equal to that portion of the Security Deposit used by Landlord. If Tenant complies fully and faithfully with all of the provisions of this Lease, the Security Deposit shall be returned to Tenant after the Expiration Date and surrender of the Premises to Landlord.

 

(b)            At Tenant’s election, in place of the cash Security Deposit, Tenant may provide a letter of credit. If Tenant elects to provide a letter of credit, then prior to the Effective Date, Tenant shall deliver a letter of credit (“Letter of Credit”) to Landlord, and maintain the Letter of Credit in full force and effect through the Term, as set forth herein, from a commercial bank or trust company satisfactory to Landlord maintaining branch banks in the metropolitan Philadelphia area or a letter of credit office at which the Letter of Credit may be drawn upon (the “Issuing Bank”), in the amount of the $100,000, to be held by Landlord as additional security for the faithful performance and observance by Tenant of all its obligations under the provisions of this Lease. Any such Letter of Credit shall be in a form approved by Landlord, which approval shall not be unreasonably withheld, conditioned or delayed so long as it meets the requirements of this Section 26(b) and is otherwise generally consistent with the form of letter of credit used by any major or regional financial institution in the metropolitan Philadelphia area.

 

(i)           The Letter of Credit shall be unconditional, irrevocable, transferable, and payable to Landlord on sight (i) at a metropolitan Philadelphia area financial institution, or (ii) by overnight mail or delivery service to the Issuing Bank’s letter of credit office, in partial or full draws. Any and all fees or costs charged by the Issuing Bank in connection with the Letter of Credit, including any assignment thereof by Landlord, shall be paid by Tenant, subject to reimbursement by Landlord, as expressly provided below.

 

(ii)          The Letter of Credit shall expire not earlier than twelve (12) months after the date of delivery thereof to Landlord and shall provide that the same shall be automatically renewed for successive twelve (12) month periods through a date which is not earlier than ninety (90) days after the Expiration Date, unless written notice of nonrenewal has been given by the Issuing Bank to Landlord and Landlord’s attorney by registered or certified mail, return receipt requested, not less than ninety (90) days prior to the expiration of the then current period. If the Issuing Bank does not renew the Letter of Credit, and if Tenant does not deliver a substitute Letter of Credit in the in the amount of the then current balance, at least forty-five (45) days prior to the expiration of the then current period, then, in addition to its rights granted under Section 26 of this Lease, Landlord shall have the right to draw on the existing Letter of Credit.

 

 44

 

 

(iii)         Landlord shall have the right to draw upon the Letter of Credit in whole or in part and apply the proceeds thereof as may be necessary to compensate Landlord for any damages incurred by Landlord on account of an Event of Default, whereupon Tenant, within twenty (20) days after receipt of written demand, shall forthwith restore the Letter of Credit to the then current amount. Should Landlord elect to draw the full amount of the Letter of Credit upon an Event of Default, Tenant expressly waives any right it might otherwise have to prevent Landlord from drawing on the Letter of Credit and agrees that an action for damages, and not injunctive or other equitable relief, shall be Tenant’s sole remedy in the event Tenant disputes Landlord’s claim to any such amounts.

 

(iv)        The Letter of Credit shall be subject to the Uniform Customs and Practice for Documentary Credits, International Chamber of Commerce Publication No. 600 (2007 Revision).

 

(v)          The Issuing Bank shall have a Moody’s rating of at least “A-3” (or other comparable rating). If at any time (a) the Issuing Bank is either (i) closed by the Federal Deposit Insurance Corporation (“FDIC”) or any other governmental authority, or (ii) declared insolvent by the FDIC or other governmental agency for any reason, or (b) Landlord reasonably believes that Issuing Bank will either be (y) closed by the FDIC or any governmental authority, or (z) declared insolvent by the FDIC or other governmental authority for any reason, Tenant shall, within five (5) days after either the occurrence of such closure or declaration of insolvency or notice from Landlord that Landlord reasonably believes that Issuing Bank will close or be declared insolvent, either (1) provide Landlord a replacement Letter of Credit satisfying all of the terms of this Section 26, or (2) post a cash security deposit in the amount of the then current balance of the Letter of Credit with Landlord, and if Tenant fails to comply with this subsection 26(e)(1) or (2), an Event of Default shall be deemed to have occurred as of the end of such five (5) day period.

 

(vi)         Landlord shall have the right to pledge or assign its interest in the Letter of Credit and proceeds thereof to any Mortgagee of the Premises. In the event of a sale or transfer of Landlord’s estate or interest in the Premises, Landlord shall have the right to transfer, at Tenant’s cost, the Letter of Credit, or the proceeds thereof, to the extent not applied as set forth above, to the vendee or transferee as the new landlord under this Lease, and to the extent the Letter of Credit, or proceeds thereof, to the extent not applied as set forth above, are so transferred, Landlord shall be considered released by Tenant from all liability for the return of the Letter of Credit, or proceeds thereof, but only if the transferee assumes all of Landlord’s obligations under this Lease, respecting the Letter of Credit and otherwise. No Mortgagee or purchaser of the Premises at any foreclosure proceeding brought under the provisions of any Mortgage shall (regardless of whether the Lease is at the time in question subordinated to the lien of any Mortgage) be liable to Tenant or any other person for any or all of such sums or the return of any Letter of Credit (or any other or additional security deposit or other payment made by Tenant under the provisions of this Lease), unless Landlord has actually delivered the Letter of Credit, or proceeds thereof, to such Mortgagee or purchaser. If requested by any such Mortgagee or purchaser, Tenant shall obtain an amendment to the Letter of Credit which names such Mortgagee or purchaser as the beneficiary thereof in lieu of Landlord, and the costs incurred by Tenant in obtaining any such amendment shall be reimbursed by Landlord as a credit against the next installment of Minimum Annual Rent due following Tenant’s delivery of the amendment in question.

 

 45

 

 

27.  Broker. Tenant represents and warrants to Landlord that Tenant has not consulted or negotiated with any broker or finder with regard to this Lease except the Broker representing Tenant. Landlord and Tenant each will indemnify the other against, and hold the other harmless from, any claims for fees or commissions from anyone with whom either of them has consulted or negotiated with regard to the Premises and this Lease, including attorneys’ fees at all tribunal levels incurred in connection with the defense of any such claim, with the exception of the Brokers. Landlord will pay the fees or commissions due to Brokers pursuant to a separate written agreement between Landlord and Broker.

 

28. Mortgagee Approval. Intentionally omitted.

 

29. Tenant Improvements.

 

(a)            Other than as otherwise set forth in this Lease, Tenant accepts the Premises in its “AS IS” “WHERE IS” condition, with all faults, and Landlord shall have no obligations whatsoever to improve or pay for any improvements to the Premises for Tenant’s use and occupancy thereof except only as provided in this Section 29. Tenant intends to make improvements to the Premises (the “Tenant Improvements”), and pursuant to Section 29, shall be responsible for the cost thereof, and will have plans for such Tenant Improvements designed and approved by Landlord in accordance with Section 29(b) below, and constructed by Tenant in accordance with Section 29(c) below. Tenant confirms all Tenant Improvements are for the immediate use and benefit of Tenant only.

 

(b)           Tenant’s improvement plans and specifications for such Tenant Improvements to the Premises shall be prepared by a licensed architect selected by Tenant and subject to the approval by Landlord, such approval not to be unreasonably withheld, conditioned or delayed. The plans and specifications for the Tenant Improvements will be prepared in sufficient detail to permit Tenant to construct the Tenant Improvements, and shall include, as applicable, demising walls, a partition layout (dimensioned), door location and door schedule including hardware, reflected ceiling plan, telephone and electrical outlets with locations (dimensioned), special electrical, HVAC and/or plumbing work, mechanicals, special loading requirements, such as the location of file cabinets and special equipment, openings in the walls or floors, all necessary sections and details for special equipment and fixtures, and finishes including, without limitation, carpentry and millwork, floor coverings, wall coverings, color schedules, and any other special finishes. The plans for the Tenant Improvements shall be prepared in accordance, and shall comply in all respects, with all Laws for the issuance of a Building Permit from the City of Phoenix. Landlord shall not unreasonably withhold, condition or delay its approval of the plans and specifications for the Tenant Improvements. Within ten (10) days after receipt, Landlord shall provide to Tenant in writing either its approval of such plans and specifications of the Tenant Improvements submitted by Tenant, or any specific comments or objections that Landlord may have. If Landlord fails to respond within such ten (10) day period, Tenant’s plans and specifications shall be deemed approved or Tenant may deemed such delay a Landlord Delay as defined below. If Landlord timely provides to Tenant Landlord’s comments or objections to the plans and specifications of the Tenant Improvements, Tenant will revise such plans and specifications to address such comments or objections and re-submit the plans and specifications and Landlord will continue to approve or object to the same in the process set forth above until such plans and specifications of the Tenant Improvements are finally approved or deemed approved by Landlord. Upon approval or deemed approval by Landlord, the plans and specifications for the Tenant Improvements shall become final and shall not be materially changed without Landlord’s further approval, which shall not be unreasonably withheld, conditioned or delayed (as finally approved, the “Final Plans”, a copy of which shall be attached to and become a part of this Lease as Exhibit “F”). Landlord’s review or approval of the Tenant Improvement Plans does not constitute a code review and shall not be a representation or warranty of Landlord that the Tenant Improvement Plans are fit for any use, comply with any Laws or satisfy all requirements of the City of Phoenix and the Cotton Center CCR’s and the Allred CC&Rs, and Tenant shall have no right to rely upon any such review or approval thereof by Landlord. Landlord shall have no liability to Tenant or any third party by reason of such review or approval, and Landlord’s review of the Tenant Improvement Plans and monitoring of construction shall be solely for its own benefit.

 

 46

 

 

(c)           Tenant shall complete the Tenant Improvements to the Premises in accordance with the Final Plans, all applicable Laws, and all applicable provisions of this Lease including, but not limited to, provisions relating to Alterations, the provision of insurance, the delivery of Lien Waivers (as defined below) pursuant to Section 29(f) below, and the delivery of permits to Landlord pursuant to Section 29(c) below. The contractors selected by Tenant for bidding on the Tenant Improvements shall be subject to the approval of Landlord, which shall not be unreasonably withheld, conditioned or delayed. Landlord hereby approves the following contractor and subcontractors: DPR Construction, Commonwealth Electric, and Harris Mechanical. Tenant shall require all contractors and subcontractors to be adequately insured as reasonably required by Landlord, naming Landlord and the Landlord Additional Insureds, as additional insureds. The Tenant Improvements shall be the property of Tenant until the expiration or termination of this Lease, as the same may be extended as set forth herein at that time without payment by Landlord, the Tenant Improvements, including without limitation any laboratory fixtures and improvements, shall remain on the Premises and become the property of Landlord unless Landlord gives notice to Tenant, at the time of Landlord’s approval thereof, to remove all or any part thereof at the expiration or termination of this Lease, in which event Tenant will remove all or such designated parts, will repair any resulting damage and will restore the Premises to the condition existing prior to Tenant’s installation of the Tenant Improvements, all in accordance with Section 21(a) above.

 

(d)           All construction relating to the Tenant Improvements shall be done in a good and workmanlike manner and shall comply in all respects at the time of completion with all Laws of the City of Phoenix and all other governmental authorities having jurisdiction over the Premises. Tenant shall obtain all governmental approvals and permits related to the Tenant Improvements and promptly deliver copies of the same to Landlord prior to the start of any work relating to the Tenant Improvements. Promptly after the substantial completion of the Tenant Improvements, Tenant shall provide Landlord with the following documents with respect to the Premises and the Tenant Improvements, if required by the City of Phoenix or other applicable Laws: (i) a Certificate of Occupancy; (ii) a full set of final and un-appealable permits and approvals; (iii) “as-built” plans (hard copy and CAD); and, (iv) a statement of completion by a licensed architect confirming that the Tenant Improvements were completed in accordance with the Final Plans. Except to the extent caused by the active negligence or willful misconduct of Landlord or its Agents, Tenant will indemnify, defend, and hold harmless the Landlord Additional Insureds and their respective Agents from and against any and all claims, actions, damages, proceedings, costs, liability and expense (including reasonable fees of attorneys, investigators and experts) which may be asserted against, imposed upon, or incurred by any of the Landlord Additional Insureds or their respective Agents and arising out of or in connection with loss of life, personal injury or damage to property in or about the Premises or arising out of Tenant’s performance of the work to install the Tenant Improvements, whether in contract or tort, occasioned wholly or in part by any act or omission of Tenant or its contractors and workers. Tenant’s obligations pursuant to this Section 29(d) shall survive the expiration or termination of this Lease. In case any action or proceeding is brought against any of the Landlord Additional Insureds or their respective Agents by reason of any such claim, Tenant, upon notice from any of the Landlord Additional Insureds or their respective Agents, will, at Tenant’s sole cost and expense, resist and defend such action or proceeding with counsel acceptable to such Landlord Additional Insureds and their respective Agents.

 

 47

 

 

(e)          Tenant shall, subject to Section 29(f) below, pay the costs, expenses and fees incurred for the construction of the Tenant Improvements, including without limitation (i) architectural, engineering and design costs, (ii) the cost charged to Tenant by the general contractor and all subcontractors for performing such construction, (iii) project management fees, (iv) construction permit fees, and (v) costs of built-in furniture, (vi) mechanical and structural engineering fees, and, up to Fifty Thousand Dollars ($50,000) for the costs of the FEE incorporated into the Premises (together, the “Tenant Improvement Costs”).

 

(f)            Landlord shall provide an allowance to Tenant not to exceed Four Hundred Seventy-Two Thousand Five Hundred Twenty-Two Dollars and Fifty Cents ($472,522.50) (based on Twenty-Two Dollars and Fifty Cents ($22.50) per rentable square foot of the Premises) (the “Tenant Improvement Allowance”) which shall be used by Tenant to pay for the Tenant Improvement Costs in accordance with Section 29(e) above. In no event shall Landlord be responsible for any of the Tenant Improvement Costs in excess of the Tenant Improvement Allowance. Accordingly, Tenant shall be responsible for all Tenant Improvement Costs in excess of the Tenant Improvement Allowance.

 

(g)          Tenant shall promptly pay all Tenant Improvement Costs as they become due. Tenant may submit to Landlord no more than two (2) applications for payment reimbursement to be applied against the Tenant Improvement Allowance (each, a “Reimbursement Application”). Each Reimbursement Application shall include: (i) executed statutory unconditional waivers of liens and releases on final payment, in compliance with A.R.S. § 33-1008 or any other or statute now or hereafter in effect, reasonably satisfactory to Landlord, from all of Tenant’s contractors, subcontractors, suppliers, and materialmen performing work at the Premises in connection with the Tenant Improvements confirming the payment in full of all Tenant Improvement Costs included in the then current Reimbursement Application (collectively, the “Lien Waivers”); (ii) sufficient evidence of payment from Tenant to Tenant’s contractor of all Tenant Improvement Costs included in the then current Reimbursement Application; and (iii) a certification completed by Tenant’s architect confirming the Tenant Improvements included in the then current Reimbursement Application were performed in accordance with the Tenant Improvement Plans (collectively, the “Partial Reimbursement Requirements”). When the Tenant Improvements are completed in their entirety, as a condition of the final Reimbursement Application, Tenant shall provide: (i) executed final Lien Waivers, confirming the payment in full of all Tenant Improvement Costs up to the limit of the Tenant Improvement Allowance and the release of liens against the Premises; (ii) sufficient evidence of payment from Tenant to Tenant’s contractor(s) of all Tenant Improvement Costs up to the limit of the Tenant Improvement Allowance; and (iii) a certification completed by Tenant’s architect confirming the Tenant Improvements are complete and were performed in accordance with the Tenant Improvement Plans (collectively, the “Final Reimbursement Requirements”). Landlord shall have thirty (30) days after the receipt of each complete Reimbursement Application to submit its reimbursement payment to Tenant. Landlord shall not be required to issue any reimbursement payment to Tenant if the Reimbursement Application does not include the Partial Reimbursement Requirements or the Final Reimbursement Requirements, as the case may be.

 

 48

 

 

(h)           Tenant shall make a complete reimbursement submission for the Tenant Improvement Costs up to the amount of the Tenant Improvement Allowance no later than one (1) year after the Commencement Date. Landlord shall not be required to make payments on account of the Tenant Improvement Allowance for any Tenant Improvement Costs not submitted to Landlord by the foregoing date, and Tenant shall not have any claim to any portion of the Tenant Improvement Allowance not properly used by such date. In no event shall any portion of the Tenant Improvement Allowance be used to offset Tenant’s Rent obligations.

 

(i)            In addition to the Tenant Improvement Allowance, provided no Event of Default exists under the Lease, Tenant shall have the one (1) time right, upon written notice to Landlord no later than April 1, 2019 to have Landlord provide an additional allowance (the “Additional Allowance”) in an amount up to the product of (i) Thirty Dollars ($30.00), multiplied by (ii) the square feet of rentable area in the Premises. If Tenant fails timely to elect for Landlord to provide the Additional Allowance then Tenant’s right to the Additional Allowance will automatically lapse and be of no further force and effect. If Tenant timely elects for Landlord to provide the Additional Allowance, then (x) the Additional Allowance as determined by Tenant by notice to Landlord, shall only be applied toward Tenant Improvements, and (y) except as provided in Section 4(d) the Additional Allowance will be deemed to be included in the term “Tenant Improvement Allowance”. Commencing on the March 1, 2019, Tenant shall begin repaying, and thereafter repay each calendar month, the Additional Allowance to Landlord as set forth herein. The Additional Allowance will be amortized at an annual interest rate of eleven percent (11%) in 85 equal monthly installments. If the Additional Allowance is elected by Tenant, Landlord and Tenant shall promptly enter into an amendment to the Lease specifying the amount of the Additional Allowance and the applicable installments or payments thereof.

 

(j)            Notwithstanding anything in this Lease to the contrary, the period to which the Abatement is applicable (three calendar months) shall be extended by any delay in Tenant’s completion of the Tenant Improvements arising from the acts or omissions of Landlord or its Agents, including without limitation, (i) Landlord’s failure to deliver the Premises to Tenant with all Building Systems in good working order and repair, (ii) Landlord’s failure to provide comments and approvals on a timely basis as required by this Lease, or (iii) Landlord’s failure to provide Tenant and its contractors access to the Premises or services reasonably required to perform the Tenant Improvements.

 

 49

 

 

30. Right of First Refusal.

 

(a)            Subject to the terms and provisions of this Section 30, provided that (a) there then exists no Event of Default by Tenant under this Lease, nor any event that with the giving of notice and/or the passage of time would constitute a default, (b) Tenant, its Strategic Partners, and Permitted Transferees occupy at least 80% of the Premises, during the initial 36 months of the Term, Tenant has the option to lease all of space immediately adjacent to the Premises (being 14,462 rentable square feet) (the “Expansion Space”), pursuant to the terms of this Section 30. Landlord shall notify Tenant when Landlord desires to lease such adjacent space and constructs a “speculative suite” or when Landlord is prepared to respond to a proposal or request for proposals from a third party (“Availability Notice”). Tenant must exercise its option within five (5) business days from receipt of the Availability Notice. If Landlord has constructed the speculative suite in the Expansion Space, the terms and conditions for the Expansion Space shall be the terms and conditions set forth in the Availability Notice. If Landlord has not constructed the speculative suite in the Expansion Space, if Tenant exercises its option, the Expansion Space shall be added to this Lease on the date set forth in the Availability Notice (the “Expansion Date”) and all Lease obligations of the parties remain the same, except: (i) if the Expansion Date is within the first 15 months of the Term, the Minimum Annual Rent for the Expansion Space shall be calculated at the same per square foot basis then in effect for the initial Premises, with annual increases occurring as set forth in Section 1(f) above, the Tenant Improvement Allowance for the Expansion Premises shall be prorated to reflect the then remaining Term, and any other financial obligations based upon square footage shall be proportionate to the terms specified in this Lease; and (ii) if the Expansion Date is after the first 15 months of the Term, the Minimum Annual Rent and other financial terms based upon square footage shall be equal to the Fair Market Value determine in the same manner as provided in Section 4(c). Unless otherwise agreed to in writing by the Parties, increases in Minimum Rent and Operating Expenses become effective at the earlier of (i) the date when Tenant opens for business in the adjacent space, and (ii) 60 days after delivery of the adjacent space to Tenant. If Tenant does not exercise its option within the five (5) business day period, subject to the immediately following sentence, Landlord may proceed to lease the adjacent space to third parties; provided that if the rental rate terms to be agreed to with third parties are more favorable than those that had been offered to Tenant by ten percent (10%) or more, Landlord shall submit an offer to lease to Tenant on such terms (“Second Availability Notice”), and Tenant shall, for a period of five (5) business days, have the right to accept such terms and lease the Expansion Space pursuant thereto. In addition, if Landlord does not enter into a lease agreement with a third party tenant for the adjacent space within six (6) months of Landlord’s delivery to Tenant of the Availability Notice, then if Landlord thereafter desires to lease such adjacent space or respond to a proposal or request for proposals from a third party, Landlord shall provide to Tenant another Availability Notice and the terms and conditions set forth above shall apply; provided, that in no event shall Landlord be required to provide an Availability Notice more than two (2) times during the Term. If Tenant fails to accept such terms within such period, then Tenant’s “right of first refusal” is deemed void. Tenant acknowledges that Landlord shall have no obligation to construct any improvements whatsoever to such adjacent space, except as may be set forth in the Availability Notice or the Second Availability Notice.

 

 50

 

 

(b)              If Tenant exercises such right of first refusal, the parties enter into an amendment concerning the leasing of such Expansion Space.

 

31.  Miscellaneous. The captions in this Lease are for convenience only, are not a part of this Lease and do not in any way define, limit, describe or amplify the terms of this Lease.

 

(a)              This Lease represents the entire agreement between the parties hereto and there are no collateral or oral agreements or understandings between Landlord and Tenant with respect to the Premises or the Property. No representations or promises will be binding on the parties to this Lease except those representations and promises expressly contained in this Lease. 

(b)              This Lease shall not be modified in any manner except by an instrument in writing executed by the parties.

 

(c)              The masculine (or neuter) pronoun and the singular number shall include the masculine, feminine and neuter genders and the singular and plural number. The word “including” followed by any specific item(s) is deemed to refer to examples rather than to be words of limitation. The word “person” includes a natural person, a partnership, a corporation, a limited liability company, an association and any other form of business association or entity.

 

(d)             Both parties having participated fully and equally in the negotiation and preparation of this Lease, this Lease shall not be more strictly construed, nor any ambiguities in this Lease resolved, against either Landlord or Tenant.

 

(e)             Each covenant, agreement, obligation, term, condition or other provision contained in this Lease shall be deemed and construed as a separate and independent covenant of the party bound by, undertaking or making the same, not dependent on any other provision of this Lease unless otherwise expressly provided. All of the terms and conditions set forth in this Lease shall apply throughout the Term unless otherwise expressly set forth herein.

 

(f)               If any provisions of this Lease shall be declared unenforceable in any respect, such unenforceability shall not affect any other provision of this Lease, and each such provision shall be deemed to be modified, if possible, in such a manner as to render it enforceable and to preserve to the extent possible the intent of the parties as set forth herein.

 

(g)              This Lease shall be construed and enforced in accordance with the Laws of the State of Arizona (without the application of any conflict of laws principles).

 

(h)              This Lease shall be binding upon and inure to the benefit of Landlord and Tenant and their respective permitted successors and assigns. All persons liable for the obligations of Tenant or Landlord under this Lease shall be jointly and severally liable for such obligations.

 

51

 

 

(i)               Tenant shall not record this Lease or any memorandum thereof, or otherwise file this Lease with any governmental authority, without Landlord’s prior consent.

 

        (j)              Whenever it is provided that Landlord’s or Tenant’s consent is required, unless another standard is provided in this Lease with respect to such specific consent, neither Landlord nor Tenant, as applicable will unreasonably withhold, condition or delay such consent or approval (such consent or approval and such exercise of judgment being collectively referred to as “consent”). If Landlord delays, conditions or refuses such consent, Tenant waives any claim for money damages (including any claim for money damages by way of setoff, counterclaim or defense) based upon any claim or assertion that Landlord unreasonably withheld, conditioned or delayed consent. Tenant’s sole remedy will be specific performance. Failure on the part of Tenant to seek relief within thirty (30) days after the date upon which Landlord has withheld, conditioned or delayed its consent will be deemed a waiver of any right to dispute the reasonableness of such withholding, conditioning or delaying of consent.

 

(k)             This Lease may be executed in multiple counterparts, each of which, when assembled to include an original signature for each party contemplated to sign this Lease, will constitute a complete and fully executed original. All such fully executed counterparts will collectively constitute a single Lease agreement.

 

(l)               Time periods for Landlord’s or Tenant’s performance under any provisions of this Lease shall be extended for periods of time during which the non-performing party’s performance is prevented due to circumstances beyond the party’s control, including without limitation, including acts of God; fire or other casualty; unreasonable governmental delay; inability to procure labor, materials, supplies, power or transportation despite reasonable efforts; strikes; unusual inclement weather; or, where applicable, the passage of time while waiting for an adjustment of insurance proceeds (“Force Majeure”). Any time limits required to be met by either party hereunder, whether specifically made subject to Force Majeure or not, except those related to the surrender of the Premises by the end of the Term or payment of Fixed Basic Rent or Additional Rent, will, unless specifically stated to the contrary elsewhere in this Lease, be automatically extended by the number of days by which any required performance is delayed due to Force Majeure. The lack of capital shall not be an event of Force Majeure.

 

        (m)             Unless otherwise specified, in computing any period of time described herein, the day of the act or event after which the designated period of time begins to run is not to be included and the last day of the period so computed is to be included, unless such last day is a Saturday, Sunday or legal holiday for national banks in the State of Arizona (such day which is neither Saturday, Sunday or legal holiday), in which event the period shall run until the end of the next day which is neither a Saturday, Sunday, or a legal holiday.

 

                 (n)              Time is of the essence with respect to the parties’ obligations under this Lease.

 

(o)              Each of Landlord and Tenant agrees that it will not raise or assert as a defense to any obligation under this Lease, or make any claim that this Lease is invalid or unenforceable, due to any failure of this document or this Lease to comply with ministerial requirements, including requirements for corporate seals, attestations, witnesses, notarizations or other similar requirements, and each party hereby waives the right to assert any such defense or make any claim of invalidity or unenforceability due to any of the foregoing.

 

52

 

 

(p)              Landlord and Tenant expressly agree that if the signature of Landlord and/or Tenant on this Lease is not an original, but is a digital, mechanical or electronic reproduction (such as, but not limited to, an e-mail or PDF, then such digital, mechanical or electronic reproduction shall be as enforceable, valid and binding as, and the legal equivalent to, an authentic and traditional ink-on-paper original wet signature penned manually by its signatory.

 

(q)              This Lease is submitted to Tenant on the understanding that it will not be considered an offer by Landlord and will not bind Landlord in any way until (a) Tenant has duly executed and delivered the required number of originals to Landlord and (b) Landlord has executed and delivered one of such originals to Tenant. Tenant’s offer of this Agreement shall be irrevocable and open for acceptance by Landlord until 5:00 p.m. on the fifteenth (15th) day after execution and delivery hereof by Tenant, and if not accepted by then may be withdrawn by Tenant.

 

(r)              Any State statutory provisions dealing with termination rights due to casualty, condemnation, delivery of possession or any other matter dealt with by this Lease are superseded by the terms of this Lease.

 

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURES ON FOLLOWING PAGE

 

53

 

 

 THE PARTIES to this Lease, intending to be legally bound, have executed and delivered this Lease as of the date on which this Lease has been fully executed by Landlord and Tenant.

 

      LANDLORD:
         
      WPT LAND 2 LP
         
      By: WPT Land 2 GP LLC,
        its sole general partner
       
Dated: 3/4/2019      
      By: /s/ Anthony A. Nichols, Jr.
      Name: Anthony A. Nichols, Jr.
    Title: Senior Vice President
         
      TENANT:
         
      23andMe, Inc., a Delaware corporation
         
      By: /s/ Anne Wojcicki
      Name: Anne Wojcicki
      Title: CEO
         
Date: March 1, 2019      
      By: /s/ Steve Schoch
      Name: Steve Schoch
      Title: CFO
         
      Approved as to Form 23andMe Legal Dept.
Date: March 1, 2019  
      By AH/jmh

 

 

 

 

EXHIBIT “A”

 

PLAN SHOWING PREMISES

 

A-1

 

 

EXHIBIT “B”

 

BUILDING RULES

 

1.    Any sidewalks, lobbies, passages, elevators and stairways shall not be obstructed or used by Tenant for any purpose other than ingress and egress from and to the Premises. Landlord shall in all cases retain the right to control or prevent access by all persons whose presence, in the judgment of Landlord, shall be prejudicial to the safety, peace or character of the Property.

 

2.    The toilet rooms, toilets, urinals, sinks, faucets, plumbing or other service apparatus of any kind shall not be used for any purposes other than those for which they were installed, and no sweepings, rubbish, rags, ashes, chemicals or other refuse or injurious substances shall be placed therein or used in connection therewith or left in any lobbies, passages, elevators or stairways.

 

3.    Tenant shall not impair in any way the fire safety system and shall comply with all safety, fire protection and evacuation procedures and regulations established by Landlord, any governmental agency or any insurance company insuring the Building, including without limitation the insurer’s Red Tag Permit System, Hot Work Permit System and all other fire protection impairment procedures. No person shall go on the roof without Landlord’s prior written permission.

 

4.    Without Landlord’s prior written consent, Tenant shall not hang, install, mount, suspend or attach anything from or to any sprinkler, plumbing, utility or other lines. I

 

5.    Tenant shall not change any locks nor place additional locks upon any doors or any access codes or systems without first providing to Landlord keys, access cards or fobs or codes to such locks or systems so that at all times Landlord has pass keys or access cards or fobs or knowledge of the access codes. No additional locks or bolts of any kind will be placed on any of the doors or windows by Tenant. Tenant will, on the expiration or earlier termination of Tenant’s tenancy, deliver to Landlord all keys (or fobs or access cards, as the case may be) to any space within the Building either furnished to or otherwise procured by Tenant, and in the event of the loss of any keys, fobs or access cards furnished, Tenant will pay to Landlord the cost thereof.

 

6.    Tenant shall not cause excessive noise or any disturbance, nor use nor keep in the Building any matter having an offensive odor, nor explosive or highly flammable material, nor shall any animals other than handicap assistance dogs in the company of their masters be brought into or kept in or about the Property.

 

7.    If Tenant desires to introduce electrical, signaling, telegraphic, telephonic, protective alarm or other wires, apparatus or devices, Landlord shall direct where and how the same are to be placed, and except as so directed, no installation boring or cutting shall be permitted. Landlord shall have the right to prevent and to cut off the transmission of excessive or dangerous current of electricity or annoyances into or through the Building or the Premises and to require the changing of wiring connections or layout at Tenant’s expense, to the extent that Landlord may deem necessary, and further to require compliance with such reasonable rules as Landlord may establish relating thereto, and in the event of non-compliance with the requirements or rules, Landlord shall have the right immediately to cut wiring or to do what it considers necessary to remove the danger, annoyance or electrical interference with apparatus in any part of the Building. All wires installed by Tenant must be clearly tagged at the distributing boards and junction boxes and elsewhere where required by Landlord, with the number of the office/laboratory space to which said wires lead, and the purpose for which the wires respectively are used, together with the name of the concern, if any, operating same. Tenant shall not use any method of heating, air conditioning or air cooling other than that provided by Landlord.

 

B-1

 

 

8.    Tenant shall not place weights anywhere beyond the safe carrying capacity of the Building which is designed to normal office/laboratory space building standards for floor loading capacity.

 

9.    The use of rooms as sleeping quarters is strictly prohibited at all times. Tenant shall not use the Property for any type of residential or childcare use.

 

10.  Tenant shall comply with all parking regulations promulgated by Landlord from time to time for the orderly use of the vehicle parking areas. Parked vehicles shall not be used for vending or any other business or other activity while parked in the parking areas. Vehicles shall be parked only in striped parking spaces, except for loading and unloading, which shall occur solely in zones marked for such purpose, and be so conducted as to not unreasonably interfere with traffic flow within the Property or with loading and unloading areas of other tenants. Employee and tenant vehicles shall not be parked in spaces marked for visitor parking or other specific use. All vehicles entering or parking in the parking areas shall do so at owner’s sole risk and Landlord assumes no responsibility for any damage, destruction, vandalism or theft. Tenant shall cooperate with Landlord in any measures implemented by Landlord to control abuse of the parking areas, including without limitation access control programs, tenant and guest vehicle identification programs, and validated parking programs, provided that no such validated parking program shall result in Tenant being charged for spaces to which it has a right to free use under its Lease. Each vehicle owner shall promptly respond to any sounding vehicle alarm or horn, and failure to do so may result in temporary or permanent exclusion of such vehicle from the parking areas. Any vehicle which violates the parking regulations may be cited, towed at the expense of the owner, temporarily or permanently excluded from the parking areas, or subject to other lawful consequence.

 

11.  Tenant and its Agents shall not smoke in the Building or at the Building entrances and exits. If any individual owner, employee, invitee, or representative of Tenant is found to be smoking other than in permitted smoking areas, then Tenant will pay Landlord One Hundred and 00/100 Dollars ($100.00) per such occurrence. Landlord may fully restrict smoking on the Land in Landlord’s sole election.

 

12.  Tenant shall provide Landlord with a written identification of any vendors engaged by Tenant to perform services for Tenant at the Premises (examples: janitorial service, trash haulers, security guards/monitors, telecommunications installers/maintenance), and all vendors shall be subject to Landlord’s reasonable approval. Landlord reserves the right to refuse entry into the Building of any person. No mechanics shall be allowed to work on the Building or Building Systems other than those engaged by Landlord. Tenant shall permit Landlord’s employees and contractors and no one else to clean the Premises unless Landlord consents in writing. Tenant assumes all responsibility for protecting its Premises from theft and vandalism and Tenant shall see each day before leaving the Premises that all lights are turned out and that the windows and the doors are closed and securely locked. Tenant acknowledges that Landlord’s election to provide surveillance or security in or about the Premises or the Building, its Parking Areas, or in or about the Land is subject to Landlord’s sole discretion. Landlord shall have no liability in connection with the decision whether or not to provide, or any failure of, such services and Tenant hereby waives all claims based thereon.

 

13.  Tenant shall comply with any move-in/move-out rules provided by Landlord and with any rules provided by Landlord.

 

B-2

 

 

14.   Tenant shall not place oversized cartons, crates or boxes in any area for trash pickup without Landlord’s prior approval. Tenant shall be responsible for all trash pickup of normal office refuse placed in ordinary office trash receptacles only. Excessive amounts of trash or other out-of-the-ordinary refuse loads will be removed by Tenant’s at Tenant’s expense. If at Tenant’s request, Landlord consents to Tenant having a dumpster on the Property, Tenant shall locate the dumpster in the area designated by Landlord and shall keep and maintain the dumpster clean and painted with lids and doors in good working order and, at Landlord’s request, locked.

 

15.  Tenant shall comply with the following sustainability requirements:

 

a.        Tenant shall provide within ten (10) days after Landlord’s request from time to time, reasonably requested energy and water consumption data and related information in connection with Tenant’s use of the Premises and all construction, maintenance, repairs, cleaning, trash disposal and recycling relating to the Premises performed by or on behalf of Tenant -- all to be used for purposes of monitoring and improving building efficiencies.

 

b.         Low/No VOC Paint. Tenant shall use only interior paints and coatings (including primers) meeting the environmental requirements of the current Green Seal™ Environmental Standard For Paints And Coatings - GS-11.

 

c.         Green Cleaning Products. All cleaning products used in the Premises must be certified under the current Green Seal™ Environmental Standard for Industrial and Institutional Cleaners - GS-37.

 

d.         Recycling. The following items must be recycled according to local capabilities, guidelines and regulations: (i) Paper; (ii) Cardboard; (iii) Plastics; (iv) Aluminum Cans/Metals; and (v) Glass.

 

16.   Tenant shall cause all of Tenant’s Agents to comply with these Building Rules.

 

17.  Landlord reserves the right to rescind, suspend or modify any rules or regulations and to make such other rules and regulations as, in Landlord’s reasonable judgment, may from time to time be needed for the safety, care, maintenance, operation and cleanliness of the Property. Notice of any action by Landlord referred to in these Building Rules, given to Tenant, shall have the same force and effect as if originally made a part of the foregoing Lease. New rules or regulations will not, however, be unreasonably inconsistent with the proper and rightful enjoyment of the Premises by Tenant under this Lease.

 

18.  These Building Rules are not intended to give Tenant any rights or claims in the event that Landlord does not enforce any of them against any other tenants or if Landlord does not have the right to enforce them against any other tenants and such nonenforcement will not constitute a waiver as to Tenant.

 

B-3

 

 

EXHIBIT “C”

 

PAYMENT RIDER

 

All Minimum Annual Rent, Annual Operating Expenses, Additional Taxes, and other sums, fees and charges payable under the Lease shall be paid by good check or wire transfer of immediately available federal funds, to WPT LAND 2 LP as follows:

 

If remitted by U.S. Mail:

 

Remitter address:

 

WPT Land 2 LP et al

PO Box 714856

Cincinnati, OH 45271-4856

 

Overnight address:

 

WPT Land 2 LP et al

Attn: Wholesale Lockbox # 714856

895 Central Ave, Suite 600

Cincinnati, OH 45202

 

If remitted by wire transfer:

 

Bank Name: [***]

Bank Address: [***]

Beneficiary: [***]

Account number: [***]

Routing number: [***]

 

Landlord may elect to institute a direct payment requirement upon notice given to Tenant in which event Tenant shall provide such information and complete such authorizations as Landlord may reasonably require for ACH transfers.

 

C-1

 

 

EXHIBIT “D”

 

PARKING AREA PLAN

 

SEE ATTACHED

 

D-1

 

 

EXHIBIT “E”

 

TENANT ESTOPPEL CERTIFICATE

 

Please refer to the documents described in Schedule 1 hereto, (the “Lease Documents”) including the “Lease” therein described; all defined terms in this Certificate shall have the same meanings as set forth in the Lease unless otherwise expressly set forth herein. The undersigned Tenant hereby certifies that it is the tenant under the Lease. Tenant hereby further acknowledges that it has been advised that the Lease may be collaterally assigned in connection with a proposed financing secured by the Property and/or may be assigned in connection with a sale of the Property and certifies both to Landlord and to any and all prospective mortgagees and purchasers of the Property, including any trustee on behalf of any holders of notes or other similar instruments, any holders from time to time of such notes or other instruments, and their respective successors and assigns (the “Beneficiaries”) that as of the date hereof:

 

1.    The information set forth in attached Schedule 1 is true and correct.

 

2.    Tenant is in occupancy of the Premises and the Lease is in full force and effect, and, except by such writings as are identified on Schedule l, has not been modified, assigned, supplemented or amended since its original execution, nor are there any other agreements between Landlord and Tenant concerning the Premises, whether oral or written.

 

3.     All conditions under the Lease to be satisfied or performed by Landlord have been satisfied and performed.

 

4.    Tenant is not in default under the Lease Documents, Tenant has not received any notice of default under the Lease Documents, and, to Tenant’s knowledge, there are no events which have occurred that, with the giving of notice and/or the passage of time, would result in a default by Tenant under the Lease Documents.

 

5.    Tenant has not paid any Rent due under the Lease more than thirty (30) days in advance of the date due under the Lease and Tenant has no rights of setoff, counterclaim, concession or other rights of diminution of any Rent due and payable under the Lease except as set forth in Schedule 1.

 

6.    To Tenant’s knowledge, there are no uncured defaults on the part of Landlord under the Lease Documents, Tenant has not sent any notice of default under the Lease Documents to Landlord, and there are no events which have occurred that, with the giving of notice and/or the passage of time, would result in a default by Landlord thereunder, and that at the present time Tenant has no claim against Landlord under the Lease Documents.

 

7.    Except as expressly set forth in Part G of Schedule 1, there are no provisions for any, and Tenant has no, options with respect to the Premises or all or any portion of the Property.

 

8.    No action, voluntary or involuntary, is pending against Tenant under federal or state bankruptcy or insolvency law.

 

9.    The undersigned has the authority to execute and deliver this Certificate on behalf of Tenant and acknowledges that all Beneficiaries will rely upon this Certificate in purchasing the Property or extending credit to Landlord or its successors in interest.

 

E-1

 

 

10.  This Certificate shall be binding upon the successors, assigns and representatives of Tenant and any party claiming through or under Tenant and shall inure to the benefit of all Beneficiaries.

 

IN WITNESS WHEREOF, Tenant has executed this Certificate this ____ day of __________, 2____.

 

   
     
  By:
  Title:

 

 

E-2

 

 

SCHEDULE 1 TO TENANT ESTOPPEL CERTIFICATE

 

Lease Documents, Lease Terms and Current Status

 

A.Date of Lease:

 

B.Parties:

 

  1.Landlord:

 

  2.Tenant:

 

C.Premises:

 

D.Modifications, Assignments, Supplements or Amendments to Lease:

 

E.Commencement Date:

 

F.Expiration of Current Term:

 

G.Option Rights:

 

H.Security Deposit Paid to Landlord: $

 

I.Current Minimum Annual Rent: $

 

J.Current Annual Operating Expenses: $

 

K.Current Additional Taxes: $

 

L.Current Total Rent: $

 

M.Square Feet Demised:

 

SCHEDULE-1

 

 

EXHIBIT “F”

 

TENANT IMPROVEMENT PLANS AND SPECIFICATIONS

  

F-1

 

 

EXHIBIT “G”

 

HARARDOUS MATERIALS LIST

 

WILL BE PROVIDED BY TENANT BEFORE OCCUPANCY

 

G-1

 

 

 

EXHIBIT “H”

 

SIGN PLAN AND SPECIFICATIONS

 

NONE

 

H-1

 

 

FIRST AMENDMENT TO LEASE AGREEMENT

 

 THIS FIRST AMENDMENT TO LEASE AGREEMENT (this “Amendment”) is made on this 17th day of June, 2019, by and between WPT LAND 2 LP, a Delaware limited partnership (“Landlord”), and 23andMe, Inc., a Delaware corporation (“Tenant”).

 

BACKGROUND:

 

A.              Landlord and Tenant entered into a certain Lease Agreement dated March 1, 2019 (the “Original Lease”) covering that certain premises containing approximately 21,001 rentable square feet (the “Original Premises”), being Suite 100 located in the building (the “Building”) known as 4415 Cotton Center Boulevard, Building 5, Phoenix, Arizona 85040, as more fully described in the Lease B. Tenant has exercised its right of first refusal set forth in Section 30 of the Original Lease with respect to the Expansion Space (being 14,462 rentable square feet) and the parties desire to amend the Original Lease to include the Expansion Space as part of the Premises, subject to the provisions of this Amendment. Accordingly, Landlord and Tenant desire to amend the Lease.

 

NOW, THEREFORE, the parties hereto, in consideration of the mutual promises and covenants contained herein and in the Lease, and intending to be legally bound, hereby agree that the Lease is amended as follows:

 

1.               All capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to them in the Lease. The Original Lease as amended by this First Amendment is sometimes referred to herein as the “Lease.”

 

2.                Landlord and Tenant agree and confirm that the Commencement Date is March 8, 2019 and the Expiration Date is July 31, 2026.

 

3.                From and after August 1, 2019 (the “Expansion Date”), the Expansion Space shall be added to the Premises. Accordingly, from and after the Expansion Date the Premises shall consist of 35,463 rentable square feet and all references to the “Premises” in the Lease shall be to and mean 35,463 rentable square feet. The entire Premises shall be referred to as “Suite 100.” Exhibit A to the Original Lease is hereby replaced by the Exhibit A attached to this Amendment. Landlord and Tenant stipulate and agree to the rentable square footages set forth in this First Amendment and the Lease. Landlord and Tenant agree that “Common Area” shall not include any interior portions of the Building.

 

4.                To reflect the increased size of the Premises, from and after the Expansion Date, Tenant’s “Minimum Annual Rent” obligation shall be as follows:

Lease Period  Per RSF  Annual  Monthly 
3/8/19 – 7/31/19*;**  $13.50  $283,514.00  $23,626.13 
8/1/19 – 7/31/20***, ****  $13.50  $478,751.50  $39,895.88 
8/1/20 – 7/31/21  $13.91  $493,290.00  $41,107.53 
8/1/21 – 7/31/22  $14.32  $507,830.00  $42,319.18 
8/1/22 – 7/31/23  $14.75  $523,079.00  $43,589.94 
8/1/23 – 7/31/24  $15.19  $538,683.00  $44,890.25 
8/1/24 – 7/31/25  $15.65  $554,996.00  $46,249.66 
8/1/25 – 7/31/26  $16.12  $571,664.00  $47,638.63 

 

 

 

*In accordance with the Original Lease, except as set forth in the next succeeding sentence, with respect to the Original Premises, Monthly Rent based on the Minimum Annual Rent but not Annual Operating Expense, payments (or the Management Fee which is a part of Operating Expenses and shall be calculated as if such monthly Minimum Annual Rent is being paid in full) or Additional Taxes (as defined below) payments, shall be abated (the “Abatement”) for the first three (3) full calendar months (being April, May and June, 2019) following the Commencement Date. Should this Lease be terminated during the initial Term by Landlord as a result of an uncured Event of Default (as defined below) by Tenant under this Lease, Landlord shall be entitled to recover from Tenant (in addition to all other rights and remedies available to Landlord) such Abatement. The first Lease month was March, 2019.

 

**Based only on the Original Premises.

 

***Includes the Original Premises and the Expansion Space.

 

**** With respect to the Expansion Space only, Monthly Rent based on the Minimum Annual Rent but not Annual Operating Expense, payments (or the Management Fee which is a part of Operating Expenses and shall be calculated as if such monthly Minimum Annual Rent is being paid in full) or Additional Taxes (as defined below) payments, shall be abated (the “Expansion Abatement”) in the aggregate amount of $48,809.25 for the first three (3) full calendar months (being August, September and October, 2019) following the Expansion Date. Should this Lease be terminated during the initial Term by Landlord as a result of an uncured Event of Default (as defined below) by Tenant under this Lease, Landlord shall be entitled to recover from Tenant (in addition to all other rights and remedies available to Landlord) such Expansion Abatement.

 

  5.               To reflect the increased size of the Premises, from and after the Expansion Date, estimated Annual Operating Expenses for 2019 shall increase to $163,129.80, payable in equal monthly installments of $13,594.15, subject to adjustment and reconciliation as provided in the Lease. Likewise, from and after the Expansion Date, Tenant’s Share shall be increased from 59.20% to 100%.

 

  6.               The Security Deposit shall be increased to One Hundred Sixty-Nine Thousand Dollars ($169,000.00). Tenant shall deposit with Landlord, on or before the Expansion Date, the increased amount of Sixty-Nine Thousand Dollars ($69,000.00).

 

  7.               From and after the Expansion Date, Tenant shall have the right to use a total of ninety-six (96) unreserved, uncovered parking spaces, and a total of twenty (20) reserved, canopy parking spaces (eight (8) in addition to the currently permitted twelve (12) reserved, canopy parking spaces) which additional covered parking spaces shall be considered “Covered Parking Spaces,” and Tenant shall pay the monthly charge provided in Section 3(b) of the Original Lease for each Covered Parking Space. The location of all one hundred sixteen (116) parking spaces are shown on the attached Exhibit AA, attached to an made a part of this First Amendment, which shall replace Exhibit D to the Original Lease.

 

2

 

 

  8.               As provided in Section 11(a) and (b) of the Original Lease, from and after the Expansion Date, Tenant shall have the exclusive right to install or maintain any Building Mounted Sign. The last sentence of Section 11(b) is hereby deleted from the Lease.

 

  9.               Other than as set forth in this First Amendment, Tenant accepts the Expansion Space in its “as is” “where is” condition and Landlord shall have no obligations whatsoever to improve or pay for improvements to the Premises for Tenant’s use and occupancy, except only as provided in this Section 9. Tenant intends to make improvements to the Expansion Space (the “Tenant Expansion Improvements”), and pursuant to Section 9, shall be responsible for the cost thereof, and will have plans for such Tenant Expansion Improvements designed and approved by Landlord in accordance with Section 9(a) below, and constructed by Tenant in accordance with Section 9(b) below. Tenant confirms all Tenant Expansion Improvements are for the immediate use and benefit of Tenant only.

    (a)       Tenant’s improvement plans and specifications for such Tenant Expansion Improvements to the Expansion Space shall be prepared by a licensed architect selected by Tenant and subject to the approval by Landlord, such approval not to be unreasonably withheld, conditioned or delayed. The plans and specifications for the Tenant Expansion Improvements will be prepared in sufficient detail to permit Tenant to construct the Tenant Expansion Improvements, and shall include, as applicable, demising walls, a partition layout (dimensioned), door location and door schedule including hardware, reflected ceiling plan, telephone and electrical outlets with locations (dimensioned), special electrical, HVAC and/or plumbing work, mechanicals, special loading requirements, such as the location of file cabinets and special equipment, openings in the walls or floors, all necessary sections and details for special equipment and fixtures, and finishes including, without limitation, carpentry and millwork, floor coverings, wall coverings, color schedules, and any other special finishes. The plans for the Tenant Expansion Improvements shall be prepared in accordance, and shall comply in all respects, with all Laws for the issuance of a Building Permit from the City of Phoenix. Landlord shall not unreasonably withhold, condition or delay its approval of the plans and specifications for the Tenant Expansion Improvements. Within ten (10) days after receipt, Landlord shall provide to Tenant in writing either its approval of such plans and specifications of the Tenant Expansion Improvements submitted by Tenant, or any specific comments or objections that Landlord may have. If Landlord fails to respond within such ten (10) day period, Tenant’s plans and specifications shall be deemed approved or Tenant may deemed such delay a Landlord Delay as defined below. If Landlord timely provides to Tenant Landlord’s comments or objections to the plans and specifications of the Tenant Expansion Improvements, Tenant will revise such plans and specifications to address such comments or objections and re-submit the plans and specifications and Landlord will continue to approve or object to the same in the process set forth above until such plans and specifications of the Tenant Expansion Improvements are finally approved or deemed approved by Landlord. Upon approval or deemed approval by Landlord, the plans and specifications for the Tenant Expansion Improvements shall become final and shall not be materially changed without Landlord’s further approval, which shall not be unreasonably withheld, conditioned or delayed (as finally approved, the “Final Expansion Plans”, a copy of which shall be attached to and become a part of this First Amendment as Exhibit “AB”). Landlord’s review or approval of the Tenant Expansion Improvements plans does not constitute a code review and shall not be a representation or warranty of Landlord that the Tenant Expansion Improvements plans are fit for any use, comply with any Laws or satisfy all requirements of the City of Phoenix and the Cotton Center CCR’s and the Allred CC&Rs, and Tenant shall have no right to rely upon any such review or approval thereof by Landlord. Landlord shall have no liability to Tenant or any third party by reason of such review or approval, and Landlord’s review of the Tenant Expansion Improvements plans and monitoring of construction shall be solely for its own benefit.

 

3

 

 

    (b)       Tenant shall complete the Tenant Expansion Improvements to the Expansion Space and integrate the same with the Original Premises in accordance with the Final Expansion Plans, all applicable Laws, and all applicable provisions of this First Amendment and the Original Lease including, but not limited to, provisions relating to Alterations, the provision of insurance, the delivery of Lien Waivers pursuant to Section 9(f) below, and the delivery of permits to Landlord pursuant to Section 9(c) below. The contractors selected by Tenant for bidding on the Tenant Expansion Improvements shall be subject to the approval of Landlord, which shall not be unreasonably withheld, conditioned or delayed. Landlord hereby approves the following contractor and subcontractors: DPR Construction, Commonwealth Electric, and Harris Mechanical. Tenant shall require all contractors and subcontractors to be adequately insured as reasonably required by Landlord, naming Landlord and the Landlord Additional Insureds, as additional insureds. The Tenant Expansion Improvements shall be the property of Tenant until the expiration or termination of this Lease, as the same may be extended as set forth herein at that time without payment by Landlord, the Tenant Expansion Improvements, including without limitation any laboratory fixtures and improvements, shall remain on the Premises and become the property of Landlord unless Landlord gives notice to Tenant, at the time of Landlord’s approval thereof, to remove all or any part thereof at the expiration or termination of this Lease, in which event Tenant will remove all or such designated parts, will repair any resulting damage and will restore the Expansion Premises to the condition existing prior to Tenant’s installation of the Tenant Expansion Improvements, all in accordance with Section 21(a) of the Original Lease.

 

(c)           All construction relating to the Tenant Expansion Improvements shall be done in a good and workmanlike manner and shall comply in all respects at the time of completion with all Laws of the City of Phoenix and all other governmental authorities having jurisdiction over the Premises. Tenant shall obtain all governmental approvals and permits related to the Tenant Expansion Improvements and promptly deliver copies of the same to Landlord prior to the start of any work relating to the Tenant Expansion Improvements. Promptly after the substantial completion of the Tenant Expansion Improvements, Tenant shall provide Landlord with the following documents with respect to the Premises and the Tenant Improvements, if required by the City of Phoenix or other applicable Laws: (i) a Certificate of Occupancy; (ii) a full set of final and un-appealable permits and approvals; (iii) “as-built” plans (hard copy and CAD); and, (iv) a statement of completion by a licensed architect confirming that the Tenant Expansion Improvements were completed in accordance with the Final Expansion Plans. Except to the extent caused by the active negligence or willful misconduct of Landlord or its Agents, Tenant will indemnify, defend, and hold harmless the Landlord Additional Insureds and their respective Agents from and against any and all claims, actions, damages, proceedings, costs, liability and expense (including reasonable fees of attorneys, investigators and experts) which may be asserted against, imposed upon, or incurred by any of the Landlord Additional Insureds or their respective Agents and arising out of or in connection with loss of life, personal injury or damage to property in or about the Premises or arising out of Tenant’s performance of the work to install the Tenant Expansion Improvements, whether in contract or tort, occasioned wholly or in part by any act or omission of Tenant or its contractors and workers. Tenant’s obligations pursuant to this Section 9(c) shall survive the expiration or termination of this Lease. In case any action or proceeding is brought against any of the Landlord Additional Insureds or their respective Agents by reason of any such claim, Tenant, upon notice from any of the Landlord Additional Insureds or their respective Agents, will, at Tenant’s sole cost and expense, resist and defend such action or proceeding with counsel acceptable to such Landlord Additional Insureds and their respective Agents.

 

4

 

 

  (d)        Tenant shall, subject to Section 9(e) below, pay the costs, expenses and fees incurred for the construction of the Tenant Expansion Improvements, including without limitation (i) architectural, engineering and design costs, (ii) the cost charged to Tenant by the general contractor and all subcontractors for performing such construction, (iii) project management fees, (iv) construction permit fees, and (v) costs of built-in furniture, (vi) mechanical and structural engineering fees, and, up to Twenty Thousand Dollars ($20,000) for the costs of the FEE incorporated into the Expansion Space (together, the “Tenant Expansion Improvement Costs”).

 

   (e)       Landlord shall provide an allowance to Tenant not to exceed Two Hundred Eighty-Nine Thousand Two Hundred Forty Dollars and No Cents ($289,240.00) (based on Twenty Dollars ($20.00) per rentable square foot of the Expansion Space) (the “Tenant Expansion Improvement Allowance”) which shall be used by Tenant to pay for the Tenant Expansion Improvement Costs in accordance with Section 9(d) above. In no event shall Landlord be responsible for any of the Tenant Expansion Improvement Costs in excess of the Tenant Expansion Improvement Allowance. Accordingly, Tenant shall be responsible for all Tenant Expansion Improvement Costs in excess of the Tenant Expansion Improvement Allowance.

   

   (f)        Tenant shall promptly pay all Tenant Expansion Improvement Costs as they become due. Tenant may submit to Landlord no more than two (2) applications for payment reimbursement to be applied against the Tenant Expansion Improvement Allowance (each, a “Expansion Reimbursement Application”). Each Expansion Reimbursement Application shall include: (i) executed statutory unconditional Lien Waivers; (ii) sufficient evidence of payment from Tenant to Tenant’s contractor of all Tenant Expansion Improvement Costs included in the then current Expansion Reimbursement Application; and (iii) a certification completed by Tenant’s architect confirming the Tenant Expansion Improvements included in the then current Expansion Reimbursement Application were performed in accordance with the Tenant Expansion Improvement Plans (collectively, the “Partial Expansion Reimbursement Requirements”). When the Tenant Expansion Improvements are completed in their entirety, as a condition of the final Expansion Reimbursement Application, Tenant shall provide: (i) executed final Lien Waivers, confirming the payment in full of all Tenant Expansion Improvement Costs up to the limit of the Tenant Expansion Improvement Allowance and the release of liens against the Premises; (ii) sufficient evidence of payment from Tenant to Tenant’s contractor(s) of all Tenant Expansion Improvement Costs up to the limit of the Tenant Expansion Improvement Allowance; and (iii) a certification completed by Tenant’s architect confirming the Tenant Expansion Improvements are complete and were performed in accordance with the Tenant Expansion Improvement Plans (collectively, the “Final Expansion Reimbursement Requirements”). Landlord shall have thirty (30) days after the receipt of each complete Reimbursement Application to submit its reimbursement payment to Tenant. Landlord shall not be required to issue any reimbursement payment to Tenant if the Reimbursement Application does not include the Partial Expansion Reimbursement Requirements or the Final Expansion Reimbursement Requirements, as the case may be.

   

5

 

 

    (g)       Tenant shall make a complete reimbursement submission for the Tenant Expansion Improvement Costs up to the amount of the Tenant Expansion Improvement Allowance no later than one (1) year after the Expansion Date. Landlord shall not be required to make payments on account of the Tenant Expansion Improvement Allowance for any Tenant Expansion Improvement Costs not submitted to Landlord by the foregoing date, and Tenant shall not have any claim to any portion of the Tenant Expansion Improvement Allowance not properly used by such date. In no event shall any portion of the Tenant Expansion Improvement Allowance be used to offset Tenant’s Rent obligations.

 

    (h)       Landlord and Tenant acknowledge that Tenant has not elected to avail itself of the Additional Allowance, and, accordingly, Tenant no longer has any right to the Additional Allowance under Section 29(i) of the Original Lease.

 

10.             The parties agree that they have dealt with no brokers in connection with this First Amendment, except for the Brokers identified in Section 1(1) of the Original Lease, whose commission with respect to this First Amendment shall be paid by Landlord pursuant to separate agreement. Each party agrees to indemnify and hold the other harmless from any and all claims for commissions or fees in connection with this First Amendment from any other real estate brokers or agents with whom they may have dealt.

 

        11.             Except as expressly modified herein, the terms and conditions of the Lease shall remain unchanged and in full force and effect.

 

12.             Tenant acknowledges and agrees that the Lease is in full force and effect and Tenant has no claims or offsets against Rent due or to become due hereunder. The Lease, as amended by this First Amendment, represents the entire agreement between the parties hereto and there are no collateral or oral agreements or understandings between Landlord and Tenant with respect to the Premises or the Property.

 

13.            This First Amendment shall be binding upon and inure to the benefit of the parties and their respective successors and permitted assigns. Both parties having participated fully and equally in the negotiation and preparation of this First Amendment, this First Amendment shall not be more strictly construed, nor any ambiguities in this First Amendment resolved, against either Landlord or Tenant.

 

14.             Each covenant, agreement, obligation, term, condition or other provision contained in this First Amendment shall be deemed and construed as a separate and independent covenant of the party bound by, undertaking or making the same, not dependent on any other provision of this First Amendment unless otherwise expressly provided.

 

6

 

 

15.              If any provisions of this First shall be declared unenforceable in any respect, such unenforceability shall not affect any other provision of this First Amendment, and each such provision shall be deemed to be modified, if possible, in such a manner as to render it enforceable and to preserve to the extent possible the intent of the parties as set forth herein. 

 

16.              This First Amendment shall be construed and enforced in accordance with the Laws of the State of Arizona (without the application of any conflict of laws principles). Any Arizona statutory provisions dealing with termination rights due to casualty, condemnation, delivery of possession or any other matter dealt with by this Lease are superseded by the terms of this Lease.

 

17.              Each of Landlord and Tenant agrees that it will not raise or assert as a defense to any obligation under this First Amendment, or make any claim that this First Amendment or the Lease is invalid or unenforceable, due to any failure of this document or the Lease to comply with ministerial requirements, including requirements for corporate seals, attestations, witnesses, notarizations or other similar requirements, and each party hereby waives the right to assert any such defense or make any claim of invalidity or unenforceability due to any of the foregoing.

 

18.              This First Amendment may be executed in multiple counterparts, each of which, when assembled to include an original signature for each party contemplated to sign this First Amendment, will constitute a complete and fully executed original. All such fully executed counterparts will collectively constitute a single First Amendment. Tenant expressly agrees that if the signature of Landlord and/or Tenant on this First Amendment is not an original, but is a digital, mechanical or electronic reproduction (such as, but not limited to, a photocopy, fax, email, PDF,), then such digital, mechanical or electronic reproduction shall be as enforceable, valid and binding as, and the legal equivalent to, an authentic and traditional ink-on-paper original wet signature penned manually by its signatory.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK; SIGNATURE PAGE

FOLLOWS]

 

7

 

 

IN WITNESS WHEREOF, Landlord and Tenant, intending to be legally bound, have executed this Amendment as of the day and year first above written.

 

      Landlord:
         
      WPT LAND 2 LP
         
      By: WPT Land 2 GP LLC, its general partner
         
        By: /s/ Anthony A. Nichols, Jr.
          Anthony A. Nichols, Jr.
Date: June 17, 2019       Senior Vice President
           
      TENANT:
           
      23andMe Inc.
           
      By: /s/ Anne Wojcicki
        Anne Wojcicki
Date: June 17, 2019     CEO
         
         
      By: /s/ Steve Schoch
        Steve Schoch
Date: June 17, 2019     CFO
           
      Approved as to form
      23andMe Legal Department
           
      By: /s/ H. Sedwick / jmh
         
         
       

 

8

 

 

ASSIGNMENT AND ASSUMPTION OF LEASE

 

THIS ASSIGNMENT AND ASSUMPTION OF LEASE (this “Agreement”) is entered into as of June 25, 2020 by and between 23ANDME, INC., a Delaware corporation (“Assignor”) and CARIS MPI INC., a Texas corporation (“Assignee”) .

 

A.                 WPT LAND 2 LP, a Delaware limited partnership (“Landlord”), as landlord, and Assignor, as tenant, entered into that certain Lease Agreement dated March 1, 2019 (the “Original Lease”), as amended by First Amendment to Lease Agreement (“First Amendment”) dated June 17, 2019 (collectively, the “Lease”), for the lease of the premises commonly known as Suite 100 of the located at 4415 Cotton Center Boulevard, Phoenix, Maricopa County, Arizona (as more particularly described in the Lease, the “Premises”).

 

B.                  Subject to all of the terms and conditions of this Agreement, (i) Assignor desires to assign to Assignee all of Assignor’s rights and obligations under the Lease, as amended herein, and (ii) Assignee desires to assume from Assignor, all of Assignor’s rights and remaining obligations under the Lease as of the Effective Date (as defined below) and any obligations arising from and after the Effective Date.

 

AGREEMENT

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1.                   Assignment and Assumption. Subject to Section 7 below, effective as the date that the Consent (as defined in Section 7) is fully executed and delivered by Landlord, Assignor and Assignee (the “Effective Date”) , Assignor does hereby transfer, assign, convey, set over, and deliver unto Assignee all of Assignor’s right, title, and interest in, to, and under the Lease. Assignee does hereby assume and agree to perform all of Assignor’s duties, liabilities, and obligations in, to, and under the Lease as of, from and after the Effective Date. Accordingly, Assignee shall pay and perform directly to Landlord, for Landlord’s benefit, all monetary and non-monetary obligations accruing under the Lease on and after the Effective Date.

 

2.                   Premises “As-Is”; FF&E. Assignee shall accept the Premises in its existing “AS-IS” condition as of the Effective Date and expressly acknowledges that Assignor shall not be obligated to provide or pay for any improvements (other than any improvements that were performed by Assignor prior to the Effective Date for which Assignor has no further obligation to pay for or perform as of the Effective Date) . Notwithstanding anything to the contrary in the Lease, Assignee acknowledges that neither Assignor nor Landlord have any responsibility for work which may be required to prepare or remodel the Premises for Assignee’s use, and that Assignor has not made any representations of any kind, either express or implied, in connection with improvements or physical conditions on, or otherwise bearing on, the use or condition of the Premises and Assignee shall rely solely on Assignee’s own inspection and examination of such items and not on any representations of Assignor, of any kind, either express or implied. Subject to Section 7 below, Assignor shall deliver possession of the Premises to Assignee with the construction items listed on Exhibit A-1 attached hereto and the lab items listed on Exhibit A-2 attached hereto which shall become the property of Assignee as of the Effective Date (collectively, the “FF&E”) . As additional consideration for Assignee entering into this Agreement, on or prior to the Effective Date, Assignor shall execute a Quitclaim Bill of Sale (the “Quitclaim”) , in the form attached hereto as Exhibit B, to Assignee for consideration of $1.00 from Assignee for the FF&E and shall deliver the Quitclaim to Assignee concurrent with the mutual execution and delivery of the Consent. Assignor makes no representation or warranty as to the FF&E, and hereby expressly DISCLAIMS ANY WARRANTIES AS TO MERCHANTABILITY, CONDITION, USABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Assignee shall be solely responsible for and shall pay any sales, use or transfer taxes or similar taxes payable with respect to any applicable governmental authority to the transfer of the FF&E to Assignee and Assignee hereby agrees to indemnify, defend, protect and hold Assignor harmless from and against any and all claims, losses and damages, including without limitation, reasonable attorneys’ fees and disbursements, which may at any time be asserted against or suffered by Assignor by reason of Assignee’s failure to pay any applicable taxes.

 

1

 

 

3.                   Security Deposit. As of the date hereof, Landlord holds a security deposit of $169,000 (the “Security Deposit”) with respect to the Lease. The parties acknowledge that such Security Deposit will continue to be held by Landlord following the Effective Date and all rights of Assignor to the Security Deposit shall be assigned to Assignee as of the Effective Date, subject to Assignee’s payment obligation set forth below. Concurrent with Assignee’s execution and delivery of this Agreement to Assignor and as a condition to the effectiveness of this Agreement, Assignee shall reimburse Assignor for the amount of such Security Deposit by paying to Assignor an amount equal to $169,000 by wire transfer of immediately available funds to wire transfer coordinates to be provided by Assignor.

 

4.                   Reconciliations. Within five (5) business days following Assignee’s receipt of any reconciliation statements of Operating Expenses provided by Landlord to Assignee in accordance with Section 6 of the Original Lease for calendar years 2019 (to the extent Assignor has not received the same as of the Effective Date) and 2020 (collectively, the “Reconciliation Statements”), Assignee shall tender a copy of the same to Assignor. If the amount of the Operating Expenses paid by Assignor prior to the Effective Date exceeds Assignor’s actual share of such items as indicated in the Reconciliation Statements, then Assignee shall reimburse Assignor for such excess within thirty (30) days of Assignor’s receipt of any refund or credit from Landlord with respect to such overpayment.

 

5.                   Tenant Improvement Work. Assignee hereby expressly acknowledges and agrees that as of the Effective Date, Assignee shall assume all of Assignor’s obligations and liabilities with respect to the performance of and payment for the Tenant Improvements (with reasonable modifications to the existing plans approved by Landlord) and the Tenant Expansion Improvements and all other work performed with respect to the Premises (collectively, the “Tenant Improvement Work”), including without limitation, the completion of all such Tenant Improvement Work currently under construction at the Building in accordance with the terms of the Lease. Assignee hereby acknowledges and agrees that (a) Assignor shall terminate the existing construction contract with Assignor’s general contractor for the Tenant Improvement Work, DPR Construction (“DPR”), (b) from and after the Effective Date, Assignee shall promptly enter into a new construction contract with a contractor selected by Assignee and approved by Landlord for the performance of the Tenant Improvement Work and (c) Assignee shall be solely responsible for the completion of the Tenant Improvement Work and shall comply with all the terms and conditions of the Lease related to the performance of the Tenant Improvement Work. Assignee further acknowledges and agrees that as of the Effective Date, Assignor has no obligations to perform any of the Tenant Improvement Work, including without limitation, any work to be performed under the permits described on Exhibit C attached hereto issued with respect to the Tenant Improvement Work (collectively, the “Existing Permits”), or to close out any of the Existing Permits. In addition, Assignee shall be solely responsible for obtaining, at its sole cost and expense, any other permits and other governmental approvals required with respect to the Tenant Improvement Work. Assignee hereby assumes and agrees to perform all of Assignor’s obligations with respect to the Existing Permits and to perform all requirements for the close-out of the Existing Permits and any such other permits obtaining in connection with the Tenant Improvement Work. Assignor hereby represents and warrants that Assignor has paid all amounts payable by Assignor as of the date hereof with respect to the Tenant Improvement Work. Assignee hereby acknowledges and agrees that as of the date hereof, Landlord has paid to Assignor all of the Tenant Improvement Allowance payable pursuant to the Original Lease and that no portion of the Tenant Improvement Allowance shall be paid to Assignor nor assigned or payable to Assignee hereunder or pursuant to the Lease. In addition, Assignee hereby acknowledges and agrees that as of the date hereof, Landlord has paid to Assignor $11,590.00 of the Tenant Expansion Improvement Allowance payable to Tenant pursuant to the First Amendment and accordingly, the balance of the Tenant Expansion Improvement Allowance is $277,650.00.

 

2

 

 

6.                   Indemnity. Assignee shall indemnify, defend, and hold harmless Assignor from and against any and all liabilities, obligations, damages, penalties, claims, costs, charges and expenses (including, without limitation, reasonable attorneys’ fees) which may be imposed upon, incurred by, or asserted against Assignor, arising out of or relating to the Lease and/or the Consent from and after the Effective Date, including without limitation, the construction and completion of the Tenant Improvement Work, any breach of Assignee’s obligations pursuant to Section 5 above and any liability of Assignor for the Surviving Rent Obligation (as defined in the Consent) or any breach of this Agreement or the Consent by Assignee. Assignee’s indemnity obligations hereunder shall survive the expiration or earlier termination of the Lease.

 

7.                   Landlord’s Consent. Notwithstanding anything to the contrary set forth in this Agreement, this Agreement and the obligations of the parties hereunder are expressly conditioned upon Assignor obtaining prior written consent to this Agreement by Landlord, in form and content acceptable to Assignor and Assignee (the “Consent”). Assignee shall promptly deliver to Assignor any documents and information as may be requested by Landlord regarding Assignee’s business or financial condition with respect to providing such Consent. In the event that, for any reason, the Consent of Landlord to this Agreement is not obtained within thirty (30) days after execution of this Agreement by Assignor and Assignee, then either party may terminate this Agreement by giving the other party written notice thereof, in which event this this Agreement shall terminate and neither party shall have any obligation hereunder. Upon such termination, Assignor shall return to Assignee the Security Deposit paid by Assignee to Assignor pursuant to Section 3. Notwithstanding anything to the contrary set forth in the Consent, solely as between Assignor and Assignee, in the event of a conflict between this Agreement and the Consent, the terms of this Agreement shall control.

 

8.                   Notices. Any and all notices, approvals or demands required or permitted under this Agreement shall be in writing, shall be served either personally, by United States certified mail, postage prepaid, return receipt requested or by reputable overnight carrier and, shall be deemed to have been given or made on the day on which it was received and shall be addressed to the parties at the addresses set forth below. If a party refuses or fails to accept delivery of a notice, such notice shall be given upon attempted delivery thereof. Any party may, from time to time, by like notice, give notice of any change of address, and in such event, the address of such party shall be deemed to have been changed accordingly.

 

If to Assignor:

 

 

 

 

 

If to Assignee:

 

23andme, Inc.

223 N. Mathilda Avenue

Sunnyvale, CA 94086

Attn: Chief Legal and Regulatory Officer

Email: ###

 

Caris MPI, Inc.

750 West John Carpenter Freeway, Suite 800

Irving, TX 75039

Attention: Caris Legal Department

Email: ###

 

9.                   Assignee Covenants. Assignee hereby covenants and agrees that until such time as Assignor is fully released from any and all liability under the Lease pursuant to the terms of the Consent, Assignee shall (a) immediately provide Assignor with a copy of any notices of default or breach under the Lease, or any notices relating to the Surviving Obligation (as defined in the Consent) received from Landlord or any other party, (b) immediately reimburse Assignor upon demand for any amounts paid by Assignor for the Surviving Rent Obligation, together with a five percent (5%) administrative charge and interest thereon (at the rate of interest payable under the Lease for any unpaid rent) until such amount is paid in full to Assignor, (c) promptly notify Assignor in writing of any default or breach under the Lease or any event which may, with notice or the passage of time or both, may constitute a default or breach under the Lease of which Assignee has knowledge, (d) not amend or modify the Lease in any manner which may increase Assignor’s liabilities or obligations under the Lease or the Consent, (e) fully and timely perform all of Assignee’s obligations under the Lease, as amended from time to time, and (f) until the Tenant Release Date (as defined in the Consent), not assign or otherwise Transfer any of Assignee’s rights or obligations under the Lease, the Consent or this Agreement. Assignee’s obligations hereunder shall survive the expiration or earlier termination of the Lease.

 

3

 

 

10.                 Successors and Assigns. This Agreement is binding on and inures to the benefit of the parties hereto and their respective successors and assigns. Notwithstanding any assignment, subletting or other transfer by Assignee of the Lease or the Premises or any portion thereof or consent thereto by Landlord, Assignee shall remain fully liable under this Agreement and shall not be released from performing any of the terms, covenants and conditions of this Agreement for so long as Assignor remains liable under the Lease pursuant to the terms of the Consent.

 

11.                 Counterparts. Assignor and Assignee may execute this Agreement in multiple counterparts, each of which constitutes an original, and all of which, collectively, constitute only one agreement. The signatures of all of the parties need not appear on the same counterpart, and delivery of an executed counterpart signature page by electronic means (e.g., scanned PDF by e-mail) is as effective as executing and delivering this Agreement in the presence of the other parties to this Agreement. This Agreement is effective upon delivery of one executed counterpart from each party to the other parties. THE PARTIES HERETO CONSENT AND AGREE THAT THIS AGREEMENT MAY BE SIGNED AND/OR TRANSMITTED BY USING ELECTRONIC SIGNATURE TECHNOLOGY (E.G., VIA DOCUSIGN OR SIMILAR ELECTRONIC SIGNATURE TECHNOLOGY), AND THAT SUCH SIGNED ELECTRONIC RECORD SHALL BE VALID AND AS EFFECTIVE TO BIND THE PARTY SO SIGNING AS A PAPER COPY BEARING SUCH PARTY’S HAND-WRITTEN SIGNATURE. THE PARTIES FURTHER CONSENT AND AGREE THAT (1) TO THE EXTENT A PARTY SIGNS THIS AGREEMENT USING ELECTRONIC SIGNATURE TECHNOLOGY, BY CLICKING “SIGN”, SUCH PARTY IS SIGNING THIS AGREEMENT ELECTRONICALLY, AND (2) THE ELECTRONIC SIGNATURES APPEARING ON THIS AGREEMENT SHALL BE TREATED, FOR PURPOSES OF VALIDITY, ENFORCEABILITY AND ADMISSIBILITY, THE SAME AS HAND-WRITTEN SIGNATURES.

 

12.                Authority and Consent. Each of Assignor and Assignee represents to the other that this Agreement has been duly authorized, executed, and delivered by and on behalf of such party and constitutes the valid, binding, and enforceable agreement of such party in accordance with the terms of this Agreement.

 

13.                 No Construction Against Drafting Party. Each of Assignor and Assignee acknowledges that such party and their respective counsel have had an opportunity to review this Agreement and that this Agreement will not be construed for or against either party merely because such party prepared or drafted this Agreement or any particular provision thereof.

 

14.                 Choice of Law. The laws of the state, commonwealth, or jurisdiction where the Premises are located (without giving effect to its conflict of laws principles) govern all matters arising out of or relating to this Agreement and the transactions it contemplates, including its interpretation, construction, performance, and enforcement.

 

4

 

 

15.                 Attorneys’ Fees. In the event any proceeding to enforce any provision of this Agreement, the party prevailing in such proceeding shall be entitled, in addition to such other relief as may be granted, to receive from the other party all reasonable attorneys’ fees and costs incurred in connection with such proceeding and any appeal therefrom.

 

16.                 Entire Agreement. This Agreement and the attached exhibits, which are hereby incorporated into and made a part of this Agreement, set forth the entire agreement between the parties with respect to the matters set forth herein. There have been no additional oral or written representations or agreements.

[SIGNATURE PAGE FOLLOWS]

 

5

 

 

IN WITNESS WHEREOF, the parties hereby execute this Agreement as of the date first written above.

 

  ASSIGNOR:
   
  23ANDME, INC., a Delaware corporation
   
  By: /s/ Steve Schoch
     
  Print Name: Steve Schoch
     
  Title: CFO
   
   
  ASSIGNEE:
   
  CARIS MPI, INC., a Texas corporation
   
  By: /s/ David D. Halbert
     
  Print Name: David D. Halbert
     
  Title: CEO

 

6

 

 

EXHIBIT A-1

 

LIST OF CONSTRUCTION ITEMS

 

 

Exhibit A-1-1

 

 

EXHIBIT A-2
 

LIST OF LAB ITEMS
 

(see attached)

 

Exhibit A-2-1

 

 

EXHIBIT B

 

FORM OF QUITCLAIM BILL OF SALE

 

QUITCLAIM BILL OF SALE

 

23ANDME, INC., Delaware corporation (“Seller”) having its principal place of business at 223 N. Mathilda Avenue, Sunnyvale, California, in consideration of $1.00 and other valuable consideration, receipt and sufficiency whereof is hereby acknowledged, does hereby quitclaim and convey to CARIS MPI, INC., a Texas corporation (“Buyer”), the personal property described on Schedule 1 attached hereto (collectively, the “FF&E”) located at the premises having the address of 4415 Cotton Center Boulevard, Phoenix, Arizona.

 

All warranties of quality, condition, fitness of use, and merchantability are hereby excluded and Buyer accepts the FF&E in its “as is” / “where is” condition.

 

IN WITNESS WHEREOF, Seller has caused this quitclaim bill of sale as of June 25, 2020.

 

  SELLER:
   
  23ANDME, INC., a Delaware coporation
   
  By: /s/ Steve Schoch, CFO        
  Name: Steve Schoch, CFO
  Date: 06/26/20

 

Exhibit B-1

 

 

SCHEDULE 1 TO QUITCLAIM BILL OF SALE

 

List of FF&E

 

Exhibit B-2

 

 

EXHIBIT C

 

LIST OF EXISTING PERMITS

  

Exhibit C-1

 

Exhibit 10.3(b)

 

INDUSTRIAL REAL ESTATE LEASE

(Single-Tenant Facility)

 

 

ARTICLE ONE: BASIC TERMS

 

This Article One contains the Basic Terms of this Lease between the Landlord and Tenant named below. Other Articles, Sections and Paragraphs of the Lease referred to in this Article One explain and define the Basic Terms and are to be read in conjunction with the Basic Terms.

 

Section 1.01. Date of Lease. August 19, 2009.

 

Section 1.02. Landlord (include legal entity). Liberty Cotton Center, LLC, a Delaware limited liability company.

 

LANDLORD:

Liberty Cotton Center, LLC

2930 East Camelback Road, Suite 318

Phoenix, AZ 85016

Attn: Senior Vice President/City Manager

 

Section 1.03. Tenant (include legal entity). CDx Holdings, Inc., a Delaware corporation.

 

TENANT:

CDx Holdings, Inc.

Attn: Joe Ellison, Vice President, Human Resources

8400 Esters Boulevard

Suite 190

Irving, TX 75063

 

Section 1.04. Property. The "Property" (also referred to as the "Leased Premises") is located at 4610 South 44th Place, Phoenix, Arizona 85040, and consists of 66,012 rentable square feet based on a standard perimeter drip line measurement ("Building") and the right to use the other improvements located on the land and the common areas described in Paragraph 4.03(a) relating to Building as described or depicted in Exhibit "A". Landlord has provided to Tenant the architects' certification of the rentable square footage and the calculations of such square footage prior to execution of this Lease, and Tenant acknowledges receipt of such certification as provided in the letter from Balmer Architectural Group, dated June 11, 2008.

 

Section 1.05. Lease Term. Ten (10) years and six (6) months beginning on March 1, 2010.

 

Section 1.06. Permitted Uses (See Article Five). Twenty-four hour, seven day a week access and use for general office use; medical diagnostic; laboratory-based research; other medical review services; imaging center; clinical and anatomic pathology laboratory services; molecular genetic laboratory services; cytogenetic laboratory services; Biosafety level 2 laboratory associated activities: processing of any type of bodily fluids, tissues, or other products associated with or derived from human or animal tissues, cell lines, bacterial cultures, viral cultures; recombinant DNA work; diagnostic medical laboratory and related services, testing and administration; use and appropriate disposal of hazardous chemicals and biohazardous waste.

 

 

 

 

Section 1.07. Tenant's Guarantor (if none, so state). NONE.

 

Section 1.08. Brokers (See Article Fourteen) (See 13.15).

 

LANDLORD'S BROKERS:

Mark S. Krison

CB Richard Ellis

Senior Vice President

2415 East Camelback Road

Phoenix, AZ 85016-4290

 

TENANT'S BROKER:

Scott T. Collier and Greg Bast

Jones Lang LaSalle Americas, Inc.

8343 Douglas Avenue, Suite 100

Dallas, TX 75225

 

Section 1.09. Commission Payable to Landlord's Broker (See Article Fourteen). Pursuant to separate agreement.

 

Section 1.10. Security Deposit. None.

 

Section 1.11. Vehicle Parking Spaces Allocated to Tenant. Two Hundred Sixty Four (264) vehicle parking spaces at the locations set for in Exhibit "A" attached hereto for Tenant's exclusive use.

 

Section 1.12. Rent and Other Charges Payable by Tenant.

 

(a)         Base Rent. Base Rent shall be made per month, plus all applicable rental taxes and privilege taxes, as provided in Section 3.05 and pursuant the following (which amounts (other than for months 1-6) each include an amortized portion of the Tenant Allowance equal to $2.927):

 

Months 1-6 $0.00 per rentable square feet per year
Months 7-18 $19.897 per rentable square feet per year
Months 19-30 $20.321 per rentable square feet per year
Months 31-42 $20.756 per rentable square feet per year
Months 43-54 $21.202 per rentable square feet per year
Months 55-66 $21.659 per rentable square feet per year
Months 67-78 $22.127 per rentable square feet per year
Months 79-90 $22.607 per rentable square feet per year
Months 91-102 $23.099 per rentable square feet per year
Months 103-114 $23.603 per rentable square feet per year
Months 115-126 $24.120 per rentable square feet per year

 

-2-

 

 

(b)        Other Periodic Payments. (i) Real Property Taxes (See Section 4.02); (ii) Common Area Costs (See Section 4.03); (iii) Insurance Premiums (See Section 4.04); (iv) Impounds for Insurance Premiums and Property Taxes (See Section 4.07); and (v) Maintenance, Repairs and Alterations (See Article Six), including all applicable rental and privilege taxes on said Periodic Payments.

 

Section 1.13. Landlord's Share of Profit on Assignment or Sublease (See Section 9.05). Fifty percent (50%) of the Profit (the "Landlord's Share").

 

Section 1.14. Riders/Exhibits. The following Riders or Exhibits are attached to and made a part of this Lease (if none, so state):

 

(a)         Exhibit "A" Diagram of Property with Parking Designated.

 

(b)         Exhibit "B" Work Letter Agreement.

 

(c)         Exhibit "C" Building Rules

 

ARTICLE TWO: LEASE TERM

 

Section 2.01. Lease of Property For Lease Term. Landlord leases the Property to Tenant and Tenant leases the Property from Landlord for the Lease Term. The Lease Term is for the period stated in Section 1.05 above and shall begin and end on the dates specified in Section 1.05 above, unless the beginning or end of the Lease Term is changed under any provision of this Lease. The "Commencement Date" shall be the date specified in Section 1.05 above for the beginning of the Lease Term.

 

Section 2.02. Exempt Property. The definition of Property in Section 1.04 shall exclude any advertising structure positioned on the roof of any building, all antennae, satellite dishes and any other communication equipment and all banners or signs promoting the Property; provided, however, such excluded area and structures on the roof shall not interfere with Tenant's installation or use of the rooftop exhaust fans and satellite dishes (subject to the language at the end of this Section) installed for Tenant's use at the locations shown on the Tenant's Space Plan that is approved by Landlord. Further excluded from the definition of Property is all internal space designed to house mechanical equipment, conduit, wires, HVAC ducting and hookups with any such systems, including all mechanical run areas and casements, which are currently in use or to be used in the future. Provided that Tenant is not in default under this lease, Tenant shall have the right to install, maintain and repair a satellite dish antenna (the "Antenna") on the Building under and subject to the following conditions:

 

(a)            Tenant shall comply with all applicable rules, laws, regulations and restrictions applicable to the Property and shall obtain, and deliver to Landlord written evidence of, any approval(s) required under any recorded covenants or restrictions applicable to the Property.

 

(b)            Tenant shall obtain Landlord's prior approval of the location of the Antenna on the Property and of the specifications for the Antenna. If Landlord approves installation of the Antenna on the roof of the Building, Tenant agrees to consult with Landlord's roofing contractor prior to installation and strictly to comply with the roofing contractor's recommendations and requirements. Tenant shall pay all costs incurred by Landlord in connection with the Antenna including without limitation all architectural, engineering, contractors' and legal fees.

 

-3-

 

 

(c)              Tenant shall comply with the provisions of Section 6 (Alterations) of this Lease.

 

(d)             At least 3 business days prior to installation, Tenant shall notify Landlord of the date and time of the installation. Tenant shall install the Antenna only if Landlord is present with Tenant at the installation.

 

(e)             Tenant shall maintain the Antenna in a safe, good and orderly condition. The installation, maintenance, repair and removal of the Antenna shall be performed at Tenant's sole expense in a manner which will not impair the integrity of, damage or adversely affect the warranty applicable to, the roof or any other portion of the Property.

 

(f)              No later than the expiration or sooner termination of the Term, at Tenant's sole expense, Tenant shall remove the Antenna and repair any resulting damage.

 

(g)             Tenant's indemnification of Landlord pursuant to Section 5.05 of this Lease also applies to the Antenna and Tenant's use of any portion of the Property therefor. Without limiting the foregoing, Tenant solely shall be responsible for any damages or injury caused by or in any way relating to the Antenna, including, but not limited to, damage or injury caused by reason of the Antenna collapsing or being blown from the roof or any other portion of the Property.

 

Section 2.03. Early Occupancy. If Tenant occupies the Property and commences business operations prior to the scheduled Commencement Date, the Commencement Date herein shall adjust to such earlier date, the Expiration Date shall be adjusted accordingly, and Tenant's occupancy of the Property shall be subject to all of the provisions of this Lease, including the obligation to commence paying Additional Rent; provided that Tenant may not commence business operations until the Tenant Improvements (as defined in the Work Letter Agreement attached as Exhibit "B" hereto) have been completed. If Tenant so requests, Landlord will allow Tenant limited access to the Property to begin installing equipment, fixtures, furniture and cabling and/or to properly coordinate such work with the construction of the Tenant Improvements. Any such access will be subject to Landlord's prior consent in each instance, which consent will not be unreasonably withheld but may be conditioned on Tenant's work not unreasonably interfering with the construction of the Tenant Improvements. Any such use of the Property is also subject to, and Tenant must comply with and observe, all applicable laws, all safety rules and procedures, and all other terms and conditions of this Lease. Except as provided in the first sentence of this Section 2.02, in no event may Tenant conduct business in the Property during such early access period.

 

Section 2.04. Holding Over. Tenant shall vacate the Property upon the expiration or earlier termination of this Lease. Tenant shall reimburse Landlord for and indemnify Landlord against all reasonable damages which Landlord incurs from Tenant's delay in vacating the Property. If Tenant does not vacate the Property upon the expiration or earlier termination of the Lease and Landlord thereafter accepts rent from Tenant, Tenant's occupancy of the Property shall be a "month-to-month" tenancy, subject to all of the terms of this Lease and any governmental statutes which are applicable to a month-to-month tenancy, but do not conflict with any provision contained in this Lease, except that the Base Rent then in effect shall be increased by one hundred fifty percent (150%).

 

-4-

 

 

ARTICLE THREE: BASE RENT

 

Section 3.01. Time and Manner of Payment. Upon execution of this Lease, Tenant shall pay Landlord the Base Rent in the amount stated in Section l.12(a) above for the first month of the Lease Term. On the first day of the first month of the Lease Term and each month thereafter, Tenant shall pay Landlord the Base Rent, in advance, without offset, deduction or prior demand. The Base Rent shall be payable at Landlord's address or at such other place as Landlord may designate in writing.

 

Section 3.02. Option To Renew. At the expiration of the Lease Term, Tenant will have the option of extending the term of the Lease for two (2) additional terms (the "Renewal Options") of five (5) years each (collectively, the "Renewal Terms"); provided, however, that Tenant is not in material default beyond any applicable cure period under the Lease on the date of giving such notice or on the date of commencement of such Renewal Term; and provided, further that Tenant has not been in default (after the expiration of any notice and cure periods) under the Lease more than three (3) times previously. Tenant shall notify Landlord in writing of its intention to exercise any Renewal Option ("Tenant's Notice") not later than nine (9) months prior to expiration of the Lease Term or first renewal period, as the case may be. Any termination of the Lease shall result in automatic termination of the Renewal Options herein. The Renewal Terms shall be upon all of the terms and conditions of this Lease, except that the following rights and obligations of Tenant during the original Lease Term of this Lease shall not apply during any Renewal Term: (a) any right to rent-free or abated rent possession; (b) any right to further extension of the term of the Lease beyond the Renewal Terms set forth herein above; (c) any right to an additional Tenant Improvement Allowance during the Renewal Terms, and (d) any right to continue to pay the same Base Rent. The Base Rent for the Renewal Term shall be at Fair Market Value. Landlord shall provide Tenant with written notice of its proposed determination of Fair Market Value for the Property within thirty (30) days after receipt of Tenant's Notice. The parties shall have forty-five (45) days after Landlord has provided Tenant with Landlord's proposed determination of Fair Market Value for the Property in order to agree on the Base Rent during such extended term. If the parties fail to agree on the Base Rent for such extended term during that period, then (i) either party may elect to terminate this Lease at the end of the applicable term or (ii) the parties may agree to determine the Fair Market Rental through an appraisal. In the event the parties elect to establish the Fair Market Rental through an appraisal process, Landlord and Tenant shall each appoint one appraiser within thirty (30) days thereafter; provided, however, that if either party fails to designate an appraiser within the time period specified, then the appraiser who is designated shall conclusively determine the Fair Market Rental. If two (2) appraisers are designated, then they shall submit within thirty (30) days after the second thereof has been designated their appraisals of the Fair Market Rental. Landlord and Tenant intend that the "Fair Market Rental" shall be deemed to be the rentable square feet of industrial space that is then being charged for industrial space located in industrial buildings in the vicinity of and involving the use of the Property that are comparable in quality and offer similar amenities to the Property and involving arms length, new leases with similar terms and conditions, taking into account the savings to the Landlord in putting a new tenant into possession of the Property and all concessions offered in such other arms length new leases in the market (including without limitation free rent, tenant improvement allowances, leasing commissions, and moving allowances). The spaces used for comparison shall be comparable in size, quality and design to the Property, and such spaces used for comparison shall be comparable to the Property with respect to their location within such buildings, the quality and quantity of tenant improvements installed at each landlord's expense, and the financial strength of Tenant. Should the two appraisers be unable to agree within said thirty (30) days, the two appraisers shall each submit an independent written appraisal and together they shall designate one (1) additional person as appraiser within five (5) days following the expiration of said thirty (30) day period; provided however, that if the difference between the two appraisals is five percent (5%) or less of the lowest appraisal, then an additional appraiser shall not be designated and the Fair Market Rental shall equal the average of the two (2) appraisals that are submitted. The third appraiser shall submit an independent written appraisal within thirty (30) days following his or her appointment. If the two appraisers cannot agree upon a third appraiser, then either party hereunder may request that the presiding Judge of the Maricopa County Superior Court appoint such third appraiser. In the event a third appraiser is appointed, the Fair Market Rental shall be equal to the average of the two (2) written appraisals which are closest, and third (3rd) appraisal shall be disregarded. Each party shall bear the costs of the appraiser appointed by it. If three (3) appraisers are appointed, each party shall bear the cost of the appraiser appointed by it and the parties shall share equally in the cost of the third appraiser. No person shall be appointed or designated an appraiser unless he or she is (i) an independent appraiser who is a currently certified member of the American Institute of Real Estate Appraisers (with MM designation) and unless he or she has at least five (5) years experience as an appraiser in Maricopa County, or (ii) a real estate broker with at least ten (10) years experience in leasing of commercial industrial space in the vicinity of the Property. The third appraiser shall not have ever been employed (full-time or part-time or on a consulting basis) by Landlord or Tenant. In the event that the Fair Market Rental is not established before the commencement of the extended term, Tenant shall continue to pay the Base Rent in effect as of the end of the original term; when the Fair Market Rental has been established, the new Base Rent shall be retroactively effective as of the beginning of the extended term, and Tenant shall pay Landlord any deficiency with in thirty (30) days after the establishment of the new Base Rent. If Tenant has overpaid the Base Rent during such period, such overpayment shall be, at the election of Tenant, either offset against rent thereafter coming due or refunded by Landlord to Tenant. Notwithstanding the foregoing, if either Landlord or Tenant is not satisfied with the Fair Market Rental determined by the appraisal process, such party may elect to terminate this Lease at the end of the applicable term by providing written notice to the other party within ten (10) days after the Fair Market Rent is determined by the appraiser(s).

 

-5-

 

 

Section 3.03. Intentionally Deleted.

 

Section 3.04. Termination; Advance Payments. Upon termination of this Lease under Article Seven (Damage or Destruction), Article Eight (Condemnation) or any other termination not resulting from Tenant's default, and after Tenant has vacated the Property in the manner required by this Lease, Landlord shall refund or credit to Tenant (or Tenant's successor) any advance rent or other advance payments made by Tenant to Landlord, and any amounts paid for real property taxes and other reserves which apply to any time periods after termination of the Lease.

 

Section 3.05. Rental/Privilege Taxes. Tenant shall pay Landlord any and all privilege, commercial rental tax, transactional, excise or other taxes (not including Landlord's income taxes) imposed or levied by any taxing authority against Landlord for, or on Landlord's right to receive or the receipt by Landlord of, Base Rent, Additional Rent and any other charges or sums payable by Tenant under this Lease, said taxes to be paid and due at the time provided for payment of said Base Rent, Additional Rent or other sums or charges by Tenant. Upon collection of such amounts, Landlord shall timely pay such taxes.

 

ARTICLE FOUR: OTHER CHARGES PAYABLE BY TENANT

 

Section 4.01. Additional Rent. All charges payable by Tenant other than Base Rent are called "Additional Rent." Unless this Lease provides otherwise, Tenant shall pay all Additional Rent then due with the next monthly installment of Base Rent. The term "rent" shall mean Base Rent and Additional Rent. Additional Rent shall be payable upon the Commencement Date. During the first six (6) months of this Lease (i.e., the period of time in which no Base Rent is due and payable), Additional Rent shall be due and payable on the first day of each calendar month.

 

Section 4.02. Property Taxes.

 

(a)         Real Property Taxes. Tenant shall pay all real property taxes on the Property (including any fees, taxes or assessments against, or as a result of, any tenant improvements installed on the Property by or for the benefit of Tenant) during the Lease Term. Subject to Paragraph 4.02(c) and Section 4.07 below, such payment shall be made at least ten (10) days prior to the delinquency date of the taxes. Within such ten (10) day period, Tenant shall furnish Landlord with satisfactory evidence that the real property taxes have been paid. Landlord shall reimburse Tenant for any real property taxes paid by Tenant covering any period of time prior to or after the Lease Term. If Tenant fails to pay the real property taxes when due, Landlord may pay the taxes and Tenant shall reimburse Landlord for the amount of such tax payment as Additional Rent.

 

(b)         Definition of "Real Property Tax." "Real property tax" means: (i) any fee, license fee, license tax, business license fee, commercial rental tax, levy, charge, assessment, penalty or tax imposed by any taxing authority against the Property; (ii) any tax against Landlord's business of leasing the Property; (iii) any tax or charge for fire protection, streets, sidewalks, road maintenance, refuse or other services provided to the Property by any governmental agency; (iv) any tax imposed upon this transaction or based upon a re-assessment of the Property due to a change of ownership, as defined by applicable law, or other transfer of all or part of Landlord's interest in the Property; and (v) any charge or fee replacing any tax previously included within the definition of real property tax. "Real property tax" does not, however, include Landlord's federal or state income, franchise, inheritance or estate taxes.

 

(c)         Joint Assessment. If the Property is not separately assessed, Landlord shall reasonably determine Tenant's share of the real property tax payable by Tenant under Section 4.02(a) from the assessor's worksheets or other reasonably available information. Tenant shall pay such share to Landlord within fifteen (15) days after receipt of Landlord's written statement. Tenant shall have the right to review the method of calculation for Tenant's share of real property tax, and Landlord, upon request by Tenant, shall make available to Tenant the methods and calculations for such determination. If Tenant disagrees with Landlord's above determination, such dispute will be resolved according to the arbitration provisions set forth below.

 

-6-

 

 

(d)         Personal Property Taxes.

 

(i)         Tenant shall pay all taxes charged against trade fixtures, furnishings, equipment or any other personal property belonging to Tenant. Tenant shall use Tenant's best efforts to have personal property taxed separately from the Property.

 

(ii)         If any of Tenant's personal property is taxed with the Property, Tenant shall pay Landlord the taxes for the personal property within fifteen (15) days after Tenant receives a written statement from Landlord for such personal property taxes.

 

(e)        Tenant's Right to Contest Taxes. Tenant may attempt to have the assessed valuation of the Property reduced or may initiate proceedings to contest the real property taxes. If required by law, Landlord shall join in the proceedings brought by Tenant. However, Tenant shall pay all costs of the proceedings, including any costs or fees incurred by Landlord. Upon the final determination of any proceeding or contest, Tenant shall immediately pay the real property taxes due, together with all costs, charges, interest and penalties incidental to the proceedings. If Tenant does not pay the real property taxes when due and contests such taxes, Tenant shall not be in default under this Lease for nonpayment of such taxes if Tenant deposits funds with Landlord or opens an interest-bearing account reasonably acceptable to Landlord in the joint names of Landlord and Tenant. The deposit shall be applied to the real property taxes due, as determined at such proceedings.

 

Section 4.03. Common Areas; Use, Maintenance and Costs.

 

(a)         Common Areas. As used in this Lease, "Common Areas" shall mean all areas which are available for the common use of tenants of the Cotton Center Park, including Tenant, and which are not leased or held for the exclusive use of Tenant or other tenants, including, but not limited to, parking areas, driveways, sidewalks, loading areas, access roads, corridors, landscaping and planted areas. Landlord, from time to time, may change the size, location, nature and use of any of the Common Areas, convert Common Areas into leaseable areas, construct additional parking facilities (including parking structures) in the Common Areas, and increase or decrease Common Area land and/or facilities. Tenant acknowledges that such activities may result in inconvenience to Tenant. Except in an emergency, Landlord shall provide reasonable advance written notice to Tenant of any such activities and shall in no event materially impair ingress and egress to the Property unless such impairment is required by applicable law.

 

(i)          Liberty Cotton Center. The Leased Premises is located within a business park known as the Liberty Cotton Center ("Liberty Cotton Center"). Tenant, its agents, assigns, customers, designees, employees, guests, invitees, licensees, representatives, successors, tenants, visitors, and others, shall have the nonexclusive right to use all drives, sidewalks and other common facilities and areas (collectively, the "Liberty Common Areas") located within Liberty Cotton Center, including the right of ingress and egress to 44th Street, jointly with Landlord, other owners, tenants and occupants therein, and their respective agents, assigns, customers, designees, employees, guests, invitees, licensees, representatives, servants, successors, tenants, visitors, and others. Landlord represents and warrants that it has the legal right and authority to grant such rights to use the Liberty Common Areas to Tenant. Tenants, its agent, representatives, licensees, or employees shall not use any of the Liberty Common Areas in a manner which obstructs or interferes with the reasonable use thereof by others.

 

-7-

 

 

(ii)         Cotton Center Park. Liberty Cotton Center is a business park within a larger business park known as The Cotton Center (the "Cotton Center Park"). Tenant, its agents, assigns, customers, designees, employees, guests, invitees, licensees, representatives, successors, tenants, visitors, and others, shall also have the nonexclusive right to use all drives, sidewalks and other common areas and facilities (collectively, the "Cotton Center Common Areas") located within Cotton Center Park, jointly with Landlord, other owners, tenants and occupants therein, and their respective agents, assigns, customers, designees, employees, guests, invitees, licensees, representatives, servants, successors, tenants, visitors, and others. Landlord represents and warrants that it has the legal right and authority to grant such rights to use the Cotton Center Common Areas to Tenant. Tenant, its agents, assigns, customers, designees, employees, guests, invitees, licensees, representatives, servants, successors, tenants, visitors, and others, shall not use any of the Cotton Center Common Areas in a manner which obstructs or interferes with the reasonable use thereof by others.

 

(b)         Use of Common Areas. Tenant shall have the nonexclusive right (in common with other tenants and all others to whom Landlord has granted or may grant such rights) to use the Common Areas for the purposes intended, subject to such reasonable rules and regulations as Landlord may establish from time to time. Tenant shall abide by such rules and regulations and shall use its best effort to cause others who use the Common Areas with Tenant's express or implied permission to abide by Landlord's rules and regulations. At any time, Landlord may temporarily close any Common Areas to perform any acts in the Common Areas as, in Landlord's judgment, are desirable to improve Cotton Center Park or Liberty Cotton Center. Landlord shall provide Tenant with five (5) days prior written notice of all anticipated closures of the Common Area, along with the estimated time period Landlord expects such closure to continue. However, in emergency situations, Landlord shall provide the foregoing notice as soon as reasonably possible. Tenant shall not interfere with the rights of Landlord, other tenants or any other person entitled to use the Common Areas.

 

(c)         Specific Provision re: Vehicle Parking. Tenant shall be entitled to use the number of vehicle parking spaces in the Property allocated to Tenant in Section 1.11 of the Lease, at the locations designated on the Diagram of the Property attached hereto as Exhibit "A," without paying any additional rent. Of the allocated parking spaces, Landlord agrees that one hundred (100) of such parking spaces shall be covered and lit spaces, the location of such spaces of which will be mutually agreed upon by Tenant and Landlord and which improvements shall occur prior to the Commencement Date. Tenant's parking shall be reserved and shall be limited to vehicles no larger than standard size automobiles or pickup utility vehicles. Tenant shall not cause large trucks or other large vehicles to be parked within Cotton Center Park or on the adjacent public streets. Temporary parking of large delivery vehicles in Cotton Center Park may be permitted by the rules and regulations established by Landlord. Vehicles shall be parked only in striped parking spaces and not in driveways, loading areas or other locations not specifically designated for parking. Handicapped spaces shall only be used by those legally permitted to use them. If Tenant parks more vehicles in the parking area than the number set forth in Section 1.11 of this Lease, such conduct shall be a breach of this Lease, unless prior written consent for such parking is given by Landlord. In addition to Landlord's other remedies under the Lease, Tenant shall pay a daily charge determined by Landlord for each such additional vehicle. A breach shall not be deemed to occur under this Section unless written notice to Tenant of such violation is given. Notwithstanding the foregoing, no more than two (2) written notices shall be required during any twelve (12) calendar months for such matter to be a breach. Tenant shall be entitled to install covered parking at its sole cost and expense, provided Tenant complies with all applicable rules, laws, regulations and restrictions applicable to the Property and such improvements, and subject to the requirements in Section 6.05 below.

 

-8-

 

 

(d)          Maintenance of Common Areas. Landlord shall maintain the Common Areas in good order, condition and repair and while in control of the Association applicable to the Property, shall operate Liberty Cotton Center, in Landlord's sole discretion, as a first-class industrial/commercial real property development. Tenant shall pay Tenant's pro rata share (as determined below) of all costs incurred by Landlord for the operation and maintenance of the Common Areas. Common Area costs include, but are not limited to, costs and expenses for the following: gardening and landscaping; utilities, water and sewage charges; maintenance of signs (other than tenant's signs); premiums for liability, property damage, fire and other types of casualty insurance on the Common Areas and worker's compensation insurance; all property taxes and assessments levied on or attributable to the Common Areas; any and all Association fees, assessments due and charges for any Owner's Association covering Cotton Center Park; all personal property taxes levied on or attributable to personal property used in connection with the Common Areas; straight-line depreciation on personal property owned by Landlord which is consumed in the operation or maintenance of the Common Areas; rental or lease payments paid by Landlord for rented or leased personal property used in the operation or maintenance of the Common Areas; fees for required licenses and permits; repairing, resurfacing, repaving, maintaining, painting, lighting, cleaning, refuse removal, security and similar items; a reasonable allowance to Landlord for Landlord's supervision and management of the Common Areas and the real property of Landlord upon which the Property is located, not to exceed three percent (3%) of the total of the gross Base Rent and the gross Additional Rent of the Property for the calendar year; and all Common Area improvements. Notwithstanding the foregoing, the cost of any replacement (as opposed to repairs) of the roof of the Building shall be amortized (with interest determined at the prevailing loan rate available to Landlord) on a straight-line basis over the useful life the replacement in accordance with generally accepted accounting principles, consistently applied. Landlord may cause any or all of such services to be provided by third parties and the cost of such services shall be included in Common Area costs. Common Area costs shall not include depreciation of real property which forms part of the Common Areas.

 

(e)         Tenant's Share and Payment. Tenant shall pay as Additional Rent, Tenant's annual pro rata share of all Common Area costs (prorated for any fractional month) upon written notice from Landlord that such costs are due and payable, and in any event prior to delinquency. Tenant's pro rata share shall be calculated by dividing the square foot area of the Building, as set forth in Section 1.04 of the Lease, by the aggregate square foot area of all buildings which are leased or held for lease by tenants, as of the date on which the computation is made. Any changes in the Common Area costs and/or the aggregate area of the Property leased or held for lease during the Lease Term shall be effective on the first day of the month after such change occurs. Landlord may, at Landlord's election, estimate in advance and charge to Tenant as Common Area costs, all real property taxes for which Tenant is liable under Section 4.02 of the Lease, all insurance premiums for which Tenant is liable under Section 4.04 of the Lease, all maintenance and repair costs for which Tenant is liable under Section 6.04 of the Lease, and all other Common Area costs payable by Tenant hereunder. At Landlord's election, such statements of estimated Common Area costs shall be delivered, and at the request of Landlord, payable in monthly intervals to Landlord. Landlord may adjust such estimates at any time based upon Landlord's experience and reasonable anticipation of costs. Such adjustments shall be effective as of the next rent payment date after notice to Tenant. Within sixty (60) days after the end of each calendar year of the Lease Term, Landlord shall deliver to Tenant a statement prepared in accordance with generally accepted accounting principles setting forth, in reasonable detail, the Common Area costs paid or incurred by Landlord during the preceding calendar year and Tenant's pro rata share. Upon receipt of such statement, there shall be an adjustment between Landlord and Tenant, with payment to or credit given by Landlord (as the case may be) so that Landlord shall receive the entire amount of Tenant's share of such costs and expenses for such period. Landlord shall use its best efforts to effect an equitable preparation of bills of services rendered to the building and to any other property owned by Landlord. Landlord agrees to keep, books and records showing the Operating Expenses in accordance with generally accepted accounting principles consistently maintained on a year-to-year basis. Tenant, at its cost, may examine and audit the books and records of Landlord pertaining to the Common Area Operating Expenses for the current or previous years of the Lease Term or Renewal Term for the purposes of verifying that such expenses were paid, the amounts thereof and the accuracy of Landlord's annual accounting and Tenant's pro rata share required herein. Any overpayment or underpayment of Tenant's allocable share of Common Area Operating Expenses correctly shown by such audit shall be promptly reconciled by a payment equal to the amount thereof by Landlord to Tenant, or by Tenant to Landlord, as the case may be. If the results of such audit correctly show that Tenant's allocable share has been overpaid by five percent (5%) or more, Landlord shall promptly reimburse Tenant for the reasonable cost of such audit in addition to the amount overpaid. Not more than one such audit shall be conducted by Tenant for each calendar year during the term hereof If at any time during the Lease Term or Renewal Term Landlord discovers Landlord has failed to include any item(s) that are appropriate Common Area Operating Expenses under this Section during the current or previous years, Tenant shall be obligated to promptly pay such deficient amount following notification of such matter.

 

-9-

 

 

(f)          Utilities. Tenant shall pay directly to the appropriate supplier, the cost of all natural gas, heat, light, power, sewer service, telephone, water, refuse disposal and other utilities and services supplied to the Property. However, if any services or utilities are jointly metered with other property, Landlord shall make a reasonable determination of Tenant's proportionate share of the cost of such utilities and services and Tenant shall pay such share to Landlord within fifteen (15) days after receipt of Landlord's written statement. Tenant shall have the right to review the method of calculation for Tenant's pro-rata share of utilities, and Landlord, upon request by Tenant, shall make available to Tenant the methods, calculations, and billings for such determination. If Tenant disagrees with Landlord's above determination, such dispute will be resolved according to the arbitration provisions set forth below.

 

Section 4.04. Insurance Policies.

 

(a)         Liability Insurance. During the Lease Term, Tenant shall maintain a policy of commercial general liability insurance (sometimes known as broad form comprehensive general liability insurance) insuring Tenant against liability for bodily injury, property damage (including loss of use of property) and personal injury arising out of the operation, use or occupancy of the Property. Tenant shall name Landlord as an additional insured under such policy. The amount of such insurance shall be Five Million Dollars ($5,000,000) per occurrence. The liability insurance obtained by Tenant under this Section 4.04(a) shall (i) be primary and non-contributing; (ii) contain cross-liability endorsements; and (iii) insure Landlord against Tenant's performance under Section 5.05, if the matters giving rise to the indemnity under Section 5.05 result from the negligence or other acts or failure to act where a duty to act exists on the part of Tenant. The amount and coverage of such insurance shall not limit Tenant's liability nor relieve Tenant of any other obligation under this Lease. Landlord may also obtain comprehensive public liability insurance in an amount and with coverage determined by Landlord insuring Landlord against liability arising out of ownership, operation, use or occupancy of the Property. The policy obtained by Landlord shall not be contributory and shall not provide primary insurance.

 

(b)         Property and Rental Income Insurance. During the Lease Term, Landlord shall maintain policies of insurance covering loss of or damage to the Property and Common Areas in the full amount of its replacement value. Such policy shall contain an Inflation Guard Endorsement and shall provide protection against all perils included within the classification of fire, extended coverage, vandalism, malicious mischief, special extended perils (all risk), sprinkler leakage and any other perils which Landlord deems reasonably necessary. Landlord shall have the right to obtain flood insurance if required by any lender holding a security interest in the Property. Landlord shall not obtain insurance for Tenant's fixtures or equipment or Building improvements installed by Tenant on the Property. During the Lease Term, Landlord shall also maintain a rental income insurance policy, with loss payable to Landlord, in an amount equal to one year's Base Rent, plus to the extent available and deemed appropriate by Landlord, the Additional Rent, including without limitation, estimated real property taxes and insurance premiums. Tenant shall be liable for the payment of any deductible amount under Landlord's insurance covering damage to the Property or Tenant's insurance policies maintained pursuant to this Section 4.04, in an amount not to exceed Ten Thousand Dollars ($10,000) per occurrence. Tenant shall not do or permit anything to be done which invalidates any such insurance policies.

 

(c)         Payment of Premiums. Subject to Section 4.07, Tenant shall pay all premiums for the insurance policies described in Section 4.04(a) and (b) (whether obtained by Landlord or Tenant) within fifteen (15) days after Tenant's receipt of a copy of the premium statement or other evidence of the amount due, except Landlord shall pay all premiums for non-primary comprehensive public liability insurance which Landlord elects to obtain as provided in Section 4.04(a). If insurance policies maintained by Landlord cover improvements on real property other than the Property, Landlord shall deliver to Tenant a statement of the premium applicable to the Property showing in reasonable detail how Tenant's share of the premium was computed. If the Lease Term expires before the expiration of an insurance policy maintained by Landlord, Tenant shall be liable for Tenant's prorated share of the insurance premiums. Before the Commencement Date, Tenant shall deliver to Landlord a copy of any policy of insurance which Tenant is required to maintain under this Section 4.04. At least thirty (30) days prior to the expiration of any such policy, Tenant shall deliver to Landlord a renewal of such policy. As an alternative to providing a policy of insurance, Tenant shall have the right to provide Landlord a certificate of insurance, executed by an authorized officer of the insurance company, showing that the insurance which Tenant is required to maintain under this Section 4.04 is in full force and effect and containing such other information which Landlord reasonably requires.

 

-10-

 

 

(d)         General Insurance Provisions.

 

(i)          Any insurance which Tenant is required to maintain under this Lease shall include a provision which requires the insurance carrier to give Landlord not less than fifteen (15) days' written notice prior to any cancellation or modification of such coverage.

 

(ii)         If Tenant fails to deliver any policy, certificate or renewal to Landlord required under this Lease within the prescribed time period or if any such policy is canceled or modified during the Lease Term without Landlord's consent, Landlord may obtain such insurance, in which case Tenant shall reimburse Landlord for the cost of such insurance within thirty (30) days after receipt of a statement that indicates the cost of such insurance.

 

(iii)        Tenant shall maintain all insurance required under this Lease with companies holding a "General Policy Rating" of A-8 or better, as set forth in the most current issue of "Best Key Rating Guide". Landlord and Tenant acknowledge the insurance markets are rapidly changing and that insurance in the form and amounts described in this Section 4.04 may not be available in the future. Tenant acknowledges that the insurance described in this Section 4.04 is for the primary benefit of Landlord. If at any time during the Lease Term, Tenant is unable to maintain the insurance required under the Lease, Tenant shall nevertheless maintain insurance coverage which is customary and commercially reasonable in the insurance industry for Tenant's type of business, as that coverage may change from time to time. Landlord makes no representation as to the adequacy of such insurance to protect Landlord or Tenant's interests. Therefore, Tenant shall obtain any such additional property or liability insurance which Tenant deems necessary to protect Landlord and Tenant.

 

(iv)       Unless prohibited under any applicable insurance policies maintained, Landlord and Tenant each hereby waive any and all rights of recovery against the other, or against the officers, employees, or representatives of the other, for loss of or damage to its property or the property of others under its control, if such loss or damage is covered by any insurance policy in force (whether or not described in this Lease) at the time of such loss or damage. Upon obtaining the required policies of insurance, Landlord and Tenant shall give notice to the insurance carriers of this mutual waiver of subrogation.

 

Section 4.05. Late Charges. Tenant's failure to pay rent promptly may cause Landlord to incur unanticipated costs. The exact amount of such costs are impractical or extremely difficult to ascertain. Such costs may include, but are not limited to, processing and accounting charges and late charges which may be imposed on Landlord by any ground lease, mortgage or trust deed encumbering the Property. Therefore, if Landlord does not receive any rent payment within ten (10) days after it becomes due following written demand by Landlord to Tenant, Tenant shall immediately pay Landlord a late charge equal to five percent (5%) of the overdue amount. The parties agree that such late charge represents a fair and reasonable estimate of the costs Landlord will incur by reason of such late payment.

 

-11-

 

 

Section 4.06. Interest on Past Due Obligations. If Landlord does not receive any rent payment within ten (10) days after it becomes due following written demand by Landlord to Tenant and a five (5) business day opportunity to cure, and Landlord has provided such notice two (2) times during any twelve (12) calendar months, any such amount shall bear interest at the rate of eight percent (8%) per annum from the due date of such amount and the Tenant shall immediately pay to Landlord such interest. However, interest shall not be payable on late charges to be paid by Tenant under this Lease. The payment of interest on such amounts shall not excuse or cure any default by Tenant under this Lease. If the interest rate specified in this Lease is higher than the rate permitted by law, the interest rate is hereby decreased to the maximum legal interest rate permitted by law.

 

Section 4.07. Impounds for Insurance Premiums and Real Property Taxes. If requested by any ground lessor or lender to whom Landlord has granted a security interest in the Property, or if Landlord does not receive any rent payment within ten (10) days after it becomes due following written demand by Landlord to Tenant and a five (5) business day opportunity to cure, and Landlord has provided such notice two (2) times in any twelve (12) calendar months Tenant shall pay Landlord a sum equal to one-twelfth (1/12) of the annual real property taxes and insurance premiums payable by Tenant under this Lease, together with each payment of Base Rent. Landlord shall hold such payments in a non-interest bearing impound account. If unknown, Landlord shall reasonably estimate the amount of real property taxes and insurance premiums when due. Tenant shall pay any deficiency of funds in the impound account to Landlord upon written request. If Tenant monetarily defaults under this Lease, Landlord may apply any funds in the impound account to any monetary obligation then due under this Lease.

 

Section 4.08. Building Security. Tenant, at Tenant's sole cost and expense, shall provide for the security of the Property. Tenant acknowledges that Landlord shall not be liable for any damage, injury or loss suffered by Tenant or Tenant's employees, agents, contractors or invitees arising from the inadequacy or failure of any Property security measures, unless caused by Landlord's actions, omissions, intentional misconduct or gross negligence.

 

ARTICLE FIVE: USE OF PROPERTY

 

Section 5.01. Permitted Uses. Tenant may use the Property only for the Permitted Uses set forth in Section 1.06 above. Except to the extent such rules contradict any express term in this Lease, Tenant agrees to comply with the building rules attached to this Lease as Exhibit "C" as they may be amended from time to time; provided, that any such amendments shall not be imposed in a discriminatory manner to Tenant.

 

Section 5.02. Manner of Use. Tenant shall not cause or permit the Property to be used in any way which constitutes a violation of any law, ordinance (including but not limited to zoning ordinances) or governmental regulation or order, which unreasonably annoys or interferes with the rights of other tenants of Landlord, or which constitutes a nuisance or waste. Tenant's use of the Property shall be subject to and shall not violate any applicable CC&R's or other restrictions of record. Tenant shall obtain and pay for all permits, including a Certificate of Occupancy, required for Tenant's occupancy of the Property and shall promptly take all actions necessary to comply with all applicable statutes, ordinances, rules, regulations, orders and requirements regulating the use by Tenant of the Property, including the Occupational Safety and Health Act.

 

-12-

 

 

Section 5.03. Hazardous Materials. As used in this Lease, the term "Hazardous Material" means any flammable items, explosives, radioactive materials, hazardous or toxic substances, material or waste or related materials, including any substances defined as or included in the definition of "hazardous substances", "hazardous wastes", "hazardous materials" or "toxic substances" now or subsequently regulated under any applicable federal, state or local laws or regulations, including without limitation petroleum-based products, paints, solvents, lead, cyanide, DDT, printing inks, acids, pesticides, ammonia compounds and other chemical products, asbestos, PCBs and similar compounds, and including any different products and materials which are subsequently found to have adverse effects on the environment or the health and safety of persons. Other than Hazardous Materials used in the ordinary course of Tenant's business, Tenant shall not cause or permit any Hazardous Material to be generated, produced, brought upon, used, stored, treated or disposed of in or about the Property by Tenant, its agents, employees, contractors, sublessees or invitees without the prior written consent of Landlord; provided however, Tenant shall be allowed to store and use nominal amounts of commercially available cleaning products without the consent of Landlord. Tenant shall provide Landlord with ten (10) days advance written notice, setting forth an itemization of all such Hazardous Materials, with a detailed description thereof, and the intended volume, location and use of such Materials at the Property, prior to the use or allowance of any cleaning products or any other products, materials or substances which are Hazardous Materials as defined above or which have or may have adverse affects on the environment or the health and safety of persons. Landlord shall be entitled to take into account such other factors or facts as Landlord deems to be relevant in determining whether to grant or withhold consent to Tenant's proposed activity with respect to Hazardous Material not used in the ordinary course of Tenant's business. In no event, however, shall Landlord be required to consent to the installation or use of any storage tanks in or on the Property.

 

To the extent Tenant stores and uses any Hazardous Materials in or about the Property in accordance with the provisions of Section 5.03, Tenant shall be obligated to provide Landlord with a Phase I Environmental Report prepared in accordance with current ASTM standards or such other appropriate environmental review that relates to the actual Hazardous Materials stored, generated, or used by Tenant at the Property. The Phase I Environmental Report, addressed and certified to Landlord and Landlord's lender, if any, shall be dated as of the date Tenant vacates the Property. Tenant shall bear the cost of the Phase I Environmental Report and shall also be responsible for any and all costs, penalties and fines incurred for any environmental contamination and subsequent remediation at the Property. Should Tenant fail to timely deliver to Landlord the foregoing Report, Landlord may cause a Phase I Environmental Report to be prepared to like effect and Tenant shall be liable to Landlord for the actual cost of said Report. Should the Report provided by either Landlord or Tenant state that a hazardous condition exists in or on the Property or that the Property cannot be used or leased in a hazard-free condition (unless the hazardous condition existed prior to the Commencement Date under the Lease), to the extent Tenant caused such condition, Tenant shall forthwith cause the hazardous condition to be fully corrected at Tenant's expense. In addition, to the extent Tenant caused such condition Tenant shall be required to pay to Landlord monthly, on or before the first day of each month, an amount equal to the Base Rent and Additional Rent in the highest amount due under the Lease for the last year of the Lease Term, for any period following expiration of the Lease Term until the Property is restored to a hazard free condition. This requirement shall not be construed as an extension of an expired or terminated Lease, but solely as damages to Landlord due to such hazardous condition(s) existing at the Property which prevent Landlord from re-leasing the Property. Tenant, following such expiration or termination of this Lease, shall be allowed access to the Property, only to the extent necessary to remove or otherwise correct any hazardous condition, and shall conduct no gainful business activity whatsoever at said Property. The provisions of this Section 5.03 shall survive the expiration or any termination of this Lease.

 

-13-

 

 

Section 5.04. Signs and Auctions. Subject to Section 6.05, Tenant shall not place any exterior signs on the Property without Landlord's prior written consent, which shall not be unreasonably withheld. All signage shall be in compliance with all applicable laws and ordinances and all signage criteria of Landlord which will be provided to Tenant upon request thereof. To the extent or in the event Landlord erects a monument sign at or near the entrances to the Property, Tenant shall be entitled to a pro rata share of such signage. Tenant shall not conduct or permit any auctions or sheriffs sales at the Property. Notwithstanding the foregoing, Tenant shall have the exclusive right to building signage permitted on the Building.

 

Section 5.05. Indemnity. Except for claims arising out of or caused by Landlord's gross negligence, or willful misconduct, Tenant shall indemnify Landlord against and hold Landlord harmless from any and all reasonable costs, claims or liability arising from: (a) Tenant's use of the Property; (b) the conduct of Tenant's business or anything else done or permitted by Tenant to be done in or about the Property, including any contamination of the Property or any other property resulting from the presence or use of Hazardous Material caused or permitted by Tenant; (c) any breach or default in the performance of Tenant's obligations under this Lease; (d) any material misrepresentation or breach of warranty by Tenant under this Lease; or (e) other acts or omissions of Tenant. Tenant shall defend Landlord against any such cost, claim or liability at Tenant's expense with counsel reasonably acceptable to Landlord or, at Landlord's election, Tenant shall reimburse Landlord for all reasonable legal fees or costs incurred by Landlord in connection with any such claim. As a material part of the consideration to Landlord, Tenant assumes all risk of damage to property or injury to persons in or about the Property arising from any claims caused by Tenant or its employees and Tenant hereby waives all claims in respect thereof against Landlord, except for any claim arising out of Landlord's gross negligence or willful misconduct. As used in this Section, the term "Tenant" shall include Tenant's employees, officers and directors, if applicable.

 

Section 5.06. Landlord's Access. Landlord or its agents may enter the Property during business hours, except in an emergency (a) during the last six (6) months of the Lease Term to show the Property to potential buyers, investors or tenants or other parties, (b) to do any other act or to inspect and conduct tests in order to monitor Tenant's compliance with all applicable environmental laws and all laws governing the presence and use of Hazardous Material, or (c) for any other purpose Landlord deems reasonably necessary. Landlord shall give Tenant Forty-eight (48) hours prior written notice of such entry, except in the case of an emergency. However, Landlord agrees that access to certain areas of the Property may be restricted in order to comply with applicable governmental laws, rules and regulations concerning Tenant's operations therein and that in the case of every entry, Landlord shall be accompanied by a representative designated by Tenant and Landlord agrees that it shall abide by all health and safety requirements during such entry, including wearing protective gear, if necessary. During the last six (6) months of the Lease Term, Landlord may place customary "For Sale" or "For Lease" signs on the Property.

 

-14-

 

 

Section 5.07. Quiet Possession. If Tenant pays the rent and complies with all other terms of this Lease, Tenant may occupy and enjoy the Property for the full Lease Term, subject to the provisions of this Lease.

 

ARTICLE SIX: CONDITION OF PROPERTY; MAINTENANCE, REPAIRS AND ALTERATIONS

 

Section 6.01. Existing Conditions. Tenant accepts the Property in its condition as of the execution of the Lease, subject to all recorded matters, laws, ordinances, and governmental regulations and orders. Except as provided herein, Tenant acknowledges that neither Landlord nor any agent of Landlord has made any representation as to the condition of the Property or the suitability of the Property for Tenant's intended use. Tenant represents and warrants that Tenant has made its own inspection of and inquiry regarding the condition of the Property and is not relying on any representations of Landlord or any Broker with respect thereto. If Landlord or Landlord's Broker has provided a Property Information Sheet or other Disclosure Statement regarding the Property, a copy is attached as an exhibit to the Lease.

 

Section 6.02. Exemption of Landlord from Liability. Landlord shall not be liable for any damage or injury to the person, business ( or any loss of income therefrom), goods, wares, merchandise or other property of Tenant, Tenant's employees, invitees, customers or any other person in or about the Property, whether such damage or injury is caused by or results from: (a) fire, steam, electricity, water, gas or rain; (b) the breakage, leakage, obstruction or other defects of pipes, sprinklers, wires, appliances, plumbing, air conditioning or lighting fixtures or any other cause; (c) conditions arising in or about the Property or upon other portions of Cotton Center Park, or from other sources or places; or (d) any act or omission of any other tenant of Cotton Center Park. Landlord shall not be liable for any such damage or injury even though the cause of or the means of repairing such damage or injury are not accessible to Tenant. The provisions of this Section 6.02 shall not, however, exempt Landlord from liability for Landlord's gross negligence or willful misconduct.

 

Section 6.03. Landlord's Obligations. Except as provided in Article Seven (Damage or Destruction) and Article Eight (Condemnation), Landlord shall keep the following in good order, condition and repair: the foundations, exterior walls and roof of the Property (including painting the exterior surface of the exterior walls of the Property not more often than once every five (5) years, if necessary), sidewalks and parking lots, and all Common Area components of electrical and plumbing, Landlord shall not be obligated to maintain or repair windows, doors, plate glass, the interior surfaces of exterior walls, or any improvements installed by Tenant. Landlord shall maintain the Property in an attractive, first class and fully operative condition under this Section 6.03 and shall make or commence repairs within thirty (30) days after receipt of written notice from Tenant of the need for such repairs. In the event Landlord does not timely make such repairs, Tenant may make such repairs and collect such amounts from Landlord in accordance with the arbitration provisions set forth below. Prior to the Commencement Date, Landlord covenants to install, at its sole expense, up to approximately 1,000 square feet of new windows on the first floor of the Building, the quality being at least equivalent to the windows being replaced. As to Tenant's office space in the Property, Landlord shall use commercially reasonable efforts to not materially affect Tenant's use of the Property during repairs, maintenance and building or construction activity. As to Tenant's laboratory areas and Landlord's work or activities which could reasonably be expected to impact Tenant's laboratory business, Landlord shall not perform any proposed repairs, maintenance or building or construction activities, including but not limited to cutting off electricity, utilities, water, drainage capacity, HVAC or plumbing, or disrupting ingress or egress through the rear or the front entrances, or performing work which would reasonably be expected to result in ground vibrations at the Property that would interfere with such laboratory business, without giving Tenant not less than seventy two (72) hours advanced written notice (except in the case of an emergency) so that Tenant can take appropriate advance action where possible to avoid damage to equipment, protect lab samples, and protect laboratory tests being performed.

 

-15-

 

 

Section 6.04. Tenant's Obligations.

 

(a)         Except as provided in Article Seven (Damage or Destruction) and Article Eight (Condemnation), Tenant shall keep all portions of the Property (including nonstructural, interior, exterior, and landscaped areas, portions, systems and equipment) in good order, condition and repair (including interior repainting and refinishing, as needed). If any portion of the Property or any system or equipment in the Property which Tenant is obligated to repair cannot be fully repaired or restored, Tenant shall promptly replace such portion of the Property or system or equipment in the Property, regardless of whether the benefit of such replacement extends beyond the Lease Term; but if the benefit or useful life of such replacement extends beyond the Lease Term (as such term may be extended by exercise of any options), the useful life of such replacement shall be prorated over the remaining portion of the Lease Term (as extended), and Tenant shall be liable only for that portion of the cost which is applicable to the Lease Term (as extended). Tenant shall maintain a preventive maintenance contract providing for the regular inspection and maintenance of the heating and air conditioning system by a licensed heating and air conditioning contractor. If any part of the Property is damaged by any act or omission of Tenant, Tenant shall pay Landlord the cost of repairing or replacing such damaged property, whether or not Landlord would otherwise be obligated to pay the cost of maintaining or repairing such property. It is the intention of Landlord and Tenant that at all times Tenant shall maintain the portions of the Property which Tenant is obligated to maintain in an attractive, first-class and fully operative condition.

 

(b)         Landlord shall provide electric capacity of not less than 1600 amps to Tenant, such service to be made available at the exterior wall entry point of the Building wherein the Property is located, and shall provide any necessary maintenance or replacement thereof when required. Tenant shall be responsible to obtain electrical service from the power provider of its choice, and Landlord shall not be responsible for interruptions in such service. Tenant shall be responsible for and provide distribution of the power and electrical service from the entry point of the Building to the areas required for use thereof by Tenant, and Tenant shall be responsible for all repairs, maintenance and replacement of such electrical service and related equipment from the point of entry at the Building during the Lease Term. The foregoing responsibilities of Tenant shall include payment for the cost and expense of installation and any repairs, replacements, or upgrades, of such power and electrical service from said entry point to the remainder of the Building used or occupied by Tenant and all costs related to installing and causing service to commence, including payment of any security deposits required by any utility company serving the Property.

 

-16-

 

 

(c)        If Tenant installs any rubberized, non-breathable or similar flooring at the Property, Tenant shall provide and be responsible for sealcoating and installation of moisture barriers required for any such flooring, all in accordance with all specifications of the provider of such flooring or sealcoating, sufficient as necessary to prevent moisture and liquids from leaking or seeping underneath the flooring and sealcoating and sufficient to prevent any bubbling, blisters, separation or other conditions resulting from water or liquid below the flooring installed by Tenant or within the concrete floor, and from any and all damages occurring by reason thereof. It shall be Tenant's responsibility and obligation to install, maintain, repair or replace such flooring and sealcoating in order to meet the foregoing requirements, and Tenant shall pay all costs and expenses for such installation, maintenance, repair or replacement thereof. Tenant shall make its own inspection of and inquiry regarding the concrete floor at the Property, and as to any flooring and any sealcoating which exists at the Property, whether provided by Landlord or a prior Tenant, and Tenant hereby waives and relinquishes any claims against or liability of Landlord as to such flooring and sealcoating, or any damages or losses occurring by reason of any defect in, or inadequacy of, such flooring and any sealcoating, including, without limitation, any right or claim against Landlord for repair, maintenance or replacement thereof during the Lease Term. Nothing is this subsection shall be deemed to waive any claims against the Landlord arising out of or caused by Landlord's gross negligence or willful misconduct. Tenant shall make such tests and investigation as Tenant deems necessary prior to execution of this Lease, to determine and satisfy Tenant as to the condition of said flooring and any sealcoating.

 

(d)         Tenant shall fulfill all of Tenant's obligations under this Section 6.04 at Tenant's sole expense. If Tenant fails to maintain, repair or replace the Property as required by this Section 6.04, Landlord may, if Tenant has failed to cure such issue within ten (10) days after written notice from Landlord to Tenant (except that no prior notice shall be required in the case of an emergency), perform such maintenance or repair (including replacement, as needed) on behalf of Tenant. In the event of an emergency, Landlord shall notify Tenant as soon as reasonably possible. In such case, Tenant shall reimburse Landlord for all reasonable costs incurred in performing such maintenance or repair immediately upon demand.

 

Section 6.05. Alterations, Additions, and Improvements.

 

(a)        After the Tenant Improvements are constructed, Tenant shall not make any alterations, additions, or improvements to the Property without Landlord's prior written consent, which consent shall not to be unreasonably withheld, conditioned, or delayed, except for non-structural alterations which do not cumulatively exceed a total cost of Fifty Thousand Dollars ($50,000.00) over the Lease Term and which are not visible from the outside of any building of which the Property is part. Landlord may require Tenant to provide demolition and/or lien and completion bonds in form and amount satisfactory to Landlord. Tenant shall promptly remove any alterations, additions, or improvements constructed in violation of this Section 6.05(a) upon Landlord's written request. All alterations, additions, and improvements shall be done in a good and workmanlike manner, in conformity with applicable laws and regulations, and by a licensed contractor approved by Landlord. Upon completion of any such work, Tenant shall provide Landlord with "as built" plans, copies of all construction contracts, and proof of payment for all labor and materials including appropriate lien releases. Landlord shall have no responsibility or liability for any death or injury to persons, including but not limited to Tenant, Tenant's officers, directors, members, employees, personnel, contractors, invitees and/or any third persons in or upon the real property of Landlord, or for damage to property caused by alterations, additions or improvements made to the Property by Tenant, whether or not made pursuant to Landlord's prior written consent as required herein, and Tenant hereby indemnifies Landlord against any such liability, obligation, cost or expense arising therefrom.

 

-17-

 

 

(b)         Tenant shall pay when due all claims for labor and material furnished to the Property. Tenant shall give Landlord at least ten (10) days prior written notice of the commencement of any work on the Property, regardless of whether Landlord's consent to such work is required. Landlord may elect to record and post notices of non-responsibility on the Property.

 

(c)        Tenant shall not make any alterations, additions, or improvements to the Property, including but not limited to mezzanines, storage areas or any other structure, which increase or add to the usable square footage of the Property. Tenant is hereby informed that the construction of any such structure or addition which increases the usable square footage is strictly prohibited and shall be deemed a material breach of this Lease.

 

Section 6.06. Condition upon Termination. Upon the termination of the Lease, Tenant shall surrender the Property and all alterations, additions and improvements to Landlord, broom clean and in the same condition as received except for ordinary wear and tear which Tenant was not otherwise obligated to remedy under any provision of this Lease; provided, however, Tenant shall be responsible for and obligated to, at the cost of Tenant, remedy any bubbling, blistering, leakage and separation occurring with respect to any flooring and any sealcoating so as to deliver and surrender the Property upon termination of the Lease to Landlord in good repair and condition. At the termination of the Lease, Tenant shall not be required to remove any flooring and sealcoating from the Property. However, Tenant shall not be obligated to repair any damage which Landlord is required to repair under Article Seven (Damage or Destruction). In addition, Landlord may require Tenant to remove any alterations, additions or improvements (whether or not made with Landlord's consent) prior to the expiration of the Lease and to restore the Property to its prior condition; provided, however that the office space on the Property shall only be required to be returned to its condition existing on the Commencement Date; and provided, further that the laboratory space on the Property shall only be required to be returned to the equivalent of office space, including the removal of all alterations, additions, improvements (whether or not made with Landlord's consent) and non-office related laboratory equipment and plumbing, all at Tenant's expense. All alterations, additions and improvements which Landlord has not required Tenant to remove shall become Landlord's property and shall be surrendered to Landlord upon the expiration or earlier termination of the Lease, except that Tenant may remove any of Tenant's machinery or equipment which can be removed without material damage to the Property provided all obligations of Tenant have been fully met and satisfied hereunder. Any trade fixture, machinery or equipment that has been bolted, wired or otherwise attached to the Building by ventilation which was paid for with the Tenant Allowance pursuant to the Work Letter Agreement, shall be deemed fixtures to the Building and shall remain at the Property following termination hereof, unless Tenant has fully performed all of its obligations hereunder. Tenant shall repair, at Tenant's expense, any damage to the Property caused by the removal of any such machinery or equipment. In no event, however, shall Tenant remove any of the following machinery or equipment (which shall be deemed Landlord's property) without Landlord's prior written consent: any power wiring or power panels; lighting or lighting fixtures; wall coverings; drapes, blinds or other window coverings; carpets or other floor coverings; heaters, air conditioners or any other heating or air conditioning equipment; fencing or security gates; or other similar building operating equipment and decorations. Except as provided herein to the contrary, Tenant shall not be obligated to remove any improvements installed as part of the original Tenant Improvements pursuant to the Work Letter Agreement.

 

-18-

 

 

ARTICLE SEVEN: DAMAGE OR DESTRUCTION

 

Section 7.01. Partial Damage to Property.

 

(a)         Tenant shall notify Landlord in writing immediately upon the occurrence of any damage to the Property. If the Property is only partially damaged (meaning, less than fifty percent (50%) of the Property is untenantable as a result of such damage or less than fifty percent (50%) of Tenant's operations are materially impaired) and if the proceeds received by Landlord from the insurance policies described in Section 4.04(b) are sufficient to pay for the necessary repairs, this Lease shall remain in effect and Landlord shall repair the damage as soon as reasonably possible. Landlord may elect (but is not required) to repair any damage to Tenant's fixtures, equipment, or improvements.

 

(b)         If the insurance proceeds received by Landlord are not sufficient to pay the entire cost of repair, or if the cause of the damage is not covered by the insurance policies which Landlord maintains under Section 4.04(b), Landlord may elect either to (i) repair the damage as soon as reasonably possible, in which case this Lease shall remain in full force and effect, or (ii) terminate this Lease as of the date the damage occurred. Landlord shall notify Tenant within thirty (30) days after receipt of notice of the occurrence of the damage whether Landlord elects to repair the damage or terminate the Lease. If Landlord elects to repair the damage and the damage was due to an act or omission of Tenant, or Tenant's employees, agents, contractors or invitees, Tenant shall pay Landlord the "deductible amount" (if any) under Landlord's insurance policies and the difference between the actual cost of repair and any insurance proceeds received by Landlord. If Landlord elects to terminate the Lease, Tenant may elect to continue this Lease in full force and effect, in which case Tenant shall repair any damage to the Property to the condition that existed prior to such damage. Tenant shall pay the cost of such repairs, except that upon satisfactory completion of such repairs, Landlord shall deliver to Tenant any insurance proceeds received by Landlord for the damage repaired by Tenant. Tenant shall give Landlord written notice of such election within ten (10) days after receiving Landlord's termination notice.

 

-19-

 

 

(c)         If the damage to the Property occurs during the last six (6) months of the Lease Term and such damage will require more than thirty (30) days to repair, either Landlord or Tenant may elect to terminate this Lease as of the date the damage occurred, regardless of the sufficiency of any insurance proceeds. The party electing to terminate this Lease shall give written notification to the other party of such election within thirty (30) days after Tenant's notice to Landlord of the occurrence of the damage.

 

Section 7.02. Substantial or Total Destruction. If the Property is substantially or totally destroyed by any cause whatsoever (meaning, the damage to the Property is greater than partial damage as described in Section 7.01), and regardless of whether Landlord receives any insurance proceeds, this Lease shall terminate as of the date the destruction occurred. Notwithstanding the preceding sentence, if the Property can be rebuilt within six (6) months after the date of destruction, Landlord may elect to rebuild the Property at Landlord's own expense, in which case this Lease shall remain in full force and effect. Landlord shall notify Tenant of such election within thirty (30) days after Tenant's notice of the occurrence of total or substantial destruction. If Landlord so elects, Landlord shall rebuild the Property at Landlord's sole expense, except that if the destruction was caused by an act or omission of Tenant, Tenant shall pay Landlord the difference between the actual cost of rebuilding and any insurance proceeds received by Landlord.

 

Section 7.03. Temporary Reduction of Rent. If the Property is destroyed or damaged and Landlord or Tenant repairs or restores the Property pursuant to the provisions of this Article Seven, any rent payable during the period of such damage, repair and or restoration shall be reduced according to the degree, if any, to which Tenant's use of the Property is impaired. However, the reduction shall not exceed the sum of one year's payment of Base Rent, insurance premiums and real property taxes. Except for such possible reduction in Base Rent, insurance premiums and real property taxes, Tenant shall not be entitled to any compensation, reduction, or reimbursement from Landlord as a result of any damage, destruction, repair, or restoration of or to the Property.

 

Section 7.04. Waiver. Tenant waives the protection of any statute, code or judicial decision which grants a tenant the right to terminate a lease in the event of the substantial or total destruction of the leased property. Tenant agrees that the provisions of Section 7.02 above shall govern the rights and obligations of Landlord and Tenant in the event of any substantial or total destruction to the Property.

 

ARTICLE EIGHT: CONDEMNATION

 

If all or any portion of the Property is taken under the power of eminent domain or sold under the threat of that power (all of which are called "Condemnation"), this Lease shall terminate as to the part taken or sold on the date the condemning authority takes title or possession, whichever occurs first. If more than twenty percent (20%) of the floor area of the Building is taken, either Landlord or Tenant may terminate this Lease as of the date the condemning authority takes title or possession, by delivering written notice to the other within ten (10) days after receipt of written notice of such taking (or in the absence of such notice, within ten (10) days after the condemning authority takes title or possession). If neither Landlord nor Tenant terminates this Lease, this Lease shall remain in effect as to the portion of the Property not taken, except that the Base Rent and Additional Rent shall be reduced in proportion to the reduction in the floor area of the Property. Any Condemnation award or payment shall be distributed in the following order: (a) first, to any ground lessor, mortgagee or beneficiary under a deed of trust encumbering the Property, the amount of its interest in the Property; (b) second, to Tenant, for any award available to Tenant under Arizona law so long as such award does not reduce the amount available to Landlord; and (c) third, to Landlord, the remainder of such award, whether as compensation for reduction in the value of the leasehold, the taking of the fee, or otherwise. If this Lease is not terminated, Landlord shall repair any damage to the Property caused by the Condemnation, except that Landlord shall not be obligated to repair any damage for which Tenant has been reimbursed by the condemning authority. If the severance damages received by Landlord are not sufficient to pay for such repair, Landlord shall have the right to either terminate this Lease or make such repair at Landlord's expense.

 

-20-

 

 

ARTICLE NINE: ASSIGNMENT AND SUBLETTING

 

Section 9.01. Landlord's Consent Required. No portion of the Property or of Tenant's interest in this Lease may be acquired by any other person or entity, whether by sale, assignment, mortgage, sublease, transfer, operation of law, or act of Tenant, without Landlord's prior written consent, except as provided in Section 9.02 below. Landlord has the right to grant or withhold its consent as provided in Section 9.05 below. Any attempted transfer without consent shall be void and shall constitute a non-curable breach of this Lease. If Tenant is a partnership or limited liability company, any cumulative transfer of more than twenty percent (20%) of the partnership or membership interests shall require Landlord's consent. If Tenant is a corporation, upon any change in the ownership of a controlling interest of the voting stock of the corporation, Tenant shall immediately notify Landlord, in writing, of such change in ownership.

 

Section 9.02. Tenant Affiliate. Tenant may assign this Lease or sublease the Property, without Landlord's consent, to any corporation which controls, is controlled by or is under common control with Tenant, or to any corporation resulting from the merger of or consolidation with Tenant ("Tenant's Affiliate"), including, without limitation, Caris MPI, Inc. and Caris Diagnostics, Inc. In such case, any Tenant's Affiliate shall assume in writing all of Tenant's obligations under this Lease.

 

Section 9.03. No Release of Tenant. No transfer permitted by this Article Nine, whether with or without Landlord's consent, shall release Tenant or change Tenant's primary liability to pay the rent and to perform all other obligations of Tenant under this Lease. Landlord's acceptance of rent from any other person is not a waiver of any provision of this Article Nine. Consent to one transfer is not a consent to any subsequent transfer. If Tenant's transferee defaults under this Lease, Landlord may proceed directly against Tenant without pursuing remedies against the transferee. Landlord may consent to subsequent assignments or modifications of this Lease by Tenant's transferee, without notifying Tenant or obtaining its consent. Such action shall not relieve Tenant's liability under this Lease.

 

Section 9.04. Intentionally Omitted.

 

Section 9.05. Landlord's Consent.

 

(a)        Tenant's request for consent to any transfer described in Section 9.01 shall set forth in writing the details of the proposed transfer, including the name, business and financial condition of the prospective transferee, financial details of the proposed transfer (e.g., the term of and the rent and security deposit payable under any proposed assignment or sublease), and any other information Landlord deems relevant. Landlord shall have the right to withhold consent, if reasonable, or to grant consent, based on the following factors: (i) the business of the proposed assignee or subtenant and the proposed use of the Property; (ii) the net worth and financial reputation of the proposed assignee or subtenant; (iii) Tenant's compliance with all of its obligations under the Lease; and (iv) such other factors as Landlord may reasonably deem relevant.

 

-21-

 

 

(b)         If Tenant assigns or subleases to other than a Tenant Affiliate, the following shall apply:

 

(i)         Tenant shall pay to Landlord as Additional Rent under the Lease the Landlord's Share (stated in Section 1.13) of the Profit (defined below) on such transaction as and when received by Tenant, unless Landlord gives written notice to Tenant and the assignee or subtenant that Landlord's Share shall be paid by the assignee or subtenant to Landlord directly. The "Profit" means (A) all amounts paid to Tenant for such assignment or sublease, including "key" money, monthly rent in excess of the monthly rent payable under the Lease, and all fees and other consideration paid for the assignment or sublease, including fees under any collateral agreements, less (B) costs and expenses directly incurred by Tenant in connection with the execution and performance of such assignment or sublease for real estate broker's commissions and costs of renovation or construction of tenant improvements required under such assignment or sublease. Tenant is entitled to recover such costs and expenses before Tenant is obligated to pay the Landlord's Share to Landlord. The Profit in the case of a sublease of less than all the Property is the rent allocable to the subleased space as a percentage on a square footage basis.

 

(ii)         Tenant shall provide Landlord a written statement certifying all amounts to be paid from any assignment or sublease of the Property within thirty (30) days after the transaction documentation is signed, and Landlord may inspect Tenant's books and records to verify the accuracy of such statement. On written request, Tenant shall promptly furnish to Landlord copies of all the transaction documentation, all of which shall be certified by Tenant to be complete, true and correct. Landlord's receipt of Landlord's Share shall not be a consent to any further assignment or subletting. The breach of Tenant's obligation under this Section 9.05(b) shall be a material default of the Lease.

 

Section 9.06. No Merger. No merger shall result from Tenant's sublease of the Property under this Article Nine, Tenant's surrender of this Lease or the termination of this Lease in any other manner. In any such event, Landlord may terminate any or all subtenancies or succeed to the interest of Tenant as sublandlord under any or all subtenancies.

 

ARTICLE TEN: DEFAULTS; REMEDIES

 

Section 10.01. Covenants and Conditions. Tenant's performance of each of Tenant's obligations under this Lease is a condition as well as a covenant. Tenant's right to continue in possession of the Property is conditioned upon such performance. Time is of the essence in the performance of all covenants and conditions.

 

-22-

 

 

Section 10.02. Defaults. Tenant shall be in material default under this Lease:

 

(a)         If Tenant fails to pay rent or any other charge when due within ten (10) days after written notice provided that no more than two (2) written notices shall be required during any 12 calendar month period;

 

(b)         If Tenant fails to perform any of Tenant's non-monetary obligations under this Lease for a period of thirty (30) days after written notice from Landlord; provided that if more than thirty (30) days are required to complete such performance, Tenant shall not be in default if Tenant commences such performance within the thirty (30) day period and thereafter diligently pursues its completion. However, Landlord shall not be required to give such cure period if Tenant's failure to perform constitutes a non-curable breach of this Lease (e.g., a transfer in violation of Article Nine above). The notice required by this Section is intended to satisfy any and all notice requirements imposed by law on Landlord and is not in addition to any such requirement.

 

(c)         (i) If Tenant makes a general assignment or general arrangement for the benefit of creditors; (ii) if a petition for adjudication of bankruptcy or for reorganization or rearrangement is filed by or against Tenant and is not dismissed within sixty (60) days; (iii) if a trustee or receiver is appointed to take possession of substantially all of Tenant's assets located at the Property or of Tenant's interest in this Lease and possession is not restored to Tenant within sixty (60) days; or (iv) if substantially all of Tenant's assets located at the Property or of Tenant's interest in this Lease is subjected to attachment, execution or other judicial seizure which is not discharged within sixty (60) days. If a court of competent jurisdiction determines that any of the acts described in this subparagraph (d) are not a default under this Lease, and a trustee is appointed to take possession (or if Tenant remains a debtor in possession) and such trustee or Tenant transfers Tenant's interest hereunder, then Landlord shall receive, as Additional Rent, the excess, if any, of the rent (or any other consideration) paid in connection with such assignment or sublease over the rent payable by Tenant under this Lease.

 

Section 10.03. Remedies. On the occurrence of any material default by Tenant, Landlord may, at any time thereafter, with or without notice or demand (unless notice is required as set forth in this Lease or as required under Arizona law) and without limiting Landlord in the exercise of any right or remedy which Landlord may have:

 

(a)         Terminate Tenant's right to possession of the Property by any lawful means, in which case this Lease shall terminate and Tenant shall immediately surrender possession of the Property to Landlord. In such event, Landlord shall be entitled to recover from Tenant all damages incurred by Landlord by reason of Tenant's default, including (i) the worth at the time of the award of the unpaid Base Rent, Additional Rent and other charges which Landlord had earned at the time of the termination; (ii) the worth at the time of the award of the amount by which the unpaid Base Rent, Additional Rent and other charges which Landlord would have earned after termination until the time of the award exceeds the amount of such rental loss that Tenant proves Landlord could have reasonably avoided; (iii) the worth at the time of the award of the amount by which the unpaid Base Rent, Additional Rent and other charges which Tenant would have paid for the balance of the Lease Term after the time of award exceeds the amount of such rental loss that Tenant proves Landlord could have reasonably avoided; and (iv) any other amount necessary to compensate Landlord for all the detriment proximately caused by Tenant's failure to perform its obligations under the Lease or which in the ordinary course of things would be likely to result therefrom, including, but not limited to, any reasonable costs or expenses Landlord incurs in maintaining or preserving the Property after such default, the cost of recovering possession of the Property, expenses of reletting, including necessary renovation or alteration of the Property, Landlord's reasonable attorneys' fees incurred in connection therewith, and any real estate commission paid or payable. As used in subparts (i) and (ii) above, the "worth at the time of the award" is computed by allowing interest on unpaid amounts at the rate of eight percent (8%) per annum, or such lesser amount as may then be the maximum lawful rate. As used in subpart (iii) above, the "worth at the time of the award" is computed by discounting such amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of the award, plus one percent (1%). If Tenant has abandoned the Property, Landlord shall have the option of (i) retaking possession of the Property and recovering from Tenant the amount specified in this Section 10.03(a), or (ii) proceeding under Section 10.03(b). Notwithstanding the above language in this Section, nothing shall waive, impact, or ameliorate Landlord's duty to mitigate its damages.

 

-23-

 

 

(b)          Maintain Tenant's right to possession, in which case this Lease shall continue in effect whether or not Tenant has abandoned the Property. In such event, Landlord shall be entitled to enforce all of Landlord's rights and remedies under this Lease including the right to recover the rent as it becomes due;

 

(c)         Pursue recovery of any damages, including but not limited to rent or any other charges due and owing to Landlord under this Lease, against any property, real or personal, subject to a security interest, mortgage, pledge, landlord's lien or other lien of Landlord provided by statute or provided for under the terms of this Lease in favor of Landlord against the property of the Tenant; and/or

 

(d)         Pursue any other remedy now or hereafter available to Landlord under the laws or judicial decisions of the state in which the Property is located.

 

Section 10.04.    Intentionally Deleted.

 

Section 10.05.  Automatic Termination. Notwithstanding any other term or provision hereof to the contrary, the Lease shall terminate on the occurrence of any act which affirms the Landlord's intention to terminate the Lease as provided in Section 10.03 hereof, including the filing of an unlawful detainer action against Tenant. On such termination, Landlord's damages for default shall include all costs and fees, including reasonable attorneys' fees that Landlord incurs in connection with the filing, commencement, pursuing and/or defending of any action in any bankruptcy court or other court with respect to the Lease; the obtaining of relief from any stay in bankruptcy restraining any action to evict Tenant; or the pursuing of any action with respect to Landlord's right to possession of the Property. All such damages suffered (apart from Base Rent, Additional Rent and other charges payable hereunder) shall constitute pecuniary damages which must be reimbursed to Landlord prior to assumption of the Lease by Tenant or any successor to Tenant in any bankruptcy or other proceeding.

 

-24-

 

 

Section 10.06.    Abandonment. Any trade fixtures, Tenant alternations and personal property not removed by Tenant or its secured lender with ten (10) days from the termination or expiration of this Lease shall be deemed abandoned, and such items may, in any manner Landlord's deems appropriate, in its sole discretion, be removed, destroyed and disposed of by Landlord at Tenant's expense. Tenant waives all claims against Landlord for any damages resulting from Landlord's retention, destruction and disposition of such property.

 

Section 10.07.    Cumulative Remedies. Landlord's exercise of any right or remedy shall not prevent it from exercising any other right or remedy.

 

Section 10.08.    Landlord Default and Tenant's Remedies. In the event Landlord defaults in payments or performance of its obligations hereunder, Tenant shall provide written notice to Landlord with opportunity to cure within thirty (30) days thereafter. Landlord shall not be deemed to be in default hereunder if Landlord cures such default during the foregoing thirty (30) day period or if such non-performance requires more than thirty (30) days to cure, Landlord shall commence curing the default within such thirty (30) day period and thereafter diligently pursue said cure completion. To the extent Landlord fails to cure any default as set forth in this Section 10.08, Tenant shall not be entitled to withhold Rent hereunder, but Tenant shall be entitled to undertake a claim relative to such default against Landlord in accordance with the arbitration provisions set forth below.

 

ARTICLE ELEVEN: PROTECTION OF LENDERS/ASSOCIATIONS

 

Section 11.01. Subordination. Landlord shall have the right to subordinate this Lease to any ground lease, deed of trust or mortgage encumbering the Property, any advances made on the security thereof, any renewals, modifications, consolidations, replacements or extensions thereof, whenever made or recorded, and any commercially reasonable covenants, conditions or restrictions to which the Property is subject by Landlord. Tenant shall cooperate with Landlord and any lender which is acquiring a security interest in the Property or the Lease. Tenant shall execute such further documents and assurances as Landlord or such lender may reasonably require, provided that Tenant's obligations under this Lease shall not be increased in any material way (the performance of ministerial acts shall not be deemed material), and Tenant shall not be deprived of its rights under this Lease. Tenant's right to quiet possession of the Property during the Lease Term shall not be disturbed if Tenant pays the rent and performs all of Tenant's obligations under this Lease and is not otherwise in default. If any ground lessor, beneficiary or mortgagee elects to have this Lease superior to the lien of its ground lease, deed of trust or mortgage and gives written notice thereof to Tenant, this Lease shall be deemed superior to such ground lease, deed of trust or mortgage whether this Lease is dated prior or subsequent to the date of said ground lease, deed of trust or mortgage or the date of recording thereof. In connection with any required subordination, Landlord shall cause any mortgagee or beneficiary under a deed of trust to not disturb Tenant, and Landlord shall deliver to Tenant a commercially reasonable Non-Disturbance agreement at the time of any such encumbrance.

 

-25-

 

 

Section 11.02.   Attornment. If Landlord's interest in the Property is acquired by any ground lessor, beneficiary under a deed of trust, mortgagee, or purchaser at a foreclosure sale, Tenant shall attorn to the transferee of or successor to Landlord's interest in the Property and recognize such transferee or successor as Landlord under this Lease. Tenant waives the protection of any statute or rule of law which gives or purports to give Tenant any right to terminate this Lease or surrender possession of the Property upon the transfer of Landlord's interest.

 

 

Section 11.03.   Signing of Documents. Tenant shall sign and deliver any instrument or documents reasonably necessary or appropriate to evidence any such attornment or subordination or agreement to do so. If Tenant fails to do so within ten (10) days after written request, Tenant hereby makes, constitutes and irrevocably appoints Landlord, or any transferee or successor of Landlord, the attorney-in-fact of Tenant to execute and deliver any such instrument or document.

 

Section 11.04.    Estoppel Certificates.

 

(a)         Upon either party's written request, the party to which the request is directed shall execute, acknowledge and deliver to the requesting party a written statement certifying: (i) that none of the terms or provisions of this Lease have been changed (or if they have been changed, stating how they have been changed); (ii) that this Lease has not been canceled or terminated; (iii) the last date of payment of the Base Rent and other charges and the time period covered by such payment; (iv) that the requested party is not in default under this Lease (or, if the requested party is claimed to be in default, stating why); and (v) such other representations or information with respect to the requested party or the Lease as the requesting party may reasonably request or which any prospective purchaser or encumbrancer of the Property may require. The requested party shall deliver such statement to the requesting party within ten ( 10) days after the requesting party's request. Landlord may give any such statement by the requested party to any prospective purchaser or encumbrancer of the Property and such purchaser or encumbrancer, as well as Landlord, may rely conclusively upon such statement as true and correct. Tenant may give any such statement by the requested party to any third party that has reason to rely upon such statement, and such third party, as well was Tenant, may rely conclusively upon such statement as true and correct.

 

(b)         If the requested party does not deliver such statement to requesting party within such ten (10) day period, the requesting party, and any prospective purchaser or encumbrancer, may conclusively presume and rely upon the following facts: (i) that the terms and provisions of this Lease have not been changed except as otherwise represented by the requesting party; (ii) that this Lease has not been canceled or terminated except as otherwise represented by requesting party; (iii) that not more than one month's Base Rent or other charges have been paid in advance; and (iv) that the requesting party is not in default under the Lease. In such event, the requested party shall be estopped from denying the truth of such facts.

 

Section 11.05. Tenant's Financial Condition. Within ten (10) days after written request from Landlord, Tenant shall deliver to Landlord such financial statements as Landlord reasonably requires to verify the net worth of Tenant or any assignee, subtenant, or guarantor of Tenant. In addition, Tenant shall deliver to any lender designated by Landlord any financial statements required by such lender to facilitate the financing or refinancing of the Property. Tenant represents and warrants to Landlord that each such financial statement is a true and accurate statement as of the date of such statement. All financial statements shall be confidential and shall be used only for the purposes set forth in this Lease.

 

-26-

 

 

ARTICLE TWELVE: LEGAL COSTS

 

Section 12.01.    Arbitration. The parties shall endeavor in good faith to promptly resolve disputes hereunder or need for interpretation of any portion of this Lease (the "Claim") by direct negotiations between executives who have authority to settle the matter. Such negotiations shall be conducted in the spirit of collaboration and compromise to avoid more extreme dispute resolution procedures and at the same time approximating satisfaction of the mutual interests of the parties. Any party may give the other notice of dispute not resolved in the normal course of business. Within five (5) days after delivery of the notice of dispute, the executives of both parties shall meet at a mutually acceptable time and place, telephonically or in person, and thereafter as often as they reasonably deem necessary to attempt to resolve the dispute. A party may elect, upon five (5) days notice, after the initial meeting (or attempted meeting if the initial meeting has not occurred because the other party has failed to attend the initial meeting) to proceed with binding arbitration of the dispute. The arbitration process shall be as follows:

 

(a)          Initiation of Arbitration. In order to initiate an arbitration hereunder, the party wishing to make a claim (the "Initiator") shall give a written notice of demand for arbitration hereunder (the "Initial Notice") to the other party (the "Respondent") and provide the name of the "Initial Arbitrator" (as hereinafter defined).

 

(b)          Initial Notice. To be valid the Initial Notice must include the following: (i)  a short statement of the claim, including the elements of the claim, cause and effect; (ii) a proposed resolution (the "Initial Resolution") of the claim involved; (iii) the name of the arbitrator proposed by the Initiator (the "Initial Arbitrator"); (iv) the address, phone number and facsimile information of both the Initiator and the Initial Arbitrator; (v) the date of the Initial Notice; and (vi) the signature of the Initiator. The Initial Notice may include other matters as shall be deemed appropriate by the Initiator, but it may not contain any conditions to the effectiveness of the Initial Notice nor any other matter which affects the validity of the Initial Notice.

 

(c)         Response. The Respondent is bound to respond to the Initial Notice in writing within ten (10) business days of the Initial Notice (the "Response") or suffer the consequences as hereinafter defined. If the Respondent fails to timely respond with a valid Response, the Initial Resolution shall become effective as an arbitration award hereunder. A valid Response must be one of the following described below: (i) a Second Arbitrator; (ii) Disputation of the Initial Resolution; or (iii) Acceptance.

 

-27-

 

 

(i)         Second Arbitrator. If the Respondent wishes to dispute the Initial Resolution and/or precipitate a panel of three arbitrators (Respondent may elect to use the Initial Arbitrator), the Respondent must timely deliver a written notice (the "Second Notice") to the Initiator and the Initial Arbitrator, which to be valid, must include the following: (a) a short statement of the response, including the factual disputes with the Initial Notice, other facts supporting the Respondents position; (b) a proposed resolution ("Second Resolution") of the claim, such as alternative amounts of payment, disbursements or damages or alternative resolutions of the claim; (c) the name of the arbitrator proposed by the Respondent (the "Second Arbitrator") if desired; (d) the address, phone number and facsimile information of both the Respondent and the Second Arbitrator; (e) the date of the Response; and (f) the signature of the Respondent. The Response may include other matters as shall be deemed appropriate by the Respondent, but it may not contain any conditions to the effectiveness of the Response nor any other matter which affects the validity of the Response. If a valid Second Arbitrator notice is timely given, the Second Arbitrator and the Initial Arbitrator shall meet and agree on a third arbitrator; if they do not or cannot within ten (10) days following the Response, then the Initiator, the Respondent and/or either Arbitrator may request to have the Maricopa County Superior Court name the third arbitrator. Upon completing the panel of arbitrators, the panel shall begin the arbitration process to ascertain information to make its award. The Arbitrators shall make an award of either the Initial Resolution or the Second Resolution.

 

(ii) Disputation of Initial Resolution. The Respondent may choose to only dispute the Initial Resolution. If the Respondent selects this alternative, the Respondent must timely file a Response including the following: (a) a short statement of the response, including the factual disputes with the Initial Notice and other facts supporting the Respondents position; (b) a proposed resolution (the "Second Resolution") of the claims, such as alternative amounts of damages, disbursements or alternative resolutions of the claims; (c) the address, phone number and facsimile information of the Respondent; (d) the date of the Response; and (e) the signature of the Respondent. The Response may include other matters as shall be deemed appropriate by the Respondent, including claims of the Respondent, but it may not contain any conditions to the effectiveness of the Response nor any other matter which affects the validity of the Response. If the Response does not name the Second Arbitrator, the Initial Arbitrator shall make the award as it deems appropriate in view of the facts as it determines them to be.

 

(iii) Acceptance. If the Respondent fails to timely give a valid notice of Second Arbitrator or Disputation, or if the Respondent gives notice of Acceptance of the Initial Resolution, then it may be implemented and acted upon by both parties hereto.

 

(d) Counterclaim. The Respondent may include a Counterclaim in the Response. If the Respondent makes a Counterclaim, the Initiator shall be obligated to respond in the same time and in the same fashion as the Respondent, except that the Initial Arbitrator shall be the Initiator's arbitrator for both the initial claim and the counterclaim.

 

(e) Arbitration Costs. In the absence of an award of arbitration costs hereunder, the costs of the arbitration shall be divided equally between the parties hereto. The arbitrator shall award reasonable attorneys fees and costs to the successful party.

 

(f) Scope of Arbitration. Arbitration may be invoked for all claims relating in any manner to this Lease except for Landlord's rights under Arizona law to proceed with forcible detainer or eviction actions. The award of the arbitration shall be enforceable in courts of competent jurisdiction.

 

-28-

 

 

Section 12.02.   Legal Proceedings. Tenant shall indemnify Landlord against and hold Landlord harmless from all reasonable costs, expenses, demands and liability Landlord may incur if Landlord becomes or is made a party to any claim or action (a) instituted by Tenant against any third party, or by any third party against Tenant, or by or against any person holding any interest under or using the Property by license of or agreement with Tenant; (b) for foreclosure of any lien for labor or material furnished to or for Tenant or such other person; (c) otherwise arising out of or resulting from any act or transaction of Tenant or such other person; or ( d) necessary to protect Landlord's interest under this Lease in a bankruptcy proceeding, or other proceeding under Title 11 of the United States Code, as amended. Tenant shall defend Landlord against any such claim or action at Tenant's expense with counsel reasonably acceptable to Landlord or, at Landlord's election, Tenant shall reimburse Landlord for any reasonable legal fees or costs Landlord incurs in any such claim or action.

 

Section 12.03.    Landlord's Consent. Tenant shall pay Landlord's reasonable attorneys' fees, not to exceed $2,500 per request, incurred in connection with Tenant's request for Landlord's consent under Article Nine (Assignment and Subletting), or in connection with any other act which Tenant proposes to do and which requires Landlord's consent.

 

ARTICLE THIRTEEN:     MISCELLANEOUS PROVISIONS

 

Section 13.01.  Periodic Rental Activity Updates. From the date of the execution of this Lease through and including six (6) months thereafter, Landlord agrees to provide Joe Ellison and Scott T. Collier, managing director of Jones Lang LaSalle, periodic rental activity updates, summarizing the general status of negotiations with prospective tenants for vacant space within Liberty Cotton Center, subject to Jones Lang LaSalle entering into a confidentiality agreement satisfactory to Landlord in its sole discretion.

 

Section 13.02.    Intentionally Deleted.

 

Section 13.03.    Intentionally Deleted.

 

Section 13.04.    Landlord's Liability; Certain Duties.

 

(a)         As used in this Lease, the term "Landlord" means only the current owner or owners of the fee title to the Property or the leasehold estate under a ground lease of the Property at the time in question. Each Landlord is obligated to perform the obligations of Landlord under this Lease only during the time such Landlord owns such interest or title. Any Landlord who transfers its title or interest is relieved of all liability with respect to the obligations of Landlord under this Lease to be performed on or after the date of transfer. However, each Landlord shall deliver to its transferee all funds that Tenant previously paid if such funds have not yet been applied under the terms of this Lease.

 

(b)         Tenant shall give written notice of any failure by Landlord to perform any of its obligations under this Lease to Landlord and to any ground lessor, mortgagee or beneficiary under any deed of trust encumbering the Property whose name and address have been furnished to Tenant in writing. Landlord shall not be in default under this Lease unless Landlord (or such ground lessor, mortgagee or beneficiary) fails to cure such non-performance within thirty (30) days after receipt of Tenant's notice. However, if such non-performance reasonably requires more than thirty (30) days to cure, Landlord shall not be in default if such cure is commenced within such thirty (30) day period and thereafter diligently pursued to completion.

 

-29-

 

 

(c)         Notwithstanding any term or provision herein to the contrary, the liability of Landlord for the performance of its duties and obligations under this Lease is limited to Landlord's interest in the Property, and neither the Landlord nor its partners, shareholders, officers or other principals shall have any personal liability under this Lease.

 

Section 13.05.   Severability. A determination by a court of competent jurisdiction that any provision of this Lease or any part thereof is illegal or unenforceable shall not cancel or invalidate the remainder of such provision or this Lease, which shall remain in full force and effect.

 

Section 13.06.   Interpretation. The captions of the Articles or Sections of this Lease are to assist the parties in reading this Lease and are not a part of the terms or provisions of this Lease. Whenever required by the context of this Lease, the singular shall include the plural and the plural shall include the singular. The masculine, feminine and neuter genders shall each include the other. In any provision relating to the conduct, acts or omissions of Tenant, unless otherwise stated the term "Tenant" shall include Tenant's agents, employees, contractors, invitees, successors or others using the Property with Tenant's expressed or implied permission.

 

Section 13.07.   Incorporation of Prior Agreements; Modifications. This Lease is the only agreement between the parties pertaining to the lease of the Property and no other agreements are effective. All of the agreements, conditions, covenants, terms, warranties and provisions of the Lease relating to the Property are expressly contained in this Lease, and none shall be implied. Tenant acknowledges and agrees that no prior information provided or statement made by the Landlord or its agents have in any way induced Tenant to enter into this Lease. All amendments to this Lease shall be in writing and signed by all parties. Any other attempted amendment shall be void.

 

Section 13.08.         Notices. All notices required or permitted under this Lease or otherwise given between Landlord and Tenant shall be in writing and shall be personally delivered or sent by certified mail, return receipt requested, postage prepaid or nationally recognized overnight delivery service. Notices to Tenant shall be delivered to the address specified in Section 1.03 above, with a copy to Tenant's counsel at:

 

TENANT'S COUNSEL: 

Ballard Spahr Andrews & Ingersoll

3300 North Central Avenue

Suite 1800

Phoenix, Arizona 85012

Attn: Jeffrey Pitcher, Esq.

 

-30-

 

 

Notices to Landlord shall be delivered to the address specified in Section 1.02 above, with a copy to Landlord's counsel at:

 

LANDLORD'S COUNSEL:

Quarles & Brady LLC

Two North Central Avenue

Phoenix, Arizona 85004

Attn: Scott M. Berg, Esq.

 

All notices shall be effective upon delivery. Except as provided above for notice to Tenant at the Property, either party may change its notice address upon written notice to the other party.

 

Section 13.09.   Waivers. All waivers must be in writing and signed by the waiving party. Landlord's failure to enforce any provision of this Lease or its acceptance of rent shall not be a waiver and shall not prevent Landlord from enforcing that provision or any other provision of this Lease in the future. No statement on a payment check from Tenant or in a letter accompanying a payment check shall be binding on Landlord. Landlord may, with or without notice to Tenant, negotiate such check without being bound to the conditions of such statement.

 

Section 13.10.   No Recordation. Tenant shall not record this Lease without prior written consent from Landlord. However, either Landlord or Tenant may require that a "Short Form" memorandum of this Lease executed by both parties be recorded. The party requiring such recording shall pay all transfer taxes and recording fees.

 

Section 13.11.   Binding Effect; Choice of Law. This Lease binds any party who legally acquires any rights or interest in this Lease from Landlord or Tenant. However, Landlord shall have no obligation to Tenant's successor unless the rights or interests of Tenant's successor are acquired in accordance with the terms of this Lease. The laws of the state in which the Property is located shall govern this Lease.

 

Section 13.12.   Corporate Authority; Partnership Authority; Limited Liability Company Authority. If Tenant is a corporation, each person signing this Lease on behalf of Tenant represents and warrants that he has full authority to do so and that this Lease binds the corporation. Within thirty (30) days after this Lease is signed, Tenant shall deliver to Landlord a certified copy of a resolution of Tenant's Board of Directors authorizing the execution of this Lease or other evidence of such authority reasonably acceptable to Landlord. If Tenant is a partnership, each person or entity signing this Lease for Tenant represents and warrants that he or it is a general partner of the partnership, that he or it has full authority to sign for the partnership and that this Lease binds the partnership and all general partners of the partnership. Tenant shall give written notice to Landlord of any general partner's withdrawal or addition. Within thirty (30) days after this Lease is signed, Tenant shall deliver to Landlord a copy of Tenant's recorded statement of partnership or certificate of limited partnership. If Tenant is a limited liability company, each person or entity signing this Lease for Tenant represents and warrants that he or it is a member of the limited liability company, that he or it has full authority to sign for the limited liability company and that this Lease binds the limited liability company and all members of the limited liability company. Tenant shall give written notice to Landlord of any member's withdrawal or addition. Within thirty (30) days after this Lease is signed, Tenant shall deliver to Landlord a certified copy of a resolution of Tenant's members authorizing the execution of this Lease or other evidence of such authority reasonably acceptable to Landlord. Any such entity acting as Tenant's Guarantor under this Lease shall deliver to Landlord a certified copy of a resolution from either the Guarantor's Board of Directors, general partners or members authorizing the execution of the Guaranty or other evidence of such authority reasonably acceptable to Landlord.

 

-31-

 

 

Section 13.13.   Joint and Several Liability. All parties signing this Lease as Tenant shall be jointly and severally liable for all obligations of Tenant.

 

Section 13.14.   Force Majeure. If Landlord cannot perform any of its obligations due to events beyond Landlord's control, the time provided for performing such obligations shall be extended by a period of time equal to the duration of such events. Events beyond Landlord's control include, but are not limited to, acts of God, war, civil commotion, labor disputes, strikes, fire, flood or other casualty, shortages of labor or material, government regulation or restriction and weather conditions.

 

Section 13.15.   Execution of Lease. This Lease may be executed in counterparts and, when all counterpart documents are executed, the counterparts shall constitute a single binding instrument. Landlord's delivery of this Lease to Tenant shall not be deemed to be an offer to lease and shall not be binding upon either party until executed and delivered by both parties.

 

Section 13.16.   Survival. All representations and warranties of Landlord and Tenant shall survive the termination of this Lease.

 

Section 13.17.   Broker's Fee. When this Lease is signed by and delivered to both Landlord and Tenant, Landlord shall pay a real estate commission to Landlord's and Tenants brokers named in Section 1.08 above (collectively, the "Broker"), in accordance with the separate agreement between Landlord and such Broker for services rendered to Landlord by Broker in this transaction. Nothing contained in this Lease shall impose any obligation on Landlord to pay a commission or fee to any party other than Broker.

 

Section 13.18.  Protection of Brokers. If Landlord sells the Property, or assigns Landlord's interest in this Lease, the buyer or assignee shall, by accepting such conveyance of the Property or assignment of the Lease, be conclusively deemed to have agreed to make any commission payments to Broker if required of Landlord under this Article Thirteen, to the extent same has not been previously paid. If Broker shall bring a legal action to enforce or declare rights under this provision, the prevailing party in such action shall be entitled to reasonable attorneys' fees to be paid by the losing party. Such attorneys' fees shall be fixed by the court in such action.

 

Section 13.19.   No Blocked Persons. Landlord nor Tenant nor any of their affiliates, officers, directors, partners or members is an entity or person (or to Landlord's and Tenant's knowledge, owned or controlled by an entity or person) that is listed in the Annex to, or is otherwise subject to the provisions of, Executive Order 13224 issued on September 24, 2001 ("EO13224"), whose name appears on the United States Treasury Department's Office of Foreign Assets Control most current list of "Specifically Designated National and Blocked Persons" who commits, threatens to commit or supports "terrorism," as that term is defined in EO13224 or who is otherwise affiliated with any entity or person listed above.

 

-32-

 

 

ARTICLE FOURTEEN: SIGNATURES

 

Section 14.01.  Counterparts/Facsimile Signatures. This Agreement may be executed in any number of counterparts, each of which will for all purposes be deemed to be an original, and when all counterpart documents are executed, the counterparts shall constitute a single binding instrument. Facsimile signatures on this Agreement shall be deemed binding the same as original signatures, and upon and execution and forwarding of this Agreement by facsimile, the parties so forwarding shall immediately mail the original signed document to said other party.

 

Section 14.02.   IN ANY REAL ESTATE TRANSACTION, IT IS RECOMMENDED THAT YOU CONSULT WITH A PROFESSIONAL, SUCH AS A CIVIL ENGINEER, INDUSTRIAL HYGIENIST OR OTHER PERSON WITH EXPERIENCE IN EVALUATING THE CONDITION OF THE PROPERTY, INCLUDING THE POSSIBLE PRESENCE OF ASBESTOS, HAZARDOUS MATERIALS AND UNDERGROUND STORAGE TANKS.

 

-33-

 

 

Signed on August 19, 2009, at 11 a.m."LANDLORD"

 

LIBERTY COTTON CENTER, LLCLIBERTY COTTON CENTER, LLC
      
By: Liberty Cotton Center II, LLC, its sole MemberBy: Liberty Cotton Center II, LLC, its sole Member
  By: Liberty Property Limited Partnership, its sole Member  By: Liberty Property Limited Partnership, its sole Member
    By: Liberty Property Trust, Sole General Partner    By: Liberty Property Trust, Sole General Partner

 

By: /s/ Michael T. Hagan  By:/s/ Robert Goldschmidt
Name: Michael T. Hagan  Name:Robert Goldschmidt
Title: Chief Investment Officer  Title:Senior Vice President, & Regional Director

 

Signed on August 12, 2009, at 5 p.m."TENANT"
  
 CDX HOLDINGS, INC., a Delaware corporation

 

  By:/s/ Laurie Johansen
  Name:Laurie Johansen
  Its:Vice Chairman

 

-34-

 

 

EXHIBIT "A"

DIAGRAM OF PROPERTY WITH PARKING INDICATED

 

 

 

EXHIBIT "B"

WORK LETTER AGREEMENT

 

The undersigned Landlord and Tenant are executing concurrently with this Work Letter Agreement, a written Industrial Real Estate Lease (the "Lease") covering those certain premises more particularly described in Section 1.04 of the Lease, (hereinafter referred to as "Premises"), commonly known as Liberty Cotton Center -Building 16.

 

1.            Representatives

 

Landlord appoints Landlord's Representative to act for Landlord in all matters covered by this Work Letter. Tenant appoints Tenant's Representative to act for Tenant in all matters covered by this Work Letter. All inquiries, requests, instructions, authorizations and other communications with respect to the matters covered by this Work Letter will be made to Landlord's Representative or Tenant's Representative, as the case may be. Tenant will not make any inquiries of or requests to, and will not give any instructions or authorizations to, any other employee or agent of Landlord, including Landlord's architect, engineers and contractors or any of their agents or employees, with regard to matters covered by this Work Letter. Either party may change its Representative under this Work Letter at anytime with three (3) days prior written notice to the other party.

 

  Tenant's Representative: Joe Ellison
    Senior Vice President -
    Human Resources & Administration
    8400 Esters Boulevard
    Irving, Texas  75063
    Phone:  [***]
     
  Landlord's Representative: Jim Schow
    Liberty Property Trust
    2390 East Camelback Road, Suite 318
    Phoenix, AZ  85016
    Phone:  [***]

 

2.            Tenant's Plans And Specifications

 

(a) Tenant agrees, at its sole cost and expense, through its representative, at the firm, The Lauck Group and Lord Aeck & Sargent. ("Space Planner") to furnish a space plan and specifications, including the space layout and improvement plan for the Premises ("Tenant's Space Plan") required for the performance of the work to construct the improvements to the building desired by Tenant (hereinafter referred to as the "Tenant Improvements"). Tenant's Space Plan shall include but not be limited to partition layout, reflected ceiling plans and electrical outlets, electrical switches and telephone outlets and locations. Tenant and Landlord agree to utilize a licensed and bonded contractor ("Contractor") as the Contractor for construction of the Tenant Improvements. Scott and Reid General Contractors, Inc., DPR Construction and Hardison Downey Construction Inc. are acceptable to Landlord.

 

 

 

(b)          The Space Planner shall be responsible for providing to Tenant, with a copy to Landlord, a complete set of documents, including Tenant's Space Plan, which are permit ready and have completed plan check by the government agency having jurisdiction, for construction of the Tenant Improvements, the quantity and description of materials, equipment and other items required for bidding by the Contractor. The Space Planner shall be responsible for completion and coordination of the architectural, mechanical, electrical and plumbing drawings. Landlord, Tenant and Contractor shall cooperate to the best of their ability to provide all information required for such coordination.

 

(c)          Tenant shall be responsible to pay the Space Planner's fees for the Tenant's Space Plan, which Landlord will reimburse Tenant by charging said reimbursement against the Tenant Allowance provided under this Agreement; however, all interior design or decorating services, such as selection of wall paint colors and/or wall coverings, fixtures, carpeting, and any or all other decorator or interior design services and extraordinary work required by Tenant of the Space Planner shall be paid by the Tenant at the time and to the extent the Space Planner has provided such services for the Tenant's Space Plans, and such services shall not be reimbursed by Landlord to Tenant and Landlord shall have no liability therefor.

 

(d)          All plans and specifications referred to hereinabove in Sections a, b and c are subject to the Landlord's approval, which the Landlord agrees will not be unreasonably withheld.

 

3.            Landlord's Approval

 

Landlord may withhold its approval of any Tenant Space Plan, Tenant Working Drawings, Tenant Extra Work or Change Orders which require work which:

 

(a)         adversely affects the structural integrity of the Building, or any part of the heating, ventilating, air conditioning, plumbing, mechanical, electrical, communication or other systems of the Building;

 

(b)         is not approved by the holder of any mortgage or deed of trust. encumbering the Building at the time the work is proposed;

 

(c)          would not be approved by a prudent owner of property similar to the Building;

 

(d)         violates any agreement which affects the Building or binds Landlord;

 

(e)          Landlord reasonably believes will increase the projected cost of operation or maintenance of any of the systems of the Building;

 

(f)          Landlord reasonably believes will reduce the rental value of the Premises or the sale value of the Building at the end of the Term;

 

(g)         does not conform to applicable building codes or is not approved by any governmental authority with jurisdiction over the Premises; or

 

-37-

 

 

(h)          is not consistent with or is inferior to the Building standard tenant improvements.

 

4.            Schedule of Tenant Improvement Activities

 

(a)         On or before five (5) days after the execution of the Lease ("Submission Date"), Tenant shall cooperate with and submit to Space Planner the information (the "Tenant Information") necessary for the Space Planner to prepare the Tenant's Space Plan for the Premises. Tenant's Space Plan shall be completed in accordance with the requirements of Tenant within thirty (30) days after the execution of the Lease.

 

(b)          Tenant, through the Contractor, will promptly prepare a preliminary estimate of the cost of Tenant's Improvements as set forth in the Tenant Space Plan (the "Tenant's Estimated Construction Cost"). If the Tenant's Estimated Construction Cost is more than the Tenant Allowance, Tenant will so notify Landlord in writing and Tenant will either:

 

(i)         agree in writing to pay the amount by which the Tenant's Estimated Construction Cost exceeds the Tenant Allowance and as though that amount were Tenant Extra Work, subject to Paragraph 5, or

 

(ii)        revise the Tenant Space Plan in order to assure that the Tenant's Estimated Construction Cost is either (A) no more than the Tenant Allowance e, or (B) in excess of the Tenant Allowance by an amount which Tenant agrees to pay pursuant to clause (i) immediately above. Upon Tenant's fulfillment of its obligation in either clause (i) or clause (ii) immediately above, the Tenant's Estimated Construction Cost will be deemed approved. If the Tenant's Estimated Construction Cost is less than the Tenant Allowance, the Tenant's Estimated Construction Cost will be deemed approved without notice to Tenant.

 

(c)          After approval of the Tenant's Estimated Construction Cost, Space Planner will prepare and deliver to Tenant, Landlord and Contractor working drawings for the Premises ("Tenant Working Drawings"). Tenant shall cause Contractor to prepare from the documents a cost proposal (the "Tenant Cost Proposal") for construction of Tenant's Improvements in accordance with the Tenant Working Drawings, and a Construction Schedule which will set forth estimated time frames for completion of construction. If the Tenant Cost Proposal is less than the sum of the Tenant Allowance and any amount in excess of the Tenant Allowance which Tenant has agreed to pay pursuant to Paragraph 4b, Tenant will take steps necessary to complete construction of the improvements to the Premises. If the Tenant Cost Proposal is more than the Tenant Allowance, plus any amount which Tenant has agreed to pay pursuant to clause (i) of Paragraph 4b immediately above (the "Maximum Approved Cost"), Tenant will so notify Landlord in writing and Tenant shall either (i) agree in writing to pay the amount by which the Tenant Cost Proposal exceeds the Maximum Approved Cost as if that additional amount were Tenant Extra Work, subject to Paragraph 5, or (ii) revise the Tenant Working Drawings in order to assure that the Tenant Cost Proposal is no more than the Maximum Approved Cost. Upon Tenant's fulfillment of its obligations in either clause (i) or clause (ii) above, Tenant will take steps necessary to complete construction of the improvements to the Premises.

 

-38-

 

 

 

(d)    All work shall be performed by the Contractor and/or contractors approved by Landlord. Landlord approves of Scott and Reid General Contractors, Inc. as general contractor and The Lauck Group as space planner. Following approval of the Tenant Working Drawings and the Tenant Cost Proposal, Tenant will cause Space Planner to make application to the appropriate governmental authorities for necessary approvals and building permits. Upon receipt of the necessary approvals and permits and subject to receipt of the payment required under Paragraph 5, the Contractor will begin construction. The Contractor may substitute materials of comparable or better quality if the materials specified in Tenant's Working Drawings are unavailable or not available within the time required for timely completion.

 

5.       Payment For Tenant Extra Work

 

Tenant shall pay Contractor for Tenant Extra Work as completed.

 

6.       Change Orders

 

Tenant may authorize changes in the work during construction only on written instructions to Landlord's Representative on a form approved by Landlord. All such changes will be subject to Landlord prior written approval in accordance with Paragraph 3. Landlord may disapprove any change which would materially delay the scheduled completion of work. Prior to commencing any change, the Tenant will prepare and deliver to Landlord, for Landlord's approval, a change order (the "Change Order") setting forth the total cost of such change, which will include associated architectural, engineering and construction contractor's fees. If Landlord fails to approve such Change Order within five (5) days after delivery by Tenant, Tenant will be deemed to have withdrawn the proposed change and Contractor will not proceed to perform the change.

 

7.     Mezzanine Improvements. Landlord acknowledges that the Tenant Improvements shall include the construction of a mechanical riser approximately 12,000 square foot in size to house mechanical equipment at the Premises (the "Mezzanine"). The Mezzanine shall be subject to the same review and approval process as the rest of the Tenant Improvements. The square footage added to the Premises as a result of the Mezzanine shall not be used in calculating Base Rent or Additional Rent.

 

8.       Construction Of The Premises

 

(a)      Tenant shall cause Contractor to construct the Tenant Improvements within the Premises under a contract with the Tenant following receipt of the final Tenant Working Drawings and necessary approvals and permits. All subcontractors awarded shall be at market rates.

 

(b)      Landlord shall have the right to approve Tenant's choice of the contractor to perform any of the nonstandard items listed in subparagraph (a) immediately above in Landlord's discretion, not to be unreasonable withheld. Any contractor employed by Tenant shall be commercially licensed, bonded and insured, with copies of all documentation evidencing such matters delivered to Landlord prior to the contractor beginning any work at or upon the Premises.

 

-39-

 

 

9.Tenant's Punch List

 

(a)      When the Contractor believes the Tenant Improvements are substantially completed, and prior to Tenant's possession of the Premises, Tenant shall give Landlord one (1) week prior written notification for Landlord to inspect the Tenant Improvements. Landlord's representative shall completely examine the Premises and complete with Tenant's representative a list of all visible items to be completed by Contractor to finish the work. Such list shall be formalized by Landlord and signed by both Landlord and Tenant. The Tenant Improvements shall be deemed "substantially completed" when the Premises, as improved, can be legally occupied by Tenant without material interference with Tenant's business, with only minor "punch list" items remaining to be completed. Landlord's good faith and reasonable determination of substantial completion shall be conclusive. Further, issuance of a certificate of occupancy by the appropriate governmental entity shall be deemed substantial completion.

 

(b)      Landlord shall diligently proceed to have all items noted on the list completed as soon as possible. Any work damaged during Tenant's move in or occupancy shall be repaired or replaced at Tenant's sole cost and expense.

 

10.Tenant Improvements At Landlord's Cost And Expense

 

Landlord agrees to provide Tenant an allowance of Seventy-Five Dollars $75.00 per rentable square foot for the 66,012 rentable square feet of the Premises to complete its Tenant Improvements in the Premises ("Tenant Allowance") for a total of Four Million Nine Hundred Fifty Thousand Nine Hundred ($4,950,900). The Tenant Allowance may be utilized by Tenant for any and all city permits, space planning (in the amount limited by Section 2c), engineering, architectural and construction costs. The Tenant Allowance shall be used only to plan and construct improvements which are real property fixtures that will remain with the Premises, and may not be used to purchase or construct trade fixtures, furniture, or other personal property. Landlord shall pay directly to such persons or entities that portion of the Tenant Allowance for the amounts owed (or pay to Tenant and such person or entity by joint check if requested by Tenant), subject to Tenant's delivery to Landlord of (1) copies of the relevant invoices, and (2) conditional lien releases, as applicable, in statutory form, with respect to the construction work or materials for which payment is being made and for which a mechanics, materialmen's or professional lien may be asserted under applicable law. All aggregate costs of Tenant Improvements in excess of the Tenant Allowance shall be the sole responsibility of the Tenant including any and all change order expenses.

 

11.Building Standards

 

Tenant shall utilize materials equivalent to or better in quality than the Landlord's Building standard tenant improvement items (the Building Standard) in order to assure the consistent quality and appearance of the Building.

 

-40-

 

 

12.Shell Construction

 

Landlord shall only provide as part of the initial construction of the Building the following items: (i) outside walls, columns and unfinished concrete floors, broom clean; (ii) Building Standard electric capacity of not less than 1,600 amps to the Building core, per building specifications; and (iii) water lines to the Building (with Tenant to be responsible for all costs of hook-up of all and any utilities, water, sewer and other similar services with the City in which the Premises is located), including the costs related to energizing Tenant's electrical service, and the cost of meter installation and meters, which shall be paid for by Tenant and/or included in the Tenant Allowance. Landlord represents that the shell Building is currently in conformance with ADA requirements.

 

13.Responsibility For Design

 

Tenant will be responsible for the design, function and maintenance of all improvements.

 

14.Indemnity

 

Except for claims arising out of or caused by Landlord's gross negligence or willful misconduct, Tenant shall indemnify Landlord against and hold Landlord harmless from any and all reasonable costs, claims or liability arising from: (a) any work performed on or about the Premises by or at Tenant's request; (b) any breach or default in the performance of Tenant's obligations under this Work Letter; or (c) any other acts or omissions of Tenant. Tenant shall defend Landlord against any such cost, claim or liability at Tenant's expense with counsel reasonably acceptable to Landlord or, at Landlord's election, Tenant shall reimburse Landlord for any reasonable legal fees or costs incurred by Landlord in connection with any such claim. As a material part of the consideration to Landlord, Tenant assumes all risk of damage to property or injury to persons in or about the Premises arising from any claims caused by Tenant's or its employees. And except when resulting from Landlord's gross negligence or willful misconduct, Tenant hereby waives all claims in respect thereof against Landlord. As used in this Section, the term "Tenant" shall include Tenant or Tenant's employees, officers and directors, if applicable.

 

15.Lien Protection

 

Tenant shall pay when due all claims for labor or materials furnished or alleged to have been furnished to or for Tenant for use in completing any work at or upon the Premises, which claims are or may be secured by any mechanic's liens against the Premises or any interest therein. Tenant shall give Landlord not less than ten (10) days prior written notice of any work done on or in the Premises and Landlord shall have the right to post a notice of non-responsibility in or on the Premises as may be allowed by law. If Tenant or Landlord shall contest the validity of any such lien, claim or demand, the Tenant, shall, at its sole cost and expense, defend and protect itself, the Premises and Landlord against the same and shall pay and satisfy any such adverse judgment that may be rendered thereon before the enforcement thereof against the Landlord or the Premises. If Landlord shall require, Tenant shall furnish to Landlord a surety bond satisfactory to Landlord in an amount equal to one and one half times the amount of such contested lien claim or demand, indemnifying Landlord against liability for the same, as required by law to hold the Premises free from the effect of such lien or claim. In addition, Landlord may require Tenant to pay Landlord's reasonable attorney fees and costs in participating in such action if Landlord shall deem it is in its best interest to do so.

 

-41-

 

 

16.Force Majeure

 

If Landlord cannot perform any of its obligations due to events beyond Landlord's control, the time provided for performing such obligations shall be extended by a period of time equal to the duration of such events. Events beyond Landlord's control include, but are not limited to, acts of God, war, civil commotion, labor disputes, strikes, fire, flood or other casualty, shortages of labor or material, government regulation or restriction and weather conditions. Acts which are not beyond Landlord's control, include, but are not limited to lack of sufficient funds for any liabilities or obligations, failure to pay for labor or materials, or any other matter within the Landlord's reasonable control or ability to resolve.

 

17.Miscellaneous

 

In the event of any conflict between the terms of this Work Letter Agreement and the remainder of the Lease, the terms of this Work Letter Agreement will control.

 

Tenant Initiails     Landlord Initials  

 

-42-

 

 

EXHIBIT "C"

BUILDING RULES

 

Any inconsistencies between the provisions of the Lease and the rules contained herein shall be resolved in favor of the Lease provisions.

 

1.           Any sidewalks, lobbies, passages and stairways shall not be obstructed or used by Tenant for any purpose other than ingress and egress from and to the Property. Landlord shall in all cases retain the right to control or prevent access by all persons whose presence, in the judgment of Landlord, shall be prejudicial to the safety, peace or character of the Property.

 

2.           The toilet rooms, toilets, urinals, sinks, faucets, plumbing or other service apparatus of any kind shall not be used for any purposes other than those for which they were installed, and no sweepings, rubbish, rags, ashes, chemicals or other refuse or injurious substances shall be placed therein or used in connection therewith or left in any lobbies, passages, elevators or stairways.

 

3.            Tenant shall not impair in any way the fire safety system and shall comply with all safety, fire protection and evacuation procedures and regulations established by Landlord or any governmental agency. No person shall go on the roof without Landlord's prior written permission.

 

4.            Skylights, windows, doors and transoms shall not be covered or obstructed by Tenant, and Tenant shall not install any window covering which would affect the exterior appearance of the Building, except as approved in writing by Landlord. Tenant shall not remove, without Landlord's prior written consent, any shades, blinds or curtains in the Property.

 

5.            Without Landlord's prior written consent, Tenant shall not hang, install, mount, suspend or attach anything from or to any sprinkler, plumbing, utility or other lines. If Tenant hangs, installs, mounts, suspends or attaches anything from or to any doors, windows, walls, floors or ceilings, Tenant shall spackle and sand all holes and repair any damage caused thereby or by the removal thereof at or prior to the expiration or termination of the Lease. Except as otherwise provided in the Lease, if Tenant elects to seal the floor, Tenant shall seal the entire unfinished floor area within the Property.

 

6.            Except for secured areas of the Property required by Tenant's business to be secured or otherwise locked, for which Tenant will provide Landlord a key or other immediate access mode, Tenant shall not change any locks nor place additional locks upon any doors.

 

7.            Tenant shall not use nor keep in the Building any matter having an offensive odor, nor explosive or highly flammable material, nor shall any animals other than handicap assistance dogs in the company of their masters be brought into or kept in or about the Property.

 

8.            If Tenant desires to introduce electrical, signaling, telegraphic, telephonic, protective alarm or other wires, apparatus or devices, Landlord shall direct where and how the same are to be placed, and except as so directed, no installation boring or cutting shall be permitted. Landlord shall have the right to prevent and to cut off the transmission of excessive or dangerous current of electricity or annoyances into or through the Building or the Property and to require the changing of wiring connections or layout at Tenant's expense, to the extent that Landlord may deem necessary, and further to require compliance with such reasonable rules as Landlord may establish relating thereto, and in the event of non-compliance with the requirements or rules, Landlord shall have the right immediately to cut wiring or to do what it considers necessary to remove the danger, annoyance or electrical interference with apparatus in any part of the Building. All wires installed by Tenant must be clearly tagged at the distributing boards and junction boxes and elsewhere where required by Landlord, with the number of the office to which said wires lead, and the purpose for which the wires respectively are used, together with the name of the concern, if any, operating same.

 

-43-

 

 

9.            Tenant shall not place weights anywhere beyond the safe carrying capacity of the Building.

 

10.          The use of rooms as sleeping quarters is strictly prohibited at all times.

 

11.         Tenant shall have the right, at Tenant's sole risk and responsibility, to use only Tenant's share of the parking spaces at the Property as reasonably determined by Landlord. Except as otherwise provided in the Lease, Tenant shall comply with all parking regulations promulgated by Landlord from time to time for the orderly use of the vehicle parking areas, including without limitation the following: Parking shall be limited to automobiles, passenger or equivalent vans, motorcycles, light four wheel pickup trucks and (in designated areas) bicycles. No vehicles shall be left in the parking lot overnight without Landlord's prior written approval. Parked vehicles shall not be used for vending or any other business or other activity while parked in the parking areas. Vehicles shall be parked only in striped parking spaces, except for loading and unloading, which shall occur solely in zones marked for such purpose, and be so conducted as to not unreasonably interfere with traffic flow within the Property or with loading and unloading areas of other tenants. Employee and tenant vehicles shall not be parked in spaces marked for visitor parking or other specific use. All vehicles entering or parking in the parking areas shall do so at owner's sole risk and Landlord assumes no responsibility for any damage, destruction, vandalism or theft. Tenant shall cooperate with Landlord in any measures implemented by Landlord to control abuse of the parking areas, including without limitation access control programs, tenant and guest vehicle identification programs, and validated parking programs, provided that no such validated parking program shall result in Tenant being charged for spaces to which it has a right to free use under its Lease. Each vehicle owner shall promptly respond to any sounding vehicle alarm or horn, and failure to do so may result in temporary or permanent exclusion of such vehicle from the parking areas. Any vehicle which violates the parking regulations may be cited, towed at the expense of the owner, temporarily or permanently excluded from the parking areas, or subject to other lawful consequence.

 

12.          If Landlord designates the Building as a non-smoking building, Tenant and its Agents shall not smoke in the Building nor at the Building entrances and exits.

 

13.         If at Tenant's request, Landlord consents to Tenant having a dumpster at the Property, Tenant shall locate the dumpster in the area designated by Landlord and shall keep and maintain the dumpster clean and painted with lids and doors in good working order and, at Landlord's request, locked.

 

14.         Tenant shall provide Landlord with a written identification of any vendors engaged by Tenant to perform services for Tenant at the Property (examples: cleaners, security guards/monitors, trash haulers, telecommunications installers/maintenance).

 

15.         Tenant shall comply with any reasonable move-in/move-out rules provided by Landlord.

 

16.         Tenant shall cause all of Tenant's Agents to comply with these Building Rules.

 

17.         Landlord reserves the right to rescind, suspend or modify any rules or regulations and to make such other rules and regulations as, in Landlord's reasonable judgment, may from time to time be needed for the safety, care, maintenance, operation and cleanliness of the Property. Notice of any action by Landlord referred to in this section, given to Tenant, shall have the same force and effect as if originally made a part of the foregoing Lease. New rules or regulations will not, however, be unreasonably inconsistent with the proper and rightful enjoyment of the Property by Tenant under the Lease.

 

18.        These Building Rules are not intended to give Tenant any rights or claims in the event that Landlord does not enforce any of them against any other tenants or if Landlord does not have the right to enforce them against any other tenants and such nonenforcement will not constitute a waiver as to Tenant.

 

-44-

 

 

LEASE ASSIGNMENT AND ASSUMPTION AGREEMENT

 

LEASE ASSIGNMENT AND ASSUMPTION AGREEMENT (this "Agreement") dated as of November 22, 2011 between CARIS LIFE SCIENCES, INC. (formerly CDX HOLDINGS, INC.), a Delaware corporation ("Assignor'') and CARIS MPI, INC., a Delaware corporation ("Assignee").

 

W I T N E S S E T H:

 

WHEREAS, Assignor is the tenant under that certain Industrial Real Estate Lease (Single-Tenant Facility) (the "Lease") dated August 19, 2009, between Assignor and Liberty Cotton Center, LLC ("Landlord'') relating to certain premises (the ''Premises'') consisting of approximately 66,012 rentable square feet located in the building known as Cotton Center Building 16, located at 4610 South 44th Place, Phoenix, AZ 85040.

 

WHEREAS, Assignor and Assignee desire that Assignor transfer its right, title and interest in, to and under the Lease to Assignee upon the terms and conditions set forth herein; and

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be bound hereby, the parties hereto hereby agree as follows:

 

SECTION 1. Effective as of the date hereof, Assignor hereby assigns to Assignee all of Assignor's right, title and interest in, to and under the Lease, including without limitation any security deposit thereunder, any prepaid rent or other prepaid amounts thereunder and any right to receive any refund from or make any claim against Landlord thereunder.

 

SECTION 2. Assignee hereby assumes the performance and observance of all of the covenants, conditions and provisions in the Lease to be performed and observed by Assignor from and after the date hereof.

 

SECTION 3. Assignee hereby represents and warrants that it has the sole and unencumbered right and power to enter into this Agreement and this Agreement has been duly authorized, executed and delivered by and on behalf of Assignee.

 

SECTION 4. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. No provision of this Agreement shall inure to the benefit of any other person or entity.

 

SECTION 5. No provision of this Agreement shall be modified, waived or terminated, except by an instrument in writing signed by the party against whom enforcement of such modification, waiver or termination is sought.

 

SECTION 6. This Agreement shall be construed in accordance with and governed by the law of the State of Arizona.

 

 

 

SECTION 7. This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. In making proof of this Agreement, it shall not be necessary to produce or account for more than one such counterpart.

 

[Remainder of the page intentionally left blank]

 

2

 

 

IN WITNESS WHEREOF, the parties have executed and delivered this Agreement as of the date first above written.

 

  Assignor:
   
  CARIS LIFE SCIENCES, INC.
   
  By: /s/ Laura I. Johansen 
    Name: Laura I. Johansen 
    Title: President

 

  Assignee:
   
  CARIS MPI, INC.
   
  By: /s/ Laura I. Johansen 
    Name: Laura I. Johansen 
    Title: President

 

3

 

 

FIRST AMENDMENT TO LEASE AGREEMENT

 

THIS FIRST AMENDMENT TO LEASE AGREEMENT (this "First Amendment") dated for reference purposes as May 9, 2019, is made by and between WPT PROPERTIES LP, a Delaware limited partnership ("Landlord"), and CARIS MPI, INC., a Texas corporation ("Tenant").

 

BACKGROUND:

 

A.        Liberty Property Limited Partnership, mistakenly identified as Liberty Cotton Center, LLC ("Liberty"), and Caris Life Sciences, Inc. (fonnerly CDx Holdings, Inc.) (''Caris") entered into that certain Industrial Real Estate Lease (Single-Tenant Facility) dated August 19, 2009 (the "Lease"), covering certain Leased Premises containing approximately 66,012 rentable square feet of space (the "Leased Premises"), being the entire building known as and located at 4610 South 44th Place, Phoenix, Arizona (the "Building"), as more fully described in the Lease.

 

B.        By that certain Lease Assignment and Assumption Agreement dated November 22, 2011, Caris assigned to Tenant, all of Caris' right, title and interest in, to and under the Lease.

 

C.        By that certain Assignment and Assumption of Leases dated October 3, 2016, WPT Land 2 LP assumed all of Liberty's right, title and interest, in, to and under the Lease.

 

D.        In connection with its acquisition of the Building, by that certain Assignment and Assumption of Leases dated June 8, 2018, Landlord assumed all of WPT Land 2 LP's right, title and interest, in, to and under the Lease.

 

E.        Tenant desires to extend the Term and modify other sections of the Lease, and Landlord has agreed to such extension and modifications, subject to the provisions of this First Amendment. Accordingly, Landlord and Tenant desire to amend the Lease.

 

NOW, THEREFORE, the parties hereto, in consideration of the mutual promises and covenants contained herein and in the Lease, and intending to be legally bound, hereby agree that the Lease is amended as follows:

 

1.        Incorporation. The above Background is incorporated herein by reference.

 

2.        Defined Terms; Conflict. All capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to them in the Lease. In the event there is a conflict between the terms of the Lease and this First Amendment, this First Amendment shall control.

 

3.        Term. The Lease is hereby amended to extend the Term for one (1) additional period of sixty-four (64) months (the "Extended Term"), commencing on September 1, 2020, and expiring at 11:59 P .M. local time on December 31, 2025 (the "Expiration Date").

 

1

 

 

4.     Base Rent. Effective as of September 1, 2020, and continuing through and including the Expiration Date, Tenant's Base Rent obligation for the Leased Premises shall be as follows and all Rent shall be paid in accordance with the terms of the Lease:

 

Period  PSF/annum  Annual  Monthly 
9/1/2020 – 12/31/2020 *  $18.80  $--------  $ 103,418.80 
1/1/2021 – 8/31/2021  $18.80  $1,241,025.00  $103,418.80 
9/1/2021 – 8/31/2022  $19.30  $1,274,031.60  $106,169.30 
9/1/2022 – 8/31/2023  $19.80  $1,307,037.60  $108,919.80 
9/1/2023 – 8/31/2024  $20.30  $1,340,043.60  $111,670.30 
9/1/2024 – 8/31/2025  $20.80  $1,373,049.60  $114,420.80 
9/1/2025 – 12/31/2025  $21.30  $1,406,055.60  $117,171.30 

 

* Notwithstanding the foregoing, Base Rent, but not Additional Rent, shall be abated for the first four (4) months of the Extended Term. Should there occur an uncured Event of Default by Tenant during said four (4) month period, then such abatement shall cease. Landlord's management fee shall not be reduced on account of the abatement in Base Rent, and the Base Rent abatement shall be disregarded for purposes of calculating any management fee based on a percentage of rental revenues.

 

Tenant shall have the right to make all payments of Rent to Landlord via electronic funds transfer.

 

5.     Annual Operating Expenses. All Additional Rent applicable to the Leased Premises shall continue to be paid by Tenant, in addition to the Base Rent, subject to adjustment and reconciliation and in accordance with the terms and conditions of the Lease.

 

6.     Options to Extend Term. The parties acknowledge and agree that the Extended Term constitutes for purposes of Section 3.02 of the Lease the first Option Term, and, notwithstanding anything to the contrary set forth is such Section 3.02 of the Lease, the terms and conditions of this First Amendment shall control. Accordingly, Tenant shall have the right to extend the Term for only one (1) additional period of 5-years, which right is subject to all of the terms and conditions of Section 3.02 of the Lease.

 

7.     Parking. The parties acknowledge and confirm that Tenant enjoys the right to use 264 parking spaces at the Leased Premises without additional charge (the "Required Parking Spaces''). Landlord shall have the right to relocate all or any of the surface parking spaces of the Required Parking Spaces to areas within reasonably close proximity to the Leased Premises as shown on Exhibit "A" to this First Amendment. Any such relocation of the Required Parking shall be at Landlord's sole cost, the new parking spaces shall be paved and striped, and any covered and lit parking space shall be replaced with a covered and lit parking space. Such relocated parking spaces may, but are not required to, be located within a structured parking facility. If, in the future, it becomes evident through an accurate written accounting of Tenants parking which is delivered to Tenant and denotes actual usage and the average number of cars in Tenants parking lot five days per week for a 30 day period illustrates that on a daily basis Tenant is using less than 75% of the Required Parking Spaces due to changes in mobility use (such as shared automobiles and autonomous automobiles and other technology driven changes) then upon notice to Tenant, Landlord may recapture an amount of parking spaces equal to the percentage of Required Parking Spaces not being used by Tenant.

 

2

 

 

8.     Security Deposit. No additional Security Deposit is required from Tenant.

 

9.     Tenant Improvements; Tenant Allowance. Tenant is in possession of the Leased Premises. Landlord shall have no obligations whatsoever to improve or pay for improvements to the Leased Premises for Tenant's continued use and occupancy thereof, except as follows:

 

(a)    Any improvements, alterations, or additions Tenant undertakes to remodel or reconstruct the Leased Premises are herein referred to as "Tenant Improvements". Pursuant to Section 9(e) of this First Amendment, Tenant shall be responsible for the cost of any Tenant Improvements, and Tenant will have plans for such Tenant Improvements designed and approved in accordance with Section 9(b) of this First Amendment, and constructed by Tenant in accordance with Section 9(c) of this First Amendment. Tenant confirms all Tenant Improvements are for the immediate use and benefit of Tenant only.

 

(b)    Tenant's improvement specifications and plans for such Tenant Improvements to the Leased Premises shall be prepared by an architect or engineer selected by Tenant, subject to the prior approval of Landlord, which such approval shall not be unreasonably withheld ("Tenant's Architect"). SmithGroup, Inc. are architects acceptable to Landlord. The plans for the Tenant Improvements will be prepared in sufficient detail to permit Tenant to construct the Tenant Improvements, and shall include, as applicable, a partition layout (dimensioned), door location and door schedule including hardware, reflected ceiling plan, telephone and electrical outlets with locations (dimensioned), special electrical, cabling, HVAC and/or plumbing work, mechanicals, special loading requirements, such as the location of file cabinets and special equipment, openings in the walls or floors, all necessary sections and details for special equipment and fixtures, and finishes including, without limitation, carpentry and millwork, floor coverings, wall coverings, color schedules, and any other special finishes. The plans for the Tenant Improvements shall be prepared in accordance, and shall comply in all material respects, with all Laws. Landlord shall not unreasonably withhold, condition or delay its approval of the plans for the Tenant Improvements and Landlord may withhold its approval for any of the reasons enumerated in Section 3 of Exhibit "B" of the Lease. Within ten (10) days after receipt, Landlord shall respond to any specifications and plans of the Tenant Improvements submitted by Tenant, stating any specific comments or objections that Landlord may have. If Landlord fails to respond within such ten (10) day period, Tenant's plans shall be deemed approved. Tenant will continue to submit plans and specifications and Landlord will continue to approve or disapprove the same in the process set forth above until such are approved or deemed approved by Landlord. Upon approval by Landlord, the plans and specifications for the Tenant Improvements shall become final and shall not be materially changed without Landlord's further approval, which shall not be unreasonably withheld, conditioned or delayed (as finally approved, the "Tenant Improvement Plans"). Landlord's review or approval of the Tenant Improvement Plans does not constitute a code review and shall not be a representation or warranty of Landlord that the Tenant Improvement Plans are fit for any use or comply with any Laws or other legal requirements, and Tenant shall have no right to rely upon any review or approval for such purposes. Landlord shall have no liability to Tenant or any third party by reason of such review or approval, and Landlord's review of any plans and specifications and monitoring of construction shall be solely for its own benefit. The Tenant Improvements be shall be the property of Tenant until the expiration or termination of the Lease, as amended hereby, at which time and without payment by Landlord, the Tenant Improvements shall remain on the Leased Premises and become the property of Landlord, subject to the terms and conditions of Section 6.06 of the Lease.

 

3

 

 

(c)    Tenant shall complete the Tenant Improvements to the Leased Premises substantially in accordance with the Tenant Improvement Plans and applicable provisions of the Lease, including but not limited to Section 6.05 (Alterations, Additions and Improvements) and Section 6.06 (Condition upon Termination) of the Lease, the provision of insurance, the delivery of Lien Waivers (as defined hereunder) pursuant to Section 9(g) of this First Amendment, and the delivery of permits to Landlord pursuant lo Section 9(d) of this First Amendment. The contractors selected by Tenant for bidding (and awarding of work) on the Tenant Improvements shall be licensed and qualified for the work they are to perform and shall be subject to the approval of Landlord, which shall not be unreasonably withheld, conditioned or delayed. DPR Construction and Oakland Construction are contractors acceptable to Landlord. Landlord reserves the right to require Tenant to use contractors designated by Landlord for any part of the Tenant Improvements Tenant shall require all contractors and subcontractors to be adequately insured by maintaining commercial general liability insurance with limits of coverage not less than $1,000,000 combined single limit with a $2,000,000 general aggregate limit, naming Landlord and the Landlord Additional Insureds, as additional insureds, and at least ten (10) days prior lo the commencement of construction, Tenant shall deliver a certificate of insurance for each of Tenant's contractors and their subcontractors to Landlord evidencing such insurance.

 

(d)    All construction relating to the Tenant Improvements shall be done in a good and workmanlike manner and shall comply in all respects at the time of completion with all Laws of the governmental authorities having jurisdiction. Tenant shall obtain all governmental approvals and pennits related to the Tenant Improvements and promptly deliver copies of same to Landlord prior to the start of any work. Within sixty days after the substantial completion of the Tenant Improvements, Tenant shall provide Landlord with the following documents with respect to the Leased Premises and the Tenant Improvement, if required: (i) a Certificate of Occupancy; (ii) a full set of final and un-appealable permits and approvals; (iii) "as-built'' plans (hard copy and CAD); and, (iv) a statement of completion in accordance with the Tenant Improvement Plans by Tenant In addition to the right of Landlord and its Agents to inspect the Leased Premises as set forth in Section 5.06 of the Lease, Landlord and its Agents shall have the right, at its sole cost and expense, to conduct a walk-through inspection of the Leased Premises as completed by Tenant. The warranties from Tenant's contractor(s) shall be for the benefit of Landlord, as well as Tenant, and Tenant shall deliver copies of such warranties to Landlord promptly upon receipt. As used herein, "substantial completion" of the Tenant Improvements occurs when all aspects of the Tenant Improvements are complete in accordance with the Tenant Improvement Plans, save only minor punchlist items, the completion of which, by their nature, do not materially interfere with Tenant's instnllation of its trade fixtures and equipment and operation of its business therein.

 

(e)    Tenant shall, subject to Section 9(f) of this First Amendment below, pay the costs, expenses and fees incurred for the construction of the Tenant Improvements, including without limitation (i) architectural, engineering and design costs, (ii) the cost charged to Tenant by the general contractor and all subcontractors for performing such construction, (iii) construction pennit fees, (iv) costs of built-in furniture, and (v) mechanical and structural engineering fees, credited against the Tenant Improvement Allowance (as defined hereunder) upon Landlord's receipt of each Reimbursement Application (as defined hereunder) (together, the "Tenant Improvement Costs"). In no event shall Landlord charge to Tenant, or deduct from the Tenant Improvement Allowance, any fee for any supervision, project management, or oversight Landlord elects to undertake during Tenant's construction of the Tenant Improvement Work except that Landlord may charge Tenant for Landlord's actual out-of-pocket costs reasonably incurred with respect to any third party engineers engaged by Landlord in connection with Landlord's review of the Tenant Improvement Plans. Landlord has no obligation to provide any construction administration or management services to Tenant.

 

4

 

 

 

(f)           Landlord shall provide an allowance to Tenant of Four Hundred Ninety-Five Thousand Ninety Dollars ($495,090.00) (the “Tenant Improvement Allowance”) (based on Seven Dollars and Fifty Cents ($7.50) per rentable square foot) which shall be used by Tenant to pay for the Tenant Improvement Costs in accordance with Section 9(e) of this First Amendment. The Tenant Allowance shall be applied to the actual out-of-pocket costs and expenses incurred by Tenant in connection with the Tenant Improvements for labor, materials, design, architectural and engineering fees, and project management fees, but not for any “soft costs” (for example, excluded costs will be attorney fees, costs of permits, moving expenses, furniture purchase, moving, assembly and disassembly, telecommunication cabling costs and similar “soft costs”).

 

(g)          Tenant shall promptly pay all Tenant Improvement Costs as they become due. Tenant may submit to Landlord (no more frequently than every three months) application(s) for payment reimbursement to be applied against the Tenant Improvement Allowance (each, a “Reimbursement Application”). Each Reimbursement Application shall include: (i) executed partial payment releases of liens (which shall be notarized and provide a specific amount for which such lien is being waived), reasonably satisfactory to Landlord, from Tenant’s general contractor and first tier subcontractors, as certified by Tenant, confirming the payment in full of all Tenant Improvement Costs included in the then current Reimbursement Application (collectively, the “Lien Waivers”); (ii) sufficient evidence of payment from Tenant to Tenant’s general contractor of all Tenant Improvement Costs included in the then current Reimbursement Application; and, (iii) a statement completed by Tenant or Tenant’s project manager stating that the Tenant Improvements included in the then current Reimbursement Application were substantially completed and performed in accordance with the Tenant Improvement Plans (collectively, the “Partial Reimbursement Requirements”). When the Tenant Improvements are substantially completed in their entirety, as a condition of the final Reimbursement Application, Tenant shall provide: (i) executed final Lien Waivers, confirming the payment in full of all Tenant Improvement Costs up to the limit of the Tenant Improvement Allowance and the release of liens against the Leased Premises from Tenant’s general contractor and first tier subcontractors; (ii) sufficient evidence of payment from Tenant to Tenant’s general contractor of all Tenant Improvement Costs up to the limit of the Tenant Improvement Allowance; and (iii) a statement completed by Tenant or Tenant’s project manager stating that the Tenant Improvements are substantially complete and were performed in accordance with the Tenant Improvement Plans (collectively, the “Final Reimbursement Requirements”). Landlord shall have thirty (30) days after the receipt of each complete Reimbursement Application to submit its reimbursement payment to Tenant. Landlord shall not be required to issue any reimbursement payment to Tenant if the Reimbursement Application does not include the Partial Reimbursement Requirements or the Final Reimbursement Requirements, as the case maybe.

 

5

 

 

(h)          Tenant shall make a complete reimbursement submission for the Tenant Improvement Allowance no later than March 31, 2020. Landlord shall not be required to make payments on account of the Tenant Improvement Allowance for any Tenant Improvement Costs not submitted to Landlord by the foregoing date, and Tenant shall not have any claim to any portion of the Tenant Improvement Allowance not properly used by such date.

 

10.         Insurance. The liability insurance policy required to be maintained by Tenant pursuant to Section 4.4(a) of the Lease shall also name Landlord, Workspace Property Management, L.P., Workspace Property Trust, L.P., and each of their respective directors, officers, partners, shareholders, members, employees, and mortgagees (“Landlord Additional Insureds”) as additional insureds.

 

11.          Indemnification. The indemnification of Landlord by Tenant pursuant to Section 5.05 of the Lease is hereby extended to the Landlord Additional Insureds on the same terms and provisions of Section 5.05.

 

12.         Notices. The address for notices to Landlord’s counsel in Section 13.08 of the Lease is changes to: McCausland Keen + Buckman, 80 W. Lancaster Avenue, 4th Floor, Devon, PA 19333, Attn.,: Stephan K. Pahides, Esq.

 

13.         Brokers. Landlord and Tenant each covenants and represents to the other that it has dealt with no brokers in connection with this First Amendment other than Newmark Knight Frank (“NKF”), representing Tenant, and CBRE Group, Inc., representing Landlord (collectively, the “Brokers”). Landlord agrees to pay a one-time leasing commission in an amount equal to 5% of the net new NNN base rent (commencing on September 1, 2020) to NKF pursuant to a separate agreement entered into by NKF. Landlord and Tenant each agrees to indemnify and bold the other harmless from any and all claims for commissions or fees in connection with this First Amendment from any real estate brokers or agents employed by or with whom they have dealt, other than the Brokers.

 

14.          Survival. All references to the “Lease” shall refer to the Lease as modified by this First Amendment. Except as expressly modified herein, the terms and conditions of the Lease shall remain unchanged and in full force and effect in accordance with its terms. Specifically, without limitation, in the event of any default by either party of any of its obligations under the Lease, as hereby amended, the non-defaulting party shall be entitled to pursue nil remedies available under the Lease, as hereby amended, or otherwise available at law or in equity.

 

15.          Lease Confirmation. Except as amended hereby, the Lease remains in full force and effect and is hereby ratified and confirmed. The Lease hereby constitutes the entire agreement between Landlord and Tenant with respect to the Leased Premises, may be amended or altered only by written agreement executed by both parties, supersedes all prior agreements, whether written or oral, between the parties, and is binding on the parties’ successors and assigns.

 

6

 

 

16.         Successors and Assigns. This First Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.

 

17.         Ministerial Actions. Each of Landlord and Tenant agrees that it will not raise or assert as a defense to any obligation under this First Amendment, or make any claim that this First Amendment or the Lease is invalid or unenforceable, due to any failure of this document or the Lease to comply with ministerial requirements, including requirements for corporate seals, attestations, witnesses, notarizations or other similar requirements, and each party hereby waives the right to assert any such defense or make any claim of invalidity or unenforccabllity due to any of the foregoing.

 

18.         Signatures; Multiple Counterparts. This First Amendment may be executed in multiple counterparts, each of which, when assembled to include an original signature for each party contemplated to sign this First Amendment, will constitute a complete and fully executed original. All such fully executed counterparts will collectively constitute a single First Amendment. Landlord and Tenant each expressly agrees that if the signature of Landlord and/or Tenant on this First Amendment is not an original, but is a digital, mechanical or electronic reproduction (such as, but not limited to, e-mail, PDF, or JPEG), then such digital, mechanical or electronic reproduction shall be as enforceable, valid and binding as, and the legal equivalent to, an authentic  and  traditional  ink-on-paper original wet signature penned manually by its signatory.

 

19.          No Publication. Neither Landlord nor Tenant shall publicize in a medium of general circulation available to the general public (e.g., trade journals, newspapers, radio, television, internet, etc.) the terms of or the transaction evidenced by this Amendment. The foregoing prohibition is not applicable to disclosures required by applicable laws, non-public disclosures made in connection with efforts to sell or finance the Building, or non-published statements made to parties on a need-to-know basis in the ordinary course of the business of operating the Building. 

 

20.         NOTICE. In any real estate transaction,  it is recommended that the tenant consult with a professional, such as a civil engineer, industrial hygienist or other person with experience in evaluation the condition of the property, including the possible presence of asbestos, hazardous materials and underground storage tanks.

 

[SIGNATURE PAGE FOLLOWS]

 

7

 

 

IN WITNESS WHEREOF, Landlord and Tenant, intending to be legally bound, have executed this First Amendment as of the day and year last below written.

 

  LANDLORD:
     
  WPT PROPERTIES LP
     
  By: WPT PROPERTIES GP LLC,
  its general partner
     
  By: /s/ Anthony A. Nichols, Jr.
    Anthony A. Nichols, Jr.
    Senior Vice President
  Date: May 9, 2019

 

  TENANT:
     
  CARIS MPI, INC.
     
  By: /s/ David D. Halbert
  Name: David D. Halbert
  Title: CEO
  Date: May 8, 2019

 

 

 

8

 

 

 

SECOND AMENDMENT TO LEASE AGREEMENT

 

THIS SECOND AMENDMENT TO LEASE AGREEMENT (this “Second Amendment”) dated for reference purposes as August __, 2019, is made by and between WPT PROPERTIES LP, a Delaware limited partnership (“Landlord”), and CARIS MPI, INC., a Texas corporation (“Tenant”).

 

BACKGROUND:

 

A.          Liberty Property Limited Partnership, mistakenly identified as Liberty Cotton Center, LLC (“Liberty”), and Caris Life Sciences, Inc. (formerly CDx Holdings, Inc.) (“Caris”) entered into that certain Industrial Real Estate Lease (Single-Tenant Facility) dated August 19, 2009 (the “Original Lease”), covering certain Leased Premises containing approximately 66,012 rentable square feet of space (the “Leased Premises”), being the entire building known as and located at 4610 South 44th Place, Phoenix, Arizona (the “Building”), as more fully described in the Lease.

 

B.          By that certain Lease Assignment and Assumption Agreement dated November 22, 2011, Caris assigned to Tenant, all of Caris’ right, title and interest in, to and under the Lease.

 

C.           By that certain Assignment and Assumption of Leases dated October 3, 2016, WPT Land 2 LP assumed all of Liberty’s right, title and interest, in, to and under the Lease.

 

D.          In connection with its acquisition of the Building, by that certain Assignment and Assumption of Leases dated June 8, 2018, Landlord assumed all of WPT Land 2 LP’s right, title and interest, in, to and under the Lease.

 

E.           Landlord and Tenant entered into that certain First Amendment to Lease Agreement dated May 9, 2019 (the “First Amendment” amending the Original Lease to, among other things, extend the Term. (The Original Lease as amended by the First Amendment is sometimes referred to herein as the “Lease.”)

 

F.           Tenant desires to further extend the Term of the Lease, and Landlord has agreed to such further extension, subject to the provisions of this Second Amendment. Accordingly, Landlord and Tenant desire to amend the Lease.

 

NOW, THEREFORE, the parties hereto, in consideration of the mutual promises and covenants contained herein and in the Lease, and intending to be legally bound, hereby agree that the Lease is amended as follows:

 

1.           Incorporation. The above Background is incorporated herein by reference.

 

2.           Defined Terms; Conflict. All capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to them in the Lease. In the event there is a conflict between the terms of the Lease and this Second Amendment, this Second Amendment shall control.

 

 

 

 

3.           Term. The First Amendment extended the Term for one (1) additional period of sixty-four (64) months, commencing on September 1, 2020, and expiring at 11:59 P.M. local time on December 31, 2025. The Extended Term shall be further extended for an additional period of sixty (60) months, commencing on January 1, 2025, so that the Term ends on December 31, 2029, which date shall now be the Expiration Date. For the avoidance of doubt, the “Extended Term” shall be and mean the period commencing on September 1, 2020, and expiring at 11:59 P.M. local time on December 31, 2029 and the “Expiration Date” shall be and mean December 31, 2029.

 

4.          Base Rent. Effective as of September 1, 2020, and continuing through and including the Expiration Date, Tenant’s Base Rent obligation for the Leased Premises shall be as follows and all Rent shall be paid in accordance with the terms of the Lease:

 

Period  PSF/annum   Annual   Monthly 
9/1/2020 – 12/31/2020 *  $18.80   $--------   $103,418.80 
1/1/2021 – 8/31/2021  $18.80   $1,241,025.00   $103,418.80 
9/1/2021 – 8/31/2022  $19.30   $1,274,031.60   $106,169.30 
9/1/2022 – 8/31/2023  $19.80   $1,307,037.60   $108,919.80 
9/1/2023 – 8/31/2024  $20.30   $1,340,043.60   $111,670.30 
9/1/2024 – 8/31/2025  $20.80   $1,373,049.60   $114,420.80 
9/1/2025 – 8/31/2025  $21.30   $1,406,055.60   $117,171.30 
9/1/2025 – 8/31/2026  $21.80   $1,439,061.60   $119,921.80 
9/1/2026 – 8/31/2027  $22.30   $1,472,067.60   $122,672.30 
9/1/2027 – 8/31/2028  $22.80   $1,505,073.60   $125,422.80 
9/1/2028 – 8/31/2029  $23.30   $1,538,079.60   $128,173.30 
9/1/2029 – 12/31/2029  $23.80   $1,571,085.60   $130,923.80 

 

* Notwithstanding the foregoing, Base Rent, but not Additional Rent, shall be abated for the first four (4) months of the Extended Term. Should there occur an uncured Event of Default by Tenant during said four (4) month period, then such abatement shall cease. Landlord’s management fee shall not be reduced on account of the abatement in Base Rent, and the Base Rent abatement shall be disregarded for purposes of calculating any management fee based on a percentage of rental revenues.

 

Tenant shall have the right to make all payments of Rent to Landlord via electronic funds transfer.

 

5.           Annual Operating Expenses. All Additional Rent applicable to the Leased Premises shall continue to be paid by Tenant, in addition to the Base Rent, subject to adjustment and reconciliation and in accordance with the terms and conditions of the Lease.

 

6.           Options to Extend Term. The parties acknowledge and agree that the Extended Term constitutes for purposes of Section 3.02 of the Lease the first Option Term (notwithstanding that the extension period is for a total of one hundred twenty-four (124) months), and, notwithstanding anything to the contrary set forth is such Section 3.02 of the Lease, the terms and conditions of this Second Amendment shall control. Accordingly, Tenant shall have the right to extend the Term for only one (1) additional period of 5-years, which right is subject to all of the terms and conditions of Section 3.02 of the Lease.

 

2

 

 

7.           Security Deposit. No additional Security Deposit is required from Tenant.

 

8.           Tenant Improvements; Tenant Allowance. Tenant is in possession of the Leased Premises. Other than as specifically provided in the First Amendment, Landlord shall have no obligations whatsoever to improve or pay for improvements to the Leased Premises for Tenant’s continued use and occupancy thereof.

 

9.           Brokers. Landlord and Tenant each covenant and represent to the other that it has dealt with no brokers in connection with this Second Amendment. Landlord and Tenant each agree to indemnify and hold the other harmless from any and all claims for commissions or fees in connection with this Second Amendment from any real estate brokers or agents employed by or with whom they have dealt.

 

10.         Survival. All references to the “Lease” shall refer to the Lease as modified by this Second Amendment. Except as expressly modified herein, the terms and conditions of the Lease shall remain unchanged and in full force and effect in accordance with its terms. Specifically, without limitation, in the event of any default by either party of any of its obligations under the Lease, as hereby amended, the non-defaulting party shall be entitled to pursue all remedies available under the Lease, as hereby amended, or otherwise available at law or in equity.

 

11.         Lease Confirmation. Except as amended hereby, the Lease remains in full force and effect and is hereby ratified and confirmed. The Lease hereby constitutes the entire agreement between Landlord and Tenant with respect to the Leased Premises, may be amended or altered only by written agreement executed by both parties, supersedes all prior agreements, whether written or oral, between the parties, and is binding on the parties’ successors and assigns.

 

12.         Successors and Assigns. This Second Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.

 

13.         Ministerial Actions. Each of Landlord and Tenant agrees that it will not raise or assert as a defense to any obligation under this Second Amendment, or make any claim that this Second Amendment or the Lease is invalid or unenforceable, due to any failure of this document or the Lease to comply with ministerial requirements, including requirements for corporate seals, attestations, witnesses, notarizations or other similar requirements, and each party hereby waives the right to assert any such defense or make any claim of invalidity or unenforceability due to any of the foregoing.

 

14.         Signatures; Multiple Counterparts. This Second Amendment may be executed in multiple counterparts, each of which, when assembled to include an original signature for each party contemplated to sign this Second Amendment, will constitute a complete and fully executed original. All such fully executed counterparts will collectively constitute a single Second Amendment. Landlord and Tenant each expressly agrees that if the signature of Landlord and/or Tenant on this Second Amendment is not an original, but is a digital, mechanical or electronic reproduction (such as, but not limited to, e-mail, PDF, or JPEG), then such digital, mechanical or electronic reproduction shall be as enforceable, valid and binding as, and the legal equivalent to, an authentic and traditional ink-on-paper original wet signature penned manually by its signatory.

 

3

 

 

15.         No Publication. Neither Landlord nor Tenant shall publicize in a medium of general circulation available to the general public (e.g., trade journals, newspapers, radio, television, internet, etc.) the terms of or the transaction evidenced by this Amendment. The foregoing prohibition is not applicable to disclosures required by applicable laws, non-public disclosures made in connection with efforts to sell or finance the Building, or non-published statements made to parties on a need-to-know basis in the ordinary course of the business of operating the Building.

 

16.         Notice. In any real estate transaction, it is recommended that the tenant consult with a professional, such as a civil engineer, industrial hygienist or other person with experience in evaluation the condition of the property, including the possible presence of asbestos, hazardous materials and underground storage tanks.

 

[SIGNATURE PAGE FOLLOWS]

 

4

 

 

IN WITNESS WHEREOF, Landlord and Tenant, intending to be legally bound, have executed this Second Amendment as of the day and year last below written.

 

 

  LANDLORD:
     
  WPT PROPERTIES LP
     
  By: WPT PROPERTIES GP LLC,
  its general partner
     
  By: /s/ Anthony A. Nichols, Jr.
    Anthony A. Nichols, Jr.
    Senior Vice President

 

  TENANT:
     
  CARIS MPI, INC.
     
  By: /s/ David D. Halbert
  Name: David D. Halbert
  Title: CEO
  Date: 9/19/2019

 

5

 

 

CORRECTED AND RESTATED SECOND AMENDMENT TO LEASE AGREEMENT

 

THIS CORRECTED AND RESTATED SECOND AMENDMENT TO LEASE AGREEMENT (this “Second Amendment”) dated for reference purposes as June 9, 2020, is made by and between WPT PROPERTIES LP, a Delaware limited partnership (“Landlord”), and CARIS MPI, INC., a Texas corporation (“Tenant”).

 

BACKGROUND:

 

A.          Liberty Property Limited Partnership, mistakenly identified as Liberty Cotton Center, LLC (“Liberty”), and Caris Life Sciences, Inc. (formerly CDx Holdings, Inc.) (“Caris”) entered into that certain Industrial Real Estate Lease (Single-Tenant Facility) dated August 19, 2009 (the “Original Lease”), covering certain Leased Premises containing approximately 66,012 rentable square feet of space (the “Leased Premises”), being the entire building known as and located at 4610 South 44th Place, Phoenix, Arizona (the “Building”), as more fully described in the Lease.

 

B.          By that certain Lease Assignment and Assumption Agreement dated November 22, 2011, Caris assigned to Tenant, all of Caris’ right, title and interest in, to and under the Lease.

 

C.          By that certain Assignment and Assumption of Leases dated October 3, 2016, WPT Land 2 LP assumed all of Liberty’s right, title and interest, in, to and under the Lease.

 

D.          In connection with its acquisition of the Building, by that certain Assignment and Assumption of Leases dated June 8, 2018, Landlord assumed all of WPT Land 2 LP’s right, title and interest, in, to and under the Lease.

 

E.           Landlord and Tenant entered into that certain First Amendment to Lease Agreement dated May 9, 2019 (the “First Amendment” amending the Original Lease to, among other things, extend the Term. (The Original Lease as amended by the First Amendment is sometimes referred to herein as the “Lease.”)

 

F.           Tenant desires to further extend the Term of the Lease, and Landlord has agreed to such further extension, subject to the provisions of this Second Amendment. Accordingly, Landlord and Tenant desire to amend the Lease.

 

NOW, THEREFORE, the parties hereto, in consideration of the mutual promises and covenants contained herein and in the Lease, and intending to be legally bound, hereby agree that the Lease is amended as follows:

 

l.            Incorporation. The above Background is incorporated herein by reference.

 

2.           Defined Terms: Conflict. All capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to them in the Lease. In the event there is a conflict between the terms of the Lease and this Second Amendment, this Second Amendment shall control.

 

 

 

 

3.           Term. The First Amendment extended the Term for one (1) additional period of sixty-four (64) months, commencing on September 1, 2020, and expiring at 11:59 P.M. local time on December 31, 2025. The Extended Term shall be further extended for an additional period of sixty (60) months, commencing on January 1, 2026, so that the Term ends on December 31, 2030, which date shall now be the Expiration Date. For the avoidance of doubt, the “Extended Term” shall be and mean the period commencing on September 1, 2020, and expiring at 11:59 P.M. local time on December 31, 2030 and the “Expiration Date” shall be and mean December 31, 2030.

 

4.           Base Rent. Effective as of September 1, 2020, and continuing through and including the Expiration Date, Tenant’s Base Rent obligation for the Leased Premises shall be as follows and all Rent shall be paid in accordance with the terms of the Lease:

 

Period  PSF/annum   Annual   Monthly 
  9/1/2020 – 12/31/2020*  $18.80   $--------   $103,418.80 
 1/1/2021 – 8/31/2021  $18.80   $1,241,025.00   $103,418.80 
 9/1/2021 – 8/31/2022  $19.30   $1,274,031.60   $106,169.30 
 9/1/2022 – 8/31/2023  $19.80   $1,307,037.60   $108,919.80 
 9/1/2023 – 8/31/2024  $20.30   $1,340,043.60   $111,670.30 
 9/1/2024 – 8/31/2025  $20.80   $1,373,049.60   $114,420.80 
 9/1/2025 – 12/31/2025  $21.30   $1,406,055.60   $117,171.30 
 1/1/2026 – 12/31/2026  $21.30   $1,406,055.60   $117,171.30 
 1/1/2027 – 12/31/2027  $21.80   $1,439,061.60   $119,921.80 
 1/1/2028 – 12/31/2028  $22.30   $1,472,067.60   $122,672.30 
 1/1/2029 – 12/31/2029  $22.80   $1,505,073.60   $125,422.80 
 1/1/2030 – 12/31/2030  $23.30   $1,538,079.60   $128,173.30 

 

* Notwithstanding the foregoing, Base Rent, but not Additional Rent, shall be abated for the first four (4) months of the Extended Term. Should there occur an uncured Event of Default by Tenant during said four (4) month period, then such abatement shall cease. Landlord’s management fee shall not be reduced on account of the abatement in Base Rent, and the Base Rent abatement shall be disregarded for purposes of calculating any management fee based on a percentage of rental revenues.

 

Tenant shall have the right to make all payments of Rent to Landlord via electronic funds transfer.

 

5.           Annual Operating Expenses. All Additional Rent applicable to the Leased Premises shall continue to be paid by Tenant, in addition to the Base Rent, subject to adjustment and reconciliation and in accordance with the terms and conditions of the Lease.

 

6.           Options to Extend Term. The parties acknowledge and agree that the Extended Term constitutes for purposes of Section 3.02 of the Lease the first Option Term (notwithstanding that the extension period is for a total of one hundred twenty-four (124) months), and, notwithstanding anything to the contrary set forth is such Section 3.02 of the Lease, the terms and conditions of this Second Amendment shall control. Accordingly, Tenant shall have the right to extend the Term for only one (1) additional period of 5-years, which right is subject to all of the terms and conditions of Section 3.02 of the Lease.

 

2

 

 

7.           Security Deposit. No additional Security Deposit is required from Tenant.

 

8.           Tenant Improvements; Tenant Allowance. Tenant is in possession of the Leased Premises. Other than as specifically provided in the First Amendment, Landlord shall have no obligations whatsoever to improve or pay for improvements to the Leased Premises for Tenant’s continued use and occupancy thereof.

 

9.           Brokers. Landlord and Tenant each covenant and represent to the other that it has dealt with no brokers in connection with this Second Amendment. Landlord and Tenant each agree to indemnify and hold the other harmless from any and all claims for commissions or fees in connection with this Second Amendment from any real estate brokers or agents employed by or with whom they have dealt.

 

10.         Survival. All references to the “Lease” shall refer to the Lease as modified by this Second Amendment. Except as expressly modified herein, the terms and conditions of the Lease shall remain unchanged and in full force and effect in accordance with its terms. Specifically, without limitation, in the event of any default by either party of any of its obligations under the Lease, as hereby amended, the non-defaulting party shall be entitled to pursue all remedies available under the Lease, as hereby amended, or otherwise available at law or in equity.

 

11.         Lease Confirmation. Except as amended hereby, the Lease remains in full force and effect and is hereby ratified and confirmed. The Lease hereby constitutes the entire agreement between Landlord and Tenant with respect to the Leased Premises, may be amended or altered only by written agreement executed by both parties; supersedes all prior agreements, whether written or oral, between the parties, and is binding on the parties’ successors and assigns.

 

12.         Successors and Assigns. This Second Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.

 

13.         Ministerial Actions. Each of Landlord and Tenant agrees that it will not raise or assert as a defense to any obligation under this Second Amendment, or make any claim that this Second Amendment or the Lease is invalid or unenforceable, due to any failure of this document or the Lease to comply with ministerial requirements, including requirements for corporate seals, attestations, witnesses, notarizations or other similar requirements, and each party hereby waives the right to assert any such defense or make any claim of invalidity or unenforceability due to any of the foregoing.

 

14.         Signatures; Multiple Counterparts. This Second Amendment may be executed in multiple counterparts, each of which, when assembled to include an original signature for each party contemplated to sign this Second Amendment, will constitute a complete and fully executed original. All such fully executed counterparts will collectively constitute a single Second Amendment. Landlord and Tenant each expressly agrees that if the signature of Landlord and/or Tenant on this Second Amendment is not an original, but is a digital, mechanical or electronic reproduction (such as, but not limited to, e-mail, PDF, or JPEG), then such digital, mechanical or electronic reproduction shall be as enforceable, valid and binding as, and the legal equivalent to, an authentic and traditional ink-on-paper original wet signature penned manually by its signatory.

 

3

 

 

15.         No Publication. Neither Landlord nor Tenant shall publicize in a medium of general circulation available to the general public (e.g., trade journals, newspapers, radio, television, internet, etc.) the terms of or the transaction evidenced by this Amendment. The foregoing prohibition is not applicable to disclosures required by applicable laws, non-public disclosures made in connection with efforts to sell or finance the Building, or non-published statements made to parties on a need-to-know basis in the ordinary course of the business of operating the Building.

 

16.         Notice. In any real estate transaction, it is recommended that the tenant consult with a professional, such as a civil engineer, industrial hygienist or other person with experience in evaluation the condition of the property, including the possible presence of asbestos, hazardous materials and underground storage tanks.

 

[SIGNATURE PAGE FOLLOWS]

 

4

 

 

IN WITNESS WHEREOF, Landlord and Tenant, intending to be legally bound, have executed this Second Amendment as of the day and year last below written.

 

  LANDLORD:
     
  WPT PROPERTIES LP
     
  By: WPT PROPERTIES GP LLC,
  its general partner
     
  By: /s/ Anthony A. Nichols, Jr.
    Anthony A. Nichols, Jr.
    Senior Vice President
  Date: June 9, 2020

 

  TENANT:
     
  CARIS MPI, INC.
     
  By: /s/ David D. Halbert
  Name: David D. Halbert
  Title: CEO
  Date: April 30, 2020

 

5

 

 

Exhibit 10.3(c)

 

LEASE

 

BETWEEN

 

KCP NNN II LEASEHOLD 4, LLC,

 

A DELAWARE LIMITED LIABILITY COMPANY,

 

AS LANDLORD,

 

AND

 

CARIS MPI, INC.,

 

A TEXAS CORPORATION,

 

AS TENANT

 

DATED AS OF JULY 25, 2019

 

 

 

 

LEASE

 

THIS LEASE (this “Lease”), dated as of July 25, 2019 (the “Effective Date”), is between KCP NNN II LEASEHOLD 4, LLC, a Delaware limited liability company (herein, as further defined in Paragraph 33, called “Landlord”), and CARIS MPI, INC., a Texas corporation (herein called “Tenant”).

 

NOW THEREFORE, in consideration of the mutual covenants and promises hereinafter set forth, and intending to be legally bound, the parties agree as follows:

 

1.            Demise of Premises.

 

In consideration of the rents and covenants herein stipulated to be paid and performed, Landlord hereby demises and lets to Tenant, and Tenant hereby lets from Landlord, for the term herein described, the premises (herein called the “Premises”) commonly known as 3600 W. Royal Lane, Irving, Texas 75063, consisting of:

 

(a)         That parcel of land described on Exhibit l(a) attached hereto and made a part hereof, together with all of Landlord’s right, title and interest, if any, in and to all easements, rights of way, appurtenances, strips and gores of land, mineral rights, water rights and other interests, rights and benefits thereunto belonging, and to all public or private streets, roads, avenues, alleys, or passways, open or proposed, on or abutting the parcel of land (collectively, the “Land Parcel”);

 

(b)         All buildings on and other improvements on the Land Parcel, including an office building containing approximately 114,500 rentable square feet of space (the “Building”); parking areas on the Land Parcel; and Landlord’s right, title and interest in all systems, building fixtures, amenities, facilities, machinery and equipment used in the operation of the facility and other improvements, conduits, ducts, hot water heaters, oil burners, domestic water systems, and installations including those used to provide fire protection, heat, exhaust, ventilation, air conditioning, electrical power, light, plumbing, refrigeration, gas, sewer and water thereto, all elevators, escalators, canopies, and the physical structure of all signs, which are used for the operation of the Building (collectively, with the Building, the “Improvements”);

 

(c)         Landlord’s right, title and interest in all intangible property used in connection with the Land Parcel and Improvements including, without limitation, all contract rights, guarantees, licenses, permits, registrations and warranties relating to the ownership or the maintenance of the Land Parcel or the Improvements, or both (the “Intangible Personal Property”).

 

2.            Title and Condition.

 

(a)         The Premises are demised and let subject to (i) the existing state of the title as of the Commencement Date, including the Permitted Exceptions (as set forth and defined in Exhibit 2(a)), (ii) any state of facts which an accurate survey or physical inspection thereof might show, (iii) all zoning regulations, restrictions, rules and ordinances, building restrictions and other laws and regulations now in effect or hereafter adopted by any governmental authority having jurisdiction, and (iv) the condition of any buildings, structures and other improvements located thereon, as of the Commencement Date, without representation or warranty by Landlord except as otherwise expressly set forth herein. Tenant represents that it has examined the title to, zoning of and other restrictions applicable to, and the condition of, the Premises as of the Effective Date and has found the same to be satisfactory to it.

 

1

 

 

(b)         EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS LEASE AND THE WORK LETTER ATTACHED HERETO AS EXHIBIT 2(b) (THE “WORK LETTER”), LANDLORD SHALL NOT BE OBLIGATED TO PROVIDE OR PAY FOR ANY IMPROVEMENT WORK OR SERVICES RELATED TO THE IMPROVEMENT OF THE PREMISES, AND TENANT ACKNOWLEDGES AND AGREES THAT THE PREMISES ARE LEASED “AS IS”, WITH TENANT ACCEPTING ALL DEFECTS, IF ANY; AND LANDLORD MAKES NO WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, WITH RESPECT TO THE PREMISES (WITHOUT LIMITATION, LANDLORD MAKES NO WARRANTY AS TO THE HABITABILITY, FITNESS OR SUITABILITY OF THE PREMISES FOR A PARTICULAR PURPOSE, NOR AS TO COMPLIANCE WITH ANY LAWS, RULES OR REGULATIONS, NOR AS TO THE ABSENCE OF ANY TOXIC OR OTHERWISE HAZARDOUS SUBSTANCES).

 

3.            Use of Premises.

 

Subject to applicable Legal Requirements, Tenant may use the Premises for general office purposes and any other office-related uses typical or ancillary thereto, provided all such uses shall comply with applicable Legal Requirements and any restrictive covenants applicable to the Premises (each, a “Permitted Use” and collectively, the “Permitted Uses”). Without limiting the generality of the foregoing, Tenant shall have twenty-four (24) hour, seven days per week access to and may use the Premises for (and the Permitted Uses shall include): (i) medical diagnostics, (ii) laboratory-based research, (iii) other medical review services, (iv) imaging center, (v) clinical and anatomic pathology laboratory services, (vi) molecular genetic laboratory services, (vii) cytogenetic laboratory services, (viii) Biosafety level 2 laboratory associated activities, (ix) processing of any type of bodily fluids, tissues, or other products associated with or derived from human or animal tissues, cell lines, bacterial cultures, viral cultures, recombinant DNA, work, diagnostic medical laboratory and related services, testing and administration, and (x) use and appropriate disposal of hazardous chemicals and biohazardous waste. Tenant shall, at its own cost and expense, obtain and maintain any and all licenses, permits, and approvals necessary or appropriate for its use, occupation and operation of the Premises for the Permitted Uses. Tenant shall not permit or cause any act to be done in or about the Premises that will violate any applicable Legal Requirements or that could reasonably be expected to increase the existing rate of insurance on the Premises. Tenant shall not commit or allow to be committed or exist any waste upon the Premises or any public or private nuisance.

 

4.            Term; Access; Tenant Improvements; Property Management.

 

(a)         The term of this Lease shall commence on the Effective Date (the “Commencement Date”) and continue in full force and effect thereafter and expire on June 30, 2035 (the “Initial Term”), unless sooner terminated or extended as hereinafter provided or otherwise agreed by Landlord and Tenant in writing. Upon expiration of the Initial Term, provided Tenant is not then in default under this Lease, Tenant may renew this Lease for two (2) additional periods of sixty (60) months each, exercisable in accordance with the terms of Exhibit 4(a) attached hereto (each, a “Renewal Term”). The definition “Term” shall mean the Initial Term plus any Renewal Term, unless sooner terminated as hereinafter provided in this Lease.

 

2

 

 

(b)          Tenant shall be permitted to self-manage the Premises or to engage a property manager reasonably acceptable to Landlord to manage the Premises. Tenant may (but shall not be obligated to) engage Landlord or an Affiliate of Landlord to provide such property management services pursuant to a separate property management agreement between Tenant and Landlord or such Affiliate, which property management agreement shall provide for a management fee not to exceed three percent (3.0%) of the annual Rent (without regard to any abatement period provided for in this Lease).

 

5.            Rent.

 

(a)          Tenant covenants to pay to Landlord, as rent for the Premises during the Term of this Lease basic rent in the amounts set forth on Exhibit 5 attached hereto (herein called the “Basic Rent”), in advance on the first Business Day of each calendar month during the Term by wire or other electronic transfer of immediately available funds to the Landlord at the address set forth above or to such other person or such other place or account as Landlord from time to time may designate to Tenant in writing; provided, Landlord may designate to Tenant in writing that all but not less than all of the monthly Basic Rent be paid directly to a Mortgagee (as hereinafter defined) or an institutional payment agent. Basic Rent for any partial calendar month included in the Term shall be prorated. Basic Rent for any partial calendar month at the beginning of the Term shall be paid by Tenant on the Effective Date.

 

(b)          Tenant covenants that all other amounts, liabilities and obligations which Tenant assumes or agrees to pay or discharge pursuant to this Lease together with every fine, penalty, interest and cost which may be added for nonpayment or late payment thereof, shall constitute additional rent hereunder (herein called “Additional Rent” and, together with Basic Rent, “Rent”). In the event of any failure by Tenant to pay or discharge any Additional Rent due Landlord, Landlord shall have all rights, powers and remedies provided herein or by law in the case of nonpayment of Basic Rent. Tenant also covenants to pay to Landlord on demand an amount (the “Late Charge”) equal to one percent (1 %) of the payment amount then due on all installments of Basic Rent or Additional Rent due to Landlord which are more than fifteen (15) days overdue, to cover Landlord’s administrative expenses; provided that Landlord shall not impose a Late Charge for the first such late payment of Basic Rent in any calendar year if such Basic Rent payment is paid within three (3) Business Days following Tenant’s receipt of written notice from Landlord of such delinquency. The actual amount of Landlord’s administrative expenses arising by reason of a late payment will be difficult to ascertain, and the parties agree that the Late Charge as calculated above is a reasonable estimate thereof. In addition, in the event any amount of Basic Rent or Additional Rent due to Landlord is not paid within fifteen (15) days of the due date thereof, Tenant further covenants to pay to Landlord on demand interest on each such delinquent amount of Basic Rent and Additional Rent due to Landlord from the due date until such amount is paid in full at the per annum rate of interest (the “Default Rate”) equal to an annual rate of three percent (3%) plus the annual “prime rate” as reported by the Wall Street Journal (the “Prime Rate”), but in no event shall the Default Rate exceed the maximum rate permitted by law; provided that Landlord shall not impose such interest for the first late payment of Rent in any calendar year if such Rent payment is paid within three (3) Business Days following Tenant’s receipt of written notice from Landlord of such delinquency. If the Wall Street Journal is no longer published or the Wall Street Journal discontinues publication of the “prime rate,” then Landlord shall designate a reasonably comparable prime rate as the Prime Rate. Notwithstanding anything in this Lease to the contrary, (i) Tenant’s obligation to pay Additional Rent shall be abated from the Commencement Date through and including December 31, 2019, provided, however, such abatement of Additional Rent shall not relieve Tenant of its obligation to maintain the Required Insurance as required herein during the period of such abatement, and if Tenant fails to maintain such Required Insurance and Landlord exercises its rights under Subparagraph 12(c), Tenant shall be fully liable for the costs thereof notwithstanding the abatement of Additional Rent from the Effective Date through December 31, 2019; and (ii) from the Commencement Date through and including December 31, 2019, Landlord shall, at its sole cost, manage (or cause to be managed) the Premises and maintain such service agreements as reasonably required to keep the Premises in the same condition as exists on the Commencement Date, excluding ordinary wear and tear, casualty, condemnation, and damage caused by Tenant, its Affiliates, agents, representatives, employees, or contractors. For the avoidance of doubt, commencing January 1, 2020 and continuing through the Term, (i) Tenant shall be fully responsible for all Additional Rent as set forth in this Lease, (ii) Paragraph 10 of this Lease shall govern the maintenance, repair and replacement of the Premises, and (iii) subject to Subparagraph 4(b), Tenant shall be responsible for the management of the Premises. Landlord and Tenant shall cooperate and work in good faith to ensure the orderly transition of the management of the Premises from Landlord to Tenant hereunder.

 

3

 

 

6.            Net Lease; Non-Terminability.

 

(a)          Except as otherwise expressly set forth in this Lease, this is an absolutely net lease to Landlord. It is the intent of the parties hereto that the Basic Rent payable under this Lease shall be an absolutely net return to the Landlord and that the Tenant shall pay all costs and expenses relating to the Premises and the business carried on therein, unless otherwise expressly provided to the contrary in this Lease. Any amount or obligation relating to the Premises which is not expressly declared to be that of the Landlord shall be deemed to be an obligation of the Tenant to be performed by the Tenant at the Tenant’s expense. Except as expressly provided in this Lease, Basic Rent and Additional Rent shall be paid by Tenant without notice or demand, setoff, counterclaim, suspension, deduction or defense.

 

(b)          Except as expressly provided in this Lease, Tenant agrees that it will remain obligated under this Lease in accordance with its terms, and that it will not take any action to terminate, rescind or avoid this Lease, notwithstanding (i) the bankruptcy, insolvency, reorganization, composition, readjustment, liquidation, dissolution, or winding-up or other proceeding affecting Landlord or its successors in interest or (ii) any action with respect to this Lease which may be taken by any trustee or receiver of Landlord or its successors in interest or by any court in any such proceeding.

 

(c)          Except as expressly provided in this Lease, Tenant waives, to the extent permitted by law, all rights which may now or hereafter be conferred by law (i) to quit, terminate or surrender this Lease or the Premises or any part thereof or (ii) to any abatement, suspension, deferment or reduction of the Basic Rent or Additional Rent.

 

4

 

 

7.            Taxes and Assessments; Tax and Insurance Escrow; Compliance with Law; Environmental Matters.

 

(a)          Subject to Paragraph 18 below, and to the abatement of Additional Rent as set forth in Paragraph 5(b) above, Tenant shall pay or discharge all Impositions, as hereinafter defined, when due. Notwithstanding the foregoing provision of this Subparagraph 7(a), Tenant shall not be required to pay any franchise, corporate, estate, inheritance, succession, transfer, net income or excess profits taxes of Landlord hereunder (other than (i) any taxes on gross receipts or similar taxes imposed or levied upon, assessed against or measured by the Basic Rent or Additional Rent or levied upon or assessed against the Premises, (ii) any Texas Franchise Taxes included in the definition of Impositions and (iii) any such tax, assessment, charge or levy imposed or levied upon or assessed against Landlord in substitution for or in place of an Imposition). Tenant agrees to furnish to Landlord, within thirty (30) days after written request therefor, evidence of the payment of all Impositions. Subject to Paragraph 18 below, and to the abatement of Additional Rent as set forth in Paragraph 5(b) above, Tenant shall pay all Taxes and charges for utilities consumed on the Premises that are due and payable at any time or from time to time during the Term, and for any Taxes and utility charges that are assessed, become a lien, or accrue during any year of the Term (regardless of when payable), which obligation shall survive the termination or expiration of this Lease; provided, however, if this Lease expires or is terminated for any reason other than the Tenant’s default, all such Taxes and utility charges for the year of such expiration or termination shall be prorated as of the date of termination. Taxes for the year in which the Term commences shall be prorated from the Commencement Date (subject to the abatement of Additional Rent through December 31, 2019). For the avoidance of doubt, it is agreed that Landlord is responsible for payment of the cost of Impositions for the period from the Commencement Date through December 31, 2019 and Landlord covenants to timely pay the same as and when due.

 

(b)         In the event that any special assessment levied or assessed against the Premises during the Term hereof may be legally paid in installments, Tenant shall have the option to pay such special assessment in installments. In such event, Tenant shall be liable only for those installments of the special assessment that become due and payable prior to the expiration of the Term, plus any accrued interest and penalties relating thereto. For purposes of this Lease, the term

“Imposition” means:

 

(i)           all real estate taxes and assessments which become due during the Term and all other assessments, levies, fees, water and sewer rents and charges, and all other governmental charges of every kind, general and special, ordinary and extraordinary, whether or not the same shall have been within the express contemplation of the parties hereto, together with any interest and penalties thereon, which are, at any time, imposed or levied upon or assessed against (A) the Premises or any part thereof, (B) any Basic Rent or any Additional Rent, (C) this Lease or the leasehold estate hereby created or which arise in respect of the ownership, operation, possession, occupancy or use of the Premises and which either become due during the Term or accrue during the Term;

 

5

 

 

(ii)          any gross receipts or similar taxes imposed or levied upon, assessed against or measured solely by the Basic Rent or Additional Rent hereunder or levied upon or assessed against the Premises (but calculated assuming the Basic Rent and Additional Rent are the only receipts of Landlord);

 

(iii)         all sales and use taxes which may be levied or assessed against, or payable by, Landlord or Tenant on account of the payment of Rent or leasing or use of the Premises or any portion thereof and all franchise, margin and business taxes under Chapter 171 of the Texas Tax Code (“Texas Franchise Taxes”) to the extent arising solely from Rent payable under this Lease (all taxes and other governmental charges referred to in the foregoing clauses (i), (ii) and (iii) being referred to collectively as “Taxes”); and

 

(iv)        all charges for water, gas, light, heat, telephone, electricity, power and other utilities and communications services rendered or used on or about the Premises.

 

(c)          Except as otherwise expressly provided in this Lease (including, without limitation, Subparagraph 10(b) hereof and the Work Letter), Tenant shall, at its expense, make all payments required under and otherwise comply with, cause the Premises to comply with, and cause the use of the Premises to comply with, all Legal Requirements, including those which require the making of any structural, unforeseen or extraordinary changes, whether or not any of the same involve a change of policy on the part of the body enacting the same, including but not limited to, the Americans With Disabilities Act of 1990 (42 U.S.C. Section 12101 et seq.) and the Texas Architectural Barriers Act, Art. 9102, Tex. Civ. Stat. Ann. (1994), as the same may be may be amended and supplemented from time to time. Tenant shall comply with the provisions of all agreements, instruments and restrictions existing at the Effective Date and included in the Permitted Exceptions or thereafter created pursuant to the express provisions of this Lease. Tenant shall provide Landlord (and any Mortgagee of whom Tenant has been provided written notice) with notice as soon as reasonably possible of any written complaints pertaining to any alleged violation of any Legal Requirements and/or the commencement of any proceedings or investigation (of which Tenant has knowledge) under any Legal Requirements affecting or pertaining to the Premises. For purposes of this Lease, the term “Legal Requirements” means collectively (i) all laws, rules, regulations, ordinances or orders, in effect from time to time, of all federal, state, local, county and other governmental authorities having authority over the Premises, any portion thereof, the use thereof, or Tenant, including without limitation, all Environmental Laws and the Americans With Disabilities Act of 1990, 42 U.S.C. Section 12101 et seq., (ii) any covenants, restrictions or agreements included in the Permitted Exceptions and (iii) any covenants, restrictions or agreements included in the Easements (as defined below).

 

(d)         Tenant shall not cause or permit any Prohibited Hazardous Material to be discharged from or be released at the Premises in violation of Environmental Laws and shall, in respect of Prohibited Hazardous Materials, promptly: (A) remove, remediate and dispose of all Prohibited Hazardous Materials in compliance with applicable Environmental Law but in any event, prior to the end of the Term; (B) pay any Claim (as defined below) against Tenant, any Indemnified Party (as defined below) or the Premises arising therefrom; (C) remove any charge or lien upon any of the Premises relating thereto; (D) defend (with counsel selected by Tenant and reasonably acceptable to the Indemnified Parties), indemnify and hold harmless Landlord, any Mortgagee and their respective officers, directors, trustees, members, partners, shareholders, beneficiaries, employees and agents (herein collectively called “Indemnified Parties” and individually an “Indemnified Party”) from any and all Claims resulting from any Prohibited Hazardous Materials; and (E) without limitation of the foregoing, comply, at its sole cost and expense, during the Term in all respects with all Environmental Laws applicable to the Premises in regard to all Prohibited Hazardous Materials. Tenant shall notify Landlord (and any Mortgagee of whom Tenant has been provided written notice) in writing of any Prohibited Hazardous Material that is discharged from or onto or released at the Premises (whether originating thereon, placed therein by third parties or migrating to the Premises from other property) within five (5) Business Days after Tenant first has knowledge of such existence or discharge. For purposes of this Lease, the following terms shall have the following meanings:

 

6

 

 

(1)   “Hazardous Material” means any hazardous or toxic material, substance or waste which is defined by those or similar terms or is regulated as such under any Environmental Laws.

 

 

(2) “Environmental Laws” means any statute, law, ordinance, rule or regulation of any local, county, state or federal authority having jurisdiction over the Premises or any portion thereof or its use, which pertains to environmental, health or safety matters and/or the regulation of any hazardous or toxic materials, substance or waste, including but not limited to: (a) the Federal Water Pollution Control Act (33 U.S.C. §1317 et seq.) as amended; (b) the Federal Resource Conservation and Recovery Act (42 U.S.C. §6901 et seq.) as amended; (c) the Comprehensive Environmental Response Compensation and Liability Act (42 U.S.C. §9601 et seq.) as amended; (d) the Toxic Substance Control Act (15 U.S.C. §2601 et seq.), as amended; and

(e) the Clean Air Act (42, U.S. §7401 et seq.), as amended.

 

(3) “Legal Hazardous Materials” means any Hazardous Materials used, in compliance with Legal Requirements and Environmental Laws, in the ordinary course of operation of Tenant’s and its subtenants’ business and use, repair and maintenance of the Premises.

 

(4) “Prohibited Hazardous Materials” means all Hazardous Materials, other than Legal Hazardous Materials, that existed in, on or under the surface of the ground of the Premises on or prior to the Effective Date or (ii) are discharged from, released at or migrate onto the Premises during the Term, unless caused by Landlord or any of Landlord’s Affiliates, agents, contractors or invitees. Legal Hazardous Materials used by Tenant or its subtenants in violation of Environmental Laws shall constitute Prohibited Hazardous Materials.

 

(5) “Claims” shall mean all claims, expenses, liability, loss and damage, including reasonable attorneys’ fees and expenses.

 

Tenant’s obligations and liabilities under this Paragraph 7 shall survive the expiration or earlier termination of this Lease.

 

7

 

 

8.            Indemnification.

 

Tenant agrees to pay, and to protect, defend (with counsel selected by Tenant and reasonably acceptable to Landlord), indemnify and hold harmless Landlord and the other Indemnified Parties from and against any and all liabilities, losses, damages, costs, expenses (including all reasonable attorneys’ fees and expenses), causes of action, suits, claims, demands or judgments of any nature (herein collectively called “Damages”) whatsoever arising from (i) any use, condition or event occurring on the Premises during the Term and caused by Tenant, its Affiliates, agents, employees, or contractors (including without limitation, the construction of any Alterations), (ii) any injury to, or the death of, any person or damage to property on the Premises during the Term or arising by reason of any event or occurrence on or about the Premises during the Term and caused by Tenant, its Affiliates, agents, employees, or contractors, (iii) any injury to, or the death of, any person or damage to property upon adjoining sidewalks, streets or rights of way or in any manner growing out of or connected with the use, condition or occupation of the Premises during the Term and caused by Tenant, its Affiliates, agents, employees, or contractors, (iv) any violation by Tenant of any agreement or condition of this Lease and failure to cure such violation within any applicable notice and cure periods, or any contract or agreement to which Tenant is a party or which pertains to the Premises or any part thereof or the ownership, occupancy or use thereof, and (v) any violation by Tenant of any Legal Requirement; provided, however, the obligations of Tenant under this Paragraph 8 shall not apply as to an Indemnified Party with respect to claims arising solely from the grossly negligent or affirmative negligent acts or willful misconduct of any Indemnified Party. If an Indemnified Party shall be made a party to any litigation with respect to the matters covered by this Paragraph 8, Tenant shall, at its option, either defend, at Tenant’s sole cost and expense, such Indemnified Party with counsel selected by Tenant and reasonably acceptable to such Indemnified Party or pay all costs and reasonable attorneys’ fees and expenses incurred or paid by such Indemnified Party in connection with such litigation. In the event Tenant shall, pursuant to this Paragraph 8, discharge any claim against an Indemnified Party, Tenant shall be subrogated to the rights of the Indemnified Party with respect thereto, except that in no event shall Tenant be thereby subrogated to a claim against another Indemnified Party to the extent Tenant is obligated to indemnify the other Indemnified Party with respect thereto. The Tenant’s obligations and liabilities under this Paragraph 8 shall survive expiration or earlier termination of this Lease.

 

9.            Liens.

 

Tenant will not, directly or indirectly, create or permit to be created and to remain for more than sixty (60) days after the creation thereof, and will, subject to Paragraph 18 below, promptly discharge, at Tenant’s expense, within sixty (60) days after receipt of notice thereof any mechanics’ and materialman’s liens against the Premises for any labor, services or materials to be furnished to Tenant. Other than as set forth in the Work Letter, nothing contained in this Lease shall be construed as constituting the consent or request, expressed or implied, by Landlord to or for the performance of any labor or services or of the furnishing of any materials for any construction, alteration, addition, repair or demolition of or to the Premises or any part thereof by any contractor, subcontractor, laborer, materialman or vendor. Notice is hereby given that Landlord will not be liable for any labor, services or materials furnished or to be furnished to Tenant, or to anyone holding the Premises or any part thereof, and that no mechanic’s, construction or other liens for any such labor, services or materials shall attach to or affect the interest of Landlord in and to the Premises.

 

8

 

 

10.          Maintenance and Repairs.

 

(a)          Tenant Maintenance and Repairs. Subject to the terms set forth in the Work Letter, Tenant has accepted the condition, state of repair and appearance of the Premises as of the Effective Date. Except as otherwise expressly provided in this Lease (including Subparagraph 10(b), Paragraph 13 and Paragraph 14 below) and subject to Subparagraph 12(f), Tenant agrees that during the Term, at its expense, it shall put, keep and maintain the Premises, including any altered, rebuilt, additional or substituted buildings, structures and other improvements thereto or thereon, in good and safe condition, repair and appearance, reasonable wear and tear excepted, and shall make all repairs and replacements necessary therefor. If Tenant fails to make such repairs or replacements beyond all applicable notice and cure periods, Landlord may, at its option, make the repairs and non-capital replacements on Tenant’s behalf and the costs of such repair or non-capital replacements shall be charged to Tenant as Additional Rent. Tenant will keep the Premises orderly and free and clear of rubbish. Tenant covenants to perform or observe all terms, covenants and conditions of any easement, restriction, covenant, declaration and maintenance agreement to which the Premises are subject (collectively, as the same may be amended from time to time by instrument executed or consented to by Landlord and Tenant, the “Easements”), including any obligation or performance required of Landlord under such Easements, including without limitation, payment of all amounts due from Landlord or Tenant (whether as assessments, service fees, dues or other charges) under such Easements. Following the Effective Date, Landlord shall not enter into any Easements or modify any existing Easements without Tenant’s prior written approval, which approval shall not be unreasonably withheld, conditioned, or delayed so long as the same do not adversely restrict Tenant’s use of the Premises for any Permitted Use, materially and adversely impact Tenant’s business operations, or materially increase Tenant’s costs, provided, however, the foregoing restriction shall not apply to Landlord’s grant of a Mortgage and related financing instruments, subject to Paragraph 23.

 

(b)          Landlord Maintenance and Repairs. Except as expressly provided in this Lease, Landlord shall not be responsible for the cost or performance of any maintenance, repairs, alterations or replacements of the Premises or any part thereof except for structural repairs and/or replacements of the load bearing or structural walls and foundations of the Building and for the replacement of the Building’s roof surface and roof membrane (except to the extent any such repair or replacement is required due to the acts or omissions of Tenant or Tenant’s Affiliates, employees, agents, contractors or invitees). All such work performed on behalf of Landlord must be performed by contractors and workmen who are qualified to do the work involved and where necessary, duly licensed.

 

(c)         Landlord Access to Premises. Landlord, any Mortgagee and their respective agents and designees may, in the company of a representative of Tenant if Tenant so requires, enter upon and inspect the Premises at reasonable times during normal business hours and on reasonable prior notice and show the Premises to prospective Mortgagees and/or purchasers.

 

9

 

 

11.          Alterations.

 

(a)         Tenant may make or suffer to be made any alterations, additions or improvements in, on or to the Premises or any part thereof (“Alterations”), provided Tenant shall not make any Alterations which would (i) involve changes in the exterior of the Building or other improvements on the Land Parcel that would be shown on an ALTA/ACSM survey, (ii) reasonably be expected to materially reduce the fair market value of the Premises, (iii) be inconsistent with the Permitted Uses, (iv) create, or materially increase the likelihood of, a hazardous or illegal condition, (v) materially affect the Building’s elevator shafts, footings, foundations, structural portions of load-bearing walls, structural floors and subfloors, structural columns and beams, curtain walls, and the structural components of the Building’s roof (collectively, the “Building Structure”), (vi) materially affect the exterior walls and window systems, roof, foundation, structural portions and the Building’s mechanical (including elevators), electrical, plumbing, security, communication, life safety, heating, ventilating and air-conditioning systems (collectively, the “Building Systems”) or the parking lot on the Land Parcel, or (vii) result in the rescinding or modification of any waiver or standstill agreement as to environmental compliance matters, zoning or any other Legal Requirements granted by any governmental agency without, in each such case, submitting a written request for and obtaining the prior written consent of Landlord, which consent shall not be unreasonably withheld, conditioned or delayed (except Landlord reserves the right to withhold consent in its sole discretion with respect to Alterations affecting the Building Structure) (Alterations described in any one or more of the foregoing clauses (i) - (vii) being referred to as “Restricted Alterations”). Redecoration of the interior of the Premises, such as painting, wallpapering and replacement of floor covering, shall not constitute Alterations for purposes of this Lease. Without limitation of Landlord’s right to withhold its consent to Restricted Alterations, Landlord may withhold its consent if an Event of Default then exists. In the event Tenant makes any changes in or to any mechanical component of the Premises (for example, a portion of the HVAC system), Tenant shall install mechanical equipment of equal or greater value and utility. All Alterations shall be constructed in a good and workmanlike manner in compliance with all Legal Requirements. Tenant’s obligation to remove any Alterations which Tenant installs pursuant to this Paragraph 11 shall be governed by Paragraph 26 herein. In no event shall Tenant be required to remove any element of the Premises which existed on the Effective Date.

 

(b)         Subject to the terms of the Work Letter with respect to the Tenant Improvements (as defined in the Work Letter), Tenant shall satisfy the following conditions in connection with all Alterations:

 

(i)           Tenant shall pay or cause to be paid the entire cost of such Alterations;

 

(ii)          Tenant shall take all necessary steps to prevent the imposition of liens against the Premises as a result of such Alterations;

 

(iii)         Tenant shall obtain and pay for all building, occupancy and other required permits and shall comply with all applicable governmental requirements and deliver copies of all such permits to Landlord as soon as reasonably possible following issuance thereof;

 

(iv)         Tenant shall cause the construction of Alterations, once commenced, to be diligently pursued to completion;

 

(v)          If the Alterations include any changes or new matter which would be shown on an updated ALTA/ACSM survey of the Premises (including Table A and other items customarily required by institutional lenders), then Tenant shall obtain and submit to Landlord (and, if requested, Mortgagee), promptly following substantial completion of the Alterations, a revised ALTA/ACSM survey of the Premises certified to, and in a form reasonably satisfactory to, Landlord and any Mortgagee of which Tenant has been provided written notice; and

 

10

 

 

(vi)        Tenant shall provide Landlord copies of as-built plans for all Alterations as soon as reasonably possible following substantial completion of such Alterations.

 

(c)          Except as Landlord and Tenant otherwise agree in writing, all Alterations other than Severable Additions shall at once become a part of the realty and belong to Landlord. Severable Additions and Tenant’s Property may be removed from the Premises upon, or at any time prior to, the expiration or earlier termination of this Lease, provided that Tenant shall repair any damage to the Premises resulting from such removal. For purposes of this Lease, the term (A) “Severable Additions” shall mean all additions to the Premises during the Term which (i) are readily removable without causing material damage to the Premises, and (ii) are not required for lawful occupancy of the Premises, and (B) “Tenant’s Property” shall mean, collectively, all trade fixtures and personal property, including, without limitation, furnishings, furniture, equipment, sign faces, computers, computer related equipment on property, cabling, safes, communications equipment and other equipment for use in connection with the conduct of Tenant’s business regardless of the manner in which they are installed. The obligations of Tenant under this Paragraph 11 shall survive expiration or earlier termination of this Lease.

 

12.          Insurance.

 

(a)          Tenant shall maintain, or cause to be maintained, at its sole expense, the following insurance on the Premises during the Term (herein called the “Required Insurance”):

 

(i)           Property insurance (“Property Insurance”) insuring the Tenant Improvements, any Alterations and Tenant’s Property for all risks of direct physical loss and for perils covered by the causes of loss-special form (all risk, extended coverage) and, in addition, ordinance or law coverage (with highest sublimit as is reasonably available) and boiler and machinery coverage (if applicable). Property Insurance shall include the following coverages: fire, windstorm, hail, explosion, vandalism, riot, civil commotion, smoke, sprinkler and water damage, if applicable flood and earthquake, explosion, collapse and underground hazards. Such insurance shall be written on a replacement cost basis with an agreed value equal to the full insurable replacement value of the property covered thereby. Except with respect to Tenant’s Property, the policy shall include Landlord and any Mortgagees as loss payees, as their respective interests may appear.

 

(ii)          General liability insurance naming the Landlord and any Mortgagee as additional insureds against any and all claims as are customarily covered under a standard policy form routinely accepted, for bodily injury, death and property damage occurring in or about the Premises. Such insurance shall have a combined single limit of not less than Three Million Dollars ($3,000,000) per occurrence with a minimum Five Million Dollars ($5,000,000) aggregate limit and excess umbrella liability insurance in the amount of at least Ten Million Dollars ($10,000,000). Such liability insurance shall be primary and not contributing to any insurance available to all additional insureds and any liability insurance carried by the additional insureds shall be in excess thereto. In no event shall the limits of such insurance be considered as limiting the liability of Tenant under this Lease.

 

11

 

 

(iii)         Business interruption insurance with coverage for Rent for twelve (12) months following a Casualty, naming Landlord and any Mortgagee as loss payees, which coverage may be included in Tenant’s Property Insurance.

 

(iv)         During any period of construction on the Premises, builder’s risk insurance insuring perils covered by the loss-special form (all risk, extended coverage) shall be purchased for the value of the alteration and/or additions made to the Premises when the work is not insured under the Tenant’s property insurance policy. Each builder’s risk policy shall name Landlord and any Mortgagee as additional insureds. Tenant shall also cause all contractors to comply with the liability insurance requirements in this Paragraph 12, including primary and non-contributory Additional Insured status for the Landlord and any Mortgagee and including waiver of subrogation for the benefit of the Landlord and any Mortgagee.

 

(v)          Workers’ compensation insurance as required by Legal Requirements and employers’ liability insurance with minimum liability limits of One Million Dollars ($1,000,000).

 

(vi)        Pollution liability insurance, naming Landlord and any Mortgagee as additional insureds, applicable to bodily injury; property damage, including loss of use of damaged property or of property that has not been physically injured or destroyed; cleanup costs; and defense, including costs and expenses incurred in the investigation, defense, or settlement of claims; all in connection with any loss arising from the Premises in an amount not less than $3,000,000 each occurrence and aggregate. Such liability insurance shall be primary and not contributing to any insurance available to all additional insureds and any liability insurance carried by the additional insureds shall be in excess thereto. In no event shall the limits of such insurance be considered as limiting the liability of Tenant under this Lease.

 

(b)          The policies required to be maintained by Tenant and Landlord hereunder shall be with companies having a general policy rating of A- or better and a financial class of VII or better by A.M. Best Company, Inc. Insurers shall be authorized to do business in the state in which the Premises are located. Except as may be otherwise specified in Subparagraph 12(a) or otherwise agreed to by Landlord and Tenant, any deductible amounts under any Required Insurance hereunder shall not exceed Fifty Thousand Dollars ($50,000). Certificates of insurance (as to property insurance, using ACORD Form No. 28 (or the equivalent or replacement thereof), and as to liability insurance, using Accord Form 25-S (or the equivalent or replacement thereof)), together with reasonable evidence of payment of the premiums therefor, shall be delivered, with respect to Tenant’s Required Insurance, to Landlord (and each Mortgagee of which Tenant has been provided written notice), and with respect to Landlord’s Required Coverage, to Tenant. Thereafter, prior to the expiration date of each required policy, each of Landlord and Tenant shall provide to the other (and with respect to Tenant’s Required Insurance, to any Mortgagee of which Tenant has been provided written notice), evidence reasonably satisfactory to such party of payment of the premiums for such policies, provided, however, in the case of renewals, notwithstanding the foregoing, each party may provide the other with binders therefor prior to expiration to be followed by certificates of insurance in the forms as required above. Landlord and Tenant shall each have the right to provide insurance coverage which it is obligated to carry pursuant to the terms hereof in a blanket policy, provided such blanket policy affords coverage to the Premises and to Landlord, any Mortgagee, or Tenant (as applicable) as required by this Lease. Each policy of insurance shall provide notification to Tenant, Landlord and any Mortgagee (as applicable) at least thirty (30) days prior to any non-renewal, cancellation or modification to reduce the insurance coverage, provided, however, that only ten (10) days’ notice shall be required for cancellation due to non-payment of premiums.

 

12

 

 

(c)          In the event Tenant does not purchase the Required Insurance or keep the same in full force and effect, Landlord may, but shall not be obligated to, purchase such insurance and pay the premium therefor. Tenant shall repay to Landlord, as Additional Rent, the amount so paid promptly upon demand together with interest at the Default Rate on such payment from the date expended until the date reimbursed. In addition, Landlord may recover from Tenant and Tenant agrees to pay, as Additional Rent, any and all expenses (including reasonable attorneys’ fees) and actual damages which Landlord may sustain by reason of the failure of Tenant to obtain and maintain the Required Insurance.

 

(d)          Tenant shall indemnify and hold harmless Landlord for any liability incurred by Landlord arising out of any deductibles for Required Insurance.

 

(e)          Landlord shall, at all times during the Term, procure and maintain. or cause to be procured and maintained, a policy or policies of insurance (subject to reimbursement pursuant to this Lease), causing the Premises (but specifically excluding the Tenant Improvements, any Alterations, and Tenant’s Property) to be insured under all-risk (special form or equivalent) property coverage covering the full replacement cost of the Premises (other than the Tenant Improvements, Alterations, and Tenant’s Property) and including standard extended coverage endorsement perils, flood hazards (if applicable), leakage from fire protective devices and other water damage (plus such additional endorsements or special coverages Landlord, in its sole and absolute discretion, may consider appropriate), and such other insurance (if any) that Landlord reasonably deems appropriate for the Premises from time to time (such policy or policies, collectively, “Landlord’s Required Coverage”) provided that such coverage and amounts are then typically carried by landlords of comparable properties in the Irving, Texas market. All insurance maintained by or on behalf of Landlord shall be with such deductibles as Landlord reasonably determines would be carried by landlords of comparable properties in the Irving, Texas market. Landlord’s obligation to carry the Landlord’s Required Coverage may be brought within the coverage of a so-called blanket policy or policies of insurance carried and maintained by or on behalf of Landlord so long as the coverages required herein are provided. Tenant shall pay to Landlord as Additional Rent all Insurance Expenses (as defined below) within thirty (30) days after Tenant’s receipt of an invoice therefor. Tenant’s obligation to pay Insurance Expenses shall survive the expiration or early termination of this Lease. Insurance Expenses for any partial calendar year during the Term shall be prorated.

 

(f)          Without limitation of any other waiver of Claims set forth in this Lease, each of Tenant and Landlord waives any Claim for property loss, damage or injury it may have against the other to the extent any such Claim is covered by the property insurance actually maintained by a party or which would have been covered by any property insurance required pursuant to the terms of this Lease to be in effect at the time of such loss, damage or injury regardless of whether the negligence of the other party caused such property loss, damage or injury. Each party shall cause each policy of the insurance required to be carried by it under this Lease to contain the agreement of the insurer to waive subrogation against Tenant, Landlord or any Indemnified Party (as applicable) in respect of any such Claim as well as acknowledgement by the insurer that the foregoing waiver of claim will not adversely affect the coverage afforded thereby. If both parties maintain (or are required to maintain) insurance that covers the same property, then Tenant’s insurance shall be deemed the applicable insurance for purposes of this provision (as the primary insurance coverage as hereinabove provided). Any indemnity provided by Landlord and Tenant in this Lease is subject to this Paragraph 12(f).

 

13

 

 

(g)          Notwithstanding anything to the contrary contained in this Lease, in the event of any termination of this Lease pursuant to the terms and conditions of Paragraph 13 below: (i) if Landlord has not already received the same directly from Tenant’s insurer, Tenant shall assign and deliver to Landlord (or to any party designated by Landlord) insurance proceeds received by Tenant under Tenant’s Property Insurance covering the Tenant Improvements and Alterations in an amount equal to the unamortized portion of the Allowance (as defined in the Work Letter), with such amortization to be calculated, as of the date of termination of the Lease, on a straight-line basis over the Initial Term, (ii) the remainder of any insurance proceeds payable to or received by Tenant with respect to such insurance shall belong solely to Tenant, and (iii) any insurance money received by Landlord and/or Mortgagee (in connection with the casualty event that caused the termination of the Lease) under Tenant’s Property Insurance in excess of the amount owed to Landlord under subclause (i) hereinabove above shall be promptly reimbursed to or, if applicable, endorsed over to Tenant. This subparagraph (g) shall survive any early termination of the Lease under Paragraph 13 below.

 

13.          Casualty.

 

(a)          Tenant shall give prompt written notice to the Landlord (and any Mortgagee of which Tenant has been provided written notice) of any fire or other casualty to the Premises (“Casualty Loss”). In the event the Premises shall be partially or totally destroyed by a Casualty Loss so as to become partially or totally untenantable, then unless Landlord shall elect to terminate this Lease as hereinafter provided, the damage to the Premises shall be promptly repaired as set forth below in this Paragraph 13, and the Basic Rent payable by Tenant to Landlord shall be equitably abated in proportion to the portion of the Premises rendered untenantable until the earlier of such time that Tenant either reopens in the Premises or is required to recommence Basic Rent payments hereunder. There shall be no abatement of Additional Rent in the event of a Casualty Loss.

 

(b)          If (i) more than fifty percent (50%) of the leasable area of the Building shall be damaged or destroyed by a Casualty Loss, or (ii) Landlord’s reconstruction or repair of the Premises is not capable of being completed with twelve (12) months, or (iii) the Casualty Loss occurs during the last year of the Term, Tenant has not delivered a Renewal Notice, and Landlord’s reconstruction or repair is not capable of being completed within ninety (90) days, or (iv) all or any part of the Premises are damaged or destroyed at any time by the occurrence of any risk not insured under the insurance that Landlord is required to procure and maintain (or caused to be procured and maintained) hereunder, or (v) any Mortgagee shall require that the insurance proceeds payable as a result of such Casualty Loss be applied to the payment of mortgage debt secured by the Premises, then in any of such cases, Landlord, at its sole option, may terminate this Lease by giving written notice to Tenant of Landlord’s election so to terminate, such notice to be given within sixty (60) days after the occurrence of such Casualty Loss. If this Lease is not terminated, the parties shall restore the Premises as contemplated in Subparagraph 13(c). For purposes of this Paragraph 13, any determination of the portion of the Building which is damaged by the Casualty Loss or tenantable shall be made by a reputable and qualified licensed engineer having at least ten (10) years of experience with properties similar to the Premises, such engineer to be retained by Landlord and reasonably acceptable to Tenant. The results of such determination shall be promptly provided to Tenant.

 

14

 

 

(c)          Landlord will not carry insurance of any kind on the Tenant Improvements, Alterations or Tenant’s Property, and shall not be obligated to repair any damage thereto or replace the same. Landlord shall be solely responsible to restore the Premises to the condition that existed immediately prior to such casualty, exclusive of any of the Tenant Improvements, any Alterations and Tenant’s Property or any other additions, improvements, fixtures and equipment installed by Tenant, and subject to Legal Requirements then in effect. Tenant shall be solely responsible for the restoration and repair of the Tenant Improvements, Alterations and Tenant’s Property, which restoration and repair work shall be performed after Landlord restores the Premises as required herein (or causes same to be so restored) and delivers the Premises (or the portion thereof affected by the Casualty Loss) to Tenant, and to the extent Landlord or any Mortgagee received proceeds of Tenant’s Property Insurance covering the Tenant Improvements and Alterations, such proceeds shall be made available to Tenant for such repair and restoration work. Tenant agrees that during any period of reconstruction or repair of the Premises, it will continue the operation of its business within the Premises to the extent practicable. Tenant shall perform all such work with diligence and in accordance with the terms and conditions of the provisions of this Lease governing Alterations. Notwithstanding anything herein to the contrary, any Basic Rent abatement provided for in this Paragraph 13 shall cease upon restoration of the Premises by Landlord in the condition required herein and delivery of the Premises to Tenant, and Tenant shall commence paying full Basic Rent effective as of such date. As part of Tenant’s restoration work hereunder, Tenant, at Tenant’s sole cost, shall repair and replace the Tenant Improvements, Alterations, and Tenant’s Property in a manner and to at least a condition equal to that prior to the Casualty Loss.

 

(d)          In addition, if (i) more than fifty percent (50%) of the leasable area of the Building is rendered untenantable by a Casualty Loss and, in the reasonable opinion of Landlord and Tenant, based on the recommendation of a licensed engineer as described in Subparagraph 13(b), such damage cannot be repaired within twelve (12) months after the receipt of insurance proceeds and all applicable governmental permits, or (ii) during the last year of the Term, more than fifty percent (50%) of the leasable area of the Building is rendered untenantable by a Casualty Loss and, in the reasonable opinion of Landlord and Tenant (based on the recommendation of a licensed engineer as described in Subparagraph 13(b)), such damage cannot be repaired within ninety (90) days after the receipt of insurance proceeds and all applicable governmental permits, then Tenant shall have the right to terminate this Lease by written notice to Landlord delivered within thirty (30) days after the date on which such engineer’s opinion is delivered to Tenant (which Landlord shall provide to Tenant within sixty (60) days after the date of the Casualty Loss). Upon termination of this Lease pursuant to this Paragraph 13, Basic Rent and Additional Rent shall be apportioned as of the date of the Casualty Loss. If, following a Casualty Loss, Tenant has the right to terminate this Lease under this provision but Tenant fails to deliver Tenant’s termination notice to Landlord within the time period stated herein, such right to terminate with respect to the Casualty Loss in question shall be deemed waived. Notwithstanding anything in this Paragraph to the contrary, Tenant shall not have the right to terminate this Lease pursuant to this Paragraph 13 or be entitled to any Basic Rent abatement to the extent such Casualty Loss was caused by the act or neglect of Tenant or its employees, agents, or contractors.

 

15

 

 

14.          Condemnation.

 

(a)          If the whole of the Premises shall be acquired or condemned by eminent domain for any public or quasi-public use or purpose (a sale in lieu of condemnation to be deemed a taking for the purposes of this Paragraph 14), then the Term shall cease and terminate as of the date of possession being required by the condemning authority and all Basic Rent and Additional Rent shall be paid through that date.

 

(b)          If any material part of the Premises or Building shall be acquired or condemned by eminent domain for any public or quasi-public use or purpose, and the taking would prevent or materially interfere with the use of the Premises or Building for the purpose for which they are then being used, then the Term shall cease and terminate as of the date of possession being acquired by the condemning authority and all Basic Rent and Additional Rent shall be paid through that date. In the event of a partial taking or condemnation. which is not extensive enough to render the Lease terminable as provided above, then Landlord shall promptly restore the Premises (but not the Tenant Improvements, any Alterations or Tenant’s Property) or cause same to be restored to make the remaining portions of the Premises (outside the Building) reasonably functional, and with respect to the remaining portions of the Building, to cause the same to be an architectural whole, and this Lease shall continue in full force and effect, except that the Basic Rent shall be equitably adjusted to the extent of the taking that affected the Premises. Notwithstanding the foregoing, Landlord’s obligation to restore or cause restoration hereunder exists (i) only if and/or to the extent that the condemnation or similar award received by Landlord is sufficient to compensate Landlord for its restoration costs, and/or (ii) the area unaffected by the condemnation may, as determined by Landlord’s reasonable judgment, be restored as a profitable and self-functioning premises.

 

(c)          Landlord shall be entitled to the entire award for any claim for a taking (or the proceeds of private sale in lieu thereof) of the Premises or for any portion of the Building, without deduction or offset for Tenant’s estate or interest; provided, however, Tenant may, in a separate proceeding, make a separate claim for the unamortized portion of any Alterations paid for by Tenant with no reimbursement from Landlord, trade fixtures and other Tenant’s Property and Tenant’s moving, relocation and other business expenses (including loss of lease value) to the extent that Tenant’s claim does not diminish the claims or awards of Landlord.

 

15.          Building Signage. Tenant shall have the right to install Tenant’s name or trade name on up to two (2) exterior walls of the Building (each, a “Tenant Building Sign”). Prior to installing a Tenant Building Sign, Tenant shall submit the proposed signage design, location and specifications to Landlord for Landlord’s approval, not to be unreasonably withheld, conditioned or delayed. Each Tenant Building Sign shall be installed at the expense of Tenant and shall be installed in compliance with the City of Irving, Texas Building Codes and all other Legal Requirements. In addition, at the expiration or termination of this Lease, Tenant shall, at its sole cost and expense, remove each Tenant Building Sign and restore the affected areas of the Building where such Tenant Building Sign was installed to the condition as existed prior to such Tenant Building Sign installation, normal wear and tear and casualty excepted.

 

16

 

 

16.          Assignment and Subletting.

 

(a)         Subject to Subparagraph 16(b) below, Tenant shall not, without the prior written consent of Landlord, which consent shall not be unreasonably withheld, conditioned or delayed: (a) assign or in any manner transfer this Lease or any estate or interest therein, or (b) sublet any portion of the Premises (any of the events in clauses (a) and (b) being a “Transfer”). In this regard, Tenant acknowledges and agrees that Landlord’s acceptance of Rent from an assignee or subtenant shall not be deemed to constitute Landlord’s consent to such assignment or sublease. In addition, Landlord shall also be entitled to charge Tenant a $2,000.00 fee for processing any Tenant request for such Transfer (inclusive of any attorneys’ fees and costs incurred by Landlord), regardless of whether or not Landlord grants its consent. Consent by Landlord to one or more Transfers shall not operate as a waiver of Landlord’s rights as to any Transfers. Subject to Subpargraph 16(b) below, if Tenant is a corporation, partnership or other entity and if at any time during the Term the person or persons who own, directly or indirectly, a majority of either the outstanding voting rights or the outstanding ownership interests of Tenant at the time of the execution of this Lease cease to own a majority of such voting rights, ownership interests or control (except as a result of transfers by devise or descent), the loss of a majority of such voting rights, ownership interests or control shall be deemed to be a Transfer and, therefore, subject in all respects to the provisions of this Paragraph 16. Any Transfer in violation of this Paragraph shall, at Landlord’s option, be deemed an Event of Default, and shall be voidable by Landlord. Notwithstanding the foregoing, nor anything in this Lease to the contrary, nothing contained in this Lease shall mean or imply that Landlord’s consent is required in the event that Tenant or its direct or indirect parent elects to go “public” and Tenant shall not be required to obtain Landlord’s consent to a change in the ownership of the voting stock of Tenant or its direct or indirect parent so long as such stock of Tenant or its direct or indirect parent is listed on a public securities exchange at the time of the transfer.

 

(b)          Tenant may assign this Lease to a successor to Tenant by merger, consolidation, recapitalization, reorganization, or the purchase of all or substantially all of Tenant’s assets (“Permitted Successor Event”), or assign this Lease or sublet all or a portion of the Premises to an Affiliate of Tenant, without the written consent of Landlord, provided that all of the following conditions are satisfied (each a “Permitted Transfer”, and any transferee of a Permitted Transfer being a “Permitted Transferee”): (a) no Event of Default shall exist; (b) Tenant must give Landlord written notice at least 15 days prior to such Transfer; (c) the Transfer is not a subterfuge by Tenant to avoid its obligations under this Lease or to avoid obtaining consent to a Transfer that would otherwise require Landlord’s consent; and (d) if the Transfer is a Permitted Successor Event, the Permitted Transferee shall have, immediately after giving effect to such Permitted Transfer, a Tangible Net Worth (as defined below) at least equal to $50,000,000.00, as evidenced to Landlord’s reasonable satisfaction, which evidence shall include the Permitted Transferee’s latest audited financial statements. Tenant’s notice to Landlord hereunder shall include information and documentation evidencing the Permitted Transfer and reasonable evidence showing that each of the above conditions has been satisfied. Partial assignments of this Lease shall not be permitted under any circumstances. For purposes of this Subparagraph 16(b), the term “Tangible Net Worth” means the excess of total assets over total liabilities, in each case as determined in accordance with GAAP (as hereafter defined) excluding, however, from the determination of total assets all assets which would be classified as intangible assets under GAAP including goodwill, licenses, patents, trademarks, trade names, copyrights and franchises.

 

17

 

 

(c)          Any assignee or sublessee of an interest in and to this Lease shall be deemed, by acceptance of such assignment or sublease or by taking actual or constructive possession of all or any portion of the Premises, to have assumed all of the obligations set forth in or arising under this Lease. Such assumption shall be effective as of the earlier of the date of such assignment or sublease or the date on which the assignee or sublessee obtains possession of all or any portion of the Premises; however, with specific regard to any assignment, the assignee shall be responsible for all unsatisfied obligations of Tenant under this Lease, regardless of when such obligations arose and when such assumption became effective.

 

(d)          Notwithstanding any Transfer and except as otherwise expressly set forth in the Guaranty (as defined in Paragraph 41), and/or as otherwise agreed to by Landlord in writing, Tenant and any Guarantor of Tenant’s obligations under this Lease shall at all times remain fully responsible and liable for the payment of the Rent herein specified and for compliance with all of Tenant’s other obligations under this Lease (even if Transfers occur subsequent to the Transfer by Tenant, and regardless of whether or not Landlord’s approval has been obtained for such future assignments and sublettings). If Tenant consummates a Transfer (other than a Permitted Transfer), Tenant shall pay to Landlord, as Additional Rent, fifty percent (50%) of all sums received by Tenant in excess of the Rent payable by Tenant hereunder which is attributable to any subletting of all or any portion of the Premises so subleased, and fifty percent (50%) of all consideration received on account of or attributable to any assignment of this Lease, in each case net of all reasonable and documented expenses and costs incurred by Tenant in connection with such Transfer, including, without limitation, commissions, allowances, improvement costs and other concessions provided to the sublessee or assignee. Finally, in the event of sublease of all or a portion of the Premises, it is understood and agreed that upon any Event of Default by Tenant under this Lease, Landlord may collect any rent due under the terms of the sublease and apply the amount collected to the next Rent payable hereunder; and all such rentals collected by Tenant shall be held in trust for Landlord and immediately forwarded to Landlord.

 

17.          Financial Statements.

 

Tenant will deliver to Landlord (and, if requested, to any Mortgagee) the following with respect to Tenant and any guarantor of this Lease (each a “Principal”): within one hundred fifty (150) days after the end of each fiscal year of each Principal and thereafter, within twenty (20) days after receipt of written request by Landlord (such request to be limited to no more than one time in any twelve (12) month period unless such request is in connection with a prospective sale or financing of the Premises by Landlord, in which case Landlord shall not be so limited) in connection with any transfer of Landlord’s interest in this Lease, copies of the financial statements and reports with respect to each Principal and its consolidated subsidiaries, setting forth in each case, in comparative form, the figures for the previous fiscal year, all in reasonable detail and accompanied by the report thereon, each containing an opinion unqualified as to limitations imposed by the applicable Principal on the scope of the audit, prepared by a firm of independent certified public accountants of recognized national standing selected by such Principal which opinion shall state that the consolidated financial statements of the Principal and its consolidated subsidiaries fairly present the financial condition of the companies (including the results of their operations and changes in financial position) being reported upon, have been prepared in accordance with accounting principles generally accepted in the U.S. consistently applied (“GAAP”) and that the examination of such accounts in connection with such financial statements has been made in accordance with auditing standards generally accepted in the United States and, accordingly, included such tests of the accounting records and such other auditing procedures as were considered necessary in the circumstances, provided, however, if it is not the practice of a Principal to have financial reports prepared and certified by a firm of independent public accountants then any such report may instead be prepared by the Principal and certified to by, and to the best knowledge of, its chief financial officer; and further provided that any financial reports delivered to Landlord upon Landlord’s written request (i.e., not in the ordinary course of a Principal’s business auditing cycle) shall not be required to be certified by a firm of independent public accountants and may instead be prepared by such Principal and certified to by, and to the best knowledge of, its chief financial officer. Landlord shall hold and shall cause each Mortgagee to hold in confidence any non-public financial report and other information delivered to Landlord or a Mortgagee pursuant to this Paragraph I 7, except that Landlord and any such Mortgagee may disclose such reports and information (i) to the extent required by Legal Requirements and (ii) to prospective lenders, investors and purchasers and the financial advisors, accountants and attorneys of Landlord, Mortgagee and such prospective lenders, investors and purchasers, all to the extent so provided in the ordinary course of Landlord’s and such Mortgagees’ business provided any such disclosure party agrees to maintain the confidentiality required by this Paragraph 17. In the event that a Principal shall be required to file its financial statements with the Securities and Exchange Commission and such statements are available for review on the Commission’s EDGAR system, Tenant shall be deemed to be in compliance with the requirements of this Paragraph 17 as to such Principal.

 

18

 

 

18.          Permitted Contests.

 

Tenant shall not be required to (i) pay any Imposition; (ii) comply with any Legal Requirements; (iii) discharge or remove any lien, encumbrance or charge; or (iv) obtain any waivers or settlements or make any 10(a), changes to the physical condition of the Premises or take any other action with respect to any asserted defect in the Premises as required under Subparagraph so long as Tenant shall contest, in good faith and at its expense, the existence, the amount or the validity thereof, the amount of the damages caused thereby, or the extent of its liability therefor, by appropriate proceedings provided that (A) during the pendency of the contest there is prevented (1) the collection of, or other realization upon, the tax, assessment, levy, fee, rent or charge or lien, encumbrance or charge so contested (or in the alternative, Tenant pays the full amount in dispute under protest); (2) the sale, forfeiture or loss of the Premises, or any part thereof, or the Basic Rent or any Additional Rent, or any portion thereof; (3) any interference with the payment of the Basic Rent or any Additional Rent, or any portion thereof; and (4) any impairment of the fair market value of the Premises; (B) Tenant provides to Landlord title insurance over, of if title insurance is not available, such other security against any such lien, encumbrance or charge as Landlord shall reasonably request; and (C) such contest shall not subject Landlord or any Mortgagee to the risk of any criminal liability. While any such proceedings are pending, so long as all of the foregoing conditions continue to be met, Landlord shall not pay, remove or cause to be discharged the tax, assessment, levy, fee, rent or charge or lien, encumbrance or charge thereby being contested. Tenant further agrees that each such contest shall be prosecuted to a final conclusion as soon as reasonably possible. Tenant shall pay, indemnify, defend (with counsel selected by Tenant and reasonably acceptable to Landlord) and hold harmless the Indemnified Parties against, any and all losses, judgments, decrees and costs (including all reasonable attorneys’ fees and expenses) in connection with any such contest and shall, promptly after the final settlement, compromise or determination of such contest, fully pay and discharge the amounts which shall be levied, assessed, charged or imposed or be determined to be payable therein or in connection therewith, together will all penalties, fines, interests, costs and expenses thereof or in connection therewith, and perform all acts, the performance of which shall be ordered or decreed as a result thereof. The obligations of Tenant under this Paragraph 18 shall survive expiration or earlier termination of this Lease.

 

19

 

 

19.          Tenant Default Provisions.

 

(a)          Any of the following occurrences or acts shall constitute an event of default (herein called an “Event of Default”) under this Lease:

 

(i)           If Tenant, at any time during the continuance of this Lease (and regardless of the pendency of any bankruptcy, reorganization, receivership, insolvency or other proceedings, at law, in equity, or before any administrative tribunal, which have or might have the effect of preventing Tenant from complying with the terms of this Lease), shall (A) fail to make any payment when due of Basic Rent and such failure continues for five (5) days following written notice from Landlord to Tenant specifying such failure, (B) fail to make any payment when due of Additional Rent and such failure continues for thirty (30) days following written notice from Landlord or Mortgagee to Tenant specifying such failure, (C) fail in any material respect to maintain any insurance required to be carried by Tenant under this Lease and such failure continues for two (2) Business Days following Tenant’s receipt of Landlord’s notice of same, or (D) fail to observe or perform in any material respect any other provision hereof for thirty (30) days following written notice from Landlord to Tenant specifying such failure, provided, that in the case of any default referred to in this Lease which is reasonably susceptible of cure but cannot with diligence be cured within such thirty (30) day period, then, upon receipt by Landlord of a certificate of Tenant signed by an officer of Tenant stating the reason such default cannot be cured within thirty (30) days, describing the efforts being undertaken by Tenant to cure such default and reasonably estimating the cure period, and provided that Tenant at all times proceeds with good faith due diligence to cure such default, the time within which such failure may be cured shall be extended for such period, as may be necessary to complete the curing of the same with continuous, good faith due diligence; or

 

(ii)          If Tenant or Guarantor shall file a petition commencing a voluntary case under the Federal Bankruptcy Code or any other federal or state law (as now or hereafter in effect) relating to bankruptcy, insolvency, reorganization, winding-up or adjustment of debts (hereinafter singly a “Bankruptcy Law” and collectively “Bankruptcy Laws”) and such proceeding is not discharged within sixty (60) days after the date of filing or if Tenant or Guarantor shall (A) apply for or consent to the appointment of, or the taking of possession by, any receiver, custodian, trustee, United States Trustee or liquidator (or other similar official) of the Premises or any part thereof or of any substantial portion of Tenant’s property and any such application or appointment is not withdrawn or vacated within sixty (60) days after the filing or entry thereof, or (B) generally not pay its debts as they become due, or admit in writing its inability to pay its debts generally as they become due, or (C) make a general assignment for the benefit of its creditors, or (D) fail to controvert in timely and appropriate manner, or in writing acquiesce to, any petition commencing an involuntary case against Tenant or Guarantor or otherwise filed against Tenant or Guarantor pursuant to any Bankruptcy Law; or

 

20

 

 

(iii)         If an order for relief against Tenant or Guarantor shall be entered in any involuntary case under the Federal Bankruptcy Code or any similar order against Tenant or Guarantor shall be entered pursuant to any other Bankruptcy Law, or if a petition commencing an involuntary case against Tenant or Guarantor or proposing the reorganization of Tenant under any Bankruptcy Law shall be filed and not be discharged or denied within ninety (90) days after such filing, or if a proceeding or case shall be commenced in any court of competent jurisdiction seeking (A) the liquidation, reorganization, dissolution, winding-up or adjustment of debts of Tenant or Guarantor, or (B) the appointment of a receiver, custodian, trustee, United States Trustee or liquidator (or any similar official) of the Premises or any part thereof or of Tenant or Guarantor or of any substantial portion of Tenant’s or Guarantor’s property, or (C) any similar relief as to Tenant or Guarantor pursuant to any Bankruptcy Law, and any such proceeding or case shall continue undismissed, or an order, judgment or decree approving or ordering any of the foregoing shall be entered and continue unstayed and in effect for ninety (90) days.

 

(b)          If an Event of Default shall have happened and be continuing, Landlord shall have, in its sole discretion, the following rights:

 

(i)           To terminate the Term of this Lease by written notice to Tenant. Thereupon, the Term of this Lease and the estate hereby granted shall terminate on the date on which Landlord sends such notice as completely and with the same effect as if such date were the date fixed herein for the expiration of the term of this Lease, and all rights of Tenant hereunder shall terminate, but Tenant shall remain liable as provided herein.

 

(ii)          To (A) re-enter and repossess the Premises or any part thereof by force, summary proceedings, ejections or otherwise and (B) remove all persons and property therefrom, whether or not the Lease has been terminated pursuant to clause (i) above, Tenant hereby expressly waiving, to the extent permitted by law, any and all notices to quit, cure or vacate provided by current or any future law. Landlord shall have no liability by reason of any such re-entry, repossession or removal. No such re-entry or taking of possession of the Premises by Landlord shall be construed as an election on Landlord’s part to terminate the Term of this Lease unless a written notice of such intention be given to Tenant pursuant to clause (i) above.

 

(iii)         To use reasonable efforts to relet the Premises or any part thereof for the account of Tenant, in the name of Tenant or Landlord or otherwise, without notice to Tenant, for such term or terms (which may be greater or less than the period which would otherwise have constituted the balance of the Term of this Lease) and on such conditions (which may include concessions or free rent) and for such uses as Landlord may reasonably determine; provided the foregoing shall not be construed to reduce the obligation of Landlord to mitigate its damages to the extent required by law.

 

(iv)         In the event of re-entry or repossession of the Premises or removal of persons or property therefrom by reason of the occurrence of an Event of Default, Tenant shall pay to Landlord all Basic Rent and Additional Rent, in each case to and including the date of such re-entry, repossession or removal; and, thereafter, until the Term has expired or has been terminated, Tenant shall, whether or not the Premises shall have been relet, be liable to Landlord for, and shall pay to Landlord (A) all Basic Rent and all Additional Rent as and when such amounts would be payable under this Lease by Tenant in the absence of any such re-entry, repossession or removal, together with all reasonable expenses of Landlord in connection with such reletting efforts, if any (including, without limitation, all reasonable repossession costs, brokerage commissions, reasonable attorneys’ fees and expenses, employee’s expenses, reasonable alteration costs and expenses of preparation for such reletting), less (B) the net proceeds, if any, of any reletting effected for the account of Tenant pursuant to Subparagraph 19(b)(iii) above. Notwithstanding the foregoing, in the event any such reletting is for a term longer than the balance of the Term, Tenant shall be responsible for only a proportionate part of the expenses based on the balance of the Term as compared to the fixed minimum term of the reletting. Tenant shall pay such amounts on the dates on which Rent would be payable under this Lease in the absence of such re-entry, repossession or removal, and Landlord shall be entitled to recover the same from Tenant on each such date.

 

21

 

 

(v)          In the event of the termination of the Term by reason of the occurrence of an Event of Default, whether or not Landlord shall have collected any damages pursuant to Subparagraph 19(b)(iv) above with respect to the period prior to such termination, Landlord shall be entitled to recover from Tenant, and Tenant shall pay to Landlord on demand, as and for liquidated and agreed final damages for Tenant’s default and in lieu of all liquidated and agreed current damages in respect of Basic Rent and Additional Rent due beyond the date of such termination (it being agreed that it would be impracticable or extremely difficult to fix the actual damages), an amount equal to the sum of:

 

(A)         all Basic Rent and Additional Rent, in each case from the date of such termination for what is or would have been, in the absence of such termination, the then unexpired Term, discounted on a monthly basis at an annual rate equal to the then quoted semi-annual yields (which shall be converted to monthly yields) on U.S. Treasury securities maturing nearest the end of the Term (as if no termination had occurred) plus one percent (1%) (such rate being the “Discount Rate”), over (2) the then fair rental value of the Premises for the same period, discounted on a monthly basis at the Discount Rate; plus

 

(B)         Landlord’s other reasonable expenses incurred as a result of such Event of Default. If any applicable Legal Requirement shall limit the amount of liquidated final damages to less than the foregoing amount, Landlord shall be entitled to the maximum amount allowable under such law.

 

(c)          No termination of this Lease pursuant to Subparagraph 19(b)(i), by operation of law or otherwise, and no repossession of the Premises or any part thereof pursuant to Subparagraph 19(b)(ii) or otherwise, and no re letting of the Premises or any part thereof pursuant to Subparagraph 19(b)(iii), and no payment of any amounts by Tenant under Subparagraph 19(b) or the exercise by Landlord of any of its other rights under Subparagraph 19(b) shall, except to the extent of such payment, relieve Tenant of any liabilities under this Lease which by express provision of this Lease survive such expiration, termination, repossession, reletting or purchase.

 

(d)          In the event Tenant retains possession beyond the expiration or earlier termination of the Term, then, without limitation of Landlord’s other rights and remedies arising by reason of or in respect of such holdover, Tenant shall pay Basic Rent for such holdover period at a rate, for the first three months of such holdover period, equal to one hundred twenty-five percent (125%) of the Basic Rent due for the last full calendar month immediately prior to such holdover period and thereafter at a rate equal to one hundred fifty percent (150%) of the Basic Rent due for such calendar month, and Tenant shall also continue to perform all of its other obligations under this Lease, including the payment of all Additional Rent.

 

22

 

 

(e)          In the event Tenant fails to perform any of its obligations under this Lease with respect to the maintenance, repair and/or restoration of the Premises and if (i) Tenant does not correct such failure within thirty (30) days following receipt of notice thereof from Landlord or, if the correction cannot with diligence be corrected within such period, Tenant does not undertake such correction and thereafter diligently pursue such correction or (ii) if an emergency condition exists which involves the threat of imminent personal injury or material property damage, Tenant fails to correct or initiate correction of such condition promptly following notice from Landlord, then, in either such event, Landlord may re-enter the Premises for the purpose of making such correction, provided Landlord complies with any Legal Requirements applicable to such entry, gives Tenant reasonable advance notice of such re-entry considering the circumstances and takes reasonable measures to minimize to the extent practicable any adverse impact on Tenant’s business and its occupancy of the Premises.

 

20.          Additional Rights of Landlord; Landlord Waiver of Lien.

 

(a)          The rights and remedies set forth in Subparagraph 19(b) may be exercised in any order and in any combination whatsoever. No right or remedy herein conferred upon or reserved to Landlord is intended to be exclusive of any other right or remedy, and each and every right and remedy shall be cumulative and in addition to any other right or remedy given hereunder or now or hereafter existing at law or in equity. The failure of Landlord to insist at any time upon the strict performance of any covenant or agreement or to exercise any option, right, power or remedy contained in this Lease shall not be construed as a waiver or a relinquishment thereof for the future. A receipt by Landlord of any Basic Rent, any Additional Rent or any other sum payable hereunder with knowledge of the breach of any covenant or agreement contained in this Lease shall not be deemed a waiver of such breach, and no waiver by Landlord of any provision of this Lease shall be deemed to have been made unless expressed in writing and signed by Landlord. In addition to other remedies provided in this Lease, Landlord shall be entitled, to the extent permitted by Legal Requirements, to injunctive relief in case of the violation, or attempted or threatened violation, of any of the covenants, agreements, conditions or provision of this Lease, or to a decree or judgment compelling performance of any of the covenants, agreements, conditions or provisions of this Lease, or to any other remedy allowed to Landlord at law or in equity.

 

(b)          To the extent permitted by law, Tenant hereby waives and surrenders for itself and all those claiming under it, including creditors of all kinds, any right or privilege which it or any of them may have under any present or future constitution, statute or rule of law to redeem the Premises or to have a continuance of this Lease for the Term hereby demised or for a lesser period after termination of Tenant’s right of occupancy by order or judgment of any court or by any legal process or writ, or under the terms of this Lease or after the termination of the Term of this Lease as herein provided.

 

23

 

 

(c)          Landlord waives its statutory lien rights under Section 54.021 of the Texas Property Code as well as any constitutional and contractual liens with respect to Tenant’s personal property located at the Premises. Notwithstanding anything to the contrary herein, however, Landlord does not waive, relinquish or subordinate any liens, rights or remedies that Landlord may now have, or shall ever enjoy, as a judgment creditor or under any warehouseman’s lien in the event that Landlord is required by applicable law to store Tenant’s property if such property is abandoned by Tenant following a default by Tenant under this Lease.

 

21.          Notices, Demands and Other Instruments.

 

Any notice, demand, request, consent, approval, or other instrument (“Notice”) which may be permitted, required or desired to be given in connection herewith shall be given in writing and directed to Tenant or Landlord (as applicable) as follows:

 

  If to Tenant: Prior to July 1, 2020:
    Caris MPI, Inc.
    750 W. John Carpenter Freeway, Suite 800
    Irving, TX 75039
    Attention: Michael Halbert, SVP Human Resources
    Facsimile: [***]
    Email: [***]
     
  with a copy to: Caris MPI, Inc.
    750 W. John Carpenter Freeway, Suite 800
    Irving, TX 75039
    Attention: Legal Department
    Facsimile: [***]
    Email: [***]
     
    From and After July 1, 2020:
    Caris MPI, Inc.
    3600 W. Royal Lane
    Irving, TX 75063
    Facsimile: [***]
    Email: [***]

 

24

 

 

  with a copy to: Caris MPI, Inc.
    3600 W. Royal Lane
    Irving, TX 75063
    Attention: Legal Department
    Facsimile: [***]
    Email: [***]
     
  If to Landlord: KCP NNN II Leasehold 4, LLC
    c/o Kawa Capital Partners LLC
    21500 Biscayne Boulevard, Suite 700
    Aventura, Florida 33180
    Attention: General Counsel
    Facsimile: [***]
    Email: [***]
     
  With a copy to: Greenberg Traurig, P.A.
    333 S.E. 2nd Avenue, Suite 4400
    Miami, Florida 33131
    Attention: Gavin Loughlin
    Facsimile: [***]
    Email: [***]

 

Notices shall be either (i) personally delivered (including delivery by reputable overnight courier service) to the offices set forth above, in which case they shall be deemed delivered on the date of delivery to said offices or (ii) sent by facsimile or email (as applicable), provided that for any notices sent by facsimile or email a copy shall also be sent by personal delivery or overnight delivery service. Any notice actually received or deemed received pursuant to the foregoing provisions on a non-Business Day or after the close of business of the recipient on a Business Day shall be deemed received on the next Business Day. Either party may by written notice to the other party given as provided hereunder change its address for service of Notice to any other recognized business address in the continental United States. Any address so designated shall include a street address for courier delivery.

 

22.         Transfer by Landlord. Landlord shall be free to transfer its fee interest in the Premises or any part thereof or interest therein. Landlord shall be released from the responsibility for the performance of any liabilities and obligations which shall arise under the terms, covenants and conditions of this Lease subsequent to the date of any such transfer. Such instrument assigning Landlord’s interest in this Lease shall evidence the fact that such assignee or transferee has assumed full and complete liability for all future obligations and responsibilities of Landlord (subject to the limitations set forth in Paragraph 36 of this Lease), which will arise under, out of and/or in connection with this Lease from and after the effective date of such assignment or transfer. In the event that Landlord transfers its interest in this Lease, Tenant agrees to attorn to such assignee or transferee with respect to Tenant’s obligations under this Lease provided such assignee or transferee recognizes Tenant’s rights under this Lease. Tenant shall, upon Landlord’s or such transferee’s written request and at no out-of-pocket expense to Tenant, enter into an attornment agreement providing for such attornment. The transferring Landlord and its officers, directors, trustees, members, partners, shareholders, beneficiaries, employees and agents shall remain Indemnified Parties with respect to any event or occurrence that has happened prior to such transfer.

 

25

 

 

23.          Mortgaging by Landlord.

 

Landlord shall be free to grant one or more mortgages, deeds of trust or like security interest in the Premises and this Lease and/or enter into a ground lease with respect to the Premises (each such mortgage, deed of trust, like security interest or ground lease, and any renewals, replacements, or extensions thereof, being a “Mortgage”) to one or more mortgagees, deed of trust trustees, other grantees or ground lessors (individually, together with each holder of any note secured thereby, a “Mortgagee”) on the condition that either (a) this Lease shall be superior to the Mortgage, or (b) if this Lease is to be subordinate to the Mortgage, Tenant receives from the Mortgagee a subordination and nondisturbance agreement reasonably acceptable to Tenant and the Mortgagee pursuant to which Tenant shall confirm the subordination of this Lease to such Mortgage and Mortgagee recognizes this Lease and agrees not to disturb Tenant’s interest in this Lease or possession of the Premises so long as an Event of Default has not occurred and is continuing under this Lease (an “SNDA”), provided that in no event shall this Lease be subordinated to a junior mortgage without the prior written consent of any then-existing Mortgagee. Tenant shall execute such SNDA within ten (10) Business Days after receipt of such SNDA in form reasonably acceptable to Tenant. Any such recognition and non-disturbance agreement shall provide that, in the event of a conflict between the Mortgage and this Lease, casualty insurance proceeds shall be received, used and applied as provided in this Lease. Tenant agrees to attorn, at the request of any Mortgagee, to such Mortgagee or other transferee upon a transfer of title by reason of foreclosure of such Mortgage or deed in lieu of foreclosure thereof or termination of any such ground lease. In connection with any proposed transfer, pledge or mortgage of Landlord’s fee interest in the Premises or any portion of the ownership interests in Landlord, Tenant shall, within ten (10) Business Days after receipt of Landlord’s written request therefor, provide Landlord and the proposed transferee and/or Mortgagee with confirmation in writing that Tenant shall recognize such transferee and Mortgagee as such in the event of the consummation of the transaction described in such notice. Without limitation of the foregoing, a SNDA substantially in the form attached hereto as Exhibit 23 shall be deemed reasonable for all relevant purposes.

 

Without limiting the generality of the foregoing, at the written direction of Landlord, Tenant shall agree in writing in respect of a first Mortgage for the benefit of the Mortgagee thereunder that (i) the Mortgagee is a direct assignee of Landlord’s interest under this Lease and (ii) until said Mortgage has been released of record, all payments of Basic Rent are to be made as set forth in said direction and no subsequent direction by Landlord shall be honored by Tenant until said Mortgage has been released of record unless the Mortgagee consents in writing to such subsequent direction. Any Mortgagee which becomes an assignee of Landlord’s interest in this Lease, whether by foreclosure of a Mortgage or pursuant to a deed in lieu thereof, or any successor to such assignee, shall not be obligated to perform any duty, covenant or condition required to be performed by Landlord under any of the terms hereof (except for obligations that first arise on and after such time as the Mortgagee shall obtain title to the Premises following foreclosure or deed in lieu of foreclosure), but on the contrary, Tenant and Landlord, by their respective executions hereof, each acknowledge and agree that notwithstanding any such assignment each and all of such duties, covenants or conditions required to be performed by Landlord shall survive any such assignment and shall be and remain the sole liability of Landlord. Subject to the prior sentence, any transferee of Landlord’s interest which acquires such interest from a Mortgagee, and any purchaser of such interest at a foreclosure sale in respect of a Mortgage (or transferee of a deed in lieu of such a foreclosure), shall not be obligated to any duty, covenant or condition required to be performed by Landlord under any of the terms hereof, which obligation first arises prior to said transferee’s or purchaser’s acquisition of Landlord’s interest under this Lease, shall not otherwise be liable for the defaults of any prior Landlord hereunder and shall not be obligated to account for or be subject to any offset in respect of (and Tenant shall be given no credit for) any payment of rent made more than thirty (30) days in advance of the due date of such payment unless and then only to the extent such rental payment is actually received by such transferee. Without limiting the foregoing, Tenant acknowledges and agrees that the rights of all such assignees, purchasers and transferees in and to Basic Rent and Additional Rent shall not be subject to any abatement whatsoever, or be subject to any defense, setoff, counterclaim or recoupment or reduction of any kind by reason of any event or circumstance which occurred prior to the date upon which any such assignee, purchaser or transferee obtained title to the Premises or the Landlord’s interest in this Lease.

 

26

 

 

24.          Estoppel Certificates.

 

(a)          Tenant shall at any time and from time to time (but in no event more than twice in any twelve (12) month period, unless such request is in connection with a prospective sale or financing of the Premises by Landlord, in which case Landlord shall not be so limited), within ten (10) Business Days following receipt by Tenant of a written request therefor from Landlord or any Mortgagee, execute, acknowledge and deliver to such requesting party executed Tenant’s Certificates substantially in the forms attached hereto as Exhibit 24-1 and Exhibit 24-2; together with such other factually correct information pertaining to this Lease as may be reasonably requested by Landlord or any Mortgagee. Any such certificate may be relied upon by any Mortgagee, prospective purchaser or prospective Mortgagee of the Premises or any interest in Landlord.

 

(b)          Landlord shall at any time and from time to time, within ten (10) Business Days following receipt by Landlord of a written request therefor from Tenant, execute, acknowledge and deliver to Tenant (or as Tenant may reasonably direct), a certificate reciting factually correct information pertaining to this Lease as reasonably requested by Tenant, including, without limitation, whether to Landlord’s actual knowledge Tenant is then in default hereunder, the last dates and amounts of Rent paid hereunder and the dates of any modifications to this Lease. Such certificates may be relied upon by the parties to whom Tenant requests that they be addressed and their respective successors and assigns, including Tenant’s actual and prospective lenders, subtenants and assignees and any potential purchaser of Tenant or a direct or indirect interest in Tenant.

 

25.          No Merger.

 

There shall be no merger of this Lease or the leasehold estate hereby created with the fee estate in the Premises or any part thereof by reason of the same person acquiring or holding, directly or indirectly, this Lease or the leasehold estate hereby created or any interest in this Lease or in such leasehold estate as well as the fee estate in the Premises or any portion thereof.

 

27

 

 

26.          Surrender.

 

Upon expiration or earlier termination of this Lease, Tenant shall peaceably surrender the Premises to Landlord in the condition in which the Premises is to be kept under the other provisions of this Lease, including without limitation, Paragraph 10, ordinary wear and tear and damage by casualty excepted. Tenant shall, at Tenant’s expense, remove from the Premises prior to such expiration or termination all of Tenant’s Property, and immediately repair any damage caused by such removal. Any of Tenant’s Property not so removed within ninety (90) days following such expiration or earlier termination shall, at Landlord’s election, become the property of Landlord. Landlord may thereafter cause such Tenant’s Property to be removed and disposed of and the cost of repairing any damage caused by such removal shall be borne by Tenant. Tenant shall not be required to remove any Alterations unless Landlord designated at the time of its approval of such Alteration that such Alteration shall be removed by Tenant upon expiration or sooner termination of this Lease. Landlord expressly agrees that Tenant shall not be obligated at the expiration or earlier termination of this Lease to remove any of the Tenant Improvements (as defined in the Work Letter) that are of a type and nature included in general office space offered for lease.

 

27.          Severability.

 

Each and every covenant and agreement contained in this Lease is separate and independent, and the breach of any thereof by Landlord shall not discharge or relieve Tenant from any obligation hereunder. If any term or provision of this Lease or the application thereof to any person or circumstances shall at any time be invalid and unenforceable, the remainder of this Lease, or the application of such term or provision to persons or circumstances or at any time other than those to which it is invalid or unenforceable, shall not be affected thereby, and each such remaining term and provision of this Lease shall valid and shall be enforced to the extent permitted by law.

 

28.          Savings Clause.

 

No provision contained in this Lease which purports to obligate the Tenant to pay any amount of interest or any fees, costs or expenses which are in excess of the maximum permitted by applicable Legal Requirements shall be effective to the extent that it calls for payment of any interest or other sums in excess of such maximum.

 

29.          Binding Effect.

 

Subject to Paragraph 23, all of the covenants, conditions and obligations contained in this Lease shall be binding upon and inure to the benefit of the respective successors and assigns of Landlord and Tenant. No amendment of this Lease shall be effective unless expressed in writing executed by Landlord and Tenant.

 

30.          Memorandum of Lease.

 

Simultaneously with the execution and delivery hereof, Landlord and Tenant shall enter into and record, at Tenant’s expense, a memorandum of this Lease in the form of Exhibit 30 attached hereto. Following expiration or earlier termination of the Term, Tenant shall, at the request of Landlord, execute an appropriate termination of such memorandum in recordable form.

 

28

 

 

31.          Table of Contents; Headings.

 

The table of contents and headings used in this Lease are for convenient reference only and shall not to any extent have the effect of modifying, amending or changing the provisions of this Lease.

 

32.          Governing Law; Litigation

 

This Lease shall be governed by and interpreted under the laws of the state in which the Premises are located. In the event of litigation between the parties with respect to this Lease, the losing party shall reimburse the prevailing party for all reasonable attorneys’ fees and expenses incurred by the prevailing party with respect thereto.

 

33.          Certain Definitions.

 

(a)         The term “Business Day” shall mean a day other than Saturday, Sunday or any day on which regular U.S. mail is not delivered or banks are generally closed in the State of Texas.

 

(b)          The term “Lease” means this Lease, as amended and modified from time to time, together with any memorandum or short form of lease entered into for the purpose of recording.

 

(c)          The term “Landlord” means the owner of the rights of the Landlord under this Lease and upon any assignment or transfer of such rights, except an assignment or transfer made as security for an obligation, any heirs, successors and assigns. The assignor or transferor shall be relieved of all future duties and obligations under this Lease provided the assignee or the transferee shall expressly agree in writing to be bound by and to assume all the covenants of Landlord hereunder arising from and after such assignment or transfer.

 

(d)          An “Affiliate” of a party shall mean a person or entity (i) which directly or indirectly through one or more intermediaries controls, or is controlled by, or is under a common control with, the applicable party, (ii) which beneficially owns or holds fifty percent (50%) or more (by number of votes) of any class of the voting stock of the applicable party, or (iii) fifty percent (50%) or more (by number of votes) of the voting stock (or in the case of a person which is not a corporation, fifty percent (50%) or more of the equity interest) of which is beneficially owned or held by the applicable party or its Subsidiary.

 

(e)          The term “control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a person or entity through the ownership of voting securities, by contract of otherwise.

 

(f)          The term “Subsidiary” shall mean any Business Entity of which more than fifty percent (50%) of the equity interests at the time outstanding shall at the time be owned, directly or indirectly, by any other Business Entity or collectively by any Business Entity and its Affiliates.

 

29

 

 

(g)          The term “Business Entity” shall mean an entity other than an individual or a government agency or political subdivision thereof.

 

(h)         The term “Person” shall mean an individual, partnership, corporation, limited liability company, limited liability partnership, trust, unincorporated organization or other business entity or a government or agency or political subdivision thereof.

 

(i)           The term “Insurance Expenses” shall mean all premiums, deductibles and other expenses actually incurred by Landlord with respect to the Landlord’s Required Coverage under Subparagraph 12(e).

 

34.          Assignment of Intangibles.

 

(a)          Landlord hereby assigns to Tenant, without recourse, all Intangible Personal Property for use by Tenant during the Term. Such assignment shall terminate upon the expiration or earlier termination of the Term or, if earlier, upon termination of Tenant’s right of possession of the Premises following the occurrence of an Event of Default.

 

(b)          No later than ninety (90) days following the expiration or earlier termination of this Lease, Landlord may require in a written notice to Tenant that Tenant assign to Landlord, effective as of such expiration or earlier termination of the Term, all rights of Tenant in and to such Intangible Personal Property used by Tenant in connection with the Premises as is designated by Landlord in such notice, including, without limitation, any contract rights, guaranties, licenses, permits, registrations and warranties (including without limitation licenses, permits and registrations pertaining to any clean-up or remediation of Hazardous Material on or about the Premises to the extent such licenses, permits and registrations may be assigned to Landlord) but excluding any trade names, service marks, corporate names, or other business licenses, phone numbers, and the like, used by Tenant or its Affiliates or its assignees or subtenants in the operation of their respective businesses. Subject to and without release of any obligation of Tenant to Landlord under this Lease which by the terms of this Lease survives the termination or expiration of this Lease, including without limitation Tenant’s indemnity obligations under Paragraphs 7 and 8 of this Lease, Landlord shall assume any future obligations of Tenant in respect of any such assigned Intangible Personal Property in form reasonably acceptable to Landlord and Tenant. Tenant shall execute such assignments and/or bills of sale of the Intangible Personal Property as Landlord may reasonably request, provided the same do not impose any additional liability on Tenant and are otherwise reasonably acceptable to Tenant. The obligations of Tenant under this Paragraph 34 shall survive the expiration or earlier termination of this Lease.

 

35.          Exhibits.

 

The following Exhibits attached hereto are hereby incorporated by reference into this Lease and made a part hereof:

 

Exhibit l(a) (Legal Description)

Exhibit 2(a) (Permitted Exceptions)

 

30

 

 

Exhibit 2(b) (Work Letter)

Exhibit 4(a) (Renewal Options)

Exhibit 5 (Basic Rent Chart)

Exhibit 23 (Form of SNDA)

Exhibit 24-1 (Estoppel Certificate)

Exhibit 24-2 (Estoppel Certificate)

Exhibit 30 (Memorandum of Lease)

Exhibit 41 (Guaranty)

 

36.          Landlord Defaults; Exculpatory Clause.

 

(a)      In the event of any default by Landlord, Tenant shall have the right to exercise any legal or equitable remedies (except as otherwise provided herein), but, prior to exercising any such remedies, Tenant shall give Landlord and any Mortgagee of whom Tenant has been provided written notice, written notice specifying such default with particularity, and Landlord shall have a period of thirty (30) days following Landlord’s receipt of such written notice in which to cure such default; provided, however, that if such default reasonably requires more than thirty (30) days to cure, Landlord shall have a reasonable period of time to cure such default, provided Landlord commences the cure within such thirty (30) day period and thereafter diligently prosecutes such cure to completion. In no event shall Tenant have the right to offset Rent, to terminate or rescind this Lease or to exercise self-help (except as expressly provided in this Lease or by applicable Legal Requirements) as a result of Landlord’s default. Notwithstanding anything to the contrary contained in this Lease, Landlord and Tenant each hereby waives its right to recover consequential damages (including, but not limited to, lost profits), special damages or punitive damages arising out of any default by the other.

 

(b)      If a default by Landlord is curable but is not cured by Landlord within the applicable notice and cure period (and Landlord has in fact ceased efforts to cure same), and provided that the cure of such default will have no material adverse effect on the Building Structure, Tenant may, upon five (5) Business Days’ prior written notice to Landlord (or sooner, if a bona fide emergency), cure the default and bill Landlord for the actual out-of-pocket costs incurred by Tenant to cure the default, which shall be due within thirty (30) days following invoice. Tenant shall not have the right to offset Rent for any sums due hereunder.

 

(c)      Notwithstanding any provision of this Lease to the contrary, the liability of Landlord under and with respect to this Lease shall be limited to the interest of Landlord in the Premises, and, upon assignment by Landlord, any sales proceeds resulting from such sale as to any then existing default by Landlord hereunder and any judgment in favor of Tenant or any party claiming by, through or under Tenant against Landlord shall be collectible only out of Landlord’s interest in the Premises and any proceeds, rents, awards, and income derived therefrom, and in no event shall any judgment for damages be entered against Landlord which is in excess of the value of such interest plus such proceeds, rents, awards, and income. IN FURTHERANCE OF THE FOREGOING, AND EXCEPT TO THE EXTENT TENANT IS A JUDGMENT CREDITOR AS HEREINABOVE DESCRIBED, TENANT HEREBY WAIVES ITS STATUTORY LIEN UNDER SECTION 91.004 OF THE TEXAS PROPERTY CODE.

 

31

 

 

37.          Jury Waiver.

 

LANDLORD AND TENANT WAIVE THEIR RESPECTIVE RIGHTS TO TRIAL BY JURY OF ANY CONTRACT OR TORT CLAIM, COUNTERCLAIM, CROSS-COMPLAINT, OR CAUSE OF ACTION IN ANY ACTION, PROCEEDINGS, OR HEARING BROUGHT BY EITHER PARTY AGAINST THE OTHER ON ANY MATTER ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS LEASE, THE RELATIONSHIP OF LANDLORD AND TENANT, OR TENANT’S USE OR OCCUPANCY OF THE PREMISES, INCLUDING WITHOUT LIMITATION ANY CLAIM OF INJURY OR DAMAGE OR THE ENFORCEMENT OF ANY REMEDY UNDER ANY CURRENT OR FUTURE LAW, STATUTE, REGULATION, CODE, OR ORDINANCE.

 

38.          Quiet Enjoyment.

 

So long as an Event of Default does not exist, Tenant shall be entitled to peaceful and quiet enjoyment of the Premises, subject, however, to the express terms and conditions of this Lease.

 

 

39.           Landlord’s Representations and Warranties. Landlord represents and warrants to Tenant that, as of the Effective Date:

 

(a)       Conflict; Title. This Lease does not conflict with, and its execution by Landlord shall not result in a default or event of default under, any other agreement to which Landlord is bound. As of the Effective Date, there is no debt or mortgage lien granted by Landlord or any Affiliate of Landlord and encumbering the Premises other than the Deed of Trust, Assignment of Leases and Rents, and Security Agreement dated on or about the date hereof in favor of Citibank, N.A. Landlord will provide Tenant with a copy of Landlord’s title insurance policy for the Premises (together with copies of any exception documents referenced therein) within ten (10) Business Days following receipt thereof by Landlord.

 

(b)      Claims or Proceedings. To Landlord’s knowledge, there are no claims, causes of action or other proceedings pending or threatened in respect to the ownership, operation or environmental condition of the Premises or any part thereof, except for claims which are fully insured and as to which the insurer has accepted defense without reservation.

 

(c)       Condemnation. Etc. To Landlord’s knowledge, there is no existing, pending or contemplated, threatened or anticipated condemnation of any part of the Premises, repaving, widening, change of grade or limitation on use of streets, roads, or highways abutting, change in the zoning classification of the Premises, or special tax or assessment to be levied against the Premises due to capital improvements to be constructed on, near or adjacent to the Premises.

 

(d)      Hazardous Materials. Other than any matters disclosed in that certain Phase I Environmental Site Assessment dated June 17, 2019 and prepared by EBI Consulting under Project No. 1119003692, to Landlord’s knowledge, there are no Hazardous Materials in the Building or the Premises, other than those in compliance with Legal Requirements and Environmental Laws that are customarily used in connection with the operation and maintenance of an office building.

 

(e)       Prohibited Persons and Transactions. Landlord represents and warrants to Tenant that Landlord is currently in compliance with and shall at times during the Term (including any extension thereof) remain in compliance with the regulations of Office of Foreign Asset Control (the “OFAC”) of the Department of the Treasury (including those named on OFAC’s Specially Designated and Blocked Persons List) and any statute, executive order (including the September 24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism), or other governmental action relating thereto.

 

32

 

 

As used herein, “Landlord’s knowledge” means the actual (not constructive or imputed) knowledge of Daniel Amer and Emily Jones (“Landlord’s Representatives”) as of the Effective Date after performing reasonable inspections of his or her files regarding the Premises. Landlord represents and warrants to Tenant that Landlord’s Representatives are the individuals within Landlord’s organization most familiar with the Building and Premises and most likely to know the information subject to Landlord’s representations and warranties hereunder. Tenant acknowledges and agrees that Landlord’s Representatives are named solely for the purpose of defining and narrowing the scope of knowledge of Landlord and not for the purpose of imposing any liability or creating any duties running from such individuals to Tenant.

 

40.           Tenant Allowance and Tenant Improvements. Landlord will provide to Tenant the Allowance (as defined in the Work Letter) to be applied to the cost of the Tenant Improvement Costs as set forth in the Work Letter attached as Exhibit 2(b) hereto, which Work Letter is hereby made a part of this Lease, and its provisions shall control in the event of a conflict with the provisions contained in this Lease. If Landlord fails to pay to Tenant any installment of the Allowance within thirty (30) days following the date when due pursuant to the Work Letter, then such late payment shall bear interest at the Default Rate from the date due until paid.

 

41.Guaranty.

 

The obligations of Tenant under this Lease are guaranteed by Caris Life Sciences, Ltd., a Cayman Islands exempted limited company (“Guarantor”) pursuant to a Guaranty of substantially even date herewith in the form attached hereto as Exhibit 41 and made a part hereof for all purposes (the “Guaranty”). Landlord’s receipt of the Guaranty, duly executed by the Guarantor, shall be a condition to the effectiveness of this Lease.

 

33

 

 

42.           Letter of Credit.

 

(a)      Tenant shall deliver to Landlord, within ten (10) Business Days after Tenant’s execution of this Lease, an unconditional, clean, irrevocable letter of credit (the “L-C”) in the amount set forth in Paragraph 42(c) below (the “L-C Amount”), which L-C shall be issued by a money-center, solvent and nationally recognized bank (a bank which accepts deposits, maintains accounts, has a local Dallas, Texas office which will negotiate a letter of credit, and whose deposits are insured by the FDIC) reasonably acceptable to Landlord (such approved, issuing bank being referred to herein as the “Bank”), which Bank must have either (i) an S&P long term rating of A (or better) and an S&P short term rating of A-1 (or better) or (ii) a Moody’s long term rating of A2 (or better) and a Moody’s short term rating of P-1 (or better) (collectively, the “Bank’s Credit Rating Threshold”), and which L-C shall be in form and substance reasonably acceptable to Landlord. Tenant shall pay all expenses, points and/or fees incurred by Tenant in obtaining the L-C. The L-C shall (i) be “callable” at sight, irrevocable and unconditional, (ii) subject to Subparagraph 42(c), be maintained in effect, whether through renewal or extension, for the period commencing on or about the date of this Lease and continuing until the date (the “L-C Expiration Date”) that is no less than one hundred twenty (120) days after the expiration of the Term, and Tenant shall deliver a new L-C or certificate of renewal or extension to Landlord at least sixty (60) days prior to the expiration of the L-C then held by Landlord, without any action whatsoever on the part of Landlord, (iii) be fully assignable by Landlord, its successors and assigns, (iv) permit partial draws and multiple presentations and drawings, and (v) be otherwise subject to the Uniform Customs and Practices for Documentary Credits (1993-Rev), International Chamber of Commerce Publication #500, or the International Standby Practices-ISP 98, International Chamber of Commerce Publication #590. Landlord, or its then managing agent, shall have the right to draw down an amount up to the face amount of the L-C if any of the following shall have occurred or be applicable: (A) such amount is due to Landlord under the terms and conditions of this Lease and Tenant has not paid such amount as and when due hereunder after taking into account any applicable notice and cure period, or (B) Tenant has filed a voluntary petition under the U.S. Bankruptcy Code or any state bankruptcy code (collectively, “Bankruptcy Code”), or (C) an involuntary petition has been filed against Tenant under the Bankruptcy Code and remains undismissed for ninety (90) days, or (D) the Lease has been rejected, or is deemed rejected, under Section 365 of the U.S. Bankruptcy Code, following the filing of a voluntary petition by Tenant under the Bankruptcy Code, or the filing of an involuntary petition against Tenant under the Bankruptcy Code which remains undismissed for ninety (90) days, or (E) the Bank has notified Landlord that the L-C will not be renewed or extended through the L-C Expiration Date, or (F) Tenant is placed into receivership or conservatorship, or becomes subject to similar proceedings under Federal or State law, or (G) Tenant executes an assignment for the benefit of creditors, or (H) if (1) any of the Bank’s Fitch Ratings (or other comparable ratings to the extent the Fitch Ratings are no longer available) have been reduced below the Bank’s Credit Rating Threshold, or (2) there is otherwise a material adverse change in the financial condition of the Bank, and Tenant has failed to provide Landlord with a replacement letter of credit, conforming in all respects to the requirements of this Paragraph 42 (including, but not limited to, the requirements placed on the issuing Bank more particularly set forth in this Paragraph 42(a)), in the amount of the applicable L-C Amount, within thirty (30) days following Landlord’s written demand therefor (with no other notice or cure or grace period being applicable thereto, notwithstanding anything in this Lease to the contrary) (each of the foregoing being an “L-C Draw Event”). The L-C shall be honored by the Bank regardless of whether Tenant disputes Landlord’s right to draw upon the L-C. In the event of an assignment by Tenant of its interest in this Lease (and irrespective of whether Landlord’s consent is required for such assignment), the acceptance of any replacement or substitute letter of credit by Landlord from the assignee shall be subject to Landlord’s prior written approval, in Landlord’s sole and absolute discretion, and any reasonable attorney’s fees incurred by Landlord in connection with such determination shall be payable by Tenant to Landlord within thirty (30) days of billing.

 

34

 

 

(b)      Tenant hereby acknowledges and agrees that Landlord is entering into this Lease in material reliance upon the ability of Landlord to draw upon the L-C upon the occurrence of any L-C Draw Event. In the event of any L-C Draw Event, Landlord may, but without obligation to do so, and without notice to Tenant (except in connection with an L-C Draw Event under Paragraph 42(a)(H) above), draw upon the L-C, in part or in whole, to cure any such L-C Draw Event and to compensate Landlord for any and all damages of any kind or nature sustained resulting from Tenant’s Event of Default under this Lease or other L-C Draw Event and to compensate Landlord for any and all damages arising out of, or incurred in connection with, the termination of this Lease as a result of such Event of Default. The use, application or retention of the L-C, or any portion thereof, by Landlord shall not prevent Landlord from exercising any other right or remedy provided by this Lease or by any applicable Legal Requirement, it being intended that Landlord shall not first be required to proceed against the L-C, and such L-C shall not operate as a limitation on any recovery to which Landlord may otherwise be entitled. Tenant agrees and acknowledges that (i) the L-C constitutes a separate and independent contract between Landlord and the Bank, (ii) Tenant is not a third-party beneficiary of such contract, (iii) Tenant has no property interest whatsoever in the L-C or the proceeds thereof, and (iv) in the event Tenant becomes a debtor under any chapter of the Bankruptcy Code, Tenant is placed into receivership or conservatorship, or there is an event of a receivership, conservatorship or a bankruptcy filing by, or on behalf of, Tenant, neither Tenant, any trustee, nor Tenant’s bankruptcy estate shall have any right to restrict or limit Landlord’s claim and/or rights to the L-C or the proceeds thereof by application of Section 502(b)(6) of the U.S. Bankruptcy Code or otherwise.

 

(c)      The L-C Amount shall initially be equal to the amount of $3,435,000.00. Subject to the terms and conditions of Subparagraphs 42(c), and provided that the Reduction Condition (as defined below) is satisfied on each applicable Reduction Date (as defined below), the L-C Amount shall be reduced as follows:

  

Date of Reduction
(each, a “Reduction Date”)
  Amount of Reduction   Remaining L-C Amount 
June 1, 2023  $343,500.00   $3,091,500.00 
June 1, 2024  $343,500.00   $2,748,000.00 
June 1, 2025  $343,500.00   $2,404,500.00 
June 1, 2026  $343,500.00   $2,061,000.00 
June 1, 2027  $343,500.00   $1,717,500.00 
June 1, 2028  $343,500.00   $1,374,000.00 
June 1, 2029  $343,500.00   $1,030,500.00 
June 1, 2030  $343,500.00   $687,000.00 
June 1, 2031  $343,500.00   $343,500.00 
June 1, 2032  $343,500.00   $0.00 

 

(d)      The reduction of the L-C Amount is subject to each of the following conditions (collectively, the “Reduction Condition”):

 

(1)      As of the applicable Reduction Date, no Event of Default then exists; and

 

(2)     The audited financial statements (as provided in Paragraph I 7) for the fiscal year immediately preceding the applicable Reduction Date evidence that Tenant and Guarantor had an aggregate Tangible Net Worth in excess of $25,000,000.00.

 

35

 

 

(e)      In the event that Tenant is eligible for a reduction of the L-C Amount, Tenant shall have the right to reduce the L-C Amount as set forth above via the delivery to Landlord of either (x) an amendment to the existing L-C (in form and content reasonably acceptable to Landlord) modifying the L-C Amount to the amount then required under this Paragraph 42, or (y) an entirely new L-C (in the form and content otherwise required in this Paragraph 42) in the total L-C Amount then required under this Paragraph 42 (in which instance Landlord shall promptly return to Tenant the previously delivered L-C upon Landlord’s receipt of the replacement L-C).

 

(f)       If, as a result of any drawing by Landlord of all or any portion of the L-C, the amount of the L-C shall be less than the then-required L-C Amount, Tenant shall, within five (5) Business Days thereafter, provide Landlord with additional letter(s) of credit in an amount equal to the deficiency, and any such additional letter(s) of credit shall comply with all of the provisions of this Paragraph 42. Tenant further covenants and warrants that it will neither assign nor encumber the L-C or any part thereof and that neither Landlord nor its successors or assigns will be bound by any such assignment, encumbrance, attempted assignment or attempted encumbrance. Without limiting the generality of the foregoing, if the L-C expires earlier than the L-C Expiration Date, Landlord will accept a renewal thereof (such renewal letter of credit to be in effect and delivered to Landlord, as applicable, not later than sixty (60) days prior to the expiration of the L-C then held by Landlord), which shall be irrevocable and automatically renewable as above provided through the L-C Expiration Date upon the same terms as the expiring L-C or such other terms as may be acceptable to Landlord in its sole discretion. If the L-C is not timely renewed, or if Tenant fails to maintain the L-C in the amount and in accordance with the terms set forth in this Paragraph 42, Landlord shall have the right to present the L-C to the Bank in accordance with the terms of this Paragraph 42, and the proceeds of the L-C shall be applied by Landlord against any Rent payable by Tenant under this Lease that is not paid when due and/or to pay for all losses and damages that Landlord has suffered as a result of any Event of Default by Tenant under this Lease. In such event (i) any unused proceeds shall constitute the property of Landlord (and not Tenant’s property or, in the event of a receivership, conservatorship, or a bankruptcy filing by, or on behalf of, Tenant, property of such receivership, conservatorship or Tenant’s bankruptcy estate) and need not be segregated from Landlord’s other assets, but shall be applied by Landlord to Tenant’s obligations under this Lease as they become due, and (ii) Landlord agrees to pay to Tenant within thirty (30) days after the L-C Expiration Date the amount of any proceeds of the L-C received by Landlord and not applied against any Rent payable by Tenant under this Lease that was not paid when due or used to pay for any losses and/or damages suffered by Landlord as a result of any Event of Default by Tenant under this Lease; provided, however, that if prior to the L-C Expiration Date a voluntary petition is filed by Tenant, or an involuntary petition is filed against Tenant by any of Tenant’s creditors, under the Bankruptcy Code, then Landlord shall not be obligated to make such payment in the amount of the unused L-C proceeds until either all preference issues relating to payments under this Lease have been resolved in such bankruptcy or reorganization case or such bankruptcy or reorganization case has been dismissed.

 

36

 

 

(g)      The L-C shall also provide that Landlord may, at any time and without notice to Tenant and without first obtaining Tenant’s consent thereto, transfer (one or more times) all or any portion of its interest in and to the L-C to another party, person or entity, in connection with the assignment by Landlord of its rights and interests in and to this Lease. In the event of a transfer of Landlord’s interest in under this Lease, Landlord shall transfer the L-C, in whole or in part, to the transferee and thereupon Landlord shall, without any further agreement between the parties, be released by Tenant from all liability therefor to the extent so transferred, and it is agreed that the provisions hereof shall apply to every transfer or assignment of the whole of said L-C to a new landlord. Other than in connection with an assignment of the Lease as security for a mortgage or deed of trust now or later encumbering the Premises or any portion thereof, Landlord shall not transfer the Letter of Credit except to a transferee of Landlord’s interest in the Lease. In connection with any such transfer of the L-C by Landlord, Tenant shall, at Tenant’s sole cost and expense, execute and submit to the Bank such applications, documents and instruments as may be reasonably necessary to effectuate such transfer and Tenant shall be responsible for paying the Bank’s transfer and processing fees in connection therewith; provided that, Landlord shall have the right (in its sole discretion), but not the obligation, to pay such fees on behalf of Tenant, in which case Tenant shall reimburse Landlord within ten (10) Business Days after Tenant’s receipt of an invoice from Landlord therefor.

 

(h)      Landlord and Tenant (i) acknowledge and agree that in no event or circumstance shall the L-C or any renewal thereof or substitute therefor or any proceeds thereof be deemed to be or treated as a “security deposit” under any law applicable to security deposits in the commercial context, as such section now exists or as it may be hereafter amended or succeeded (the “Security Deposit Laws”), (ii) acknowledge and agree that the L-C (including any renewal thereof or substitute therefor or any proceeds thereof) is not intended to serve as a security deposit, and the Security Deposit Laws shall have no applicability or relevancy thereto, and (iii) waive any and all rights, duties and obligations that any such party may now, or in the future will, have relating to or arising from the Security Deposit Laws. Tenant hereby irrevocably waives and relinquishes the provisions of any law, now or hereafter in effect, which (x) establish the time frame by which a landlord must refund a security deposit under a lease, and/or (y) provide that a landlord or sublandlord may claim from a security deposit only those sums reasonably necessary to remedy defaults in the payment of rent, to repair damage caused by a tenant or to clean the premises, it being agreed that Landlord may, in addition, claim those sums specified in this Paragraph 42 and those sums reasonably necessary to (A) compensate Landlord for any loss or damage caused by an Event of Default by Tenant under this Lease, including any damages Landlord suffers following termination of this Lease as a result of such Event of Default, and/or (B) compensate Landlord for any and all damages arising out of, or incurred in connection with, the termination of this Lease as a result of an Event of Default by Tenant.

 

(i)       Tenant agrees not to interfere in any way with any payment to Landlord of the proceeds of the L-C, either prior to or following a “draw” by Landlord of all or any portion of the L-C, regardless of whether any dispute exists between Tenant and Landlord as to Landlord’s right to draw down all or any portion of the L-C. No condition or term of this Lease shall be deemed to render the L-C conditional and thereby afford the Bank a justification for failing to honor a drawing upon such L-C in a timely manner. Tenant shall not request or instruct the Bank of any L-C to refrain from paying sight draft(s) drawn under such L-C.

 

43.           DTPA.

 

TENANT HEREBY WAIVES ALL ITS RIGHTS UNDER THE DECEPTIVE TRADE PRACTICES - CONSUMER PROTECTION ACT, SECTION 17.41 ET SEQ. OF THE TEXAS BUSINESS AND COMMERCE CODE, A LAW THAT GIVES CONSUMERS SPECIAL RIGHTS AND PROTECTIONS. AFTER CONSULTATION WITH AN ATTORNEY OF TENANT’S OWN SELECTION, TENANT VOLUNTARILY CONSENTS TO THIS WAIVER.

 

37

 

 

44.           Roof Rights. Tenant shall have the right to use a portion of the roof area of the Building to install, repair and maintain a satellite antenna dish with associated antennae and cables (the “Satellite System”), provided that the Satellite System is not greater than three (3) feet in diameter, does not protrude above the parapet wall of the Building, the weight of the Satellite System is less than one hundred fifty (150) pounds and does not impair the structural integrity of the roof. The installation and operation of the Satellite System shall be at Tenant’s sole cost and expense. Prior to the installation of the Satellite System, Tenant shall obtain Landlord’s prior approval, which will not be unreasonably withheld, delayed or conditioned, of the location, type and method of installation of the Satellite System. Landlord may condition its approval on Tenant’s ensuring that such installation or the maintenance of the Satellite System does not invalidate any roof warranties in favor of Landlord. Tenant agrees to hire a roofing contractor approved by Landlord for all penetrations, attachments or other work to the roof. Tenant shall, at its sole cost and expense, comply with all applicable Legal Requirements, including but not limited to securing all necessary permits for the installation and operation of the Satellite System. Tenant shall be solely responsible for the maintenance of the Satellite System. Tenant shall be responsible for liability and property insurance for the Satellite System consistent with the requirements of this Lease. In the event the Satellite System causes interference to equipment used by Landlord, Tenant shall use reasonable efforts, and shall cooperate with Landlord to promptly eliminate such interference. Tenant shall, upon the expiration or termination of this Lease, at its sole cost and expense, remove the Satellite System and repair any damage to the roof or other parts of the Building caused by such removal and return that portion of the roof of the Building that has been affected by the Satellite System to the condition it was in prior to the installation of the Satellite System, normal wear and tear and casualty excepted. Landlord shall not charge Tenant for the use of the roof space for the Satellite System.

 

45.           Broker. Landlord and Tenant each represent and warrant that it has dealt with no broker, agent or other person in connection with this Lease other than ESRP Advisory Dallas, LLC (“Broker”) and each party agrees to indemnify and hold the other party harmless from and against any claims by any other broker, agent or other persons claiming a commission or other form of compensation by virtue of having dealt with the party other than Broker with regard to this leasing transaction. Landlord covenants and agrees to pay the lease commissions due to Broker for services performed in connection with this Lease pursuant to the written lease commission agreement between Landlord and Broker.

 

46.          Authoritv. Landlord and Tenant each represent and warrant to the other that such party is duly organized, validly existing, and in good standing under the laws of the state of its organization, and is duly qualified to transact business in Texas.

 

4 7.         Counterparts. This Lease may be executed in separate counterparts, each such counterpart being deemed an original, and all of which taken together shall constitute one and the same instrument.

 

48.           OFAC. Tenant represents and warrants to Landlord that Tenant is currently in compliance with and shall at times during the Term (including any extension thereof) remain in compliance with the OFAC regulations of the Department of the Treasury (including those named on OFAC’s Specially Designated and Blocked Persons List) and any statute, executive order (including the September 24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism), or other governmental action relating thereto.

 

38

 

 

49.           Force Majeure. Neither party shall be held responsible for delays in the performance of its obligations hereunder when caused by acts of terrorists, war (whether declared or not) or national conflicts; strikes, lockouts, labor disputes, boycotts or work stoppages not caused by or limited to such party, or its contractors or subcontractors; natural disasters, such as earthquake, hurricane or flood; governmental restrictions, regulations or controls; or delay in obtaining or inability to obtain labor, materials or reasonable substitutes therefor, any of which (a) could not reasonably have been anticipated by such party; (b) is beyond the reasonable control of such party; and (c) could not be prevented or overcome, wholly or in part, by the exercise of due diligence by such party (“Force Majeure”), provided that this shall not apply (i) to excuse any failure of either party to comply with any monetary obligations hereunder.

 

50.           Calculation of Charges. Landlord and Tenant are knowledgeable and experienced in commercial transactions and agree that each provision of this Lease for determining charges, amounts and additional rental payments by Tenant are commercially reasonable, and as to each such charge or amount, constitutes a “method by which the charge is to be computed” for purposes of Section 93.012 (Assessment of Charges) of the Texas Property Code, as such section now exists or as it may be hereafter amended or succeeded, even though such methods may not state a precise mathematical formula for determining such charges. ACCORDINGLY, TENANT VOLUNTARILY AND KNOWINGLY WAIVES ALL RIGHTS AND BENEFITS OF TENANT UNDER SECTION 93.012 OF THE TEXAS PROPERTY CODE; provided, however, that nothing contained in this waiver however is intended to limit or impair, except as otherwise expressly set forth in this Lease to the contrary, any other remedy available to Tenant under this Lease or at law or in equity (other than Section 93.012, Texas Property Code). In addition, nothing in this Paragraph 50 shall constitute a waiver of Tenant’s right to dispute and/or initiate a claim disputing Landlord’s methods of calculating or determining amounts owed by Tenant hereunder and/or Landlord’s calculation or determination of Additional Rent.

 

[Signature page follows.]

 

39

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Lease as of the day and year first above set forth.

   
  LANDLORD:
   
  KCP NNN II LEASEHOLD 4, LLC,
  a Delaware limited liability company
   
  By: /s/ Daniel Ades              
  Name: Daniel Ades
  Title: Chief Executive Officer

 

  TENANT:
   
  CARIS MPI, INC.,
  a Texas corporation
   
  By: /s/ David D. Halbert
  Name: David D. Halbert
  Title: CEO

 

[Signature Page to Lease]

 

 

 

EXHIBIT l(a)

 

LEGAL DESCRIPTION

  

 

 

EXHIBIT 2(a)

 

PERMITTED EXCEPTIONS

 

 

 

EXHIBIT 2(b)

 

WORK LETTER

 

THIS WORK LETTER (this “Work Letter”) is attached to and made a part of the Lease dated July___, 2019 (the “Lease”), by and between KCP NNN II LEASEHOLD 4, LLC, a Delaware limited liability company (“Landlord”), and CARIS MPI, INC., a Texas corporation (“Tenant”), for the Premises described in the Lease. Capitalized terms used but not otherwise defined in this Work Letter shall have the meanings set forth in the Lease. This Work Letter is attached to, and forms a part of, the Lease. Should any inconsistency arise between this Work Letter and any other provision of the Lease as to the specific matters which are the subject of this Work Letter, the terms and conditions of this Exhibit shall control. Time is of the essence of this Work Letter.

 

  1.          Acceptance of Premises. Except as set forth in the Lease or this Work Letter, Tenant accepts the Premises in their AS-IS condition on the Effective Date.

 

  2.          Tenant Improvements. This Work Letter sets forth the agreement with respect to the construction of the Tenant Improvements (as defined below). All improvements to the Premises and/or the Building constructed by Tenant pursuant to this Work Letter are referred to herein collectively as the “Tenant Improvements.” The terms, definitions and other provisions of the Lease are hereby incorporated into this Work Letter by reference. In accordance with the provisions of this Work Letter, Tenant will construct and install the Tenant Improvements in the Premises in accordance with the Final Plans (defined below), at Tenant’s sole cost and expense, subject to payment of the Allowance pursuant to the terms and conditions herein. Tenant shall diligently pursue the completion of such Tenant Improvements pursuant to the terms and conditions of this Work Letter. Tenant anticipates completing the Tenant Improvements and occupying the Premises in accordance with the following timeline:

 

Phase Location Anticipated Occupancy Date
Phase I Approx.  57,250  square  feet  of  the Building On or about August 1, 2020
Phase II Approx.  28,625  square  feet  of  the Building On or about April 1, 2022
Phase III Approx.  28,625  square  feet  of  the Building On or about April 1, 2023

 

Each of Phase I, Phase II and Phase III described above may be referred to herein as a “Phase” and collectively as “Phases”. Tenant shall have no liability in the event of a failure to meet all or any of the foregoing anticipated occupancy dates, each of the same being an estimate only. Tenant may, in its sole discretion, accelerate the occupancy date of a Phase without Landlord’s prior written consent. Tenant shall not materially modify the size of the Phases without Landlord’s prior written consent, which consent shall not be unreasonably delayed, conditioned or withheld, provided, however, no such modification nor the failure to meet all or any of the anticipated occupancy dates shall affect Tenant’s obligation to pay Basic Rent or Additional Rent as and when required by the Lease.

 

 

 

  3.          Plans and Specifications; Permits. It is agreed that Tenant will develop plans and necessary specifications for completion of the Tenant Improvements in accordance with this Work Letter and the following provisions and procedures:

 

(a)      No later than one hundred (100) days after the Effective Date with respect to Phase I and, with respect to the other Phases, no later than one hundred fifty (150) days prior to the anticipated construction start date for such Phase, Tenant shall submit or cause Tenant’s architect to submit to Landlord, for Landlord’s review and approval, a space plan for the applicable Phase (the “Space Plan”), showing the final layout for such Phase, including without limitation, all exterior improvements, walls, corridors, entrances, exits, doors and interior partitions, and the locations of all kitchens, beverage and dining areas, reception area(s), and other areas required for Tenant’s occupancy, in sufficient form to serve as the basis for the Construction Drawings for such Phase. Within ten (10) Business Days after Landlord receives the Space Plan, Landlord shall either approve or not approve the Space Plan based on the following matters (individually, a “Design Issue” and, collectively, the “Design Issues”): (i) adverse effect on or incompatibility with the Building Structure or Building Systems; (ii) effect on the exterior appearance of the Building or other exterior portions of the Premises, (iii) conflict, inconsistency or incompatibility with the base building design, (iv) non-compliance with applicable Legal Requirements, or (v) omissions or other missing or incomplete information. If Landlord does not approve such Space Plan, Landlord shall provide Tenant with specific written comments detailing the reasons Landlord denied approval. Tenant shall cause such Space Plan to be revised to address Landlord’s comments, and shall resubmit same for Landlord’s review and approval in accordance with this Section (except that the time period for Landlord’s response shall be three (3) Business Days for subsequent submissions). This procedure shall be repeated until the Space Plan is finally approved by Landlord and written approval has been delivered to and received by Tenant (such date, as applicable, the “Space Plan Approval Date”).

 

(b)     No later than seventy-five (75) days after each Space Plan Approval Date, Tenant shall prepare or cause Tenant’s architect to prepare (based on the Space Plan for such Phase as finally approved by Tenant and Landlord) and deliver to Landlord written drawings, plans and specifications for the construction of the Tenant Improvements in such Phase (collectively, the “Construction Drawings”). The Construction Drawings for each Phase shall include, without limitation, (i) fully dimensioned architectural plans; (ii) reflective ceiling plan with light switches; (iii) electric power circuitry diagram; (iv) complete structural (if required), mechanical, electrical, plumbing, HVAC, telecommunication and cabling plans; (v) color and finish selections; and (vi) all such other information or plans as may be required for the construction of the Tenant Improvements in such Phase. Tenant’s architect shall consult with Landlord’s architect, Landlord’s engineer(s) and other Building design professionals designated by Landlord in the preparation of the Construction Drawings with respect to the Building Structure and Building Systems. The Construction Drawings shall be in form and content sufficient for submission to the applicable governmental authority, to obtain all necessary building permits for completion of the Tenant Improvements contemplated therein. Within ten (10) Business Days after Landlord receives the Construction Drawings for a Phase, Landlord shall either approve or not approve such Construction Drawings based on the Design Issues. If Landlord does not approve the Construction Drawings, Landlord shall provide Tenant with specific written comments detailing the reasons Landlord denied approval. Tenant shall cause the Construction Drawings to be revised to address Landlord’s comments and shall resubmit same for Landlord’s review and approval in accordance with this Section within ten (10) Business Days of receiving Landlord’s written comments, except that the time period for Landlord’s response shall be three (3) Business Days for subsequent submissions. This procedure shall be repeated until the Construction Drawings for a Phase are finally approved by Landlord and written approval has been delivered to and received by Tenant, whereupon such approved Construction Drawings shall become the “Final Construction Drawings” for such Phase.

 

 

 

(c)      Tenant acknowledges and agrees that Tenant is solely responsible for obtaining, and shall work promptly and diligently to obtain, the building permit from the applicable governmental authority and all other permits from any other governmental authority as may be required in connection with the construction and performance of the Tenant Improvements. Promptly after Tenant receives Landlord’s approval of the Final Construction Drawings for a Phase, Tenant shall submit such approved Final Construction Drawings to the applicable governmental authorities and, if required pursuant to any applicable Legal Requirements, to all other governmental authorities having jurisdiction over the Premises for approval and the issuance of the Building Permit (as defined below). Tenant shall promptly notify Landlord of any changes to the Final Construction Drawings required by such governmental authorities and Landlord shall have the same approval rights (as set forth in Section 3(a) and Section 3(b)) with respect to any such changes to the extent they raise a Design Issue. Each building permit for the construction and installation of the Tenant Improvements in a Phase shall be referred to herein as a “Building Permit” and the date such Building Permit is issued by the applicable governmental authority shall be referred to herein as a “Building Permit Date.” Copies of the Building Permit and any other governmental approvals or permits obtained by Tenant in connection with the Tenant Improvements shall be delivered to Landlord promptly after Tenant’s receipt of the same. The Final Construction Drawings for a Phase as approved by Landlord and all applicable governmental authorities shall be referred to herein as the “Final Plans” for such Phase. Tenant must submit to Landlord one (1) complete set of the Final Plans for such Phase prior to commencing construction of the Tenant Improvements for such Phase.

 

(d)     If Landlord and Tenant cannot agree on final Space Plans or Construction Drawings for a Phase within forty (40) days after Tenant’s initial submission thereof to Landlord, then any such dispute shall be resolved by the following process: Landlord and Tenant shall have a period of ten (10) days from the request of either party to mutually agree on a reputable and qualified independent architect that must have at least ten (10) years of experience with work similar to the Tenant Improvements, to resolve such dispute. If the parties fail to agree, then each of Tenant and Landlord shall have an additional five (5) days to select an architect meeting the same minimum qualifications set forth above, and the two (2) architects selected shall select a third architect who shall resolve the dispute in question. If either of Landlord or Tenant fail to make its respective selection of an architect within the additional 5-day period provided for above, then the remaining party’s selection shall be the expert who shall resolve the dispute in question. Once the architect has been selected in accordance with this provision, the architect shall render a decision on the dispute as soon as reasonably possible, but in any event within a period of fifteen (15) days.

 

 

 

  4.           General Contractor; Subcontractors and Budget.

 

(a)     Tenant shall select one or more qualified general contractors to perform the installation of each Phase of the Tenant Improvements, subject to Landlord’s prior written approval, which approval shall not be unreasonably withheld, conditioned, or delayed (each, a “General Contractor”). Tenant represents that Tenant intends to conduct a competitive bid process to select the General Contractor for the Tenant Improvements for each Phase in accordance with customary construction practices or Tenant shall select a General Contractor for such Phase based on a negotiated fee, which General Contractor shall be required to competitively bid all major subcontracts. Tenant shall enter into a construction contract for the construction and installation of the Tenant Improvements for a Phase with the applicable General Contractor (each, a “GC Agreement”), which GC Agreement shall (i) require progress payments no more frequently than monthly, (ii) include a detailed construction schedule for the performance and completion of such Tenant Improvements, (iii) include retainage of ten percent (10%) until final completion of such Tenant Improvements for the applicable Phase, (iv) include the General Contractor’s agreement to attend any Landlord and Tenant construction meetings, and (v) provide from the General Contractor in favor of Tenant and Landlord, a customary warranty of the Tenant Improvements in such Phase for a period of at least one (1) year from the date of substantial completion of such Tenant Improvements. A true, correct and complete copy of the GC Agreement with each General Contractor, and all amendments thereto, will be provided to Landlord. Tenant acknowledges and agrees that the Tenant Improvements shall be constructed and installed only by parties holding all appropriate licenses as required by applicable Legal Requirements.

 

(b)     Tenant shall also furnish to Landlord a roster identifying all subcontractors performing any of the Tenant Improvements, which, upon Landlord’s request, shall be updated from time to time to add any new subcontractors performing the Tenant Improvements. All subcontractors performing work that impacts the Building Systems, Building Structure, Building exteriors, or areas outside the Building shall be subject to Landlord’s prior written approval (prior to selection), which shall not be unreasonably withheld, conditioned, or delayed.

 

(c)      No later than thirty (30) days after completion of the Final Construction Drawings for a Phase, Tenant shall provide Landlord with a detailed budget for the Tenant Improvements in such Phase, showing all Tenant Improvement Costs for such Phase (the “Construction Budget”). The Construction Budget for each Phase shall be certified, to the best of Tenant’s knowledge, as the final, accurate and complete budget for the Tenant Improvement Costs for such Phase. Tenant acknowledges that Tenant is obligated to pay the Tenant Improvement Costs (subject to the Allowance).

 

(d)      Upon the issuance of all necessary building permits and governmental approvals for the Tenant Improvements in each Phase, Tenant shall diligently pursue the completion of such Tenant Improvements pursuant to the terms and conditions of this Work Letter. Tenant shall use commercially reasonable efforts to cause the Tenant Improvements for the entire Premises to be completed in accordance with the Final Construction Drawings within six (6) years following the Effective Date, subject to extension for force majeure as set forth in the GC Agreement and provided no Event of Default by Landlord exists under the Lease (including this Work Letter) that affects the Tenant Improvements beyond applicable notice and cure periods.

 

 

 

  5.           Allowance.

 

(a)      Landlord will provide Tenant with an allowance of $6,940,000.00 (the “Allowance”) as a credit against the Tenant Improvement Costs, which Allowance shall be allocated as follows: $3,575,000.00 to Phase I, $1,717,500.00 to Phase II, and $1,647,500.00 to Phase III (each such amount, a “Phase Cap”). “Tenant Improvement Costs” means, collectively, all the actual costs of designing, engineering, permitting (including impact fees), and constructing the Tenant Improvements in accordance with the Final Plans (as amended by all Change Orders, as hereafter defined) and all other hard and soft costs associated with the preparation of the Premises for Tenant’s use and occupancy, including Tenant’s costs for design, architectural, and engineering consultants; all costs associated with the installation and completion of the Tenant Improvements; all conduit, cabling and wiring for Tenant’s telecommunications, computer and/or data systems; and all other furnishings, :fixtures and equipment permanently attached and made a part of the Premises required for Tenant’s use and occupancy of the Premises. Notwithstanding anything herein to the contrary, in no event shall the Allowance be used for the purchase of Tenant’s Property, other than conduit, cabling and wiring for Tenant’s telecommunications, computer and data systems in the Premises. If the Tenant Improvement Costs exceed the Allowance, Tenant will be solely responsible for and pay the full amount of such excess costs as and when due. In addition, Tenant shall pay to Landlord, within thirty (30) days after receipt of Landlord’s written demand therefor, a construction management and oversight fee equal to One and 50/100 Percent (1.50%) of the hard costs component of the total Tenant Improvement Costs for a Phase to compensate Landlord for reviewing the plans for the Tenant Improvements for such Phase, reviewing and processing Allowance Requests, and for costs incurred by Landlord in facilitating Tenant’s completion of the Tenant Improvements for such Phase. Landlord reserves the right to deduct such fee from the Allowance.

 

 

 

(b)      Provided no Event of Default by Tenant exists under the Lease (including this Work Letter) beyond applicable notice and cure periods, then commencing after the Building Permit Date for a Phase, Landlord shall pay to Tenant the Allowance (or so much thereof as is necessary to cover the Tenant Improvement Costs for such Phase, subject to the applicable Phase Cap), less a ten percent (10%) retainage (which retainage shall be payable as part of the final draw for each Phase hereunder), in periodic disbursements pursuant to the terms and conditions set forth in this Section. For each of the periodic disbursements (individually and collectively, as applicable, an “Allowance Request”), Tenant shall deliver to Landlord the following documentation: (i) a request to disburse from Tenant containing an approval by Tenant of the work done and a good faith estimate of the cost and time to complete the Tenant Improvements for such Phase; (ii) a copy of the application and certificate for payment in the form of AIA documents G702 and G703 signed by the General Contractor and Tenant’s architect submitted for all work for which disbursement is to be made to a date specified therein (or other invoice in the case of invoices for architecture or engineering fees or materials to be incorporated into the Tenant Improvements); (iii) from the General Contractor, any contractor under a direct contract with Tenant, and any subcontractor or material supplier that provided services or materials in the completion of the Tenant Improvements for which the Allowance Request is being made, a statutorily compliant conditional waiver and release on progress payment for the requested disbursement (conditioned only on the payment of the requested disbursement) and from the General Contractor, any contractor under a direct contract with Tenant, and any subcontractor or material supplier that provided services or materials in the completion of the Tenant Improvements for which the immediately prior Allowance Request was made, a statutorily compliant unconditional waiver and release on progress payment for the previously requested disbursement; (iv) copies of paid invoices, paid receipts and other reasonably satisfactory evidence of payment from the General Contractor, major subcontractors/material suppliers; and (v) such other supporting data, documents or information as Landlord or Mortgagee may reasonably require. Upon substantial completion of the Tenant Improvements for a Phase, Tenant shall submit to Landlord a written request for the final disbursement of the Allowance for such Phase (each, a “Final Request”), together with the following documentation: (1) reasonable evidence of substantial completion of the Tenant Improvements for such Phase; (2) a Certificate of Occupancy or local equivalent for such Phase, or if not available because of the Phase nature of the Tenant Improvements, then evidence of final approval for such Phase issued by the City of Irving authorizing Tenant’s use of such portion of the Building; (3) a certificate of completion in form and substance reasonably satisfactory to Landlord from Tenant’s architect certifying that completion of the Tenant Improvements has been achieved, and to Tenant’s architect’s knowledge, the same were completed in accordance with all applicable Legal Requirements and substantially in accordance with the Final Plans (including all Change Orders), (4) from the General Contractor, any contractor under a direct contract with Tenant, and any subcontractor or material supplier that provided services or materials in the completion of the Tenant Improvements for which the Final Request is being made, a statutorily compliant conditional final waiver and release on progress payment for the requested disbursement (conditioned only on the payment of the requested disbursement) and, within ten (10) Business Days after the Final Request disbursement was made, from the General Contractor, any contractor under a direct contract with Tenant, and any subcontractor or material supplier that provided services or materials in the completion of the Tenant Improvements for which such Final Request was made, a statutorily compliant final and unconditional waiver and release for such Final Request, (5) two sets of copies of detailed as-built plans of the Tenant Improvements for such Phase, and (6) copies of all such invoices, contracts, or other supporting data as Landlord or Mortgagee may reasonably require. As used herein “substantial completion,” “substantially completed,” and any derivations thereof mean the Tenant Improvements in the applicable Phase are substantially completed and a Certificate of Occupancy or local equivalent for such Phase has been issued, or if not available because of the Phase nature of the Tenant Improvements, then evidence of final approval for such Phase issued by the City of Irving authorizing Tenant’s use of such Phase of the Building. Substantial completion shall have occurred even though minor details of construction, decoration, and mechanical adjustments remain to be completed.

 

 

 

(c)      Provided Tenant shall have complied with the provisions of this Section and there is no uncured Event of Default under the Lease, then within forty (40) days after Landlord’s receipt of an Allowance Request or the Final Request, as the case may be, together with the accompanying documentation required herein, Landlord shall pay to Tenant the amount shown on such Allowance Request or Final Request (less a ten (10%) retainage for each Allowance Request). In no event shall Landlord be required to disburse the Allowance for a Phase (i) before the Building Permit Date for such Phase, (ii) more than one time per month, (iii) when an uncured Event of Default exists under the Lease, or (iv) in excess of the Phase Cap for such Phase.

 

(d)     In the event the Tenant Improvement Costs are less than the Allowance or Tenant does not otherwise use the entire Allowance by seventy-two (72) months following the Effective Date, then any such unused portion of the Allowance shall be applied to Basic Rent next coming due under the Lease until the entire unused portion has been disbursed.

 

  6.           Construction of the Improvements; Change Orders.

 

(a)     The Tenant Improvements shall be completed in a good and workmanlike manner, free of liens and in compliance with the Final Plans (including any Change Orders) and all applicable Legal Requirements.

 

(b)     Tenant will abide by the provisions of the Lease with regard to mechanic’s or construction liens relating to the Tenant Improvements.

 

(c)     Any damage to the Premises to the extent caused by Tenant, its contractors, subcontractors or agents must be promptly repaired by Tenant, at its expense.

 

(d)     Tenant shall have the ability to request and authorize changes to the Tenant Improvements during construction. If Tenant requires or desires any changes that deviate from the Final Construction Drawings, after same have been approved by each of Landlord and Tenant, Tenant shall request such change in writing to Landlord and such request will be accompanied by (i) all plans and specifications if necessary to show and explain the changes from the approved Final Construction Drawings, and (ii) a change order setting forth any cost (including associated architectural and engineering fees) or savings and any potential incompatibility with or impact on the exterior of the Premises, base building, Building Structure, or Building Systems, in each case associated with the proposed change. Within five (5) Business Days after Landlord receives Tenant’s proposed change(s) and all required supporting information, Landlord in its reasonable judgment shall either approve or not approve such change(s) based on the Design Issues. If Landlord does not approve such changes, Landlord shall provide Tenant with specific written comments detailing the reasons Landlord denied approval. If Landlord does not approve Tenant’s proposed change(s), Tenant shall either withdraw the proposed change(s) or cause the proposed change order (and related plans and specifications) to be adjusted in order to address Landlord’s comments, and shall resubmit same for Landlord’s review and approval in accordance with this Section (including the time period for Landlord’s response, which shall be three (3) Business Days). Unless Tenant withdraws the proposed change, this procedure shall be repeated until the proposed change is finally approved by Landlord and written approval has been delivered to and received by Tenant, whereupon Tenant shall cause Tenant’s architect and the General Contractor to document the proposed change through a final change order (each a “Change Order” and, collectively, “Change Orders”), which Change Order(s) shall include a revised Construction Budget and become part of the Final Plans. Notwithstanding anything in this Section 6(d) to the contrary, Landlord’s approval shall not be required for Change Orders that do not raise any Design Issues, provided that (i) the net increase in the Construction Budget for the applicable Phase resulting from all such Change Orders does not exceed (in the aggregate) two percent (2%) of the Tenant Improvement Costs for such Phase, and (ii) Tenant provides Landlord with prior written notice of each such Change Order indicating that it is a Change Order permitted without Landlord’s approval under this Work Letter, which notice shall include a copy of such Change Order.

 

 

 

  7.           Insurance. The General Contractor and Tenant’s other contractors must obtain and keep in force throughout their performance of the applicable Tenant Improvements the following insurance in the following minimum amounts: (i) Commercial General Liability Insurance on a primary basis and without any right of contribution from any insurance carried by Landlord covering the Premises on an occurrence basis against all claims for personal injury, bodily injury, death and property damage with a combined single limit of $5,000,000.00 for the General Contractor (which may be achieved through an umbrella or excess coverage policy), and $1,000,000.00 for other contractors; (ii) Workers’ Compensation in statutory required amounts and Employers’ Liability Insurance for an amount of not less than $1,000,000.00, both in accordance with the laws of the State of Texas; (iii) “Builder’s Risk” insurance or an equivalent form per industry standards, covering the full replacement value of the Tenant Improvements, and any such policy will contain a provision requiring the insurance carriers to waive their rights of subrogation against Landlord; (iv) in the event a motor vehicle is to be used by such contractor in connection with its business operations from the Premises, Comprehensive Automobile Liability Insurance coverage with limits of not less than $3,000,000.00 combined single limit coverage against bodily injury liability and property damage liability arising out of the use by or on behalf of such contractor, its agents and employees of any owned, non-owned or hired motor vehicles; and (v) such other insurance or coverages as Landlord or its lender reasonably requires. Prior to their entry into the Premises for the accomplishment of any work, Tenant shall furnish to Landlord all certificates of insurance for the insurance required herein, naming Landlord and Mortgagee as additional insureds or loss payees, as applicable.

 

  8.           Representatives. Tenant has designated Michael Halbert at tel. ### and email: ### as its sole representative with respect to the matters set forth in this Work Letter, who shall have full authority and responsibility to act on behalf of the Tenant as required in this Work Letter, until further written notice to Landlord. Landlord has designated (i) David Israel of PKV Investment Management at tel. ### and email: ### and (ii) Steve Jarvis of JLL at tel. ### and email: ###, as its sole representatives with respect to the matters set forth in this Work Letter, who shall have full authority and responsibility to act on behalf of the Landlord as required in this Work Letter, until further written notice to Tenant.

 

   9.           Landlord’s Role and Rights. Notwithstanding anything herein to the contrary, the parties acknowledge that neither Landlord nor its property manager is an architect or engineer, and that the Tenant Improvements will be designed and performed by independent architects, engineers and Tenant’s contractors engaged by Tenant. Landlord and its property manager have no responsibility for construction means, methods or techniques or safety precautions in connection with the Tenant Improvements and do not guarantee that the Final Plans or Tenant Improvements will be free from errors, omissions or defects, and have no liability therefor. Landlord’s review and approval of the Space Plan, Final Construction Drawings, Change Orders, or Final Plans, and Landlord’s designations, lists, recommendations or approvals concerning Tenant’s contractors are not a warranty, covenant or assurance as to the quality or adequacy thereof or of the Final Plans or the Tenant Improvements, or the design thereof, or of their compliance with Legal Requirements, or that the Final Construction Drawings are sufficient to enable Tenant’s contractor to obtain a building permit for the Tenant Improvements. Tenant will permit access to the Premises, and inspection of the Tenant Improvements by Landlord and Landlord’s architects, engineers, contractors and other representatives, with reasonable prior notice and at reasonable times during the period in which the Tenant Improvements are being planned, constructed and installed and following substantial completion of the Tenant Improvements. In the event Tenant fails to comply with the provisions of this Work Letter, in addition to all other rights and remedies of Landlord set forth in the Lease, Landlord shall have the right upon twenty-four (24) hours’ advance notice to Tenant (which may be oral and delivered to Tenant’s representative designated in Section 8 above, provided that such notice is also sent by email or other written form) to require Tenant to cease the Tenant Improvements until such time as Tenant is in full compliance with the provisions of this Work Letter. Landlord and Tenant agree to cooperate with each other and use commercially reasonable and good faith efforts at all times to facilitate the timely planning, performance and completion of the Tenant Improvements.

 

 

 

EXHIBIT 4(a)

 

RENEWAL OPTIONS

 

1st RENEWAL.      Provided that Tenant is not in default of any of the terms, covenants and conditions of the Lease beyond any applicable cure period as of the date of the Renewal Notice or as of the scheduled commencement date of the Renewal Term, at the expiration of the Initial Term Tenant shall have the right and option to extend the Term of this Lease for one (1) further term of sixty (60) months (the “Renewal Period”). Such extension of the Initial Term shall be on the same terms, covenants and conditions as provided for in the Initial Term except that (i) the Basic Rent during such Renewal Period shall be at the fair market rental in effect at the time of the commencement of the Renewal Period for equivalent properties, of equivalent size, in equivalent areas and appropriate consideration shall be given to the length of the renewal term, market escalations, the credit of Tenant, and concessions generally applicable to comparable renewal terms, including free rent, improvement allowances, and commissions (if any), amenities, common area factors, availability of parking and the charges therefor, building signage rights, and the quality, size, and location of the Building (the “Fair Market Rent”), provided, however, notwithstanding anything herein to the contrary, in no event shall the monthly Basic Rent payable during the Renewal Term be less than the Basic Rent payable during the last month of the Initial Term), and (ii) Landlord shall not be obligated to make any improvements or alterations in or to the Premises nor shall there be any improvement allowance, rental abatement or other tenant concessions provided by Landlord in connection with the Renewal Term notwithstanding the consideration of those items in determining the Fair Market Rent.

 

Tenant shall deliver written notice (the “Renewal Notice”) to Landlord of Tenant’s election to exercise the renewal option granted herein not more than eighteen (18) months nor less than fourteen (14) months prior to the expiration of the Initial Term. In the event Tenant fails to deliver a Renewal Notice within the time period set forth above, Tenant’s right to extend the term hereof shall expire and be of no further force and effect.

 

Landlord and Tenant shall negotiate in good faith to determine the Basic Rent for the Renewal Term for a period of thirty (30) days after the date on which Landlord receives the Renewal Notice. In the event Landlord and Tenant fail to agree in writing upon the Fair Market Rent within said 30-day period, Tenant may (upon written notice to Landlord within five (5) Business Days following the expiration of said 30-day period) waive its right to renew and rescind the Renewal Notice, or if Tenant fails to deliver such written notice within such five (5) Business Day Period, the Fair Market Rent shall be determined by the appraisal procedure set forth below:

 

■     Within ten (10) days of the expiration of the 30-day period, each party, by giving written notice to the other party, shall appoint an appraiser to render a written opinion of the Fair Market Rent for the Renewal Period. Each appraiser must be a member of the Appraisal Institute of America (MAI) for at least five years and with at least ten (10) years’ experience in the appraisal of rental rates of office properties in the area in which the Premises are located and otherwise unaffiliated with either Landlord or Tenant. The two appraisers shall render their written opinion of the Fair Market Rent for the Renewal Period to Landlord and Tenant within ten (10) days after the appointment of the second appraiser. If the Fair Market Rent of each appraiser is within five percent (5%) of each other, then the average of the two appraisals of Fair Market Rent shall be the Basic Rent for the Renewal Period (subject to the minimum rate defined in this renewal option). If one party does not appoint its appraiser as provided above, then the one appointed shall determine the Fair Market Rent. The Fair Market Rent so determined under this subparagraph shall be binding on Landlord and Tenant.

 

 

 

■     If the Fair Market Rent determined by the appraisers is more than five percent (5%) apart, then the two appraisers shall pick a third appraiser within ten (10) days after the two appraisers have rendered their opinions of Fair Market Rent as provided above. If the two appraisers are unable to agree on the third appraiser within said ten (10) day period, Landlord and Tenant shall mutually agree on a third appraiser within ten (10) days thereafter. The third appraiser shall be a person who has not previously acted in any capacity for either party and must meet the qualifications stated above.

 

■     Within ten (10) days after its appointment, the third appraiser shall render its written opinion of the Fair Market Rent for the Renewal Period (“Third Opinion”), and the Fair Market Rent for the Renewal Period shall be the appraisal of Fair Market Rent made by Landlord’s or Tenant’s appraiser that is closest to the Fair Market Rent specified in the Third Opinion (subject to the minimum rate defined in this renewal option). If the Fair Market Rent set forth in the Third Opinion is equidistant from the Fair Market Rent made by Landlord’s or Tenant’s appraiser, then the Fair Market Rent contained in the Third Opinion shall be the Basic Rent during the Renewal Period. The Fair Market Rent so determined under this subparagraph shall be binding on Landlord and Tenant.

 

■    Each party shall bear the cost of its own appraiser and, if applicable, one-half (1/2) the cost of the third appraiser.

 

After the Fair Market Rent for the Renewal Period has been established in accordance with the terms hereof, Landlord and Tenant shall promptly execute an amendment to this Lease to reflect the Basic Rent for the Renewal Period.

 

2nd RENEWAL.     Provided that Tenant is not in default of any of the terms, covenants and conditions of the Lease beyond any applicable cure period as of the date of the 2nd Renewal Notice or as of the scheduled commencement date of the 2nd Renewal Term and Tenant renewed the Lease following the Initial Term as set forth above, Tenant shall have the right and option to extend the Term for one (1) additional term of sixty (60) months beyond the expiration of the Renewal Period (the “2nd Renewal Period”). Such extension shall be on the same terms, covenants and conditions as provided for in the Renewal Period except that (i) the Basic Rent during the 2nd Renewal Period shall be at Fair Market Rent, provided, however, notwithstanding anything herein to the contrary, in no event shall the monthly Basic Rent payable during the 2nd Renewal Term be less than the Basic Rent payable during the last month of the Renewal Term) and (ii) Landlord shall not be obligated to make any improvements or alterations in or to the Premises nor shall there be any improvement allowance, rental abatement or other tenant concessions provided by Landlord in connection with the 2nd Renewal Term notwithstanding the consideration of those items in determining the Fair Market Rent.

 

 

 

Tenant shall deliver written notice (the “2nd Renewal Notice”) to Landlord of Tenant’s election to exercise the renewal option granted herein not more than eighteen (18) months nor less than fourteen (14) months prior to the expiration of Renewal Period. In the event Tenant fails to deliver the 2nd Renewal Notice within the time period set forth above, Tenant’s right to extend the Term for the 2nd Renewal Period shall expire and be of no further force and effect.

 

Landlord and Tenant shall negotiate in good faith to determine the Basic Rent for the 2nd Renewal Term for a period of thirty (30) days after the date on which Landlord receives the 2nd Renewal Notice. In the event Landlord and Tenant fail to agree in writing upon the Fair Market Rent within said 30-day period, Tenant may (upon written notice to Landlord within five (5) Business Days following the expiration of said 30-day period) waive its right to renew and rescind the Renewal Notice, or if Tenant fails to deliver such written notice within such five (5) Business Day Period, the Fair Market Rent shall be determined by the appraisal procedure set forth above.

 

After the Fair Market Rent for the 2nd Renewal Period has been established in accordance with the terms hereof, Landlord and Tenant shall promptly execute an amendment to this Lease to reflect the Basic Rent for the 2nd Renewal Period.

 

Tenant shall not have the right to renew the Lease for the Renewal Period or the 2nd Renewal Period for any amount of space less than the entire Premises under the Lease. Additionally, Tenant’s rights to renew the Lease for the Renewal Period or the 2nd Renewal Period are personal to Tenant and its Permitted Transferees.

 

 

 

EXHIBIT 5

 

BASIC RENT CHART

 

Phase

Location

Phase I

Approx. 57,250 square feet of the Building

Phase II

Approx. 28,625 square feet of the Building

Phase III Approx. 28,625 square feet of the Building

 

[Remainder of Page Intentionally Blank - Basic Rent Schedule Appears on Following Page]

 

 

 

 

Period  Phase I  Phase II  Phase III  Annual Basic Rent   Monthly Basic
Rent
 
Commencement Date - 6/30/2020  X        $0.00   $0.00 
7/1/2020 - 6/30/2021  X         1,116,375.00    93,031.25 
7/1/2021 - 6/30/2022  X  X      1,708,053.75    142,337.81 
7/1/2022 - 6/30/2023  X  X  X   2,322,953.10    193,579.43 
7/1/2023 - 6/30/2024  X  X  X   2,369,412.16    197,451.01 
7/1/2024 - 6/30/2025  X  X  X   2,416,800.41    201,400.03 
7/1/2025 - 6/30/2026  X  X  X   2,465,136.41    205,428.03 
7/1/2026 - 6/30/2027  X  X  X   2,514,439.14    209,536.60 
7/1/2027 - 6/30/2028  X  X  X   2,564,727.92    213,727.33 
7/1/2028 - 6/30/2029  X  X  X   2,616,022.48    218,001.87 
7/1/2029 - 6/30/2030  X  X  X   2,668,342.93    222,361.91 
7/1/2030 - 6/30/2031  X  X  X   2,721,709.79    226,809.15 
7/1/2031 - 6/30/2032  X  X  X   2,776,143.99    231,345.33 
7/1/2032 - 6/30/2033  X  X  X   2,831,666.87    235,972.24 
7/1/2033 - 6/30/2034  X  X  X   2,888,300.20    240,691.68 
7/1/2034 - 6/30/2035  X  X  X   2,946,066.21    245,505.52 

 

 

 

 

EXHIBIT 23

 

FORM OF SNDA

 

[see following page]

 

 

 

RETURN TO:

 

Citibank, N.A.

388 Greenwich Street, 6th Floor

New York, NY 10013

Attn: Ana Rosu Marmann

 

SUBORDINATION, NON-DISTURBANCE AND ATTORNMENT AGREEMENT

 

THIS SUBORDINATION, NON-DISTURBANCE AND ATTORNMENT AGREEMENT (hereinafter referred to as “Agreement”) made as of the __ day of July, 2019, among CITIBANK, N.A., a national banking association, as administrative agent (in such capacity, together with its successors, assigns, designees and/or nominees, collectively hereinafter referred to as “Administrative Agent”) for the Lenders (defined below), CARIS MPI, INC., a Texas corporation (hereinafter referred to as “Tenant”), and KCP NNN II LEASEHOLD 4, LLC, a Delaware limited liability company (hereinafter referred to as “Landlord”).

 

RECITALS:

 

A.           Tenant is the tenant and lessee under a certain Lease dated July __, 2019 (as the same may now or hereafter be amended, restated, replaced or otherwise modified, collectively, the “Lease”) relating to the premises described in the Lease (hereinafter referred to as the “Premises”), located at the real property more particularly described on Exhibit A attached hereto (hereinafter referred to as the “Property”).

 

B.            Certain lenders (the “Lenders”) have made or are making one or more loans (collectively, the “Loan”), which such Loan is (i) secured by a deed of trust, mortgage or security deed (as the same may be amended, restated, extended, or otherwise modified from time to time, the “Mortgage”) and an assignment of leases and rents (as the same may be amended, restated, extended, or otherwise modified from time to time, the “Assignment of Leases”), in each case, from Landlord to Lender covering the Property including the Premises, and (ii) evidenced by certain other documents and instruments by and among Lender and Landlord, among others (the same, together with the Mortgage and Assignment of Leases, collectively, the “Loan Documents”).

 

C.            Tenant has agreed that the Lease shall be subject and subordinate to the Loan and Loan Documents, provided Tenant is assured of continued occupancy of the Premises under the terms of the Lease.

 

NOW, THEREFORE, for and in consideration of the mutual covenants herein contained, the sum of Ten Dollars ($10.00) and other good and valuable considerations, the receipt and sufficiency of which are hereby acknowledged, and notwithstanding anything in the Lease to the contrary, it is hereby agreed as follows:

 

 

 

 

1.             Subordination and Consent. Subject to Section 2 below, Administrative Agent, Tenant and Landlord do hereby covenant and agree that the Lease with all rights, options, liens and charges created thereby (including, without limitation, any option or rights contained in the Lease, or otherwise existing, to acquire any or all of the Premises, or any superior leasehold interest therein), is and shall continue to be subject and subordinate in all respects to the lien and terms of the Loan Documents, and to any renewals, modifications, consolidations, replacements and extensions thereof and to all advances made thereunder. Tenant acknowledges that Landlord will execute and deliver to Administrative Agent an assignment of the Lease as security for the Loan, and Tenant hereby expressly consents to such assignment. Tenant agrees that if there is a default by Landlord in the performance and observance of any of the terms of such Loan, Administrative Agent may, at its option, demand all rents due under the Lease be paid by Tenant directly to Administrative Agent on behalf of the Lenders at the address specified below, or as otherwise specified by Administrative Agent. Tenant agrees that upon Tenant’s receipt of Administrative Agent’s written request for payment of rent directly to Administrative Agent on behalf of the Lenders, Tenant will thereafter timely remit any and all payments due under the Lease directly to, and payable to the order of, Administrative Agent on behalf of the Lenders. Such payments to Administrative Agent on behalf of the Lenders will constitute performance of Tenant’s payment obligations under the Lease and Landlord hereby agrees that Tenant shall receive credit against rent due under the Lease for any such payments made to Administrative Agent.

 

2.            Non-Disturbance. Administrative Agent does hereby agree with Tenant that, in the event Administrative Agent succeeds to Landlord’s interest in the Premises by foreclosure, conveyance in lieu of foreclosure or otherwise, so long as Tenant complies with and performs its obligations under the Lease, (a) the Lease shall continue in full force and effect as a direct Lease between Administrative Agent and Tenant, upon and subject to all of the terms, covenants and conditions of the Lease, for the balance of the term of the Lease and any renewals thereof, and Administrative Agent will not disturb the possession of Tenant, (b) Tenant’s occupancy and possession of the Premises and Tenant’s other rights and privileges under the Lease, including, without limitation, the use and distribution of insurance and condemnation proceeds as set forth in the Lease, shall not be disturbed or interfered with by Administrative Agent (1) in the exercise of any of its foreclosure or other rights under the Mortgage, (2) by any conveyance in lieu of foreclosure, or (3) by any other action taken by Administrative Agent during the term of the Lease and any renewals thereof, except in each case as may be permitted as by a successor Landlord in accordance with the terms of the Lease, and ( c) the Premises shall be subject to the Lease and Administrative Agent shall recognize Tenant as the tenant of the Premises for the remainder of the term of the Lease (including any renewals thereof) in accordance with the provisions thereof; provided, however, that Administrative Agent shall not be:

 

(i)              subject to any claims, offsets or defenses which Tenant might have against any prior landlord (including Landlord), except for offset rights expressly provided for in the Lease and for which Administrative Agent received written notice of the matter giving rise to such offset and was afforded the opportunity to cure as required by this Agreement;

 

 

 

(ii)             liable for any act or omission of any prior landlord (including Landlord), except acts or omissions that are continuing at the time of attornment of which Administrative Agent received written notice and was afforded the opportunity to cure as required by this Agreement;

 

(iii)            bound by any rent or additional rent which Tenant might have paid more than one (1) month in advance or any security deposit (which has not, as such, been transferred to Administrative Agent) or other prepaid charge paid to any prior landlord (including Landlord);

 

(iv)            bound by any amendment or modification of the Lease as to (a) any reduction in the term of the Lease, (b) any reduction in the rent payable under the Lease, or (c) a material reduction of the obligations of Tenant or a material increase of the obligations of Landlord under the Lease, unless Administrative Agent has approved or consented to such amendment or modification in writing;

 

(v)             liable for any deposit that Tenant may have given to any previous landlord (including Landlord) which has not, as such, been transferred to Administrative Agent; or

 

(vi)            obligated to reimburse Tenant for the cost of any Tenant Improvements constructed by or on behalf of Tenant in accordance with the Work Letter; provided, however, following Administrative Agent’s succession to Landlord’s interest in the Premises by foreclosure, conveyance in lieu of foreclosure or otherwise, if Administrative Agent fails to pay to Tenant any installment of the Allowance when due pursuant to the Work Letter, then, provided that Tenant has satisfied all of the requirements set forth in the Work Letter with respect to such disbursement of the Allowance, Tenant shall be entitled to offset against Rent next becoming due under the Lease the amount of the installment then due until such amount has been fully offset.

 

Except to the extent required under applicable law or in order for Administrative Agent to avail itself and the Lenders of and complete the foreclosure or other remedy, and provided that such complaint or action does not seek termination of Tenant’s interest and estate under the Lease, Administrative Agent shall not name Tenant in any foreclosure or other action or proceeding initiated by Administrative Agent pursuant to the Loan Documents. Tenant acknowledges and agrees that it has no right or option of any nature whatsoever, whether pursuant to the Lease or otherwise, to purchase the Premises or the Property, or any portion thereof or any interest therein, and to the extent that Tenant has had, or hereafter acquires, any such right or option, the same is hereby acknowledged to be subject and subordinate to the lien and terms of the Loan Documents and is hereby waived and released as against Administrative Agent and the Lenders.

 

3.             Attornment. Tenant does hereby agree with Administrative Agent that, in the event Administrative Agent becomes the owner of the Property by foreclosure, conveyance in lieu of foreclosure or otherwise, then the Lease shall continue as a direct Lease between Tenant and Administrative Agent upon all of the terms, covenants, conditions and agreements set forth in the Lease and this Agreement, and Tenant shall attorn to and recognize Administrative Agent as the landlord under the Lease, and shall perform and observe Tenant’s obligations thereunder, for the remainder of the term thereof. Tenant further covenants and agrees to execute and deliver upon request of Administrative Agent an agreement of attornment reasonably acceptable to Administrative Agent or any subsequent titleholder of the Premises, which agreement shall include non-disturbance provisions reasonably acceptable to Tenant. This Agreement, when fully executed, delivered and recorded, satisfies the requirement in Section 23 of the Lease relating to the grant of a non-disturbance agreement with respect to the Mortgage.

 

 

 

4.            Lease Defaults. In the event Landlord shall fail to perform or observe any of the terms, conditions or agreements in the Lease, Tenant shall give written notice thereof to Administrative Agent and Administrative Agent shall have the right (but not the obligation) to cure such default. Other than as provided in Section 36(b) of the Lease, Tenant shall not take any action with respect to such default under the Lease, including without limitation any action in order to terminate, rescind or avoid the Lease or to withhold any rent or other monetary obligations thereunder, for a period equal to the greater of (a) the period of time afforded Landlord under the Lease to cure or remedy such default or (b) thirty (30) days following receipt of such written notice by Administrative Agent; provided, however, that in the case of any default which cannot with diligence be cured within said period, if Administrative Agent shall proceed promptly to cure such default and thereafter prosecute the curing of such default with diligence and continuity, the time within which such default may be cured shall be extended for such period as may be necessary to complete the curing of such default with diligence and continuity, not to exceed one hundred eighty (180) days in the aggregate. 

 

5.            Obligations and Liability of Administrative Agent. Administrative Agent shall have no obligations nor incur any liability with respect to any warranties of any nature whatsoever, whether pursuant to the Lease or otherwise, including, without limitation, any warranties respecting use, compliance with zoning, hazardous wastes or environmental laws, Landlord’s title, Landlord’s authority, habitability, fitness for purpose or possession. Furthermore, in the event that Administrative Agent shall acquire Landlord’s interest in the Property, Administrative Agent shall have no obligation, nor incur any liability, beyond Administrative Agent’s then equity interest, if any, in the Property, and Tenant shall look exclusively to such equity interest of Administrative Agent, if any, in the Property for the payment and discharge of any obligations or liability imposed upon Administrative Agent hereunder, under the Lease (or under any new lease with Tenant), and Administrative Agent is hereby released and relieved of any other obligations or liability hereunder, under the Lease or under any such new lease. Administrative Agent shall not, either by virtue of the Loan Documents or this Agreement, be or become a mortgagee in possession or be or become subject to any liability or obligation under the Lease or otherwise until Administrative Agent shall have acquired the Landlord’s interest in the Property and, except as specifically set forth in this Agreement, such liability or obligation of Administrative Agent under the Lease (as modified by the terms of this Agreement) shall extend only to those liability or obligations accruing subsequent to the date that Administrative Agent has acquired Landlord’s interest in the Property. Neither the Loan Documents nor this Agreement shall, prior to Administrative Agent’s acquisition of Landlord’s interest in the Property, operate to place responsibility for the control, care, management or repair of the Property upon Administrative Agent or impose upon Administrative Agent responsibility for the carrying out of any of the terms or conditions of the Lease, and Administrative Agent shall not be responsible or liable for any waste committed on either the Premises or the Property by any party whatsoever, for any dangerous or defective condition of the Property or for any negligence in the management, upkeep, repair or control of either the Premises or the Property.

 

 

 

6.            Severability. If any portion or portions of this Agreement shall be held invalid or inoperative, then all of the remaining portions shall remain in full force and effect, and, so far as is reasonable and possible, effect shall be given to the intent manifested by the portion or portions held to be invalid or inoperative.

 

7.             Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Texas.

 

8.             Notices. Until the Mortgage has been released of record and a copy of such release delivered to Tenant, Tenant will mail or deliver to Administrative Agent, at the address and in the manner herein below provided, a copy of all notices required to be given to the Landlord by Tenant under and pursuant to the terms and provisions of the Lease, provided that Administrative Agent agrees to keep any information contained in such notices confidential. All notices or other communications required or permitted to be given pursuant to the provisions hereof shall be in writing and shall be considered as properly given if (i) mailed to the addressee by first class United States mail, postage prepaid, registered or certified with return receipt requested, (ii) by delivering same in person to the addressee, or (iii) by delivery to a third party commercial delivery service for same day or next day delivery to the office of the addressee with proof of delivery. Notice so given shall be effective, as applicable, upon (i) the third (3rd) day following the day such notice is deposited with the U.S. Postal Service, (ii) delivery to the addressee, or (iii) upon delivery to such third party delivery service. Notice given in any other manner shall be effective only if and when received by the addressee. For purposes of notice, the addresses of the parties shall be:

 

Administrative Agent: Citibank, N .A.
  388 Greenwich Street, 6th Floor
  New York, New York 10013
  Attention: CMBS Real Estate Legal Notices
   
   
Landlord: KCP NNN II Leasehold 4, LLC
  c/o Kawa Capital Partners LLC
  21500 Biscayne Boulevard, Suite 700
  Aventura, Florida 33180
  Attention: General Counsel
   
Tenant: Caris MPI, Inc.
  750 W. John Carpenter Freeway, Suite 800
  Irving, TX 75039
  Attention: Michael Halbert, SVP Human Resources
   
with a copy to: Caris MPI, Inc.
  750 W. John Carpenter Freeway, Suite 800
  Irving, TX 75039
  Attention: Legal Department
   

 

 

 

Notwithstanding the foregoing, any party shall have the right to change its address for notice hereunder to any other location within the continental United States by the giving of thirty (30) days’ notice to the other parties in the manner set forth herein. Any address so designated shall include a street address for courier delivery.

 

9.            Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, legal representatives, successors, successors-in-title and assigns, it being understood that the obligations and agreements herein of each of the parties shall extend to any person who shall have succeeded to its interest under the Loan Documents and the Lease. Without limitation of any provision contained herein, as used herein, the term (i) “landlord” refers to Landlord and to any successor to the interest of Landlord under the Lease and (ii) “Administrative Agent” refers to Administrative Agent acting as authorized agent of the Lenders and to any assignee of the note secured by the Mortgage and Administrative Agent’s servicer of the Loan, if any.

 

10.          Tenant’s Personal Propertv. In no event shall the Mortgage cover or encumber (and shall not be construed as subjecting in any manner to the lien thereof) any of Tenant’s moveable trade fixtures, business equipment, furniture, signs or other personal property at any time placed on or about the Premises.

 

11.          Counterparts. This Agreement may be executed in one or more counterparts, each of which when so executed shall be deemed to be an original, but all of which when taken together shall constitute one and the same instrument. This Agreement, if executed by Tenant but not by all parties necessary to fully execute the same, is valid for only thirty (30) days from the date Tenant executed this Agreement. This Agreement is contingent upon Tenant receiving an original fully executed copy of the Agreement within such 30-day period, the failure of which shall automatically cause this Agreement to become null and void.

 

12.         Headings. The headings, captions, and arrangements used in this Agreement are for convenience only and shall not affect the interpretation of this Agreement.

 

 

[SIGNATURE PAGE FOLLOWS]

 

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement under seal as of the date first above written.

 

  ADMINISTRATIVE AGENT:
   
  CITIBANK, N.A.
   
   
  By:  
  its Authorized Signatory

 

ACKNOWLEDGMENT

 

STATE OF ____________ )  
  ) ss:
COUNTY OF __________ )  

 

On the ___day of ____, in the year 2019, before me, the undersigned, a Notary Public in and for said State, personally appeared __________, personally known to me or proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his capacity, and that by his signature on the instrument, the individual, or the person upon behalf of which the individual acted, executed the instrument.

 

   
  Notary Public
[SEAL]  

 

 

 

  TENANT:
   
  CARIS MPI, INC.,
  a Texas corporation
   
   
  By:  
  Name:  
  Title:  

 

ACKNOWLEDGMENT

 

STATE OF TEXAS §  
  §
COUNTY OF     §  

 

This instrument was acknowledged before me on July _____, 2019, by ____________, ___________ of Caris MPI, Inc., a Texas corporation, on behalf of said corporation.

 

   
  Notary Public in and for the State of Texas
   
  My commission expires:    

 

 

 

  LANDLORD:
   
  KCP NNN II LEASEHOLD 4, LLC,
  a Delaware limited liability company
   
   
  By:  
    Name: Daniel Ades
    Title: Chief Executive Officer

 

ACKNOWLEDGMENT

 

STATE OF ____________ )  
  ) ss:
COUNTY OF __________ )  

 

On the ____ day of ___, in the year 2019, before me, the undersigned, a Notary Public in and for said State, personally appeared Daniel Ades, as Chief Executive Officer of KCP NNN II Leasehold 4, LLC, personally known to me or proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his capacity, and that by his signature on the instrument, the individual, or the person upon behalf of which the individual acted, executed the instrument.

   
  Notary Public
[SEAL]  

 

 

 

EXHIBIT A TO SNDA

 

LEGAL DESCRIPTION

 

 

 

EXHIBIT 24-1

 

ESTOPPEL CERTIFICATE

 

The undersigned, CARIS MPI, INC., a Texas corporation (the “Tenant”), is the tenant under a lease (the “Lease”) dated ____________, 2019, between Tenant and _______________________, a Delaware limited liability company, as the landlord (the “Landlord”), of certain real property located at 3600 W. Royal Lane, Irving, Texas 75063, and legally described on attached Exhibit A (the “Premises”). With the understanding that _______________ _________________, (together with its successors and assigns, “Lender”), a(n) ___________, will rely upon the covenants, representations and statements made herein in [select one]

 

[---making a mortgage loan of $______________, more or less (the “Loan”) to Landlord evidenced by [a Promissory Note] (the “Note”) in the aggregate principal amount of the Loan, executed by Landlord in favor of Lender and secured by a [Mortgage and Security Agreement] (the “Deed of Trust”) creating a first lien on the Premises and Landlord’s interest in the Lease and by an [Assignment of Leases and Rents] (the “Assignment of Leases and Rents”) creating a direct and absolute assignment to Lender of all of Landlord’s rights, title and interest as Landlord in and to the Lease and all rent due thereunder], [OR]

 

[---acquiring title to the land forming part of the Premises and leasing the same back to Landlord pursuant to a Ground Lease.]

 

Tenant understands that Lender will rely upon the covenants, representations and warranties made herein [in making the Loan or entering into said Ground Lease transaction] and Tenant hereby covenants and certifies as follows (terms used herein which are not otherwise defined herein shall have the meaning ascribed to them in the Lease) as of the date hereof:

 

1.         The Tenant is the owner and holder of all rights, title and interest in the leasehold estate created by the Lease and has no actual knowledge of any prior assignment of the Landlord’s interest in the Lease, except as described above in favor of Lender.

 

2.          Tenant and/or its Affiliates and subtenants are in possession of the Premises and have accepted the condition thereof.

 

3.          Attached hereto is a true and correct copy of the Lease and the following amendments thereto: [If none, state “None.”] The Lease is in full force and effect and has not been modified, supplemented, canceled or amended in any respect except as stated above.

 

4.          The Term of the Lease commenced on _____________, _____________, and continues through ___________ [unless extended as provided in the Lease]. The Tenant is currently obligated to pay Basic Rent in monthly installments in the amount of $___________, which rent obligation is continuing and is not past due or delinquent in any respect. No installment of rent has been prepaid more than thirty (30) days before it comes due.

 

 

 

5.          To Tenant’s actual knowledge, no event has occurred or is continuing which would constitute a default by either the Tenant or the Landlord under the Lease or would constitute such a default but for the requirement that notice be given or that a period of time elapse or both.

 

6.         Beginning with the payment of Basic Rent due ______ , Tenant hereby acknowledges and agrees to comply with Landlord’s authorization and direction to Tenant to make all payments of Basic Rent due under the Lease directly to Lender until otherwise advised in writing by Lender by wire transfer of immediately available funds to Lender pursuant to instructions given by Lender from time to time.

 

7.          For so long as the Loan is outstanding, Tenant agrees to deliver to Lender (at the address provided hereinbelow) a courtesy copy of any written notice by Tenant to Landlord claiming default by Landlord under the Lease, and Tenant authorizes Landlord to provide to Lender copies of any financial statements required to be provided by Tenant to Landlord under the Lease, provided that Lender shall keep such financial statements confidential. Lender’s notice address is as follows:

 

   
   
   
   
Attention:      

 

8.          Without the prior written consent of the Lender, Tenant agrees not to enter into any agreement subordinating, terminating, amending or modifying the Lease, so long as [the Loan has not been repaid in full]. Any such attempted subordination, modification, amendment or termination shall be void. In the event that the Lease shall be amended, modified or supplemented with the Lender’s prior written consent, the Lease as so amended, modified or supplemented shall continue to be subject to the provisions of this Certificate.

 

9.          This Certificate may not be modified orally or in any manner other than by an agreement, in writing, signed by the parties hereto or their respective successors in interest. This Certificate shall inure to the benefit of and be binding upon the parties hereto, and their respective successors and assigns, and to no other person or entities. The representations, warranties and agreements made herein shall survive the closing of [the Loan or Ground Lease transaction] between the Lender and Landlord.

 

10.       Tenant agrees that it shall, pursuant to Paragraph 23 of the Lease and any Subordination, Non-Disturbance and Attornment Agreement between Tenant and Lender, attorn to and recognize Lender as the Landlord under the Lease, should Lender become the Landlord under the Lease.

 

11.        In the event title to the Premises, or any part thereof, is acquired by or becomes vested in the Tenant, whether pursuant to the Lease or otherwise, there shall be no merger of estates and the Lease shall not terminate or be affected thereby unless and until any Mortgage has been released.

 

 

 

12.        For so long as the [Loan is outstanding or the Ground Lease continues], Lender or its designee may upon reasonable prior notice (and, at the option of Tenant, accompanied by a representative of Tenant) enter upon the Premises during regular business hours to visit or inspect the Premises at such reasonable times as Lender or its designee may request. Receipt by Tenant of a recorded release of the Deed of Trust shall be prima facie evidence that the Loan is no longer outstanding.

 

13.        The Lease and this Certificate have been duly authorized, executed and delivered by Tenant and constitute legal, valid and binding instruments enforceable against Tenant in accordance with their respective terms, except to the extent limited by bankruptcy, insolvency or similar laws affecting creditor’s rights generally and general principles of equity.

 

14.        As between Landlord and Tenant, the execution and delivery of this Certificate shall in no way expand the rights or obligations of the Landlord and Tenant arising under the Lease.

 

15.        The Guaranty is in full force and effect and is binding upon, and enforceable against, Guarantor in accordance with its terms.

 

This Certificate shall be governed by the laws of Texas.

 

Tenant also makes the above certifications and representations for the benefit of Landlord and its successors and assigns, with the understanding that they will be relied upon by Landlord.

 

IN WITNESS WHEREOF, this Certificate has been duly executed and delivered by the undersigned as of _____________, _____________.

 

  TENANT:
   
 
   
  By:  
  Name:  
  Its:  

 

 

 

EXHIBIT 24-2

 

ESTOPPEL CERTIFICATE

 

 The undersigned, CARIS MPI, INC., a Texas corporation (the “Tenant”), is the tenant under a lease (the “Lease”) dated _______________, 2019, between Tenant and _____________________, a Delaware limited liability company, as the landlord (the “Landlord”) of certain real property located in the County of Dallas, State of Texas commonly known as 3600 W. Royal Lane, Irving, Texas 75063, and legally described on attached Exhibit A attached hereto (the “Premises”). With the understanding that ___________________ (together with its successors and assigns, “Purchaser”) will rely upon the representations and warranties made herein in purchasing the Premises and accepting an assignment of Landlord’s interest in the Lease [ or purchasing the ownership interests in Landlord], Tenant hereby certifies as follows (terms used herein which are not otherwise defined herein shall have the meaning ascribed to them in the Lease) as of the date hereof:

 

1.          The Tenant is the owner and holder of all rights, title and interest in the leasehold estate created by the Lease and has no actual knowledge of any prior assignment of the Landlord’s interest in the Lease except the assignment by Landlord pursuant to [reference mortgage and/or assignment of leases and rents].

 

2.          Tenant and/or its Affiliates and subtenants are in possession of the Premises and have accepted the condition thereof.

 

3.          Attached hereto is a true and correct copy of the Lease and the following amendments thereto: [If none, state “None.”] The Lease is in full force and effect and has not been modified, supplemented, canceled or amended in any respect except as stated above.

 

4.          The Term of the Lease commenced on ___________ and continues through ________ [unless extended as provided in the Lease]. The Tenant is currently obligated to pay Basic Rent in monthly installments in the amount of $_______, which rent obligation is continuing and is not past due or delinquent in any respect. No installment of rent has been prepaid more than thirty (30) days before it comes due.

 

5.          To Tenant’s actual knowledge, no event has occurred or is continuing which would constitute a default by either the Tenant or the Landlord under the Lease or would constitute such a default but for the requirement that notice be given or that a period of time elapse or both.

 

6.          The Lease and this Certificate have been duly authorized, executed and delivered by Tenant and constitute legal, valid and binding instruments enforceable against Tenant in accordance with their respective terms, except to the extent limited by bankruptcy, insolvency or similar laws affecting creditor’s rights generally incurred.

 

7.          The Guaranty is in full force and effect and is binding upon, and enforceable against, Guarantor in accordance with its terms.

 

 

 

This Certificate shall be governed by the laws of Texas.

 

Tenant also makes the above certifications for the benefit of Landlord and its successors and assigns, with the understanding that they will be relied upon by Landlord.

 

IN WITNESS WHEREOF, this Certificate has been duly executed and delivered by the undersigned as of ____________, ______.

 

  TENANT:
   
 
   
  By:  
  Name:  
  Its:  

 

 

 

EXHIBIT 30

 

Prepared by and

when recorded send to:

 

Greenberg Traurig, P.A.

Attn: Michael Larson 

333 S.E. 2nd Ave., Suite 4400

Miami, FL 33131

 

 

MEMORANDUM OF LEASE

 

This MEMORANDUM OF LEASE (this “Memorandum”) is made and entered into effective as of _______, 2019 (the “Effective Date”), by and between ______________________, a Delaware limited liability company (“Landlord”), and CARIS MPI, INC., a Texas corporation (“Tenant”).

 

I.          Lease. Concurrently herewith, Landlord and Tenant have entered into that certain Lease (as amended from time to time, the “Lease”), pursuant to which Landlord has leased to Tenant, and Tenant has leased from Landlord, those certain premises commonly known as 3600 W. Royal Lane, Irving, Dallas County, Texas 75063, more particularly described on Exhibit A attached hereto and made a part hereof (the “Real Property”), and all buildings located on the Real Property, together with all rights, privileges, easements and appurtenances belonging to or in any way pertaining to said premises and together with the improvements and fixtures located upon said premises (collectively, the “Premises”).

 

2.          Term. The effective date of the Lease is ______, 2019, and the initial Term thereunder expires June 30, 2035. Tenant has the right to renew the term of the Lease for two (2) periods of sixty (60) months each, as more fully set forth in the Lease.

 

3.          Notice. This Memorandum is executed for the purpose of recordation in the Real Property Records of Dallas County, Texas, in order to give notice of the key terms, provisions and conditions of the Lease, and is not intended and shall not be construed, to define, limit or modify the Lease. In the event of a conflict between the terms of the Lease and this Memorandum, the terms of the Lease shall control. Any party acquiring any interest in the Real Property or the Premises on or after the date hereof shall do so subject to the terms and provisions of the Lease and Tenant’s rights thereunder.

 

4.          Counterparts. This Memorandum may be executed in separate counterparts, each such counterpart being deemed an original, and all of which taken together shall constitute one and the same instrument.

 

[Signature Pages Follow]

 

 

 

IN WITNESS WHEREOF, this Memorandum is executed as of the dates set forth in the acknowledgments below to be effective as of the Effective Date.

 

LANDLORD:  
   
___________________________ ,  
a Delaware limited liability company  
   
   
By:    
Name:    
Title:    

 

STATE OF ___________ §  
  §
COUNTY OF     §  

 

This instrument was acknowledged before me on ____________, 2019, by _________________, __________________ of ___________________, a Delaware limited liability company, on behalf of said limited liability company.

 

   
  Notary Public in and for the State of _____________________
   
  My commission expires:    

 

 

 

TENANT:  
   
CARIS MPI, INC.,  
a Texas corporation  
   
   
By:    
Name:    
Title:    

 

STATE OF TEXAS §  
  §
COUNTY OF     §  

 

This instrument was acknowledged before me on ___________, 2019, by ________________, ________________ of Caris MPI, Inc., a Texas corporation, on behalf of said corporation.

 

   
  Notary Public in and for the State of Texas
   
  My commission expires:    

 

 

 

EXHIBIT A TO MEMORANDUM OF LEASE

 

LEGAL DESCRIPTION

 

 

 

 

EXHIBIT 41

 

GUARANTY

 

[see following page]

 

 

 

 

GUARANTY OF LEASE

 

THIS GUARANTY OF LEASE (this “Guarantv”) is made as of this __ day of July, 2019, by Caris Life Sciences, Ltd., a Cayman Islands exempted limited company (“Guarantor”), in favor of KCP NNN II LEASEHOLD 4, LLC, a Delaware limited liability company (“Landlord”).

 

 

RECITALS

 

A.Landlord and Caris MPI, Inc., a Texas corporation (“Tenant”), have entered into that certain Lease dated as of July , ____2019 (said Lease, as hereafter supplemented, amended, restated, renewed, extended, replaced or modified, hereinafter referred to as the “Lease”), pursuant to which Tenant leases from Landlord certain Premises (as defined in the Lease) commonly known as 3600 W. Royal Lane, Irving, Texas 75063, all as more particularly described in said Lease.

 

B.Landlord has required as a condition to its execution and performance of the Lease that Guarantor execute and deliver this Guaranty of all of the obligations of Tenant arising and all sums due by Tenant under the Lease. The execution and delivery of this Guaranty by Guarantor is a material inducement to Landlord for the execution and performance of the Lease.

 

C.Guarantor owns directly or indirectly all of the ownership interest in Tenant and, having a financial interest in Tenant, will be benefited by the Lease. Accordingly, Guarantor has agreed to execute, deliver and perform this Guaranty.

 

NOW, THEREFORE, in consideration of the Recitals set forth above and for other good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, Guarantor covenants and agrees as follows:

 

1.             Recitals: Defined Terms. The Recitals set forth above are incorporated herein and shall be deemed terms and provisions hereof. All capitalized terms which are not expressly defined in this Guaranty shall have the same meanings herein as are ascribed to such terms in the Lease.

 

2.            Guaranty. For the consideration described herein and subject to the limitations hereof, Guarantor hereby absolutely and unconditionally guarantees to Landlord:

 

(a)           the full and prompt payment when due, whether upon acceleration or otherwise, and at all times thereafter, of any and all rentals, charges, debts and obligations of Tenant pursuant to the Lease for the payment of money, however created, arising or evidenced, whether direct or indirect, absolute or contingent, now or hereafter existing, due or to become due, known or unknown to Guarantor at the time of the execution of this Guaranty including, without limitation, all Basic Rent and Additional Rent, amounts required to discharge mechanics’ and materialmen’s liens and claims therefor, and any other sums which may now be or hereafter become due by Tenant under the Lease;

 

 

(b)            the payment of all Enforcement Costs (as hereinafter defined); and

 

 

 

 

(c)            the full, complete and punctual observance, performance and satisfaction of all covenants, terms, conditions, obligations, duties and agreements of Tenant under the Lease.

 

All amounts due and debts, liabilities and payment obligations described in Paragraph 2(a) and 2(b) are referred to herein as the “Liabilities.” All obligations described in Paragraph 2(c) are referred to herein as the “Obligations.”

 

3.             Landlord’s Remedies.

 

(a)            This Guaranty is an absolute, unconditional, irrevocable, present and continuing guaranty of payment and performance and not merely a guaranty of collection. In the event of any default by Tenant under the Lease, after the expiration of any notice and cure period applicable thereto, Guarantor agrees on demand by Landlord to pay all Liabilities then due hereunder, regardless of any defense, right of setoff or claim which Tenant or Guarantor may have against Landlord. In the event that there shall be any default by Tenant in the due and timely performance and observance of the Obligations after the expiration of any notice and cure period applicable thereto, then, in such event, Guarantor agrees, on demand by Landlord: (i) to perform such Obligations, and (ii) to indemnify and hold Landlord and the other Indemnified Parties (as defined in the Lease) harmless from and against any and all loss, damage, cost, expense, injury or liability Landlord or the other Indemnified Parties may suffer or incur in connection with the exercise of their rights under the Lease or this Guaranty. If Guarantor fails to commence and pursue diligently the performance of the Obligations within five (5) Business Days after its receipt of written notice from Landlord demanding the performance of Guarantor, then, either before or after pursuing any other remedy of Landlord against Guarantor or Tenant and regardless of whether Landlord shall ever pursue any such other remedy, Landlord shall have the right (but not the obligation) to perform such Obligations or to call upon any other reputable parties to perform such Obligations, with such changes or modifications as Landlord reasonably deems necessary or appropriate, and shall have the right to expend such sums as Landlord in its reasonable discretion deems proper in order so to complete the performance of such Obligations. During the course of the performance of any Obligations undertaken by Landlord or by any other party on behalf of Landlord, Guarantor shall pay on demand any amounts due to third parties in connection therewith. All amounts required to be paid under this Section 3 shall be included within the term “Liabilities,” and all obligations required to be performed under this Section 3 shall be included within the term “Obligations.”

 

(b) Notwithstanding anything to the contrary herein contained, in any action to enforce any of the liabilities or obligations of Guarantor under this Guaranty, Landlord, at its election, may proceed against Guarantor with or without: (i) joining Tenant in any such action; (ii) commencing any action against or obtaining any judgment against Tenant; or (iii) commencing any proceeding to enforce or realize upon any collateral or other security (including, without limitation, any security deposit or other guaranties) which may be given to secure Tenant’s obligations under the Lease, or to obtain any judgment, decree or foreclosure sale with respect thereto. Nevertheless, the maintenance of any action or proceeding by Landlord to recover any sum or sums that may be or become due under the Lease or to secure the performance of any of the other terms, covenants and conditions of the Lease shall not preclude Landlord from demanding and receiving the payment of such sums and the performance of such other terms, covenants and conditions from Guarantor, or from thereafter instituting and maintaining subsequent actions or proceedings for any subsequent default or defaults of Tenant under the Lease. Guarantor does hereby consent that, without affecting the liability of Guarantor under this Guaranty and without notice to Guarantor, time may be given by Landlord to Tenant for payment of Basic Rent and Additional Rent and such other sums and performance of said other terms, covenants and conditions, or any of them, and such time extended and indulgence granted from time to time, or Tenant may be dispossessed or Landlord may avail itself of or exercise any or all of the rights and remedies against Tenant provided by Legal Requirements or by the Lease, and may proceed either against Tenant alone or jointly against Tenant and Guarantor or against Guarantor alone without first proceeding or exhausting any remedy or claim against Tenant.

 

 

 

 

4.             Return of Payments: Duty to Remain Informed.

 

(a)            Guarantor agrees that, if at any time all or any part of any payment theretofore applied by Landlord to any Liabilities is rescinded or returned by Landlord for any reason whatsoever (including, without limitation, the insolvency, bankruptcy, liquidation or reorganization of any party), such Liabilities shall, for the purposes of this Guaranty, be deemed to have continued in existence to the extent of such payment, notwithstanding such application by Landlord, and this Guaranty shall continue to be effective or be reinstated, as the case may be, as to such Liabilities, all as though such application by Landlord had not been made. Guarantor does hereby further agree that with respect to any payments made by Guarantor hereunder, Guarantor shall not have any rights based on suretyship, subrogation or otherwise to stand in the place of Landlord so as to compete with Landlord as a creditor of Tenant, and Guarantor hereby waives all such rights to the fullest extent permitted by Legal Requirements.

 

(b)           Guarantor assumes the responsibility to remain informed of the financial condition of Tenant and of all other circumstances bearing risk of Tenant’s default under the Lease which reasonable inquiry would reveal, and agrees that Landlord shall have no duty to advise Guarantor of information known to it regarding any such condition or circumstance.

 

5.             No Discharge. Guarantor agrees that the obligations, covenants and agreements of Guarantor under this Guaranty shall not be affected or impaired by any act of Landlord, or any event or condition except the full, final and unavoidable performance of all Obligations and payment of all Liabilities and any other sums due hereunder. Guarantor agrees that the liability of Guarantor under this Guaranty shall not be discharged, reduced or otherwise affected by, and Guarantor hereby irrevocably consents to: (i) any subsequent change, modification or amendment of the Lease in any of its terms, covenants and conditions, or in the Basic Rent and Additional Rent or any other sums payable thereunder, or in the Premises demised thereby (whether said Premises be expanded, contracted, relocated, substituted or otherwise altered), and to any assignments of the Lease and to any subletting of the Premises, and to any extensions or renewals of the Lease or its Term; (ii) the renewal or extension of time for the payment of the Liabilities or performance of the Obligations under the Lease; (iii) any transfer, waiver, compromise, settlement, modification, surrender or release of Tenant’s obligations under the Lease; (iv) the existence of any defenses to enforcement of the Lease; (v) any failure, omission, delay or inadequacy, whether entire or partial, of Landlord to exercise any right, power or remedy regarding the Lease or to enforce or realize upon (or to make any guarantor a party to the enforcement or realization upon) any of Landlord’s security for the Lease, including, but not limited to, any impairment or release of such security by Landlord; (vi) the existence of any setoff, claim or counterclaim or the reduction or diminution of the Liabilities, or any defense of any kind or nature which Guarantor may have against Tenant or which Tenant or Guarantor has against Landlord; (vii) the application of payments received from any source to the payment of any obligation other than the Liabilities, even though Landlord might lawfully have elected to apply such payments to any part or all of the Liabilities; (viii) the addition or release of any and all other guarantors, obligors and other persons liable for the payment of the Liabilities and/or performance of the Obligations, and the acceptance or release of any and all other security for the payment of the Liabilities and/or performance of the Obligations; (ix) any distress or reentry by Landlord or dispossession of Tenant or any action or remedy taken by Landlord under the Lease following an Event of Default thereunder, including termination of the Lease (in which event the Obligations and Liabilities of Guarantor shall not be reduced, released or otherwise affected and shall continue to accrue as if the Lease had not been so terminated); or (x) any failure of Landlord to notify Guarantor of any default by Tenant under the Lease; all whether or not Guarantor shall have had notice or knowledge of any act, omission or event referred to in the foregoing clauses (i) through (x) inclusive of this Paragraph. In the event that the Lease is modified, renewed or extended in any respect by agreement between Landlord and Tenant either pursuant to an option granted in the Lease or otherwise, or in the event that Tenant holds over beyond the Term of the Lease, then the obligations of Guarantor under this Guaranty shall extend to the full and faithful performance and observance of all of the covenants, terms and conditions of the Lease and of any such modification, renewal or extension thereof. Guarantor intends that Guarantor shall remain liable hereunder as a principal until the full, final and unavoidable performance of all of the Obligations and the full, final and unavoidable payment of all Liabilities, notwithstanding any fact, act, event or occurrence which might otherwise operate as a legal or equitable discharge of a surety or guarantor.

 

 

 

 

6.             Application of Amounts Received. Any amounts received by Landlord from whatsoever source on account of any Liabilities may be applied by Landlord toward the payment of such Liabilities and in such order of application, as Landlord may from time to time elect.

 

7.             Waiver.

 

(a)            Guarantor expressly waives: (i) notice of the acceptance by Landlord of this Guaranty; (ii) notice of the existence, creation, payment or nonpayment of the Liabilities; (iii) presentment, demand, notice of dishonor, protest and all other notices whatsoever; and (iv) any failure by Landlord to inform Guarantor of any facts Landlord may now or hereafter know about Tenant, the Lease or the Premises, it being understood and agreed that Guarantor has and will maintain knowledge of and is familiar with Tenant’s financial condition and business affairs, and that Landlord has no duty so to inform, and that Guarantor is fully responsible for being and remaining informed by, Tenant of all circumstances bearing on the Lease and this Guaranty. No modification or waiver of any of the provisions of this Guaranty will be binding upon the parties hereto except as expressly set forth in a writing duly signed and delivered on behalf of the parties hereto. No notice to or demand on Guarantor, in any case shall, of itself, entitle Guarantor to any other or further notice or demand in similar or other circumstances.

 

(b)            To the extent permitted by Legal Requirements, this Guaranty shall be effective as a waiver of, and Guarantor waives, any and all rights, defenses or remedies to which Guarantor may have or may otherwise have been entitled under any suretyship laws or similar laws in effect from time to time including, but not limited to, Section 17.001 of the Texas Civil Practice and Remedies Code, Texas Rule of Civil Procedure 31, and Chapter 43 of the Civil Practice and Remedies Code, entitled Principal and Surety, including without limitation, notice, discharge, levy and subrogation. To the extent permitted by Legal Requirements, Grantor additionally waives the benefit of any statute of limitations affecting Guarantor’s liability under this Guaranty.

 

 

 

 

8.             Enforcement Costs. If: (i) the Lease or this Guaranty is placed in the hands of an attorney for enforcement or collection or is enforced or collected through any legal proceeding, or (ii) an attorney is retained to represent Landlord in any proceeding (including, without limitation, any bankruptcy, reorganization, receivership or other proceeding affecting creditors’ rights) involving a claim under the Lease or this Guaranty, then Guarantor shall pay to Landlord upon demand all reasonable attorneys’ fees, costs and expenses, including, without limitation, court costs and filing fees, and all other reasonable out-of-pocket costs and expenses incurred in connection therewith (all of which are referred to herein as “Enforcement Costs”), in addition to all other amounts due hereunder.

 

9.             Transfer of Lease. Notwithstanding any assignment or transfer of the Lease or any interest therein by Landlord, for collateral purposes or otherwise, each and every immediate and successive assignee, transferee, or other successor in interest with respect to Landlord’s interest under the Lease shall, to the extent of the interests assigned or transferred, be entitled to the benefits of this Guaranty to the same extent as if such assignee or transferee were Landlord. Any Mortgagee holding a collateral assignment of the Lease is expressly entitled to the benefits of this Guaranty.

 

10.             Subordinated Debt. Any indebtedness of Tenant to Guarantor (the “Subordinated Debt”) now or hereafter existing is hereby subordinated to the Liabilities. Guarantor agrees that, after receipt of written notice that an Event of Default exists under the Lease and during the continuance of such Event of Default, Guarantor will not seek, accept or retain for Guarantor’s own account, any payment from Tenant on account of the Subordinated Debt until the full, final and unavoidable payment of the Liabilities. Any payments received by Guarantor on account of the Subordinated Debt while an Event of Default exists under the Lease shall be collected and received by Guarantor in trust for Landlord and shall be paid over to Landlord on account of the Liabilities without impairing or releasing the obligations of Guarantor under this Guaranty except to the except of the payments so paid.

 

11.           Binding Effect: Successors and Assigns.

 

(a)            This Guaranty shall bind Guarantor and its successors and assigns; provided that Guarantor shall not be entitled to transfer or delegate its obligations under this Guaranty without Landlord’s prior written consent, which consent may be withheld in Landlord’s sole discretion.

 

(b)            It is agreed that Guarantor’s liability hereunder is independent of any other guaranties or other obligations at any time in effect with respect to the Liabilities, the Obligations or any part thereof and that Guarantor’s liability hereunder may be enforced regardless of the existence, validity, enforcement or non-enforcement of any such other guaranties or other obligations.

 

 

 

 

(c)            This Guaranty shall inure to the benefit of, and may be enforced by, Landlord and Landlord’s successors and assigns under the Lease.

 

12.           One-Time Assignment of Guarantv. Notwithstanding Section 1 l(a), in connection with a Transfer that is a Permitted Successor Event, Guarantor shall have a one-time right, upon not less than thirty (30) days’ prior written notice to Landlord, to assign its obligations under this Guaranty provided that the following requirements are satisfied at the time of the Permitted Successor Event:

 

(i)            no material default has occurred under this Guaranty beyond any applicable notice and cure period therefor and no Event of Default exists under the Lease which will not be cured in connection with the Permitted Successor Event;

 

(ii)           the proposed assignee is not an Affiliate of Guarantor and such non-Affiliate proposed assignee shall have a Tangible Net Worth equal to or greater than $50,000,000, as evidenced by such assignee’s latest audited financial statements or other evidence reasonably satisfactory to Landlord;

 

(iii)          Guarantor shall provide Landlord with such corporate organizational documents, evidence of authority, good standing, and other similar materials as Landlord may reasonably require with respect to the proposed assignee;

 

(iv)          the proposed assignee shall be in compliance with OF AC regulations of the US Department of Treasury (including those named on OFAC’s Specially Designated and Blocked Persons List) and any statute, executive order (including the September 24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism), or other governmental action relating thereto;

 

(v)           the replacement guarantor shall enter into a replacement guaranty in the same form as this Guaranty other than the deletion of this Section 12 and any updates to the names of the parties, dates, and references to the documents referred to herein; and

 

(vi)         any and all reasonable costs and expenses of Landlord incurred in connection with the foregoing assignment (including, without limitation, Landlord’s reasonable attorneys’ fees, costs and disbursements) up to $2,000.00 are paid to Landlord at or prior to the consummation of the assignment of the Guaranty.

 

Upon Landlord’s reasonable determination that the foregoing requirements have been satisfied (such date referred to herein as the “Release Date”), then Guarantor shall not have any liability for the Liabilities or Obligations to the extent arising from any circumstance, condition, action, omission or event with respect to the Lease or Tenant first occurring after the Release Date; provided, however, that Guarantor shall remain liable under this Guaranty for any Liabilities or Obligations to the extent arising from any circumstance, condition, action, omission or event occurring on or prior to the Release Date. Landlord shall provide Guarantor with written confirmation of the Release Date.

 

 

 

 

13.          Miscellaneous.

 

(a)           This Guaranty constitutes the entire agreement between Guarantor and Landlord with respect to the subject matter hereof and supersedes any and all such prior agreements and understandings, both written and oral. This Guaranty may not be modified or amended except by a written instrument signed by Landlord and Guarantor.

 

(b)            This Guaranty shall be governed by the laws of the State of Texas without reference to the conflicts of law principles of that state.

 

(c)            The headings of Paragraphs in this Guaranty are for convenience only and shall not be construed in any way to limit or define the content, scope or intent of the provisions hereof. As used in this Guaranty, the singular shall include the plural, and masculine, feminine and neuter pronouns shall be fully interchangeable where the context so requires.

 

(d)            If this Guaranty is executed by more than one person or entity, then references to “Guarantor” herein shall be deemed to refer to each such person or entity and the liability of each such person or entity shall be joint and several, and the release by Landlord of any of them shall not release or affect in any manner the obligations of any other of them and this Guaranty shall not be revoked, discharged or impaired as to any such persons or entitles by reason of the death or incapacity or insolvency of any other of them.

 

(e)           If any provision of this Guaranty, or any paragraph, sentence, clause, phrase or word, or the application thereof, in any circumstances, is adjudicated by a court of competent jurisdiction to be invalid, the validity of the remainder of this Guaranty shall be construed as if such invalid part were never included herein.

 

(f)            Time is of the essence of this Guaranty.

 

(g)           All payments to be made hereunder shall be made in in currency and coin of the United States of America which is legal tender for public and private debts at the time of payment.

 

(h)           This Guaranty may be executed at different times and in any number of originals or counterparts, each of which shall be deemed an original, but all of which together shall constitute only one instrument.

 

 

 

 

(i)           Any notice, demand or request by Landlord to Guarantor or by Guarantor to Landlord hereunder shall be in writing and shall be directed to Landlord or Guarantor (as applicable) as follows:

 

If to Guarantor: Prior to July 1. 2020:
  Caris Life Sciences, Ltd.
  c/o Caris MPI, Inc.
  750 W. John Carpenter Freeway, Suite 800
  Irving, Texas 75039
  Attention: Michael Halbert, SVP Human Resources
  Facsimile: [***]
  Email: [***]
   
with a copy to: Caris Life Sciences, Ltd.
  c/o Caris MPI, Inc.
  750 W. John Carpenter Freeway, Suite 800
  Irving, Texas 75039
  Attention: Legal Department
  Facsimile: [***]
  Email: [***]
   
  From and after July 1. 2020:
  Caris Life Sciences, Ltd.
  c/o Caris MPI, Inc.
  3600 W. Royal Lane
  Irving, Texas 75063
  Attention: Michael Halbert, SVP Human Resources
  Facsimile: [***]
  Email: [***]
   
with a copy to: Caris Life Sciences, Ltd.
  c/o Caris MPI, Inc.
  3600 W. Royal Lane
  Irving, Texas 75063
  Attention: Legal Department
  Facsimile: [***]
  Email: [***]
   
If to Landlord: KCP NNN II Leasehold 4, LLC
  c/o Kawa Capital Partners LLC
  21500 Biscayne Boulevard, Suite 700
  Aventura, Florida 33180
  Attention: General Counsel
  Facsimile: [***]
  Email: [***]
 
with a copy to: Greenberg Traurig, P.A.
  333 S.E. 2nd Avenue, Suite 4400
  Miami, Florida 33131
  Attention: Gavin Loughlin
  Facsimile: [***]
  Email: [***]

 

 

 

 

Notices shall be either (i) personally delivered (including delivery by reputable overnight courier service) to the offices set forth above, in which case they shall be deemed delivered on the date of delivery to said offices, or (ii) sent by facsimile or email (as applicable), provided that for any notices sent by facsimile or email a copy shall also be sent by personal delivery or overnight delivery service. Any notice actually received or deemed received pursuant to the foregoing provisions on a non-Business Day or after the close of business of the recipient on a Business Day shall be deemed received on the next Business Day. Either party may by written notice to the other party given as provided hereunder change its address for service of notice to any other recognized business address in the continental United States. Any address so designated shall include a street address for courier delivery.

 

(j)            GUARANTOR KNOWINGLY, IRREVOCABLY, VOLUNTARILY, AND INTENTIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY OR AGAINST LANDLORD OR ON ANY MATTER ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS GUARANTY, THE LEASE, ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN), ACTIONS OF GUARANTOR, THE TENANT OR THE LANDLORD, OR THE RELATIONSHIPS BETWEEN GUARANTOR, TENANT AND LANDLORD. THIS PROVISION IS A MATERIAL INDUCEMENT FOR LANDLORD ACCEPTING THIS GUARANTY FROM GUARANTOR. Landlord and Guarantor agree to be subject to the jurisdiction of state or federal courts sitting in or for Dallas County, Texas, to accept service of process in any action brought in Texas and to accept service by certified mail or personal service and Landlord and Guarantor waive any objection to personal jurisdiction in any such action.

 

(k)           Within ten (10) Business Days after receipt of Landlord’s written request, Guarantor shall execute and deliver to Landlord a written statement certifying: (i) the continuing effect and enforceability of this Guaranty; (ii) the absence of any modification of this Guaranty or, if there has been any such modification, stating the same; and (iii) to the knowledge of the signatory, the absence of a default by Landlord under the Lease or the Guaranty, or, if there is such a default, stating the same. Each such statement shall be addressed to, and may be relied upon (and the certificate shall so recite) by Landlord, any Mortgagee, any purchaser of all or part of the Premises and such purchaser’s lender.

 

[Remainder of Page Intentionally Left Blank]

 

 

 

 

IN WITNESS WHEREOF, the undersigned has executed this Guaranty as of the day and year first above set forth.

 

GUARANTOR:

 

CARIS LIFE SCIENCES, LTD.,

 

a Cayman Islands exempted limited company

 

By:    
Name:    
Its:    

 

STATE OF TEXAS §  
  §  
COUNTY OF DALLAS §  

 

This instrument was acknowledged before me on July___, 2019, by________, ______of Caris Life Sciences, Ltd., a Cayman Islands exempted limited company, on behalf of said entity.

 

   
  Notary Public in and for the State of Texas
   
  My commission expires:_________

 

 

 

 

Exhibit 10.4(a)

 

CARIS LIFE SCIENCES, INC.

 

AMENDED AND RESTATED 2020 INCENTIVE PLAN

 

1.PURPOSE; ELIGIBILITY.

 

1.1           General Purpose. The purpose of the Caris Life Sciences, Inc. Amended and Restated 2020 Incentive Plan (the “Plan”), is to enable Caris Life Sciences, Inc., a Texas corporation (the “Company”), and any Affiliate to align and link the interests of the Company Group’s Employees, Consultants and Directors with the interests of the Shareholders via the issuance of Awards, the value of which are linked directly to sustained growth in the value of the Company. The Plan as amended and restated shall be effective as of the date of approval by the Shareholders (the “Effective Date”).

 

1.2           Eligible Award Recipients. The persons eligible to receive Awards are the Employees, Consultants and Directors (each, a “Service Provider”) of the Company Group.

 

1.3           Available Awards. The purpose of the Plan is to provide a means by which eligible recipients of Awards may be given an opportunity to benefit from increases in value of the Common Stock through the granting of one or more of the following Awards: (a) Options, (b) Restricted Awards, (c) Performance Awards and (d) Share Appreciation Rights.

 

2.DEFINITIONS.

 

2.1           “Administrator” means the Directors or the Committee appointed by the Directors in accordance with Section 3.5.

 

2.2           “Affiliate” means any parent corporation or Subsidiary of the Company, whether now or hereafter existing, as those terms are defined in Sections 424(e) and (f), respectively, of the Code.

 

2.3           “Applicable Laws” means any applicable legal requirements relating to the administration of and the issuance of ownership interests and/or other securities under equity-based compensation plans, including, without limitation, U.S. state corporate laws, U.S. federal and state securities laws, the Code and the requirements of any stock exchange or quotation system upon which the Common Stock may be listed or quoted and the laws of any other country or jurisdiction where Awards are granted under the Plan. For all purposes of this Plan, references to statutes and regulations shall be deemed to include any successor statutes or regulations, where necessary as determined by the Administrator in its sole discretion.

 

2.4           “Articles” means the Company’s Articles of Association.

 

2.5           “Award” means any right granted under the Plan, including an Option, a Restricted Award, a Performance Award and a Share Appreciation Right.

 

2.6           “Award Agreement” means a written agreement between the Company and a holder of an Award evidencing the terms and conditions of an individual Award grant. Each Award Agreement shall be subject to the terms and conditions of the Plan.

 

 

 

 

2.7           “Beneficial Owner” has the meaning assigned to such term in Rule 13d-3 and Rule 13d-5 under the Exchange Act, except that in calculating the beneficial ownership of any particular “person” (as that term is used in Section 13(d)(3) of the Exchange Act), such “person” shall be deemed to have beneficial ownership of all securities that such “person” has the right to acquire by conversion or exercise of other securities, whether such right is currently exercisable or is exercisable only after the passage of time. The terms “Beneficially Owns” and “Beneficially Owned” have a corresponding meaning.

 

2.8           “Board” means the Board of Directors of the Company, as constituted from time to time.

 

2.9           “Cashless Exercise” has the meaning set forth in Section 6.3.

 

2.10         “Change of Control” shall mean

 

(a)         the direct or indirect sale, transfer, conveyance, exclusive license or other disposition (other than by way of merger or consolidation), in one or a series of related transactions, of all or substantially all of the properties or assets of the Company and its subsidiaries, taken as a whole, to any “person” (as that term is used in Section 13(d)(3) of the Exchange Act, which includes any two or more persons acting as a group);

 

(b)         the adoption of a plan relating to the liquidation or dissolution of the Company;

 

(c)         acquisition by any “person” of Beneficial Ownership of 50% or more (on a fully-diluted basis) of either (i) the then outstanding shares of Common Stock of the Company, taking into account as outstanding for this purpose such Common Stock issuable upon the exercise of options or warrants, the conversion of convertible stock or debt, and the exercise of any similar right to acquire such Common Stock (the “Outstanding Company Common Stock”) or (ii) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”);

 

(d)         the consummation of a reorganization, merger, consolidation, statutory share exchange or similar form of corporate transaction involving the Company that requires the approval of the Shareholders pursuant to the TBOC, whether for such transaction or the issuance of securities in the transaction; or

 

(e)         the following individuals cease for any reason to constitute a majority of the number of Directors then serving: individuals who, on the Effective Date, constitute the Board and any new Director (other than a Director whose initial assumption of office is in connection with an actual or threatened election contest, including, but not limited to, a consent solicitation, relating to the election of Directors of the Company) whose appointment or election by the Board or nomination for election by the Shareholders was approved or recommended by either (x) a vote of at least a majority of the Directors then still in office who either were Directors on the Effective Date or whose appointment, election or nomination for election was previously so approved or recommended, or (y) a Permitted Holder.

 

 2 

 

 

Notwithstanding the foregoing, a transaction of any type shall not constitute a Change of Control if (A) it constitutes an initial public offering or a secondary public offering that results in any security of the Company being listed (or approved for listing) on any securities exchange or designated (or approved for designation) as a national market security on an interdealer quotation system; (B) its sole purpose is to change the jurisdiction of the Company’s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company’s securities immediately before such transaction; (C) it is an acquisition by any employee benefit plan sponsored or maintained by the Company or any subsidiary; or (D) immediately following the transaction, (i) more than 50% of the total voting power of the entity resulting from such transaction, or if applicable, the ultimate parent entity that directly or indirectly has beneficial ownership of sufficient voting securities eligible to elect a majority of the members of the board of directors (or the analogous governing body) of the entity resulting from such transaction, is represented by the Outstanding Company Voting Securities that were outstanding immediately prior to such transaction (or, if applicable, is represented by shares into which the Outstanding Company Voting Securities were converted pursuant to such transaction), and such voting power among the holders thereof is in substantially the same proportion as the voting power of the Outstanding Company Voting Securities among the holders thereof immediately prior to the transaction or (ii) a Permitted Holder continues to maintain voting control, directly or indirectly and whether by equity ownership, contract or otherwise, of the Company. If a Change of Control constitutes a payment event with respect to any Award that provides for the deferral of compensation and is subject to Section 409A of the Code, the transaction or event must be both a Change of Control under this definition and constitute a “change in control event,” as defined in Treasury Regulation §1.409A-3(i)(5) to the extent required by Section 409A of the Code. The Administrator shall have full and final authority, which shall be exercised in good faith, to determine conclusively whether a Change of Control of the Company has occurred pursuant to the above definition, and the date of the occurrence of such Change of Control and any incidental matters relating thereto.

 

2.11         “Code” means the Internal Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder.

 

2.12         “Committee” means a committee of one or more Directors appointed by the Directors to administer the Plan in accordance with Section 3.5.

 

2.13         “Common Stock” means a share of Class A common stock of the Company, par value US$0.001 per share, or Class B common stock of the Company, par value US$0.001 per share, as applicable, issued subject to and in accordance with the provisions of the TBOC and the Articles and having the rights provided for in the Articles.

 

2.14         “Company” means Caris Life Sciences, Inc., a Texas corporation, or any successor thereto.

 

2.15         “Company Group” means the Company and its Affiliates, or one of the members of the Company Group, as applicable.

 

 3 

 

 

2.16         “Competing Business” means any business entity principally engaged in (i) the discovery, research, development and commercialization of any clinical application involving or relating to microvesicles, exosomes, proteins or nucleic acids, irrespective of their form (including messenger RNA, miRNA and any other molecular bio-markers, bio-signatures, particles, substances or entities); (ii) molecular profiling and therapeutic decision support in the oncology field; (iii) artificial intelligence; or (iv) any other business that the Company is then conducting or planning to conduct.

 

2.17         “Consultant” means any person, including an advisor or contractor, (a) engaged by the Company Group to render consulting or advisory services and who is compensated for such services or who provides bona fide services to the Company Group pursuant to a written agreement or (b) who is a director of an Affiliate; provided that, except as otherwise permitted in Section 5.3(b) hereof, such person is a natural person and such services are not in connection with the offer or sale of securities in a capital raising transaction and do not directly or indirectly promote or maintain a market for the Company’s securities.

 

2.18         “Continuous Service” means that the Participant’s service with the Company Group, whether as an Employee, Director or Consultant, is not interrupted or terminated. The Participant’s Continuous Service shall not be deemed to have terminated merely because of a change in the capacity in which the Participant renders service to the Company Group as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant’s Continuous Service. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or a Director will not constitute an interruption of Continuous Service. The Administrator, the chief executive officer of the Company or the president of the Company, in that party’s sole discretion, may determine whether Continuous Service shall be considered interrupted in the case of any leave of absence approved by that party, including sick leave, military leave or any other personal leave.

 

2.19         “Date of Grant” means the date on which the Administrator adopts a resolution, or takes other appropriate action, expressly granting an Award to a Participant or, if a different date is set forth in such resolution, or determined by the Administrator, as the Date of Grant, then such date as is set forth in such resolution.

 

2.20         “Detrimental Activity” means: (i) violation of the terms of any agreement with or policy of the Company Group concerning non-competition, non-disclosure, confidentiality, intellectual property, non-disparagement, privacy or exclusivity; (ii) disclosure of the Company Group’s confidential information to anyone outside the Company Group, without prior written authorization from the Company Group, or in conflict with the interests of the Company Group, whether the confidential information was acquired or disclosed by the Participant during or after employment by the Company Group; (iii) failure or refusal to disclose promptly or assign to the Company Group all right, title and interest in any invention, work product or idea, patentable or not, made or conceived by the Participant during employment by the Company Group, relating in any manner to the interests of the Company Group or, the failure or refusal to do anything reasonably necessary to enable the Company Group to secure a patent where appropriate in the United States and in other countries; (iv) the conviction of, or plea of guilty or no contest to, a felony or a crime involving moral turpitude; (v) the commission of an act involving willful malfeasance or material fiduciary breach with respect to the Company Group; (vi) gross negligence or willful misconduct with respect to the Company Group; (vii) any breach of a restrictive covenant contained in any employment agreement, Award Agreement or other agreement between the Participant and the Company Group, during any period for which a restrictive covenant prohibiting Detrimental Activity, or other similar conduct or act, is applicable to the Participant during or after employment by the Company Group; (viii) any attempt directly or indirectly to induce any Employee of the Company Group to be employed or perform services or acts in conflict with the interests of the Company Group; (ix) any attempt, in conflict with the interests of the Company Group, directly or indirectly, to solicit the trade or business of any current or prospective customer, client, supplier or partner of the Company Group; or (x) any material breach or non-compliance with the terms of the Plan or an Award Agreement.

 

 4 

 

 

2.21         “Director” means a director of the Company.

 

2.22         “Disability” means a physical or mental disability or infirmity of the Participant that prevents the normal performance of substantially all of the Participant’s duties for a continuous period in excess of 90 days or for more than 180 days during any one year period.

 

2.23         “Employee” means any person employed by the Company Group. Mere service as a Director or payment of a director’s fee by the Company Group shall not be sufficient to constitute “employment” by the Company Group.

 

2.24         “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder from time to time.

 

2.25         “Fair Market Value” means, as of any date, the value, on a fully diluted basis, of a Common Stock as determined in good faith by a nationally recognized valuation firm; provided, however, that, in the event that the Company conducts an initial public offering, the Fair Market Value on the date of the Company’s initial public offering of its Common Stock shall be the initial price to the public of the Common Stock, and thereafter (i) if the Common Stock are admitted to quotation on a national securities exchange, the Fair Market Value on any given date shall not be less than the average of the highest bid and lowest asked prices of the Common Stock reported for such date or, if no bid and asked prices were reported for such date, for the last day preceding such date for which such prices were reported or (ii) if the Common Stock are admitted to trading on an applicable securities exchange, the Fair Market Value on any date shall not be less than the closing price reported for the Common Stock on such exchange or system for such date or, if no sales were reported for such date, for the last date preceding the date for such a sale was reported. Any determination of Fair Market Value made pursuant to this Plan shall be made without regard to any minority interest status or the limited liquidity of the Common Stock and shall be final, binding and conclusive with respect to all Awards granted under this Plan. If the Common Stock are not listed on an established securities exchange or regularly quoted by a recognized securities dealer, then Fair Market Value shall be established in good faith, in compliance with the requirements of Section 409A of the Code.

 

2.26         “Form S-8” has the meaning set forth in Section 5.3(b).

 

2.27         “GAAP” means the United States Generally Accepted Accounting Principles, as in effect from time to time.

 

 5 

 

 

2.28         “Incentive Stock Option” means an Option that is intended to comply with the requirements of Section 422 of the Code or any successor provision thereto.

 

2.29         “Listing Date” means the first date upon which any security of the Company is listed (or approved for listing) upon notice of issuance on any securities exchange or designated (or approved for designation) upon notice of issuance as a national market security on an interdealer quotation system.

 

2.30         “Market Stand-Off” has the meaning set forth in Section 15.

 

2.31         “Net Exercise Period” has the meaning set forth in Section 11.7.

 

2.32         “Nonqualified Stock Option” means an Option that is not intended or fails to comply with the requirements of Section 422 of the Code or any successor provision thereto.

 

2.33         “Non-Employee Director” means a Director who is a “non-employee director” within the meaning of Rule 16b-3.

 

2.34         “Option” means an option to purchase Common Stock that is either an Incentive Stock Option or Nonqualified Stock Option.

 

2.35         “Option Agreement” means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an individual Option grant. Each Option Agreement shall be subject to the terms and conditions of the Plan and need not be identical.

 

2.36         “Optionholder” means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.

 

2.37         “Participant” means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award.

 

2.38         “Performance Award” means an Award entitling the recipient to receive Common Stock or a cash payment upon the attainment of Performance Goals.

 

2.39         “Performance Goals” means, for a Performance Period, one or more goals established in writing by the Administrator for the Performance Period based upon one or more performance criteria. Depending on the performance criteria used to establish such Performance Goals, the Performance Goals may be expressed in terms of overall Company performance or the performance of a division, operating or business unit, or an individual.

 

2.40         “Performance Period” means the Company’s fiscal year, or any other period of time as the Administrator may select, over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant’s right to, and the payment of, a Performance Award.

 

 6 

 

 

2.41         “Permitted Holders” means (i) David D. Halbert, (ii) his spouse, widow, widower, domestic partner, parents, grandparents, lineal descendants, siblings and lineal descendants of siblings (in each case whether by blood relation, adoption, marriage or domestic partnership) of such person and heirs and any trusts or other holding, investment or estate planning vehicles for the benefit of any of the foregoing (collectively, together with David D. Halbert, “Halbert Family Members”) and (iii) any Person, any affiliate of, or corporation, general partnership, limited partnership, limited liability company, private limited company or other entity that directly or indirectly controls, is controlled by, or is under common control with, the Halbert Family Members, or any Permitted Trust primarily for the benefit of the Halbert Family Members. The phrase “controlled by” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise, and “Permitted Trust” means a bona fide trust where each trustee is (i) a Halbert Family Member, (ii) a professional in the business of providing trustee services, including private professional fiduciaries, trust companies and bank trust departments, or (iii) an individual who may be removed and replaced at the sole discretion of a Halbert Family Member.

 

2.42         “Permitted Transferee” means (i) any spouse, parents, siblings (by blood, marriage or adoption) or lineal descendants (by blood, marriage or adoption) of a Participant; (ii) any trust or other similar entity for the benefit of a Participant or the Participant’s spouse, parents, siblings or lineal descendants; provided, however, that any transfer made by a Participant to a Permitted Transferee may only be made if the Permitted Transferee, prior to the time of transfer of Common Stock, agrees in writing to be bound by the terms of this Agreement and provides written notice to the Company of such transfer.

 

2.43         “Person” means an individual, partnership, corporation, limited liability company, joint stock company, unincorporated organization or association, trust, joint venture, association or other similar entity, whether or not a legal entity.

 

2.44         “Plan” has the meaning set forth in Section 1.1.

 

2.45         “Related Rights” has the meaning set forth in Section 7.3(a).

 

2.46         “Restricted Award” means a Restricted Share or an RSU.

 

2.47         “Restricted Award Agreement” has the meaning set forth in Section 7.1.

 

2.48         “Restricted Share” has the meaning set forth in Section 7.1.

 

2.49         “Right of First Refusal” has the meaning set forth in Section 11.8.

 

2.50         “Right of Repurchase” has the meaning set forth in Section 11.9.

 

2.51         “RSU” has the meaning set forth in Section 7.1.

 

2.52         “Rule 16b-3” means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.

 

2.53         “Rule 701” has the meaning set forth in Section 5.3(a).

 

2.54         “SAR exercise price” has the meaning set forth in Section 7.3(b).

 

 7 

 

 

2.55         “Securities Act” means the Securities Act of 1933, as amended.

 

2.56         “Service Provider” has the meaning set forth in Section 1.2.

 

2.57         “Share Appreciation Right” means the right pursuant to an award granted under Section 7.3 to receive an amount equal to the excess, if any, of (A) the Fair Market Value, as of the date such Share Appreciation Right or portion thereof is surrendered, of the Common Stock covered by such right or such portion thereof, over (B) the aggregate SAR exercise price of such right or such portion thereof.

 

2.58         “Shareholder” means a shareholder of the Company.

 

2.59         “Subsidiary” means any foreign or domestic corporation, limited liability company, partnership or other entity of which 50% or more of the outstanding voting equity securities or voting power is Beneficially Owned directly or indirectly by the Company. For purposes of determining eligibility for the grant of Incentive Stock Options under the Plan, the term “Subsidiary” shall be defined in the manner required by Section 424(f) of the Code.

 

2.60         “TBOC” means the Texas Business Organizations Code.

 

3.ADMINISTRATION.

 

3.1           Administration by Directors. The Plan shall be administered by the Directors unless and until the Directors delegate administration to a Committee, as provided in Section 3.5.

 

3.2           Powers of Administrator. The Administrator shall have the power and authority to select and grant Awards, pursuant to the terms of the Plan, to Participants nominated for participation in the Plan by the Company’s chief executive officer.

 

3.3           Specific Powers. In particular, the Administrator shall have the authority: (i) to construe and interpret the Plan and apply its provisions; (ii) to promulgate, amend and rescind rules and regulations relating to the administration of the Plan; (iii) to authorize any person to execute, on behalf of the Company, any instrument required to carry out the purposes of the Plan; (iv) to determine when Awards are to be granted under the Plan; (v) from time to time to select, subject to the limitations set forth in this Plan, those Participants to whom Awards shall be granted; (vi) to determine the number of shares and class of Common Stock to be made subject to each Award; (vii) to prescribe the terms and conditions of each Award, including, without limitation, the exercise price and medium of payment, vesting, net exercise and Right of Repurchase provisions, and to specify the provisions of the Award Agreement relating to such grant or sale; (viii) to amend any outstanding Awards, including for the purpose of modifying the time or manner of vesting, the purchase price or exercise price, or the term of any outstanding Award; provided, however, that if any such amendment impairs a Participant’s rights or increases a Participant’s obligations under his or her Award or creates or increases a Participant’s federal income tax liability with respect to an Award, such amendment shall also be subject to the Participant’s consent (provided, however, a cancellation of an Award where the Participant receives a payment equal in value to the Fair Market Value of the vested Award or, in the case of vested Options, the difference between the Fair Market Value of the Common Stock subject to an Option and the exercise price, shall not constitute an impairment of the Participant’s rights that requires consent); (ix) to determine the duration and purpose of leaves of absences which may be granted to a Participant without constituting termination of their employment for purposes of the Plan, which periods shall be no shorter than the periods generally applicable to Employees under the Company’s employment policies; (x) to make decisions with respect to outstanding Options that may become necessary upon a change in corporate control or an event that triggers anti-dilution adjustments; and (xi) to exercise discretion to make any and all other determinations which it determines to be necessary or advisable for administration of the Plan.

 

 8 

 

 

3.4           Decisions Final. All decisions made by the Administrator pursuant to the provisions of the Plan shall be final, binding and conclusive on the Company and the Participants.

 

3.5           The Committee.

 

(a)         General. The Directors may delegate administration of the Plan to a Committee or Committees consisting of one or more Directors, and the term “Committee” shall apply to any person or persons to whom such authority has been delegated. If administration is delegated to a Committee, the Committee shall have, in connection with the administration of the Plan, the powers theretofore possessed by the Directors, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Directors or the Administrator shall thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Directors. The Directors may abolish the Committee at any time and reassume responsibility for the administration of the Plan. The members of the Committee shall be appointed by and serve at the pleasure of the Directors. From time to time, the Directors may increase or decrease the size of the Committee, add additional members to, remove members (with or without cause) from, appoint new members in substitution therefor, and fill vacancies, however caused, in the Committee. The Committee shall act pursuant to a vote of the majority of its members or, in the case of a Committee comprised of only two members, the unanimous consent of its members, whether present or not, or by the written consent of the majority of its members and minutes shall be kept of all of its meetings and copies thereof shall be provided to the Directors. Subject to the limitations prescribed by the Plan and the Directors, the Committee may establish and follow such rules and regulations for the conduct of its business as it may determine to be advisable.

 

(b)         Committee Composition when Common Stock are Publicly Traded. At such time as the Common Stock are publicly traded, in the discretion of the Directors, the Committee may consist solely of two or more Non-Employee Directors who meet the independence requirements of any securities market on which the Common Stock are traded. The Directors shall have discretion to determine whether or not they intend to comply with the exemption requirements of Rule 16b-3 of the Code. However, if the Directors intend to satisfy such exemption requirements with respect to any insider subject to Section 16 of the Exchange Act, the Committee shall be a compensation committee of the Directors that at all times consists solely of two or more Non-Employee Directors. Within the scope of such authority, the Directors or the Committee may delegate to a committee of one or more Directors who are not Non-Employee Directors the authority to grant Awards to eligible persons who are not then subject to Section 16 of the Exchange Act.

 

 9 

 

 

3.6           Indemnification. In addition to such other rights of indemnification as they may have as Directors or members of the Committee, and to the extent allowed by Applicable Law, the Administrator shall be indemnified by the Company against the reasonable expenses, including attorney’s fees, actually incurred in connection with any action, suit or proceeding or in connection with any appeal therein, to which the Administrator may be party by reason of any action taken or failure to act under or in connection with the Plan or any Award granted under the Plan, and against all amounts paid by the Administrator in settlement thereof (provided that the settlement has been approved by the Company, which approval shall not be unreasonably withheld) or paid by the Administrator in satisfaction of a judgment in any such action, suit or proceeding, except in relation to matters as to which it shall be adjudged in such action, suit or proceeding that such Administrator did not act in good faith; provided, however, that within 60 days after institution of any such action, suit or proceeding, such Administrator shall, in writing, offer the Company the opportunity at its own expense to handle and defend such action, suit or proceeding.

 

3.7           Reliance on Experts. In making any determination or in taking or not taking any action under this Plan, the Administrator may obtain and may rely upon the advice of experts, including employees of and professional advisors to the Company. No director, officer or agent of the Company Group shall be liable for any such action or determination taken or made or omitted in good faith.

 

4.COMMON STOCK SUBJECT TO THE PLAN.

 

4.1           Share Reserve. Subject to the provisions of Section 12.1 relating to adjustments upon changes in the Common Stock, the shares that may be issued pursuant to Awards shall consist of the Company’s authorized but unissued Common Stock or Common Stock held by the Company in its treasury, or a combination thereof, and the maximum aggregate amount of the Common Stock which may be issued upon exercise of all Awards under the Plan shall not exceed 133,500,000 shares, all of which may be issued as Incentive Stock Options. To the extent permitted by Applicable Laws or any applicable exchange rule, any Common Stock issued under this Plan that are issued (a) in connection with the Company’s acquisition of an unaffiliated business entity, (b) to the employees of such entity, and (c) in substitution of equity incentive awards previously issued to such employees by such entity shall not reduce the number of Common Stock available for issuance under the Plan.

 

4.2           Reversion of Shares to the Share Reserve. If any Award shall for any reason expire or otherwise terminate, in whole or in part, without having been exercised in full, the Common Stock not acquired under such Award shall revert to and again become available for issuance under the Plan. If Common Stock issued under the Plan are reacquired by the Company pursuant to the terms of any provision of this Plan, including a Net Exercise Offer under Section 11.8 or the Right of Repurchase of unvested Common Stock under Section 11.9, such shares shall again be available for purposes of the Plan.

 

4.3           Source of Shares. The Common Stock subject to the Plan may be authorized but unissued Common Stock or reacquired Common Stock, however reacquired.

 

4.4           Availability of Shares. During the terms of the Awards, the Company shall keep available at all times the number of Common Stock required to satisfy such Awards.

 

 10 

 

 

5.ELIGIBILITY.

 

5.1           Eligibility. Awards may be granted to Employees, Directors and Consultants nominated for participation in the Plan, subject to the approval of the Company’s compensation committee.

 

5.2           Consultants.

 

(a)         Prior to the Listing Date, a Consultant shall not be eligible for the grant of an Award if, at the time of grant, either the offer or the sale of the Company’s securities to such Consultant is not exempt under Rule 701 of the Securities Act (“Rule 701”) because of the nature of the services that the Consultant is providing to the Company, or because the Consultant is not a natural person, or as otherwise provided by Rule 701, unless the Company determines that such grant need not comply with the requirements of Rule 701 and will satisfy another exemption under the Securities Act as well as comply with all Applicable Laws.

 

(b)         From and after the Listing Date, a Consultant shall not be eligible for the grant of an Award if, at the time of grant, a Form S-8 Registration Statement under the Securities Act (“Form S-8”) is not available to register either the offer or the sale of the Company’s securities to such Consultant because of the nature of the services that the Consultant is providing to the Company, or because the Consultant is not a natural person, or as otherwise provided by the rules governing the use of Form S-8, unless the Company determines both (i) that such grant (1) shall be registered in another manner under the Securities Act (e.g., on a Form S-3 Registration Statement) or (2) does not require registration under the Securities Act in order to comply with the requirements of the Securities Act, if applicable, and (ii) that such grant complies with the securities laws of all other relevant jurisdictions.

 

5.3           Directors. Each Director of the Company shall be eligible to receive discretionary grants of Awards under the Plan.

 

6.OPTION PROVISIONS.

 

The Administrator may from time to time grant Options to Service Providers. Each Option shall be in such form and shall contain such terms and conditions as the Administrator shall deem appropriate, including whether such Options granted shall be Incentive Stock Options or Nonqualified Stock Options and the class of Common Stock that each underlying share is with respect to. Each Option shall be evidence by an Option Agreement that shall expressly identify the Option as Incentive Stock Option or Nonqualified Stock Option. The provisions of separate Options need not be identical, but each Option shall include (through incorporation of provisions hereof by reference in the Option or otherwise) the substance of each of the following provisions:

 

6.1           Term. No Option shall be exercisable after the expiration of 10 years from the date it was granted.

 

6.2           Exercise Price of an Option. The exercise price of each Option shall be not less than the greater of (a) 100% of the Fair Market Value of the Common Stock subject to the Option on the date the Option is granted and (b) the par value of the Common Stock. Notwithstanding the foregoing, an Option may be granted with an exercise price lower than 100% of Fair Market Value of the Common Stock subject to the Option on the date it is granted (but not less than par value) if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section 424(a) of the Code.

 

 11 

 

 

6.3           Consideration. The purchase price of Common Stock acquired pursuant to an Option shall be paid, to the extent permitted by Applicable Laws and regulations, either: (a) in cash, by certified or bank check or by electronic funds transfer at the time the Option is exercised; (b) by tendering to the Company other Common Stock, for redemption or repurchase by the Company, with a Fair Market Value on the date of redemption or repurchase equal to the exercise price (or portion thereof) due for the number of shares being acquired (with the proceeds of such redemption or repurchase being automatically applied by the Company towards paying the purchase price of the Common Stock); or (c) during a Net Exercise Period, by means of the Participant making an election, under the terms of the applicable Award Agreement, to receive a portion of the Common Stock underlying the Option being exercised as a cash payment and a portion as Common Stock, with instructions to the Company to apply such cash payment towards paying the purchase price of the Common Stock for which the Option is being exercised; (d) during any period for which the Common Stock are publicly traded (i.e., the Common Stock are listed on any established stock exchange or a national market system, or if the Common Stock are quoted on an applicable stock exchange or any similar system whereby the Common Stock are regularly quoted by a recognized securities dealer but closing sale prices are not reported), by a copy of instructions to a broker directing such broker to sell the Common Stock for which such Option is exercised, and to remit to the Company the aggregate Exercise Price of such Options (a “Cashless Exercise”) or (e) in any other form of legal consideration that may be acceptable to the Administrator, including without limitation with a promissory note; provided, however, if Applicable Laws require (or the Administrator otherwise considers appropriate), the par value (if any) of Common Stock, if newly issued, shall be paid in cash or cash equivalents. The interest rate payable under the terms of the promissory note shall not be less than the minimum rate (if any) required to avoid the imputation of additional interest under the Code. Subject to the foregoing, the Administrator (in its sole discretion) shall specify the term, interest rate, amortization requirements (if any) and other provisions of such note. Unless otherwise specifically provided in the Option, the purchase price of Common Stock acquired pursuant to an Option that is paid by tendering to the Company for redemption or repurchase other Common Stock acquired, directly or indirectly, from the Company, shall be paid only by Common Stock of the Company that have been held for more than six months (or such longer or shorter period of time required to avoid a charge to earnings for financial accounting purposes). Notwithstanding the foregoing, during any period for which the Common Stock are publicly traded (i.e., the Common Stock are listed on any established stock exchange or a national market system or if the Common Stock are quoted on an applicable stock exchange or any similar system whereby the Common Stock are regularly quoted by a recognized securities dealer but closing sale prices are not reported), a Cashless Exercise, exercise with a promissory note or other transaction by a Director or executive officer that involves or may involve a direct or indirect extension of credit or arrangement of an extension of credit by the Company, or an Affiliate in violation of Section 402(a) of the Sarbanes-Oxley Act (codified as Section 13(k) of the Exchange Act shall be prohibited with respect to any Award under this Plan.

 

6.4           Vesting; Exercisability. The Administrator will determine the vesting and exercisability provisions of each Option (which may be based on performance criteria, passage of time or other factors or any combination thereof), which provisions will be set forth in the applicable Award Agreement. Unless the Administrator or the terms of the Plan or the Award Agreement expressly provides otherwise, once exercisable, an Option will remain exercisable until the expiration or earlier termination of the Option.

 

 12 

 

 

6.5           Procedure for Exercise. An exercisable Option may be exercised in whole or in part and will be deemed exercised when the Company receives: (a) written or electronic notice of exercise (in accordance with the Award Agreement) from the person entitled to exercise the Option, and (b) full payment for the Common Stock with respect to which the Option is exercised (including provision for any applicable tax withholding); provided that if any person other than the Participant exercises the Option, such person will be required to provide evidence sufficient to reasonably establish that he or she is entitled to do so. Full payment may consist of any consideration and method of payment authorized by the Administrator and permitted by the Award Agreement and the Plan. Common Stock issued upon exercise of an Option will be issued in the name of the Participant or, if requested by the Participant, in the name of the Participant and his or her spouse. Exercising an Option in any manner will decrease the number of Common Stock thereafter available for sale under the Option, by the number of Common Stock as to which the Option is exercised. Unless otherwise determined by the Administrator, any fractional Common Stock acquired upon the exercise of an Option shall be rounded up to the nearest whole Common Stock.

 

6.6           Termination of Continuous Service. Upon the termination of an Optionholder’s Continuous Service:

 

(a)         other than as a result of the Optionholder’s death or Disability, the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination) until the earlier of (i) the date 90 days following the termination of the Optionholder’s Continuous Service and (ii) the expiration of the term of the Option as set forth in the Option Agreement, after which time the Option shall terminate; or

 

(b)         as a result of the Optionholder’s death or Disability, the Optionholder (or the Optionholder’s estate, by a person who acquired the right to exercise the Option by bequest or inheritance or by a person designated to exercise the Option upon the Optionholder’s death) may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination), but only until the earlier of (i) the date 12 months following such termination and (ii) the expiration of the term of the Option as set forth in the Option Agreement, after which time the Option shall terminate.

 

If the Optionholder does not exercise his or her Option within the time specified in the Option Agreement, the Option shall terminate. Unless otherwise provided in an Option Agreement or in an employment agreement the terms of which have been approved by the Administrator, outstanding Options that are not exercisable at the time an Optionholder’s Continuous Service terminates shall be forfeited and expire at the close of business on the date of such termination.

 

6.7           Substitution of Share Appreciation Rights. The Administrator may provide in an Award Agreement evidencing the grant of an Option that the Administrator, in its sole discretion, shall have the right to substitute a Share Appreciation Right for such Option at any time prior to or upon exercise of such Option; provided that such Share Appreciation Right shall be exercisable with respect to the same number of Common Stock for which such substituted Option would have been exercisable.

 

 13 

 

 

6.8           Incentive Stock Options. The exercise price per Share of an Incentive Stock Option shall be fixed by the Administrator at the time of grant or shall be determined by a method specified by the Administrator at the time of grant, but in no event shall the exercise price of an Option be less than the minimum exercise price specified in Section 6.2. No Incentive Stock Option may be issued to any individual who, at the time the Incentive Stock Option is granted, owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any of its Subsidiaries, unless (i) the exercise price determined as of the date of grant is at least 110% of the Fair Market Value on the date of grant of the Shares subject to such Incentive Stock Option and (ii) the Incentive Stock Option is not exercisable more than five (5) years from the date of grant thereof. No Participant shall be granted any Incentive Stock Option which would result in such Participant receiving a grant of Incentive Stock Options that would have an aggregate Fair Market Value in excess of $100,000, determined as of the time of grant, that would be exercisable for the first time by such Participant during any fiscal year. Any grants in excess of this limit shall be treated as Nonqualified Stock Options. No Incentive Stock Option may be granted under the Plan after the tenth (10th) anniversary of the Effective Date. The terms of any Incentive Stock Option granted under the Plan shall comply in all respects with the provisions of Section 422 of the Code, or any successor provision thereto, as amended from time to time.

 

6.9           Early Exercise Options. The Administrator may, in its discretion, provide that an Option may be exercised prior to the date such Option has vested by express provision in the applicable Award Agreement (such Option, an “Early Exercise Option”). If the Optionholder elects to exercise all or a portion of any Early Exercise Option before it is vested, the shares of Common Stock acquired under the Option that are attributable to the unvested portion of the Option shall be Restricted Shares. The applicable Award Agreement shall specify the extent (if any) to which and the time (if ever) at which the Optionholder will be entitled to dividends, voting and other rights in respect of such Restricted Shares prior to any vesting, and the restrictions imposed on such Restricted Shares and the conditions of release or lapse of such restrictions. Unless otherwise expressly provided in the applicable Award Agreement, Restricted Shares received from an Early Exercise Option shall be subject to Section 7.1.

 

7.PROVISIONS OF AWARDS OTHER THAN OPTIONS.

 

7.1           Restricted Awards. The Administrator may from time to time award (or sell at a purchase price determined by the Administrator) restricted shares of Common Stock (“Restricted Shares”) or restricted stock units (“RSUs”) under the Plan to eligible Participants. The Award Agreement evidencing a Restricted Award (a “Restricted Award Agreement”) shall contain the terms established by the Administrator for that Award, as well as any other terms, provisions, or restrictions that the Administrator may impose on the Award (including, but not limited to, the class of Common Stock that the shares that are subject to a Restricted Award are with respect to); in each case subject to the applicable provisions and limitations of this Section 7 and the other applicable provisions and limitations of this Plan. The terms and conditions of Restricted Award Agreements may change from time to time, and the terms and conditions of separate Restricted Award Agreements need not be identical, but each Restricted Award Agreement shall include (through incorporation of provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:

 

(a)           Purchase Price. The purchase price of a Restricted Award shall be determined by the Administrator at the Date of Grant, and may be stated as cash, property or a contract for prior or future services. In no event will such purchase price be less than the par value of the Common Stock.

 

 14 

 

 

(b)           Consideration. The consideration for Common Stock acquired pursuant to a Restricted Award Agreement shall be paid either in cash, by certified or bank check or by electronic funds transfer.

 

(c)           Vesting. The restrictions imposed on the exercise and/or settling of a Restricted Award and the subsequent issue of Common Stock (which may be based on performance criteria, passage of time or other factors or any combination thereof) will be set forth in the applicable Award Agreement.

 

(d)           Termination of Participant’s Continuous Service. Unless the Administrator otherwise expressly provides, Common Stock subject to a Restricted Award that remain subject to vesting conditions that have not been satisfied by the time specified in the applicable Award Agreement (including the termination of the Participant’s Continuous Service), will not vest and in the case of RSUs, will be canceled without payment to the Participant therefor, in each case to the extent not prohibited by law. The Award Agreement shall specify any other terms or conditions of the repurchase or cancellation, as the case may be, if the Award fails to vest. Any other Restricted Award that has not been exercised as of a termination of the Participant’s Continuous Service shall terminate on that date unless otherwise expressly provided by the Administrator in the applicable Award Agreement.

 

7.2           Performance Awards.

 

(a)           The Administrator may from time to time grant Performance Awards to any eligible Participant. Each Performance Award shall be in such form and shall contain such terms and conditions as the Administrator shall deem appropriate. The terms and conditions of separate Performance Awards need not be identical. The value of Performance Awards may be linked to any one or more specific criteria determined by the Administrator, in each case on a specified date or dates or over any period or periods determined by the Administrator. In making such determinations, the Administrator shall consider (among such other factors as it deems relevant in light of the specific type of Award) the contributions, responsibilities and other compensation of the particular Service Provider. Performance Awards may be paid in cash, Common Stock or both, as determined by the Administrator.

 

(b)           Without limiting Section 7.2(a), the Administrator may grant Performance Awards in the form of a cash bonus payable upon the attainment of objective Performance Goals, or such other criteria, whether or not objective, which are established by the Administrator, in each case on a specified date or dates or over any period or periods determined by the Administrator.

 

 15 

 

 

7.3           Share Appreciation Rights.

 

(a)           General. Share Appreciation Rights may be granted either alone or, provided the requirements of Section 7.3(b) are satisfied, in tandem with all or part of any Option granted under the Plan (“Related Rights”). Related Rights may be granted either at or after the time of the grant of such Option. Share Appreciation Rights shall be in such form and shall contain such terms and conditions as the Administrator shall deem appropriate and the provisions of separate Share Appreciation Rights need not be identical.

 

(b)           Grant Requirements. A Share Appreciation Right may only be granted if the Share Appreciation Right: (i) does not provide for the deferral of compensation within the meaning of Section 409A of the Code; or (ii) satisfies the requirements of Section 8.3 hereof. A Share Appreciation Right does not provide for a deferral of compensation if: (A) the value of the Common Stock the excess over which the right provides for payment upon exercise (the “SAR exercise price”) may never be less than the Fair Market Value of the underlying Common Stock on the date the right is granted; (B) the Common Stock subject to the right are traded on an established securities market; (C) only such traded Common Stock may be delivered in settlement of the right upon exercise; and (D) the right does not include any feature for the deferral of compensation other than the deferral of recognition of income until the exercise of the right.

 

(c)           Vesting, Exercise and Payment. The Administrator will determine the vesting and exercisability provisions of each Share Appreciation Right (which may be based on performance criteria, passage of time or other factors or any combination thereof), which provisions will be set forth in the applicable Award Agreement. Unless the Administrator otherwise expressly provides, once exercisable a Share Appreciation Right will remain exercisable until the expiration or earlier termination of the Share Appreciation Right. Upon exercise thereof, the holder of a Share Appreciation Right shall be entitled to receive from the Company, an amount equal to the product of (i) the excess of the Fair Market Value, on the date of such written request, of one Common Stock over the SAR exercise price per Common Stock specified in such Share Appreciation Right or its related Option, multiplied by (ii) the number of shares for which such Share Appreciation Right shall be exercised. Payment with respect to the exercise of a Share Appreciation Right that satisfies the requirements of Section 7.3(b)(i) shall be paid on the date of exercise and made in Common Stock (with or without restrictions as to substantial risk of forfeiture and transferability, as determined by the Administrator in its sole discretion), valued at Fair Market Value on the date of exercise. Payment with respect to the exercise of a Share Appreciation Right that does not satisfy the requirements of Section 7.3(b)(i) shall be paid at the time specified in the Award in accordance with the provisions of Section 8.3. Payment may be made in the form of Common Stock (with or without restrictions as to substantial risk of forfeiture and transferability, as determined by the Administrator in its sole discretion), cash or a combination thereof, as determined by the Administrator.

 

(d)           Exercise Price; Term. The Administrator shall set the terms and conditions or restrictions on the exercise of a Share Appreciation Right, but in no event shall a Share Appreciation Right have an exercise price less than 100% of the Fair Market Value of one Common Stock on the Date of Grant of such Share Appreciation Right or a term of greater than 10 years. A Related Right granted simultaneously with or subsequent to the grant of an Option and in conjunction therewith or in the alternative thereto shall have the same exercise price as the related Option, and shall be exercisable only to the same extent as the related Option; provided, however, that a Share Appreciation Right, by its terms, shall be exercisable only when the Fair Market Value per Common Stock subject to the Share Appreciation Right and related Option exceeds the exercise price per share thereof and no Share Appreciation Rights may be granted in tandem with an Option unless the Administrator determines that the requirements of Section 7.3(b)(i) are satisfied.

 

 16 

 

 

(e)           Reduction in the Underlying Option Shares. Upon any exercise of a Share Appreciation Right, the number of Common Stock for which any related Option shall be exercisable shall be reduced by the number of shares for which the Share Appreciation Right shall have been exercised. The number of Common Stock for which a Share Appreciation Right shall be exercisable shall be reduced upon any exercise of any related Option by the number of Common Stock for which such Option shall have been exercised.

 

(f)           Written Request. Any election by a Participant to receive cash in full or partial settlement of a Share Appreciation Right, and any exercise of such Share Appreciation Right for cash, may be made only by a written request filed with the Corporate Secretary of the Company during the period beginning on the third business day following the date of release for publication by the Company of quarterly or annual summary statements of earnings and ending on the twelfth business day following such date. Within 30 days of the receipt by the Company of a written request to receive cash in full or partial settlement of a Share Appreciation Right or to exercise such Share Appreciation Right for cash, the Administrator shall, in its sole discretion, either consent to or disapprove, in whole or in part, such written request. A written request to receive cash in full or partial settlement of a Share Appreciation Right or to exercise a Share Appreciation Right for cash may provide that, in the event the Administrator shall disapprove such written request, such written request shall be deemed to be an exercise of such Share Appreciation Right for Common Stock.

 

(g)           Disapproval by Administrator. If the Administrator disapproves in whole or in part any election by a Participant to receive cash in full or partial settlement of a Share Appreciation Right or to exercise such Share Appreciation Right for cash, such disapproval shall not affect such Optionholder’s right to exercise such Share Appreciation Right at a later date, to the extent that such Share Appreciation Right shall be otherwise exercisable, or to elect the form of payment at a later date, provided that an election to receive cash upon such later exercise shall be subject to the approval of the Administrator. Additionally, such disapproval shall not affect such Optionholder’s right to exercise any related Option.

 

(h)           Termination of Continuous Service. Upon the termination of the Continuous Service of a Participant who holds a Share Appreciation Right:

 

(i)other than as a result of the Participant’s death or Disability, the Participant may exercise his or her Share Appreciation Right (to the extent that the Participant was entitled to exercise such Share Appreciation Right as of the date of termination) until the earlier of (1) the date 90 days following the termination of the Participant’s Continuous Service and (2) the expiration of the term of the Share Appreciation Right as set forth in the Award Agreement, after which time the Share Appreciation Right shall terminate; or

 

 17 

 

 

(ii)as a result of the Participant’s death or Disability, the Participant (or the Participant’s estate, by a person who acquired the right to exercise the Share Appreciation Right by bequest or inheritance or by a person designated to exercise the Share Appreciation Right upon the Participant’s death) may exercise his or her Share Appreciation Right (to the extent that the Participant was entitled to exercise such Share Appreciation Right as of the date of termination), but only until the earlier of (i) the date 12 months following such termination and (ii) the expiration of the term of the Share Appreciation Right as set forth in the Award Agreement, after which time the Share Appreciation Right shall terminate.

 

If the Participant does not exercise his or her Share Appreciation Right within the time specified in the Award Agreement, the Share Appreciation Right shall terminate. Unless otherwise provided in an Award Agreement or in an employment agreement the terms of which have been approved by the Administrator, outstanding Share Appreciation Rights that are not exercisable at the time a Participant’s Continuous Service terminates shall be forfeited and expire at the close of business on the date of such termination.

 

8.PROVISIONS APPLICABLE TO ALL AWARDS

 

8.1           Award Agreements. The Administrator shall have sole and exclusive authority to determine the terms and conditions pursuant to which an Award may be made. By accepting an Award, a Participant shall be deemed to have accepted and agreed to the terms and conditions of the Plan and the Award Agreement. The Administrator may require that a Participant promptly execute and return to the Company his or her Award Agreement evidencing the Participant’s acceptance of and agreement to the terms and conditions of the Plan and the Award as a condition precedent to any Common Stock becoming issuable or deliverable by the Company pursuant to the Award. In addition, the Administrator may require that the spouse of any married Participant also promptly execute and return to the Company the Award Agreement evidencing the Award granted to the Participant or such other spousal consent form that the Administrator may require in connection with the grant of the Award.

 

8.2           Non-Transferability of Awards. Unless determined otherwise by the Administrator, an Award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution; provided, however, that the Administrator may, subject to Applicable Laws and such terms and conditions as it shall specify, permit the transfer of an Award, other than an Incentive Stock Option, for no consideration to a Permitted Transferee. Any Award transferred to a Permitted Transferee shall be further transferable only by last will and testament or the laws of descent and distribution or, for no consideration, to another Permitted Transferee of the Participant. During the lifetime of a Participant, an Award shall be exercisable only by the Participant or by a Permitted Transferee to whom such Award has been transferred in accordance with this Section 8.2. In no event may an Award be transferred to any person who has joined or is supporting a Competing Business.

 

 18 

 

 

8.3           Section 409A. Notwithstanding any contrary provision in the Plan or an Award Agreement, if any provision of the Plan or an Award Agreement contravenes any regulations or guidance promulgated under Section 409A of the Code or would cause an Award to be subject to additional taxes, accelerated taxation, interest and/or penalties under Section 409A of the Code, such provision of the Plan or Award Agreement may be modified by the Administrator without the consent of the Participant in any manner the Administrator deems reasonable or necessary. In making such modifications the Administrator shall attempt, but shall not be obligated, to maintain, to the maximum extent practicable, the original intent of the applicable provision without contravening the provisions of Section 409A of the Code. Moreover, any discretionary authority that the Administrator may have pursuant to the Plan shall not be applicable to an Award that is subject to Section 409A of the Code to the extent such discretionary authority would contravene Section 409A of the Code or the guidance promulgated thereunder. In the event that it is reasonably determined by the Administrator that, as a result of Section 409A of the Code, payments in respect of any Award under the Plan may not be made at the time contemplated by the terms of the Plan or the relevant Award Agreement, as the case may be, without causing the Participant holding such Award to be subject to taxation under Section 409A of the Code, including as a result of the fact that the Participant is a “specified employee” under Section 409A of the Code, the Company will make such payment on the first day that would not result in the Participant incurring any tax liability under Section 409A of the Code. The Company shall use commercially reasonable efforts to implement the provisions of this Section 8.3 in good faith; provided that neither the Company, its Affiliates, the Administrator nor any of the officers, employees, managers, directors or representatives of the Company Group shall have any liability to Participants with respect to this Section 8.3.

 

9.CONDITIONS UPON ISSUANCE OF COMMON STOCK.

 

9.1           Legal Compliance. Notwithstanding any other provision of the Plan, any Award Agreement or any other agreement entered into by the Company pursuant to the Plan, an Award may not be issued or exercised, and no Common Stock may be issued in connection with an Award unless the exercise of such Award and the issuance and delivery of such Common Stock will comply with Applicable Laws, including, without limitation, the Securities Act, the Exchange Act, U.S. state securities laws and regulations, and the regulations of any stock exchange or other securities market on which the Company’s securities may then be traded, and will be further subject to the approval of counsel for the Company with respect to such compliance. All certificates for Common Stock delivered under the Plan shall be subject to such transfer orders and other restrictions as the Administrator may deem advisable under the rules, regulations, and other requirements of the U.S. Securities and Exchange Commission, any exchange upon which the Common Stock are then listed, and any applicable securities law, and the Administrator may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions. To the extent and at such time or times as the Company is relying upon the exemption from registration under Section 12(g) of the Exchange Act pursuant to Rule 12h-1 thereunder, the Company shall deliver semiannually the financial and risk information described under Rule 701(e)(3), (4) and (5) under the Securities Act; provided that the Company is subject to such delivery requirements thereunder. Any financial or other information relating to the Company obtained by Participants in connection with or as a result of this Plan or their Awards shall be treated as confidential by the Participants, their spouses and/or their beneficiaries, as applicable.

 

 19 

 

 

9.2           Investment Representations. As a condition to the exercise and/or issuance of an Award, the Company may require the person acquiring such Award to represent and warrant at the time of any such acquisition that the Common Stock are being acquired only for investment and without any present intention to sell or distribute such Common Stock if, in the opinion of counsel for the Company, such a representation is required.

 

9.3           Inability to Obtain Authority. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company’s counsel to be necessary to the lawful issuance and sale of any Common Stock hereunder, will relieve the Company of any liability in respect of the failure to issue or sell such Common Stock as to which such requisite authority will not have been obtained.

 

10.USE OF PROCEEDS FROM COMMON STOCK.

 

Proceeds from the sale of Common Stock pursuant to Awards shall constitute general funds of the Company.

 

11.MISCELLANEOUS.

 

11.1         Acceleration of Exercisability and Vesting. The Administrator shall have the power to accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest in accordance with the Plan, notwithstanding the provisions in the Award stating the time at which it may first be exercised or the time during which it will vest.

 

11.2         Shareholder Rights. No Participant shall be deemed to be the holder of, or to have any of the rights of a Shareholder with respect to, any Common Stock subject to such Award unless and until (a) the Participant has satisfied all requirements for exercise of the Award pursuant to its terms, including the full satisfaction of any tax withholding liabilities and (b) his or her name has been entered on the Company’s Register of Shareholders, and no adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities or other property) or distributions of other rights for which the record date is prior to the date such Common Stock certificate is issued, except as provided in Section 12.1, hereof.

 

11.3         No Employment or other Service Rights. Nothing in the Plan or any instrument executed or Award granted pursuant thereto shall confer upon any Participant any right to continue to serve the Company Group in the capacity in effect at the time the Award was granted or shall affect the right of the Company Group to terminate (a) the employment of an Employee with or without notice and with or without cause, (b) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the Company Group or (c) the service of a Director pursuant to the Articles or the TBOC, and any applicable provisions of the corporate law of the jurisdiction in which the Company or the Affiliate is incorporated, as the case may be.

 

11.4         Transfer, Approved Leave of Absence. For purposes of the Plan, no termination of Continuous Service by an Employee shall be deemed to result from either (a) a transfer to the employment of the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate to another; or (b) an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the Employee’s right to re¬employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing.

 

 20 

 

 

11.5         Investment Assurances. The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Award, (a) to give written assurances satisfactory to the Company as to the Participant’s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Award; and (b) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Award for the Participant’s own account and not with any present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, shall be inoperative if (i) the issuance of the Common Stock upon the exercise or acquisition of Common Stock under the Award has been registered under a then currently effective registration statement under the Securities Act or (ii) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on share certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.

 

11.6         Withholding Obligations. Common Stock will be delivered to a Participant only after the Participant has satisfied any tax withholding requirements relating to the exercise, vesting or acquisition of such Common Stock. To the extent provided by the terms of an Award Agreement and subject to the discretion of the Administrator, the Participant may satisfy any federal, state or local tax withholding obligation relating to the exercise or acquisition of Common Stock under an Award by any of the following means (in addition to the Company’s right to withhold from any compensation paid to the Participant by the Company) or by a combination of such means: (a) tendering a cash payment; (b) authorizing the Company to issue and then immediately redeem or repurchase at Fair Market Value Common Stock out of the Common Stock issued to the Participant as a result of the exercise or acquisition of Common Stock under the Award; or (c) tendering to the Company currently owned and unencumbered Common Stock of the Company for redemption or repurchase and, in each of (b) and (c), immediately tendering the redemption or repurchase price paid by the Company in respect of such Common Stock back to the Company; provided, however, that the Company shall redeem or repurchase only that number of Common Stock having a Fair Market Value equal to the minimum amount of tax required to be withheld under Applicable Laws.

 

11.7         Net Exercise Offer. The Company may, from time to time and in the Administrator’s sole and exclusive discretion, allow the net exercise of Options granted to a Participant pursuant to the Plan by issuing a notice to all Participants that sets forth: (a) the existence of a net exercise window; and (b) the duration of the window (the “Net Exercise Period”).

 

 21 

 

 

11.8         Right of First Refusal. Each Award Agreement may provide that, if the Common Stock are not readily tradable on an established securities market, the Company shall have a right of first refusal as described in this Section 11.8 (the “Right of First Refusal”). The Right of First Refusal may be exercisable in connection with any proposed sale, hypothecation, gift or other disposition of Common Stock, if purchased by the Participant pursuant to an Award Agreement, other than transfers to a Permitted Transferee. If a Shareholder desires to accept a bona fide third-party offer to purchase any or all of his Common Stock, the Common Stock shall first be tendered to the Company for its repurchase or redemption upon the same terms and conditions (as to timing and price) as are set forth in the bona fide offer. In the case of a proposed gift or other non-compensatory transfer of Common Stock, the purchase price per Common Stock under the Right of First Refusal shall be the Fair Market Value determined at the time of the proposed gift or other transfer.

 

11.9         Right of Repurchase. Each Award Agreement may provide that, following a termination of the Participant’s Continuous Service, the Company may repurchase the Participant’s Common Stock acquired under the Plan as provided in this Section 11.9 (the “Right of Repurchase”). The Right of Repurchase shall be exercisable at a price equal to (a) the Fair Market Value of vested Common Stock or, in the case of exercisable options, the Fair Market Value of the Common Stock underlying such unexercised options less the aggregate exercise price of such options or (b) in the case of unvested Common Stock, the lesser of the purchase price at which such Common Stock were acquired under the Plan or the Fair Market Value of such Common Stock. The Award Agreement may specify the period of time following a termination of the Participant’s Continuous Service during which the Right of Repurchase may be exercised; provided that such exercise may in any event be extended to a date that is within 60 days after the date that is six months after the date that such Common Stock were issued to the Participant. Notwithstanding the above, nothing in this Plan is intended to interfere with the Company’s right to repurchase or redeem any Common Stock set forth in the Articles.

 

11.10       Termination of Repurchase and First Refusal Rights. Each Award Agreement shall provide that the Right of Repurchase with respect to vested Common Stock and the Right of First Refusal shall have no effect with respect to, or shall lapse and cease to have effect when the issuer’s securities become publicly traded or a determination is made by counsel for the Company that such Rights of First Refusal and Rights of Repurchase are not permitted under applicable federal or state securities laws.

 

11.11       Recoupment Provisions. Any Awards granted under the Plan shall be subject to any clawback or recoupment policies and procedures that are required under Applicable Laws.

 

12.ADJUSTMENTS UPON CHANGES IN ORDINARY SHARES.

 

12.1         Capitalization Adjustments.

 

(a)         Upon (or, as may be necessary to effect the adjustment, immediately prior to): any reclassification, recapitalization, share split (including a share split in the form of a share dividend) or reverse share split; any merger, combination, consolidation, or other reorganization; any split-up, spin-off, or similar extraordinary dividend distribution in respect of the Common Stock; or any exchange of Common Stock or other securities of the Company, or any similar, unusual or extraordinary corporate transaction in respect of the Common Stock; then the Administrator shall equitably and proportionately adjust (i) the number and type of Common Stock (or other securities) that thereafter may be made the subject of Awards (including the specific share limits, maximums and numbers of shares set forth elsewhere in this Plan), (ii) the number, amount and type of Common Stock (or other securities or property) subject to any outstanding Awards, (iii) the grant, purchase, or exercise price of any outstanding Awards, and/or (iv) the securities, cash or other property deliverable upon exercise or vesting of any outstanding Awards, in each case to the extent necessary to preserve (but not increase) the level of incentives intended by this Plan and the then-outstanding Awards.

 

 22 

 

 

(b)         Unless otherwise expressly provided in the applicable Award Agreement, upon (or, as may be necessary to effect the adjustment, immediately prior to) any event or transaction described in the preceding paragraph or a sale of all or substantially all of the business or assets of the Company as an entirety, the Administrator shall equitably and proportionately adjust the performance standards applicable to any then-outstanding performance-based Awards to the extent necessary to preserve (but not increase) the level of incentives by this Plan and the then-outstanding performance-based Awards.

 

(c)         It is intended that, if possible, any adjustments contemplated by the preceding two paragraphs shall be made in a manner that satisfies Applicable Laws (including, without limitation and as applicable in the circumstances, Section 424 of the Code and Section 409A of the Code) and accounting (so as to not trigger any charge to earnings with respect to such adjustment) requirements.

 

(d)         Any good faith determination by the Administrator as to whether an adjustment is required in the circumstances pursuant to this Section 12.1, and the extent and nature of any such adjustment, shall be final, binding and conclusive on all persons.

 

(e)         Unless otherwise expressly provided by the Administrator, in no event shall a conversion of one or more outstanding shares of the Company’s Preference Stock or any new issuance of securities by the Company for consideration be deemed, in and of itself, to require an adjustment pursuant to this Section 12.1.

 

12.2         Dissolution or Liquidation. In the event of a dissolution or liquidation of the Company, then all outstanding Awards shall terminate immediately prior to such event.

 

12.3         Change of Control. In the event of a Change of Control of the Company, or such other transaction in which all classes of the Common Stock outstanding immediately prior to the transaction are converted by virtue of the transaction into other property, whether in the form of securities, cash or otherwise, then, the Company, to the extent permitted by Applicable Law, but otherwise in the sole discretion of the Administrator may provide for: (i) the continuation of outstanding Awards by the Company (if the Company is the surviving entity); (ii) the assumption of the Plan and such outstanding Awards by the surviving entity or its parent; (iii) the substitution by the surviving entity or its parent of Awards with substantially the same terms (including an award to acquire the same consideration paid to the Shareholders in the transaction described in this Section 12.3) for such outstanding Awards and, if appropriate, subject to the equitable adjustment provisions of Section 12.1 hereof; (iv) the acceleration of the vesting, settlement and delivery of all Awards outstanding under the Plan; (v) the cancellation of any outstanding Awards in consideration for a payment (in cash or other property) equal in value to the Fair Market Value of vested Awards, or in the case of an Option or Share Appreciation Right, the difference between the Fair Market Value and the exercise price for the Common Stock subject to exercise (i.e., to the extent vested) under any outstanding Option or Share Appreciation Right; or (vi) the cancellation of such outstanding Awards without payment of any consideration. If Awards would be canceled without consideration for vested Awards, the Participant shall have the right, exercisable during the later of the ten-day period ending on the fifth day prior to such merger or consolidation or ten days after the Administrator provides the Award holder a notice of cancellation, to exercise such Awards in whole or in part without regard to any installment exercise provisions in the Award Agreement; provided that the Administrator may, in its discretion, condition the exercise of any Award on the consummation of the Change of Control.

 

 23 

 

 

12.4         Sale of a Business. In the event that a Service Provider’s Continuous Service with the Company Group terminates because of the sale or other divestiture of a Subsidiary or other business unit of the Company Group, then (i) any outstanding time-based Award made to such Participant shall vest pro rata as of the date of termination and (ii) the treatment of any outstanding Performance Award made to such Participant shall be determined by the Administrator in its sole and exclusive discretion at the time the Subsidiary or other business unit of the Company Group is divested.

 

12.5         Compliance with Section 409A. No action shall be taken under this Article 12 that will cause an Award to fail to comply with Section 409A of the Code, to the extent applicable to such Award. Any adjustments to outstanding Awards shall be effected in a manner which shall preclude the enlargement or dilution of rights and benefits under such options and shall be conducted in compliance with Section 409A of the Code.

 

13.AMENDMENT OF THE PLAN AND AWARDS.

 

13.1         Amendment of Plan. The Administrator at any time, and from time to time, may amend, suspend or terminate the Plan in accordance with Applicable Law. However, except as provided in Section 12.1 relating to adjustments upon changes in the Common Stock, no amendment shall be effective unless approved by the Shareholders to the extent Shareholder approval is necessary to satisfy any Applicable Law or any applicable securities exchange listing requirements. At the time of such amendment, the Directors shall determine, upon advice from counsel, whether such amendment will be contingent on Shareholder approval.

 

13.2         Shareholder Approval. The Directors may, in their sole discretion, submit any other amendment to the Plan for Shareholder approval.

 

13.3         No Impairment of Rights. Rights under any Award granted before amendment of the Plan shall not be impaired by any amendment of the Plan (and shall continue to be subject to the terms of the Plan as in effect as of immediately prior to the applicable amendment) unless (a) the Company requests the consent of the Participant and (b) the Participant consents in writing. However, a cancellation of an Award where the Participant receives a payment equal in value to the Fair Market Value of the vested Award or, in the case of vested Options, the difference between the Fair Market Value and the exercise price, shall not be an impairment of the Participant’s rights that requires consent of the Participant.

 

 24 

 

 

13.4         Amendment of Awards. The Administrator at any time, and from time to time, may amend the terms of any one or more Awards or, as approved by the Directors and subject to Applicable Laws, provide for the substitution of a new Award for an existing Award; provided, however, that the Administrator may not effect any amendment which would otherwise constitute an impairment of the rights under any Award unless (a) the Company requests the consent of the Participant and (b) the Participant consents in writing. For the avoidance of doubt, the cancellation of an Award where the Participant receives a payment equal in value to the Fair Market Value of the vested Award or, in the case of vested Options, the difference between the Fair Market Value of the Common Stock underlying the Option and the aggregate exercise price, shall not be an impairment of the Participant’s rights that requires consent of the Participant.

 

14.GENERAL PROVISIONS.

 

14.1         Other Compensation Arrangements. Nothing contained in this Plan shall prevent the Administrator from adopting other or additional compensation arrangements, subject to Shareholder approval if such approval is required; and such arrangements may be either generally applicable or applicable only in specific cases.

 

14.2         Recapitalizations. Each Award Agreement shall contain provisions required to reflect the provisions of Section 12.1.

 

14.3         Delivery. Except in the event of an early exercise of an Option as provided in Section 6.9, upon exercise of a right granted under this Plan, the Company shall issue Common Stock or pay any amounts due within a reasonable period of time thereafter. Subject to any statutory or regulatory obligations the Company may otherwise have, for purposes of this Plan, 30 days shall be considered a reasonable period of time.

 

14.4         Other Provisions.

 

(a)         The Award Agreements authorized under the Plan may contain such other provisions not inconsistent with this Plan, including, without limitation, restrictions upon the exercise of the Awards, as the Administrator may deem advisable.

 

(b)         Unless explicitly provided otherwise in an Award Agreement, if there is a conflict between the terms of the Plan and an Award Agreement, the terms of the Plan shall control.

 

14.5         Cancellation and Rescission of Awards for Detrimental Activity.

 

(a)         Upon exercise, payment or delivery pursuant to an Award, the Participant shall certify in a manner acceptable to the Company that the Participant has not engaged in any Detrimental Activity.

 

(b)         Unless the Award Agreement specifies otherwise, the Administrator may cancel, rescind, suspend, withhold or otherwise limit or restrict any unexpired, unpaid, or deferred Awards at any time if the Participant engages in any Detrimental Activity.

 

 25 

 

 

(c)         In the event a Participant engages in Detrimental Activity after any exercise, payment or delivery pursuant to an Award, during any period for which any restrictive covenant prohibiting such activity is applicable to the Participant, such exercise, payment or delivery may be rescinded within one year thereafter. In the event of any such rescission, the Participant shall pay to the Company the amount of any gain realized or payment received as a result of the exercise, payment or delivery, in such manner and on such terms and conditions as may be required by the Company. The Company shall be entitled to set off against the amount of any such gain any amount owed to the Participant by the Company.

 

(d)         At the Administrator’s discretion, the Company may exercise the right of rescission set forth in this Section 14.5 via the mandatory redemption or repurchase of the Participant’s Common Stock at a price equal to the price paid by the Participant to acquire the Common Stock.

 

14.6         Paperless Administration. In the event that the Company establishes, for itself or using the services of a third party, an automated system for the documentation, granting or exercise of Awards, such as a system using an interne website or interactive voice response, then the paperless documentation, granting or exercise of Awards by a Participant may be permitted through the use of such an automated system.

 

14.7         No Rights to Awards. No Service Provider or other person shall have any claim to be granted any Award pursuant to the Plan, and neither the Company nor the Administrator is obligated to treat Service Providers, Participants or any other persons uniformly.

 

14.8         Unfunded Status of Awards. The Plan is intended to be an “unfunded” plan for incentive compensation. With respect to any payments not yet made to a Participant pursuant to an Award, nothing contained in the Plan or any Award Agreement shall give the Participant any rights that are greater than those of a general creditor of the Company Group.

 

14.9         Expenses. The expenses of administering the Plan shall be borne by the Company Group.

 

15.MARKET STAND-OFF.

 

Each Award Agreement shall provide that, in connection with any underwritten public offering by the Company of its equity securities pursuant to an effective registration statement filed under the Securities Act, including the Company’s initial public offering, the Participant shall agree not to sell, make any short sale of, loan, hypothecate, pledge, grant any option for the repurchase of, transfer the economic consequences of ownership or otherwise dispose or transfer for value or otherwise agree to engage in any of the foregoing transactions with respect to any Common Stock without the prior written consent of the Company or its underwriters, for such period of time from and after the effective date of such registration statement as may be requested by the Company or such underwriters (the “Market Stand-Off”). In order to enforce the Market Stand-Off, the Company may impose stop-transfer instructions with respect to the Common Stock acquired under this Plan until the end of the applicable stand-off period. If there is any change in the number of outstanding Common Stock by reason of a share split, reverse share split, share dividend, recapitalization (excluding issuances of Common Stock in the ordinary course of business), combination, reclassification, dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off or a spin-off), a merger or consolidation; a reverse merger or similar transaction, then any new, substituted or additional securities which are by reason of such transaction distributed with respect to any Common Stock subject to the Market Stand-Off, or into which such Common Stock thereby become convertible, shall immediately be subject to the Market Stand-Off.

 

 26 

 

 

16.EFFECTIVE DATE OF PLAN.

 

The Plan shall become effective as of the Effective Date.

 

17.TERMINATION OR SUSPENSION OF THE PLAN.

 

Unless terminated by the Directors at an earlier date pursuant to Section 13.1 hereof, the Plan will continue in effect for a term of ten (10) years commencing on the Effective Date. No Award shall be granted pursuant to the Plan after such date, but Awards theretofore granted may extend beyond that date. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.

 

18.CHOICE OF LAW; WAIVER OF JURY TRIAL.

 

The laws of the State of Texas shall govern all questions concerning the construction, validity and interpretation of this Plan and any Award Agreement. The Participant hereby irrevocably waives all right to trial by jury in any action, proceeding or counterclaim arising out of or relating to this Plan and/or any Award Agreement.

 

 27 

 

 

Exhibit 10.4(b)

 

CARIS LIFE SCIENCES, INC.

 

2020 INCENTIVE PLAN

 

INCENTIVE STOCK OPTION AWARD AGREEMENT

 

This Incentive Stock Option Award Agreement (the “Agreement”) is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Caris Life Sciences, Inc., a Texas corporation (the “Company”), and the participant named below (the “Participant”). Capitalized terms not defined herein shall have the meaning ascribed to them in the Company’s 2020 Incentive Plan (the “Plan”).

 

Participant: [                 ]

 

Address: [                 ]

 

Grant Number: [                 ]

 

Exercise Price Per Share: [                 ]

 

Date of Grant: [                 ]

 

Expiration Date: [                 ]

 

Vesting Commencement Date: [                 ]

 

WHEREAS, the Company desires to grant options to purchase shares of common stock of the Company, par value US$0.001 per share (the “Shares”) to certain employees of the Company;

 

WHEREAS, the Company has adopted the Plan in order to effect such grants; and

 

WHEREAS, the Administrator has determined that it is in the interest of the Company to grant these options to the Participant.

 

NOW, THEREFORE, in consideration of the services to be rendered by the Participant to the Company and subject to the terms and conditions set forth herein and in the Plan, the parties hereto agree as follows:

 

1.            Grant of Option. The Company hereby grants to Participant an option (this “Option”) to purchase the total number of Shares set forth above as Total Shares of Common Stock at the Exercise Price Per Share set forth above (the “Exercise Price”), subject to all of the terms and conditions of this Agreement and the Plan. The Option is intended to be an Incentive Stock Option within the meaning of Section 422 of the United States Internal Revenue Code of 1986, as amended (the “Code”), although the Company makes no representation or guarantee that this Option will qualify as an Incentive Stock Option. Participant shall not be granted any Incentive Stock Option which would result in the Participant receiving a grant of Incentive Stock Options that would have an aggregate Fair Market Value in excess of $100,000, determined as of the Date of Grant, that would be exercisable for the first time by the Participant during any fiscal year. Any grant in excess of this limit shall be treated as Nonqualified Stock Options. Should the Participant hold, in addition to this Option, one or more other options to purchase Shares which become exercisable for the first time in the same calendar year as this option, then for purposes of the foregoing limitations on the exercisability of such options as Incentive Stock Options, this Option and each of those other options shall be deemed to become first exercisable in that calendar year on the basis of the chronological order in which they were granted, except to the extent otherwise provided under Applicable Law or regulation.

 

 

 

 

2.            Exercise Period; Vesting.

 

2.1.            Exercisability. Unless expired as provided in Section 3 of this Agreement, this Option may be exercised in whole or in part from time to time to the extent they have become vested, during the period of Participant’s Continuous Service and pursuant to the terms of Section 4. Upon exercise of a portion of this Option that has vested in accordance with the vesting schedule set forth in Section 2.2, Participant shall receive Shares in accordance with Section 5.5, in each case subject to the restrictions on transfer set forth in Sections 7 and 10 below.

 

2.2.            Vesting. The Option shall become vested based on the table referenced on page 1. This Option may not be exercised for less than a full share.

 

3.            Expiration. This Option shall expire on the Expiration Date set forth above or earlier as provided in Section 4 below or, if applicable, pursuant to Section 6 of the Plan.

 

4.            Termination of Continuous Service.

 

4.1.            Other than as a Result of Death or Disability. Unless otherwise provided in an agreement the terms of which have been approved by the Administrator, if Participant’s Continuous Service is terminated for any reason, except death or Disability, the Participant may exercise this Option (to the extent that the Participant was entitled to exercise such Option as of the date of termination) until the earlier of (i) the date ninety (90) days following the termination of the Participant’s Continuous Service and (ii) the Expiration Date, after which time this Option shall terminate.

 

4.2.            Because of Death or Disability. If Participant’s Continuous Service is terminated because of the death or Disability of Participant, the Participant (or the Participant’s estate, by a person who acquired the right to exercise this Option by bequest or inheritance or by a person designated to exercise this Option upon the Participant’s death) may exercise the Participant’s Option (to the extent that the Participant was entitled to exercise such Option as of the date of termination), but only until the earlier of (i) the date twelve (12) months following such termination and (ii) the Expiration Date, after which time this Option shall terminate.

 

4.3.            No Employment Rights. Nothing in the Plan or this Agreement shall confer on Participant any right to continue to serve the Company Group in the capacity in effect as of the Date of Grant or shall affect the right of the Company Group to terminate the Participant’s employment with or without notice and with or without cause or shall give the Participant any right to be reemployed by the Company Group following a termination of employment for any reason.

 

Page 2

2024

 

 

4.4.            Cancellation and Rescission of Options for Detrimental Activity.

 

(a)            The Administrator may cancel, rescind, suspend, withhold or otherwise limit or restrict any Options at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.

 

(b)            Upon exercise, payment or delivery pursuant to exercise of this Option, the Participant shall certify in a manner acceptable to the Company that he or she is in compliance with the terms and conditions of the Plan and has not engaged in any Detrimental Activity. In the event a Participant engages in Detrimental Activity after the exercise, payment or delivery of any Shares pursuant to this Agreement, during any period for which any restrictive covenant prohibiting such activity is applicable to the Participant, such exercise, payment or delivery may be rescinded within one (1) year thereafter. In the event of any such rescission, the Participant shall pay to the Company the amount of any gain realized or payment received as a result of the exercise, payment or delivery of such Shares, in such manner and on such terms and conditions as may be required by the Company. The Company shall be entitled to setoff against the amount of any such gain any amount owed to the Participant by the Company.

 

(c)            At the Administrator’s discretion, the Company may exercise the right of rescission set forth in this Section 4.4 via the mandatory redemption or repurchase of the Participant’s Shares at a price equal to the price paid by the Participant to acquire the Shares.

 

5.            Manner of Exercise.

 

5.1.            Share Option Exercise Agreement. To exercise this Option, Participant (or the Participant’s estate, by a person who acquired the right to exercise this Option by bequest or inheritance or by a person designated to exercise this Option upon the Participant’s death) must deliver to the Company an executed share option exercise agreement in the form attached hereto as Exhibit A, or in such other form as may be approved by the Administrator from time to time (the “Exercise Agreement”), which shall set forth, inter alia, (a) Participant’s election to exercise this Option, (b) the number of Shares being purchased, (c) any restrictions imposed on the Shares and (d) any representations, warranties and agreements regarding Participant’s investment intent and access to information as may be required by the Company to comply with Applicable Laws. If someone other than Participant exercises this Option, then such person must submit evidence reasonably acceptable to the Company verifying that such person is entitled to do so.

 

5.2.            Limitations on Exercise and Issuance. The Option may not be exercised unless such exercise is in compliance with all Applicable Laws as are in effect on the date of exercise and the Shares underlying the exercised Option may not be issued until the Participant executes an Adoption Agreement to become a Shareholder to that certain Voting Agreement of the Company by and among the Company and each of its Shareholders.

 

5.3.            Payment. The entire Exercise Price shall be payable in full by cash or check for an amount equal to the aggregate exercise price of the Shares being purchased. Alternatively, in the sole discretion of the Administrator and upon such terms and at such times as the Administrator shall approve, the Exercise Price may be paid by:

 

Page 3

2024

 

 

(a)            tendering to the Company other Shares, for redemption or repurchase by the Company, with a Fair Market Value on the date of redemption or repurchase equal to the exercise price (or portion thereof) due for the number of Shares being acquired (with the proceeds of such redemption or repurchase being automatically applied by the Company towards paying the purchase price of the Shares) (collectively a “Share For Share Exercise”); provided, however, that the Shares used in such Share for Share Exercise (i) have either (1) been held for more than six (6) months (or such longer or shorter period of time required to avoid a charge to earnings for financial accounting purposes) and have been paid for within the meaning of SEC Rule 144 (and if such shares were purchased from the Company by use of a promissory note, such note has been fully paid with respect to such shares); or (2) were obtained by Participant in the open public market; and (ii) are clear of all liens, claims, encumbrances or security interests;

 

(b)            during any period for which the Shares are publicly traded (i.e., the Shares are listed on any established stock exchange or a national market system, or if the Shares are quoted on an applicable stock exchange or any similar system whereby the Shares are regularly quoted by a recognized securities dealer but closing sale prices are not reported), by a copy of instructions to a broker directing such broker to sell the Shares for which this Option is exercised, and to remit to the Company the aggregate Exercise Price of this Option (a “Cashless Exercise”); provided, however, a Cashless Exercise by a Participant officer that involves or may involve a direct or indirect extension of credit or arrangement of an extension of credit by the Company Group in violation of Section 402(a) of the Sarbanes-Oxley Act (codified as Section 13(k) of the Securities Exchange Act of 1934, 15 U.S.C. § 78m(k)) shall be prohibited;

 

(c)            during a Net Exercise Period, by means of the Participant electing in the Exercise Agreement to receive a portion of the Shares underlying this Option as a cash payment and a portion as Shares, with instructions to the Company to apply such cash payment towards paying the purchase price of the Shares for which this Option is being exercised; provided that in no event shall the cash payment received by the Participant pursuant to such election exceed the aggregate exercise price of the Shares for which this Option is being exercised;

 

(d)            by any other form of legal consideration that may be acceptable to the Administrator, including without limitation with a full-recourse promissory note. However, if there is a stated par value of the Shares and Applicable Laws require, the par value of the Shares, if newly issued, shall be paid in cash or cash equivalents. The interest rate payable under the terms of the promissory note shall not be less than the minimum rate (if any) required to avoid the imputation of additional interest under the Code. Subject to the foregoing, the Administrator (in its sole discretion) shall specify the term, interest rate, amortization requirements (if any) and other provisions of such note. Exercise with a promissory note or other transaction by a Participant officer that involves or may involve a direct or indirect extension of credit or arrangement of an extension of credit by the Company Group in violation of Section 402(a) of the Sarbanes-Oxley Act (codified as Section 13(k) of the Securities Exchange Act of 1934, 15 U.S.C. § 78m(k)) shall be prohibited; or

 

(e)             by any combination of the foregoing.

 

Page 4

2024

 

 

5.4.            Tax Withholding. Prior to the issuance of the Shares upon exercise of this Option, Participant must satisfy any tax withholding obligations relating to the exercise of this Option and the acquisition of the Shares. If the Administrator permits, in addition to the Exercise Price payment alternatives in Section 5.3, Participant may provide for payment of withholding taxes upon exercise of this Option by (a) authorizing the Company to issue and then immediately redeem or repurchase, at Fair Market Value, Shares out of the Shares issued to the Participant as a result of the exercise of this Option or (b) tendering to the Company currently owned and unencumbered Shares of the Company for redemption or repurchase and, in each of (a) and (b), immediately tendering the redemption or repurchase price paid by the Company in respect of such Shares back to the Company.

 

5.5.            Issuance of Shares. Provided that the Exercise Agreement and payment are in form and substance satisfactory to counsel for the Company, the Company shall issue the Shares registered in the name of Participant or, if requested by the Participant, in the name of the Participant and the Participant’s spouse, and shall deliver certificates representing the Shares with the appropriate legends affixed thereto.

 

6.            Compliance with Laws and Regulations. The exercise of this Option and the issuance and transfer of Shares shall be subject to compliance by the Company and Participant with all Applicable Laws and with all applicable requirements of any stock exchange on which the Shares may be listed at the time of such issuance or transfer. Participant understands that the Company is under no obligation to register or qualify the Shares with any federal or state securities commission or any stock exchange to effect such compliance.

 

7.            Nontransferability of Option. The Option may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than to a designated beneficiary upon the Participant’s death or by will or by the laws of descent and distribution. During the lifetime of a Participant, this Option shall be exercisable only by the Participant. No assignment or transfer of this Option, or the rights represented thereby, whether voluntary or involuntary, by operation of law or otherwise (except to a designated beneficiary upon death by will or the laws of descent or distribution) will vest in the assignee or transferee any interest or right herein whatsoever, but immediately upon such assignment or transfer this Option will terminate and become of no further effect.

 

8.            Privileges of Share Ownership. Participant shall not have any of the rights of a Shareholder with respect to any Shares until the Shares are issued to Participant.

 

9.            Restrictive Covenants. As a condition to the grant of this Option, the Participant agrees to comply with the restrictive covenants (each a “Restrictive Covenant”) set forth in any Proprietary Information, Intellectual Property, Restrictive Covenant and Arbitration Agreement (the “PIIA”) or other agreement or policy that may be in effect between the Participant and the Company Group. The Participant understands that the cancellation of any Option or rights under this Agreement may occur for any violation or lack of enforceability of any Restrictive Covenant and such cancellation may not be adequate recompense for the damages potentially sustained by the Company. Such cancellation shall be in addition to any equitable and legal rights the Company Group has or may have and shall not constitute a release of any claim that the Company Group may have for damages, past, present or future. In addition, a breach by the Participant of any provisions of any Restrictive Covenant that occurs after any exercise of any Option or delivery of Shares pursuant to this Agreement (including any breach occurring after termination of employment) shall cause the exercise of this Option and the delivery of any Shares under this Agreement to be rescinded (and if the Participant has previously sold the Shares issued pursuant to this Agreement, the Participant would be required to pay back to the Company Group the pre-tax proceeds received from the sale of such Shares).

 

Page 5

2024

 

 

At the Administrator’s discretion, the Company may exercise the right of rescission set forth in this Section 9 via the mandatory redemption or repurchase of the Participant’s Shares at a price equal to the aggregate Exercise Price paid by the Participant for the Shares.

 

10.          Restrictions on Transfer.

 

10.1.          Securities Law Restrictions. Regardless of whether the offering and sale of the Shares under the Plan has been registered under the Securities Act, the securities laws of another jurisdiction or registered or qualified under the securities laws of any state, the Company at its discretion may impose restrictions upon the sale, pledge or other transfer of such Shares (including the placement of appropriate legends on share certificates or the imposition of stop-transfer instructions) if, in the judgment of the Company, such restrictions are necessary or desirable in order to achieve compliance with the Securities Act, the securities laws of another jurisdiction, the securities laws of any state or any other law.

 

10.2.          Market Stand-Off. In the event of an underwritten public offering by the Company of its equity securities pursuant to an effective registration statement filed under the Securities Act, including the Company’s initial public offering, the Participant shall not sell, make any short sale of, loan, hypothecate, pledge, grant any option for the repurchase of, transfer the economic consequences of ownership or otherwise dispose or transfer for value or otherwise agree to engage in any of the foregoing transactions with respect to any of the Shares or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Shares (whether such Shares or any such securities are then owned by the Participant or are thereafter acquired) without the prior written consent of the Company or its underwriters, for such period of time from and after the effective date of such registration statement as may be requested by the Company or such underwriters (the “Market Stand-Off”). In order to enforce the Market Stand-Off, the Company may impose stop-transfer instructions with respect to the Shares acquired under this Agreement until the end of the applicable stand-off period. If there is any change in the number of outstanding Shares by reason of a share split, reverse share split, share dividend, recapitalization, combination, reclassification, dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off or a spin-off), a merger or consolidation, a reverse merger or similar transaction, then any new, substituted or additional securities which are by reason of such transaction distributed with respect to any Shares subject to the Market Stand-Off, or into which such Shares thereby become convertible, shall immediately be subject to the Market Stand-Off.

 

10.3.          Right of Repurchase. Following a termination of the Participant’s Continuous Service, the Company may repurchase the Participant’s Shares acquired under the Plan as provided in this Section (the “Right of Repurchase”). With respect to any vested portion of this Option and any Shares acquired upon exercise of this Option, the Right of Repurchase shall be exercisable at a purchase price (the “Purchase Price”) equal to (i) the Fair Market Value of vested Shares (the “Share Repurchase Right”) or (ii) in the case of a vested Option (the “Option Repurchase Right”), the Fair Market Value of the Shares underlying the vested portion of this Option less the aggregate exercise price of such portion of this Option (in each case as of the date the written notice described in Section 10.3(b) is delivered). For the avoidance of doubt, any unvested portion of this Option will be forfeited for no consideration.

 

Page 6

2024

 

 

(a)            Condition Precedent to Exercise. The Right of Repurchase shall be exercisable following the later of: (i) the date when the Participant’s Continuous Service terminates for any reason, with or without cause, including (without limitation) death or Disability; and (ii) the date when this Option is exercised.

 

(b)            Exercise of Right of Repurchase. The Company shall exercise the Right of Repurchase by written notice delivered to the Participant. The notice shall set forth the date on which the repurchase is to be effected, which must occur within thirty-one (31) days of the notice. The certificate(s) representing any Shares to be repurchased shall, prior to the close of business on the date specified for the repurchase, be delivered to the Company (to the extent not already in the Company’s custody) properly endorsed for transfer; provided, however, that the failure to deliver such certificate(s) to the Company shall not prevent the Company from repurchasing any Shares under this Agreement. The Company shall, concurrently with the receipt of such certificate(s), pay to the Participant the Purchase Price determined according to this Section 10.3. Payment shall be made in cash or cash equivalents or by canceling indebtedness to the Company incurred by the Participant.

 

10.4.          Right of First Refusal. If the Shares are not readily tradable on an established securities market and the Participant proposes to sell, pledge, gift or otherwise transfer any Share, or any interest in such Shares, to any third party (the “Transferee”), the Company shall have a right of first refusal to purchase all (and not less than all) of such Shares (the “Right of First Refusal”). If the Participant desires to transfer Shares, the Participant shall first tender to the Company for its repurchase or redemption, via a written transfer notice (“Transfer Notice”) describing in full the proposed transfer, including the number of Shares proposed to be transferred, the proposed transfer price, the name and address of the proposed Transferee and proof satisfactory to the Company that the proposed sale or transfer will not violate any Applicable Laws, all of the Shares proposed to be transferred to the Transferee. The Transfer Notice shall be signed both by the Participant and the proposed Transferee and must constitute a binding commitment of both parties to the transfer of the Shares. The Company shall have the right to redeem or repurchase all, and not less than all, of the Shares on the same terms and conditions (as to timing and price) of the proposal described in the Transfer Notice by delivery of a notice of exercise of the Right of First Refusal within thirty (30) days after the date the Transfer Notice is received by the Company; provided, however, that in the case of a proposed gift or other non-compensatory transfer of Shares, the purchase price per Share under this Right of First Refusal shall be the Fair Market Value of the Shares determined at the time of the proposed transfer.

 

10.5.          Additional Provisions Relating to Rights of Repurchase and First Refusal.

 

(a)            Additional Shares or Substituted Securities. If there is any change in the number of outstanding Shares by reason of a share split, reverse share split, share dividend, recapitalization (excluding any issuances of securities by the Company for consideration), combination, reclassification, dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off or a spin-off), a merger or consolidation; a reverse merger or similar transaction, then (i) any new, substituted or additional securities or other property (including money paid other than as an ordinary cash dividend) which are by reason of such transaction distributed with respect to any Shares subject to a Right of Repurchase or a Right of First Refusal or into which such Shares thereby become convertible shall immediately be subject to the Right of Repurchase and the Right of First Refusal; and (ii) appropriate adjustments to reflect the distribution of such securities or property shall be made to the number and/or class of the Shares subject to this provision and to the price per Share to be paid upon the exercise of the Right of Repurchase or Right of First Refusal; provided, however, that the aggregate Purchase Price payable for the Shares shall remain the same.

 

Page 7

2024

 

 

(b)            Termination of Rights of Repurchase and First Refusal. Any other provision of Section 10.3 notwithstanding, the Right of Repurchase with respect to vested Shares shall lapse with respect to the Shares that are registered under a then effective registration statement under applicable federal securities laws and the issuer is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act or becomes an investment company registered or required to be registered under the United States Investment Company Act of 1940. If the Shares are readily tradable on an established securities market when the Participant desires to transfer such Shares, the Company shall have no Right of First Refusal, and the Participant shall have no obligation to comply with the procedures prescribed by Section 10.4.

 

(c)            Termination of Rights as Participant and Shareholder. If the Company makes available to a Participant, at the time and place and in the amount and form provided in this Agreement, the consideration for this Option to be repurchased pursuant to the Company’s Option Repurchase Right in accordance with Section 10.3, then after such time such Participant shall no longer have any rights as a Participant in respect of such Option (other than the right to receive payment of such consideration in accordance with this Agreement). If the Company makes available to a Participant, at the time and place and in the amount and form provided in this Agreement, the consideration for the Shares to be repurchased or redeemed pursuant to the Company’s Share Repurchase Right in accordance with Section 10.3 or Right of First Refusal in accordance with Section 10.4, then after such time such Participant shall no longer have any rights as a Shareholder in respect of such Shares (other than the right to receive payment of such consideration in accordance with this Agreement). Such Shares shall be deemed to have been repurchased in accordance with the applicable provisions hereof, whether or not the certificate(s) therefore have been delivered as required by this Agreement.

 

10.6.          Investment Intent at Grant. If the grant of this Option under the Plan is not registered under applicable federal or state securities laws, but an exemption is available which requires an investment representation or any other representation, the Participant (a) shall, and hereby does, represent and agree, at the time of grant of this Option, that the security being acquired upon the grant of this Option is being acquired for investment purposes, and not with a view to the sale or distribution thereof, and (b) shall make such other representations as are deemed necessary or appropriate by the Company and its counsel.

 

10.7.          Investment Intent at Exercise. If the sale of the Shares under the Plan is not registered under applicable federal or state securities laws, but an exemption is available which requires an investment representation or other representation, the Participant shall represent and agree at the time of exercise that the Shares being acquired upon exercise of this Option are being acquired for investment purposes, and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or appropriate by the Company and its counsel.

 

Page 8

2024

 

 

10.8.          Legends. All certificates evidencing the Shares purchased under this Agreement in an unregistered transaction shall bear the following legend (and such other restrictive legends as are required or deemed advisable under the provisions of any Applicable Law):

 

“THE SHARES OF COMMON STOCK EVIDENCED BY THIS CERTIFICATE ARE SUBJECT TO AND TRANSFERABLE ONLY IN ACCORDANCE WITH THAT CERTAIN CARIS LIFE SCIENCES, INC. 2020 INCENTIVE PLAN, THE INCENTIVE STOCK OPTION AWARD AGREEMENT AND THE EXERCISE AGREEMENT PURSUANT TO WHICH THE SHARES EVIDENCED BY THIS CERTIFICATE WERE ISSUED, COPIES OF WHICH ARE ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. NO TRANSFER OR PLEDGE OF THE SHARES EVIDENCED HEREBY MAY BE MADE EXCEPT IN ACCORDANCE WITH AND SUBJECT TO THE PROVISIONS OF SAID PLAN AND INCENTIVE STOCK OPTION AWARD AGREEMENT AND THE TERMS OF THE EXERCISE AGREEMENT.”

 

10.9.          Removal of Legends. If, in the opinion of the Company and its counsel, any legend placed on a share certificate representing the Shares sold under this Agreement no longer is required, the holder of such certificate shall be entitled to exchange such certificate for a certificate representing the same number of Shares but without such legend.

 

10.10.        Administration. Any determination by the Company and its counsel in connection with any of the matters set forth in this Section 10 shall be conclusive and binding on the Participant and all other persons.

 

11.          Qualification as an Incentive Stock Option. It is understood that this Option is intended to qualify as an incentive stock option as defined in Section 422 of the Code to the extent permitted under Applicable Law. Accordingly, the Participant understands that in order to obtain the benefits of an incentive stock option, no sale or other disposition may be made of shares for which incentive stock option treatment is desired within one (1) year following the date of exercise of this Option or within two (2) years from the Date of Grant. The Participant understands and agrees that the Company shall not be liable or responsible for any additional tax liability the Participant incurs in the event that the Internal Revenue Service for any reason determines that this Option does not qualify as an incentive stock option within the meaning of the Code.

 

12.          Exchange Act. Notwithstanding anything contained in the Plan or this Agreement to the contrary, if the consummation of any transaction under the Plan or this Agreement would result in the possible imposition of liability on the Participant pursuant to Section 16(b) of the Exchange Act, the Administrator shall have the right, in its sole discretion, but shall not be obligated, to defer such transaction to the extent necessary to avoid such liability, but in no event for a period in excess of 180 days.

 

Page 9

2024

 

 

13.          General.

 

13.1.          Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by Participant or the Company to the Administrator for review. The resolution of such a dispute by the Administrator shall be final and binding on the Company and Participant.

 

13.2.          Entire Agreement. The Plan is incorporated herein by reference. This Agreement and the Plan constitute the entire agreement of the parties and supersede all prior undertakings and agreements with respect to the subject matter hereof. If any inconsistency should exist between the nondiscretionary terms and conditions of this Agreement and the Plan, the Plan shall govern and control. Notwithstanding the above, nothing in this Agreement shall be deemed to amend any agreement, whether entered into prior to or after the date hereof, between the Company and the Participant.

 

13.3.          Notices. Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the Corporate Secretary/General Counsel of the Company at its principal corporate offices. Any notice required to be given or delivered to Participant shall be in writing and addressed to Participant at the address indicated above or to such other address as such party may designate in writing from time to time to the Company. All notices shall be deemed to have been given or delivered upon: (a) personal delivery; (b) five (5) days after deposit in the United States mail by certified or registered mail (return receipt requested); (c) two (2) business days after deposit with any return receipt express courier (prepaid); or (d) one (1) business day after transmission by facsimile.

 

13.4.          Successors and Assigns. The Company may assign any of its rights under this Agreement. This Agreement shall be binding upon and inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement shall be binding upon Participant and Participant’s heirs, executors, administrators, legal representatives, successors and assigns.

 

13.5.          Choice of Law. This Agreement, including, but not limited to, its enforceability, interpretation and legal effect, shall be governed by and construed in accordance with the laws of the State of Texas without giving effect to its conflict of law principles. If any provision of this Agreement is determined by a court or tribunal of competent jurisdiction to be illegal or unenforceable, then such provision will be enforced to the maximum extent possible and the other provisions will remain fully effective and enforceable. Subject to Section 13.6, the courts of the State of Texas, for Dallas County or any Federal Court having jurisdiction in that county shall have exclusive jurisdiction with respect to any dispute or litigation arising under this Agreement.

 

Page 10

2024

 

 

13.6.          Arbitration. The terms of this Agreement are subject to any arbitration provisions of any PIIA or other agreement or policy that may be in effect between the Participant and the Company. If no such other agreement or policy is in effect, then the following arbitration provisions shall govern: Subject to the Company’s remedies for breach or threatened breach of a Restrictive Covenant, any other dispute, controversy, or claim arising out of or relating to this Agreement or breach thereof, will be submitted to arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association. The arbitration of any dispute, controversy, or claim will take place in Dallas, Texas. Judgment on the award rendered by the arbitrator may be entered in any court of competent jurisdiction. In reaching the arbitrator’s decision, the arbitrator will have no authority to ignore, change, modify, add to or delete from any provision of this Agreement, but instead is limited to interpreting this Agreement.

 

13.7.          No Employment or Other Service Rights. Nothing in the Plan or this Agreement shall confer on Participant any right to continue to serve the Company Group in the capacity in effect as of the Date of Grant or shall affect the right of the Company Group to terminate the Participant’s (a) employment with or without notice and with or without cause, (b) service pursuant to the terms of a consulting agreement with the Company Group or (c) service as a Director pursuant to the Articles or the TBOC, and any applicable provisions of the corporate law of the jurisdiction in which the Company or the Affiliate is incorporated, as the case may be; or shall give the Participant any right to be reemployed or reengaged by the Company Group following a termination of employment or services for any reason.

 

13.8.          No Right to Future Awards. This Option and all other equity-based awards under the Plan are discretionary. This Option does not confer on the Participant any right or entitlement to receive another award of Option or any other equity-based award at any time in the future or in respect of any future period.

 

13.9.          Severability. If any provision of this Agreement is held to be illegal or invalid for any reason, such illegality or invalidity shall not affect the remaining provisions of this Agreement, but this Agreement shall be construed and enforced as if such illegal or invalid provision had never been included herein.

 

13.10.        Amendment. Notwithstanding anything herein or in the Plan to the contrary, the Administrator may, at any time, alter, amend, suspend or modify this Agreement; provided, however, that no amendment or modification of this Agreement shall materially and adversely impair the rights of the Participant with respect to any then outstanding Options without the consent of the Participant.

 

14.          Acceptance. Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. Participant has read and understands the terms and provisions thereof, and by executing below, accepts the terms and conditions of this Agreement governing this Option and the terms and conditions of the Plan governing this Option and any and all other outstanding options held by the Participant as of the date of execution. Participant acknowledges that there may be adverse tax consequences upon exercise of this Option or disposition of the Shares and that Participant should consult a tax advisor prior to such exercise or disposition.

 

[Signatures on Following Page]

 

Page 11

2024

 

 

In witness whereof, the Company has caused this Agreement to be executed by its duly authorized representative effective as of [                ].

 

 CARIS LIFE SCIENCES, INC.
   
By:
Name:
Title:             

 

Participant:

 

 Acceptance Date:

 

Page 12

2024

 

Exhibit 10.4(c)

 

CARIS LIFE SCIENCES, INC.

 

2020 INCENTIVE PLAN

 

NONQUALIFIED STOCK OPTION AWARD AGREEMENT

 

This Nonqualified Stock Option Award Agreement (the “Agreement”) is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Caris Life Sciences, Inc., a Texas corporation (the “Company”), and the participant named below (the “Participant”). Capitalized terms not defined herein shall have the meaning ascribed to them in the Company’s 2020 Incentive Plan (the “Plan”).

 

Participant: [                      ]

Address: [                            ]

Grant Number: [                           ]

Exercise Price Per Share: [                          ]

Date of Grant: [                          ]

Expiration Date: [                          ]

Vesting Commencement Date: [                         ]

 

WHEREAS, the Company desires to grant options to purchase shares of common stock of the Company, par value US$0.001 per share (the “Shares”) to certain employees, consultants and/or directors of the Company;

 

WHEREAS, the Company has adopted the Plan in order to effect such grants; and

 

WHEREAS, the Administrator has determined that it is in the interest of the Company to grant these options to the Participant.

 

NOW, THEREFORE, in consideration of the services to be rendered by the Participant to the Company and subject to the terms and conditions set forth herein and in the Plan, the parties hereto agree as follows:

 

1.            Grant of Option. The Company hereby grants to Participant an option (this “Option”) to purchase the total number of Shares set forth above as Total Shares of Common Stock at the Exercise Price Per Share set forth above (the “Exercise Price”), subject to all of the terms and conditions of this Agreement and the Plan.

 

2.            Exercise Period; Vesting.

 

2.1            Exercisability. Unless expired as provided in Section 3 of this Agreement, this Option may be exercised in whole or in part from time, to time to the extent they have become vested, during the period of Participant’s Continuous Service and pursuant to the terms of Section 4. Upon exercise of a portion of this Option, Participant shall receive Shares in accordance with Section 5.5, in each case subject to the restrictions on transfer set forth in Sections 7 and 10 below.

 

2.2            Vesting. The Option shall become vested based on the table referenced on page 1. This Option may not be exercised for less than a full share.

 

 

 

 

3.            Expiration. This Option shall expire on the Expiration Date set forth above or earlier as provided in Section 4 below or, if applicable, pursuant to Section 6 of the Plan.

 

4.            Termination of Continuous Service.

 

4.1            Other than as a Result of Death or Disability. Unless otherwise provided in an agreement the terms of which have been approved by the Administrator, if Participant’s Continuous Service is terminated for any reason, except death or Disability, the Participant may exercise this Option (to the extent that the Participant was entitled to exercise such Option as of the date of termination) until the earlier of (i) the date ninety (90) days following the termination of the Participant’s Continuous Service and (ii) the Expiration Date, after which time this Option shall terminate.

 

4.2            Because of Death or Disability. If Participant’s Continuous Service is terminated because of the death or Disability of Participant, the Participant (or the Participant’s estate, by a person who acquired the right to exercise this Option by bequest or inheritance or by a person designated to exercise this Option upon the Participant’s death) may exercise the Participant’s Option (to the extent that the Participant was entitled to exercise such Option as of the date of termination), but only until the earlier of (i) the date twelve (12) months following such termination and (ii) the Expiration Date, after which time this Option shall terminate.

 

4.3            No Employment or Other Service Rights. Nothing in the Plan or this Agreement shall confer on Participant any right to continue to serve the Company Group in the capacity in effect as of the Date of Grant or shall affect the right of the Company Group to terminate the Participant’s (a) employment with or without notice and with or without cause, (b) service pursuant to the terms of a consulting agreement with the Company Group or (c) service as a Director pursuant to the Articles or the TBOC, and any applicable provisions of the corporate law of the jurisdiction in which the Company or the Affiliate is incorporated, as the case may be; or shall give the Participant any right to be reemployed or reengaged by the Company Group following a termination of employment or services for any reason.

 

4.4            Cancellation and Rescission of Options for Detrimental Activity.

 

(a)             The Administrator may cancel, rescind, suspend, withhold or otherwise limit or restrict any Options at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.

 

(b)             Upon exercise, payment or delivery pursuant to exercise of this Option, the Participant shall certify in a manner acceptable to the Company that he or she is in compliance with the terms and conditions of the Plan and has not engaged in any Detrimental Activity. In the event a Participant engages in Detrimental Activity after the exercise, payment or delivery of any Shares pursuant to this Agreement, during any period for which any restrictive covenant prohibiting such activity is applicable to the Participant, such exercise, payment or delivery may be rescinded within one (1) year thereafter. In the event of any such rescission, the Participant shall pay to the Company the amount of any gain realized or payment received as a result of the exercise, payment or delivery of such Shares, in such manner and on such terms and conditions as may be required by the Company. The Company shall be entitled to setoff against the amount of any such gain any amount owed to the Participant by the Company.

 

Page 2

2024

 

 

(c)             At the Administrator’s discretion, the Company may exercise the right of rescission set forth in this Section 4.4 via the mandatory redemption or repurchase of the Participant’s Shares at a price equal to the price paid by the Participant to acquire the Shares.

 

5.            Manner of Exercise.

 

5.1            Share Option Exercise Agreement. To exercise this Option, Participant (or the Participant’s estate, by a person who acquired the right to exercise this Option by bequest or inheritance or by a person designated to exercise this Option upon the Participant’s death) must deliver to the Company an executed share option exercise agreement in the form attached hereto as Exhibit A, or in such other form as may be approved by the Administrator from time to time (the “Exercise Agreement”), which shall set forth, inter alia, (a) Participant’s election to exercise this Option, (b) the number of Shares being purchased, (c) any restrictions imposed on the Shares and (d) any representations, warranties and agreements regarding Participant’s investment intent and access to information as may be required by the Company to comply with Applicable Laws. If someone other than Participant exercises this Option, then such person must submit evidence reasonably acceptable to the Company verifying that such person is entitled to do so.

 

5.2            Limitations on Exercise and Issuance. This Option may not be exercised unless such exercise is in compliance with all Applicable Laws as are in effect on the date of exercise and the Shares underlying the exercised Option may not be issued until the Participant executes an Adoption Agreement to become a Shareholder to that certain Voting Agreement of the Company by and among the Company and each of its Shareholders.

 

5.3            Payment. The entire Exercise Price shall be payable in full by cash or check for an amount equal to the aggregate exercise price of the Shares being purchased. Alternatively, in the sole discretion of the Administrator and upon such terms and at such times as the Administrator shall approve, the Exercise Price may be paid by:

 

(a)             tendering to the Company other Shares, for redemption or repurchase by the Company, with a Fair Market Value on the date of redemption or repurchase equal to the exercise price (or portion thereof) due for the number of Shares being acquired (with the proceeds of such redemption or repurchase being automatically applied by the Company towards paying the purchase price of the Shares) (collectively a “Share For Share Exercise”); provided, however, that the Shares used in such Share for Share Exercise (i) have either (1) been held for more than six (6) months (or such longer or shorter period of time required to avoid a charge to earnings for financial accounting purposes) and have been paid for within the meaning of SEC Rule 144 (and if such shares were purchased from the Company by use of a promissory note, such note has been fully paid with respect to such shares); or (2) were obtained by Participant in the open public market; and (ii) are clear of all liens, claims, encumbrances or security interests;

 

Page 3

2024

 

 

(b)             during any period for which the Shares are publicly traded (i.e., the Shares are listed on any established stock exchange or a national market system, or if the Shares are quoted on an applicable stock exchange or any similar system whereby the Shares are regularly quoted by a recognized securities dealer but closing sale prices are not reported), by a copy of instructions to a broker directing such broker to sell the Shares for which this Option is exercised, and to remit to the Company the aggregate Exercise Price of this Option (a “Cashless Exercise”); provided, however, a Cashless Exercise by a Director or Participant officer that involves or may involve a direct or indirect extension of credit or arrangement of an extension of credit by the Company Group in violation of Section 402(a) of the Sarbanes-Oxley Act (codified as Section 13(k) of the Securities Exchange Act of 1934, 15 U.S.C. § 78m(k)) shall be prohibited;

 

(c)             during a Net Exercise Period, by means of the Participant electing in the Exercise Agreement to receive a portion of the Shares underlying this Option as a cash payment and a portion as Shares, with instructions to the Company to apply such cash payment towards paying the purchase price of the Shares for which this Option is being exercised; provided that in no event shall the cash payment received by the Participant pursuant to such election exceed the aggregate exercise price of the Shares for which this Option is being exercised;

 

(d)             by any other form of legal consideration that may be acceptable to the Administrator, including without limitation with a promissory note. However, if there is a stated par value of the Shares and Applicable Laws require, the par value of the Shares, if newly issued, shall be paid in cash or cash equivalents. The interest rate payable under the terms of the promissory note shall not be less than the minimum rate (if any) required to avoid the imputation of additional interest under the Code. Subject to the foregoing, the Administrator (in its sole discretion) shall specify the term, interest rate, amortization requirements (if any) and other provisions of such note. Exercise with a promissory note or other transaction by a Director or Participant officer that involves or may involve a direct or indirect extension of credit or arrangement of an extension of credit by the Company Group in violation of Section 402(a) of the Sarbanes-Oxley Act (codified as Section 13(k) of the Securities Exchange Act of 1934, 15 U.S.C. § 78m(k)) shall be prohibited; or

 

(e)             by any combination of the foregoing.

 

5.4            Tax Withholding. Prior to the issuance of the Shares upon exercise of this Option, Participant must satisfy any tax withholding obligations relating to the exercise of this Option and the acquisition of the Shares. If the Administrator permits, in addition to the Exercise Price payment alternatives in Section 5.3, Participant may provide for payment of withholding taxes upon exercise of this Option by (a) authorizing the Company to issue and then immediately redeem or repurchase, at Fair Market Value, Shares out of the Shares issued to the Participant as a result of the exercise of this Option or (b) tendering to the Company currently owned and unencumbered Shares of the Company for redemption or repurchase and, in each of (a) and (b), immediately tendering the redemption or repurchase price paid by the Company in respect of such Shares back to the Company.

 

5.5            Issuance of Shares. Provided that the Exercise Agreement and payment are in form and substance satisfactory to counsel for the Company, the Company shall issue the Shares registered in the name of Participant or, if requested by the Participant, in the name of the Participant and the Participant’s spouse, and shall deliver certificates representing the Shares with the appropriate legends affixed thereto.

 

Page 4

2024

 

 

6.            Compliance with Laws and Regulations. The exercise of this Option and the issuance and transfer of Shares shall be subject to compliance by the Company and Participant with all Applicable Laws and with all applicable requirements of any stock exchange on which the Shares may be listed at the time of such issuance or transfer. Participant understands that the Company is under no obligation to register or qualify the Shares with any federal or state securities commission or any stock exchange to effect such compliance.

 

7.            Nontransferability of Option. Unless determined otherwise by the Administrator, this Option may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent and distribution; provided, however, that the Administrator may, subject to Applicable Laws and such terms and conditions as it shall specify, permit the transfer of this Option for no consideration to a Permitted Transferee. An Option transferred to a Permitted Transferee shall be further transferable only by last will and testament or the laws of descent and distribution or, for no consideration, to another Permitted Transferee of the Participant. During the lifetime of a Participant, this Option shall be exercisable only by the Participant or by a Permitted Transferee to whom this Option has been transferred in accordance with this Section 7. In no event may this Option be transferred to any person who has joined or is supporting a Competing Business.

 

8.            Privileges of Share Ownership. Participant shall not have any of the rights of a Shareholder with respect to any Shares until the Shares are issued to Participant.

 

9.            Restrictive Covenants. As a condition to the grant of this Option, the Participant agrees to comply with the restrictive covenants (each a “Restrictive Covenant”) set forth in any Proprietary Information, Intellectual Property, Restrictive Covenant and Arbitration Agreement (the “PIIA”) or other agreement or policy that may be in effect between the Participant and the Company Group. The Participant understands that the cancellation of any Option or rights under this Agreement may occur for any violation or lack of enforceability of any Restrictive Covenant and such cancellation may not be adequate recompense for the damages potentially sustained by the Company Group. Such cancellation shall be in addition to any equitable and legal rights the Company Group has or may have and shall not constitute a release of any claim that the Company Group may have for damages, past, present or future. In addition, a breach by the Participant of any provisions of any Restrictive Covenant that occurs after any exercise of any Option or delivery of the Shares pursuant to this Agreement (including any breach occurring after termination of Continuous Service) shall cause the exercise of this Option and the delivery of the Shares under this Agreement to be rescinded (and if the Participant has previously sold the Shares issued pursuant to this Agreement, the Participant would be required to pay back to the Company Group the pre-tax proceeds received from the sale of such Shares).

 

At the Administrator’s discretion, the Company may exercise the right of rescission set forth in this Section 9 via the mandatory redemption or repurchase of the Participant’s Shares at a price equal to the aggregate Exercise Price paid by the Participant for the Shares.

 

Page 5

2024

 

 

10.         Restrictions on Transfer.

 

10.1         Securities Law Restrictions. Regardless of whether the offering and sale of the Shares under the Plan has been registered under the Securities Act, the securities laws of another jurisdiction or registered or qualified under the securities laws of any state, the Company at its discretion may impose restrictions upon the sale, pledge or other transfer of such Shares (including the placement of appropriate legends on share certificates or the imposition of stop-transfer instructions) if, in the judgment of the Company, such restrictions are necessary or desirable in order to achieve compliance with the Securities Act, the securities laws of another jurisdiction, the securities laws of any state or any other law.

 

10.2         Market Stand-Off. In the event of an underwritten public offering by the Company of its equity securities pursuant to an effective registration statement filed under the Securities Act, including the Company’s initial public offering, the Participant shall not sell, make any short sale of, loan, hypothecate, pledge, grant any option for the repurchase of, transfer the economic consequences of ownership or otherwise dispose or transfer for value or otherwise agree to engage in any of the foregoing transactions with respect to any of the Shares or any securities convertible into or exercisable or exchangeable (directly or indirectly) for the Shares (whether such Shares or any such securities are then owned by the Participant or are thereafter acquired) without the prior written consent of the Company or its underwriters, for such period of time from and after the effective date of such registration statement as may be requested by the Company or such underwriters (the “Market Stand-Off”). In order to enforce the Market Stand-Off, the Company may impose stop-transfer instructions with respect to the Shares acquired under this Agreement until the end of the applicable stand-off period. If there is any change in the number of outstanding Shares by reason of a share split, reverse share split, share dividend, recapitalization, combination, reclassification, dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off or a spin-off), a merger or consolidation, a reverse merger or similar transaction, then any new, substituted or additional securities which are by reason of such transaction distributed with respect to any of the Shares subject to the Market Stand-Off, or into which such Shares thereby become convertible, shall immediately be subject to the Market Stand-Off.

 

10.3         Right of Repurchase. Following a termination of the Participant’s Continuous Service, the Company may repurchase the Participant’s Shares acquired under the Plan as provided in this Section (the “Right of Repurchase”). With respect to any vested portion of this Option and any Shares acquired upon exercise of this Option, the Right of Repurchase shall be exercisable at a purchase price (the “Purchase Price”) equal to (i) the Fair Market Value of vested Shares (the “Share Repurchase Right”); or (ii) in the case of a vested Option (the “Option Repurchase Right”), the Fair Market Value of the Shares underlying the vested portion of this Option less the aggregate exercise price of such portion of this Option (in each case as of the date the written notice described in Section 10.3(b) is delivered). For the avoidance of doubt, any unvested portion of this Option will be forfeited for no consideration.

 

(a)             Condition Precedent to Exercise. The Right of Repurchase shall be exercisable following the later of: (i) the date when the Participant’s Continuous Service terminates for any reason, with or without cause, including (without limitation) death or Disability; and (ii) the date when this Option is exercised.

 

Page 6

2024

 

 

(b)             Exercise of Right of Repurchase. The Company shall exercise the Right of Repurchase by written notice delivered to the Participant. The notice shall set forth the date on which the repurchase is to be effected, which must occur within thirty-one (31) days of the notice. The certificate(s) representing any of the Shares to be repurchased shall, prior to the close of business on the date specified for the repurchase, be delivered to the Company (to the extent not already in the Company’s custody) properly endorsed for transfer; provided, however, that the failure to deliver such certificate(s) to the Company shall not prevent the Company from repurchasing any Shares under this Agreement. The Company shall, concurrently with the receipt of such certificate(s), pay to the Participant the Purchase Price determined according to this Section 10.3. Payment shall be made in cash or cash equivalents or by canceling indebtedness to the Company incurred by the Participant.

 

10.4         Right of First Refusal. If the Shares are not readily tradable on an established securities market and the Participant proposes to sell, pledge, gift or otherwise transfer any Share, or any interest in such Shares, to any third party other than a Permitted Transferee (the “Transferee”) the Company shall have a right of first refusal to purchase all (and not less than all) of such Shares (the “Right of First Refusal”). If the Participant desires to transfer Shares, the Participant shall first tender to the Company for its repurchase or redemption, via a written transfer notice (“Transfer Notice”) describing in full the proposed transfer, including the number of Shares proposed to be transferred, the proposed transfer price, the name and address of the proposed Transferee and proof satisfactory to the Company that the proposed sale or transfer will not violate any Applicable Laws, all of the Shares proposed to be transferred to the Transferee. The Transfer Notice shall be signed both by the Participant and the proposed Transferee and must constitute a binding commitment of both parties to the transfer of the Shares. The Company shall have the right to redeem or repurchase all, and not less than all, of the Shares on the same terms and conditions (as to timing and price) of the proposal described in the Transfer Notice by delivery of a notice of exercise of the Right of First Refusal within thirty (30) days after the date the Transfer Notice is received by the Company; provided, however, that in the case of a proposed gift or other non-compensatory transfer of Shares, the purchase price per Share under this Right of First Refusal shall be the Fair Market Value of the Shares determined at the time of the proposed transfer.

 

10.5         Additional Provisions Relating to Rights of Repurchase and First Refusal.

 

(a)             Additional Shares or Substituted Securities. If there is any change in the number of outstanding Shares by reason of a share split, reverse share split, share dividend, recapitalization (excluding any issuances of securities by the Company for consideration), combination, reclassification, dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off or a spin-off), a merger or consolidation; a reverse merger or similar transaction, then (i) any new, substituted or additional securities or other property (including money paid other than as an ordinary cash dividend) which are by reason of such transaction distributed with respect to any Shares subject to a Right of Repurchase or a Right of First Refusal or into which such Shares thereby become convertible shall immediately be subject to the Right of Repurchase and the Right of First Refusal; and (ii) appropriate adjustments to reflect the distribution of such securities or property shall be made to the number and/or class of the Shares subject to this provision and to the price per share of the Shares to be paid upon the exercise of the Right of Repurchase or Right of First Refusal; provided, however, that the aggregate Purchase Price payable for the Shares shall remain the same.

 

Page 7

2024

 

 

(b)             Termination of Rights of Repurchase and First Refusal. Any other provision of Section 10.3 notwithstanding, the Right of Repurchase with respect to vested Shares shall lapse with respect to the Shares that are registered under a then effective registration statement under applicable federal securities laws and the issuer is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act or becomes an investment company registered or required to be registered under the United States Investment Company Act of 1940. If the Shares are readily tradable on an established securities market when the Participant desires to transfer such Shares, the Company shall have no Right of First Refusal, and the Participant shall have no obligation to comply with the procedures prescribed by Section 10.4.

 

(c)             Termination of Rights as Participant and Shareholder. If the Company makes available to a Participant, at the time and place and in the amount and form provided in this Agreement, the consideration for this Option to be repurchased pursuant to the Company’s Option Repurchase Right in accordance with Section 10.3, then after such time such Participant shall no longer have any rights as a Participant in respect of such Option (other than the right to receive payment of such consideration in accordance with this Agreement). If the Company makes available to a Participant, at the time and place and in the amount and form provided in this Agreement, the consideration for the Shares to be repurchased or redeemed pursuant to the Company’s Share Repurchase Right in accordance with Section 10.3 or Right of First Refusal in accordance with Section 10.4, then after such time such Participant shall no longer have any rights as a Shareholder in respect of such Shares (other than the right to receive payment of such consideration in accordance with this Agreement). Such Shares shall be deemed to have been repurchased in accordance with the applicable provisions hereof, whether or not the certificate(s) therefore have been delivered as required by this Agreement.

 

10.6         Investment Intent at Grant. If the grant of this Option under the Plan is not registered under applicable federal or state securities laws, but an exemption is available which requires an investment representation or any other representation, the Participant (a) shall, and hereby does, represent and agree, at the time of grant of this Option, that the security being acquired upon the grant of this Option is being acquired for investment purposes, and not with a view to the sale or distribution thereof, and (b) shall make such other representations as are deemed necessary or appropriate by the Company and its counsel.

 

10.7         Investment Intent at Exercise. If the sale of the Shares under the Plan is not registered under applicable federal or state securities laws, but an exemption is available which requires an investment representation or other representation, the Participant shall represent and agree at the time of exercise that the Shares being acquired upon exercise of this Option are being acquired for investment purposes, and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or appropriate by the Company and its counsel.

 

10.8         Legends. All certificates evidencing the Shares purchased under this Agreement in an unregistered transaction shall bear the following legend (and such other restrictive legends as are required or deemed advisable under the provisions of any Applicable Law):

 

Page 8

2024

 

 

“THE SHARES OF COMMON STOCK EVIDENCED BY THIS CERTIFICATE ARE SUBJECT TO AND TRANSFERABLE ONLY IN ACCORDANCE WITH THAT CERTAIN CARIS LIFE SCIENCES, INC. 2020 INCENTIVE PLAN, THE NONQUALIFIED STOCK OPTION AWARD AGREEMENT AND THE EXERCISE AGREEMENT PURSUANT TO WHICH THE SHARES EVIDENCED BY THIS CERTIFICATE WERE ISSUED, COPIES OF WHICH ARE ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. NO TRANSFER OR PLEDGE OF THE SHARES EVIDENCED HEREBY MAY BE MADE EXCEPT IN ACCORDANCE WITH AND SUBJECT TO THE PROVISIONS OF SAID PLAN AND NONQUALIFIED STOCK OPTION AWARD AGREEMENT AND THE TERMS OF THE EXERCISE AGREEMENT.”

 

10.9         Removal of Legends. If, in the opinion of the Company and its counsel, any legend placed on a share certificate representing the Shares sold under this Agreement no longer is required, the holder of such certificate shall be entitled to exchange such certificate for a certificate representing the same number of Shares but without such legend.

 

10.10       Administration. Any determination by the Company and its counsel in connection with any of the matters set forth in this Section 10 shall be conclusive and binding on the Participant and all other persons.

 

11.         Exchange Act. Notwithstanding anything contained in the Plan or this Agreement to the contrary, if the consummation of any transaction under the Plan or this Agreement would result in the possible imposition of liability on the Participant pursuant to Section 16(b) of the Exchange Act, the Administrator shall have the right, in its sole discretion, but shall not be obligated, to defer such transaction to the extent necessary to avoid such liability, but in no event for a period in excess of 180 days.

 

12.         General.

 

12.1         Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by Participant or the Company to the Administrator for review. The resolution of such a dispute by the Administrator shall be final and binding on the Company and Participant.

 

12.2         Entire Agreement. The Plan is incorporated herein by reference. This Agreement and the Plan constitute the entire agreement of the parties and supersede all prior undertakings and agreements with respect to the subject matter hereof. If any inconsistency should exist between the nondiscretionary terms and conditions of this Agreement and the Plan, the Plan shall govern and control. Notwithstanding the above, nothing in this Agreement shall be deemed to amend any agreement, whether entered into prior to or after the date hereof, between the Company and the Participant.

 

12.3         Notices. Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the Corporate Secretary/General Counsel of the Company at its principal corporate offices. Any notice required to be given or delivered to Participant shall be in writing and addressed to Participant at the address indicated above or to such other address as such party may designate in writing from time to time to the Company. All notices shall be deemed to have been given or delivered upon: (a) personal delivery; (b) five (5) days after deposit in the United States mail by certified or registered mail (return receipt requested); (c) two (2) business days after deposit with any return receipt express courier (prepaid); or (d) one (1) business day after transmission by facsimile.

 

Page 9

2024

 

 

12.4         Successors and Assigns. The Company may assign any of its rights under this Agreement. This Agreement shall be binding upon and inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement shall be binding upon Participant and Participant’s heirs, executors, administrators, legal representatives, successors and assigns.

 

12.5         Choice of Law. This Agreement, including, but not limited to, its enforceability, interpretation and legal effect, shall be governed by and construed in accordance with the laws of the State of Texas without giving effect to its conflict of law principles. If any provision of this Agreement is determined by a court or tribunal of competent jurisdiction to be illegal or unenforceable, then such provision will be enforced to the maximum extent possible and the other provisions will remain fully effective and enforceable. Subject to Section 12.6, the courts of the State of Texas, for Dallas County or any Federal Court having jurisdiction in that county shall have exclusive jurisdiction with respect to any dispute or litigation arising under this Agreement.

 

12.6         Arbitration. The terms of this Agreement are subject to any arbitration provisions of any PIIA or other agreement or policy that may be in effect between the Participant and the Company. If no such other agreement or policy is in effect, then the following arbitration provisions shall govern: Subject to the Company’s remedies for breach or threatened breach of a Restrictive Covenant, any other dispute, controversy, or claim arising out of or relating to this Agreement or breach thereof, will be submitted to arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association. The arbitration of any dispute, controversy, or claim will take place in Dallas, Texas. Judgment on the award rendered by the arbitrator may be entered in any court of competent jurisdiction. In reaching the arbitrator’s decision, the arbitrator will have no authority to ignore, change, modify, add to or delete from any provision of this Agreement, but instead is limited to interpreting this Agreement.

 

12.7         No Right to Future Awards. This Option and all other equity-based awards under the Plan are discretionary. This Option does not confer on the Participant any right or entitlement to receive another award of Option or any other equity-based award at any time in the future or in respect of any future period.

 

12.8         Severability. If any provision of this Agreement is held to be illegal or invalid for any reason, such illegality or invalidity shall not affect the remaining provisions of this Agreement, but this Agreement shall be construed and enforced as if such illegal or invalid provision had never been included herein.

 

12.9         Amendment. Notwithstanding anything herein or in the Plan to the contrary, the Administrator may, at any time, alter, amend, suspend or modify this Agreement; provided, however, that no amendment or modification of this Agreement shall materially and adversely impair the rights of the Participant with respect to any then outstanding Options without the consent of the Participant.

 

13.         Acceptance. Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. Participant has read and understands the terms and provisions thereof, and by executing below, accepts the terms and conditions of this Agreement governing this Option and the terms and conditions of the Plan governing this Option and any and all other outstanding options held by the Participant as of the date of execution. Participant acknowledges that there may be adverse tax consequences upon exercise of this Option or disposition of the Shares and that Participant should consult a tax advisor prior to such exercise or disposition.

 

[Signatures on Following Page]

 

Page 10

2024

 

 

In witness whereof, the Company has caused this Agreement to be executed by its duly authorized representative effective as of [                      ].

 

 CARIS LIFE SCIENCES, INC.
   
By:
Name:[                          ]
Title:[                          ]

 

Participant: [                          ]
  
 Acceptance Date: [                          ]

 

 

Exhibit 10.4(d)

 

CARIS LIFE SCIENCES, INC.

  

2020 INCENTIVE PLAN

 

NONQUALIFIED STOCK OPTION AWARD AGREEMENT

 

This Nonqualified Stock Option Award Agreement (the “Agreement”) is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Caris Life Sciences, Inc., a Texas corporation (the “Company”), and the participant named below (the “Participant”). Capitalized terms not defined herein shall have the meaning ascribed to them in the Company’s 2020 Incentive Plan (the “Plan”).

 

Participant: [               ]

Address: [               ]

Grant Number: [               ]

Exercise Price Per Share: [               ]

Date of Grant: [               ]

Expiration Date: [               ]

Vesting Commencement Date: [               ]

 

WHEREAS, the Company desires to grant options to purchase shares of common stock of the Company, par value US$0.001 per share (the “Shares”) to certain employees, consultants and/or directors of the Company;

 

WHEREAS, the Company has adopted the Plan in order to effect such grants; and

 

WHEREAS, the Administrator has determined that it is in the interest of the Company to grant these options to the Participant.

 

NOW, THEREFORE, in consideration of the services to be rendered by the Participant to the Company and subject to the terms and conditions set forth herein and in the Plan, the parties hereto agree as follows:

 

1.             Grant of Option. The Company hereby grants to Participant an option (this “Option”) to purchase the total number of Shares set forth above as Total Shares of Common Stock at the Exercise Price Per Share set forth above (the “Exercise Price”), subject to all of the terms and conditions of this Agreement and the Plan.

 

2.             Exercise Period; Vesting.

 

2.1             Exercisability. Unless expired as provided in Section 3 of this Agreement, this Option may be exercised in whole or in part from time to time, to the extent they have become vested, during the period of Participant’s Continuous Service and pursuant to the terms of Section 4. Upon exercise of a portion of this Option, Participant shall receive Shares in accordance with Section 5.5, in each case subject to the restrictions on transfer set forth in Sections 7 and 10 below.

 

2.2             Vesting. The Option shall become vested based on the table referenced on page 1. This Option may not be exercised for less than a full share.

 

 

 

 

3.             Expiration. This Option shall expire on the Expiration Date set forth above or earlier as provided in Section 4 below or, if applicable, pursuant to Section 6 of the Plan.

 

4.             Termination of Continuous Service.

 

4.1             Other than as a Result of Death or Disability. Unless otherwise provided in an agreement the terms of which have been approved by the Administrator, if Participant’s Continuous Service is terminated for any reason, except death or Disability, the Participant may exercise this Option (to the extent that the Participant was entitled to exercise such Option as of the date of termination) until the earlier of (i) the date ninety (90) days following the termination of the Participant’s Continuous Service and (ii) the Expiration Date, after which time this Option shall terminate.

 

4.2             Because of Death or Disability. If Participant’s Continuous Service is terminated because of the death or Disability of Participant, the Participant (or the Participant’s estate, by a person who acquired the right to exercise this Option by bequest or inheritance or by a person designated to exercise this Option upon the Participant’s death) may exercise the Participant’s Option (to the extent that the Participant was entitled to exercise such Option as of the date of termination), but only until the earlier of (i) the date twelve (12) months following such termination and (ii) the Expiration Date, after which time this Option shall terminate.

 

4.3             No Employment or Other Service Rights. Nothing in the Plan or this Agreement shall confer on Participant any right to continue to serve the Company Group in the capacity in effect as of the Date of Grant or shall affect the right of the Company Group to terminate the Participant’s (a) employment with or without notice and with or without cause, (b) service pursuant to the terms of a consulting agreement with the Company Group or (c) service as a Director pursuant to the Articles or the TBOC, and any applicable provisions of the corporate law of the jurisdiction in which the Company or the Affiliate is incorporated, as the case may be; or shall give the Participant any right to be reemployed or reengaged by the Company Group following a termination of employment or services for any reason.

 

4.4             Cancellation and Rescission of Options for Detrimental Activity.

 

(a)             The Administrator may cancel, rescind, suspend, withhold or otherwise limit or restrict any Options at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.

 

(b)             Upon exercise, payment or delivery pursuant to exercise of this Option, the Participant shall certify in a manner acceptable to the Company that he or she is in compliance with the terms and conditions of the Plan and has not engaged in any Detrimental Activity. In the event a Participant engages in Detrimental Activity after the exercise, payment or delivery of any Shares pursuant to this Agreement, during any period for which any restrictive covenant prohibiting such activity is applicable to the Participant, such exercise, payment or delivery may be rescinded within one (1) year thereafter. In the event of any such rescission, the Participant shall pay to the Company the amount of any gain realized or payment received as a result of the exercise, payment or delivery of such Shares, in such manner and on such terms and conditions as may be required by the Company. The Company shall be entitled to setoff against the amount of any such gain any amount owed to the Participant by the Company.

 

Page 2

2024

 

 

(c)             At the Administrator’s discretion, the Company may exercise the right of rescission set forth in this Section 4.4 via the mandatory redemption or repurchase of the Participant’s Shares at a price equal to the price paid by the Participant to acquire the Shares.

 

5.             Manner of Exercise.

 

5.1             Share Option Exercise Agreement. To exercise this Option, Participant (or the Participant’s estate, by a person who acquired the right to exercise this Option by bequest or inheritance or by a person designated to exercise this Option upon the Participant’s death) must deliver to the Company an executed share option exercise agreement in the form attached hereto as Exhibit A, or in such other form as may be approved by the Administrator from time to time (the “Exercise Agreement”), which shall set forth, inter alia, (a) Participant’s election to exercise this Option, (b) the number of Shares being purchased, (c) any restrictions imposed on the Shares and (d) any representations, warranties and agreements regarding Participant’s investment intent and access to information as may be required by the Company to comply with Applicable Laws. If someone other than Participant exercises this Option, then such person must submit evidence reasonably acceptable to the Company verifying that such person is entitled to do so.

 

5.2             Limitations on Exercise and Issuance. This Option may not be exercised unless such exercise is in compliance with all Applicable Laws as are in effect on the date of exercise and the Shares underlying the exercised Option may not be issued until the Participant executes an Adoption Agreement to become a Shareholder to that certain Voting Agreement of the Company by and among the Company and each of its Shareholders.

 

5.3             Payment. The entire Exercise Price shall be payable in full by cash or check for an amount equal to the aggregate exercise price of the Shares being purchased. Alternatively, in the sole discretion of the Administrator and upon such terms and at such times as the Administrator shall approve, the Exercise Price may be paid by:

 

(a)             tendering to the Company other Shares, for redemption or repurchase by the Company, with a Fair Market Value on the date of redemption or repurchase equal to the exercise price (or portion thereof) due for the number of Shares being acquired (with the proceeds of such redemption or repurchase being automatically applied by the Company towards paying the purchase price of the Shares) (collectively a “Share For Share Exercise”); provided, however, that the Shares used in such Share for Share Exercise (i) have either (1) been held for more than six (6) months (or such longer or shorter period of time required to avoid a charge to earnings for financial accounting purposes) and have been paid for within the meaning of SEC Rule 144 (and if such shares were purchased from the Company by use of a promissory note, such note has been fully paid with respect to such shares); or (2) were obtained by Participant in the open public market; and (ii) are clear of all liens, claims, encumbrances or security interests;

 

Page 3

2024

 

 

(b)             during any period for which the Shares are publicly traded (i.e., the Shares are listed on any established stock exchange or a national market system, or if the Shares are quoted on an applicable stock exchange or any similar system whereby the Shares are regularly quoted by a recognized securities dealer but closing sale prices are not reported), by a copy of instructions to a broker directing such broker to sell the Shares for which this Option is exercised, and to remit to the Company the aggregate Exercise Price of this Option (a “Cashless Exercise”); provided, however, a Cashless Exercise by a Director or Participant officer that involves or may involve a direct or indirect extension of credit or arrangement of an extension of credit by the Company Group in violation of Section 402(a) of the Sarbanes-Oxley Act (codified as Section 13(k) of the Securities Exchange Act of 1934, 15 U.S.C. § 78m(k)) shall be prohibited;

 

(c)             during a Net Exercise Period, by means of the Participant electing in the Exercise Agreement to receive a portion of the Shares underlying this Option as a cash payment and a portion as Shares, with instructions to the Company to apply such cash payment towards paying the purchase price of the Shares for which this Option is being exercised; provided that in no event shall the cash payment received by the Participant pursuant to such election exceed the aggregate exercise price of the Shares for which this Option is being exercised;

 

(d)             by any other form of legal consideration that may be acceptable to the Administrator, including without limitation with a promissory note. However, if there is a stated par value of the Shares and Applicable Laws require, the par value of the Shares, if newly issued, shall be paid in cash or cash equivalents. The interest rate payable under the terms of the promissory note shall not be less than the minimum rate (if any) required to avoid the imputation of additional interest under the Code. Subject to the foregoing, the Administrator (in its sole discretion) shall specify the term, interest rate, amortization requirements (if any) and other provisions of such note. Exercise with a promissory note or other transaction by a Director or Participant officer that involves or may involve a direct or indirect extension of credit or arrangement of an extension of credit by the Company Group in violation of Section 402(a) of the Sarbanes-Oxley Act (codified as Section 13(k) of the Securities Exchange Act of 1934, 15 U.S.C. § 78m(k)) shall be prohibited; or

 

(e)             by any combination of the foregoing.

 

5.4             Tax Withholding. Prior to the issuance of the Shares upon exercise of this Option, Participant must satisfy any tax withholding obligations relating to the exercise of this Option and the acquisition of the Shares. If the Administrator permits, in addition to the Exercise Price payment alternatives in Section 5.3, Participant may provide for payment of withholding taxes upon exercise of this Option by (a) authorizing the Company to issue and then immediately redeem or repurchase, at Fair Market Value, Shares out of the Shares issued to the Participant as a result of the exercise of this Option or (b) tendering to the Company currently owned and unencumbered Shares of the Company for redemption or repurchase and, in each of (a) and (b), immediately tendering the redemption or repurchase price paid by the Company in respect of such Shares back to the Company.

 

5.5             Issuance of Shares. Provided that the Exercise Agreement and payment are in form and substance satisfactory to counsel for the Company, the Company shall issue the Shares registered in the name of Participant or, if requested by the Participant, in the name of the Participant and the Participant’s spouse, and shall deliver certificates representing the Shares with the appropriate legends affixed thereto.

 

Page 4

2024

 

 

6.             Compliance with Laws and Regulations. The exercise of this Option and the issuance and transfer of Shares shall be subject to compliance by the Company and Participant with all Applicable Laws and with all applicable requirements of any stock exchange on which the Shares may be listed at the time of such issuance or transfer. Participant understands that the Company is under no obligation to register or qualify the Shares with any federal or state securities commission or any stock exchange to effect such compliance.

 

7.             Nontransferability of Option. Unless determined otherwise by the Administrator, this Option may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent and distribution; provided, however, that the Administrator may, subject to Applicable Laws and such terms and conditions as it shall specify, permit the transfer of this Option for no consideration to a Permitted Transferee. An Option transferred to a Permitted Transferee shall be further transferable only by last will and testament or the laws of descent and distribution or, for no consideration, to another Permitted Transferee of the Participant. During the lifetime of a Participant, this Option shall be exercisable only by the Participant or by a Permitted Transferee to whom this Option has been transferred in accordance with this Section 7. In no event may this Option be transferred to any person who has joined or is supporting a Competing Business.

 

8.             Privileges of Share Ownership. Participant shall not have any of the rights of a Shareholder with respect to any Shares until the Shares are issued to Participant.

 

9.             Restrictive Covenants.

 

9.1             Generally. As a condition to the grant of this Option, the Participant agrees to comply with the following restrictive covenants (each a “Restrictive Covenant”):

 

(a)             To assist Participant in the performance of the Participant’s duties for the Company Group, the Company Group has provided and will provide to Participant certain Confidential Information and Trade Secrets. Participant agrees that during the period of Participant’s service to the Company Group and at all times thereafter, Participant shall not, on Participant’s own behalf or on behalf of any third party, directly or indirectly divulge or make use of any Confidential Information or Trade Secrets without prior written consent of the Company, which consent may be withheld in the Company’s absolute discretion; provided, however, that Participant may make disclosures required by a valid order or subpoena issued by a court or administrative agency of competent jurisdiction, in which event Participant will promptly notify the Company of such order or subpoena, in a reasonable time prior to such disclosure so that the Company has the opportunity to protect its interests. Participant further agrees that if Participant is questioned about information subject to this Agreement by anyone not authorized to receive such information, Participant will promptly notify an officer of the Company.

 

(b)             Participant agrees to hold in confidence all Confidential Information, Trade Secrets and company records received from the Company or at the Company’s expense and shall not at any time directly or indirectly disclose, publish or use any Confidential Information, Trade Secrets and/or company records for the benefit of anyone other than Company. This restriction shall apply to all information received prior to or after the effective date of this Agreement and continue in effect after the Participant’s service ends in perpetuity, or until such information becomes a part of the public domain through means other than wrongful disclosure.

 

Page 5

2024

 

 

(c)             “Confidential Information” means information about the Company Group and its employees, customers, processes, technology and other information that is not generally known outside of the Company Group, which Participant learns in connection with Participant’s service with the Company Group and which would be useful to competitors of the Company Group. Confidential Information includes, but is not limited to: (1) business and employment policies, marketing methods and strategies and the targets of those methods and strategies, financial data, business plans, promotional materials, pricing and pricing strategies, profit and loss statements, and sales and account records; (2) present and prospective customer lists, customer preferences and buying patterns, distribution records and customer credit information; (3) the Company Group’s inventions, innovations, improvements, discoveries, methods, research data and results, databases, research techniques and methodology, analytical approaches, software, and programs; and (4) the nature, origin, composition and development of the Company Group’s brands, products and services.

 

“Trade Secrets” means Confidential Information which meets the additional requirements of the Uniform Trade Secrets Act or similar state law.

 

9.2             Cancellation. The Participant understands that the cancellation of any Option or rights under this Agreement may occur for any violation or lack of enforceability of any Restrictive Covenant and such cancellation may not be adequate recompense for the damages potentially sustained by the Company Group. Such cancellation shall be in addition to any equitable and legal rights the Company Group has or may have and shall not constitute a release of any claim that the Company Group may have for damages, past, present or future. In addition, a breach by the Participant of any provisions of any Restrictive Covenant that occurs after any exercise of any Option or delivery of the Shares pursuant to this Agreement (including any breach occurring after termination of Continuous Service) shall cause the exercise of this Option and the delivery of the Shares under this Agreement to be rescinded (and if the Participant has previously sold the Shares issued pursuant to this Agreement, the Participant would be required to pay back to the Company Group the pre-tax proceeds received from the sale of such Shares).

 

9.3             Rescission. At the Administrator’s discretion, the Company may exercise the right of rescission set forth in this Section 9 via the mandatory redemption or repurchase of the Participant’s Shares at a price equal to the aggregate Exercise Price paid by the Participant for the Shares.

 

10.             Restrictions on Transfer.

 

10.1           Securities Law Restrictions. Regardless of whether the offering and sale of the Shares under the Plan has been registered under the Securities Act, the securities laws of another jurisdiction or registered or qualified under the securities laws of any state, the Company at its discretion may impose restrictions upon the sale, pledge or other transfer of such Shares (including the placement of appropriate legends on share certificates or the imposition of stop-transfer instructions) if, in the judgment of the Company, such restrictions are necessary or desirable in order to achieve compliance with the Securities Act, the securities laws of another jurisdiction, the securities laws of any state or any other law.

 

Page 6

2024

 

 

10.2           Market Stand-Off. In the event of an underwritten public offering by the Company of its equity securities pursuant to an effective registration statement filed under the Securities Act, including the Company’s initial public offering, the Participant shall not sell, make any short sale of, loan, hypothecate, pledge, grant any option for the repurchase of, transfer the economic consequences of ownership or otherwise dispose or transfer for value or otherwise agree to engage in any of the foregoing transactions with respect to any of the Shares or any securities convertible into or exercisable or exchangeable (directly or indirectly) for the Shares (whether such Shares or any such securities are then owned by the Participant or are thereafter acquired) without the prior written consent of the Company or its underwriters, for such period of time from and after the effective date of such registration statement as may be requested by the Company or such underwriters (the “Market Stand-Off”). In order to enforce the Market Stand-Off, the Company may impose stop-transfer instructions with respect to the Shares acquired under this Agreement until the end of the applicable stand-off period. If there is any change in the number of outstanding Shares by reason of a share split, reverse share split, share dividend, recapitalization, combination, reclassification, dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off or a spin-off), a merger or consolidation, a reverse merger or similar transaction, then any new, substituted or additional securities which are by reason of such transaction distributed with respect to any of the Shares subject to the Market Stand-Off, or into which such Shares thereby become convertible, shall immediately be subject to the Market Stand-Off.

 

10.3           Right of Repurchase. Following a termination of the Participant’s Continuous Service, the Company may repurchase the Participant’s Shares acquired under the Plan as provided in this Section (the “Right of Repurchase”). With respect to any vested portion of this Option and any Shares acquired upon exercise of this Option, the Right of Repurchase shall be exercisable at a purchase price (the “Purchase Price”) equal to (i) the Fair Market Value of vested Shares (the “Share Repurchase Right”); or (ii) in the case of a vested Option (the “Option Repurchase Right”), the Fair Market Value of the Shares underlying the vested portion of this Option less the aggregate exercise price of such portion of this Option (in each case as of the date the written notice described in Section 10.3(b) is delivered). For the avoidance of doubt, any unvested portion of this Option will be forfeited for no consideration.

 

(a)             Condition Precedent to Exercise. The Right of Repurchase shall be exercisable following the later of: (i) the date when the Participant’s Continuous Service terminates for any reason, with or without cause, including (without limitation) death or Disability; and (ii) the date when this Option is exercised.

 

(b)             Exercise of Right of Repurchase. The Company shall exercise the Right of Repurchase by written notice delivered to the Participant. The notice shall set forth the date on which the repurchase is to be effected, which must occur within thirty-one (31) days of the notice. The certificate(s) representing any of the Shares to be repurchased shall, prior to the close of business on the date specified for the repurchase, be delivered to the Company (to the extent not already in the Company’s custody) properly endorsed for transfer; provided, however, that the failure to deliver such certificate(s) to the Company shall not prevent the Company from repurchasing any Shares under this Agreement. The Company shall, concurrently with the receipt of such certificate(s), pay to the Participant the Purchase Price determined according to this Section 10.3. Payment shall be made in cash or cash equivalents or by canceling indebtedness to the Company incurred by the Participant.

 

Page 7

2024

 

 

10.4           Right of First Refusal. If the Shares are not readily tradable on an established securities market and the Participant proposes to sell, pledge, gift or otherwise transfer any Share, or any interest in such Shares, to any third party other than a Permitted Transferee (the “Transferee”) the Company shall have a right of first refusal to purchase all (and not less than all) of such Shares (the “Right of First Refusal”). If the Participant desires to transfer Shares, the Participant shall first tender to the Company for its repurchase or redemption, via a written transfer notice (“Transfer Notice”) describing in full the proposed transfer, including the number of Shares proposed to be transferred, the proposed transfer price, the name and address of the proposed Transferee and proof satisfactory to the Company that the proposed sale or transfer will not violate any Applicable Laws, all of the Shares proposed to be transferred to the Transferee. The Transfer Notice shall be signed both by the Participant and the proposed Transferee and must constitute a binding commitment of both parties to the transfer of the Shares. The Company shall have the right to redeem or repurchase all, and not less than all, of the Shares on the same terms and conditions (as to timing and price) of the proposal described in the Transfer Notice by delivery of a notice of exercise of the Right of First Refusal within thirty (30) days after the date the Transfer Notice is received by the Company; provided, however, that in the case of a proposed gift or other non-compensatory transfer of Shares, the purchase price per Share under this Right of First Refusal shall be the Fair Market Value of the Shares determined at the time of the proposed transfer.

 

10.5           Additional Provisions Relating to Rights of Repurchase and First Refusal.

 

(a)             Additional Shares or Substituted Securities. If there is any change in the number of outstanding Shares by reason of a share split, reverse share split, share dividend, recapitalization (excluding any issuances of securities by the Company for consideration), combination, reclassification, dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off or a spin-off), a merger or consolidation; a reverse merger or similar transaction, then (i) any new, substituted or additional securities or other property (including money paid other than as an ordinary cash dividend) which are by reason of such transaction distributed with respect to any Shares subject to a Right of Repurchase or a Right of First Refusal or into which such Shares thereby become convertible shall immediately be subject to the Right of Repurchase and the Right of First Refusal; and (ii) appropriate adjustments to reflect the distribution of such securities or property shall be made to the number and/or class of the Shares subject to this provision and to the price per share of the Shares to be paid upon the exercise of the Right of Repurchase or Right of First Refusal; provided, however, that the aggregate Purchase Price payable for the Shares shall remain the same.

 

(b)             Termination of Rights of Repurchase and First Refusal. Any other provision of Section 10.3 notwithstanding, the Right of Repurchase with respect to vested Shares shall lapse with respect to the Shares that are registered under a then effective registration statement under applicable federal securities laws and the issuer is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act or becomes an investment company registered or required to be registered under the United States Investment Company Act of 1940. If the Shares are readily tradable on an established securities market when the Participant desires to transfer such Shares, the Company shall have no Right of First Refusal, and the Participant shall have no obligation to comply with the procedures prescribed by Section 10.4.

 

Page 8

2024

 

 

(c)             Termination of Rights as Participant and Shareholder. If the Company makes available to a Participant, at the time and place and in the amount and form provided in this Agreement, the consideration for this Option to be repurchased pursuant to the Company’s Option Repurchase Right in accordance with Section 10.3, then after such time such Participant shall no longer have any rights as a Participant in respect of such Option (other than the right to receive payment of such consideration in accordance with this Agreement). If the Company makes available to a Participant, at the time and place and in the amount and form provided in this Agreement, the consideration for the Shares to be repurchased or redeemed pursuant to the Company’s Share Repurchase Right in accordance with Section 10.3 or Right of First Refusal in accordance with Section 10.4, then after such time such Participant shall no longer have any rights as a Shareholder in respect of such Shares (other than the right to receive payment of such consideration in accordance with this Agreement). Such Shares shall be deemed to have been repurchased in accordance with the applicable provisions hereof, whether or not the certificate(s) therefore have been delivered as required by this Agreement.

 

10.6           Investment Intent at Grant. If the grant of this Option under the Plan is not registered under applicable federal or state securities laws, but an exemption is available which requires an investment representation or any other representation, the Participant (a) shall, and hereby does, represent and agree, at the time of grant of this Option, that the security being acquired upon the grant of this Option is being acquired for investment purposes, and not with a view to the sale or distribution thereof, and (b) shall make such other representations as are deemed necessary or appropriate by the Company and its counsel.

 

10.7           Investment Intent at Exercise. If the sale of the Shares under the Plan is not registered under applicable federal or state securities laws, but an exemption is available which requires an investment representation or other representation, the Participant shall represent and agree at the time of exercise that the Shares being acquired upon exercise of this Option are being acquired for investment purposes, and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or appropriate by the Company and its counsel.

 

10.8           Legends. All certificates evidencing the Shares purchased under this Agreement in an unregistered transaction shall bear the following legend (and such other restrictive legends as are required or deemed advisable under the provisions of any Applicable Law):

 

“THE SHARES OF COMMON STOCK EVIDENCED BY THIS CERTIFICATE ARE SUBJECT TO AND TRANSFERABLE ONLY IN ACCORDANCE WITH THAT CERTAIN CARIS LIFE SCIENCES, INC. 2020 INCENTIVE PLAN, THE NONQUALIFIED STOCK OPTION AWARD AGREEMENT AND THE EXERCISE AGREEMENT PURSUANT TO WHICH THE SHARES EVIDENCED BY THIS CERTIFICATE WERE ISSUED, COPIES OF WHICH ARE ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. NO TRANSFER OR PLEDGE OF THE SHARES EVIDENCED HEREBY MAY BE MADE EXCEPT IN ACCORDANCE WITH AND SUBJECT TO THE PROVISIONS OF SAID PLAN AND NONQUALIFIED STOCK OPTION AWARD AGREEMENT AND THE TERMS OF THE EXERCISE AGREEMENT.”

 

Page 9

2024

 

 

10.9           Removal of Legends. If, in the opinion of the Company and its counsel, any legend placed on a share certificate representing the Shares sold under this Agreement no longer is required, the holder of such certificate shall be entitled to exchange such certificate for a certificate representing the same number of Shares but without such legend.

 

10.10         Administration. Any determination by the Company and its counsel in connection with any of the matters set forth in this Section 10 shall be conclusive and binding on the Participant and all other persons.

 

11.            Exchange Act. Notwithstanding anything contained in the Plan or this Agreement to the contrary, if the consummation of any transaction under the Plan or this Agreement would result in the possible imposition of liability on the Participant pursuant to Section 16(b) of the Exchange Act, the Administrator shall have the right, in its sole discretion, but shall not be obligated, to defer such transaction to the extent necessary to avoid such liability, but in no event for a period in excess of 180 days.

 

12.            General.

 

12.1           Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by Participant or the Company to the Administrator for review. The resolution of such a dispute by the Administrator shall be final and binding on the Company and Participant.

 

12.2           Entire Agreement. The Plan is incorporated herein by reference. This Agreement and the Plan constitute the entire agreement of the parties and supersede all prior undertakings and agreements with respect to the subject matter hereof. If any inconsistency should exist between the nondiscretionary terms and conditions of this Agreement and the Plan, the Plan shall govern and control. Notwithstanding the above, nothing in this Agreement shall be deemed to amend any agreement, whether entered into prior to or after the date hereof, between the Company and the Participant.

 

12.3           Notices. Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the Corporate Secretary/General Counsel of the Company at its principal corporate offices. Any notice required to be given or delivered to Participant shall be in writing and addressed to Participant at the address indicated above or to such other address as such party may designate in writing from time to time to the Company. All notices shall be deemed to have been given or delivered upon: (a) personal delivery; (b) five (5) days after deposit in the United States mail by certified or registered mail (return receipt requested); (c) two (2) business days after deposit with any return receipt express courier (prepaid); or (d) one (1) business day after transmission by facsimile.

 

12.4           Successors and Assigns. The Company may assign any of its rights under this Agreement. This Agreement shall be binding upon and inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement shall be binding upon Participant and Participant’s heirs, executors, administrators, legal representatives, successors and assigns.

 

Page 10

2024

 

 

12.5           Choice of Law. This Agreement, including, but not limited to, its enforceability, interpretation and legal effect, shall be governed by and construed in accordance with the laws of the State of Texas without giving effect to its conflict of law principles. If any provision of this Agreement is determined by a court or tribunal of competent jurisdiction to be illegal or unenforceable, then such provision will be enforced to the maximum extent possible and the other provisions will remain fully effective and enforceable. Subject to Section 12.6, the courts of the State of Texas, for Dallas County or any Federal Court having jurisdiction in that county shall have exclusive jurisdiction with respect to any dispute or litigation arising under this Agreement.

 

12.6          Arbitration. Subject to the Company’s remedies for breach or threatened breach of a Restrictive Covenant, any other dispute, controversy, or claim arising out of or relating to this Agreement or breach thereof, will be submitted to arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association. The arbitration of any dispute, controversy, or claim will take place in Dallas, Texas. Judgment on the award rendered by the arbitrator may be entered in any court of competent jurisdiction. In reaching the arbitrator’s decision, the arbitrator will have no authority to ignore, change, modify, add to or delete from any provision of this Agreement, but instead is limited to interpreting this Agreement.

 

12.7           No Right to Future Awards. This Option and all other equity-based awards under the Plan are discretionary. This Option does not confer on the Participant any right or entitlement to receive another award of Option or any other equity-based award at any time in the future or in respect of any future period.

 

12.8           Severability. If any provision of this Agreement is held to be illegal or invalid for any reason, such illegality or invalidity shall not affect the remaining provisions of this Agreement, but this Agreement shall be construed and enforced as if such illegal or invalid provision had never been included herein.

 

12.9           Amendment. Notwithstanding anything herein or in the Plan to the contrary, the Administrator may, at any time, alter, amend, suspend or modify this Agreement; provided, however, that no amendment or modification of this Agreement shall materially and adversely impair the rights of the Participant with respect to any then outstanding Options without the consent of the Participant.

 

13.           Acceptance. Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. Participant has read and understands the terms and provisions thereof, and by executing below, accepts the terms and conditions of this Agreement governing this Option and the terms and conditions of the Plan governing this Option and any and all other outstanding options held by the Participant as of the date of execution. Participant acknowledges that there may be adverse tax consequences upon exercise of this Option or disposition of the Shares and that Participant should consult a tax advisor prior to such exercise or disposition.

 

[Signatures on Following Page]

 

Page 11

2024

 

 

In witness whereof, the Company has caused this Agreement to be executed by its duly authorized representative effective as of [               ].

 

 CARIS LIFE SCIENCES, INC.
   
By:
Name:[               ]
Title:[               ]

 

Participant:[               ]

 

Acceptance Date: [               ]

 

 

 

Exhibit 10.4(e)

 

CARIS LIFE SCIENCES, INC.

 

2020 INCENTIVE PLAN

 

RESTRICTED STOCK UNIT AWARD AGREEMENT

 

This Restricted Stock Unit Award Agreement (the “Agreement”) is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Caris Life Sciences, Inc., a Texas corporation (the “Company”), and the participant named below (the “Participant”). Capitalized terms not defined herein shall have the meaning ascribed to them in the Company’s 2020 Incentive Plan (the “Plan”).

 

Participant: [                ]
   
Address:  [                ]
   
Grant Number: [                ]
   
Total Restricted Stock Units: [                ]
   
Date of Grant: [                ]
   
Expiration Date: [                ]

 

 

WHEREAS, the Company desires to grant restricted stock units (“RSUs”) with respect to shares of common stock of the Company, par value US$0.001 per share (the “Shares”) to certain employees, consultants and/or directors of the Company;

 

WHEREAS, the Company has adopted the Plan in order to effect such grants; and

 

WHEREAS, the Administrator has determined that it is in the interest of the Company to grant these RSUs to the Participant.

 

NOW, THEREFORE, in consideration of the services to be rendered by the Participant to the Company and subject to the terms and conditions set forth herein and in the Plan, the parties hereto agree as follows:

 

1.             Grant of RSUs. The Company hereby grants to Participant the number of RSUs set forth above as Total Restricted Stock Units, each entitling Participant to receive one Share upon settlement, subject to all of the terms and conditions of this Agreement and the Plan, including vesting.

 

Page 1

2024

 

 

2.             Vesting; Settlement of RSUs.

 

2.1.             Vesting. RSUs shall vest only upon the occurrence, on or before the Expiration Date, of either (1) an IPO or (2) a Change of Control (each a “Vesting Date”), subject to the Participant’s Continuous Service with the Company through the Vesting Date. For the purposes of this Agreement, an “IPO” means the occurrence of an initial public offering that results in any security of the Company being listed (or approved for listing) on any securities exchange or designated (or approved for designation) as a national market security on an interdealer quotation system, on or before the date set forth above as Expiration Date. Unless otherwise determined by the Administrator in its sole discretion, if Participant’s Continuous Service is terminated for any reason, all outstanding RSUs that are not vested at the date of such termination shall be cancelled and terminated without any payment.

 

2.2.             Settlement. Pursuant to such procedures established by the Administrator, and subject to any deferral of delivery pursuant to Section 8.2, the Company shall issue whole Shares to the Participant in settlement of the vested portion of the RSUs as soon as administratively practicable after the applicable Vesting Date.

 

2.3.             Tax Withholding. Prior to the issuance of the Shares upon settlement of the RSUs, Participant must satisfy any tax withholding obligations relating to the settlement of the RSUs and the acquisition of the Shares. The Company shall hold back a portion of the RSUs otherwise deliverable to the Participant to cover any such required withholdings. If Shares are used to pay all or a portion of such withholding tax obligation, the number of Shares that may be withheld, surrendered, or reduced shall be limited to the number of Shares equal in value to the aggregate amount of such liabilities based on the greatest statutory withholding rates applicable to Participant for federal, state, foreign, or local tax purposes, including payroll taxes, that may be utilized without creating adverse accounting treatment with respect to the RSUs, as determined by the Company. If the Administrator permits, Participant may provide for payment of withholding taxes upon settlement of the RSUs by (a) authorizing the Company to issue and then immediately redeem or repurchase, at Fair Market Value, Shares out of the Shares issued to the Participant as a result of the settlement of the RSUs or (b) tendering to the Company currently owned and unencumbered Shares of the Company for redemption or repurchase and, in each of (a) and (b), immediately tendering the redemption or repurchase price paid by the Company in respect of such Shares back to the Company.

 

3.             Cancellation and Rescission of RSUs for Detrimental Activity.

 

3.1.             The Administrator may cancel, rescind, suspend, withhold or otherwise limit or restrict any RSUs at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.

 

3.2.             Upon settlement or delivery pursuant to settlement of the RSUs, the Participant shall certify in a manner acceptable to the Company that the Participant is in compliance with the terms and conditions of the Plan and has not engaged in any Detrimental Activity. In the event a Participant engages in Detrimental Activity after the settlement or delivery of any Shares pursuant to this Agreement, during any period for which any restrictive covenant prohibiting such activity is applicable to the Participant, such settlement or delivery may be rescinded within one (1) year thereafter. In the event of any such rescission, the Participant shall pay to the Company the amount of any gain realized or payment received as a result of the settlement or delivery of such Shares, in such manner and on such terms and conditions as may be required by the Company. The Company shall be entitled to setoff against the amount of any such gain any amount owed to the Participant by the Company.

 

2

 

 

3.3.             At the Administrator’s discretion, the Company may exercise the right of rescission set forth in this Section 3 via the mandatory redemption or repurchase of the Participant’s Shares. It is expressly agreed by the Participant that, since the Participant is not making any monetary payment or incurring any monetary obligation to the Company for the issuance of the Shares, no purchase price or other consideration shall be payable to the Participant by the Company for the Company’s redemption or repurchase of the Participant’s Shares.

 

4.             Compliance with Laws and Regulations. The settlement of the RSUs and the issuance and transfer of Shares shall be subject to compliance by the Company and Participant with all Applicable Laws and with all applicable requirements of any stock exchange on which the Shares may be listed at the time of such issuance or transfer. Participant understands that the Company is under no obligation to register or qualify the Shares with any federal or state securities commission or any stock exchange to effect such compliance.

 

5.             Nontransferability of the RSUs. Unless determined otherwise by the Administrator, the RSUs may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent and distribution; provided, however, that the Administrator may, subject to Applicable Laws and such terms and conditions as it shall specify, permit the transfer of the RSUs for no consideration to a Permitted Transferee. RSUs transferred to a Permitted Transferee shall be further transferable only by last will and testament or the laws of descent and distribution or, for no consideration, to another Permitted Transferee of the Participant. In no event may the RSUs be transferred to any person who has joined or is supporting a Competing Business.

 

6.             Privileges of Share Ownership. Participant shall not have any of the rights of a shareholder with respect to any Shares until the Shares are issued and delivered to the Participant in such manner as the Company, in its sole discretion, shall deem appropriate.

 

7.             Restrictive Covenants. As a condition to the grant and settlement of the RSUs, the Participant agrees to comply with the restrictive covenants (each a “Restrictive Covenant”) set forth in any Proprietary Information, Intellectual Property, Restrictive Covenant and Arbitration Agreement (the “PIIA”) or other agreement or policy that may be in effect between the Participant and the Company Group. The Participant understands that the cancellation of any RSUs or rights under this Agreement may occur for any violation or lack of enforceability of any Restrictive Covenant and such cancellation may not be adequate recompense for the damages potentially sustained by the Company Group. Such cancellation shall be in addition to any equitable and legal rights the Company Group has or may have and shall not constitute a release of any claim that the Company Group may have for damages, past, present or future. In addition, a breach by the Participant of any provisions of any Restrictive Covenant that occurs after any delivery of the Shares pursuant to this Agreement (including any breach occurring after termination of employment) shall cause the delivery of the Shares under this Agreement to be rescinded (and if the Participant has previously sold the Shares issued pursuant to this Agreement, the Participant would be required to pay back to the Company Group the pre-tax proceeds received from the sale of such Shares).

 

3

 

 

7.1.             At the Administrator’s discretion, the Company may exercise the right of rescission set forth in this Section 7 via the mandatory redemption or repurchase of the Participant’s Shares. It is expressly agreed by the Participant that, since the Participant is not making any monetary payment or incurring any monetary obligation to the Company for the issuance of the Shares, no purchase price or other consideration shall be payable to the Participant by the Company for the Company’s redemption or repurchase of the Participant’s Shares.

 

8.             Restrictions on Transfer.

 

8.1.             Securities Law Restrictions. Regardless of whether the offering and sale of the Shares under the Plan has been registered under the Securities Act, the securities laws of another jurisdiction or registered or qualified under the securities laws of any state, the Company at its discretion may impose restrictions upon the sale, pledge or other transfer of such Shares (including the placement of appropriate legends on share certificates or the imposition of stop-transfer instructions) if, in the judgment of the Company, such restrictions are necessary or desirable in order to achieve compliance with the Securities Act, the securities laws of another jurisdiction, the securities laws of any state or any other law.

 

8.2.             Market Stand-Off. In the event of an underwritten public offering by the Company of its equity securities pursuant to an effective registration statement filed under the Securities Act, including the Company’s IPO, the Participant shall not sell, make any short sale of, loan, hypothecate, pledge, grant any option for the repurchase of, transfer the economic consequences of ownership or otherwise dispose or transfer for value or otherwise agree to engage in any of the foregoing transactions with respect to any of the Shares or any securities convertible into or exercisable or exchangeable (directly or indirectly) for the Shares (whether such Shares or any such securities are then owned by the Participant or are thereafter acquired) without the prior written consent of the Company or its underwriters, for such period of time from and after the effective date of such registration statement as may be requested by the Company or such underwriters (the “Market Stand-Off”). In order to enforce the Market Stand-Off, the Company may impose stop-transfer instructions with respect to the Shares acquired under this Agreement until the end of the applicable stand-off period. If there is any change in the number of outstanding Shares by reason of a share split, reverse share split, share dividend, recapitalization, combination, reclassification, dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off or a spin-off), a merger or consolidation, a reverse merger or similar transaction, then any new, substituted or additional securities which are by reason of such transaction distributed with respect to any of the Shares subject to the Market Stand-Off, or into which such Shares thereby become convertible, shall immediately be subject to the Market Stand-Off. To the extent the vesting of any RSUs occurs during the Market Stand-Off, the Administrator retains the right, in its sole discretion, to defer the delivery of Shares underlying the RSUs until promptly following the termination of the Market Stand-Off; provided, however, that in no event shall the delivery of such Shares be later than March 15th of the calendar year following the calendar year in which the RSUs vest.

 

4

 

 

8.3.             Right of Repurchase. Following a termination of the Participant’s Continuous Service, the Company may repurchase the Participant’s Shares acquired under the Plan as provided in this Section (the “Right of Repurchase”). With respect to any vested RSUs and any Shares acquired upon settlement of the RSUs, the Right of Repurchase shall be exercisable at a purchase price (the “Purchase Price”) equal to (i) the Fair Market Value of vested Shares (the “Share Repurchase Right”); or (ii) in the case of a vested RSU (the “RSU Repurchase Right”), the Fair Market Value of the Shares underlying the vested RSUs (in each case as of the date the written notice described in Section 8.3(b) is delivered). For the avoidance of doubt, any unvested RSUs will be forfeited for no consideration.

 

(a)             Condition Precedent to Settlement. The Right of Repurchase shall be exercisable following the later of: (i) the date when the Participant’s Continuous Service terminates for any reason, with or without cause, including (without limitation) death or Disability; and (ii) the date when the RSUs are settled.

 

(b)             Exercise of Right of Repurchase. The Company shall exercise the Right of Repurchase by written notice delivered to the Participant. The notice shall set forth the date on which the repurchase is to be effected, which must occur within thirty-one (31) days of the notice. The certificate(s) representing any of the Shares to be repurchased shall, prior to the close of business on the date specified for the repurchase, be delivered to the Company (to the extent not already in the Company’s custody) properly endorsed for transfer; provided, however, that the failure to deliver such certificate(s) to the Company shall not prevent the Company from repurchasing any Shares under this Agreement. The Company shall, concurrently with the receipt of such certificate(s), pay to the Participant the Purchase Price determined according to this Section 8.3. Payment shall be made in cash or cash equivalents or by canceling indebtedness to the Company incurred by the Participant.

 

8.4.             Right of First Refusal. If the Shares are not readily tradable on an established securities market and the Participant proposes to sell, pledge, gift or otherwise transfer any Share, or any interest in such Shares, to any third party other than a Permitted Transferee (the “Transferee”) the Company shall have a right of first refusal to purchase all (and not less than all) of such Shares (the “Right of First Refusal”). If the Participant desires to transfer Shares, the Participant shall first tender to the Company for its repurchase or redemption, via a written transfer notice (“Transfer Notice”) describing in full the proposed transfer, including the number of Shares proposed to be transferred, the proposed transfer price, the name and address of the proposed Transferee and proof satisfactory to the Company that the proposed sale or transfer will not violate any Applicable Laws, all of the Shares proposed to be transferred to the Transferee. The Transfer Notice shall be signed both by the Participant and the proposed Transferee and must constitute a binding commitment of both parties to the transfer of the Shares. The Company shall have the right to redeem or repurchase all, and not less than all, of the Shares on the same terms and conditions (as to timing and price) of the proposal described in the Transfer Notice by delivery of a notice of exercise of the Right of First Refusal within thirty (30) days after the date the Transfer Notice is received by the Company; provided, however, that in the case of a proposed gift or other non-compensatory transfer of Shares, the purchase price per Share under this Right of First Refusal shall be the Fair Market Value of the Shares determined at the time of the proposed transfer.

 

5

 

 

8.5.             Additional Provisions Relating to Rights of Repurchase and First Refusal.

 

(a)             Additional Shares or Substituted Securities. If there is any change in the number of outstanding Shares by reason of a share split, reverse share split, share dividend, recapitalization (excluding any issuances of securities by the Company for consideration), combination, reclassification, dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off or a spin-off), a merger or consolidation; a reverse merger or similar transaction, then (i) any new, substituted or additional securities or other property (including money paid other than as an ordinary cash dividend) which are by reason of such transaction distributed with respect to any Shares subject to a Right of Repurchase or a Right of First Refusal or into which such Shares thereby become convertible shall immediately be subject to the Right of Repurchase and the Right of First Refusal; and (ii) appropriate adjustments to reflect the distribution of such securities or property shall be made to the number and/or class of the Shares subject to this provision and to the price per share of the Shares to be paid upon the exercise of the Right of Repurchase or Right of First Refusal; provided, however, that the aggregate Purchase Price payable for the Shares shall remain the same.

 

(b)             Termination of Rights of Repurchase and First Refusal. Any other provision of Section 8.3 notwithstanding, the Right of Repurchase with respect to vested Shares shall lapse with respect to the Shares that are registered under a then effective registration statement under applicable federal securities laws and the issuer is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act or becomes an investment company registered or required to be registered under the United States Investment Company Act of 1940. If the Shares are readily tradable on an established securities market when the Participant desires to transfer such Shares, the Company shall have no Right of First Refusal, and the Participant shall have no obligation to comply with the procedures prescribed by Section 8.4.

 

(c)             Termination of Rights as Participant and Shareholder. If the Company makes available to a Participant, at the time and place and in the amount and form provided in this Agreement, the consideration for the RSUs to be repurchased pursuant to the Company’s RSUs Repurchase Right in accordance with Section 8.3, then after such time such Participant shall no longer have any rights as a Participant in respect of such RSUs (other than the right to receive payment of such consideration in accordance with this Agreement). If the Company makes available to a Participant, at the time and place and in the amount and form provided in this Agreement, the consideration for the Shares to be repurchased or redeemed pursuant to the Company’s Share Repurchase Right in accordance with Section 8.3 or Right of First Refusal in accordance with Section 8.4, then after such time such Participant shall no longer have any rights as a Shareholder in respect of such Shares (other than the right to receive payment of such consideration in accordance with this Agreement). Such Shares shall be deemed to have been repurchased in accordance with the applicable provisions hereof, whether or not the certificate(s) therefore have been delivered as required by this Agreement.

 

8.6.             Investment Intent at Grant. If the grant of the RSUs under the Plan is not registered under applicable federal or state securities laws, but an exemption is available which requires an investment representation or any other representation, the Participant (a) shall, and hereby does, represent and agree, at the time of grant of the RSUs, that the security being acquired upon the grant of the RSUs is being acquired for investment purposes, and not with a view to the sale or distribution thereof, and (b) shall make such other representations as are deemed necessary or appropriate by the Company and its counsel.

 

8.7.             Investment Intent at Settlement. If the sale of the Shares under the Plan is not registered under applicable federal or state securities laws, but an exemption is available which requires an investment representation or other representation, the Participant shall represent and agree at the time of settlement that the Shares being acquired upon settlement of the RSUs are being acquired for investment purposes, and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or appropriate by the Company and its counsel.

 

6

 

 

8.8.             Legends. All certificates evidencing the Shares acquired under this Agreement in an unregistered transaction shall bear the following legend (and such other restrictive legends as are required or deemed advisable under the provisions of any Applicable Law):

 

“THE SHARES OF COMMON STOCK EVIDENCED BY THIS CERTIFICATE ARE SUBJECT TO AND TRANSFERABLE ONLY IN ACCORDANCE WITH THAT CERTAIN CARIS LIFE SCIENCES, INC. 2020 INCENTIVE PLAN AND THE RESTRICTED STOCK UNIT AWARD AGREEMENT PURSUANT TO WHICH THE SHARES EVIDENCED BY THIS CERTIFICATE WERE ISSUED, COPIES OF WHICH ARE ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. NO TRANSFER OR PLEDGE OF THE SHARES EVIDENCED HEREBY MAY BE MADE EXCEPT IN ACCORDANCE WITH AND SUBJECT TO THE PROVISIONS OF SAID PLAN AND THE RESTRICTED STOCK UNIT AWARD AGREEMENT.”

 

8.9.             Removal of Legends. If, in the opinion of the Company and its counsel, any legend placed on a share certificate representing the Shares sold under this Agreement no longer is required, the holder of such certificate shall be entitled to exchange such certificate for a certificate representing the same number of Shares but without such legend.

 

8.10.             Administration. Any determination by the Company and its counsel in connection with any of the matters set forth in this Section 8 shall be conclusive and binding on the Participant and all other persons.

 

9.             Exchange Act. Notwithstanding anything contained in the Plan or this Agreement to the contrary, if the consummation of any transaction under the Plan or this Agreement would result in the possible imposition of liability on the Participant pursuant to Section 16(b) of the Exchange Act, the Administrator shall have the right, in its sole discretion, but shall not be obligated, to defer such transaction to the extent necessary to avoid such liability, but in no event for a period in excess of 180 days.

 

10.           Compliance with Code Section 409A. Notwithstanding any contrary provision herein or in the Plan, if any RSU is deemed to be a “deferral of compensation” under Code Section 409A or any regulations or guidance promulgated thereunder or could cause any person to recognize additional taxes, penalties or interest under Code Section 409A, the Board may, in its sole discretion and without the consent of any person, unilaterally modify such provision: (i) to comply with, or avoid being subject to, Code Section 409A, or to avoid the imposition of any additional taxes, penalties or interest under Code Section 409A, and (ii) to maintain, to the maximum extent practicable, the original intent of the applicable provision without contravening the provisions of Code Section 409A. This Section 10 does not create an obligation on the part of the Board to modify the Plan or this Agreement and does not guarantee that any person shall not be subject to additional taxes, penalties or interest under Code Section 409A.

 

7

 

 

11.           Expiration. The RSUs shall expire on the Expiration Date set forth above.

 

12.           General.

 

12.1.           Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by Participant or the Company to the Administrator for review. The resolution of such a dispute by the Administrator shall be final and binding on the Company and Participant.

 

12.2.           Entire Agreement. The Plan is incorporated herein by reference. This Agreement and the Plan constitute the entire agreement of the parties and supersede all prior undertakings and agreements with respect to the subject matter hereof. If any inconsistency should exist between the nondiscretionary terms and conditions of this Agreement and the Plan, the Plan shall govern and control. Notwithstanding the above, nothing in this Agreement shall be deemed to amend any agreement, whether entered into prior to or after the date hereof, between the Company and the Participant.

 

12.3.           Notices. Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the Corporate Secretary/Chief Legal Officer of the Company at its principal corporate offices. Any notice required to be given or delivered to Participant shall be in writing and addressed to Participant at the address indicated above or to such other address as such party may designate in writing from time to time to the Company. All notices shall be deemed to have been given or delivered upon: (a) personal delivery; (b) five (5) days after deposit in the United States mail by certified or registered mail (return receipt requested); (c) two (2) business days after deposit with any return receipt express courier (prepaid); or (d) one (1) business day after transmission by facsimile.

 

12.4.           Successors and Assigns. The Company may assign any of its rights under this Agreement. This Agreement shall be binding upon and inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement shall be binding upon Participant and Participant’s heirs, executors, administrators, legal representatives, successors and assigns.

 

12.5.           Choice of Law and Venue. This Agreement, including, but not limited to, its enforceability, interpretation and legal effect, shall be governed by and construed in accordance with the laws of the State of Texas without giving effect to its conflict of law principles. If any provision of this Agreement is determined by a court or tribunal of competent jurisdiction to be illegal or unenforceable, then such provision will be enforced to the maximum extent possible and the other provisions will remain fully effective and enforceable. Subject to Section 12.6, the courts of the State of Texas, for Dallas County or any Federal Court having jurisdiction in that county shall have exclusive jurisdiction with respect to any dispute or litigation arising under this Agreement.

 

12.6.           Arbitration. The terms of this Agreement are subject to any arbitration provisions of any PIIA or other agreement or policy that may be in effect between the Participant and the Company. If no such other agreement or policy is in effect, then the following arbitration provisions shall govern: Subject to the Company’s remedies for breach or threatened breach of a Restrictive Covenant, any other dispute, controversy, or claim arising out of or relating to this Agreement or breach thereof, will be submitted to arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association. The arbitration of any dispute, controversy, or claim will take place in Dallas, Texas. Judgment on the award rendered by the arbitrator may be entered in any court of competent jurisdiction. In reaching the arbitrator’s decision, the arbitrator will have no authority to ignore, change, modify, add to or delete from any provision of this Agreement, but instead is limited to interpreting this Agreement.

 

8

 

 

12.7.           No Employment or Other Service Rights. Nothing in the Plan or this Agreement shall confer on Participant any right to continue to serve the Company Group in the capacity in effect as of the Date of Grant or shall affect the right of the Company Group to terminate the Participant’s (a) employment with or without notice and with or without cause, (b) service pursuant to the terms of a consulting agreement with the Company Group or (c) service as a Director pursuant to the Articles or the TBOC, and any applicable provisions of the corporate law of the jurisdiction in which the Company or the Affiliate is incorporated, as the case may be; or shall give the Participant any right to be reemployed or reengaged by the Company Group following a termination of employment or services for any reason.

 

12.8.           No Right to Future Awards. This award of RSUs and all other equity-based awards under the Plan are discretionary. This award does not confer on the Participant any right or entitlement to receive another award of RSUs or any other equity-based award at any time in the future or in respect of any future period.

 

12.9.           Severability. If any provision of this Agreement is held to be illegal or invalid for any reason, such illegality or invalidity shall not affect the remaining provisions of this Agreement, but this Agreement shall be construed and enforced as if such illegal or invalid provision had never been included herein.

 

12.10.         Amendment. Notwithstanding anything herein or in the Plan to the contrary, the Administrator may, at any time, alter, amend, suspend or modify this Agreement; provided, however, that no amendment or modification of this Agreement shall materially and adversely impair the rights of the Participant with respect to any then outstanding RSUs without the consent of the Participant.

 

13.           Spousal Consent. I agree to cause any current or future spouse of mine to deliver to the Company a consent in the form of the consent attached hereto validly executed by such spouse on the date hereof or promptly after any such person becomes my spouse, as applicable.

 

14.           Acceptance. Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. Participant has read and understands the terms and provisions thereof, and by executing below, accepts the terms and conditions of this Agreement governing the RSUs and the terms and conditions of the Plan governing the RSUs and any and all other outstanding RSUs held by the Participant as of the date of execution. Participant acknowledges that there may be adverse tax consequences upon settlement of the RSUs or disposition of the Shares and that Participant should consult a tax advisor prior to such settlement or disposition.

 

15.           Release of Claims. In consideration of the grant of the RSUs provided to Participant under this Agreement and after having sufficient time to consult with Participant’s own counsel, Participant and each of Participant’s respective heirs, executors, administrators, representatives, agents, successors and assigns (collectively, the “Participant Parties”) hereby irrevocably and unconditionally release and forever discharge the Company, the Company’s former, current and future parents, subsidiaries and affiliates, and each predecessor, successor and affiliate of each of the aforementioned entities, and each of their respective officers, employees, directors, shareholders and agents from any and all claims, actions, causes of action, rights, judgments, obligations, damages, demands, accountings or liabilities of whatever kind or character (collectively, “Claims”), including, without limitation, any Claims under any federal, state, local or foreign law, that the Participant Parties may have, or in the future may possess, arising from or relating to any RSU or other equity or equity-based award previously granted under the Plan; provided, however, that Participant does not release, discharge or waive any rights to the RSUs and to the Shares provided under this Agreement that is contingent upon the execution by Participant of this release of claims. This Section 15 does not apply to any Claims that the Participant Parties may have as of the date Participant signs this Agreement arising under the Federal Age Discrimination in Employment Act of 1967, as amended, and the applicable rules and regulations promulgated thereunder.

 

[SIGNATURE PAGE TO FOLLOW]

 

9

 

 

In witness whereof, the Company has caused this Agreement to be executed by its duly authorized representative effective as of [               ].

 

 CARIS LIFE SCIENCES, INC.
   
By:
Name:[               ]
Title:[               ]
   
  
 Participant

 

[Signatures Page to RSU Award Agreement]

 

 

 

SPOUSAL ACKNOWLEDGEMENT

 

The undersigned spouse of the Participant has read and hereby approves the foregoing Restricted Stock Unit Award Agreement. In consideration of the Company’s granting the Participant the right to acquire the Shares in accordance with the terms of such Agreement, the undersigned hereby agrees to be irrevocably bound by all the terms of such Agreement and the Plan, including (without limitation) (i) the right of the Company (or its assigns) to purchase any Shares in which the Participant is not vested at the time of the Participant’s cessation of Continuous Service, and (ii) any sale or by the Participant or any settlement of any Shares contemplated by such Agreement, and for purposes of any community property laws and all other laws conveys all of the undersigned’s right, title and interest in and to such Shares to the purchaser of such Shares.

 

 

PARTICIPANT’S SPOUSE 

   
  Address:
     
   

 

 

 

Exhibit 10.4(f)

 

CARIS LIFE SCIENCES, INC.

 

2020 INCENTIVE PLAN

 

RESTRICTED STOCK UNIT AWARD AGREEMENT

 

This Restricted Stock Unit Award Agreement (the “Agreement”) is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Caris Life Sciences, Inc., a Texas corporation (the “Company”), and the participant named below (the “Participant”). Capitalized terms not defined herein shall have the meaning ascribed to them in the Company’s 2020 Incentive Plan (the “Plan”).

 

Participant: [                ]
   
Address:  [                ]
   
Grant Number: [                ]
   
Total Restricted Stock Units: [                ]
   
Date of Grant: [                ]
   
Expiration Date: [                ]

 

WHEREAS, the Company desires to grant restricted stock units (“RSUs”) with respect to shares of common stock of the Company, par value US$0.001 per share (the “Shares”) to certain employees, consultants and/or directors of the Company;

 

WHEREAS, the Company has adopted the Plan in order to effect such grants; and

 

WHEREAS, the Administrator has determined that it is in the interest of the Company to grant these RSUs to the Participant.

 

NOW, THEREFORE, in consideration of the services to be rendered by the Participant to the Company and subject to the terms and conditions set forth herein and in the Plan, the parties hereto agree as follows:

 

1.             Grant of RSUs. The Company hereby grants to Participant the number of RSUs set forth above as Total Restricted Stock Units, each entitling Participant to receive one Share upon settlement, subject to all of the terms and conditions of this Agreement and the Plan, including vesting.

 

Page 1

2024

 

 

2.             Vesting; Settlement of RSUs.

 

2.1.             Vesting. RSUs shall vest only upon the occurrence, on or before the Expiration Date, of either (1) an IPO or (2) a Change of Control (each a “Vesting Date”), subject to the Participant’s Continuous Service with the Company through the Vesting Date. For the purposes of this Agreement, an “IPO” means the occurrence of an initial public offering that results in any security of the Company being listed (or approved for listing) on any securities exchange or designated (or approved for designation) as a national market security on an interdealer quotation system, on or before the date set forth above as Expiration Date. Unless otherwise determined by the Administrator in its sole discretion, if Participant’s Continuous Service is terminated for any reason, all outstanding RSUs that are not vested at the date of such termination shall be cancelled and terminated without any payment.

 

2.2.             Settlement. Pursuant to such procedures established by the Administrator, and subject to any deferral of delivery pursuant to Section 8.2, the Company shall issue whole Shares to the Participant in settlement of the vested portion of the RSUs as soon as administratively practicable after the applicable Vesting Date.

 

2.3.             Tax Withholding. Prior to the issuance of the Shares upon settlement of the RSUs, Participant must satisfy any tax withholding obligations relating to the settlement of the RSUs and the acquisition of the Shares. The Company shall hold back a portion of the RSUs otherwise deliverable to the Participant to cover any such required withholdings. If Shares are used to pay all or a portion of such withholding tax obligation, the number of Shares that may be withheld, surrendered, or reduced shall be limited to the number of Shares equal in value to the aggregate amount of such liabilities based on the greatest statutory withholding rates applicable to Participant for federal, state, foreign, or local tax purposes, including payroll taxes, that may be utilized without creating adverse accounting treatment with respect to the RSUs, as determined by the Company. If the Administrator permits, Participant may provide for payment of withholding taxes upon settlement of the RSUs by (a) authorizing the Company to issue and then immediately redeem or repurchase, at Fair Market Value, Shares out of the Shares issued to the Participant as a result of the settlement of the RSUs or (b) tendering to the Company currently owned and unencumbered Shares of the Company for redemption or repurchase and, in each of (a) and (b), immediately tendering the redemption or repurchase price paid by the Company in respect of such Shares back to the Company.

 

3.             Cancellation and Rescission of RSUs for Detrimental Activity.

 

3.1.             The Administrator may cancel, rescind, suspend, withhold or otherwise limit or restrict any RSUs at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.

 

3.2.             Upon settlement or delivery pursuant to settlement of the RSUs, the Participant shall certify in a manner acceptable to the Company that the Participant is in compliance with the terms and conditions of the Plan and has not engaged in any Detrimental Activity. In the event a Participant engages in Detrimental Activity after the settlement or delivery of any Shares pursuant to this Agreement, during any period for which any restrictive covenant prohibiting such activity is applicable to the Participant, such settlement or delivery may be rescinded within one (1) year thereafter. In the event of any such rescission, the Participant shall pay to the Company the amount of any gain realized or payment received as a result of the settlement or delivery of such Shares, in such manner and on such terms and conditions as may be required by the Company. The Company shall be entitled to setoff against the amount of any such gain any amount owed to the Participant by the Company.

 

2

 

 

3.3.             At the Administrator’s discretion, the Company may exercise the right of rescission set forth in this Section 3 via the mandatory redemption or repurchase of the Participant’s Shares. It is expressly agreed by the Participant that, since the Participant is not making any monetary payment or incurring any monetary obligation to the Company for the issuance of the Shares, no purchase price or other consideration shall be payable to the Participant by the Company for the Company’s redemption or repurchase of the Participant’s Shares.

 

4.             Compliance with Laws and Regulations. The settlement of the RSUs and the issuance and transfer of Shares shall be subject to compliance by the Company and Participant with all Applicable Laws and with all applicable requirements of any stock exchange on which the Shares may be listed at the time of such issuance or transfer. Participant understands that the Company is under no obligation to register or qualify the Shares with any federal or state securities commission or any stock exchange to effect such compliance.

 

5.             Nontransferability of the RSUs. Unless determined otherwise by the Administrator, the RSUs may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent and distribution; provided, however, that the Administrator may, subject to Applicable Laws and such terms and conditions as it shall specify, permit the transfer of the RSUs for no consideration to a Permitted Transferee. RSUs transferred to a Permitted Transferee shall be further transferable only by last will and testament or the laws of descent and distribution or, for no consideration, to another Permitted Transferee of the Participant. In no event may the RSUs be transferred to any person who has joined or is supporting a Competing Business.

 

6.             Privileges of Share Ownership. Participant shall not have any of the rights of a shareholder with respect to any Shares until the Shares are issued and delivered to the Participant in such manner as the Company, in its sole discretion, shall deem appropriate.

 

7.             Restrictive Covenants.

 

7.1.             Generally. As a condition to the grant of the RSUs, the Participant agrees to comply with the following restrictive covenants (each a “Restrictive Covenant”):

 

(a)             To assist Participant in the performance of the Participant’s duties for the Company Group, the Company Group has provided and will provide to Participant certain Confidential Information and Trade Secrets. Participant agrees that during the period of Participant’s service to the Company Group and at all times thereafter, Participant shall not, on Participant’s own behalf or on behalf of any third party, directly or indirectly divulge or make use of any Confidential Information or Trade Secrets without prior written consent of the Company, which consent may be withheld in the Company’s absolute discretion; provided, however, that Participant may make disclosures required by a valid order or subpoena issued by a court or administrative agency of competent jurisdiction, in which event Participant will promptly notify the Company of such order or subpoena, in a reasonable time prior to such disclosure so that the Company has the opportunity to protect its interests. Participant further agrees that if Participant is questioned about information subject to this Agreement by anyone not authorized to receive such information, Participant will promptly notify an officer of the Company.

 

3

 

 

(b)             Participant agrees to hold in confidence all Confidential Information, Trade Secrets and company records received from the Company or at the Company’s expense and shall not at any time directly or indirectly disclose, publish or use any Confidential Information, Trade Secrets and/or company records for the benefit of anyone other than Company. This restriction shall apply to all information received prior to or after the effective date of this Agreement and continue in effect after the Participant’s service ends in perpetuity, or until such information becomes a part of the public domain through means other than wrongful disclosure.

 

(c)             “Confidential Information” means information about the Company Group and its employees, customers, processes, technology and other information that is not generally known outside of the Company Group, which Participant learns in connection with Participant’s service with the Company Group and which would be useful to competitors of the Company Group. Confidential Information includes, but is not limited to: (1) business and employment policies, marketing methods and strategies and the targets of those methods and strategies, financial data, business plans, promotional materials, pricing and pricing strategies, profit and loss statements, and sales and account records; (2) present and prospective customer lists, customer preferences and buying patterns, distribution records and customer credit information; (3) the Company Group’s inventions, innovations, improvements, discoveries, methods, research data and results, databases, research techniques and methodology, analytical approaches, software, and programs; and (4) the nature, origin, composition and development of the Company Group’s brands, products and services.

 

7.2.             “Trade Secrets” means Confidential Information which meets the additional requirements of the Uniform Trade Secrets Act or similar state law.

 

7.3.             Cancellation. The Participant understands that the cancellation of any RSUs or rights under this Agreement may occur for any violation or lack of enforceability of any Restrictive Covenant and such cancellation may not be adequate recompense for the damages potentially sustained by the Company Group. Such cancellation shall be in addition to any equitable and legal rights the Company Group has or may have and shall not constitute a release of any claim that the Company Group may have for damages, past, present or future. In addition, a breach by the Participant of any provisions of any Restrictive Covenant that occurs after any delivery of the Shares pursuant to this Agreement (including any breach occurring after termination of employment) shall cause the delivery of the Shares under this Agreement to be rescinded (and if the Participant has previously sold the Shares issued pursuant to this Agreement, the Participant would be required to pay back to the Company Group the pre-tax proceeds received from the sale of such Shares).

 

7.4.             Rescission. At the Administrator’s discretion, the Company may exercise the right of rescission set forth in this Section 7 via the mandatory redemption or repurchase of the Participant’s Shares. It is expressly agreed by the Participant that, since the Participant is not making any monetary payment or incurring any monetary obligation to the Company for the issuance of the Shares, no purchase price or other consideration shall be payable to the Participant by the Company for the Company’s redemption or repurchase of the Participant’s Shares.

 

4

 

 

8.             Restrictions on Transfer.

 

8.1.             Securities Law Restrictions. Regardless of whether the offering and sale of the Shares under the Plan has been registered under the Securities Act, the securities laws of another jurisdiction or registered or qualified under the securities laws of any state, the Company at its discretion may impose restrictions upon the sale, pledge or other transfer of such Shares (including the placement of appropriate legends on share certificates or the imposition of stop-transfer instructions) if, in the judgment of the Company, such restrictions are necessary or desirable in order to achieve compliance with the Securities Act, the securities laws of another jurisdiction, the securities laws of any state or any other law.

 

8.2.             Market Stand-Off. In the event of an underwritten public offering by the Company of its equity securities pursuant to an effective registration statement filed under the Securities Act, including the Company’s IPO, the Participant shall not sell, make any short sale of, loan, hypothecate, pledge, grant any option for the repurchase of, transfer the economic consequences of ownership or otherwise dispose or transfer for value or otherwise agree to engage in any of the foregoing transactions with respect to any of the Shares or any securities convertible into or exercisable or exchangeable (directly or indirectly) for the Shares (whether such Shares or any such securities are then owned by the Participant or are thereafter acquired) without the prior written consent of the Company or its underwriters, for such period of time from and after the effective date of such registration statement as may be requested by the Company or such underwriters (the “Market Stand-Off”). In order to enforce the Market Stand-Off, the Company may impose stop-transfer instructions with respect to the Shares acquired under this Agreement until the end of the applicable stand-off period. If there is any change in the number of outstanding Shares by reason of a share split, reverse share split, share dividend, recapitalization, combination, reclassification, dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off or a spin-off), a merger or consolidation, a reverse merger or similar transaction, then any new, substituted or additional securities which are by reason of such transaction distributed with respect to any of the Shares subject to the Market Stand-Off, or into which such Shares thereby become convertible, shall immediately be subject to the Market Stand-Off. To the extent the vesting of any RSUs occurs during the Market Stand-Off, the Administrator retains the right, in its sole discretion, to defer the delivery of Shares underlying the RSUs until promptly following the termination of the Market Stand-Off; provided, however, that in no event shall the delivery of such Shares be later than March 15th of the calendar year following the calendar year in which the RSUs vest.

 

8.3.             Right of Repurchase. Following a termination of the Participant’s Continuous Service, the Company may repurchase the Participant’s Shares acquired under the Plan as provided in this Section (the “Right of Repurchase”). With respect to any vested RSUs and any Shares acquired upon settlement of the RSUs, the Right of Repurchase shall be exercisable at a purchase price (the “Purchase Price”) equal to (i) the Fair Market Value of vested Shares (the “Share Repurchase Right”); or (ii) in the case of a vested RSU (the “RSU Repurchase Right”), the Fair Market Value of the Shares underlying the vested RSUs (in each case as of the date the written notice described in Section 8.3(b) is delivered). For the avoidance of doubt, any unvested RSUs will be forfeited for no consideration.

 

5

 

 

(a)             Condition Precedent to Settlement. The Right of Repurchase shall be exercisable following the later of: (i) the date when the Participant’s Continuous Service terminates for any reason, with or without cause, including (without limitation) death or Disability; and (ii) the date when the RSUs are settled.

 

(b)             Exercise of Right of Repurchase. The Company shall exercise the Right of Repurchase by written notice delivered to the Participant. The notice shall set forth the date on which the repurchase is to be effected, which must occur within thirty-one (31) days of the notice. The certificate(s) representing any of the Shares to be repurchased shall, prior to the close of business on the date specified for the repurchase, be delivered to the Company (to the extent not already in the Company’s custody) properly endorsed for transfer; provided, however, that the failure to deliver such certificate(s) to the Company shall not prevent the Company from repurchasing any Shares under this Agreement. The Company shall, concurrently with the receipt of such certificate(s), pay to the Participant the Purchase Price determined according to this Section 8.3. Payment shall be made in cash or cash equivalents or by canceling indebtedness to the Company incurred by the Participant.

 

8.4.             Right of First Refusal. If the Shares are not readily tradable on an established securities market and the Participant proposes to sell, pledge, gift or otherwise transfer any Share, or any interest in such Shares, to any third party other than a Permitted Transferee (the “Transferee”) the Company shall have a right of first refusal to purchase all (and not less than all) of such Shares (the “Right of First Refusal”). If the Participant desires to transfer Shares, the Participant shall first tender to the Company for its repurchase or redemption, via a written transfer notice (“Transfer Notice”) describing in full the proposed transfer, including the number of Shares proposed to be transferred, the proposed transfer price, the name and address of the proposed Transferee and proof satisfactory to the Company that the proposed sale or transfer will not violate any Applicable Laws, all of the Shares proposed to be transferred to the Transferee. The Transfer Notice shall be signed both by the Participant and the proposed Transferee and must constitute a binding commitment of both parties to the transfer of the Shares. The Company shall have the right to redeem or repurchase all, and not less than all, of the Shares on the same terms and conditions (as to timing and price) of the proposal described in the Transfer Notice by delivery of a notice of exercise of the Right of First Refusal within thirty (30) days after the date the Transfer Notice is received by the Company; provided, however, that in the case of a proposed gift or other non-compensatory transfer of Shares, the purchase price per Share under this Right of First Refusal shall be the Fair Market Value of the Shares determined at the time of the proposed transfer.

 

8.5.             Additional Provisions Relating to Rights of Repurchase and First Refusal.

 

(a)             Additional Shares or Substituted Securities. If there is any change in the number of outstanding Shares by reason of a share split, reverse share split, share dividend, recapitalization (excluding any issuances of securities by the Company for consideration), combination, reclassification, dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off or a spin-off), a merger or consolidation; a reverse merger or similar transaction, then (i) any new, substituted or additional securities or other property (including money paid other than as an ordinary cash dividend) which are by reason of such transaction distributed with respect to any Shares subject to a Right of Repurchase or a Right of First Refusal or into which such Shares thereby become convertible shall immediately be subject to the Right of Repurchase and the Right of First Refusal; and (ii) appropriate adjustments to reflect the distribution of such securities or property shall be made to the number and/or class of the Shares subject to this provision and to the price per share of the Shares to be paid upon the exercise of the Right of Repurchase or Right of First Refusal; provided, however, that the aggregate Purchase Price payable for the Shares shall remain the same.

 

6

 

 

(b)             Termination of Rights of Repurchase and First Refusal. Any other provision of Section 8.3 notwithstanding, the Right of Repurchase with respect to vested Shares shall lapse with respect to the Shares that are registered under a then effective registration statement under applicable federal securities laws and the issuer is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act or becomes an investment company registered or required to be registered under the United States Investment Company Act of 1940. If the Shares are readily tradable on an established securities market when the Participant desires to transfer such Shares, the Company shall have no Right of First Refusal, and the Participant shall have no obligation to comply with the procedures prescribed by Section 8.4.

 

(c)             Termination of Rights as Participant and Shareholder. If the Company makes available to a Participant, at the time and place and in the amount and form provided in this Agreement, the consideration for the RSUs to be repurchased pursuant to the Company’s RSUs Repurchase Right in accordance with Section 8.3, then after such time such Participant shall no longer have any rights as a Participant in respect of such RSUs (other than the right to receive payment of such consideration in accordance with this Agreement). If the Company makes available to a Participant, at the time and place and in the amount and form provided in this Agreement, the consideration for the Shares to be repurchased or redeemed pursuant to the Company’s Share Repurchase Right in accordance with Section 8.3 or Right of First Refusal in accordance with Section 8.4, then after such time such Participant shall no longer have any rights as a Shareholder in respect of such Shares (other than the right to receive payment of such consideration in accordance with this Agreement). Such Shares shall be deemed to have been repurchased in accordance with the applicable provisions hereof, whether or not the certificate(s) therefore have been delivered as required by this Agreement.

 

8.6.             Investment Intent at Grant. If the grant of the RSUs under the Plan is not registered under applicable federal or state securities laws, but an exemption is available which requires an investment representation or any other representation, the Participant (a) shall, and hereby does, represent and agree, at the time of grant of the RSUs, that the security being acquired upon the grant of the RSUs is being acquired for investment purposes, and not with a view to the sale or distribution thereof, and (b) shall make such other representations as are deemed necessary or appropriate by the Company and its counsel.

 

8.7.             Investment Intent at Settlement. If the sale of the Shares under the Plan is not registered under applicable federal or state securities laws, but an exemption is available which requires an investment representation or other representation, the Participant shall represent and agree at the time of settlement that the Shares being acquired upon settlement of the RSUs are being acquired for investment purposes, and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or appropriate by the Company and its counsel.

 

7

 

 

8.8.             Legends. All certificates evidencing the Shares acquired under this Agreement in an unregistered transaction shall bear the following legend (and such other restrictive legends as are required or deemed advisable under the provisions of any Applicable Law):

 

“THE SHARES OF COMMON STOCK EVIDENCED BY THIS CERTIFICATE ARE SUBJECT TO AND TRANSFERABLE ONLY IN ACCORDANCE WITH THAT CERTAIN CARIS LIFE SCIENCES, INC. 2020 INCENTIVE PLAN AND THE RESTRICTED STOCK UNIT AWARD AGREEMENT PURSUANT TO WHICH THE SHARES EVIDENCED BY THIS CERTIFICATE WERE ISSUED, COPIES OF WHICH ARE ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. NO TRANSFER OR PLEDGE OF THE SHARES EVIDENCED HEREBY MAY BE MADE EXCEPT IN ACCORDANCE WITH AND SUBJECT TO THE PROVISIONS OF SAID PLAN AND THE RESTRICTED STOCK UNIT AWARD AGREEMENT.”

 

8.9.             Removal of Legends. If, in the opinion of the Company and its counsel, any legend placed on a share certificate representing the Shares sold under this Agreement no longer is required, the holder of such certificate shall be entitled to exchange such certificate for a certificate representing the same number of Shares but without such legend.

 

8.10.           Administration. Any determination by the Company and its counsel in connection with any of the matters set forth in this Section 8 shall be conclusive and binding on the Participant and all other persons.

 

9.             Exchange Act. Notwithstanding anything contained in the Plan or this Agreement to the contrary, if the consummation of any transaction under the Plan or this Agreement would result in the possible imposition of liability on the Participant pursuant to Section 16(b) of the Exchange Act, the Administrator shall have the right, in its sole discretion, but shall not be obligated, to defer such transaction to the extent necessary to avoid such liability, but in no event for a period in excess of 180 days.

 

10.           Compliance with Code Section 409A. Notwithstanding any contrary provision herein or in the Plan, if any RSU is deemed to be a “deferral of compensation” under Code Section 409A or any regulations or guidance promulgated thereunder or could cause any person to recognize additional taxes, penalties or interest under Code Section 409A, the Board may, in its sole discretion and without the consent of any person, unilaterally modify such provision: (i) to comply with, or avoid being subject to, Code Section 409A, or to avoid the imposition of any additional taxes, penalties or interest under Code Section 409A, and (ii) to maintain, to the maximum extent practicable, the original intent of the applicable provision without contravening the provisions of Code Section 409A. This Section 10 does not create an obligation on the part of the Board to modify the Plan or this Agreement and does not guarantee that any person shall not be subject to additional taxes, penalties or interest under Code Section 409A.

 

11.           Expiration. The RSUs shall expire on the Expiration Date set forth above.

 

8

 

 

12.           General.

 

12.1.           Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by Participant or the Company to the Administrator for review. The resolution of such a dispute by the Administrator shall be final and binding on the Company and Participant.

 

12.2.           Entire Agreement. The Plan is incorporated herein by reference. This Agreement and the Plan constitute the entire agreement of the parties and supersede all prior undertakings and agreements with respect to the subject matter hereof. If any inconsistency should exist between the nondiscretionary terms and conditions of this Agreement and the Plan, the Plan shall govern and control. Notwithstanding the above, nothing in this Agreement shall be deemed to amend any agreement, whether entered into prior to or after the date hereof, between the Company and the Participant.

 

12.3.           Notices. Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the Corporate Secretary/Chief Legal Officer of the Company at its principal corporate offices. Any notice required to be given or delivered to Participant shall be in writing and addressed to Participant at the address indicated above or to such other address as such party may designate in writing from time to time to the Company. All notices shall be deemed to have been given or delivered upon: (a) personal delivery; (b) five (5) days after deposit in the United States mail by certified or registered mail (return receipt requested); (c) two (2) business days after deposit with any return receipt express courier (prepaid); or (d) one (1) business day after transmission by facsimile.

 

12.4.           Successors and Assigns. The Company may assign any of its rights under this Agreement. This Agreement shall be binding upon and inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement shall be binding upon Participant and Participant’s heirs, executors, administrators, legal representatives, successors and assigns.

 

12.5.           Choice of Law and Venue. This Agreement, including, but not limited to, its enforceability, interpretation and legal effect, shall be governed by and construed in accordance with the laws of the State of Texas without giving effect to its conflict of law principles. If any provision of this Agreement is determined by a court or tribunal of competent jurisdiction to be illegal or unenforceable, then such provision will be enforced to the maximum extent possible and the other provisions will remain fully effective and enforceable. Subject to Section 12.6, the courts of the State of Texas, for Dallas County or any Federal Court having jurisdiction in that county shall have exclusive jurisdiction with respect to any dispute or litigation arising under this Agreement.

 

12.6.           Arbitration. The terms of this Agreement are subject to any arbitration provisions of any PIIA or other agreement or policy that may be in effect between the Participant and the Company. If no such other agreement or policy is in effect, then the following arbitration provisions shall govern: Subject to the Company’s remedies for breach or threatened breach of a Restrictive Covenant, any other dispute, controversy, or claim arising out of or relating to this Agreement or breach thereof, will be submitted to arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association. The arbitration of any dispute, controversy, or claim will take place in Dallas, Texas. Judgment on the award rendered by the arbitrator may be entered in any court of competent jurisdiction. In reaching the arbitrator’s decision, the arbitrator will have no authority to ignore, change, modify, add to or delete from any provision of this Agreement, but instead is limited to interpreting this Agreement.

 

9

 

 

12.7.           No Employment or Other Service Rights. Nothing in the Plan or this Agreement shall confer on Participant any right to continue to serve the Company Group in the capacity in effect as of the Date of Grant or shall affect the right of the Company Group to terminate the Participant’s (a) employment with or without notice and with or without cause, (b) service pursuant to the terms of a consulting agreement with the Company Group or (c) service as a Director pursuant to the Articles or the TBOC, and any applicable provisions of the corporate law of the jurisdiction in which the Company or the Affiliate is incorporated, as the case may be; or shall give the Participant any right to be reemployed or reengaged by the Company Group following a termination of employment or services for any reason.

 

12.8.           No Right to Future Awards. This award of RSUs and all other equity-based awards under the Plan are discretionary. This award does not confer on the Participant any right or entitlement to receive another award of RSUs or any other equity-based award at any time in the future or in respect of any future period.

 

12.9.           Severability. If any provision of this Agreement is held to be illegal or invalid for any reason, such illegality or invalidity shall not affect the remaining provisions of this Agreement, but this Agreement shall be construed and enforced as if such illegal or invalid provision had never been included herein.

 

12.10.         Amendment. Notwithstanding anything herein or in the Plan to the contrary, the Administrator may, at any time, alter, amend, suspend or modify this Agreement; provided, however, that no amendment or modification of this Agreement shall materially and adversely impair the rights of the Participant with respect to any then outstanding RSUs without the consent of the Participant.

 

13.           Spousal Consent. I agree to cause any current or future spouse of mine to deliver to the Company a consent in the form of the consent attached hereto validly executed by such spouse on the date hereof or promptly after any such person becomes my spouse, as applicable.

 

14.           Acceptance. Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. Participant has read and understands the terms and provisions thereof, and by executing below, accepts the terms and conditions of this Agreement governing the RSUs and the terms and conditions of the Plan governing the RSUs and any and all other outstanding RSUs held by the Participant as of the date of execution. Participant acknowledges that there may be adverse tax consequences upon settlement of the RSUs or disposition of the Shares and that Participant should consult a tax advisor prior to such settlement or disposition.

 

15.           Release of Claims. In consideration of the grant of the RSUs provided to Participant under this Agreement and after having sufficient time to consult with Participant’s own counsel, Participant and each of Participant’s respective heirs, executors, administrators, representatives, agents, successors and assigns (collectively, the “Participant Parties”) hereby irrevocably and unconditionally release and forever discharge the Company, the Company’s former, current and future parents, subsidiaries and affiliates, and each predecessor, successor and affiliate of each of the aforementioned entities, and each of their respective officers, employees, directors, shareholders and agents from any and all claims, actions, causes of action, rights, judgments, obligations, damages, demands, accountings or liabilities of whatever kind or character (collectively, “Claims”), including, without limitation, any Claims under any federal, state, local or foreign law, that the Participant Parties may have, or in the future may possess, arising from or relating to any RSU or other equity or equity-based award previously granted under the Plan; provided, however, that Participant does not release, discharge or waive any rights to the RSUs and to the Shares provided under this Agreement that is contingent upon the execution by Participant of this release of claims. This Section 15 does not apply to any Claims that the Participant Parties may have as of the date Participant signs this Agreement arising under the Federal Age Discrimination in Employment Act of 1967, as amended, and the applicable rules and regulations promulgated thereunder.

 

[SIGNATURE PAGE TO FOLLOW]

 

10

 

 

In witness whereof, the Company has caused this Agreement to be executed by its duly authorized representative effective as of the Date of Grant set forth on the coverage page hereof.

 

 CARIS LIFE SCIENCES, INC.
   
By:
Name:[               ]
Title:[               ]
   
  
 Participant

 

[Signatures Page to RSU Award Agreement]

 

 

 

SPOUSAL ACKNOWLEDGEMENT

 

The undersigned spouse of the Participant has read and hereby approves the foregoing Restricted Stock Unit Award Agreement. In consideration of the Company’s granting the Participant the right to acquire the Shares in accordance with the terms of such Agreement, the undersigned hereby agrees to be irrevocably bound by all the terms of such Agreement and the Plan, including (without limitation) (i) the right of the Company (or its assigns) to purchase any Shares in which the Participant is not vested at the time of the Participant’s cessation of Continuous Service, and (ii) any sale or by the Participant or any settlement of any Shares contemplated by such Agreement, and for purposes of any community property laws and all other laws conveys all of the undersigned’s right, title and interest in and to such Shares to the purchaser of such Shares.

 

 

PARTICIPANT’S SPOUSE 

   
  Address:
     
   

 

 

Exhibit 10.4(g)

 

CARIS LIFE SCIENCES, INC.

2020 INCENTIVE PLAN

RESTRICTED STOCK UNIT AWARD AGREEMENT

 

This Restricted Stock Unit Award Agreement (the “Agreement”) is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Caris Life Sciences, Inc., a Texas corporation (the “Company”), and the participant named below (the “Participant”). Capitalized terms not defined herein shall have the meaning ascribed to them in the Company’s 2020 Incentive Plan (the “Plan”).

 

Participant: [_______]
   
Address: [_______]
   
Grant Number: [_______]
   
Total Restricted Stock Units: [_______]
   
Date of Grant: [_______]
   
Expiration Date: [_______]

 

WHEREAS, the Company desires to grant restricted stock units (“RSUs”) with respect to shares of common stock of the Company, par value US$0.001 per share (the “Shares”) to certain employees, consultants and/or directors of the Company;

 

WHEREAS, the Company has adopted the Plan in order to effect such grants; and

 

WHEREAS, the Administrator has determined that it is in the interest of the Company to grant these RSUs to the Participant.

 

NOW, THEREFORE, in consideration of the services to be rendered by the Participant to the Company and subject to the terms and conditions set forth herein and in the Plan, the parties hereto agree as follows:

 

1.            Grant of RSUs. The Company hereby grants to Participant the number of RSUs set forth above as Total Restricted Stock Units, each entitling Participant to receive one Share upon settlement, subject to all of the terms and conditions of this Agreement and the Plan, including vesting.

 

1 

 

 

2.            Vesting; Settlement of RSUs.

 

2.1.          Two vesting requirements must be satisfied on or before the Expiration Date in order for an RSU to vest: (i) a “Service-Based Requirement”, and (ii) a requirement that the Company complete either an IPO or a Change of Control (a “Liquidity Event Requirement”). The RSUs will not vest (in whole or in part) if only one (or if neither) of such requirements is satisfied on or before the Expiration Date. One hundred percent (100%) of the RSUs will vest on the first date on or before the Expiration Date upon which both (i) the Service-Based Requirement and (ii) the Liquidity Event Requirement are satisfied with respect to the RSUs (the “Vesting Date”). Unless otherwise determined by the Administrator in its sole discretion, if Participant’s Continuous Service is terminated for any reason prior to the Vesting Date, all outstanding RSUs that are not vested at the date of such termination shall be cancelled and terminated without any payment.

 

2.2.          The Service-Based Requirement will be satisfied on the date of the Company’s first Annual Meeting of Shareholders held after the completion of an IPO, subject to the Participant’s Continuous Service with the Company through such date.

 

2.3.          The Liquidity Event Requirement will be satisfied (as to any then-outstanding RSUs that have not previously been terminated pursuant to the Plan or this Agreement) on the earlier to occur of (i) an IPO or (ii) a Change of Control. For the purposes of this Agreement, an “IPO” means the occurrence of an initial public offering that results in any security of the Company being listed (or approved for listing) on any securities exchange or designated (or approved for designation) as a national market security on an interdealer quotation system, on or before the date set forth above as Expiration Date

 

2.4.          Notwithstanding the above and anything to the contrary in the Plan, this Agreement or any other prior or future agreement that purportedly applies to the RSUs: in no event shall the vesting or settlement of the RSUs be accelerated or deferred in connection with any event or otherwise unless such acceleration or deferral is specifically approved by the Administrator after taking into account the impact of such acceleration or deferral under the requirements of Code Section 409A.

 

2.5.          Settlement. Pursuant to such procedures established by the Administrator, and subject to any deferral of delivery pursuant to Section 8.2, the Company shall issue whole Shares to the Participant in settlement of the RSUs that meet both the Service-Based Requirement and the Liquidity Event Requirement as soon as administratively practicable after the Vesting Date.

 

2.6.          Tax Withholding. Participant shall have full responsibility, and the Company shall have no responsibility, for satisfying any liability for any federal, state or local income or other taxes required by law to be paid with respect to the RSUs.

 

3.            Cancellation and Rescission of RSUs for Detrimental Activity.

 

3.1.          The Administrator may cancel, rescind, suspend, withhold or otherwise limit or restrict any RSUs at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity (as applicable).

 

2 

 

 

3.2.          Upon settlement or delivery pursuant to settlement of the RSUs, the Participant shall certify in a manner acceptable to the Company that the Participant is in compliance with the terms and conditions of the Plan and has not engaged in any Detrimental Activity (as applicable). In the event a Participant engages in Detrimental Activity (as applicable) after the settlement or delivery of any Shares pursuant to this Agreement, during any period for which any restrictive covenant prohibiting such activity is applicable to the Participant, such settlement or delivery may be rescinded within one (1) year thereafter. In the event of any such rescission, the Participant shall pay to the Company the amount of any gain realized or payment received as a result of the settlement or delivery of such Shares, in such manner and on such terms and conditions as may be required by the Company. The Company shall be entitled to setoff against the amount of any such gain any amount owed to the Participant by the Company.

 

3.3.          At the Administrator’s discretion, the Company may exercise the right of rescission set forth in this Section 3 via the mandatory redemption or repurchase of the Participant’s Shares. It is expressly agreed by the Participant that, since the Participant is not making any monetary payment or incurring any monetary obligation to the Company for the issuance of the Shares, no purchase price or other consideration shall be payable to the Participant by the Company for the Company’s redemption or repurchase of the Participant’s Shares.

 

4.            Compliance with Laws and Regulations. The settlement of the RSUs and the issuance and transfer of Shares shall be subject to compliance by the Company and Participant with all Applicable Laws and with all applicable requirements of any stock exchange on which the Shares may be listed at the time of such issuance or transfer. Participant understands that the Company is under no obligation to register or qualify the Shares with any federal or state securities commission or any stock exchange to effect such compliance.

 

5.            Nontransferability of the RSUs. Unless determined otherwise by the Administrator, the RSUs may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent and distribution; provided, however, that the Administrator may, subject to Applicable Laws and such terms and conditions as it shall specify, permit the transfer of the RSUs for no consideration to a Permitted Transferee. RSUs transferred to a Permitted Transferee shall be further transferable only by last will and testament or the laws of descent and distribution or, for no consideration, to another Permitted Transferee of the Participant. In no event may the RSUs be transferred to any person who has joined or is supporting a Competing Business.

 

6.            Privileges of Share Ownership. Participant shall not have any of the rights of a shareholder with respect to any Shares until the Shares are issued and delivered to the Participant in such manner as the Company, in its sole discretion, shall deem appropriate.

 

3 

 

 

7.            Restrictive Covenants.

 

7.1.          Generally. As a condition to the grant of the RSUs, the Participant agrees to comply with the following restrictive covenants (each a “Restrictive Covenant”):

 

(a)            To assist Participant in the performance of the Participant’s duties for the Company Group, the Company Group has provided and will provide to Participant certain Confidential Information and Trade Secrets. Participant agrees that during the period of Participant’s service to the Company Group and at all times thereafter, Participant shall not, on Participant’s own behalf or on behalf of any third party, directly or indirectly divulge or make use of any Confidential Information or Trade Secrets without prior written consent of the Company, which consent may be withheld in the Company’s absolute discretion; provided, however, that Participant may make disclosures required by a valid order or subpoena issued by a court or administrative agency of competent jurisdiction, in which event Participant will promptly notify the Company of such order or subpoena, in a reasonable time prior to such disclosure so that the Company has the opportunity to protect its interests. Participant further agrees that if Participant is questioned about information subject to this Agreement by anyone not authorized to receive such information, Participant will promptly notify an officer of the Company.

 

(b)            Participant agrees to hold in confidence all Confidential Information, Trade Secrets and company records received from the Company or at the Company’s expense and shall not at any time directly or indirectly disclose, publish or use any Confidential Information, Trade Secrets and/or company records for the benefit of anyone other than Company. This restriction shall apply to all information received prior to or after the effective date of this Agreement and continue in effect after the Participant’s service ends in perpetuity, or until such information becomes a part of the public domain through means other than wrongful disclosure.

 

(c)            “Confidential Information” means information about the Company Group and its employees, customers, processes, technology and other information that is not generally known outside of the Company Group, which Participant learns in connection with Participant’s service with the Company Group and which would be useful to competitors of the Company Group. Confidential Information includes, but is not limited to: (1) business and employment policies, marketing methods and strategies and the targets of those methods and strategies, financial data, business plans, promotional materials, pricing and pricing strategies, profit and loss statements, and sales and account records; (2) present and prospective customer lists, customer preferences and buying patterns, distribution records and customer credit information; (3) the Company Group’s inventions, innovations, improvements, discoveries, methods, research data and results, databases, research techniques and methodology, analytical approaches, software, and programs; and (4) the nature, origin, composition and development of the Company Group’s brands, products and services.

 

(d)            “Trade Secrets” means Confidential Information which meets the additional requirements of the Uniform Trade Secrets Act or similar state law..

 

7.2.          Cancellation. The Participant understands that the cancellation of any RSUs or rights under this Agreement may occur for any violation or lack of enforceability of any Restrictive Covenant and such cancellation may not be adequate recompense for the damages potentially sustained by the Company Group. Such cancellation shall be in addition to any equitable and legal rights the Company Group has or may have and shall not constitute a release of any claim that the Company Group may have for damages, past, present or future. In addition, a breach by the Participant of any provisions of any Restrictive Covenant that occurs after any delivery of the Shares pursuant to this Agreement (including any breach occurring after termination of employment) shall cause the delivery of the Shares under this Agreement to be rescinded (and if the Participant has previously sold the Shares issued pursuant to this Agreement, the Participant would be required to pay back to the Company Group the pre-tax proceeds received from the sale of such Shares).

 

4 

 

 

7.3.          Rescission. At the Administrator’s discretion, the Company may exercise the right of rescission set forth in this Section 7 via the mandatory redemption or repurchase of the Participant’s Shares. It is expressly agreed by the Participant that, since the Participant is not making any monetary payment or incurring any monetary obligation to the Company for the issuance of the Shares, no purchase price or other consideration shall be payable to the Participant by the Company for the Company’s redemption or repurchase of the Participant’s Shares.

 

8.            Restrictions on Transfer.

 

8.1.          Securities Law Restrictions. Regardless of whether the offering and sale of the Shares under the Plan has been registered under the Securities Act, the securities laws of another jurisdiction or registered or qualified under the securities laws of any state, the Company at its discretion may impose restrictions upon the sale, pledge or other transfer of such Shares (including the placement of appropriate legends on share certificates or the imposition of stop-transfer instructions) if, in the judgment of the Company, such restrictions are necessary or desirable in order to achieve compliance with the Securities Act, the securities laws of another jurisdiction, the securities laws of any state or any other law.

 

8.2.          Market Stand-Off. In the event of an underwritten public offering by the Company of its equity securities pursuant to an effective registration statement filed under the Securities Act, including the Company’s IPO, the Participant shall not sell, make any short sale of, loan, hypothecate, pledge, grant any option for the repurchase of, transfer the economic consequences of ownership or otherwise dispose or transfer for value or otherwise agree to engage in any of the foregoing transactions with respect to any of the Shares or any securities convertible into or exercisable or exchangeable (directly or indirectly) for the Shares (whether such Shares or any such securities are then owned by the Participant or are thereafter acquired) without the prior written consent of the Company or its underwriters, for such period of time from and after the effective date of such registration statement as may be requested by the Company or such underwriters (the “Market Stand-Off”). In order to enforce the Market Stand-Off, the Company may impose stop-transfer instructions with respect to the Shares acquired under this Agreement until the end of the applicable stand-off period. If there is any change in the number of outstanding Shares by reason of a share split, reverse share split, share dividend, recapitalization, combination, reclassification, dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off or a spin-off), a merger or consolidation, a reverse merger or similar transaction, then any new, substituted or additional securities which are by reason of such transaction distributed with respect to any of the Shares subject to the Market Stand-Off, or into which such Shares thereby become convertible, shall immediately be subject to the Market Stand-Off. To the extent the vesting of any RSUs occurs during the Market Stand-Off, the Administrator retains the right, in its sole discretion, to defer the delivery of Shares underlying the RSUs until promptly following the termination of the Market Stand-Off; provided, however, that in no event shall the delivery of such Shares be later than March 15th of the calendar year following the calendar year in which the RSUs vest.

 

5 

 

 

8.3.          Right of Repurchase. Following a termination of the Participant’s Continuous Service, the Company may repurchase the Participant’s Shares acquired under the Plan as provided in this Section (the “Right of Repurchase”). With respect to any vested RSUs and any Shares acquired upon settlement of the RSUs, the Right of Repurchase shall be exercisable at a purchase price (the “Purchase Price”) equal to (i) the Fair Market Value of vested Shares (the “Share Repurchase Right”); or (ii) in the case of a vested RSU (the “RSU Repurchase Right”), the Fair Market Value of the Shares underlying the vested RSUs (in each case as of the date the written notice described in Section 8.3(b) is delivered). For the avoidance of doubt, any unvested RSUs will be forfeited for no consideration.

 

(a)            Condition Precedent to Settlement. The Right of Repurchase shall be exercisable following the later of: (i) the date when the Participant’s Continuous Service terminates for any reason, with or without cause, including (without limitation) death or Disability; and (ii) the date when the RSUs are settled.

 

(b)            Exercise of Right of Repurchase. The Company shall exercise the Right of Repurchase by written notice delivered to the Participant. The notice shall set forth the date on which the repurchase is to be effected, which must occur within thirty-one (31) days of the notice. The certificate(s) representing any of the Shares to be repurchased shall, prior to the close of business on the date specified for the repurchase, be delivered to the Company (to the extent not already in the Company’s custody) properly endorsed for transfer; provided, however, that the failure to deliver such certificate(s) to the Company shall not prevent the Company from repurchasing any Shares under this Agreement. The Company shall, concurrently with the receipt of such certificate(s), pay to the Participant the Purchase Price determined according to this Section 8.3. Payment shall be made in cash or cash equivalents or by canceling indebtedness to the Company incurred by the Participant.

 

8.4.          Right of First Refusal. If the Shares are not readily tradable on an established securities market and the Participant proposes to sell, pledge, gift or otherwise transfer any Share, or any interest in such Shares, to any third party other than a Permitted Transferee (the “Transferee”) the Company shall have a right of first refusal to purchase all (and not less than all) of such Shares (the “Right of First Refusal”). If the Participant desires to transfer Shares, the Participant shall first tender to the Company for its repurchase or redemption, via a written transfer notice (“Transfer Notice”) describing in full the proposed transfer, including the number of Shares proposed to be transferred, the proposed transfer price, the name and address of the proposed Transferee and proof satisfactory to the Company that the proposed sale or transfer will not violate any Applicable Laws, all of the Shares proposed to be transferred to the Transferee. The Transfer Notice shall be signed both by the Participant and the proposed Transferee and must constitute a binding commitment of both parties to the transfer of the Shares. The Company shall have the right to redeem or repurchase all, and not less than all, of the Shares on the same terms and conditions (as to timing and price) of the proposal described in the Transfer Notice by delivery of a notice of exercise of the Right of First Refusal within thirty (30) days after the date the Transfer Notice is received by the Company; provided, however, that in the case of a proposed gift or other non-compensatory transfer of Shares, the purchase price per Share under this Right of First Refusal shall be the Fair Market Value of the Shares determined at the time of the proposed transfer.

 

6 

 

 

8.5.          Additional Provisions Relating to Rights of Repurchase and First Refusal.

 

(a)            Additional Shares or Substituted Securities. If there is any change in the number of outstanding Shares by reason of a share split, reverse share split, share dividend, recapitalization (excluding any issuances of securities by the Company for consideration), combination, reclassification, dissolution or liquidation of the Company, any corporate separation or division (including, but not limited to, a split-up, a split-off or a spin-off), a merger or consolidation; a reverse merger or similar transaction, then (i) any new, substituted or additional securities or other property (including money paid other than as an ordinary cash dividend) which are by reason of such transaction distributed with respect to any Shares subject to a Right of Repurchase or a Right of First Refusal or into which such Shares thereby become convertible shall immediately be subject to the Right of Repurchase and the Right of First Refusal; and (ii) appropriate adjustments to reflect the distribution of such securities or property shall be made to the number and/or class of the Shares subject to this provision and to the price per share of the Shares to be paid upon the exercise of the Right of Repurchase or Right of First Refusal; provided, however, that the aggregate Purchase Price payable for the Shares shall remain the same.

 

(b)            Termination of Rights of Repurchase and First Refusal. Any other provision of Section 8.3 notwithstanding, the Right of Repurchase with respect to vested Shares shall lapse with respect to the Shares that are registered under a then effective registration statement under applicable federal securities laws and the issuer is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act or becomes an investment company registered or required to be registered under the United States Investment Company Act of 1940. If the Shares are readily tradable on an established securities market when the Participant desires to transfer such Shares, the Company shall have no Right of First Refusal, and the Participant shall have no obligation to comply with the procedures prescribed by Section 8.4.

 

(c)            Termination of Rights as Participant and Shareholder. If the Company makes available to a Participant, at the time and place and in the amount and form provided in this Agreement, the consideration for the RSUs to be repurchased pursuant to the Company’s RSUs Repurchase Right in accordance with Section 8.3, then after such time such Participant shall no longer have any rights as a Participant in respect of such RSUs (other than the right to receive payment of such consideration in accordance with this Agreement). If the Company makes available to a Participant, at the time and place and in the amount and form provided in this Agreement, the consideration for the Shares to be repurchased or redeemed pursuant to the Company’s Share Repurchase Right in accordance with Section 8.3 or Right of First Refusal in accordance with Section 8.4, then after such time such Participant shall no longer have any rights as a Shareholder in respect of such Shares (other than the right to receive payment of such consideration in accordance with this Agreement). Such Shares shall be deemed to have been repurchased in accordance with the applicable provisions hereof, whether or not the certificate(s) therefore have been delivered as required by this Agreement.

 

8.6.          Investment Intent at Grant. If the grant of the RSUs under the Plan is not registered under applicable federal or state securities laws, but an exemption is available which requires an investment representation or any other representation, the Participant (a) shall, and hereby does, represent and agree, at the time of grant of the RSUs, that the security being acquired upon the grant of the RSUs is being acquired for investment purposes, and not with a view to the sale or distribution thereof, and (b) shall make such other representations as are deemed necessary or appropriate by the Company and its counsel.

 

7 

 

 

8.7.          Investment Intent at Settlement. If the sale of the Shares under the Plan is not registered under applicable federal or state securities laws, but an exemption is available which requires an investment representation or other representation, the Participant shall represent and agree at the time of settlement that the Shares being acquired upon settlement of the RSUs are being acquired for investment purposes, and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or appropriate by the Company and its counsel.

 

8.8.          Legends. All certificates evidencing the Shares acquired under this Agreement in an unregistered transaction shall bear the following legend (and such other restrictive legends as are required or deemed advisable under the provisions of any Applicable Law):

 

“THE SHARES OF COMMON STOCK EVIDENCED BY THIS CERTIFICATE ARE SUBJECT TO AND TRANSFERABLE ONLY IN ACCORDANCE WITH THAT CERTAIN CARIS LIFE SCIENCES, INC. 2020 INCENTIVE PLAN AND THE RESTRICTED STOCK UNIT AWARD AGREEMENT PURSUANT TO WHICH THE SHARES EVIDENCED BY THIS CERTIFICATE WERE ISSUED, COPIES OF WHICH ARE ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. NO TRANSFER OR PLEDGE OF THE SHARES EVIDENCED HEREBY MAY BE MADE EXCEPT IN ACCORDANCE WITH AND SUBJECT TO THE PROVISIONS OF SAID PLAN AND THE RESTRICTED STOCK UNIT AWARD AGREEMENT.”

 

8.9.          Removal of Legends. If, in the opinion of the Company and its counsel, any legend placed on a share certificate representing the Shares sold under this Agreement no longer is required, the holder of such certificate shall be entitled to exchange such certificate for a certificate representing the same number of Shares but without such legend.

 

8.10.        Administration. Any determination by the Company and its counsel in connection with any of the matters set forth in this Section 8 shall be conclusive and binding on the Participant and all other persons.

 

9.            Exchange Act. Notwithstanding anything contained in the Plan or this Agreement to the contrary, if the consummation of any transaction under the Plan or this Agreement would result in the possible imposition of liability on the Participant pursuant to Section 16(b) of the Exchange Act, the Administrator shall have the right, in its sole discretion, but shall not be obligated, to defer such transaction to the extent necessary to avoid such liability, but in no event for a period in excess of 180 days.

 

10.          Compliance with Code Section 409A. Notwithstanding any contrary provision herein or in the Plan, if any RSU is deemed to be a “deferral of compensation” under Code Section 409A or any regulations or guidance promulgated thereunder or could cause any person to recognize additional taxes, penalties or interest under Code Section 409A, the Board may, in its sole discretion and without the consent of any person, unilaterally modify such provision: (i) to comply with, or avoid being subject to, Code Section 409A, or to avoid the imposition of any additional taxes, penalties or interest under Code Section 409A, and (ii) to maintain, to the maximum extent practicable, the original intent of the applicable provision without contravening the provisions of Code Section 409A. This Section 10 does not create an obligation on the part of the Board to modify the Plan or this Agreement and does not guarantee that any person shall not be subject to additional taxes, penalties or interest under Code Section 409A.

 

8 

 

 

11.          Expiration. The RSUs shall expire on the Expiration Date set forth above.

 

12.          General.

 

12.1.        Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by Participant or the Company to the Administrator for review. The resolution of such a dispute by the Administrator shall be final and binding on the Company and Participant.

 

12.2.        Entire Agreement. The Plan is incorporated herein by reference. This Agreement and the Plan constitute the entire agreement of the parties and supersede all prior undertakings and agreements with respect to the subject matter hereof. If any inconsistency should exist between the nondiscretionary terms and conditions of this Agreement and the Plan, the Plan shall govern and control. Notwithstanding the above, nothing in this Agreement shall be deemed to amend any agreement, whether entered into prior to or after the date hereof, between the Company and the Participant.

 

12.3.        Notices. Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the Corporate Secretary/Chief Legal Officer of the Company at its principal corporate offices. Any notice required to be given or delivered to Participant shall be in writing and addressed to Participant at the address indicated above or to such other address as such party may designate in writing from time to time to the Company. All notices shall be deemed to have been given or delivered upon: (a) personal delivery; (b) five (5) days after deposit in the United States mail by certified or registered mail (return receipt requested); (c) two (2) business days after deposit with any return receipt express courier (prepaid); or (d) one (1) business day after transmission by facsimile.

 

12.4.        Successors and Assigns. The Company may assign any of its rights under this Agreement. This Agreement shall be binding upon and inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement shall be binding upon Participant and Participant’s heirs, executors, administrators, legal representatives, successors and assigns.

 

12.5.        Choice of Law and Venue. This Agreement, including, but not limited to, its enforceability, interpretation and legal effect, shall be governed by and construed in accordance with the laws of the State of Texas without giving effect to its conflict of law principles. If any provision of this Agreement is determined by a court or tribunal of competent jurisdiction to be illegal or unenforceable, then such provision will be enforced to the maximum extent possible and the other provisions will remain fully effective and enforceable. Subject to Section 12.6, the courts of the State of Texas, for Dallas County or any Federal Court having jurisdiction in that county shall have exclusive jurisdiction with respect to any dispute or litigation arising under this Agreement.

 

12.6.        Arbitration.   If no such other agreement or policy is in effect, then the following arbitration provisions shall govern:  Subject to the Company’s remedies for breach or threatened breach of a Restrictive Covenant, any other dispute, controversy, or claim arising out of or relating to this Agreement or breach thereof, will be submitted to arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association.  The arbitration of any dispute, controversy, or claim will take place in Dallas, Texas.  Judgment on the award rendered by the arbitrator may be entered in any court of competent jurisdiction.  In reaching the arbitrator’s decision, the arbitrator will have no authority to ignore, change, modify, add to or delete from any provision of this Agreement, but instead is limited to interpreting this Agreement.

 

9 

 

 

12.7.        No Employment or Other Service Rights. Nothing in the Plan or this Agreement shall confer on Participant any right to continue to serve the Company Group in the capacity in effect as of the Date of Grant or shall affect the right of the Company Group to terminate the Participant’s (a) employment with or without notice and with or without cause, (b) service pursuant to the terms of a consulting agreement with the Company Group or (c) service as a Director pursuant to the Articles or the TBOC, and any applicable provisions of the corporate law of the jurisdiction in which the Company or the Affiliate is incorporated, as the case may be; or shall give the Participant any right to be reemployed or reengaged by the Company Group following a termination of employment or services for any reason.

 

12.8.        No Right to Future Awards. This award of RSUs and all other equity-based awards under the Plan are discretionary. This award does not confer on the Participant any right or entitlement to receive another award of RSUs or any other equity-based award at any time in the future or in respect of any future period.

 

12.9.        Severability. If any provision of this Agreement is held to be illegal or invalid for any reason, such illegality or invalidity shall not affect the remaining provisions of this Agreement, but this Agreement shall be construed and enforced as if such illegal or invalid provision had never been included herein.

 

12.10.      Amendment. Notwithstanding anything herein or in the Plan to the contrary, the Administrator may, at any time, alter, amend, suspend or modify this Agreement; provided, however, that no amendment or modification of this Agreement shall materially and adversely impair the rights of the Participant with respect to any then outstanding RSUs without the consent of the Participant.

 

13.          Spousal Consent. I agree to cause any current or future spouse of mine to deliver to the Company a consent in the form of the consent attached hereto validly executed by such spouse on the date hereof or promptly after any such person becomes my spouse, as applicable.

 

14.          Acceptance. Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. Participant has read and understands the terms and provisions thereof, and by executing below, accepts the terms and conditions of this Agreement governing the RSUs and the terms and conditions of the Plan governing the RSUs and any and all other outstanding RSUs held by the Participant as of the date of execution. Participant acknowledges that there may be adverse tax consequences upon settlement of the RSUs or disposition of the Shares and that Participant should consult a tax advisor prior to such settlement or disposition.

 

10 

 

 

15.          Release of Claims. In consideration of the grant of the RSUs provided to Participant under this Agreement and after having sufficient time to consult with Participant’s own counsel, Participant and each of Participant’s respective heirs, executors, administrators, representatives, agents, successors and assigns (collectively, the “Participant Parties”) hereby irrevocably and unconditionally release and forever discharge the Company, the Company’s former, current and future parents, subsidiaries and affiliates, and each predecessor, successor and affiliate of each of the aforementioned entities, and each of their respective officers, employees, directors, shareholders and agents from any and all claims, actions, causes of action, rights, judgments, obligations, damages, demands, accountings or liabilities of whatever kind or character (collectively, “Claims”), including, without limitation, any Claims under any federal, state, local or foreign law, that the Participant Parties may have, or in the future may possess, arising from or relating to any RSU or other equity or equity-based award previously granted under the Plan; provided, however, that Participant does not release, discharge or waive any rights to the RSUs and to the Shares provided under this Agreement that is contingent upon the execution by Participant of this release of claims. This Section 15 does not apply to any Claims that the Participant Parties may have as of the date Participant signs this Agreement arising under the Federal Age Discrimination in Employment Act of 1967, as amended, and the applicable rules and regulations promulgated thereunder.

 

 

[SIGNATURE PAGE TO FOLLOW]

 

11 

 

 

In witness whereof, the Company has caused this Agreement to be executed by its duly authorized representative effective as of [_______].

 

  CARIS LIFE SCIENCES, INC.
     
  By:  
  Name: [_______]
  Title: [_______]

 

  
 Participant

 

[Signature Page to Director 2025 RSU Award Agreement]

 

 

 

 

SPOUSAL ACKNOWLEDGEMENT

 

The undersigned spouse of the Participant has read and hereby approves the foregoing Restricted Stock Unit Award Agreement. In consideration of the Company’s granting the Participant the right to acquire the Shares in accordance with the terms of such Agreement, the undersigned hereby agrees to be irrevocably bound by all the terms of such Agreement and the Plan, including (without limitation) (i) the right of the Company (or its assigns) to purchase any Shares in which the Participant is not vested at the time of the Participant’s cessation of Continuous Service, and (ii) any sale or by the Participant or any settlement of any Shares contemplated by such Agreement, and for purposes of any community property laws and all other laws conveys all of the undersigned’s right, title and interest in and to such Shares to the purchaser of such Shares.

 

  PARTICIPANT’S SPOUSE  
   
  Address:
     
   

 

 

 

Exhibit 10.5

 

CARIS LIFE SCIENCES, INC.
2025 INCENTIVE PLAN

 

1.            PURPOSE. The purpose of the Caris Life Sciences, Inc. 2025 Incentive Plan (this “Plan”) is to enable Caris Life Sciences, Inc., a Texas corporation, and the other members of the Company Group to align and link the interests of the Company Group’s Employees, Consultants and Directors (each, a “Service Provider”) with the interests of the Shareholders via the issuance of Awards, the value of which are linked directly to the value of the Company. This Plan shall be effective as of the date of approval by the Shareholders (the “Effective Date”).

 

2.            DEFINITIONS

 

2.1            “Administrator” means the Board or the Committee appointed by the Board in accordance with Section 3.5.

 

2.2            “Annual Increase” has the meaning set forth in Section 4.1.

 

2.3            “Applicable Laws” means any applicable legal requirements relating to the administration of and the issuance of ownership interests and other securities under equity-based compensation plans, including, without limitation, U.S. state corporate laws, U.S. federal and state securities laws, the Code and the requirements of any stock exchange or quotation system upon which the Common Stock may be listed or quoted and the laws of any other country or jurisdiction where Awards are granted under this Plan.

 

2.4            “Award” means any right granted under this Plan, including an Option, a Restricted Award, a Performance Award and a Share Appreciation Right.

 

2.5            “Award Agreement” means a written agreement or instrument between the Company and a holder of an Award evidencing the terms and conditions of an individual Award grant. Each Award Agreement shall be subject to the terms and conditions of this Plan.

 

2.6            “Beneficial Owner” has the meaning assigned to such term in Rule 13d-3 and Rule 13d-5 under the Exchange Act, except that in calculating the beneficial ownership of any particular “person” (as that term is used in Section 13(d)(3) of the Exchange Act), such “person” shall be deemed to have beneficial ownership of all securities that such “person” has the right to acquire by conversion or exercise of other securities, whether such right is currently exercisable or is exercisable only after the passage of time. The terms “Beneficially Owns” and “Beneficially Owned” have corresponding meanings.

 

2.7            “Board” means the Board of Directors of the Company, as constituted from time to time.

 

2.8            “Certificate of Formation” means the Company’s Amended and Restated Certificate of Formation, as amended from time to time.

 

 

 

 

2.9            “Change of Control” means:

 

(a)            the direct or indirect sale, transfer, conveyance[, exclusive license] or other disposition (other than by way of merger or consolidation), in one or a series of related transactions, of all or substantially all of the properties or assets of the Company Group, taken as a whole, to any “person” (as that term is used in Section 13(d)(3) of the Exchange Act, which includes any two or more persons acting as a group);

 

(b)            the adoption of a plan relating to the liquidation or dissolution of the Company;

 

(c)            acquisition by any “person” of Beneficial Ownership of 50% or more (on a fully-diluted basis) of either (i) the then-outstanding Shares (the “Outstanding Company Common Stock”) or (ii) the combined voting power of the then-outstanding voting securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”), in each case taking into account as outstanding for this purpose such Common Stock issuable upon the exercise of options or warrants, the conversion of convertible stock or debt, and the exercise of any similar right to acquire such Common Stock to the extent exercisable or convertible;

 

(d)            the consummation of a reorganization, merger, consolidation, statutory share exchange or similar form of corporate transaction involving the Company that requires the approval of the Shareholders pursuant to the TBOC, whether for such transaction or the issuance of securities in the transaction; or

 

(e)            the following individuals cease for any reason to constitute a majority of the number of Directors then serving: individuals who, on the Effective Date, constitute the Board and any new Director (other than a Director whose initial assumption of office is in connection with an actual or threatened election contest, including, but not limited to, a consent solicitation, relating to the election of Directors) whose appointment or election by the Board or nomination for election by the Shareholders was approved or recommended by either (x) a vote of at least a majority of the Directors then still in office who either were Directors on the Effective Date or whose appointment, election or nomination for election was previously so approved or recommended, or (y) a Permitted Holder.

 

Notwithstanding the foregoing, a transaction of any type shall not constitute a Change of Control if (A) its sole purpose is to change the jurisdiction of the Company’s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company’s securities immediately before such transaction; (B) it is an acquisition by any employee benefit plan sponsored or maintained by the Company Group; or (C) immediately following the transaction, more than 50% of the total voting power of the entity resulting from such transaction, or if applicable, the ultimate parent entity that directly or indirectly has beneficial ownership of sufficient voting securities eligible to elect a majority of the members of the board of directors (or the analogous governing body) of the entity resulting from such transaction, is (i) represented by the Outstanding Company Voting Securities that were outstanding immediately prior to such transaction (or if applicable, is represented by shares into which the Outstanding Company Voting Securities were converted pursuant to such transaction), and such voting power among the holders thereof is in substantially the same proportion as the voting power of the Outstanding Company Voting Securities among the holders thereof immediately prior to the transaction or (ii) controlled directly or indirectly and whether by equity ownership, contract or otherwise, by one or more Permitted Holders. If a Change of Control constitutes a payment event with respect to any Award that provides for the deferral of compensation and is subject to Section 409A of the Code, the transaction or event must be both a Change of Control under this definition and constitute a “change in control event,” as defined in Treasury Regulation §1.409A-3(i)(5) to the extent required by Section 409A of the Code. The Administrator shall have full and final authority, which shall be exercised in good faith, to determine conclusively whether a Change of Control has occurred pursuant to the above definition, and the date of the occurrence of such Change of Control and any incidental matters relating thereto.

 

 2 

 

 

2.10          “Code” means the Internal Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder.

 

2.11          “Committee” means a committee of one or more Directors appointed by the Board to administer this Plan in accordance with Section 3.5.

 

2.12          “Common Stock” means the Class A common stock of the Company, par value US$0.001 per share, issued subject to and in accordance with the provisions of the TBOC and the Certificate of Formation and having the rights provided for in the Certificate of Formation.

 

2.13          “Company” means Caris Life Sciences, Inc., a Texas corporation, or any successor thereto.

 

2.14          “Company Group” means the Company and any subsidiary (which for this purpose means any foreign or domestic corporation, limited liability company, partnership or other entity of which 50% or more of the outstanding voting equity securities or voting power is Beneficially Owned directly or indirectly by the Company, and for purposes of determining eligibility for the grant of Incentive Stock Options under the Plan, it shall be defined in the manner required by Section 424(f) of the Code) and any person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, the Company.

 

2.15          “Competing Business” means any person (including Employee), entity or business that: (a) engages or proposes to engage in any conduct or action in furtherance of any discovery, research, development, provision, performance, marketing, sale or other commercialization of any product, service or application that (i) directly or indirectly involves molecular profiling of any human-derived sample or specimen and associated therapeutic decision support for any clinical or research purposes, including but not limited to applications of artificial intelligence to the same or (ii) is directly or indirectly related to use of aptamers to identify, discover, detect or otherwise bind aptamer targets; or (b) that is otherwise competitive with the business of the Company Group.

 

2.16          “Consultant” means any person, including an advisor or contractor, (a) engaged by the Company Group to render consulting or advisory services and who is compensated for such services or who provides bona fide services to the Company Group pursuant to a written agreement or (b) who is a director of the Company Group; provided that, except as otherwise permitted in Section 5.2, such person is a natural person and such services are not in connection with the offer or sale of securities in a capital raising transaction and do not directly or indirectly promote or maintain a market for the Company’s securities.

 

 3 

 

 

2.17          “Continuous Service” means that a Participant’s service with the Company Group, whether as an Employee, Director or Consultant, is not interrupted or terminated. A Participant’s Continuous Service shall not be deemed to have terminated merely because of a change in the capacity in which the Participant renders service to the Company Group as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant’s Continuous Service. For example, a change in status from an Employee of the Company to a Consultant of another member of the Company Group or a Director will not constitute an interruption of Continuous Service. The Administrator, or its designee, which shall include any person delegated authority to grant Awards under this Plan pursuant to Section 3.5, in that party’s sole discretion, may determine whether Continuous Service shall be considered interrupted in the case of any leave of absence approved by that party, including sick leave, military leave or any other personal leave.

 

2.18          “Date of Grant” means the date on which the Administrator adopts a resolution, or takes other appropriate action, expressly granting an Award to a Participant, or if a different date is set forth in such resolution, or determined by the Administrator, as the Date of Grant, then such date as is set forth in such resolution.

 

2.19          “Detrimental Activity” means: (i) violation of the terms of any agreement with or policy of the Company Group concerning non-competition, non-disclosure, confidentiality, intellectual property, non-disparagement, privacy or exclusivity; (ii) disclosure of the Company Group’s confidential information to anyone outside the Company Group, without prior written authorization from the Company Group, or in conflict with the interests of the Company Group, whether the confidential information was acquired or disclosed by the Participant during or after employment by the Company Group; (iii) failure or refusal to disclose promptly or assign to the Company Group all right, title and interest in any invention, work product or idea, patentable or not, made or conceived by the Participant during employment by the Company Group, relating in any manner to the interests of the Company Group or, the failure or refusal to do anything reasonably necessary to enable the Company Group to secure a patent where appropriate in the United States and in other countries; (iv) the conviction of, or plea of guilty or no contest to, a felony or a crime involving moral turpitude; (v) the commission of an act involving willful malfeasance or material fiduciary breach with respect to the Company Group; (vi) gross negligence or willful misconduct with respect to the Company Group; (vii) any breach of a restrictive covenant contained in any employment agreement, Award Agreement or other agreement between the Participant and the Company Group, during any period for which a restrictive covenant prohibiting Detrimental Activity, or other similar conduct or act, is applicable to the Participant during or after employment by the Company Group; (viii) any attempt directly or indirectly to induce any Employee of the Company Group to be employed or perform services or acts in conflict with the interests of the Company Group; (ix) any attempt, in conflict with the interests of the Company Group, directly or indirectly, to solicit the trade or business of any current or prospective customer, client, supplier or partner of the Company Group; or (x) any material breach or non-compliance with the terms of this Plan or an Award Agreement.

 

 4 

 

 

2.20          “Director” means a director of the Company.

 

2.21          “Disability” means a physical or mental disability or infirmity of the Participant that prevents the normal performance of substantially all of the Participant’s duties for a continuous period in excess of 90 days or for more than 180 days during any one-year period.

 

2.22          “Effective Date” has the meaning set forth in Section 1.

 

2.23          “Employee” means any person employed by the Company Group and who is an employee within the meaning of Section 3401(c) of the Code. Mere service as a Director or payment of a director’s fee by the Company Group shall not be sufficient to constitute “employment” by the Company Group.

 

2.24          “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder from time to time.

 

2.25          “Fair Market Value” means, with respect to a Share, the fair market value thereof as of the relevant date of determination, as determined in accordance with the valuation methodology approved by the Administrator (based on objective criteria) from time to time. In the absence of any alternative valuation methodology approved by the Administrator, Fair Market Value shall be deemed to be equal to the closing selling price of a Share on the Nasdaq Stock Exchange (or such established national securities exchange as may be designated by the Administrator) on the trading day immediately preceding the date as of which such valuation is made, or in the event that the Common Stock is not listed for trading on the Nasdaq Stock Exchange or such other national securities exchange as may be designated by the Administrator but is quoted on an automated system, in any such case, on the valuation date (or if there were no sales on the valuation date, the average of the highest and lowest quoted selling prices as reported on said composite tape or automated system for the most recent day during which a sale occurred). The definition of Fair Market Value may differ depending on whether Fair Market Value is in reference to the grant, exercise, vesting, settlement or payout of an Award.

 

2.26          “Incentive Stock Option” means an Option that is intended to comply with the requirements of Section 422 of the Code or any successor provision thereto.

 

2.27          “Nonqualified Stock Option” means an Option that is not intended or fails to comply with the requirements of Section 422 of the Code or any successor provision thereto.

 

2.28          “Non-Employee Director” means a Director who qualifies as a “non-employee director” under Rule 16b-3.

 

2.29          “Option” means an option to purchase Common Stock that is either an Incentive Stock Option or Nonqualified Stock Option.

 

2.30          “Option Agreement” means a written agreement or instrument between the Company and a Participant evidencing the terms and conditions of an individual Option grant. Each Option Agreement shall be subject to the terms and conditions of this Plan and need not be identical.

 

 5 

 

 

2.31          “Participant” means a person to whom an Award is granted pursuant to this Plan. or if applicable, such other person who holds an outstanding Award.

 

2.32          “Performance Award” means an Award entitling the recipient to receive Common Stock or a cash payment upon the attainment of Performance Goals.

 

2.33          “Performance Goals” means, for a Performance Period, one or more goals established in writing by the Administrator for the Performance Period based upon one or more performance criteria. Depending on the performance criteria used to establish such Performance Goals, the Performance Goals may be expressed in terms of overall Company performance (including absolute or relative Share performance) or the performance of a division, operating or business unit, or an individual.

 

2.34          “Performance Period” means the Company’s fiscal year, or any other period of time as the Administrator may select, over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant’s right to, and the payment of, a Performance Award.

 

2.35          “Permitted Holders” means (i) David D. Halbert, (ii) his spouse, widow, widower, domestic partner, parents, grandparents, lineal descendants, siblings and lineal descendants of siblings (in each case whether by blood relation, adoption, marriage or domestic partnership) of such person and heirs and any trusts or other holding, investment or estate planning vehicles for the benefit of any of the foregoing (collectively, together with David D. Halbert, “Halbert Family Members”) and (iii) any Person, any affiliate of, or corporation, general partnership, limited partnership, limited liability company, private limited company or other entity that directly or indirectly controls, is controlled by, or is under common control with, the Halbert Family Members, or any Permitted Trust primarily for the benefit of the Halbert Family Members. The phrase “controlled by” means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise, and “Permitted Trust” means a bona fide trust where each trustee is (i) a Halbert Family Member, (ii) a professional in the business of providing trustee services, including private professional fiduciaries, trust companies and bank trust departments, or (iii) an individual who may be removed and replaced at the sole discretion of a Halbert Family Member.

 

2.36          “Permitted Transferee” means (i) any spouse, parents, siblings (by blood, marriage or adoption) or lineal descendants (by blood, marriage or adoption) of a Participant; (ii) any trust or other similar entity for the benefit of a Participant or the Participant’s spouse, parents, siblings or lineal descendants; provided, however, that any transfer made by a Participant to a Permitted Transferee may only be made if the Permitted Transferee, prior to the time of transfer of Common Stock, agrees in writing to be bound by the terms of this Agreement and provides written notice to the Company of such transfer.

 

2.37          “Person” means an individual, partnership, corporation, limited liability company, joint stock company, unincorporated organization or association, trust, joint venture, association or other similar entity, whether or not a legal entity.

 

 6 

 

 

2.38          “Plan” has the meaning set forth in Section 1.

 

2.39          “Related Rights” has the meaning set forth in Section 6.4(a).

 

2.40          “Restricted Award” means a Restricted Share or an RSU.

 

2.41          “Restricted Award Agreement” has the meaning set forth in Section 6.2.

 

2.42          “Restricted Share” has the meaning set forth in Section 6.2.

 

2.43          “RSU” has the meaning set forth in Section 6.2.

 

2.44          “Rule 16b-3” means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.

 

2.45          “SAR Exercise Price” has the meaning set forth in Section 6.4(b).

 

2.46          “Securities Act” means the U.S. Securities Act of 1933, as amended, and the rules and regulations promogulated thereunder from time to time.

 

2.47          “Service Provider” has the meaning set forth in Section 1.

 

2.48          “Share” means a share of Common Stock.

 

2.49          “Share Appreciation Right” means the right pursuant to an award granted under Section 6.4 to receive an amount equal to the excess, if any, of (A) the Fair Market Value, as of the date such Share Appreciation Right or portion thereof is surrendered, of the Shares covered by such right or such portion thereof, over (B) the aggregate SAR Exercise Price of such right or such portion thereof.

 

2.50          “Share Reserve” has the meaning set forth in Section 4.1.

 

2.51          “Shareholder” means a shareholder of the Company.

 

2.52          “TBOC” means the Texas Business Organizations Code.

 

3.            ADMINISTRATION

 

3.1            Administration by Directors. This Plan shall be administered by the Board unless and until the Board delegates administration to a Committee, as provided in Section 3.5.

 

3.2            Powers of Administrator. The Administrator shall have the power and authority to select and grant Awards, pursuant to the terms of this Plan, to Participants nominated for participation in this Plan by the Company’s Chief Executive Officer or determined by the Administrator.

 

 7 

 

 

3.3            Specific Powers. In particular, the Administrator shall have the authority: (i) to construe and interpret this Plan and apply its provisions; (ii) to promulgate, amend and rescind rules and regulations relating to the administration of this Plan and to interpret this Plan and the Awards granted thereunder; (iii) to authorize any person to execute, on behalf of the Company, any instrument required to carry out the purposes of this Plan; (iv) to determine when Awards are to be granted under this Plan; (v) from time to time to select, subject to the limitations set forth in this Plan, those Participants to whom Awards shall be granted; (vi) to determine the number of Shares to be made subject to each Award; (vii) to prescribe the terms and conditions of each Award, including, without limitation, the exercise price, Performance Goals and medium of payment, vesting, and net exercise provisions, and to specify the provisions of the Award Agreement relating to such grant or sale; (viii) to amend any outstanding Awards, including for the purpose of modifying the time or manner of vesting, the purchase price or exercise price, Performance Goals or the term of any outstanding Award in accordance with this Plan; (ix) to determine the duration and purpose of leaves of absences which may be granted to a Participant without constituting termination of their employment for purposes of this Plan, which periods shall be no shorter than the periods generally applicable to Employees under the Company Group’s employment policies; (x) establish or verify satisfaction of, or the level of performance with respect to, Performance Goals or other conditions applicable to grant, exercisability, vesting or payment; (xi) to make decisions with respect to outstanding Awards that may become necessary upon a change in corporate control or an event that triggers anti-dilution adjustments; (xii) to correct any defect, omission or inconsistency in this Plan, in a manner and to the extent it is deemed necessary or expedient to make this Plan fully effective; and (xiii) to exercise discretion to make any and all other determinations which it determines to be necessary or advisable for administration of this Plan.

 

3.4            Decisions Final. All decisions made by the Administrator pursuant to the provisions of this Plan shall be final, binding and conclusive on the Company and the Participants.

 

3.5            The Committee. To the extent permitted under Applicable Laws, the Board may delegate administration of this Plan to a Committee or Committees consisting of one or more Directors, and the term “Committee” shall apply to any person or persons to whom such authority has been delegated. If administration is delegated to a Committee, the Committee shall have, in connection with the administration of this Plan, the powers theretofore possessed by the Board, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board or the Administrator shall thereafter, to the extent the delegation is applicable, be to the Committee or subcommittee), subject, however, to such resolutions not inconsistent with the provisions of this Plan, as may be adopted from time to time by the Board. Within the scope of such authority, the Board or the Committee may delegate to a committee of one or more Directors or officers of the Company Group the authority to grant Awards to eligible persons who are not then subject to Section 16 of the Exchange Act. Additionally, within the scope of such authority, the Board or the Committee may delegate to (i) one or more of its members, (ii) one or more officers of the Company Group or (iii) one or more agents or advisors such administrative duties with respect to this Plan as it may deem appropriate or advisable under such conditions and limitations as it may set at the time of such delegation or thereafter. The Committee or any individuals to whom it has delegated duties or powers as aforesaid may employ one or more individuals to render advice with respect to any responsibility the Committee or such individuals may have under this Plan.

 

 8 

 

 

3.6            Indemnification. In addition to such other rights of indemnification as they may have as Directors or members of the Committee, and to the extent allowed by Applicable Laws, the Administrator shall be indemnified by the Company against the reasonable expenses, including attorney’s fees, actually incurred in connection with any action, suit or proceeding or in connection with any appeal therein, to which the Administrator may be party by reason of any action taken or failure to act under or in connection with this Plan or any Award granted under this Plan, and against all amounts paid by the Administrator in settlement thereof (provided that the settlement has been approved by the Company, which approval shall not be unreasonably withheld) or paid by the Administrator in satisfaction of a judgment in any such action, suit or proceeding, except in relation to matters as to which it shall be adjudged in such action, suit or proceeding that such Administrator did not act in good faith; provided, however, that within 60 days after institution of any such action, suit or proceeding, such Administrator shall, in writing, offer the Company the opportunity at its own expense to handle and defend such action, suit or proceeding.

 

3.7            Reliance on Experts. In making any determination or in taking or not taking any action under this Plan, the Administrator may obtain and may rely upon the advice of experts, including employees of and professional advisors to the Company. No director, officer or agent of the Company Group shall be liable for any such action or determination taken or made or omitted in good faith.

 

4.            COMMON STOCK SUBJECT TO THIS PLAN

 

4.1            Share Reserve. Subject to the provisions of Section 9 relating to adjustments upon changes in the Common Stock, the maximum aggregate number of Shares that may be issued upon exercise of all Awards under this Plan shall not exceed an amount equal to (a) 5% of all classes of the Company’s common stock on a fully diluted basis after giving effect to the Company’s initial public offering (the “Offering”) (assuming the exercise of any outstanding warrants and conversion of all preferred stock and senior convertible notes, and including, but not limited to, shares subject to outstanding awards under the Amended and Restated 2020 Plan, and the issuance of the Company’s common stock contemplated to be sold in the Offering), plus (b) the number of shares that would return to the share reserve of the Amended and Restated 2020 Plan following the pricing of the Offering (the “Share Reserve”). Notwithstanding the foregoing, the Share Reserve shall increase on January 1 of each calendar year during the term of this Plan beginning in 2026, by a number of Shares as approved by the Administrator following consultation with the Company; provided, that such increase (if any) shall be no greater than the amount by which (y) 4% of the aggregate number of outstanding shares of all classes of the Company’s common stock as of the last day of the immediately preceding fiscal year exceeds (z) the aggregate number of Shares remaining available for grant under the Plan on the last day of the immediately preceding fiscal year (the “Annual Increase”). To the extent permitted by Applicable Laws or any applicable exchange rule, any Common Stock issued under this Plan that is issued (i) in connection with the Company’s acquisition of an unaffiliated business entity, (ii) to the employees of such entity and (iii) in substitution of equity incentive awards previously issued to such employees by such entity shall not reduce the number of Shares available for issuance under this Plan. Any of the authorized Shares may be used for any type of Award under this Plan, and any or all of the Shares may be allocated to Incentive Stock Options; provided that the maximum number of Shares that may be issued pursuant to Incentive Stock Options under this Plan may not exceed the Share Reserve (as it may be increased from time to time, including through the Annual Increase). “Amended and Restated 2020 Plan” means the Caris Life Sciences, Inc. 2020 Incentive Plan, as amended and restated.

 

 9 

 

 

4.2            Reversion of Shares to the Share Reserve. If an Award or any portion thereof (i) expires or otherwise terminates without all of the Shares covered by such Award having been issued, or (ii) is settled in cash (i.e., the Participant receives cash rather than Shares), such expiration, termination or settlement will not reduce (or otherwise offset) the number of Shares that may be available for issuance under this Plan. If any Shares issued pursuant to an Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required to vest such Shares in the Participant, then the Shares that are forfeited or repurchased will revert to and again become available for issuance under this Plan. Any Shares reacquired by the Company in satisfaction of tax withholding obligations on an Award or as consideration for the exercise or purchase price of an Award will again become available for issuance under this Plan.

 

4.3            Source of Shares. The Shares subject to this Plan may be authorized but unissued Common Stock or reacquired Common Stock, however reacquired.

 

4.4            Availability of Shares. During the terms of the Awards, the Company shall keep available at all times the number of Shares required to satisfy such Awards.

 

4.5            Director Award Limit. Notwithstanding any provision to the contrary in this Plan or in any policy of the Company, the sum of cash compensation and the Fair Market Value of all Awards that may be granted to a Director who is not an Employee under this Plan during any calendar year shall not exceed $1,000,000 during a Director’s first year of service as a Director and $750,000 for any year thereafter.

 

5.            ELIGIBILITY

 

5.1            Eligibility. Awards may be granted to Service Providers selected for participation in this Plan, subject to the approval of the Administrator.

 

5.2            Consultants. A Consultant shall not be eligible for the grant of an Award if, at the time of grant, a registration statement is not available to register either the offer or the sale of the Company’s securities to such Consultant because of the nature of the services that the Consultant is providing to the Company Group, or because the Consultant is not a natural person, or as otherwise provided by the rules governing the use of the registration statement, unless the Company determines both (a) that such grant (i) shall be registered in another manner under the Securities Act or (ii) does not require registration under the Securities Act in order to comply with the requirements of the Securities Act, if applicable, and (b) that such grant complies with the securities laws of all other relevant jurisdictions.

 

5.3            Directors. Each Director shall be eligible to receive discretionary grants of Awards under this Plan, subject to Section 4.5.

 

 10 

 

 

6.            AWARD PROVISIONS

 

6.1            Options. The Administrator may from time to time grant Options to Service Providers. Each Option shall be in such form and shall contain such terms and conditions as the Administrator shall deem appropriate, including whether such Options granted shall be Incentive Stock Options or Nonqualified Stock Options. Each Option shall be evidenced by an Option Agreement that shall expressly identify the Option as Incentive Stock Option or Nonqualified Stock Option. The provisions of separate Options need not be identical, but each Option shall include (through incorporation of provisions hereof by reference in the Option or otherwise) the substance of each of the following provisions:

 

(a)            Term. No Option shall be exercisable after the expiration of 10 years from the date it was granted.

 

(b)            Exercise Price of an Option. The exercise price per Share of each Option shall be not less than the greater of (i) 100% of the Fair Market Value of a Share on the date the Option is granted and (ii) the par value of the Common Stock. Notwithstanding the foregoing, an Option may be granted with a per Share exercise price lower than 100% of Fair Market Value of a Share on the date it is granted (but not less than par value) if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section 424(a) of the Code.

 

(c)            Consideration. The purchase price of Common Stock acquired pursuant to an Option shall be paid, to the extent permitted by Applicable Laws and regulations, either: (i) in cash, by certified or bank check or by electronic funds transfer at the time the Option is exercised; (ii) by tendering to the Company other Common Stock, for redemption or repurchase by the Company, with a Fair Market Value on the date of redemption or repurchase equal to the exercise price (or portion thereof) due for the number of shares being acquired (with the proceeds of such redemption or repurchase being automatically applied by the Company towards paying the purchase price of the Common Stock); (iii) by a copy of instructions to a broker directing such broker to sell the Common Stock for which such Option is exercised, and to remit to the Company the aggregate exercise price of such Options; or (iv) in any other form of legal consideration that may be acceptable to the Administrator. Unless otherwise specifically provided in the Option, the purchase price of Common Stock acquired pursuant to an Option that is paid by tendering to the Company for redemption or repurchase other Common Stock acquired, directly or indirectly, from the Company, shall be paid only by Common Stock of the Company that has been held for more than six months (or such longer or shorter period of time required to avoid a charge to earnings for financial accounting purposes). Notwithstanding the foregoing, any transaction by a Director or executive officer that involves or may involve a direct or indirect extension of credit or arrangement of an extension of credit by the Company Group in violation of Section 402(a) of the Sarbanes-Oxley Act (codified as Section 13(k) of the Exchange Act) shall be prohibited with respect to any Award under this Plan.

 

(d)            Vesting; Exercisability. The Administrator will determine the vesting and exercisability provisions of each Option (which may be based on performance criteria, passage of time, or other factors, or any combination thereof), which provisions will be set forth in the applicable Award Agreement. Unless the Administrator or the terms of this Plan or the Award Agreement expressly provides otherwise, once exercisable, an Option will remain exercisable until the expiration or earlier termination of the Option. The Administrator may adjust the vesting or exercisability provisions of an Option to reflect any approved leave of absence or less-than-full-time employment that is not a termination of Continuous Service.

 

 11 

 

 

(e)            Procedure for Exercise. An exercisable Option may be exercised in whole or in part and will be deemed exercised when the Company receives: (i) written or electronic notice of exercise (in accordance with the Award Agreement) from the person entitled to exercise the Option, and (ii) full payment for the Common Stock with respect to which the Option is exercised (including provision for any applicable tax withholding); provided that if any person other than the Participant exercises the Option, such person will be required to provide evidence sufficient to reasonably establish that he or she is entitled to do so. Full payment may consist of any consideration and method of payment authorized by the Administrator and permitted by the Award Agreement and this Plan. Common Stock issued upon exercise of an Option will be issued in the name of the Participant, or if requested by the Participant, in the name of the Participant and the Participant’s spouse. Exercising an Option in any manner will decrease the number of Shares thereafter available for sale under the Option, by the number of Shares as to which the Option is exercised.

 

(f)            Termination of Continuous Service. Upon the termination of a Participant’s Continuous Service, and unless otherwise provided by the Administrator or in the applicable Award Agreement:

 

(i)            other than as a result of the Participant’s death or Disability, the Participant may exercise the Participant’s Option (to the extent that the Participant was entitled to exercise such Option as of the date of termination) until the earlier of (x) the date 90 days following the termination of the Participant’s Continuous Service and (y) the expiration of the term of the Option as set forth in the Option Agreement, after which time the Option shall terminate; or

 

(ii)            as a result of the Participant’s death or Disability, the Participant (or the Participant’s estate, by a person who acquired the right to exercise the Option by bequest or inheritance or by a person designated to exercise the Option upon the Participant’s death) may exercise the Participant’s Option (to the extent that the Participant was entitled to exercise such Option as of the date of termination), but only until the earlier of (x) the date 12 months following such termination and (y) the expiration of the term of the Option as set forth in the Option Agreement, after which time the Option shall terminate.

 

(g)            If the Participant does not exercise the Participant’s Option within the time specified in the Option Agreement, the Option shall terminate. Unless otherwise provided in an Option Agreement or in an employment agreement the terms of which have been approved by the Administrator, outstanding Options that are not exercisable at the time the Participant’s Continuous Service terminates shall be forfeited and expire at the close of business on the date of such termination.

 

(h)            Substitution of Share Appreciation Rights. The Administrator may provide in an Award Agreement evidencing the grant of an Option that the Administrator, in its sole discretion, shall have the right to substitute a Share Appreciation Right for such Option at any time prior to or upon exercise of such Option; provided that such Share Appreciation Right shall be exercisable with respect to the same number of Shares for which such substituted Option would have been exercisable.

 

 12 

 

 

(i)            Incentive Stock Options. The exercise price per Share of an Incentive Stock Option shall be fixed by the Administrator at the time of grant or shall be determined by a method specified by the Administrator at the time of grant, but in no event shall the exercise price of an Option be less than the minimum exercise price specified in Section 6.1(b). No Incentive Stock Option may be issued to any individual who, at the time the Incentive Stock Option is granted, owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, unless (i) the exercise price determined as of the date of grant is at least 110% of the Fair Market Value on the date of grant of the Common Stock subject to such Incentive Stock Option; and (ii) the Incentive Stock Option is not exercisable more than five years from the date of grant thereof. No Participant shall be granted any Incentive Stock Option which would result in such Participant receiving a grant of Incentive Stock Options that would have an aggregate Fair Market Value in excess of $100,000, determined as of the time of grant, that would be exercisable for the first time by such Participant during any fiscal year. Any grants in excess of this limit shall be treated as Nonqualified Stock Options. No Incentive Stock Option may be granted under this Plan after the tenth anniversary of the Effective Date. The terms of any Incentive Stock Option granted under this Plan shall comply in all respects with the provisions of Section 422 of the Code, or any successor provision thereto, as amended from time to time.

 

6.2            Restricted Awards. The Administrator may from time to time award (or sell at a purchase price determined by the Administrator) restricted Shares (“Restricted Shares”) or restricted stock units with respect to Shares (“RSUs”) under this Plan to eligible Participants. The Award Agreement evidencing a Restricted Award (a “Restricted Award Agreement”) shall contain the terms established by the Administrator for that Award, as well as any other terms, provisions, or restrictions that the Administrator may impose on the Award; in each case subject to the applicable provisions and limitations of this Section 6.2 and the other applicable provisions and limitations of this Plan. The terms and conditions of Restricted Award Agreements may change from time to time, and the terms and conditions of separate Restricted Award Agreements need not be identical, but each Restricted Award Agreement shall include (through incorporation of provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:

 

(a)            Purchase Price. The purchase price of a Restricted Award shall be determined by the Administrator at the Date of Grant, and may be stated as cash, property or a contract for prior or future services. In no event will such purchase price be less than the par value of a Share.

 

(b)            Consideration. The consideration for Common Stock acquired pursuant to a Restricted Award Agreement shall be paid either in cash, by certified or bank check or by electronic funds transfer.

 

(c)            Vesting. The restrictions imposed on the exercise and settling of a Restricted Award and the subsequent issuance of Common Stock (which may be based on performance criteria, passage of time or other factors or any combination thereof) will be set forth in the applicable Award Agreement.

 

 13 

 

 

(d)            Termination of Participant’s Continuous Service. Unless the Administrator otherwise expressly provides, Common Stock subject to a Restricted Award that remain subject to vesting conditions that have not been satisfied by the time specified in the applicable Award Agreement (including the termination of the Participant’s Continuous Service), will not vest and in the case of RSUs, will be canceled without payment to the Participant therefor, in each case to the extent not prohibited by law. The Award Agreement shall specify any other terms or conditions of the repurchase or cancellation, as the case may be, if the Award fails to vest. Any other Restricted Award that has not been exercised as of a termination of the Participant’s Continuous Service shall terminate on that date unless otherwise expressly provided by the Administrator in the applicable Award Agreement.

 

6.3            Performance Awards.

 

(a)            The Administrator may from time to time grant Performance Awards to any eligible Participant. Each Performance Award shall be in such form and shall contain such terms and conditions as the Administrator shall deem appropriate. The terms and conditions of separate Performance Awards need not be identical. The value of Performance Awards may be linked to any one or more specific criteria determined by the Administrator, in each case on a specified date or dates or over any period or periods determined by the Administrator. In making such determinations, the Administrator shall consider (among such other factors as it deems relevant in light of the specific type of Award) the contributions, responsibilities and other compensation of the particular Service Provider. Performance Awards may be paid in cash, Common Stock or both, as determined by the Administrator.

 

(b)            Without limiting Section 6.3(a), the Administrator may grant Performance Awards in the form of a cash bonus payable upon the attainment of objective Performance Goals, or such other criteria, whether or not objective, which are established by the Administrator, in each case on a specified date or dates or over any period or periods determined by the Administrator.

 

(c)            Notwithstanding the satisfaction of any Performance Goals, the number of Shares granted, issued, retainable or vested under an Award, or the amount of cash payable under an Award on account of either financial performance or personal performance evaluations, may, to the extent specified in the Award Agreement, be adjusted by the Committee on the basis of such further considerations as the Committee shall determine, including but not limited to those set forth in Section 10.2.

 

6.4            Share Appreciation Rights.

 

(a)            General. Share Appreciation Rights may be granted either alone, or, provided that the requirements of Section 6.4(b) are satisfied, in tandem with all or part of any Option granted under this Plan (“Related Rights”). Related Rights may be granted either at or after the time of the grant of such Option. Share Appreciation Rights shall be in such form and shall contain such terms and conditions as the Administrator shall deem appropriate, and the provisions of separate Share Appreciation Rights need not be identical.

 

 14 

 

 

(b)            Grant Requirements. A Share Appreciation Right may only be granted if the Share Appreciation Right: (i) does not provide for the deferral of compensation within the meaning of Section 409A of the Code; or (ii) satisfies the requirements of Section 7.3. A Share Appreciation Right does not provide for a deferral of compensation if: (A) the value of the Common Stock the excess over which the right provides for payment upon exercise (the “SAR Exercise Price”) may never be less than the Fair Market Value of the underlying Common Stock on the date the right is granted; (B) the Common Stock subject to the right are traded on an established securities market; (C) only such traded Common Stock may be delivered in settlement of the right upon exercise; and (D) the right does not include any feature for the deferral of compensation other than the deferral of recognition of income until the exercise of the right.

 

(c)            Vesting, Exercise and Payment. The Administrator will determine the vesting and exercisability provisions of each Share Appreciation Right (which may be based on performance criteria, passage of time or other factors or any combination thereof), which provisions will be set forth in the applicable Award Agreement. Unless the Administrator otherwise expressly provides, once exercisable a Share Appreciation Right will remain exercisable until the expiration or earlier termination of the Share Appreciation Right. Upon exercise thereof, the holder of a Share Appreciation Right shall be entitled to receive from the Company, an amount equal to the product of (i) the excess of the Fair Market Value, on the date of such written request, of one Common Stock over the SAR Exercise Price per Common Stock specified in such Share Appreciation Right or its related Option, multiplied by (ii) the number of Shares for which such Share Appreciation Right shall be exercised. Payment with respect to the exercise of a Share Appreciation Right that satisfies the requirements of Section 6.4(b) shall be paid on the date of exercise and made in Common Stock (with or without restrictions as to substantial risk of forfeiture and transferability, as determined by the Administrator in its sole discretion), valued at Fair Market Value on the date of exercise. Payment with respect to the exercise of a Share Appreciation Right that does not satisfy the requirements of Section 6.4(b) shall be paid at the time specified in the Award in accordance with the provisions of Section 7.3. Payment may be made in the form of Common Stock (with or without restrictions as to substantial risk of forfeiture and transferability, as determined by the Administrator in its sole discretion), cash or a combination thereof, as determined by the Administrator.

 

(d)            SAR Exercise Price; Term. The Administrator shall set the terms and conditions or restrictions on the exercise of a Share Appreciation Right, but in no event shall a Share Appreciation Right have an exercise price less than 100% of the Fair Market Value of one Common Stock on the Date of Grant of such Share Appreciation Right or a term of greater than 10 years. A Related Right granted simultaneously with or subsequent to the grant of an Option and in conjunction therewith or in the alternative thereto shall have the same exercise price as the related Option, and shall be exercisable only to the same extent as the related Option; provided, however, that a Share Appreciation Right, by its terms, shall be exercisable only when the Fair Market Value per Common Stock subject to the Share Appreciation Right and related Option exceeds the exercise price per Share thereof, and no Share Appreciation Rights may be granted in tandem with an Option unless the Administrator determines that the requirements of Section 6.4(b) are satisfied.

 

(e)            Reduction in the Underlying Option Shares. Upon any exercise of a Share Appreciation Right, the number of Common Stock for which any related Option shall be exercisable shall be reduced by the number of Shares for which the Share Appreciation Right shall have been exercised. The number of Common Stock for which a Share Appreciation Right shall be exercisable shall be reduced upon any exercise of any related Option by the number of Common Stock for which such Option shall have been exercised.

 

 15 

 

 

(f)            Written Request. Any election by a Participant to receive cash in full or partial settlement of a Share Appreciation Right, and any exercise of such Share Appreciation Right for cash, may be made only by a written request filed with the Corporate Secretary of the Company during the period beginning on the third business day following the date of release for publication by the Company of quarterly or annual summary statements of earnings and ending on the twelfth business day following such date. Within 30 days of the receipt by the Company of a written request to receive cash in full or partial settlement of a Share Appreciation Right or to exercise such Share Appreciation Right for cash, the Administrator shall, in its sole discretion, either consent to or disapprove, in whole or in part, such written request. A written request to receive cash in full or partial settlement of a Share Appreciation Right or to exercise a Share Appreciation Right for cash may provide that, in the event the Administrator shall disapprove such written request, such written request shall be deemed to be an exercise of such Share Appreciation Right for Common Stock.

 

(g)            Disapproval by Administrator. If the Administrator disapproves in whole or in part any election by a Participant to receive cash in full or partial settlement of a Share Appreciation Right or to exercise such Share Appreciation Right for cash, such disapproval shall not affect such Participant’s right to exercise such Share Appreciation Right at a later date, to the extent that such Share Appreciation Right shall be otherwise exercisable, or to elect the form of payment at a later date, provided that an election to receive cash upon such later exercise shall be subject to the approval of the Administrator. Additionally, such disapproval shall not affect such Participant’s right to exercise any related Option.

 

(h)            Termination of Continuous Service. Upon the termination of the Continuous Service of a Participant who holds a Share Appreciation Right, and unless otherwise provided by the Administrator or in the applicable Award Agreement:

 

(i)            other than as a result of the Participant’s death or Disability, the Participant may exercise the Participant’s Share Appreciation Right (to the extent that the Participant was entitled to exercise such Share Appreciation Right as of the date of termination) until the earlier of (x) the date 90 days following the termination of the Participant’s Continuous Service and (y) the expiration of the term of the Share Appreciation Right as set forth in the Award Agreement, after which time the Share Appreciation Right shall terminate; or

 

(ii)            as a result of the Participant’s death or Disability, the Participant (or the Participant’s estate, by a person who acquired the right to exercise the Share Appreciation Right by bequest or inheritance or by a person designated to exercise the Share Appreciation Right upon the Participant’s death) may exercise the Participant’s Share Appreciation Right (to the extent that the Participant was entitled to exercise such Share Appreciation Right as of the date of termination), but only until the earlier of (x) the date 12 months following such termination and (y) the expiration of the term of the Share Appreciation Right as set forth in the Award Agreement, after which time the Share Appreciation Right shall terminate.

 

 16 

 

 

(iii)            If the Participant does not exercise the Participant’s Share Appreciation Right within the time specified in the Award Agreement, the Share Appreciation Right shall terminate. Unless otherwise provided in an Award Agreement or in an employment agreement the terms of which have been approved by the Administrator, outstanding Share Appreciation Rights that are not exercisable at the time a Participant’s Continuous Service terminates shall be forfeited and expire at the close of business on the date of such termination.

 

6.5            Other Share-Based Awards.

 

(a)            The Administrator may grant other Share-based awards not otherwise described by the terms of this Plan, including, but not limited to, the grant or offer for sale of unrestricted Shares and the grant of deferred Shares or deferred Share units, in such amounts and subject to such terms and conditions, including performance conditions, as the Administrator shall determine, in its sole discretion. Such Awards may involve the transfer of actual Shares to Participants, or payment in cash or otherwise of amounts based on the value of Shares.

 

(b)            The Administrator, at any time and from time to time, may grant cash-based awards that settle in Shares to a Participant in such amounts and upon such terms as the Administrator shall determine, in its sole discretion, including performance conditions.

 

(c)            Payment, if any, with respect to Awards granted pursuant to this Section 6.5 shall be made in accordance with the terms of the applicable Award Agreement, in cash, Shares or a combination of both as determined by the Administrator in its sole discretion.

 

7.            PROVISIONS APPLICABLE TO ALL AWARDS

 

7.1            Award Agreements. The Administrator shall have sole and exclusive authority to determine the terms and conditions pursuant to which an Award may be made. By accepting an Award, a Participant shall be deemed to have accepted and agreed to the terms and conditions of this Plan and the Award Agreement. The Administrator may require that a Participant promptly execute and return to the Company the Participant’s Award Agreement evidencing the Participant’s acceptance of and agreement to the terms and conditions of this Plan and the Award as a condition precedent to any Common Stock becoming issuable or deliverable by the Company pursuant to the Award. In addition, the Administrator may require that the spouse of any married Participant also promptly execute and return to the Company the Award Agreement evidencing the Award granted to the Participant or such other spousal consent form that the Administrator may require in connection with the grant of the Award.

 

7.2            Non-Transferability of Awards. Unless determined otherwise by the Administrator, an Award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution; provided, however, that the Administrator may, subject to Applicable Laws and such terms and conditions as it shall specify, permit the transfer of an Award, other than an Incentive Stock Option, for no consideration to a Permitted Transferee. Any Award transferred to a Permitted Transferee shall be further transferable only by last will and testament or the laws of descent and distribution, or for no consideration, to another Permitted Transferee of the Participant. During the lifetime of a Participant, an Award shall be exercisable only by the Participant or by a Permitted Transferee to whom such Award has been transferred in accordance with this Section 7.2. In no event may an Award be transferred to any person who has joined or is supporting a Competing Business.

 

 17 

 

 

7.3            Section 409A. Notwithstanding any contrary provision in this Plan or an Award Agreement, if any provision of this Plan or an Award Agreement contravenes any regulations or guidance promulgated under Section 409A of the Code or would cause an Award to be subject to additional taxes, accelerated taxation, interest and penalties under Section 409A of the Code, such provision of this Plan or Award Agreement may be modified by the Administrator without the consent of the Participant in any manner the Administrator deems reasonable or necessary. In making such modifications the Administrator shall attempt, but shall not be obligated, to maintain, to the maximum extent practicable, the original intent of the applicable provision without contravening the provisions of Section 409A of the Code. Moreover, any discretionary authority that the Administrator may have pursuant to this Plan shall not be applicable to an Award that is subject to Section 409A of the Code to the extent such discretionary authority would contravene Section 409A of the Code or the guidance promulgated thereunder. In the event that it is reasonably determined by the Administrator that, as a result of Section 409A of the Code, payments in respect of any Award under this Plan may not be made at the time contemplated by the terms of this Plan or the relevant Award Agreement, as the case may be, without causing the Participant holding such Award to be subject to taxation under Section 409A of the Code, including as a result of the fact that the Participant is a “specified employee” under Section 409A of the Code, the Company will make such payment on the first day that would not result in the Participant incurring any tax liability under Section 409A of the Code. The Company shall use commercially reasonable efforts to implement the provisions of this Section 7.3 in good faith; provided that none of the Company Group, the Administrator nor any of the officers, employees, managers, directors or representatives of the Company Group shall have any liability to Participants with respect to this Section 7.3.

 

7.4            Compliance with Rule 16b-3. It is the Company’s intent that this Plan and the Awards comply in all respects with Rule 16b-3 of the Exchange Act. If the consummation of any transaction under this Plan would result in the possible imposition of liability on a Participant pursuant to Section 16(b) of the Exchange Act, the Administrator shall have the right, but not the obligation, to defer such transaction or the effectiveness of such action to the extent necessary to avoid such liability.

 

8.            CONDITIONS UPON ISSUANCE OF COMMON STOCK

 

8.1            Legal Compliance. Notwithstanding any other provision of this Plan, any Award Agreement or any other agreement entered into by the Company pursuant to this Plan, an Award may not be issued or exercised, and no Common Stock may be issued in connection with an Award unless the exercise of such Award and the issuance and delivery of such Common Stock will comply with Applicable Laws, including, without limitation, the Securities Act, the Exchange Act, U.S. state securities laws and regulations, and the regulations of any stock exchange or other securities market on which the Company’s securities may then be traded, and will be further subject to the approval of counsel for the Company with respect to such compliance. All certificates for Common Stock delivered under this Plan shall be subject to such transfer orders and other restrictions as the Administrator may deem advisable under the rules, regulations, and other requirements of the U.S. Securities and Exchange Commission, any exchange upon which the Common Stock are then listed, and any applicable securities law, and the Administrator may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.

 

 18 

 

 

8.2            Investment Representations. As a condition to the exercise and issuance of an Award, the Company may require the person acquiring such Award to represent and warrant at the time of any such acquisition that the Common Stock are being acquired only for investment and without any present intention to sell or distribute such Common Stock if, in the opinion of counsel for the Company, such a representation is required.

 

8.3            Inability to Obtain Authority. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company’s counsel to be necessary to the lawful issuance and sale of any Common Stock hereunder, will relieve the Company of any liability in respect of the failure to issue or sell such Common Stock as to which such requisite authority will not have been obtained.

 

9.            ADJUSTMENTS UPON CHANGES IN COMMON STOCK

 

9.1            Capitalization Adjustments.

 

(a)            Upon (or, as may be necessary to effect the adjustment, immediately prior to): any reclassification, recapitalization, share split (including a share split in the form of a share dividend) or reverse share split; any merger, combination, consolidation, or other reorganization; any split-up, spin-off, or similar extraordinary dividend distribution in respect of the Common Stock; or any exchange of Common Stock or other securities of the Company, or any similar, unusual or extraordinary corporate transaction in respect of the Common Stock; then subject to any required action by the Shareholders under Applicable Laws, the Administrator shall equitably and proportionately adjust (i) Share Reserve, (ii) the number and type of Common Stock (or other securities) that thereafter may be made the subject of Awards (including the specific share limits, maximums and numbers of shares set forth elsewhere in this Plan), (iii) the number, amount and type of Common Stock (or other securities or property) subject to any outstanding Awards, (iv) the grant, purchase, or exercise price of any outstanding Awards, or (v) the securities, cash or other property deliverable upon exercise or vesting of any outstanding Awards, in each case to the extent necessary to preserve (but not increase) the level of incentives intended by this Plan and the then-outstanding Awards.

 

(b)            Unless otherwise expressly provided in the applicable Award Agreement, upon (or as may be necessary to effect the adjustment, immediately prior to) any event or transaction described in the preceding paragraph or a sale of all or substantially all of the business or assets of the Company as an entirety, the Administrator shall equitably and proportionately adjust the performance criteria applicable to any then-outstanding performance-based Awards to the extent necessary to preserve (but not increase) the level of incentives by this Plan and the then-outstanding performance-based Awards, which adjustments need not be uniform as between different Participants, Awards or types of Awards.

 

(c)            It is intended that, if possible, any adjustments contemplated by the preceding two paragraphs shall be made in a manner that satisfies Applicable Laws (including, without limitation and as applicable in the circumstances, Section 424 of the Code and Section 409A of the Code) and accounting (so as to not trigger any charge to earnings with respect to such adjustment) requirements.

 

 19 

 

 

(d)            Any good-faith determination by the Administrator as to whether an adjustment is required in the circumstances pursuant to this Section 9.1, and the extent and nature of any such adjustment, shall be final, binding and conclusive on all persons.

 

9.2            Dissolution or Liquidation. In the event of a dissolution or liquidation of the Company, then all outstanding Awards shall terminate immediately prior to such event.

 

9.3            Change of Control. In the event of a Change of Control, or such other transaction in which all of the Common Stock outstanding immediately prior to the transaction are converted by virtue of the transaction into other property, whether in the form of securities, cash or otherwise, then the Company, to the extent permitted by Applicable Laws, but otherwise in the sole discretion of the Administrator may provide for: (a) the continuation of outstanding Awards by the Company (if the Company is the surviving entity); (b) the assumption of this Plan and such outstanding Awards by the surviving entity or its parent; (c) the substitution by the surviving entity or its parent of Awards with substantially the same terms (including an award to acquire the same consideration paid to the Shareholders in the transaction described in this Section 9.3) for such outstanding Awards and, if appropriate, subject to the equitable adjustment provisions of Section 9.1; (d) the acceleration of the vesting, settlement and delivery of all Awards outstanding under this Plan; (e) the cancellation of any outstanding Awards in consideration for a payment (in cash or other property) equal in value to the Fair Market Value of vested Awards, or in the case of an Option or Share Appreciation Right, the difference between the Fair Market Value and the exercise price for the Common Stock subject to exercise (i.e., to the extent vested) under any outstanding Option or Share Appreciation Right; or (f) the cancellation of such outstanding Awards without payment of any consideration. If Awards would be canceled without consideration for vested Awards, the Participant shall have the right, exercisable during the later of the ten-day period ending on the fifth day prior to such merger or consolidation or ten days after the Administrator provides the Award holder a notice of cancellation, to exercise such Awards in whole or in part without regard to any installment exercise provisions in the Award Agreement; provided that the Administrator may, in its discretion, condition the exercise of any Award on the consummation of the Change of Control.

 

9.4            Compliance with Section 409A. No action shall be taken under this Section 9 that will cause an Award to fail to comply with Section 409A of the Code, to the extent applicable to such Award. Any adjustments to outstanding Awards shall be effected in a manner that shall preclude the enlargement or dilution of rights and benefits under such options and shall be conducted in compliance with Section 409A of the Code.

 

10.          AMENDMENT OF THIS PLAN AND AWARDS

 

10.1          Amendment of Plan. The Administrator at any time, and from time to time, may amend, suspend or terminate this Plan in accordance with Applicable Laws. However, no amendment shall be effective unless approved by the Shareholders to the extent Shareholder approval is necessary to satisfy any Applicable Law. Any amendment that under the requirements of Applicable Laws must be approved by the Shareholders shall not be effective unless and until such Shareholder approval has been obtained in compliance with such law or rule.

 

 20 

 

 

10.2          Amendment of Awards. The Administrator at any time, and from time to time, may amend the terms of any one or more Awards, or subject to Applicable Laws, provide for the substitution of a new Award for an existing Award. For the avoidance of doubt, the Administrator shall have the authority (without Shareholder approval) to (a) amend any outstanding Option or Share Appreciation Right to reduce its exercise price per share or (b) cancel any Option or Share Appreciation Right in exchange for cash or another Award. Additionally, the Administrator may appropriately adjust any evaluation of performance under a Performance Goal to (i) eliminate the effects of charges for restructurings, discontinued operations, any other unusual or infrequent items and all items of gain, loss or expense determined to be unusual or infrequent in nature; (ii) exclude any of the following events that occur during a Performance Period: (A) asset write-downs or impairments, (B) litigation, claims, judgments or settlements, (C) the effect of changes in tax law, accounting standards or other such laws or provisions affecting reported results and (D) accruals for reorganization and restructuring programs; or (iii) account for any (x) material acquisition, disposition, merger, spin-off or other similar transaction, or new or existing joint venture or (y) gain, loss or expense determined to be unusual or infrequent in nature, or otherwise materially outside the scope of those anticipated in the Company’s plans at the time such Performance Goals were originally set.

 

10.3          No Impairment of Rights. Rights under any Award granted before amendment of this Plan shall not be impaired by any amendment of this Plan (and shall continue to be subject to the terms of this Plan as in effect as of immediately prior to the applicable amendment), and rights under Awards shall not be materially impaired by any amendment of an Award, unless the Participant consents in writing; provided, however, that no consent is required if the Administrator determines in its sole discretion and prior to a Change of Control that such amendment is either required or advisable in order for the Company Group, this Plan or the Award to satisfy any Applicable Law, regulation or stock exchange listing requirement or to avoid adverse tax or financial accounting consequences. A cancellation of an Award where the Participant receives a payment equal in value to the Fair Market Value of the vested Award or, in the case of vested Options, the difference between the Fair Market Value and the exercise price, shall not be an impairment of the Participant’s rights that requires consent of the Participant.

 

11.          GENERAL PROVISIONS

 

11.1          Acceleration of Exercisability and Vesting. The Administrator shall have the power to accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest in accordance with this Plan, notwithstanding the provisions in the Award stating the time at which it may first be exercised or the time during which it will vest.

 

11.2          Shareholder Rights. With respect to Shares subject to an Award granted under this Plan, a Participant shall not be deemed to be a Shareholder, and the Participant shall not have any of the rights or privileges of a Shareholder, until Shares have been issued to the Participant or the Participant’s nominee following exercise of the Participant’s right under this Plan. No adjustments shall be made for dividends (ordinary or extraordinary, whether in cash, securities or other property) or distribution or other rights for which the record date occurs prior to the date of such issuance, except as otherwise expressly provided herein or as determined by the Administrator. Shares acquired under this Plan shall be subject to the Company’s Insider Trading Policy to the extent applicable to a Participant.

 

 21 

 

 

11.3          No Employment or other Service Rights. Nothing in this Plan or any instrument executed or Award granted pursuant thereto shall confer upon any Participant any right to continue to serve the Company Group in the capacity in effect at the time the Award was granted or shall affect the right of the Company Group to terminate (a) the employment of an Employee with or without notice and with or without cause, (b) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the Company Group or (c) the service of a Director pursuant to the Certificate of Formation or the TBOC, and any applicable provisions of the corporate law of the jurisdiction in which a Company Group member is incorporated, as the case may be.

 

11.4          No Rights to Awards. No Service Provider or other person shall have any claim to be granted any Award pursuant to this Plan, and neither the Company nor the Administrator is obligated to treat Service Providers, Participants or any other persons uniformly.

 

11.5          Transfer, Approved Leave of Absence. For purposes of this Plan, no termination of Continuous Service by an Employee shall be deemed to result from either (a) a transfer to the employment within the Company Group; or (b) an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the Employee’s right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing.

 

11.6          Withholding Obligations. Common Stock will be delivered to a Participant only after the Participant has satisfied any tax withholding requirements relating to the exercise, vesting or acquisition of such Common Stock. To the extent provided by the terms of an Award Agreement and subject to the discretion of the Administrator, the Participant may satisfy any federal, state or local tax withholding obligation relating to the exercise or acquisition of Common Stock under an Award by any of the following means (in addition to the Company’s right to withhold from any compensation paid to the Participant by the Company Group) or by a combination of such means: (a) tendering a cash payment; (b) authorizing the Company to issue and then immediately redeem or repurchase Common Stock at Fair Market Value; or (c) tendering to the Company currently owned and unencumbered Common Stock of the Company for redemption or repurchase, and in each of clauses (b) and (c), immediately tendering the redemption or repurchase price paid by the Company in respect of such Common Stock back to the Company.

 

11.7          Other Compensation Arrangements. Nothing contained in this Plan shall prevent the Administrator from adopting other or additional compensation arrangements, subject to Shareholder approval if such approval is required; and such arrangements may be either generally applicable or applicable only in specific cases.

 

11.8          Delivery. Upon exercise of a right granted under this Plan, the Company shall issue Common Stock or pay any amounts due within a reasonable period of time thereafter. Subject to any statutory or regulatory obligations the Company may otherwise have, for purposes of this Plan, 30 days shall be considered a reasonable period of time.

 

 22 

 

 

11.9          Other Provisions. The Award Agreements authorized under this Plan may contain such other provisions not inconsistent with this Plan, including, without limitation, restrictions upon the exercise of the Awards, as the Administrator may deem advisable. Unless explicitly provided otherwise in an Award Agreement, if there is a conflict between the terms of this Plan and an Award Agreement, the terms of this Plan shall control.

 

11.10        Recoupment Provisions. Any Awards granted under this Plan shall be subject to any clawback or recoupment policies and procedures that are required under Applicable Laws or any Company Group policy as enacted, adopted or modified from time to time.

 

11.11        Cancellation and Rescission of Awards for Detrimental Activity.

 

(a)            Upon exercise, payment or delivery pursuant to an Award, the Participant shall, if requested, certify in a manner acceptable to the Company that the Participant has not engaged in any Detrimental Activity.

 

(b)            Unless the Award Agreement specifies otherwise, the Administrator may cancel, rescind, suspend, withhold or otherwise limit or restrict any unexpired, unpaid or deferred Awards at any time if the Participant engages in any Detrimental Activity.

 

(c)            In the event a Participant engages in Detrimental Activity after any exercise, payment or delivery pursuant to an Award, during any period for which any restrictive covenant prohibiting such activity is applicable to the Participant, such exercise, payment or delivery may be rescinded within one year thereafter. In the event of any such rescission, the Participant shall pay to the Company the amount of any gain realized or payment received as a result of the exercise, payment or delivery, in such manner and on such terms and conditions as may be required by the Company. The Company shall be entitled to set off against the amount of any such gain any amount owed to the Participant by the Company Group.

 

(d)            At the Administrator’s discretion, the Company may exercise the right of rescission set forth in this Section 11.11 via the mandatory redemption or repurchase of the Participant’s Common Stock at a price equal to the price paid by the Participant to acquire the Common Stock.

 

11.12        Paperless Administration. In the event that the Company establishes, for itself or using the services of a third party, an automated system for the documentation, granting or exercise of Awards, such as a system using an internet website or interactive voice response, then the paperless documentation, granting or exercise of Awards by a Participant may be permitted through the use of such an automated system.

 

11.13        Unfunded Status of Awards. This Plan is intended to be an “unfunded” plan for incentive compensation. With respect to any payments not yet made to a Participant pursuant to an Award, nothing contained in this Plan or any Award Agreement shall give the Participant any rights that are greater than those of a general creditor of the Company Group.

 

 23 

 

 

11.14        Expenses. The expenses of administering this Plan shall be borne by the Company Group.

 

11.15        Notices. All notices or other communications by a Participant to the Company under or in connection with this Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof.

 

11.16        Severability. If any provision of this Plan is, or becomes, or is deemed to be invalid, illegal or unenforceable in any jurisdiction or as to any Participant, or would disqualify this Plan under any law deemed applicable by the Administrator, such provision shall be construed or deemed amended to conform to the Applicable Laws, or if it cannot be construed or deemed amended without, in the determination of the Administrator, materially altering the intent of this Plan, such provision shall be stricken as to such jurisdiction or Participant and the remainder of this Plan shall remain in full force and effect.

 

11.17        Interpretation. The definitions of terms in this Plan shall apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The use of the words “and” and “or” can mean both “and” and “or” where such construction would be applicable. The words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation.” The word “will” shall be construed to have the same meaning and effect as the word “shall.” Section headings are included for convenience of reference only and shall not affect the interpretation of this Plan, and all references to Sections shall be construed to refer to Sections of this Plan. Unless the context requires otherwise, (a) any definition of or reference to any document shall be construed as referring to such document as from time to time amended, supplemented or otherwise modified, (b) any reference to any Person shall be construed to include such Person’s successors and assigns, and (c) any reference to any Applicable Law shall, unless otherwise specified, refer to such law or regulation as amended, modified or supplemented from time to time.

 

12.            EFFECTIVE DATE OF PLAN. This Plan shall become effective as of the Effective Date.

 

13.            TERMINATION OR SUSPENSION OF THIS PLAN. Unless terminated by the Directors at an earlier date pursuant to Section 10.1, this Plan will continue in effect for a term of ten years commencing on the Effective Date. No Award shall be granted pursuant to this Plan after such date, but Awards theretofore granted may extend beyond that date. No Awards may be granted under this Plan while this Plan is suspended or after it is terminated.

 

14.            CHOICE OF LAW; WAIVER OF JURY TRIAL. The laws of the State of Texas shall govern all questions concerning the construction, validity and interpretation of this Plan and any Award Agreement. BY ACCEPTING AN AWARD, EACH PARTICIPANT IRREVOCABLY WAIVES ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS PLAN OR ANY AWARD AGREEMENT.

 

 24 

 

 

Exhibit 10.6

 

CARIS LIFE SCIENCES, INC.
EMPLOYEE STOCK PURCHASE PLAN

 

1.             PURPOSE. The purpose of the Caris Life Sciences, Inc. Employee Stock Purchase Plan (this “Plan”) is to provide Eligible Employees of the Company Group with an opportunity to acquire a stock ownership interest in the Company. This Plan is intended to qualify as an “employee stock purchase plan” under Section 423 of the Code and shall be administered, interpreted and construed in a manner consistent with the requirements of Section 423 of the Code. This Plan shall be effective as of the date of approval by the Shareholders (the “Effective Date”).

 

2.             DEFINITIONS

 

2.1           “Administrator” means the Board or the Committee appointed by the Board in accordance with Section 3.5.

 

2.2           “Agent” means the brokerage firm, bank or other financial institution, entity or person(s), if any, engaged, retained, appointed or authorized to act as the agent of the Company or an Eligible Employee with regard to this Plan.

 

2.3           “Annual Increase” has the meaning set forth in Section 4.1.

 

2.4           “Applicable Laws” means any applicable legal requirements relating to the administration of and the issuance of ownership interests and other securities under equity-based compensation plans, including, without limitation, U.S. state corporate laws, U.S. federal and state securities laws, the Code and the requirements of any stock exchange or quotation system upon which the Common Stock may be listed or quoted and the laws of any other country or jurisdiction where rights are granted under this Plan.

 

2.5           “Beneficial Owner” has the meaning assigned to such term in Rule 13d-3 and Rule 13d-5 under the Exchange Act, except that in calculating the beneficial ownership of any particular “person” (as that term is used in Section 13(d)(3) of the Exchange Act), such “person” shall be deemed to have beneficial ownership of all securities that such “person” has the right to acquire by conversion or exercise of other securities, whether such right is currently exercisable or is exercisable only after the passage of time. The terms “Beneficially Owns” and “Beneficially Owned” have corresponding meanings.

 

2.6           “Board” means the Board of Directors of the Company, as constituted from time to time.

 

2.7           “Certificate of Formation” means the Company’s Amended and Restated Certificate of Formation, as amended from time to time.

 

2.8           “Code” means the Internal Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder.

 

2.9           “Committee” means a committee of one or more Directors appointed by the Board to administer this Plan in accordance with Section 3.5.

 

 

 

2.10         “Common Stock” means the Class A common stock of the Company, par value US$0.001 per share, issued subject to and in accordance with the provisions of the TBOC and the Certificate of Formation and having the rights provided for in the Certificate of Formation.

 

2.11         “Company” means Caris Life Sciences, Inc., a Texas corporation, or any successor thereto.

 

2.12         “Company Group” means the Company and each of its parent corporations and subsidiary corporations, whether now or hereafter existing, as those terms are defined in Sections 424(e) and (f), respectively, of the Code, or one of the members of the Company Group, as applicable.

 

2.13         “Compensation” of an Eligible Employee means, unless otherwise determined by the Administrator, the gross base compensation or wages received by such Eligible Employee as compensation for services to the Company Group, excluding overtime payments, sales commissions, incentive compensation, bonuses, expense reimbursements, income received in connection with any compensatory equity awards, fringe benefits and other special payments.

 

2.14         “Effective Date” has the meaning set forth in Section 1.

 

2.15         “Eligible Employee” means:

 

(a)           An Employee who does not, immediately after any rights under this Plan are granted, own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of Shares and other securities of the Company or another member of the Company Group (as determined under Section 423(b)(3) of the Code). For purposes of the foregoing, the rules of Section 424(d) of the Code with regard to the attribution of stock ownership shall apply in determining the stock ownership of an individual, and stock that an Employee may purchase under outstanding options shall be treated as stock owned by the Employee.

 

(b)           Provided that, prior to the commencement of an Offering Period, the Administrator may, in its discretion, determine that Employees who are a highly compensated employees within the meaning of Section 423(b)(4)(D) of the Code may not participate in such Offering.

 

(c)           Notwithstanding the foregoing, an Employee shall not be eligible to participate in an Offering Period if: (i) in the event the Administrator designates a service requirement, such Employee has not met the service requirement designated by the Administrator pursuant to Section 423(b)(4)(A) of the Code (which service requirement may not be more than two years); (ii) such Employee’s customary employment is for 20 hours per week or less; (iii) such Employee’s customary employment is for less than five months in any calendar year; or (iv) such Employee is a citizen or resident of a non-U.S. jurisdiction and the grant of a right to purchase Shares under this Plan to such Employee would be prohibited under the laws of such non-U.S. jurisdiction or the grant of a right to purchase Shares under this Plan to such Employee in compliance with the laws of such non-U.S. jurisdiction would cause this Plan to violate the requirements of Section 423 of the Code, as determined by the Administrator in its sole discretion; provided that any exclusion in clauses (i), (ii), (iii) or (iv) shall be applied in an identical manner under each Offering Period to all Employees, in accordance with Treas. Reg. Section 1.423-2(e).

 

2

 

 

2.16         “Employee” means any person employed by the Company Group and who is an employee within the meaning of Section 3401(c) of the Code. Mere service as a Director or payment of a director’s fee by the Company Group shall not be sufficient to constitute “employment” by the Company Group. For purposes of this Plan, the employment relationship shall be treated as continuing intact while the individual is on sick leave or other leave of absence approved by the Company Group and meeting the requirements of Treas. Reg. Section 1.421-1(h)(2). Where the period of leave exceeds three months and the individual’s right to reemployment is not guaranteed either by statute or by contract, the employment relationship shall be deemed to have terminated on the first day immediately following such three-month period.

 

2.17         “Enrollment Date” means the first Trading Day of each Offering Period.

 

2.18         “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder from time to time.

 

2.19         “Fair Market Value” means, with respect to a Share, the fair market value thereof as of the relevant date of determination, as determined in accordance with the valuation methodology approved by the Administrator (based on objective criteria) from time to time. In the absence of any alternative valuation methodology approved by the Administrator, Fair Market Value shall be deemed to be equal to the closing selling price of a Share on the Nasdaq Stock Exchange (or such established national securities exchange as may be designated by the Administrator) on the trading day immediately preceding the date as of which such valuation is made, or in the event that the Common Stock is not listed for trading on the Nasdaq Stock Exchange or such other national securities exchange as may be designated by the Administrator but is quoted on an automated system, in any such case, on the valuation date (or if there were no sales on the valuation date, the average of the highest and lowest quoted selling prices as reported on said composite tape or automated system for the most recent day during which a sale occurred).

 

2.20         “Offering” means an offer under this Plan of a right to purchase Shares that may be exercised during an Offering Period as further described in Section 4.2. Unless otherwise specified by the Administrator, each Offering to the Eligible Employees shall be deemed a separate Offering, even if the dates and other terms of the applicable Offering Periods of each such Offering are identical, and the provisions of this Plan will separately apply to each Offering. To the extent permitted by Treas. Reg. Section 1.423-2(a)(1), the terms of each separate Offering need not be identical, provided that the terms and an Offering thereunder together satisfy Treas. Reg. Section 1.423-2(a)(2) and (a)(3).

 

2.21         “Offering Document” means the document setting forth the terms of an Offering as approved by the Administrator.

 

2.22         “Offering Period” has the meaning given to such term in Section 6.

 

2.23         “Participant” means any Eligible Employee who has executed a subscription agreement and been granted rights to purchase Shares pursuant to this Plan.

 

3

 

 

2.24         “Payday” means the regular and recurring established day for payment of Compensation to an Employee.

 

2.25         “Person” means an individual, partnership, corporation, limited liability company, joint stock company, unincorporated organization or association, trust, joint venture, association or other similar entity, whether or not a legal entity.

 

2.26         “Plan” has the meaning set forth in Section 1.

 

2.27         “Purchase Date” means the last Trading Day of the applicable Purchase Period or such other date as determined by the Administrator prior to the commencement of an Offering Period.

 

2.28         “Purchase Period” shall refer to one or more periods within an Offering Period, as designated by the Administrator. Unless designated otherwise by the Administrator prior to the commencement of an Offering Period, the Purchase Period for each Offering Period shall be the same as the applicable Offering Period.

 

2.29         “Purchase Price” means the purchase price designated by the Administrator prior to the commencement of an Offering Period (which purchase price shall not be less than 85% of the Fair Market Value of a Share on (x) first day of the Offering Period or (y) the Purchase Date for such Offering Period, whichever is lower); provided, however, that, in the event no purchase price is designated by the Administrator prior to the commencement of an Offering Period, the purchase price for such Offering Period shall be 85% of the Fair Market Value of a Share on (x) first day of the Offering Period or (y) the Purchase Date for such Offering Period, whichever is lower; provided, further, however, that the Purchase Price may be adjusted by the Administrator pursuant to Section 10 and shall not be less than the par value of a Share.

 

2.30         “Securities Act” means the U.S. Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder from time to time.

 

2.31         “Share” means a share of Common Stock.

 

2.32         “Share Reserve” has the meaning set forth in Section 4.1.

 

2.33         “Shareholder” means a shareholder of the Company.

 

2.34         “Subsidiary” means any foreign or domestic corporation, limited liability company, partnership or other entity of which 50% or more of the outstanding voting equity securities or voting power is Beneficially Owned directly or indirectly by the Company. For purposes of determining eligibility for the grant of Shares under the Plan, the term “Subsidiary” shall be defined in the manner required by Section 424(f) of the Code.

 

2.35         “TBOC” means the Texas Business Organizations Code.

 

2.36         “Trading Day” means a day on which national stock exchanges in the United States are open for trading.

 

4

 

 

2.37         “Treas. Reg.” means U.S. Department of the Treasury regulations.

 

3.            ADMINISTRATION

 

3.1           Administration by Directors. This Plan shall be administered by the Board unless and until the Board delegates administration to a Committee, as provided in Section 3.5.

 

3.2           Powers of Administrator. The Administrator shall have the power and authority to determine when and how rights to purchase Shares shall be granted and the provisions of each Offering (which need not be identical). The Administrator may delegate administrative tasks under this Plan to the services of an Agent or Employee to assist in the administration of this Plan, including establishing and maintaining an individual securities account under this Plan for each Participant.

 

3.3           Specific Powers. In particular, the Administrator shall have the authority: (i) to construe and interpret this Plan and apply its provisions; (ii) to promulgate, amend and rescind rules and regulations relating to the administration of this Plan; (iii) to authorize any person to execute, on behalf of the Company, any instrument required to carry out the purposes of this Plan; (iv) to impose a mandatory holding period pursuant to which Employees may not dispose of or transfer Shares purchased under this Plan for a period of time determined by the Administrator in its discretion; (v) to exercise such powers and to perform such acts as the Administrator deems necessary or expedient to promote the best interests of the Company Group and to carry out the intent that this Plan be treated as an “employee stock purchase plan” within the meaning of Section 423 of the Code; (vi) to adopt sub-plans applicable to particular Subsidiaries or locations, which sub-plans may be designed to be outside the scope of Section 423 of the Code; (vii) to correct any defect, omission or inconsistency in this Plan, in a manner and to the extent it shall deem necessary or expedient to make this Plan fully effective; and (viii) to exercise discretion to make any and all other determinations which it determines to be necessary or advisable for administration of this Plan.

 

3.4           Decisions Final. All decisions made by the Administrator pursuant to the provisions of this Plan shall be final, binding and conclusive on the Company and the Participants.

 

3.5           The Committee. To the extent permitted under Applicable Laws, the Board may delegate administration of this Plan to a Committee or Committees consisting of one or more Directors, and the term “Committee” shall apply to any person or persons to whom such authority has been delegated. If administration is delegated to a Committee, the Committee shall have, in connection with the administration of this Plan, the powers theretofore possessed by the Board, including the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board or the Administrator shall thereafter, to the extent the delegation is applicable, be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of this Plan, as may be adopted from time to time by the Board. Subject to the limitations prescribed by this Plan and the Board, the Committee may establish and follow such rules and regulations for the conduct of its business as it may determine to be advisable.

 

5

 

 

3.6           Indemnification. In addition to such other rights of indemnification as they may have as Directors or members of the Committee, and to the extent allowed by Applicable Laws, the Administrator shall be indemnified by the Company against the reasonable expenses, including attorney’s fees, actually incurred in connection with any action, suit or proceeding or in connection with any appeal therein, to which the Administrator may be party by reason of any action taken or failure to act under or in connection with this Plan, and against all amounts paid by the Administrator in settlement thereof (provided that the settlement has been approved by the Company, which approval shall not be unreasonably withheld) or paid by the Administrator in satisfaction of a judgment in any such action, suit or proceeding, except in relation to matters as to which it shall be adjudged in such action, suit or proceeding that such Administrator did not act in good faith; provided, however, that within 60 days after institution of any such action, suit or proceeding, such Administrator shall, in writing, offer the Company the opportunity at its own expense to handle and defend such action, suit or proceeding.

 

3.7           Reliance on Experts. In making any determination or in taking or not taking any action under this Plan, the Administrator may obtain and may rely upon the advice of experts, including employees of and professional advisors to the Company. No director, officer or agent of the Company Group shall be liable for any such action or determination taken or made or omitted in good faith.

 

4.           COMMON STOCK SUBJECT TO THIS PLAN

 

4.1           Number of Shares. Subject to the provisions of Section 10 relating to adjustments upon changes in the Common Stock, the aggregate number of Shares that may be issued pursuant to rights granted under this Plan shall be an amount equal to 0.85% of the fully diluted shares of all classes of the Company’s common stock after giving effect to the Company’s initial public offering (the “Offering”) (assuming the exercise of any outstanding warrants and conversion of all preferred stock and senior convertible notes, and including, but not limited to, shares subject to outstanding awards under the Amended and Restated 2020 Plan, and the issuance of the Company’s common stock contemplated to be sold in the Offering) (the “Share Reserve”). Notwithstanding the foregoing, the Share Reserve shall automatically increase on January 1 of each calendar year during the term of this Plan beginning in 2026, by a number of Shares equal to 1% of all classes of the Company’s common stock outstanding on the last day of the immediately preceding fiscal year, unless the Administrator should decide to increase the number of Shares available under this Plan by a lesser amount (the “Annual Increase”). The “Amended and Restated 2020 Plan” means the Caris Life Sciences, Inc. 2020 Incentive Plan, as amended and restated.

 

4.2           Reversion of Shares to the Share Reserve. If any right granted under this Plan shall for any reason terminate without having been exercised, the Shares not purchased under such right shall again become available for issuance under this Plan.

 

4.3           Source of Shares. The Shares subject to this Plan may be authorized but unissued Common Stock or reacquired Common Stock, however reacquired.

 

6

 

 

5.            ELIGIBILITY

 

5.1           Eligibility. Any Eligible Employee employed by the Company Group on a given Enrollment Date for an Offering Period shall be eligible to participate in this Plan during such Offering Period, subject to the requirements of this Section 5 and the limitations imposed by Section 423(b) of the Code.

 

5.2           Enrollment in this Plan.

 

(a)           Except as otherwise determined by the Administrator, an Eligible Employee may become a Participant in this Plan for an Offering Period by delivering a subscription agreement to the Company by such time prior to the Enrollment Date for such Offering Period designated by the Administrator and in such form as the Company provides.

 

(b)           Except as otherwise determined by the Administrator, each subscription agreement shall designate a whole percentage of such Eligible Employee’s Compensation to be withheld by the Company Group member employing such Eligible Employee on each Payday during the Offering Period as payroll deductions under this Plan. The percentage of Compensation designated by an Eligible Employee may not be less than 1% and may not be more than the maximum percentage designated by the Administrator (which percentage shall be 15% in the absence of any such designation) as payroll deductions. The payroll deductions made for each Participant shall be credited to an account for such Participant under this Plan and shall be deposited with the general funds of the Company.

 

(c)           The Administrator may designate that a Participant may increase or decrease the percentage of Compensation designated in the Participant’s subscription agreement, subject to the limits of this Section 5.2, or may suspend the Participant’s payroll deductions, at any time during an Offering Period (and in the absence of any specific designation by the Administrator, a Participant may not increase the Participant’s payroll deduction elections during an Offering Period); provided, however, that the Administrator may limit the number of changes a Participant may make to the Participant’s payroll deduction elections during each Offering Period in the applicable Offering Document. Any such change or suspension of payroll deductions shall be effective with the first full payroll period following the Company’s receipt of the new subscription agreement (or such shorter or longer period as may be specified by the Administrator in the applicable Offering Document). In the event a Participant suspends the Participant’s payroll deductions, such Participant’s cumulative payroll deductions prior to the suspension shall remain in the Participant’s account and shall be applied to the purchase of Shares on the next occurring Purchase Date and shall not be paid to such Participant unless the Participant withdraws from participation in this Plan pursuant to Section 8.

 

(d)           Except as otherwise determined by the Administrator, a Participant may participate in this Plan only by means of payroll deduction and may not make contributions by lump-sum payment for any Offering Period.

 

7

 

 

5.3           Payroll Deductions. Except as otherwise determined by the Administrator, payroll deductions for a Participant shall commence on the first Payday following the Enrollment Date and shall end on the last Payday in the Offering Period to which the Participant’s authorization is applicable, unless sooner terminated by the Participant as provided in Section 8 or suspended by the Participant or the Administrator. Notwithstanding any other provisions of this Plan to the contrary, in non-U.S. jurisdictions where participation in this Plan through payroll deductions is prohibited, the Administrator may provide that an Eligible Employee may elect to participate through contributions to the Participant’s account under this Plan in a form acceptable to the Administrator in lieu of or in addition to payroll deductions; provided, however, that, for any Offering, the Administrator shall take into consideration any limitations under Section 423 of the Code when applying an alternative method of contribution.

 

5.4           Effect of Enrollment. A Participant’s completion of a subscription agreement will enroll such Participant in this Plan for each subsequent Offering Period on the terms contained therein until the Participant either submits a new subscription agreement, withdraws from participation as provided in Section 8 or otherwise becomes ineligible to participate in this Plan.

 

5.5           Limitation on Purchase of Shares. An Eligible Employee may be granted rights under this Plan only if such rights, together with any other rights granted to such Eligible Employee under “employee stock purchase plans” of the Company Group, as specified by Section 423(b)(8) of the Code, do not permit such employee’s rights to purchase Common Stock to accrue at a rate that exceeds $25,000 of the Fair Market Value of Common Stock (determined as of the first day of the Offering Period during which such rights are granted) for each calendar year in which such rights are outstanding at any time. This limitation shall be applied in accordance with Section 423(b)(8) of the Code.

 

5.6           Suspension of Payroll Deductions. Notwithstanding the foregoing, to the extent necessary to comply with Section 423(b)(8) of the Code and Section 5.5 or the other limitations set forth in this Plan, a Participant’s payroll deductions may be suspended by the Administrator at any time during an Offering Period. The balance of the amount credited to the account of each Participant that has not been applied to the purchase of Shares in such circumstance shall be paid to such Participant in one lump-sum in cash as soon as reasonably practicable after the Purchase Date.

 

5.7           Non-U.S. Employees. In order to facilitate participation in this Plan, the Administrator may provide for such special terms applicable to Participants who are citizens or residents of a non-U.S. jurisdiction, as the Administrator may consider necessary or appropriate to accommodate differences in local law, tax policy or custom; provided, however, that the Administrator shall take into consideration any limitations under Section 423 of the Code. Such special terms may be set forth in an addendum to this Plan in the form of an appendix or sub-plan. Without limiting the foregoing, the Administrator is specifically authorized to adopt rules and procedures with respect to Participants who are non-U.S. nationals or employed in non-U.S. jurisdictions regarding the exclusion of particular Subsidiaries from participation in this Plan, eligibility to participate, the definition of Compensation, handling of payroll deductions or other contributions by Participants, payment of interest, conversion of local currency, data privacy and security, payroll tax, withholding procedures, establishment of bank or trust accounts to hold payroll deductions or contributions.

 

8

 

 

6.            OFFERING PERIODS. The Administrator may from time to time make Offerings under this Plan to Eligible Employees during one or more periods (each, an “Offering Period”) selected by the Administrator. The Administrator may, in its discretion, designate the length of an Offering Period, provided that no Offering Period shall exceed 27 months in duration. Each Offering Period shall consist of one or more Purchase Periods, as designated by the Administrator, during which rights granted under this Plan shall be exercised and purchases of Shares carried out in accordance with this Plan. The provisions of separate Offerings or Offering Periods under this Plan need not be identical. Unless designated otherwise by the Administrator, the first Offering Period under this Plan shall begin on the first Trading Day on or following July 1, 2026 and shall end on December 31, 2026 (the “Initial Offering”). Thereafter, and unless designated otherwise by the Administrator, each Offering Period shall commence on the first Trading Day on or following January 1 and July 1 and shall end on June 30 and December 31, respectively. The Initial Offering and each Offering Period thereafter shall consist of a single Purchase Period unless designated otherwise by the Administrator.

 

7.            GRANT AND EXERCISE OF RIGHTS

 

7.1           Grant of Rights. On the Enrollment Date of each Offering Period, each Eligible Employee participating in such Offering Period shall be granted a right to purchase, and shall have the right to buy, on each Purchase Date during such Offering Period (at the applicable Purchase Price), subject to the limits in Section 5.5, such number of whole Shares as is determined by dividing (a) such Participant’s payroll deductions accumulated prior to such Purchase Date and retained in the Participant’s account as of the Purchase Date by (b) the applicable Purchase Price (rounded down to the nearest whole Share); provided, that, fractional Shares may be issued upon the exercise of rights granted under the Plan if permitted under the applicable Offering Document. The right shall expire on the earliest of: (x) the last Purchase Date of the Offering Period, (y) the last day of the Offering Period, and (z) the date on which the Participant withdraws in accordance with Section 8.

 

7.2           Exercise of Rights. On each Purchase Date, each Participant’s accumulated payroll deductions shall be applied to the purchase of whole Shares, up to the maximum number of Shares permitted pursuant to the terms of this Plan, at the Purchase Price, but no Participant has a right to receive a fractional Share. Any cash in lieu of fractional Shares remaining after the purchase of Shares upon exercise of a purchase right shall be returned to the Participant in one lump sum payment in a subsequent payroll check. Shares issued pursuant to this Plan may be evidenced in such manner as the Administrator may determine and may be issued in certificated form or issued pursuant to book-entry procedures.

 

7.3           Pro Rata Allocation of Shares. If the Administrator determines that, on a given Purchase Date, the number of Shares with respect to which rights are to be exercised may exceed (a) the number of Shares that were available for issuance under this Plan on the Enrollment Date of the applicable Offering Period or (b) the number of Shares available for issuance under this Plan on such Purchase Date, the Administrator may in its sole discretion provide that the Company shall make a pro rata allocation of the Shares available for purchase on such Enrollment Date or Purchase Date, as applicable, in as uniform a manner as shall be practicable and as it shall determine in its sole discretion to be equitable among all Participants for whom rights to purchase Shares are to be exercised pursuant to this Section 7 on such Purchase Date, and shall either (i) continue all Offering Periods then in effect or (ii) terminate any or all Offering Periods then in effect in accordance with this Plan. The Company may make pro rata allocation of the Shares available on the Enrollment Date of any applicable Offering Period pursuant to the preceding sentence, notwithstanding any authorization of additional Shares for issuance under this Plan by Shareholders subsequent to such Enrollment Date. The balance of the amount credited to the account of each Participant that has not been applied to the purchase of Shares shall be paid to such Participant in one lump sum in cash as soon as reasonably practicable after the Purchase Date or such earlier date as determined by the Administrator.

 

9

 

 

7.4           Transfer of Shares. Unless determined otherwise by the Administrator, no Participant may transfer Shares purchased pursuant to this Plan out of the Participant’s account with the Agent during the two-year period from the Enrollment Date of the Offering Period in which the Shares were purchased other than in the case of a sale of such Shares.

 

8.            WITHDRAWAL; CESSATION OF ELIGIBILITY

 

8.1           Withdrawal. A Participant may withdraw all (but not less than all) of the payroll deductions credited to the Participant’s account and not yet used to exercise the Participant’s rights under this Plan at any time by giving written notice to the Company in a form acceptable to the Company no later than 30 days prior to the end of the Offering Period (or such shorter or longer period as may be designated by the Administrator). All of the Participant’s payroll deductions credited to the Participant’s account during an Offering Period shall be paid to such Participant as soon as reasonably practicable after receipt of notice of withdrawal and such Participant’s rights for the Offering Period shall be automatically terminated, and no further payroll deductions for the purchase of Shares shall be made for such Offering Period. If a Participant withdraws from an Offering Period, payroll deductions shall not resume at the beginning of the next Offering Period unless the Participant timely delivers to the Company a new subscription agreement.

 

8.2           Future Participation. A Participant’s withdrawal from an Offering Period shall not have any effect upon the Participant’s eligibility to participate in any similar plan that may hereafter be adopted by the Company or in subsequent Offering Periods that commence after the termination of the Offering Period from which the Participant withdraws.

 

8.3           Cessation of Eligibility. Upon a Participant’s ceasing to be an Eligible Employee for any reason, the Participant shall be deemed to have elected to withdraw from this Plan pursuant to this Section 8 and the payroll deductions credited to such Participant’s account during the Offering Period shall be paid to such Participant or, in the case of such Participant’s death, to the Participant’s beneficiary, as soon as reasonably practicable after such cessation of eligibility, and such Participant’s rights for the Offering Period shall be automatically terminated; provided, however, that, unless designated otherwise by the Administrator, a Participant whose employment with the Company Group terminates for any reason other than the Participant’s death less than 30 days prior to the next Purchase Date in the then-current Offering Period in which the Participant is enrolled shall not be deemed to withdraw from this Plan until immediately following the Participant’s exercise of rights on such Purchase Date.

 

10

 

 

9.            CONDITIONS UPON ISSUANCE OF COMMON STOCK

 

9.1           Legal Compliance. Notwithstanding any other provision of this Plan, no Common Stock may be issued under this Plan unless the issuance and delivery of such Common Stock will comply with Applicable Laws, including, without limitation, the Securities Act, the Exchange Act, U.S. state securities laws and regulations, and the regulations of any stock exchange or other securities market on which the Company’s securities may then be traded, and will be further subject to the approval of counsel for the Company with respect to such compliance. All certificates for Common Stock delivered under this Plan shall be subject to such transfer orders and other restrictions as the Administrator may deem advisable under the rules, regulations, and other requirements of the U.S. Securities and Exchange Commission, any exchange upon which the Common Stock are then listed, and any applicable securities law, and the Administrator may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.

 

9.2           Inability to Obtain Authority. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company’s counsel to be necessary to the lawful issuance and sale of any Common Stock hereunder, will relieve the Company of any liability in respect of the failure to issue or sell such Common Stock as to which such requisite authority will not have been obtained.

 

9.3           Conditions to Issuance of Shares. The Company shall not be required to issue or deliver any certificate or certificates for, or make any book entries evidencing, Shares purchased upon the exercise of rights under this Plan prior to fulfillment of all of the following conditions: (a) the admission of such Shares to listing on all stock exchanges, if any, on which the Shares are then listed; (b) the completion of any registration or other qualification of such Shares under any state or federal law or under the rulings or regulations of the Securities and Exchange Commission or any other governmental regulatory body that the Administrator shall, in its absolute discretion, deem necessary or advisable; (c) the obtaining of any approval or other clearance from any state or federal governmental agency that the Administrator shall, in its absolute discretion, determine to be necessary or advisable; (d) the payment to the Company of all amounts that it is required to withhold under federal, state or local law upon exercise of the rights, if any; and (e) the lapse of such reasonable period of time following the exercise of the rights as the Administrator may from time to time establish.

 

10.          ADJUSTMENTS UPON CHANGES IN COMMON STOCK.

 

10.1         Capitalization Adjustments.

 

(a)           Upon (or, as may be necessary to effect the adjustment, immediately prior to): any reclassification, recapitalization, share split (including a share split in the form of a share dividend) or reverse share split; any merger, combination, consolidation, or other reorganization; any split-up, spin-off, or similar extraordinary dividend distribution in respect of the Common Stock; or any exchange of Common Stock or other securities of the Company, or any similar, unusual or extraordinary corporate transaction in respect of the Common Stock; then, subject to any required action by the Shareholders under Applicable Law, the Administrator shall equitably and proportionately adjust (i) the Share Reserve, (ii) the class(es) and number of Shares and price per Share subject to outstanding rights; and (iii) the Purchase Price with respect to any outstanding rights.

 

11

 

 

(b)           It is intended that, if possible, any adjustments contemplated by the preceding two paragraphs shall be made in a manner that satisfies Applicable Laws and accounting (so as to not trigger any charge to earnings with respect to such adjustment) requirements.

 

(c)           Any good-faith determination by the Administrator as to whether an adjustment is required in the circumstances pursuant to this Section 10.1, and the extent and nature of any such adjustment, shall be final, binding and conclusive on all persons.

 

10.2         Dissolution or Liquidation. In the event of a dissolution or liquidation of the Company, then this Plan shall terminate and payment shall be made to Participants in accordance with Section 14.

 

10.3         Other Adjustments. In the event of (x) any transaction or event described in Section 10.1, (y) any unusual or nonrecurring transactions or events affecting the Company Group or its the financial statements or (z) changes in Applicable Laws or accounting principles, the Administrator, in its discretion, and on such terms and conditions as it deems appropriate, shall be authorized to take any one or more of the following actions:

 

(a)           to provide for either (i) the termination of any outstanding right in exchange for an amount of cash, if any, equal to the amount that would have been obtained upon the exercise of such right had such right been currently exercisable or (ii) the replacement of such outstanding right with other rights or property selected by the Administrator in its sole discretion;

 

(b)           to provide that the outstanding rights under this Plan shall be assumed by the successor or survivor corporation, or a parent or Subsidiary thereof, or shall be substituted by similar rights covering the stock of the successor or survivor corporation, or a parent or Subsidiary thereof, with appropriate adjustments as to the number and kind of stock and prices;

 

(c)           to make adjustments in the number and type of Shares (or other securities or property) subject to outstanding rights under this Plan or in the terms and conditions of outstanding rights and rights that may be granted in the future;

 

(d)           to provide that Participants’ accumulated payroll deductions may be used to purchase Shares prior to the next occurring Purchase Date on such date as the Administrator determines in its sole discretion, following which the Participants’ rights under the ongoing Offering Period(s) shall be terminated; or

 

(e)           to provide that all outstanding rights shall terminate without being exercised.

 

10.4         No Adjustment Under Certain Circumstances. Unless determined otherwise by the Administrator, no adjustment or action described in this Section 10 shall be authorized to the extent that such adjustment or action would cause this Plan to fail to satisfy the requirements of Section 423 of the Code.

 

12

 

 

11.          AMENDMENT OF THIS PLAN.

 

11.1         Amendment of Plan. The Administrator at any time, and from time to time, may amend, suspend or terminate this Plan in accordance with Applicable Laws. However, no amendment shall be effective unless approved by the Shareholders to the extent Shareholder approval is necessary to satisfy any Applicable Laws. Any amendment that under the requirements of Applicable Laws must be approved by the Shareholders shall not be effective unless and until such Shareholder approval has been obtained in compliance with such law or rule.

 

11.2         No Impairment of Rights. Rights granted before amendment of this Plan shall not be impaired by any amendment of this Plan (and shall continue to be subject to the terms of this Plan as in effect as of immediately prior to the applicable amendment), unless (a) the Company requests the consent of the Participant and (b) the Participant consents in writing.

 

11.3         Certain Amendments. Notwithstanding any other provision of this Plan, without Shareholder consent and without regard to whether any Participant rights may be considered to have been adversely affected and after taking into account Section 423 of the Code, the Administrator shall be entitled to change or terminate the Offering Periods, limit the frequency or number of changes in the amount withheld from Compensation during an Offering Period, establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, permit payroll withholding in excess of the amount designated by a Participant in order to adjust for delays or mistakes in the Company’s processing of payroll withholding elections, establish reasonable waiting and adjustment periods or accounting and crediting procedures to ensure that amounts applied toward the purchase of Shares for each Participant properly correspond with amounts withheld from the Participant’s Compensation and establish such other limitations or procedures as the Administrator determines in its sole discretion to be advisable that are consistent with this Plan. In the event the Administrator determines that the ongoing operation of this Plan may result in unfavorable financial accounting consequences, the Administrator may, in its discretion, to the extent necessary or desirable and without Shareholder approval, modify or amend this Plan to reduce or eliminate such accounting consequence including, but not limited to: (a) altering the Purchase Price for any Offering Period including an Offering Period underway at the time of the change in Purchase Price; and (b) shortening any Offering Period so that the Offering Period ends on a new Purchase Date, including an Offering Period underway at the time of the Administrator’s action.

 

11.4         No Amendment Under Certain Circumstances. Unless determined otherwise by the Administrator, no amendment described in this Section 11 shall be authorized to the extent that such amendment would cause this Plan to fail to satisfy the requirements of Section 423 of the Code.

 

12.          GENERAL PROVISIONS.

 

12.1         Shareholder Rights. With respect to Shares subject to a right granted under this Plan, a Participant shall not be deemed to be a Shareholder, and the Participant shall not have any of the rights or privileges of a Shareholder, until Shares have been issued to the Participant or the Participant’s nominee following exercise of the Participant’s rights under this Plan. No adjustments shall be made for dividends (ordinary or extraordinary, whether in cash securities or other property) or distribution or other rights for which the record date occurs prior to the date of such issuance, except as otherwise expressly provided herein or as determined by the Administrator. Shares acquired under this Plan shall be subject to the Company’s Insider Trading Policy to the extent applicable to a Participant.

 

13

 

 

12.2         Restriction upon Assignment. A right granted under this Plan shall not be transferable other than by will or the Applicable Laws of descent and distribution and is exercisable during the Participant’s lifetime only by the Participant. Except in the case of a Participant’s death, a right under this Plan may not be exercised to any extent except by the Participant. The Company shall not recognize and shall be under no duty to recognize any assignment or alienation of the Participant’s interest in this Plan, the Participant’s rights under this Plan or any rights thereunder.

 

12.3         Interest. No interest shall accrue on the payroll deductions or contributions of a Participant under this Plan.

 

12.4         Equal Rights and Privileges. All Eligible Employees shall have equal rights and privileges under this Plan to the extent necessary so that this Plan qualifies as an “employee stock purchase plan” within the meaning of Section 423 of the Code. Any provision of this Plan that is inconsistent with the equal rights and privileges requirement of Section 423 of the Code will, without further act or amendment by the Company, the Board or the Administrator, be reformed to comply with the equal rights and privileges requirement of Section 423 of the Code.

 

12.5         Use of Funds. All payroll deductions received or held by the Company under this Plan may be used by the Company for any corporate purpose, and the Company shall not be obligated to segregate such payroll deductions.

 

12.6         Notice of Disposition of Shares. Each Participant shall give prompt notice to the Company of any disposition or other transfer of any Shares purchased upon exercise of a right under this Plan if such disposition or transfer is made: (a) within two years from the Enrollment Date of the Offering Period in which the Shares were purchased or (b) within one year after the Purchase Date on which such Shares were purchased. Such notice shall specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by the Participant in such disposition or other transfer.

 

12.7         No Employment or other Service Rights. Nothing in this Plan or any instrument executed or right granted pursuant thereto shall confer upon any Participant any right to continue to serve the Company Group or shall affect the right of the Company Group to terminate (a) the employment of an Employee with or without notice and with or without cause, (b) the service of a Consultant pursuant to the terms of such Consultant’s agreement with the Company Group or (c) the service of a Director pursuant to the Certificate of Formation or the TBOC, and any applicable provisions of the corporate law of the jurisdiction in which a Company Group member is incorporated, as the case may be.

 

12.8         No Rights. No person shall have any claim to be granted any right pursuant to this Plan.

 

14

 

 

12.9         Withholding Obligations. At the time a Participant’s rights under this Plan are exercised, in whole or in part, or at the time some or all of the Shares issued under this Plan are disposed of, the Participant must make adequate provision for the Company’s federal, state or other tax withholding obligations, if any, that arise upon the exercise of the right or the disposition of the Shares. At any time, the Company may, but shall not be obligated to, withhold from the Participant’s compensation or Shares received pursuant to this Plan the amount necessary for the Company to meet applicable withholding obligations, including any withholding required to make available to the Company any tax deductions or benefits attributable to sale or early disposition of Shares by the Participant.

 

12.10       Other Compensation Arrangements. Nothing contained in this Plan shall prevent the Administrator from adopting other or additional compensation arrangements, subject to Shareholder approval if such approval is required; and such arrangements may be either generally applicable or applicable only in specific cases.

 

12.11       Delivery. Upon exercise of a right granted under this Plan, the Company shall issue Common Stock or pay any amounts due within a reasonable period of time thereafter. Subject to any statutory or regulatory obligations the Company may otherwise have, for purposes of this Plan, 30 days shall be considered a reasonable period of time.

 

12.12       Recoupment Provisions. Any rights granted under this Plan shall be subject to any clawback or recoupment policies and procedures that are required under Applicable Laws or any Company Group policy as enacted, adopted or modified from time to time.

 

12.13       Paperless Administration. In the event that the Company establishes, for itself or using the services of a third party, an automated system for the documentation, granting or exercise of rights, such as a system using an internet website or interactive voice response, then the paperless documentation, granting or exercise of rights by a Participant may be permitted through the use of such an automated system.

 

12.14       Unfunded Status. This Plan is intended to be an “unfunded” plan for incentive compensation. With respect to any payments not yet made to a Participant pursuant to a right, nothing contained in this Plan shall give the Participant any rights that are greater than those of a general creditor of the Company Group.

 

12.15       Expenses. The expenses of administering this Plan shall be borne by the Company Group.

 

12.16       Notices. All notices or other communications by a Participant to the Company under or in connection with this Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof.

 

12.17       Severability. If any provision of this Plan is, or becomes, or is deemed to be invalid, illegal or unenforceable in any jurisdiction or as to any Participant, or would disqualify this Plan under any law deemed applicable by the Administrator, such provision shall be construed or deemed amended to conform to the Applicable Laws, or if it cannot be construed or deemed amended without, in the determination of the Administrator, materially altering the intent of this Plan, such provision shall be stricken as to such jurisdiction or Participant and the remainder of this Plan shall remain in full force and effect; provided, however, that no such construction, deemed amendment or striking of a provision of this Plan shall cause this Plan to no longer comply with Section 423 of the Code.

 

15

 

 

12.18       Interpretation. The definitions of terms in this Plan shall apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The use of the words “and” and “or” can mean both “and” and “or” where such construction would be applicable. The words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation.” The word “will” shall be construed to have the same meaning and effect as the word “shall.” Section headings are included for convenience of reference only and shall not affect the interpretation of this Plan, and all references to Sections shall be construed to refer to Sections of this Plan. Unless the context requires otherwise, (a) any definition of or reference to any document shall be construed as referring to such document as from time to time amended, supplemented or otherwise modified, (b) any reference to any Person shall be construed to include such Person’s successors and assigns, and (c) any reference to any Applicable Laws shall, unless otherwise specified, refer to such law or regulation as amended, modified or supplemented from time to time.

 

13.          EFFECTIVE DATE OF PLAN. This Plan shall become effective as of the Effective Date.

 

14.          TERMINATION OR SUSPENSION OF THIS PLAN. This Plan will continue in effect until terminated by the Directors pursuant to Section 11.1. No rights shall be granted pursuant to this Plan after such date, but rights theretofore granted may extend beyond that date. No rights may be granted under this Plan while this Plan is suspended or after it is terminated. Upon termination of this Plan, the balance in each Participant’s account shall be refunded as soon as practicable after such termination, without any interest thereon, or then effective Offering Period may be shortened so that the purchase of Shares occurs prior to the termination of this Plan.

 

15.           CHOICE OF LAW; WAIVER OF JURY TRIAL. The laws of the State of Texas shall govern all questions concerning the construction, validity and interpretation of this Plan. BY PARTICIPATING IN THIS PLAN, EACH PARTICIPANT IRREVOCABLY WAIVES ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS PLAN.

 

16

 

 

Exhibit 10.7

 

EMPLOYMENT AGREEMENT

 

This Employment Agreement (“Agreement”), dated as of February 1, 2010 (the “Effective Date”), is made between Caris Life Sciences, Inc., a Delaware Corporation (the “Company”), and David Spetzler (the “Employee”).

 

RECITALS:

 

A.            The Company is engaged in the business of providing diagnostics products and services, including, without limitation, pathology and work flow solutions, tissue banking and diagnostics and analysis, molecular diagnostics, lab services and other related services and products to pharmaceutical companies, physicians, health care providers and others throughout the United States (which, together with any other business in which the Company engages is hereinafter referred to collectively as the “Business”).

 

B.            The Company and the Employee desire to enter into this Agreement to govern the employment relationship between them.

 

NOW THEREFORE, in consideration of the foregoing Recitals (which are hereby incorporated by reference), the agreements hereafter set forth and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

ARTICLE I.
EMPLOYMENT AND ACCEPTANCE

 

1.1            Employment by the Company. The Company hereby agrees to employ the Employee for a three (3) year term (the “Term”) commencing on the Effective Date, and expiring three (3) years from the Effective Date. During the Term, the Employee shall serve in the capacity of Senior Scientist subject to the direction of the Senior Vice President, Group Head, Research and Molecular Diagnostics or their designee. Upon expiration of the Term this Agreement will automatically renew for successive one (1) year periods unless terminated in accordance with the terms hereof.

 

1.2            Duties and Responsibilities. During the Term, the Employee shall devote the Employee’s best efforts and all of the Employee’s business time and services to the Company, its affiliates and subsidiaries, and shall carry out all Company policies and directives in a manner which will promote and develop the Company’s best interests. The Employee shall have the duties and authority assigned to the Employee by the Senior Vice President, Group Head, Research and Molecular Diagnostics, and as set forth in the Company’s Bylaws, policies and procedures from time to time in force.

 

1.3            Company Representations and Warranties. The Company represents and warrants that (i) it has full authority to enter into this Agreement, and (ii) that it is not restricted in any manner from employing the Employee under the terms and conditions set forth in this Agreement.

 

 

 

 

1.4            Acceptance of Employment by the Employee. The Employee hereby accepts such employment and represents and warrants that (i) the Employee has full authority to enter into this Agreement. (ii) the Employee is not restricted in any manner from providing services hereunder or from engaging in the Business and (iii) the Employee is not aware of any situation creating a conflict of interest between the Employee and the Company.

 

ARTICLE II.
COMPENSATION AND OTHER BENEFITS

 

2.1            Annual Salary. The Company shall pay the Employee a salary at the rate of $102,000 per year of employment hereunder (the “Annual Salary”). The Annual Salary shall be payable in accordance with the payroll policies of the Company as from time to time in effect (but no less often than monthly), less such deductions as shall be required to be withheld by applicable law and regulations. The Senior Vice President, Group Head, Research and Molecular Diagnostics shall review the Employee’s performance each year this Agreement is in effect and decide whether to increase the Employee’s Annual Salary.

 

2.2            Annual Bonus. In addition to the Annual Salary, the Company may award a bonus to the Employee following the end of each fiscal year during the Term based on the Company’s audited financial performance for the fiscal year as well as the Employee’s individual contribution to the Company. The performance criteria used to calculate the bonus shall be determined by the Chief Financial Officer and communicated to the Employee in writing within thirty (30) days of December 1st preceding each year and will be established with a targeted prorated bonus of 20% of Annual Salary. Any annual bonus payable will be subject to the approval of the Board and shall be paid in accordance with the Company’s normal payroll policies.

 

2.3            Stock Options and Other Equity Incentives. Subject to approval by the Board of Directors, the Company shall grant to Employee stock options with an exercise price as determined by the Board of Directors. All such options shall be granted pursuant to the terms of the Caris Life Sciences, Inc.’s 2007 Incentive Stock Plan and an option agreement. In addition, the Company may, in its sole discretion, from time to time grant stock options or other equity based incentives to Employee. Employee shall have the right to exercise any vested options in accordance with the time periods set forth in the Caris Life Sciences, Inc.’s 2007 Incentive Stock Plan and the applicable option agreement.

 

2.4            Vacation Policy. The Employee shall be entitled to paid time off in accordance with the Company’s PTO Accrual Plan as set forth in the Company’s Employee Benefits Summary, dated March 2005, a copy of which has been provided to the Employee, as such PTO Accrual Plan may be amended from time to time.

 

2.5            Participation in Employee Benefit Plans. At the Employee’s option, the Company agrees to permit the Employee during the Term, if and to the extent eligible, to participate in any group life, health care or group disability insurance plan, pension plan, similar benefit plan or other so-called “fringe benefits” of the Company (collectively “Benefits”) which may be made generally available to other employees of the Company and on such terms as the Benefits are made generally available to such employees.

 

2

 

 

2.6            Expenses. The Company shall pay or reimburse the Employee for all business expenses reasonably and necessarily incurred by the Employee during the Term in the performance of the Employee’s services under this Agreement, in each case in accordance with Company policy.

 

ARTICLE III.
RESTRICTIONS

 

3.1            Nondisclosure of Confidential Information.

 

(a)            Recognition of Company Rights; Nondisclosure. For so long as Employee is employed by the Company (whether during the term of this Agreement or after its expiration, the “Employment”), Employee will have access to Confidential Information, including Confidential Information Employee has not accessed prior to the date of this Agreement. Employee recognizes that the Company’s business interests require the fullest practical protection and confidential treatment of the Confidential Information. At all time during the Employment and thereafter, Employee will hold in strictest confidence and will not disclose, use, provide access to, or publish any Confidential Information, except as such disclosure, use or publication may be required in connection with Employee’s services for the Company. Employee agrees that all Confidential Information, whether prepared by Employee or otherwise coming into Employee’s possession, shall remain the exclusive property of the Company during Employee’s employment with the Company. Employee will obtain the Company’s written approval before publishing or submitting for publication any material (written, oral, or otherwise) that relates to Employee’s work at the Company, any Confidential Information and/or any material that incorporates any Confidential Information. Employee hereby assigns to the Company any rights Employee may have or acquire in such Confidential Information and recognizes that all Confidential Information is the sole property of the Company and its assigns.

 

(b)            Confidential Information. “Confidential Information” means all information, not generally known within the relevant trade group or by the public, including all Work Product (as defined below), intellectual property, business plans, training materials, software programs, promotional materials, illustrations, designs, plans, data bases, sources of supply, customer lists, supplier lists, trade secrets, and all other valuable or unique information and techniques acquired, developed or used by the Company relating to its business, operations, suppliers, information systems, employees and customers, regardless of whether such information is in writing, on computer disk or disk drive or in any other form. Employee expressly acknowledges and agrees that Confidential Information constitutes trade secrets and/or confidential and proprietary business information of the Company (or its subsidiary, or its customers or suppliers, as the case may be). Confidential Information shall not include information which is or becomes generally available to the public other than through disclosure by Employee or by any other person or entity under a duty or obligation to maintain the confidentiality thereof.

 

(c)            No Improper Use of Information of Prior Employers and Others. During the Employment, Employee shall not improperly use or disclose any confidential information or-trade secrets, if any, of any former employer or any other person to whom Employee has an obligation of confidentiality, and Employee will not bring onto the premises, or make available to any employees of the Company, any unpublished documents or any property belonging to any former employer or any other person to whom Employee has an obligation of confidentiality unless consented to in writing by the former employer or person. In the performance of Employee’s duties for the Company, Employee will only use information which is (i) generally known and used by persons and expertise comparable to that of Employee, (ii) common knowledge in the industry or otherwise legally in the public domain, or (iii) otherwise provided or developed by the Company. Employee acknowledges that the Company has expressly informed Employee that the Company does not want any access, privilege, benefit or knowledge of such confidential or proprietary information of others. Employee represents and warrants that to Employee’s knowledge Employee has no obligations, legal, in contract, or otherwise, inconsistent with the terms of this Agreement or with Employee’s undertaking employment with the Company to perform the duties described herein.

 

3

 

 

(d)            Penalties for Violation of Non-Disclosure Policy. In addition to the legal and equitable remedies set forth herein by applicable law, Employee understands that violation of any non-disclosure provision of this Agreement shall be subject to discipline, up to and including discharge.

 

3.2            Assignment of Work Product. Any information or innovations, including, but not limited to, inventions, improvements, methods, technology, programs, customer lists, reports, distribution records, brochures, instructions, manuals, processes, etc., which are, during the course of the Employment, conceived, developed, or improved upon by Employee for use by the Company or any of its subsidiaries, alone or in conjunction with other employees or consultants (collectively, the “Work Product”), shall be the exclusive property of the Company, and during the Employment and at all times thereafter, Employee shall not use, duplicate, reveal or take with Employee any such Work Product or other materials of the Company, other than in furtherance of the performance of his duties to the Company, whether under this Agreement or otherwise. To the extent that any of the Work Product is capable of protection by copyright as a “work made for hire” pursuant to the United States Copyright Act, Employee acknowledges that such Work Product is created within the scope of his Employment and, as such, is property of the Company. To the extent that any such Work Product, whether protected by copyright or otherwise, is not a “work made for hire,” Employee hereby assigns to the Company all rights in such material. Employee hereby agrees to execute any documents at any time reasonably required by the Company in connection with the registration of copyright, patent application or other perfection of the Company’s ownership of the Work Product.

 

3.3            Covenant Not to Compete.

 

(a)            Business Relationships and Goodwill. Employee acknowledges and agrees that as an employee and representative of the Company, Employee is responsible for building and maintaining business relationships and goodwill with current and future physicians, customers, payors, patients and prospects on a personal level. Employee acknowledges and agrees that such responsibility creates a special relationship of trust and confidence between the Company, Employee, and those persons or entities. Employee further acknowledges that such responsibility creates a high risk and opportunity for Employee to misappropriate these relationships and the goodwill existing between the Company and such persons. Employee acknowledges and agrees that it is fair and reasonable for the Company to take steps to protect itself from the risk of such misappropriation.

 

(b)            Consideration. Employee acknowledges and agrees that in exchange for its agreement in Section 3.3(c) below, Employee will receive substantial and valuable consideration from the Company including, but not limited to (i) Confidential Information (defined below), (ii) compensation and other benefits, and (iii) exposure to the Company’s physicians, payors, customers, patients, and prospects.

 

4

 

 

(c)            Scope of Noncompetition Obligation. During the Employment, and for a period of two (2) years after the termination of the Employment for any reason, Employee shall not, directly or indirectly, either acting alone, or as a stockholder, partner, associate, creditor, consultant, adviser, franchiser, franchisee, director, officer, owner, employee or agent of any other person or entity, or in any other capacity, engage in or provide managed care services of any kind to a company engaged in the Same Business (as defined below) in the Territory (as defined below); provided, however, the restriction contained in this Section 3.3 shall not prohibit Employee from owning not more than 1% of the outstanding stock of any class of any publicly traded corporation, so long as Employee does not actively participate in the business of such corporation. For purposes of this section:

 

(i)the term “Same Business” shall mean any company that engages or proposes to engage in the Business; and

 

(ii)the term “Territory” shall be defined as the United States.

 

(d)            No Prohibition on Working. Employee acknowledges and agrees that this Agreement does not restrict Employee’s ability to find employment within any geographical area after the termination of the Employment; provided that Employee is not employed in violation of the noncompetition obligations detailed herein.

 

3.4            Nonsolicitation of Customers. Employee agrees that Employee shall not at any time during the Employment, whether or not initiated by Employee, divert away or attempt to divert away any business from the Company to another company, business, or individual. Further, Employee shall not, for a period of two (2) years following the termination of the Employment for any reason, contact, solicit, attempt to solicit or divert, or attempt to divert business from, either directly or indirectly, any Company Customer. “Company Customer” means any person, company, or business that is or was a customer or prospective customer of Company, including but not limited to physicians, payors or other customers.

 

3.5            Nonrecruitment of Employees. Employee agrees that during the Employment and for a period of two (2) years after termination of the Employment for any reason, Employee shall not, on Employee’s own behalf or on behalf of any other person or entity, hire, solicit, seek to hire, or offer employment to any person who was employed by the Company on the date of termination of the Employment, or who is a current employee of the Company. Employee further agrees that Employee will not, in any other manner attempt, directly or indirectly, to influence, induce, or encourage any person who was employed by the Company on the date of termination of the Employment or who is a current or prospective employee of the Company to leave the employment of the Company.

 

5

 

 

3.6            Non-Interference with Business Relations. Employee agrees that during the Employment, and for a period of two (2) years after the termination of the Employment for any reason, Employee shall not, directly or indirectly, (a) solicit, advise, persuade or otherwise induce any person to participate in or with any entity or person which provides services comparable to those provided by the Company or by facilities managed or owned by the Company or any of its subsidiaries, (b) do anything, intentionally or recklessly, to discredit or otherwise injure the reputation or goodwill of the Company or any of its affiliates or subsidiaries, (c) solicit, induce or attempt to solicit or induce any customer, employee, independent contractor, distributor, manufacturer or other professional or any other business relation of the Company (or any subsidiary) to cease or reduce the level of business between such business relation and the Company (or any subsidiary), or (d) in any way interfere with the Company’s (or any subsidiary’s) relationship with any customer, employee, independent contractor, distributor, manufacturer or other professional or business relation of the Company or subsidiary.

 

3.7            Reasonableness of Restrictions. Employee acknowledges and agrees that, given the nature of the Business, and the Company’s proposed Business plans, the restrictions imposed upon Employee by this ARTICLE III and the purposes for such restrictions are reasonable and are designed to protect the trade secrets, confidential and proprietary business information and the future success of the Company and its subsidiaries without unduly restricting Employee. Specifically, Employee acknowledges that the restrictions and covenants contained in this ARTICLE III will not prohibit Employee from pursuing Employee’s career upon termination of Employee’s employment relationship with the Company. If, at the time of enforcement of this Agreement, a court shall hold that any of the duration, scope or geographic restrictions stated herein are unreasonable under circumstances then existing, the parties agree (and shall stipulate, if necessary, in an appropriate pleading) that the maximum duration, scope or geographic area reasonable under such circumstances shall be substituted for the stated duration, scope or geographic area. Employee further agrees not to challenge the enforceability or the enforcement of the restrictive covenants in this ARTICLE III. Employee specifically recognizes and affirms that the restrictive covenants contained in this ARTICLE III are material and important terms of this Agreement, and Employee further agrees that should all or any part or application of any provision of this ARTICLE III be held or found invalid or unenforceable for any reason whatsoever by a court of competent jurisdiction in an action, or by an arbitrator in an arbitration, the Company shall be entitled to receive from employee all stock options and Company stock held by Employee obtained as result of the stock options being granted to Employee on the date hereof. If Employee has sold, transferred, or otherwise disposed of company stock obtained through the exercise of such stock options, the Company shall be entitled to receive from Employee the difference between the option price paid by Employee and the fair market value of such Company stock on the date of sale, transfer, or other disposition.

 

3.8            Severability. Employee agrees that the non-disclosure, non-competition, and non-solicitation covenants set forth herein each constitute separate agreements independently supported by good and adequate consideration. If a court of competent jurisdiction determines that any restriction in a clause or provision of this ARTICLE III is void, illegal, or unenforceable, the other clauses and provisions of this ARTICLE III shall remain in full force and effect.

 

3.9            Return of the Company Property. When Employee’s Employment terminates for any reason, Employee will promptly (within twenty-four (24) hours) deliver to the Company any and all Confidential Information, drawings, notes, memoranda, specifications, devices, formulas and documents, together with all copies thereof and any other material containing or disclosing any works made for hire, or third party information. Employee further agrees that any property situated on the Company’s premises and owned by the Company including computers, computer disks and computer hard disk drives and other computer storage media, filing cabinets or other work areas, is subject to inspection by the Company personnel at anytime with or without notice.

 

6

 

 

3.10            Notification of New Employer. In the event that the Employment is terminated for any reason, Employee hereby consents to the notification by the Company to Employee’s new employer of Employee’s rights and obligations under this ARTICLE III. In addition, in the event that Employee plans to render services to a company that works in a similar field as the Company, Employee agrees to provide the Company with as much notice as possible of Employee’s intention to join that company or business but in no event will Employee provide less than two weeks notice of that intention; provided, however, the provision of such notice and the Company’s receipt thereof shall not constitute a waiver of any breach of any provision of this Agreement.

 

3.11            Equitable and Other Relief. Employee understands and agrees that, in the event Employee breaches this ARTICLE III, the Company will suffer immediate and irreparable harm that cannot be accurately calculated in monetary damages. Consequently, Employee acknowledges and agrees that the Company shall be entitled to immediate injunctive relief, either by temporary or permanent injunction, to prevent such violation. Employee acknowledges and agrees that such injunctive relief shall be in addition to any other legal or equitable relief to which the Company would be entitled. In addition, the Company shall be entitled to recover its attorneys’ fees and costs from Employee should the Company be required to file suit to enforce its rights under this ARTICLE III, if the Company prevails in such suit. In the event that Employee is found to have breached all or any part or application of any provision of this ARTICLE III by a court of competent jurisdiction in an action, or by an arbitrator in an arbitration, Employee further agrees that the Company shall be entitled to receive from Employee all stock options and Company stock held by Employee obtained as result of the stock options being granted to Employee on the Effective Date; provided that the Company agrees to pay Employee an amount equal to the exercise price of any such options. If Employee has sold, transferred, or otherwise disposed of Company stock obtained through the exercise of such stock options, the Company shall be entitled to receive from Employee the difference between the option price paid by Employee and the fair market value of the Company stock on the date of sale, transfer, or other disposition.

 

ARTICLE IV.
TERMINATION

 

4.1            Upon Death or Disability. This Agreement shall terminate upon the Employee’s death or Disability. For purposes of this Agreement, “Disability” shall mean physical or mental disability of the Employee resulting in the Employee’s inability to perform substantially all of the essential functions of the Employee’s duties and responsibilities with the Company for (i) a period of twelve (12) consecutive weeks, or (ii) for shorter periods aggregating twelve (12) weeks during any twelve-month period. If this Agreement terminates as a result of the Employee’s death or Disability, the Company’s obligation to the Employee or the Employee’s estate shall be limited to the payment of accrued and unpaid Annual Salary earned and any accrued and unpaid Benefits vested up to the date of termination, and in the event of Disability, any disability benefits to which the Employee is entitled hereunder. In addition, upon termination due to death or Disability, the Company shall pay the Employee or the Employee’s estate any annual bonus referred to in Section 2.2 above that would otherwise be due for the fiscal year of termination, prorated to the number of days in the fiscal year for which the Employee was employed, and payable at the same time as the bonus would have otherwise been due had the Employee’s employment not been terminated.

 

7

 

 

4.2            Termination for Cause or Voluntary Termination. If the Company terminates the Employee at any time for Cause or if the Employee terminates the Employee’s employment at any time other than for Good Reason, the Company’s obligation to the Employee shall be limited solely to the payment of accrued and unpaid Annual Salary and any accrued but unpaid Benefits vested earned up to the date of termination. As used in this Agreement, the term “Cause” shall mean any of the following: (i) the Employee’s commission of an act involving dishonesty, lack of loyalty or breach of fiduciary responsibility involving the Company or any affiliate or successor thereof, (ii) failure of the Employee to perform the Employee’s duties and responsibilities, which has not been corrected by the Employee within thirty (30) days after the Employee’s receipt of a written notice from the Senior Vice President, Group Head, Research and Molecular Diagnostics specifying such failure in reasonable detail, (iii) any material breach by the Employee of the terms of this Agreement, which has not been corrected, if correctable, by the Employee within thirty (30) days after the Employee’s receipt of a written notice from the Senior Vice President, Group Head, Research and Molecular Diagnostics specifying such breach in reasonable detail, (iv) commission of a misdemeanor which causes material injury to the business, reputation or financial condition of the Company, (v) commission of a felony or (vi) commission of an act which a majority of the Board determines to constitute insubordination. As used in this Agreement, the term “Good Reason” shall mean the voluntary termination of employment by the Employee with the Company within sixty (60) days after the occurrence of any of the following events, without the Employee’s express written consent: (i) the reduction of the Employee’s Annual Salary, or (ii) any material breach by the Company of the terms of this Agreement which has not been corrected by the Company within thirty (30) days after the Company’s receipt of written notice from the Employee of such breach.

 

4.3            Termination Without Cause or for Good Reason. If the Company terminates the Employee at any time without Cause or if Employee terminates for good reason, the Company shall be obligated to (i) pay the Employee any accrued and unpaid Benefits vested up to the date of termination, (ii) pay the Employee a lump sum equal to one (1) month of the Employee’s then current Annual Salary, and (iii) pay the Employee any annual bonus referred to in Section 2.2 above that would otherwise be due for the fiscal year of termination, prorated to the number of days in the fiscal year for which the Employee was employed, and payable at the same time as the bonus would have otherwise been due had the Employee’s employment not been terminated.

 

8

 

 

ARTICLE V.
MISCELLANEOUS

 

5.1            Notices. Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered personally, sent by nationally-recognized overnight delivery service or sent by certified or registered mail, postage prepaid, return receipt requested, address as set forth below; receipt shall be deemed to occur on the earlier of the date of actual receipt or receipt by the sender of confirmation that the delivery was completed or that the addressee has refused to accept such delivery or has changed its address without giving notice of such change as set forth herein:

 

  (a) if to the Company, to:
   
    Caris Diagnostics, Inc.
    8400 Esters Boulevard, Suite 190
    Irving, TX 75063
    Attention: Chief Executive Officer
   
  (b) if to the Employee, to:
   
    David Spetzler
    [***]
    [***]

 

Either party may change its address for notice hereunder by notice to the other party hereto.

 

5.2            Entire Agreement. This Agreement contains the entire agreement between the parties with respect to the subject matter hereof and supercedes all prior discussions and agreements, written or oral, with respect thereto.

 

5.3            Waivers and Amendments. This Agreement may be amended, suspended, cancelled, renewed or extended, and the terms and conditions hereof may be waived, only by a written instrument signed by both parties or, in the case of a waiver, by the party waiving compliance. No delay on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof. Nor shall any waiver on the part of any party of any such right, power or privilege hereunder, nor any single or partial exercise of any right, power or privilege hereunder, preclude any other or further exercise thereof or the exercise of any other right, power or privilege hereunder.

 

5.4            Assignment. This Agreement shall inure to the benefit of and shall be binding upon the Employee and the Employee’s executor, administrator, heirs, personal representative and assigns, and the Company and its successors and assigns; provided, however, that the Employee shall not be entitled to assign any of the Employee’s rights or delegate any of the Employee’s duties under this Agreement. The Employee agrees that this Agreement may be freely assigned by the Company to any person or entity which succeeds to all or any significant portion of the Company’s assets or Business, whether pursuant to a sale of assets, sale of stock, merger or other similar transaction.

 

5.5            Severability: Construction. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held by a count of competent jurisdiction to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement. Use of the word “including” shall not be limited by the terms following such word. All references to singular or plural terms shall mean the other where appropriate. The term “subsidiary” shall refer to subsidiaries of the Company now existing or hereafter formed or acquired.

 

9

 

 

5.6            Choice of Law. This Agreement shall be governed by, and construed in accordance with the internal laws (as opposed to conflict of laws provisions) of the State of Arizona.

 

5.7            Headings. The section and subsection headings contained in this Agreement are for reference purposes only and shall not effect in any way the meaning or interpretation of this Agreement.

 

5.8            Counterparts. This Agreement may be executed in separate counterparts, each of which when executed and delivered shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

5.9            Indemnification. The Employee shall be entitled to the full benefit of any and all indemnification provisions contained in the Company’s Certificate of Incorporation as amended from time to time, and/or Bylaws, and the Company shall provide indemnification to the Employee to the same extent as it indemnifies any other officer or director of the Company. Irrespective of the provisions in the Company’s Certificate of Incorporation as amended from time to time, or Bylaws, the Company shall indemnify the Employee to the fullest extent provided under Section 145 of the Delaware General Corporation Law, including but not limited to advancement of expenses to the fullest extent provided by such statute.

 

5.10            Dispute Resolution. Except as provided below, in the event of any dispute, claim or disagreement arising out of or in connection with this Agreement, including, without limitation, the negotiation, execution, interpretation, performance or non-performance of this Agreement, the parties shall first submit the dispute, claim or disagreement to non-binding mediation administered by the American Arbitration Association (the “AAA”) in accordance with its Employment Mediation Rules. The place of mediation shall be Phoenix, Arizona. If the dispute, claim or disagreement is not resolved within 30 days after the initial mediation meeting among the parties and the mediator, or if the mediation is otherwise terminated, then either party may submit the dispute, claim or disagreement to binding arbitration administered by the AAA in accordance with the provisions of its Employment Arbitration Rules (the “Rules”) and, except as otherwise provided in this Agreement, such arbitration shall be the sole means of dispute resolution. The place of arbitration shall be Phoenix, Arizona. The arbitration shall be conducted by a panel of three arbitrators selected in accordance with the Rules, unless the parties otherwise agree to one arbitrator. Any mediator or arbitrator selected under this Section 5.10 shall be a practicing attorney experienced in employment agreements and acquisitions and shall not have been employed or engaged by or affiliated with either of the parties or their respective affiliates. Each party shall initially bear its own costs and expenses in connection with any mediation or arbitration hereunder, including, without limitation, its attorneys’ fees, and an equal share of the mediator’s or arbitrator’s and administrative fees of mediation or arbitration. The decision of the arbitrators shall be in writing and shall state the reasons therefore. Judgment upon an arbitration award may be entered in any court of competent jurisdiction and shall be final, binding and non-appealable. Notwithstanding anything in this Section 5.10 to the contrary, each party shall be entitled to seek injunctive or other equitable relief in any court of competent jurisdiction without first submitting the matter to mediation or arbitration in accordance with the provisions of this Section 5.10, even if a similar or related matter has already been referred to meditation or arbitration in accordance with the terms of this Section 5.10. Venue for any action permitted to be brought in court under this Section 5.10 shall be the appropriate state and federal courts located in Maricopa County, Arizona.

 

10

 

 

5.11            Representation. The Employee has consulted with and relied upon independent legal counsel in determining whether to sign this Agreement, and has not relied upon the company nor the company’s counsel to represent the Employee’s interests.

 

[SIGNATURE PAGE FOLLOWS]

 

11

 

 

Upon execution of this Agreement and thereafter, Company covenants and agrees that it shall provide Employee with Confidential Information as defined herein.

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the date first above written.

 

  CARIS LIFE SCIENCES, INC.
   
  By: /s/ Laura I. Johansen
  Name: Laura I. Johansen
  Title: Vice Chairman
   
  EMPLOYEE:
   
  /s/ David Spetzler
  David Spetzler

 

12

 

 

Exhibit 10.8

 

FIRST AMENDMENT
TO
EMPLOYMENT AGREEMENT

 

THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT, dated as of July 27, 2015 (the “Amendment”), to the Employment Agreement, effective February 1, 2010 (the “Agreement”) is entered into by and between Caris Science, Inc (the “Company”), and David Spetzler (“Employee”). Caris and Employee are sometimes referred to individually as a “Party” or collectively as the “Parties”. Terms not otherwise defined herein shall have the meaning described to them in the Agreement.

 

RECITALS

 

WHEREAS, the parties hereto desire to amend the certain terms of the Agreement as hereinafter set forth.

 

WHEREAS, except as amended by the provisions of this Amendment, the terms and provisions contained in the Agreement shall continue to govern the rights and obligations of the parties, and all provisions and covenants in the Agreement shall remain in full force and effect as stated therein. In the event of any conflict between the terms of this Amendment and the Agreement, the terms of the Agreement shall control.

 

NOW, THEREFORE, in consideration of the mutual representations, warranties, covenants, and agreements contained in the Agreement and for other good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:

 

1.The Recital A, including the definition of “Business” is hereby deleted in its entirety and replaced with the following:

 

A.            The Company is engaged in the business of providing diagnostic, therapy guidance, therapeutic products and services, including, without limitation, pathology and work flow solutions, tissue banking, data aggregation and analytics, disease diagnostics and analysis, molecular diagnostics, lab services, basic and developmental research, biomarker or target discovery, commercial development of related products or services, marketing, sale and commercialization that is: (i) directly or indirectly based on, connected with, or relating to lipid encapsulated bodies including intracellular or extracellular microvesicles or exosomes, (ii) directly or indirectly involved or based on use, interrogation, analysis, assessment or preparation of a human sample comprised of blood, urine, saliva or other bodily fluids or any component thereof for use in clinical assessment relating to cancer or other disease; (iii) directly or indirectly utilizes one or more libraries comprises of oligonucleotides or oligonucleotide derivatives to assess one or more molecular components of a biological, chemical or other system; or (iv) directly or indirectly involves molecular profiling of any human-derived sample or specimen and associated therapeutic decision support for any clinical or research purpose relating to or connected with cancer (collectively and singularly, hereinafter referred to as the “Business”).

 

 

 

 

2.Section 1.1 of the Agreement is amended to reflect that Employee now serves in the position of Chief Scientific Officer of the Company, subject to the direction of the Chief Executive Officer or his designee.

 

3.Section 2.1 of the Agreement is hereby deleted in its entirety and replaced with the following:

 

Section 2.1 Annual Salary. The Company shall pay the Employee a salary at the rate of $320,000.00 per year of employment hereunder (the “Annual Salary”). The Annual Salary shall be payable in accordance with the payroll policies of the Company as from time to time in effect applicable law and regulations.

 

4.Section 2.2 of the Agreement is hereby deleted in its entirety and replaced with the following:

 

Section 2.2 Annual Bonus. In addition to the Annual Salary, the Company may award a bonus to the Employee following the end of each fiscal year during the Term based on the Company’s accomplishment of business objectives and audited financial performance for the fiscal year as well as the Employee’s individual contribution to the Company. The performance criteria used to calculate the bonus shall be determined by the Company and is established at a targeted level of fifty percent (50%) of Annual Salary. Any annual bonus payable will be subject to the approval of the Board of Directors of the Company and shall be paid in accordance with the Company’s normal payroll policies.

 

5.Section 2.3 of the Agreement is amended to include the additional provision that long-term incentive program vehicles such as stock options shall automatically vest, to the extent they are not vested for Employee, upon the Company experiencing a change in control of ownership as defined in the Caris Life Sciences, LTD 2012 Incentive Plan.

 

6.Section 4.3 is hereby deleted in its entirety and replaced with the following:

 

Section 4.3 Termination Without Cause or for Good Reason. If the Company terminates the Employee at any time without Cause or if Employee terminates for Good Reason, the Company shall be obligated to (i) pay the Employee any accrued and unpaid Benefits vested up to the date of termination, (ii) pay the Employee a lump sum equal to six (6) months of the Employee’s then current Annual Salary; (iii) six (6) months of company-paid COBRA, and (iv) pay the Employee any annual bonus referred to in Section 2,2 above that would otherwise be due for the fiscal year of termination, prorated to the number of days in the fiscal year for which the Employee was employed, and payable at the same time as the bonus would have otherwise been due had the Executive’s employment not been terminated.

 

[SIGNATURE PAGE FOLLOWS]

 

2

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment on the date first above written.

 

  CARIS LIFE SCIENCES, INC.
   
  By: /s/ David D. Halbert
  Name: David D. Halbert
  Title: Chairman & CEO
   
  EMPLOYEE:
   
  /s/ David Spetzler
  David Spetzler, Ph.D.

 

3

 

 

Exhibit 10.9

EMPLOYMENT AGREEMENT

 

This Employment Agreement (“Agreement”), dated as of May 31, 2018 (the “Effective Date”), is made between Caris Science, Inc., a Texas corporation (the “Company”), and Brian Brille (the “Executive”).

 

A.            The Company and its affiliates are engaged in the business of providing diagnostics products and services, including, without limitation, pathology and work flow solutions, tissue banking, data aggregation and analytics, disease diagnostics and analysis, molecular diagnostics, lab services, basic and development research, biomarker or target discovery, commercial development of related products or services, marketing, sale and commercialization that is (i) directly or indirectly based on, connected with, or relating to lipid encapsulated bodies including intracellular or extracellular microvesicles or exosomes, or (ii) directly or indirectly involved or based on use, interrogation, analysis, assessment or preparation of a human sample comprised of blood, urine, saliva or other bodily fluids or any component thereof for use in clinical assessment relating to cancer or other disease, (iii) directly or indirectly utilizes one or more libraries comprised of oligonucleotides or oligonucleotide derivatives to assess one or more molecular components of a biological, chemical or other system, or (iv) directly or indirectly involves molecular profiling of any human-derived sample or specimen and associated therapeutic decision support for any clinical or research purpose relating to or connected with cancer (collectively and singularly, along with any other business in which the Company engages, is hereinafter referred to as the “Business”).

 

B.            The Company and the Executive desire to enter into this Agreement to govern the employment relationship between them.

 

NOW THEREFORE, in consideration of the foregoing Recitals (which are hereby incorporated by reference), the agreements hereafter set forth and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

ARTICLE I.
EMPLOYMENT AND ACCEPTANCE

 

1.1            Employment by the Company. The Company hereby agrees to employ the Executive for a three (3) year term (the “Term”) commencing on the Effective Date, and expiring three (3) years from the Effective Date. During the Term, the Executive shall serve in the capacity of Vice Chairman, subject to the direction of the Chief Executive Officer of the Company or his designee. Upon expiration of the Term, the Term of this Agreement will automatically renew for successive one (1) year periods unless terminated in accordance with the terms hereof.

 

1.2            Duties and Responsibilities. During the Term, the Executive shall devote the Executive’s best efforts and all of the Executive’s business time and services to the Company, its affiliates and subsidiaries, and shall carry out all Company policies and directives in a manner which will promote and develop the Company’s best interests, provided that Executive shall be permitted to (i) manage Executive’s personal, financial and legal affairs, (ii) participate in trade associations, (iii) serve on the board of directors of not-for-profit or tax-exempt charitable organizations, and (iv) subject to approval by the Board, not to be unreasonably withheld or delayed, serve on the board of directors or similar board of for-profit organizations (provided that service on the boards of directors of up to two for-profit entities shall be deemed approved), in each case, subject to compliance with this Agreement and provided that such activities do not materially interfere with Executive’s performance of Executive’s duties and responsibilities hereunder. The Executive shall have the duties and authority assigned to the Executive by the Chief Executive Officer, and as set forth in the Company’s Bylaws, policies and procedures from time to time in force. Among other things, Executive’s duties and responsibilities will be to:

 

(a)            Lead the Company’s Finance, Accounting, and Business Development teams, with responsibility for identifying, analyzing, and creating strategic plans for the Company; provided, however, that Executive will not have responsibility for preparing or approving the Company’s financial statements, but will have a supervisory role over those responsible for such financial statements;

 

 

 

 

(b)            Undertaking and developing major strategic initiatives and joint ventures; and

 

(c)            Assist the Company with raising capital, mergers and acquisitions, structured deals, debt financing and business development, including resultant work to enact, define, refine, and execute the Company’s strategic priorities.

 

1.3            Company Representations and Warranties. The Company represents and warrants that (i) it has full authority to enter into this Agreement, and (ii) that it is not restricted in any manner from employing the Executive under the terms and conditions set forth in this Agreement.

 

1.4            Acceptance of Employment by the Executive. The Executive hereby accepts such employment and represents and warrants that (i) the Executive has full authority to enter into this Agreement, (ii) the Executive is not restricted in any manner from providing services hereunder or from engaging in the Business and (iii) the Executive is not aware of any situation creating a conflict of interest between the Executive and the Company.

 

Executive agrees to Company performing appropriate due diligence related to his potential Employment (as defined below) and to the on-going Employment. Company may perform any and all background checks it deems necessary and require appropriate certifications prior to employing Executive and at any time during Executive’s Employment. Executive acknowledges Company’s right to perform the appropriate background checks.

 

ARTICLE II.
COMPENSATION AND OTHER BENEFITS

 

2.1            Annual Salary.

 

(a)            The Company shall pay the Executive a salary at the rate of $500,000.00 per year of Employment hereunder (the “Annual Salary”). The Annual Salary shall be payable in accordance with the payroll policies of the Company as from time to time in effect (typically biweekly), less such deductions as shall be required to be withheld by applicable law and regulations. The Chief Executive Officer shall review the Executive’s performance and decide whether to increase, but not decrease, the Executive’s Annual Salary as the Company considers pay adjustments for other executives. Within ten days of the Effective Date, the Company shall pay executive a lump sum cash payment equal to $129,807.69. [Number represents back pay owed to the Executive (50% of Annual Salary from 1/15/2018-3/31/2018 ($52,884.62), and 100% of Annual Salary from 4/1/2018-5/26/2018 ($76,923.08)).]

 

2

 

 

(b)            In accordance with the terms and conditions set out in Exhibit A, the Company shall also pay the Executive additional compensation described in Exhibit A.

 

(c)            Executive will assist Company in developing the biopharma revenues of Company. In this capacity, Executive will focus on the growth of the biopharma customer base. Executive will be eligible to receive a “Pharma Business Development Bonus” which will be based on the growth of the pharma business revenue. The Pharma Business Development Bonus is a one time bonus that will be paid on or prior to March 15, 2019. The Pharma Business Development Bonus will be equal to 5% of the pharma revenue generated above the pharma revenue target for 2018 of $6,300,000. Mergers and acquisitons, joint ventures and other similar strategic alternative transactions shall be excluded from the calculation of the pharma revenue for purposes of calculation of the Pharma Business Development Bonus.

 

2.2            Annual Bonus. In addition to the Annual Salary and compensation described in Exhibit A, the Company may, in its sole discretion, award a bonus to the Executive following the end of each fiscal year during the Term based on the Company’s audited financial performance for the fiscal year as well as the Executive’s individual contribution to the Company. The bonus will be established at a targeted eligible payout rate of one hundred percent (100%) of Annual Salary. Any annual bonus payable will be subject to the approval of the Board and shall be paid in accordance with the Company’s normal payroll policies.

 

2.3            Stock Options and Other Equity Incentives. Subject to approval by the Board of Directors, Executive may be granted stock options or other equity incentives at the sole discretion of the Company. All such options shall be granted pursuant to the terms of the Caris Life Sciences, Ltd. 2012 Incentive Stock Plan and an Option Agreement. Executive shall have the right to exercise any vested options in accordance with the time periods set forth in the Caris Life Sciences, Ltd. 2012 Incentive Stock Plan and the applicable option agreement. Long-term incentive program vehicles such as stock options shall automatically vest, to the extent they are not vested for Executive, upon the Company experiencing a Change of Control as defined in the Caris Life Sciences, LTD 2012 Incentive Plan. Notwithstanding the foregoing, the Company shall grant Executive 10,000,000 options pursuant to the terms of the Share Option Award Agreement attached hereto as Exhibit B within five days of the Effective Date.

 

2.4            Participation in Employee Benefit Plans.

 

(a)            At the Executive’s option, the Company agrees to permit the Executive during the Term, if and to the extent eligible, to participate in any group life, health care or group disability insurance plan, pension plan, similar benefit plan or other so-called “fringe benefits” of the Company (collectively “Benefits”) which may be made generally available to other executive officers of the Company and on such terms as the Benefits are made generally available to such executive officers. This includes the ability for Executive to take vacation and personal business time.

 

3

 

 

(b)            Benefits are effective as of February I, 2018. Executive will be required to pay the employee portion of the Benefits premium for the period of February 1, 2018 through May 31, 2018, which may be deducted from Executive’s first paycheck.

 

2.5            Expenses. The Company shall pay or reimburse the Executive for all business expenses reasonably and necessarily incurred by the Executive during the Term in the performance of the Executive’s services under this Agreement, in each case in accordance with Company policy.

 

ARTICLE III.
RESTRICTIONS

 

3.1            Nondisclosure of Confidential Information.

 

(a)            Recognition of Company Rights: Nondisclosure. For so long as Executive is employed by the Company (whether during the term of this Agreement or after its expiration, the “Employment”), Executive will have access to Confidential Information, including Confidential Information Executive has not accessed prior to the date of this Agreement. Executive recognizes that the Company’s business interests require the fullest practical protection and confidential treatment of the Confidential Information, At all time during the Employment and thereafter, Executive will hold in strictest confidence and will not disclose, use, provide access to, or publish any Confidential Information, except as such disclosure, use or publication may be required in connection with Executive’s services for the Company or required in connection with any dispute between Executive and the Company. Executive agrees that all Confidential Information, whether prepared by Executive or otherwise coming into Executive’s possession, shall remain the exclusive property of the Company during Executive’s Employment with the Company. Executive will obtain the Company’s written approval before publishing or submitting for publication any material (written, oral, or otherwise) that relates to Executive’s work at the Company, any Confidential Information and/or any material that incorporates any Confidential Information. Executive hereby assigns to the Company any rights Executive may have or acquire in such Confidential Information and recognizes that all Confidential Information is the sole property of the Company and its assigns.

 

(b)            Confidential Information. “Confidential Information” means all information, not generally known within the relevant trade group or by the public, including all Work Product (as defined below), intellectual property, business plans, training materials, software programs, promotional materials, illustrations, designs, plans, data bases, sources of supply, customer lists, supplier lists, trade secrets, and all other valuable or unique information and techniques acquired, developed or used by the Company relating to its business, operations, suppliers, information systems, employees and customers, regardless of whether such information is in writing, on computer disk or disk drive or in any other form. Executive expressly acknowledges and agrees that Confidential Information constitutes trade secrets and/or confidential and proprietary business information of the Company (or its subsidiary, or its customers or suppliers, as the case may be). Confidential Information shall not include information which is or becomes generally available to the public other than through disclosure by Executive or by any other person or entity under a duty or obligation to maintain the confidentiality thereof.

 

4

 

 

(c)            No Improper Use of Information of Prior Employers and Others. During the Employment, Executive shall not improperly use or disclose any confidential information or trade secrets, if any, of any former employer or any other person to whom Executive has an obligation of confidentiality, and Executive will not bring onto the premises, or make available to any employees of the Company, any unpublished documents or any property belonging to any former employer or any other person to whom Executive has an obligation of confidentiality unless consented to in writing by the former employer or person. In the performance of Executive’s duties for the Company, Executive will only use information which is (i) generally known and used by persons and expertise comparable to that of Executive, (ii) common knowledge in the industry or otherwise legally in the public domain, or (iii) otherwise provided or developed by the Company. Executive acknowledges that the Company has expressly informed Executive that the Company does not want any access, privilege, benefit or knowledge of such confidential or proprietary information of others. Executive represents and warrants that to Executive’s knowledge Executive has no obligations, legal, in contract, or otherwise, inconsistent with the terms of this Agreement or with Executive’s undertaking Employment with the Company to perform the duties described herein.

 

(d)            Penalties for Violation of Non-Disclosure Policy. In addition to the legal and equitable remedies set forth herein by applicable law, Executive understands that violation of any non-disclosure provision of this Agreement shall be subject to discipline, up to and including discharge.

 

3.2            Assignment of Work Product. Any information or innovations, including, but not limited to, inventions, improvements, methods, technology, programs, customer lists, reports, distribution records, brochures, instructions, manuals, processes, etc., which are, during the course of the Employment, conceived, developed, or improved upon by Executive for use by the Company or any of its subsidiaries, alone or in conjunction with other employees or consultants (collectively, the “Work Product”), shall be the exclusive property of the Company, and during the Employment and at all times thereafter, Executive shall not use, duplicate, reveal or take with Executive any such Work Product or other materials of the Company, other than in furtherance of the performance of his duties to the Company, whether under this Agreement or otherwise. To the extent that any of the Work Product is capable of protection by copyright as a “work made for hire” pursuant to the United States Copyright Act, Executive acknowledges that such Work Product is created within the scope of his Employment and, as such, is property of the Company. To the extent that any such Work Product, whether protected by copyright or otherwise, is not a “work made for hire,” Executive hereby assigns to the Company all rights in such material. Executive hereby agrees to execute any documents at any time reasonably required by the Company in connection with the registration of copyright, patent application or other perfection of the Company’s ownership of the Work Product.

 

3.3            Covenant Not to Compete.

 

(a)            Business Relationships and Goodwill. Executive acknowledges and agrees that as an employee and representative of the Company, Executive is responsible for building and maintaining business relationships and goodwill with current and future physicians, customers, payors, patients and prospects on a personal level. Executive acknowledges and agrees that such responsibility creates a special relationship of trust and confidence between the Company, Executive, and those persons or entities. Executive further acknowledges that such responsibility creates a high risk and opportunity for Executive to misappropriate these relationships and the goodwill existing between the Company and such persons. Executive acknowledges and agrees that it is fair and reasonable for the Company to take steps to protect itself from the risk of such misappropriation.

 

5

 

 

(b)            Consideration. Executive acknowledges and agrees that in exchange for his agreement in Section 3.3(c) below, Executive will receive substantial and valuable consideration from the Company, as set forth herein.

 

(c)            Scope of Noncompetition Obligation. During the Employment, and for a period of one (1) year after the termination of the Employment for any reason, Executive shall not, directly or indirectly, either acting alone, or as a stockholder, partner, associate, creditor, consultant, adviser, franchiser, franchisee, director, officer, owner, employee or agent of any other person or entity, or in any other capacity, engage in or provide services in purpose or function to those Executive provided to Company to any company engaged in the Same Business (as defined below) in the Territory (as defined below); provided, however, the restriction contained in this Section 3.3 shall not prohibit Executive from owning not more than 1% of the outstanding equity of any class of any entity, so long as Executive does not actively participate in the business of such corporation. For purposes of this section:

 

(i)the term “Same Business” shall mean any company that engages or proposes to engage in the Business; and

 

(ii)the term “Territory” shall be defined as all geographic area(s) where Executive performed services, and all geographic areas that Executive managed and/or supervised (either directly or indirectly). If Executive is in a position where Executive’s responsibilities are not geographically limited to an assigned location or territory or where Executive is provided Confidential Information that is not geographically limited to an assigned location or territory (such as, by way of example but not limitation, management positions, research and developers, and engineers), then Territory means every state where Company does business and/or did business during the term of Executive’s Employment, and all places where the Company had plans or reasonable expectations to do business in the future.

 

(d)            No Prohibition on Working. Executive acknowledges and agrees that this Agreement does not restrict Executive’s ability to find employment within any geographical area after the termination of the Employment; provided that Executive is not employed in violation of the noncompetition obligations detailed herein.

 

3.4            Nonsolicitation of Customers. Executive agrees that Executive shall not at any time during the Employment, whether or not initiated by Executive, divert away or attempt to divert away any business from the Company to another company, business, or individual. Further, Executive shall not, for a period of one (1) year following the termination of the Employment for any reason, contact, solicit, attempt to solicit or divert, or attempt to divert business from, either directly or indirectly, any Company Customer which Executive called upon, came into contact with, or became aware of, as a result of Executive’s Employment with Company during the last twelve (12) months Executive’s Employment with Company. “Company Customer” means any person, company, or business that is or was a customer of Company, including but not limited to physicians, payors or other customers.

 

6

 

 

3.5            Nonrecruitment of Employees. Executive agrees that during the Employment and for a period of one (1) year after termination of the Employment for any reason, Executive shall not, on Executive’s own behalf or on behalf of any other person or entity, hire, solicit, seek to hire, or offer employment to any person who was employed by the Company on the date of termination of the Employment, or who is a current employee of the Company. Executive further agrees that Executive will not, in any other manner attempt, directly or indirectly, to influence, induce, or encourage any person who was employed by the Company on the date of termination of the Employment or who is a current employee of the Company to leave the employment of the Company.

 

3.6            Non-Interference with Business Relations. Executive agrees that during the Employment, and for a period of two (2) years after the termination of the Employment for any reason, Executive shall not, directly or indirectly, (a) solicit, advise, persuade or otherwise induce any person to participate in or with any entity or person which provides services comparable to those provided by the Company or by facilities managed or owned by the Company or any of its subsidiaries, (b) do anything, intentionally or recklessly, to discredit or otherwise injure the reputation or goodwill of the Company or any of its affiliates or subsidiaries, (c) solicit, induce or attempt to solicit or induce any customer, employee, independent contractor, distributor, manufacturer or other professional or any other business relation of the Company (or any subsidiary) to cease or reduce the level of business between such business relation and the Company (or any subsidiary), or (d) in any way interfere with the Company’s (or any subsidiary’s) relationship with any customer, employee, independent contractor, distributor, manufacturer or other professional or business relation of the Company or subsidiary.

 

3.7            Reasonableness of Restrictions. Executive acknowledges and agrees that, given the nature of the Business, and the Company’s proposed Business plans, the restrictions imposed upon Executive by this ARTICLE III and the purposes for such restrictions are reasonable and are designed to protect the trade secrets, confidential and proprietary business information and the future success of the Company and its subsidiaries without unduly restricting Executive. Specifically, Executive acknowledges that the restrictions and covenants contained in this ARTICLE III will not prohibit Executive from pursuing Executive’s career upon termination of Executive’s employment relationship with the Company. If, at the time of enforcement of this Agreement, a court shall hold that any of the duration, scope or geographic restrictions stated herein are unreasonable under circumstances then existing, the parties agree (and shall stipulate, if necessary, in an appropriate pleading) that the maximum duration, scope or geographic area reasonable under such circumstances shall be substituted for the stated duration, scope or geographic area. Executive further agrees not to challenge the enforceability or the enforcement of the restrictive covenants in this ARTICLE III.

 

7

 

 

3.8            Severability. Executive agrees that the non-disclosure, non-competition, and non-solicitation covenants set forth in this ARTICLE III each constitute separate agreements independently supported by good and adequate consideration. If a court of competent jurisdiction determines that any restriction in a clause or provision of this ARTICLE III is void, illegal, or unenforceable, the other clauses and provisions of this ARTICLE III shall remain in full force and effect.

 

3.9            Return of the Company Property. When Executive’s Employment terminates for any reason, Executive will promptly (within twenty-four (24) hours) deliver to the Company any and all Confidential Information, drawings, notes, memoranda, specifications, devices, formulas and documents, together with all copies thereof and any other material containing or disclosing any works made for hire, or third party information. Executive further agrees that any property situated on the Company’s premises and owned by the Company including computers, computer disks and computer hard disk drives and other computer storage media, filing cabinets or other work areas, is subject to inspection by the Company personnel at any time with or without notice. Nothing in this Agreement shall prohibit Executive from (i) disclosing information and documents when required by law, subpoena or court order, (ii) disclosing information and documents to Executive’s attorney, financial or tax adviser for the purpose of securing legal, financial or tax advice, (iii) disclosing Executive’s post-employment restrictions in this Agreement in confidence to any potential new employer of Executive, or (iv) retaining, at any time, Executive’s personal correspondence, Executive’s personal contacts and documents related to Executive’s own personal benefits, entitlements and obligations, except where such correspondence, contracts and documents contain Confidential Information.

 

3.10            Notification of New Employer. In the event that the Employment is terminated for any reason, Executive hereby consents to the notification by the Company to Executive’s new employer of Executive’s rights and obligations under this ARTICLE III. In addition, for a period of two (2) years after termination of the Employment, in the event that Executive plans to render services to a company that works in a similar field as the Company, Executive agrees to provide the Company with as much notice as possible of Executive’s intention to join that company or business but in no event will Executive provide less than two weeks notice of that intention; provided, however, the provision of such notice and the Company’s receipt thereof shall not constitute a waiver of any breach of any provision of this Agreement.

 

3.11            Equitable and Other Relief. Executive understands and agrees that, in the event Executive breaches this ARTICLE III, the Company will suffer immediate and irreparable harm that cannot be accurately calculated in monetary damages. Consequently, Executive acknowledges and agrees that the Company shall be entitled to immediate injunctive relief, either by temporary or permanent injunction, to prevent such violation. Executive acknowledges and agrees that such injunctive relief shall be in addition to any other legal or equitable relief to which the Company would be entitled. In addition, the Company shall be entitled to recover its attorneys’ fees and costs from Executive should the Company be required to file suit to enforce its rights under this ARTICLE III, if the Company prevails in such suit.

 

8

 

 

ARTICLE IV.
TERMINATION

 

4.1            Upon Death or Disability. This Agreement shall terminate upon the Executive’s death or Disability. For purposes of this Agreement, “Disability” shall mean physical or mental disability of the Executive resulting in the Executive’s inability to perform substantially all of the essential functions of the Executive’s duties and responsibilities with the Company for (i) a period of twelve (12) consecutive weeks, or (ii) for shorter periods aggregating twelve (12) weeks during any twelve-month period. If this Agreement terminates as a result of the Executive’s death or Disability, the Company’s obligation to the Executive or the Executive’s estate shall be limited to the payment of accrued and unpaid Annual Salary earned and any accrued and unpaid Benefits vested up to the date of termination, and in the event of Disability, any disability benefits to which the Executive is entitled hereunder. In addition, upon termination due to death or Disability, the Company shall pay the Executive or the Executive’s estate any annual bonus referred to in Section 2.2 above that would otherwise be due for the fiscal year of termination, prorated to the number of days in the fiscal year for which the Executive was employed, and payable at the same time as the bonus would have otherwise been due had the Executive’s Employment not been terminated.

 

4.2            Termination for Cause or Voluntary Termination. If the Company terminates the Executive at any time for Cause or if the Executive terminates the Executive’s Employment at any time other than for Good Reason, the Company’s obligation to the Executive shall be limited solely to the payment of accrued and unpaid Annual Salary and any accrued but unpaid Benefits vested earned up to the date of termination. As used in this Agreement, the term “Cause” shall mean any of the following: (i) the Executive’s commission of an act involving dishonesty, lack of loyalty or breach of fiduciary responsibility involving the Company or any affiliate or successor thereof which causes material injury to the business, reputation or financial condition of the Company, (ii) continued and material failure of the Executive to perform the Executive’s duties and responsibilities, which has not been corrected by the Executive within thirty (30) days after the Executive’s receipt of a written notice from the Company specifying such failure in reasonable detail, (iii) any material breach by the Executive of the terms of this Agreement, which has not been corrected, if correctable, by the Executive within thirty (30) days after the Executive’s receipt of a written notice from the Company specifying such breach in reasonable detail, (iv) commission of a misdemeanor which causes material injury to the business, reputation or financial condition of the Company, or (v) commission of a felony. As used in this Agreement, the term “Good Reason” shall mean the voluntary termination of Employment by the Executive with the Company within sixty (60) days after the occurrence of any of the following events, without the Executive’s express written consent: (i) the reduction of the Executive’s Annual Salary, (ii) relocation of the Executive’s primary work location in New York City (provided, Executive may be required to work in Irving, Texas no more than 2 days a week) to a new location greater than 50 miles away, or (iii) any material breach by the Company of the terms of this Agreement which has not been corrected by the Company within thirty (30) days after the Company’s receipt of written notice from the Executive of such breach.

 

4.3            Termination Without Cause or for Good Reason. If the Company terminates the Executive at any time without Cause or if Executive terminates for Good Reason, the Company shall be obligated to (i) pay the Executive any accrued and unpaid Benefits vested up to the date of termination, (ii) pay the Executive a lump sum equal to six (6) months of the Executive’s then current Annual Salary, (iii) six (6) months of company-paid COBRA, and (iv) pay the Executive any annual bonus referred to in Section 2.2 above that would otherwise be due for the fiscal year of termination, prorated to the number of days in the fiscal year for which the Executive was employed, and payable at the same time as the bonus would have otherwise been due had the Executive’s Employment not been terminated. Further, if the Company terminates the Executive at any time without Cause, the options awarded to the Executive under the Share Option Award Agreement shall immediately vest.

 

9

 

 

ARTICLE V.
MISCELLANEOUS

 

5.1            Notices. Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered personally, sent by nationally-recognized overnight delivery service or sent by certified or registered mail, postage prepaid, return receipt requested, address as set forth below; receipt shall be deemed to occur on the earlier of the date of actual receipt or receipt by the sender of confirmation that the delivery was completed or that the addressee has refused to accept such delivery or has changed its address without giving notice of such change as set forth herein:

 

  (a) if to the Company, to:
   
    Caris Science, Inc.
    750 West John Carpenter Freeway, Suite 800
    Irving, TX 75039
    Attention: General Counsel
   
  (b) if to the Executive, to:
   
    Brian Brille
    [***]
    [***]

 

Either party may change its address for notice hereunder by notice to the other party hereto.

 

5.2            Entire Agreement. This Agreement contains the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior discussions and agreements, written or oral, with respect thereto.

 

5.3            Waivers and Amendments. This Agreement may be amended, suspended, cancelled, renewed or extended, and the terms and conditions hereof may be waived, only by a written instrument signed by both parties or, in the case of a waiver, by the party waiving compliance. No delay on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof. Nor shall any waiver on the part of any party of any such right, power or privilege hereunder, nor any single or partial exercise of any right, power or privilege hereunder, preclude any other or further exercise thereof or the exercise of any other right, power or privilege hereunder.

 

10

 

 

5.4            Assignment. This Agreement shall inure to the benefit of and shall be binding upon the Executive and the Executive’s executor, administrator, heirs, personal representative and assigns, and the Company and its successors and assigns; provided, however, that the Executive shall not be entitled to assign any of the Executive’s rights or delegate any of the Executive’s duties under this Agreement. The Executive agrees that this Agreement may be freely assigned by the Company to any person or entity which succeeds to all or any significant portion of the Company’s assets or Business, whether pursuant to a sale of assets, sale of stock, merger or other similar transaction.

 

5.5            Severability: Construction. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held by a court of competent jurisdiction to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement. Use of the word “including” shall not be limited by the terms following such word. All references to singular or plural terms shall mean the other where appropriate. The term “subsidiary” shall refer to subsidiaries of the Company now existing or hereafter formed or acquired.

 

5.6            Choice of Law. This Agreement shall be governed by, and construed in accordance with the internal laws (as opposed to conflict of laws provisions) of the State of Texas.

 

5.7            Headings. The section and subsection headings contained in this Agreement are for reference purposes only and shall not effect in any way the meaning or interpretation of this Agreement.

 

5.8            Counterparts. This Agreement may be executed in separate counterparts, each of which when executed and delivered shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

5.9            Indemnification. The Executive shall be entitled to the full benefit of any and all indemnification provisions contained in the Company’s Certificate of Incorporation as amended from time to time, and/or Bylaws, and the Company shall provide indemnification to the Executive to the same extent as it indemnifies any other officer or director of the Company. Irrespective of the provisions in the Company’s Certificate of Incorporation as amended from time to time, or Bylaws, the Company shall indemnify the Executive to the fullest extent provided under applicable law, including but not limited to advancement of expenses to the fullest extent provided by such applicable law(s). As an employee, Executive is also covered under Company’s D&O insurance policies.

 

5.10            Dispute Resolution. Except as provided below, this dispute resolution provision applies to any dispute, claim or disagreement arising out of or in connection to Executive’s Employment with Company, and including any dispute arising out of or in connection with this Agreement, including, without limitation, the negotiation, execution, interpretation, performance or non-performance of this Agreement. This dispute resolution provision applies to a covered dispute that Employer may have against Company or that Executive may have against Company or its officers, directors, shareholders, members, owners, employees, managers, agents and attorneys. This provision does not apply to claims for worker’s compensation, state disability insurance and unemployment insurance benefits; however, it does apply to retaliation claims based upon seeking such benefits. This provision does not apply to claims for employee benefits under any benefit plan covered by the Executive Retirement Income Security Act of 1974 or funded by insurance. This provision does not apply to any claim that an applicable federal statute or applicable federal Executive Order expressly states cannot be arbitrated. Nothing in this Agreement prevents the making of a report to or filing a claim or charge with a government agency, including without limitation the Equal Employment Opportunity Commission, U.S. Department of Labor, Securities and Exchange Commission, National Labor Relations Board, or Office of Federal Contract Compliance Programs. Nothing in this Agreement prevents the investigation by a government agency of any report, claim or charge otherwise covered by this Agreement. This Agreement also does not prevent federal administrative agencies from adjudicating claims and awarding remedies based on those claims, even if the claims would otherwise be covered by this Agreement. Nothing in this Agreement prevents or excuses a party from satisfying any conditions precedent and/or exhausting administrative remedies under applicable law before bringing a claim in arbitration.

 

11

 

 

The parties shall first submit the dispute, claim or disagreement to non-binding mediation administered by the American Arbitration Association (the “AAA”) in accordance with its Employment Mediation Rules. The place of mediation shall be Dallas, Texas. If the dispute, claim or disagreement is not resolved within 30 days after the initial mediation meeting among the parties and the mediator, or if the mediation is otherwise terminated, then either party may submit the dispute, claim or disagreement to binding arbitration administered by the AAA in accordance with the provisions of its Commercial Arbitration Rules (the “Rules”) and, except as otherwise provided in this Agreement, such arbitration shall be the sole means of dispute resolution. The place of arbitration shall be Dallas, Texas. The arbitration shall be conducted by one arbitrator selected in accordance with the Rules, unless the parties otherwise agree. Any mediator or arbitrator selected under this Section 5.10 shall be a practicing attorney experienced in employment agreements and acquisitions and shall not have been employed or engaged by or affiliated with either of the parties or their respective affiliates. Each party shall initially bear its own costs and expenses in connection with any mediation or arbitration hereunder, including, without limitation, its attorneys’ fees, and an equal share of the mediator’s or arbitrator’s and administrative fees of mediation or arbitration. The decision of the arbitrator shall be in writing and shall state the reasons therefore. Judgment upon an arbitration award may be entered in any court of competent jurisdiction and shall be final, binding and non-appealable. The arbitrator, and not any federal, state, or local court or agency, shall have the exclusive authority to resolve any dispute relating to the interpretation, applicability, enforceability, or formation of this section. However, the preceding sentence shall not apply to the “Class Action Waiver” described below. Regardless of anything else in this Agreement and/or the AAA rules or procedures, any dispute relating to the interpretation, applicability, enforceability or formation of the Class Action Waiver may only be determined by a court and not an arbitrator.

 

Executive and Company agree to bring any claim or dispute in arbitration on an individual basis only, and not as a class or collective action; Executive and Company waive any right for a dispute or claim to be brought, heard, or decided as a class or collective action, and the arbitrator has no power or authority to preside over a class or collective action (“Class Action Waiver”).

 

Notwithstanding anything in this Section 5.10 to the contrary, each party shall be entitled to seek injunctive or other equitable relief in any court of competent jurisdiction without first submitting the matter to mediation or arbitration in accordance with the provisions of this Section 5.10, even if a similar or related matter has already been referred to mediation or arbitration in accordance with the terms of this Section 5.10. Venue for any action permitted to be brought in court under this Section 5.10 shall be the appropriate state and federal courts located in Dallas County, Texas.

 

12

 

 

5.11            Disclosures. Nothing in this Agreement prohibits Executive from reporting an event that Executive reasonably and in good faith believes is a violation of law to the relevant law-enforcement agency (such as the Securities and Exchange Commission, Equal Employment Opportunity Commission, or Department of Labor), or from cooperating in an investigation conducted by such a government agency. This may include disclosure of trade secret or confidential information within the limitations permitted by the 2016 Defend Trade Secrets Act (DTSA). Executive is hereby provided notice that under the DTSA, (1) no individual will be held criminally or civilly liable under Federal or State trade secret law for the disclosure of a trade secret (as defined in the Economic Espionage Act) that: (A) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and made solely for the purpose of reporting or investigating a suspected violation of law; or, (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal so that it is not made public; and, (2) an individual who pursues a lawsuit for retaliation by an employer for reporting a suspected violation of the law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal, and does not disclose the trade secret, except as permitted by court order.

 

5.12            Representation. The Executive has consulted with and relied upon independent legal counsel in determining whether to sign this Agreement, and has not relied upon the company nor the company’s counsel to represent the Executive’s interests.

 

13

 

 

Upon execution of this Agreement and thereafter, Company covenants and agrees that it shall provide Executive with Confidential Information as defined herein.

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the date first above written.

 

  CARIS LIFE SCIENCES, INC.
   
  By: /s/ David D. Halbert
  Name: David D. Halbert
  Title: Chief Executive Officer
   
  EMPLOYEE:
   
  /s/ Brian Brille
  Brian Brille

 

14

 

 

Exhibit A

 

 

 

 

Exhibit 10.10

 

Caris Life Sciences, Inc.
Executive and Director Change in Control Plan

 

1.             Purpose. The purpose of the Caris Life Sciences, Inc. Executive and Director Change in Control Plan (the “Plan”) is to reduce the potential distraction of key executive management personnel and non-employee directors of Caris Life Sciences, Inc. (together with its subsidiaries, the “Company”) in the face of the uncertainty that a potential Change in Control could trigger by protecting the equity-based awards granted to selected executives and non-employee directors of the Company in the event of a Change in Control.

 

2.             Definitions. For purposes of this Plan, the following words and phrases have the meanings specified below:

 

2.1.             “Administrator” has the meaning set forth in Section 3.

 

2.2.             “Change in Control” has the meaning set forth in the Caris Life Sciences, Inc. 2020 Incentive Plan.

 

2.3.             “Change in Control Date” means the date on which a Change in Control is consummated.

 

2.4.             “Code” means the U.S. Internal Revenue Code of 1986, as amended, and any successor thereto.

 

2.5.             “Company” has the meaning set forth in Section 1.

 

2.6.             “Covered Payments” has the meaning set forth in Section 6.

 

2.7.             “Eligible Executives and Directors” has the meaning set forth in Section 4.

 

2.8.             “Excise Tax” has the meaning set forth in Section 6.

 

2.9.             “Participant” has the meaning set forth in Section 4.

 

2.10.           “Plan” has the meaning set forth in Section 1.

 

3.Administration. The Plan shall be administered by the Board of Directors of the Company or a committee of the Board of Directors of the Company that is designated by the Board of Directors of the Company (the “Administrator”). Subject to the provisions of the Plan, the Administrator shall have exclusive authority to interpret and administer the Plan, to establish, amend and rescind appropriate rules and regulations relating to the Plan, to delegate some or all of its authority under the Plan to the extent permitted by law, and to take all such steps and make all such determinations in connection with the Plan and the benefits granted pursuant to the Plan as it may deem necessary or advisable. Any decision of the Administrator in the interpretation and administration of the Plan, as described herein, shall lie within its sole and absolute discretion and shall be final, conclusive and binding on all parties concerned.

 

4.Eligibility. Eligibility under the Plan is limited to certain senior executives, officers and non-employee directors of the Company as determined by the Administrator from time to time (“Eligible Executives and Directors”). The Administrator in its sole discretion will select and notify those Eligible Executives and Directors who will participate in the Plan (“Participants”).

 

1

 

 

5.Effect of Change in Control on Equity Awards. Immediately prior to the consummation of a Change in Control and subject to the execution of a general release of claims in favor of the Company and in a form acceptable to the Company, all equity-based compensation awards granted to Participants under the Company’s equity incentive compensation plans that are outstanding awards as of the Change in Control Date shall vested in full to the extent not yet vested, with all restrictions relating to any such awards lifted immediately the consummation of the Change in Control.

 

6.Section 280G. Notwithstanding any other provision of this Plan or any other plan, arrangement or agreement to the contrary, if any of the payments or benefits provided or to be provided to a Participant or for Participant’s benefit pursuant to the terms of this Plan or otherwise (“Covered Payments”) constitute parachute payments within the meaning of Section 280G of the Code and would, but for this Section 6, be subject to the excise tax imposed under Section 4999 of the Code (or any successor provision thereto) or any similar tax imposed by state or local law or any interest or penalties with respect to such taxes (collectively, the “Excise Tax”), then the Covered Payments shall be payable either (i) in full or (ii) reduced to the minimum extent necessary to ensure that no portion of the Covered Payments is subject to the Excise Tax, whichever of the foregoing (i) or (ii) results in Participant’s receipt on an after-tax basis of the greatest amount of benefits after taking into account the applicable federal, state, local and foreign income, employment and excise taxes (including the Excise Tax). Any such reduction shall be made consistent with the requirements of Section 409A of the Code. Any determination required under this Section 6 shall be made in writing in good faith by an independent accounting firm, the fees and expenses of which shall be the responsibility of the Company.

 

7.Section 409A. Notwithstanding anything to the contrary contained in this Plan, the payments and benefits provided under this Plan are intended to comply with or be exempt from Section 409A of the Code, and the provisions of this Plan shall be interpreted or construed with that intent. The Administrator may modify the payments and benefits under this Plan at any time solely as necessary to avoid adverse tax consequences under Section 409A; provided, however, that this Section 7 shall not create any obligation on the part of the Administrator to make such modifications or take any other action. It is intended that the terms “termination” and “termination of employment” as used herein shall constitute a “separation from service” within the meaning of Section 409A. Anything in the Plan to the contrary notwithstanding, each payment of compensation made to a Participant shall be treated as a separate and distinct payment from all other such payments for purposes of Section 409A. Anything in the Plan to the contrary notwithstanding, if a Participant is a “specified employee” (within the meaning of Treasury Regulation Section 1.409A-1(i)) on the date of Participant’s termination of employment, then any payment or benefit that would be considered “nonqualified deferred compensation” within the meaning of Section 409A that such Participant is entitled to receive upon termination of employment and that otherwise would be payable during the six-month period immediately following Participant’s termination of employment shall instead be paid or made available on the first day of the seventh month following Participant’s termination of employment (or, if earlier, the date of Participant’s death). With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Section 409A: (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit; (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year; and (iii) such payments shall be made on or before the last day of Participant’s taxable year following the taxable year in which the expense occurred, or such earlier date as required hereunder.

 

8.Withholding. The Company shall be entitled to withhold from payments to or on behalf of Participant taxes and other authorized deductions.

 

2

 

 

9.Governing Law. The laws of the State of Texas shall govern all questions concerning the construction, validity and interpretation of this Plan. Participant hereby irrevocably waives all right to trial by jury in any action, proceeding or counterclaim arising out of or relating to this Plan.

 

10.Amendment and Modification. Prior to a Change in Control, this Plan and its Exhibits may be modified, amended or terminated at any time by the Administrator without notice to Participants. Following the consummation of a Change in Control, the Plan including its Exhibits shall not be discontinued, terminated or amended in any manner.

 

11.No Employment Rights. Neither this Plan nor the benefits hereunder shall be a term of the employment of any employee, and the Company shall not be obligated in any way to continue the Plan. The terms of this Plan shall not give any employee the right to be retained in the employment of the Company.

 

12.Effective Date. This Plan shall become effective as of the date of its adoption (the “Effective Date”).

 

3

 

 

Exhibit 10.11

 

Non-Employee Director Compensation Program

 

Effective as of January 1, 2025

 

Each member of the Board of Directors (the “Board”) of Caris Life Sciences, Inc. (together with its affiliates, the “Company”) who is not either (a) an employee of the Company or (b) an employee of a professional investor of the Company (each, a “Director”) shall receive compensation in accordance with this Non-Employee Director Compensation Program (this “Program”) during such Director’s period of service as a member of the Board.

 

Cash Compensation:

 

Annual Cash Retainer. $50,000 per calendar year. For the avoidance of doubt, the lead independent director retainer and committee retainers described below shall be payable in addition to the annual cash retainer.

 

Lead Independent Director Retainer. If any, $30,000 per calendar year.

 

Committee Member Retainers. $12,500 per calendar year while a Director serves on the Audit Committee of the Board. $9,000 per calendar year while a Director serves on the Compensation Committee of the Board. $6,000 per calendar year while a Director serves on the Nominating and Governance Committee of the Board.

 

Committee Chair Retainers. $25,000 per calendar year while a Director serves as the Chairperson of the Audit Committee. $18,000 per calendar year while a Director serves as the Chairperson of the Compensation Committee. $12,000 per calendar year while a Director serves as the Chairperson of the Nominating and Governance Committee. For the avoidance of doubt, the Committee Chair Retainers are payable in lieu of the Committee Member Retainers.

 

Election of Shares in Lieu of Cash. A Director may elect to receive any cash retainer, or any specified portion thereof, in shares of the Company’s common stock (“Shares”), provided such election is made prior to the later of (x) 30 days following such Director’s initial election to the Board or (y) January 1 of the calendar year with respect to which the annual cash retainer relates. If a Director elects to receive Shares in lieu of cash, the number of Shares that will be issued to such Director for a relevant quarter will be calculated based on the price per Share equal to the ten trading day average of the daily volume weighted average price per Share through and including the grant date.

 

Payment Timing. All retainers are payable in four quarterly installments in cash, delivered as soon as practicable following the last day of the applicable quarter, but in no event later than 30 days following the end of the applicable quarter; provided that, any Shares elected in lieu of cash will be delivered as determined by the Company for administrative convenience, but in all events by March 15 of the calendar year following the calendar year for which the retainer was earned.

 

Limitation. The annual compensation for a Director shall not exceed $1,000,000 for a calendar year, taking together all cash retainers and annual equity retainers (using grant date fair value) paid or granted to a Director for a calendar year.

 

Proration. All cash retainers will be pro-rated for any partial year of service, including in the year of a Director’s initial election, if applicable.

 

 

 

Equity Compensation:

 

Annual Equity Retainer. An annual grant of time-vested restricted stock units (“RSUs”) pursuant to the Caris Life Sciences, Inc. 2020 Incentive Plan or a successor plan, as applicable (the “Incentive Plan”) with a grant date fair value of $300,000 and subject to the terms of the Incentive Plan and an Award Agreement thereunder. These RSUs will vest on the first anniversary of the grant date, provided that if a Director serves through the day immediately prior to the next annual shareholders meeting occurring after the grant date, such Director’s RSUs shall remain outstanding and shall be deemed to vest on the first anniversary of the grant date, and provided further, that in the case of the 2025 annual equity retainer RSUs, such RSUs will not be eligible to vest until the occurrence of the Company’s 2026 annual meeting.

 

Initial Equity Grant. Unless otherwise determined by the Board, upon initial election to the Board, a grant of RSUs pursuant to the Incentive Plan with a grant date fair value of $500,000 and subject to the terms of the Incentive Plan and an Award Agreement thereunder. These RSUs will vest ratably in three equal annual installments on the first three anniversaries of the grant date.

 

Equity Granted Prior to the Initial Public Offering. Notwithstanding the foregoing, any RSUs granted to a Director prior to the effectiveness of the Company’s initial public offering (whether resulting from the annual equity retainer or the initial equity grant) shall not vest prior to the earlier of (x) the effective date of the Company’s initial public offering or (y) the consummation of a “change in control” (as defined in the Incentive Plan).

 

Equity Compensation Grant Timing and Settlement. Annual equity retainer RSUs, other than those granted to Directors in their initial year of service and in 2025, will be granted each year on the Company’s first regularly scheduled grant date on or immediately following the Company’s annual meeting for such year and will have a service commencement date of the annual meeting. Initial equity grant RSUs and annual equity retainer RSUs granted to Directors in their initial year of service after 2025 will be granted on the Company’s first regularly scheduled grant date on or immediately following the Director’s start date and will have a service commencement date of the start date. The 2025 annual equity retainer RSUs will be granted on the Company’s first regularly scheduled grant date in 2025 and have a service commencement date of January 1, 2025. Shares resulting from the settlement of any RSUs will be delivered as determined by the Company for administrative convenience, but in all events by March 15 of the calendar year following the calendar year in which the applicable vesting date occurred.

 

Taxes:

 

Directors are responsible for all taxes arising from any payments made pursuant to the terms of this Program and, except where required by law, the Company will not withhold taxes with respect to such payments.

 

2

 

 

Exhibit 10.12

 

INDEMNIFICATION And Advancement AGREEMENT

 

This Indemnification and Advancement Agreement (“Agreement”) is made as of ________ __, 20__ by and between Caris Life Sciences, Inc., a Texas corporation (the “Company”), and ______________, [a member of the Board of Directors/an officer/an employee/an agent] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering indemnification and advancement of expenses.

 

RECITALS

 

WHEREAS, the Board of Directors of the Company (the “Board”) believes that highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers, or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification and advancement of expenses against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation, or both;

 

WHEREAS, the Board has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities. Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors, officers, and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself. The Company’s Amended and Restated Bylaws (the “Bylaws”) and Amended and Restated Certificate of Formation (the “Certificate of Formation”) permit or require the Company to provide for the indemnification of the officers and directors of the Company. Indemnitee may also be entitled to mandatory indemnification pursuant to the Texas Business Organizations Code (as amended from time to time, the “TBOC”). The indemnification provisions set forth in the Bylaws, the Certificate of Formation, and the TBOC are not exclusive, and thereby contemplate that contracts may be entered into between the Company and its directors, officers, and other persons with respect to indemnification and advancement of expenses;

 

WHEREAS, the uncertainties relating to such insurance, to indemnification, and to advancement of expenses may increase the difficulty of attracting and retaining such persons;

 

WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company and its shareholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;

 

 

 

 

WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified;

 

WHEREAS, this Agreement is a supplement to, and in furtherance of, the Bylaws, the Certificate of Formation and any resolutions adopted pursuant thereto, as well as any rights of Indemnitee under the TBOC and under any directors’ and officers’ liability or other insurance policy, and is not a substitute therefor, and does not diminish or abrogate any rights of Indemnitee thereunder; and

 

WHEREAS, Indemnitee does not regard the protection available under the Bylaws, the Certificate of Formation, the TBOC, and available insurance as adequate in the present circumstances, and may not be willing to serve or continue to serve as [a/an] [officer/director/employee/agent] without adequate additional protection, and the Company desires Indemnitee to [serve / continue to serve] in such capacity. Indemnitee is willing to [serve / continue to serve] and to take on additional service for or on behalf of the Company on the condition that Indemnitee be so indemnified and be advanced expenses.

 

NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:

 

Section 1.               Services to the Company. Indemnitee agrees to [serve/continue to serve] as [a/an] [director/officer/employee/agent] of the Company. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law). This Agreement does not create any obligation on the Company to continue Indemnitee in such position and is not an employment contract between the Company (or any of its subsidiaries or any Enterprise (as defined below)) and Indemnitee.

 

Section 2.               Definitions. As used in this Agreement:

 

(a)            “Agent” means any person who is authorized by the Company or an Enterprise to act for or represent the interests of the Company or an Enterprise, respectively.

 

(b)            “Beneficial Owner” has the meaning given to such term in Rule 13d-3 under the Exchange Act (as defined below); provided, however, that Beneficial Owner excludes any Person otherwise becoming a Beneficial Owner by reason of the shareholders of the Company approving a merger of the Company with another entity.

 

(c)            “Business Court” means the Business Court in the First Business Court Division of the State of Texas located in Dallas, Texas.

 

(d)            A “Change in Control” means the occurrence after the date of this Agreement of any of the following events:

 

i.              Acquisition of Stock by Third Party. Any Person (as defined below) becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing fifteen percent (15%) or more of the combined voting power of the Company’s then outstanding securities unless the change in relative beneficial ownership of the Company’s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors;

 

-2-

 

 

ii.             Change in Board of Directors. During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections 2(d)(i), 2(d)(iii) or 2(d)(iv) of this Agreement) whose election by the Board or nomination for election by the Company’s shareholders was approved by a vote of at least a majority of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board;

 

iii.            Corporate Transactions. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation that would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty percent (50%) of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving entity;

 

iv.            Liquidation. The approval by the shareholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets; and

 

v.            Other Events. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act, whether or not the Company is then subject to such reporting requirement.

 

(e)            “Corporate Status” describes the status of a person who is or was acting as a director, officer, employee, or Agent of the Company or an Enterprise.

 

(f)            “Disinterested Director” means a director of the Company who is both “disinterested” and “independent” as such terms are defined in Sections 1.003 and 1.004 of the TBOC.

 

(g)            “Enterprise” means any other corporation, partnership, joint venture, trust, other enterprise or non-profit entity, including any employee benefit plan, for which Indemnitee is or was serving at the request of the Company as a director, officer, employee, or Agent.

 

(h)            “Exchange Act” means the Securities Exchange Act of 1934, as amended from time to time.

 

-3-

 

 

(i)            “Expenses” includes all reasonable attorneys’ fees and all judgments, penalties, settlements, fines, retainers, court costs, transcript costs, fees and other costs of experts and other professionals, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, excise taxes and penalties, including excise taxes assessed against Indemnitee with respect to an employee benefit plan, and all other disbursements, obligations, or expenses of the types customarily incurred in connection with preparing for or participating in a Proceeding (as defined below). Expenses also include (i) Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent, and (ii) for purposes of Section 14(e) of this Agreement only, Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee’s rights under this Agreement, by litigation or otherwise.

 

(j)            “Independent Counsel” means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the five years prior to its, his or her selection or appointment has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements) or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” does not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel.

 

(k)            “Person” has the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act; provided, however, that Person excludes (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any entity owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of stock of the Company.

 

(l)            “Proceeding” includes any threatened, pending or completed action, suit, claim, counterclaim, cross claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing, or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, legislative, regulatory, or investigative (formal or informal) nature, including any appeal therefrom, in which Indemnitee was, is, or will be involved as a party, potential party, non-party witness, or otherwise by reason of Indemnitee’s Corporate Status or by reason of any action taken by Indemnitee (or a failure to take action by Indemnitee) or of any action (or failure to act) on Indemnitee’s part while acting pursuant to Indemnitee’s Corporate Status, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification, reimbursement, or advancement of Expenses can be provided under this Agreement. A Proceeding also includes a situation the Indemnitee believes in good faith may lead to, or culminate in, the institution of a Proceeding.

 

-4-

 

 

Section 3.               Indemnity in Third-Party Proceedings. Subject to Section 9 and Section 12 of this Agreement, to the greatest extent permitted by applicable law, the Company will indemnify Indemnitee in accordance with the provisions of this Section 3 if Indemnitee is, or is threatened to be made, a respondent or defendant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 3, the Company will indemnify Indemnitee to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with, or in respect of, such Expenses, judgments, fines and amounts paid in settlement) actually incurred by Indemnitee or on Indemnitee’s behalf in connection with such Proceeding or any claim, issue, or matter therein, if Indemnitee acted in good faith and reasonably believed that Indemnitee’s conduct in his or her official capacity was in the Company’s best interests or that Indemnitee’s conduct was otherwise not opposed to the Company’s best interests, as applicable, and, in the case of a criminal Proceeding, did not have a reasonable cause to believe that Indemnitee’s conduct was unlawful.

 

Section 4.               Indemnity in Proceedings by or in the Right of the Company. Subject to Section 9 and Section 12 of this Agreement, to the greatest extent permitted by applicable law, the Company will indemnify Indemnitee in accordance with the provisions of this Section 4 if Indemnitee is, or is threatened to be made, a respondent or defendant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 4, the Company will indemnify Indemnitee to the fullest extent permitted by applicable law against all Expenses actually incurred by Indemnitee or on Indemnitee’s behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and reasonably believed that Indemnitee’s conduct in his or her official capacity was in the Company’s best interests or that Indemnitee’s conduct was otherwise not opposed to the Company’s best interests, as applicable. The Company will not indemnify Indemnitee for Expenses under this Section 4 related to any claim, issue, or matter in a Proceeding for which Indemnitee has been finally adjudged by a court to be liable to the Company for (i) willful or intentional misconduct in the performance of Indemnitee’s duty to the Company, (ii) breach of Indemnitee’s duty of loyalty owed to the Company or (iii) an act or omission not committed in good faith that constitutes a breach of a duty owed by Indemnitee to the Company, and all appeals have been exhausted or foreclosed by law.

 

Section 5.               Indemnification for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other provisions of this Agreement, to the fullest extent permitted by applicable law, the Company will indemnify Indemnitee against all Expenses actually incurred by Indemnitee in connection with any Proceeding to the extent that Indemnitee is wholly successful, on the merits or otherwise, in the defense of the Proceeding. If Indemnitee is not wholly successful in the defense of such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues, or matters in such Proceeding, the Company will indemnify Indemnitee against all Expenses actually incurred by Indemnitee or on Indemnitee’s behalf in connection with or related to each successfully resolved claim, issue or matter to the fullest extent permitted by law. For purposes of this Section 5 and without limitation, the termination of any claim, issue, or matter in such a Proceeding by dismissal, with or without prejudice, will be deemed to be a successful result as to such claim, issue, or matter.

 

Section 6.               Indemnification for Expenses of a Witness. Notwithstanding any other provisions of this Agreement, to the fullest extent permitted by applicable law, the Company will indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection with any Proceeding to which Indemnitee is not a party but to which Indemnitee is a witness, deponent, interviewee, or otherwise asked to participate or provide information.

 

-5-

 

 

Section 7.               Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of Expenses, but not, however, for the total amount thereof, the Company will indemnify Indemnitee for the portion thereof to which Indemnitee is entitled.

 

Section 8.               Additional Indemnification. Notwithstanding any limitation in Sections 3, 4, or 5 of this Agreement, for the avoidance of doubt, the Company will indemnify Indemnitee to the fullest extent permitted by applicable law (including but not limited to, the TBOC) if Indemnitee is a party to, or threatened to be made a party to, any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor).

 

Section 9.               Exclusions. Notwithstanding any other provision in this Agreement, the Company is not obligated under this Agreement to indemnify Indemnitee for:

 

(a)            any amount actually paid to or on behalf of Indemnitee under any insurance policy or other indemnity provision, subject to the Company’s compliance with Section 15(b) of this Agreement (for the avoidance of doubt, excluding any excess beyond the amount paid under any insurance policy or other indemnity provision, which shall be subject to indemnification);

 

(b)            an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act or similar provisions of state statutory law or common law;

 

(c)            reimbursement of the Company by the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act);

 

(d)            reimbursement of the Company by Indemnitee of any compensation pursuant to any compensation recoupment or clawback policy adopted by the Board or the compensation committee of the Board, including but not limited to any such policy adopted to comply with stock exchange listing requirements implementing Section 10D of the Exchange Act;

 

(e)            any Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with, or in respect of, such Expenses, judgments, fines and amounts paid in settlement) incurred by Indemnitee in a Proceeding in which Indemnitee has been found liable to the Company or because Indemnitee improperly received a personal benefit (as established by an order, including a judgment or decree of a court, and all appeals of the order are exhausted or foreclosed by law) for:

 

-6-

 

 

i.              willful or intentional misconduct in the performance of Indemnitee’s duty to the Company;

 

ii.             breach of Indemnitee’s duty of loyalty owed to the Company; or

 

iii.            an act or omission not committed in good faith that constitutes a breach of a duty owed by Indemnitee to the Company;

 

(f)            any Proceeding initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Proceeding or part of any Proceeding is to enforce Indemnitee’s rights to indemnification or advancement of Expenses under this Agreement, including a Proceeding (or any part of any Proceeding) initiated pursuant to Section 14 of this Agreement or (ii) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation; or

 

(g)            any Proceeding initiated by the Company against Indemnitee involving the enforcement by the Company of any confidentiality, non-competition, non-solicitation, non-disclosure, non-disparagement or similar restrictive covenant agreements, or the confidentiality, non-competition, non-solicitation, non-disclosure, non-disparagement or similar restrictive covenant provisions of employment, consulting, severance, equity award or similar agreements, in each case to which Indemnitee may be a party with the Company or any of its subsidiaries or any other applicable Enterprise.

 

Section 10.             Advances of Expenses.

 

(a)            Following receipt of a written affirmation by Indemnitee that Indemnitee had a good faith belief the Indemnitee has met the standard of conduct necessary for indemnification under the TBOC and this Agreement, the Company will advance, to the extent not prohibited by law, the Expenses reasonably incurred by Indemnitee in connection with any Proceeding.

 

(b)            The Company will advance the Expenses within forty (40) days after the receipt by the Company of a statement or statements requesting such advances from time to time, whether prior to or after final disposition of any Proceeding eligible for advancement of expenses.

 

(c)            Advances will be unsecured and interest free. Indemnitee hereby undertakes to repay any and all amounts so advanced (without interest) to the extent that it is finally determined that Indemnitee has not met the required standard of conduct or that indemnification is prohibited by Section 8.102 of the TBOC. No other form of undertaking is required other than the execution of this Agreement. The Company will make advances without regard to Indemnitee’s ability to repay the Expenses and without regard to Indemnitee’s ultimate entitlement to indemnification under the other provisions of this Agreement.

 

-7-

 

 

Section 11.             Procedures for Notification of Claim for Indemnification or Advancement; Settlements.

 

(a)            Indemnitee will notify the Secretary of the Company in writing of any Proceeding with respect to which Indemnitee intends to seek indemnification or advancement of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof. Indemnitee will include in the written notification to the Company a description of the nature of the Proceeding and the facts underlying the Proceeding and provide such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of such Proceeding or to advancement of Expenses. Indemnitee’s failure to notify the Company will not relieve the Company from any obligation it may have to Indemnitee under this Agreement, and any delay in so notifying the Company will not constitute a waiver by Indemnitee of any rights under this Agreement. The Secretary of the Company will, promptly upon receipt of such a request for indemnification or advancement, advise the Board in writing that Indemnitee has requested indemnification or advancement.

 

(b)            The Company will be entitled to participate in the Proceeding at its own expense.

 

(c)            The Company shall have no obligation to indemnify Indemnitee under this Agreement for amounts paid in settlement of a Proceeding without the Company’s prior written consent. The Company shall not settle any Proceeding in any manner that would impose any fine, Expense, limitation or other obligation on Indemnitee, or disparage Indemnitee or contain an admission of wrongdoing by Indemnitee, without Indemnitee’s prior written consent. Neither the Company nor Indemnitee shall unreasonably withhold consent to any proposed settlement (it being agreed that Indemnitee’s refusal to consent to a proposed settlement that would in any manner impose any fine, Expense, limitation or other obligation on Indemnitee, or disparage Indemnitee or contain an admission of wrongdoing by Indemnitee, would not be unreasonable).

 

Section 12.             Procedure Upon Application for Indemnification.

 

(a)            Unless a Change in Control has occurred, the determination of Indemnitee’s entitlement to indemnification will be made[ by the Board]1:

 

i.              [by a majority vote of the Disinterested Directors, even though less than a quorum of the Board;

 

ii.             by a committee of one or more Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Board;

 

iii.            if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by written opinion provided by Independent Counsel selected by the Board or a committee thereof, by vote in accordance with subsection(a)(i) or (a)(ii); or

 

 

1 NTD: Applicable for indemnitees other than directors.

 

-8-

 

 

iv.            if so directed by the Board, by vote of the shareholders of the Company, excluding any directors of the Company who are not Disinterested Directors.]2

 

(b)            If a Change in Control has occurred, the determination of Indemnitee’s entitlement to indemnification will be made by written opinion provided by Independent Counsel selected by Indemnitee (unless Indemnitee requests such selection be made by the Board).

 

(c)            The party selecting Independent Counsel pursuant to subsection (a)(iii) or (b) of this Section 12 will provide written notice of the selection to the other party. The notified party may, within ten (10) days after receiving written notice of the selection of Independent Counsel, deliver to the selecting party a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 2 of this Agreement, and the objection will set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected will act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or the Business Court (or the Alternative Courts) has determined that such objection is without merit. If, within thirty (30) days after the later of submission by Indemnitee of a written request for indemnification pursuant to Section 11(a) of this Agreement and the final disposition of the Proceeding, Independent Counsel has not been selected or, if selected, any objection to such selection has not been resolved, either the Company or Indemnitee may petition the Business Court (or the Alternative Courts) for resolution of any objection made by the Company or Indemnitee to the other’s selection of Independent Counsel or for the appointment as Independent Counsel of a person selected by such court or by such other person as such court designates. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 14(a) of this Agreement, Independent Counsel will be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).

 

(d)            Indemnitee will cooperate with the person, persons or entity making the determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons, or entity upon reasonable advance request any documentation or information that is not privileged or otherwise protected from disclosure and that is reasonably available to Indemnitee and reasonably necessary to such determination. The Company will advance and pay any Expenses incurred by Indemnitee in so cooperating with the person, persons or entity making the indemnification determination irrespective of the determination as to Indemnitee’s entitlement to indemnification, and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. The Company promptly will advise Indemnitee in writing of the determination that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been denied and providing a copy of any written opinion provided to the Board by Independent Counsel.

 

(e)            If it is determined that Indemnitee is entitled to indemnification, the Company will make payment to Indemnitee within forty (40) days after such determination.

 

 

2 NTD: Applicable for indemnitees that are directors.

 

-9-

 

 

Section 13.             Presumptions and Effect of Certain Proceedings.

 

(a)            In making a determination with respect to entitlement to indemnification under this Agreement, the person, persons, or entity making such determination will, to the fullest extent not prohibited by law, presume Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 11(a) of this Agreement, and the Company will, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption. Neither the failure of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper under the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, will be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.

 

(b)            If the determination of the Indemnitee’s entitlement to indemnification has not been made pursuant to Section 12 of this Agreement within sixty (60) days after the later of (i) receipt by the Company of Indemnitee’s request for indemnification pursuant to Section 11(a) of this Agreement and (ii) the final disposition of the Proceeding for which Indemnitee requested indemnification (the “Determination Period”), the requisite determination of entitlement to indemnification will, to the fullest extent not prohibited by law, be deemed to have been made and Indemnitee will be entitled to such indemnification absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification or (ii) a prohibition of such indemnification under applicable law; provided, that the Determination Period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation or information relating thereto[; and provided, further, that the Determination Period will not apply if the determination of entitlement to indemnification is to be made by the shareholders pursuant to Section 12(a)(iv) of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such determination the Board has resolved to submit such determination to the shareholders for their consideration at an annual meeting thereof to be held within seventy-five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of shareholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is made thereat]3.

 

(c)            The termination of any Proceeding or of any claim, issue, or matter therein by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, will not (except as otherwise expressly provided in this Agreement) in and of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that Indemnitee’s conduct was unlawful.

 

 

3 NTD: Applicable for indemnitees that are directors.

 

-10-

 

 

(d)            For purposes of any determination of good faith, Indemnitee will be deemed to have acted in good faith if Indemnitee acted based on (i) the records or books of account of the Company, its subsidiaries, or an Enterprise, including financial statements, (ii) information supplied to Indemnitee by the directors or officers of the Company, its subsidiaries, or an Enterprise in the course of their duties, (iii) the advice of legal counsel for the Company, its subsidiaries, or an Enterprise or (iv) information or records given or reports made to the Company or an Enterprise by an independent certified public accountant or by an appraiser, financial advisor or other expert selected with reasonable care by or on behalf of the Company, its subsidiaries, or an Enterprise. Further, Indemnitee will be deemed to have acted in a manner “not opposed to the best interests of the Company,” as referred to in this Agreement if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan. The provisions of this Section 13(d) are not exclusive and do not limit in any way the other circumstances in which the Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement.

 

(e)            The knowledge or actions, or failure to act, of any other person affiliated with the Company or an Enterprise (including, but not limited to, a director, officer, trustee, partner, managing member, Agent or employee) may not be imputed to Indemnitee for purposes of determining Indemnitee’s right to indemnification under this Agreement.

 

Section 14.             Remedies of Indemnitee.

 

(a)            Indemnitee may commence litigation against the Company in the Business Court (or, in the event that the Business Court is not then accepting filings or determines that it lacks jurisdiction, the United States District Court for the Northern District of Texas, or, if that court lacks jurisdiction, the state district courts of Dallas County, Texas (the “Alternative Courts”)) to obtain indemnification or advancement of Expenses provided by this Agreement in the event that (i) a determination is made pursuant to Section 12 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) the Company does not advance Expenses pursuant to Section 10 of this Agreement, (iii) the determination of entitlement to indemnification is not made pursuant to Section 12 of this Agreement within the Determination Period, (iv) the Company does not indemnify Indemnitee pursuant to Section 5 or 6 or the second to last sentence of Section 12(d) of this Agreement within thirty (30) days after receipt by the Company of a written request therefor, (v) the Company does not indemnify Indemnitee pursuant to Section 3, 4, 7, or 8 of this Agreement within thirty (30) days after a determination has been made that Indemnitee is entitled to indemnification, or (vi) in the event that the Company or any other person takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or Proceeding designed to deny, or to recover from, the Indemnitee the benefits provided or intended to be provided to the Indemnitee hereunder. The Company will not oppose Indemnitee’s right to seek any such adjudication.

 

(b)            If a determination is made pursuant to Section 12 of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding commenced pursuant to this Section 14 will be conducted in all respects as a de novo trial on the merits, and Indemnitee may not be prejudiced by reason of that adverse determination. In any judicial proceeding commenced pursuant to this Section 14 the Company will have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be, and will not introduce evidence of the determination made pursuant to Section 12 of this Agreement.

 

-11-

 

 

(c)            If a determination is made pursuant to Section 12 of this Agreement that Indemnitee is entitled to indemnification, the Company will be bound by such determination in any judicial proceeding commenced pursuant to this Section 14 unless (i) Indemnitee made a misstatement of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with Indemnitees’ request for indemnification, or (ii) the Company is prohibited from indemnifying Indemnitee under applicable law.

 

(d)            The Company is, to the fullest extent not prohibited by law, precluded from asserting in any judicial proceeding commenced pursuant to this Section 14 that the procedures and presumptions of this Agreement are not valid, binding, or enforceable and will stipulate in any such court that the Company is bound by all the provisions of this Agreement.

 

(e)            It is the intent of the Company that, to the fullest extent permitted by law, the Indemnitee not be required to incur legal fees or other Expenses associated with the interpretation, enforcement, or defense of Indemnitee’s rights under this Agreement, by litigation or otherwise, because the cost and expense thereof would substantially detract from the benefits intended to be extended to the Indemnitee under this Agreement. The Company, to the fullest extent permitted by law, will (within thirty (30) days after receipt by the Company of a written request therefor) advance to Indemnitee such Expenses which are incurred by Indemnitee in connection with a Proceeding concerning this Agreement, Indemnitee’s other rights to indemnification or advancement of Expenses from the Company, or concerning any directors’ and officers’ liability or other insurance policies maintained by the Company, and will indemnify Indemnitee against any and all such Expenses unless the court determines that Indemnitee’s claims in such action were made in bad faith or frivolous, or that the Company is prohibited by law from indemnifying Indemnitee for such Expenses.

 

Section 15.             Non-exclusivity; Survival of Rights; Insurance; Subrogation.

 

(a)            The indemnification and advancement of Expenses provided by this Agreement are not exclusive of any other rights to which Indemnitee may at any time be entitled under the TBOC or other applicable law, the Certificate of Formation, the Bylaws, any agreement, a vote of shareholders or a resolution of the Board, or otherwise. The indemnification and advancement of Expenses provided by this Agreement may not be limited or restricted by any amendment, alteration or repeal of this Agreement in any way with respect to any action taken or omitted by Indemnitee in Indemnitee’s Corporate Status occurring prior to any amendment, alteration or repeal of this Agreement. To the extent that a change in Texas law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Bylaws, the Certificate of Formation, or this Agreement, it is the intent of the parties hereto that Indemnitee enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy is cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, will not prevent the concurrent assertion or employment of any other right or remedy.

 

-12-

 

 

(b)            To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, or Agents of the Company, the Company will obtain a policy or policies covering Indemnitee to the maximum extent of the coverage available for any such director, officer, employee or Agent under such policy or policies, including coverage in the event the Company does not or cannot, for any reason, indemnify or advance Expenses to Indemnitee as required by this Agreement. If, at the time of the receipt of a notice of a claim pursuant to this Agreement or the commencement of a Proceeding, the Company has directors’ and officers’ liability or other applicable insurance in effect, the Company will give prompt notice of such claim or of the commencement of a Proceeding, as the case may be, to the insurers in accordance with the procedures set forth in the respective policies. The Company will thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such claim or Proceeding in accordance with the terms of such policies. Indemnitee agrees to assist the Company’s efforts to cause the insurers to pay such amounts and will comply with the terms of such policies, including selection of approved panel counsel, if required.

 

(c)            The Company’s obligation to indemnify or advance Expenses hereunder to Indemnitee for any Proceeding concerning Indemnitee’s Corporate Status with an Enterprise will be reduced by any amount Indemnitee has actually received as indemnification or advancement of Expenses from such Enterprise or such Enterprise’s insurers. The Company and Indemnitee intend that any such Enterprise (and its insurers) be the indemnitor of first resort with respect to indemnification and advancement of Expenses for any Proceeding related to or arising from Indemnitee’s Corporate Status with such Enterprise. The Company’s obligation to indemnify and advance Expenses to Indemnitee is secondary to the obligations the Enterprise or its insurers owe to Indemnitee. Indemnitee agrees to take all reasonably necessary and desirable action to obtain from an Enterprise or its insurers indemnification and advancement of Expenses for any Proceeding related to, or arising from, Indemnitee’s Corporate Status with such Enterprise.

 

(d)            In the event of any payment made by the Company under this Agreement, the Company will be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee from any Enterprise or its insurance carrier. Indemnitee will execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

 

Section 16.             Duration of Agreement. The indemnification and advancement of Expenses rights provided by or granted pursuant to this Agreement: (i) are binding upon and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), (ii) continue as to an Indemnitee who has ceased to be a director, officer, employee or Agent of the Company or of any Enterprise, and (iii) inure to the benefit of Indemnitee and Indemnitee’s spouse, assigns, heirs, devisees, executors and administrators and other legal representatives.

 

-13-

 

 

Section 17.             Severability. If any provision of this Agreement is held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) will not in any way be affected or impaired thereby and will remain enforceable to the fullest extent permitted by law; (b) such provision will be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) will be construed so as to give effect to the intent manifested thereby.

 

Section 18.             Interpretation. Any ambiguity in the terms of this Agreement will be resolved in favor of Indemnitee and in a manner to provide the maximum indemnification and advancement of Expenses permitted by law. The Company and Indemnitee intend that this Agreement provide to the fullest extent permitted by law for indemnification and advancement of Expenses in excess of that expressly provided, without limitation, by the Certificate of Formation, the Bylaws, vote of the Company’s shareholders or a resolution of the Board, or applicable law.

 

Section 19.             Enforcement.

 

(a)            The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to [continue to] serve as a director, officer, employee, or Agent of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in [serving / continuing to serve] as director, officer, employee, or Agent of the Company.

 

(b)            This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof (including any agreements regarding the arbitration of disputes regarding the subject matter of this Agreement); provided, however, that this Agreement is a supplement to and in furtherance of the Certificate of Formation, the Bylaws, any directors’ and officers’ or other insurance maintained by the Company, and applicable law, is not a substitute therefor, and does not diminish or abrogate any rights of Indemnitee thereunder.

 

Section 20.             Modification and Waiver. No supplement, modification or amendment of this Agreement is binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement will be valid unless executed in writing by the party entitled to enforce the provision to be waived and any such waiver will not be deemed or constitute a waiver of any other provisions of this Agreement nor will any waiver constitute a continuing waiver.

 

Section 21.             Notice by Indemnitee. Indemnitee agrees to promptly notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter that may be subject to indemnification or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company does not relieve the Company of any obligation that it may have to the Indemnitee under this Agreement or otherwise.

 

-14-

 

 

Section 22.             Notices. All notices, requests, demands and other communications under this Agreement will be in writing and will be deemed to have been duly given if (a) delivered by hand to the other party, (b) sent by reputable overnight courier to the other party or (c) sent by electronic mail, with receipt of oral or written confirmation that such communication has been received:

 

(a)            If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee provides to the Company.

 

(b)            If to the Company to:

 

  Name: Caris Life Sciences, Inc.
  Address: 750 W. John Carpenter Freeway, Suite 800
    Irving, TX 75039
  Attention: Secretary
  Email: GC@carisls.com

 

or to any other address as may have been furnished to Indemnitee by the Company.

 

Section 23.             Contribution. To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, will contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (a) the relative benefits received by the Company and Indemnitee as a result of the event(s) or transaction(s) giving cause to such Proceeding; or (b) the relative fault of the Company (and its directors, officers, employees and Agents) and Indemnitee in connection with such event(s) and/or transaction(s).

 

Section 24.             Applicable Law and Consent to Jurisdiction. This Agreement and the legal relations among the parties are governed by, and shall be construed and enforced in accordance with, the laws of the State of Texas, without regard to its conflict of laws rules. The Company and Indemnitee hereby irrevocably and unconditionally (a) agree that any action, claim, or proceeding between the parties arising out of or in connection with this Agreement may be brought only in the Business Court (or the Alternative Courts in the event the Business Court does not have jurisdiction over such matter) and not in any other state or federal court in the United States of America or any court in any other country, (b) consent to submit to the exclusive jurisdiction of the Business Court (and the Alternative Courts if applicable) for purposes of any action, claim, or proceeding arising out of or in connection with this Agreement, (c) waive any objection to the laying of venue of any such action, claim, or proceeding in the Business Court (or the Alternative Courts if applicable), and (d) waive, and agree not to plead or to make, any claim that any such action, claim, or proceeding brought in the Business Court (or the Alternative Courts if applicable) has been brought in an improper or inconvenient forum.

 

-15-

 

 

Section 25.             Identical Counterparts. This Agreement may be executed in one or more counterparts, each of which will for all purposes be deemed to be an original but all of which together constitute one and the same Agreement. Counterparts may be delivered via electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.

 

Section 26.             Headings. The headings of this Agreement are inserted for convenience only and do not constitute part of this Agreement or affect the construction thereof.

 

[Signature Page Follows]

 

-16-

 

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written.

 

CARIS LIFE SCIENCES, INC.     INDEMNITEE
     
By:                          
Name:   Name:                       
Title:     Address:  
       
       

 

-17-

 

 

Exhibit 16.1

 

September 12, 2024

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

 

Commissioners:

 

We have read the section titled “Change in Independent Registered Public Accounting Firm” in the Form S-1 of Caris Life Sciences, Inc. and are in agreement with the statements contained in the first two sentences of the first paragraph, and in the second through fourth paragraphs of that section. We have no basis to agree or disagree with other statements of the registrant contained therein.

 

/s/ Ernst & Young LLP

 

 

 

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the reference to our firm under the caption "Experts" and to the use of our report dated March 18, 2024, in the Registration Statement (Form S-1) and related Prospectus of Caris Life Sciences, Inc. for the registration of shares of its common stock.

 

/s/ Ernst & Young LLP

 

Dallas, Texas

May 23, 2025

 

 

 

Exhibit 23.2

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the use in this Registration Statement on Form S-1 of our report dated April 4, 2025, relating to the financial statements of Caris Life Sciences, Inc. We also consent to the reference to us under the heading "Experts" in such Registration Statement.

 

/s/ Deloitte & Touche LLP

 

San Jose, California

May 23, 2025

 

 

 

Exhibit 23.4

 

May 23, 2025

Caris Life Sciences, Inc.

750 W. John Carpenter Freeway, Suite 800

Irving, Texas 75039

 

Dear Caris Life Sciences, Inc.:

 

We, Nephron Research LLC of 767 Third Ave, 21st Floor, New York, New York, 10017, hereby consent to the filing with the Securities and Exchange Commission of a Registration Statement on Form S-1, and any amendments thereto (the “Registration Statement”) of Caris Life Sciences, Inc., and any related prospectuses of (i) our name and all references thereto, and (ii) the statements set out in the Schedule hereto. We also hereby consent to the filing of this letter as an exhibit to the Registration Statement.

 

We further consent to the reference to our firm, under the caption “Market and Industry Data” in the Registration Statement, as acting in the capacity of an author of independent industry publications.

 

Yours faithfully,  
   
/s/ Timothy Biggins  
Name: Timothy Biggins  
Designation: COO/CCO  
For and on behalf of Nephron Research LLC  

 

 

 

 

SCHEDULE

 

1.Our estimated total addressable U.S. oncology market, which is based on a market study by Nephron Research LLC that we commissioned, is comprised of opportunities in the following areas:

 

·Early detection: approximately $100 billion.
·Therapy selection: approximately $8 billion.
·MRD tracking and treatment monitoring: approximately $28 billion.
·Core biopharma services: approximately $4 billion.
·Data services for biopharma: approximately $10 billion.

 

2.We believe our expansive multi-omic technology platform has application across multiple clinical and biopharma settings that collectively represent an estimated total addressable U.S. market of approximately $150 billion in oncology, according to a market study by Nephron Research LLC (“Nephron Research”) that we commissioned.

 

3.Based on National Comprehensive Cancer Network (“NCCN”) guidelines suggesting that breast and lung cancer patients would benefit from at least two tests during therapy, and assuming that these benefits would apply to other types of solid tumors, Nephron Research estimates that approximately 520,000 newly-diagnosed advanced stage and recurrent cancer patients in the United States would benefit from repeat testing.

 

4.Accordingly, based on the newly-diagnosed patient, recurrent patient, and repeat testing patient cohorts described above, Nephron Research estimates that the total addressable U.S. market for therapy selection is comprised of approximately two million unique patient profiles annually and, assuming an average reimbursement of approximately $4,000 based on blended Medicare, commercial payer, and Medicaid coverage rates for various genomic profiling tests, amounts to approximately $8 billion.

 

5.According to the Nephron Research analysis, the number of annual unique patient profiles is expected to increase with clinical and payer adoption of broad molecular testing in earlier stages for newly- diagnosed cancer patients.

 

6.According to the Nephron Research analysis, these result in a cohort of approximately 5.6 million patients being monitored at various points in their treatment journey.

 

7.Assuming a range of two to three tests annually for each patient, consistent with MolDX coverage policy for MRD, pricing of $2,500 per reference test and $1,650 per follow-up blood test, in each case based on pricing for other tests available on the market, Nephron Research estimates that the total addressable U.S. market for MRD tracking tests represents approximately 16 million tests annually and amounts to approximately $28 billion.

 

 

 

 

8.According to the Nephron Research analysis, oncology testing associated with clinical trials includes approximately 250,000 cancer patients in targeted therapy clinical trials.

 

9.Assuming five tests (one therapy selection test to establish cancer type and determine the therapeutic intervention(s) and four monitoring tests for follow-up consistent with typical trial designs) for each trial participant and pricing of $5,000 per therapy selection test and $1,950 per monitoring test, based on existing reimbursement rates for other tests available on the market, Nephron Research estimates that the addressable U.S. market for oncology testing in clinical trials is approximately $3.2 billion.

 

10.Assuming approximately 25 Phase 1b trials progress to Phase 2 each year based on recent historical data from ClinicalTrials.gov, with each trial having two partners per customary industry practice (a specialty lab and a distributable kit) and an average contract price of $10 million based on Nephron Research’s market analysis, the addressable U.S. market for the development of companion diagnostics tests is estimated to be approximately $500 million.

 

11.Assuming a rate of rare mutation of 4.0% within the population of newly-diagnosed cancer patients in the United States with advanced-stage solid tumor cancers, based on data from the National Institutes of Health, and an average reimbursement per patient of $10,000 based on Nephron Research’s market analysis, the addressable U.S. market for commercial services that include identification of patients for approved therapies is estimated to be approximately $300 million.

 

12.According to the Nephron Research analysis, it is estimated that approximately $70 billion of the $262 billion spent in 2023 represented R&D investments in discovery, pre-trial costs, and real-world evidence, areas where matched genomic data has demonstrated use cases for biopharma applications.

 

13.Based on Nephron Research’s market analysis, approximately 14% of the estimated $70 billion in R&D investments in 2023 was allocated towards such data and services, resulting in an estimated total addressable U.S. market for this opportunity of approximately $10 billion.